<SEC-DOCUMENT>0001390478-15-000050.txt : 20151110
<SEC-HEADER>0001390478-15-000050.hdr.sgml : 20151110
<ACCEPTANCE-DATETIME>20151109165220
ACCESSION NUMBER:		0001390478-15-000050
CONFORMED SUBMISSION TYPE:	10-Q
PUBLIC DOCUMENT COUNT:		14
CONFORMED PERIOD OF REPORT:	20150930
FILED AS OF DATE:		20151109
DATE AS OF CHANGE:		20151109

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Galena Biopharma, Inc.
		CENTRAL INDEX KEY:			0001390478
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-Q
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-33958
		FILM NUMBER:		151216385

	BUSINESS ADDRESS:	
		STREET 1:		4640 SW MACADAM AVENUE
		STREET 2:		SUITE 270
		CITY:			PORTLAND
		STATE:			OR
		ZIP:			97239
		BUSINESS PHONE:		855 855 GALE

	MAIL ADDRESS:	
		STREET 1:		4640 SW MACADAM AVENUE
		STREET 2:		SUITE 270
		CITY:			PORTLAND
		STATE:			OR
		ZIP:			97239

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	RXi Pharmaceuticals Corp
		DATE OF NAME CHANGE:	20110926

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	GALENA BIOPHARMA, INC.
		DATE OF NAME CHANGE:	20110922

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	RXI PHARMACEUTICALS CORP
		DATE OF NAME CHANGE:	20110921
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-Q
<SEQUENCE>1
<FILENAME>gale-20150930x10q.htm
<DESCRIPTION>10-Q
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
	<head>
		<!-- Document created using Wdesk 1 -->
		<!-- Copyright 2015 Workiva -->
		<title>10-Q</title>
	</head>
	<body style="font-family:Times New Roman;font-size:10pt;">
<a name="s5F8367669D48586AB3DFFA66D1DEA2D5"></a><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="1"></td></tr><tr><td width="100%"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr></table></div></div><div style="line-height:120%;text-align:center;font-size:18pt;"><font style="font-family:Helvetica,sans-serif;font-size:18pt;font-weight:bold;">UNITED STATES</font></div><div style="line-height:120%;text-align:center;font-size:18pt;"><font style="font-family:Helvetica,sans-serif;font-size:18pt;font-weight:bold;">SECURITIES AND EXCHANGE COMMISSION</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Helvetica,sans-serif;font-size:12pt;font-weight:bold;">WASHINGTON, D.C. 20549</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">&#160;</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">________________________________</font></div><div style="line-height:120%;text-align:center;font-size:18pt;"><font style="font-family:Helvetica,sans-serif;font-size:18pt;font-weight:bold;">FORM 10-Q</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">&#160;</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">________________________________</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="2"></td></tr><tr><td width="4%"></td><td width="96%"></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Wingdings;font-size:10pt;">&#253;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-weight:bold;">QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:4px;text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-weight:bold;">For the quarterly period ended </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-weight:bold;">September&#160;30, 2015</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-weight:bold;">&#32;</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-weight:bold;">OR</font></div><div style="line-height:120%;padding-bottom:8px;font-size:10.5pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="2"></td></tr><tr><td width="4%"></td><td width="96%"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:16px;padding-left:24px;text-indent:-24px;font-size:10pt;"><font style="font-family:Wingdings;font-size:10pt;">&#168;</font></div><div style="font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="padding-bottom:16px;padding-left:24px;text-indent:-24px;font-size:10.5pt;"><font style="font-family:Helvetica,sans-serif;font-size:10.5pt;"><br></font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-weight:bold;">TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</font></div></td></tr></table></div></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-weight:bold;">Commission File Number: 001-33958</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#160;</font><font style="font-family:Helvetica,sans-serif;font-size:9pt;">&#160;</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">_______________________________</font></div><div style="line-height:120%;text-align:center;"><img src="logo-vertical.jpg" style="height:80px;width:100px;"></div><div style="line-height:120%;text-align:center;font-size:24pt;"><font style="font-family:Helvetica,sans-serif;font-size:24pt;font-weight:bold;">Galena Biopharma, Inc.</font></div><div style="line-height:120%;text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;font-style:italic;">(Exact name of registrant as specified in its charter)</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#160;</font><font style="font-family:Helvetica,sans-serif;font-size:9pt;">&#160;</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">________________________________</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:94.81481481481482%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td width="48%"></td><td width="3%"></td><td width="49%"></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-weight:bold;">Delaware</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-weight:bold;">20-8099512</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;font-style:italic;">(State of incorporation)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;font-style:italic;">(I.R.S. Employer Identification No.)</font></div></td></tr></table></div></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-weight:bold;">2000 Crow Canyon Place, Suite 380, San Ramon, CA 94583</font></div><div style="line-height:120%;padding-bottom:8px;text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-weight:bold;">(855)&#160;855-4253</font></div><div style="line-height:120%;text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;font-style:italic;">(Address, including zip code, and telephone number, including </font></div><div style="line-height:120%;text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;font-style:italic;">area code, of registrant's principal executive offices)</font></div><div style="line-height:120%;text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;font-weight:bold;">4640 SW Macadam Avenue, Suite 270, Portland, OR 97239</font></div><div style="line-height:120%;text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;font-style:italic;">(Former address, if changed since last report)</font></div><div style="line-height:120%;padding-bottom:8px;text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">&#160;&#160;</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">________________________________</font></div><div style="line-height:120%;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">Indicate by check mark whether the Registrant (1)&#160;has filed all reports required to be filed by Section&#160;13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12&#160;months (or for such shorter period that the Registrant was required to file such reports), and (2)&#160;has been subject to such filing requirements for the past 90&#160;days.&#160;&#160;&#160;&#160;Yes&#160;&#160;</font><font style="font-family:Wingdings;font-size:9pt;">&#253;</font><font style="font-family:Helvetica,sans-serif;font-size:9pt;">&#160;&#160;&#160;&#160;No&#160;&#160;</font><font style="font-family:Wingdings;font-size:9pt;">&#168;</font><font style="font-family:Helvetica,sans-serif;font-size:9pt;">&#32;</font></div><div style="line-height:120%;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;"><br></font></div><div style="line-height:120%;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule&#160;405 of Regulation&#160;S-T (&#167;232.405 of this chapter) during the preceding 12&#160;months (or for such shorter time that the registrant was required to submit and post such files).&#160;&#160;&#160;Yes&#160; </font><font style="font-family:Wingdings;font-size:9pt;">&#253;</font><font style="font-family:Helvetica,sans-serif;font-size:9pt;">&#160;&#160;&#160;&#160;No&#160;&#160;</font><font style="font-family:Wingdings;font-size:9pt;">&#168;</font><font style="font-family:Helvetica,sans-serif;font-size:9pt;">&#32;</font></div><div style="line-height:120%;text-indent:32px;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;"><br></font></div><div style="line-height:120%;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; and &#8220;smaller reporting company&#8221; in Rule&#160;12b-2 of the Exchange Act (Check one):</font></div><div style="line-height:120%;padding-bottom:8px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="7"></td></tr><tr><td width="26%"></td><td width="1%"></td><td width="3%"></td><td width="40%"></td><td width="26%"></td><td width="1%"></td><td width="3%"></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">Large&#160;accelerated&#160;filer</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:16px;text-align:left;padding-left:24px;text-indent:-24px;font-size:9pt;"><font style="font-family:Wingdings;font-size:9pt;">&#168;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">Accelerated&#160;filer</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Wingdings;font-size:9pt;">&#253;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">Non-accelerated filer</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:16px;text-align:left;padding-left:24px;text-indent:-24px;font-size:9pt;"><font style="font-family:Wingdings;font-size:9pt;">&#168;</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">(Do not check if a smaller reporting company)</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">Smaller&#160;reporting&#160;company</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:16px;text-align:left;padding-left:24px;text-indent:-24px;font-size:9pt;"><font style="font-family:Wingdings;font-size:9pt;">&#168;</font></div></td></tr></table></div></div><div style="line-height:120%;text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act):&#160;&#160;&#160;&#160;</font><font style="font-family:Wingdings;font-size:9pt;">&#168;</font><font style="font-family:Helvetica,sans-serif;font-size:9pt;">&#160;&#160;Yes&#160;&#160;&#160;&#160;</font><font style="font-family:Wingdings;font-size:9pt;">&#253; </font><font style="font-family:Helvetica,sans-serif;font-size:9pt;">&#160;No</font></div><div style="line-height:120%;text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">As of </font><font style="font-family:Helvetica,sans-serif;font-size:9pt;">October&#160;31, 2015</font><font style="font-family:Helvetica,sans-serif;font-size:9pt;">, Galena Biopharma, Inc. had outstanding </font><font style="font-family:Helvetica,sans-serif;font-size:9pt;">161,906,753</font><font style="font-family:Helvetica,sans-serif;font-size:9pt;">&#32;shares of common stock, $0.0001 par value per share, exclusive of treasury shares.</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="1"></td></tr><tr><td width="100%"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr></table></div></div><br><hr style="page-break-after:always"><a name="s0623A29E3C735937B2D2F4207223A852"></a><br><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#00497f;font-weight:bold;">GALENA BIOPHARMA, INC.</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#00497f;font-weight:bold;">FORM 10-Q - Quarterly Report</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#00497f;font-weight:bold;">For the Three and Nine Months Ended September 30, 2015</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#00497f;font-weight:bold;">TABLE OF CONTENTS</font></div><div style="line-height:120%;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">&#160;</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="6"></td></tr><tr><td width="5%"></td><td width="1%"></td><td width="5%"></td><td width="1%"></td><td width="83%"></td><td width="5%"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;font-weight:bold;text-decoration:underline;">Part</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;font-weight:bold;text-decoration:underline;">No.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;font-weight:bold;text-decoration:underline;">Item</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;font-weight:bold;text-decoration:underline;">No.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;font-weight:bold;text-decoration:underline;">Description</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;font-weight:bold;text-decoration:underline;">Page</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;font-weight:bold;text-decoration:underline;">No.</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">I</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:Helvetica,sans-serif;font-size:10pt;color:#0000ff;text-decoration:underline;" href="#s29D999D6A98B535AA8EEDE22DB35F917"><font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#0000ff;text-decoration:underline;">FINANCIAL INFORMATION</font></a></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">1</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:Helvetica,sans-serif;font-size:10pt;color:#0000ff;text-decoration:underline;" href="#s2DAECEB029695A3BBA03BBECB8168255"><font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#0000ff;text-decoration:underline;">Financial Statements</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><a style="font-family:Helvetica,sans-serif;font-size:10pt;color:#0000ff;text-decoration:underline;" href="#s2DAECEB029695A3BBA03BBECB8168255">2</a></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#0000ff;text-decoration:underline;">Condensed Consolidated Balance Sheets as of September 30, 2015 (unaudited) and December 31, 2014</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><a style="font-family:Helvetica,sans-serif;font-size:10pt;text-decoration:underline;" href="#s26C46051CF975F7C9181E906383FC3C1">2</a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#0000ff;text-decoration:underline;">Condensed Consolidated Statements of Comprehensive Loss (unaudited) for the three and nine months ended September 30, 2015 and 2014</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><a style="font-family:Helvetica,sans-serif;font-size:10pt;text-decoration:underline;" href="#sEE6B0639E54D54E383CCABA475AB1CCC">3</a></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#0000ff;text-decoration:underline;">Condensed Consolidated Statement of Stockholders' Equity (unaudited) for the nine months ended September 30, 2015</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><a style="font-family:Helvetica,sans-serif;font-size:10pt;text-decoration:underline;" href="#sB64E8BDBB16E5191B4E4042FBA4A3671">4</a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#0000ff;text-decoration:underline;">Condensed Consolidated Statements of Cash Flows (unaudited) for the nine months ended September 30, 2015 and 2014</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><a style="font-family:Helvetica,sans-serif;font-size:10pt;text-decoration:underline;" href="#sE443A4621E40513A8F4009B370EBF582">5</a></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:Helvetica,sans-serif;font-size:10pt;color:#0000ff;text-decoration:underline;" href="#s4FF570552E9C55B6B6A321B4CC91D993"><font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#0000ff;text-decoration:underline;">Notes to Condensed Consolidated Financial Statements (unaudited)</font></a></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><a style="font-family:Helvetica,sans-serif;font-size:10pt;color:#0000ff;text-decoration:underline;" href="#s4FF570552E9C55B6B6A321B4CC91D993">6</a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">2</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:Helvetica,sans-serif;font-size:10pt;color:#0000ff;text-decoration:underline;" href="#s6625643D3DDD535D86CCD6A9C7458D1F"><font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#0000ff;text-decoration:underline;">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><a style="font-family:Helvetica,sans-serif;font-size:10pt;" href="#s359754F5FB8D59BA8748C4AB14C4B621">26</a></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">3</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:Helvetica,sans-serif;font-size:10pt;color:#0000ff;text-decoration:underline;" href="#s7584FFB80EBE5FD3B2E7666E684A0966"><font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#0000ff;text-decoration:underline;">Quantitative and Qualitative Disclosures About Market Risk</font></a></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><a style="font-family:Helvetica,sans-serif;font-size:10pt;" href="#s7584FFB80EBE5FD3B2E7666E684A0966">40</a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">4</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:Helvetica,sans-serif;font-size:10pt;color:#0000ff;text-decoration:underline;" href="#s644700A3FB855EF0BA1ED4F30BD9757C"><font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#0000ff;text-decoration:underline;">Controls and Procedures</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><a style="font-family:Helvetica,sans-serif;font-size:10pt;" href="#s644700A3FB855EF0BA1ED4F30BD9757C">41</a></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">II</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:Helvetica,sans-serif;font-size:10pt;color:#0000ff;text-decoration:underline;" href="#s903205EAEC5E525596163163AE5F602D"><font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#0000ff;text-decoration:underline;">OTHER INFORMATION</font></a></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">1</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#0000ff;text-decoration:underline;">Legal Proceedings</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><a style="font-family:Helvetica,sans-serif;font-size:10pt;text-decoration:underline;" href="#s8A43068AD6EA57BEA1C78C530E5F20E5">42</a></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">1A</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#0000ff;text-decoration:underline;">Risk Factors</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><a style="font-family:Helvetica,sans-serif;font-size:10pt;" href="#s76F6AEAD21315C35B693A1582D410A6E">43</a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">6</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:Helvetica,sans-serif;font-size:10pt;color:#0000ff;text-decoration:underline;" href="#s727BEEC68CA650F2ADAE6DB3BA7C7192"><font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#0000ff;text-decoration:underline;">Exhibits</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><a style="font-family:Helvetica,sans-serif;font-size:10pt;" href="#s727BEEC68CA650F2ADAE6DB3BA7C7192">47</a></div></td></tr><tr><td colspan="5" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:Helvetica,sans-serif;font-size:10pt;text-decoration:underline;" href="#s727BEEC68CA650F2ADAE6DB3BA7C7192"><font style="font-family:Helvetica,sans-serif;font-size:10pt;text-decoration:underline;">Index to Exhibits</font></a></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><a style="font-family:Helvetica,sans-serif;font-size:10pt;" href="#s727BEEC68CA650F2ADAE6DB3BA7C7192">47</a></div></td></tr><tr><td colspan="5" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:Helvetica,sans-serif;font-size:10pt;color:#0000ff;text-decoration:underline;" href="#s8F04B2C7308D5E4EAFC1DF4A9ABB0973"><font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#0000ff;text-decoration:underline;">Signatures</font></a></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><a style="font-family:Helvetica,sans-serif;font-size:10pt;" href="#s8F04B2C7308D5E4EAFC1DF4A9ABB0973">48</a></div></td></tr><tr><td colspan="5" style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;text-decoration:underline;">EX-10.6</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td colspan="5" style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;text-decoration:underline;">EX-10.7</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td colspan="5" style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;text-decoration:underline;">EX-31.1</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td colspan="5" style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;text-decoration:underline;">EX-31.2</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td colspan="5" style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;text-decoration:underline;">EX-32.1</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr></table></div></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><br><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1</font></div></div><hr style="page-break-after:always"><a name="s29D999D6A98B535AA8EEDE22DB35F917"></a><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><br><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#00497f;font-weight:bold;">PART I FINANCIAL INFORMATION</font></div><a name="s2DAECEB029695A3BBA03BBECB8168255"></a><div style="line-height:120%;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#00497f;font-weight:bold;">ITEM&#160; 1. FINANCIAL STATEMENTS</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><a name="s26C46051CF975F7C9181E906383FC3C1"></a><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#00497f;font-weight:bold;">GALENA BIOPHARMA, INC.</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#00497f;font-weight:bold;">CONDENSED CONSOLIDATED BALANCE SHEETS</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#00497f;font-weight:bold;">(Amounts in thousands, except share and per share data)</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"></td></tr><tr><td width="71%"></td><td width="1%"></td><td width="12%"></td><td width="1%"></td><td width="1%"></td><td width="1%"></td><td width="12%"></td><td width="1%"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">September 30, 2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">December&#160;31, 2014</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">(Unaudited)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">ASSETS</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">Current assets:</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">Cash and cash equivalents</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">34,812</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">23,650</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:middle;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">Restricted cash</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">401</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">200</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">Prepaid expenses and other current assets</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">1,174</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">1,237</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:middle;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">Current assets held for sale, net</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">17,801</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">27,013</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">Total current assets</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">54,188</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">52,100</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">Equipment and furnishings, net</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">288</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">285</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">In-process research and development</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">12,864</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">12,864</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">GALE-401 rights</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">9,255</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">9,255</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">Goodwill</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">5,898</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">5,897</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">Deposits and other assets</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">176</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">87</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">Total assets</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">82,669</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">80,488</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">LIABILITIES AND STOCKHOLDERS&#8217; EQUITY</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">Current liabilities:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:middle;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">Accounts payable</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">1,238</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">1,886</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">Accrued expenses and other current liabilities</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">7,329</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">8,885</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:middle;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">Fair value of warrants potentially settleable in cash</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">16,661</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">5,383</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">Current portion of long-term debt</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">4,166</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">3,910</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:middle;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">Current liabilities held for sale</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">7,697</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">7,169</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">Total current liabilities</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">37,091</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">27,233</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">Deferred tax liability</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">5,053</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">5,053</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">Contingent purchase price consideration</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">6,582</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">6,651</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">Long-term debt, net of current portion</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">1,526</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">4,492</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">Total liabilities</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">50,252</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">43,429</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">Commitments and contingencies</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;"><br></font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">Stockholders&#8217; equity:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:middle;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">Preferred stock, $0.0001&#160;par value; 5,000,000&#160;shares authorized; no shares issued and outstanding</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">Common stock, $0.0001&#160;par value; 275,000,000&#160;shares authorized, 162,575,446 shares issued and 161,900,446 shares outstanding at September 30, 2015; 200,000,000 shares authorized, 130,146,341&#160;shares issued and 129,471,341 shares&#160;outstanding at December&#160;31, 2014</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">15</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">12</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:middle;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">Additional paid-in capital</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">295,956</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">256,377</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">Accumulated deficit</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">(259,705</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">(215,481</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">)</font></div></td></tr><tr><td style="vertical-align:middle;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">Less treasury shares at cost, 675,000 shares</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">(3,849</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">(3,849</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">)</font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:44px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">Total stockholders&#8217; equity</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">32,417</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">37,059</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:middle;padding-left:44px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">Total liabilities and stockholders&#8217; equity</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">82,669</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">80,488</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">See accompanying notes to condensed consolidated financial statements.</font></div><br><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2</font></div></div><hr style="page-break-after:always"><a name="sEE6B0639E54D54E383CCABA475AB1CCC"></a><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s0623A29E3C735937B2D2F4207223A852"><font style="font-family:inherit;font-size:10pt;">Table of Contents</font></a></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#00497f;font-weight:bold;">GALENA BIOPHARMA, INC.</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#00497f;font-weight:bold;">CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#00497f;font-weight:bold;">(Amounts in thousands, except share and per share data)</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#00497f;font-weight:bold;">(Unaudited)</font></div></div><br><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"></td></tr><tr><td width="45%"></td><td width="1%"></td><td width="11%"></td><td width="1%"></td><td width="1%"></td><td width="1%"></td><td width="11%"></td><td width="1%"></td><td width="1%"></td><td width="1%"></td><td width="11%"></td><td width="1%"></td><td width="1%"></td><td width="1%"></td><td width="11%"></td><td width="1%"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Three Months Ended September 30,</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Nine Months Ended September 30,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">2014</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">2014</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Operating expenses:</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Research and development</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">5,740</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">7,025</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">18,762</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">21,463</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">General and administrative</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">2,895</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">3,542</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">7,869</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">12,744</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:44px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Total operating expenses</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">8,635</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">10,567</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">26,631</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">34,207</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Operating loss</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(8,635</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(10,567</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(26,631</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(34,207</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Non-operating income (expense):</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Change in fair value of warrants potentially settleable in cash</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">2,134</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">6,735</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(981</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">13,174</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Interest income (expense), net</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(158</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(297</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(607</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(925</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Other income (expense)</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">307</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">597</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">69</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(59</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:44px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Total non-operating income (expense), net</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">2,283</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">7,035</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(1,519</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">12,190</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Loss from continuing operations</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(6,352</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(3,532</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(28,150</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(22,017</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Discontinued operations</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Loss from discontinued operations, including $8,071 impairment charge from classification as held for sale for three and nine months ended September 30, 2015</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(11,674</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(2,641</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(16,074</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(6,633</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Net loss</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(18,026</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(6,173</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(44,224</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(28,650</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Net loss per common share:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Basic and diluted net loss per share, continuing operations</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(0.04</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(0.03</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(0.18</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(0.19</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Basic and diluted net loss per share, discontinued operations</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(0.07</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(0.02</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(0.11</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(0.06</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Basic net loss per share</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(0.11</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(0.05</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(0.29</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(0.25</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Weighted-average common shares outstanding: basic and diluted</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">161,857,522</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">119,038,656</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">153,000,857</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">117,767,791</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:8px;text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">See accompanying notes to condensed consolidated financial statements.</font></div><br><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3</font></div></div><hr style="page-break-after:always"><a name="sB64E8BDBB16E5191B4E4042FBA4A3671"></a><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s0623A29E3C735937B2D2F4207223A852"><font style="font-family:inherit;font-size:10pt;">Table of Contents</font></a></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#00497f;font-weight:bold;">GALENA BIOPHARMA, INC.</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#00497f;font-weight:bold;">CONDENSED CONSOLIDATED STATEMENT OF STOCKHOLDERS' EQUITY</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#00497f;font-weight:bold;">(Amounts in thousands, except share amounts)</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#00497f;font-weight:bold;">(Unaudited)</font></div></div><br><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:98.24561403508771%;border-collapse:collapse;text-align:left;"><tr><td colspan="23"></td></tr><tr><td width="39%"></td><td width="10%"></td><td width="1%"></td><td width="1%"></td><td width="1%"></td><td width="7%"></td><td width="1%"></td><td width="1%"></td><td width="1%"></td><td width="7%"></td><td width="1%"></td><td width="1%"></td><td width="1%"></td><td width="7%"></td><td width="1%"></td><td width="1%"></td><td width="1%"></td><td width="7%"></td><td width="1%"></td><td width="1%"></td><td width="1%"></td><td width="7%"></td><td width="1%"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="6" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:7pt;"><font style="font-family:Helvetica,sans-serif;font-size:7pt;">Common Stock</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:7pt;"><font style="font-family:Helvetica,sans-serif;font-size:7pt;">Additional Paid-In Capital</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:7pt;"><font style="font-family:Helvetica,sans-serif;font-size:7pt;">Accumulated Deficit</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:7pt;"><font style="font-family:Helvetica,sans-serif;font-size:7pt;">Treasury Stock</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:7pt;"><font style="font-family:Helvetica,sans-serif;font-size:7pt;">Total</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:7pt;"><font style="font-family:Helvetica,sans-serif;font-size:7pt;">Shares Issued</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:7pt;"><font style="font-family:Helvetica,sans-serif;font-size:7pt;">Amount</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Balance at December 31, 2014</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">130,146,341</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">12</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">256,377</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">(215,481</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">(3,849</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">37,059</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Issuance of common stock</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">32,158,685</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">3</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">47,413</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">47,416</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Common stock warrants issued in connection with March 2015 common stock offering</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">(10,296</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">(10,296</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Issuance of common stock in connection with employee stock purchase plan</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">231,312</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">309</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">309</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Stock-based compensation for directors and employees</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">2,122</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">2,122</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Exercise of stock options</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">39,108</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">31</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">31</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Net loss</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">(44,224</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">(44,224</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Balance at September 30, 2015</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">162,575,446</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">15</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">295,956</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">(259,705</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">(3,849</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">32,417</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:8px;text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">See accompanying notes to condensed consolidated financial statements.</font></div><br><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4</font></div></div><hr style="page-break-after:always"><a name="sE443A4621E40513A8F4009B370EBF582"></a><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s0623A29E3C735937B2D2F4207223A852"><font style="font-family:inherit;font-size:10pt;">Table of Contents</font></a></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#00497f;font-weight:bold;">GALENA BIOPHARMA, INC.</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#00497f;font-weight:bold;">CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#00497f;font-weight:bold;">(Amounts in thousands)</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#00497f;font-weight:bold;">(Unaudited)</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div></div><br><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"></td></tr><tr><td width="69%"></td><td width="1%"></td><td width="13%"></td><td width="1%"></td><td width="1%"></td><td width="1%"></td><td width="13%"></td><td width="1%"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-bottom:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">For the Nine Months Ended September 30,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;border-bottom:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;border-bottom:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">2014</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Cash flows from operating activities:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Cash flows from continuing operating activities:</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Net loss from continuing operations</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">(28,150</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">(22,017</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Adjustment to reconcile net loss to net cash used in operating activities:</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Depreciation and amortization expense</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">304</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">340</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Non-cash stock-based compensation</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">1,334</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">3,878</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Change in fair value of common stock warrants</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">982</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">(13,174</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Change in fair value of contingent consideration</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">(69</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">59</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Changes in operating assets and liabilities:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:84px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Prepaid expenses and other assets</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">(26</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">(348</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:84px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Accounts payable</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">(648</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">54</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:84px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Accrued expenses and other current liabilities</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-bottom:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">(1,556</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-bottom:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">2,465</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Net cash used in continuing operating activities</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-bottom:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">(27,829</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;border-bottom:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">(28,743</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Cash flows from discontinued operating activities:</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Net loss from discontinued operations</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">(16,074</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">(6,633</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Impairment charge from classification of assets held for sale</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">8,071</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Changes in operating assets and liabilities attributable to discontinued operations</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-bottom:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">2,956</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-bottom:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">3,241</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Net cash used in discontinued operating activities</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-bottom:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">(5,047</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;border-bottom:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">(3,392</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;font-weight:bold;">Net cash used in operating activities</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-bottom:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">(32,876</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;border-bottom:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">(32,135</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Cash flows from investing activities:</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Change in restricted cash</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">(201</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Cash paid for acquisition of GALE-401 rights</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">(2,315</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Cash paid for purchase of equipment and furnishings</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-bottom:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">(81</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-bottom:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">(48</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Net cash used in continuing investing activities</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">(282</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">(2,363</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Net cash used in discontinued investing activities</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;border-bottom:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">(534</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;border-bottom:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">(3,056</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;font-weight:bold;">Net cash used in investing activities</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-bottom:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">(816</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;border-bottom:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">(5,419</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Cash flows from financing activities:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Net proceeds from issuance of common stock</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">47,416</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Net proceeds from exercise of stock options</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">31</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">4,342</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Proceeds from exercise of warrants</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">10,717</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Proceeds from common stock issued in connection with ESPP</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">309</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">263</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Principle payments on long-term debt</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-bottom:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">(2,902</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-bottom:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">(908</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;font-weight:bold;">Net cash provided by financing activities</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-bottom:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">44,854</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-bottom:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">14,414</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Net increase (decrease) in cash and cash equivalents</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">11,162</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">(23,140</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Cash and cash equivalents at the beginning of period</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">23,650</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">47,787</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Cash and cash equivalents at end of period</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;border-bottom:3px double #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;border-bottom:3px double #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">34,812</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;border-bottom:3px double #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;border-bottom:3px double #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">24,647</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;font-weight:bold;">Supplemental disclosure of cash flow information:</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Cash received during the periods for interest</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-bottom:3px double #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-bottom:3px double #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">12</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-bottom:3px double #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-bottom:3px double #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">13</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Cash paid during the periods for interest</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-bottom:3px double #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-bottom:3px double #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">437</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-bottom:3px double #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-bottom:3px double #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">632</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;font-weight:bold;">Supplemental disclosure of non-cash investing and financing activities:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Fair value of warrants issued in connection with common stock recorded as cost of equity</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-bottom:3px double #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-bottom:3px double #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">10,296</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-bottom:3px double #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-bottom:3px double #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">27,026</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Reclassification of warrant liabilities upon exercise</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:3px double #000000;border-bottom:3px double #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;border-bottom:3px double #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:3px double #000000;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:3px double #000000;border-bottom:3px double #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;border-bottom:3px double #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">27,020</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:3px double #000000;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div><font style="font-family:Helvetica,sans-serif;font-size:10pt;">See accompanying notes to condensed consolidated financial statements.</font></div><br><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5</font></div></div><hr style="page-break-after:always"><a name="s4FF570552E9C55B6B6A321B4CC91D993"></a><div><div style="line-height:120%;text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;font-weight:bold;" href="#s0623A29E3C735937B2D2F4207223A852"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Table of Contents</font></a></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#00497f;font-weight:bold;">GALENA BIOPHARMA, INC.</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#00497f;font-weight:bold;">NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#00497f;font-weight:bold;">(Unaudited)</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div></div><br><div style="line-height:120%;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;"><br></font></div><a name="sDD361449576453BEB2624EC0FD0A94A5"></a><div style="line-height:120%;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#00497f;font-weight:bold;">1.  Business and Basis of Presentation</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#006ebf;font-weight:bold;">Overview</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-weight:bold;">&#160;</font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;text-indent:66px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Galena Biopharma, Inc. (&#8220;we,&#8221; &#8220;us,&#8221; &#8220;our,&#8221; &#8220;Galena&#8221; or the &#8220;company&#8221;) is a biopharmaceutical company committed to the development and commercialization of targeted oncology therapeutics that address major unmet medical needs. Galena&#8217;s development portfolio is focused primarily on addressing the rapidly growing patient populations of cancer survivors by harnessing the power of the immune system to prevent cancer recurrence. The Company&#8217;s pipeline consists of multiple mid- to late-stage clinical assets, including novel cancer immunotherapy programs led by NeuVax&#8482; (nelipepimut-S),GALE-301 and GALE-302.&#160;NeuVax is currently in a pivotal, Phase 3 clinical trial with several concurrent Phase 2 trials ongoing both as a single agent and in combination with other therapies. GALE-301 is in a Phase 2a clinical trial in ovarian and endometrial cancers in addition to GALE-302 in combination with GALE-301 in ovarian and breast cancers.&#160;</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#006ebf;font-weight:bold;text-decoration:underline;">Novel Cancer Immunotherapies</font></div><div style="line-height:120%;text-align:left;text-indent:66px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;text-indent:66px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Our targeted cancer immunotherapy approach is currently based upon two key areas: preventing secondary recurrence of cancer, which is becoming increasingly important as the number of cancer survivors continues to grow; and, transitioning earlier in the breast cancer treatment spectrum via primary prevention. Once a patient&#8217;s tumor becomes metastatic, the outcome is most often fatal, making the prevention of recurrence a potentially critical component of overall patient care. Our programs primarily target patients in the adjuvant (after-surgery) setting who have relatively healthy immune systems, but may still have minimal residual disease.  Minimal residual disease, or single cancer cells (occult cancer cells) or micrometastasis, are undetectable by current radiographic scanning technologies, but we know can result in disease recurrence.</font></div><div style="line-height:120%;text-align:left;text-indent:66px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Our therapies utilize an immunodominant peptide combined with the immune adjuvant, recombinant human granulocyte macrophage-colony stimulating factor (rhGM-CSF), and work by harnessing the patient&#8217;s own immune system to seek out and attack any residual cancer cells. Using peptide immunogens has many potential clinical advantages, including a favorable safety profile, since these drugs may lack the toxicities typical of most cancer therapies. They also have the potential to evoke long-lasting protection through activation of the immune system and a convenient, intradermal mode of delivery. We are currently engaged in multiple clinical trials with NeuVax&#8482; (nelipepimut-S), GALE-301, and GALE-302, targeting the prevention of recurrence in breast, gastric, ovarian and endometrial cancers.</font></div><div style="line-height:120%;text-align:left;text-indent:66px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:32px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#006ebf;font-style:italic;font-weight:bold;">NeuVax&#8482; (nelipepimut-S)</font></div><div style="line-height:120%;text-align:left;padding-left:32px;text-indent:66px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;text-indent:66px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">NeuVax&#8482; (nelipepimut-S), our lead product candidate, is a cancer immunotherapy targeting human epidermal growth factor receptor (HER2) expressing cancers. NeuVax is the immunodominant nonapeptide derived from the extracellular domain of the HER2 protein, a well-established and validated target for therapeutic intervention in breast and gastric carcinomas. The NeuVax vaccine is combined with GM-CSF for injection under the skin, or intradermal administration. Data has shown that an increased presence of circulating tumor cells (CTCs) may predict Disease Free Survival (DFS) and Overall Survival (OS)-suggesting a dormancy of isolated micrometastases, which, over time, may lead to recurrence. After binding to specific HLA molecules on antigen presenting cells, the nelipepimut-S sequence stimulates specific cytotoxic T lymphocyte (CTLs). These activated CTLs recognize, neutralize and destroy, through cell lysis, HER2 expressing cancer cells, including occult cancer cells and micrometastatic foci. The nelipepimut immune response can also generate CTLs to other immunogenic peptides through inter- and intra-antigenic epitope spreading.</font></div><br><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;font-weight:bold;" href="#s0623A29E3C735937B2D2F4207223A852"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Table of Contents</font></a></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#00497f;font-weight:bold;">GALENA BIOPHARMA, INC.</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#00497f;font-weight:bold;">NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS - Continued</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#00497f;font-weight:bold;">(Unaudited)</font></div></div><br><div style="line-height:120%;padding-bottom:13px;text-align:left;text-indent:66px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">We have multiple trials currently ongoing for NeuVax. For our pivotal, Phase 3 PRESENT (</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-weight:bold;">P</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">revention of </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-weight:bold;">R</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">ecurrence in </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-weight:bold;">E</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">arly-</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-weight:bold;">S</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">tage, Node- Positive Breast Cancer with Low to Intermediate HER2 </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-weight:bold;">E</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">xpression with </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-weight:bold;">NeuVax T</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">reatment) trial, NeuVax is targeting the </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">30,000</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">-</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">40,000</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;of the </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">230,000</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;female breast cancer patients annually diagnosed in the U.S. who are at a higher risk of their breast cancer recurring, which we refer to as &#8220;disease recurrence,&#8221; after achieving &#8220;no evidence of disease&#8221; (NED) status, (or becoming a &#8220;survivor&#8221;) with standard-of-care therapy (surgery, chemotherapy, radiation). These high-risk patients have a particular molecular signature and disease status: HER2 IHC 1+/2+ (oncoprotein associated with aggressive tumor growth), node positive (disease present in the axillary lymph nodes prior to surgery), and HLA A2/A3 (human leukocyte antigen from A2/A3 patients who have the same loci of genes which represents approximately </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">65%</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;of the population). Up to </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">25%</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;of resectable, node-positive breast cancer patients, having no radiographic evidence of disease following surgery and adjuvant chemo/radiation therapy, are expected to relapse within three years following diagnosis. The prognosis upon recurrence is very poor. These cancer patients presumably still had isolated, undetected tumor CTCs that led to a recurrence of cancer in the breast (local recurrence) or in another location (metastatic disease).  In addition to our Phase 3 trial, we currently have two additional Phase 2 breast cancer trials ongoing with NeuVax in combination with trastuzumab (Herceptin</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">&#174;</sup></font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">; Genentech/Roche) targeting the prevention of recurrence in expanded indications.  </font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;text-indent:66px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">We also recently announced our intent to initiate a Phase 2 trial with NeuVax as a single agent in patients with ductal carcinoma in situ (DCIS) in collaboration with the National Cancer Institute (NCI), potentially transitioning NeuVax earlier in the treatment cycle towards primary prevention.  The trial will have an immunological endpoint evaluating NeuVax peptide-specific cytotoxic T lymphocyte (CTL; CD8+ T cell) response in vaccinated patients. DCIS, is defined by the NCI as a noninvasive condition in which abnormal cells are found in the lining of a breast duct, and is the most common type of breast cancer.  The abnormal cells have not spread outside the duct to other tissues in the breast.  In some cases, DCIS may become invasive cancer and spread to other tissues, and at this time, there is no way to know which lesions could become invasive.  Current treatment options for DCIS include breast-conserving surgery and radiation therapy with or without tamoxifen, breast-conserving surgery without radiation therapy, or total mastectomy with or without tamoxifen.  According to the American Cancer Society, in 2014 there were an estimated </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">51,933</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;diagnoses of DCIS.</font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;text-indent:66px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">We currently have a number of ongoing or planned clinical trials designed to expand the clinical and geographical footprint of NeuVax:</font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:108px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:84px;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Phase 3 Ongoing: Our Phase 3 PRESENT (</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-weight:bold;">P</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">revention of </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-weight:bold;">R</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">ecurrence in </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-weight:bold;">E</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">arly- </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-weight:bold;">S</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">tage, Node-Positive Breast Cancer with Low to Intermediate HER2 </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-weight:bold;">E</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">xpression with </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-weight:bold;">NeuVax</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-weight:bold;">T</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">reatment) study targeted enrollment of </font><font style="font-family:Helvetica;font-size:10pt;">700</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;HER2 1+/2+ patients under a Special Protocol Assessment (SPA) granted by the U.S. Food and Drug Administration (FDA). The multinational, multicenter, randomized, double-blinded PRESENT trial is ongoing in North America, Western and Eastern Europe, and Israel. The trial is fully enrolled with </font><font style="font-family:Helvetica;font-size:10pt;">758</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;patients. </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:108px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:84px;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Phase 2b Ongoing: A randomized, multicenter, investigator-sponsored, </font><font style="font-family:Helvetica;font-size:10pt;">300</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;patient Phase 2b clinical trial is enrolling HER2 1+/2+ node-positive and high-risk node-negative breast cancer patients who are HLA A2+, A3+, A24+ or A26+ to study NeuVax in combination with trastuzumab in the adjuvant setting.  This trial is co-funded by Genentech/Roche (providing both trastuzumab and monetary support) and Galena (providing NeuVax and monetary support).</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:108px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:84px;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Phase 2 Ongoing: An investigator-sponsored trial is ongoing to study NeuVax in combination with trastuzumab. The study will enroll </font><font style="font-family:Helvetica;font-size:10pt;">100</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;node positive and negative HER2 IHC 3+ patients or HER2 gene-amplified breast cancer patients who are HLA A2+ or HLA A3+ and are determined to be at high-risk for recurrence. Partial funding for this trial comes from the Department of Defense (DoD) through the Congressionally Directed Medical Research Program via legislation known as the Defense Appropriations Act. The grant was awarded under a Breast Cancer Research Program with the Breakthrough Award given to the lead investigator for the trial.</font></div></td></tr></table><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:108px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><br><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;font-weight:bold;" href="#s0623A29E3C735937B2D2F4207223A852"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Table of Contents</font></a></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#00497f;font-weight:bold;">GALENA BIOPHARMA, INC.</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#00497f;font-weight:bold;">NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS - Continued</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#00497f;font-weight:bold;">(Unaudited)</font></div></div><br><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:108px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:84px;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Phase 2 Planned: A clinical trial, entitled, VADIS: Phase 2 trial of the Nelipepimut-S Peptide </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-weight:bold;">VA</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">ccine in Women with </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-weight:bold;">D</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">C</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-weight:bold;">IS </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">of the Breast is planned to initiate by the end of 2015/early 2016. The Phase 2 trial will be a single-blind, double arm, randomized, controlled trial in pre- or post-menopausal patients with DCIS and are HLA-A2 positive.  VADIS will be co-funded and run in collaboration with the National Cancer Institute (NCI).</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:108px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:90px;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Phase 2 Planned: A Phase 2 clinical trial in patients with gastric cancer is expected to initiate in 2016.  The trial will be run in India by our partner, Dr. Reddy&#8217;s Laboratories, Ltd., as part of our NeuVax commercialization agreement in that region with Dr. Reddy&#8217;s. </font></div></td></tr></table><div style="line-height:120%;text-align:left;padding-left:32px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#006ebf;font-style:italic;font-weight:bold;">GALE-301 and GALE-302</font></div><div style="line-height:120%;text-align:left;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:66px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Our second immunotherapy franchise targets folate binding protein (FBP) receptor-alpha, a well-validated therapeutic target, which&#160;is highly over-expressed (20-80 fold) in ovarian, endometrial and breast cancers. Both GALE-301 (E39) and GALE-302 (E39&#8217;) are immunogenic peptides that can stimulate CTLs to recognize and destroy FBP-expressing cancer cells. GALE-301 consists of the FBP peptide E39 combined with GM-CSF, and is currently in a Phase 2a clinical trial for the prevention of recurrence in patients with ovarian and endometrial cancers. GALE-302 is an attenuated version of the E39 peptide and is currently in a Phase 1b randomized, single-center trial investigating a novel vaccination series using GALE-301 and GALE-302 to evaluate the immune response and monitor long-term immunity.  Current treatments after surgery for these diseases are principally with platinum based chemotherapeutic agents and patients suffer a high recurrence rate; and, most patients relapse with an extremely poor prognosis. Although not powered for efficacy, promising preliminary results from the Phase 2a clinical trial of GALE-301 were presented in September 2015 at the European Cancer Congress and demonstrated statistically significant data with the estimate for disease free survival at two years at 85.7% (1000 mcg dose group) vs. 33.6% for the control group (p &lt; .02), and that GALE-301 was well-tolerated with primarily Grade 1 and 2 toxicities and elicited a strong&#160;</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;">in vivo&#160;</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">immune response. </font></div><div style="line-height:120%;text-align:left;text-indent:66px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-indent:66px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">According to the NCI Surveillance, Epidemiology, and End Results (SEER) Program, new cases of ovarian cancer occur at an annual rate of </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">12.1</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;per </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">100,000</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;women in the U.S., with an estimated </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">21,290</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;cases for 2015. Although ovarian cancer represents about </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">1.3%</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;of all cancers, it represents about </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">2.4%</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;of all cancer deaths, or an estimated </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">14,180</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;deaths in 2015. &#160;Approximately </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">1.3%</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;of women will be diagnosed with ovarian cancer at some point during their lifetime (2010 - 2012 data). &#160;The prevalence of ovarian cancer in the U.S. is about </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">192,000</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;women, and the five-year survivorship for women with ovarian cancer is </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">45.6%</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">.&#160;Due to the lack of specific symptoms, the majority of ovarian cancer patients are diagnosed at later stages of the disease, with an estimated </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">75%</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;of women presenting with advanced-stage (III or IV) disease. These patients have their tumors routinely surgically debulked to minimal residual disease, and then are treated with platinum- and/or taxane-based chemotherapy. While many patients respond to this treatment regimen and become clinically free-of-disease, the majority of these patients will relapse.  Depending upon their level of residual disease, the risk for recurrence after completion of primary therapy ranges from </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">60%</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;to </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">85%</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">.  Unfortunately for these women, once the disease recurs, treatment options are limited and the disease remains incurable.</font></div><div style="line-height:120%;text-align:left;text-indent:66px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:66px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">According to the NCI SEER Program, new cases of endometrial cancer occur at an annual rate of </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">25.1</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;per </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">100,000</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;women in the U.S., with an estimated </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">54,870</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;cases for 2015. Although endometrial cancer represents about </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">3.3%</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;of all cancers, it represents about </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">1.7%</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;of all cancer deaths, or an estimated </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">10,170</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;deaths in 2015. &#160;Approximately </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">2.8%</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;of women will be diagnosed with endometrial cancer at some point during their lifetime (2010 - 2012 data). &#160;The prevalence of endometrial cancer in the U.S. is about </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">620,000</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;women, and the five-year survivorship for women with endometrial cancer is </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">81.7%</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">.&#160;</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><br><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;font-weight:bold;" href="#s0623A29E3C735937B2D2F4207223A852"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Table of Contents</font></a></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#00497f;font-weight:bold;">GALENA BIOPHARMA, INC.</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#00497f;font-weight:bold;">NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS - Continued</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#00497f;font-weight:bold;">(Unaudited)</font></div></div><br><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#006ebf;font-weight:bold;text-decoration:underline;">Hematology</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:32px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#006ebf;font-style:italic;font-weight:bold;">GALE-401 (anagrelide controlled release (CR))</font></div><div style="line-height:120%;text-align:left;padding-left:32px;text-indent:66px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:66px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">In January 2014, we announced the acquisition of the worldwide rights to anagrelide controlled release (CR), which we renamed GALE-401, through our acquisition of Mills Pharmaceuticals, LLC. GALE-401 contains the active ingredient anagrelide, an FDA-approved product, for the treatment of patients with myeloproliferative neoplasms (MPNs) to lower abnormally elevated platelet levels. The currently available immediate release (IR) version of anagrelide causes adverse events that are believed to be dose and plasma concentration dependent. Therefore, reducing the maximum concentration (Cmax) is hypothesized to reduce the side effects, but preserve efficacy.</font></div><div style="line-height:120%;text-align:left;text-indent:66px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:66px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Multiple Phase 1 studies in </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">98</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;healthy subjects have shown GALE-401 reduces the Cmax of anagrelide following oral administration, appears to be well-tolerated at the doses administered, and to be capable of reducing platelet levels. The Phase 1 program provided the desired PK/PD (pharmacokinetic/pharmacodynamic) profile to enable the initiation of the ongoing Phase 2 proof-of-concept trial. The Phase 2, open label, single arm, proof-of-concept trial enrolled </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">18</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;patients in the United States for the treatment of thrombocytosis, or elevated platelet counts in patients with MPNs. Phase 2 top-line safety and efficacy data was presented in June 2015 at the European Hematology Association 20</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">th</sup></font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;Congress, and we expect to present a more mature data set at the 57th American Society of Hematology Annual Meeting in December 2015. Based on a regulatory meeting with the FDA, Galena believes a 505(b)(2) regulatory filing is an acceptable pathway for development and potential approval of GALE-401.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#006ebf;font-weight:bold;text-decoration:underline;">Strategic Review of Commercial Operations</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">During the quarter ended September 30, 2015, we completed a strategic review of the company&#8217;s commercial business including the ongoing sale, distribution and marketing of our two commercial products, Abstral</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">&#174;</sup></font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;(fentanyl) Sublingual Tablets and Zuplenz</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">&#174;</sup></font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;(ondansetron) Oral Soluble Film (our &#8220;commercial business&#8221; asset group). As a result of the review, we made a determination to sell or otherwise dispose of our commercial business.  </font></div><div style="line-height:120%;text-align:left;text-indent:66px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#006ebf;font-weight:bold;">Basis of Presentation and Significant Accounting Policies</font></div><div style="line-height:120%;text-indent:32px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-indent:66px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">The accompanying consolidated financial statements included herein have been prepared by Galena pursuant to the rules and regulations of the Securities and Exchange Commission (SEC). Unless the context otherwise indicates, references in these notes to the &#8220;company,&#8221; &#8220;we,&#8221; &#8220;us&#8221; or &#8220;our&#8221; refer to Galena, our wholly owned subsidiary, Apthera, Inc., or &#8220;Apthera,&#8221; and our wholly owned subsidiary, Mills Pharmaceuticals, LLC or "Mills."</font></div><div style="line-height:120%;text-indent:66px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;">Discontinued Operations - </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">As described in Note 12, we met the relevant criteria for reporting our commercial business as held for sale and in discontinued operations in the accompanying unaudited interim financial statements as of the three and nine month periods ended September&#160;30, 2015 and 2014, pursuant to FASB Topic 205-20, Presentation of Financial Statements - Discontinued Operations, and FASB Topic 360, Property, Plant, and Equipment.</font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;">Uses of Estimates in Preparation of Financial Statements</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;&#8212; The preparation of these consolidated financial statements in accordance with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the reporting period. Actual results could differ materially from those estimates.</font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;">Principles of Consolidation</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;&#8212;&#160;The consolidated financial statements include the accounts of Galena and its wholly owned subsidiaries. All material intercompany accounts have been eliminated in consolidation.</font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;">Reclassifications</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;&#8212; Certain prior year amounts have been reclassified to conform to current year presentation. These reclassifications had no effect on net loss per share.</font></div><br><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;font-weight:bold;" href="#s0623A29E3C735937B2D2F4207223A852"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Table of Contents</font></a></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#00497f;font-weight:bold;">GALENA BIOPHARMA, INC.</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#00497f;font-weight:bold;">NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS - Continued</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#00497f;font-weight:bold;">(Unaudited)</font></div></div><br><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;">Cash and Cash Equivalents</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;&#8212; The company considers all highly liquid debt instruments with an original maturity of </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">90</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;days&#160;or less to be cash equivalents. Cash equivalents consist primarily of amounts invested in money market accounts and demand deposits.</font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;">Restricted Cash</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;&#8212; Restricted cash consists of certificates of deposit on hand with the company&#8217;s financial institutions as collateral for its corporate credit cards.</font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;">Fair Value of Financial Instruments</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;&#8212; The carrying amounts reported in the balance sheet for cash equivalents, accounts receivable, accounts payable, and capital leases approximate their fair values due to their short-term nature and market rates of interest.</font></div><div style="line-height:120%;text-indent:66px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-indent:66px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;">Equipment and Furnishings</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;&#8212; Equipment and furnishings are stated at cost and depreciated using the straight-line method based on the estimated useful lives (generally </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">three</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;to </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">five</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;years) of the related assets.</font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:8px;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;">Goodwill and Intangible Assets</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;&#8212; Goodwill and indefinite-lived intangible assets are not amortized but are tested annually for impairment at the reporting unit level, or more frequently if events and circumstances indicate impairment may have occurred. Factors the company considers important that could trigger an interim review for impairment include, but are not limited to, the following:</font></div><div style="line-height:120%;padding-left:67px;padding-bottom:8px;text-align:left;"><font style="padding-bottom:8px;text-align:left;font-family:Helvetica,sans-serif;font-size:10pt;padding-right:28px;">&#8226;</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Significant changes in the manner of its use of acquired assets or the strategy for its overall business;</font></div><div style="line-height:120%;padding-left:67px;padding-bottom:8px;text-align:left;"><font style="padding-bottom:8px;text-align:left;font-family:Helvetica,sans-serif;font-size:10pt;padding-right:28px;">&#8226;</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Significant negative industry or economic trends;</font></div><div style="line-height:120%;padding-left:67px;padding-bottom:8px;text-align:left;"><font style="padding-bottom:8px;text-align:left;font-family:Helvetica,sans-serif;font-size:10pt;padding-right:28px;">&#8226;</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Significant decline in stock price for a sustained period; and</font></div><div style="line-height:120%;padding-left:67px;text-align:left;"><font style="text-align:left;font-family:Helvetica,sans-serif;font-size:10pt;padding-right:28px;">&#8226;</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Significant decline in market capitalization relative to net book value.</font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Goodwill and other intangible assets with indefinite lives are evaluated for impairment first by a qualitative assessment to determine the likelihood of impairment. If it is determined that impairment is more likely than not, the company will then proceed to the two step impairment test. The first step is to compare the fair value of the reporting unit to the carrying amount of the reporting unit. If the carrying amount exceeds the fair value, a second step must be followed to calculate impairment. Otherwise, if the fair value of the reporting unit exceeds the carrying amount, the goodwill is not considered to be impaired as of the measurement date. In its review of the carrying value of the goodwill for its single reporting unit and its indefinite-lived intangible assets, the company determines fair values of its goodwill using the market approach, and its indefinite-lived intangible assets using the income approach.</font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-indent:66px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Intangible assets not considered indefinite-lived are reviewed for impairment when facts or circumstances suggest that the carrying value of these assets may not be recoverable. The company&#8217;s policy is to identify and record impairment losses, if necessary, on intangible assets when events and circumstances indicate that the assets might be impaired and the undiscounted cash flows estimated to be generated by those assets are less than the carrying amounts.</font></div><div style="line-height:120%;text-indent:66px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-indent:66px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">The company performed its review for impairment using the qualitative assessment for both goodwill and indefinite-lived intangible assets, as well as assets not considered to be indefinite-lived, and has determined that there has been no impairment to these assets as of </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">September&#160;30, 2015</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">.</font></div><div style="line-height:120%;text-indent:66px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><br><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;font-weight:bold;" href="#s0623A29E3C735937B2D2F4207223A852"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Table of Contents</font></a></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#00497f;font-weight:bold;">GALENA BIOPHARMA, INC.</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#00497f;font-weight:bold;">NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS - Continued</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#00497f;font-weight:bold;">(Unaudited)</font></div></div><br><div style="line-height:120%;text-indent:66px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;">Assets Held for Sale </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">- The company generally considers assets to be held for sale when (i) when the transaction has been approved by the board of directors or management vested with authority to approve the transaction, (ii) the assets are available for immediate sale in their present condition, (iii) the company has initiated an active program to locate a buyer and other actions required to complete the plan to sell the assets, (iv) consummation of the transaction is probable, (v) the assets are being actively marketing for sale at a price that is reasonable in relation to the current fair value, and (vi) the transaction is expected to qualify for recognition as a completed sale, within one year. Following the classification of property and equipment for sale, the company discontinues depreciating the asset and writes down the asset to the lower of the carrying value or fair market value, if needed. As described in Note 12, actions taken by the company's management vested with the board of directors' authority caused the company to meet the relevant criteria for reporting the commercial operations as held for sale.</font></div><div style="line-height:120%;text-indent:32px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-indent:66px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;">Acquisitions and In-Licensing &#8212;</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;For all in-licensed products and technologies, we perform an analysis to determine whether we hold a variable interest or a controlling financial interest in a variable interest entity. On the basis of our interpretations and conclusions, we determine whether the acquisition falls under the purview of variable interest entity accounting and if so, consider the necessity to consolidate the acquisition. As of </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">September&#160;30, 2015</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">, we determined there were no variable interest entities required to be consolidated.</font></div><div style="line-height:120%;text-indent:32px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-indent:66px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">We also perform an analysis to determine if the assets and liabilities acquired in an acquisition qualify as a "business." The excess of the purchase price over the fair value of the net assets acquired can only be recognized as goodwill in a business combination. The Company completes its valuation analysis no later than twelve months from the date of the acquisition.</font></div><div style="line-height:120%;text-indent:32px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;">Contingent Purchase Price Consideration</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;&#8212; Contingent consideration in business combinations is recorded at the estimated fair value as of the acquisition date. The fair value of the contingent consideration is re-measured at each reporting period with any adjustments in fair value included in our consolidated statement of comprehensive loss.</font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;">Patents and Patent Application Costs</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;&#8212; Although the company believes that its patents and underlying technology have continuing value, the amount of future benefits to be derived from the patents is uncertain. Patent costs are, therefore, expensed as incurred.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;">Share-based Compensation</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;&#8212; The company follows the provisions of the FASB ASC Topic 718, &#8220;</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;">Compensation&#160;&#8212; Stock Compensation&#8221;</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;(&#8220;ASC 718&#8221;), which requires the measurement and recognition of compensation expense for all stock-based payment awards made to employees, non-employee directors, and consultants, including stock options and warrants. Stock compensation expense based on the grant date fair value estimated in accordance with the provisions of ASC&#160;718 is recognized as an expense over the requisite service period.</font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">For stock options and warrants granted as consideration for services rendered by non-employees, the company recognizes compensation expense in accordance with the requirements of FASB ASC Topic 505-50 (&#8220;ASC 505-50&#8221;), &#8220; </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;">Equity Based Payments to Non- Employees</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">.&#8221; Non-employee option and warrant grants that do not vest immediately upon grant are recorded as an expense over the vesting period. At the end of each financial reporting period prior to vesting, the value of these options and warrants, as calculated using the Black-Scholes option-pricing model, is re-measured using the fair value of the company&#8217;s common stock and the non-cash compensation recognized during the period is adjusted accordingly. Since the fair market value of options and warrants granted to non-employees is subject to change in the future, the amount of the future compensation expense will include fair value re-measurements until the stock options are fully vested.</font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;">Research and Development Expenses</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;&#8212; Research and development costs are expensed as incurred. Included in research and development costs are wages, benefits and other operating costs, facilities, supplies, external services and overhead related to our research and development departments, and clinical trial expenses.</font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><br><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">11</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;font-weight:bold;" href="#s0623A29E3C735937B2D2F4207223A852"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Table of Contents</font></a></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#00497f;font-weight:bold;">GALENA BIOPHARMA, INC.</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#00497f;font-weight:bold;">NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS - Continued</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#00497f;font-weight:bold;">(Unaudited)</font></div></div><br><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Clinical trial expenses include direct costs associated with contract research organizations (CROs), as well as patient-related costs at sites at which our trials are being conducted.</font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Direct costs associated with our CROs are generally payable on a time and materials basis, or when certain enrollment and monitoring milestones are achieved. Expense related to a milestone is recognized in the period in which the milestone is achieved or in which we determine that it is more likely than not that it will be achieved.</font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">The invoicing from clinical trial sites can lag several months. We accrue these site costs based on our estimate of upfront set-up costs upon the screening of the first patient at each site, and the patient related costs based on our knowledge of patient enrollment status at each site.</font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;">Income Taxes</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;&#8212; The company recognizes liabilities or assets for the deferred tax consequences of temporary differences between the tax basis of assets or liabilities and their reported amounts in the financial statements in accordance with FASB ASC&#160;740-10, &#8220;</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;">Accounting for Income Taxes&#8221; (&#8220;ASC 740-10&#8221;).</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;These temporary differences will result in taxable or deductible amounts in future years when the reported amounts of the assets or liabilities are recovered or settled. </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;">ASC 740-10</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;requires that a valuation allowance be established when management determines that it is more likely than not that all or a portion of a deferred asset will not be realized. The company evaluates the realizability of its net deferred income tax assets and valuation allowances as necessary, at least on an annual basis. During this evaluation, the company reviews its forecasts of income in conjunction with other positive and negative evidence surrounding the realizability of its deferred income tax assets to determine if a valuation allowance is required. Adjustments to the valuation allowance will increase or decrease the company&#8217;s income tax provision or benefit. The recognition and measurement of benefits related to the company&#8217;s tax positions requires significant judgment, as uncertainties often exist with respect to new laws, new interpretations of existing laws, and rulings by taxing authorities. Differences between actual results and the company&#8217;s assumptions or changes in the company&#8217;s assumptions in future periods are recorded in the period they become known.</font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-indent:66px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">There was no income tax expense or benefit for the three and nine months periods ended </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">September&#160;30, 2015</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;and 2014. We continue to maintain a full valuation allowance against our net deferred tax assets.</font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;">Concentrations of Credit Risk</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;&#8212; Financial instruments that potentially subject the company to significant concentrations of credit risk consist principally of cash and cash equivalents. The company maintains cash balances in several accounts with two banks, which at times are in excess of federally insured limits. As of </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">September&#160;30, 2015</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">, the company&#8217;s cash equivalents were invested in money market mutual funds. The company&#8217;s investment policy does not allow investment in any debt securities rated less than &#8220;investment grade&#8221; by national ratings services. The company has not experienced any losses on its deposits of cash and cash equivalents. The company maintains significant cash and cash equivalents at two financial institutions that are in excess of federally insured limits.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;">Comprehensive Loss</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;&#8212; Comprehensive loss consists of our net loss, with no other comprehensive income items for the periods presented.</font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><br><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">12</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;font-weight:bold;" href="#s0623A29E3C735937B2D2F4207223A852"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Table of Contents</font></a></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#00497f;font-weight:bold;">GALENA BIOPHARMA, INC.</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#00497f;font-weight:bold;">NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS - Continued</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#00497f;font-weight:bold;">(Unaudited)</font></div></div><br><div style="line-height:120%;text-align:left;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;text-decoration:underline;">Effect of Recent Accounting Pronouncements</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;</font></div><div style="line-height:120%;text-align:left;text-indent:65px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">In April 2014, the FASB issued ASU 2014-08, Reporting Discontinued Operations and Disclosures of Disposals of Components of an Entity, or ASU 2014-08. Under ASU 2014-08, only disposals representing a strategic shift in operations that have a major effect on the company&#8217;s operations and financial results should be presented as discontinued operations. Additionally, ASU 2014-08 requires expanded disclosures about discontinued operations that will provide financial statement users with more information about the assets, liabilities, income, and expenses of discontinued operations. The amendments in ASU 2014-08 are effective for fiscal years, and interim periods within those years, beginning after December 15, 2014. The company adopted this guidance in the first quarter of 2015 and has applied it in the accompanying interim financial statements for presentation and disclosure of the commercial business as discontinued operations (see Note 12). </font></div><div style="line-height:120%;text-align:left;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">In May 2014, the FASB issued ASU No.&#160;2014-09,&#160;Revenue from Contracts with Customers: Topic 606,&#160;or ASU 2014-09. ASU 2014-09 establishes the principles for recognizing revenue and develops a common revenue standard for U.S. GAAP. The standard outlines a single comprehensive model for entities to use in accounting for revenue arising from contracts with customers and supersedes most current revenue recognition guidance, including industry-specific guidance. In applying the new revenue recognition model to contracts with customers, an entity: (1) identifies the contract(s) with a customer; (2) identifies the performance obligations in the contract(s); (3) determines the transaction price; (4) allocates the transaction price to the performance obligations in the contract(s); and (5) recognizes revenue when (or as) the entity satisfies a performance obligation.&#160;The accounting standards update applies to all contracts with customers except those that are within the scope of other topics in the FASB Accounting Standards Codification.&#160;The accounting standards update also requires significantly expanded quantitative and qualitative disclosures regarding the nature, amount, timing and uncertainty of revenue and cash flows arising from contracts with customers.&#160;This guidance is effective for fiscal years and interim periods within those years beginning after December 15, 2016, which is effective for the company for the year ending December 31, 2017. The FASB delayed in the effective date of the accounting standards update to fiscal years and interim periods within those years beginning on or after December 15, 2017, which is pending approval.&#160;The company is currently evaluating the impact that the implementation of ASU 2014-09 will have on the company&#8217;s financial statements. </font></div><div style="line-height:120%;text-align:left;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">In August 2014, the FASB issued ASU No. 2014-15,&#160;Disclosure of Uncertainties about an Entity&#8217;s Ability to Continue as a Going Concern, or ASU 2014-15. ASU 2014-15 will explicitly require management to assess an entity&#8217;s ability to continue as a going concern, and to provide related footnote disclosure in certain circumstances. The new standard will be effective for all entities in the first annual period ending after December 15, 2016. Earlier adoption is permitted. The company is not early adopting ASU 2014-15. The company is currently evaluating the impact that the implementation of ASU 2014-15 will have on the company&#8217;s financial statements, and the actual impact will be dependent upon the company&#8217;s liquidity and the nature or significance of future events or conditions that exist upon adopting the updated standard.</font></div><div style="line-height:120%;text-align:left;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">In January 2015, the FASB issued ASU No. 2015-01, Simplifying Income Statement Presentation by Eliminating the Concept of Extraordinary Items, or ASU 2015-01.&#160;ASU 2015-01 eliminates from GAAP the concept of extraordinary items. ASU 2015-01 is effective for fiscal years and interim periods beginning after December 15, 2015. Early adoption is permitted. The company does not expect that the adoption of ASU 2015-01 will have a material impact on its consolidated financial statements.</font></div><div style="line-height:120%;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;"><br></font></div><br><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">13</font></div></div><hr style="page-break-after:always"><a name="s51477A928E33569BB8A4477FF1C67AFF"></a><div><div style="line-height:120%;text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;font-weight:bold;" href="#s0623A29E3C735937B2D2F4207223A852"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Table of Contents</font></a></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#00497f;font-weight:bold;">GALENA BIOPHARMA, INC.</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#00497f;font-weight:bold;">NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS - Continued</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#00497f;font-weight:bold;">(Unaudited)</font></div></div><br><div style="line-height:120%;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#00497f;font-weight:bold;">2.  Fair Value Measurements</font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:12px;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">The company follows ASC&#160;820, &#8220;Fair Value Measurements and Disclosures,&#8221; (&#8220;ASC 820&#8221;) for the company&#8217;s financial assets and liabilities that are re-measured and reported at fair value at each reporting period, and are re-measured and reported at fair value at least annually using a fair value hierarchy that is broken down into three levels. Level inputs are defined as follows:</font></div><div style="line-height:120%;padding-bottom:12px;padding-left:108px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Level&#160;1&#160;&#8212; quoted prices in active markets for identical assets or liabilities.</font></div><div style="line-height:120%;padding-bottom:12px;padding-left:108px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Level&#160;2&#160;&#8212; other significant observable inputs for the assets or liabilities through corroboration with market data at the measurement date.</font></div><div style="line-height:120%;padding-left:108px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Level&#160;3&#160;&#8212; significant unobservable inputs that reflect management&#8217;s best estimate of what market participants would use to price the assets or liabilities at the measurement date.</font></div><div style="line-height:120%;text-indent:106px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-indent:66px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">The company categorized its cash equivalents as Level&#160;1. The valuations for Level&#160;1 were determined based on a &#8220;market approach&#8221; using quoted prices in active markets for identical assets. Valuation of these assets does not require a significant degree of judgment. The company categorized its warrants potentially settleable in cash as Level&#160;2 inputs. The warrants are measured at market value on a recurring basis and are being marked to market each quarter-end until they are completely settled. The warrants are valued using an appropriate pricing model, using assumptions consistent with our application of ASC&#160;718. The contingent purchase price consideration is categorized as Level 3 inputs and is measured at its estimated fair value on a recurring basis and is adjusted at each quarter-end until it is completely settled. The contingent purchase price consideration is valued based on the expected timing of milestones, the expected probability of success for each milestone and discount rates based on a corporate debt interest rate index publicly issued.</font></div><div style="line-height:120%;text-indent:66px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-indent:66px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">As discussed in Note 12, the Company met the relevant criteria for reporting the commercial operations as held for sale as of September 30, 2015, and as a result, assessed the commercial asset group for impairment pursuant to ASC Topic 360, </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;">Property, Plant, and Equipment.</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;The net carrying value of the commercial asset group was compared to its fair value as of September 30, 2105. The Company determined that the fair value using a risk adjusted net present value of deal consideration received from bids from potential acquirers, which the Company concluded was a Level 3 input. The Company determined that the carrying value exceeded its fair value and as a result recorded an $8.1 million impairment charge on assets classified as held for sale in the quarterly period ended September 30, 2015.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-indent:66px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">The following tables present information about our assets and liabilities measured at fair value on a recurring basis in the condensed consolidated balance sheets (in thousands):</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">&#160;</font><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"></td></tr><tr><td width="41%"></td><td width="1%"></td><td width="12%"></td><td width="1%"></td><td width="1%"></td><td width="1%"></td><td width="12%"></td><td width="1%"></td><td width="1%"></td><td width="1%"></td><td width="12%"></td><td width="1%"></td><td width="1%"></td><td width="1%"></td><td width="12%"></td><td width="1%"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;font-weight:bold;text-decoration:underline;">Description</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">September&#160;30, 2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Quoted&#160;Prices&#160;In&#160;&#160;&#160;&#160;</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Active Markets</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">(Level 1)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Significant&#160;Other</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Observable&#160;</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Inputs (Level 2)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Unobservable&#160;</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Inputs</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">(Level 3)</font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Assets:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Cash equivalents</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">32,618</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">32,618</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Assets held for sale</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">17,801</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">17,801</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:middle;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Total assets measured and recorded at fair value</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">50,419</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">32,618</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">17,801</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Liabilities:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Warrants potentially settleable in cash</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">16,661</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">16,661</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Contingent purchase price consideration</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">6,582</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">6,582</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:middle;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Total liabilities measured and recorded at fair value</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">23,243</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">16,661</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">6,582</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><br><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">14</font></div></div><hr style="page-break-after:always"><a name="s51477A928E33569BB8A4477FF1C67AFF"></a><div><div style="line-height:120%;text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;font-weight:bold;" href="#s0623A29E3C735937B2D2F4207223A852"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Table of Contents</font></a></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#00497f;font-weight:bold;">GALENA BIOPHARMA, INC.</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#00497f;font-weight:bold;">NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS - Continued</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#00497f;font-weight:bold;">(Unaudited)</font></div></div><br><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"></td></tr><tr><td width="41%"></td><td width="1%"></td><td width="12%"></td><td width="1%"></td><td width="1%"></td><td width="1%"></td><td width="12%"></td><td width="1%"></td><td width="1%"></td><td width="1%"></td><td width="12%"></td><td width="1%"></td><td width="1%"></td><td width="1%"></td><td width="12%"></td><td width="1%"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;font-weight:bold;text-decoration:underline;">Description</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">December&#160;31, 2014</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Quoted&#160;Prices&#160;In&#160;&#160;&#160;&#160;</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Active Markets</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">(Level 1)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Significant&#160;Other</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Observable&#160;</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Inputs (Level 2)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Unobservable&#160;</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Inputs</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">(Level 3)</font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Assets:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Cash equivalents</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">19,477</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">19,477</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Total assets measured and recorded at fair value</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">19,477</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">19,477</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Liabilities:</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Warrants potentially settleable in cash</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">5,383</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">5,383</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Contingent purchase price consideration</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">6,651</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">6,651</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Total liabilities measured and recorded at fair value</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">12,034</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">5,383</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">6,651</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">The company did not transfer any financial instruments into or out of Level 3 classification during the three and nine months ended </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">September&#160;30, 2015</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;or 2014. A reconciliation of the beginning and ending Level 3 liabilities for the nine months ended </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">September&#160;30, 2015</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;is as follows (in thousands):</font></div><div style="line-height:120%;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">&#160;</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"></td></tr><tr><td width="86%"></td><td width="1%"></td><td width="12%"></td><td width="1%"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Fair Value</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Measurements</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Using&#160;Significant</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Unobservable</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Inputs</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">(Level 3)</font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Balance, January&#160;1, 2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">6,651</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Change in the estimated fair value of the contingent purchase price consideration</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(69</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Balance at September&#160;30, 2015</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">6,582</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">The fair value of the contingent purchase price consideration is measured at the end of each reporting period using Level 3 inputs in a probability-weighted, discounted cash-outflow model. The significant unobservable assumptions include the probability of achieving each milestone, the date we expect to reach the milestone, and a determination of present value factors used to discount future expected cash outflows. </font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><a name="s5FED8D70326A59ADB458158231801EE9"></a><div style="line-height:120%;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#00497f;font-weight:bold;">3.  Accrued Expenses and Other Current Liabilities</font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-indent:66px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Accrued expenses and other current liabilities consist of the following (in thousands):</font></div><div style="line-height:120%;text-indent:66px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"></td></tr><tr><td width="71%"></td><td width="1%"></td><td width="12%"></td><td width="1%"></td><td width="1%"></td><td width="1%"></td><td width="12%"></td><td width="1%"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">September&#160;30, 2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">December&#160;31, 2014</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Clinical trial costs</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">5,179</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">6,967</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Compensation and related benefits</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">992</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">1,040</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Professional fees</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">1,121</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">821</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Interest expense</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">37</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">57</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Accrued expenses and other current liabilities</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">7,329</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">8,885</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><a name="s0DDC0E0EAB0C5822970967F71FEFEA1A"></a><div style="line-height:120%;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#00497f;font-weight:bold;">4.  Long-term Debt</font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-indent:66px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">On May 8, 2013 we entered into a loan and security agreement with Oxford Finance LLC, as collateral agent, and related lenders under which we borrowed the first tranche of </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$10 million</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;(the "Loan"). The Loan payment terms include </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">12</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;months of interest-only payments at the fixed coupon rate of </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">8.45%</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">, followed by </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">30</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;months of amortization of principal and interest until maturity in November 2016. In connection with the Loan, we paid the lender a </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">1%</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;cash facility fee and a </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">5.5%</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;cash final payment and granted to the lenders </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">seven</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">-year warrants to purchase up to </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">182,186</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;shares of our common stock at an exercise price of </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$2.47</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">, which equaled a </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">20</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">-day average market price of our common stock prior to the date of the grant.</font></div><br><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">15</font></div></div><hr style="page-break-after:always"><a name="sF65D59C677DE5904B813A95EA9E7CB47"></a><div><div style="line-height:120%;text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;font-weight:bold;" href="#s0623A29E3C735937B2D2F4207223A852"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Table of Contents</font></a></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#00497f;font-weight:bold;">GALENA BIOPHARMA, INC.</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#00497f;font-weight:bold;">NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS - Continued</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#00497f;font-weight:bold;">(Unaudited)</font></div></div><br><div style="line-height:120%;padding-bottom:12px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#00497f;font-weight:bold;">5. Legal Proceedings, Commitments and Contingencies</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;">Legal Proceedings</font></div><div style="line-height:120%;text-align:left;text-indent:65px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;">In re Galena Biopharma, Inc. Securities Litigation and In Re Galena Biopharma, Inc. Derivative Litigation</font></div><div style="line-height:120%;text-align:left;padding-left:48px;text-indent:65px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">On August 4, 2015, plaintiffs in the voluntarily dismissed Delaware derivative action have filed a motion seeking to file under seal a derivative complaint in the District Court.  That motion was granted and on August 31, 2015, that action was consolidated with </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;">In Re Galena Biopharma, Inc. Derivative Litigation</font><font style="font-family:inherit;font-size:10pt;">.</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">On or about September 15, 2015, a federal securities lawsuit was filed in the U.S. District Court for the District of Oregon entitled, </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;">Riley v. Galena Biopharma, Inc., et al</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">.  The time to answer or otherwise plead has been extended by agreement of the parties.</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">We intend to vigorously defend against and seek resolution to the foregoing claims.  As of September 30, 2015, we have not recorded any</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-weight:bold;">&#32;</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">liabilities with respect to the claims in our consolidated financial statements.  We believe that claims are covered under our liability insurance, and we have notified our insurance carriers of the claims.  The insurers have responded by requesting additional information and by reserving their rights under the policies, including the rights to deny coverage under various policy exclusions.  Subject to their reservation of rights, we are being reimbursed by our insurance carriers for significant portion of all legal fees relating to our defense of the claims. We have entered into certain undertaking agreements with our directors related to the litigation by which we have agreed to advance reasonable legal fees and costs for the litigation under certain conditions.</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;">SEC Investigation</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">We are aware that the Securities and Exchange Commission (SEC) is investigating certain matters relating to the use of certain outside investor-relations professionals by us and other public companies.  We have been in contact with the SEC staff through our counsel and are cooperating with the investigation.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;">ANDA Litigation</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;On October 23, 2015, Orexo AB (&#8220;Orexo&#8221;) and Galena Biopharma, Inc. (the &#8220;Company&#8221;) entered into a settlement and license agreement with Actavis Laboratories FL, Inc. (&#8220;Actavis&#8221;) to resolve pending patent litigation brought by the Orexo against Actavis involving Abstral&#174; (fentanyl) sublingual tablets.  The pending patent litigation was filed by Orexo in the U.S. District Court for the District of New Jersey in response to Actavis&#8217; submission of an Abbreviated New Drug Application (&#8220;ANDA&#8221;) to the U.S. Food and Drug Administration (&#8220;FDA&#8221;), seeking marketing approval for a generic version of Abstral.  As a result of the settlement and license agreement, Actavis will be permitted to enter the market with a generic or authorized generic version of Abstral in the United States June 2018 or earlier under certain circumstances. The Court has entered an order dismissing with prejudice the litigation against Actavis.  Details of the settlement are confidential, and the parties have submited the agreement to the Federal Trade Commission and the Department of Justice, as required by federal law. The expiration date for the latest expiring Abstral patent listed in the FDA&#8217;s Orange Book is September 2019.</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;">Commitments</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">The company acquires assets still in development and enters into research and development arrangements with third parties that often require milestone and royalty payments based on the progress of the asset through development stages. Milestone payments may be required, for example, upon approval of the product for marketing by a regulatory agency. In certain agreements, the company is required to make royalty payments based upon a percentage of the sales.</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">These arrangements may be material individually, and in the unlikely event that milestones for multiple products covered by these arrangements were reached in the same period, the aggregate charge to expense could be material to the results of operations. In addition, these arrangements often give the company the discretion to unilaterally terminate development of the product, which the company might do for clinical, business or other reasons, which would allow the company to avoid making the contingent payments.</font></div><br><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">16</font></div></div><hr style="page-break-after:always"><a name="sF65D59C677DE5904B813A95EA9E7CB47"></a><div><div style="line-height:120%;text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;font-weight:bold;" href="#s0623A29E3C735937B2D2F4207223A852"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Table of Contents</font></a></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#00497f;font-weight:bold;">GALENA BIOPHARMA, INC.</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#00497f;font-weight:bold;">NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS - Continued</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#00497f;font-weight:bold;">(Unaudited)</font></div></div><br><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">The company applies the disclosure provisions FASB ASC Topic 460 (&#8220;ASC 460&#8221;), &#8220; </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;">Guarantor&#8217;s Accounting and Disclosure Requirements for Guarantees, Including Indirect Guarantees of Indebtedness of Others</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;&#8221;, to its agreements that contain guarantee or indemnification clauses. The company provides (i)&#160;indemnifications of varying scope and size to certain investors and other parties for certain losses suffered or incurred by the indemnified party in connection with various types of third-party claims and (ii)&#160;indemnifications of varying scope and size to officers and directors against third party claims arising from the services they provide to us. These indemnifications give rise only to the disclosure provisions of ASC&#160;460. To date, the company has not incurred costs as a result of these obligations and does not expect to incur material costs in the future. Accordingly, the company has not accrued any liabilities in its financial statements related to these indemnifications.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><a name="sDDFE3AB118D55E9C9895F4190A891668"></a><div style="line-height:120%;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#00497f;font-weight:bold;">6.  Stockholders&#8217; Equity</font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;">Preferred Stock</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;&#8212; The company has authorized up to </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">5,000,000</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#160;shares of preferred stock, </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$0.0001</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#160;par value per share, for issuance. The preferred stock will have such rights, preferences, privileges and restrictions, including voting rights, dividend rights, conversion rights, redemption privileges and liquidation preferences, as shall be determined by the company&#8217;s Board of Directors upon its issuance. To date, the company has not issued any preferred shares.</font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;">Common Stock</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;&#8212; The company has authorized up to </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">275,000,000</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#160;shares of common stock, </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$0.0001</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#160;par value per share, for issuance.</font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;">November 2014 Purchase Agreement with Lincoln Park Capital, LLC - </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">On November 18, 2014, the company entered into a purchase agreement with Lincoln Park Capital, LLC (LPC), pursuant to which the company has the right to sell to LPC up to </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$50 million</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;in shares of the company's common stock, subject to certain limitations and conditions over the </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">36</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;month term of the purchase agreement. Pursuant to the purchase agreement, LPC initially purchased </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">2.5 million</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;shares of the company's common stock at </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$2.00</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;per share and the company issued </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">631,221</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;shares of common stock to LPC as a commitment fee, which was recorded as a cost of capital. As a result of this initial issuance, the company received initial net proceeds of </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$4.9 million</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">, after deducting commissions and other offering expenses. In addition to LPC&#8217;s initial purchase of our common stock under the purchase agreement, during the first quarter of 2015, we received net proceeds of </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$4.4 million</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;from LPC&#8217;s subsequent purchases of a total of </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">2.7 million</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;shares of our common stock, excluding the commitment fee shares. </font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;">At Market Issuance Sales Agreements </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">- On May 24, 2013 the Company entered into At Market Issuance Sales Agreements (ATM) with MLV &amp; Co. LLC and Maxim Group LLC (the Agents). From time to time during the term of the ATM, we may issue and sell through the Agents, shares of our common stock, and the Agents collect a fee equal to </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">3%</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;of the gross proceeds from the sale of shares, up to a total limit of </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$20 million</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;in gross proceeds. The ATM is available to the company until it is terminated by the Agents or the company. During the first quarter of 2015, we received </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$2.3 million</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;in net proceeds from the sale of </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">1.4 million</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;shares of our common stock through the ATM. There were no sales of our common stock under the ATM during the three months ended September 30, 2015 or during the three and nine months ended September 30, 2014.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;">March 2015 Underwritten Public Offering</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;- On March 18, 2015 the company closed an underwritten public offering of </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">24,358,974</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;units at a price to the public of </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$1.56</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;per unit for gross proceeds of </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$38 million</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;(the "March 2015 Offering"). Each unit consists of one share of common stock, and a warrant to purchase </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">0.50</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;of a share of common stock at an exercise price of </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$2.08</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;per share. The March 2015 Offering included an over-allotment option for the underwriters to purchase an additional </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">3,653,846</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;shares of common stock and/or warrants to purchase up to </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">1,826,923</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;shares of common stock. On March 18, 2015, the underwriters exercised their over-allotment option to purchase warrants to purchase an aggregate of </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">1,826,923</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;shares of common stock. On April 10, 2015, the underwriters exercised their over-allotment option to purchase </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">3,653,846</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;shares of common stock for additional net proceeds of </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$5.4 million</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">. The total net proceeds of the March 2015 Offering, including the exercise of the over-allotment option to purchase the warrants, were </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$40.8 million</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">, after deducting underwriting discounts and commissions and offering expenses payable by the company. </font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><br><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">17</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;font-weight:bold;" href="#s0623A29E3C735937B2D2F4207223A852"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Table of Contents</font></a></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#00497f;font-weight:bold;">GALENA BIOPHARMA, INC.</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#00497f;font-weight:bold;">NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS - Continued</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#00497f;font-weight:bold;">(Unaudited)</font></div></div><br><div style="line-height:120%;text-indent:66px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Shares of common stock for future issuance are reserved for as follows (in thousands):</font></div><div style="line-height:120%;text-indent:66px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td width="84%"></td><td width="15%"></td><td width="1%"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">As of September&#160;30, 2015</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Warrants outstanding</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">22,308</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Stock options outstanding</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">11,188</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Options reserved for future issuance under the Company&#8217;s 2007 Incentive Plan</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">10,251</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Shares reserved for future issuance under the Employee Stock Purchase Plan</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">528</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Total reserved for future issuance</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">44,275</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><a name="s4AC19B3E41C754A2B4604175BA82FF6A"></a><div style="line-height:120%;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#00497f;font-weight:bold;">7.  Warrants</font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">The following is a summary of warrant activity for the nine months ended </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">September&#160;30, 2015</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;(in thousands):</font></div><div style="line-height:120%;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">&#160;</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="24"></td></tr><tr><td width="21%"></td><td width="8%"></td><td width="1%"></td><td width="1%"></td><td width="8%"></td><td width="1%"></td><td width="1%"></td><td width="8%"></td><td width="1%"></td><td width="1%"></td><td width="8%"></td><td width="1%"></td><td width="1%"></td><td width="8%"></td><td width="1%"></td><td width="1%"></td><td width="8%"></td><td width="1%"></td><td width="1%"></td><td width="8%"></td><td width="1%"></td><td width="1%"></td><td width="8%"></td><td width="1%"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">March 2015 Warrants</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">September</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">2013</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Warrants</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">December</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">2012</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Warrants</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">April&#160;2011</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Warrants</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">March</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">2011</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Warrants</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">March</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">2010</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Warrants</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Consultant</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">and Oxford Warrants</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Total</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Outstanding, January 1, 2015</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">3,973</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">3,031</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">615</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">176</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">25</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">720</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">8,540</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Issued</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">14,006</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">14,006</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Expired</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">(238</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">(238</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Outstanding, September&#160;30, 2015</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">14,006</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">3,973</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">3,031</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">615</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">176</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">25</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">482</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">22,308</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Expiration</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">March 2020</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">September 2018</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">December 2017</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:3px double #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">April 2017</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">March 2016</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">March 2016</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Varies 2014-2020</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr></table></div></div><div style="line-height:120%;text-indent:66px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-indent:66px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Warrants consist of warrants potentially settleable in cash, which are liability-classified warrants, and equity-classified warrants.</font></div><div style="line-height:120%;text-indent:32px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-indent:66px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;">Warrants classified as liabilities</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-indent:66px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Liability-classified warrants consist of warrants to purchase common stock issued in connection with equity financings in March 2015, September 2013, December 2012,&#160;April 2011,&#160;March 2011,&#160;and March 2010. These warrants are potentially settleable in cash and were determined not to be indexed to our common stock.</font></div><div style="line-height:120%;text-indent:32px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-indent:66px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">The estimated fair value of outstanding warrants accounted for as liabilities is determined at each balance sheet date. Any decrease or increase in the estimated fair value of the warrant liability since the most recent balance sheet date is recorded in the condensed consolidated statement of comprehensive loss as other income (expense). The fair value of the warrants is estimated using an appropriate pricing model with the following inputs:</font></div><div style="line-height:120%;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">&#160;</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="24"></td></tr><tr><td width="23%"></td><td width="1%"></td><td width="10%"></td><td width="1%"></td><td width="1%"></td><td width="1%"></td><td width="10%"></td><td width="1%"></td><td width="1%"></td><td width="1%"></td><td width="10%"></td><td width="1%"></td><td width="1%"></td><td width="1%"></td><td width="10%"></td><td width="1%"></td><td width="1%"></td><td width="1%"></td><td width="10%"></td><td width="1%"></td><td width="1%"></td><td width="1%"></td><td width="10%"></td><td width="1%"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="23" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">As of September&#160;30, 2015</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">March 2015 Warrants</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">September</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">2013</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Warrants</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">December</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">2012</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Warrants</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">April&#160;2011</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Warrants</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">March</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">2011</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Warrants</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">March</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">2010</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Warrants</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">Strike price</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">2.08</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">2.50</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">1.83</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">0.65</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">0.65</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">2.02</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">Expected term (years)</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">4.47</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">2.97</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">2.23</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">1.56</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">0.43</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">0.49</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">Volatility %</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">74.99</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">76.85</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">75.45</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">69.48</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">72.42</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">68.33</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">%</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">Risk-free rate %</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">1.25</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">0.91</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">0.70</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">0.50</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">0.06</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">0.08</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">%</font></div></td></tr></table></div></div><div style="line-height:120%;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">&#160;</font></div><br><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">18</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;font-weight:bold;" href="#s0623A29E3C735937B2D2F4207223A852"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Table of Contents</font></a></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#00497f;font-weight:bold;">GALENA BIOPHARMA, INC.</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#00497f;font-weight:bold;">NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS - Continued</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#00497f;font-weight:bold;">(Unaudited)</font></div></div><br><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="20"></td></tr><tr><td width="36%"></td><td width="1%"></td><td width="10%"></td><td width="1%"></td><td width="1%"></td><td width="1%"></td><td width="10%"></td><td width="1%"></td><td width="1%"></td><td width="1%"></td><td width="10%"></td><td width="1%"></td><td width="1%"></td><td width="1%"></td><td width="10%"></td><td width="1%"></td><td width="1%"></td><td width="1%"></td><td width="10%"></td><td width="1%"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="19" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">As of December&#160;31, 2014</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">September</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">2013</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Warrants</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">December</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">2012</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Warrants</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">April&#160;2011</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Warrants</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">March</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">2011</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Warrants</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">March</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">2010</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Warrants</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">Strike price</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">2.50</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">1.90</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">0.65</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">0.65</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">2.15</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">Expected term (years)</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">3.72</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">2.98</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">2.31</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">1.18</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">1.24</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">Volatility %</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">75.60</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">76.85</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">78.24</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">77.38</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">77.12</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">%</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">Risk-free rate %</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">1.30</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">1.09</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">0.80</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">0.32</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">0.35</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">%</font></div></td></tr></table></div></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">The expected volatility assumptions are based on the company's implied volatility in combination with the implied volatilities of similar publicly traded entities. The expected life assumption is based on the remaining contractual terms of the warrants. The risk-free rate is based on the zero coupon rates in effect at the time of valuation. The dividend yield used in the pricing model is zero, because the company has no present intention to pay cash dividends.</font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">The changes in fair value of the warrant liability for the nine months ended </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">September&#160;30, 2015</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;were as follows (in thousands):</font></div><div style="line-height:120%;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">&#160;</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="28"></td></tr><tr><td width="24%"></td><td width="1%"></td><td width="8%"></td><td width="1%"></td><td width="1%"></td><td width="1%"></td><td width="8%"></td><td width="1%"></td><td width="1%"></td><td width="1%"></td><td width="8%"></td><td width="1%"></td><td width="1%"></td><td width="1%"></td><td width="8%"></td><td width="1%"></td><td width="1%"></td><td width="1%"></td><td width="8%"></td><td width="1%"></td><td width="1%"></td><td width="1%"></td><td width="8%"></td><td width="1%"></td><td width="1%"></td><td width="1%"></td><td width="8%"></td><td width="1%"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">March 2015 Warrants</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">September</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">2013</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Warrants</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">December</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">2012</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Warrants</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">April&#160;2011</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Warrants</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">March</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">2011</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Warrants</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">March</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">2010</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Warrants</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Total</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">Warrant liability, January&#160;1, 2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">2,560</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">2,027</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">625</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">163</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">8</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">5,383</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">Fair value of warrants issued</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">10,296</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">10,296</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">Change in fair value of warrants</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">1,313</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">(157</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">(162</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">(10</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">2</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">(4</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">982</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">Warrant liability, September&#160;30, 2015</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">11,609</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">2,403</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">1,865</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">615</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">165</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">4</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">16,661</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;">Warrants classified as equity</font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Equity-classified warrants consist of warrants issued in connection with consulting services provided to us. Additionally, on May 8, 2013 as a part of our Loan financing, we granted Oxford Financial LLC warrants to purchase up to </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">182,186</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;shares of common stock at an exercise price of </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$2.47</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">, which equaled to the </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">20</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">-day average market price of our common stock prior to the date of the grant. The warrants were valued using an appropriate pricing model as described in Note 9, below. The fair value assumptions for the grant included a volatility of </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">75.34%</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">, expected term of </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">seven</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;years, risk-free rate of </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">1.20%</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">, and a dividend rate of </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">0.00%</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">. The fair value of the warrants granted was </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$1.93</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;per share. These warrants are recorded in equity at fair value upon issuance, and not as liabilities, and are not subject to adjustment to fair value in subsequent reporting periods.</font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><br><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">19</font></div></div><hr style="page-break-after:always"><a name="s6310C5FE6F56532F9715FB1A60658A61"></a><div><div style="line-height:120%;text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;font-weight:bold;" href="#s0623A29E3C735937B2D2F4207223A852"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Table of Contents</font></a></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#00497f;font-weight:bold;">GALENA BIOPHARMA, INC.</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#00497f;font-weight:bold;">NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS - Continued</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#00497f;font-weight:bold;">(Unaudited)</font></div></div><br><div style="line-height:120%;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#00497f;font-weight:bold;">8.  Stock-Based Compensation</font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;">Options to Purchase Shares of Common Stock</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;&#8212; The company follows the provisions ASC&#160;718, which requires the measurement and recognition of compensation expense for all share-based payment awards made to employees, non-employee directors, including employee stock options. Stock compensation expense based on the grant date fair value estimated in accordance with the provisions of ASC&#160;718 is recognized as an expense over the requisite service period.</font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">For stock options and warrants granted in consideration for services rendered by non-employees, the company recognizes compensation expense in accordance with the requirements of ASC Topic 505-50. Non-employee option and warrant grants that do not vest immediately upon grant are recorded as an expense over the vesting period. At the end of each financial reporting period prior to vesting, the value of these options and warrants, as calculated using the Black-Scholes option-pricing model, is re-measured using the fair value of the company&#8217;s common stock and the non-cash compensation recognized during the period is adjusted accordingly. Since the fair market value of options and warrants granted to non-employees is subject to change in the future, the amount of the future compensation expense will include fair value re-measurements until the stock options and warrants are fully vested.</font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">The following table summarizes the components of stock-based compensation expense in the condensed consolidated statements of comprehensive loss for the three and nine months ended </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">September&#160;30, 2015</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;and 2014, respectively (in thousands):</font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"></td></tr><tr><td width="41%"></td><td width="1%"></td><td width="12%"></td><td width="1%"></td><td width="1%"></td><td width="1%"></td><td width="12%"></td><td width="1%"></td><td width="1%"></td><td width="1%"></td><td width="12%"></td><td width="1%"></td><td width="1%"></td><td width="1%"></td><td width="12%"></td><td width="1%"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Three Months Ended September 30,</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Nine Months Ended September 30,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">2014</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">2014</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Research and development</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">83</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">92</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">253</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">438</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">General and administrative</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">492</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">990</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">1,081</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">3,440</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Total stock-based compensation from continuing operations</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">575</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">1,082</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">1,334</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">3,878</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Stock based compensation from discontinued operations</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">275</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">217</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">788</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">557</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-indent:66px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">The company uses the Black-Scholes option-pricing model and the following weighted-average assumptions to determine the fair value of all its stock options granted:</font></div><div style="line-height:120%;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">&#160;</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12"></td></tr><tr><td width="41%"></td><td width="13%"></td><td width="1%"></td><td width="1%"></td><td width="13%"></td><td width="1%"></td><td width="1%"></td><td width="13%"></td><td width="1%"></td><td width="1%"></td><td width="13%"></td><td width="1%"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Three Months Ended September 30,</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Nine Months Ended September 30,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">2014</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">2014</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Risk free interest rate</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">2.02</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">1.50</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">2.02</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">%</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Volatility</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">79.10</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">74.20</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">79.47</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">%</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Expected lives (years)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">0.00</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">6.12</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">6.09</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">6.15</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Expected dividend yield</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">%</font></div></td></tr></table></div></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">The weighted-average fair value of options granted during the nine months ended </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">September&#160;30, 2015</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;was </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$1.14</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;per share. There were no stock options granted during the three months ended </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">September&#160;30, 2015</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">.</font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><br><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">20</font></div></div><hr style="page-break-after:always"><a name="s6310C5FE6F56532F9715FB1A60658A61"></a><div><div style="line-height:120%;text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;font-weight:bold;" href="#s0623A29E3C735937B2D2F4207223A852"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Table of Contents</font></a></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#00497f;font-weight:bold;">GALENA BIOPHARMA, INC.</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#00497f;font-weight:bold;">NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS - Continued</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#00497f;font-weight:bold;">(Unaudited)</font></div></div><br><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">The company&#8217;s expected common stock price volatility assumption is based upon the company's own implied volatility in combination with the implied volatility of a basket of comparable companies. The expected life assumptions for employee grants were based upon the simplified method provided for under ASC&#160;718-10, which averages the contractual term of the company&#8217;s options of </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">ten years</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;with the average vesting term of </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">four years</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;for an average of </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">six years</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">. The expected life assumptions for non-employees were based upon the contractual term of the option. The dividend yield assumption is zero, because the company has never paid cash dividends and presently has no intention to do so. The risk-free interest rate used for each grant was also based upon prevailing short-term interest rates. The company has estimated an annualized forfeiture rate of </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">15%</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;for options granted to its employees, </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">8%</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;for options granted to senior management and zero for non-employee directors. The company will record additional expense if the actual forfeitures are lower than estimated and will record a recovery of prior expense if the actual forfeiture rates are higher than estimated.</font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">As of </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">September&#160;30, 2015</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">, there was </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$4,815,000</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;of unrecognized compensation cost related to outstanding options that is expected to be recognized as a component of the company&#8217;s operating expenses over a weighted-average period of </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">2.34</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;years.</font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">As of </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">September&#160;30, 2015</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">, an aggregate of </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">26,500,000</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;shares of common stock were reserved for issuance under the company&#8217;s 2007 Incentive Plan, including </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">11,188,000</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;shares subject to outstanding common stock options granted under the plan and </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">10,251,000</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;shares available for future grants. The administrator of the plan determines the times when an option may become exercisable. Vesting periods of options granted to date have not exceeded </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">four years</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">. The options will expire, unless previously exercised, no later than </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">ten years</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;from the grant date. </font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">The following table summarizes option activity of the company:</font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="11"></td></tr><tr><td width="56%"></td><td width="13%"></td><td width="1%"></td><td width="1%"></td><td width="1%"></td><td width="12%"></td><td width="1%"></td><td width="1%"></td><td width="1%"></td><td width="12%"></td><td width="1%"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Total</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Number of</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Shares </font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">(In Thousands)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Weighted</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Average</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Exercise</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Price</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Aggregate</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Intrinsic</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Value</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">(In Thousands)</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Outstanding at January&#160;1, 2015</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">8,590</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">3.25</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Granted</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">3,682</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">1.73</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Exercised</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(39</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">0.79</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">37</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Cancelled</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(1,045</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">2.44</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">21</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Outstanding at September&#160;30, 2015</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">11,188</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">2.83</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">690</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Options exercisable at September&#160;30, 2015</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">6,622</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">3.32</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">618</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">The aggregate intrinsic values of outstanding and exercisable options at </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">September&#160;30, 2015</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;were calculated based on the closing price of the company&#8217;s common stock as reported on The NASDAQ Capital Market on </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">September&#160;30, 2015</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;of </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$1.58</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;per share. The aggregate intrinsic value equals the positive difference between the closing fair market value of the company&#8217;s common stock and the exercise price of the underlying options.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><a name="sE0ACECAD0D6558A7A743B29A66D56B01"></a><div style="line-height:120%;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#00497f;font-weight:bold;">9. Other Income (Expense)</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Other income (expense) is summarized as follows (in thousands):</font></div><div style="line-height:120%;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">&#160;</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"></td></tr><tr><td width="45%"></td><td width="1%"></td><td width="11%"></td><td width="1%"></td><td width="1%"></td><td width="1%"></td><td width="11%"></td><td width="1%"></td><td width="1%"></td><td width="1%"></td><td width="11%"></td><td width="1%"></td><td width="1%"></td><td width="1%"></td><td width="11%"></td><td width="1%"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Three Months Ended September 30,</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Nine Months Ended September 30,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">2014</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">2014</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Change in fair value of the contingent purchase price liability</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">307</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">597</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">69</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(59</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Total other income (expense)</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">307</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">597</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">69</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(59</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><br><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">21</font></div></div><hr style="page-break-after:always"><a name="s4656FE83A8575E8DBDBCBCFFC8AF8205"></a><div><div style="line-height:120%;text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;font-weight:bold;" href="#s0623A29E3C735937B2D2F4207223A852"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Table of Contents</font></a></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#00497f;font-weight:bold;">GALENA BIOPHARMA, INC.</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#00497f;font-weight:bold;">NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS - Continued</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#00497f;font-weight:bold;">(Unaudited)</font></div></div><br><div style="line-height:120%;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#00497f;font-weight:bold;">10.  Net Loss Per Share</font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">The company accounts for and discloses net loss per common share in accordance with FASB ASC Topic 260 &#8220;</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;">Earnings per Share.&#8221;</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;Basic net loss per common share is computed by dividing net loss attributable to common stockholders by the weighted-average number of common shares outstanding. Diluted net loss per common share is computed by dividing net loss attributable to common stockholders by the weighted-average number of common shares that would have been outstanding during the period assuming the issuance of common shares for all potential dilutive common shares outstanding. Potential common shares consist of shares issuable upon the exercise of stock options and warrants. </font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">The following table sets forth the potentially dilutive common shares excluded from the calculation of net loss per common share because their inclusion would be anti-dilutive (in thousands):</font></div><div style="line-height:120%;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">&#160;</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="6"></td></tr><tr><td width="67%"></td><td width="15%"></td><td width="1%"></td><td width="1%"></td><td width="15%"></td><td width="1%"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">&#160;Three and Nine Months Ended September 30,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">2014</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Warrants to purchase common stock</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">22,308</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">8,540</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Options to purchase common stock</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">11,188</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">8,994</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Total</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">33,496</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">17,534</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><a name="s6A58FE740AC05060A6E44E4A3F278172"></a><div style="line-height:120%;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#00497f;font-weight:bold;">11.  License Agreements</font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">As part of its business, the company enters into licensing agreements with third parties that often require milestone and royalty payments based on the progress of the licensed assets through development and commercial stages. Milestone payments may be required, for example, upon approval of the product for marketing by a regulatory agency, and the company may be required to make royalty payments based upon a percentage of net sales of the product. The expenditures required under these arrangements in any period may be material and are likely to fluctuate from period to period.</font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">These arrangements sometimes permit the company to unilaterally terminate development of the product and thereby avoid future contingent payments; however, the company is unlikely to cease development if the compound successfully achieves clinical testing objectives.</font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">In conjunction with the acquisition of NeuVax</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">TM</sup></font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">, the company acquired rights and assumed obligations under a license agreement among Apthera and The University of Texas M. D. Anderson Cancer Center (&#8220;MDACC&#8221;) and The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc. (&#8220;HJF&#8221;) which grants exclusive worldwide rights to a U.S. patent covering the nelipepimut-S peptide and several U.S. and foreign patents and patent applications covering methods of using the peptide as a vaccine. Under the terms of this license, we are required to pay an annual maintenance fee of </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$200,000</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">, a milestone payment of </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$200,000</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;upon commencing the Phase 3 PRESENT trial of NeuVax and other clinical milestone payments, as well as royalty payments based on sales of NeuVax or other therapeutic products developed from the licensed technologies. </font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Effective April 30, 2009, we entered into a license agreement with Kwangdong Pharmaceutical Co, Ltd (Kwangdong).  Under the agreement, we granted Kwangdong exclusive rights to seek marketing approval in The Republic of Korea (South Korea) for our NeuVax product candidate for the treatment of breast cancer following its approval by the FDA or the European Medicines Agency, and to market, sell and distribute NeuVax in South Korea assuming such approval is obtained. </font></div><br><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">22</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;font-weight:bold;" href="#s0623A29E3C735937B2D2F4207223A852"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Table of Contents</font></a></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#00497f;font-weight:bold;">GALENA BIOPHARMA, INC.</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#00497f;font-weight:bold;">NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS - Continued</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#00497f;font-weight:bold;">(Unaudited)</font></div></div><br><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Effective December&#160;3, 2012, we entered into a license and supply agreement with ABIC Marketing Limited, a subsidiary of Teva Pharmaceuticals (&#8220;ABIC&#8221;), under which we granted ABIC exclusive rights to seek marketing approval in Israel for our NeuVax product candidate for intradermal injection for the treatment of breast cancer following its approval by the FDA or the European Medicines Agency, and to market, sell and distribute NeuVax in Israel assuming such approval is obtained. ABIC&#8217;s rights also include a right of first refusal in Israel for all future indications for which NeuVax may be approved. Under the license and supply agreement, ABIC will assume responsibility for regulatory registration of NeuVax in Israel, provide financial support for local development, and commercialize the product in the region in exchange for making royalty payments to us based on future sales of NeuVax. ABIC also agrees in the license and supply agreement to purchase from us all supplies of NeuVax at a price determined according to a specified formula.</font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Effective January 14, 2014, we entered into a strategic development and commercialization partnership with Dr. Reddy&#8217;s Laboratories Ltd. (&#8220;Dr. Reddy&#8217;s&#8221;), under which we licensed commercial rights in India to Dr. Reddy&#8217;s for NeuVax in breast and gastric cancers. Under the agreement, Dr. Reddy&#8217;s will lead the Phase 2 development of NeuVax in India in gastric cancer, significantly expanding the potential patient population addressable with NeuVax.</font></div><div style="line-height:120%;text-align:left;text-indent:66px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">On January 12, 2014, we acquired worldwide rights to anagrelide controlled release (CR) formulation, which we renamed GALE-401, through our acquisition of Mills Pharmaceuticals, LLC ("Mills") and Mills became a wholly owned subsidiary. GALE-401 contains the active ingredient anagrelide, an FDA-approved product that has been in use since the late 1990s for the treatment of essential thrombocythemia (ET). Mills holds an exclusive license to develop and commercialize anagrelide CR formulation, pursuant to a license agreement with BioVascular, Inc. Under the terms of the license agreement, Mills has agreed to pay BioVascular, Inc. a mid-to-low single digit royalty on net revenue from the sale of licensed products as well as future cash milestone payments based on the achievement of specified regulatory milestones. Mills is also responsible for patent prosecution and maintenance.</font></div><div style="line-height:120%;text-align:left;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><a name="sa915a28da92047a79b7b6d9f7c57888b"></a><div style="line-height:120%;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#00497f;font-weight:bold;">12.  Discontinued Operations, Assets Held for Sale</font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:66px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">As part of the company's strategic objective to focus its resources on its development pipeline, our management and board of directors have decided and committed to pursue a plan to sell or otherwise divest the company&#8217;s commercial business.  A brief summary of each product in our commercial business is provided below.</font></div><div style="line-height:120%;text-align:left;text-indent:66px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:66px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Abstral</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">&#174;</sup></font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;(fentanyl) Sublingual Tablets, is a treatment option for inadequately controlled breakthrough cancer pain (BTcP), which is estimated to affect more than </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">50%</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;of all cancer patients. Abstral is approved by the FDA, and is a sublingual (under the tongue) tablet for the management of breakthrough pain in patients with cancer, </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">18</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;years of age and older, who are already receiving, and who are tolerant to, opioid therapy for their persistent baseline cancer pain. The Abstral formulation delivers the analgesic power and increased bioavailability of micronized fentanyl in a sublingual tablet that is designed to dissolve under the tongue in seconds and provide relief of breakthrough pain within minutes. Abstral is a transmucosal immediate release fentanyl (TIRF) product with product class oversight by the TIRF Risk Evaluation and Mitigation Strategy (REMS) access program. </font></div><div style="line-height:120%;text-align:left;text-indent:66px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:66px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Zuplenz</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">&#174;</sup></font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;(ondansetron) Oral Soluble Film, is approved by the FDA in adult patients for the prevention of highly and moderately emetogenic chemotherapy-induced nausea and vomiting (CINV), radiotherapy-induced nausea and vomiting (RINV), and post-operative nausea and vomiting (PONV). Zuplenz is also approved in pediatric patients treated with moderately emetogenic CINV. Nausea and vomiting are two of the most common side-effects experienced by post-surgery patients and patients receiving chemotherapy or radiation. Zuplenz utilizes MonoSol&#8217;s proprietary PharmFilm</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">&#174; </sup></font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">technology, an oral soluble film that dissolves on the tongue in less than 30 seconds, therefore eliminating the burden of swallowing pills during periods of emesis. The active pharmaceutical ingredient in Zuplenz, ondansetron, belongs to a class of medications called serotonin 5-HT3 receptor antagonists and works by blocking the action of serotonin, a natural substance that may cause nausea and vomiting. </font></div><div style="line-height:120%;text-align:left;text-indent:66px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><br><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">23</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;font-weight:bold;" href="#s0623A29E3C735937B2D2F4207223A852"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Table of Contents</font></a></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#00497f;font-weight:bold;">GALENA BIOPHARMA, INC.</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#00497f;font-weight:bold;">NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS - Continued</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#00497f;font-weight:bold;">(Unaudited)</font></div></div><br><div style="line-height:120%;text-align:left;text-indent:66px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">The company met the relevant criteria for reporting the commercial business as held for sale and in discontinued operations in the accompanying unaudited interim financial statements as of and for the three and nine month periods ended September 30, 2015, and 2014, pursuant to FASB Topic 205-20,&#160;Presentation of Financial Statements--Discontinued Operations, and FASB Topic 360,&#160;Property, Plant, and Equipment. The company has assessed the commercial business net asset group for impairment pursuant to FASB Topic 360, as discussed in Note 2, determining that the carrying value exceed the fair value of the assets, therefore has recorded a $8.1 million impairment charge as of September 30, 2015. </font></div><div style="line-height:120%;text-align:left;text-indent:66px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:66px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">The company entered into an agreement with a third party firm to assist the company with the divestiture of its commercial operations including identifying potential acquirers. Pursuant to the terms of the agreement, in the event the company successfully completes a divestiture through the sale of its commercial operations to a third-party, the company is obligated to pay a success fee to the third party firm in an amount up to </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$900,000</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;of cash consideration received, 5% of realized future revenue and payment streams, as well as reimbursement for reasonable out-of-pocket expenses. </font></div><div style="line-height:120%;text-align:left;text-indent:66px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-indent:66px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">The company has also entered into compensatory arrangements related to the divestiture of our commercial business with certain members of commercial management.  Under the terms of these arrangements, if the company meets certain sales and margin numbers in the fourth quarter of 2015 and successfully completes a divestiture through sale of its commercial operations to a third-party, the company may pay a retention fee to the three employees in a combined total amount equal to the lesser of </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$400,000</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;or </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">3%</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;of cash consideration received as upfront payment in the transaction, with payment to each employee portion conditioned on his or her continued employment through the closing date of such a divestiture of one or both products and satisfaction of other terms. These employees may also receive severance payments equal to one month&#8217;s salary for between four and seven months in event the divestiture does not result in continued employment with the acquirer</font><font style="font-family:inherit;font-size:10pt;">.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-indent:66px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">The following table presents a reconciliation of the carrying amounts of assets and liabilities of the commercial operations to assets held for sale, net in the balance sheets (in thousands):</font></div><div style="line-height:120%;text-align:center;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:682px;border-collapse:collapse;text-align:left;"><tr><td colspan="8"></td></tr><tr><td width="490px"></td><td width="8px"></td><td width="79px"></td><td width="4px"></td><td width="5px"></td><td width="8px"></td><td width="79px"></td><td width="4px"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">September 30, 2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">December 31, 2014</font></div></td></tr><tr><td colspan="8" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Carrying amounts of assets included as part of discontinued operations:</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Accounts receivable</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">1,238</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">1,535</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Inventories</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">1,318</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">655</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Prepaid expenses and other current assets</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">1,064</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">1,747</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Equipment and furnishings, net</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">241</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">270</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Abstral rights, net</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">13,738</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">14,533</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Zuplenz rights</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">8,101</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">8,101</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Goodwill</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">172</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">172</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Impairment charge from classification as assets held for sale</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(8,071</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Total current assets held for sale</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">17,801</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">27,013</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td colspan="8" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Carrying amounts of liabilities included as part of discontinued operations:</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Accounts payable</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">1,359</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">385</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Accrued expenses and other current liabilities</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">6,338</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">6,784</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Total current liabilities held for sale</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">7,697</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">7,169</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;text-align:center;text-indent:66px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><br><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">24</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;font-weight:bold;" href="#s0623A29E3C735937B2D2F4207223A852"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Table of Contents</font></a></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#00497f;font-weight:bold;">GALENA BIOPHARMA, INC.</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#00497f;font-weight:bold;">NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS - Continued</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#00497f;font-weight:bold;">(Unaudited)</font></div></div><br><div style="line-height:120%;text-align:left;text-indent:66px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">The following table represents the components attributable to the commercial operations that are presented in the consolidated statement of comprehensive loss as discontinued operations (in thousands):</font></div><div style="line-height:120%;text-align:center;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:681px;border-collapse:collapse;text-align:left;"><tr><td colspan="16"></td></tr><tr><td width="300px"></td><td width="8px"></td><td width="78px"></td><td width="4px"></td><td width="5px"></td><td width="8px"></td><td width="77px"></td><td width="4px"></td><td width="5px"></td><td width="8px"></td><td width="78px"></td><td width="4px"></td><td width="5px"></td><td width="8px"></td><td width="78px"></td><td width="4px"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Three Months Ended September 30,</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Nine Months Ended September 30,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">2014</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">2014</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Net revenue</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">2,166</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">1,620</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">8,298</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">6,124</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Cost of revenue</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(712</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(247</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(1,573</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(925</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Amortization of certain acquired intangible assets</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(208</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(70</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(795</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(259</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Research and development</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(160</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(219</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(339</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(619</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Selling, general, and administrative</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(4,672</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(3,725</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(13,577</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(10,954</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Non-operating income (expense)</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(17</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(17</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Impairment charge from classification as assets held for sale</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(8,071</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(8,071</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Loss from discontinued operations</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(11,674</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(2,641</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(16,074</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(6,633</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td></tr></table></div></div><div style="line-height:120%;text-align:left;text-indent:66px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-indent:66px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">The following table presents significant operating non-cash items and capital expenditures related to discontinued operations (in thousands):</font></div><div style="line-height:120%;text-indent:66px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:682px;border-collapse:collapse;text-align:left;"><tr><td colspan="8"></td></tr><tr><td width="490px"></td><td width="8px"></td><td width="79px"></td><td width="4px"></td><td width="5px"></td><td width="8px"></td><td width="79px"></td><td width="4px"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">September 30, 2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">September 30, 2014</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Impairment of assets held for sale</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">8,071</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Depreciation and amortization</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">858</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">319</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Stock-based compensation</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">788</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">557</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Purchases of property and equipment</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(34</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Cash paid for acquisition of Zuplenz rights</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(500</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(3,056</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><a name="sBEE4756CB08753A88D4F4FBCD13790B8"></a><div style="line-height:120%;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#00497f;font-weight:bold;">13.  Subsequent Events</font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">The company evaluated all events or transactions that occurred after </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">September&#160;30, 2015</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;up through the date these financial statements were issued. Other than as disclosed elsewhere in the notes to the condensed consolidated financial statements, the company did not have any material recognizable or unrecognizable subsequent events.</font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><br><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">25</font></div></div><hr style="page-break-after:always"><a name="s359754F5FB8D59BA8748C4AB14C4B621"></a><br><div style="line-height:120%;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#00497f;font-weight:bold;">ITEM&#160;2. MANAGEMENT&#8217;S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;">In this </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">section</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;">, "Galena," &#8220;we,&#8221; &#8220;our,&#8221; &#8220;ours&#8221; and &#8220;us&#8221; refer to Galena Biopharma, Inc. and its consolidated subsidiaries, Apthera, Inc., or &#8220;Apthera,&#8221; and Mills Pharmaceuticals, LLC, or "Mills."</font></div><div style="line-height:120%;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;">This management&#8217;s discussion and analysis of financial condition as of September 30, 2015 and results of operations for the three and nine months ended September 30, 2015 and 2014, respectively, should be read in conjunction with management&#8217;s discussion and analysis of financial condition and results of operations included in our Annual Report on Form 10-K for the year ended December&#160;31, 2014 which was filed with the SEC on March 5, 2015.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;">The discussion and analysis below includes certain forward-looking statements related to the commercialization of our products in the U.S., our future financial condition and results of operations and potential for profitability, the sufficiency of our cash resources, our ability to obtain additional equity or debt financing, possible partnering or other strategic opportunities for the development of our products, as well as other statements related to the progress and timing of our product commercialization and development activities, present or future licensing, collaborative or financing arrangements or that otherwise relate to future periods, which are all forward-looking statements as defined by the Private Securities Litigation Reform Act of 1995. These statements represent, among other things, the expectations, beliefs, plans and objectives of management and/or assumptions underlying or judgments concerning the future financial performance and other matters discussed in this document. The words &#8220;may,&#8221; &#8220;will,&#8221; &#8220;should,&#8221; &#8220;plan,&#8221; &#8220;believe,&#8221; &#8220;estimate,&#8221; &#8220;intend,&#8221; &#8220;anticipate,&#8221; &#8220;project,&#8221; and &#8220;expect&#8221; and similar expressions are intended to connote forward-looking statements. All forward-looking statements involve certain risks, including the uncertainties and other factors described in our Annual Report on Form 10-K for the year ended December&#160;31, 2014 that could cause our actual commercialization efforts, development activities, financial condition and results of operations, and business prospects and opportunities to differ materially from these expressed in, or implied by, those forward-looking statements. We caution investors not to place significant reliance on the forward-looking statements contained in this report. These statements, like all statements in this report, speak only as of the date of this report (unless another date is indicated) and we undertake no obligation to update or revise forward-looking statements.</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><br><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">26</font></div></div><hr style="page-break-after:always"><a name="sB7467757F6115CA2B2691C98EE2FAFF6"></a><br><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#00497f;font-weight:bold;">Overview</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;text-indent:66px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Galena Biopharma, Inc. (&#8220;we,&#8221; &#8220;us,&#8221; &#8220;our,&#8221; &#8220;Galena&#8221; or the &#8220;company&#8221;) is a biopharmaceutical company committed to the development and commercialization of targeted oncology therapeutics that address major unmet medical needs. Galena&#8217;s development portfolio is focused primarily on addressing the rapidly growing patient populations of cancer survivors by harnessing the power of the immune system to prevent cancer recurrence. The Company&#8217;s pipeline consists of multiple mid- to late-stage clinical assets, including novel cancer immunotherapy programs led by NeuVax&#8482; (nelipepimut-S), GALE-301 and GALE-302.&#160; NeuVax is currently in a pivotal, Phase 3 clinical trial with several concurrent Phase 2 trials ongoing both as a single agent and in combination with other therapies. GALE-301 is in a Phase 2a clinical trial in ovarian and endometrial cancers in addition to GALE-302 in combination with GALE-301 in ovarian and breast cancers.&#160;</font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">We are seeking to build value for shareholders through pursuit of the following objectives:</font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Develop novel cancer immunotherapies to address unmet medical needs through the use of peptide-based vaccines targeting well-established tumor antigens.  One of our key strategies is to target the adjuvant, minimum residual disease setting, in high risk patients who are more likely to benefit from treatment via immunotherapy. Our immunotherapy programs are currently targeting two key areas: secondary prevention to seek to significantly decrease the risk of disease recurrence in breast cancer, gastric cancer, endometrial and ovarian cancers; and moving towards primary prevention in breast cancer.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Expand our development pipeline by enhancing the clinical and geographic footprint of our technologies. We can accomplish this through the initiation of new clinical trials as well as through acquisition of additional development stage products in oncology indications. </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Leverage valuable partnerships and collaborations, as well as investigator-sponsored trial arrangements, to maximize the scope of potential clinical opportunities in a cost effective and efficient manner.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Maximize the value of our commercial assets through divestiture.  During the quarter ended September 30, 2015, we completed a strategic review of our commercial business and operations, and as a result of that review have decided to sell or otherwise divest our commercial business.  We believe this disposition will allow us to focus our resources on our valuable and expanding clinical development programs and maximize the value of these assets to our shareholders</font><font style="font-family:inherit;font-size:10pt;">.</font></div></td></tr></table><br><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">27</font></div></div><hr style="page-break-after:always"><a name="sB7467757F6115CA2B2691C98EE2FAFF6"></a><br><div style="line-height:120%;text-align:left;text-indent:66px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">The chart below summarizes the current status of our clinical development pipeline</font><font style="font-family:inherit;font-size:10pt;">:</font></div><div style="line-height:120%;text-align:left;text-indent:66px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;"><img src="pipelineimageq32015.jpg" style="height:405px;width:684px;"></div><div style="line-height:120%;text-align:left;text-indent:66px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#006ebf;font-weight:bold;text-decoration:underline;">Novel Cancer Immunotherapies</font></div><div style="line-height:120%;text-align:left;text-indent:66px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;text-indent:66px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Our targeted cancer immunotherapy approach is currently based upon two key areas: preventing secondary recurrence of cancer, which is becoming increasingly important as the number of cancer survivors continues to grow; and, transitioning earlier in the breast cancer treatment spectrum via primary prevention. Once a patient&#8217;s tumor becomes metastatic, the outcome is most often fatal, making the prevention of recurrence a potentially critical component of overall patient care. Our programs primarily target patients in the adjuvant (after-surgery) setting who have relatively healthy immune systems, but may still have minimal residual disease.  Minimal residual disease, or single cancer cells (occult cancer cells) or micrometastasis, are undetectable by current radiographic scanning technologies, but we know can result in disease recurrence.</font></div><div style="line-height:120%;text-align:left;text-indent:66px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Our therapies utilize an immunodominant peptide combined with the immune adjuvant, recombinant human granulocyte macrophage-colony stimulating factor (rhGM-CSF), and work by harnessing the patient&#8217;s own immune system to seek out and attack any residual cancer cells. Using peptide immunogens has many potential clinical advantages, including a favorable safety profile, since these drugs may lack the toxicities typical of most cancer therapies. They also have the potential to evoke long-lasting protection through activation of the immune system and a convenient, intradermal mode of delivery. We are currently engaged in multiple clinical trials with NeuVax&#8482; (nelipepimut-S), GALE-301, and GALE-302, targeting the prevention of recurrence in breast, gastric, ovarian and endometrial cancers.</font></div><div style="line-height:120%;text-align:left;text-indent:66px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:66px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:66px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><br><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">28</font></div></div><hr style="page-break-after:always"><a name="sB7467757F6115CA2B2691C98EE2FAFF6"></a><br><div style="line-height:120%;text-align:left;padding-left:32px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#006ebf;font-style:italic;font-weight:bold;">NeuVax&#8482; (nelipepimut-S)</font></div><div style="line-height:120%;text-align:left;padding-left:32px;text-indent:66px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;text-indent:66px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">NeuVax&#8482; (nelipepimut-S), our lead product candidate, is a cancer immunotherapy targeting human epidermal growth factor receptor (HER2) expressing cancers. NeuVax is the immunodominant nonapeptide derived from the extracellular domain of the HER2 protein, a well-established and validated target for therapeutic intervention in breast and gastric carcinomas. The NeuVax vaccine is combined with GM-CSF for injection under the skin, or intradermal administration. Data has shown that an increased presence of circulating tumor cells (CTCs) may predict Disease Free Survival (DFS) and Overall Survival (OS)-suggesting a dormancy of isolated micrometastases, which, over time, may lead to recurrence. After binding to specific HLA molecules on antigen presenting cells, the nelipepimut-S sequence stimulates specific cytotoxic T lymphocyte (CTLs). These activated CTLs recognize, neutralize and destroy, through cell lysis, HER2 expressing cancer cells, including occult cancer cells and micrometastatic foci. The nelipepimut immune response can also generate CTLs to other immunogenic peptides through inter- and intra-antigenic epitope spreading.</font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;text-decoration:underline;">Breast Cancer:</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;According to the National Cancer Institute, over 230,000 women in the U.S. are diagnosed with breast cancer annually. While improved diagnostics and targeted therapies have decreased breast cancer mortality in the U.S., metastatic breast cancer remains incurable. Approximately 75% of breast cancer patients have tissue test positive for some increased amount of the HER2 receptor, which is associated with disease progression and decreased survival. Only approximately 20% to 30% of all breast cancer patients-those with HER2 immunohistochemistry (IHC) 3+ disease, or IHC 2+ and fluorescence in situ hybridization (FISH) positive-have a HER2 directed, approved treatment option available. This leaves the majority of breast cancer patients with low-to-intermediate HER2 IHC 1+/2+ ineligible for therapy and without an effective targeted treatment option to prevent cancer recurrence.</font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;text-indent:66px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">We have multiple trials currently ongoing for NeuVax. For our pivotal, Phase 3 PRESENT (</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-weight:bold;">P</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">revention of </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-weight:bold;">R</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">ecurrence in </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-weight:bold;">E</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">arly-</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-weight:bold;">S</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">tage, Node- Positive Breast Cancer with Low to Intermediate HER2 </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-weight:bold;">E</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">xpression with </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-weight:bold;">NeuVax T</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">reatment) trial, NeuVax is targeting the 30,000-40,000 of the 230,000 female breast cancer patients annually diagnosed in the U.S. who are at a higher risk of their breast cancer recurring, which we refer to as &#8220;disease recurrence,&#8221; after achieving &#8220;no evidence of disease&#8221; (NED) status, (or becoming a &#8220;survivor&#8221;) with standard-of-care therapy (surgery, chemotherapy, radiation). These high-risk patients have a particular molecular signature and disease status: HER2 IHC 1+/2+ (oncoprotein associated with aggressive tumor growth), node positive (disease present in the axillary lymph nodes prior to surgery), and HLA A2/A3 (human leukocyte antigen from A2/A3 patients who have the same loci of genes which represents approximately 65% of the population). Up to 25% of resectable, node-positive breast cancer patients, having no radiographic evidence of disease following surgery and adjuvant chemo/radiation therapy, are expected to relapse within three years following diagnosis. The prognosis upon recurrence is very poor. These cancer patients presumably still had isolated, undetected tumor CTCs that led to a recurrence of cancer in the breast (local recurrence) or in another location (metastatic disease).  In addition to our Phase 3 trial, we currently have two additional Phase 2 breast cancer trials ongoing with NeuVax in combination with trastuzumab (Herceptin</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">&#174;</sup></font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">; Genentech/Roche) targeting the prevention of recurrence in expanded indications.  </font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;text-indent:66px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">We also recently announced our intent to initiate a Phase 2 trial with NeuVax as a single agent in patients with ductal carcinoma in situ (DCIS) in collaboration with the National Cancer Institute (NCI), potentially transitioning NeuVax earlier in the treatment cycle towards primary prevention.  The trial will have an immunological endpoint evaluating NeuVax peptide-specific cytotoxic T lymphocyte (CTL; CD8+ T cell) response in vaccinated patients. DCIS, is defined by the NCI as a noninvasive condition in which abnormal cells are found in the lining of a breast duct, and is the most common type of breast cancer.  The abnormal cells have not spread outside the duct to other tissues in the breast.  In some cases, DCIS may become invasive cancer and spread to other tissues, and at this time, there is no way to know which lesions could become invasive.  Current treatment options for DCIS include breast-conserving surgery and radiation therapy with or without tamoxifen, breast-conserving surgery without radiation therapy, or total mastectomy with or without tamoxifen.  According to the American Cancer Society, in 2014 there were an estimated 51,933 diagnoses of DCIS.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-indent:66px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><br><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">29</font></div></div><hr style="page-break-after:always"><a name="sB7467757F6115CA2B2691C98EE2FAFF6"></a><br><div style="line-height:120%;padding-bottom:13px;text-align:left;text-indent:66px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">We currently have a number of ongoing or planned clinical trials designed to expand the clinical and geographical footprint of NeuVax:</font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:108px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:84px;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Phase 3 Ongoing: Our Phase 3 PRESENT (</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-weight:bold;">P</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">revention of </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-weight:bold;">R</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">ecurrence in </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-weight:bold;">E</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">arly- </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-weight:bold;">S</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">tage, Node-Positive Breast Cancer with Low to Intermediate HER2 </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-weight:bold;">E</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">xpression with </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-weight:bold;">NeuVax</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-weight:bold;">T</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">reatment) study targeted enrollment of 700 HER2 1+/2+ patients under a Special Protocol Assessment (SPA) granted by the U.S. Food and Drug Administration (FDA). The multinational, multicenter, randomized, double-blinded PRESENT trial is ongoing in North America, Western and Eastern Europe, and Israel. The trial is fully enrolled with 758 patients. </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:108px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:84px;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Phase 2b Ongoing: A randomized, multicenter, investigator-sponsored, 300 patient Phase 2b clinical trial is enrolling HER2 1+/2+ node-positive and high-risk node-negative breast cancer patients who are HLA A2+, A3+, A24+ or A26+ to study NeuVax in combination with trastuzumab in the adjuvant setting.  This trial is co-funded by Genentech/Roche (providing both trastuzumab and monetary support) and Galena (providing NeuVax and monetary support).</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:108px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:84px;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Phase 2 Ongoing: An investigator-sponsored trial is ongoing to study NeuVax in combination with trastuzumab. The study will enroll 100 node positive and negative HER2 IHC 3+ patients or HER2 gene-amplified breast cancer patients who are HLA A2+ or HLA A3+ and are determined to be at high-risk for recurrence. Partial funding for this trial comes from the Department of Defense (DoD) through the Congressionally Directed Medical Research Program via legislation known as the Defense Appropriations Act. The grant was awarded under a Breast Cancer Research Program with the Breakthrough Award given to the lead investigator for the trial.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:108px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:84px;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Phase 2 Planned: A clinical trial, entitled, VADIS: Phase 2 trial of the Nelipepimut-S Peptide </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-weight:bold;">VA</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">ccine in Women with </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-weight:bold;">D</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">C</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-weight:bold;">IS </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">of the Breast is planned to initiate by the end of 2015/early 2016. The Phase 2 trial will be a single-blind, double arm, randomized, controlled trial in pre- or post-menopausal patients with DCIS and are HLA-A2 positive.  VADIS will be co-funded and run in collaboration with the National Cancer Institute (NCI).</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:108px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:90px;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Phase 2 Planned: A Phase 2 clinical trial in patients with gastric cancer is expected to initiate in 2016.  The trial will be run in India by our partner, Dr. Reddy&#8217;s Laboratories, Ltd., as part of our NeuVax commercialization agreement in that region with Dr. Reddy&#8217;s. </font></div></td></tr></table><div style="line-height:120%;text-indent:66px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;text-decoration:underline;">Gastric Cancer:</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;Gastric cancer (also known as stomach cancer) is a disease in which the cells forming the inner lining of the stomach become abnormal and start to divide uncontrollably, forming a cancerous tumor mass. Cancer can develop in any of the five sections of the stomach. Symptoms and outcomes of the disease will vary depending on the location of the cancer. Stomach cancer is one of the leading causes of cancer deaths in several areas of the world, most notably Republic of Korea and other Asian countries. Annually, almost one million people will be diagnosed worldwide with stomach cancer and over 700,000 will die from the disease. More than 90% of stomach cancers are caused by adenocarcinomas, malignant cancers that originate in glandular tissues. Overexpression of the HER2 receptor occurs in approximately 20% of gastric and gastro-esophageal junction adenocarcinomas, predominantly those of the intestinal type. Overall, without regard to the stage of cancer, only approximately 28% of patients with stomach cancer live at least five years following diagnosis and new adjuvant treatments are needed to prevent disease recurrence</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><br><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">30</font></div></div><hr style="page-break-after:always"><a name="sB7467757F6115CA2B2691C98EE2FAFF6"></a><br><div style="line-height:120%;text-align:left;padding-left:32px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#006ebf;font-style:italic;font-weight:bold;">GALE-301 and GALE-302</font></div><div style="line-height:120%;text-align:left;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:66px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Our second immunotherapy franchise targets folate binding protein (FBP) receptor-alpha, a well-validated therapeutic target, which&#160;is highly over-expressed (20-80 fold) in ovarian, endometrial and breast cancers. Both GALE-301 (E39) and GALE-302 (E39&#8217;) are immunogenic peptides that can stimulate CTLs to recognize and destroy FBP-expressing cancer cells. GALE-301 consists of the FBP peptide E39 combined with GM-CSF, and is currently in a Phase 2a clinical trial for the prevention of recurrence in patients with ovarian and endometrial cancers. GALE-302 is an attenuated version of the E39 peptide and is currently in a Phase 1b randomized, single-center trial investigating a novel vaccination series using GALE-301 and GALE-302 to evaluate the immune response and monitor long-term immunity.  Current treatments after surgery for these diseases are principally with platinum based chemotherapeutic agents and patients suffer a high recurrence rate; and, most patients relapse with an extremely poor prognosis. Although not powered for efficacy, promising preliminary results from the Phase 2a clinical trial of GALE-301 were presented in September 2015 at the European Cancer Congress and demonstrated statistically significant data with the estimate for disease free survival at two years at 85.7% (1000 mcg dose group) vs. 33.6% for the control group (p &lt; .02), and that GALE-301 was well-tolerated with primarily Grade 1 and 2 toxicities and elicited a strong&#160;</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;">in vivo&#160;</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">immune response. </font></div><div style="line-height:120%;text-align:left;text-indent:66px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-indent:66px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Ovarian and Endometrial Cancer:  According to the NCI Surveillance, Epidemiology, and End Results (SEER) Program, new cases of ovarian cancer occur at an annual rate of 12.1 per 100,000 women in the U.S., with an estimated 21,290 cases for 2015. Although ovarian cancer represents about 1.3% of all cancers, it represents about 2.4% of all cancer deaths, or an estimated 14,180 deaths in 2015. &#160;Approximately 1.3% of women will be diagnosed with ovarian cancer at some point during their lifetime (2010 - 2012 data). &#160;The prevalence of ovarian cancer in the U.S. is about 192,000 women, and the five-year survivorship for women with ovarian cancer is 45.6%.&#160;Due to the lack of specific symptoms, the majority of ovarian cancer patients are diagnosed at later stages of the disease, with an estimated 75% of women presenting with advanced-stage (III or IV) disease. These patients have their tumors routinely surgically debulked to minimal residual disease, and then are treated with platinum- and/or taxane-based chemotherapy. While many patients respond to this treatment regimen and become clinically free-of-disease, the majority of these patients will relapse.  Depending upon their level of residual disease, the risk for recurrence after completion of primary therapy ranges from 60% to 85%.  Unfortunately for these women, once the disease recurs, treatment options are limited and the disease remains incurable.</font></div><div style="line-height:120%;text-align:left;text-indent:66px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:66px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">According to the NCI SEER Program, new cases of endometrial cancer occur at an annual rate of 25.1 per 100,000 women in the U.S., with an estimated 54,870 cases for 2015. Although endometrial cancer represents about 3.3% of all cancers, it represents about 1.7% of all cancer deaths, or an estimated 10,170 deaths in 2015. &#160;Approximately 2.8% of women will be diagnosed with endometrial cancer at some point during their lifetime (2010 - 2012 data). &#160;The prevalence of endometrial cancer in the U.S. is about 620,000 women, and the five-year survivorship for women with endometrial cancer is 81.7%.&#160;</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#006ebf;font-weight:bold;text-decoration:underline;">Hematology</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:32px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#006ebf;font-style:italic;font-weight:bold;">GALE-401 (anagrelide controlled release (CR))</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:66px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">In January 2014, we announced the acquisition of the worldwide rights to anagrelide controlled release (CR), which we renamed GALE-401, through our acquisition of Mills Pharmaceuticals, LLC. GALE-401 contains the active ingredient anagrelide, an FDA-approved product, for the treatment of patients with myeloproliferative neoplasms (MPNs) to lower abnormally elevated platelet levels. The currently available immediate release (IR) version of anagrelide causes adverse events that are believed to be dose and plasma concentration dependent. Therefore, reducing the maximum concentration (Cmax) is hypothesized to reduce the side effects, but preserve efficacy.</font></div><div style="line-height:120%;text-align:left;text-indent:66px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><br><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">31</font></div></div><hr style="page-break-after:always"><a name="sB7467757F6115CA2B2691C98EE2FAFF6"></a><br><div style="line-height:120%;text-align:left;text-indent:66px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Multiple Phase 1 studies in </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">98</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;healthy subjects have shown GALE-401 reduces the Cmax of anagrelide following oral administration, appears to be well-tolerated at the doses administered, and to be capable of reducing platelet levels. The Phase 1 program provided the desired PK/PD (pharmacokinetic/pharmacodynamic) profile to enable the initiation of the ongoing Phase 2 proof-of-concept trial. The Phase 2, open label, single arm, proof-of-concept trial enrolled </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">18</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;patients in the United States for the treatment of thrombocytosis, or elevated platelet counts in patients with MPNs. Phase 2 top-line safety and efficacy data was presented in June 2015 at the European Hematology Association 20</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">th</sup></font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;Congress, and we expect to present a more mature data set at the 57th American Society of Hematology Annual Meeting in December 2015. Based on a regulatory meeting with the FDA, Galena believes a 505(b)(2) regulatory filing is an acceptable pathway for development and potential approval of GALE-401.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:66px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;text-decoration:underline;">Myeloproliferative neoplasms</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">: MPNs are a closely related group of hematological malignancies in which the bone marrow cells that produce the body&#8217;s blood cells develop and function abnormally. The main MPNs are Polycythemia Vera (PV), Essential Thrombocythemia (ET), Primary Myelofibrosis (PMF), and Chronic Myelogenous Leukemia (CML), all of which are associated with high platelet counts. The MPNs are progressive blood cancers that can strike anyone at any age, and for which there is no known cure.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#006ebf;font-weight:bold;text-decoration:underline;">Strategic Review of Commercial Operations</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">During the quarter ended September 30, 2015, we completed a strategic review of the company&#8217;s commercial business including the ongoing sale, distribution and marketing of our two commercial products, Abstral</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">&#174;</sup></font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;(fentanyl) Sublingual Tablets and Zuplenz</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">&#174;</sup></font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;(ondansetron) Oral Soluble Film (our &#8220;commercial business&#8221; asset group). As a result of the review, we made a determination to sell or otherwise dispose of our commercial business.  </font></div><div style="line-height:120%;text-align:left;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:32px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#006ebf;font-style:italic;font-weight:bold;">Abstral</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#006ebf;font-style:italic;font-weight:bold;"><sup style="vertical-align:top;line-height:120%;font-size:pt">&#174;</sup></font><font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#006ebf;font-style:italic;font-weight:bold;">&#32;(fentanyl) Sublingual Tablets</font></div><div style="line-height:120%;text-align:left;padding-left:32px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;text-indent:66px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Abstral</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">&#174; </sup></font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(fentanyl) Sublingual Tablets, is a treatment option for inadequately controlled breakthrough cancer pain (BTcP), which is estimated to affect more than 50% of all cancer patients. Abstral is approved by the FDA, and is a sublingual (under the tongue) tablet for the management of breakthrough pain in patients with cancer, 18 years of age and older, who are already receiving, and who are tolerant to, opioid therapy for their persistent baseline cancer pain. The Abstral formulation delivers the analgesic power and increased bioavailability of micronized fentanyl in a sublingual tablet that is designed to dissolve under the tongue in seconds and provide relief of breakthrough pain within minutes. Abstral is a transmucosal immediate release fentanyl (TIRF) product with product class oversight by the TIRF Risk Evaluation and Mitigation Strategy (REMS) access program. </font></div><div style="line-height:120%;text-align:left;padding-left:32px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#006ebf;font-style:italic;font-weight:bold;">Zuplenz</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#006ebf;font-style:italic;font-weight:bold;"><sup style="vertical-align:top;line-height:120%;font-size:pt">&#174;</sup></font><font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#006ebf;font-style:italic;font-weight:bold;">&#32;(ondansetron) Oral Soluble Film</font></div><div style="line-height:120%;text-align:left;padding-left:32px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:66px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Zuplenz</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">&#174;</sup></font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;(ondansetron) Oral Soluble Film, is approved by the FDA in adult patients for the prevention of highly and moderately emetogenic chemotherapy-induced nausea and vomiting (CINV), radiotherapy-induced nausea and vomiting (RINV), and post-operative nausea and vomiting (PONV). Zuplenz is also approved in pediatric patients treated with moderately emetogenic CINV. Nausea and vomiting are two of the most common side-effects experienced by post-surgery patients and patients receiving chemotherapy or radiation. Zuplenz utilizes MonoSol&#8217;s proprietary PharmFilm</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">&#174; </sup></font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">technology, an oral soluble film that dissolves on the tongue in less than 30 seconds, therefore eliminating the burden of swallowing pills during periods of emesis. The active pharmaceutical ingredient in Zuplenz, ondansetron, belongs to a class of medications called serotonin 5-HT3 receptor antagonists and works by blocking the action of serotonin, a natural substance that may cause nausea and vomiting. </font></div><div style="line-height:120%;text-indent:66px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-indent:66px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><br><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">32</font></div></div><hr style="page-break-after:always"><a name="s297EF6FB8560590AA70F8D2079ED4273"></a><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><br><div style="line-height:144%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#00497f;font-weight:bold;">Recent Operational Developments (in reverse chronological order)</font></div><div style="line-height:120%;text-align:left;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;text-decoration:underline;">GALE-302 Immunological Data Optimizing GALE-301 Presented</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">&#32;</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">- We presented preliminary immunologic data for our GALE-301 and GALE-302 Phase 1b clinical trial at the Society for Immunotherapy of Cancer (SITC) 30th Anniversary Annual Meeting.</font></div><div style="line-height:120%;text-align:left;text-indent:66px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">On November 7, 2015 we presented the poster, entitled, "Preliminary report of a clinical trial supporting the sequential use of an attenuated E39 peptide (E39&#8217;) to optimize the immunologic response to the FBP (E39+GM-CSF) vaccine," that compared three primary vaccine series (PVS) sequences of GALE-301 (E39) and GALE-302 (E39&#8217;) in ovarian and breast cancer patients to optimize the ex vivo immune responses, local reactions (LR), and delayed type hypersensitivity (DTH) reactions.  The data demonstrated that the in vivo immune response is enhanced with the use of the attenuated E39&#8217; (GALE-302) after E39 (GALE-301).  The optimal vaccination sequence utilizing three inoculations of GALE-301 followed by three inoculations of GALE-302 produced the most prominent and statistically significant LR and DTH responses.</font></div><div style="line-height:120%;text-align:left;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;text-decoration:underline;">Patent Infringement Litigation -</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">&#32;</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">We have settled the patent infringement litigation involving Abstral.</font></div><div style="line-height:120%;text-align:left;text-indent:65px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">On October 23, 2015, we, Orexo AB and Actavis Laboratories Fl, Inc. (&#8220;Actavis&#8221;) entered into a settlement and license agreement, which will permit Actavis to enter the market with a generic or authorized generic version of Abstral in June 2018 or earlier under certain circumstances. The litigation, Orexo AB v. Actavis Laboratories FL, Inc., CA No. 3:15-cv-00826, has been dismissed with prejudice by the United States District Court for the District of New Jersey and the agreement has been filed with the Federal Trade Commission and the Department of Justice under applicable law.</font></div><div style="line-height:120%;text-align:left;text-indent:65px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;text-decoration:underline;">Strategic Review of Commercial Operations -</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">&#32;</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">We conducted a strategic review of our commercial operations and decided to divest our commercial assets and discontinue our commercial operations.</font></div><div style="line-height:120%;text-align:left;text-indent:65px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">During the quarter ended September 30, 2015, we completed a strategic review of the commercial assets and operations and have decided to focus our resources on our pipeline of product development candidates. As a result, we have decided to sell or otherwise dispose of our marketed products, Abstral and Zuplenz, and discontinue our commercial operations.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;text-decoration:underline;">Collaboration with the National Cancer Institute on NeuVax</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">&#32;- We announced a Phase 2 clinical trial with NeuVax in Ductal Carcinoma in Situ Patients.</font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">On September 30, 2015, we announced a collaboration with the National Cancer Institute (NCI) to initiate a Phase 2 clinical trial with NeuVax in patients diagnosed with Ductal Carcinoma in Situ (DCIS).  The trial will be entitled VADIS: Phase 2 trial of the Nelipepimut-S Peptide </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-weight:bold;">Va</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">ccine in Women with </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-weight:bold;">DC</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">I</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-weight:bold;">S</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;of the Breast</font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">.</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;&#32;The University of Texas M.D. Anderson Cancer Center (MDACC) Cancer Prevention Agent Development Program, Early Phase Clinical Research Consortium Organization will be the lead clinical trial site for this multi-center trial.  The Consortium is funded through the Division of Cancer Prevention at NCI, which will provide financial and administrative support for the trial.  We will provide NeuVax, as well as additional financial and administrative support.  The single-blind, double arm, randomized, controlled trial is expected to initiate in the fourth quarter of 2015/first quarter of 2016.</font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;text-decoration:underline;">GALE-301 Phase 2a Clinical Trial Data Presented</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">&#32;- We announced positive data for our GALE-301 Phase 2a clinical trial.</font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">On September 28, 2015 we announced the poster presentation of positive data from the GALE-301 Phase 2a portion of the Phase 1/2a clinical trial at the European Cancer Congress 2015, providing updated data for all ovarian and endometrial cancer patients who have received at least twelve months of treatment on the study.&#160;The poster was entitled, entitled, </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;">Preliminary results of the phase I/IIa dose finding trial of a folate binding protein vaccine GALE-301 (E39) + GM-CSF in ovarian and endometrial cancer patients to prevent recurrence</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">, and as presented, the clinical recurrence rate based on all treatment cohorts was 41% in the Vaccine Group (VG) (n=29) versus 55% in the Control Group (CG) (n=22), p=0.41.&#160;However, in the 1000 mcg VG cohort (n=15), there have only been two clinical recurrences (13.3% versus 55% CG, p=0.02), and the two-year Disease Free Survival (DFS) </font></div><br><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">33</font></div></div><hr style="page-break-after:always"><a name="s297EF6FB8560590AA70F8D2079ED4273"></a><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><br><div style="line-height:120%;padding-bottom:13px;text-align:left;font-size:12pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">estimate is 85.7% (1000 mcg patients) versus 33.6% (CG), p &lt; 0.02, as compared by Kaplan-Meir and Log rank tests. Safety, immunologic, and clinical recurrence data are continuing to</font><font style="font-family:inherit;font-size:12pt;">&#32;</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">be collected.&#160;</font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;text-indent:66px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;text-decoration:underline;">IDMC Recommends Reduction in Cardiac Monitoring in the PRESENT Trial</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">&#32;- We announced that the Independent Data Monitoring Committee (IDMC) for the NeuVax Phase 3 clinical trial recommended to the Company that it can reduce the cardiac toxicity monitoring for patients in our PRESENT study.</font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;text-indent:66px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">On August 24, 2015 we announced that the Independent Data Monitoring Committee (IDMC) for the NeuVax Phase 3 clinical trial recommended to the Company that we can reduce the cardiac toxicity monitoring for patients in our PRESENT study. Following its most recent meeting in June 2015, the IDMC recommended routine cardiac monitoring could be reduced in the PRESENT trial and that such a reduction is justified and consistent with the pre-specified Cardiac Toxicity Monitoring Stopping Rules defined in the study protocol. The IDMC concluded that cardiac toxicity monitoring by echocardiogram (ECHO) or multiple-gated acquisition (MUGA) scans could be reduced. The IDMC had no other suggestions and recommended the trial continue as planned.</font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;text-indent:66px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;text-decoration:underline;">GALE 401 Phase 2 Clinical Trial Data Presented</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">&#32;</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">- We presented data from our Phase 2 clinical trial of GALE-401 at the European Hematology Association 20th Congress </font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;text-indent:66px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">On June 15, 2015, we announced our poster presentation entitled P</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;">hase 2 Study of a Novel Controlled-Release Formulation of Anagrelide (GALE-401) in Subjects with Myeloproliferative Neoplasm (MPN)-Related Thrombocytosis</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">,&#160;which was presented on June 13, 2015.&#160;The Phase 2 study demonstrated that GALE-401 was well tolerated with primarily Grade 1 and 2 toxicities in 16 of the 18 subjects enrolled.&#160;The efficacy shown in the trial compares favorably to historical anagrelide immediate release (IR) response rates with the following platelet response: overall response rate (ORR) of 78% (14/18); complete response (CR) of 39% (7/18); partial response (PR) of 39% (7/18).&#160;The median time to response was 5 weeks (range, 3-10), and the median duration of response has not yet been reached. </font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;text-indent:66px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;text-decoration:underline;">Published Abstracts related to GALE-301 and Leica Biosystem&#8217;s Companion Diagnostic</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">&#32;</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">- We presented two abstract publications at the American Society of Clinical Oncology (ASCO) 2015 Annual Meeting.</font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;text-indent:66px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">On May 27, 2015, we announced two abstract publications at the ASCO 2015 Annual Meeting related to our cancer immunotherapy programs:</font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;text-indent:66px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">We presented data related to GALE-301 in abstract #e14031, entitled, </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;">Preliminary Results of the Phase I/IIa Dose Finding Trial of a Folate Binding Protein Vaccine (E39+GM-CSF) in Ovarian and Endometrial Cancer Patients to Prevent Recurrence</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">. The more mature data set from this trial was presented in September 2015 as mentioned above. </font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;text-indent:66px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">We presented data related to our NeuVax Phase 3 PRESENT trial companion diagnostic in abstract #e11609, entitled, </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;">Analytical Validation of BOND Oracle HER2 IHC System for Identifying Low to Intermediate HER2 Expressing Breast Cancer in NeuVax PRESENT Phase 3 Clinical Trial</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">. This data demonstrated a direct correlation between cell line receptor load, quantitative measure of HER2 protein, and IHC score. The ability to discriminate HER2 protein expression at the low and intermediate levels in breast cancer tumors will identify patients for new treatments in development such as NeuVax. Specifically, the validation of the Bond Oracle HER2 IHC System to distinguish lower levels of HER2+ expressions supports its use as a companion diagnostic.</font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;text-indent:66px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;text-decoration:underline;">NeuVax Phase 3 PRESENT Over-Enrollment Completed</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">&#32;- We announced the completion of enrollment in our NeuVax Phase 3 PRESENT clinical trial.</font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;text-indent:66px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">On April 14, 2015, we announced the completion of enrollment in the NeuVax&#8482; Phase 3 PRESENT clinical trial. As anticipated, we over-enrolled the trial by 7.7% with a total of 758 patients now in the intent-to-treat (ITT) population.  The PRESENT protocol called for 700 patients; and we expect this higher number of ITT patients will increase the confidence in both the timing and quality of the statistics and the final outcome of the trial. The primary endpoint is currently expected to be reached in 2018, after a total of 141 events (recurrence or death) occur, or the last patient dosed reaches her 36th month of treatment, whichever comes later.</font></div><br><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">34</font></div></div><hr style="page-break-after:always"><a name="s297EF6FB8560590AA70F8D2079ED4273"></a><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><br><div style="line-height:120%;padding-bottom:13px;text-align:left;text-indent:66px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;text-decoration:underline;">Expanded Patient Population in NeuVax Combination Trial</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">&#32;- We announced the expansion of the patient population in the NeuVax and trastuzumab combination trial in HER2 1+/2+ patients to include HLA A24+ or HLA-A26+ patients.</font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;text-indent:66px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">On March 26, 2015, we announce that women with the human leukocyte antigen (HLA) - A24+ or HLA-A26+ allele are now eligible for enrollment into the ongoing Phase 2b clinical trial with NeuVax in combination with trastuzumab.  The trial evaluates node positive and triple negative, node negative breast cancer patients with immunohistochemistry (IHC) HER2 1+/2+ expressing tumors who are disease-free after standard of care therapy.</font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;text-indent:66px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;text-decoration:underline;">Enrolled 700th Patient in NeuVax Phase 3 PRESENT Clinical Trial</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">&#32;-We announced enrollment of the 700th patient in our Phase 3 PRESENT clinical trial.</font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;text-indent:66px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">On February 9, 2015, we announced the enrollment in the NeuVax Phase 3 PRESENT clinical trial of the 700th patient, which is the patient enrollment target as defined by the PRESENT Phase 3 clinical trial protocol. </font></div><div style="line-height:120%;text-align:left;text-indent:66px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:66px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:66px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:66px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><br><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">35</font></div></div><hr style="page-break-after:always"><a name="sC92C38A3445E5960BA88AC2E3044A8C1"></a><br><div style="line-height:120%;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#00497f;font-weight:bold;">Results of Operations for the Three and Nine Months Ended </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#00497f;font-weight:bold;">September&#160;30, 2015</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#00497f;font-weight:bold;">&#32;and 2014 </font></div><div style="line-height:120%;text-indent:54px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-indent:54px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Our net loss for the three months ended </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">September&#160;30, 2015</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;increased approximately </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$11.9 million</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">, primarily attributable to a $8.1 million impairment charge from classification of our commercial asset group as held for sale for the three months ended </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">September&#160;30, 2015</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;and a </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$6.7 million</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;non-cash gain on our warrant liability for the three months ended </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">September&#160;30, 2014</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">, compared to a </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$2.1 million</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;non-cash gain on our warrant liability for the three months ended </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">September&#160;30, 2015</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">. This was partially offset by a </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$1.9 million</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;reduction in operating loss for the three months ended </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">September&#160;30, 2015</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;compared to the three months ended </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">September&#160;30, 2014</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">.</font></div><div style="line-height:120%;text-indent:54px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.90243902439025%;border-collapse:collapse;text-align:left;"><tr><td colspan="11"></td></tr><tr><td width="53%"></td><td width="1%"></td><td width="13%"></td><td width="1%"></td><td width="1%"></td><td width="1%"></td><td width="13%"></td><td width="1%"></td><td width="1%"></td><td width="14%"></td><td width="1%"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;font-style:italic;">(dollars in thousands)</font></div></td><td colspan="10" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;font-weight:bold;">Three Months Ended September 30,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;font-weight:bold;">2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;font-weight:bold;">2014</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;font-weight:bold;">% Change</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Operating loss</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(8,635</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(10,567</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">18</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#160;%</font></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Non-operating income (expense)</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">2,283</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">7,035</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(68</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)%</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Loss from discontinued operations</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(11,674</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(2,641</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(342</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)%</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Net loss</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(18,026</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(6,173</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(192</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)%</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Net loss per common share:</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Basic and diluted net loss per share, continuing operations</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(0.04</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(0.03</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(33</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)%</font></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Basic and diluted net loss per share, discontinued operations</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(0.07</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(0.02</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(250</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)%</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Basic net loss per share</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(0.11</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(0.05</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(120</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)%</font></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-indent:54px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Or net loss for the nine months ended </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">September&#160;30, 2015</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;increased approximately </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$15.6 million</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">, primarily attributable to a $8.1 million impairment charge from classification of our commercial asset group as held for sale for the three months ended </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">September&#160;30, 2015</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;and a $13.2 million non-cash gain on our warrant liability for the nine months ended </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">September&#160;30, 2014</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">, compared to a $1.0 million non-cash loss on our warrant liability for the nine months ended </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">September&#160;30, 2015</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">. This was partially offset by a </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$7.6 million</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;reduction in operating loss for the nine months ended </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">September&#160;30, 2015</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;compared to the nine months ended </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">September&#160;30, 2014</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">.</font></div><div style="line-height:120%;text-indent:54px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.90243902439025%;border-collapse:collapse;text-align:left;"><tr><td colspan="11"></td></tr><tr><td width="53%"></td><td width="1%"></td><td width="13%"></td><td width="1%"></td><td width="1%"></td><td width="1%"></td><td width="13%"></td><td width="1%"></td><td width="1%"></td><td width="14%"></td><td width="1%"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;font-style:italic;">(dollars in thousands)</font></div></td><td colspan="10" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;font-weight:bold;">Nine Months Ended September 30,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;font-weight:bold;">2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;font-weight:bold;">2014</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;font-weight:bold;">% Change</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Operating loss</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(26,631</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(34,207</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">22</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#160;%</font></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Non-operating income (expense)</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(1,519</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">12,190</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(112</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)%</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Loss from discontinued operations</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(16,074</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(6,633</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(142</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)%</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Net loss</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(44,224</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(28,650</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(54</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)%</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Net loss per common share:</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Basic and diluted net loss per share, continuing operations</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(0.18</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(0.19</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">5</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#160;%</font></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Basic and diluted net loss per share, discontinued operations</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(0.11</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(0.06</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(83</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)%</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Basic net loss per share</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(0.29</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(0.25</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(16</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)%</font></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><br><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">36</font></div></div><hr style="page-break-after:always"><a name="sC92C38A3445E5960BA88AC2E3044A8C1"></a><br><div style="line-height:120%;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#006ebf;font-style:italic;font-weight:bold;">Research and Development Expense</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-indent:54px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Research and development expense consists primarily of clinical trial expenses, compensation-related costs for our employees dedicated to research and development activities, compensation paid to our Scientific Advisory Board (&#8220;SAB&#8221;) members, and licensing fees and patent prosecution costs. Research and development expense for the three and nine months ended </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">September&#160;30, 2015</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">2014</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">, respectively, was as follows (dollars in thousands):</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="22"></td></tr><tr><td width="33%"></td><td width="1%"></td><td width="9%"></td><td width="1%"></td><td width="1%"></td><td width="1%"></td><td width="9%"></td><td width="1%"></td><td width="1%"></td><td width="8%"></td><td width="1%"></td><td width="1%"></td><td width="1%"></td><td width="9%"></td><td width="1%"></td><td width="1%"></td><td width="1%"></td><td width="9%"></td><td width="1%"></td><td width="1%"></td><td width="8%"></td><td width="1%"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="10" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;font-weight:bold;">Three Months Ended September 30,</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="10" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;font-weight:bold;">Nine Months Ended September 30,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;font-weight:bold;">2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;font-weight:bold;">2014</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;font-weight:bold;">% Change</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;font-weight:bold;">2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;font-weight:bold;">2014</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;font-weight:bold;">% Change</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Research and development expense</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">5,740</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">7,025</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(18</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">18,762</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">21,463</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(13</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)%</font></div></td></tr></table></div></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:54px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">The decreases of 18% and 13% for the three and nine months ended </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">September&#160;30, 2015</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;compared to the three and nine months ended </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">September&#160;30, 2014</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;in research and development expense was primarily related to the completion of our enrollment efforts for the Phase 3 PRESENT clinical trial in the second quarter of 2015. We expect research and development expense related to our PRESENT trial to decrease throughout 2015 as we transition to the monitoring and follow-up phase. The expected decrease in costs could be partially offset by the increase in research and development expense related to enrollment efforts in our NeuVax combination clinical trials, ongoing trial costs related to our GALE-301 Phase 2 clinical trial, and completion of our Phase 2 clinical trial of the GALE-401 program. </font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#006ebf;font-style:italic;font-weight:bold;">General and Administrative Expense</font></div><div style="line-height:120%;text-indent:32px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-indent:54px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">General and administrative expense includes compensation-related costs for our employees dedicated to general and administrative activities, legal fees, audit and tax fees, consultants and professional services, and general corporate expenses. General and administrative expense for the three and nine months ended </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">September&#160;30, 2015</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">2014</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">, respectively, was as follows (dollars in thousands):</font></div><div style="line-height:120%;text-indent:32px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:95.80487804878048%;border-collapse:collapse;text-align:left;"><tr><td colspan="22"></td></tr><tr><td width="33%"></td><td width="1%"></td><td width="9%"></td><td width="1%"></td><td width="1%"></td><td width="1%"></td><td width="9%"></td><td width="1%"></td><td width="1%"></td><td width="8%"></td><td width="1%"></td><td width="1%"></td><td width="1%"></td><td width="9%"></td><td width="1%"></td><td width="1%"></td><td width="1%"></td><td width="9%"></td><td width="1%"></td><td width="1%"></td><td width="8%"></td><td width="1%"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="10" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;font-weight:bold;">Three Months Ended September 30,</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="10" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;font-weight:bold;">Nine Months Ended September 30,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;font-weight:bold;">2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;font-weight:bold;">2014</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;font-weight:bold;">% Change</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;font-weight:bold;">2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;font-weight:bold;">2014</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;font-weight:bold;">% Change</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">General and administrative expense</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">2,895</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">3,542</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(18</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">7,869</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">12,744</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(38</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)%</font></div></td></tr></table></div></div><div style="line-height:120%;text-indent:32px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:54px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">The </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">18%</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">38%</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;decreases in selling, general, and administrative expense for the three and nine months ended </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">September&#160;30, 2015</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;compared to the three and nine months ended </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">September&#160;30, 2014</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">, respectively, was driven by the $0.7 million and $3 million incurred in legal expenses during the three and nine months ended </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">September&#160;30, 2014</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">, respectively, related to the ongoing litigation and proceedings described in Part II, Item 1 of this report. During the third quarter of 2014 we exceeded the retention (deductible) under our insurance policy and have been realizing significant insurance recoveries against the fees associated with the litigation and proceedings referenced above. </font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#006ebf;font-style:italic;font-weight:bold;">Non-Operating Income </font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Non-operating income for the three and nine months ended </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">September&#160;30, 2015</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">2014</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">, respectively, was as follows (dollars in thousands):</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="22"></td></tr><tr><td width="33%"></td><td width="1%"></td><td width="9%"></td><td width="1%"></td><td width="1%"></td><td width="1%"></td><td width="9%"></td><td width="1%"></td><td width="1%"></td><td width="8%"></td><td width="1%"></td><td width="1%"></td><td width="1%"></td><td width="9%"></td><td width="1%"></td><td width="1%"></td><td width="1%"></td><td width="9%"></td><td width="1%"></td><td width="1%"></td><td width="8%"></td><td width="1%"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="10" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;font-weight:bold;">Three Months Ended September 30,</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="10" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;font-weight:bold;">Nine Months Ended September 30,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;font-weight:bold;">2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;font-weight:bold;">2014</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;font-weight:bold;">% Change</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;font-weight:bold;">2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;font-weight:bold;">2014</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;font-weight:bold;">% Change</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">Change in fair value of warrants potentially settleable in cash</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">2,134</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">6,735</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(68</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(981</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">13,174</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(107</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)%</font></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">Interest income (expense), net</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(158</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(297</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(47</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(607</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(925</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(34</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)%</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">Other income (expense)</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">307</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">597</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(49</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">69</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(59</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(217</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)%</font></div></td></tr><tr><td style="vertical-align:top;padding-left:44px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">Total non-operating income (expense), net</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">2,283</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">7,035</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(68</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(1,519</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">12,190</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(112</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)%</font></div></td></tr></table></div></div><br><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">37</font></div></div><hr style="page-break-after:always"><a name="sC92C38A3445E5960BA88AC2E3044A8C1"></a><br><div style="line-height:120%;text-indent:54px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">The decrease in our non-operating income (increase in our net non-operating expense) during the three and nine months ended </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">September&#160;30, 2015</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;compared to the three and nine months ended </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">September&#160;30, 2014</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;was primarily due to a increase in the change in fair value of warrants accounted for as liabilities. This increase in the estimated fair value of our warrant liabilities was primarily due to the increase in our common stock price, which is one of the most impactful inputs into the pricing model we use to estimate the fair value of our warrant liabilities.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#006ebf;font-style:italic;font-weight:bold;">Income Taxes</font></div><div style="line-height:120%;text-indent:32px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-indent:66px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">For the three and nine months ended </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">September&#160;30, 2015</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;and 2014, there was no income tax benefit or expense recognized.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#006ebf;font-style:italic;font-weight:bold;">Discontinued Operations</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">During the quarter ended </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">September&#160;30, 2015</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">, we conducted a strategic review of our commercial business and operations, and as a result of that review have decided to sell or otherwise divest our commercial business.  We believe this disposition will allow us to focus our resources on our valuable and expanding clinical development programs and maximize the value of these assets to our shareholders.</font></div><div style="line-height:120%;text-indent:66px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-indent:66px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">The following table represents the components attributable to the commercial operations that are presented in the consolidated statement of operations as discontinued operations (in thousands):</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.90243902439025%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"></td></tr><tr><td width="45%"></td><td width="1%"></td><td width="11%"></td><td width="1%"></td><td width="1%"></td><td width="1%"></td><td width="11%"></td><td width="1%"></td><td width="1%"></td><td width="1%"></td><td width="11%"></td><td width="1%"></td><td width="1%"></td><td width="1%"></td><td width="11%"></td><td width="1%"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Three Months Ended September 30,</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Nine Months Ended September 30,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">2014</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">2014</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Net revenue</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">2,166</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">1,620</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">8,298</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">6,124</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Cost of revenue</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(712</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(247</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(1,573</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(925</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Amortization of certain acquired intangible assets</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(208</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(70</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(795</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(259</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Research and development</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(160</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(219</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(339</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(619</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Selling, general, and administrative</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(4,672</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(3,725</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(13,577</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(10,954</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Non-operating income (loss)</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(17</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(17</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Impairment charge from classification of assets held for sale</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(8,071</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(8,071</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Loss from discontinued operations</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(11,674</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(2,641</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(16,074</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(6,633</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-indent:66px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Discontinued operations comprise net revenue, cost of revenue, and expenses attributable to our commercial operations, which we plan to divest.</font></div><div style="line-height:120%;text-indent:66px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-left:48px;text-indent:36px;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;padding-right:12px;">&#8226;</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;">Net Revenue </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">included in discontinued operations comprises revenue from the sale of Abstral, which were provided by our commercial operations. </font></div><div style="line-height:120%;padding-left:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-left:48px;text-indent:36px;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;padding-right:12px;">&#8226;</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;">Cost of revenue </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">included in discontinued operations consists of direct products costs and related overhead, Abstral royalties based on net revenue, inventory obsolescence, and other direct costs. </font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-left:48px;text-indent:36px;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;padding-right:12px;">&#8226;</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;">Research and development expense</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;included in discontinued operations consists of expenses related to our Abstral RELIEF trial and other product stability costs.</font></div><div style="line-height:120%;padding-left:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-left:48px;text-indent:36px;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;padding-right:12px;">&#8226;</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;">Selling, general and administrative </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">included in discontinued operations consists of all other expenses of our commercial operations that are required in order to market and sell our marketed products. These expenses include all personnel related costs, marketing, data, consulting, legal, consulting, and other outsider services necessary to support the commercial operations. </font></div><div style="line-height:120%;padding-left:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-left:48px;text-indent:36px;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;padding-right:12px;">&#8226;</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;">Impairment charge from classification of assets held for sale </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">included in discontinued operations relates the carrying value of the intangible assets, net that was in excess of fair value by $8.1 million for the three and nine months ended September 30, 2015.</font></div><div style="line-height:120%;padding-left:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><br><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">38</font></div></div><hr style="page-break-after:always"><a name="s70B5CC40F6E65A53AB4FB06EFB87664D"></a><br><div style="line-height:120%;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#00497f;font-weight:bold;">Liquidity and Capital Resources</font></div><div style="line-height:120%;text-indent:32px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-indent:66px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">We had cash and cash equivalents of approximately </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$34.8 million</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;as of </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">September&#160;30, 2015</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">, compared with </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$23.7 million</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;as of December&#160;31, 2014. </font></div><div style="line-height:120%;text-indent:66px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-indent:66px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">The increase of approximately </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$11.2 million</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;in our cash and cash equivalents from December&#160;31, 2014 to </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">September&#160;30, 2015</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;was attributable primarily to $47.4 million in net proceeds from issuance of common stock and warrants to purchase common stock, partially offset by $32.9 million used in operating activities, $2.9 million in payments on long-term debt, and $0.5 million for a milestone related to our acquisition of U.S. rights to Zuplenz.</font></div><div style="line-height:120%;text-indent:66px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:66px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">On March 18, 2015, we announced the closing of our underwritten public offering of 24,358,974 shares of common stock and 12,179,487 warrants to purchase our common stock at an exercise price of $2.08. The underwriters also exercised their over-allotment option to purchase warrants to purchase an aggregate of 1,826,923 shares of our common stock. On April 10, 2015 the underwriters exercised their option to purchase an additional 3,653,846 shares of common stock for additional net proceeds of $5.4 million. The total net proceeds to us were approximately $40.8 million. </font></div><div style="line-height:120%;text-align:left;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">We expect to continue to incur losses from our discontinued operations in the fourth quarter of 2015 as management actively focuses on locating a buyer for our commercial operations. In the absence of revenue from the commercialization of Abstral, Zuplenz or our product candidates, our potential sources of operational funding are proceeds from the sale of equity and funded research and development payments and payments received under partnership and collaborative agreements.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#006ebf;font-style:italic;font-weight:bold;">Cash Flows</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:66px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">The following table summarizes our cash flows from operating, investing, and financing activities for the nine months ended </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">September&#160;30, 2015</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">September&#160;30, 2014</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;($ in thousands):</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:95.12670565302143%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"></td></tr><tr><td width="59%"></td><td width="1%"></td><td width="18%"></td><td width="1%"></td><td width="1%"></td><td width="1%"></td><td width="18%"></td><td width="1%"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">For the Nine Months Ended September 30,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">2014</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">Cash flows from continuing operations:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">Cash flows used in continuing operating activities</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(27,829</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(28,743</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">Cash flows used in continuing investing activities</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(282</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(2,363</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">Cash flows provided by continuing financing activities</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">44,854</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">14,414</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">Total cash flows provided by (used in) continuing operating activities</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">16,743</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(16,692</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">Cash flows from discontinued operations:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">Cash flows used in discontinued operating activities</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(5,047</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(3,392</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">Cash flows used in discontinued investing activities</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(534</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(3,056</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">Total cash flows provided by (used in) discontinued operating activities</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(5,581</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(6,448</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">Total cash flows:</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">Cash flows used in operating activities</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(32,876</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(32,135</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">Cash flows used in investing activities</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(816</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(5,419</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">Cash flows provided by financing activities</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">44,854</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">14,414</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">Total increase (decrease) in cash and cash equivalents</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">11,162</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(23,140</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><br><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">39</font></div></div><hr style="page-break-after:always"><a name="s70B5CC40F6E65A53AB4FB06EFB87664D"></a><br><div style="line-height:120%;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#006ebf;font-style:italic;font-weight:bold;">Net Cash Flow from Operating Activities</font></div><div style="line-height:120%;text-indent:32px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-indent:66px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Net cash used in operating activities increased </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$0.7 million</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;for the nine months ended </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">September&#160;30, 2015</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">, compared to the nine months ended </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">September&#160;30, 2014</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">. The increase in cash used in operating activities was driven by an increase of </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$1.7 million</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;cash used in our discontinued operations activities, partially offset by a reduction of </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$0.9 million</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;for the continuing operating activities. The increase in total net cash used in continuing operating activities was due to a </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$11.4 million</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;increase in non-cash charges, partially offset by an increase in net loss from continuing operations of </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$6.1 million</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;and an increase in payments on accounts payable and other current liabilities of </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$4.7 million</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;for the nine months ended </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">September&#160;30, 2015</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">, compared to the nine months ended </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">September&#160;30, 2014</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#006ebf;font-style:italic;font-weight:bold;">Net Cash Flow from Investing Activities</font></div><div style="line-height:120%;text-indent:32px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-indent:66px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Net cash used in investing activities was </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$0.8 million</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;for the nine months ended </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">September&#160;30, 2015</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">, compared with </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$5.4 million</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;for the nine months ended </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">September&#160;30, 2014</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">. The decrease was due to the $2.1 million initial payment for GALE-401 rights and the $3.1 million initial cash payment for U.S. right to Zuplenz during the nine months ended </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">September&#160;30, 2014</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;compared to the $0.5 million milestone payment for U.S. rights to Zuplenz during the nine months ended </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">September&#160;30, 2015</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">. </font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#006ebf;font-style:italic;font-weight:bold;">Net Cash Flow from Financing Activities</font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-indent:66px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Net cash provided by financing activities was </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$44.9 million</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;for the nine months ended </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">September&#160;30, 2015</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">, compared with </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$14.4 million</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;for the nine months ended </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">September&#160;30, 2014</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">. The increase was primarily attributable to $42.2 million in net proceeds from the issuance of common stock and warrants to purchase common stock during the nine months ended </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">September&#160;30, 2015</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;compared to net proceeds of common stock warrant exercises of&#160;$10.7 million&#160;and net proceeds of common stock option exercises of&#160;$4.1 million&#160;during the nine months ended&#160;</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">September&#160;30, 2014</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">. The cash flows provided by financing activities were partially offset by principle payments on long-term debt of $2.9 million and $0.9 million for the nine month periods ended </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">September&#160;30, 2015</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;and 2014, respectively.</font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><a name="s6625643D3DDD535D86CCD6A9C7458D1F"></a><div style="line-height:120%;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#00497f;font-weight:bold;">Off-Balance Sheet Arrangements</font></div><div style="line-height:120%;text-indent:32px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-indent:66px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">We have not entered into any off-balance sheet financing arrangements other than operating leases.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#00497f;font-weight:bold;">Critical Accounting Policies and Estimates</font></div><div style="line-height:120%;text-indent:32px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-indent:66px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">In our Annual Report on Form 10-K for the year ended December&#160;31, 2014, we disclosed our critical accounting policies and estimates upon which our financial statements are derived. There have been no changes to these policies since December&#160;31, 2014 that are not included in Note 1 of the accompanying condensed consolidated financial statements for the three and nine months ended September 30, 2015. Readers are encouraged to read our Annual Report on Form 10-K in conjunction with this report.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><a name="s7584FFB80EBE5FD3B2E7666E684A0966"></a><div style="line-height:120%;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#00497f;font-weight:bold;">&#160;ITEM&#160;3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK.</font></div><div style="line-height:120%;text-indent:32px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-indent:32px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">The primary objective of our investment activities is to preserve capital. We do not utilize hedging contracts or similar instruments.</font></div><div style="line-height:120%;text-indent:32px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">We are exposed to certain market risks relating primarily to interest rate risk on our cash and cash equivalents and risks relating to the financial viability of the institutions which hold our capital and through which we have invested our funds. We manage the latter risks by investing primarily in money market mutual funds.</font></div><div style="line-height:120%;text-indent:32px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">In addition, we are exposed to foreign currency exchange rate fluctuations relating to payments we make to certain vendors and suppliers and license partners using foreign currencies. We do not hedge against foreign currency risks. Consequently, changes in exchange rates could adversely affect our operating results and stock price. Such losses have not been significant to date.</font></div><div style="line-height:120%;text-indent:32px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><br><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">40</font></div></div><hr style="page-break-after:always"><a name="s644700A3FB855EF0BA1ED4F30BD9757C"></a><br><div style="line-height:120%;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#00497f;font-weight:bold;">ITEM&#160;4. CONTROLS AND PROCEDURES</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#006ebf;font-weight:bold;">Disclosure Controls and Procedures</font></div><div style="line-height:120%;text-indent:32px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-indent:32px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">As of the end of the period covered by this quarterly report on Form 10-Q, our principal executive officer and our principal financial officer (the &#8220;Certifying Officers&#8221;), evaluated the effectiveness of our disclosure controls and procedures. Disclosure controls and procedures are controls and procedures designed to reasonably assure that information required to be disclosed in our reports filed under the Securities Exchange Act of 1934 (the &#8220;Exchange Act&#8221;), such as this quarterly report on Form 10-Q, is recorded, processed, summarized and reported within the time periods specified in the SEC rules and forms. Disclosure controls and procedures are also designed to reasonably assure that such information is accumulated and communicated to our management, including the Certifying Officers, as appropriate to allow timely decisions regarding required disclosure. Based on these evaluations, the Certifying Officers have concluded, that, as of the end of the period covered by this quarterly report on Form 10-Q:</font></div><div style="line-height:120%;text-indent:32px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(a)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">our disclosure controls and procedures were effective to provide reasonable assurance that information required to be disclosed by us in the reports we file or submit under the Exchange Act was recorded, processed, summarized and reported within the time periods specified in the SEC&#8217;s rules and forms; and</font></div></td></tr></table><div style="line-height:120%;padding-left:4px;text-align:left;padding-left:48px;text-indent:-48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(b)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">our disclosure controls and procedures were effective to provide reasonable assurance that material information required to be disclosed by us in the reports we file or submit under the Exchange Act was accumulated and communicated to our management, including the Certifying Officers, as appropriate to allow timely decisions regarding required disclosure.</font></div></td></tr></table><div style="line-height:120%;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#006ebf;font-weight:bold;">Changes in Internal Control over Financial Reporting</font></div><div style="line-height:120%;text-indent:32px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-indent:32px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">There has been no change in our internal control over financial reporting that occurred during the three months ended </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">September&#160;30, 2015</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.</font></div><div style="line-height:120%;text-indent:32px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><br><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">41</font></div></div><hr style="page-break-after:always"><a name="s903205EAEC5E525596163163AE5F602D"></a><br><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#00497f;font-weight:bold;">PART II - OTHER INFORMATION</font></div><a name="s8A43068AD6EA57BEA1C78C530E5F20E5"></a><div style="line-height:120%;padding-bottom:16px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#00497f;font-weight:bold;">ITEM&#160;1. LEGAL PROCEEDINGS</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;">Legal Proceedings</font></div><div style="line-height:120%;text-align:left;text-indent:65px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;">In re Galena Biopharma, Inc. Securities Litigation and In Re Galena Biopharma, Inc. Derivative Litigation</font></div><div style="line-height:120%;text-align:left;padding-left:48px;text-indent:65px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">On August 4, 2015, plaintiffs in the voluntarily dismissed Delaware derivative action have filed a motion seeking to file under seal a derivative complaint in the District Court.  That motion was granted and on August 31, 2015, that action was consolidated with </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;">In Re Galena Biopharma, Inc. Derivative Litigation</font><font style="font-family:inherit;font-size:10pt;">.</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">On or about September 15, 2015, a federal securities lawsuit was filed in the U.S. District Court for the District of Oregon entitled, </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;">Riley v. Galena Biopharma, Inc., et al</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">.  The time to answer or otherwise plead has been extended by agreement of the parties.</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">We intend to vigorously defend against and seek resolution to the foregoing claims.  As of September 30, 2015, we have not recorded any</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-weight:bold;">&#32;</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">liabilities with respect to the claims in our consolidated financial statements.  We believe that claims are covered under our liability insurance, and we have notified our insurance carriers of the claims.  The insurers have responded by requesting additional information and by reserving their rights under the policies, including the rights to deny coverage under various policy exclusions.  Subject to their reservation of rights, we are being reimbursed by our insurance carriers for significant portion of all legal fees relating to our defense of the claims. We have entered into certain undertaking agreements with our directors related to the litigation by which we have agreed to advance reasonable legal fees and costs for the litigation under certain conditions.</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;">SEC Investigation</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">We are aware that the Securities and Exchange Commission (SEC) is investigating certain matters relating to the use of certain outside investor-relations professionals by us and other public companies.  We have been in contact with the SEC staff through our counsel and are cooperating with the investigation.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;">ANDA Litigation</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;On October 23, 2015, Orexo AB (&#8220;Orexo&#8221;) and Galena Biopharma, Inc. (the &#8220;Company&#8221;) entered into a settlement and license agreement with Actavis Laboratories FL, Inc. (&#8220;Actavis&#8221;) to resolve pending patent litigation brought by the Orexo against Actavis involving Abstral&#174; (fentanyl) sublingual tablets.  The pending patent litigation was filed by Orexo in the U.S. District Court for the District of New Jersey in response to Actavis&#8217; submission of an Abbreviated New Drug Application (&#8220;ANDA&#8221;) to the U.S. Food and Drug Administration (&#8220;FDA&#8221;), seeking marketing approval for a generic version of Abstral.  As a result of the settlement and license agreement, Actavis will be permitted to enter the market with a generic or authorized generic version of Abstral in the United States June 2018 or earlier under certain circumstances. The Court has entered an order dismissing with prejudice the litigation against Actavis.  Details of the settlement are confidential, and the parties have submited the agreement to the Federal Trade Commission and the Department of Justice, as required by federal law. The expiration date for the latest expiring Abstral patent listed in the FDA&#8217;s Orange Book is September 2019.</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><br><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">42</font></div></div><hr style="page-break-after:always"><a name="s76F6AEAD21315C35B693A1582D410A6E"></a><br><div style="line-height:120%;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#00497f;font-weight:bold;">ITEM 1A. RISK FACTORS</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-indent:66px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;">In addition the risk factors included in our Annual Report on Form 10-K for the year ended December 31, 2014 and in our previously filed Quarterly Reports on Form 10-Q for the quarters ended March 31, 2015 and June 30, 2015 filed with the SEC, you should consider the following new or updated risk factors:</font></div><div style="line-height:120%;text-indent:66px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#006ebf;font-weight:bold;">Risks Related to Our Business</font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">We have determined to sell or otherwise dispose of our marketed products, Abstral, and Zuplenz, and we do not know whether the process will result in significant value for our stockholders.</font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">We have determined to sell or otherwise dispose of our marketed products, Abstral and Zuplenz, and discontinue our commercial operations in order to focus our resources on our clinical development programs. There can be no assurance that any sale of our marketed products could be completed in a timely manner, on a cost-effective basis, on terms favorable to us, or at all. The sale of assets entails numerous potential risks, including:</font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">diversion of resources and management&#8217;s attention from the operation of our business;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">loss of key employees in anticipation of or following such a sale;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">insufficient sale proceeds to offset transaction-related expenses;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">negative effects on our reported results of operations from discontinued operations, disposition-related charges, amortization of expenses related to intangibles and charges for impairment of long-term assets; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">damage to our existing investor, customer and supplier relationships.</font></div></td></tr></table><div style="line-height:120%;text-align:left;padding-left:96px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">If there is not sufficient interest from potential purchasers, we may seek to transfer Abstral and Zuplenz back to the companies from which we acquired the products, and cease our commercial operations, including separating our commercial operation employees.  We do not know whether or at what cost we would be able to transfer the products, or if there would be any continuing obligations required of us following the transfer of either or both products.  We would expect to incur significant costs associated with separating our commercial operations employees from our company.</font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">We believe that our strategy will result in significant future net savings to us, but there is no assurance that we will obtain any significant proceeds from the sale or other disposition of our commercial operations or that the process will result in significant value for our stockholders.  If we sell or discontinue our commercial operations, we will have no recurring revenue unless and until we are able to obtain marketing approval of one or more of our product candidates.</font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">We are subject, directly or indirectly, to U.S. federal and state health care fraud and abuse and false claims laws and regulations. Prosecutions under such laws have increased in recent years and we may become subject to such investigations or litigation. If we are unable to, or have not fully complied with such laws, we could face substantial penalties.</font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Our commercial operations are directly, or indirectly through our customers and health care professionals, subject to various U.S. federal and state fraud and abuse laws, including, without limitation, the federal Anti-Kickback Statute, federal False Claims Act, federal Sunshine Act, and federal Foreign Corrupt Practices Act. These laws may impact, among other things, our product sales, and marketing and education programs.</font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">The federal Anti-Kickback Statute prohibits persons from knowingly and willfully soliciting, offering, receiving, or providing remuneration, directly or indirectly, in exchange for or to induce either the referral of an individual, or the furnishing or arranging for a good or service, for which payment may be made under a federal health care program such as the Medicare and Medicaid programs. Several courts have interpreted the statute&#8217;s intent requirement to mean that if any one purpose of an arrangement involving remuneration is to induce referrals of federal health care covered business, the statute has been violated. The Anti-Kickback Statute is broad, and despite a series of narrow safe harbors, prohibits many arrangements and practices that are lawful in businesses outside of the health care industry. Penalties for violations of the federal Anti-Kickback Statute include criminal penalties and civil and administrative sanctions such as fines, imprisonment and possible exclusion from Medicare, Medicaid and other federal health care programs. An alleged violation of the Anti-Kickback Statute may be used as a predicate offense to establish liability pursuant to other federal laws and regulations such as the federal False Claims Act. Many states </font></div><br><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">43</font></div></div><hr style="page-break-after:always"><a name="s76F6AEAD21315C35B693A1582D410A6E"></a><br><div style="line-height:120%;padding-bottom:13px;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">have also adopted laws similar to the federal Anti-Kickback Statute, some of which apply to the referral of patients for health care items or services reimbursed by any source, not only Medicare and Medicaid programs.</font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">The federal False Claims Act prohibits persons from knowingly filing, or causing to be filed, a false claim to, or the knowing use of false statements to obtain payment from, the federal government. Suits filed under the False Claims Act, known as &#8220;qui tam&#8221; actions, can be brought by any individual on behalf of the government and such individuals, commonly known as &#8220;relators&#8221; or &#8220;whistleblowers,&#8221; may share in any amounts paid by the entity to the government in fines or settlement. The frequency of filing qui tam actions has increased significantly in recent years, causing greater numbers of health care companies to have to defend a False Claim Act action. The federal Patient Protection and Affordable Care Act includes provisions expanding the ability of certain relators to bring actions that would have been dismissed under prior law. When an entity is determined to have violated the federal False Claims Act, it may be required to pay up to three times the actual damages sustained by the government, plus civil penalties for each separate false claim. The Deficit Reduction Act of 2005 encouraged states to enact or modify their state false claims acts to be at least as effective as the federal False Claims Act by granting states a portion of any federal Medicaid funds recovered through Medicaid-related actions. Most states have enacted state false claims laws, and many of those states included laws including qui tam provisions.</font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">The federal Patient Protection and Affordable Care Act includes provisions known as the Physician Payments Sunshine Act, which requires manufacturers of drugs, biologics, devices and medical supplies covered under Medicare and Medicaid to record any transfers of value to physicians and teaching hospitals and to report this data beginning in 2013 to the Centers for Medicare and Medicaid Services for subsequent public disclosures. Manufacturers must also disclose investment interests held by physicians and their family members. Failure to submit the required information may result in civil monetary penalties of up to $1 million per year for knowing violations and may result in liability under other federal laws or regulations. Similar reporting requirements have also been enacted on the state level in the U.S., and an increasing number of countries worldwide either have adopted or are considering similar laws requiring transparency of interactions with health care professionals. In addition, some states such as Massachusetts and Vermont imposed an outright ban on certain gifts to physicians. These laws could affect our product promotional activities by limiting the kinds of interactions we could have with hospitals, physicians or other potential purchasers or users of our system. Both the disclosure laws and gift bans also will impose administrative, cost and compliance burdens on us.</font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">We are unable to predict whether we could become subject to actions under any of these laws, or the impact of such actions. If we are found to be in violation of any of the laws described above and other applicable state and federal fraud and abuse laws, we may be subject to penalties, including civil and criminal penalties, damages, fines, or an administrative action of suspension or exclusion from government health care reimbursement programs and the curtailment or restructuring of our commercial operations.</font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">In addition, to the extent we commence commercial operations and conduct clinical trials overseas, we will be subject to the Foreign Corrupt Practices Act and other countries&#8217; anti-corruption/anti-bribery regimes, such as the U.K. Bribery Act. The Foreign Corrupt Practices Act prohibits improper payments or offers of payments to foreign governments and their officials for the purpose of obtaining or retaining business. Safeguards we implement to discourage improper payments or offers of payments by our employees, consultants, sales agents or distributors may be ineffective, and violations of the Foreign Corrupt Practices Act and similar laws may result in severe criminal or civil sanctions, or other liabilities or proceedings against us, any of which would likely harm our reputation, business, financial conditions and results of operations.</font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">Risks associated with operating in foreign countries could materially adversely affect our product development.</font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">We conduct our Phase 3 PRESENT study of NeuVax in countries outside of the U.S. Consequently, we are, and will continue to be, subject to risks related to operating in foreign countries. Risks associated with conducting operations in foreign countries include:</font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">differing regulatory requirements for drug approvals and regulation of approved drugs in foreign countries;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">unexpected changes in tariffs, trade barriers and regulatory requirements; economic weakness, including inflation, or political instability in particular foreign economies and markets; compliance </font></div></td></tr></table><br><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">44</font></div></div><hr style="page-break-after:always"><a name="s76F6AEAD21315C35B693A1582D410A6E"></a><br><div style="line-height:120%;padding-left:96px;text-align:left;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">with tax, employment, immigration and labor laws for employees living or traveling abroad; foreign taxes, including withholding of payroll taxes;</font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">foreign currency fluctuations, which could result in increased operating expenses or reduced revenues, and other obligations incident to doing business or operating in another country;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">workforce uncertainty in countries where labor unrest is more common than in the U.S.;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">production shortages resulting from any events affecting raw material supply or manufacturing capabilities abroad; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">business interruptions resulting from geopolitical actions, including war and terrorism.</font></div></td></tr></table><div style="line-height:120%;text-align:left;padding-left:96px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">In addition, there may be political instability, including war, terrorism, riots, civil insurrection or social unrest, and natural or man-made disasters, including famine, flood, fire, earthquake, storm or disease, which could seriously harm the progress of our clinical trials at sites in particular foreign countries or regions. For example, approximately 39% of our Phase 3 PRESENT trial sites and approximately 44% of patients who have been randomized in the trial are in Russia and The Ukraine. The occupation of certain portions of Ukrainian territory by Russian-backed separatists and ongoing political and civil unrest there could disrupt activities at these trial sites. It is also possible that Russia could retaliate against the imposition of sanctions by the U.S. and the European Union by banning or restricting business activities in Russia by U.S. companies, including the conduct of clinical trials, which could have a material, adverse effect on patient enrollment or ongoing activities at our Phase 3 PRESENT sites in Russia.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-weight:bold;">We may not be successful in obtaining approval as a biological product or obtain favorable market exclusivity in the U.S. or in foreign jurisdictions for our NeuVax product candidates.</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">We intend to seek data exclusivity or market exclusivity provided under the Federal Food, Drug and Cosmetic Act, or FDCA, and similar laws in other countries. We believe that NeuVax will qualify for 12 years of data exclusivity under the Biologics Price Competition and Innovation Act of 2009, or BPCIA, which was enacted as part of the Patient Protection and Affordable Care Act and the Health Care and Education Affordability Reconciliation Act of 2010 (collectively, the Affordable Care Act or ACA) enacted in March 2010. Under the BPCIA, an application for a biosimilar product cannot be submitted to the FDA until four years, or approved by the FDA until 12 years, after the original brand product identified as the reference product is approved under a BLA, The BPCIA provides an abbreviated pathway for the approval of biosimilar and interchangeable biological products. The new abbreviated regulatory pathway establishes legal authority for the FDA to review and approve biosimilar biologics, including the possible designation of a biosimilar as interchangeable based on its similarity to an existing brand product. The new law is complex and is only beginning to be interpreted and implemented by the FDA. While it is uncertain when any such processes may be fully adopted by the FDA, any such processes could have a material adverse effect on the future commercial prospects for our biological products. There is also a risk that the U.S. Congress could amend the BPCIA to shorten this exclusivity period as proposed by President Obama, potentially creating the opportunity for biosimilar competition sooner than anticipated after the expiration of our patent protection. Moreover, the extent to which a biosimilar, once approved, will be substituted for any reference product in a way that is similar to traditional generic substitution for non-biological products is not yet clear, and will depend on a number of marketplace and regulatory factors that are still developing.</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">If NeuVax is not considered a biologic that would qualify for exclusivity under the BPCIA, it may be eligible for market exclusivity as a drug under the FDCA. The FDCA provides a five-year period of non-patent marketing exclusivity within the U.S. to the first applicant to gain approval of an NDA for a new chemical entity. A drug is a new chemical entity if the FDA has not previously approved any other new drug containing the same active moiety, which is the molecule or ion responsible for the action of the drug substance. During the exclusivity period, the FDA may not accept for review an abbreviated new drug application, or ANDA, or a 505(b)(2) NDA, submitted by another company for another version of such drug where the applicant does not own or have a legal right of reference to all the data required for approval. However, an application may be submitted after four years if it contains a certification of patent invalidity or non-infringement. The FDCA also provides three years of marketing exclusivity for an NDA, 505(b)(2) NDA or supplement to an existing NDA if new clinical investigations, other than bioavailability studies, that were conducted or sponsored by the applicant are deemed by FDA to be essential to the approval of the application, for example, for new indications, dosages, or strengths of an existing drug. This three-year exclusivity covers only the conditions associated with the new clinical investigations and does not prohibit the FDA from approving ANDAs for drugs containing the original active agent.</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><br><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">45</font></div></div><hr style="page-break-after:always"><a name="s76F6AEAD21315C35B693A1582D410A6E"></a><br><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">In some countries outside of the U.S., peptide vaccines, such as NeuVax, are regulated as chemical drugs rather than as biologics and may or may not be eligible for non-patent exclusivity.</font></div><div style="line-height:120%;padding-top:24px;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#006ebf;font-weight:bold;">Risks Related to Our Capital Structure</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">Our outstanding warrants may result in dilution to our stockholders.</font></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Our outstanding March 2011 and April 2011 warrants to purchase a total of 791,398 shares of common stock as of December&#160;31, 2014 at a current exercise price of $0.65 per share contain so-called full-ratchet anti-dilution provisions. Our outstanding March 2010 and December 2012 warrants to purchase 25,000 and 3,031,311 shares of common stock as of December&#160;31, 2014 at current exercise prices of $2.02 per share and $1.83 per share, respectively, contain so-called weighted-average anti-dilution provisions. These anti-dilution provisions may be triggered by the issuance of the shares being offered hereby or upon any future issuance by us of shares of our common stock or common stock equivalents at a price per share below the then-exercise price of the warrants, subject to some exceptions.</font></div><div style="line-height:120%;padding-top:16px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">To the extent that these anti-dilution provisions are triggered in the future, we would be required to reduce the exercise price of all of the warrants on either a full-ratchet or weighted-average basis, which would have a dilutive effect on our stockholders.</font></div><div style="line-height:120%;padding-top:16px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:12px;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><br><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">46</font></div></div><hr style="page-break-after:always"><a name="s727BEEC68CA650F2ADAE6DB3BA7C7192"></a><br><div style="line-height:120%;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#00497f;font-weight:bold;">ITEM&#160;6. EXHIBITS</font></div><div style="line-height:120%;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">&#160;</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"></td></tr><tr><td width="8%"></td><td width="1%"></td><td width="44%"></td><td width="47%"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;font-weight:bold;text-decoration:underline;">Exhibit</font></div><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;font-weight:bold;text-decoration:underline;">Number</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">&#160;&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;font-weight:bold;text-decoration:underline;">Description</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:1px;padding-right:2px;"><div style="padding-bottom:1px;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">10.6</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:1px;padding-right:2px;"><div style="padding-bottom:1px;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Settlement and License agreement dated October 23, 2015 between Galena Biopharma, Inc., Actavis Laboratories FL, Inc., and Orexo AB. (3) **</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:1px;padding-right:2px;"><div style="padding-bottom:1px;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">10.7</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:1px;padding-right:2px;"><div style="padding-bottom:1px;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Employment Offer Letter effective October 30, 2015, between Galena Biopharma, Inc. and Bijan Nejadnik, M.D. * **</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:1px;padding-right:2px;"><div style="padding-bottom:1px;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">31.1</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:1px;padding-right:2px;"><div style="padding-bottom:1px;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Sarbanes-Oxley Act Section 302 Certification of Mark W. Schwartz, Ph.D.**</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:1px;padding-right:2px;"><div style="padding-bottom:1px;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">31.2</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:1px;padding-right:2px;"><div style="padding-bottom:1px;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Sarbanes-Oxley Act Section 302 Certification of Ryan M. Dunlap.**</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:1px;padding-right:2px;"><div style="padding-bottom:1px;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">32.1</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:1px;padding-right:2px;"><div style="padding-bottom:1px;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Sarbanes-Oxley Act Section 906 Certification of Mark W. Schwartz, Ph.D., and Ryan M. Dunlap.**</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:1px;padding-right:2px;"><div style="padding-bottom:1px;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">101.INS</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:1px;padding-right:2px;"><div style="padding-bottom:1px;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">XBRL Instance Document.**</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:1px;padding-right:2px;"><div style="padding-bottom:1px;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">101.SCH</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:1px;padding-right:2px;"><div style="padding-bottom:1px;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">XBRL Taxonomy Extension Schema.**</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:1px;padding-right:2px;"><div style="padding-bottom:1px;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">101.CAL</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:1px;padding-right:2px;"><div style="padding-bottom:1px;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">XBRL Taxonomy Extension Calculation.**</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:1px;padding-right:2px;"><div style="padding-bottom:1px;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">101.DEF</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:1px;padding-right:2px;"><div style="padding-bottom:1px;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">XBRL Taxonomy Extension Definition.**</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:1px;padding-right:2px;"><div style="padding-bottom:1px;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">101.LAB</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:1px;padding-right:2px;"><div style="padding-bottom:1px;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">XBRL Taxonomy Extension Label.**</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:1px;padding-right:2px;"><div style="padding-bottom:1px;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">101.PRE</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:1px;padding-right:2px;"><div style="padding-bottom:1px;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">XBRL Taxonomy Extension Presentation.**</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">101.PRE</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">&#160;&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">XBRL Taxonomy Extension Presentation.**</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="2"></td></tr><tr><td width="6%"></td><td width="94%"></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">*</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Indicates a management contract or compensatory plan or arrangement.</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">**</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Filed herewith. </font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(1)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Previously filed as an Exhibit to the Registrant's Form 8-K filed on March 16, 2015 and incorporated herein by reference.</font></div><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(2)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Previously filed as Annex B to the Registrant's Proxy Statement on Schedule 14A filed on April 30, 2015 and incorporated by reference herein by reference.</font></div><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(3)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Portions of the Exhibit filed herewith have been omitted pursuant to a request for confidential treatment.</font></div></td></tr></table></div></div><br><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">47</font></div></div><hr style="page-break-after:always"><a name="s8F04B2C7308D5E4EAFC1DF4A9ABB0973"></a><br><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">SIGNATURES</font></div><div style="line-height:120%;text-indent:32px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-indent:32px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.</font></div><div style="line-height:120%;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">&#160;</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"></td></tr><tr><td width="47%"></td><td width="5%"></td><td width="1%"></td><td width="47%"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">GALENA BIOPHARMA, INC.</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">By:</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">/s/ </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;">Mark W. Schwartz</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">Mark W. Schwartz, Ph.D.</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">President and Chief Executive Officer</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:13px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:13px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:13px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:13px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">Date: November&#160;9, 2015</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">By:</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">/s/ </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;">Ryan M. Dunlap</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">Ryan M. Dunlap</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">Vice President and Chief Financial Officer</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:13px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:13px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:13px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:13px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">Date: November&#160;9, 2015</font></div></td></tr></table></div></div><br><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">48</font></div></div>	</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.6
<SEQUENCE>2
<FILENAME>gale20150930ex106.htm
<DESCRIPTION>EXHIBIT 10.6
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
	<head>
		<!-- Document created using Wdesk 1 -->
		<!-- Copyright 2015 Workiva -->
		<title>Exhibit</title>
	</head>
	<body style="font-family:Times New Roman;font-size:10pt;">
<a name="s718CD66BBECB5B9C28DFED72C1B16187"></a><div><div style="line-height:120%;text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Exhibit 10.7</font></div><div style="line-height:120%;text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">*** Text Omitted and Filed Separately</font></div><div style="line-height:120%;text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Confidential Treatment Requested</font></div><div style="line-height:120%;text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Under 17 C.F.R. &#167;&#167; 200.80(b)(4) and 240.24b-2</font></div></div><br><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">SETTLEMENT AND LICENSE AGREEMENT</font></div><div style="line-height:120%;text-align:justify;text-indent:56px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#32;This Settlement and License Agreement (hereinafter referred to as &#8220;Agreement&#8221;) dated as of this 23</font><font style="font-family:inherit;font-size:12pt;"><sup style="vertical-align:top;line-height:120%;font-size:8pt">rd</sup></font><font style="font-family:inherit;font-size:12pt;">&#32;day of October, 2015 (the &#8220;Effective Date&#8221;), by and among Actavis Laboratories FL, Inc., a company organized and existing under the laws of the State of Florida, having a principal place of business at 4955 Orange Drive, Davie, FL 33314 (&#8220;Actavis&#8221;), Orexo AB, a company organized and existing under the laws of Sweden, having a principal place of business at Virdings all&#233; 32 A, 05 Uppsala, Sweden SE-751 (&#8220;Orexo&#8221;), and Galena Biopharma Inc., having a principle place of business at 4640 SW Macadam Avenue, Portland, OR 97239 (&#8220;Galena&#8221;).  Actavis, Orexo and Galena each are sometimes referred to herein as a &#8220;Party&#8221; and collectively referred to herein as &#8220;Parties.&#8221;</font></div><div style="line-height:138%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">WHEREAS, Orexo is the owner of U.S. Patent Nos. 6,759,059, 6,761,910 and 7,910,132, which are listed in the United States Food and Drug Administration&#8217;s (&#8220;FDA&#8221;) publication </font><font style="font-family:inherit;font-size:12pt;font-style:italic;">Approved Drug Products with Therapeutic Equivalence Evaluations</font><font style="font-family:inherit;font-size:12pt;">&#32;(&#8220;Orange Book&#8221;) for Abstral</font><font style="font-family:inherit;font-size:12pt;"><sup style="vertical-align:top;line-height:120%;font-size:8pt">&#174;</sup></font><font style="font-family:inherit;font-size:12pt;">, Fentanyl Sublingual Tablets, Eq 0.1 mg base, Eq 0.2 mg base, Eq 0.3 mg base, Eq 0.4 mg base, Eq 0.6 mg base and Eq 0.8 mg base. </font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">WHEREAS, Galena is the holder of the Galena New Drug Application (&#8220;NDA&#8221;) No. 022510 and currently manufacturers and markets Fentanyl Sublingual Tablets, Eq 0.1 mg base, Eq 0.2 mg base, Eq 0.3 mg base, Eq 0.4 mg base, Eq 0.6 mg base and Eq 0.8 mg base under NDA No. 022510 (&#8220;Abstral&#8221;); and</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">WHEREAS, Actavis filed Abbreviated New Drug Application (&#8220;ANDA&#8221;) No. 207338 with the FDA, containing certifications pursuant to&#160;21 U.S.C. &#167;&#160;355(j)(2)(A)(vii)(IV) and seeking approval to market generic versions of Abstral before the expiration of U.S. Patent Nos. 6,759,059, 6,761,910 and 7,910,132, which is pending approval at the FDA; and</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">WHEREAS, Orexo and Actavis are parties to a patent infringement litigation captioned, </font><font style="font-family:inherit;font-size:12pt;font-style:italic;">Orexo AB v. Actavis Laboratories FL, Inc., </font><font style="font-family:inherit;font-size:12pt;">No. 3:15-cv-00826, pending in the United States District Court for the District of New Jersey before the Honorable Peter Sheridan (&#8220;Litigation&#8221;), alleging infringement by Actavis of U.S. Patent Nos. 6,759,059, 6,761,910 and 7,910,132 based on Actavis&#8217;s filing of the Actavis ANDA; and</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">WHEREAS, Orexo and Actavis wish to fully settle the Litigation upon the terms and subject to the conditions set forth below. </font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">NOW, THEREFORE, in consideration of the mutual promises and covenants contained in this Agreement and for other good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged, the Parties agree as follows:</font></div><div style="line-height:120%;padding-left:48px;text-align:left;text-indent:48px;"><font style="text-align:left;font-family:inherit;font-size:12pt;padding-right:24px;">1.</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Definitions.</font><font style="font-family:inherit;font-size:12pt;">&#32;&#32;The following terms, when used with initial capital letters shall have the meaning set forth below.</font></div><div style="line-height:120%;text-align:left;padding-left:72px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;padding-left:96px;padding-bottom:16px;text-align:justify;text-indent:48px;"><font style="padding-bottom:16px;text-align:justify;font-family:inherit;font-size:12pt;padding-right:24px;">a.</font><font style="font-family:inherit;font-size:12pt;">&#32;&#8220;Actavis ANDA&#8221; shall mean ANDA No. 207338 as of the Effective Date and any later filed amendments, supplements or replacements thereto seeking </font></div><br><div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">1</font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><hr style="page-break-after:always"><a name="s718CD66BBECB5B9C28DFED72C1B16187"></a><div><div style="line-height:120%;text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Exhibit 10.7</font></div><div style="line-height:120%;text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">*** Text Omitted and Filed Separately</font></div><div style="line-height:120%;text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Confidential Treatment Requested</font></div><div style="line-height:120%;text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Under 17 C.F.R. &#167;&#167; 200.80(b)(4) and 240.24b-2</font></div></div><br><div style="line-height:120%;padding-left:96px;padding-bottom:16px;text-align:justify;"><font style="font-family:inherit;font-size:12pt;">approval of a generic product that is AB-Rated to Abstral, excluding additions or substitutions of ingredients which constitute a major amendment to ANDA No. 207338, or if post approval, the addition or substitution requires FDA approval pursuant 21 CFR 314.70(b).</font></div><div style="line-height:120%;padding-left:96px;padding-bottom:16px;text-align:justify;text-indent:48px;"><font style="padding-bottom:16px;text-align:justify;font-family:inherit;font-size:12pt;padding-right:24px;">b.</font><font style="font-family:inherit;font-size:12pt;">&#8220;Actavis</font><font style="font-family:inherit;font-size:12pt;font-style:italic;">&#32;</font><font style="font-family:inherit;font-size:12pt;">Product&#8221; shall mean any product made, used, sold, offered for sale, imported or distributed pursuant to the Actavis ANDA.</font></div><div style="line-height:120%;padding-left:96px;padding-bottom:16px;text-align:justify;text-indent:48px;"><font style="padding-bottom:16px;text-align:justify;font-family:inherit;font-size:12pt;padding-right:24px;">c.</font><font style="font-family:inherit;font-size:12pt;">&#8220;Affiliate&#8221; shall mean with respect to a Party, any Person that directly or indirectly, through one or more intermediaries, controls, is controlled by, or is under common control with, such Party. For the purposes of this definition, &#8220;control&#8221; (including the terms &#8220;controlled by&#8221; and &#8220;under common control with&#8221;) of a business entity means (a) the direct or indirect ownership of more than fifty percent (50%) of the voting stock or other voting interest in such entity, (b) the right to appoint more than fifty percent (50%) of the directors or management of such entity, or (c) the power to otherwise control or direct the decisions of the board of directors or similar body governing the affairs of such entity.</font></div><div style="line-height:120%;padding-left:96px;padding-bottom:16px;text-align:justify;text-indent:48px;"><font style="padding-bottom:16px;text-align:justify;font-family:inherit;font-size:12pt;padding-right:24px;">d.</font><font style="font-family:inherit;font-size:12pt;">&#8220;AG Product&#8221; shall mean Eq 0.1 mg base, Eq 0.2 mg base, Eq 0.3 mg base, Eq 0.4 mg base, Eq 0.6 mg base and Eq 0.8 mg base of </font><font style="font-family:inherit;font-size:12pt;">Fentanyl Citrate</font><font style="font-family:inherit;font-size:12pt;">&#32;products </font><font style="font-family:inherit;font-size:12pt;">that are manufactured, sold or distributed pursuant to the Galena NDA </font><font style="font-family:inherit;font-size:12pt;">but not under Abstral</font><font style="font-family:inherit;font-size:12pt;"><sup style="vertical-align:top;line-height:120%;font-size:8pt">&#174; </sup></font><font style="font-family:inherit;font-size:12pt;">trademark or a successor trademark thereto</font><font style="font-family:inherit;font-size:12pt;">.</font><font style="font-family:inherit;font-size:12pt;">&#32;&#32;</font></div><div style="line-height:120%;padding-left:96px;padding-bottom:16px;text-align:justify;text-indent:48px;"><font style="padding-bottom:16px;text-align:justify;font-family:inherit;font-size:12pt;padding-right:24px;">e.</font><font style="font-family:inherit;font-size:12pt;">&#8220;FDA&#8221; shall mean the United States Food and Drug Administration, and any successor agency thereto.</font></div><div style="line-height:120%;padding-left:96px;padding-bottom:16px;text-align:justify;text-indent:48px;"><font style="padding-bottom:16px;text-align:justify;font-family:inherit;font-size:12pt;padding-right:24px;">f.</font><font style="font-family:inherit;font-size:12pt;">&#8220;Galena NDA&#8221; shall mean New Drug Application (a &#8220;NDA&#8221;) No.  0</font><font style="font-family:inherit;font-size:12pt;">22510, </font><font style="font-family:inherit;font-size:12pt;">and any amendments and supplements thereto.</font></div><div style="line-height:120%;padding-left:96px;padding-bottom:16px;text-align:justify;text-indent:48px;"><font style="padding-bottom:16px;text-align:justify;font-family:inherit;font-size:12pt;padding-right:24px;">g.</font><font style="font-family:inherit;font-size:12pt;">&#8220;Generic Equivalent&#8221; shall mean: (i) a product approved under an ANDA or pursuant to an application under 21 U.S.C. &#167; 355(b)(2) for which Abstral is the reference listed drug, or (ii) an AG Product.</font></div><div style="line-height:120%;padding-left:96px;padding-bottom:16px;text-align:justify;text-indent:48px;"><font style="padding-bottom:16px;text-align:justify;font-family:inherit;font-size:12pt;padding-right:24px;">h.</font><font style="font-family:inherit;font-size:12pt;">&#8220;License Effective Date&#8221; shall mean June </font><font style="font-family:inherit;font-size:11pt;">[&#8230;***&#8230;]</font><font style="font-family:inherit;font-size:12pt;">, 2018, or an earlier date as permitted in Section 5.  </font></div><div style="line-height:120%;padding-left:96px;padding-bottom:16px;text-align:justify;text-indent:48px;"><font style="padding-bottom:16px;text-align:justify;font-family:inherit;font-size:12pt;padding-right:24px;">i.</font><font style="font-family:inherit;font-size:12pt;">&#8220;Licensed Patents&#8221; shall mean U.S. Patent Nos. 6,759,059, 6,761,910 and 7,910,132.  </font></div><div style="line-height:120%;padding-left:96px;padding-bottom:16px;text-align:justify;text-indent:48px;"><font style="padding-bottom:16px;text-align:justify;font-family:inherit;font-size:12pt;padding-right:24px;">j.</font><font style="font-family:inherit;font-size:12pt;">&#8220;Losses&#8221; shall mean all pending and potential claims, demands, all manner of actions, causes of action, suits, debts, liabilities, losses, damages, attorneys&#8217; fees, costs, expenses, judgments, settlements, interest, punitive damages and other damages or costs of whatever nature, whether known or unknown, pending or future, certain or contingent.</font></div><div style="line-height:120%;padding-left:96px;padding-bottom:16px;text-align:justify;text-indent:48px;"><font style="padding-bottom:16px;text-align:justify;font-family:inherit;font-size:11pt;padding-right:24px;">k.</font><font style="font-family:inherit;font-size:12pt;">&#8220;Measurement Date&#8221; means </font><font style="font-family:inherit;font-size:11pt;">[&#8230;***&#8230;]</font><font style="font-family:inherit;font-size:12pt;">.</font></div><br><div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">2</font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><hr style="page-break-after:always"><a name="s718CD66BBECB5B9C28DFED72C1B16187"></a><div><div style="line-height:120%;text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Exhibit 10.7</font></div><div style="line-height:120%;text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">*** Text Omitted and Filed Separately</font></div><div style="line-height:120%;text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Confidential Treatment Requested</font></div><div style="line-height:120%;text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Under 17 C.F.R. &#167;&#167; 200.80(b)(4) and 240.24b-2</font></div></div><br><div style="line-height:120%;padding-left:96px;padding-bottom:16px;text-align:justify;text-indent:48px;"><font style="padding-bottom:16px;text-align:justify;font-family:inherit;font-size:12pt;padding-right:24px;">l.</font><font style="font-family:inherit;font-size:12pt;">&#8220;Person&#8221; shall mean any individual, corporation, association, partnership (general or limited), joint venture, trust, estate, limited liability company, limited liability partnership, unincorporated organization, government (or any agency or political subdivision thereof) or other legal Person or organization.</font></div><div style="line-height:120%;padding-left:96px;padding-bottom:16px;text-align:justify;text-indent:48px;"><font style="padding-bottom:16px;text-align:justify;font-family:inherit;font-size:12pt;padding-right:24px;">m.</font><font style="font-family:inherit;font-size:12pt;">&#8220;Related Parties&#8221; shall mean a Party&#8217;s Affiliates, directors, officers, employees, agents, representatives, assigns, predecessors, successors or other related parties. </font></div><div style="line-height:120%;padding-left:96px;padding-bottom:16px;text-align:justify;text-indent:48px;"><font style="padding-bottom:16px;text-align:justify;font-family:inherit;font-size:12pt;padding-right:24px;">n.</font><font style="font-family:inherit;font-size:12pt;">&#8220;Territory&#8221; shall mean the United States and its territories, possessions and commonwealths, including Puerto Rico.</font></div><div style="line-height:120%;padding-left:96px;padding-bottom:16px;text-align:justify;text-indent:48px;"><font style="padding-bottom:16px;text-align:justify;font-family:inherit;font-size:12pt;padding-right:24px;">o.</font><font style="font-family:inherit;font-size:12pt;">&#8220;Third Party&#8221; shall mean any Person other than the Parties or their Affiliates.</font></div><div style="line-height:120%;padding-left:96px;padding-bottom:16px;text-align:justify;text-indent:48px;"><font style="padding-bottom:16px;text-align:justify;font-family:inherit;font-size:12pt;padding-right:24px;">p.</font><font style="font-family:inherit;font-size:12pt;">&#8220;Wholesaler Affiliate&#8221; shall </font><font style="font-family:inherit;font-size:12pt;">mean </font><font style="font-family:inherit;font-size:12pt;">a subsidiary or Affiliate of a Party whose primary business is wholesale distribution of pharmaceutical products.  A Wholesaler Affiliate shall not be deemed to be an Affiliate of a Party for purposes of this Agreement.  For clarity, </font><font style="font-family:inherit;font-size:11pt;">[&#8230;***&#8230;]</font></div><div style="line-height:120%;padding-left:48px;padding-bottom:16px;text-align:justify;text-indent:48px;"><font style="padding-bottom:16px;text-align:justify;font-family:inherit;font-size:12pt;padding-right:24px;">2.</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Releases.</font><font style="font-family:inherit;font-size:12pt;">&#32;&#32;Upon the terms and subject to the conditions of this Agreement, in consideration of the mutual execution of this Agreement and the mutual agreement to be legally bound by the terms hereof, each Party, on behalf of itself and its Related Parties, hereby releases, acquits and forever discharges the other Parties and their Related Parties from any and all Losses arising out of, derived from, predicated upon or relating to (a) the Litigation, including any of the claims or counterclaims that were brought or could have been brought against the other Parties</font><font style="font-family:inherit;font-size:12pt;font-style:italic;">&#32;</font><font style="font-family:inherit;font-size:12pt;">in the Litigation, or (b) under the Licensed Patents with respect to the Actavis Product and/or Actavis ANDA; provided, however, that nothing in this Agreement shall prevent or impair the right of any Party to bring a proceeding in court or any other forum for a breach of this Agreement or any representation, warranty or covenant herein. The Parties agree to stipulate to the dismissal of the Litigation with prejudice, with each side bearing its own costs and attorneys&#8217; fees.  Promptly following the execution of this Agreement, the Parties shall file with the United States District Court for the District of New Jersey the Dismissal Order attached as Exhibit A.</font></div><div style="line-height:120%;padding-left:48px;text-align:justify;text-indent:48px;"><font style="text-align:justify;font-family:inherit;font-size:12pt;padding-right:24px;">3.</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Release of Unknown Claims</font><font style="font-family:inherit;font-size:12pt;">.  Each Party acknowledges and agrees that:</font><font style="font-family:inherit;font-size:10pt;">&#32;<br></font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:240px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:144px;"><font style="font-family:inherit;font-size:12pt;">a.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">It may have sustained Losses that are presently unknown and unsuspected, and that such Losses might give rise to Losses in the future.  Nevertheless, each Party acknowledges and agrees that this Agreement has been negotiated and agreed upon, notwithstanding the existence of such possible Losses and that such unknown Losses are released under Section 2. </font></div></td></tr></table><br><div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">3</font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><hr style="page-break-after:always"><a name="s718CD66BBECB5B9C28DFED72C1B16187"></a><div><div style="line-height:120%;text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Exhibit 10.7</font></div><div style="line-height:120%;text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">*** Text Omitted and Filed Separately</font></div><div style="line-height:120%;text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Confidential Treatment Requested</font></div><div style="line-height:120%;text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Under 17 C.F.R. &#167;&#167; 200.80(b)(4) and 240.24b-2</font></div></div><br><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:240px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:144px;"><font style="font-family:inherit;font-size:12pt;">b.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">This Agreement may be pleaded as a full and complete defense to, and used as a basis for injunction against, any proceeding that may be instituted, prosecuted or attempted in breach hereof. </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:240px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:144px;"><font style="font-family:inherit;font-size:12pt;">c.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">In connection with this Agreement, the Parties and all of their Affiliates and each of their respective predecessors, successors, assigns, agents, officers, directors, shareholders, employees and representatives expressly waive and relinquish all rights and benefits afforded by Section 1542 of the California Civil Code, which provides as follows:</font><font style="font-family:inherit;font-size:12pt;">&#32;</font></div></td></tr></table><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:192px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">A GENERAL RELEASE DOES NOT EXTEND TO CLAIMS WHICH THE CREDITOR DOES NOT KNOW OR SUSPECT TO EXIST IN HIS OR HER FAVOR AT THE TIME OF EXECUTING THE RELEASE, WHICH IF KNOWN TO HIM OR HER MUST HAVE MATERIALLY AFFECTED HIS OR HER SETTLEMENT WITH THE DEBTOR.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Further, the Parties and all of their Affiliates and each of their respective predecessors, successors, assigns, agents, officers, directors, shareholders, employees and representatives expressly waive and relinquish all rights and benefits afforded by any law in any other jurisdiction similar to Section 1542 of the California Civil Code.</font></div><div style="line-height:120%;padding-left:48px;padding-bottom:16px;text-align:justify;text-indent:48px;"><font style="padding-bottom:16px;text-align:justify;font-family:inherit;font-size:12pt;padding-right:24px;">4.</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Patent Validity and Infringement.</font><font style="font-family:inherit;font-size:12pt;">&#32;&#32;Solely for the purposes of the enforcement of the present Agreement and with applicability </font><font style="font-family:inherit;font-size:12pt;">exclusively to the Actavis ANDA and the Actavis Product</font><font style="font-family:inherit;font-size:12pt;">, Actavis, for itself and its Affiliates, acknowledges, agrees and admits that the </font><font style="font-family:inherit;font-size:11pt;">[&#8230;***&#8230;]</font><font style="font-family:inherit;font-size:12pt;">.  For the avoidance of doubt, Actavis&#8217;s admission herein shall not apply and shall have no effect outside the United States or to any product other than the Actavis Product or to any ANDA other than the Actavis ANDA.  Further, neither Orexo nor Galena nor their respective Affiliates shall refer to or rely on such admission and any other stipulation, admission or concession regarding the Licensed Patents in any proceeding outside the United States or any proceeding with Actavis or its Affiliates involving a product other than the Actavis Product or an ANDA other than the Actavis ANDA.</font><font style="font-family:inherit;font-size:12pt;">&#32;</font></div><div style="line-height:120%;padding-left:48px;padding-bottom:16px;text-align:justify;text-indent:48px;"><font style="padding-bottom:16px;text-align:justify;font-family:inherit;font-size:12pt;padding-right:24px;">5.</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">License Grant.</font><font style="font-family:inherit;font-size:12pt;">&#32;&#32;Upon the terms and subject to the conditions of this Agreement, effective as of the License Effective Date, Orexo grants on behalf of itself and its Affiliates to Actavis and its Affiliates a </font><font style="font-family:inherit;font-size:11pt;">[&#8230;***&#8230;]</font><font style="font-family:inherit;font-size:12pt;">&#32;(subject to Section 14) license to the Licensed Patents, (i) to make, have made, use, import, offer for sale and sell Actavis Product in or for the Territory, and (ii) to make and have made the Actavis Product outside the Territory only for use, sale and importation in or for the Territory, in each case in </font><font style="font-family:inherit;font-size:11pt;">[&#8230;***&#8230;]</font><font style="font-family:inherit;font-size:12pt;">.  Orexo and its Affiliates and Galena and its Affiliates explicitly retain the right themselves to market at any time </font><font style="font-family:inherit;font-size:12pt;">an AG Product.</font><font style="font-family:inherit;font-size:12pt;">&#32;&#32;</font><font style="font-family:inherit;font-size:12pt;">Nothing in this Agreement shall prevent Orexo and/or Galena, including their respective Affiliates, from continuing to manufacture and market branded Abstral&#174;.  </font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:144px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:138%;font-size:12pt;padding-left:96px;"><font style="font-family:inherit;font-size:12pt;">a.</font></div></td><td style="vertical-align:top;"><div style="line-height:138%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Acceleration of License Grant.  The License Effective Date will be accelerated to the earlier of the following dates: (i) the date on which a Third </font></div></td></tr></table><br><div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">4</font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><hr style="page-break-after:always"><a name="s718CD66BBECB5B9C28DFED72C1B16187"></a><div><div style="line-height:120%;text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Exhibit 10.7</font></div><div style="line-height:120%;text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">*** Text Omitted and Filed Separately</font></div><div style="line-height:120%;text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Confidential Treatment Requested</font></div><div style="line-height:120%;text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Under 17 C.F.R. &#167;&#167; 200.80(b)(4) and 240.24b-2</font></div></div><br><div style="line-height:138%;padding-left:144px;padding-bottom:16px;text-align:justify;"><font style="font-family:inherit;font-size:12pt;">Party is permitted to commercially sell a Generic Equivalent product under authorization from Orexo, Galena and/or their Affiliates (by licenses, sublicense, covenant not to sue or otherwise) (&#8220;Authorized Third Party Launch&#8221;); (ii) </font><font style="font-family:inherit;font-size:12pt;">the date that Orexo and/or its Affiliates and/or Galena and/or its Affiliates launches an AG Product (&#8220;AG Launch&#8221;); (iii)</font><font style="font-family:inherit;font-size:12pt;">&#32;the date of a final, nonappealable judicial order (other than a petition to the Supreme Court for a writ of certiorari) holding that all of the then asserted and adjudicated claims of the Licensed Patents are invalid, canceled, unenforceable or not infringed by a Generic Equivalent (&#8220;Final Court Decision&#8221;); and (iv) the date on which a Third Party commercially launches a Generic Equivalent product in the Territory without authorization from Orexo or its Affiliates (by license, sublicense, covenant not to sue or otherwise) (&#8220;Unauthorized Third Party Launch&#8221;), provided that, with respect to this subclause (iv) only, in the event that Orexo, Galena or their respective Affiliates subsequently succeed in having such Third Party cease its sales of Generic Equivalent product, then the license granted to Actavis and its Affiliates in Section 5 shall be suspended at such time as the Third Party&#8217;s Generic Equivalent product is no longer being commercially sold in the Territory, and shall resume on the date that the License Effective Date would have occurred but for the Unauthorized Third Party Launch of a Generic Equivalent product.  The meaning of &#8220;License Effective Date&#8221; will thereafter be revised to mean the date of occurrence of the earlier aforementioned circumstance.  Pursuant to</font><font style="font-family:inherit;font-size:12pt;">&#32;subclause (iv) only, </font><font style="font-family:inherit;font-size:12pt;">if each and every unlicensed Third Party is found to infringe a valid, enforceable Licensed Patent and pays damages to Orexo (through either judgment or settlement),&#160;then (1) [&#8230;***&#8230;]; (2) [&#8230;***&#8230;]; and (3)&#160;&#160;[&#8230;***&#8230;].</font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:144px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:96px;"><font style="font-family:inherit;font-size:11pt;">b.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:11pt;">[&#8230;***&#8230;]</font><font style="font-family:inherit;font-size:12pt;">.  (1) Beginning on the earlier of </font><font style="font-family:inherit;font-size:11pt;">[&#8230;***&#8230;] </font><font style="font-family:inherit;font-size:12pt;">or one hundred and eighty (180) days prior to an Authorized Third Party Launch and </font><font style="font-family:inherit;font-size:11pt;">[&#8230;***&#8230;]</font><font style="font-family:inherit;font-size:12pt;">, Orexo grants Actavis and its Affiliates </font><font style="font-family:inherit;font-size:11pt;">[&#8230;***&#8230;]</font><font style="font-family:inherit;font-size:12pt;">&#32;to the Licensed Patents, (i) to make, have made, use, import, offer for sale and sell Actavis Product in or for the Territory, and (ii) to make and have made the Actavis Product outside the Territory only for use, sale and importation in or for the Territory and Actavis </font><font style="font-family:inherit;font-size:11pt;">[&#8230;***&#8230;]</font><font style="font-family:inherit;font-size:12pt;">&#32;prior to the </font><font style="font-family:inherit;font-size:11pt;">[&#8230;***&#8230;]</font><font style="font-family:inherit;font-size:12pt;">, based upon </font><font style="font-family:inherit;font-size:11pt;">[&#8230;***&#8230;]</font><font style="font-family:inherit;font-size:12pt;">.  Galena will provide </font><font style="font-family:inherit;font-size:11pt;">[&#8230;***&#8230;]</font><font style="font-family:inherit;font-size:12pt;">.  In the event there is an Authorized Third Party Launch before </font><font style="font-family:inherit;font-size:11pt;">[&#8230;***&#8230;]</font><font style="font-family:inherit;font-size:12pt;">, Galena shall provide </font><font style="font-family:inherit;font-size:11pt;">[&#8230;***&#8230;]</font><font style="font-family:inherit;font-size:12pt;">&#32;or as soon as reasonably practical after such Authorized Third Party Launch date is known, and continuing until </font><font style="font-family:inherit;font-size:11pt;">[&#8230;***&#8230;]</font><font style="font-family:inherit;font-size:12pt;">&#32;has been provided or until Actavis is permitted to launch under this Section 5(b), whichever occurs first.  (2) Beginning on the </font><font style="font-family:inherit;font-size:11pt;">[&#8230;***&#8230;]</font><font style="font-family:inherit;font-size:12pt;">.  </font></div></td></tr></table><br><div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">5</font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><hr style="page-break-after:always"><a name="s718CD66BBECB5B9C28DFED72C1B16187"></a><div><div style="line-height:120%;text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Exhibit 10.7</font></div><div style="line-height:120%;text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">*** Text Omitted and Filed Separately</font></div><div style="line-height:120%;text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Confidential Treatment Requested</font></div><div style="line-height:120%;text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Under 17 C.F.R. &#167;&#167; 200.80(b)(4) and 240.24b-2</font></div></div><br><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:144px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:96px;"><font style="font-family:inherit;font-size:11pt;">c.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Pre-Marketing Activities.  Notwithstanding the License Effective Date and the restrictions contained herein, Actavis and its Affiliates shall be permitted to: (a) </font><font style="font-family:inherit;font-size:11pt;">[&#8230;***&#8230;]</font><font style="font-family:inherit;font-size:12pt;">&#32;(or 180 days prior to an Authorized Third Party Launch) </font><font style="font-family:inherit;font-size:11pt;">[&#8230;***&#8230;]</font><font style="font-family:inherit;font-size:12pt;">&#32;(or 180 days prior to an Authorized Third Party Launch), and (b) </font><font style="font-family:inherit;font-size:11pt;">[&#8230;***&#8230;]</font><font style="font-family:inherit;font-size:12pt;">&#32;(including disclosure of the License Effective Date) </font><font style="font-family:inherit;font-size:11pt;">[&#8230;***&#8230;]</font><font style="font-family:inherit;font-size:12pt;">&#32;(or 180 days prior to and Authorized Third Party Launch) </font><font style="font-family:inherit;font-size:11pt;">[&#8230;***&#8230;]</font><font style="font-family:inherit;font-size:12pt;">&#32;(or 180 days prior to and Authorized Third Party Launch).  </font></div></td></tr></table><div style="line-height:120%;padding-left:48px;padding-bottom:16px;text-align:justify;text-indent:48px;"><font style="padding-bottom:16px;text-align:justify;font-family:inherit;font-size:12pt;padding-right:24px;">6.</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Retention of Certain Rights.</font><font style="font-family:inherit;font-size:12pt;">&#32;&#32;Nothing set forth herein shall be deemed to give Orexo or its Affiliates or Galena or its Affiliates any control over any marketing exclusivity that may be granted to Actavis by the FDA in connection with the Actavis ANDA or the Actavis Product.  </font><font style="font-family:inherit;font-size:11pt;">&#32;</font></div><div style="line-height:120%;padding-left:48px;padding-bottom:16px;text-align:justify;text-indent:48px;"><font style="padding-bottom:16px;text-align:justify;font-family:inherit;font-size:11pt;padding-right:24px;">7.</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Covenant Not to Sue.</font><font style="font-family:inherit;font-size:12pt;">&#32;&#32;Provided that Actavis complies with the terms of this Agreement, Orexo and Galena, on behalf of themselves and their Affiliates,  covenant to Actavis that they will not sue, assert any claim or counterclaim against, otherwise participate in any action or proceeding against Actavis and its Affiliates or any of their shareholders, licensees, sublicensees, customers, suppliers, importers, manufacturers, distributors, insurers, or any heirs, administrators, executors, predecessors, successors, or assigns of the foregoing, or cause, assist, or authorize any person or entity to do any of the foregoing, in each case claiming or otherwise asserting that the Actavis ANDA or the Actavis Product or the manufacture, use, sale, offer for sale, or importation of the Actavis Product, in or for the Territory infringes the Licensed Patents or any other U.S. patents or patent applications owned, licensed or controlled by Orexo, Galena or any of their Affiliates either now or in the future (&#8220;Covenant Not To Sue Patents&#8221;). Orexo and Galena shall impose this covenant not to sue on any Third Party to which Orexo, Galena or any of their Affiliates may after the Effective Date assign, license or otherwise transfer or grant any patent rights subject to this covenant not to sue.</font></div><div style="line-height:120%;padding-left:48px;padding-bottom:16px;text-align:justify;text-indent:48px;"><font style="padding-bottom:16px;text-align:justify;font-family:inherit;font-size:12pt;padding-right:24px;">8.</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">New Patent Listings in the Orange Book.</font><font style="font-family:inherit;font-size:12pt;">&#32;&#32;For any new patents that are listed in the future in FDA&#8217;s Orange Book for Abstral, the covenant not to sue in Section 7 shall hereby be treated as a non-exclusive license to those new patents so that Actavis and its Affiliates may file a &#8220;Paragraph IV Certification&#8221; under 21 U.S.C. &#167; 355(j)(2)(A)(vii)(IV) (as amended or replaced) in connection with any such patents, with respect to the Actavis ANDA. </font></div><div style="line-height:120%;padding-left:48px;padding-bottom:16px;text-align:justify;text-indent:48px;"><font style="padding-bottom:16px;text-align:justify;font-family:inherit;font-size:11pt;padding-right:24px;">9.</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Covenant Not to Challenge and Assist Challenges to Patents</font><font style="font-family:inherit;font-size:12pt;">.  Actavis, its Affiliates, and its Related Parties shall not (1)&#160;</font><font style="font-family:inherit;font-size:11pt;">[&#8230;***&#8230;] </font><font style="font-family:inherit;font-size:12pt;">in any litigation or proceeding in any court or administrative agency having jurisdiction to consider the issue, except as may be required pursuant to compulsory legal process in litigation initiated by </font><font style="font-family:inherit;font-size:12pt;">a Third Party without assistance or encouragement by Actavis, its Affiliates or Related Parties or as expressly permitted in subsections (3)-(5) herein; and/or (2)&#160; </font><font style="font-family:inherit;font-size:11pt;">[&#8230;***&#8230;] </font><font style="font-family:inherit;font-size:12pt;">or as expressly permitted in subsections (3)-(5) herein</font><font style="font-family:inherit;font-size:12pt;">.  Notwithstanding this Section 9, Actavis may (3) </font><font style="font-family:inherit;font-size:12pt;">maintain a &#8220;Paragraph IV Certification&#8221; in the Actavis ANDA with respect to the Licensed Patents or amend the Actavis ANDA to contain a &#8220;Paragraph IV Certification&#8221; with respect to any patent listed in the </font></div><br><div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">6</font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><hr style="page-break-after:always"><a name="s718CD66BBECB5B9C28DFED72C1B16187"></a><div><div style="line-height:120%;text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Exhibit 10.7</font></div><div style="line-height:120%;text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">*** Text Omitted and Filed Separately</font></div><div style="line-height:120%;text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Confidential Treatment Requested</font></div><div style="line-height:120%;text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Under 17 C.F.R. &#167;&#167; 200.80(b)(4) and 240.24b-2</font></div></div><br><div style="line-height:120%;padding-left:48px;padding-bottom:16px;text-align:justify;"><font style="font-family:inherit;font-size:12pt;">Orange Book for Abstral; (4) challenge the infringement, validity, enforceability or patentability of any claim of the Licensed Patents or any other patents listed in the Orange Book for Abstral in any litigation or proceeding in any court with respect to any product other than the Actavis Product or any ANDA other than the Actavis ANDA (for the avoidance of doubt, submitting a Paragraph IV Certification to the Licensed Patents or any other patents listed in the Orange Book for Abstral and sending a notice letter regarding the same qualifies as litigation), or (5) file a petition with the U.S. Patent and Trademark Office requesting reexamination, inter partes review, or other post grant review of any claims of any Licensed Patents or any other patents listed in the Orange Book for Abstral for which Orexo or Galena initiates a district court litigation against Actavis with a claim of infringement with respect to any product other than the Actavis Product or any ANDA other than the Actavis ANDA. </font></div><div style="line-height:120%;padding-left:48px;padding-bottom:16px;text-align:justify;text-indent:48px;"><font style="padding-bottom:16px;text-align:justify;font-family:inherit;font-size:12pt;padding-right:24px;">10.</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Supply of Authorized Generic</font><font style="font-family:inherit;font-size:12pt;">. In the event that </font><font style="font-family:inherit;font-size:11pt;">[&#8230;***&#8230;]</font><font style="font-family:inherit;font-size:12pt;">&#32;or one hundred and eighty (180) days prior to an Authorized Third Party Launch (i) FDA has not granted final approval of the Actavis ANDA, or (ii) Actavis cannot manufacture commercial launch quantities of Actavis Product, and upon Actavis providing notice of (i) and/or (ii) to Orexo and Galena at least one hundred and eighty (180) days prior to the foregoing date, Galena and Actavis and/or one or more Affiliates thereof will enter into a non-exclusive supply agreement for the AG Product under mutually agreeable terms consistent with all applicable terms of this Agreement. Such supply agreement will provide that (x) Galena or an Affiliate will deliver to Actavis or an Affiliate of Actavis </font><font style="font-family:inherit;font-size:11pt;">[&#8230;***&#8230;]</font><font style="font-family:inherit;font-size:12pt;">, (y) </font><font style="font-family:inherit;font-size:11pt;">[&#8230;***&#8230;]</font><font style="font-family:inherit;font-size:12pt;">&#32;or one hundred and eighty (180) days prior to an Authorized Third Party Launch; and (z) </font><font style="font-family:inherit;font-size:11pt;">[&#8230;***&#8230;]</font><font style="font-family:inherit;font-size:12pt;">.  </font></div><div style="line-height:120%;padding-left:48px;padding-bottom:16px;text-align:justify;text-indent:48px;"><font style="padding-bottom:16px;text-align:justify;font-family:inherit;font-size:12pt;padding-right:24px;">11.</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Most Favored Licensee and Notice.</font><font style="font-family:inherit;font-size:12pt;">&#32;&#32;Orexo and Galena represent and covenant to Actavis that the terms of the Agreement being offered to Actavis are and will be equivalent to or better than the terms being offered by Orexo or its Affiliates and/or Galena and its Affiliates to any Third Party with respect to any license(s) or other permissions(s) to Generic Equivalent product(s) (&#8220;Third Party Agreement&#8221;) with respect to </font><font style="font-family:inherit;font-size:11pt;">[&#8230;***&#8230;]</font><font style="font-family:inherit;font-size:12pt;">&#32;(</font><font style="font-family:inherit;font-size:11pt;">[&#8230;***&#8230;]</font><font style="font-family:inherit;font-size:12pt;">).  If Orexo and/or its Affiliates and/or Galena and/or its Affiliates have entered or enter into a Third Party Agreement providing such Third Party with more favorable terms, then the applicable terms in this Agreement will be automatically amended to provide such more favorable terms to Actavis.  Orexo and/or Galena shall notify Actavis of any more favorable terms from </font><font style="font-family:inherit;font-size:11pt;">[&#8230;***&#8230;] </font><font style="font-family:inherit;font-size:12pt;">within seven (7) business days.  </font><font style="font-family:inherit;font-size:12pt;">Orexo and Galena further agree that they will provide Actavis at least ninety (90) calendar days&#8217; advance notice of Orexo or its Affiliates&#8217; </font><font style="font-family:inherit;font-size:12pt;">or Galena or its Affiliates&#8217; </font><font style="font-family:inherit;font-size:12pt;">or a Third Party&#8217;s launch of an AG Product, provided such launch is prior to the dates set forth in </font><font style="font-family:inherit;font-size:11pt;">[&#8230;***&#8230;]</font><font style="font-family:inherit;font-size:12pt;">.  </font></div><div style="line-height:120%;padding-left:48px;padding-bottom:16px;text-align:justify;text-indent:48px;"><font style="padding-bottom:16px;text-align:justify;font-family:inherit;font-size:12pt;padding-right:24px;">12.</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Waiver of Regulatory Exclusivities.</font><font style="font-family:inherit;font-size:12pt;">&#32;&#32;To the extent permitted by FDA and applicable statutes and regulations, Orexo and its Affiliates and Galena and its Affiliates hereby waive with respect to the Actavis ANDA and Actavis Product only any and all regulatory exclusivities granted by the FDA to Orexo and/or Galena for Abstral that may prevent approval or marketing of the Actavis Product in the Territory under the Actavis ANDA as of the License Effective Date under the terms of this Agreement.  To the extent that FDA has granted any regulatory exclusivities or otherwise prevents approval or launch of the Actavis Product, Orexo, Galena and/or their respective Affiliates agree, at Actavis&#8217;s </font></div><br><div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">7</font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><hr style="page-break-after:always"><a name="s718CD66BBECB5B9C28DFED72C1B16187"></a><div><div style="line-height:120%;text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Exhibit 10.7</font></div><div style="line-height:120%;text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">*** Text Omitted and Filed Separately</font></div><div style="line-height:120%;text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Confidential Treatment Requested</font></div><div style="line-height:120%;text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Under 17 C.F.R. &#167;&#167; 200.80(b)(4) and 240.24b-2</font></div></div><br><div style="line-height:120%;padding-left:48px;padding-bottom:16px;text-align:justify;"><font style="font-family:inherit;font-size:12pt;">request, to confirm with FDA (in a form reasonably acceptable to Actavis) the licenses and waivers granted by Orexo hereunder, and shall do so within ten (10) business days of receiving Actavis&#8217;s request.</font></div><div style="line-height:120%;padding-left:48px;padding-bottom:16px;text-align:justify;text-indent:48px;"><font style="padding-bottom:16px;text-align:justify;font-family:inherit;font-size:12pt;padding-right:24px;">13.</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Representations and Warranties.</font><font style="font-family:inherit;font-size:12pt;">&#32;&#32;</font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:192px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:144px;"><font style="font-family:inherit;font-size:11pt;">a.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Each Party hereto represents and warrants to the other Party that, as of the date hereof: </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:216px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:204px;"><font style="font-family:inherit;font-size:12pt;">i.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">this Agreement is a legal, valid and binding obligation of the warranting Party, enforceable against such Party in accordance with its terms, except as enforcement may be limited by bankruptcy, insolvency, reorganization, moratorium or similar laws affecting creditors&#8217; rights generally or by general principles of equity;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:216px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:204px;"><font style="font-family:inherit;font-size:12pt;">ii.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">the warranting Party is not subject to any judgment, order, injunction, decree or award of any court, administrative agency or governmental body that would or might interfere with its performance of any of its material obligations hereunder; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:216px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:204px;"><font style="font-family:inherit;font-size:12pt;">iii.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">the warranting Party has full power and authority to enter into and perform its obligations under this Agreement in accordance with its terms. </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:192px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:144px;"><font style="font-family:inherit;font-size:11pt;">b.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Orexo represents and warrants that it owns all right and title to the Licensed Patents and Orexo has the right to grant the licenses hereunder and to settle the Litigation.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:192px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:144px;"><font style="font-family:inherit;font-size:11pt;">c.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Orexo and Galena represent and warrant that as of the Effective Date, Orexo and its Affiliates and Galena and its Affiliates shall not, and shall not cause or encourage any Affiliate or Third Party to initiate or otherwise undertake any activity, directly or indirectly, against the Actavis ANDA or Actavis Product to: (i) interfere with Actavis&#8217;s efforts to obtain and maintain FDA approval of the Actavis ANDA or the Actavis Product, including, but not limited to, the filing of suit against FDA, and/or the filing or submission of any Citizen Petitions, correspondence or other written submissions with FDA or any regulatory or governmental authority, or (ii) interfere with Actavis&#8217;s efforts to market the Actavis Product in accordance with the terms of this Agreement, unless Orexo or its Affiliates and Galena and its Affiliates undertakes such activity defined in subparts (i) or (ii) pursuant to court order or as otherwise requested by FDA or required by law.  </font></div></td></tr></table><br><div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">8</font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><hr style="page-break-after:always"><a name="s718CD66BBECB5B9C28DFED72C1B16187"></a><div><div style="line-height:120%;text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Exhibit 10.7</font></div><div style="line-height:120%;text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">*** Text Omitted and Filed Separately</font></div><div style="line-height:120%;text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Confidential Treatment Requested</font></div><div style="line-height:120%;text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Under 17 C.F.R. &#167;&#167; 200.80(b)(4) and 240.24b-2</font></div></div><br><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:192px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:144px;"><font style="font-family:inherit;font-size:11pt;">d.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Orexo and its Affiliates and Galena and its Affiliates represent and warrant that they shall not Officially Discontinue Abstral</font><font style="font-family:inherit;font-size:12pt;"><sup style="vertical-align:top;line-height:120%;font-size:8pt">&#174; </sup></font><font style="font-family:inherit;font-size:12pt;">prior to the expiration of the Licensed Patents, unless required, requested or recommended in writing by the FDA or other governmental authority or applicable law.  For avoidance of doubt, nothing in this Paragraph prohibits Orexo or its Affiliates and Galena and its Affiliates from taking any action, or causing others to take any action, Orexo or Galena reasonably determines is necessary to provide for the safety and efficacy of any Orexo or Galena product.  &#8220;Officially Discontinue&#8221; shall mean any of: (i) delisting Abstral</font><font style="font-family:inherit;font-size:12pt;"><sup style="vertical-align:top;line-height:120%;font-size:8pt">&#174; </sup></font><font style="font-family:inherit;font-size:12pt;">with the FDA; (ii) delisting the Licensed Patents from the Orange Book unless Orexo reasonably determines in good faith that such delisting is required under applicable law; (iii) seeking action with the FDA to withdraw Abstral</font><font style="font-family:inherit;font-size:12pt;"><sup style="vertical-align:top;line-height:120%;font-size:8pt">&#174; </sup></font><font style="font-family:inherit;font-size:12pt;">from the market, unless required, requested or recommended by the FDA or another governmental authority to do so; or (iv) deleting, removing or canceling any National Drug Code(s) for Abstral</font><font style="font-family:inherit;font-size:12pt;"><sup style="vertical-align:top;line-height:120%;font-size:8pt">&#174; </sup></font><font style="font-family:inherit;font-size:12pt;">from the applicable National Drug File.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:192px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:144px;"><font style="font-family:inherit;font-size:11pt;">e.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Actavis represents and warrants that it has produced to Orexo&#8217;s counsel in this Patent Litigation all correspondence with FDA regarding Actavis&#8217;s ANDA, and that the produced correspondence contains an accurate representation of the Actavis Product as it exists as of the Effective Date.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:192px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:144px;"><font style="font-family:inherit;font-size:11pt;">f.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Actavis represents and warrants that, as of the Effective Date, (i) Actavis or its Affiliates own all right, title and interest in, to and under the Actavis ANDA, and Actavis and its Affiliates have not granted or assigned to any Third Party, directly or indirectly, any rights under or to the Actavis ANDA or the Actavis Product, (ii) Actavis and its Affiliates will not transfer ownership, in whole or in part, of said Actavis ANDA, except to an Affiliate of Actavis or in accordance with Section 14, until the expiration of the license granted herein, and (iii) Actavis has the right to settle the Litigation.</font></div></td></tr></table><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:96px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">EXCEPT AS EXPRESSLY PROVIDED IN THIS AGREEMENT, NO PARTY MAKES ANY REPRESENTATIONS OR WARRANTIES, EXPRESS OR IMPLIED, EITHER IN FACT OR BY OPERATION OF APPLICABLE LAW, AND EACH PARTY HEREBY EXPRESSLY DISCLAIMS SUCH WARRANTIES.</font><font style="font-family:inherit;font-size:11pt;">&#32;&#32;</font></div><div style="line-height:120%;padding-left:48px;padding-bottom:16px;text-align:justify;text-indent:48px;"><font style="padding-bottom:16px;text-align:justify;font-family:inherit;font-size:12pt;padding-right:24px;">14.</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Assignments.</font><font style="font-family:inherit;font-size:12pt;">&#32;&#32;No Party hereto may assign any of its rights or obligations under this Agreement without the prior written consent of the other Parties, which consent shall not be unreasonably withheld, conditioned or delayed.  </font><font style="font-family:inherit;font-size:12pt;">Notwithstanding the foregoing, (a) any Party may assign its rights and obligations under this Settlement Agreement to any of its Affiliates, (b) Orexo may assign its rights and obligations under this Settlement Agreement to any successor in interest to Orexo&#8217;s entire business or to the Licensed Patents, (c) Galena </font></div><br><div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">9</font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><hr style="page-break-after:always"><a name="s718CD66BBECB5B9C28DFED72C1B16187"></a><div><div style="line-height:120%;text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Exhibit 10.7</font></div><div style="line-height:120%;text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">*** Text Omitted and Filed Separately</font></div><div style="line-height:120%;text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Confidential Treatment Requested</font></div><div style="line-height:120%;text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Under 17 C.F.R. &#167;&#167; 200.80(b)(4) and 240.24b-2</font></div></div><br><div style="line-height:120%;padding-left:48px;padding-bottom:16px;text-align:justify;"><font style="font-family:inherit;font-size:12pt;">may assign its rights and obligations under this Settlement Agreement to any Third Party in connection with a sale, transfer or other disposition of its rights to </font><font style="font-family:inherit;font-size:12pt;">Abstral</font><font style="font-family:inherit;font-size:12pt;"><sup style="vertical-align:top;line-height:120%;font-size:8pt">&#174; </sup></font><font style="font-family:inherit;font-size:12pt;">and the Galena NDA and (d) Actavis may assign its rights and obligations under this Settlement Agreement to any </font><font style="font-family:inherit;font-size:12pt;">Third Party in connection with a merger, reorganization, change of control or sale of all or substantially all of the applicable business or assets of Actavis to which this Agreement relates, or to a Third Party in connection with any divestiture of the Actavis ANDA, but without prior written consent</font><font style="font-family:inherit;font-size:12pt;">. In each case ((a) through (d)), provided that (A) notwithstanding any such assignment, such Party shall remain liable for its and its Affiliates&#8217; performance under this Settlement Agreement as if such Party remained a party hereto; (B) no such assignment shall in any manner relieve, limit or impair the obligations of that Party hereunder; and (C) following a transfer by a Party to its Affiliate, any subsequent transaction that would cause such Affiliate to cease to be an Affiliate of such Party shall be deemed to be an assignment of this Settlement Agreement subject to this Section.</font><font style="font-family:inherit;font-size:12pt;">&#32;Any purported assignment in violation of the foregoing shall be null and void </font><font style="font-family:inherit;font-size:12pt;font-style:italic;">ab initio </font><font style="font-family:inherit;font-size:12pt;">and of no force or effect.</font></div><div style="line-height:120%;padding-left:48px;padding-bottom:16px;text-align:justify;text-indent:48px;"><font style="padding-bottom:16px;text-align:justify;font-family:inherit;font-size:12pt;padding-right:24px;">15.</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Effect of Bankruptcy.</font><font style="font-family:inherit;font-size:12pt;">&#32;&#32;For avoidance of doubt, all rights and licenses granted under or pursuant to any section of this Agreement are, and shall otherwise be deemed to be, for purposes of Section 365(n) of the U.S. Bankruptcy Code (the &#8220;Bankruptcy Code&#8221;), licenses of &#8220;intellectual property&#8221; as defined under the Bankruptcy Code.  The Parties shall retain and may fully exercise all of their respective rights and elections under the Bankruptcy Code; provided, however, that should Orexo become a party to a bankruptcy proceeding and such proceeding is not dismissed within thirty (30) days then, to the extent permitted by law, this Agreement and the licenses granted by Orexo hereunder shall be adopted by any bankruptcy trustee or relevant third party charged with the disposition of same, and shall not be rejected by same, it being the Parties&#8217; intent that, in such event, Actavis and its Affiliates and sublicensees shall be entitled to retain the rights granted to them hereunder.</font></div><div style="line-height:120%;padding-left:48px;padding-bottom:16px;text-align:justify;text-indent:48px;"><font style="padding-bottom:16px;text-align:justify;font-family:inherit;font-size:12pt;padding-right:24px;">16.</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Medicare Modernization Act Filings.</font><font style="font-family:inherit;font-size:12pt;">&#32;&#32;In accordance with the applicable provisions of the Medicare Modernization Act, Orexo and Actavis shall submit this Agreement to the Federal Trade Commission Bureau of Competition and the Assistant Attorney General in charge of the Antitrust Division of the Department of Justice as soon as practicable following the Effective Date and in no event later than ten (10) business days following the Effective Date. </font></div><div style="line-height:120%;padding-left:48px;padding-bottom:16px;text-align:justify;text-indent:48px;"><font style="padding-bottom:16px;text-align:justify;font-family:inherit;font-size:12pt;padding-right:24px;">17.</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Continued Cooperation.</font><font style="font-family:inherit;font-size:12pt;">&#32;&#32;Each Party shall, at its own cost and expense, take all actions and do all things reasonably necessary or proper, including under applicable law, to make effective and further the intents and purposes of the transactions contemplated by this Agreement, including executing any further instruments reasonably requested by the other Parties.  On or after the Effective Date, Actavis shall inform Orexo and Galena of any additions or substitutions of ingredients which constitute a major amendment to ANDA No. 207338, or if post approval, the addition or substitution requires FDA approval pursuant 21 CFR 314.70(b) within thirty (30) calendar  days of acceptance of those additions or substitutions by FDA. </font></div><br><div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">10</font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><hr style="page-break-after:always"><a name="s718CD66BBECB5B9C28DFED72C1B16187"></a><div><div style="line-height:120%;text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Exhibit 10.7</font></div><div style="line-height:120%;text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">*** Text Omitted and Filed Separately</font></div><div style="line-height:120%;text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Confidential Treatment Requested</font></div><div style="line-height:120%;text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Under 17 C.F.R. &#167;&#167; 200.80(b)(4) and 240.24b-2</font></div></div><br><div style="line-height:120%;padding-left:48px;padding-bottom:16px;text-align:justify;text-indent:48px;"><font style="padding-bottom:16px;text-align:justify;font-family:inherit;font-size:12pt;padding-right:24px;">18.</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Audit by Actavis</font><font style="font-family:inherit;font-size:12pt;">.  Galena and its Affiliates shall keep adequate records of </font><font style="font-family:inherit;font-size:11pt;">[&#8230;***&#8230;]</font><font style="font-family:inherit;font-size:12pt;">.  </font><font style="font-family:inherit;font-size:11pt;">[&#8230;***&#8230;]</font><font style="font-family:inherit;font-size:12pt;">, such records (including those of Galena&#8217;s Affiliates) shall be kept at each of their principal places of business and shall be open for inspection at Actavis&#8217;s cost at reasonable times and upon reasonable notice by an independent certified auditor selected by Actavis, and which is reasonably acceptable to Galena, for the sole purpose of inspecting the amounts reported to Actavis under Section 5(b).  </font></div><div style="line-height:120%;padding-left:48px;padding-bottom:16px;text-align:justify;text-indent:48px;"><font style="padding-bottom:16px;text-align:justify;font-family:inherit;font-size:12pt;padding-right:24px;">19.</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Entire Agreement.</font><font style="font-family:inherit;font-size:12pt;">&#32;&#32;This Agreement (including all attachments hereto) constitutes the entire agreement and understanding between the Parties with respect to the subject matter hereof and supersedes all prior agreements or understandings, oral or written, with respect to such matters. The Parties may amend, waive or modify the provisions of this Agreement, including this provision, only by mutual agreement in writing duly executed by the Parties hereto.</font></div><div style="line-height:120%;padding-left:48px;padding-bottom:16px;text-align:justify;text-indent:48px;"><font style="padding-bottom:16px;text-align:justify;font-family:inherit;font-size:12pt;padding-right:24px;">20.</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Interpretation.</font><font style="font-family:inherit;font-size:12pt;">&#32;&#32;The Parties agree and acknowledge that this Agreement is the product of both Parties, each of whom have been represented by legal counsel, and shall not be construed against either of the Parties.  The words &#8220;hereof,&#8221; &#8220;herein,&#8221; &#8220;hereto&#8221; and &#8220;hereunder&#8221; and words of similar import, when used in this Agreement, shall refer to this Agreement as a whole and not to any particular provision of this Agreement.  Headings of paragraphs or sections of this Agreement are for reference only and shall not be deemed to be a part of this Agreement.</font></div><div style="line-height:120%;padding-left:48px;padding-bottom:16px;text-align:justify;text-indent:48px;"><font style="padding-bottom:16px;text-align:justify;font-family:inherit;font-size:12pt;padding-right:24px;">21.</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Notices.</font><font style="font-family:inherit;font-size:12pt;">&#32;&#32;All notices or other communications hereunder shall be deemed to have been duly given and made if in writing and if served by personal delivery upon a Party, if delivered by registered or certified mail (return receipt requested) or by a reputable overnight express courier service (charges prepaid), or such other address as may be designated in writing hereafter, in the same manner, by such person as follows: </font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">In the case of Orexo:</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:48px;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Orexo AB</font></div><div style="line-height:120%;text-align:left;padding-left:96px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">P.O. Box 303 <br>SE-751 05 Uppsala </font></div><div style="line-height:120%;text-align:left;padding-left:48px;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Sweden</font></div><div style="line-height:120%;text-align:left;padding-left:48px;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Attention:  Nikolaj Sorensen, CEO and President </font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">In the case of Galena:</font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:48px;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Galena Biopharma, Inc. </font></div><div style="line-height:120%;text-align:left;padding-left:48px;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">2000 Crow Canyon Place, Suite 380</font></div><div style="line-height:120%;text-align:left;padding-left:48px;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">San Ramon, CA 94583</font></div><div style="line-height:120%;text-align:left;padding-left:48px;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Attn: General Counsel </font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">In the case of Actavis:</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><br><div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">11</font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><hr style="page-break-after:always"><a name="s718CD66BBECB5B9C28DFED72C1B16187"></a><div><div style="line-height:120%;text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Exhibit 10.7</font></div><div style="line-height:120%;text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">*** Text Omitted and Filed Separately</font></div><div style="line-height:120%;text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Confidential Treatment Requested</font></div><div style="line-height:120%;text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Under 17 C.F.R. &#167;&#167; 200.80(b)(4) and 240.24b-2</font></div></div><br><div style="line-height:120%;text-align:left;padding-left:48px;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Actavis, Inc.</font></div><div style="line-height:120%;text-align:left;padding-left:48px;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Morris Corporate Center III </font></div><div style="line-height:120%;text-align:left;padding-left:48px;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">400 Interpace Parkway </font></div><div style="line-height:120%;text-align:left;padding-left:48px;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Parsippany, NJ 07054</font></div><div style="line-height:120%;text-align:left;padding-left:48px;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Attn: General Counsel</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Such notices will be deemed to have been given on the date delivered in the case of hand delivery or delivery by overnight courier, or on the fifth (5th) business day following the date of postmark in the case of delivery by mail.</font></div><div style="line-height:120%;padding-left:48px;padding-bottom:16px;text-align:justify;text-indent:48px;"><font style="padding-bottom:16px;text-align:justify;font-family:inherit;font-size:12pt;padding-right:24px;">22.</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Confidentiality.</font><font style="font-family:inherit;font-size:12pt;">&#32;&#32;The terms of this Agreement and the information exchanged between the Parties pursuant to this Agreement shall be maintained in confidence by the Parties and not be used or disclosed to Third Parties except that: (i) the Parties may disclose that the Parties have settled the Litigation and that Actavis has the ability to launch the Actavis Product as of the dates in Sections 1(h) and 5(b), (ii) the Parties may disclose this Agreement to their attorneys, advisors, and representatives who are subject to obligations of confidentiality consistent with this Agreement, (iii) Actavis may disclose the terms of this Agreement to Teva Pharmaceutical Industries Ltd. and its Affiliates and any Third Party in connection with a potential or actual merger, reorganization, change of control or sale of all or substantially all of the applicable business or assets of Actavis to which this Agreement relates, or to a Third Party in connection with any divestiture of the Actavis ANDA,  in accordance with confidentiality terms at least as restrictive as the terms hereof, (iv) Galena or Orexo may disclose the terms of this Agreement to any Third Party in connection with a potential or actual sale, transfer or other disposition of the rights to Abstral</font><font style="font-family:inherit;font-size:12pt;"><sup style="vertical-align:top;line-height:120%;font-size:8pt">&#174; </sup></font><font style="font-family:inherit;font-size:12pt;">and Galena NDA, in accordance with confidentiality terms at least as restrictive as the terms hereof, (v) Orexo may disclose the terms of this Agreement to Third Parties in connection with patent litigation involving the Licensed Patents or in connection with settlement discussions and agreements with alleged infringers of the Licensed Patents, subject to such Third Parties undertaking to keep the terms of this Agreement strictly confidential in accordance with confidentiality terms at least as restrictive as the terms hereof, and (vi) as otherwise required by law, including without limitation SEC reporting requirements, or by the rules or regulations of any stock exchange that the Parties are subject to. In any such event the Party making such disclosure under subsection (vi) shall (A) provide the other Parties with as much advance notice as reasonably practicable of the required disclosure, (B) cooperate with the other Parties in any attempt to prevent or limit the disclosure, and (C) limit any disclosure to the specific purpose at issue. If a Party is subpoenaed or otherwise required by law to give testimony or provide information which in any way relates to this Agreement, such Party shall give the other Parties prompt notice of such requirement and, unless otherwise required by law, shall make no disclosure until the other Parties have had a reasonable opportunity to contest the right of the requesting person to such disclosure.  The Parties shall provide each other with all reasonable cooperation and generally make their employees available to give testimony or to provide reasonable assistance in connection with any lawsuits, claims, proceedings and investigations relating to this Agreement.</font></div><br><div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">12</font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><hr style="page-break-after:always"><a name="s718CD66BBECB5B9C28DFED72C1B16187"></a><div><div style="line-height:120%;text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Exhibit 10.7</font></div><div style="line-height:120%;text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">*** Text Omitted and Filed Separately</font></div><div style="line-height:120%;text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Confidential Treatment Requested</font></div><div style="line-height:120%;text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Under 17 C.F.R. &#167;&#167; 200.80(b)(4) and 240.24b-2</font></div></div><br><div style="line-height:120%;padding-left:48px;padding-bottom:16px;text-align:justify;text-indent:48px;"><font style="padding-bottom:16px;text-align:justify;font-family:inherit;font-size:12pt;padding-right:24px;">23.</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Choice of Law and Jurisdiction.</font><font style="font-family:inherit;font-size:12pt;">&#32;&#32;This Agreement and any dispute arising out of or related to this Agreement shall be governed by and construed in accordance with the laws of the State of New York, without giving effect to its conflict of laws principles.  With respect to any proceeding relating to this Agreement, each Party irrevocably agrees and consents to the exclusive jurisdiction of the federal and state courts in New York and waives any objection to venue of any such proceeding brought in any such court.</font></div><div style="line-height:120%;padding-left:48px;text-align:justify;text-indent:48px;"><font style="text-align:justify;font-family:inherit;font-size:12pt;padding-right:24px;">24.</font><font style="font-family:inherit;font-size:12pt;">&#32;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Equitable Relief for Orexo and Galena</font><font style="font-family:inherit;font-size:12pt;">.  Actavis acknowledges and agrees that its obligations and undertakings under this Agreement are reasonable and necessary to protect the legitimate interests of Orexo and Galena, that Orexo and Galena would not have entered into this Agreement in the absence of such provisions, and that Actavis&#8217;s threatened breach or failure to comply with material terms of this Agreement shall cause Orexo and Galena significant and irreparable harm, the amount of which shall be extremely difficult to estimate and ascertain, and for which money damages shall not be adequate.  Actavis further acknowledges and agrees that Orexo and/or Galena shall have the right to apply to any court of competent jurisdiction for an injunction order restraining any breach or threatened breach of this Agreement and specifically enforcing the terms and provisions of this Agreement, without the necessity of posting any bond or security, in addition to seeking any other remedy available to Orexo and Galena in law or equity.   Nothing in the preceding sentence, however, shall limit Actavis&#8217;s ability to seek and recover damages for an improperly issued injunction, and, for the avoidance of doubt, Orexo and Galena agree not to assert that the absence of a bond limits restricts Actavis&#8217;s ability to seek and recover damages for an improperly issued injunction.  </font><font style="font-family:inherit;font-size:11pt;">&#32;&#32;</font></div><div style="line-height:138%;text-align:left;padding-left:96px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;padding-left:48px;padding-bottom:16px;text-align:justify;text-indent:48px;"><font style="padding-bottom:16px;text-align:justify;font-family:inherit;font-size:12pt;padding-right:24px;">25.</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Equitable Relief for Actavis</font><font style="font-family:inherit;font-size:12pt;">.  Orexo and Galena acknowledge and agree that their obligations and undertakings under this Agreement are reasonable and necessary to protect the legitimate interests of Actavis, that Actavis would not have entered into this Agreement in the absence of such provisions, and that Orexo and/or Galena&#8217;s threatened breach or failure to comply with material terms of this Agreement shall cause Actavis significant and irreparable harm, the amount of which shall be extremely difficult to estimate and ascertain, and for which money damages shall not be adequate.  Orexo and Galena further acknowledge and agree that Actavis shall have the right to apply to any court of competent jurisdiction for an injunction order restraining any breach or threatened breach of this Agreement and specifically enforcing the terms and provisions of this Agreement, without the necessity of posting any bond or security, in addition to seeking any other remedy available to Actavis in law or equity.   Nothing in the preceding sentence, however, shall limit Orexo and Galena&#8217;s ability to seek and recover damages for an improperly issued injunction, and, for the avoidance of doubt, Actavis agrees not to assert that the absence of a bond limits restricts Orexo or Galena&#8217;s ability to seek and recover damages for an improperly issued injunction.</font></div><div style="line-height:120%;padding-left:48px;padding-bottom:16px;text-align:justify;text-indent:48px;"><font style="padding-bottom:16px;text-align:justify;font-family:inherit;font-size:12pt;padding-right:24px;">26.</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Counterparts.</font><font style="font-family:inherit;font-size:12pt;">&#32;&#32;This Agreement may be executed in any number of counterparts, and execution by each of the Parties of any one of such counterparts will constitute due execution of this Agreement.  Each such counterpart hereof shall be deemed to be an original instrument, and all such counterparts together shall constitute but one agreement.  Any </font></div><br><div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">13</font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><hr style="page-break-after:always"><a name="s718CD66BBECB5B9C28DFED72C1B16187"></a><div><div style="line-height:120%;text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Exhibit 10.7</font></div><div style="line-height:120%;text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">*** Text Omitted and Filed Separately</font></div><div style="line-height:120%;text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Confidential Treatment Requested</font></div><div style="line-height:120%;text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Under 17 C.F.R. &#167;&#167; 200.80(b)(4) and 240.24b-2</font></div></div><br><div style="line-height:120%;padding-left:48px;padding-bottom:16px;text-align:justify;"><font style="font-family:inherit;font-size:12pt;">signature exchanged in portable document format (pdf) via facsimile or electronic transmission shall be deemed to be an original signature.</font></div><div style="line-height:120%;padding-left:48px;padding-bottom:16px;text-align:justify;text-indent:48px;"><font style="padding-bottom:16px;text-align:justify;font-family:inherit;font-size:12pt;padding-right:24px;">27.</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Severability.</font><font style="font-family:inherit;font-size:12pt;">&#32;&#32;If any provision of this Agreement is held invalid, illegal or unenforceable for any reason, the Parties shall negotiate in good faith for a substitute provision to continue the intent and purpose of such invalid provisions, and the validity, legality and enforceability of the remaining provisions shall not be in any way impaired thereby. </font></div><div style="line-height:120%;padding-left:48px;padding-bottom:16px;text-align:justify;text-indent:48px;"><font style="padding-bottom:16px;text-align:justify;font-family:inherit;font-size:12pt;padding-right:24px;">28.</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">No Waiver.</font><font style="font-family:inherit;font-size:12pt;">&#32;&#32;The failure of any Party to enforce at any time for any period the provisions of or any rights deriving from this Agreement shall not be construed to be a waiver of such provisions or rights or the right of such Party thereafter to enforce such provisions.</font></div><div style="line-height:120%;padding-left:48px;padding-bottom:16px;text-align:justify;text-indent:48px;"><font style="padding-bottom:16px;text-align:justify;font-family:inherit;font-size:12pt;padding-right:24px;">29.</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Third Party Beneficiaries.</font><font style="font-family:inherit;font-size:12pt;">&#32;&#32;Except as expressly provided herein, nothing in this Agreement, either express or implied, is intended to or shall confer upon any Third Party any legal or equitable right, benefit or remedy of any nature whatsoever under or by reason of this Agreement.</font></div><div style="line-height:120%;padding-left:48px;padding-bottom:16px;text-align:justify;text-indent:48px;"><font style="padding-bottom:16px;text-align:justify;font-family:inherit;font-size:12pt;padding-right:24px;">30.</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Term.</font><font style="font-family:inherit;font-size:12pt;">&#32;&#32;This Agreement shall terminate on </font><font style="font-family:inherit;font-size:12pt;">the date of expiration of the latest expiring patent from among the Licensed Patents and any patents added to the Orange Book after the Effective Date of this Settlement Agreement.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:center;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">[Signature page follows]</font></div><br><div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">14</font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><hr style="page-break-after:always"><a name="s718CD66BBECB5B9C28DFED72C1B16187"></a><div><div style="line-height:120%;text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Exhibit 10.7</font></div><div style="line-height:120%;text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">*** Text Omitted and Filed Separately</font></div><div style="line-height:120%;text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Confidential Treatment Requested</font></div><div style="line-height:120%;text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Under 17 C.F.R. &#167;&#167; 200.80(b)(4) and 240.24b-2</font></div></div><br><div style="line-height:120%;padding-bottom:16px;text-align:center;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">This Agreement is signed as indicated below by duly authorized representatives of Orexo, Galena and Actavis, respectively, effective as of the date first written above.</font></div><div style="line-height:120%;font-size:12pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"></td></tr><tr><td width="8%"></td><td width="41%"></td><td width="9%"></td><td width="42%"></td></tr><tr><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:16px;padding-bottom:16px;padding-right:2px;"><div style="padding-bottom:16px;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">ACTAVIS LABORATORIES FL, INC.</font></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:16px;padding-bottom:16px;padding-right:2px;"><div style="padding-bottom:16px;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">OREXO AB</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">By:</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">_____/S/_____________________</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">By:</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">_____/S/________________________</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Name:</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">A. Robert D. Bailey__________</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Name:</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Nikolaj  Sorenson_______________</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Title:</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">EVP &amp; Chief Legal Officer_____</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:16px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Title:</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">CEO &amp; President_______________</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">GALENA BIOPHARMA INC.</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:16px;padding-right:2px;"><div style="padding-bottom:16px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">By:</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">_____/S/___________________</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:16px;padding-right:2px;"><div style="padding-bottom:16px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Name:</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Mark W. Schwartz____________</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:16px;padding-right:2px;"><div style="padding-bottom:16px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Title:</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">President &amp; CEO_____________</font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><br><div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">15</font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><hr style="page-break-after:always"><a name="s718CD66BBECB5B9C28DFED72C1B16187"></a><div><div style="line-height:120%;text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Exhibit 10.7</font></div><div style="line-height:120%;text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">*** Text Omitted and Filed Separately</font></div><div style="line-height:120%;text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Confidential Treatment Requested</font></div><div style="line-height:120%;text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Under 17 C.F.R. &#167;&#167; 200.80(b)(4) and 240.24b-2</font></div></div><br><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><br><div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">16</font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><hr style="page-break-after:always"><a name="s0F00A5C00FE4A0D5383DED72C1E2DD35"></a><div><div style="line-height:120%;text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Exhibit 10.7</font></div><div style="line-height:120%;text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">*** Text Omitted and Filed Separately</font></div><div style="line-height:120%;text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Confidential Treatment Requested</font></div><div style="line-height:120%;text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Under 17 C.F.R. &#167;&#167; 200.80(b)(4) and 240.24b-2</font></div></div><br><div style="line-height:240%;padding-bottom:13px;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">EXHIBIT A</font></div><div style="line-height:240%;padding-bottom:13px;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">[District Court Dismissal]</font></div><br><div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><hr style="page-break-after:always"><a name="s0F00A5C00FE4A0D5383DED72C1E2DD35"></a><div><div style="line-height:120%;text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Exhibit 10.7</font></div><div style="line-height:120%;text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">*** Text Omitted and Filed Separately</font></div><div style="line-height:120%;text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Confidential Treatment Requested</font></div><div style="line-height:120%;text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Under 17 C.F.R. &#167;&#167; 200.80(b)(4) and 240.24b-2</font></div></div><br><div style="line-height:138%;padding-bottom:13px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:138%;padding-bottom:13px;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">IN THE UNITED STATES DISTRICT COURT</font></div><div style="line-height:138%;padding-bottom:13px;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">FOR THE DISTRICT OF NEW JERSEY</font></div><div style="line-height:138%;padding-bottom:13px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;font-size:12pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="2"></td></tr><tr><td width="50%"></td><td width="50%"></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="padding-bottom:16px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="padding-bottom:16px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">OREXO AB,</font></div><div style="padding-bottom:16px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-style:italic;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Plaintiff</font><font style="font-family:inherit;font-size:12pt;">,</font></div><div style="padding-bottom:16px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#160;&#160;&#160;&#160;&#160;&#160;v.</font></div><div style="padding-bottom:16px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">ACTAVIS LABORATORIES FL, INC.</font></div><div style="padding-bottom:16px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-style:italic;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Defendant</font><font style="font-family:inherit;font-size:12pt;">.</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;"><div style="padding-bottom:13px;text-align:center;padding-left:18px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#160;</font></div><div style="padding-bottom:13px;text-align:center;padding-left:18px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="padding-bottom:16px;text-align:center;padding-left:18px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Civil Action No. 3:15-cv-00826 (PGS/DEA)</font></div><div style="padding-bottom:16px;text-align:center;padding-left:18px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="padding-bottom:16px;text-align:center;padding-left:18px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></td></tr></table></div></div><div style="line-height:138%;padding-bottom:13px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:138%;padding-bottom:13px;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">JOINT STIPULATION OF DISMISSAL</font></div><div style="line-height:138%;padding-bottom:13px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:240%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Pursuant to Rules 41(a)(1) and 41(c) of the Federal Rules of Civil Procedure, Plaintiff Orexo AB and Defendant Actavis Laboratories FL, Inc. hereby stipulate and agree that Civil Action No. 3:15-cv-00826 (PGS/DEA), including all claims, counterclaims, and affirmative defenses asserted, are hereby dismissed with prejudice, and without costs, disbursements or attorneys&#8217; fees to any party.&#160; </font></div><div style="line-height:240%;padding-bottom:16px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">SO ORDERED this day of __________________, 2015.</font></div><div style="line-height:240%;padding-bottom:16px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:138%;padding-bottom:13px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="line-height:138%;padding-bottom:13px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">United States District Judge</font></div><br><div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div>	</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.7
<SEQUENCE>3
<FILENAME>gale20150930ex107.htm
<DESCRIPTION>EXHIBIT 10.7
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
	<head>
		<!-- Document created using Wdesk 1 -->
		<!-- Copyright 2015 Workiva -->
		<title>Exhibit</title>
	</head>
	<body style="font-family:Times New Roman;font-size:10pt;">
<a name="s8138E1E1D73ED9170246CF693391FAE1"></a><div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><br><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">EMPLOYMENT AGREEMENT</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">This Employment Agreement (this &#8220;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Agreement</font><font style="font-family:inherit;font-size:12pt;">&#8221;) is made and entered into as of October 30, 2015 (the &#8220;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Effective Date</font><font style="font-family:inherit;font-size:12pt;">&#8221;) by and between Galena Biopharma, Inc., a Delaware corporation (the &#8220;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Company</font><font style="font-family:inherit;font-size:12pt;">&#8221;, or &#8220;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Employer</font><font style="font-family:inherit;font-size:12pt;">&#8221;), and Bijan Nejadnik, M.D., an individual and resident of the State of </font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">[California]</font><font style="font-family:inherit;font-size:12pt;">&#32;(&#8220;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Employee</font><font style="font-family:inherit;font-size:12pt;">&#8221;).</font></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">BACKGROUND</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Employer and Employee desire that Employee serve as the Company&#8217;s Chief Medical Officer on the terms set forth in this Agreement.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">AGREED TERMS</font></div><div style="line-height:120%;padding-left:0px;padding-bottom:16px;text-align:left;text-indent:48px;"><font style="padding-bottom:16px;text-align:left;font-family:inherit;font-size:12pt;padding-right:48px;">1.</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Engagement</font><font style="font-family:inherit;font-size:12pt;">.  Commencing on the Effective Date, Employer shall employ Employee, and Employee shall serve, as the Executive Vice President and Chief Medical Officer of the Company.  Employee understands that his duties may change from time to time in the discretion of Employer&#8217;s Board of Directors (hereinafter the &#8220;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Board</font><font style="font-family:inherit;font-size:12pt;">&#8221;), but such duties shall be consistent with the duties customarily assigned to the Chief Medical Officer of a company substantially comparable as of the Effective Date to Employer. As a condition to the Employee&#8217;s employment by the Employer, Employee and Employer shall execute the Employee Confidentiality, Non-Competition, and Proprietary Information Agreement attached hereto as Exhibit 1 and made a part hereof (the &#8220;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Confidentiality Agreement</font><font style="font-family:inherit;font-size:12pt;">&#8221;).</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">2.</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Duties</font><font style="font-family:inherit;font-size:12pt;">.  Employee shall perform faithfully, diligently and to the best of his ability all duties assigned to him by the Board. Employee shall perform the services contemplated under this Agreement in accordance with the policies established by the Board and under the direction of the Company&#8217;s President and Chief Executive Officer.  Employee shall have such corporate power and authority as shall reasonably be required to enable his to discharge his duties under this Agreement. Employee&#8217;s services hereunder shall be rendered at the Company&#8217;s principal executive offices, except for travel when and as required in the performance of Employee&#8217;s duties hereunder.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">3.</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Time and Efforts</font><font style="font-family:inherit;font-size:12pt;">.  Employee shall devote all of his business time, efforts, attention and energies to Employer&#8217;s business and the discharge of his duties hereunder. Notwithstanding the foregoing, except as otherwise agreed to in writing, Employee shall have the right to perform such incidental services as are necessary in connection with (a) his private, passive investments, (b) charitable or community activities, (c) participation in trade or professional organizations and (d) service on the board of directors (or comparable body) of not more than one third-party entity or organization that does not compete with the Company Business (as defined in the Confidentiality Agreement), so long as the foregoing do not interfere with Employee&#8217;s performance of his duties hereunder as determined in good faith by the Company.</font></div><br><div><div style="line-height:120%;text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">-  .</font></div></div><hr style="page-break-after:always"><a name="s8138E1E1D73ED9170246CF693391FAE1"></a><div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><br><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">4.</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Compensation</font><font style="font-family:inherit;font-size:12pt;">.  As the total consideration for Employee&#8217;s services rendered under this Agreement, Employer shall pay or provide Employee the following compensation and benefits:</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:96px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">4.1</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Signing Bonus</font><font style="font-family:inherit;font-size:12pt;">.  Employee shall be entitled to a one-time signing bonus (the &#8220;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Signing Bonus</font><font style="font-family:inherit;font-size:12pt;">&#8221;) of $100,000.00, payable on the first payroll date following the Effective Date.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:96px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">4.2</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Salary</font><font style="font-family:inherit;font-size:12pt;">.  Employee shall be entitled to receive an annual base salary during the Term of $400,000.00 (hereinafter the &#8220;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Base Salary</font><font style="font-family:inherit;font-size:12pt;">&#8221;), payable in accordance with the usual payroll practices of Employer as established from time to time.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:96px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">4.3</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Discretionary Bonus</font><font style="font-family:inherit;font-size:12pt;">.  Employee shall be eligible to receive during each calendar year, commencing in 2016, a discretionary annual target performance bonus of up to 30% of the Base Salary.  The amount of any such bonus shall be determined by the Board, or the Compensation Committee of the Board, in their sole discretion.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:96px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">4.4</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Stock Option</font><font style="font-family:inherit;font-size:12pt;">.  As soon as practicable on or after the Effective Date, the Company shall grant Employee under the Company&#8217;s Amended and Restated 2007 Incentive Plan, as amended (the &#8220;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Plan</font><font style="font-family:inherit;font-size:12pt;">&#8221;), a stock option (&#8220;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Option</font><font style="font-family:inherit;font-size:12pt;">&#8221;) to purchase 350,000 shares of the Company&#8217;s common stock. The Option shall vest in sixteen (16) equal quarterly installments of 21,875 shares each over four years beginning on the first quarterly anniversary of the Effective Date, provided, in each case, that Employee remains in the continuous employ of Employer through such quarterly anniversary date. The Option shall (a) be exercisable at an exercise price per share equal to the closing market price of the Company common stock on the date of the grant, (b)&#160;have a term of ten years, and (c) be on such other terms as shall be set forth in the Company&#8217;s customary form of stock option agreement under the Plan evidencing the Option.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:96px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">4.5</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Expense Reimbursement</font><font style="font-family:inherit;font-size:12pt;">.  Employer shall reimburse Employee for reasonable business expenses incurred by Employee in connection with the performance of Employee&#8217;s duties in accordance with Employer&#8217;s usual practices and policies in effect from time to time. Any reimbursements hereunder shall be paid to Employee in accordance with the Company&#8217;s expense reimbursement policies and procedures from time to time in effect. </font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:96px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">4.6</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Vacation</font><font style="font-family:inherit;font-size:12pt;">.  Employee shall be entitled to up to 20 days, prorated for any period of less than a full calendar year, of paid &#8220;time off&#8217; (vacation days plus sick time/personal time) for each calendar year in accordance with the Company&#8217;s policies from time to time in effect, in addition to holidays observed by the Company.  Paid time off may be taken at such times and intervals as the Employee shall determine, subject to the conflicting business needs of the Company, and otherwise shall be subject to the Company&#8217;s policies in effect from time to time.  The number of paid time off days will accrue per pay period and will stop accruing in a calendar year once 20 days have been accrued.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:96px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">4.7</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Employee Benefits</font><font style="font-family:inherit;font-size:12pt;">.  The Company shall provide Employee and his dependents, if any, with coverage under any and all medical, dental and vision plans and other benefit programs available generally to the Company&#8217;s senior executives and their dependents, to </font></div><br><div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">2</font></div><div style="line-height:120%;text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">-  .</font></div></div><hr style="page-break-after:always"><a name="s8138E1E1D73ED9170246CF693391FAE1"></a><div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><br><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">the extent Employee and his dependents satisfy the applicable eligibility requirements, and the Company shall pay, directly or indirectly, the premiums associated with any such medical plans to the same extent the Company pays such premiums for other senior executives of the Company. Employee shall be eligible to participate in any medical insurance and other employee benefits made available generally by Employer to all senior executives under Employer&#8217;s plans and employment policies in effect from time to time.  Employee acknowledges and agrees that any such plans or policies now or hereafter in effect may be modified or terminated by Employer at any time in its discretion.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:96px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">4.8</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Payroll Taxes</font><font style="font-family:inherit;font-size:12pt;">.  Employer shall have the right to deduct from the compensation and benefits due to Employee hereunder any and all sums required for social security and withholding taxes and for any other federal, state, or local tax or charge which may be in effect or hereafter enacted or required as a charge on the compensation or benefits of Employee.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">5.</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Termination</font><font style="font-family:inherit;font-size:12pt;">. This Agreement and Employee&#8217;s employment may be terminated as set forth in this Section 5.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:96px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">5.1</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Termination by Employer for Cause; Termination by Employee</font><font style="font-family:inherit;font-size:12pt;">.  Employer may terminate Employee&#8217;s employment hereunder for &#8220;Cause&#8221; (as hereinafter defined) upon notice to Employee.  &#8220;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Cause</font><font style="font-family:inherit;font-size:12pt;">&#8221; for the purpose of this Agreement shall mean any of the following:</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:144px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(a)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">Employee&#8217;s breach of any material term of this Agreement, including its Exhibits; provided that the first occasion of any particular breach shall not constitute Cause unless Employee shall have previously received written notice from Employer stating the nature of such breach and affording Employee at least ten days to correct such breach;</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:144px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(b)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">Employee s conviction of, or plea of guilty or nolo contendere to, any felony or other crime of moral turpitude;</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:144px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(c)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">Employee&#8217;s act of fraud or dishonesty injurious to Employer or its reputation;</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:144px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(d)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">Employee&#8217;s continual failure or refusal to perform his material duties as required under this Agreement after written notice from Employer stating the nature of such failure or refusal and affording Employee at least ten days to correct the same;</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:144px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(e)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">Employee&#8217;s act or omission that, in the reasonable determination of Employer&#8217;s Board (or a Committee of the Board), indicates alcohol or drug abuse by Employee; or</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:144px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(f)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">Employee&#8217;s act or personal conduct that, in the judgment of the Board (or a Committee of the Board), gives rise to a material risk of liability of Employee or Employer under federal or applicable state law for discrimination, or sexual or other forms of harassment, or other similar liabilities to subordinate employees.</font></div><br><div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">3</font></div><div style="line-height:120%;text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">-  .</font></div></div><hr style="page-break-after:always"><a name="s8138E1E1D73ED9170246CF693391FAE1"></a><div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><br><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Employee may terminate his employment hereunder, for any reason or no reason, upon 30 days prior notice to Employer. </font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Upon termination of Employee&#8217;s employment by Employer for Cause or by Employee for any reason, all compensation and benefits to Employee hereunder shall cease except that Employee shall be entitled to payment, not later than the date of termination, of (i) any accrued but unpaid salary and unused paid time off (only as accrued during the then-current year of employment), and (ii) reimbursement of business expenses accrued but unpaid as of the date of termination.  </font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:96px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">5.2</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Termination by Employer without Cause</font><font style="font-family:inherit;font-size:12pt;">.  Employer may also terminate Employee&#8217;s employment without Cause; provided, however, that Employer shall remain obligated to continue paying in accordance with Section 4.1 Employee&#8217;s Base Salary at the time of termination for a period of six months following the termination. Upon any termination pursuant to this Section 5.2, Employee shall be entitled to payment of any unused vacation time (only as accrued as of the date of such termination as provided in this Agreement and in accordance with applicable law) and reimbursement of business expenses accrued but unpaid as of the date of termination.  </font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:96px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">5.3</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Death or Disability</font><font style="font-family:inherit;font-size:12pt;">.  Employee&#8217;s employment will terminate automatically in the event of Employee&#8217;s death or upon notice from Employer in event of Employee&#8217;s permanent disability.  Employee&#8217;s &#8220;permanent disability&#8221; shall have the meaning ascribed to such term in any policy of disability insurance maintained by Employer (or Employee, as the case may be) with respect to Employee, or if no such policy is then in effect, shall mean Employee&#8217;s inability to fully perform his duties hereunder with or without reasonable accommodation for any period of at least ninety (90) consecutive days, or for a total of one hundred twenty (120) days, whether or not consecutive, within any period of one hundred eighty (180) consecutive days.  Upon termination of Employee&#8217;s employment as aforesaid, all compensation and benefits to Employee hereunder shall cease and Employee, or Employee&#8217;s heirs or personal representatives, as applicable, shall be entitled to the same compensation and benefits as provided in Section&#160;5.1 for termination by Employer for Cause.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">6.</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Indemnification; Insurance.</font><font style="font-family:inherit;font-size:12pt;">&#32;&#32;</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:96px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">6.1</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Indemnification</font><font style="font-family:inherit;font-size:12pt;">.  In the event that Employee is made a party or threatened to be made a party to any action, suit, or proceeding, whether civil, criminal, administrative or investigative (a "</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Proceeding</font><font style="font-family:inherit;font-size:12pt;">"), other than any Proceeding initiated by Employee or the Company related to any contest or dispute between Employee and the Company or any of its affiliates with respect to this Agreement or Employee 's employment hereunder, by reason of the fact that the Employee is or was a director or officer of the Company, or any affiliate of the Company, or is or was serving at the request of the Company as a director, officer, member, employee or agent of another corporation or a partnership, joint venture, trust or other enterprise, Employee shall be indemnified and held harmless by the Company to the fullest extent permitted under applicable law and the Company's bylaws from and against any liabilities, costs, claims and expenses, including all costs and expenses incurred in defense of any Proceeding (including reasonable attorneys' fees).  Costs and expenses incurred by Employee in defense of such Proceeding </font></div><br><div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">4</font></div><div style="line-height:120%;text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">-  .</font></div></div><hr style="page-break-after:always"><a name="s8138E1E1D73ED9170246CF693391FAE1"></a><div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><br><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(including attorneys' fees) shall be paid by the Company in advance of the final disposition of such litigation upon receipt by the Company of: (i) a written request for payment; (ii) appropriate documentation evidencing the incurrence, amount and nature of the costs and expenses for which payment is being sought; and (iii) an undertaking adequate under applicable law made by or on behalf of Employee to repay the amounts so paid if it shall ultimately be determined that Employee is not entitled to be indemnified by the Company under this Agreement. </font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:96px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">6.2</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Insurance</font><font style="font-family:inherit;font-size:12pt;">.  During the Employment term, the Company shall purchase and maintain, at its own expense, directors' and officers' liability insurance providing coverage to Employee on terms that are no less favorable than the coverage provided to other directors and similarly situated executives of the Company.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">7.</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Clawback Provisions</font><font style="font-family:inherit;font-size:12pt;">.  Notwithstanding any other provisions in this Agreement to the contrary, any incentive-based compensation, or any other compensation, paid to Employee pursuant to this Agreement or any other agreement or arrangement with the Company which is or may become subject to recovery under any law, government regulation or stock exchange listing requirement, will be subject to such deductions and clawback as may be required to be made pursuant to such law, government regulation or stock exchange listing requirement (or any policy adopted by the Company pursuant to any such law, government regulation or stock exchange listing requirement).  The Company will make any determination for clawback or recovery in its sole discretion and in accordance with any applicable law or regulation.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">8.</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Severable Provisions</font><font style="font-family:inherit;font-size:12pt;">.  The provisions of this Agreement are severable and if any one or more provisions is determined to be illegal or otherwise unenforceable, in whole or in part, the remaining provisions, and any partially unenforceable provisions to the extent enforceable, shall nevertheless be binding and enforceable.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">9.</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Successors and Assigns</font><font style="font-family:inherit;font-size:12pt;">.  This Agreement shall inure to the benefit of and shall be binding upon and enforceable by the parties and their respective successors, assigns, heirs and representatives; provided, however, that neither party may assign this Agreement without the prior written consent of the other party; and, provided further, that this Agreement may be assigned by the Company to a successor (whether direct or indirect, by purchase, merger, consolidation or otherwise) to all or substantially all of the business or assets of Employer.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">10.</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Entire Agreement</font><font style="font-family:inherit;font-size:12pt;">.  This Agreement, including the Confidentiality Agreement, contains the entire agreement of the parties relating to the subject matter hereof, and the parties hereto have made no agreements, representations or warranties relating to the subject matter of this Agreement that are not set forth otherwise therein or herein. Except as expressly provided herein, this Agreement (including the Confidentiality Agreement) supersedes any and all prior or contemporaneous agreements, written or oral, between Employee and Employer relating to the subject matter hereof.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">11.</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Amendment</font><font style="font-family:inherit;font-size:12pt;">. No modification of this Agreement shall be valid unless made in writing, approved by the Board (or a committee of the Board) and signed by the parties hereto.  The parties hereto agree that in no event shall an oral modification of this Agreement be enforceable or valid.</font></div><br><div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">5</font></div><div style="line-height:120%;text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">-  .</font></div></div><hr style="page-break-after:always"><a name="s8138E1E1D73ED9170246CF693391FAE1"></a><div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><br><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">12.</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Governing Law; Arbitration</font><font style="font-family:inherit;font-size:12pt;">.  </font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:96px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">12.1</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Governing Law</font><font style="font-family:inherit;font-size:12pt;">.  This Agreement is and shall be governed and construed in accordance with the laws of the State of California without giving effect to the choice-of-law rules of California.  </font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:96px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">12.2</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">Employer and Employee agree that arbitration pursuant to this Section&#160;12.2 shall be the sole and exclusive method for resolving any claim or dispute arising out of or relating to the rights and obligations of the Company and Employee pursuant to this Agreement.  Employer and Employee shall mutually agree on the arbitrator; provided, however, that if Employer and Employee cannot mutually agree on the arbitrator, either Employer or Employee can request that JAMS, Inc. (&#8220;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">JAMS</font><font style="font-family:inherit;font-size:12pt;">&#8221;) select the arbitrator.  The arbitrator shall have at least ten (10) years&#8217; experience with respect to employment matters.  Any such arbitration shall be held in San Francisco, California, under JAMS&#8217;s Employment Arbitration Rules &amp; Procedures (the &#8220;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">JAMS Rules &amp; Procedures</font><font style="font-family:inherit;font-size:12pt;">&#8221;) then in effect.  A copy of the current JAMS Rules &amp; Procedures is attached hereto as </font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Exhibit&#160;A</font><font style="font-family:inherit;font-size:12pt;">.  The JAMS Rules &amp; Procedures are also available online at www.jamsadr.com/rules-employment arbitration .  The arbitrator shall set a limited time period and establish procedures designed to reduce the cost and time for discovery while allowing Employer and Employee an opportunity, adequate in the sole judgment of the arbitrator, to discover relevant information from the opposing parties about the subject matter of the dispute.  The arbitrator shall rule upon motions to compel or limit discovery and shall have the authority to impose sanctions, including attorneys&#8217; fees and costs, to the same extent as a court of law or equity, should the arbitrator determine that discovery was sought without substantial justification or that discovery was refused or objected to without substantial justification.  The decision of the arbitrator shall be written, shall be in accordance with applicable law, and shall be supported by written findings of fact and conclusions of law which shall set forth the basis for the decision of the arbitrator.  The arbitrator shall render a written decision on the claim or dispute presented as soon as practicable and in any event not more than forty-five (45) days after the close of evidence and briefing.  The decision of the arbitrator as to the validity and amount of any claim disputed by Employer and Employee shall be binding and conclusive upon such parties to this Agreement, and notwithstanding anything in this Section&#160;12.2, such parties shall be required to act in accordance with such decision.  Judgment upon any award rendered by the arbitrator may be entered in any court having jurisdiction.  Employer will pay all costs of the arbitration, including administrative and arbitrator fees, other than costs the parties would normally incur in a civil action.  In the event that a judgment is made pursuant to this Section 12.2, all reasonable out of pocket costs and reasonable legal costs incurred by the prevailing party shall be paid by the non-prevailing party.  Any decision, judgment, ruling, finding, award or other determination of the arbitrator and any information disclosed in the course of any arbitration hereunder shall be kept confidential by Employer and Employee, and any court order to enforce the decision, judgment, ruling, finding, award or other determination of the arbitrator shall be filed under seal.  This agreement to arbitrate is freely negotiated between Employee and Employer and is mutually entered into between the parties.  Each party fully understands and agrees that they are giving up certain rights otherwise afforded them by civil court actions, including, but not limited to, the right to a jury trial.</font></div><br><div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">6</font></div><div style="line-height:120%;text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">-  .</font></div></div><hr style="page-break-after:always"><a name="s8138E1E1D73ED9170246CF693391FAE1"></a><div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><br><div style="line-height:120%;padding-bottom:16px;text-align:left;padding-left:96px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-style:italic;font-weight:bold;">/</font><font style="font-family:inherit;font-size:12pt;font-style:italic;font-weight:bold;text-decoration:underline;">s/ BN</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">&#32;By initialing here, Employee acknowledges he has read this Section&#160;12.2 and agrees with the arbitration provisions herein.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">13.</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Notice</font><font style="font-family:inherit;font-size:12pt;">.  All notices and other communications under this Agreement shall be in writing and mailed, electronically mailed, telecopied (in case of notice to Employer only) or delivered by hand or by a nationally recognized courier service guaranteeing overnight delivery to a party at the following address (or to such other address as such party may have specified by notice given to the other party pursuant to the provision):</font></div><div style="line-height:120%;text-align:left;padding-left:96px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">If to Employer:</font></div><div style="line-height:120%;text-align:left;padding-left:96px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:96px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Galena Biopharma, Inc.</font></div><div style="line-height:120%;text-align:left;padding-left:96px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Attention: Chief Executive Officer</font></div><div style="line-height:120%;text-align:left;padding-left:96px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">2000 Crow Canyon Place, Suite 380 <br>San Ramon, California 95483</font></div><div style="line-height:120%;text-align:left;padding-left:96px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Phone: 855-855-4253</font></div><div style="line-height:120%;text-align:left;padding-left:96px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:96px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">If to Employee:</font></div><div style="line-height:120%;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:96px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Through the Company e-mail or the Company regular mail box, if utilized by the Company, or if Employee shall no longer be employed, to Employee&#8217;s address as reflected in the books and records of Employer.  </font></div><div style="line-height:120%;text-align:left;padding-left:96px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">14.</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Survival</font><font style="font-family:inherit;font-size:12pt;">.  Sections 6 through 13 and Section 16 shall survive the termination of this Agreement.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">15.</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Counterparts</font><font style="font-family:inherit;font-size:12pt;">.  This Agreement may be executed in counterparts, each of which shall be deemed to be an original and all of which together shall be deemed to be one and the same agreement.  Each party may sign this Agreement using an electronic or handwritten signature, whether on an original or an electronic counterpart of this Agreement.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">16.</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Attorney&#8217;s Fees</font><font style="font-family:inherit;font-size:12pt;">.  In any action or proceeding to construe or enforce any provision of this Agreement the prevailing party shall be entitled to recover its or his reasonable attorneys&#8217; fees and other costs of suit in addition to any other recoveries.</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">[Signature Page Follows]</font></div><br><div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">7</font></div><div style="line-height:120%;text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">-  .</font></div></div><hr style="page-break-after:always"><a name="s8138E1E1D73ED9170246CF693391FAE1"></a><div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><br><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">By signing below, each party acknowledges that it or he has read and understands this Agreement, and each party agrees to be bound by the terms of this Agreement.</font></div><div style="line-height:120%;font-size:12pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="2"></td></tr><tr><td width="50%"></td><td width="50%"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">EMPLOYER</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Galena Biopharma, Inc.</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:12pt;"><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">By:</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;font-style:italic;">&#160;/s/ Mark W. Schwartz</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#160;&#160;&#160;Mark W. Schwartz, Ph.D.</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#160;&#160;&#160;President and Chief Executive Officer</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">EMPLOYEE</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-style:italic;text-decoration:underline;">/s/ Bijan Nejadnik</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Bijan Nejadnik, M.D.</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr></table></div></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><br><div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">8</font></div><div style="line-height:120%;text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">-  .</font></div></div>	</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>4
<FILENAME>gale20150930ex311.htm
<DESCRIPTION>EXHIBIT 31.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
	<head>
		<!-- Document created using Wdesk 1 -->
		<!-- Copyright 2015 Workiva -->
		<title>Exhibit</title>
	</head>
	<body style="font-family:Times New Roman;font-size:10pt;">
<a name="s092D3D61CF9C591CB94DC60DA55E91B3"></a><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><br><div style="line-height:120%;text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Exhibit&#160;31.1</font></div><div style="line-height:120%;padding-top:12px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">CERTIFICATION OF CHIEF EXECUTIVE OFFICER</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div style="line-height:120%;padding-top:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">I, Mark W. Schwartz, certify that:</font></div><div style="line-height:120%;padding-top:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1. I have reviewed this Quarterly Report on Form 10-Q of Galena Biopharma, Inc.;</font></div><div style="line-height:120%;padding-top:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</font></div><div style="line-height:120%;padding-top:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;</font></div><div style="line-height:120%;padding-top:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4. The registrant&#8217;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules&#160;13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:</font></div><div style="line-height:120%;padding-top:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</font></div><div style="line-height:120%;padding-top:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;</font></div><div style="line-height:120%;padding-top:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">c) Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</font></div><div style="line-height:120%;padding-top:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">d) Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting; and</font></div><div style="line-height:120%;padding-top:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5. The registrant&#8217;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions):</font></div><div style="line-height:120%;padding-top:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information; and</font></div><div style="line-height:120%;padding-top:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font></div><div style="line-height:120%;padding-top:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Dated: </font><font style="font-family:inherit;font-size:10pt;">November&#160;9, 2015</font><font style="font-family:inherit;font-size:10pt;">&#32;</font></div><div style="line-height:120%;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="2"></td></tr><tr><td width="61%"></td><td width="39%"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">/s/ Mark W. Schwartz</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Mark W. Schwartz</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">President and Chief Executive Officer</font></div></td></tr></table></div></div><br><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div>	</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>5
<FILENAME>gale20150930ex312.htm
<DESCRIPTION>EXHIBIT 31.2
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
	<head>
		<!-- Document created using Wdesk 1 -->
		<!-- Copyright 2015 Workiva -->
		<title>Exhibit</title>
	</head>
	<body style="font-family:Times New Roman;font-size:10pt;">
<a name="sBD6213F465A05CFD8292315A32415CAB"></a><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><br><div style="line-height:120%;text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Exhibit&#160;31.2</font></div><div style="line-height:120%;padding-top:12px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">CERTIFICATION OF PRINCIPAL FINANCIAL AND ACCOUNTING OFFICER</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div style="line-height:120%;padding-top:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">I, Ryan M. Dunlap, certify that:</font></div><div style="line-height:120%;padding-top:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1. I have reviewed this Quarterly Report on Form 10-Q of Galena Biopharma, Inc.;</font></div><div style="line-height:120%;padding-top:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</font></div><div style="line-height:120%;padding-top:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;</font></div><div style="line-height:120%;padding-top:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4. The registrant&#8217;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules&#160;13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:</font></div><div style="line-height:120%;padding-top:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</font></div><div style="line-height:120%;padding-top:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;</font></div><div style="line-height:120%;padding-top:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">c) Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</font></div><div style="line-height:120%;padding-top:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">d) Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting; and</font></div><div style="line-height:120%;padding-top:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5. The registrant&#8217;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions):</font></div><div style="line-height:120%;padding-top:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information; and</font></div><div style="line-height:120%;padding-top:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font></div><div style="line-height:120%;padding-top:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Dated: </font><font style="font-family:inherit;font-size:10pt;">November&#160;9, 2015</font><font style="font-family:inherit;font-size:10pt;">&#32;</font></div><div style="line-height:120%;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="2"></td></tr><tr><td width="61%"></td><td width="39%"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">/s/ Ryan M. Dunlap</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Ryan M. Dunlap</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Vice President, Chief Financial Officer</font></div></td></tr></table></div></div><br><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div>	</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>6
<FILENAME>gale20150930ex321.htm
<DESCRIPTION>EXHIBIT 32.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
	<head>
		<!-- Document created using Wdesk 1 -->
		<!-- Copyright 2015 Workiva -->
		<title>Exhibit</title>
	</head>
	<body style="font-family:Times New Roman;font-size:10pt;">
<a name="sC63EA0F777C5550FB59327151E87FC64"></a><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><br><div style="line-height:120%;text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Exhibit&#160;32.1</font></div><div style="line-height:120%;padding-top:12px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">CERTIFICATION PURSUANT TO</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">18 U.S.C. SECTION 1350</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">AS ADOPTED PURSUANT TO</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In connection with the accompanying Quarterly Report of Galena Biopharma, Inc., (the &#8220;Company&#8221;) on Form 10-Q for the quarter ended September 30, 2015 as filed with the Securities and Exchange Commission on the date hereof (the &#8220;Report&#8221;), the undersigned officers of the Company certify, pursuant to 18 U.S.C. &#167; 1350, as adopted pursuant to &#167; 906 of the Sarbanes-Oxley Act of 2002, that to their knowledge:</font></div><div style="line-height:120%;padding-top:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1. The Report fully complies with the requirements of Section&#160;13(a) or 15(d) of the Securities Exchange Act of 1934; and</font></div><div style="line-height:120%;padding-top:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2. The information contained in the Report fairly presents, in all material respects, the Company&#8217;s financial condition and result of operations.</font></div><div style="line-height:120%;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td width="46%"></td><td width="8%"></td><td width="46%"></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">/s/ Mark W. Schwartz</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">/s/ Ryan M. Dunlap</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Mark W. Schwartz</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Ryan M. Dunlap</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">President and Chief Executive Officer</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Vice President, Chief Financial Officer</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">November&#160;9, 2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">November 9, 2015</font></div></td></tr></table></div></div><br><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div>	</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.INS
<SEQUENCE>7
<FILENAME>gale-20150930.xml
<DESCRIPTION>XBRL INSTANCE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!--XBRL Document Created with Wdesk from Workiva-->
<!--p:5214DC136A5B55B89073757B18699AA7,x:b7f109e4e90747c095b385d692dfd08b-->
<xbrli:xbrl xmlns:country="http://xbrl.sec.gov/country/2013-01-31" xmlns:currency="http://xbrl.sec.gov/currency/2014-01-31" xmlns:dei="http://xbrl.sec.gov/dei/2014-01-31" xmlns:exch="http://xbrl.sec.gov/exch/2014-01-31" xmlns:gale="http://www.galenabiopharma.com/20150930" xmlns:invest="http://xbrl.sec.gov/invest/2013-01-31" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:naics="http://xbrl.sec.gov/naics/2011-01-31" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:num="http://www.xbrl.org/dtr/type/numeric" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:sic="http://xbrl.sec.gov/sic/2011-01-31" xmlns:stpr="http://xbrl.sec.gov/stpr/2011-01-31" xmlns:us-gaap="http://fasb.org/us-gaap/2014-01-31" xmlns:us-roles="http://fasb.org/us-roles/2014-01-31" xmlns:us-types="http://fasb.org/us-types/2014-01-31" xmlns:utreg="http://www.xbrl.org/2009/utr" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsd="http://www.w3.org/2001/XMLSchema" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
	<link:schemaRef xlink:href="gale-20150930.xsd" xlink:type="simple" />
	<xbrli:context id="FD2015Q3YTD">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-01-01</xbrli:startDate>
			<xbrli:endDate>2015-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2015Q4Oct31">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-10-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2014Q4">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2014-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2015Q3">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-09-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2014Q3QTD">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2014-07-01</xbrli:startDate>
			<xbrli:endDate>2014-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2015Q3QTD">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-07-01</xbrli:startDate>
			<xbrli:endDate>2015-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2014Q3YTD">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2014-01-01</xbrli:startDate>
			<xbrli:endDate>2014-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2015Q3YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-01-01</xbrli:startDate>
			<xbrli:endDate>2015-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2015Q3_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-09-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2015Q3YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-01-01</xbrli:startDate>
			<xbrli:endDate>2015-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2015Q3_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-09-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2014Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2014-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2015Q3_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-09-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2014Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2014-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2014Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2014-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2015Q3_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-09-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2015Q3YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-01-01</xbrli:startDate>
			<xbrli:endDate>2015-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2014Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2014-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2014Q3">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2014-09-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2013Q4">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2013-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2015Q3YTD_us-gaap_PropertyPlantAndEquipmentByTypeAxis_gale_EquipmentFurnitureAndFixturesMember_us-gaap_RangeAxis_us-gaap_MaximumMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">gale:EquipmentFurnitureAndFixturesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MaximumMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-01-01</xbrli:startDate>
			<xbrli:endDate>2015-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2015Q3YTD_us-gaap_PropertyPlantAndEquipmentByTypeAxis_gale_EquipmentFurnitureAndFixturesMember_us-gaap_RangeAxis_us-gaap_MinimumMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">gale:EquipmentFurnitureAndFixturesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MinimumMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-01-01</xbrli:startDate>
			<xbrli:endDate>2015-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2014Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2014-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2015Q3_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-09-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2015Q3YTD_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-01-01</xbrli:startDate>
			<xbrli:endDate>2015-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2015Q3_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-09-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2015Q3_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-09-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2015Q3_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-09-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2015Q3_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-09-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2014Q4_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2014-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2014Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2014-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2014Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2014-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2014Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2014-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2013Q2MAY8">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2013-05-07</xbrli:startDate>
			<xbrli:endDate>2013-05-08</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2013Q2May8">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2013-05-08</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2013Q2May8_us-gaap_LongtermDebtTypeAxis_gale_FirstTrancheMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">gale:FirstTrancheMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2013-05-08</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2013Q2May8_us-gaap_RangeAxis_us-gaap_MaximumMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MaximumMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2013-05-08</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2015Q3QTD_dei_LegalEntityAxis_gale_MLVCo.LLCandMaximGroupLLCMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="dei:LegalEntityAxis">gale:MLVCo.LLCandMaximGroupLLCMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-07-01</xbrli:startDate>
			<xbrli:endDate>2015-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2015Q1Mar18">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-03-18</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2015Q1Mar18">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-03-18</xbrli:startDate>
			<xbrli:endDate>2015-03-18</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2014Q4Nov18_dei_LegalEntityAxis_gale_LincolnParkCapitalLLCMember_us-gaap_StatementClassOfStockAxis_us-gaap_CommonStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="dei:LegalEntityAxis">gale:LincolnParkCapitalLLCMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2014-11-18</xbrli:startDate>
			<xbrli:endDate>2014-11-18</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2015Q3QTD_dei_LegalEntityAxis_gale_LincolnParkCapitalLLCMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="dei:LegalEntityAxis">gale:LincolnParkCapitalLLCMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-07-01</xbrli:startDate>
			<xbrli:endDate>2015-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2014Q4YTD_dei_LegalEntityAxis_gale_MLVCo.LLCandMaximGroupLLCMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="dei:LegalEntityAxis">gale:MLVCo.LLCandMaximGroupLLCMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2014-01-01</xbrli:startDate>
			<xbrli:endDate>2014-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2015Q2Apr10">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-04-10</xbrli:startDate>
			<xbrli:endDate>2015-04-10</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2014Q4_dei_LegalEntityAxis_gale_MLVCo.LLCandMaximGroupLLCMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="dei:LegalEntityAxis">gale:MLVCo.LLCandMaximGroupLLCMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2014-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2014Q4Nov18">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2014-11-18</xbrli:startDate>
			<xbrli:endDate>2014-11-18</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2014Q4Nov18_dei_LegalEntityAxis_gale_LincolnParkCapitalLLCMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="dei:LegalEntityAxis">gale:LincolnParkCapitalLLCMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2014-11-18</xbrli:startDate>
			<xbrli:endDate>2014-11-18</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2015Q2Mar18ToApr10">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-03-18</xbrli:startDate>
			<xbrli:endDate>2015-04-10</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2014Q4Nov18_dei_LegalEntityAxis_gale_LincolnParkCapitalLLCMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="dei:LegalEntityAxis">gale:LincolnParkCapitalLLCMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2014-11-18</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2014Q4_us-gaap_ClassOfWarrantOrRightAxis_gale_DecemberTwoThousandTwelveWarrantMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">gale:DecemberTwoThousandTwelveWarrantMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2014-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2014Q4_us-gaap_ClassOfWarrantOrRightAxis_gale_SeptemberTwoThousandThirteenWarrantMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">gale:SeptemberTwoThousandThirteenWarrantMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2014-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2014Q4YTD_us-gaap_ClassOfWarrantOrRightAxis_gale_SeptemberTwoThousandThirteenWarrantMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">gale:SeptemberTwoThousandThirteenWarrantMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2014-01-01</xbrli:startDate>
			<xbrli:endDate>2014-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2014Q4_us-gaap_ClassOfWarrantOrRightAxis_gale_MarchTwoThousandTenWarrantMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">gale:MarchTwoThousandTenWarrantMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2014-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2014Q4YTD_us-gaap_ClassOfWarrantOrRightAxis_gale_DecemberTwoThousandTwelveWarrantMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">gale:DecemberTwoThousandTwelveWarrantMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2014-01-01</xbrli:startDate>
			<xbrli:endDate>2014-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2014Q4_us-gaap_ClassOfWarrantOrRightAxis_gale_AprilTwoThousandElevenWarrantMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">gale:AprilTwoThousandElevenWarrantMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2014-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2014Q4_us-gaap_ClassOfWarrantOrRightAxis_gale_MarchTwoThousandElevenWarrantMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">gale:MarchTwoThousandElevenWarrantMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2014-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2014Q4YTD_us-gaap_ClassOfWarrantOrRightAxis_gale_MarchTwoThousandTenWarrantMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">gale:MarchTwoThousandTenWarrantMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2014-01-01</xbrli:startDate>
			<xbrli:endDate>2014-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2014Q4YTD_us-gaap_ClassOfWarrantOrRightAxis_gale_AprilTwoThousandElevenWarrantMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">gale:AprilTwoThousandElevenWarrantMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2014-01-01</xbrli:startDate>
			<xbrli:endDate>2014-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2014Q4YTD_us-gaap_ClassOfWarrantOrRightAxis_gale_MarchTwoThousandElevenWarrantMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">gale:MarchTwoThousandElevenWarrantMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2014-01-01</xbrli:startDate>
			<xbrli:endDate>2014-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2015Q3_us-gaap_ClassOfWarrantOrRightAxis_gale_AprilTwoThousandElevenWarrantMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">gale:AprilTwoThousandElevenWarrantMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-09-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2015Q3_us-gaap_ClassOfWarrantOrRightAxis_gale_MarchTwoThousandElevenWarrantMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">gale:MarchTwoThousandElevenWarrantMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-09-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2015Q3_us-gaap_ClassOfWarrantOrRightAxis_gale_MarchTwoThousandTenWarrantMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">gale:MarchTwoThousandTenWarrantMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-09-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2015Q3_us-gaap_ClassOfWarrantOrRightAxis_gale_DecemberTwoThousandTwelveWarrantMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">gale:DecemberTwoThousandTwelveWarrantMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-09-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2015Q3_us-gaap_ClassOfWarrantOrRightAxis_gale_SeptemberTwoThousandThirteenWarrantMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">gale:SeptemberTwoThousandThirteenWarrantMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-09-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2015Q3_us-gaap_ClassOfWarrantOrRightAxis_gale_MarchTwoThousandFifteenWarrantsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">gale:MarchTwoThousandFifteenWarrantsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-09-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2015Q3YTD_us-gaap_ClassOfWarrantOrRightAxis_gale_SeptemberTwoThousandThirteenWarrantMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">gale:SeptemberTwoThousandThirteenWarrantMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-01-01</xbrli:startDate>
			<xbrli:endDate>2015-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2015Q3YTD_us-gaap_ClassOfWarrantOrRightAxis_gale_MarchTwoThousandFifteenWarrantsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">gale:MarchTwoThousandFifteenWarrantsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-01-01</xbrli:startDate>
			<xbrli:endDate>2015-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2015Q3YTD_us-gaap_ClassOfWarrantOrRightAxis_gale_MarchTwoThousandElevenWarrantMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">gale:MarchTwoThousandElevenWarrantMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-01-01</xbrli:startDate>
			<xbrli:endDate>2015-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2015Q3YTD_us-gaap_ClassOfWarrantOrRightAxis_gale_DecemberTwoThousandTwelveWarrantMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">gale:DecemberTwoThousandTwelveWarrantMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-01-01</xbrli:startDate>
			<xbrli:endDate>2015-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2015Q3YTD_us-gaap_ClassOfWarrantOrRightAxis_gale_MarchTwoThousandTenWarrantMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">gale:MarchTwoThousandTenWarrantMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-01-01</xbrli:startDate>
			<xbrli:endDate>2015-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2015Q3YTD_us-gaap_ClassOfWarrantOrRightAxis_gale_AprilTwoThousandElevenWarrantMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">gale:AprilTwoThousandElevenWarrantMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-01-01</xbrli:startDate>
			<xbrli:endDate>2015-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2014Q4_us-gaap_ClassOfWarrantOrRightAxis_gale_MarchTwoThousandFifteenWarrantsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">gale:MarchTwoThousandFifteenWarrantsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2014-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2014Q4_us-gaap_ClassOfWarrantOrRightAxis_gale_ConsultantWarrantsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">gale:ConsultantWarrantsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2014-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2015Q3YTD_us-gaap_ClassOfWarrantOrRightAxis_gale_ConsultantWarrantsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">gale:ConsultantWarrantsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-01-01</xbrli:startDate>
			<xbrli:endDate>2015-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2015Q3_us-gaap_ClassOfWarrantOrRightAxis_gale_ConsultantWarrantsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">gale:ConsultantWarrantsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-09-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2014Q3QTD_us-gaap_ClassOfWarrantOrRightAxis_gale_ConsultantWarrantsMember_us-gaap_RangeAxis_us-gaap_MinimumMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">gale:ConsultantWarrantsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MinimumMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2014-07-01</xbrli:startDate>
			<xbrli:endDate>2014-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2014Q3QTD_us-gaap_ClassOfWarrantOrRightAxis_gale_ConsultantWarrantsMember_us-gaap_RangeAxis_us-gaap_MaximumMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">gale:ConsultantWarrantsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MaximumMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2014-07-01</xbrli:startDate>
			<xbrli:endDate>2014-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2015Q3YTD_us-gaap_TitleOfIndividualAxis_gale_TwoZeroZeroSevenIncentivePlanMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:TitleOfIndividualAxis">gale:TwoZeroZeroSevenIncentivePlanMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-01-01</xbrli:startDate>
			<xbrli:endDate>2015-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2015Q3_us-gaap_TitleOfIndividualAxis_gale_TwoZeroZeroSevenIncentivePlanMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:TitleOfIndividualAxis">gale:TwoZeroZeroSevenIncentivePlanMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-09-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2015Q3YTD_us-gaap_RangeAxis_us-gaap_MinimumMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MinimumMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-01-01</xbrli:startDate>
			<xbrli:endDate>2015-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2015Q3YTD_us-gaap_RangeAxis_us-gaap_MaximumMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MaximumMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-01-01</xbrli:startDate>
			<xbrli:endDate>2015-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2015Q3QTD_us-gaap_StatementOperatingActivitiesSegmentAxis_us-gaap_SegmentDiscontinuedOperationsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementOperatingActivitiesSegmentAxis">us-gaap:SegmentDiscontinuedOperationsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-07-01</xbrli:startDate>
			<xbrli:endDate>2015-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2015Q3QTD_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-07-01</xbrli:startDate>
			<xbrli:endDate>2015-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2014Q3QTD_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2014-07-01</xbrli:startDate>
			<xbrli:endDate>2014-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2014Q3YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2014-01-01</xbrli:startDate>
			<xbrli:endDate>2014-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2015Q3QTD_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-07-01</xbrli:startDate>
			<xbrli:endDate>2015-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2015Q3YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-01-01</xbrli:startDate>
			<xbrli:endDate>2015-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2015Q3YTD_us-gaap_StatementOperatingActivitiesSegmentAxis_us-gaap_SegmentDiscontinuedOperationsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementOperatingActivitiesSegmentAxis">us-gaap:SegmentDiscontinuedOperationsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-01-01</xbrli:startDate>
			<xbrli:endDate>2015-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2014Q3QTD_us-gaap_StatementOperatingActivitiesSegmentAxis_us-gaap_SegmentDiscontinuedOperationsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementOperatingActivitiesSegmentAxis">us-gaap:SegmentDiscontinuedOperationsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2014-07-01</xbrli:startDate>
			<xbrli:endDate>2014-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2015Q3QTD_us-gaap_StatementOperatingActivitiesSegmentAxis_us-gaap_SegmentContinuingOperationsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementOperatingActivitiesSegmentAxis">us-gaap:SegmentContinuingOperationsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-07-01</xbrli:startDate>
			<xbrli:endDate>2015-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2014Q3QTD_us-gaap_StatementOperatingActivitiesSegmentAxis_us-gaap_SegmentContinuingOperationsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementOperatingActivitiesSegmentAxis">us-gaap:SegmentContinuingOperationsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2014-07-01</xbrli:startDate>
			<xbrli:endDate>2014-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2014Q3YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2014-01-01</xbrli:startDate>
			<xbrli:endDate>2014-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2014Q3YTD_us-gaap_StatementOperatingActivitiesSegmentAxis_us-gaap_SegmentDiscontinuedOperationsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementOperatingActivitiesSegmentAxis">us-gaap:SegmentDiscontinuedOperationsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2014-01-01</xbrli:startDate>
			<xbrli:endDate>2014-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2015Q3YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-01-01</xbrli:startDate>
			<xbrli:endDate>2015-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2014Q3YTD_us-gaap_StatementOperatingActivitiesSegmentAxis_us-gaap_SegmentContinuingOperationsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementOperatingActivitiesSegmentAxis">us-gaap:SegmentContinuingOperationsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2014-01-01</xbrli:startDate>
			<xbrli:endDate>2014-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2014Q3QTD_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2014-07-01</xbrli:startDate>
			<xbrli:endDate>2014-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2015Q3YTD_us-gaap_StatementOperatingActivitiesSegmentAxis_us-gaap_SegmentContinuingOperationsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementOperatingActivitiesSegmentAxis">us-gaap:SegmentContinuingOperationsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-01-01</xbrli:startDate>
			<xbrli:endDate>2015-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2015Q3YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_EmployeeStockOptionMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-01-01</xbrli:startDate>
			<xbrli:endDate>2015-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2015Q3YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_WarrantMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-01-01</xbrli:startDate>
			<xbrli:endDate>2015-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2014Q3YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_EmployeeStockOptionMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2014-01-01</xbrli:startDate>
			<xbrli:endDate>2014-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2014Q3YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_WarrantMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2014-01-01</xbrli:startDate>
			<xbrli:endDate>2014-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2015Q3_dei_LegalEntityAxis_gale_MDAndersonCancerCenterMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="dei:LegalEntityAxis">gale:MDAndersonCancerCenterMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-09-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2014Q3YTD_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_gale_CommercialBusinessSegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">gale:CommercialBusinessSegmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2014-01-01</xbrli:startDate>
			<xbrli:endDate>2014-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2015Q3YTD_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_gale_CommercialBusinessSegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">gale:CommercialBusinessSegmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-01-01</xbrli:startDate>
			<xbrli:endDate>2015-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2015Q3QTD_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_gale_CommercialBusinessSegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">gale:CommercialBusinessSegmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-07-01</xbrli:startDate>
			<xbrli:endDate>2015-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2014Q3QTD_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_gale_CommercialBusinessSegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">gale:CommercialBusinessSegmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2014-07-01</xbrli:startDate>
			<xbrli:endDate>2014-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2015Q3_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_gale_CommercialBusinessSegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">gale:CommercialBusinessSegmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-09-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2014Q4_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_gale_CommercialBusinessSegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">gale:CommercialBusinessSegmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2014-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2014Q4YTD_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_gale_CommercialBusinessSegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">gale:CommercialBusinessSegmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2014-01-01</xbrli:startDate>
			<xbrli:endDate>2014-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2015Q3_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_gale_ZuplenzRightsMember_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_gale_CommercialBusinessSegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">gale:ZuplenzRightsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">gale:CommercialBusinessSegmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-09-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2014Q4_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_gale_ZuplenzRightsMember_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_gale_CommercialBusinessSegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">gale:ZuplenzRightsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">gale:CommercialBusinessSegmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2014-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2015Q3_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_gale_AbstralRightsNetMember_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_gale_CommercialBusinessSegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">gale:AbstralRightsNetMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">gale:CommercialBusinessSegmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-09-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2014Q4_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_gale_AbstralRightsNetMember_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_gale_CommercialBusinessSegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">gale:AbstralRightsNetMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">gale:CommercialBusinessSegmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2014-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:unit id="shares">
		<xbrli:measure>xbrli:shares</xbrli:measure>
	</xbrli:unit>
	<xbrli:unit id="usdPerShare">
		<xbrli:divide>
			<xbrli:unitNumerator>
				<xbrli:measure>iso4217:USD</xbrli:measure>
			</xbrli:unitNumerator>
			<xbrli:unitDenominator>
				<xbrli:measure>xbrli:shares</xbrli:measure>
			</xbrli:unitDenominator>
		</xbrli:divide>
	</xbrli:unit>
	<xbrli:unit id="usd">
		<xbrli:measure>iso4217:USD</xbrli:measure>
	</xbrli:unit>
	<xbrli:unit id="number">
		<xbrli:measure>xbrli:pure</xbrli:measure>
	</xbrli:unit>
	<dei:AmendmentFlag contextRef="FD2015Q3YTD" id="Fact-F8BC110E90105BFB90879BF8D7FEFDF6">false</dei:AmendmentFlag>
	<dei:CurrentFiscalYearEndDate contextRef="FD2015Q3YTD" id="Fact-6EE101371D9B5FAB9D8211F07571EF97">--12-31</dei:CurrentFiscalYearEndDate>
	<dei:DocumentFiscalPeriodFocus contextRef="FD2015Q3YTD" id="Fact-C9B6A83F197E557791B070E9560FD6FE">Q2</dei:DocumentFiscalPeriodFocus>
	<dei:DocumentFiscalYearFocus contextRef="FD2015Q3YTD" id="Fact-2CBB071261555757A86B1AF0FB7293C8">2015</dei:DocumentFiscalYearFocus>
	<dei:DocumentPeriodEndDate contextRef="FD2015Q3YTD" id="Fact-C8E521AE978C54539505CC2AE98560D4">2015-09-30</dei:DocumentPeriodEndDate>
	<dei:DocumentType contextRef="FD2015Q3YTD" id="Fact-D9D740F7F2BA55E085DE383E0FB3FF40">10-Q</dei:DocumentType>
	<dei:EntityCentralIndexKey contextRef="FD2015Q3YTD" id="Fact-54B5F40E7B1C5C139646E1307FAE84BE">0001390478</dei:EntityCentralIndexKey>
	<dei:EntityCommonStockSharesOutstanding contextRef="I2015Q4Oct31" decimals="INF" id="Fact-76C0F7E875A15BB1919C16B611206BA4" unitRef="shares">161906753</dei:EntityCommonStockSharesOutstanding>
	<dei:EntityFilerCategory contextRef="FD2015Q3YTD" id="Fact-33A6CAC8994C549491C4C894E86C0A9B">Accelerated Filer</dei:EntityFilerCategory>
	<dei:EntityRegistrantName contextRef="FD2015Q3YTD" id="Fact-DBE6F6A61F75517DA9D567ABDF6B30C5">Galena Biopharma, Inc.</dei:EntityRegistrantName>
	<dei:TradingSymbol contextRef="FD2015Q3YTD" id="Fact-D961219108E15A6FAFF46689E25187AC">GALE</dei:TradingSymbol>
	<gale:AnnualMaintenanceFee contextRef="FI2015Q3_dei_LegalEntityAxis_gale_MDAndersonCancerCenterMember" decimals="INF" id="Fact-3BB2F4AED3EE5DB7876A520E00F7B9B9" unitRef="usd">200000</gale:AnnualMaintenanceFee>
	<gale:AtMarketIssuanceSalesAgreementsMaximumGrossProceeds contextRef="FD2014Q4YTD_dei_LegalEntityAxis_gale_MLVCo.LLCandMaximGroupLLCMember" decimals="-6" id="Fact-86AE2A2F6F735270B59C737FBBB3CC17" unitRef="usd">20000000</gale:AtMarketIssuanceSalesAgreementsMaximumGrossProceeds>
	<gale:AtMarketIssuanceSalesAgreementsPercentofGrossProceeds contextRef="FI2014Q4_dei_LegalEntityAxis_gale_MLVCo.LLCandMaximGroupLLCMember" decimals="2" id="Fact-2CC49459DD285245B1E9121786A74EDA" unitRef="number">0.03</gale:AtMarketIssuanceSalesAgreementsPercentofGrossProceeds>
	<gale:ChangeInFairValueOfCommonStockWarrantsIssuedInConnectionWithVariousEquityFinancings contextRef="FD2014Q3YTD" decimals="-3" id="Fact-D76362B460675A15B05A01BA6CA06E07" unitRef="usd">13174000</gale:ChangeInFairValueOfCommonStockWarrantsIssuedInConnectionWithVariousEquityFinancings>
	<gale:ChangeInFairValueOfCommonStockWarrantsIssuedInConnectionWithVariousEquityFinancings contextRef="FD2015Q3YTD" decimals="-3" id="Fact-EA453353E4E65682A19358674831751E" unitRef="usd">-982000</gale:ChangeInFairValueOfCommonStockWarrantsIssuedInConnectionWithVariousEquityFinancings>
	<gale:ChangeInFairValueOfContingentPurchaseConsideration contextRef="FD2014Q3YTD" decimals="-3" id="Fact-EBF1DB68E7C3520382B6497316B8F516" unitRef="usd">-59000</gale:ChangeInFairValueOfContingentPurchaseConsideration>
	<gale:ChangeInFairValueOfContingentPurchaseConsideration contextRef="FD2015Q3YTD" decimals="-3" id="Fact-E57BFCE4F75C5863BD461A79090F103A" unitRef="usd">69000</gale:ChangeInFairValueOfContingentPurchaseConsideration>
	<gale:ChangeInFairValueOfContingentPurchasePriceConsideration contextRef="FD2014Q3QTD" decimals="-3" id="Fact-3D95E66D0AF351189C0FB58A6379C822" unitRef="usd">-597000</gale:ChangeInFairValueOfContingentPurchasePriceConsideration>
	<gale:ChangeInFairValueOfContingentPurchasePriceConsideration contextRef="FD2014Q3YTD" decimals="-3" id="Fact-D3866FFF619451BDAA05E897C9686E01" unitRef="usd">59000</gale:ChangeInFairValueOfContingentPurchasePriceConsideration>
	<gale:ChangeInFairValueOfContingentPurchasePriceConsideration contextRef="FD2015Q3QTD" decimals="-3" id="Fact-3E056357250054108F98DD3B1C8313C4" unitRef="usd">-307000</gale:ChangeInFairValueOfContingentPurchasePriceConsideration>
	<gale:ChangeInFairValueOfContingentPurchasePriceConsideration contextRef="FD2015Q3YTD" decimals="-3" id="Fact-E7C88EF959265078AAB12A59AC50620D" unitRef="usd">-69000</gale:ChangeInFairValueOfContingentPurchasePriceConsideration>
	<gale:ChangeInFairValueOfContingentPurchasePriceConsideration contextRef="FD2015Q3YTD_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member" decimals="-3" id="Fact-C7814373E1B65C219143B290562BF04F" unitRef="usd">-69000</gale:ChangeInFairValueOfContingentPurchasePriceConsideration>
	<gale:ChangeInFairValueOfWarrantLiabilities contextRef="FD2015Q3YTD" decimals="-3" id="Fact-F22214C15E1D5084A6169C0D890C7857" unitRef="usd">982000</gale:ChangeInFairValueOfWarrantLiabilities>
	<gale:ChangeInFairValueOfWarrantLiabilities contextRef="FD2015Q3YTD_us-gaap_ClassOfWarrantOrRightAxis_gale_AprilTwoThousandElevenWarrantMember" decimals="-3" id="Fact-8606A3DEBF2A5D9D8430E282311C4484" unitRef="usd">-10000</gale:ChangeInFairValueOfWarrantLiabilities>
	<gale:ChangeInFairValueOfWarrantLiabilities contextRef="FD2015Q3YTD_us-gaap_ClassOfWarrantOrRightAxis_gale_DecemberTwoThousandTwelveWarrantMember" decimals="-3" id="Fact-1BC39C35B0A351F483F2345B8CA2FA3F" unitRef="usd">-162000</gale:ChangeInFairValueOfWarrantLiabilities>
	<gale:ChangeInFairValueOfWarrantLiabilities contextRef="FD2015Q3YTD_us-gaap_ClassOfWarrantOrRightAxis_gale_MarchTwoThousandElevenWarrantMember" decimals="-3" id="Fact-CDE5672F5EA451FC8B773CE3BB9F811C" unitRef="usd">2000</gale:ChangeInFairValueOfWarrantLiabilities>
	<gale:ChangeInFairValueOfWarrantLiabilities contextRef="FD2015Q3YTD_us-gaap_ClassOfWarrantOrRightAxis_gale_MarchTwoThousandFifteenWarrantsMember" decimals="-3" id="Fact-EB25C8B915675F188EC6C6004CB9C171" unitRef="usd">1313000</gale:ChangeInFairValueOfWarrantLiabilities>
	<gale:ChangeInFairValueOfWarrantLiabilities contextRef="FD2015Q3YTD_us-gaap_ClassOfWarrantOrRightAxis_gale_MarchTwoThousandTenWarrantMember" decimals="-3" id="Fact-11AED4E4F2F25FA99745518954E83678" unitRef="usd">-4000</gale:ChangeInFairValueOfWarrantLiabilities>
	<gale:ChangeInFairValueOfWarrantLiabilities contextRef="FD2015Q3YTD_us-gaap_ClassOfWarrantOrRightAxis_gale_SeptemberTwoThousandThirteenWarrantMember" decimals="-3" id="Fact-EB27584381A1555A893BFB3B9D94DF92" unitRef="usd">-157000</gale:ChangeInFairValueOfWarrantLiabilities>
	<gale:ClassOfWarrantsOrRightsExpirationDate contextRef="FD2014Q3QTD_us-gaap_ClassOfWarrantOrRightAxis_gale_ConsultantWarrantsMember_us-gaap_RangeAxis_us-gaap_MaximumMember" id="Fact-7F5C20D706125EC1B2787D0C048E62CB">2020-12-31</gale:ClassOfWarrantsOrRightsExpirationDate>
	<gale:ClassOfWarrantsOrRightsExpirationDate contextRef="FD2014Q3QTD_us-gaap_ClassOfWarrantOrRightAxis_gale_ConsultantWarrantsMember_us-gaap_RangeAxis_us-gaap_MinimumMember" id="Fact-97F6DD6705045FDF899634488DDA35C6">2014-12-31</gale:ClassOfWarrantsOrRightsExpirationDate>
	<gale:ClassOfWarrantsOrRightsExpirationDate contextRef="FD2015Q3YTD_us-gaap_ClassOfWarrantOrRightAxis_gale_AprilTwoThousandElevenWarrantMember" id="Fact-9DFDEF823BEC541180A4C0A6C0F432EC">2017-04-30</gale:ClassOfWarrantsOrRightsExpirationDate>
	<gale:ClassOfWarrantsOrRightsExpirationDate contextRef="FD2015Q3YTD_us-gaap_ClassOfWarrantOrRightAxis_gale_DecemberTwoThousandTwelveWarrantMember" id="Fact-916DDE2B688458A0BDFE398D503CE6B9">2017-12-31</gale:ClassOfWarrantsOrRightsExpirationDate>
	<gale:ClassOfWarrantsOrRightsExpirationDate contextRef="FD2015Q3YTD_us-gaap_ClassOfWarrantOrRightAxis_gale_MarchTwoThousandElevenWarrantMember" id="Fact-FCD0BEE53D15566D9C8230B2B1A3F1CE">2016-03-31</gale:ClassOfWarrantsOrRightsExpirationDate>
	<gale:ClassOfWarrantsOrRightsExpirationDate contextRef="FD2015Q3YTD_us-gaap_ClassOfWarrantOrRightAxis_gale_MarchTwoThousandFifteenWarrantsMember" id="Fact-E34EA798C0F754A683B0196E256B037B">2020-03-18</gale:ClassOfWarrantsOrRightsExpirationDate>
	<gale:ClassOfWarrantsOrRightsExpirationDate contextRef="FD2015Q3YTD_us-gaap_ClassOfWarrantOrRightAxis_gale_MarchTwoThousandTenWarrantMember" id="Fact-7292C50CBFC751508618F528D517C3D0">2016-03-31</gale:ClassOfWarrantsOrRightsExpirationDate>
	<gale:ClassOfWarrantsOrRightsExpirationDate contextRef="FD2015Q3YTD_us-gaap_ClassOfWarrantOrRightAxis_gale_SeptemberTwoThousandThirteenWarrantMember" id="Fact-ABEBA25515995CF0AB7C55225AE14CB2">2018-09-18</gale:ClassOfWarrantsOrRightsExpirationDate>
	<gale:ClassofWarrantorRightAverageMarketPriceUsedForExercisePrice contextRef="D2013Q2MAY8" id="Fact-BC9B25C873CD5C72B02AC13D08577365">P20D</gale:ClassofWarrantorRightAverageMarketPriceUsedForExercisePrice>
	<gale:ClassofWarrantorRightExpired contextRef="FD2015Q3YTD" decimals="-3" id="Fact-819A5A0360AE5E329D1BAE0640865974" unitRef="shares">238000</gale:ClassofWarrantorRightExpired>
	<gale:ClassofWarrantorRightExpired contextRef="FD2015Q3YTD_us-gaap_ClassOfWarrantOrRightAxis_gale_ConsultantWarrantsMember" decimals="-3" id="Fact-32698C417ED95AB38B5D1CCAF8649740" unitRef="shares">238000</gale:ClassofWarrantorRightExpired>
	<gale:ClassofWarrantorRightGranted contextRef="FD2015Q3YTD" decimals="-3" id="Fact-BD3A6B6CEDD152A6A390CE6F418D3B96" unitRef="shares">14006000</gale:ClassofWarrantorRightGranted>
	<gale:ClassofWarrantorRightGranted contextRef="FD2015Q3YTD_us-gaap_ClassOfWarrantOrRightAxis_gale_AprilTwoThousandElevenWarrantMember" decimals="-3" id="Fact-41C4DCC7C98851849211C4E93367A7E4" unitRef="shares">0</gale:ClassofWarrantorRightGranted>
	<gale:ClassofWarrantorRightGranted contextRef="FD2015Q3YTD_us-gaap_ClassOfWarrantOrRightAxis_gale_ConsultantWarrantsMember" decimals="-3" id="Fact-F02F82F51AE1550192DDADD42DAF927A" unitRef="shares">0</gale:ClassofWarrantorRightGranted>
	<gale:ClassofWarrantorRightGranted contextRef="FD2015Q3YTD_us-gaap_ClassOfWarrantOrRightAxis_gale_DecemberTwoThousandTwelveWarrantMember" decimals="-3" id="Fact-CA0B70004E3A5EFF9621E399D80E1BC5" unitRef="shares">0</gale:ClassofWarrantorRightGranted>
	<gale:ClassofWarrantorRightGranted contextRef="FD2015Q3YTD_us-gaap_ClassOfWarrantOrRightAxis_gale_MarchTwoThousandElevenWarrantMember" decimals="-3" id="Fact-772B6A16425A5EA4B60339A965E7FE17" unitRef="shares">0</gale:ClassofWarrantorRightGranted>
	<gale:ClassofWarrantorRightGranted contextRef="FD2015Q3YTD_us-gaap_ClassOfWarrantOrRightAxis_gale_MarchTwoThousandFifteenWarrantsMember" decimals="-3" id="Fact-914DBEA5DD105174881621938D3E5342" unitRef="shares">14006000</gale:ClassofWarrantorRightGranted>
	<gale:ClassofWarrantorRightGranted contextRef="FD2015Q3YTD_us-gaap_ClassOfWarrantOrRightAxis_gale_MarchTwoThousandTenWarrantMember" decimals="-3" id="Fact-39F28FF1C8475204A2E1D6724E43641F" unitRef="shares">0</gale:ClassofWarrantorRightGranted>
	<gale:ClassofWarrantorRightGranted contextRef="FD2015Q3YTD_us-gaap_ClassOfWarrantOrRightAxis_gale_SeptemberTwoThousandThirteenWarrantMember" decimals="-3" id="Fact-B8639EEC639B54D7954712649E04B7DD" unitRef="shares">0</gale:ClassofWarrantorRightGranted>
	<gale:ClassofWarrantorRightTerm contextRef="D2013Q2MAY8" id="Fact-2BC63CCBB3ED563EB2C942E422CF53D3">P7Y</gale:ClassofWarrantorRightTerm>
	<gale:ClosingPriceOfCommonStock contextRef="FI2015Q3_us-gaap_TitleOfIndividualAxis_gale_TwoZeroZeroSevenIncentivePlanMember" decimals="2" id="Fact-0155962C2BEB51DFBEDBD56EEB79F783" unitRef="usdPerShare">1.58</gale:ClosingPriceOfCommonStock>
	<gale:CommonStockCapitalSharesReservedForFutureIssuanceOfEmployeeStockPurchasePlan contextRef="FI2015Q3" decimals="-3" id="Fact-A3C03DD5866B51E38C9755620AD5FBAA" unitRef="shares">528000</gale:CommonStockCapitalSharesReservedForFutureIssuanceOfEmployeeStockPurchasePlan>
	<gale:ContingentPurchasePriceConsiderationNetOfCurrentPortion contextRef="FI2014Q4" decimals="-3" id="Fact-851DDB3EDE2A55168776469A2D5A3255" unitRef="usd">6651000</gale:ContingentPurchasePriceConsiderationNetOfCurrentPortion>
	<gale:ContingentPurchasePriceConsiderationNetOfCurrentPortion contextRef="FI2015Q3" decimals="-3" id="Fact-746F0244CBAB59FB8C793BD827C1AB9C" unitRef="usd">6582000</gale:ContingentPurchasePriceConsiderationNetOfCurrentPortion>
	<gale:ContractResearchPayable contextRef="FI2014Q4" decimals="-3" id="Fact-E7D6369E0D495338B604A5C2845AF7AC" unitRef="usd">6967000</gale:ContractResearchPayable>
	<gale:ContractResearchPayable contextRef="FI2015Q3" decimals="-3" id="Fact-4BB2F1C3F3F95D199DAD60CED6D835C8" unitRef="usd">5179000</gale:ContractResearchPayable>
	<gale:DebtInstrumentCashFacilityFee contextRef="I2013Q2May8" decimals="INF" id="Fact-C9546E5C84A85DB0B8F4A1B6CCAB66DF" unitRef="number">0.01</gale:DebtInstrumentCashFacilityFee>
	<gale:DebtInstrumentCashFinalPayment contextRef="I2013Q2May8" decimals="INF" id="Fact-9096A2D56B6F520C873C35E9DE3B55B3" unitRef="number">0.055</gale:DebtInstrumentCashFinalPayment>
	<gale:DebtInstrumentTermInterestOnly contextRef="D2013Q2MAY8" id="Fact-C0FE3CEE7E3B5928B1A416310B67D0D0">P12M</gale:DebtInstrumentTermInterestOnly>
	<gale:DeficitAccumulatedDuringDevelopmentalStage contextRef="FI2014Q4" decimals="-3" id="Fact-206F001C55385105850CB0B404C79B36" unitRef="usd">-215481000</gale:DeficitAccumulatedDuringDevelopmentalStage>
	<gale:DeficitAccumulatedDuringDevelopmentalStage contextRef="FI2015Q3" decimals="-3" id="Fact-4587808D868253BEB5115C493933C9F4" unitRef="usd">-259705000</gale:DeficitAccumulatedDuringDevelopmentalStage>
	<gale:DisposalGroupIncludingDiscontinuedOperationContingentLiabilityFromDivestitureAgreement contextRef="FI2015Q3_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_gale_CommercialBusinessSegmentMember" decimals="INF" id="Fact-49690F9BA34FBB9F8948DE3607E45A65" unitRef="usd">900000</gale:DisposalGroupIncludingDiscontinuedOperationContingentLiabilityFromDivestitureAgreement>
	<gale:DisposalGroupIncludingDiscontinuedOperationContingentRetentionFees contextRef="FI2015Q3_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_gale_CommercialBusinessSegmentMember" decimals="INF" id="Fact-0BA1662F8D8DBF377917DE3AFA490878" unitRef="usd">400000</gale:DisposalGroupIncludingDiscontinuedOperationContingentRetentionFees>
	<gale:DisposalGroupIncludingDiscontinuedOperationContingentRetentionFeesPercentageofConsiderationReceived contextRef="FI2015Q3_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_gale_CommercialBusinessSegmentMember" decimals="INF" id="Fact-C7D9C2DA444CC19C254EDE3BE4673B63" unitRef="number">0.03</gale:DisposalGroupIncludingDiscontinuedOperationContingentRetentionFeesPercentageofConsiderationReceived>
	<gale:DisposalGroupIncludingDiscontinuedOperationResearchandDevelopment contextRef="FD2014Q3QTD_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_gale_CommercialBusinessSegmentMember" decimals="-3" id="Fact-64849C81FE36F957B575DE63915BBBB6" unitRef="usd">219000</gale:DisposalGroupIncludingDiscontinuedOperationResearchandDevelopment>
	<gale:DisposalGroupIncludingDiscontinuedOperationResearchandDevelopment contextRef="FD2014Q3YTD_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_gale_CommercialBusinessSegmentMember" decimals="-3" id="Fact-34B06E1703FC3D7F0057DE6391595EDC" unitRef="usd">619000</gale:DisposalGroupIncludingDiscontinuedOperationResearchandDevelopment>
	<gale:DisposalGroupIncludingDiscontinuedOperationResearchandDevelopment contextRef="FD2015Q3QTD_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_gale_CommercialBusinessSegmentMember" decimals="-3" id="Fact-2B2E6BC4E1CD4EA701E2DE63915E9811" unitRef="usd">160000</gale:DisposalGroupIncludingDiscontinuedOperationResearchandDevelopment>
	<gale:DisposalGroupIncludingDiscontinuedOperationResearchandDevelopment contextRef="FD2015Q3YTD_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_gale_CommercialBusinessSegmentMember" decimals="-3" id="Fact-8AAEE4674FFC476E9595DE63915768F8" unitRef="usd">339000</gale:DisposalGroupIncludingDiscontinuedOperationResearchandDevelopment>
	<gale:EmployeeServiceShareBasedCompensationUnrecognizedCompensationCosts contextRef="FD2015Q3YTD" decimals="-3" id="Fact-FCE785FF858F5C51AAD3295D1EB33EAA" unitRef="usd">4815000</gale:EmployeeServiceShareBasedCompensationUnrecognizedCompensationCosts>
	<gale:EmployeeServiceShareBasedCompensationUnrecognizedCompensationCostsWeightedAveragePeriodOfRecognition contextRef="FD2015Q3YTD" id="Fact-BEC6C2685265531E8D851D0355E30956">P2Y4M2D</gale:EmployeeServiceShareBasedCompensationUnrecognizedCompensationCostsWeightedAveragePeriodOfRecognition>
	<gale:EstimatedAnnualizedForfeitureRateForOptionsGrantedToEmployees contextRef="FD2015Q3YTD" decimals="2" id="Fact-58DAF5179A615B169FF56F3BD1E2C8BB" unitRef="number">0.15</gale:EstimatedAnnualizedForfeitureRateForOptionsGrantedToEmployees>
	<gale:EstimatedAnnualizedForfeitureRateForOptionsGrantedToSeniorManagement contextRef="FD2015Q3YTD" decimals="2" id="Fact-03E96378151F5948A41EBEDDE48CF759" unitRef="number">0.08</gale:EstimatedAnnualizedForfeitureRateForOptionsGrantedToSeniorManagement>
	<gale:FairValueOfWarrantLiabilityAssumptionsExpectedTerm contextRef="FD2014Q4YTD_us-gaap_ClassOfWarrantOrRightAxis_gale_AprilTwoThousandElevenWarrantMember" id="Fact-0F6EDD8E646E539994C61540802D9A07">P2Y3M22D</gale:FairValueOfWarrantLiabilityAssumptionsExpectedTerm>
	<gale:FairValueOfWarrantLiabilityAssumptionsExpectedTerm contextRef="FD2014Q4YTD_us-gaap_ClassOfWarrantOrRightAxis_gale_DecemberTwoThousandTwelveWarrantMember" id="Fact-6251540DEB335A9BB89C9E62044168DB">P2Y11M23D</gale:FairValueOfWarrantLiabilityAssumptionsExpectedTerm>
	<gale:FairValueOfWarrantLiabilityAssumptionsExpectedTerm contextRef="FD2014Q4YTD_us-gaap_ClassOfWarrantOrRightAxis_gale_MarchTwoThousandElevenWarrantMember" id="Fact-688DD2785A2F5EBC8B7D1C3A0A743DCB">P1Y2M5D</gale:FairValueOfWarrantLiabilityAssumptionsExpectedTerm>
	<gale:FairValueOfWarrantLiabilityAssumptionsExpectedTerm contextRef="FD2014Q4YTD_us-gaap_ClassOfWarrantOrRightAxis_gale_MarchTwoThousandTenWarrantMember" id="Fact-0FF87F2B10A55D2B8665877A3D1CEE43">P1Y2M27D</gale:FairValueOfWarrantLiabilityAssumptionsExpectedTerm>
	<gale:FairValueOfWarrantLiabilityAssumptionsExpectedTerm contextRef="FD2014Q4YTD_us-gaap_ClassOfWarrantOrRightAxis_gale_SeptemberTwoThousandThirteenWarrantMember" id="Fact-850FCD3F7EBE5C99B879E0DA9F83E288">P3Y8M19D</gale:FairValueOfWarrantLiabilityAssumptionsExpectedTerm>
	<gale:FairValueOfWarrantLiabilityAssumptionsExpectedTerm contextRef="FD2015Q3YTD_us-gaap_ClassOfWarrantOrRightAxis_gale_AprilTwoThousandElevenWarrantMember" id="Fact-6B9CBB56344F5655BE3356EFD342BEF6">P1Y6M22D</gale:FairValueOfWarrantLiabilityAssumptionsExpectedTerm>
	<gale:FairValueOfWarrantLiabilityAssumptionsExpectedTerm contextRef="FD2015Q3YTD_us-gaap_ClassOfWarrantOrRightAxis_gale_DecemberTwoThousandTwelveWarrantMember" id="Fact-B2F1C059F456536D81C80B233D3AD3E6">P2Y2M23D</gale:FairValueOfWarrantLiabilityAssumptionsExpectedTerm>
	<gale:FairValueOfWarrantLiabilityAssumptionsExpectedTerm contextRef="FD2015Q3YTD_us-gaap_ClassOfWarrantOrRightAxis_gale_MarchTwoThousandElevenWarrantMember" id="Fact-9F8ED4DE58B3581B9641B50C79D2B436">P5M5D</gale:FairValueOfWarrantLiabilityAssumptionsExpectedTerm>
	<gale:FairValueOfWarrantLiabilityAssumptionsExpectedTerm contextRef="FD2015Q3YTD_us-gaap_ClassOfWarrantOrRightAxis_gale_MarchTwoThousandFifteenWarrantsMember" id="Fact-AD93BAB2477758A5B734FA8626FAEB0B">P4Y5M19D</gale:FairValueOfWarrantLiabilityAssumptionsExpectedTerm>
	<gale:FairValueOfWarrantLiabilityAssumptionsExpectedTerm contextRef="FD2015Q3YTD_us-gaap_ClassOfWarrantOrRightAxis_gale_MarchTwoThousandTenWarrantMember" id="Fact-9CB9DD740D505B92A7454899E635A4F8">P5M27D</gale:FairValueOfWarrantLiabilityAssumptionsExpectedTerm>
	<gale:FairValueOfWarrantLiabilityAssumptionsExpectedTerm contextRef="FD2015Q3YTD_us-gaap_ClassOfWarrantOrRightAxis_gale_SeptemberTwoThousandThirteenWarrantMember" id="Fact-B4B87B6B983F5064ACED332189DE403C">P2Y11M19D</gale:FairValueOfWarrantLiabilityAssumptionsExpectedTerm>
	<gale:FairValueOfWarrantsIssuedInConnectionWithCommonStockRecordedAsCostOfEquity contextRef="FD2014Q3YTD" decimals="-3" id="Fact-A35248498F1D5A7FABE4E231D129A3AA" unitRef="usd">27026000</gale:FairValueOfWarrantsIssuedInConnectionWithCommonStockRecordedAsCostOfEquity>
	<gale:FairValueOfWarrantsIssuedInConnectionWithCommonStockRecordedAsCostOfEquity contextRef="FD2015Q3YTD" decimals="-3" id="Fact-AF8BA0B9F19D5A4FA29A55A9D97E5960" unitRef="usd">10296000</gale:FairValueOfWarrantsIssuedInConnectionWithCommonStockRecordedAsCostOfEquity>
	<gale:FairValueOfWarrantsLiabilities contextRef="FI2014Q4" decimals="-3" id="Fact-D97D1A7974C6513290C2F4E7199E4FD5" unitRef="usd">5383000</gale:FairValueOfWarrantsLiabilities>
	<gale:FairValueOfWarrantsLiabilities contextRef="FI2014Q4_us-gaap_ClassOfWarrantOrRightAxis_gale_AprilTwoThousandElevenWarrantMember" decimals="-3" id="Fact-CB79B81DDAEF5B81A030FAC84A6AF2A9" unitRef="usd">625000</gale:FairValueOfWarrantsLiabilities>
	<gale:FairValueOfWarrantsLiabilities contextRef="FI2014Q4_us-gaap_ClassOfWarrantOrRightAxis_gale_DecemberTwoThousandTwelveWarrantMember" decimals="-3" id="Fact-CFDBF678DC51569E8AF568AF6D2E15C6" unitRef="usd">2027000</gale:FairValueOfWarrantsLiabilities>
	<gale:FairValueOfWarrantsLiabilities contextRef="FI2014Q4_us-gaap_ClassOfWarrantOrRightAxis_gale_MarchTwoThousandElevenWarrantMember" decimals="-3" id="Fact-60B6302E25575A58B4B2DD6A8A71EB69" unitRef="usd">163000</gale:FairValueOfWarrantsLiabilities>
	<gale:FairValueOfWarrantsLiabilities contextRef="FI2014Q4_us-gaap_ClassOfWarrantOrRightAxis_gale_MarchTwoThousandFifteenWarrantsMember" decimals="-3" id="Fact-50CED73CEAA356489BCD60F4EA9E8DC1" unitRef="usd">0</gale:FairValueOfWarrantsLiabilities>
	<gale:FairValueOfWarrantsLiabilities contextRef="FI2014Q4_us-gaap_ClassOfWarrantOrRightAxis_gale_MarchTwoThousandTenWarrantMember" decimals="-3" id="Fact-9ED91EDC0FF354E395B0E1AC2ADBAF4F" unitRef="usd">8000</gale:FairValueOfWarrantsLiabilities>
	<gale:FairValueOfWarrantsLiabilities contextRef="FI2014Q4_us-gaap_ClassOfWarrantOrRightAxis_gale_SeptemberTwoThousandThirteenWarrantMember" decimals="-3" id="Fact-4A70786359E752A4917454C5FC4F1BFE" unitRef="usd">2560000</gale:FairValueOfWarrantsLiabilities>
	<gale:FairValueOfWarrantsLiabilities contextRef="FI2015Q3" decimals="-3" id="Fact-71652632860957C09AE8655CA3B76229" unitRef="usd">16661000</gale:FairValueOfWarrantsLiabilities>
	<gale:FairValueOfWarrantsLiabilities contextRef="FI2015Q3_us-gaap_ClassOfWarrantOrRightAxis_gale_AprilTwoThousandElevenWarrantMember" decimals="-3" id="Fact-6AC68227E5FB57BA8B4F4078D864078B" unitRef="usd">615000</gale:FairValueOfWarrantsLiabilities>
	<gale:FairValueOfWarrantsLiabilities contextRef="FI2015Q3_us-gaap_ClassOfWarrantOrRightAxis_gale_DecemberTwoThousandTwelveWarrantMember" decimals="-3" id="Fact-135DA79CC18D553FA7FACA6C1733CEA4" unitRef="usd">1865000</gale:FairValueOfWarrantsLiabilities>
	<gale:FairValueOfWarrantsLiabilities contextRef="FI2015Q3_us-gaap_ClassOfWarrantOrRightAxis_gale_MarchTwoThousandElevenWarrantMember" decimals="-3" id="Fact-FBA12BDB14B751739B6F6D7912571D7D" unitRef="usd">165000</gale:FairValueOfWarrantsLiabilities>
	<gale:FairValueOfWarrantsLiabilities contextRef="FI2015Q3_us-gaap_ClassOfWarrantOrRightAxis_gale_MarchTwoThousandFifteenWarrantsMember" decimals="-3" id="Fact-FA4D59E2F87B524BADCD7DABE18581B0" unitRef="usd">11609000</gale:FairValueOfWarrantsLiabilities>
	<gale:FairValueOfWarrantsLiabilities contextRef="FI2015Q3_us-gaap_ClassOfWarrantOrRightAxis_gale_MarchTwoThousandTenWarrantMember" decimals="-3" id="Fact-3273C21B358153959E531E35F860CC1C" unitRef="usd">4000</gale:FairValueOfWarrantsLiabilities>
	<gale:FairValueOfWarrantsLiabilities contextRef="FI2015Q3_us-gaap_ClassOfWarrantOrRightAxis_gale_SeptemberTwoThousandThirteenWarrantMember" decimals="-3" id="Fact-75B854E18E955A19A0484F44B7B60346" unitRef="usd">2403000</gale:FairValueOfWarrantsLiabilities>
	<gale:FairValueOfWarrantsPotentiallySettleableInCash contextRef="FI2014Q4" decimals="-3" id="Fact-24FFD02DC98D5E2F884A20B78DDACE45" unitRef="usd">5383000</gale:FairValueOfWarrantsPotentiallySettleableInCash>
	<gale:FairValueOfWarrantsPotentiallySettleableInCash contextRef="FI2014Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-3" id="Fact-6A98148FD0095357A3533C80C3A98D12" unitRef="usd">0</gale:FairValueOfWarrantsPotentiallySettleableInCash>
	<gale:FairValueOfWarrantsPotentiallySettleableInCash contextRef="FI2014Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-3" id="Fact-243F077736ED58AF9AEBB47545748B94" unitRef="usd">5383000</gale:FairValueOfWarrantsPotentiallySettleableInCash>
	<gale:FairValueOfWarrantsPotentiallySettleableInCash contextRef="FI2014Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-3" id="Fact-3374BE5B5D9D539093FD64DDFC029B98" unitRef="usd">0</gale:FairValueOfWarrantsPotentiallySettleableInCash>
	<gale:FairValueOfWarrantsPotentiallySettleableInCash contextRef="FI2014Q4_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-3" id="Fact-65FE8E04160F581888EB66B2CD071411" unitRef="usd">5383000</gale:FairValueOfWarrantsPotentiallySettleableInCash>
	<gale:FairValueOfWarrantsPotentiallySettleableInCash contextRef="FI2015Q3" decimals="-3" id="Fact-9BFE1D35988F583C80DBF6A8BF2F9715" unitRef="usd">16661000</gale:FairValueOfWarrantsPotentiallySettleableInCash>
	<gale:FairValueOfWarrantsPotentiallySettleableInCash contextRef="FI2015Q3_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-3" id="Fact-7B7B04C003C956FB95634589DBB46E84" unitRef="usd">0</gale:FairValueOfWarrantsPotentiallySettleableInCash>
	<gale:FairValueOfWarrantsPotentiallySettleableInCash contextRef="FI2015Q3_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-3" id="Fact-D235F435996457A59F3F29BED694BB01" unitRef="usd">16661000</gale:FairValueOfWarrantsPotentiallySettleableInCash>
	<gale:FairValueOfWarrantsPotentiallySettleableInCash contextRef="FI2015Q3_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-3" id="Fact-BA1E0B9B635552C9AC41AA7564FE10CB" unitRef="usd">0</gale:FairValueOfWarrantsPotentiallySettleableInCash>
	<gale:FairValueOfWarrantsPotentiallySettleableInCash contextRef="FI2015Q3_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-3" id="Fact-1C0BF15AE266556396006B460DCBC340" unitRef="usd">16661000</gale:FairValueOfWarrantsPotentiallySettleableInCash>
	<gale:FairValueofWarrantsGranted contextRef="FD2015Q3YTD" decimals="-3" id="Fact-2744460D601155E6A781EB013D57159E" unitRef="usd">10296000</gale:FairValueofWarrantsGranted>
	<gale:FairValueofWarrantsGranted contextRef="FD2015Q3YTD_us-gaap_ClassOfWarrantOrRightAxis_gale_MarchTwoThousandFifteenWarrantsMember" decimals="-3" id="Fact-E0C41629B49251FC99E442144B2719BA" unitRef="usd">10296000</gale:FairValueofWarrantsGranted>
	<gale:FairValueofWarrantsGranted contextRef="FD2015Q3YTD_us-gaap_ClassOfWarrantOrRightAxis_gale_SeptemberTwoThousandThirteenWarrantMember" decimals="-3" id="Fact-164E193454FE5B25995E07E42A8F2622" unitRef="usd">0</gale:FairValueofWarrantsGranted>
	<gale:FairValueofWarrantsGrantedperShare contextRef="I2013Q2May8" decimals="2" id="Fact-C4547E2D40745B77B420894EDD63D9FB" unitRef="usdPerShare">1.93</gale:FairValueofWarrantsGrantedperShare>
	<gale:FutureMilestonePayment contextRef="FI2015Q3_dei_LegalEntityAxis_gale_MDAndersonCancerCenterMember" decimals="INF" id="Fact-D064349B7FD254F7B9F710FA72F7394F" unitRef="usd">200000</gale:FutureMilestonePayment>
	<gale:GALE401rights contextRef="FI2014Q4" decimals="-3" id="Fact-9A69694BCD575627963C89EA13E128FC" unitRef="usd">9255000</gale:GALE401rights>
	<gale:GALE401rights contextRef="FI2015Q3" decimals="-3" id="Fact-F8954BF6A9025DB58EC90BD0A6477148" unitRef="usd">9255000</gale:GALE401rights>
	<gale:InProcessResearchDevelopment contextRef="FI2014Q4" decimals="-3" id="Fact-B1330B82EC415C809ACE4B37AC18FA1E" unitRef="usd">12864000</gale:InProcessResearchDevelopment>
	<gale:InProcessResearchDevelopment contextRef="FI2015Q3" decimals="-3" id="Fact-AE4BFA544EF2577EAF8961336EB1F27A" unitRef="usd">12864000</gale:InProcessResearchDevelopment>
	<gale:LossOnWarrantExchange contextRef="FD2014Q3QTD" decimals="-3" id="Fact-3D814AA3A1D8524BAD86A397A6C2CE17" unitRef="usd">-6735000</gale:LossOnWarrantExchange>
	<gale:LossOnWarrantExchange contextRef="FD2014Q3YTD" decimals="-3" id="Fact-920D306FCBA55123B43186AEA5D36B57" unitRef="usd">-13174000</gale:LossOnWarrantExchange>
	<gale:LossOnWarrantExchange contextRef="FD2015Q3QTD" decimals="-3" id="Fact-CEF27A85A04955C0AFA62FD03CC6DED8" unitRef="usd">-2134000</gale:LossOnWarrantExchange>
	<gale:LossOnWarrantExchange contextRef="FD2015Q3YTD" decimals="-3" id="Fact-4B58811B36635BD6B8EF256903C04F7F" unitRef="usd">981000</gale:LossOnWarrantExchange>
	<gale:MaximumMaturityPeriodToConsiderAllHighlyLiquidDebtInstrumentsAsCashAndCashEquivalents contextRef="FD2014Q3QTD" id="Fact-3CDE0BDEF8AD5FD6B68CCB840AA7FFE6">P90D</gale:MaximumMaturityPeriodToConsiderAllHighlyLiquidDebtInstrumentsAsCashAndCashEquivalents>
	<gale:NetProceedsFromExerciseOfCommonStockWarrants contextRef="FD2014Q3YTD" decimals="-3" id="Fact-CFFFE6D979FD5AAB88C583829B1EFABB" unitRef="usd">10717000</gale:NetProceedsFromExerciseOfCommonStockWarrants>
	<gale:NetProceedsFromExerciseOfCommonStockWarrants contextRef="FD2015Q3YTD" decimals="-3" id="Fact-16A70114A9AC56478266041667ACD32B" unitRef="usd">0</gale:NetProceedsFromExerciseOfCommonStockWarrants>
	<gale:NumberofDaysAveragedforExercisePrice contextRef="D2013Q2MAY8" id="Fact-90665427827755E1A4189BDBEB8EF9AC">P20D</gale:NumberofDaysAveragedforExercisePrice>
	<gale:NumberofSharesPerUnit contextRef="I2015Q1Mar18" decimals="INF" id="Fact-3E86F2925DAD5BF7985B2641629AC6F2" unitRef="shares">0.50</gale:NumberofSharesPerUnit>
	<gale:OptionsReservedForFutureIssuanceUnderCompaniesIncentivePlan contextRef="FI2015Q3" decimals="-3" id="Fact-FA41845C6E905342A198DEA52967418F" unitRef="shares">10251000</gale:OptionsReservedForFutureIssuanceUnderCompaniesIncentivePlan>
	<gale:PercentageofCancerPatientsAffectedbyInadequatelyControlledBreakthroughCancerPainBTcP contextRef="FD2015Q3YTD" decimals="INF" id="Fact-6CF8C8A47DAE4102A048DE3130414EBA" unitRef="number">0.5</gale:PercentageofCancerPatientsAffectedbyInadequatelyControlledBreakthroughCancerPainBTcP>
	<gale:ProceedsFromIssuanceorSaleofEquityNetUnderwritingDiscountsCommissionsandOfferingExpenses contextRef="D2015Q2Apr10" decimals="-5" id="Fact-A55B18CD100B5AE6907E06ABDE2FF715" unitRef="usd">5400000</gale:ProceedsFromIssuanceorSaleofEquityNetUnderwritingDiscountsCommissionsandOfferingExpenses>
	<gale:ProceedsFromIssuanceorSaleofEquityNetUnderwritingDiscountsCommissionsandOfferingExpenses contextRef="D2015Q2Mar18ToApr10" decimals="-5" id="Fact-7118CC7597755FDE8421009C62F670FE" unitRef="usd">40800000</gale:ProceedsFromIssuanceorSaleofEquityNetUnderwritingDiscountsCommissionsandOfferingExpenses>
	<gale:PurchaseAgreementTerm contextRef="D2014Q4Nov18" id="Fact-134D3B9441C35FDD8DE8DC7D52DD82C8">P36M</gale:PurchaseAgreementTerm>
	<gale:ReclassificationOfWarrantLiabilityUponExercise contextRef="FD2014Q3YTD" decimals="-3" id="Fact-43117CD78B065E5F9E4440CADFE5DD55" unitRef="usd">27020000</gale:ReclassificationOfWarrantLiabilityUponExercise>
	<gale:ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationPeriod contextRef="FD2015Q3YTD_us-gaap_TitleOfIndividualAxis_gale_TwoZeroZeroSevenIncentivePlanMember" id="Fact-53E39E8B53F152B29BA75C1279BAB03A">P10Y</gale:ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationPeriod>
	<gale:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpiredInPeriodIntrinsicValue contextRef="FD2015Q3YTD" decimals="-3" id="Fact-9D58AFDFF4DA5766830471B85521D411" unitRef="usd">21000</gale:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpiredInPeriodIntrinsicValue>
	<gale:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateAggregateIntrinsicValue contextRef="FD2015Q3YTD" id="Fact-3958482CEC1E54DAB3A6645FAC8A6434" unitRef="usd" xsi:nil="true" />
	<gale:StockIssuedDuringPeriodSharesOverallotmentOption contextRef="D2015Q1Mar18" decimals="0" id="Fact-15D46A113A4954FB8C150E7816642914" unitRef="shares">1826923</gale:StockIssuedDuringPeriodSharesOverallotmentOption>
	<gale:StockIssuedDuringPeriodSharesOverallotmentOption contextRef="D2015Q2Apr10" decimals="INF" id="Fact-6CC4D5EDF7FC5A0686FB2FE4963B853C" unitRef="shares">3653846</gale:StockIssuedDuringPeriodSharesOverallotmentOption>
	<gale:WarrantStrikePrice contextRef="FI2014Q4_us-gaap_ClassOfWarrantOrRightAxis_gale_AprilTwoThousandElevenWarrantMember" decimals="2" id="Fact-93A559B71261528A97DF57F844DF92D6" unitRef="usdPerShare">0.65</gale:WarrantStrikePrice>
	<gale:WarrantStrikePrice contextRef="FI2014Q4_us-gaap_ClassOfWarrantOrRightAxis_gale_DecemberTwoThousandTwelveWarrantMember" decimals="2" id="Fact-2B36D52DDFF65564BD2FFA914D41748B" unitRef="usdPerShare">1.90</gale:WarrantStrikePrice>
	<gale:WarrantStrikePrice contextRef="FI2014Q4_us-gaap_ClassOfWarrantOrRightAxis_gale_MarchTwoThousandElevenWarrantMember" decimals="2" id="Fact-E6993097B2645CC6AC0606D1E042E9F3" unitRef="usdPerShare">0.65</gale:WarrantStrikePrice>
	<gale:WarrantStrikePrice contextRef="FI2014Q4_us-gaap_ClassOfWarrantOrRightAxis_gale_MarchTwoThousandTenWarrantMember" decimals="2" id="Fact-EE695BBC487E5C45A406F3A342A415CD" unitRef="usdPerShare">2.15</gale:WarrantStrikePrice>
	<gale:WarrantStrikePrice contextRef="FI2014Q4_us-gaap_ClassOfWarrantOrRightAxis_gale_SeptemberTwoThousandThirteenWarrantMember" decimals="2" id="Fact-FEB54ED65BC65CE0A8B5096EB140BA09" unitRef="usdPerShare">2.50</gale:WarrantStrikePrice>
	<gale:WarrantStrikePrice contextRef="FI2015Q3_us-gaap_ClassOfWarrantOrRightAxis_gale_AprilTwoThousandElevenWarrantMember" decimals="2" id="Fact-2DEB9C14A4915F9A9545CD9ED55F6249" unitRef="usdPerShare">0.65</gale:WarrantStrikePrice>
	<gale:WarrantStrikePrice contextRef="FI2015Q3_us-gaap_ClassOfWarrantOrRightAxis_gale_DecemberTwoThousandTwelveWarrantMember" decimals="2" id="Fact-0CC09553723F56ED9FCB070CC5B11540" unitRef="usdPerShare">1.83</gale:WarrantStrikePrice>
	<gale:WarrantStrikePrice contextRef="FI2015Q3_us-gaap_ClassOfWarrantOrRightAxis_gale_MarchTwoThousandElevenWarrantMember" decimals="2" id="Fact-9387AC171598543F89757801E2292675" unitRef="usdPerShare">0.65</gale:WarrantStrikePrice>
	<gale:WarrantStrikePrice contextRef="FI2015Q3_us-gaap_ClassOfWarrantOrRightAxis_gale_MarchTwoThousandFifteenWarrantsMember" decimals="2" id="Fact-BFBB33B5E9995CF3BDE78C1426AB9453" unitRef="usdPerShare">2.08</gale:WarrantStrikePrice>
	<gale:WarrantStrikePrice contextRef="FI2015Q3_us-gaap_ClassOfWarrantOrRightAxis_gale_MarchTwoThousandTenWarrantMember" decimals="2" id="Fact-98C835B3DA4F5C6C9F1765CFDD76EED8" unitRef="usdPerShare">2.02</gale:WarrantStrikePrice>
	<gale:WarrantStrikePrice contextRef="FI2015Q3_us-gaap_ClassOfWarrantOrRightAxis_gale_SeptemberTwoThousandThirteenWarrantMember" decimals="2" id="Fact-670945DC4E9E545F8987A6D73E64A8D9" unitRef="usdPerShare">2.50</gale:WarrantStrikePrice>
	<gale:WarrantsFairValueAssumptionsExpectedVolatility contextRef="FI2014Q4_us-gaap_ClassOfWarrantOrRightAxis_gale_AprilTwoThousandElevenWarrantMember" decimals="4" id="Fact-3D86588B3E8C5A319E1964F378F51378" unitRef="number">0.7824</gale:WarrantsFairValueAssumptionsExpectedVolatility>
	<gale:WarrantsFairValueAssumptionsExpectedVolatility contextRef="FI2014Q4_us-gaap_ClassOfWarrantOrRightAxis_gale_DecemberTwoThousandTwelveWarrantMember" decimals="4" id="Fact-C8AA32CCCE03573180B51B51F4A65F09" unitRef="number">0.7685</gale:WarrantsFairValueAssumptionsExpectedVolatility>
	<gale:WarrantsFairValueAssumptionsExpectedVolatility contextRef="FI2014Q4_us-gaap_ClassOfWarrantOrRightAxis_gale_MarchTwoThousandElevenWarrantMember" decimals="4" id="Fact-9927F98ADFC356B9A80782C1C523A997" unitRef="number">0.7738</gale:WarrantsFairValueAssumptionsExpectedVolatility>
	<gale:WarrantsFairValueAssumptionsExpectedVolatility contextRef="FI2014Q4_us-gaap_ClassOfWarrantOrRightAxis_gale_MarchTwoThousandTenWarrantMember" decimals="4" id="Fact-C551137FD06B5526854DFECAC35186A2" unitRef="number">0.7712</gale:WarrantsFairValueAssumptionsExpectedVolatility>
	<gale:WarrantsFairValueAssumptionsExpectedVolatility contextRef="FI2014Q4_us-gaap_ClassOfWarrantOrRightAxis_gale_SeptemberTwoThousandThirteenWarrantMember" decimals="4" id="Fact-4DBC38B0625B514F8134229D879D086B" unitRef="number">0.7560</gale:WarrantsFairValueAssumptionsExpectedVolatility>
	<gale:WarrantsFairValueAssumptionsExpectedVolatility contextRef="FI2015Q3_us-gaap_ClassOfWarrantOrRightAxis_gale_AprilTwoThousandElevenWarrantMember" decimals="4" id="Fact-2D8B67F9163856B6950F7C53D73A6679" unitRef="number">0.6948</gale:WarrantsFairValueAssumptionsExpectedVolatility>
	<gale:WarrantsFairValueAssumptionsExpectedVolatility contextRef="FI2015Q3_us-gaap_ClassOfWarrantOrRightAxis_gale_DecemberTwoThousandTwelveWarrantMember" decimals="4" id="Fact-B4CD9F19C42C5AD1990C121E1D2739C9" unitRef="number">0.7545</gale:WarrantsFairValueAssumptionsExpectedVolatility>
	<gale:WarrantsFairValueAssumptionsExpectedVolatility contextRef="FI2015Q3_us-gaap_ClassOfWarrantOrRightAxis_gale_MarchTwoThousandElevenWarrantMember" decimals="4" id="Fact-80F3D08BEE0159649BBF6BB6DC4B22BE" unitRef="number">0.7242</gale:WarrantsFairValueAssumptionsExpectedVolatility>
	<gale:WarrantsFairValueAssumptionsExpectedVolatility contextRef="FI2015Q3_us-gaap_ClassOfWarrantOrRightAxis_gale_MarchTwoThousandFifteenWarrantsMember" decimals="4" id="Fact-CF3668B8F2605B338A4266E5FD9EA492" unitRef="number">0.7499</gale:WarrantsFairValueAssumptionsExpectedVolatility>
	<gale:WarrantsFairValueAssumptionsExpectedVolatility contextRef="FI2015Q3_us-gaap_ClassOfWarrantOrRightAxis_gale_MarchTwoThousandTenWarrantMember" decimals="4" id="Fact-648A593E8E30551B9F1592B3CBF42030" unitRef="number">0.6833</gale:WarrantsFairValueAssumptionsExpectedVolatility>
	<gale:WarrantsFairValueAssumptionsExpectedVolatility contextRef="FI2015Q3_us-gaap_ClassOfWarrantOrRightAxis_gale_SeptemberTwoThousandThirteenWarrantMember" decimals="4" id="Fact-EA0B4FD711025329AD3924A62B5C4C54" unitRef="number">0.7685</gale:WarrantsFairValueAssumptionsExpectedVolatility>
	<gale:WarrantsFairValueAssumptionsRiskFreeInterestRate contextRef="FI2014Q4_us-gaap_ClassOfWarrantOrRightAxis_gale_AprilTwoThousandElevenWarrantMember" decimals="4" id="Fact-35E811D7F034542086C7F4E7F225B0C4" unitRef="number">0.0080</gale:WarrantsFairValueAssumptionsRiskFreeInterestRate>
	<gale:WarrantsFairValueAssumptionsRiskFreeInterestRate contextRef="FI2014Q4_us-gaap_ClassOfWarrantOrRightAxis_gale_DecemberTwoThousandTwelveWarrantMember" decimals="4" id="Fact-1FD0376BCB2F53E2A9C3EEC43E427BC3" unitRef="number">0.0109</gale:WarrantsFairValueAssumptionsRiskFreeInterestRate>
	<gale:WarrantsFairValueAssumptionsRiskFreeInterestRate contextRef="FI2014Q4_us-gaap_ClassOfWarrantOrRightAxis_gale_MarchTwoThousandElevenWarrantMember" decimals="4" id="Fact-4FC81218BDE8579DA9303CEEF06194C6" unitRef="number">0.0032</gale:WarrantsFairValueAssumptionsRiskFreeInterestRate>
	<gale:WarrantsFairValueAssumptionsRiskFreeInterestRate contextRef="FI2014Q4_us-gaap_ClassOfWarrantOrRightAxis_gale_MarchTwoThousandTenWarrantMember" decimals="4" id="Fact-3CF8F22BEC2057D5B70B3F40DEA331F0" unitRef="number">0.0035</gale:WarrantsFairValueAssumptionsRiskFreeInterestRate>
	<gale:WarrantsFairValueAssumptionsRiskFreeInterestRate contextRef="FI2014Q4_us-gaap_ClassOfWarrantOrRightAxis_gale_SeptemberTwoThousandThirteenWarrantMember" decimals="4" id="Fact-337FC6251F57572AB00B0CD707D552D7" unitRef="number">0.0130</gale:WarrantsFairValueAssumptionsRiskFreeInterestRate>
	<gale:WarrantsFairValueAssumptionsRiskFreeInterestRate contextRef="FI2015Q3_us-gaap_ClassOfWarrantOrRightAxis_gale_AprilTwoThousandElevenWarrantMember" decimals="4" id="Fact-45F675E1EE055AFB8690E723C00ABC3D" unitRef="number">0.0050</gale:WarrantsFairValueAssumptionsRiskFreeInterestRate>
	<gale:WarrantsFairValueAssumptionsRiskFreeInterestRate contextRef="FI2015Q3_us-gaap_ClassOfWarrantOrRightAxis_gale_DecemberTwoThousandTwelveWarrantMember" decimals="4" id="Fact-E119CCD01DE95F21A0E021F6AB9A8B69" unitRef="number">0.0070</gale:WarrantsFairValueAssumptionsRiskFreeInterestRate>
	<gale:WarrantsFairValueAssumptionsRiskFreeInterestRate contextRef="FI2015Q3_us-gaap_ClassOfWarrantOrRightAxis_gale_MarchTwoThousandElevenWarrantMember" decimals="4" id="Fact-C3ECB0F310805537A823545434C67DBB" unitRef="number">0.0006</gale:WarrantsFairValueAssumptionsRiskFreeInterestRate>
	<gale:WarrantsFairValueAssumptionsRiskFreeInterestRate contextRef="FI2015Q3_us-gaap_ClassOfWarrantOrRightAxis_gale_MarchTwoThousandFifteenWarrantsMember" decimals="4" id="Fact-F5FFA6B9A1AC55F2930E877602316491" unitRef="number">0.0125</gale:WarrantsFairValueAssumptionsRiskFreeInterestRate>
	<gale:WarrantsFairValueAssumptionsRiskFreeInterestRate contextRef="FI2015Q3_us-gaap_ClassOfWarrantOrRightAxis_gale_MarchTwoThousandTenWarrantMember" decimals="4" id="Fact-4A42349EA9735972BAFB69A8D6E804AA" unitRef="number">0.0008</gale:WarrantsFairValueAssumptionsRiskFreeInterestRate>
	<gale:WarrantsFairValueAssumptionsRiskFreeInterestRate contextRef="FI2015Q3_us-gaap_ClassOfWarrantOrRightAxis_gale_SeptemberTwoThousandThirteenWarrantMember" decimals="4" id="Fact-8718C5B84B7B5B67ADC2711EB47AE17E" unitRef="number">0.0091</gale:WarrantsFairValueAssumptionsRiskFreeInterestRate>
	<gale:WarrantsGrantedNumberofShares contextRef="I2013Q2May8" decimals="0" id="Fact-CD4DFC5E48BC5ECDA3C8F5E956F6C147" unitRef="shares">182186</gale:WarrantsGrantedNumberofShares>
	<us-gaap:AccountsPayableCurrent contextRef="FI2014Q4" decimals="-3" id="Fact-FCBECBBE317453F0A4A07F87603B885B" unitRef="usd">1886000</us-gaap:AccountsPayableCurrent>
	<us-gaap:AccountsPayableCurrent contextRef="FI2015Q3" decimals="-3" id="Fact-91D9F1F38308553AB1CAC1336BB27851" unitRef="usd">1238000</us-gaap:AccountsPayableCurrent>
	<us-gaap:AccruedLiabilitiesCurrent contextRef="FI2014Q4" decimals="-3" id="Fact-0CD9DF122A035DD384A4E77D5FCB764D" unitRef="usd">8885000</us-gaap:AccruedLiabilitiesCurrent>
	<us-gaap:AccruedLiabilitiesCurrent contextRef="FI2015Q3" decimals="-3" id="Fact-101EE79AAE7351B8A2171F9AB350F604" unitRef="usd">7329000</us-gaap:AccruedLiabilitiesCurrent>
	<us-gaap:AccruedProfessionalFeesCurrent contextRef="FI2014Q4" decimals="-3" id="Fact-F23AB3A94DAA5A77807A383B8B220E45" unitRef="usd">821000</us-gaap:AccruedProfessionalFeesCurrent>
	<us-gaap:AccruedProfessionalFeesCurrent contextRef="FI2015Q3" decimals="-3" id="Fact-44E617728AD25722BD2305F5CC60FE7B" unitRef="usd">1121000</us-gaap:AccruedProfessionalFeesCurrent>
	<us-gaap:AdditionalPaidInCapitalCommonStock contextRef="FI2014Q4" decimals="-3" id="Fact-256C09CD84915731818764860E786722" unitRef="usd">256377000</us-gaap:AdditionalPaidInCapitalCommonStock>
	<us-gaap:AdditionalPaidInCapitalCommonStock contextRef="FI2015Q3" decimals="-3" id="Fact-817CB1F1781A5CBD9D8930A370CC7FA1" unitRef="usd">295956000</us-gaap:AdditionalPaidInCapitalCommonStock>
	<us-gaap:AdjustmentsToAdditionalPaidInCapitalTaxEffectFromShareBasedCompensation contextRef="FD2015Q3YTD" decimals="-3" id="Fact-9A5E9AD98ED95ED39B7C295D670E2E32" unitRef="usd">2122000</us-gaap:AdjustmentsToAdditionalPaidInCapitalTaxEffectFromShareBasedCompensation>
	<us-gaap:AdjustmentsToAdditionalPaidInCapitalTaxEffectFromShareBasedCompensation contextRef="FD2015Q3YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" decimals="-3" id="Fact-164C28C494C25426B46974C48528C9EC" unitRef="usd">2122000</us-gaap:AdjustmentsToAdditionalPaidInCapitalTaxEffectFromShareBasedCompensation>
	<us-gaap:AllocatedShareBasedCompensationExpense contextRef="FD2014Q3QTD_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember" decimals="-3" id="Fact-9F6830B2365056F3A78AB3EB016A8C28" unitRef="usd">92000</us-gaap:AllocatedShareBasedCompensationExpense>
	<us-gaap:AllocatedShareBasedCompensationExpense contextRef="FD2014Q3QTD_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember" decimals="-3" id="Fact-413BC12B08245DE4BAE16D0D62E12AA6" unitRef="usd">990000</us-gaap:AllocatedShareBasedCompensationExpense>
	<us-gaap:AllocatedShareBasedCompensationExpense contextRef="FD2014Q3QTD_us-gaap_StatementOperatingActivitiesSegmentAxis_us-gaap_SegmentContinuingOperationsMember" decimals="-3" id="Fact-DC0838A4DBAF56B1A2D9F627C3AE10B5" unitRef="usd">1082000</us-gaap:AllocatedShareBasedCompensationExpense>
	<us-gaap:AllocatedShareBasedCompensationExpense contextRef="FD2014Q3QTD_us-gaap_StatementOperatingActivitiesSegmentAxis_us-gaap_SegmentDiscontinuedOperationsMember" decimals="-3" id="Fact-EB74E145AF83EE1A3E5DDE97D5646EA0" unitRef="usd">217000</us-gaap:AllocatedShareBasedCompensationExpense>
	<us-gaap:AllocatedShareBasedCompensationExpense contextRef="FD2014Q3YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember" decimals="-3" id="Fact-3D4D5370B4D75B75947806E7FC615DFD" unitRef="usd">438000</us-gaap:AllocatedShareBasedCompensationExpense>
	<us-gaap:AllocatedShareBasedCompensationExpense contextRef="FD2014Q3YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember" decimals="-3" id="Fact-498B13987F9F5189AF24CA3627BEC57B" unitRef="usd">3440000</us-gaap:AllocatedShareBasedCompensationExpense>
	<us-gaap:AllocatedShareBasedCompensationExpense contextRef="FD2014Q3YTD_us-gaap_StatementOperatingActivitiesSegmentAxis_us-gaap_SegmentContinuingOperationsMember" decimals="-3" id="Fact-2F83EBB375365353823082CED5672288" unitRef="usd">3878000</us-gaap:AllocatedShareBasedCompensationExpense>
	<us-gaap:AllocatedShareBasedCompensationExpense contextRef="FD2014Q3YTD_us-gaap_StatementOperatingActivitiesSegmentAxis_us-gaap_SegmentDiscontinuedOperationsMember" decimals="-3" id="Fact-56444AC7025F0B037470DE97D7F5863C" unitRef="usd">557000</us-gaap:AllocatedShareBasedCompensationExpense>
	<us-gaap:AllocatedShareBasedCompensationExpense contextRef="FD2015Q3QTD_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember" decimals="-3" id="Fact-D62E69FDA3215A8DA80B90FD59542B6C" unitRef="usd">83000</us-gaap:AllocatedShareBasedCompensationExpense>
	<us-gaap:AllocatedShareBasedCompensationExpense contextRef="FD2015Q3QTD_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember" decimals="-3" id="Fact-C6F164B527A25342A9F8619B989E7BDE" unitRef="usd">492000</us-gaap:AllocatedShareBasedCompensationExpense>
	<us-gaap:AllocatedShareBasedCompensationExpense contextRef="FD2015Q3QTD_us-gaap_StatementOperatingActivitiesSegmentAxis_us-gaap_SegmentContinuingOperationsMember" decimals="-3" id="Fact-BC97F2FDD4F5591998A989BD2E485B93" unitRef="usd">575000</us-gaap:AllocatedShareBasedCompensationExpense>
	<us-gaap:AllocatedShareBasedCompensationExpense contextRef="FD2015Q3QTD_us-gaap_StatementOperatingActivitiesSegmentAxis_us-gaap_SegmentDiscontinuedOperationsMember" decimals="-3" id="Fact-6D6DE9BCDB94DE59D331DE97D41E27CA" unitRef="usd">275000</us-gaap:AllocatedShareBasedCompensationExpense>
	<us-gaap:AllocatedShareBasedCompensationExpense contextRef="FD2015Q3YTD_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_gale_CommercialBusinessSegmentMember" decimals="-3" id="Fact-0895D7EED85F8A174605DE69A8A16688" unitRef="usd">788000</us-gaap:AllocatedShareBasedCompensationExpense>
	<us-gaap:AllocatedShareBasedCompensationExpense contextRef="FD2015Q3YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember" decimals="-3" id="Fact-3D8F159F8F8A5E4BB5E0B5BB77D72E33" unitRef="usd">253000</us-gaap:AllocatedShareBasedCompensationExpense>
	<us-gaap:AllocatedShareBasedCompensationExpense contextRef="FD2015Q3YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember" decimals="-3" id="Fact-296787747F64558E8D931F4D7646AC6A" unitRef="usd">1081000</us-gaap:AllocatedShareBasedCompensationExpense>
	<us-gaap:AllocatedShareBasedCompensationExpense contextRef="FD2015Q3YTD_us-gaap_StatementOperatingActivitiesSegmentAxis_us-gaap_SegmentContinuingOperationsMember" decimals="-3" id="Fact-7552F71CE4295F4EA88DE398B8450501" unitRef="usd">1334000</us-gaap:AllocatedShareBasedCompensationExpense>
	<us-gaap:AllocatedShareBasedCompensationExpense contextRef="FD2015Q3YTD_us-gaap_StatementOperatingActivitiesSegmentAxis_us-gaap_SegmentDiscontinuedOperationsMember" decimals="-3" id="Fact-85A76AB393A7EEA90C75DE97D6AC8EA8" unitRef="usd">788000</us-gaap:AllocatedShareBasedCompensationExpense>
	<us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="FD2014Q3YTD" decimals="-3" id="Fact-0B774D6323B25566BCB78D1E59599442" unitRef="shares">17534000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
	<us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="FD2014Q3YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_EmployeeStockOptionMember" decimals="-3" id="Fact-997270B16F0C53BCB4609F6B58023F33" unitRef="shares">8994000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
	<us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="FD2014Q3YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_WarrantMember" decimals="-3" id="Fact-9A1F4B02E36B5B958B10DE39D79312B6" unitRef="shares">8540000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
	<us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="FD2015Q3YTD" decimals="-3" id="Fact-3A1CAB81E27454D3B8FB130A7F9357D2" unitRef="shares">33496000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
	<us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="FD2015Q3YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_EmployeeStockOptionMember" decimals="-3" id="Fact-29C69C0E291F50119A08B3D7CDFB5134" unitRef="shares">11188000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
	<us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="FD2015Q3YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_WarrantMember" decimals="-3" id="Fact-BEDB9ED4710A5F158AB3BDBCDEA5ACEE" unitRef="shares">22308000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
	<us-gaap:Assets contextRef="FI2014Q4" decimals="-3" id="Fact-2F3AE92E7B2451A59E06BD5D7B54C56D" unitRef="usd">80488000</us-gaap:Assets>
	<us-gaap:Assets contextRef="FI2015Q3" decimals="-3" id="Fact-F297BC1968695DF69B9A53DB669688E1" unitRef="usd">82669000</us-gaap:Assets>
	<us-gaap:AssetsCurrent contextRef="FI2014Q4" decimals="-3" id="Fact-36CBF658E63C5C02AEF9CF38C6DC9CC4" unitRef="usd">52100000</us-gaap:AssetsCurrent>
	<us-gaap:AssetsCurrent contextRef="FI2015Q3" decimals="-3" id="Fact-5F44798DDD9453C1AEC044A35A18A446" unitRef="usd">54188000</us-gaap:AssetsCurrent>
	<us-gaap:AssetsFairValueDisclosure contextRef="FI2014Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-3" id="Fact-A97AA4E288605E2DBAF5D9AC1028F3A9" unitRef="usd">19477000</us-gaap:AssetsFairValueDisclosure>
	<us-gaap:AssetsFairValueDisclosure contextRef="FI2014Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-3" id="Fact-E88A19A182EF55ACB2B3EB4F6125ABA3" unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
	<us-gaap:AssetsFairValueDisclosure contextRef="FI2014Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-3" id="Fact-877D0ADF230D584C8ECB7D786EE08DB7" unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
	<us-gaap:AssetsFairValueDisclosure contextRef="FI2014Q4_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-3" id="Fact-B0385B3D27445A2BAB4EBB09DE0F0A8D" unitRef="usd">19477000</us-gaap:AssetsFairValueDisclosure>
	<us-gaap:AssetsFairValueDisclosure contextRef="FI2015Q3_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-3" id="Fact-19C3589E2348568793A80AD9A8A6FACB" unitRef="usd">32618000</us-gaap:AssetsFairValueDisclosure>
	<us-gaap:AssetsFairValueDisclosure contextRef="FI2015Q3_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-3" id="Fact-3879CCF41D8E542798CD158858C5603A" unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
	<us-gaap:AssetsFairValueDisclosure contextRef="FI2015Q3_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-3" id="Fact-4DB6A8BE37045E4C9083DA4DC5B6210F" unitRef="usd">17801000</us-gaap:AssetsFairValueDisclosure>
	<us-gaap:AssetsFairValueDisclosure contextRef="FI2015Q3_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-3" id="Fact-D1706806A2CB52A4A009710C31000E22" unitRef="usd">50419000</us-gaap:AssetsFairValueDisclosure>
	<us-gaap:AssetsHeldForSaleLongLivedFairValueDisclosure contextRef="FI2015Q3_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-3" id="Fact-9B61EB540597514A79ABDE8DC18E064E" unitRef="usd">0</us-gaap:AssetsHeldForSaleLongLivedFairValueDisclosure>
	<us-gaap:AssetsHeldForSaleLongLivedFairValueDisclosure contextRef="FI2015Q3_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-3" id="Fact-1F520B783EE4BEBACFE6DE8DC1959793" unitRef="usd">0</us-gaap:AssetsHeldForSaleLongLivedFairValueDisclosure>
	<us-gaap:AssetsHeldForSaleLongLivedFairValueDisclosure contextRef="FI2015Q3_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-3" id="Fact-5FAC799967ABC4A67971DE8DC1B5ED63" unitRef="usd">17801000</us-gaap:AssetsHeldForSaleLongLivedFairValueDisclosure>
	<us-gaap:AssetsHeldForSaleLongLivedFairValueDisclosure contextRef="FI2015Q3_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-3" id="Fact-95C5B458CECD0C58B7C9DE8DC1A274C9" unitRef="usd">17801000</us-gaap:AssetsHeldForSaleLongLivedFairValueDisclosure>
	<us-gaap:AssetsOfDisposalGroupIncludingDiscontinuedOperation contextRef="FI2014Q4_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_gale_CommercialBusinessSegmentMember" decimals="-3" id="Fact-3F809D69E3C0EF91B345DE53F6EE472E" unitRef="usd">27013000</us-gaap:AssetsOfDisposalGroupIncludingDiscontinuedOperation>
	<us-gaap:AssetsOfDisposalGroupIncludingDiscontinuedOperation contextRef="FI2015Q3_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_gale_CommercialBusinessSegmentMember" decimals="-3" id="Fact-2B2F95562B783AE8841BDE53F54D7198" unitRef="usd">17801000</us-gaap:AssetsOfDisposalGroupIncludingDiscontinuedOperation>
	<us-gaap:AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent contextRef="FI2014Q4" decimals="-3" id="Fact-AFB1B80BDCB130544D91DE703697A30A" unitRef="usd">27013000</us-gaap:AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent>
	<us-gaap:AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent contextRef="FI2015Q3" decimals="-3" id="Fact-4125AE6ECAC08A3739A0DE7036999F92" unitRef="usd">17801000</us-gaap:AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent>
	<us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="FI2013Q4" decimals="-3" id="Fact-AD2EA39607FE5C75AC89311F161340C6" unitRef="usd">47787000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
	<us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="FI2014Q3" decimals="-3" id="Fact-F14CBE5622B1563986641D0AB2140C87" unitRef="usd">24647000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
	<us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="FI2014Q4" decimals="-3" id="Fact-01E7ED5CCBC055F6B1DE7DD265AD2646" unitRef="usd">23650000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
	<us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="FI2015Q3" decimals="-3" id="Fact-9FD534556DB459698C002E0351539202" unitRef="usd">34812000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
	<us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="FI2014Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-3" id="Fact-2F0F9B28439E5856BCA33BC109AEF089" unitRef="usd">19477000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
	<us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="FI2014Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-3" id="Fact-3BB81120DD4B59EC9E2BB51249B3A5D5" unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
	<us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="FI2014Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-3" id="Fact-7995D6A509065AD7AF66920202A303D0" unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
	<us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="FI2014Q4_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-3" id="Fact-CEFBD12AB08B59268C71621B9879E7B1" unitRef="usd">19477000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
	<us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="FI2015Q3_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-3" id="Fact-27E96CF6285E5982B3634DBE88309D51" unitRef="usd">32618000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
	<us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="FI2015Q3_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-3" id="Fact-8914372078635ED28C7A10D570113D0F" unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
	<us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="FI2015Q3_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-3" id="Fact-1681A49075625928825BF7860A86326C" unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
	<us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="FI2015Q3_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-3" id="Fact-4C52E9EE6C685F33A0400A38753BABDA" unitRef="usd">32618000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
	<us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease contextRef="FD2014Q3YTD" decimals="-3" id="Fact-B38E6F5621F65ADFB8C845625E7E860D" unitRef="usd">-23140000</us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease>
	<us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease contextRef="FD2015Q3YTD" decimals="-3" id="Fact-296D0C5075E9533586D2632CC8F41556" unitRef="usd">11162000</us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease>
	<us-gaap:CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations contextRef="FD2014Q3YTD" decimals="-3" id="Fact-DFD5478F292A355D90EBDE889EFF2796" unitRef="usd">-3056000</us-gaap:CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations>
	<us-gaap:CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations contextRef="FD2015Q3YTD" decimals="-3" id="Fact-6DEA322768FE844B3156DE889F0CA5C7" unitRef="usd">-534000</us-gaap:CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations>
	<us-gaap:CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations contextRef="FD2014Q3YTD" decimals="-3" id="Fact-3266EBF079E8DCD9BCEEDE7ED2EB5EF4" unitRef="usd">-3392000</us-gaap:CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations>
	<us-gaap:CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations contextRef="FD2015Q3YTD" decimals="-3" id="Fact-34B94BF1731909AA08A0DE7ED2EAB03A" unitRef="usd">-5047000</us-gaap:CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations>
	<us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef="I2013Q2May8" decimals="INF" id="Fact-46A9AC6D721454BF8639E60092E490A2" unitRef="usdPerShare">2.47</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
	<us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef="I2015Q1Mar18" decimals="INF" id="Fact-520CFFE8E4D850C3AFBBA0C613B6F9DD" unitRef="usdPerShare">2.08</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
	<us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights contextRef="I2013Q2May8_us-gaap_RangeAxis_us-gaap_MaximumMember" decimals="INF" id="Fact-CF3A692ABA2B50F39B11D1C1FC6D2D76" unitRef="shares">182186</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
	<us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights contextRef="I2015Q1Mar18" decimals="INF" id="Fact-EF6B0C6A7C4A5217BBFA15E4E147EF36" unitRef="shares">1826923</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
	<us-gaap:ClassOfWarrantOrRightOutstanding contextRef="FI2014Q4" decimals="-3" id="Fact-E81D0615B74A5B83BACB428B97D365AC" unitRef="shares">8540000</us-gaap:ClassOfWarrantOrRightOutstanding>
	<us-gaap:ClassOfWarrantOrRightOutstanding contextRef="FI2014Q4_us-gaap_ClassOfWarrantOrRightAxis_gale_AprilTwoThousandElevenWarrantMember" decimals="-3" id="Fact-9049F7DF29005245B61E7C2DE43B3065" unitRef="shares">615000</us-gaap:ClassOfWarrantOrRightOutstanding>
	<us-gaap:ClassOfWarrantOrRightOutstanding contextRef="FI2014Q4_us-gaap_ClassOfWarrantOrRightAxis_gale_ConsultantWarrantsMember" decimals="-3" id="Fact-20E31DD1D4B65252BC071C807BF353A9" unitRef="shares">720000</us-gaap:ClassOfWarrantOrRightOutstanding>
	<us-gaap:ClassOfWarrantOrRightOutstanding contextRef="FI2014Q4_us-gaap_ClassOfWarrantOrRightAxis_gale_DecemberTwoThousandTwelveWarrantMember" decimals="-3" id="Fact-07D9D5C0686E5B76A3E85C81D40A28E8" unitRef="shares">3031000</us-gaap:ClassOfWarrantOrRightOutstanding>
	<us-gaap:ClassOfWarrantOrRightOutstanding contextRef="FI2014Q4_us-gaap_ClassOfWarrantOrRightAxis_gale_MarchTwoThousandElevenWarrantMember" decimals="-3" id="Fact-DAC034EDF2A4500C93B4C7D3F40DB291" unitRef="shares">176000</us-gaap:ClassOfWarrantOrRightOutstanding>
	<us-gaap:ClassOfWarrantOrRightOutstanding contextRef="FI2014Q4_us-gaap_ClassOfWarrantOrRightAxis_gale_MarchTwoThousandFifteenWarrantsMember" decimals="-3" id="Fact-3210B281BB4558EDA8EBA63EAA0EF18F" unitRef="shares">0</us-gaap:ClassOfWarrantOrRightOutstanding>
	<us-gaap:ClassOfWarrantOrRightOutstanding contextRef="FI2014Q4_us-gaap_ClassOfWarrantOrRightAxis_gale_MarchTwoThousandTenWarrantMember" decimals="-3" id="Fact-C12050F0A70A5F409290A736CDF4D571" unitRef="shares">25000</us-gaap:ClassOfWarrantOrRightOutstanding>
	<us-gaap:ClassOfWarrantOrRightOutstanding contextRef="FI2014Q4_us-gaap_ClassOfWarrantOrRightAxis_gale_SeptemberTwoThousandThirteenWarrantMember" decimals="-3" id="Fact-44A25C015E5E5A259D88B91949CE8C53" unitRef="shares">3973000</us-gaap:ClassOfWarrantOrRightOutstanding>
	<us-gaap:ClassOfWarrantOrRightOutstanding contextRef="FI2015Q3" decimals="-3" id="Fact-CDDF0B3765175881853D5BC8EEF8303C" unitRef="shares">22308000</us-gaap:ClassOfWarrantOrRightOutstanding>
	<us-gaap:ClassOfWarrantOrRightOutstanding contextRef="FI2015Q3_us-gaap_ClassOfWarrantOrRightAxis_gale_AprilTwoThousandElevenWarrantMember" decimals="-3" id="Fact-642D8B56AE5F53D4A345949BA2A7B034" unitRef="shares">615000</us-gaap:ClassOfWarrantOrRightOutstanding>
	<us-gaap:ClassOfWarrantOrRightOutstanding contextRef="FI2015Q3_us-gaap_ClassOfWarrantOrRightAxis_gale_ConsultantWarrantsMember" decimals="-3" id="Fact-6083E5CDBC0551E38B013F06B242EAAB" unitRef="shares">482000</us-gaap:ClassOfWarrantOrRightOutstanding>
	<us-gaap:ClassOfWarrantOrRightOutstanding contextRef="FI2015Q3_us-gaap_ClassOfWarrantOrRightAxis_gale_DecemberTwoThousandTwelveWarrantMember" decimals="-3" id="Fact-AC81373C39B153229BBD94B0CBA9A006" unitRef="shares">3031000</us-gaap:ClassOfWarrantOrRightOutstanding>
	<us-gaap:ClassOfWarrantOrRightOutstanding contextRef="FI2015Q3_us-gaap_ClassOfWarrantOrRightAxis_gale_MarchTwoThousandElevenWarrantMember" decimals="-3" id="Fact-4823F320F682514693E0D1596B7C9026" unitRef="shares">176000</us-gaap:ClassOfWarrantOrRightOutstanding>
	<us-gaap:ClassOfWarrantOrRightOutstanding contextRef="FI2015Q3_us-gaap_ClassOfWarrantOrRightAxis_gale_MarchTwoThousandFifteenWarrantsMember" decimals="-3" id="Fact-3E1B3B4F413F544A9695297B59F23C95" unitRef="shares">14006000</us-gaap:ClassOfWarrantOrRightOutstanding>
	<us-gaap:ClassOfWarrantOrRightOutstanding contextRef="FI2015Q3_us-gaap_ClassOfWarrantOrRightAxis_gale_MarchTwoThousandTenWarrantMember" decimals="-3" id="Fact-AE5AD5ED10165BBBB1D7989C96E8ED27" unitRef="shares">25000</us-gaap:ClassOfWarrantOrRightOutstanding>
	<us-gaap:ClassOfWarrantOrRightOutstanding contextRef="FI2015Q3_us-gaap_ClassOfWarrantOrRightAxis_gale_SeptemberTwoThousandThirteenWarrantMember" decimals="-3" id="Fact-47BAB9EEAE495E89A42CD997310DDF22" unitRef="shares">3973000</us-gaap:ClassOfWarrantOrRightOutstanding>
	<us-gaap:CommitmentsAndContingencies contextRef="FI2014Q4" id="Fact-2ED88264306753EC924F96C0D82EFE95" unitRef="usd" xsi:nil="true" />
	<us-gaap:CommitmentsAndContingencies contextRef="FI2015Q3" id="Fact-9806068B23995E1BAB2705AC2D82027E" unitRef="usd" xsi:nil="true" />
	<us-gaap:CommonStockCapitalSharesReservedForFutureIssuance contextRef="FI2015Q3" decimals="-3" id="Fact-22F584AE598C51FCA4D1A5EB51B4EF4A" unitRef="shares">44275000</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
	<us-gaap:CommonStockParOrStatedValuePerShare contextRef="FI2014Q4" decimals="INF" id="Fact-07F470F1FFA65792B7868B80B257E954" unitRef="usdPerShare">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
	<us-gaap:CommonStockParOrStatedValuePerShare contextRef="FI2015Q3" decimals="INF" id="Fact-E02168D83A0C53FBB27022E5A293C9EE" unitRef="usdPerShare">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
	<us-gaap:CommonStockSharesAuthorized contextRef="FI2014Q4" decimals="INF" id="Fact-C26B5D764852529882290588E738B763" unitRef="shares">200000000</us-gaap:CommonStockSharesAuthorized>
	<us-gaap:CommonStockSharesAuthorized contextRef="FI2015Q3" decimals="INF" id="Fact-EB6B0A08BC3B5AF89BE0940E322215BC" unitRef="shares">275000000</us-gaap:CommonStockSharesAuthorized>
	<us-gaap:CommonStockSharesAuthorized contextRef="I2015Q1Mar18" decimals="INF" id="Fact-EF0127E4B8925B148B1B80017CD4D106" unitRef="shares">3653846</us-gaap:CommonStockSharesAuthorized>
	<us-gaap:CommonStockSharesIssued contextRef="FI2014Q4" decimals="INF" id="Fact-078072E7296E55F3A20D372E770F4C3A" unitRef="shares">110100701</us-gaap:CommonStockSharesIssued>
	<us-gaap:CommonStockSharesIssued contextRef="FI2015Q3" decimals="INF" id="Fact-A5CE4EA1DC755068A922281168527B8D" unitRef="shares">161900446</us-gaap:CommonStockSharesIssued>
	<us-gaap:CommonStockSharesOutstanding contextRef="FI2014Q4" decimals="INF" id="Fact-A38507DD75F450629996B4BC335BDC03" unitRef="shares">109425701</us-gaap:CommonStockSharesOutstanding>
	<us-gaap:CommonStockSharesOutstanding contextRef="FI2015Q3" decimals="INF" id="Fact-CD856CF5D1C35792817E3964193CF65C" unitRef="shares">162575446</us-gaap:CommonStockSharesOutstanding>
	<us-gaap:CommonStockValue contextRef="FI2014Q4" decimals="-3" id="Fact-D491E2A76CF251CC99CE82137C85E924" unitRef="usd">12000</us-gaap:CommonStockValue>
	<us-gaap:CommonStockValue contextRef="FI2015Q3" decimals="-3" id="Fact-CFBB06549CDF555D82D4AB3661AB86B8" unitRef="usd">15000</us-gaap:CommonStockValue>
	<us-gaap:ContingentConsiderationClassifiedAsEquityFairValueDisclosure contextRef="FI2014Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-3" id="Fact-8747A973E9125D93826F636A3049A846" unitRef="usd">0</us-gaap:ContingentConsiderationClassifiedAsEquityFairValueDisclosure>
	<us-gaap:ContingentConsiderationClassifiedAsEquityFairValueDisclosure contextRef="FI2014Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-3" id="Fact-67D23522332253ADAF00F76314750343" unitRef="usd">0</us-gaap:ContingentConsiderationClassifiedAsEquityFairValueDisclosure>
	<us-gaap:ContingentConsiderationClassifiedAsEquityFairValueDisclosure contextRef="FI2014Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member" decimals="-3" id="Fact-DB1033B6691C594690A369D4E15AFF68" unitRef="usd">6651000</us-gaap:ContingentConsiderationClassifiedAsEquityFairValueDisclosure>
	<us-gaap:ContingentConsiderationClassifiedAsEquityFairValueDisclosure contextRef="FI2014Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-3" id="Fact-9AA8484CD84858AC9EF0E29447974693" unitRef="usd">6651000</us-gaap:ContingentConsiderationClassifiedAsEquityFairValueDisclosure>
	<us-gaap:ContingentConsiderationClassifiedAsEquityFairValueDisclosure contextRef="FI2014Q4_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-3" id="Fact-DE9145DAD93C5FC78E7BBF30E35BBBB1" unitRef="usd">6651000</us-gaap:ContingentConsiderationClassifiedAsEquityFairValueDisclosure>
	<us-gaap:ContingentConsiderationClassifiedAsEquityFairValueDisclosure contextRef="FI2015Q3_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-3" id="Fact-C57FC61B405A51E0853950D3C2F4FF8B" unitRef="usd">0</us-gaap:ContingentConsiderationClassifiedAsEquityFairValueDisclosure>
	<us-gaap:ContingentConsiderationClassifiedAsEquityFairValueDisclosure contextRef="FI2015Q3_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-3" id="Fact-DBF5DA6ABED852FDB9C8598DEBB2305D" unitRef="usd">0</us-gaap:ContingentConsiderationClassifiedAsEquityFairValueDisclosure>
	<us-gaap:ContingentConsiderationClassifiedAsEquityFairValueDisclosure contextRef="FI2015Q3_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member" decimals="-3" id="Fact-C90105B5A5C65720B0BD9AE55EA4DEFF" unitRef="usd">6582000</us-gaap:ContingentConsiderationClassifiedAsEquityFairValueDisclosure>
	<us-gaap:ContingentConsiderationClassifiedAsEquityFairValueDisclosure contextRef="FI2015Q3_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-3" id="Fact-F1652A5E907D5A54969528566DB29FEC" unitRef="usd">6582000</us-gaap:ContingentConsiderationClassifiedAsEquityFairValueDisclosure>
	<us-gaap:ContingentConsiderationClassifiedAsEquityFairValueDisclosure contextRef="FI2015Q3_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-3" id="Fact-5E54D309C93953A69333BCFE06E6F6B4" unitRef="usd">6582000</us-gaap:ContingentConsiderationClassifiedAsEquityFairValueDisclosure>
	<us-gaap:CostsAndExpenses contextRef="FD2014Q3QTD" decimals="-3" id="Fact-7ED14AD8A2825245954969D512B2FCE2" unitRef="usd">10567000</us-gaap:CostsAndExpenses>
	<us-gaap:CostsAndExpenses contextRef="FD2014Q3YTD" decimals="-3" id="Fact-9F805093EF1A5A02B2D4DF84959E6EEE" unitRef="usd">34207000</us-gaap:CostsAndExpenses>
	<us-gaap:CostsAndExpenses contextRef="FD2015Q3QTD" decimals="-3" id="Fact-942125B310C95801B7ECE39B5A9CF402" unitRef="usd">8635000</us-gaap:CostsAndExpenses>
	<us-gaap:CostsAndExpenses contextRef="FD2015Q3YTD" decimals="-3" id="Fact-649F9130D3CE52908D2EF17DF1BC165C" unitRef="usd">26631000</us-gaap:CostsAndExpenses>
	<us-gaap:DebtInstrumentCarryingAmount contextRef="I2013Q2May8_us-gaap_LongtermDebtTypeAxis_gale_FirstTrancheMember" decimals="-6" id="Fact-03DA74A811BC5658A2F566EE8FFC1246" unitRef="usd">10000000</us-gaap:DebtInstrumentCarryingAmount>
	<us-gaap:DebtInstrumentInterestRateStatedPercentage contextRef="I2013Q2May8" decimals="INF" id="Fact-1F3D27C957C85CD7A05FD48C0A193774" unitRef="number">0.0845</us-gaap:DebtInstrumentInterestRateStatedPercentage>
	<us-gaap:DebtInstrumentTerm contextRef="D2013Q2MAY8" id="Fact-00413DF9B8E75EFB9A9A4ABD8B348CBF">P30M</us-gaap:DebtInstrumentTerm>
	<us-gaap:DeferredTaxAssetsLiabilitiesNetNoncurrent contextRef="FI2014Q4" decimals="-3" id="Fact-43D7E8E8BC8450DABE89ED54BAB8D70F" unitRef="usd">-5053000</us-gaap:DeferredTaxAssetsLiabilitiesNetNoncurrent>
	<us-gaap:DeferredTaxAssetsLiabilitiesNetNoncurrent contextRef="FI2015Q3" decimals="-3" id="Fact-04C67A9EF00B568D96D083FAC42B3CFA" unitRef="usd">-5053000</us-gaap:DeferredTaxAssetsLiabilitiesNetNoncurrent>
	<us-gaap:DepositsAssetsNoncurrent contextRef="FI2014Q4" decimals="-3" id="Fact-B536C80BD2F95A328998268406F8F0E1" unitRef="usd">87000</us-gaap:DepositsAssetsNoncurrent>
	<us-gaap:DepositsAssetsNoncurrent contextRef="FI2015Q3" decimals="-3" id="Fact-1858ABAD737059C08A35E9276153B063" unitRef="usd">176000</us-gaap:DepositsAssetsNoncurrent>
	<us-gaap:DepreciationDepletionAndAmortization contextRef="FD2014Q3YTD" decimals="-3" id="Fact-00CA46335C3B5A6FBCCE1CA031C00A4F" unitRef="usd">340000</us-gaap:DepreciationDepletionAndAmortization>
	<us-gaap:DepreciationDepletionAndAmortization contextRef="FD2014Q3YTD_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_gale_CommercialBusinessSegmentMember" decimals="-3" id="Fact-AAF4F89FD294B654B1FBDE68F4CE2425" unitRef="usd">319000</us-gaap:DepreciationDepletionAndAmortization>
	<us-gaap:DepreciationDepletionAndAmortization contextRef="FD2015Q3YTD" decimals="-3" id="Fact-1139C72EE2A552D3A708719F79A9056D" unitRef="usd">304000</us-gaap:DepreciationDepletionAndAmortization>
	<us-gaap:DepreciationDepletionAndAmortization contextRef="FD2015Q3YTD_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_gale_CommercialBusinessSegmentMember" decimals="-3" id="Fact-E3AC3EE38191A505B729DE68F4D092B0" unitRef="usd">858000</us-gaap:DepreciationDepletionAndAmortization>
	<us-gaap:DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet contextRef="FI2014Q4_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_gale_CommercialBusinessSegmentMember" decimals="-3" id="Fact-8096B9147754923748B4DE4456AF769E" unitRef="usd">1535000</us-gaap:DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet>
	<us-gaap:DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet contextRef="FI2015Q3_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_gale_CommercialBusinessSegmentMember" decimals="-3" id="Fact-8D72B09B02CD661198DFDE4456A8362A" unitRef="usd">1238000</us-gaap:DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet>
	<us-gaap:DisposalGroupIncludingDiscontinuedOperationAccountsPayable contextRef="FI2014Q4_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_gale_CommercialBusinessSegmentMember" decimals="-3" id="Fact-5591D9686B33D7224C4BDE5474C8C929" unitRef="usd">385000</us-gaap:DisposalGroupIncludingDiscontinuedOperationAccountsPayable>
	<us-gaap:DisposalGroupIncludingDiscontinuedOperationAccountsPayable contextRef="FI2015Q3_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_gale_CommercialBusinessSegmentMember" decimals="-3" id="Fact-D0C0955A6B688E1079D9DE5474DAA57C" unitRef="usd">1359000</us-gaap:DisposalGroupIncludingDiscontinuedOperationAccountsPayable>
	<us-gaap:DisposalGroupIncludingDiscontinuedOperationAccruedLiabilities contextRef="FI2014Q4_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_gale_CommercialBusinessSegmentMember" decimals="-3" id="Fact-659BB6AFCCD7C40DF167DE54B79693D1" unitRef="usd">6784000</us-gaap:DisposalGroupIncludingDiscontinuedOperationAccruedLiabilities>
	<us-gaap:DisposalGroupIncludingDiscontinuedOperationAccruedLiabilities contextRef="FI2015Q3_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_gale_CommercialBusinessSegmentMember" decimals="-3" id="Fact-E1EBE9B9823A31480F05DE54B79EE314" unitRef="usd">6338000</us-gaap:DisposalGroupIncludingDiscontinuedOperationAccruedLiabilities>
	<us-gaap:DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold contextRef="FD2014Q3QTD_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_gale_CommercialBusinessSegmentMember" decimals="-3" id="Fact-29B3FF3022E5EC517869DE5EC6FDE173" unitRef="usd">247000</us-gaap:DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold>
	<us-gaap:DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold contextRef="FD2014Q3YTD_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_gale_CommercialBusinessSegmentMember" decimals="-3" id="Fact-65105DA1C8FB7C79778CDE5EC6C1A493" unitRef="usd">925000</us-gaap:DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold>
	<us-gaap:DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold contextRef="FD2015Q3QTD_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_gale_CommercialBusinessSegmentMember" decimals="-3" id="Fact-1A48F498A34A7C1412EDDE5EC6C28D3F" unitRef="usd">712000</us-gaap:DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold>
	<us-gaap:DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold contextRef="FD2015Q3YTD_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_gale_CommercialBusinessSegmentMember" decimals="-3" id="Fact-836EFA27343D4D137D24DE5EC6DAFFE0" unitRef="usd">1573000</us-gaap:DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold>
	<us-gaap:DisposalGroupIncludingDiscontinuedOperationDepreciationAndAmortization contextRef="FD2014Q3QTD_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_gale_CommercialBusinessSegmentMember" decimals="-3" id="Fact-6A986EA3C1ACDCABDF3FDE5F7A1B3D01" unitRef="usd">70000</us-gaap:DisposalGroupIncludingDiscontinuedOperationDepreciationAndAmortization>
	<us-gaap:DisposalGroupIncludingDiscontinuedOperationDepreciationAndAmortization contextRef="FD2014Q3YTD_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_gale_CommercialBusinessSegmentMember" decimals="-3" id="Fact-5CA6E5E5ADA88D19BA88DE5F7A23C28D" unitRef="usd">259000</us-gaap:DisposalGroupIncludingDiscontinuedOperationDepreciationAndAmortization>
	<us-gaap:DisposalGroupIncludingDiscontinuedOperationDepreciationAndAmortization contextRef="FD2015Q3QTD_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_gale_CommercialBusinessSegmentMember" decimals="-3" id="Fact-4CDB87794B1DBD73E0A5DE5F7A1F2337" unitRef="usd">208000</us-gaap:DisposalGroupIncludingDiscontinuedOperationDepreciationAndAmortization>
	<us-gaap:DisposalGroupIncludingDiscontinuedOperationDepreciationAndAmortization contextRef="FD2015Q3YTD_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_gale_CommercialBusinessSegmentMember" decimals="-3" id="Fact-8FB0D67CE93A26416730DE5F7A1D605A" unitRef="usd">795000</us-gaap:DisposalGroupIncludingDiscontinuedOperationDepreciationAndAmortization>
	<us-gaap:DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense contextRef="FD2014Q3QTD_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_gale_CommercialBusinessSegmentMember" decimals="-3" id="Fact-FDFE99197040D38CB1E1DE5FBEBA36B0" unitRef="usd">3725000</us-gaap:DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense>
	<us-gaap:DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense contextRef="FD2014Q3YTD_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_gale_CommercialBusinessSegmentMember" decimals="-3" id="Fact-8FCB1B3C7CEF6B770CC3DE5FBEF5CEE9" unitRef="usd">10954000</us-gaap:DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense>
	<us-gaap:DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense contextRef="FD2015Q3QTD_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_gale_CommercialBusinessSegmentMember" decimals="-3" id="Fact-77D81962CEB91DFEA487DE5FBEB3C83B" unitRef="usd">4672000</us-gaap:DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense>
	<us-gaap:DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense contextRef="FD2015Q3YTD_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_gale_CommercialBusinessSegmentMember" decimals="-3" id="Fact-F7CFA44E4479F2E5CD16DE5FBED1D741" unitRef="usd">13577000</us-gaap:DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense>
	<us-gaap:DisposalGroupIncludingDiscontinuedOperationGoodwill1 contextRef="FI2014Q4_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_gale_CommercialBusinessSegmentMember" decimals="-3" id="Fact-732E89BC0B924A8C87E9DE52EB4EF3D0" unitRef="usd">172000</us-gaap:DisposalGroupIncludingDiscontinuedOperationGoodwill1>
	<us-gaap:DisposalGroupIncludingDiscontinuedOperationGoodwill1 contextRef="FI2015Q3_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_gale_CommercialBusinessSegmentMember" decimals="-3" id="Fact-512F44D4CF679682508DDE52EB5A75BD" unitRef="usd">172000</us-gaap:DisposalGroupIncludingDiscontinuedOperationGoodwill1>
	<us-gaap:DisposalGroupIncludingDiscontinuedOperationIntangibleAssets contextRef="FI2014Q4_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_gale_AbstralRightsNetMember_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_gale_CommercialBusinessSegmentMember" decimals="-3" id="Fact-82BB4EE22C47F9644863DE532FF58D9B" unitRef="usd">14533000</us-gaap:DisposalGroupIncludingDiscontinuedOperationIntangibleAssets>
	<us-gaap:DisposalGroupIncludingDiscontinuedOperationIntangibleAssets contextRef="FI2014Q4_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_gale_ZuplenzRightsMember_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_gale_CommercialBusinessSegmentMember" decimals="-3" id="Fact-2A279F14364BD8BB64CEDE532FEFD29B" unitRef="usd">8101000</us-gaap:DisposalGroupIncludingDiscontinuedOperationIntangibleAssets>
	<us-gaap:DisposalGroupIncludingDiscontinuedOperationIntangibleAssets contextRef="FI2015Q3_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_gale_AbstralRightsNetMember_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_gale_CommercialBusinessSegmentMember" decimals="-3" id="Fact-6F20EE32154C7C8A4887DE532FF1D36F" unitRef="usd">13738000</us-gaap:DisposalGroupIncludingDiscontinuedOperationIntangibleAssets>
	<us-gaap:DisposalGroupIncludingDiscontinuedOperationIntangibleAssets contextRef="FI2015Q3_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_gale_ZuplenzRightsMember_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_gale_CommercialBusinessSegmentMember" decimals="-3" id="Fact-B06674B1D6D6E1A76888DE532FED4576" unitRef="usd">8101000</us-gaap:DisposalGroupIncludingDiscontinuedOperationIntangibleAssets>
	<us-gaap:DisposalGroupIncludingDiscontinuedOperationInventory1 contextRef="FI2014Q4_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_gale_CommercialBusinessSegmentMember" decimals="-3" id="Fact-158B7C0A736B5B950C0CDE515727D495" unitRef="usd">655000</us-gaap:DisposalGroupIncludingDiscontinuedOperationInventory1>
	<us-gaap:DisposalGroupIncludingDiscontinuedOperationInventory1 contextRef="FI2015Q3_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_gale_CommercialBusinessSegmentMember" decimals="-3" id="Fact-63AD8CAB09A99E0365A2DE5157297D96" unitRef="usd">1318000</us-gaap:DisposalGroupIncludingDiscontinuedOperationInventory1>
	<us-gaap:DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss contextRef="FD2014Q3QTD_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_gale_CommercialBusinessSegmentMember" decimals="-3" id="Fact-83A3F2165F6F1D9C2A67DE60053EEC1A" unitRef="usd">0</us-gaap:DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss>
	<us-gaap:DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss contextRef="FD2014Q3YTD_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_gale_CommercialBusinessSegmentMember" decimals="-3" id="Fact-70D8021C455A2723E952DE60053A035B" unitRef="usd">0</us-gaap:DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss>
	<us-gaap:DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss contextRef="FD2015Q3QTD_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_gale_CommercialBusinessSegmentMember" decimals="-3" id="Fact-3193061F1BE5F78F027ADE60053C1289" unitRef="usd">-17000</us-gaap:DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss>
	<us-gaap:DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss contextRef="FD2015Q3YTD_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_gale_CommercialBusinessSegmentMember" decimals="-3" id="Fact-3D198615BDAB50DDD7FBDE60054210B4" unitRef="usd">-17000</us-gaap:DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss>
	<us-gaap:DisposalGroupIncludingDiscontinuedOperationPrepaidAndOtherAssets contextRef="FI2014Q4_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_gale_CommercialBusinessSegmentMember" decimals="-3" id="Fact-5D1E47C268F820288FB4DE51990070C7" unitRef="usd">1747000</us-gaap:DisposalGroupIncludingDiscontinuedOperationPrepaidAndOtherAssets>
	<us-gaap:DisposalGroupIncludingDiscontinuedOperationPrepaidAndOtherAssets contextRef="FI2015Q3_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_gale_CommercialBusinessSegmentMember" decimals="-3" id="Fact-C1B6CC0E81421E8DE8D7DE5198F970E5" unitRef="usd">1064000</us-gaap:DisposalGroupIncludingDiscontinuedOperationPrepaidAndOtherAssets>
	<us-gaap:DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment contextRef="FI2014Q4_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_gale_CommercialBusinessSegmentMember" decimals="-3" id="Fact-951169E1D80537FB4835DE51EFF22DD0" unitRef="usd">270000</us-gaap:DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment>
	<us-gaap:DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment contextRef="FI2015Q3_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_gale_CommercialBusinessSegmentMember" decimals="-3" id="Fact-DC8ABB2AD89A498B2723DE51EFF473CB" unitRef="usd">241000</us-gaap:DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment>
	<us-gaap:DisposalGroupIncludingDiscontinuedOperationRevenue contextRef="FD2014Q3QTD_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_gale_CommercialBusinessSegmentMember" decimals="-3" id="Fact-2F73220C49F84690AF5FDE5E8D01AAF8" unitRef="usd">1620000</us-gaap:DisposalGroupIncludingDiscontinuedOperationRevenue>
	<us-gaap:DisposalGroupIncludingDiscontinuedOperationRevenue contextRef="FD2014Q3YTD_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_gale_CommercialBusinessSegmentMember" decimals="-3" id="Fact-96254476908FD06B4399DE5E8D041581" unitRef="usd">6124000</us-gaap:DisposalGroupIncludingDiscontinuedOperationRevenue>
	<us-gaap:DisposalGroupIncludingDiscontinuedOperationRevenue contextRef="FD2015Q3QTD_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_gale_CommercialBusinessSegmentMember" decimals="-3" id="Fact-D2BD8E10921524720A2FDE5E8CFE4873" unitRef="usd">2166000</us-gaap:DisposalGroupIncludingDiscontinuedOperationRevenue>
	<us-gaap:DisposalGroupIncludingDiscontinuedOperationRevenue contextRef="FD2015Q3YTD_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_gale_CommercialBusinessSegmentMember" decimals="-3" id="Fact-A88E258FD5B6F7C28141DE5E8D086556" unitRef="usd">8298000</us-gaap:DisposalGroupIncludingDiscontinuedOperationRevenue>
	<us-gaap:EarningsPerShareBasic contextRef="FD2014Q3QTD" decimals="2" id="Fact-798FBBD491638C9C3472DE78D3022391" unitRef="usdPerShare">-0.05</us-gaap:EarningsPerShareBasic>
	<us-gaap:EarningsPerShareBasic contextRef="FD2014Q3YTD" decimals="2" id="Fact-B1ED7866EF20B7F051DFDE78D304A126" unitRef="usdPerShare">-0.25</us-gaap:EarningsPerShareBasic>
	<us-gaap:EarningsPerShareBasic contextRef="FD2015Q3QTD" decimals="2" id="Fact-B3B4745E8FF0CA2E95B4DE78D3053375" unitRef="usdPerShare">-110.00</us-gaap:EarningsPerShareBasic>
	<us-gaap:EarningsPerShareBasic contextRef="FD2015Q3YTD" decimals="2" id="Fact-95E74A5F9882A48F4502DE78D3018670" unitRef="usdPerShare">-0.29</us-gaap:EarningsPerShareBasic>
	<us-gaap:EmployeeRelatedLiabilitiesCurrent contextRef="FI2014Q4" decimals="-3" id="Fact-7FF30731CFD75A31BEC9A552415353C5" unitRef="usd">1040000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
	<us-gaap:EmployeeRelatedLiabilitiesCurrent contextRef="FI2015Q3" decimals="-3" id="Fact-C95DFE6210B751ECA52039B9983B10CA" unitRef="usd">992000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
	<us-gaap:EquityFairValueDisclosure contextRef="FI2014Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-3" id="Fact-B663D15CB81A5BFA8F9939AE0F58B3EF" unitRef="usd">0</us-gaap:EquityFairValueDisclosure>
	<us-gaap:EquityFairValueDisclosure contextRef="FI2014Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-3" id="Fact-8CA8A139DB7F5A0A892112ABB350BF43" unitRef="usd">5383000</us-gaap:EquityFairValueDisclosure>
	<us-gaap:EquityFairValueDisclosure contextRef="FI2014Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-3" id="Fact-04BB6CCCB35455848D3481CF9A3BEA87" unitRef="usd">6651000</us-gaap:EquityFairValueDisclosure>
	<us-gaap:EquityFairValueDisclosure contextRef="FI2014Q4_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-3" id="Fact-2EE484D7A29B5592BE808BFA32381DC6" unitRef="usd">12034000</us-gaap:EquityFairValueDisclosure>
	<us-gaap:EquityFairValueDisclosure contextRef="FI2015Q3_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-3" id="Fact-0E636C1C6A435AACAA989AA5D8462837" unitRef="usd">0</us-gaap:EquityFairValueDisclosure>
	<us-gaap:EquityFairValueDisclosure contextRef="FI2015Q3_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-3" id="Fact-7D80C04DA44F57FFA240A5D13DA63DAB" unitRef="usd">16661000</us-gaap:EquityFairValueDisclosure>
	<us-gaap:EquityFairValueDisclosure contextRef="FI2015Q3_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-3" id="Fact-143ECDA695735AC39019422950FC2B08" unitRef="usd">6582000</us-gaap:EquityFairValueDisclosure>
	<us-gaap:EquityFairValueDisclosure contextRef="FI2015Q3_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-3" id="Fact-C3C43FEC76D35F68AAE31FA6DC24104E" unitRef="usd">23243000</us-gaap:EquityFairValueDisclosure>
	<us-gaap:FairValueAssumptionsExpectedDividendRate contextRef="D2013Q2MAY8" decimals="4" id="Fact-5D6B4894B59857828499B5D9074B9B09" unitRef="number">0.0000</us-gaap:FairValueAssumptionsExpectedDividendRate>
	<us-gaap:FairValueAssumptionsExpectedTerm contextRef="D2013Q2MAY8" id="Fact-1C82DFB2834253668DA2CEEEB86D482B">P7Y</us-gaap:FairValueAssumptionsExpectedTerm>
	<us-gaap:FairValueAssumptionsExpectedVolatilityRate contextRef="D2013Q2MAY8" decimals="4" id="Fact-84C295ECAFB358ECA84F7A472A7351C4" unitRef="number">0.7534</us-gaap:FairValueAssumptionsExpectedVolatilityRate>
	<us-gaap:FairValueAssumptionsRiskFreeInterestRate contextRef="D2013Q2MAY8" decimals="4" id="Fact-95C880675BB45D5985FD160A066B7360" unitRef="number">0.0120</us-gaap:FairValueAssumptionsRiskFreeInterestRate>
	<us-gaap:Goodwill contextRef="FI2014Q4" decimals="-3" id="Fact-C9B0A39338415D92A22EF41C32ABC443" unitRef="usd">5897000</us-gaap:Goodwill>
	<us-gaap:Goodwill contextRef="FI2015Q3" decimals="-3" id="Fact-BC72DC7EDF6C53048930D51DA3CF3171" unitRef="usd">5898000</us-gaap:Goodwill>
	<us-gaap:ImpairmentOfLongLivedAssetsToBeDisposedOf contextRef="FD2014Q3QTD_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_gale_CommercialBusinessSegmentMember" decimals="-3" id="Fact-F0BE68ED9C2CC82D3B7EDE60B2648F35" unitRef="usd">0</us-gaap:ImpairmentOfLongLivedAssetsToBeDisposedOf>
	<us-gaap:ImpairmentOfLongLivedAssetsToBeDisposedOf contextRef="FD2014Q3YTD" decimals="-3" id="Fact-7CEAD1EFCBF28B06CC8CDE8538992891" unitRef="usd">0</us-gaap:ImpairmentOfLongLivedAssetsToBeDisposedOf>
	<us-gaap:ImpairmentOfLongLivedAssetsToBeDisposedOf contextRef="FD2014Q3YTD_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_gale_CommercialBusinessSegmentMember" decimals="-3" id="Fact-7942A0A27E000F7B1D6DDE680DA18E05" unitRef="usd">0</us-gaap:ImpairmentOfLongLivedAssetsToBeDisposedOf>
	<us-gaap:ImpairmentOfLongLivedAssetsToBeDisposedOf contextRef="FD2014Q4YTD_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_gale_CommercialBusinessSegmentMember" decimals="-3" id="Fact-329AFDB25A284A7D2BDADE53D23D842B" unitRef="usd">0</us-gaap:ImpairmentOfLongLivedAssetsToBeDisposedOf>
	<us-gaap:ImpairmentOfLongLivedAssetsToBeDisposedOf contextRef="FD2015Q3QTD_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_gale_CommercialBusinessSegmentMember" decimals="-3" id="Fact-B5AEB585720C92B0D3D4DE60B24C098C" unitRef="usd">8071000</us-gaap:ImpairmentOfLongLivedAssetsToBeDisposedOf>
	<us-gaap:ImpairmentOfLongLivedAssetsToBeDisposedOf contextRef="FD2015Q3YTD" decimals="-3" id="Fact-8C16E919D24430B18B1FDE853898542B" unitRef="usd">8071000</us-gaap:ImpairmentOfLongLivedAssetsToBeDisposedOf>
	<us-gaap:ImpairmentOfLongLivedAssetsToBeDisposedOf contextRef="FD2015Q3YTD_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_gale_CommercialBusinessSegmentMember" decimals="-3" id="Fact-35169131CE0A4C9BBA6DDE680DA40608" unitRef="usd">8071000</us-gaap:ImpairmentOfLongLivedAssetsToBeDisposedOf>
	<us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest contextRef="FD2014Q3QTD" decimals="-3" id="Fact-50C6FBF986D75AF3A54484CD56292026" unitRef="usd">-3532000</us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest>
	<us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest contextRef="FD2014Q3YTD" decimals="-3" id="Fact-0B44ED4B433E5C8D91428851159457C0" unitRef="usd">-22017000</us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest>
	<us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest contextRef="FD2015Q3QTD" decimals="-3" id="Fact-1E428362D32851E6A59322048B3486EF" unitRef="usd">-6352000</us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest>
	<us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest contextRef="FD2015Q3YTD" decimals="-3" id="Fact-69DB3B24E0A95D7183C92FB7EE9B4AA2" unitRef="usd">-28150000</us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest>
	<us-gaap:IncomeLossFromContinuingOperationsPerBasicAndDilutedShare contextRef="FD2014Q3QTD" decimals="2" id="Fact-1D4008F5EEA757F8B9048B700A874EAB" unitRef="usdPerShare">-0.03</us-gaap:IncomeLossFromContinuingOperationsPerBasicAndDilutedShare>
	<us-gaap:IncomeLossFromContinuingOperationsPerBasicAndDilutedShare contextRef="FD2014Q3YTD" decimals="2" id="Fact-73C03BBEA6125ABFBE857DBC4AA51119" unitRef="usdPerShare">-0.19</us-gaap:IncomeLossFromContinuingOperationsPerBasicAndDilutedShare>
	<us-gaap:IncomeLossFromContinuingOperationsPerBasicAndDilutedShare contextRef="FD2015Q3QTD" decimals="2" id="Fact-085F1974FF03590F89C92CEB357C834B" unitRef="usdPerShare">-0.04</us-gaap:IncomeLossFromContinuingOperationsPerBasicAndDilutedShare>
	<us-gaap:IncomeLossFromContinuingOperationsPerBasicAndDilutedShare contextRef="FD2015Q3YTD" decimals="2" id="Fact-6EA907C28BD95D95B3A44FD3B749600F" unitRef="usdPerShare">-0.18</us-gaap:IncomeLossFromContinuingOperationsPerBasicAndDilutedShare>
	<us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax contextRef="FD2014Q3QTD" decimals="-3" id="Fact-2D792893F5E5B2BE2E74DE744879D66B" unitRef="usd">-2641000</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax>
	<us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax contextRef="FD2014Q3QTD_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_gale_CommercialBusinessSegmentMember" decimals="-3" id="Fact-8350F256B990EE81ADD2DE62899CBEE8" unitRef="usd">-2641000</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax>
	<us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax contextRef="FD2014Q3YTD" decimals="-3" id="Fact-74E02DE7DE3D1FB69AECDE744BE989CD" unitRef="usd">-6633000</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax>
	<us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax contextRef="FD2014Q3YTD_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_gale_CommercialBusinessSegmentMember" decimals="-3" id="Fact-615B9B45C474798D8C9ADE628989126A" unitRef="usd">-6633000</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax>
	<us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax contextRef="FD2015Q3QTD" decimals="-3" id="Fact-FB58145FD56B84E7AFE1DE74470A6F59" unitRef="usd">-11674000</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax>
	<us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax contextRef="FD2015Q3QTD_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_gale_CommercialBusinessSegmentMember" decimals="-3" id="Fact-394CE575F8388B3D7A7FDE62897B59E7" unitRef="usd">-11674000</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax>
	<us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax contextRef="FD2015Q3YTD" decimals="-3" id="Fact-B87F2D0947324EF228FBDE7449C1D632" unitRef="usd">-16074000</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax>
	<us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax contextRef="FD2015Q3YTD_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_gale_CommercialBusinessSegmentMember" decimals="-3" id="Fact-FFE2D622639FB95B4FB3DE62897DB69A" unitRef="usd">-16074000</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax>
	<us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicAndDilutedShare contextRef="FD2014Q3QTD" decimals="2" id="Fact-ABC5FBFA5DAD689D6FEDDE78252F4D09" unitRef="usdPerShare">-0.02</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicAndDilutedShare>
	<us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicAndDilutedShare contextRef="FD2014Q3YTD" decimals="2" id="Fact-05C7FCCEA9E176A8A2E5DE782517D13A" unitRef="usdPerShare">-0.06</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicAndDilutedShare>
	<us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicAndDilutedShare contextRef="FD2015Q3QTD" decimals="2" id="Fact-086AC91E1CD00BCCE6E6DE78250B0FC1" unitRef="usdPerShare">-0.07</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicAndDilutedShare>
	<us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicAndDilutedShare contextRef="FD2015Q3YTD" decimals="2" id="Fact-52E2776AA258B38705F1DE78250A9195" unitRef="usdPerShare">-0.11</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicAndDilutedShare>
	<us-gaap:IncreaseDecreaseInAccountsPayable contextRef="FD2014Q3YTD" decimals="-3" id="Fact-2E68677D8957587FAEDC689CD67B6EFB" unitRef="usd">54000</us-gaap:IncreaseDecreaseInAccountsPayable>
	<us-gaap:IncreaseDecreaseInAccountsPayable contextRef="FD2015Q3YTD" decimals="-3" id="Fact-7E3870DE9F84596A80FE26054D108389" unitRef="usd">-648000</us-gaap:IncreaseDecreaseInAccountsPayable>
	<us-gaap:IncreaseDecreaseInAccruedLiabilities contextRef="FD2014Q3YTD" decimals="-3" id="Fact-28E82FFC66F0550F92641E52A808F10B" unitRef="usd">2465000</us-gaap:IncreaseDecreaseInAccruedLiabilities>
	<us-gaap:IncreaseDecreaseInAccruedLiabilities contextRef="FD2015Q3YTD" decimals="-3" id="Fact-8E2A59D008E95A2090CD078E5A6F4E97" unitRef="usd">-1556000</us-gaap:IncreaseDecreaseInAccruedLiabilities>
	<us-gaap:IncreaseDecreaseInAssetsHeldForSale contextRef="FD2014Q3YTD" decimals="-3" id="Fact-8266EECF23153F3ED871DE870F6DBE3A" unitRef="usd">-3241000</us-gaap:IncreaseDecreaseInAssetsHeldForSale>
	<us-gaap:IncreaseDecreaseInAssetsHeldForSale contextRef="FD2015Q3YTD" decimals="-3" id="Fact-92E9609C6475A7E5FD2FDE870F6E5F18" unitRef="usd">-2956000</us-gaap:IncreaseDecreaseInAssetsHeldForSale>
	<us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets contextRef="FD2014Q3YTD" decimals="-3" id="Fact-C0C26BD5BD355B5CA3D96912C4E49DE2" unitRef="usd">348000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
	<us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets contextRef="FD2015Q3YTD" decimals="-3" id="Fact-EEB51A3B38CF5868B69D535F8ED5DDA7" unitRef="usd">26000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
	<us-gaap:IncreaseDecreaseInRestrictedCash contextRef="FD2015Q3YTD" decimals="-3" id="Fact-1ACB90B6C1A2555A82D447F61357427F" unitRef="usd">201000</us-gaap:IncreaseDecreaseInRestrictedCash>
	<us-gaap:InterestIncomeExpenseNet contextRef="FD2014Q3QTD" decimals="-3" id="Fact-4ED985046D1A510CA1A5011BD3D20331" unitRef="usd">-297000</us-gaap:InterestIncomeExpenseNet>
	<us-gaap:InterestIncomeExpenseNet contextRef="FD2014Q3YTD" decimals="-3" id="Fact-5F04515465A45D518E063613E29EA55E" unitRef="usd">-925000</us-gaap:InterestIncomeExpenseNet>
	<us-gaap:InterestIncomeExpenseNet contextRef="FD2015Q3QTD" decimals="-3" id="Fact-CA656B056DB351EDB4210CDB06D2A70A" unitRef="usd">-158000</us-gaap:InterestIncomeExpenseNet>
	<us-gaap:InterestIncomeExpenseNet contextRef="FD2015Q3YTD" decimals="-3" id="Fact-C73B9A94C7B15E3DB79627EA931BBE69" unitRef="usd">-607000</us-gaap:InterestIncomeExpenseNet>
	<us-gaap:InterestPaid contextRef="FD2014Q3YTD" decimals="-3" id="Fact-AEA32B0F1BE759BAAD3ADBA9CB82F8AE" unitRef="usd">632000</us-gaap:InterestPaid>
	<us-gaap:InterestPaid contextRef="FD2015Q3YTD" decimals="-3" id="Fact-3CCAD7F536D55C0EB7871E4B00192D1F" unitRef="usd">437000</us-gaap:InterestPaid>
	<us-gaap:InterestPayableCurrent contextRef="FI2014Q4" decimals="-3" id="Fact-8FF2DAA492805E90A42CCACCB2F7C33C" unitRef="usd">57000</us-gaap:InterestPayableCurrent>
	<us-gaap:InterestPayableCurrent contextRef="FI2015Q3" decimals="-3" id="Fact-39AA51B8744F50E5A233AE61EEFF9A97" unitRef="usd">37000</us-gaap:InterestPayableCurrent>
	<us-gaap:Liabilities contextRef="FI2014Q4" decimals="-3" id="Fact-4FAC318DDFAB5CBC97CD8AC5FA30EECF" unitRef="usd">43429000</us-gaap:Liabilities>
	<us-gaap:Liabilities contextRef="FI2015Q3" decimals="-3" id="Fact-77DA85517863504B8962A8BD43876444" unitRef="usd">50252000</us-gaap:Liabilities>
	<us-gaap:LiabilitiesAndStockholdersEquity contextRef="FI2014Q4" decimals="-3" id="Fact-F202EB398AC5577285E76D3EBEC64CA9" unitRef="usd">80488000</us-gaap:LiabilitiesAndStockholdersEquity>
	<us-gaap:LiabilitiesAndStockholdersEquity contextRef="FI2015Q3" decimals="-3" id="Fact-B630BCE2D846593CB7CF8F70AAEF1DD2" unitRef="usd">82669000</us-gaap:LiabilitiesAndStockholdersEquity>
	<us-gaap:LiabilitiesCurrent contextRef="FI2014Q4" decimals="-3" id="Fact-534A4189F252514DA1B81008EA6FDC17" unitRef="usd">27233000</us-gaap:LiabilitiesCurrent>
	<us-gaap:LiabilitiesCurrent contextRef="FI2015Q3" decimals="-3" id="Fact-1D1C6DB7DA365E7DBCFC82A3250B74A7" unitRef="usd">37091000</us-gaap:LiabilitiesCurrent>
	<us-gaap:LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent contextRef="FI2014Q4" decimals="-3" id="Fact-C3E6E69154748A20882CDE710C3FD8DD" unitRef="usd">7169000</us-gaap:LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent>
	<us-gaap:LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent contextRef="FI2014Q4_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_gale_CommercialBusinessSegmentMember" decimals="-3" id="Fact-034B5E450BC27C400F4CDE551C81E7C0" unitRef="usd">7169000</us-gaap:LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent>
	<us-gaap:LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent contextRef="FI2015Q3" decimals="-3" id="Fact-BB834504FAD2A1C2FCEDDE710C415423" unitRef="usd">7697000</us-gaap:LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent>
	<us-gaap:LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent contextRef="FI2015Q3_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_gale_CommercialBusinessSegmentMember" decimals="-3" id="Fact-9A74F01EF20A7F940AEFDE551C88530B" unitRef="usd">7697000</us-gaap:LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent>
	<us-gaap:LongTermDebtCurrent contextRef="FI2014Q4" decimals="-3" id="Fact-DE71D43BF28B52CA9073923C8B088382" unitRef="usd">3910000</us-gaap:LongTermDebtCurrent>
	<us-gaap:LongTermDebtCurrent contextRef="FI2015Q3" decimals="-3" id="Fact-2239E6715C195BCFA4A9BDE96C0ABA99" unitRef="usd">4166000</us-gaap:LongTermDebtCurrent>
	<us-gaap:LongTermDebtNoncurrent contextRef="FI2014Q4" decimals="-3" id="Fact-09EA2039A8E55E2CAD2A8C7DE51D92E8" unitRef="usd">4492000</us-gaap:LongTermDebtNoncurrent>
	<us-gaap:LongTermDebtNoncurrent contextRef="FI2015Q3" decimals="-3" id="Fact-A53CF62E94645AF9A4D9471BDFC44F62" unitRef="usd">1526000</us-gaap:LongTermDebtNoncurrent>
	<us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="FD2014Q3YTD" decimals="-3" id="Fact-860D0C24E1EC531E9461621540191ACC" unitRef="usd">14414000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
	<us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="FD2015Q3YTD" decimals="-3" id="Fact-7115C9A24EDF50A2BFC55C21FFC31534" unitRef="usd">44854000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
	<us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="FD2014Q3YTD" decimals="-3" id="Fact-94D8379B7E09533FB7B315A297436C44" unitRef="usd">-5419000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
	<us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="FD2015Q3YTD" decimals="-3" id="Fact-1FD237B9401951218571EB6CA23BFF66" unitRef="usd">-816000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
	<us-gaap:NetCashProvidedByUsedInInvestingActivitiesContinuingOperations contextRef="FD2014Q3YTD" decimals="-3" id="Fact-8F98483C28FEBF8FDC48DE88675FD661" unitRef="usd">-2363000</us-gaap:NetCashProvidedByUsedInInvestingActivitiesContinuingOperations>
	<us-gaap:NetCashProvidedByUsedInInvestingActivitiesContinuingOperations contextRef="FD2015Q3YTD" decimals="-3" id="Fact-7F518CF64A0B2399A82BDE88675C5BAB" unitRef="usd">-282000</us-gaap:NetCashProvidedByUsedInInvestingActivitiesContinuingOperations>
	<us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="FD2014Q3YTD" decimals="-3" id="Fact-F471B06B536E53E28EE15FBEA4EBAACB" unitRef="usd">-32135000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
	<us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="FD2015Q3YTD" decimals="-3" id="Fact-D12D21C531C1500A9408CBD4CB4EE324" unitRef="usd">-32876000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
	<us-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations contextRef="FD2014Q3YTD" decimals="-3" id="Fact-50782957E0E1AC14C571DE7DD554597C" unitRef="usd">-28743000</us-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations>
	<us-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations contextRef="FD2015Q3YTD" decimals="-3" id="Fact-7D7CC5DBD15A213B279CDE7DD55339B2" unitRef="usd">-27829000</us-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations>
	<us-gaap:NetIncomeLoss contextRef="FD2014Q3QTD" decimals="-3" id="Fact-FC2A41372A75CC9ABA3DDE757229ADAE" unitRef="usd">-6173000</us-gaap:NetIncomeLoss>
	<us-gaap:NetIncomeLoss contextRef="FD2014Q3YTD" decimals="-3" id="Fact-62E5AC61D69963A78F06DE7572163AB6" unitRef="usd">-28650000</us-gaap:NetIncomeLoss>
	<us-gaap:NetIncomeLoss contextRef="FD2015Q3QTD" decimals="-3" id="Fact-C5C2A63D25A9F47F87EBDE757222312F" unitRef="usd">-18026000</us-gaap:NetIncomeLoss>
	<us-gaap:NetIncomeLoss contextRef="FD2015Q3YTD" decimals="-3" id="Fact-8D108A2C44E3B0E9854CDE757230FD37" unitRef="usd">-44224000</us-gaap:NetIncomeLoss>
	<us-gaap:NetIncomeLoss contextRef="FD2015Q3YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember" decimals="-3" id="Fact-D392D4CAAC9858AEA30823F10A24F57C" unitRef="usd">-44224000</us-gaap:NetIncomeLoss>
	<us-gaap:OperatingIncomeLoss contextRef="FD2014Q3QTD" decimals="-3" id="Fact-032B0E5FAE1E56DBBE5FE358DFC6D85C" unitRef="usd">-10567000</us-gaap:OperatingIncomeLoss>
	<us-gaap:OperatingIncomeLoss contextRef="FD2014Q3YTD" decimals="-3" id="Fact-7F6C179D042A50F4B76DB763634F63FA" unitRef="usd">-34207000</us-gaap:OperatingIncomeLoss>
	<us-gaap:OperatingIncomeLoss contextRef="FD2015Q3QTD" decimals="-3" id="Fact-48024556127C55B4BA413C19A06328F1" unitRef="usd">-8635000</us-gaap:OperatingIncomeLoss>
	<us-gaap:OperatingIncomeLoss contextRef="FD2015Q3YTD" decimals="-3" id="Fact-E23ADCC505B5524B8CA14A510ABFFB7F" unitRef="usd">-26631000</us-gaap:OperatingIncomeLoss>
	<us-gaap:OtherNonoperatingIncomeExpense contextRef="FD2014Q3QTD" decimals="-3" id="Fact-11DCD43436EB54C2B6613BF08B3CE92F" unitRef="usd">597000</us-gaap:OtherNonoperatingIncomeExpense>
	<us-gaap:OtherNonoperatingIncomeExpense contextRef="FD2014Q3YTD" decimals="-3" id="Fact-DD86AAEFEB2154CB95E0C26F1DE6DCA5" unitRef="usd">-59000</us-gaap:OtherNonoperatingIncomeExpense>
	<us-gaap:OtherNonoperatingIncomeExpense contextRef="FD2015Q3QTD" decimals="-3" id="Fact-EA655171D0FD5F2E8B8A4AE4EC47C774" unitRef="usd">307000</us-gaap:OtherNonoperatingIncomeExpense>
	<us-gaap:OtherNonoperatingIncomeExpense contextRef="FD2015Q3YTD" decimals="-3" id="Fact-5720B9EFBEB8579392546B50FAD2554A" unitRef="usd">69000</us-gaap:OtherNonoperatingIncomeExpense>
	<us-gaap:OtherOperatingIncomeExpenseNet contextRef="FD2014Q3QTD" decimals="-3" id="Fact-7EA0E17CFA8754E98CECBBF05E50DC49" unitRef="usd">7035000</us-gaap:OtherOperatingIncomeExpenseNet>
	<us-gaap:OtherOperatingIncomeExpenseNet contextRef="FD2014Q3YTD" decimals="-3" id="Fact-6CE0B08F13145B1399FD73233FD4D63E" unitRef="usd">12190000</us-gaap:OtherOperatingIncomeExpenseNet>
	<us-gaap:OtherOperatingIncomeExpenseNet contextRef="FD2015Q3QTD" decimals="-3" id="Fact-222256C759105FDBB8F3A2D5E2EFEE2F" unitRef="usd">2283000</us-gaap:OtherOperatingIncomeExpenseNet>
	<us-gaap:OtherOperatingIncomeExpenseNet contextRef="FD2015Q3YTD" decimals="-3" id="Fact-736C323115755ABA81C3120F0F35B7E3" unitRef="usd">-1519000</us-gaap:OtherOperatingIncomeExpenseNet>
	<us-gaap:PaymentsToAcquireBusinessesGross contextRef="FD2014Q3YTD" decimals="-3" id="Fact-43E98F519EF65E32BC87A94524475728" unitRef="usd">2315000</us-gaap:PaymentsToAcquireBusinessesGross>
	<us-gaap:PaymentsToAcquireBusinessesGross contextRef="FD2015Q3YTD" decimals="-3" id="Fact-B4E00A70FB575342AFAFA4AEC220FFC6" unitRef="usd">0</us-gaap:PaymentsToAcquireBusinessesGross>
	<us-gaap:PaymentsToAcquireIntangibleAssets contextRef="FD2014Q3YTD_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_gale_CommercialBusinessSegmentMember" decimals="-3" id="Fact-E9449FCADED168F945E4DE6D5A4B7915" unitRef="usd">3056000</us-gaap:PaymentsToAcquireIntangibleAssets>
	<us-gaap:PaymentsToAcquireIntangibleAssets contextRef="FD2015Q3YTD_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_gale_CommercialBusinessSegmentMember" decimals="-3" id="Fact-B2C13EDDE5F3F7D3C6B4DE6D5A480A75" unitRef="usd">500000</us-gaap:PaymentsToAcquireIntangibleAssets>
	<us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="FD2014Q3YTD" decimals="-3" id="Fact-FB6D768224F0500EB34E34DCC429DA39" unitRef="usd">48000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
	<us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="FD2014Q3YTD_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_gale_CommercialBusinessSegmentMember" decimals="-3" id="Fact-59AC33B118FF006F332DDE6CEF79F42E" unitRef="usd">0</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
	<us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="FD2015Q3YTD" decimals="-3" id="Fact-088A778BACB558178C428F7068C38D56" unitRef="usd">81000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
	<us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="FD2015Q3YTD_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_gale_CommercialBusinessSegmentMember" decimals="-3" id="Fact-EF18CD3D6A8047C07576DE6CEF7793CE" unitRef="usd">34000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
	<us-gaap:PreferredStockParOrStatedValuePerShare contextRef="FI2014Q4" decimals="INF" id="Fact-0E317CD1DF83569EB138220A311F6E8B" unitRef="usdPerShare">0.0001</us-gaap:PreferredStockParOrStatedValuePerShare>
	<us-gaap:PreferredStockParOrStatedValuePerShare contextRef="FI2015Q3" decimals="INF" id="Fact-BCDC917A54EB57A6A0762D2AFA6A6448" unitRef="usdPerShare">0.0001</us-gaap:PreferredStockParOrStatedValuePerShare>
	<us-gaap:PreferredStockSharesAuthorized contextRef="FI2014Q4" decimals="INF" id="Fact-C90171844D7A5C33AB63A15B5187FD2A" unitRef="shares">5000000</us-gaap:PreferredStockSharesAuthorized>
	<us-gaap:PreferredStockSharesAuthorized contextRef="FI2015Q3" decimals="INF" id="Fact-0224C3B68B365DF88C8C67D92AE59DF2" unitRef="shares">5000000</us-gaap:PreferredStockSharesAuthorized>
	<us-gaap:PrepaidExpenseAndOtherAssetsCurrent contextRef="FI2014Q4" decimals="-3" id="Fact-24D974BDDCF257D1932AB7A4FA83DF57" unitRef="usd">1237000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
	<us-gaap:PrepaidExpenseAndOtherAssetsCurrent contextRef="FI2015Q3" decimals="-3" id="Fact-FDF531D8B2F25150BA306726DD239B22" unitRef="usd">1174000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
	<us-gaap:ProceedsFromInterestReceived contextRef="FD2014Q3YTD" decimals="-3" id="Fact-ABF138651E3C5D059670FD4BE5AAA5E5" unitRef="usd">13000</us-gaap:ProceedsFromInterestReceived>
	<us-gaap:ProceedsFromInterestReceived contextRef="FD2015Q3YTD" decimals="-3" id="Fact-19844982AE2951DDA488063807AF266B" unitRef="usd">12000</us-gaap:ProceedsFromInterestReceived>
	<us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="FD2014Q3YTD" decimals="-3" id="Fact-6E20B7720CD251838DC26C3B69A7BA6C" unitRef="usd">0</us-gaap:ProceedsFromIssuanceOfCommonStock>
	<us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="FD2015Q3YTD" decimals="-3" id="Fact-3F1FA404BBF95023A3172A0E2BA3480B" unitRef="usd">47416000</us-gaap:ProceedsFromIssuanceOfCommonStock>
	<us-gaap:ProceedsFromIssuanceOrSaleOfEquity contextRef="D2014Q4Nov18_dei_LegalEntityAxis_gale_LincolnParkCapitalLLCMember" decimals="-5" id="Fact-97927CBB593A558EACCAFCD308AD6AB5" unitRef="usd">4900000</us-gaap:ProceedsFromIssuanceOrSaleOfEquity>
	<us-gaap:ProceedsFromIssuanceOrSaleOfEquity contextRef="D2014Q4Nov18_dei_LegalEntityAxis_gale_LincolnParkCapitalLLCMember_us-gaap_StatementClassOfStockAxis_us-gaap_CommonStockMember" decimals="INF" id="Fact-1B2FFC9374F358B8A298C943847C4686" unitRef="usd">50000000</us-gaap:ProceedsFromIssuanceOrSaleOfEquity>
	<us-gaap:ProceedsFromIssuanceOrSaleOfEquity contextRef="D2015Q1Mar18" decimals="-6" id="Fact-B68C70DE4C5F59E099AAF56125A3C0E6" unitRef="usd">38000000</us-gaap:ProceedsFromIssuanceOrSaleOfEquity>
	<us-gaap:ProceedsFromIssuanceOrSaleOfEquity contextRef="FD2014Q3YTD" decimals="-3" id="Fact-AE47D835A219574E97C6DC6961FAD0D4" unitRef="usd">263000</us-gaap:ProceedsFromIssuanceOrSaleOfEquity>
	<us-gaap:ProceedsFromIssuanceOrSaleOfEquity contextRef="FD2015Q3QTD_dei_LegalEntityAxis_gale_LincolnParkCapitalLLCMember" decimals="-5" id="Fact-B483EF13A63358B2972991A58AC09A6C" unitRef="usd">4400000</us-gaap:ProceedsFromIssuanceOrSaleOfEquity>
	<us-gaap:ProceedsFromIssuanceOrSaleOfEquity contextRef="FD2015Q3QTD_dei_LegalEntityAxis_gale_MLVCo.LLCandMaximGroupLLCMember" decimals="-5" id="Fact-22788C5B072D5E24B799C643520D30F1" unitRef="usd">2300000</us-gaap:ProceedsFromIssuanceOrSaleOfEquity>
	<us-gaap:ProceedsFromIssuanceOrSaleOfEquity contextRef="FD2015Q3YTD" decimals="-3" id="Fact-1424A97B485A55D1AAC005CB971B874B" unitRef="usd">309000</us-gaap:ProceedsFromIssuanceOrSaleOfEquity>
	<us-gaap:ProceedsFromStockOptionsExercised contextRef="FD2014Q3YTD" decimals="-3" id="Fact-0DFA0994CF5950EE946641CA7F9F9BC3" unitRef="usd">4342000</us-gaap:ProceedsFromStockOptionsExercised>
	<us-gaap:ProceedsFromStockOptionsExercised contextRef="FD2015Q3YTD" decimals="-3" id="Fact-0F270E5A6440585D960C25317D8A9ED7" unitRef="usd">31000</us-gaap:ProceedsFromStockOptionsExercised>
	<us-gaap:PropertyPlantAndEquipmentNet contextRef="FI2014Q4" decimals="-3" id="Fact-9501075A41385C2B9CECBAE2ADF69B14" unitRef="usd">285000</us-gaap:PropertyPlantAndEquipmentNet>
	<us-gaap:PropertyPlantAndEquipmentNet contextRef="FI2015Q3" decimals="-3" id="Fact-2A07657E07D25191999724EB131E94D7" unitRef="usd">288000</us-gaap:PropertyPlantAndEquipmentNet>
	<us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="FD2015Q3YTD_us-gaap_PropertyPlantAndEquipmentByTypeAxis_gale_EquipmentFurnitureAndFixturesMember_us-gaap_RangeAxis_us-gaap_MaximumMember" id="Fact-E42F818853945A80AA34BE9380175C4F">P5Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
	<us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="FD2015Q3YTD_us-gaap_PropertyPlantAndEquipmentByTypeAxis_gale_EquipmentFurnitureAndFixturesMember_us-gaap_RangeAxis_us-gaap_MinimumMember" id="Fact-5A366F8552AD53628285732FD39F4F71">P3Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
	<us-gaap:RepaymentsOfLongTermDebt contextRef="FD2014Q3YTD" decimals="-3" id="Fact-DA28449753965E4F989AD68BB385DD07" unitRef="usd">908000</us-gaap:RepaymentsOfLongTermDebt>
	<us-gaap:RepaymentsOfLongTermDebt contextRef="FD2015Q3YTD" decimals="-3" id="Fact-7AF7EEF1E3095F40BD8A7E9C97BAF955" unitRef="usd">2902000</us-gaap:RepaymentsOfLongTermDebt>
	<us-gaap:ResearchAndDevelopmentExpense contextRef="FD2014Q3QTD" decimals="-3" id="Fact-9D8578410294509B823AC93F20F696A7" unitRef="usd">7025000</us-gaap:ResearchAndDevelopmentExpense>
	<us-gaap:ResearchAndDevelopmentExpense contextRef="FD2014Q3YTD" decimals="-3" id="Fact-724F0EB53C4F572A8EBDA0989E1999A1" unitRef="usd">21463000</us-gaap:ResearchAndDevelopmentExpense>
	<us-gaap:ResearchAndDevelopmentExpense contextRef="FD2015Q3QTD" decimals="-3" id="Fact-81C18859E3E75E36A6E4CB2C39DB9053" unitRef="usd">5740000</us-gaap:ResearchAndDevelopmentExpense>
	<us-gaap:ResearchAndDevelopmentExpense contextRef="FD2015Q3YTD" decimals="-3" id="Fact-E144216307045CC39D61A2D438643941" unitRef="usd">18762000</us-gaap:ResearchAndDevelopmentExpense>
	<us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue contextRef="FI2014Q4" decimals="-3" id="Fact-D15E7255B4E054AE91ED5D945D0BD969" unitRef="usd">200000</us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue>
	<us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue contextRef="FI2015Q3" decimals="-3" id="Fact-674936CCB6BB52719C7735884EDC3282" unitRef="usd">401000</us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue>
	<us-gaap:SellingGeneralAndAdministrativeExpense contextRef="FD2014Q3QTD" decimals="-3" id="Fact-AEF75EAAA1EA5FFB83C8E3EFD4F58681" unitRef="usd">3542000</us-gaap:SellingGeneralAndAdministrativeExpense>
	<us-gaap:SellingGeneralAndAdministrativeExpense contextRef="FD2014Q3YTD" decimals="-3" id="Fact-13CCB27A53BE58E3AB9724885D32EFE7" unitRef="usd">12744000</us-gaap:SellingGeneralAndAdministrativeExpense>
	<us-gaap:SellingGeneralAndAdministrativeExpense contextRef="FD2015Q3QTD" decimals="-3" id="Fact-3C30178F85445294B3BBD8CFF9CE498B" unitRef="usd">2895000</us-gaap:SellingGeneralAndAdministrativeExpense>
	<us-gaap:SellingGeneralAndAdministrativeExpense contextRef="FD2015Q3YTD" decimals="-3" id="Fact-70EC86B2A3AD5B199D6C75811AE63822" unitRef="usd">7869000</us-gaap:SellingGeneralAndAdministrativeExpense>
	<us-gaap:ShareBasedCompensation contextRef="FD2014Q3YTD" decimals="-3" id="Fact-FFADAE9E939C5254A2FD4291C6C6CA42" unitRef="usd">3878000</us-gaap:ShareBasedCompensation>
	<us-gaap:ShareBasedCompensation contextRef="FD2014Q3YTD_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_gale_CommercialBusinessSegmentMember" decimals="-3" id="Fact-6AADA17348A5F6022528DE69A89A223E" unitRef="usd">557000</us-gaap:ShareBasedCompensation>
	<us-gaap:ShareBasedCompensation contextRef="FD2015Q3YTD" decimals="-3" id="Fact-35A01929EEA95AA081CA6E809594A082" unitRef="usd">1334000</us-gaap:ShareBasedCompensation>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 contextRef="FD2015Q3YTD_us-gaap_TitleOfIndividualAxis_gale_TwoZeroZeroSevenIncentivePlanMember" id="Fact-901A488754EF5AD9988C5F6E49AFF3F9">P4Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate contextRef="FD2014Q3QTD" decimals="INF" id="Fact-6F568B07CBE4571D9C2AD77FF3883DC6" unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate contextRef="FD2014Q3YTD" decimals="INF" id="Fact-3EBDAAE7210752AAB80B344DEE7C8F1D" unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate contextRef="FD2015Q3QTD" decimals="INF" id="Fact-56C438FA56AD5960A8BA414C6730C1E2" unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate contextRef="FD2015Q3YTD" decimals="INF" id="Fact-4623E43768BA5349B9E1D890300F20A5" unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate contextRef="FD2014Q3QTD" decimals="INF" id="Fact-3F3878B606C255E596CA2CBBF6BF8367" unitRef="number">0.791</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate contextRef="FD2014Q3YTD" decimals="INF" id="Fact-4F8B285C73ED5E1496B3CF71AF971D05" unitRef="number">0.7947</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate contextRef="FD2015Q3QTD" decimals="INF" id="Fact-0E685AD956DA5868B6C947F580DBA2E2" unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate contextRef="FD2015Q3YTD" decimals="INF" id="Fact-90A618D74FE15153A14619970072E8E1" unitRef="number">0.742</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate contextRef="FD2014Q3QTD" decimals="INF" id="Fact-2BCBC86126F25F19A357520CADB1B204" unitRef="number">0.0202</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate contextRef="FD2014Q3YTD" decimals="INF" id="Fact-3DADE0137F2A55E2B76BB14E66910F86" unitRef="number">0.0202</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate contextRef="FD2015Q3QTD" decimals="INF" id="Fact-5F86977B12385EE78F573D29E0935855" unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate contextRef="FD2015Q3YTD" decimals="INF" id="Fact-F7CF26E3B9C2561BAD23961CA882726C" unitRef="number">0.015</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized contextRef="FI2015Q3_us-gaap_TitleOfIndividualAxis_gale_TwoZeroZeroSevenIncentivePlanMember" decimals="INF" id="Fact-D160F0A2898F51D092BB23E7E826AC9C" unitRef="shares">26500000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant contextRef="FI2015Q3_us-gaap_TitleOfIndividualAxis_gale_TwoZeroZeroSevenIncentivePlanMember" decimals="INF" id="Fact-A46C590F42405654A9F4A5B79CEE15A3" unitRef="shares">10251000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber contextRef="FI2015Q3" decimals="-3" id="Fact-48F5CB0862E057E6B1DA5C1AA5D585D6" unitRef="shares">6622000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice contextRef="FI2015Q3" decimals="2" id="Fact-A98B0F55D12551F7B2701586F80D03CF" unitRef="usdPerShare">3.32</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue contextRef="FD2015Q3YTD" decimals="-3" id="Fact-6413A7998201526DAEA7D27CEDC443F3" unitRef="usd">37000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod contextRef="FD2015Q3YTD" decimals="-3" id="Fact-C70DC5FAC1255545AB47188211E47777" unitRef="shares">1045000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross contextRef="FD2015Q3YTD" decimals="-3" id="Fact-9CB8851F3A5C586DBF29EA54A3B52166" unitRef="shares">3682000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross contextRef="FD2015Q3YTD_us-gaap_TitleOfIndividualAxis_gale_TwoZeroZeroSevenIncentivePlanMember" decimals="INF" id="Fact-004B34D15BAE58D9A11C751881077DE4" unitRef="shares">11188000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue contextRef="FD2015Q3YTD" decimals="2" id="Fact-D457CFB698635639809501895ADB8552" unitRef="usdPerShare">1.14</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue contextRef="FI2014Q4" id="Fact-779E5D49067551C7A82E52E5632E7F54" unitRef="usd" xsi:nil="true" />
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue contextRef="FI2015Q3" decimals="-3" id="Fact-4F6B6570691D5F5EBE8C9F54ED870214" unitRef="usd">690000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="FI2014Q4" decimals="-3" id="Fact-1D88D6AA3C325EEDB23C164724C481F3" unitRef="shares">8590000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="FI2015Q3" decimals="-3" id="Fact-488CF0094CFF540AB348803AAFA69653" unitRef="shares">11188000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice contextRef="FI2014Q4" decimals="2" id="Fact-7D0BC2A1A3FB5D288B09259A0D39B70A" unitRef="usdPerShare">3.25</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice contextRef="FI2015Q3" decimals="2" id="Fact-BF97760B1D9A57D6B159956F5FD97F61" unitRef="usdPerShare">2.83</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue contextRef="FI2015Q3" decimals="-3" id="Fact-CC6BB54B86B656EAA397054340DD0539" unitRef="usd">618000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue>
	<us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice contextRef="FD2015Q3YTD" decimals="2" id="Fact-FF407AB06305524E809FFFE24442E3C3" unitRef="usdPerShare">0.79</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
	<us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice contextRef="FD2015Q3YTD" decimals="2" id="Fact-AE377335A8385E87AAD7DEEFBA4C1B67" unitRef="usdPerShare">2.44</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
	<us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice contextRef="FD2015Q3YTD" decimals="2" id="Fact-1427B42C5DD751CA840B7A470AD62488" unitRef="usdPerShare">1.73</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
	<us-gaap:SharePrice contextRef="I2014Q4Nov18_dei_LegalEntityAxis_gale_LincolnParkCapitalLLCMember" decimals="INF" id="Fact-6F68F2412B455DC1BBA27818EB1A7917" unitRef="usdPerShare">2.00</us-gaap:SharePrice>
	<us-gaap:SharePrice contextRef="I2015Q1Mar18" decimals="2" id="Fact-75CB849C99625A42B9B2F35F7E606B73" unitRef="usdPerShare">1.56</us-gaap:SharePrice>
	<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="FD2014Q3QTD" id="Fact-391EC19023105903B574CE0B3A50A760">P6Y1M13D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
	<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="FD2014Q3YTD" id="Fact-B1B285B4DCB456CF84A45CDCEAE9D3B4">P6Y1M24D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
	<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="FD2015Q3QTD" id="Fact-B5B5D0BE6F3852FBAA55BD2C93D30068">P0D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
	<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="FD2015Q3YTD" id="Fact-8F869F6DCC2058B6906728168DB60223">P6Y1M2D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
	<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1 contextRef="FD2015Q3YTD_us-gaap_RangeAxis_us-gaap_MaximumMember" id="Fact-47BBF4AFEC035E0C8C892B6969980132">P6Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1>
	<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1 contextRef="FD2015Q3YTD_us-gaap_RangeAxis_us-gaap_MinimumMember" id="Fact-BDC48F87C39152A08424A70692D702BA">P4Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1>
	<us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2 contextRef="FD2015Q3YTD" id="Fact-58162F862FFB5D0C85458C36ED5AA6EF">P10Y</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2>
	<us-gaap:SharesOutstanding contextRef="FI2014Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" decimals="INF" id="Fact-976C7B3DEBB7542B962BE96EE8F0D226" unitRef="shares">130146341</us-gaap:SharesOutstanding>
	<us-gaap:SharesOutstanding contextRef="FI2015Q3_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" decimals="INF" id="Fact-5E4DF37FCD825A398E5FA866378C372E" unitRef="shares">162575446</us-gaap:SharesOutstanding>
	<us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities contextRef="FD2015Q3YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" decimals="INF" id="Fact-280BBDEBB0D15F5CA8A492BBF854EBEE" unitRef="shares">0</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
	<us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans contextRef="FD2015Q3YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" decimals="INF" id="Fact-FCFF353943D95FBF9B68A6AAFA37EE95" unitRef="shares">231312</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
	<us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="D2014Q4Nov18_dei_LegalEntityAxis_gale_LincolnParkCapitalLLCMember_us-gaap_StatementClassOfStockAxis_us-gaap_CommonStockMember" decimals="INF" id="Fact-91AD5C21675451A9885FF3CAB8E77A69" unitRef="shares">631221</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
	<us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="D2015Q1Mar18" decimals="0" id="Fact-041DAB12F7AD5F6C8A6B804AA2ABDD17" unitRef="shares">24358974</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
	<us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="FD2015Q3QTD_dei_LegalEntityAxis_gale_LincolnParkCapitalLLCMember" decimals="-5" id="Fact-C21B76D538FF5182B5BE66A02F00FB5A" unitRef="shares">2700000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
	<us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="FD2015Q3QTD_dei_LegalEntityAxis_gale_MLVCo.LLCandMaximGroupLLCMember" decimals="-5" id="Fact-51B588CE85D15C95B30FEE95BF336B05" unitRef="shares">1400000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
	<us-gaap:StockIssuedDuringPeriodSharesOther contextRef="FD2015Q3YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" decimals="INF" id="Fact-383C6B049C395DAE81E56B1202034033" unitRef="shares">32158685</us-gaap:StockIssuedDuringPeriodSharesOther>
	<us-gaap:StockIssuedDuringPeriodSharesPurchaseOfAssets contextRef="D2014Q4Nov18_dei_LegalEntityAxis_gale_LincolnParkCapitalLLCMember" decimals="-5" id="Fact-3DB8CBC0BAB85B9DBAEB67C2D00CE862" unitRef="shares">2500000</us-gaap:StockIssuedDuringPeriodSharesPurchaseOfAssets>
	<us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised contextRef="FD2015Q3YTD" decimals="-3" id="Fact-598C805DA85A5B1DBCD7BCC1E8DBA773" unitRef="shares">39000</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
	<us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised contextRef="FD2015Q3YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" decimals="INF" id="Fact-E45FAC199EB25AF19FB99AA659EE4422" unitRef="shares">39108</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
	<us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities contextRef="FD2015Q3YTD" decimals="-3" id="Fact-A923E5414FB75FECB8674E28302DD3FB" unitRef="usd">-10296000</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
	<us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities contextRef="FD2015Q3YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" decimals="-3" id="Fact-236F83F77D285A229C81624257378485" unitRef="usd">-10296000</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
	<us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities contextRef="FD2015Q3YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" decimals="-3" id="Fact-1E8B59E8E38555149439B582808094A3" unitRef="usd">0</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
	<us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan contextRef="FD2015Q3YTD" decimals="-3" id="Fact-A5BCD66127145BD4BA35E09A17D5BF5F" unitRef="usd">309000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
	<us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan contextRef="FD2015Q3YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" decimals="-3" id="Fact-4033BEC606125B2A8AF817E1F29EFE3A" unitRef="usd">309000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
	<us-gaap:StockIssuedDuringPeriodValueOther contextRef="FD2015Q3YTD" decimals="-3" id="Fact-17DDBA6ED6BF5160B456A341A007AAD9" unitRef="usd">47416000</us-gaap:StockIssuedDuringPeriodValueOther>
	<us-gaap:StockIssuedDuringPeriodValueOther contextRef="FD2015Q3YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" decimals="-3" id="Fact-8BE85852DBCE57BC9508BB1C5AF34DD0" unitRef="usd">47413000</us-gaap:StockIssuedDuringPeriodValueOther>
	<us-gaap:StockIssuedDuringPeriodValueOther contextRef="FD2015Q3YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" decimals="-3" id="Fact-75FC0A13E19E58B1AD588857E5FD8F1F" unitRef="usd">3000</us-gaap:StockIssuedDuringPeriodValueOther>
	<us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="FD2015Q3YTD" decimals="-3" id="Fact-1B910BA16D8E5D4F9DE7FD4F23A52876" unitRef="usd">31000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
	<us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="FD2015Q3YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" decimals="-3" id="Fact-752FB1DDFE335C9383271F5C52FAE6DB" unitRef="usd">31000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
	<us-gaap:StockholdersEquity contextRef="FI2014Q4" decimals="-3" id="Fact-9991C05A9BF4533C9F1BBF2A1F906854" unitRef="usd">37059000</us-gaap:StockholdersEquity>
	<us-gaap:StockholdersEquity contextRef="FI2015Q3" decimals="-3" id="Fact-9D329074AF1F54A49573EF09FF6A78CE" unitRef="usd">32417000</us-gaap:StockholdersEquity>
	<us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="FI2014Q4" decimals="-3" id="Fact-E0BAD0D13CAC5A69B8B91EEAABA4E62A" unitRef="usd">37059000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
	<us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="FI2014Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" decimals="-3" id="Fact-F7F84F69638B55EFADFBD8A51AC78AD7" unitRef="usd">256377000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
	<us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="FI2014Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" decimals="-3" id="Fact-8A8573828BBE576497726DB6A69D120E" unitRef="usd">12000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
	<us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="FI2014Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember" decimals="-3" id="Fact-B598E7B7FD6F5285BFD8381390484A72" unitRef="usd">-215481000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
	<us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="FI2014Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember" decimals="-3" id="Fact-F018231A77B15937870B5799E7EE1D58" unitRef="usd">-3849000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
	<us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="FI2015Q3" decimals="-3" id="Fact-BCF001FFE92B55E7BC2C53AC86B45600" unitRef="usd">32417000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
	<us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="FI2015Q3_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" decimals="-3" id="Fact-A6CBC0A4CEA65401961D5F007BF32CF2" unitRef="usd">295956000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
	<us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="FI2015Q3_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" decimals="-3" id="Fact-22F420F192955205B99BD781FF8FDEA9" unitRef="usd">15000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
	<us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="FI2015Q3_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember" decimals="-3" id="Fact-A768747BE05B5D00B93384E6AB771503" unitRef="usd">-259705000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
	<us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="FI2015Q3_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember" decimals="-3" id="Fact-17FE9EA6505B5AE6B444DEB51F65EC6E" unitRef="usd">-3849000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
	<us-gaap:TreasuryStockShares contextRef="FI2014Q4" decimals="INF" id="Fact-8E8B18A0E5AE53FABCE5AFDAB92A55FA" unitRef="shares">675000</us-gaap:TreasuryStockShares>
	<us-gaap:TreasuryStockShares contextRef="FI2015Q3" decimals="INF" id="Fact-F6DF4F89315F5B128C23DE837305BEF1" unitRef="shares">675000</us-gaap:TreasuryStockShares>
	<us-gaap:TreasuryStockValue contextRef="FI2014Q4" decimals="-3" id="Fact-FEA0D276799051BF8510B85E389B8EAE" unitRef="usd">3849000</us-gaap:TreasuryStockValue>
	<us-gaap:TreasuryStockValue contextRef="FI2015Q3" decimals="-3" id="Fact-DE5FF7BEBDFB5118928CA856C515B371" unitRef="usd">3849000</us-gaap:TreasuryStockValue>
	<us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted contextRef="FD2014Q3QTD" decimals="0" id="Fact-5252515745975D06966EC451BECAE9FE" unitRef="shares">119038656</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
	<us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted contextRef="FD2014Q3YTD" decimals="0" id="Fact-8E9C575BE44A5FEB89BF0AA3B5573D2C" unitRef="shares">117767791</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
	<us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted contextRef="FD2015Q3QTD" decimals="0" id="Fact-F6631623664C5EA6AE3BD14CDF68401A" unitRef="shares">161857522</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
	<us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted contextRef="FD2015Q3YTD" decimals="0" id="Fact-EB9D63CAA1345215A9657B68DE8896E9" unitRef="shares">153000857</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
	<gale:ChangesInFairValueOfWarrantLiabilityTableTextBlock contextRef="FD2015Q3YTD" id="Fact-D3222F3C9A9B547996095DB7896B0284">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;text-indent:65px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;The changes in fair value of the warrant liability for the nine months ended &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;September&amp;#160;30, 2015&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; were as follows (in thousands):&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:9pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:9pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="28" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td width="24%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="8%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="8%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="8%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="8%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="8%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="8%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="8%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;March 2015 Warrants&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;September&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;2013&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;Warrants&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;December&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;2012&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;Warrants&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;April&amp;#160;2011&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;Warrants&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;March&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;2011&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;Warrants&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;March&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;2010&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;Warrants&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;Total&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:9pt;"&gt;Warrant liability, January&amp;#160;1, 2015&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:9pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:9pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:9pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:9pt;"&gt;2,560&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:9pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:9pt;"&gt;2,027&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:9pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:9pt;"&gt;625&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:9pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:9pt;"&gt;163&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:9pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:9pt;"&gt;8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:9pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:9pt;"&gt;5,383&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:9pt;"&gt;Fair value of warrants issued&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:9pt;"&gt;10,296&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:9pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:9pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:9pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:9pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:9pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:9pt;"&gt;10,296&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:9pt;"&gt;Change in fair value of warrants&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:9pt;"&gt;1,313&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:9pt;"&gt;(157&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:9pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:9pt;"&gt;(162&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:9pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:9pt;"&gt;(10&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:9pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:9pt;"&gt;2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:9pt;"&gt;(4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:9pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:9pt;"&gt;982&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:9pt;"&gt;Warrant liability, September&amp;#160;30, 2015&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:9pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:9pt;"&gt;11,609&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:9pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:9pt;"&gt;2,403&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:9pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:9pt;"&gt;1,865&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:9pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:9pt;"&gt;615&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:9pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:9pt;"&gt;165&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:9pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:9pt;"&gt;4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:9pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:9pt;"&gt;16,661&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</gale:ChangesInFairValueOfWarrantLiabilityTableTextBlock>
	<gale:CommonStockAreReservedForFutureIssuanceTableTextBlock contextRef="FD2015Q3YTD" id="Fact-FD7959E31CBD5F7C83F0BFE397E2074A">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:65px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;"&gt;March 2015 Underwritten Public Offering&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; - On March 18, 2015 the company closed an underwritten public offering of &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;24,358,974&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; units at a price to the public of &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$1.56&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; per unit for gross proceeds of &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$38 million&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; (the "March 2015 Offering"). Each unit consists of one share of common stock, and a warrant to purchase &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;0.50&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; of a share of common stock at an exercise price of &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$2.08&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; per share. The March 2015 Offering included an over-allotment option for the underwriters to purchase an additional &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;3,653,846&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; shares of common stock and/or warrants to purchase up to &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;1,826,923&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; shares of common stock. On March 18, 2015, the underwriters exercised their over-allotment option to purchase warrants to purchase an aggregate of &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;1,826,923&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; shares of common stock. On April 10, 2015, the underwriters exercised their over-allotment option to purchase &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;3,653,846&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; shares of common stock for additional net proceeds of &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$5.4 million&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;. The total net proceeds of the March 2015 Offering, including the exercise of the over-allotment option to purchase the warrants, were &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$40.8 million&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;, after deducting underwriting discounts and commissions and offering expenses payable by the company. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:65px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:66px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Shares of common stock for future issuance are reserved for as follows (in thousands):&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:66px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="3" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td width="84%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="15%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;As of September&amp;#160;30, 2015&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Warrants outstanding&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;22,308&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Stock options outstanding&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;11,188&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Options reserved for future issuance under the Company&amp;#8217;s 2007 Incentive Plan&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;10,251&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Shares reserved for future issuance under the Employee Stock Purchase Plan&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;528&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Total reserved for future issuance&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;44,275&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</gale:CommonStockAreReservedForFutureIssuanceTableTextBlock>
	<gale:ContingentConsiderationPolicyPolicyTextBlock contextRef="FD2015Q3YTD" id="Fact-5354BFF2765452559EB6ABEB7E1D59D7">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;text-indent:65px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;"&gt;Contingent Purchase Price Consideration&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; &amp;#8212; Contingent consideration in business combinations is recorded at the estimated fair value as of the acquisition date. The fair value of the contingent consideration is re-measured at each reporting period with any adjustments in fair value included in our consolidated statement of comprehensive loss.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</gale:ContingentConsiderationPolicyPolicyTextBlock>
	<gale:PatentsAndPatentApplicationCostsPolicyPolicyTextBlock contextRef="FD2015Q3YTD" id="Fact-7F086E266CB059ECB6541EC3F7FDC7AF">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;text-indent:65px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;"&gt;Patents and Patent Application Costs&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; &amp;#8212; Although the company believes that its patents and underlying technology have continuing value, the amount of future benefits to be derived from the patents is uncertain. Patent costs are, therefore, expensed as incurred.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</gale:PatentsAndPatentApplicationCostsPolicyPolicyTextBlock>
	<gale:ScheduleOfEarningPerShareToCommonShareholdersTableTextBlock contextRef="FD2015Q3YTD" id="Fact-AE96B9F459235CC1A58A9C12ACB8B016">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;text-indent:65px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;The following table sets forth the potentially dilutive common shares excluded from the calculation of net loss per common share because their inclusion would be anti-dilutive (in thousands):&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:9pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:9pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="6" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td width="67%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="15%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="15%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;&amp;#160;Three and Nine Months Ended September 30,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;2015&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;2014&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Warrants to purchase common stock&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;22,308&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;8,540&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Options to purchase common stock&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;11,188&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;8,994&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Total&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;33,496&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;17,534&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</gale:ScheduleOfEarningPerShareToCommonShareholdersTableTextBlock>
	<gale:ScheduleOfWarrantActivityTableTableTextBlock contextRef="FD2015Q3YTD" id="Fact-0BA189D51F4D5695A5D8BC8AB593F00B">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;text-indent:65px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;The following is a summary of warrant activity for the nine months ended &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;September&amp;#160;30, 2015&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; (in thousands):&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:9pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:9pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="24" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td width="21%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="8%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="8%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="8%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="8%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="8%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="8%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="8%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="8%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;March 2015 Warrants&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;September&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;2013&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;Warrants&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;December&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;2012&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;Warrants&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;April&amp;#160;2011&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;Warrants&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;March&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;2011&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;Warrants&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;March&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;2010&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;Warrants&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;Consultant&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;and Oxford Warrants&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;Total&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;Outstanding, January 1, 2015&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;3,973&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;3,031&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;615&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;176&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;25&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;720&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;8,540&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;Issued&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;14,006&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;14,006&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;Expired&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;(238&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;(238&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;Outstanding, September&amp;#160;30, 2015&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;14,006&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;3,973&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;3,031&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;615&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;176&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;25&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;482&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;22,308&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;Expiration&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;March 2020&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;September 2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;December 2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:3px double #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;April 2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;March 2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;March 2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;Varies 2014-2020&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</gale:ScheduleOfWarrantActivityTableTableTextBlock>
	<gale:ScheduleOfWarrantValuationAssumptionsTableTextBlock contextRef="FD2015Q3YTD" id="Fact-689298E182D05134A48B2820DED19671">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;text-indent:66px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;The fair value of the warrants is estimated using an appropriate pricing model with the following inputs:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:9pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:9pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="24" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td width="23%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="10%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="10%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="10%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="10%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="10%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="10%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="23" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;As of September&amp;#160;30, 2015&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;March 2015 Warrants&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;September&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;2013&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;Warrants&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;December&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;2012&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;Warrants&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;April&amp;#160;2011&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;Warrants&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;March&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;2011&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;Warrants&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;March&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;2010&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;Warrants&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:9pt;"&gt;Strike price&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:9pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:9pt;"&gt;2.08&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:9pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:9pt;"&gt;2.50&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:9pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:9pt;"&gt;1.83&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:9pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:9pt;"&gt;0.65&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:9pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:9pt;"&gt;0.65&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:9pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:9pt;"&gt;2.02&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:9pt;"&gt;Expected term (years)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:9pt;"&gt;4.47&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:9pt;"&gt;2.97&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:9pt;"&gt;2.23&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:9pt;"&gt;1.56&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:9pt;"&gt;0.43&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:9pt;"&gt;0.49&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:9pt;"&gt;Volatility %&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:9pt;"&gt;74.99&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:9pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:9pt;"&gt;76.85&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:9pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:9pt;"&gt;75.45&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:9pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:9pt;"&gt;69.48&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:9pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:9pt;"&gt;72.42&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:9pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:9pt;"&gt;68.33&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:9pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:9pt;"&gt;Risk-free rate %&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:9pt;"&gt;1.25&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:9pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:9pt;"&gt;0.91&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:9pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:9pt;"&gt;0.70&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:9pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:9pt;"&gt;0.50&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:9pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:9pt;"&gt;0.06&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:9pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:9pt;"&gt;0.08&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:9pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:9pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:9pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="20" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td width="36%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="10%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="10%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="10%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="10%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="10%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="19" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;As of December&amp;#160;31, 2014&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;September&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;2013&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;Warrants&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;December&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;2012&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;Warrants&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;April&amp;#160;2011&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;Warrants&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;March&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;2011&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;Warrants&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;March&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;2010&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;Warrants&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:9pt;"&gt;Strike price&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:9pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:9pt;"&gt;2.50&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:9pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:9pt;"&gt;1.90&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:9pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:9pt;"&gt;0.65&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:9pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:9pt;"&gt;0.65&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:9pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:9pt;"&gt;2.15&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:9pt;"&gt;Expected term (years)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:9pt;"&gt;3.72&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:9pt;"&gt;2.98&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:9pt;"&gt;2.31&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:9pt;"&gt;1.18&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:9pt;"&gt;1.24&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:9pt;"&gt;Volatility %&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:9pt;"&gt;75.60&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:9pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:9pt;"&gt;76.85&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:9pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:9pt;"&gt;78.24&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:9pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:9pt;"&gt;77.38&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:9pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:9pt;"&gt;77.12&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:9pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:9pt;"&gt;Risk-free rate %&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:9pt;"&gt;1.30&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:9pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:9pt;"&gt;1.09&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:9pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:9pt;"&gt;0.80&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:9pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:9pt;"&gt;0.32&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:9pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:9pt;"&gt;0.35&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:9pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</gale:ScheduleOfWarrantValuationAssumptionsTableTextBlock>
	<us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock contextRef="FD2015Q3YTD" id="Fact-465A12695A8D545A93CDB44E070EF081">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#00497f;font-weight:bold;"&gt;Accrued Expenses and Other Current Liabilities&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:65px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:66px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Accrued expenses and other current liabilities consist of the following (in thousands):&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:66px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="8" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td width="71%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="12%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="12%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;September&amp;#160;30, 2015&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;December&amp;#160;31, 2014&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Clinical trial costs&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;5,179&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;6,967&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Compensation and related benefits&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;992&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;1,040&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Professional fees&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;1,121&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;821&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Interest expense&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;37&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;57&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Accrued expenses and other current liabilities&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;7,329&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;8,885&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock>
	<us-gaap:BusinessCombinationsPolicy contextRef="FD2015Q3YTD" id="Fact-0288B2C4C0DC56B2AA7ABDC9F870950E">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;text-indent:66px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;As of &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;September&amp;#160;30, 2015&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;, we determined there were no variable interest entities required to be consolidated.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:66px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;We also perform an analysis to determine if the assets and liabilities acquired in an acquisition qualify as a "business." The excess of the purchase price over the fair value of the net assets acquired can only be recognized as goodwill in a business combination. The Company completes its valuation analysis no later than twelve months from the date of the acquisition.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:BusinessCombinationsPolicy>
	<us-gaap:CashAndCashEquivalentsPolicyTextBlock contextRef="FD2015Q3YTD" id="Fact-4145BCAFCB7651D494848F7CE3778C51">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;text-indent:65px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;"&gt;Cash and Cash Equivalents&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; &amp;#8212; The company considers all highly liquid debt instruments with an original maturity of &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;90&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; days&amp;#160;or less to be cash equivalents. Cash equivalents consist primarily of amounts invested in money market accounts and demand deposits.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:CashAndCashEquivalentsPolicyTextBlock>
	<us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy contextRef="FD2015Q3YTD" id="Fact-CC1B6E2AF76D597096E2F966CA4E44D0">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;text-indent:65px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;"&gt;Restricted Cash&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; &amp;#8212; Restricted cash consists of certificates of deposit on hand with the company&amp;#8217;s financial institutions as collateral for its corporate credit cards&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy>
	<us-gaap:CommitmentsAndContingenciesDisclosureTextBlock contextRef="FD2015Q3YTD" id="Fact-F3C820B67EE15DD7B534F4B2E5E84F05">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-bottom:12px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#00497f;font-weight:bold;"&gt;Legal Proceedings, Commitments and Contingencies&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;"&gt;Legal Proceedings&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:65px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:65px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;"&gt;In re Galena Biopharma, Inc. Securities Litigation and In Re Galena Biopharma, Inc. Derivative Litigation&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;padding-left:48px;text-indent:65px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;On August 4, 2015, plaintiffs in the voluntarily dismissed Delaware derivative action have filed a motion seeking to file under seal a derivative complaint in the District Court.  That motion was granted and on August 31, 2015, that action was consolidated with &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;"&gt;In Re Galena Biopharma, Inc. Derivative Litigation&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;On or about September 15, 2015, a federal securities lawsuit was filed in the U.S. District Court for the District of Oregon entitled, &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;"&gt;Riley v. Galena Biopharma, Inc., et al&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;.  The time to answer or otherwise plead has been extended by agreement of the parties.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;We intend to vigorously defend against and seek resolution to the foregoing claims.  As of September 30, 2015, we have not recorded any&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;font-weight:bold;"&gt; &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;liabilities with respect to the claims in our consolidated financial statements.  We believe that claims are covered under our liability insurance, and we have notified our insurance carriers of the claims.  The insurers have responded by requesting additional information and by reserving their rights under the policies, including the rights to deny coverage under various policy exclusions.  Subject to their reservation of rights, we are being reimbursed by our insurance carriers for significant portion of all legal fees relating to our defense of the claims. We have entered into certain undertaking agreements with our directors related to the litigation by which we have agreed to advance reasonable legal fees and costs for the litigation under certain conditions.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;"&gt;SEC Investigation&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;We are aware that the Securities and Exchange Commission (SEC) is investigating certain matters relating to the use of certain outside investor-relations professionals by us and other public companies.  We have been in contact with the SEC staff through our counsel and are cooperating with the investigation.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;"&gt;ANDA Litigation&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; On October 23, 2015, Orexo AB (&amp;#8220;Orexo&amp;#8221;) and Galena Biopharma, Inc. (the &amp;#8220;Company&amp;#8221;) entered into a settlement and license agreement with Actavis Laboratories FL, Inc. (&amp;#8220;Actavis&amp;#8221;) to resolve pending patent litigation brought by the Orexo against Actavis involving Abstral&amp;#174; (fentanyl) sublingual tablets.  The pending patent litigation was filed by Orexo in the U.S. District Court for the District of New Jersey in response to Actavis&amp;#8217; submission of an Abbreviated New Drug Application (&amp;#8220;ANDA&amp;#8221;) to the U.S. Food and Drug Administration (&amp;#8220;FDA&amp;#8221;), seeking marketing approval for a generic version of Abstral.  As a result of the settlement and license agreement, Actavis will be permitted to enter the market with a generic or authorized generic version of Abstral in the United States June 2018 or earlier under certain circumstances. The Court has entered an order dismissing with prejudice the litigation against Actavis.  Details of the settlement are confidential, and the parties have submited the agreement to the Federal Trade Commission and the Department of Justice, as required by federal law. The expiration date for the latest expiring Abstral patent listed in the FDA&amp;#8217;s Orange Book is September 2019.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;"&gt;Commitments&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;The company acquires assets still in development and enters into research and development arrangements with third parties that often require milestone and royalty payments based on the progress of the asset through development stages. Milestone payments may be required, for example, upon approval of the product for marketing by a regulatory agency. In certain agreements, the company is required to make royalty payments based upon a percentage of the sales.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;These arrangements may be material individually, and in the unlikely event that milestones for multiple products covered by these arrangements were reached in the same period, the aggregate charge to expense could be material to the results of operations. In addition, these arrangements often give the company the discretion to unilaterally terminate development of the product, which the company might do for clinical, business or other reasons, which would allow the company to avoid making the contingent payments.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;The company applies the disclosure provisions FASB ASC Topic 460 (&amp;#8220;ASC 460&amp;#8221;), &amp;#8220; &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;"&gt;Guarantor&amp;#8217;s Accounting and Disclosure Requirements for Guarantees, Including Indirect Guarantees of Indebtedness of Others&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; &amp;#8221;, to its agreements that contain guarantee or indemnification clauses. The company provides (i)&amp;#160;indemnifications of varying scope and size to certain investors and other parties for certain losses suffered or incurred by the indemnified party in connection with various types of third-party claims and (ii)&amp;#160;indemnifications of varying scope and size to officers and directors against third party claims arising from the services they provide to us. These indemnifications give rise only to the disclosure provisions of ASC&amp;#160;460. To date, the company has not incurred costs as a result of these obligations and does not expect to incur material costs in the future. Accordingly, the company has not accrued any liabilities in its financial statements related to these indemnifications.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
	<us-gaap:ComprehensiveIncomePolicyPolicyTextBlock contextRef="FD2015Q3YTD" id="Fact-7BB93C1F00EE5F84829697A0B510C9FD">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;text-indent:65px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;"&gt;Comprehensive Loss&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; &amp;#8212; Comprehensive loss consists of our net loss, with no other comprehensive income items for the periods presented.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:65px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ComprehensiveIncomePolicyPolicyTextBlock>
	<us-gaap:ConcentrationRiskCreditRisk contextRef="FD2015Q3YTD" id="Fact-A198873A79F25F8A968A5325E802ADDA">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;text-indent:65px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;"&gt;Concentrations of Credit Risk&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; &amp;#8212; Financial instruments that potentially subject the company to significant concentrations of credit risk consist principally of cash and cash equivalents. The company maintains cash balances in several accounts with two banks, which at times are in excess of federally insured limits. As of &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;September&amp;#160;30, 2015&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;, the company&amp;#8217;s cash equivalents were invested in money market mutual funds. The company&amp;#8217;s investment policy does not allow investment in any debt securities rated less than &amp;#8220;investment grade&amp;#8221; by national ratings services. The company has not experienced any losses on its deposits of cash and cash equivalents. The company maintains significant cash and cash equivalents at two financial institutions that are in excess of federally insured limits.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ConcentrationRiskCreditRisk>
	<us-gaap:ConsolidationPolicyTextBlock contextRef="FD2015Q3YTD" id="Fact-2AAD403826045643AB1CFEF98C10535E">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;text-indent:65px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;"&gt;Principles of Consolidation&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; &amp;#8212;&amp;#160;The consolidated financial statements include the accounts of Galena and its wholly owned subsidiaries. All material intercompany accounts have been eliminated in consolidation.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ConsolidationPolicyTextBlock>
	<us-gaap:DebtDisclosureTextBlock contextRef="FD2015Q3YTD" id="Fact-534656C897B65965AFDA924FA22DE4AA">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#00497f;font-weight:bold;"&gt;Long-term Debt&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:65px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:66px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;On May 8, 2013 we entered into a loan and security agreement with Oxford Finance LLC, as collateral agent, and related lenders under which we borrowed the first tranche of &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$10 million&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; (the "Loan"). The Loan payment terms include &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;12&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; months of interest-only payments at the fixed coupon rate of &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;8.45%&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;, followed by &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;30&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; months of amortization of principal and interest until maturity in November 2016. In connection with the Loan, we paid the lender a &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;1%&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; cash facility fee and a &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;5.5%&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; cash final payment and granted to the lenders &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;seven&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;-year warrants to purchase up to &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;182,186&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; shares of our common stock at an exercise price of &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$2.47&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;, which equaled a &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;20&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;-day average market price of our common stock prior to the date of the grant.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:DebtDisclosureTextBlock>
	<us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock contextRef="FD2015Q3YTD" id="Fact-64396F39C37D5DBBB5605A4702E5FD25">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#00497f;font-weight:bold;"&gt;Stock-Based Compensation&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:65px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:65px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;"&gt;Options to Purchase Shares of Common Stock&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; &amp;#8212; The company follows the provisions ASC&amp;#160;718, which requires the measurement and recognition of compensation expense for all share-based payment awards made to employees, non-employee directors, including employee stock options. Stock compensation expense based on the grant date fair value estimated in accordance with the provisions of ASC&amp;#160;718 is recognized as an expense over the requisite service period.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:65px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:65px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;For stock options and warrants granted in consideration for services rendered by non-employees, the company recognizes compensation expense in accordance with the requirements of ASC Topic 505-50. Non-employee option and warrant grants that do not vest immediately upon grant are recorded as an expense over the vesting period. At the end of each financial reporting period prior to vesting, the value of these options and warrants, as calculated using the Black-Scholes option-pricing model, is re-measured using the fair value of the company&amp;#8217;s common stock and the non-cash compensation recognized during the period is adjusted accordingly. Since the fair market value of options and warrants granted to non-employees is subject to change in the future, the amount of the future compensation expense will include fair value re-measurements until the stock options and warrants are fully vested.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:65px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:65px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;The following table summarizes the components of stock-based compensation expense in the condensed consolidated statements of comprehensive loss for the three and nine months ended &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;September&amp;#160;30, 2015&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; and 2014, respectively (in thousands):&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:65px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="16" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td width="41%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="12%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="12%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="12%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="12%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;Three Months Ended September 30,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;Nine Months Ended September 30,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;2015&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;2014&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;2015&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;2014&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Research and development&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;83&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;92&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;253&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;438&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;General and administrative&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;492&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;990&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;1,081&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;3,440&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Total stock-based compensation from continuing operations&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;575&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;1,082&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;1,334&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;3,878&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Stock based compensation from discontinued operations&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;275&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;217&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;788&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;557&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:66px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;The company uses the Black-Scholes option-pricing model and the following weighted-average assumptions to determine the fair value of all its stock options granted:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:9pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:9pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="12" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td width="41%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="13%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="13%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="13%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="13%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;Three Months Ended September 30,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;Nine Months Ended September 30,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;2015&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;2014&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;2015&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;2014&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Risk free interest rate&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;2.02&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;1.50&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;2.02&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Volatility&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;79.10&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;74.20&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;79.47&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Expected lives (years)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;0.00&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;6.12&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;6.09&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;6.15&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Expected dividend yield&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:65px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:65px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;The weighted-average fair value of options granted during the nine months ended &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;September&amp;#160;30, 2015&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; was &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$1.14&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; per share. There were no stock options granted during the three months ended &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;September&amp;#160;30, 2015&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:65px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:65px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;The company&amp;#8217;s expected common stock price volatility assumption is based upon the company's own implied volatility in combination with the implied volatility of a basket of comparable companies. The expected life assumptions for employee grants were based upon the simplified method provided for under ASC&amp;#160;718-10, which averages the contractual term of the company&amp;#8217;s options of &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;ten years&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; with the average vesting term of &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;four years&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; for an average of &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;six years&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;. The expected life assumptions for non-employees were based upon the contractual term of the option. The dividend yield assumption is zero, because the company has never paid cash dividends and presently has no intention to do so. The risk-free interest rate used for each grant was also based upon prevailing short-term interest rates. The company has estimated an annualized forfeiture rate of &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;15%&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; for options granted to its employees, &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;8%&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; for options granted to senior management and zero for non-employee directors. The company will record additional expense if the actual forfeitures are lower than estimated and will record a recovery of prior expense if the actual forfeiture rates are higher than estimated.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:65px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:65px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;As of &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;September&amp;#160;30, 2015&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;, there was &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$4,815,000&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; of unrecognized compensation cost related to outstanding options that is expected to be recognized as a component of the company&amp;#8217;s operating expenses over a weighted-average period of &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;2.34&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; years.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:65px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:65px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;As of &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;September&amp;#160;30, 2015&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;, an aggregate of &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;26,500,000&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; shares of common stock were reserved for issuance under the company&amp;#8217;s 2007 Incentive Plan, including &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;11,188,000&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; shares subject to outstanding common stock options granted under the plan and &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;10,251,000&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; shares available for future grants. The administrator of the plan determines the times when an option may become exercisable. Vesting periods of options granted to date have not exceeded &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;four years&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;. The options will expire, unless previously exercised, no later than &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;ten years&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; from the grant date. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:65px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:65px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;The following table summarizes option activity of the company:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:65px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="11" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td width="56%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="13%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="12%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="12%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;Total&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;Number of&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;Shares &lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;(In Thousands)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;Weighted&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;Average&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;Exercise&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;Price&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;Aggregate&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;Intrinsic&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;Value&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;(In Thousands)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Outstanding at January&amp;#160;1, 2015&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;8,590&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;3.25&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Granted&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;3,682&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;1.73&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Exercised&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;(39&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;0.79&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;37&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Cancelled&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;(1,045&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;2.44&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;21&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Outstanding at September&amp;#160;30, 2015&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;11,188&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;2.83&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;690&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Options exercisable at September&amp;#160;30, 2015&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;6,622&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;3.32&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;618&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:65px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:65px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;The aggregate intrinsic values of outstanding and exercisable options at &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;September&amp;#160;30, 2015&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; were calculated based on the closing price of the company&amp;#8217;s common stock as reported on The NASDAQ Capital Market on &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;September&amp;#160;30, 2015&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; of &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$1.58&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; per share. The aggregate intrinsic value equals the positive difference between the closing fair market value of the company&amp;#8217;s common stock and the exercise price of the underlying options.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
	<us-gaap:DiscontinuedOperationsPolicyTextBlock contextRef="FD2015Q3YTD" id="Fact-3056F48ED5D9B1750C2DDED66824D1CF">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;text-align:left;text-indent:65px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;"&gt;Discontinued Operations - &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;As described in Note 12, we met the relevant criteria for reporting our commercial business as held for sale and in discontinued operations in the accompanying unaudited interim financial statements as of the three and nine month periods ended September&amp;#160;30, 2015 and 2014, pursuant to FASB Topic 205-20, Presentation of Financial Statements - Discontinued Operations, and FASB Topic 360, Property, Plant, and Equipment.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:DiscontinuedOperationsPolicyTextBlock>
	<us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock contextRef="FD2015Q3YTD" id="Fact-9A5A274AE61C0D15C9E8DE2A1552C695">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#00497f;font-weight:bold;"&gt;Discontinued Operations, Assets Held for Sale&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:65px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:66px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;As part of the company's strategic objective to focus its resources on its development pipeline, our management and board of directors have decided and committed to pursue a plan to sell or otherwise divest the company&amp;#8217;s commercial business.  A brief summary of each product in our commercial business is provided below.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:66px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:66px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Abstral&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:pt"&gt;&amp;#174;&lt;/sup&gt;&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; (fentanyl) Sublingual Tablets, is a treatment option for inadequately controlled breakthrough cancer pain (BTcP), which is estimated to affect more than &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;50%&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; of all cancer patients. Abstral is approved by the FDA, and is a sublingual (under the tongue) tablet for the management of breakthrough pain in patients with cancer, &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;18&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; years of age and older, who are already receiving, and who are tolerant to, opioid therapy for their persistent baseline cancer pain. The Abstral formulation delivers the analgesic power and increased bioavailability of micronized fentanyl in a sublingual tablet that is designed to dissolve under the tongue in seconds and provide relief of breakthrough pain within minutes. Abstral is a transmucosal immediate release fentanyl (TIRF) product with product class oversight by the TIRF Risk Evaluation and Mitigation Strategy (REMS) access program. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:66px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:66px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Zuplenz&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:pt"&gt;&amp;#174;&lt;/sup&gt;&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; (ondansetron) Oral Soluble Film, is approved by the FDA in adult patients for the prevention of highly and moderately emetogenic chemotherapy-induced nausea and vomiting (CINV), radiotherapy-induced nausea and vomiting (RINV), and post-operative nausea and vomiting (PONV). Zuplenz is also approved in pediatric patients treated with moderately emetogenic CINV. Nausea and vomiting are two of the most common side-effects experienced by post-surgery patients and patients receiving chemotherapy or radiation. Zuplenz utilizes MonoSol&amp;#8217;s proprietary PharmFilm&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:pt"&gt;&amp;#174; &lt;/sup&gt;&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;technology, an oral soluble film that dissolves on the tongue in less than 30 seconds, therefore eliminating the burden of swallowing pills during periods of emesis. The active pharmaceutical ingredient in Zuplenz, ondansetron, belongs to a class of medications called serotonin 5-HT3 receptor antagonists and works by blocking the action of serotonin, a natural substance that may cause nausea and vomiting. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:66px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:66px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;The company met the relevant criteria for reporting the commercial business as held for sale and in discontinued operations in the accompanying unaudited interim financial statements as of and for the three and nine month periods ended September 30, 2015, and 2014, pursuant to FASB Topic 205-20,&amp;#160;Presentation of Financial Statements--Discontinued Operations, and FASB Topic 360,&amp;#160;Property, Plant, and Equipment. The company has assessed the commercial business net asset group for impairment pursuant to FASB Topic 360, as discussed in Note 2, determining that the carrying value exceed the fair value of the assets, therefore has recorded a $8.1 million impairment charge as of September 30, 2015. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:66px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:66px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;The company entered into an agreement with a third party firm to assist the company with the divestiture of its commercial operations including identifying potential acquirers. Pursuant to the terms of the agreement, in the event the company successfully completes a divestiture through the sale of its commercial operations to a third-party, the company is obligated to pay a success fee to the third party firm in an amount up to &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$900,000&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; of cash consideration received, 5% of realized future revenue and payment streams, as well as reimbursement for reasonable out-of-pocket expenses. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:66px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:66px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;The company has also entered into compensatory arrangements related to the divestiture of our commercial business with certain members of commercial management.  Under the terms of these arrangements, if the company meets certain sales and margin numbers in the fourth quarter of 2015 and successfully completes a divestiture through sale of its commercial operations to a third-party, the company may pay a retention fee to the three employees in a combined total amount equal to the lesser of &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$400,000&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; or &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;3%&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; of cash consideration received as upfront payment in the transaction, with payment to each employee portion conditioned on his or her continued employment through the closing date of such a divestiture of one or both products and satisfaction of other terms. These employees may also receive severance payments equal to one month&amp;#8217;s salary for between four and seven months in event the divestiture does not result in continued employment with the acquirer&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:66px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;The following table presents a reconciliation of the carrying amounts of assets and liabilities of the commercial operations to assets held for sale, net in the balance sheets (in thousands):&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:center;text-indent:0px;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:682px;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="8" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td width="490px" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="8px" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="79px" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="4px" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="5px" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="8px" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="79px" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="4px" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;September 30, 2015&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;December 31, 2014&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="8" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Carrying amounts of assets included as part of discontinued operations:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Accounts receivable&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;1,238&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;1,535&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Inventories&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;1,318&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;655&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Prepaid expenses and other current assets&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;1,064&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;1,747&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Equipment and furnishings, net&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;241&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;270&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Abstral rights, net&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;13,738&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;14,533&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Zuplenz rights&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;8,101&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;8,101&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Goodwill&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;172&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;172&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Impairment charge from classification as assets held for sale&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;(8,071&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Total current assets held for sale&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;17,801&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;27,013&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="8" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Carrying amounts of liabilities included as part of discontinued operations:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Accounts payable&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;1,359&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;385&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Accrued expenses and other current liabilities&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;6,338&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;6,784&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Total current liabilities held for sale&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;7,697&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;7,169&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:center;text-indent:66px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:66px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;The following table represents the components attributable to the commercial operations that are presented in the consolidated statement of comprehensive loss as discontinued operations (in thousands):&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:center;text-indent:0px;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:681px;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="16" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td width="300px" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="8px" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="78px" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="4px" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="5px" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="8px" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="77px" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="4px" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="5px" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="8px" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="78px" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="4px" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="5px" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="8px" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="78px" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="4px" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;Three Months Ended September 30,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;Nine Months Ended September 30,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;2015&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;2014&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;2015&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;2014&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Net revenue&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;2,166&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;1,620&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;8,298&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;6,124&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Cost of revenue&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;(712&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;(247&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;(1,573&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;(925&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Amortization of certain acquired intangible assets&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;(208&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;(70&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;(795&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;(259&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Research and development&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;(160&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;(219&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;(339&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;(619&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Selling, general, and administrative&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;(4,672&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;(3,725&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;(13,577&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;(10,954&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Non-operating income (expense)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;(17&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;(17&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Impairment charge from classification as assets held for sale&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;(8,071&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;(8,071&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Loss from discontinued operations&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;(11,674&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;(2,641&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;(16,074&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;(6,633&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:66px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:66px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;The following table presents significant operating non-cash items and capital expenditures related to discontinued operations (in thousands):&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:66px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:0px;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:682px;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="8" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td width="490px" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="8px" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="79px" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="4px" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="5px" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="8px" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="79px" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="4px" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;September 30, 2015&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;September 30, 2014&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Impairment of assets held for sale&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;8,071&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Depreciation and amortization&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;858&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;319&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Stock-based compensation&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;788&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;557&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Purchases of property and equipment&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;(34&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Cash paid for acquisition of Zuplenz rights&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;(500&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;(3,056&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock>
	<us-gaap:EarningsPerSharePolicyTextBlock contextRef="FD2015Q3YTD" id="Fact-D62E7E85DD8B5803A69BF81ED6912614">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#00497f;font-weight:bold;"&gt;Net Loss Per Share&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:65px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:65px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;The company accounts for and discloses net loss per common share in accordance with FASB ASC Topic 260 &amp;#8220;&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;"&gt;Earnings per Share.&amp;#8221;&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; Basic net loss per common share is computed by dividing net loss attributable to common stockholders by the weighted-average number of common shares outstanding. Diluted net loss per common share is computed by dividing net loss attributable to common stockholders by the weighted-average number of common shares that would have been outstanding during the period assuming the issuance of common shares for all potential dilutive common shares outstanding. Potential common shares consist of shares issuable upon the exercise of stock options and warrants. &lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:EarningsPerSharePolicyTextBlock>
	<us-gaap:EarningsPerShareTextBlock contextRef="FD2015Q3YTD" id="Fact-E3B2F492E7F1518189BD05A130913DCB">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#00497f;font-weight:bold;"&gt;Net Loss Per Share&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:65px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:65px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;The company accounts for and discloses net loss per common share in accordance with FASB ASC Topic 260 &amp;#8220;&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;"&gt;Earnings per Share.&amp;#8221;&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; Basic net loss per common share is computed by dividing net loss attributable to common stockholders by the weighted-average number of common shares outstanding. Diluted net loss per common share is computed by dividing net loss attributable to common stockholders by the weighted-average number of common shares that would have been outstanding during the period assuming the issuance of common shares for all potential dilutive common shares outstanding. Potential common shares consist of shares issuable upon the exercise of stock options and warrants. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:65px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:65px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;The following table sets forth the potentially dilutive common shares excluded from the calculation of net loss per common share because their inclusion would be anti-dilutive (in thousands):&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:9pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:9pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="6" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td width="67%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="15%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="15%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;&amp;#160;Three and Nine Months Ended September 30,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;2015&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;2014&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Warrants to purchase common stock&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;22,308&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;8,540&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Options to purchase common stock&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;11,188&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;8,994&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Total&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;33,496&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;17,534&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:EarningsPerShareTextBlock>
	<us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock contextRef="FD2015Q3YTD" id="Fact-8471F8F916FE5B66BAC37F5296030D8B">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;text-indent:65px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;A reconciliation of the beginning and ending Level 3 liabilities for the nine months ended &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;September&amp;#160;30, 2015&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; is as follows (in thousands):&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:9pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:9pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="4" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td width="86%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="12%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;Fair Value&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;Measurements&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;Using&amp;#160;Significant&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;Unobservable&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;Inputs&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;(Level 3)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Balance, January&amp;#160;1, 2015&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;6,651&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Change in the estimated fair value of the contingent purchase price consideration&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;(69&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Balance at September&amp;#160;30, 2015&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;6,582&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock>
	<us-gaap:FairValueMeasurementPolicyPolicyTextBlock contextRef="FD2015Q3YTD" id="Fact-49D2A29B2E31553C9D25DC6F3D6FCB35">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#00497f;font-weight:bold;"&gt;Fair Value Measurements&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:65px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-indent:65px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;The company follows ASC&amp;#160;820, &amp;#8220;Fair Value Measurements and Disclosures,&amp;#8221; (&amp;#8220;ASC 820&amp;#8221;) for the company&amp;#8217;s financial assets and liabilities that are re-measured and reported at fair value at each reporting period, and are re-measured and reported at fair value at least annually using a fair value hierarchy that is broken down into three levels. Level inputs are defined as follows:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;padding-left:108px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Level&amp;#160;1&amp;#160;&amp;#8212; quoted prices in active markets for identical assets or liabilities.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;padding-left:108px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Level&amp;#160;2&amp;#160;&amp;#8212; other significant observable inputs for the assets or liabilities through corroboration with market data at the measurement date.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-left:108px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Level&amp;#160;3&amp;#160;&amp;#8212; significant unobservable inputs that reflect management&amp;#8217;s best estimate of what market participants would use to price the assets or liabilities at the measurement date.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:106px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:66px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;The company categorized its cash equivalents as Level&amp;#160;1. The valuations for Level&amp;#160;1 were determined based on a &amp;#8220;market approach&amp;#8221; using quoted prices in active markets for identical assets. Valuation of these assets does not require a significant degree of judgment. The company categorized its warrants potentially settleable in cash as Level&amp;#160;2 inputs. The warrants are measured at market value on a recurring basis and are being marked to market each quarter-end until they are completely settled. The warrants are valued using an appropriate pricing model, using assumptions consistent with our application of ASC&amp;#160;718. The contingent purchase price consideration is categorized as Level 3 inputs and is measured at its estimated fair value on a recurring basis and is adjusted at each quarter-end until it is completely settled. The contingent purchase price consideration is valued based on the expected timing of milestones, the expected probability of success for each milestone and discount rates based on a corporate debt interest rate index publicly issued.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:FairValueMeasurementPolicyPolicyTextBlock>
	<us-gaap:FairValueOfFinancialInstrumentsPolicy contextRef="FD2015Q3YTD" id="Fact-0AA5DF14B6415FEA9112918A3CD30A7A">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;text-indent:65px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;"&gt;Fair Value of Financial Instruments&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; &amp;#8212; The carrying amounts reported in the balance sheet for cash equivalents, accounts receivable, accounts payable, and capital leases approximate their fair values due to their short-term nature and market rates of interest.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:FairValueOfFinancialInstrumentsPolicy>
	<us-gaap:FinancialInstrumentsDisclosureTextBlock contextRef="FD2015Q3YTD" id="Fact-71D224D99D8C5EBDB4836DB0EE2F35D4">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#00497f;font-weight:bold;"&gt;Fair Value Measurements&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:65px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-indent:65px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;The company follows ASC&amp;#160;820, &amp;#8220;Fair Value Measurements and Disclosures,&amp;#8221; (&amp;#8220;ASC 820&amp;#8221;) for the company&amp;#8217;s financial assets and liabilities that are re-measured and reported at fair value at each reporting period, and are re-measured and reported at fair value at least annually using a fair value hierarchy that is broken down into three levels. Level inputs are defined as follows:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;padding-left:108px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Level&amp;#160;1&amp;#160;&amp;#8212; quoted prices in active markets for identical assets or liabilities.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;padding-left:108px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Level&amp;#160;2&amp;#160;&amp;#8212; other significant observable inputs for the assets or liabilities through corroboration with market data at the measurement date.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-left:108px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Level&amp;#160;3&amp;#160;&amp;#8212; significant unobservable inputs that reflect management&amp;#8217;s best estimate of what market participants would use to price the assets or liabilities at the measurement date.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:106px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:66px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;The company categorized its cash equivalents as Level&amp;#160;1. The valuations for Level&amp;#160;1 were determined based on a &amp;#8220;market approach&amp;#8221; using quoted prices in active markets for identical assets. Valuation of these assets does not require a significant degree of judgment. The company categorized its warrants potentially settleable in cash as Level&amp;#160;2 inputs. The warrants are measured at market value on a recurring basis and are being marked to market each quarter-end until they are completely settled. The warrants are valued using an appropriate pricing model, using assumptions consistent with our application of ASC&amp;#160;718. The contingent purchase price consideration is categorized as Level 3 inputs and is measured at its estimated fair value on a recurring basis and is adjusted at each quarter-end until it is completely settled. The contingent purchase price consideration is valued based on the expected timing of milestones, the expected probability of success for each milestone and discount rates based on a corporate debt interest rate index publicly issued.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:66px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:66px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;As discussed in Note 12, the Company met the relevant criteria for reporting the commercial operations as held for sale as of September 30, 2015, and as a result, assessed the commercial asset group for impairment pursuant to ASC Topic 360, &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;"&gt;Property, Plant, and Equipment.&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; The net carrying value of the commercial asset group was compared to its fair value as of September 30, 2105. The Company determined that the fair value using a risk adjusted net present value of deal consideration received from bids from potential acquirers, which the Company concluded was a Level 3 input. The Company determined that the carrying value exceeded its fair value and as a result recorded an $8.1 million impairment charge on assets classified as held for sale in the quarterly period ended September 30, 2015.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:66px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;The following tables present information about our assets and liabilities measured at fair value on a recurring basis in the condensed consolidated balance sheets (in thousands):&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:9pt;"&gt;&amp;#160;&lt;/font&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="16" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td width="41%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="12%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="12%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="12%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="12%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;font-weight:bold;text-decoration:underline;"&gt;Description&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;September&amp;#160;30, 2015&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;Quoted&amp;#160;Prices&amp;#160;In&amp;#160;&amp;#160;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;Active Markets&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;(Level 1)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;Significant&amp;#160;Other&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;Observable&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;Inputs (Level 2)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;Unobservable&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;Inputs&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;(Level 3)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Assets:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Cash equivalents&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;32,618&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;32,618&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Assets held for sale&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;17,801&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;17,801&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Total assets measured and recorded at fair value&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;50,419&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;32,618&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;17,801&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Liabilities:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Warrants potentially settleable in cash&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;16,661&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;16,661&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Contingent purchase price consideration&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;6,582&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;6,582&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Total liabilities measured and recorded at fair value&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;23,243&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;16,661&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;6,582&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="16" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td width="41%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="12%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="12%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="12%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="12%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;font-weight:bold;text-decoration:underline;"&gt;Description&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;December&amp;#160;31, 2014&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;Quoted&amp;#160;Prices&amp;#160;In&amp;#160;&amp;#160;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;Active Markets&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;(Level 1)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;Significant&amp;#160;Other&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;Observable&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;Inputs (Level 2)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;Unobservable&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;Inputs&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;(Level 3)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Assets:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Cash equivalents&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;19,477&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;19,477&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Total assets measured and recorded at fair value&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;19,477&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;19,477&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Liabilities:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Warrants potentially settleable in cash&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;5,383&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;5,383&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Contingent purchase price consideration&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;6,651&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;6,651&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Total liabilities measured and recorded at fair value&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;12,034&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;5,383&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;6,651&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:65px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:65px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;The company did not transfer any financial instruments into or out of Level 3 classification during the three and nine months ended &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;September&amp;#160;30, 2015&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; or 2014. A reconciliation of the beginning and ending Level 3 liabilities for the nine months ended &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;September&amp;#160;30, 2015&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; is as follows (in thousands):&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:9pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:9pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="4" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td width="86%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="12%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;Fair Value&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;Measurements&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;Using&amp;#160;Significant&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;Unobservable&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;Inputs&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;(Level 3)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Balance, January&amp;#160;1, 2015&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;6,651&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Change in the estimated fair value of the contingent purchase price consideration&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;(69&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Balance at September&amp;#160;30, 2015&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;6,582&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:65px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;The fair value of the contingent purchase price consideration is measured at the end of each reporting period using Level 3 inputs in a probability-weighted, discounted cash-outflow model. The significant unobservable assumptions include the probability of achieving each milestone, the date we expect to reach the milestone, and a determination of present value factors used to discount future expected cash outflows.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:FinancialInstrumentsDisclosureTextBlock>
	<us-gaap:GoodwillAndIntangibleAssetsPolicyTextBlock contextRef="FD2015Q3YTD" id="Fact-37235AB8700F50779B1CC69017097EB6">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-bottom:8px;text-indent:65px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;"&gt;Goodwill and Intangible Assets&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; &amp;#8212; Goodwill and indefinite-lived intangible assets are not amortized but are tested annually for impairment at the reporting unit level, or more frequently if events and circumstances indicate impairment may have occurred. Factors the company considers important that could trigger an interim review for impairment include, but are not limited to, the following:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-left:67px;padding-bottom:8px;text-align:left;"&gt;&lt;font style="padding-bottom:8px;text-align:left;font-family:Helvetica,sans-serif;font-size:10pt;padding-right:28px;"&gt;&amp;#8226;&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Significant changes in the manner of its use of acquired assets or the strategy for its overall business;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-left:67px;padding-bottom:8px;text-align:left;"&gt;&lt;font style="padding-bottom:8px;text-align:left;font-family:Helvetica,sans-serif;font-size:10pt;padding-right:28px;"&gt;&amp;#8226;&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Significant negative industry or economic trends;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-left:67px;padding-bottom:8px;text-align:left;"&gt;&lt;font style="padding-bottom:8px;text-align:left;font-family:Helvetica,sans-serif;font-size:10pt;padding-right:28px;"&gt;&amp;#8226;&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Significant decline in stock price for a sustained period; and&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-left:67px;text-align:left;"&gt;&lt;font style="text-align:left;font-family:Helvetica,sans-serif;font-size:10pt;padding-right:28px;"&gt;&amp;#8226;&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Significant decline in market capitalization relative to net book value.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:65px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:65px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Goodwill and other intangible assets with indefinite lives are evaluated for impairment first by a qualitative assessment to determine the likelihood of impairment. If it is determined that impairment is more likely than not, the company will then proceed to the two step impairment test. The first step is to compare the fair value of the reporting unit to the carrying amount of the reporting unit. If the carrying amount exceeds the fair value, a second step must be followed to calculate impairment. Otherwise, if the fair value of the reporting unit exceeds the carrying amount, the goodwill is not considered to be impaired as of the measurement date. In its review of the carrying value of the goodwill for its single reporting unit and its indefinite-lived intangible assets, the company determines fair values of its goodwill using the market approach, and its indefinite-lived intangible assets using the income approach.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:65px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:66px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Intangible assets not considered indefinite-lived are reviewed for impairment when facts or circumstances suggest that the carrying value of these assets may not be recoverable. The company&amp;#8217;s policy is to identify and record impairment losses, if necessary, on intangible assets when events and circumstances indicate that the assets might be impaired and the undiscounted cash flows estimated to be generated by those assets are less than the carrying amounts.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:66px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:66px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;The company performed its review for impairment using the qualitative assessment for both goodwill and indefinite-lived intangible assets, as well as assets not considered to be indefinite-lived, and has determined that there has been no impairment to these assets as of &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;September&amp;#160;30, 2015&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:GoodwillAndIntangibleAssetsPolicyTextBlock>
	<us-gaap:IncomeTaxPolicyTextBlock contextRef="FD2015Q3YTD" id="Fact-7D7D25009DB1574F9AD5CD267C5B833F">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;text-indent:65px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;"&gt;Income Taxes&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; &amp;#8212; The company recognizes liabilities or assets for the deferred tax consequences of temporary differences between the tax basis of assets or liabilities and their reported amounts in the financial statements in accordance with FASB ASC&amp;#160;740-10, &amp;#8220;&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;"&gt;Accounting for Income Taxes&amp;#8221; (&amp;#8220;ASC 740-10&amp;#8221;).&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; These temporary differences will result in taxable or deductible amounts in future years when the reported amounts of the assets or liabilities are recovered or settled. &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;"&gt;ASC 740-10&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; requires that a valuation allowance be established when management determines that it is more likely than not that all or a portion of a deferred asset will not be realized. The company evaluates the realizability of its net deferred income tax assets and valuation allowances as necessary, at least on an annual basis. During this evaluation, the company reviews its forecasts of income in conjunction with other positive and negative evidence surrounding the realizability of its deferred income tax assets to determine if a valuation allowance is required. Adjustments to the valuation allowance will increase or decrease the company&amp;#8217;s income tax provision or benefit. The recognition and measurement of benefits related to the company&amp;#8217;s tax positions requires significant judgment, as uncertainties often exist with respect to new laws, new interpretations of existing laws, and rulings by taxing authorities. Differences between actual results and the company&amp;#8217;s assumptions or changes in the company&amp;#8217;s assumptions in future periods are recorded in the period they become known.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:65px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:66px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;There was no income tax expense or benefit for the three and nine months periods ended &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;September&amp;#160;30, 2015&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; and 2014. We continue to maintain a full valuation allowance against our net deferred tax assets.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:IncomeTaxPolicyTextBlock>
	<us-gaap:IntangibleAssetsDisclosureTextBlock contextRef="FD2015Q3YTD" id="Fact-2CC1EFFFA0155A86A443D3AFA6FF396A">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#00497f;font-weight:bold;"&gt;License Agreements&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:65px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:65px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;As part of its business, the company enters into licensing agreements with third parties that often require milestone and royalty payments based on the progress of the licensed assets through development and commercial stages. Milestone payments may be required, for example, upon approval of the product for marketing by a regulatory agency, and the company may be required to make royalty payments based upon a percentage of net sales of the product. The expenditures required under these arrangements in any period may be material and are likely to fluctuate from period to period.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:65px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:65px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;These arrangements sometimes permit the company to unilaterally terminate development of the product and thereby avoid future contingent payments; however, the company is unlikely to cease development if the compound successfully achieves clinical testing objectives.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:65px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:65px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;In conjunction with the acquisition of NeuVax&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:pt"&gt;TM&lt;/sup&gt;&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;, the company acquired rights and assumed obligations under a license agreement among Apthera and The University of Texas M. D. Anderson Cancer Center (&amp;#8220;MDACC&amp;#8221;) and The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc. (&amp;#8220;HJF&amp;#8221;) which grants exclusive worldwide rights to a U.S. patent covering the nelipepimut-S peptide and several U.S. and foreign patents and patent applications covering methods of using the peptide as a vaccine. Under the terms of this license, we are required to pay an annual maintenance fee of &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$200,000&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;, a milestone payment of &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$200,000&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; upon commencing the Phase 3 PRESENT trial of NeuVax and other clinical milestone payments, as well as royalty payments based on sales of NeuVax or other therapeutic products developed from the licensed technologies. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:65px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:13px;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Effective April 30, 2009, we entered into a license agreement with Kwangdong Pharmaceutical Co, Ltd (Kwangdong).  Under the agreement, we granted Kwangdong exclusive rights to seek marketing approval in The Republic of Korea (South Korea) for our NeuVax product candidate for the treatment of breast cancer following its approval by the FDA or the European Medicines Agency, and to market, sell and distribute NeuVax in South Korea assuming such approval is obtained. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:65px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Effective December&amp;#160;3, 2012, we entered into a license and supply agreement with ABIC Marketing Limited, a subsidiary of Teva Pharmaceuticals (&amp;#8220;ABIC&amp;#8221;), under which we granted ABIC exclusive rights to seek marketing approval in Israel for our NeuVax product candidate for intradermal injection for the treatment of breast cancer following its approval by the FDA or the European Medicines Agency, and to market, sell and distribute NeuVax in Israel assuming such approval is obtained. ABIC&amp;#8217;s rights also include a right of first refusal in Israel for all future indications for which NeuVax may be approved. Under the license and supply agreement, ABIC will assume responsibility for regulatory registration of NeuVax in Israel, provide financial support for local development, and commercialize the product in the region in exchange for making royalty payments to us based on future sales of NeuVax. ABIC also agrees in the license and supply agreement to purchase from us all supplies of NeuVax at a price determined according to a specified formula.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:65px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:13px;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Effective January 14, 2014, we entered into a strategic development and commercialization partnership with Dr. Reddy&amp;#8217;s Laboratories Ltd. (&amp;#8220;Dr. Reddy&amp;#8217;s&amp;#8221;), under which we licensed commercial rights in India to Dr. Reddy&amp;#8217;s for NeuVax in breast and gastric cancers. Under the agreement, Dr. Reddy&amp;#8217;s will lead the Phase 2 development of NeuVax in India in gastric cancer, significantly expanding the potential patient population addressable with NeuVax.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:66px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;On January 12, 2014, we acquired worldwide rights to anagrelide controlled release (CR) formulation, which we renamed GALE-401, through our acquisition of Mills Pharmaceuticals, LLC ("Mills") and Mills became a wholly owned subsidiary. GALE-401 contains the active ingredient anagrelide, an FDA-approved product that has been in use since the late 1990s for the treatment of essential thrombocythemia (ET). Mills holds an exclusive license to develop and commercialize anagrelide CR formulation, pursuant to a license agreement with BioVascular, Inc. Under the terms of the license agreement, Mills has agreed to pay BioVascular, Inc. a mid-to-low single digit royalty on net revenue from the sale of licensed products as well as future cash milestone payments based on the achievement of specified regulatory milestones. Mills is also responsible for patent prosecution and maintenance.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:IntangibleAssetsDisclosureTextBlock>
	<us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock contextRef="FD2015Q3YTD" id="Fact-784D86725F8F89ACD056DEE19461F7E5">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;text-align:left;text-indent:65px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;text-decoration:underline;"&gt;Effect of Recent Accounting Pronouncements&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:65px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:65px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;In April 2014, the FASB issued ASU 2014-08, Reporting Discontinued Operations and Disclosures of Disposals of Components of an Entity, or ASU 2014-08. Under ASU 2014-08, only disposals representing a strategic shift in operations that have a major effect on the company&amp;#8217;s operations and financial results should be presented as discontinued operations. Additionally, ASU 2014-08 requires expanded disclosures about discontinued operations that will provide financial statement users with more information about the assets, liabilities, income, and expenses of discontinued operations. The amendments in ASU 2014-08 are effective for fiscal years, and interim periods within those years, beginning after December 15, 2014. The company adopted this guidance in the first quarter of 2015 and has applied it in the accompanying interim financial statements for presentation and disclosure of the commercial business as discontinued operations (see Note 12). &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:36px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:65px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;In May 2014, the FASB issued ASU No.&amp;#160;2014-09,&amp;#160;Revenue from Contracts with Customers: Topic 606,&amp;#160;or ASU 2014-09. ASU 2014-09 establishes the principles for recognizing revenue and develops a common revenue standard for U.S. GAAP. The standard outlines a single comprehensive model for entities to use in accounting for revenue arising from contracts with customers and supersedes most current revenue recognition guidance, including industry-specific guidance. In applying the new revenue recognition model to contracts with customers, an entity: (1) identifies the contract(s) with a customer; (2) identifies the performance obligations in the contract(s); (3) determines the transaction price; (4) allocates the transaction price to the performance obligations in the contract(s); and (5) recognizes revenue when (or as) the entity satisfies a performance obligation.&amp;#160;The accounting standards update applies to all contracts with customers except those that are within the scope of other topics in the FASB Accounting Standards Codification.&amp;#160;The accounting standards update also requires significantly expanded quantitative and qualitative disclosures regarding the nature, amount, timing and uncertainty of revenue and cash flows arising from contracts with customers.&amp;#160;This guidance is effective for fiscal years and interim periods within those years beginning after December 15, 2016, which is effective for the company for the year ending December 31, 2017. The FASB delayed in the effective date of the accounting standards update to fiscal years and interim periods within those years beginning on or after December 15, 2017, which is pending approval.&amp;#160;The company is currently evaluating the impact that the implementation of ASU 2014-09 will have on the company&amp;#8217;s financial statements. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:36px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:65px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;In August 2014, the FASB issued ASU No. 2014-15,&amp;#160;Disclosure of Uncertainties about an Entity&amp;#8217;s Ability to Continue as a Going Concern, or ASU 2014-15. ASU 2014-15 will explicitly require management to assess an entity&amp;#8217;s ability to continue as a going concern, and to provide related footnote disclosure in certain circumstances. The new standard will be effective for all entities in the first annual period ending after December 15, 2016. Earlier adoption is permitted. The company is not early adopting ASU 2014-15. The company is currently evaluating the impact that the implementation of ASU 2014-15 will have on the company&amp;#8217;s financial statements, and the actual impact will be dependent upon the company&amp;#8217;s liquidity and the nature or significance of future events or conditions that exist upon adopting the updated standard.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:36px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:65px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;In January 2015, the FASB issued ASU No. 2015-01, Simplifying Income Statement Presentation by Eliminating the Concept of Extraordinary Items, or ASU 2015-01.&amp;#160;ASU 2015-01 eliminates from GAAP the concept of extraordinary items. ASU 2015-01 is effective for fiscal years and interim periods beginning after December 15, 2015. Early adoption is permitted. The company does not expect that the adoption of ASU 2015-01 will have a material impact on its consolidated financial statements.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
	<us-gaap:OptionIndexedToIssuersEquityDescriptionTextBlock contextRef="FD2015Q3YTD" id="Fact-625A1B8E11D85567A88204ABF42DF7EF">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#00497f;font-weight:bold;"&gt;Warrants&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:65px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:65px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;The following is a summary of warrant activity for the nine months ended &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;September&amp;#160;30, 2015&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; (in thousands):&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:9pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:9pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="24" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td width="21%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="8%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="8%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="8%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="8%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="8%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="8%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="8%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="8%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;March 2015 Warrants&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;September&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;2013&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;Warrants&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;December&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;2012&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;Warrants&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;April&amp;#160;2011&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;Warrants&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;March&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;2011&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;Warrants&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;March&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;2010&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;Warrants&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;Consultant&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;and Oxford Warrants&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;Total&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;Outstanding, January 1, 2015&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;3,973&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;3,031&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;615&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;176&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;25&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;720&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;8,540&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;Issued&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;14,006&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;14,006&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;Expired&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;(238&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;(238&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;Outstanding, September&amp;#160;30, 2015&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;14,006&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;3,973&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;3,031&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;615&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;176&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;25&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;482&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;22,308&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;Expiration&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;March 2020&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;September 2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;December 2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:3px double #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;April 2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;March 2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;March 2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;Varies 2014-2020&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:66px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:66px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Warrants consist of warrants potentially settleable in cash, which are liability-classified warrants, and equity-classified warrants.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:66px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;"&gt;Warrants classified as liabilities&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:66px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Liability-classified warrants consist of warrants to purchase common stock issued in connection with equity financings in March 2015, September 2013, December 2012,&amp;#160;April 2011,&amp;#160;March 2011,&amp;#160;and March 2010. These warrants are potentially settleable in cash and were determined not to be indexed to our common stock.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:66px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;The estimated fair value of outstanding warrants accounted for as liabilities is determined at each balance sheet date. Any decrease or increase in the estimated fair value of the warrant liability since the most recent balance sheet date is recorded in the condensed consolidated statement of comprehensive loss as other income (expense). The fair value of the warrants is estimated using an appropriate pricing model with the following inputs:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:9pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:9pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="24" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td width="23%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="10%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="10%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="10%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="10%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="10%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="10%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="23" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;As of September&amp;#160;30, 2015&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;March 2015 Warrants&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;September&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;2013&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;Warrants&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;December&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;2012&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;Warrants&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;April&amp;#160;2011&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;Warrants&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;March&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;2011&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;Warrants&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;March&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;2010&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;Warrants&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:9pt;"&gt;Strike price&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:9pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:9pt;"&gt;2.08&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:9pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:9pt;"&gt;2.50&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:9pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:9pt;"&gt;1.83&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:9pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:9pt;"&gt;0.65&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:9pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:9pt;"&gt;0.65&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:9pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:9pt;"&gt;2.02&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:9pt;"&gt;Expected term (years)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:9pt;"&gt;4.47&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:9pt;"&gt;2.97&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:9pt;"&gt;2.23&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:9pt;"&gt;1.56&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:9pt;"&gt;0.43&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:9pt;"&gt;0.49&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:9pt;"&gt;Volatility %&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:9pt;"&gt;74.99&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:9pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:9pt;"&gt;76.85&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:9pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:9pt;"&gt;75.45&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:9pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:9pt;"&gt;69.48&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:9pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:9pt;"&gt;72.42&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:9pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:9pt;"&gt;68.33&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:9pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:9pt;"&gt;Risk-free rate %&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:9pt;"&gt;1.25&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:9pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:9pt;"&gt;0.91&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:9pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:9pt;"&gt;0.70&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:9pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:9pt;"&gt;0.50&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:9pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:9pt;"&gt;0.06&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:9pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:9pt;"&gt;0.08&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:9pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:9pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:9pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="20" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td width="36%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="10%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="10%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="10%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="10%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="10%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="19" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;As of December&amp;#160;31, 2014&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;September&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;2013&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;Warrants&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;December&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;2012&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;Warrants&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;April&amp;#160;2011&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;Warrants&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;March&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;2011&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;Warrants&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;March&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;2010&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;Warrants&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:9pt;"&gt;Strike price&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:9pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:9pt;"&gt;2.50&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:9pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:9pt;"&gt;1.90&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:9pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:9pt;"&gt;0.65&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:9pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:9pt;"&gt;0.65&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:9pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:9pt;"&gt;2.15&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:9pt;"&gt;Expected term (years)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:9pt;"&gt;3.72&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:9pt;"&gt;2.98&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:9pt;"&gt;2.31&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:9pt;"&gt;1.18&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:9pt;"&gt;1.24&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:9pt;"&gt;Volatility %&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:9pt;"&gt;75.60&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:9pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:9pt;"&gt;76.85&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:9pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:9pt;"&gt;78.24&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:9pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:9pt;"&gt;77.38&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:9pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:9pt;"&gt;77.12&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:9pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:9pt;"&gt;Risk-free rate %&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:9pt;"&gt;1.30&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:9pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:9pt;"&gt;1.09&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:9pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:9pt;"&gt;0.80&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:9pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:9pt;"&gt;0.32&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:9pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:9pt;"&gt;0.35&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:9pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:65px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:65px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;The expected volatility assumptions are based on the company's implied volatility in combination with the implied volatilities of similar publicly traded entities. The expected life assumption is based on the remaining contractual terms of the warrants. The risk-free rate is based on the zero coupon rates in effect at the time of valuation. The dividend yield used in the pricing model is zero, because the company has no present intention to pay cash dividends.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:65px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;The changes in fair value of the warrant liability for the nine months ended &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;September&amp;#160;30, 2015&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; were as follows (in thousands):&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:9pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:9pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="28" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td width="24%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="8%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="8%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="8%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="8%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="8%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="8%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="8%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;March 2015 Warrants&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;September&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;2013&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;Warrants&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;December&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;2012&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;Warrants&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;April&amp;#160;2011&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;Warrants&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;March&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;2011&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;Warrants&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;March&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;2010&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;Warrants&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;Total&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:9pt;"&gt;Warrant liability, January&amp;#160;1, 2015&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:9pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:9pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:9pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:9pt;"&gt;2,560&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:9pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:9pt;"&gt;2,027&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:9pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:9pt;"&gt;625&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:9pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:9pt;"&gt;163&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:9pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:9pt;"&gt;8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:9pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:9pt;"&gt;5,383&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:9pt;"&gt;Fair value of warrants issued&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:9pt;"&gt;10,296&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:9pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:9pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:9pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:9pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:9pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:9pt;"&gt;10,296&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:9pt;"&gt;Change in fair value of warrants&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:9pt;"&gt;1,313&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:9pt;"&gt;(157&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:9pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:9pt;"&gt;(162&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:9pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:9pt;"&gt;(10&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:9pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:9pt;"&gt;2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:9pt;"&gt;(4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:9pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:9pt;"&gt;982&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:9pt;"&gt;Warrant liability, September&amp;#160;30, 2015&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:9pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:9pt;"&gt;11,609&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:9pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:9pt;"&gt;2,403&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:9pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:9pt;"&gt;1,865&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:9pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:9pt;"&gt;615&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:9pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:9pt;"&gt;165&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:9pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:9pt;"&gt;4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:9pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:9pt;"&gt;16,661&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:65px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:65px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;"&gt;Warrants classified as equity&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:65px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:65px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Equity-classified warrants consist of warrants issued in connection with consulting services provided to us. Additionally, on May 8, 2013 as a part of our Loan financing, we granted Oxford Financial LLC warrants to purchase up to &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;182,186&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; shares of common stock at an exercise price of &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$2.47&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;, which equaled to the &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;20&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;-day average market price of our common stock prior to the date of the grant. The warrants were valued using an appropriate pricing model as described in Note 9, below. The fair value assumptions for the grant included a volatility of &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;75.34%&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;, expected term of &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;seven&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; years, risk-free rate of &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;1.20%&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;, and a dividend rate of &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;0.00%&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;. The fair value of the warrants granted was &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$1.93&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; per share. These warrants are recorded in equity at fair value upon issuance, and not as liabilities, and are not subject to adjustment to fair value in subsequent reporting periods.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:OptionIndexedToIssuersEquityDescriptionTextBlock>
	<us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock contextRef="FD2015Q3YTD" id="Fact-A4AFF6B5BCA754E1B9991A8F2CBD6E79">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#00497f;font-weight:bold;"&gt; Business and Basis of Presentation&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#006ebf;font-weight:bold;"&gt;Overview&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;font-weight:bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:13px;text-align:left;text-indent:66px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Galena Biopharma, Inc. (&amp;#8220;we,&amp;#8221; &amp;#8220;us,&amp;#8221; &amp;#8220;our,&amp;#8221; &amp;#8220;Galena&amp;#8221; or the &amp;#8220;company&amp;#8221;) is a biopharmaceutical company committed to the development and commercialization of targeted oncology therapeutics that address major unmet medical needs. Galena&amp;#8217;s development portfolio is focused primarily on addressing the rapidly growing patient populations of cancer survivors by harnessing the power of the immune system to prevent cancer recurrence. The Company&amp;#8217;s pipeline consists of multiple mid- to late-stage clinical assets, including novel cancer immunotherapy programs led by NeuVax&amp;#8482; (nelipepimut-S),GALE-301 and GALE-302.&amp;#160;NeuVax is currently in a pivotal, Phase 3 clinical trial with several concurrent Phase 2 trials ongoing both as a single agent and in combination with other therapies. GALE-301 is in a Phase 2a clinical trial in ovarian and endometrial cancers in addition to GALE-302 in combination with GALE-301 in ovarian and breast cancers.&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#006ebf;font-weight:bold;text-decoration:underline;"&gt;Novel Cancer Immunotherapies&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:66px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:13px;text-align:left;text-indent:66px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Our targeted cancer immunotherapy approach is currently based upon two key areas: preventing secondary recurrence of cancer, which is becoming increasingly important as the number of cancer survivors continues to grow; and, transitioning earlier in the breast cancer treatment spectrum via primary prevention. Once a patient&amp;#8217;s tumor becomes metastatic, the outcome is most often fatal, making the prevention of recurrence a potentially critical component of overall patient care. Our programs primarily target patients in the adjuvant (after-surgery) setting who have relatively healthy immune systems, but may still have minimal residual disease.  Minimal residual disease, or single cancer cells (occult cancer cells) or micrometastasis, are undetectable by current radiographic scanning technologies, but we know can result in disease recurrence.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:66px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Our therapies utilize an immunodominant peptide combined with the immune adjuvant, recombinant human granulocyte macrophage-colony stimulating factor (rhGM-CSF), and work by harnessing the patient&amp;#8217;s own immune system to seek out and attack any residual cancer cells. Using peptide immunogens has many potential clinical advantages, including a favorable safety profile, since these drugs may lack the toxicities typical of most cancer therapies. They also have the potential to evoke long-lasting protection through activation of the immune system and a convenient, intradermal mode of delivery. We are currently engaged in multiple clinical trials with NeuVax&amp;#8482; (nelipepimut-S), GALE-301, and GALE-302, targeting the prevention of recurrence in breast, gastric, ovarian and endometrial cancers.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:66px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;padding-left:32px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#006ebf;font-style:italic;font-weight:bold;"&gt;NeuVax&amp;#8482; (nelipepimut-S)&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;padding-left:32px;text-indent:66px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:13px;text-align:left;text-indent:66px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;NeuVax&amp;#8482; (nelipepimut-S), our lead product candidate, is a cancer immunotherapy targeting human epidermal growth factor receptor (HER2) expressing cancers. NeuVax is the immunodominant nonapeptide derived from the extracellular domain of the HER2 protein, a well-established and validated target for therapeutic intervention in breast and gastric carcinomas. The NeuVax vaccine is combined with GM-CSF for injection under the skin, or intradermal administration. Data has shown that an increased presence of circulating tumor cells (CTCs) may predict Disease Free Survival (DFS) and Overall Survival (OS)-suggesting a dormancy of isolated micrometastases, which, over time, may lead to recurrence. After binding to specific HLA molecules on antigen presenting cells, the nelipepimut-S sequence stimulates specific cytotoxic T lymphocyte (CTLs). These activated CTLs recognize, neutralize and destroy, through cell lysis, HER2 expressing cancer cells, including occult cancer cells and micrometastatic foci. The nelipepimut immune response can also generate CTLs to other immunogenic peptides through inter- and intra-antigenic epitope spreading.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:13px;text-align:left;text-indent:66px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;We have multiple trials currently ongoing for NeuVax. For our pivotal, Phase 3 PRESENT (&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;font-weight:bold;"&gt;P&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;revention of &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;font-weight:bold;"&gt;R&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;ecurrence in &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;font-weight:bold;"&gt;E&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;arly-&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;font-weight:bold;"&gt;S&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;tage, Node- Positive Breast Cancer with Low to Intermediate HER2 &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;font-weight:bold;"&gt;E&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;xpression with &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;font-weight:bold;"&gt;NeuVax T&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;reatment) trial, NeuVax is targeting the &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;30,000&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;-&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;40,000&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; of the &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;230,000&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; female breast cancer patients annually diagnosed in the U.S. who are at a higher risk of their breast cancer recurring, which we refer to as &amp;#8220;disease recurrence,&amp;#8221; after achieving &amp;#8220;no evidence of disease&amp;#8221; (NED) status, (or becoming a &amp;#8220;survivor&amp;#8221;) with standard-of-care therapy (surgery, chemotherapy, radiation). These high-risk patients have a particular molecular signature and disease status: HER2 IHC 1+/2+ (oncoprotein associated with aggressive tumor growth), node positive (disease present in the axillary lymph nodes prior to surgery), and HLA A2/A3 (human leukocyte antigen from A2/A3 patients who have the same loci of genes which represents approximately &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;65%&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; of the population). Up to &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;25%&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; of resectable, node-positive breast cancer patients, having no radiographic evidence of disease following surgery and adjuvant chemo/radiation therapy, are expected to relapse within three years following diagnosis. The prognosis upon recurrence is very poor. These cancer patients presumably still had isolated, undetected tumor CTCs that led to a recurrence of cancer in the breast (local recurrence) or in another location (metastatic disease).  In addition to our Phase 3 trial, we currently have two additional Phase 2 breast cancer trials ongoing with NeuVax in combination with trastuzumab (Herceptin&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:pt"&gt;&amp;#174;&lt;/sup&gt;&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;; Genentech/Roche) targeting the prevention of recurrence in expanded indications.  &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:13px;text-align:left;text-indent:66px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;We also recently announced our intent to initiate a Phase 2 trial with NeuVax as a single agent in patients with ductal carcinoma in situ (DCIS) in collaboration with the National Cancer Institute (NCI), potentially transitioning NeuVax earlier in the treatment cycle towards primary prevention.  The trial will have an immunological endpoint evaluating NeuVax peptide-specific cytotoxic T lymphocyte (CTL; CD8+ T cell) response in vaccinated patients. DCIS, is defined by the NCI as a noninvasive condition in which abnormal cells are found in the lining of a breast duct, and is the most common type of breast cancer.  The abnormal cells have not spread outside the duct to other tissues in the breast.  In some cases, DCIS may become invasive cancer and spread to other tissues, and at this time, there is no way to know which lesions could become invasive.  Current treatment options for DCIS include breast-conserving surgery and radiation therapy with or without tamoxifen, breast-conserving surgery without radiation therapy, or total mastectomy with or without tamoxifen.  According to the American Cancer Society, in 2014 there were an estimated &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;51,933&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; diagnoses of DCIS.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:13px;text-align:left;text-indent:66px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;We currently have a number of ongoing or planned clinical trials designed to expand the clinical and geographical footprint of NeuVax:&lt;/font&gt;&lt;/div&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:108px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:84px;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&amp;#8226;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Phase 3 Ongoing: Our Phase 3 PRESENT (&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;font-weight:bold;"&gt;P&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;revention of &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;font-weight:bold;"&gt;R&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;ecurrence in &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;font-weight:bold;"&gt;E&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;arly- &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;font-weight:bold;"&gt;S&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;tage, Node-Positive Breast Cancer with Low to Intermediate HER2 &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;font-weight:bold;"&gt;E&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;xpression with &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;font-weight:bold;"&gt;NeuVax&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;font-weight:bold;"&gt;T&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;reatment) study targeted enrollment of &lt;/font&gt;&lt;font style="font-family:Helvetica;font-size:10pt;"&gt;700&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; HER2 1+/2+ patients under a Special Protocol Assessment (SPA) granted by the U.S. Food and Drug Administration (FDA). The multinational, multicenter, randomized, double-blinded PRESENT trial is ongoing in North America, Western and Eastern Europe, and Israel. The trial is fully enrolled with &lt;/font&gt;&lt;font style="font-family:Helvetica;font-size:10pt;"&gt;758&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; patients. &lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:108px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:84px;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&amp;#8226;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Phase 2b Ongoing: A randomized, multicenter, investigator-sponsored, &lt;/font&gt;&lt;font style="font-family:Helvetica;font-size:10pt;"&gt;300&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; patient Phase 2b clinical trial is enrolling HER2 1+/2+ node-positive and high-risk node-negative breast cancer patients who are HLA A2+, A3+, A24+ or A26+ to study NeuVax in combination with trastuzumab in the adjuvant setting.  This trial is co-funded by Genentech/Roche (providing both trastuzumab and monetary support) and Galena (providing NeuVax and monetary support).&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:108px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:84px;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&amp;#8226;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Phase 2 Ongoing: An investigator-sponsored trial is ongoing to study NeuVax in combination with trastuzumab. The study will enroll &lt;/font&gt;&lt;font style="font-family:Helvetica;font-size:10pt;"&gt;100&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; node positive and negative HER2 IHC 3+ patients or HER2 gene-amplified breast cancer patients who are HLA A2+ or HLA A3+ and are determined to be at high-risk for recurrence. Partial funding for this trial comes from the Department of Defense (DoD) through the Congressionally Directed Medical Research Program via legislation known as the Defense Appropriations Act. The grant was awarded under a Breast Cancer Research Program with the Breakthrough Award given to the lead investigator for the trial.&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:108px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:108px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:84px;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&amp;#8226;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Phase 2 Planned: A clinical trial, entitled, VADIS: Phase 2 trial of the Nelipepimut-S Peptide &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;font-weight:bold;"&gt;VA&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;ccine in Women with &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;font-weight:bold;"&gt;D&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;C&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;font-weight:bold;"&gt;IS &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;of the Breast is planned to initiate by the end of 2015/early 2016. The Phase 2 trial will be a single-blind, double arm, randomized, controlled trial in pre- or post-menopausal patients with DCIS and are HLA-A2 positive.  VADIS will be co-funded and run in collaboration with the National Cancer Institute (NCI).&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:108px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:90px;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&amp;#8226;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Phase 2 Planned: A Phase 2 clinical trial in patients with gastric cancer is expected to initiate in 2016.  The trial will be run in India by our partner, Dr. Reddy&amp;#8217;s Laboratories, Ltd., as part of our NeuVax commercialization agreement in that region with Dr. Reddy&amp;#8217;s. &lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="line-height:120%;text-align:left;padding-left:32px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#006ebf;font-style:italic;font-weight:bold;"&gt;GALE-301 and GALE-302&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:65px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:66px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Our second immunotherapy franchise targets folate binding protein (FBP) receptor-alpha, a well-validated therapeutic target, which&amp;#160;is highly over-expressed (20-80 fold) in ovarian, endometrial and breast cancers. Both GALE-301 (E39) and GALE-302 (E39&amp;#8217;) are immunogenic peptides that can stimulate CTLs to recognize and destroy FBP-expressing cancer cells. GALE-301 consists of the FBP peptide E39 combined with GM-CSF, and is currently in a Phase 2a clinical trial for the prevention of recurrence in patients with ovarian and endometrial cancers. GALE-302 is an attenuated version of the E39 peptide and is currently in a Phase 1b randomized, single-center trial investigating a novel vaccination series using GALE-301 and GALE-302 to evaluate the immune response and monitor long-term immunity.  Current treatments after surgery for these diseases are principally with platinum based chemotherapeutic agents and patients suffer a high recurrence rate; and, most patients relapse with an extremely poor prognosis. Although not powered for efficacy, promising preliminary results from the Phase 2a clinical trial of GALE-301 were presented in September 2015 at the European Cancer Congress and demonstrated statistically significant data with the estimate for disease free survival at two years at 85.7% (1000 mcg dose group) vs. 33.6% for the control group (p &amp;lt; .02), and that GALE-301 was well-tolerated with primarily Grade 1 and 2 toxicities and elicited a strong&amp;#160;&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;"&gt;in vivo&amp;#160;&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;immune response. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:66px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:66px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;According to the NCI Surveillance, Epidemiology, and End Results (SEER) Program, new cases of ovarian cancer occur at an annual rate of &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;12.1&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; per &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;100,000&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; women in the U.S., with an estimated &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;21,290&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; cases for 2015. Although ovarian cancer represents about &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;1.3%&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; of all cancers, it represents about &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;2.4%&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; of all cancer deaths, or an estimated &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;14,180&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; deaths in 2015. &amp;#160;Approximately &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;1.3%&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; of women will be diagnosed with ovarian cancer at some point during their lifetime (2010 - 2012 data). &amp;#160;The prevalence of ovarian cancer in the U.S. is about &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;192,000&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; women, and the five-year survivorship for women with ovarian cancer is &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;45.6%&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;.&amp;#160;Due to the lack of specific symptoms, the majority of ovarian cancer patients are diagnosed at later stages of the disease, with an estimated &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;75%&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; of women presenting with advanced-stage (III or IV) disease. These patients have their tumors routinely surgically debulked to minimal residual disease, and then are treated with platinum- and/or taxane-based chemotherapy. While many patients respond to this treatment regimen and become clinically free-of-disease, the majority of these patients will relapse.  Depending upon their level of residual disease, the risk for recurrence after completion of primary therapy ranges from &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;60%&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; to &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;85%&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;.  Unfortunately for these women, once the disease recurs, treatment options are limited and the disease remains incurable.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:66px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:66px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;According to the NCI SEER Program, new cases of endometrial cancer occur at an annual rate of &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;25.1&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; per &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;100,000&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; women in the U.S., with an estimated &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;54,870&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; cases for 2015. Although endometrial cancer represents about &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;3.3%&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; of all cancers, it represents about &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;1.7%&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; of all cancer deaths, or an estimated &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;10,170&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; deaths in 2015. &amp;#160;Approximately &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;2.8%&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; of women will be diagnosed with endometrial cancer at some point during their lifetime (2010 - 2012 data). &amp;#160;The prevalence of endometrial cancer in the U.S. is about &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;620,000&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; women, and the five-year survivorship for women with endometrial cancer is &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;81.7%&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;.&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#006ebf;font-weight:bold;text-decoration:underline;"&gt;Hematology&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;padding-left:32px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#006ebf;font-style:italic;font-weight:bold;"&gt;GALE-401 (anagrelide controlled release (CR))&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;padding-left:32px;text-indent:66px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:66px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;In January 2014, we announced the acquisition of the worldwide rights to anagrelide controlled release (CR), which we renamed GALE-401, through our acquisition of Mills Pharmaceuticals, LLC. GALE-401 contains the active ingredient anagrelide, an FDA-approved product, for the treatment of patients with myeloproliferative neoplasms (MPNs) to lower abnormally elevated platelet levels. The currently available immediate release (IR) version of anagrelide causes adverse events that are believed to be dose and plasma concentration dependent. Therefore, reducing the maximum concentration (Cmax) is hypothesized to reduce the side effects, but preserve efficacy.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:66px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:66px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Multiple Phase 1 studies in &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;98&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; healthy subjects have shown GALE-401 reduces the Cmax of anagrelide following oral administration, appears to be well-tolerated at the doses administered, and to be capable of reducing platelet levels. The Phase 1 program provided the desired PK/PD (pharmacokinetic/pharmacodynamic) profile to enable the initiation of the ongoing Phase 2 proof-of-concept trial. The Phase 2, open label, single arm, proof-of-concept trial enrolled &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;18&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; patients in the United States for the treatment of thrombocytosis, or elevated platelet counts in patients with MPNs. Phase 2 top-line safety and efficacy data was presented in June 2015 at the European Hematology Association 20&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:pt"&gt;th&lt;/sup&gt;&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; Congress, and we expect to present a more mature data set at the 57th American Society of Hematology Annual Meeting in December 2015. Based on a regulatory meeting with the FDA, Galena believes a 505(b)(2) regulatory filing is an acceptable pathway for development and potential approval of GALE-401.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#006ebf;font-weight:bold;text-decoration:underline;"&gt;Strategic Review of Commercial Operations&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:65px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;During the quarter ended September 30, 2015, we completed a strategic review of the company&amp;#8217;s commercial business including the ongoing sale, distribution and marketing of our two commercial products, Abstral&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:pt"&gt;&amp;#174;&lt;/sup&gt;&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; (fentanyl) Sublingual Tablets and Zuplenz&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:pt"&gt;&amp;#174;&lt;/sup&gt;&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; (ondansetron) Oral Soluble Film (our &amp;#8220;commercial business&amp;#8221; asset group). As a result of the review, we made a determination to sell or otherwise dispose of our commercial business.  &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:66px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#006ebf;font-weight:bold;"&gt;Basis of Presentation and Significant Accounting Policies&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:66px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;The accompanying consolidated financial statements included herein have been prepared by Galena pursuant to the rules and regulations of the Securities and Exchange Commission (SEC). Unless the context otherwise indicates, references in these notes to the &amp;#8220;company,&amp;#8221; &amp;#8220;we,&amp;#8221; &amp;#8220;us&amp;#8221; or &amp;#8220;our&amp;#8221; refer to Galena, our wholly owned subsidiary, Apthera, Inc., or &amp;#8220;Apthera,&amp;#8221; and our wholly owned subsidiary, Mills Pharmaceuticals, LLC or "Mills."&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:66px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:65px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;"&gt;Discontinued Operations - &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;As described in Note 12, we met the relevant criteria for reporting our commercial business as held for sale and in discontinued operations in the accompanying unaudited interim financial statements as of the three and nine month periods ended September&amp;#160;30, 2015 and 2014, pursuant to FASB Topic 205-20, Presentation of Financial Statements - Discontinued Operations, and FASB Topic 360, Property, Plant, and Equipment.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:65px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:65px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;"&gt;Uses of Estimates in Preparation of Financial Statements&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; &amp;#8212; The preparation of these consolidated financial statements in accordance with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the reporting period. Actual results could differ materially from those estimates.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:65px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:65px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;"&gt;Principles of Consolidation&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; &amp;#8212;&amp;#160;The consolidated financial statements include the accounts of Galena and its wholly owned subsidiaries. All material intercompany accounts have been eliminated in consolidation.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:65px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:65px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;"&gt;Reclassifications&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; &amp;#8212; Certain prior year amounts have been reclassified to conform to current year presentation. These reclassifications had no effect on net loss per share.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:65px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;"&gt;Cash and Cash Equivalents&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; &amp;#8212; The company considers all highly liquid debt instruments with an original maturity of &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;90&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; days&amp;#160;or less to be cash equivalents. Cash equivalents consist primarily of amounts invested in money market accounts and demand deposits.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:65px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:65px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;"&gt;Restricted Cash&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; &amp;#8212; Restricted cash consists of certificates of deposit on hand with the company&amp;#8217;s financial institutions as collateral for its corporate credit cards.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:65px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:65px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;"&gt;Fair Value of Financial Instruments&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; &amp;#8212; The carrying amounts reported in the balance sheet for cash equivalents, accounts receivable, accounts payable, and capital leases approximate their fair values due to their short-term nature and market rates of interest.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:66px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:66px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;"&gt;Equipment and Furnishings&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; &amp;#8212; Equipment and furnishings are stated at cost and depreciated using the straight-line method based on the estimated useful lives (generally &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;three&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; to &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;five&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; years) of the related assets.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:65px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:8px;text-indent:65px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;"&gt;Goodwill and Intangible Assets&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; &amp;#8212; Goodwill and indefinite-lived intangible assets are not amortized but are tested annually for impairment at the reporting unit level, or more frequently if events and circumstances indicate impairment may have occurred. Factors the company considers important that could trigger an interim review for impairment include, but are not limited to, the following:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-left:67px;padding-bottom:8px;text-align:left;"&gt;&lt;font style="padding-bottom:8px;text-align:left;font-family:Helvetica,sans-serif;font-size:10pt;padding-right:28px;"&gt;&amp;#8226;&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Significant changes in the manner of its use of acquired assets or the strategy for its overall business;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-left:67px;padding-bottom:8px;text-align:left;"&gt;&lt;font style="padding-bottom:8px;text-align:left;font-family:Helvetica,sans-serif;font-size:10pt;padding-right:28px;"&gt;&amp;#8226;&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Significant negative industry or economic trends;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-left:67px;padding-bottom:8px;text-align:left;"&gt;&lt;font style="padding-bottom:8px;text-align:left;font-family:Helvetica,sans-serif;font-size:10pt;padding-right:28px;"&gt;&amp;#8226;&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Significant decline in stock price for a sustained period; and&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-left:67px;text-align:left;"&gt;&lt;font style="text-align:left;font-family:Helvetica,sans-serif;font-size:10pt;padding-right:28px;"&gt;&amp;#8226;&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Significant decline in market capitalization relative to net book value.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:65px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:65px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Goodwill and other intangible assets with indefinite lives are evaluated for impairment first by a qualitative assessment to determine the likelihood of impairment. If it is determined that impairment is more likely than not, the company will then proceed to the two step impairment test. The first step is to compare the fair value of the reporting unit to the carrying amount of the reporting unit. If the carrying amount exceeds the fair value, a second step must be followed to calculate impairment. Otherwise, if the fair value of the reporting unit exceeds the carrying amount, the goodwill is not considered to be impaired as of the measurement date. In its review of the carrying value of the goodwill for its single reporting unit and its indefinite-lived intangible assets, the company determines fair values of its goodwill using the market approach, and its indefinite-lived intangible assets using the income approach.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:65px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:66px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Intangible assets not considered indefinite-lived are reviewed for impairment when facts or circumstances suggest that the carrying value of these assets may not be recoverable. The company&amp;#8217;s policy is to identify and record impairment losses, if necessary, on intangible assets when events and circumstances indicate that the assets might be impaired and the undiscounted cash flows estimated to be generated by those assets are less than the carrying amounts.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:66px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:66px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;The company performed its review for impairment using the qualitative assessment for both goodwill and indefinite-lived intangible assets, as well as assets not considered to be indefinite-lived, and has determined that there has been no impairment to these assets as of &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;September&amp;#160;30, 2015&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:66px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:66px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;"&gt;Assets Held for Sale &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;- The company generally considers assets to be held for sale when (i) when the transaction has been approved by the board of directors or management vested with authority to approve the transaction, (ii) the assets are available for immediate sale in their present condition, (iii) the company has initiated an active program to locate a buyer and other actions required to complete the plan to sell the assets, (iv) consummation of the transaction is probable, (v) the assets are being actively marketing for sale at a price that is reasonable in relation to the current fair value, and (vi) the transaction is expected to qualify for recognition as a completed sale, within one year. Following the classification of property and equipment for sale, the company discontinues depreciating the asset and writes down the asset to the lower of the carrying value or fair market value, if needed. As described in Note 12, actions taken by the company's management vested with the board of directors' authority caused the company to meet the relevant criteria for reporting the commercial operations as held for sale.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:66px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;"&gt;Acquisitions and In-Licensing &amp;#8212;&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; For all in-licensed products and technologies, we perform an analysis to determine whether we hold a variable interest or a controlling financial interest in a variable interest entity. On the basis of our interpretations and conclusions, we determine whether the acquisition falls under the purview of variable interest entity accounting and if so, consider the necessity to consolidate the acquisition. As of &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;September&amp;#160;30, 2015&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;, we determined there were no variable interest entities required to be consolidated.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:66px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;We also perform an analysis to determine if the assets and liabilities acquired in an acquisition qualify as a "business." The excess of the purchase price over the fair value of the net assets acquired can only be recognized as goodwill in a business combination. The Company completes its valuation analysis no later than twelve months from the date of the acquisition.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:65px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;"&gt;Contingent Purchase Price Consideration&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; &amp;#8212; Contingent consideration in business combinations is recorded at the estimated fair value as of the acquisition date. The fair value of the contingent consideration is re-measured at each reporting period with any adjustments in fair value included in our consolidated statement of comprehensive loss.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:65px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:65px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;"&gt;Patents and Patent Application Costs&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; &amp;#8212; Although the company believes that its patents and underlying technology have continuing value, the amount of future benefits to be derived from the patents is uncertain. Patent costs are, therefore, expensed as incurred.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:65px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;"&gt;Share-based Compensation&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; &amp;#8212; The company follows the provisions of the FASB ASC Topic 718, &amp;#8220;&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;"&gt;Compensation&amp;#160;&amp;#8212; Stock Compensation&amp;#8221;&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; (&amp;#8220;ASC 718&amp;#8221;), which requires the measurement and recognition of compensation expense for all stock-based payment awards made to employees, non-employee directors, and consultants, including stock options and warrants. Stock compensation expense based on the grant date fair value estimated in accordance with the provisions of ASC&amp;#160;718 is recognized as an expense over the requisite service period.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:65px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:65px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;For stock options and warrants granted as consideration for services rendered by non-employees, the company recognizes compensation expense in accordance with the requirements of FASB ASC Topic 505-50 (&amp;#8220;ASC 505-50&amp;#8221;), &amp;#8220; &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;"&gt;Equity Based Payments to Non- Employees&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;.&amp;#8221; Non-employee option and warrant grants that do not vest immediately upon grant are recorded as an expense over the vesting period. At the end of each financial reporting period prior to vesting, the value of these options and warrants, as calculated using the Black-Scholes option-pricing model, is re-measured using the fair value of the company&amp;#8217;s common stock and the non-cash compensation recognized during the period is adjusted accordingly. Since the fair market value of options and warrants granted to non-employees is subject to change in the future, the amount of the future compensation expense will include fair value re-measurements until the stock options are fully vested.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:65px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:65px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;"&gt;Research and Development Expenses&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; &amp;#8212; Research and development costs are expensed as incurred. Included in research and development costs are wages, benefits and other operating costs, facilities, supplies, external services and overhead related to our research and development departments, and clinical trial expenses.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:65px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:65px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Clinical trial expenses include direct costs associated with contract research organizations (CROs), as well as patient-related costs at sites at which our trials are being conducted.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:65px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:65px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Direct costs associated with our CROs are generally payable on a time and materials basis, or when certain enrollment and monitoring milestones are achieved. Expense related to a milestone is recognized in the period in which the milestone is achieved or in which we determine that it is more likely than not that it will be achieved.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:65px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:65px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;The invoicing from clinical trial sites can lag several months. We accrue these site costs based on our estimate of upfront set-up costs upon the screening of the first patient at each site, and the patient related costs based on our knowledge of patient enrollment status at each site.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:65px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:65px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;"&gt;Income Taxes&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; &amp;#8212; The company recognizes liabilities or assets for the deferred tax consequences of temporary differences between the tax basis of assets or liabilities and their reported amounts in the financial statements in accordance with FASB ASC&amp;#160;740-10, &amp;#8220;&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;"&gt;Accounting for Income Taxes&amp;#8221; (&amp;#8220;ASC 740-10&amp;#8221;).&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; These temporary differences will result in taxable or deductible amounts in future years when the reported amounts of the assets or liabilities are recovered or settled. &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;"&gt;ASC 740-10&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; requires that a valuation allowance be established when management determines that it is more likely than not that all or a portion of a deferred asset will not be realized. The company evaluates the realizability of its net deferred income tax assets and valuation allowances as necessary, at least on an annual basis. During this evaluation, the company reviews its forecasts of income in conjunction with other positive and negative evidence surrounding the realizability of its deferred income tax assets to determine if a valuation allowance is required. Adjustments to the valuation allowance will increase or decrease the company&amp;#8217;s income tax provision or benefit. The recognition and measurement of benefits related to the company&amp;#8217;s tax positions requires significant judgment, as uncertainties often exist with respect to new laws, new interpretations of existing laws, and rulings by taxing authorities. Differences between actual results and the company&amp;#8217;s assumptions or changes in the company&amp;#8217;s assumptions in future periods are recorded in the period they become known.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:65px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:66px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;There was no income tax expense or benefit for the three and nine months periods ended &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;September&amp;#160;30, 2015&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; and 2014. We continue to maintain a full valuation allowance against our net deferred tax assets.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:65px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:65px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;"&gt;Concentrations of Credit Risk&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; &amp;#8212; Financial instruments that potentially subject the company to significant concentrations of credit risk consist principally of cash and cash equivalents. The company maintains cash balances in several accounts with two banks, which at times are in excess of federally insured limits. As of &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;September&amp;#160;30, 2015&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;, the company&amp;#8217;s cash equivalents were invested in money market mutual funds. The company&amp;#8217;s investment policy does not allow investment in any debt securities rated less than &amp;#8220;investment grade&amp;#8221; by national ratings services. The company has not experienced any losses on its deposits of cash and cash equivalents. The company maintains significant cash and cash equivalents at two financial institutions that are in excess of federally insured limits.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:65px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;"&gt;Comprehensive Loss&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; &amp;#8212; Comprehensive loss consists of our net loss, with no other comprehensive income items for the periods presented.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:65px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:65px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;text-decoration:underline;"&gt;Effect of Recent Accounting Pronouncements&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:65px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:65px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;In April 2014, the FASB issued ASU 2014-08, Reporting Discontinued Operations and Disclosures of Disposals of Components of an Entity, or ASU 2014-08. Under ASU 2014-08, only disposals representing a strategic shift in operations that have a major effect on the company&amp;#8217;s operations and financial results should be presented as discontinued operations. Additionally, ASU 2014-08 requires expanded disclosures about discontinued operations that will provide financial statement users with more information about the assets, liabilities, income, and expenses of discontinued operations. The amendments in ASU 2014-08 are effective for fiscal years, and interim periods within those years, beginning after December 15, 2014. The company adopted this guidance in the first quarter of 2015 and has applied it in the accompanying interim financial statements for presentation and disclosure of the commercial business as discontinued operations (see Note 12). &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:36px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:65px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;In May 2014, the FASB issued ASU No.&amp;#160;2014-09,&amp;#160;Revenue from Contracts with Customers: Topic 606,&amp;#160;or ASU 2014-09. ASU 2014-09 establishes the principles for recognizing revenue and develops a common revenue standard for U.S. GAAP. The standard outlines a single comprehensive model for entities to use in accounting for revenue arising from contracts with customers and supersedes most current revenue recognition guidance, including industry-specific guidance. In applying the new revenue recognition model to contracts with customers, an entity: (1) identifies the contract(s) with a customer; (2) identifies the performance obligations in the contract(s); (3) determines the transaction price; (4) allocates the transaction price to the performance obligations in the contract(s); and (5) recognizes revenue when (or as) the entity satisfies a performance obligation.&amp;#160;The accounting standards update applies to all contracts with customers except those that are within the scope of other topics in the FASB Accounting Standards Codification.&amp;#160;The accounting standards update also requires significantly expanded quantitative and qualitative disclosures regarding the nature, amount, timing and uncertainty of revenue and cash flows arising from contracts with customers.&amp;#160;This guidance is effective for fiscal years and interim periods within those years beginning after December 15, 2016, which is effective for the company for the year ending December 31, 2017. The FASB delayed in the effective date of the accounting standards update to fiscal years and interim periods within those years beginning on or after December 15, 2017, which is pending approval.&amp;#160;The company is currently evaluating the impact that the implementation of ASU 2014-09 will have on the company&amp;#8217;s financial statements. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:36px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:65px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;In August 2014, the FASB issued ASU No. 2014-15,&amp;#160;Disclosure of Uncertainties about an Entity&amp;#8217;s Ability to Continue as a Going Concern, or ASU 2014-15. ASU 2014-15 will explicitly require management to assess an entity&amp;#8217;s ability to continue as a going concern, and to provide related footnote disclosure in certain circumstances. The new standard will be effective for all entities in the first annual period ending after December 15, 2016. Earlier adoption is permitted. The company is not early adopting ASU 2014-15. The company is currently evaluating the impact that the implementation of ASU 2014-15 will have on the company&amp;#8217;s financial statements, and the actual impact will be dependent upon the company&amp;#8217;s liquidity and the nature or significance of future events or conditions that exist upon adopting the updated standard.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:36px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:65px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;In January 2015, the FASB issued ASU No. 2015-01, Simplifying Income Statement Presentation by Eliminating the Concept of Extraordinary Items, or ASU 2015-01.&amp;#160;ASU 2015-01 eliminates from GAAP the concept of extraordinary items. ASU 2015-01 is effective for fiscal years and interim periods beginning after December 15, 2015. Early adoption is permitted. The company does not expect that the adoption of ASU 2015-01 will have a material impact on its consolidated financial statements.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock>
	<us-gaap:OtherIncomeAndOtherExpenseDisclosureTextBlock contextRef="FD2015Q3YTD" id="Fact-14C12F9236055785883C137DA7043A9D">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#00497f;font-weight:bold;"&gt;Other Income (Expense)&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:65px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Other income (expense) is summarized as follows (in thousands):&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:9pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:9pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="16" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td width="45%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="11%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="11%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="11%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="11%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;Three Months Ended September 30,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;Nine Months Ended September 30,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;2015&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;2014&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;2015&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;2014&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Change in fair value of the contingent purchase price liability&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;307&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;597&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;69&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;(59&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Total other income (expense)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;307&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;597&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;69&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;(59&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:OtherIncomeAndOtherExpenseDisclosureTextBlock>
	<us-gaap:PriorPeriodReclassificationAdjustmentDescription contextRef="FD2015Q3YTD" id="Fact-F3D23B8BD0AB546CACA2BCF6D2116B4B">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;text-indent:65px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;"&gt;Reclassifications&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; &amp;#8212; Certain prior year amounts have been reclassified to conform to current year presentation. These reclassifications had no effect on net loss per share.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:PriorPeriodReclassificationAdjustmentDescription>
	<us-gaap:PropertyPlantAndEquipmentPolicyTextBlock contextRef="FD2015Q3YTD" id="Fact-71A5319D80AE5B5AA3C6259820F89238">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;text-indent:66px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;"&gt;Equipment and Furnishings&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; &amp;#8212; Equipment and furnishings are stated at cost and depreciated using the straight-line method based on the estimated useful lives (generally &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;three&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; to &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;five&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; years) of the related assets.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:65px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:PropertyPlantAndEquipmentPolicyTextBlock>
	<us-gaap:ResearchAndDevelopmentExpensePolicy contextRef="FD2015Q3YTD" id="Fact-C9F29BB8A6CA5BDA9C39E894AC696A16">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;text-indent:65px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;"&gt;Research and Development Expenses&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; &amp;#8212; Research and development costs are expensed as incurred. Included in research and development costs are wages, benefits and other operating costs, facilities, supplies, external services and overhead related to our research and development departments, and clinical trial expenses.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:65px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:65px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Clinical trial expenses include direct costs associated with contract research organizations (CROs), as well as patient-related costs at sites at which our trials are being conducted.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:65px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:65px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Direct costs associated with our CROs are generally payable on a time and materials basis, or when certain enrollment and monitoring milestones are achieved. Expense related to a milestone is recognized in the period in which the milestone is achieved or in which we determine that it is more likely than not that it will be achieved.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:65px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:65px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;The invoicing from clinical trial sites can lag several months. We accrue these site costs based on our estimate of upfront set-up costs upon the screening of the first patient at each site, and the patient related costs based on our knowledge of patient enrollment status at each site.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ResearchAndDevelopmentExpensePolicy>
	<us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock contextRef="FD2015Q3YTD" id="Fact-4446F0BC4E555F04B6A0370F1844BDE9">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;text-indent:66px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Accrued expenses and other current liabilities consist of the following (in thousands):&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:66px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="8" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td width="71%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="12%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="12%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;September&amp;#160;30, 2015&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;December&amp;#160;31, 2014&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Clinical trial costs&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;5,179&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;6,967&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Compensation and related benefits&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;992&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;1,040&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Professional fees&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;1,121&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;821&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Interest expense&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;37&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;57&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Accrued expenses and other current liabilities&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;7,329&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;8,885&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock>
	<us-gaap:ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock contextRef="FD2015Q3YTD" id="Fact-CDF530B05F94C81AAF3BDE2DC117BF47">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;text-indent:66px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;The following table presents a reconciliation of the carrying amounts of assets and liabilities of the commercial operations to assets held for sale, net in the balance sheets (in thousands):&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:center;text-indent:0px;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:682px;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="8" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td width="490px" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="8px" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="79px" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="4px" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="5px" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="8px" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="79px" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="4px" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;September 30, 2015&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;December 31, 2014&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="8" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Carrying amounts of assets included as part of discontinued operations:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Accounts receivable&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;1,238&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;1,535&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Inventories&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;1,318&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;655&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Prepaid expenses and other current assets&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;1,064&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;1,747&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Equipment and furnishings, net&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;241&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;270&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Abstral rights, net&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;13,738&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;14,533&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Zuplenz rights&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;8,101&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;8,101&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Goodwill&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;172&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;172&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Impairment charge from classification as assets held for sale&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;(8,071&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Total current assets held for sale&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;17,801&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;27,013&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="8" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Carrying amounts of liabilities included as part of discontinued operations:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Accounts payable&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;1,359&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;385&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Accrued expenses and other current liabilities&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;6,338&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;6,784&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Total current liabilities held for sale&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;7,697&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;7,169&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:center;text-indent:66px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:66px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;The following table represents the components attributable to the commercial operations that are presented in the consolidated statement of comprehensive loss as discontinued operations (in thousands):&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:center;text-indent:0px;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:681px;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="16" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td width="300px" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="8px" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="78px" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="4px" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="5px" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="8px" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="77px" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="4px" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="5px" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="8px" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="78px" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="4px" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="5px" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="8px" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="78px" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="4px" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;Three Months Ended September 30,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;Nine Months Ended September 30,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;2015&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;2014&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;2015&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;2014&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Net revenue&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;2,166&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;1,620&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;8,298&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;6,124&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Cost of revenue&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;(712&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;(247&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;(1,573&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;(925&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Amortization of certain acquired intangible assets&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;(208&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;(70&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;(795&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;(259&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Research and development&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;(160&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;(219&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;(339&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;(619&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Selling, general, and administrative&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;(4,672&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;(3,725&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;(13,577&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;(10,954&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Non-operating income (expense)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;(17&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;(17&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Impairment charge from classification as assets held for sale&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;(8,071&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;(8,071&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Loss from discontinued operations&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;(11,674&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;(2,641&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;(16,074&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;(6,633&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:66px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:66px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;The following table presents significant operating non-cash items and capital expenditures related to discontinued operations (in thousands):&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:66px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:0px;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:682px;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="8" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td width="490px" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="8px" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="79px" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="4px" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="5px" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="8px" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="79px" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="4px" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;September 30, 2015&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;September 30, 2014&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Impairment of assets held for sale&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;8,071&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Depreciation and amortization&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;858&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;319&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Stock-based compensation&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;788&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;557&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Purchases of property and equipment&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;(34&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Cash paid for acquisition of Zuplenz rights&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;(500&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;(3,056&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock>
	<us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock contextRef="FD2015Q3YTD" id="Fact-AA5143E877A0596C8FDF8A4950C49F5B">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;text-indent:65px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;The following table summarizes the components of stock-based compensation expense in the condensed consolidated statements of comprehensive loss for the three and nine months ended &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;September&amp;#160;30, 2015&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; and 2014, respectively (in thousands):&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:65px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="16" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td width="41%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="12%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="12%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="12%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="12%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;Three Months Ended September 30,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;Nine Months Ended September 30,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;2015&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;2014&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;2015&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;2014&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Research and development&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;83&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;92&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;253&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;438&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;General and administrative&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;492&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;990&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;1,081&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;3,440&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Total stock-based compensation from continuing operations&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;575&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;1,082&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;1,334&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;3,878&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Stock based compensation from discontinued operations&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;275&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;217&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;788&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;557&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock>
	<us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock contextRef="FD2015Q3YTD" id="Fact-DFFCDFE0346B5B2CB2DB9DC5433B0F54">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;text-indent:66px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;The following tables present information about our assets and liabilities measured at fair value on a recurring basis in the condensed consolidated balance sheets (in thousands):&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:9pt;"&gt;&amp;#160;&lt;/font&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="16" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td width="41%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="12%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="12%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="12%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="12%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;font-weight:bold;text-decoration:underline;"&gt;Description&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;September&amp;#160;30, 2015&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;Quoted&amp;#160;Prices&amp;#160;In&amp;#160;&amp;#160;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;Active Markets&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;(Level 1)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;Significant&amp;#160;Other&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;Observable&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;Inputs (Level 2)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;Unobservable&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;Inputs&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;(Level 3)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Assets:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Cash equivalents&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;32,618&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;32,618&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Assets held for sale&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;17,801&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;17,801&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Total assets measured and recorded at fair value&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;50,419&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;32,618&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;17,801&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Liabilities:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Warrants potentially settleable in cash&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;16,661&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;16,661&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Contingent purchase price consideration&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;6,582&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;6,582&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Total liabilities measured and recorded at fair value&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;23,243&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;16,661&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;6,582&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="16" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td width="41%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="12%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="12%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="12%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="12%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;font-weight:bold;text-decoration:underline;"&gt;Description&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;December&amp;#160;31, 2014&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;Quoted&amp;#160;Prices&amp;#160;In&amp;#160;&amp;#160;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;Active Markets&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;(Level 1)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;Significant&amp;#160;Other&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;Observable&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;Inputs (Level 2)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;Unobservable&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;Inputs&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;(Level 3)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Assets:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Cash equivalents&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;19,477&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;19,477&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Total assets measured and recorded at fair value&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;19,477&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;19,477&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Liabilities:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Warrants potentially settleable in cash&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;5,383&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;5,383&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Contingent purchase price consideration&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;6,651&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;6,651&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Total liabilities measured and recorded at fair value&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;12,034&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;5,383&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;6,651&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock>
	<us-gaap:ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock contextRef="FD2015Q3YTD" id="Fact-24A6885A739C55209AC37C817D762A47">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#00497f;font-weight:bold;"&gt;Other Income (Expense)&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:65px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Other income (expense) is summarized as follows (in thousands):&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:9pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:9pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="16" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td width="45%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="11%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="11%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="11%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="11%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;Three Months Ended September 30,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;Nine Months Ended September 30,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;2015&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;2014&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;2015&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;2014&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Change in fair value of the contingent purchase price liability&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;307&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;597&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;69&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;(59&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Total other income (expense)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;307&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;597&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;69&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;(59&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock>
	<us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock contextRef="FD2015Q3YTD" id="Fact-BA630FC8B17E511B8B71E5214714E6A2">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;text-indent:65px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;The following table summarizes option activity of the company:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:65px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="11" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td width="56%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="13%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="12%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="12%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;Total&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;Number of&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;Shares &lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;(In Thousands)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;Weighted&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;Average&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;Exercise&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;Price&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;Aggregate&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;Intrinsic&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;Value&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;(In Thousands)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Outstanding at January&amp;#160;1, 2015&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;8,590&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;3.25&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Granted&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;3,682&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;1.73&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Exercised&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;(39&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;0.79&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;37&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Cancelled&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;(1,045&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;2.44&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;21&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Outstanding at September&amp;#160;30, 2015&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;11,188&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;2.83&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;690&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Options exercisable at September&amp;#160;30, 2015&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;6,622&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;3.32&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;618&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
	<us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock contextRef="FD2015Q3YTD" id="Fact-67F270493A095C1AAB7CCA33A6CD13D5">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;text-indent:66px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;The company uses the Black-Scholes option-pricing model and the following weighted-average assumptions to determine the fair value of all its stock options granted:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:9pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:9pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="12" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td width="41%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="13%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="13%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="13%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="13%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;Three Months Ended September 30,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;Nine Months Ended September 30,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;2015&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;2014&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;2015&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;2014&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Risk free interest rate&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;2.02&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;1.50&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;2.02&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Volatility&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;79.10&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;74.20&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;79.47&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Expected lives (years)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;0.00&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;6.12&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;6.09&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;6.15&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Expected dividend yield&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
	<us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy contextRef="FD2015Q3YTD" id="Fact-0FE141FC41AE53DFA6BC3D3D0226F03A">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;text-indent:65px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;"&gt;Share-based Compensation&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; &amp;#8212; The company follows the provisions of the FASB ASC Topic 718, &amp;#8220;&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;"&gt;Compensation&amp;#160;&amp;#8212; Stock Compensation&amp;#8221;&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; (&amp;#8220;ASC 718&amp;#8221;), which requires the measurement and recognition of compensation expense for all stock-based payment awards made to employees, non-employee directors, and consultants, including stock options and warrants. Stock compensation expense based on the grant date fair value estimated in accordance with the provisions of ASC&amp;#160;718 is recognized as an expense over the requisite service period.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:65px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:65px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;For stock options and warrants granted as consideration for services rendered by non-employees, the company recognizes compensation expense in accordance with the requirements of FASB ASC Topic 505-50 (&amp;#8220;ASC 505-50&amp;#8221;), &amp;#8220; &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;"&gt;Equity Based Payments to Non- Employees&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;.&amp;#8221; Non-employee option and warrant grants that do not vest immediately upon grant are recorded as an expense over the vesting period. At the end of each financial reporting period prior to vesting, the value of these options and warrants, as calculated using the Black-Scholes option-pricing model, is re-measured using the fair value of the company&amp;#8217;s common stock and the non-cash compensation recognized during the period is adjusted accordingly. Since the fair market value of options and warrants granted to non-employees is subject to change in the future, the amount of the future compensation expense will include fair value re-measurements until the stock options are fully vested.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy>
	<us-gaap:StockholdersEquityNoteDisclosureTextBlock contextRef="FD2015Q3YTD" id="Fact-4474E48346E75AD1862F1ED6CED3A460">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#00497f;font-weight:bold;"&gt;Stockholders&amp;#8217; Equity&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:65px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:65px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;"&gt;Preferred Stock&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; &amp;#8212; The company has authorized up to &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;5,000,000&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&amp;#160;shares of preferred stock, &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$0.0001&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&amp;#160;par value per share, for issuance. The preferred stock will have such rights, preferences, privileges and restrictions, including voting rights, dividend rights, conversion rights, redemption privileges and liquidation preferences, as shall be determined by the company&amp;#8217;s Board of Directors upon its issuance. To date, the company has not issued any preferred shares.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:65px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:65px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;"&gt;Common Stock&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; &amp;#8212; The company has authorized up to &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;275,000,000&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&amp;#160;shares of common stock, &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$0.0001&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&amp;#160;par value per share, for issuance.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:65px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:65px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;"&gt;November 2014 Purchase Agreement with Lincoln Park Capital, LLC - &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;On November 18, 2014, the company entered into a purchase agreement with Lincoln Park Capital, LLC (LPC), pursuant to which the company has the right to sell to LPC up to &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$50 million&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; in shares of the company's common stock, subject to certain limitations and conditions over the &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;36&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; month term of the purchase agreement. Pursuant to the purchase agreement, LPC initially purchased &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;2.5 million&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; shares of the company's common stock at &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$2.00&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; per share and the company issued &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;631,221&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; shares of common stock to LPC as a commitment fee, which was recorded as a cost of capital. As a result of this initial issuance, the company received initial net proceeds of &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$4.9 million&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;, after deducting commissions and other offering expenses. In addition to LPC&amp;#8217;s initial purchase of our common stock under the purchase agreement, during the first quarter of 2015, we received net proceeds of &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$4.4 million&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; from LPC&amp;#8217;s subsequent purchases of a total of &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;2.7 million&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; shares of our common stock, excluding the commitment fee shares. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:65px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:65px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;"&gt;At Market Issuance Sales Agreements &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;- On May 24, 2013 the Company entered into At Market Issuance Sales Agreements (ATM) with MLV &amp;amp; Co. LLC and Maxim Group LLC (the Agents). From time to time during the term of the ATM, we may issue and sell through the Agents, shares of our common stock, and the Agents collect a fee equal to &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;3%&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; of the gross proceeds from the sale of shares, up to a total limit of &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$20 million&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; in gross proceeds. The ATM is available to the company until it is terminated by the Agents or the company. During the first quarter of 2015, we received &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$2.3 million&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; in net proceeds from the sale of &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;1.4 million&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; shares of our common stock through the ATM. There were no sales of our common stock under the ATM during the three months ended September 30, 2015 or during the three and nine months ended September 30, 2014.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:65px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;"&gt;March 2015 Underwritten Public Offering&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; - On March 18, 2015 the company closed an underwritten public offering of &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;24,358,974&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; units at a price to the public of &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$1.56&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; per unit for gross proceeds of &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$38 million&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; (the "March 2015 Offering"). Each unit consists of one share of common stock, and a warrant to purchase &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;0.50&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; of a share of common stock at an exercise price of &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$2.08&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; per share. The March 2015 Offering included an over-allotment option for the underwriters to purchase an additional &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;3,653,846&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; shares of common stock and/or warrants to purchase up to &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;1,826,923&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; shares of common stock. On March 18, 2015, the underwriters exercised their over-allotment option to purchase warrants to purchase an aggregate of &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;1,826,923&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; shares of common stock. On April 10, 2015, the underwriters exercised their over-allotment option to purchase &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;3,653,846&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; shares of common stock for additional net proceeds of &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$5.4 million&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;. The total net proceeds of the March 2015 Offering, including the exercise of the over-allotment option to purchase the warrants, were &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$40.8 million&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;, after deducting underwriting discounts and commissions and offering expenses payable by the company. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:65px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:66px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Shares of common stock for future issuance are reserved for as follows (in thousands):&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:66px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="3" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td width="84%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="15%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;As of September&amp;#160;30, 2015&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Warrants outstanding&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;22,308&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Stock options outstanding&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;11,188&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Options reserved for future issuance under the Company&amp;#8217;s 2007 Incentive Plan&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;10,251&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Shares reserved for future issuance under the Employee Stock Purchase Plan&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;528&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Total reserved for future issuance&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;44,275&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
	<us-gaap:SubsequentEventsTextBlock contextRef="FD2015Q3YTD" id="Fact-53599F88B51A5715A42B0ED44DDF2E11">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#00497f;font-weight:bold;"&gt;Subsequent Events&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:65px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:65px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;The company evaluated all events or transactions that occurred after &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;September&amp;#160;30, 2015&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; up through the date these financial statements were issued. Other than as disclosed elsewhere in the notes to the condensed consolidated financial statements, the company did not have any material recognizable or unrecognizable subsequent events.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:SubsequentEventsTextBlock>
	<us-gaap:UseOfEstimates contextRef="FD2015Q3YTD" id="Fact-E0125FB0BDD6519FB5B0392CE79D4FE9">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;text-indent:65px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;"&gt;Uses of Estimates in Preparation of Financial Statements&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; &amp;#8212; The preparation of these consolidated financial statements in accordance with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the reporting period. Actual results could differ materially from those estimates.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:65px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:UseOfEstimates>
	<link:footnoteLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
	</link:footnoteLink>
</xbrli:xbrl>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>8
<FILENAME>gale-20150930.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!--XBRL Document Created with Wdesk from Workiva-->
<!-- -->
<xsd:schema attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://www.galenabiopharma.com/20150930" xmlns:gale="http://www.galenabiopharma.com/20150930" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:num="http://www.xbrl.org/dtr/type/numeric" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsd="http://www.w3.org/2001/XMLSchema">
  <xsd:import namespace="http://fasb.org/us-gaap/2014-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd" />
  <xsd:import namespace="http://fasb.org/us-roles/2014-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2014/elts/us-roles-2014-01-31.xsd" />
  <xsd:import namespace="http://fasb.org/us-types/2014-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2014/elts/us-types-2014-01-31.xsd" />
  <xsd:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
  <xsd:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" />
  <xsd:import namespace="http://www.xbrl.org/2009/arcrole/fact-explanatoryFact" schemaLocation="http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd" />
  <xsd:import namespace="http://www.xbrl.org/2009/role/negated" schemaLocation="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd" />
  <xsd:import namespace="http://www.xbrl.org/2009/role/net" schemaLocation="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd" />
  <xsd:import namespace="http://www.xbrl.org/dtr/type/non-numeric" schemaLocation="http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd" />
  <xsd:import namespace="http://www.xbrl.org/dtr/type/numeric" schemaLocation="http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd" />
  <xsd:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/country/2013-01-31" schemaLocation="http://xbrl.sec.gov/country/2013/country-2013-01-31.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/currency/2014-01-31" schemaLocation="http://xbrl.sec.gov/currency/2014/currency-2014-01-31.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/dei/2014-01-31" schemaLocation="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/exch/2014-01-31" schemaLocation="http://xbrl.sec.gov/exch/2014/exch-2014-01-31.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/invest/2013-01-31" schemaLocation="http://xbrl.sec.gov/invest/2013/invest-2013-01-31.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/naics/2011-01-31" schemaLocation="http://xbrl.sec.gov/naics/2011/naics-2011-01-31.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/sic/2011-01-31" schemaLocation="http://xbrl.sec.gov/sic/2011/sic-2011-01-31.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/stpr/2011-01-31" schemaLocation="http://xbrl.sec.gov/stpr/2011/stpr-2011-01-31.xsd" />
  <xsd:annotation>
    <xsd:appinfo>
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="gale-20150930_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:type="simple" />
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="gale-20150930_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:type="simple" />
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="gale-20150930_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple" />
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="gale-20150930_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple" />
      <link:roleType id="AccruedExpensesAndOtherCurrentLiabilities" roleURI="http://www.galenabiopharma.com/role/AccruedExpensesAndOtherCurrentLiabilities">
        <link:definition>2106100 - Disclosure - Accrued Expenses and Other Current Liabilities</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AccruedExpensesAndOtherCurrentLiabilitiesDetails" roleURI="http://www.galenabiopharma.com/role/AccruedExpensesAndOtherCurrentLiabilitiesDetails">
        <link:definition>2406402 - Disclosure - Accrued Expenses and Other Current Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AccruedExpensesAndOtherCurrentLiabilitiesTables" roleURI="http://www.galenabiopharma.com/role/AccruedExpensesAndOtherCurrentLiabilitiesTables">
        <link:definition>2306301 - Disclosure - Accrued Expenses and Other Current Liabilities (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BusinessAndBasisOfPresentation" roleURI="http://www.galenabiopharma.com/role/BusinessAndBasisOfPresentation">
        <link:definition>2101100 - Disclosure - Business and Basis of Presentation</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BusinessAndBasisOfPresentationAdditionalInformationDetail" roleURI="http://www.galenabiopharma.com/role/BusinessAndBasisOfPresentationAdditionalInformationDetail">
        <link:definition>2401402 - Disclosure - Business and Basis of Presentation (Additional Information) (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BusinessAndBasisOfPresentationPolicies" roleURI="http://www.galenabiopharma.com/role/BusinessAndBasisOfPresentationPolicies">
        <link:definition>2201201 - Disclosure - Business and Basis of Presentation (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BusinessCombinations" roleURI="http://www.galenabiopharma.com/role/BusinessCombinations">
        <link:definition>2102100 - Disclosure - Business Combinations</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BusinessCombinationsDetails" roleURI="http://www.galenabiopharma.com/role/BusinessCombinationsDetails">
        <link:definition>2402402 - Disclosure - Business Combinations (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BusinessCombinationsTables" roleURI="http://www.galenabiopharma.com/role/BusinessCombinationsTables">
        <link:definition>2302301 - Disclosure - Business Combinations (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedBalanceSheets" roleURI="http://www.galenabiopharma.com/role/CondensedConsolidatedBalanceSheets">
        <link:definition>1001000 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedBalanceSheetsParenthetical" roleURI="http://www.galenabiopharma.com/role/CondensedConsolidatedBalanceSheetsParenthetical">
        <link:definition>1001501 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedStatementOfStockholdersEquityCondensedConsolidatedStatementOfStockholdersEquity" roleURI="http://www.galenabiopharma.com/role/CondensedConsolidatedStatementOfStockholdersEquityCondensedConsolidatedStatementOfStockholdersEquity">
        <link:definition>1003000 - Statement - CONDENSED CONSOLIDATED STATEMENT OF STOCKHOLDERS' EQUITY CONDENSED CONSOLIDATED STATEMENT OF STOCKHOLDERS' EQUITY</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedStatementsOfCashFlows" roleURI="http://www.galenabiopharma.com/role/CondensedConsolidatedStatementsOfCashFlows">
        <link:definition>1004000 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedStatementsOfComprehensiveLoss" roleURI="http://www.galenabiopharma.com/role/CondensedConsolidatedStatementsOfComprehensiveLoss">
        <link:definition>1002000 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DiscontinuedOperationsAssetsHeldForSaleCarryingAmountsOfAssetsAndLiabilitiesDetails" roleURI="http://www.galenabiopharma.com/role/DiscontinuedOperationsAssetsHeldForSaleCarryingAmountsOfAssetsAndLiabilitiesDetails">
        <link:definition>2416403 - Disclosure - Discontinued Operations, Assets Held for Sale - Carrying Amounts of Assets and LIabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DiscontinuedOperationsAssetsHeldForSaleComponentsAttributableToCommercialBusinessDetails" roleURI="http://www.galenabiopharma.com/role/DiscontinuedOperationsAssetsHeldForSaleComponentsAttributableToCommercialBusinessDetails">
        <link:definition>2416404 - Disclosure - Discontinued Operations, Assets Held for Sale - Components Attributable to Commercial Business (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DiscontinuedOperationsAssetsHeldForSaleDetails" roleURI="http://www.galenabiopharma.com/role/DiscontinuedOperationsAssetsHeldForSaleDetails">
        <link:definition>2416402 - Disclosure - Discontinued Operations, Assets Held for Sale (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DiscontinuedOperationsAssetsHeldForSaleNotes" roleURI="http://www.galenabiopharma.com/role/DiscontinuedOperationsAssetsHeldForSaleNotes">
        <link:definition>2116100 - Disclosure - Discontinued Operations, Assets Held for Sale (Notes)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DiscontinuedOperationsAssetsHeldForSaleSignificantOperatingNonCashAndCapitalExpendituresDetails" roleURI="http://www.galenabiopharma.com/role/DiscontinuedOperationsAssetsHeldForSaleSignificantOperatingNonCashAndCapitalExpendituresDetails">
        <link:definition>2416405 - Disclosure - Discontinued Operations, Assets Held for Sale - Significant Operating Non-cash and Capital Expenditures (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DiscontinuedOperationsAssetsHeldForSaleTables" roleURI="http://www.galenabiopharma.com/role/DiscontinuedOperationsAssetsHeldForSaleTables">
        <link:definition>2316301 - Disclosure - Discontinued Operations, Assets Held for Sale (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DocumentAndEntityInformation" roleURI="http://www.galenabiopharma.com/role/DocumentAndEntityInformation">
        <link:definition>0001000 - Document - Document and Entity Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurements" roleURI="http://www.galenabiopharma.com/role/FairValueMeasurements">
        <link:definition>2105100 - Disclosure - Fair Value Measurements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsContingentPurchasePriceConsiderationMeasuredAtEstimatedFairValueOnRecurringBasisDetail" roleURI="http://www.galenabiopharma.com/role/FairValueMeasurementsContingentPurchasePriceConsiderationMeasuredAtEstimatedFairValueOnRecurringBasisDetail">
        <link:definition>2405402 - Disclosure - Fair Value Measurements (Contingent Purchase Price Consideration, Measured at Estimated Fair Value on Recurring Basis) (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsReconciliationOfLevel3LiabilitiesDetail" roleURI="http://www.galenabiopharma.com/role/FairValueMeasurementsReconciliationOfLevel3LiabilitiesDetail">
        <link:definition>2405403 - Disclosure - Fair Value Measurements (Reconciliation of Level 3 Liabilities) (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsTables" roleURI="http://www.galenabiopharma.com/role/FairValueMeasurementsTables">
        <link:definition>2305301 - Disclosure - Fair Value Measurements (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LegalProceedingsCommitmentsAndContingenciesDetailsDetails" roleURI="http://www.galenabiopharma.com/role/LegalProceedingsCommitmentsAndContingenciesDetailsDetails">
        <link:definition>2408401 - Disclosure - Legal Proceedings, Commitments and Contingencies Details (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LegalProceedingsCommitmentsAndContingenciesNotes" roleURI="http://www.galenabiopharma.com/role/LegalProceedingsCommitmentsAndContingenciesNotes">
        <link:definition>2108100 - Disclosure - Legal Proceedings, Commitments and Contingencies (Notes)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LicenseAgreements" roleURI="http://www.galenabiopharma.com/role/LicenseAgreements">
        <link:definition>2114100 - Disclosure - License Agreements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LicenseAgreementsAdditionalInformationDetail" roleURI="http://www.galenabiopharma.com/role/LicenseAgreementsAdditionalInformationDetail">
        <link:definition>2414401 - Disclosure - License Agreements (Additional Information) (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LongTermDebt" roleURI="http://www.galenabiopharma.com/role/LongTermDebt">
        <link:definition>2107100 - Disclosure - Long-term Debt</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LongTermDebtDetails" roleURI="http://www.galenabiopharma.com/role/LongTermDebtDetails">
        <link:definition>2407401 - Disclosure - Long-term Debt (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NetLossPerShare" roleURI="http://www.galenabiopharma.com/role/NetLossPerShare">
        <link:definition>2113100 - Disclosure - Net Loss Per Share</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NetLossPerShareCommonSharesExcludedFromNetLossDetail" roleURI="http://www.galenabiopharma.com/role/NetLossPerShareCommonSharesExcludedFromNetLossDetail">
        <link:definition>2413402 - Disclosure - Net Loss Per Share (Common Shares Excluded from Net Loss) (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NetLossPerShareTables" roleURI="http://www.galenabiopharma.com/role/NetLossPerShareTables">
        <link:definition>2313301 - Disclosure - Net Loss Per Share (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OtherIncomeExpenseNotes" roleURI="http://www.galenabiopharma.com/role/OtherIncomeExpenseNotes">
        <link:definition>2112100 - Disclosure - Other Income (Expense) (Notes)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OtherIncomeExpenseTableDetails" roleURI="http://www.galenabiopharma.com/role/OtherIncomeExpenseTableDetails">
        <link:definition>2412402 - Disclosure - Other Income (Expense) Table (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OtherIncomeExpenseTables" roleURI="http://www.galenabiopharma.com/role/OtherIncomeExpenseTables">
        <link:definition>2312301 - Disclosure - Other Income (Expense) (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SignificantCustomersAndConcentrationOfCreditRiskDetails" roleURI="http://www.galenabiopharma.com/role/SignificantCustomersAndConcentrationOfCreditRiskDetails">
        <link:definition>2415402 - Disclosure - Significant Customers and Concentration of Credit Risk (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SignificantCustomersAndConcentrationOfCreditRiskNotes" roleURI="http://www.galenabiopharma.com/role/SignificantCustomersAndConcentrationOfCreditRiskNotes">
        <link:definition>2115100 - Disclosure - Significant Customers and Concentration of Credit Risk (Notes)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SignificantCustomersAndConcentrationOfCreditRiskSignificantCustomersAndConcentrationOfCreditRiskTables" roleURI="http://www.galenabiopharma.com/role/SignificantCustomersAndConcentrationOfCreditRiskSignificantCustomersAndConcentrationOfCreditRiskTables">
        <link:definition>2315301 - Disclosure - Significant Customers and Concentration of Credit Risk Significant Customers and Concentration of Credit Risk (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensation" roleURI="http://www.galenabiopharma.com/role/StockBasedCompensation">
        <link:definition>2111100 - Disclosure - Stock Based Compensation</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationAdditionalInformationDetail" roleURI="http://www.galenabiopharma.com/role/StockBasedCompensationAdditionalInformationDetail">
        <link:definition>2411404 - Disclosure - Stock Based Compensation (Additional Information) (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationAllocatedStockBasedCompensationDetails" roleURI="http://www.galenabiopharma.com/role/StockBasedCompensationAllocatedStockBasedCompensationDetails">
        <link:definition>2411402 - Disclosure - Stock Based Compensation (Allocated Stock-based Compensation) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationAssumptionsForOptionGrantsIssuedDetail" roleURI="http://www.galenabiopharma.com/role/StockBasedCompensationAssumptionsForOptionGrantsIssuedDetail">
        <link:definition>2411403 - Disclosure - Stock Based Compensation (Assumptions for Option Grants Issued) (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationStockOptionActivityDetail" roleURI="http://www.galenabiopharma.com/role/StockBasedCompensationStockOptionActivityDetail">
        <link:definition>2411405 - Disclosure - Stock Based Compensation (Stock Option Activity) (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationTables" roleURI="http://www.galenabiopharma.com/role/StockBasedCompensationTables">
        <link:definition>2311301 - Disclosure - Stock Based Compensation (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockholdersEquity" roleURI="http://www.galenabiopharma.com/role/StockholdersEquity">
        <link:definition>2109100 - Disclosure - Stockholders' Equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockholdersEquityAdditionalInformationDetail" roleURI="http://www.galenabiopharma.com/role/StockholdersEquityAdditionalInformationDetail">
        <link:definition>2409402 - Disclosure - Stockholders' Equity (Additional Information) (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockholdersEquityCommonStockAreReservedForFutureIssuanceDetail" roleURI="http://www.galenabiopharma.com/role/StockholdersEquityCommonStockAreReservedForFutureIssuanceDetail">
        <link:definition>2409403 - Disclosure - Stockholders' Equity (Common Stock are Reserved for Future Issuance) (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockholdersEquityTables" roleURI="http://www.galenabiopharma.com/role/StockholdersEquityTables">
        <link:definition>2309301 - Disclosure - Stockholders' Equity (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SubsequentEvents" roleURI="http://www.galenabiopharma.com/role/SubsequentEvents">
        <link:definition>2117100 - Disclosure - Subsequent Events</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Warrants" roleURI="http://www.galenabiopharma.com/role/Warrants">
        <link:definition>2110100 - Disclosure - Warrants</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="WarrantsChangesInFairValueOfWarrantLiabilityDetail" roleURI="http://www.galenabiopharma.com/role/WarrantsChangesInFairValueOfWarrantLiabilityDetail">
        <link:definition>2410404 - Disclosure - Warrants (Changes in Fair Value of Warrant Liability) (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="WarrantsFairValueOfWarrantsIsEstimatedUsingBlackScholesOptionPricingModelDetail" roleURI="http://www.galenabiopharma.com/role/WarrantsFairValueOfWarrantsIsEstimatedUsingBlackScholesOptionPricingModelDetail">
        <link:definition>2410403 - Disclosure - Warrants (Fair Value of Warrants is Estimated Using Black-Scholes Option Pricing Model) (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="WarrantsScheduleOfWarrantActivityDetail" roleURI="http://www.galenabiopharma.com/role/WarrantsScheduleOfWarrantActivityDetail">
        <link:definition>2410402 - Disclosure - Warrants (Schedule of Warrant Activity) (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="WarrantsTables" roleURI="http://www.galenabiopharma.com/role/WarrantsTables">
        <link:definition>2310301 - Disclosure - Warrants (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="WarrantsWarrantsClassifiedAsEquityDetails" roleURI="http://www.galenabiopharma.com/role/WarrantsWarrantsClassifiedAsEquityDetails">
        <link:definition>2410405 - Disclosure - Warrants (Warrants Classified as Equity) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xsd:appinfo>
  </xsd:annotation>
  <xsd:element abstract="true" id="gale_AbstralMember" name="AbstralMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="gale_AbstralRightsNetMember" name="AbstralRightsNetMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="gale_AccruedInventoryPurchasesCurrent" name="AccruedInventoryPurchasesCurrent" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element id="gale_AnnualMaintenanceFee" name="AnnualMaintenanceFee" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element abstract="true" id="gale_AprilTwoThousandElevenWarrantMember" name="AprilTwoThousandElevenWarrantMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="gale_AtMarketIssuanceSalesAgreementsMaximumGrossProceeds" name="AtMarketIssuanceSalesAgreementsMaximumGrossProceeds" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element id="gale_AtMarketIssuanceSalesAgreementsPercentofGrossProceeds" name="AtMarketIssuanceSalesAgreementsPercentofGrossProceeds" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="instant" />
  <xsd:element id="gale_BusinessAcquisitionCashHeldByAcquiredEntity" name="BusinessAcquisitionCashHeldByAcquiredEntity" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant" />
  <xsd:element id="gale_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedRights" name="BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedRights" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant" />
  <xsd:element id="gale_ChangeInFairValueOfCommonStockWarrantsIssuedInConnectionWithVariousEquityFinancings" name="ChangeInFairValueOfCommonStockWarrantsIssuedInConnectionWithVariousEquityFinancings" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element id="gale_ChangeInFairValueOfContingentPurchaseConsideration" name="ChangeInFairValueOfContingentPurchaseConsideration" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element id="gale_ChangeInFairValueOfContingentPurchasePriceConsideration" name="ChangeInFairValueOfContingentPurchasePriceConsideration" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element id="gale_ChangeInFairValueOfWarrantLiabilities" name="ChangeInFairValueOfWarrantLiabilities" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element id="gale_ChangesInFairValueOfWarrantLiabilityTableTextBlock" name="ChangesInFairValueOfWarrantLiabilityTableTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration" />
  <xsd:element id="gale_ClassOfWarrantsOrRightsExpirationDate" name="ClassOfWarrantsOrRightsExpirationDate" nillable="true" substitutionGroup="xbrli:item" type="xbrli:dateItemType" xbrli:periodType="duration" />
  <xsd:element id="gale_ClassofWarrantorRightAverageMarketPriceUsedForExercisePrice" name="ClassofWarrantorRightAverageMarketPriceUsedForExercisePrice" nillable="true" substitutionGroup="xbrli:item" type="xbrli:durationItemType" xbrli:periodType="duration" />
  <xsd:element id="gale_ClassofWarrantorRightExpired" name="ClassofWarrantorRightExpired" nillable="true" substitutionGroup="xbrli:item" type="xbrli:sharesItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="gale_ClassofWarrantorRightFairValueRollForward" name="ClassofWarrantorRightFairValueRollForward" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration" />
  <xsd:element id="gale_ClassofWarrantorRightGranted" name="ClassofWarrantorRightGranted" nillable="true" substitutionGroup="xbrli:item" type="xbrli:sharesItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="gale_ClassofWarrantorRightOutstandingRollForward" name="ClassofWarrantorRightOutstandingRollForward" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration" />
  <xsd:element id="gale_ClassofWarrantorRightTerm" name="ClassofWarrantorRightTerm" nillable="true" substitutionGroup="xbrli:item" type="xbrli:durationItemType" xbrli:periodType="duration" />
  <xsd:element id="gale_ClosingPriceOfCommonStock" name="ClosingPriceOfCommonStock" nillable="true" substitutionGroup="xbrli:item" type="num:perShareItemType" xbrli:periodType="instant" />
  <xsd:element abstract="true" id="gale_CommercialBusinessSegmentMember" name="CommercialBusinessSegmentMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="gale_CommonStockAreReservedForFutureIssuanceTableTextBlock" name="CommonStockAreReservedForFutureIssuanceTableTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration" />
  <xsd:element id="gale_CommonStockCapitalSharesReservedForFutureIssuanceOfEmployeeStockPurchasePlan" name="CommonStockCapitalSharesReservedForFutureIssuanceOfEmployeeStockPurchasePlan" nillable="true" substitutionGroup="xbrli:item" type="xbrli:sharesItemType" xbrli:periodType="instant" />
  <xsd:element abstract="true" id="gale_ConsultantWarrantsMember" name="ConsultantWarrantsMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="gale_ContingentConsiderationPolicyPolicyTextBlock" name="ContingentConsiderationPolicyPolicyTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration" />
  <xsd:element id="gale_ContingentPurchasePriceConsiderationNetOfCurrentPortion" name="ContingentPurchasePriceConsiderationNetOfCurrentPortion" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element id="gale_ContractResearchPayable" name="ContractResearchPayable" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element id="gale_ContractualObligationNetSalesThreshold" name="ContractualObligationNetSalesThreshold" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element id="gale_ContractualObligationPotentialPaymentsfromNetSales" name="ContractualObligationPotentialPaymentsfromNetSales" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element id="gale_CreditMemosAcquisitionChannelInventoryCurrent" name="CreditMemosAcquisitionChannelInventoryCurrent" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element abstract="true" id="gale_CustomerFiveMember" name="CustomerFiveMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="gale_CustomerFourMember" name="CustomerFourMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="gale_CustomerOneMember" name="CustomerOneMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="gale_CustomerThreeMember" name="CustomerThreeMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="gale_CustomerTwoMember" name="CustomerTwoMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="gale_DebtInstrumentCashFacilityFee" name="DebtInstrumentCashFacilityFee" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="instant" />
  <xsd:element id="gale_DebtInstrumentCashFinalPayment" name="DebtInstrumentCashFinalPayment" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="instant" />
  <xsd:element id="gale_DebtInstrumentTermInterestOnly" name="DebtInstrumentTermInterestOnly" nillable="true" substitutionGroup="xbrli:item" type="xbrli:durationItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="gale_DecemberTwoThousandTwelveWarrantMember" name="DecemberTwoThousandTwelveWarrantMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="gale_DeficitAccumulatedDuringDevelopmentalStage" name="DeficitAccumulatedDuringDevelopmentalStage" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element id="gale_DisposalGroupIncludingDiscontinuedOperationContingentLiabilityFromDivestitureAgreement" name="DisposalGroupIncludingDiscontinuedOperationContingentLiabilityFromDivestitureAgreement" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element id="gale_DisposalGroupIncludingDiscontinuedOperationContingentLiabilityPercentageofConsideration" name="DisposalGroupIncludingDiscontinuedOperationContingentLiabilityPercentageofConsideration" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="instant" />
  <xsd:element id="gale_DisposalGroupIncludingDiscontinuedOperationContingentRetentionFees" name="DisposalGroupIncludingDiscontinuedOperationContingentRetentionFees" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element id="gale_DisposalGroupIncludingDiscontinuedOperationContingentRetentionFeesPercentageofConsiderationReceived" name="DisposalGroupIncludingDiscontinuedOperationContingentRetentionFeesPercentageofConsiderationReceived" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="instant" />
  <xsd:element id="gale_DisposalGroupIncludingDiscontinuedOperationResearchandDevelopment" name="DisposalGroupIncludingDiscontinuedOperationResearchandDevelopment" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="gale_DocumentDocumentAndEntityInformationAbstract" name="DocumentDocumentAndEntityInformationAbstract" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration" />
  <xsd:element id="gale_EmployeeServiceShareBasedCompensationUnrecognizedCompensationCosts" name="EmployeeServiceShareBasedCompensationUnrecognizedCompensationCosts" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element id="gale_EmployeeServiceShareBasedCompensationUnrecognizedCompensationCostsWeightedAveragePeriodOfRecognition" name="EmployeeServiceShareBasedCompensationUnrecognizedCompensationCostsWeightedAveragePeriodOfRecognition" nillable="true" substitutionGroup="xbrli:item" type="xbrli:durationItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="gale_EquipmentFurnitureAndFixturesMember" name="EquipmentFurnitureAndFixturesMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="gale_EstimatedAnnualizedForfeitureRateForOptionsGrantedToEmployees" name="EstimatedAnnualizedForfeitureRateForOptionsGrantedToEmployees" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="duration" />
  <xsd:element id="gale_EstimatedAnnualizedForfeitureRateForOptionsGrantedToSeniorManagement" name="EstimatedAnnualizedForfeitureRateForOptionsGrantedToSeniorManagement" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="duration" />
  <xsd:element id="gale_EstimatedYearOfPatentExpiration" name="EstimatedYearOfPatentExpiration" nillable="true" substitutionGroup="xbrli:item" type="xbrli:gYearItemType" xbrli:periodType="duration" />
  <xsd:element id="gale_FairValueOfWarrantLiabilityAssumptionsExpectedTerm" name="FairValueOfWarrantLiabilityAssumptionsExpectedTerm" nillable="true" substitutionGroup="xbrli:item" type="xbrli:durationItemType" xbrli:periodType="duration" />
  <xsd:element id="gale_FairValueOfWarrantsIssuedInConnectionWithCommonStockRecordedAsCostOfEquity" name="FairValueOfWarrantsIssuedInConnectionWithCommonStockRecordedAsCostOfEquity" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element id="gale_FairValueOfWarrantsLiabilities" name="FairValueOfWarrantsLiabilities" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element id="gale_FairValueOfWarrantsPotentiallySettleableInCash" name="FairValueOfWarrantsPotentiallySettleableInCash" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element id="gale_FairValueofWarrantsGranted" name="FairValueofWarrantsGranted" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element id="gale_FairValueofWarrantsGrantedperShare" name="FairValueofWarrantsGrantedperShare" nillable="true" substitutionGroup="xbrli:item" type="num:perShareItemType" xbrli:periodType="instant" />
  <xsd:element id="gale_FinitelivedIntangibleAssetsAcquiredContingentConsideration" name="FinitelivedIntangibleAssetsAcquiredContingentConsideration" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element id="gale_FinitelivedIntangibleAssetsAcquiredContingentConsiderationPaymentPeriod" name="FinitelivedIntangibleAssetsAcquiredContingentConsiderationPaymentPeriod" nillable="true" substitutionGroup="xbrli:item" type="xbrli:durationItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="gale_FirstTrancheMember" name="FirstTrancheMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="gale_FutureMilestonePayment" name="FutureMilestonePayment" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element id="gale_GALE401rights" name="GALE401rights" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant" />
  <xsd:element id="gale_InProcessResearchDevelopment" name="InProcessResearchDevelopment" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant" />
  <xsd:element abstract="true" id="gale_LicenseAndCollaborationAgreementsLineItems" name="LicenseAndCollaborationAgreementsLineItems" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="gale_LicenseAndCollaborationAgreementsTable" name="LicenseAndCollaborationAgreementsTable" nillable="true" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="gale_LincolnParkCapitalLLCMember" name="LincolnParkCapitalLLCMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="gale_LossContingencyPercentageofLegalFeesPaid" name="LossContingencyPercentageofLegalFeesPaid" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="instant" />
  <xsd:element id="gale_LossOnWarrantExchange" name="LossOnWarrantExchange" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="gale_MDAndersonCancerCenterMember" name="MDAndersonCancerCenterMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="gale_MLVCo.LLCandMaximGroupLLCMember" name="MLVCo.LLCandMaximGroupLLCMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="gale_MarchTwoThousandElevenWarrantMember" name="MarchTwoThousandElevenWarrantMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="gale_MarchTwoThousandFifteenWarrantsMember" name="MarchTwoThousandFifteenWarrantsMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="gale_MarchTwoThousandTenWarrantMember" name="MarchTwoThousandTenWarrantMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="gale_MaximumMaturityPeriodToConsiderAllHighlyLiquidDebtInstrumentsAsCashAndCashEquivalents" name="MaximumMaturityPeriodToConsiderAllHighlyLiquidDebtInstrumentsAsCashAndCashEquivalents" nillable="true" substitutionGroup="xbrli:item" type="xbrli:durationItemType" xbrli:periodType="duration" />
  <xsd:element id="gale_MiscellaneousOtherIncomeExpense" name="MiscellaneousOtherIncomeExpense" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element id="gale_NetProceedsFromExerciseOfCommonStockWarrants" name="NetProceedsFromExerciseOfCommonStockWarrants" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element id="gale_NumberofCommericalProducts" name="NumberofCommericalProducts" nillable="true" substitutionGroup="xbrli:item" type="xbrli:integerItemType" xbrli:periodType="instant" />
  <xsd:element id="gale_NumberofDaysAveragedforExercisePrice" name="NumberofDaysAveragedforExercisePrice" nillable="true" substitutionGroup="xbrli:item" type="xbrli:durationItemType" xbrli:periodType="duration" />
  <xsd:element id="gale_NumberofDosingStrengths" name="NumberofDosingStrengths" nillable="true" substitutionGroup="xbrli:item" type="xbrli:integerItemType" xbrli:periodType="instant" />
  <xsd:element id="gale_NumberofPatientsDiagnosedWithBreastCancerPatientsAnnually" name="NumberofPatientsDiagnosedWithBreastCancerPatientsAnnually" nillable="true" substitutionGroup="xbrli:item" type="xbrli:integerItemType" xbrli:periodType="duration" />
  <xsd:element id="gale_NumberofPatientsDiagnosedWithBreastCancerPatientsAnnuallyAtHighRiskofDiseaseRecurrence" name="NumberofPatientsDiagnosedWithBreastCancerPatientsAnnuallyAtHighRiskofDiseaseRecurrence" nillable="true" substitutionGroup="xbrli:item" type="xbrli:integerItemType" xbrli:periodType="duration" />
  <xsd:element id="gale_NumberofSharesPerUnit" name="NumberofSharesPerUnit" nillable="true" substitutionGroup="xbrli:item" type="xbrli:sharesItemType" xbrli:periodType="instant" />
  <xsd:element id="gale_NumberofTopPerformingPharmacies" name="NumberofTopPerformingPharmacies" nillable="true" substitutionGroup="xbrli:item" type="xbrli:integerItemType" xbrli:periodType="duration" />
  <xsd:element id="gale_OptionsReservedForFutureIssuanceUnderCompaniesIncentivePlan" name="OptionsReservedForFutureIssuanceUnderCompaniesIncentivePlan" nillable="true" substitutionGroup="xbrli:item" type="xbrli:sharesItemType" xbrli:periodType="instant" />
  <xsd:element abstract="true" id="gale_OrexoMember" name="OrexoMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="gale_PatentsAndPatentApplicationCostsPolicyPolicyTextBlock" name="PatentsAndPatentApplicationCostsPolicyPolicyTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration" />
  <xsd:element id="gale_PatientAssistanceProgramCurrent" name="PatientAssistanceProgramCurrent" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element id="gale_PercentageofCancerPatientsAffectedbyInadequatelyControlledBreakthroughCancerPainBTcP" name="PercentageofCancerPatientsAffectedbyInadequatelyControlledBreakthroughCancerPainBTcP" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="duration" />
  <xsd:element id="gale_ProceedsFromIssuanceorSaleofEquityNetUnderwritingDiscountsCommissionsandOfferingExpenses" name="ProceedsFromIssuanceorSaleofEquityNetUnderwritingDiscountsCommissionsandOfferingExpenses" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element id="gale_PurchaseAgreementTerm" name="PurchaseAgreementTerm" nillable="true" substitutionGroup="xbrli:item" type="xbrli:durationItemType" xbrli:periodType="duration" />
  <xsd:element id="gale_ReclassificationOfWarrantLiabilityUponExercise" name="ReclassificationOfWarrantLiabilityUponExercise" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element id="gale_SalesAndDistributionsRights" name="SalesAndDistributionsRights" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant" />
  <xsd:element id="gale_SalesAndDistributionsRightsZuplenz" name="SalesAndDistributionsRightsZuplenz" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant" />
  <xsd:element id="gale_ScheduleOfEarningPerShareToCommonShareholdersTableTextBlock" name="ScheduleOfEarningPerShareToCommonShareholdersTableTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="gale_ScheduleOfSummaryOfSignificantAccountingPoliciesLineItems" name="ScheduleOfSummaryOfSignificantAccountingPoliciesLineItems" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="gale_ScheduleOfSummaryOfSignificantAccountingPoliciesTable" name="ScheduleOfSummaryOfSignificantAccountingPoliciesTable" nillable="true" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType" xbrli:periodType="duration" />
  <xsd:element id="gale_ScheduleOfWarrantActivityTableTableTextBlock" name="ScheduleOfWarrantActivityTableTableTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration" />
  <xsd:element id="gale_ScheduleOfWarrantValuationAssumptionsTableTextBlock" name="ScheduleOfWarrantValuationAssumptionsTableTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="gale_SeptemberTwoThousandThirteenWarrantMember" name="SeptemberTwoThousandThirteenWarrantMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="gale_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationPeriod" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationPeriod" nillable="true" substitutionGroup="xbrli:item" type="xbrli:durationItemType" xbrli:periodType="duration" />
  <xsd:element id="gale_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpiredInPeriodIntrinsicValue" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpiredInPeriodIntrinsicValue" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element id="gale_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateAggregateIntrinsicValue" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateAggregateIntrinsicValue" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element id="gale_StockIssuedDuringPeriodSharesOverallotmentOption" name="StockIssuedDuringPeriodSharesOverallotmentOption" nillable="true" substitutionGroup="xbrli:item" type="xbrli:sharesItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="gale_TwoZeroZeroSevenIncentivePlanMember" name="TwoZeroZeroSevenIncentivePlanMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="gale_WarrantStrikePrice" name="WarrantStrikePrice" nillable="true" substitutionGroup="xbrli:item" type="num:perShareItemType" xbrli:periodType="instant" />
  <xsd:element id="gale_WarrantsFairValueAssumptionsExpectedVolatility" name="WarrantsFairValueAssumptionsExpectedVolatility" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="instant" />
  <xsd:element id="gale_WarrantsFairValueAssumptionsRiskFreeInterestRate" name="WarrantsFairValueAssumptionsRiskFreeInterestRate" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="instant" />
  <xsd:element id="gale_WarrantsGrantedNumberofShares" name="WarrantsGrantedNumberofShares" nillable="true" substitutionGroup="xbrli:item" type="xbrli:sharesItemType" xbrli:periodType="instant" />
  <xsd:element abstract="true" id="gale_ZuplenzMember" name="ZuplenzMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="gale_ZuplenzRightsMember" name="ZuplenzRightsMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
</xsd:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>9
<FILENAME>gale-20150930_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!--XBRL Document Created with Wdesk from Workiva-->
<!-- -->
<linkbase xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
  <roleRef roleURI="http://www.galenabiopharma.com/role/AccruedExpensesAndOtherCurrentLiabilities" xlink:href="gale-20150930.xsd#AccruedExpensesAndOtherCurrentLiabilities" xlink:type="simple" />
  <roleRef roleURI="http://www.galenabiopharma.com/role/AccruedExpensesAndOtherCurrentLiabilitiesDetails" xlink:href="gale-20150930.xsd#AccruedExpensesAndOtherCurrentLiabilitiesDetails" xlink:type="simple" />
  <roleRef roleURI="http://www.galenabiopharma.com/role/AccruedExpensesAndOtherCurrentLiabilitiesTables" xlink:href="gale-20150930.xsd#AccruedExpensesAndOtherCurrentLiabilitiesTables" xlink:type="simple" />
  <roleRef roleURI="http://www.galenabiopharma.com/role/BusinessAndBasisOfPresentation" xlink:href="gale-20150930.xsd#BusinessAndBasisOfPresentation" xlink:type="simple" />
  <roleRef roleURI="http://www.galenabiopharma.com/role/BusinessAndBasisOfPresentationAdditionalInformationDetail" xlink:href="gale-20150930.xsd#BusinessAndBasisOfPresentationAdditionalInformationDetail" xlink:type="simple" />
  <roleRef roleURI="http://www.galenabiopharma.com/role/BusinessAndBasisOfPresentationPolicies" xlink:href="gale-20150930.xsd#BusinessAndBasisOfPresentationPolicies" xlink:type="simple" />
  <roleRef roleURI="http://www.galenabiopharma.com/role/BusinessCombinations" xlink:href="gale-20150930.xsd#BusinessCombinations" xlink:type="simple" />
  <roleRef roleURI="http://www.galenabiopharma.com/role/BusinessCombinationsDetails" xlink:href="gale-20150930.xsd#BusinessCombinationsDetails" xlink:type="simple" />
  <roleRef roleURI="http://www.galenabiopharma.com/role/BusinessCombinationsTables" xlink:href="gale-20150930.xsd#BusinessCombinationsTables" xlink:type="simple" />
  <roleRef roleURI="http://www.galenabiopharma.com/role/CondensedConsolidatedBalanceSheets" xlink:href="gale-20150930.xsd#CondensedConsolidatedBalanceSheets" xlink:type="simple" />
  <roleRef roleURI="http://www.galenabiopharma.com/role/CondensedConsolidatedBalanceSheetsParenthetical" xlink:href="gale-20150930.xsd#CondensedConsolidatedBalanceSheetsParenthetical" xlink:type="simple" />
  <roleRef roleURI="http://www.galenabiopharma.com/role/CondensedConsolidatedStatementOfStockholdersEquityCondensedConsolidatedStatementOfStockholdersEquity" xlink:href="gale-20150930.xsd#CondensedConsolidatedStatementOfStockholdersEquityCondensedConsolidatedStatementOfStockholdersEquity" xlink:type="simple" />
  <roleRef roleURI="http://www.galenabiopharma.com/role/CondensedConsolidatedStatementsOfCashFlows" xlink:href="gale-20150930.xsd#CondensedConsolidatedStatementsOfCashFlows" xlink:type="simple" />
  <roleRef roleURI="http://www.galenabiopharma.com/role/CondensedConsolidatedStatementsOfComprehensiveLoss" xlink:href="gale-20150930.xsd#CondensedConsolidatedStatementsOfComprehensiveLoss" xlink:type="simple" />
  <roleRef roleURI="http://www.galenabiopharma.com/role/DiscontinuedOperationsAssetsHeldForSaleCarryingAmountsOfAssetsAndLiabilitiesDetails" xlink:href="gale-20150930.xsd#DiscontinuedOperationsAssetsHeldForSaleCarryingAmountsOfAssetsAndLiabilitiesDetails" xlink:type="simple" />
  <roleRef roleURI="http://www.galenabiopharma.com/role/DiscontinuedOperationsAssetsHeldForSaleComponentsAttributableToCommercialBusinessDetails" xlink:href="gale-20150930.xsd#DiscontinuedOperationsAssetsHeldForSaleComponentsAttributableToCommercialBusinessDetails" xlink:type="simple" />
  <roleRef roleURI="http://www.galenabiopharma.com/role/DiscontinuedOperationsAssetsHeldForSaleDetails" xlink:href="gale-20150930.xsd#DiscontinuedOperationsAssetsHeldForSaleDetails" xlink:type="simple" />
  <roleRef roleURI="http://www.galenabiopharma.com/role/DiscontinuedOperationsAssetsHeldForSaleNotes" xlink:href="gale-20150930.xsd#DiscontinuedOperationsAssetsHeldForSaleNotes" xlink:type="simple" />
  <roleRef roleURI="http://www.galenabiopharma.com/role/DiscontinuedOperationsAssetsHeldForSaleSignificantOperatingNonCashAndCapitalExpendituresDetails" xlink:href="gale-20150930.xsd#DiscontinuedOperationsAssetsHeldForSaleSignificantOperatingNonCashAndCapitalExpendituresDetails" xlink:type="simple" />
  <roleRef roleURI="http://www.galenabiopharma.com/role/DiscontinuedOperationsAssetsHeldForSaleTables" xlink:href="gale-20150930.xsd#DiscontinuedOperationsAssetsHeldForSaleTables" xlink:type="simple" />
  <roleRef roleURI="http://www.galenabiopharma.com/role/DocumentAndEntityInformation" xlink:href="gale-20150930.xsd#DocumentAndEntityInformation" xlink:type="simple" />
  <roleRef roleURI="http://www.galenabiopharma.com/role/FairValueMeasurements" xlink:href="gale-20150930.xsd#FairValueMeasurements" xlink:type="simple" />
  <roleRef roleURI="http://www.galenabiopharma.com/role/FairValueMeasurementsContingentPurchasePriceConsiderationMeasuredAtEstimatedFairValueOnRecurringBasisDetail" xlink:href="gale-20150930.xsd#FairValueMeasurementsContingentPurchasePriceConsiderationMeasuredAtEstimatedFairValueOnRecurringBasisDetail" xlink:type="simple" />
  <roleRef roleURI="http://www.galenabiopharma.com/role/FairValueMeasurementsReconciliationOfLevel3LiabilitiesDetail" xlink:href="gale-20150930.xsd#FairValueMeasurementsReconciliationOfLevel3LiabilitiesDetail" xlink:type="simple" />
  <roleRef roleURI="http://www.galenabiopharma.com/role/FairValueMeasurementsTables" xlink:href="gale-20150930.xsd#FairValueMeasurementsTables" xlink:type="simple" />
  <roleRef roleURI="http://www.galenabiopharma.com/role/LegalProceedingsCommitmentsAndContingenciesDetailsDetails" xlink:href="gale-20150930.xsd#LegalProceedingsCommitmentsAndContingenciesDetailsDetails" xlink:type="simple" />
  <roleRef roleURI="http://www.galenabiopharma.com/role/LegalProceedingsCommitmentsAndContingenciesNotes" xlink:href="gale-20150930.xsd#LegalProceedingsCommitmentsAndContingenciesNotes" xlink:type="simple" />
  <roleRef roleURI="http://www.galenabiopharma.com/role/LicenseAgreements" xlink:href="gale-20150930.xsd#LicenseAgreements" xlink:type="simple" />
  <roleRef roleURI="http://www.galenabiopharma.com/role/LicenseAgreementsAdditionalInformationDetail" xlink:href="gale-20150930.xsd#LicenseAgreementsAdditionalInformationDetail" xlink:type="simple" />
  <roleRef roleURI="http://www.galenabiopharma.com/role/LongTermDebt" xlink:href="gale-20150930.xsd#LongTermDebt" xlink:type="simple" />
  <roleRef roleURI="http://www.galenabiopharma.com/role/LongTermDebtDetails" xlink:href="gale-20150930.xsd#LongTermDebtDetails" xlink:type="simple" />
  <roleRef roleURI="http://www.galenabiopharma.com/role/NetLossPerShare" xlink:href="gale-20150930.xsd#NetLossPerShare" xlink:type="simple" />
  <roleRef roleURI="http://www.galenabiopharma.com/role/NetLossPerShareCommonSharesExcludedFromNetLossDetail" xlink:href="gale-20150930.xsd#NetLossPerShareCommonSharesExcludedFromNetLossDetail" xlink:type="simple" />
  <roleRef roleURI="http://www.galenabiopharma.com/role/NetLossPerShareTables" xlink:href="gale-20150930.xsd#NetLossPerShareTables" xlink:type="simple" />
  <roleRef roleURI="http://www.galenabiopharma.com/role/OtherIncomeExpenseNotes" xlink:href="gale-20150930.xsd#OtherIncomeExpenseNotes" xlink:type="simple" />
  <roleRef roleURI="http://www.galenabiopharma.com/role/OtherIncomeExpenseTableDetails" xlink:href="gale-20150930.xsd#OtherIncomeExpenseTableDetails" xlink:type="simple" />
  <roleRef roleURI="http://www.galenabiopharma.com/role/OtherIncomeExpenseTables" xlink:href="gale-20150930.xsd#OtherIncomeExpenseTables" xlink:type="simple" />
  <roleRef roleURI="http://www.galenabiopharma.com/role/SignificantCustomersAndConcentrationOfCreditRiskDetails" xlink:href="gale-20150930.xsd#SignificantCustomersAndConcentrationOfCreditRiskDetails" xlink:type="simple" />
  <roleRef roleURI="http://www.galenabiopharma.com/role/SignificantCustomersAndConcentrationOfCreditRiskNotes" xlink:href="gale-20150930.xsd#SignificantCustomersAndConcentrationOfCreditRiskNotes" xlink:type="simple" />
  <roleRef roleURI="http://www.galenabiopharma.com/role/SignificantCustomersAndConcentrationOfCreditRiskSignificantCustomersAndConcentrationOfCreditRiskTables" xlink:href="gale-20150930.xsd#SignificantCustomersAndConcentrationOfCreditRiskSignificantCustomersAndConcentrationOfCreditRiskTables" xlink:type="simple" />
  <roleRef roleURI="http://www.galenabiopharma.com/role/StockBasedCompensation" xlink:href="gale-20150930.xsd#StockBasedCompensation" xlink:type="simple" />
  <roleRef roleURI="http://www.galenabiopharma.com/role/StockBasedCompensationAdditionalInformationDetail" xlink:href="gale-20150930.xsd#StockBasedCompensationAdditionalInformationDetail" xlink:type="simple" />
  <roleRef roleURI="http://www.galenabiopharma.com/role/StockBasedCompensationAllocatedStockBasedCompensationDetails" xlink:href="gale-20150930.xsd#StockBasedCompensationAllocatedStockBasedCompensationDetails" xlink:type="simple" />
  <roleRef roleURI="http://www.galenabiopharma.com/role/StockBasedCompensationAssumptionsForOptionGrantsIssuedDetail" xlink:href="gale-20150930.xsd#StockBasedCompensationAssumptionsForOptionGrantsIssuedDetail" xlink:type="simple" />
  <roleRef roleURI="http://www.galenabiopharma.com/role/StockBasedCompensationStockOptionActivityDetail" xlink:href="gale-20150930.xsd#StockBasedCompensationStockOptionActivityDetail" xlink:type="simple" />
  <roleRef roleURI="http://www.galenabiopharma.com/role/StockBasedCompensationTables" xlink:href="gale-20150930.xsd#StockBasedCompensationTables" xlink:type="simple" />
  <roleRef roleURI="http://www.galenabiopharma.com/role/StockholdersEquity" xlink:href="gale-20150930.xsd#StockholdersEquity" xlink:type="simple" />
  <roleRef roleURI="http://www.galenabiopharma.com/role/StockholdersEquityAdditionalInformationDetail" xlink:href="gale-20150930.xsd#StockholdersEquityAdditionalInformationDetail" xlink:type="simple" />
  <roleRef roleURI="http://www.galenabiopharma.com/role/StockholdersEquityCommonStockAreReservedForFutureIssuanceDetail" xlink:href="gale-20150930.xsd#StockholdersEquityCommonStockAreReservedForFutureIssuanceDetail" xlink:type="simple" />
  <roleRef roleURI="http://www.galenabiopharma.com/role/StockholdersEquityTables" xlink:href="gale-20150930.xsd#StockholdersEquityTables" xlink:type="simple" />
  <roleRef roleURI="http://www.galenabiopharma.com/role/SubsequentEvents" xlink:href="gale-20150930.xsd#SubsequentEvents" xlink:type="simple" />
  <roleRef roleURI="http://www.galenabiopharma.com/role/Warrants" xlink:href="gale-20150930.xsd#Warrants" xlink:type="simple" />
  <roleRef roleURI="http://www.galenabiopharma.com/role/WarrantsChangesInFairValueOfWarrantLiabilityDetail" xlink:href="gale-20150930.xsd#WarrantsChangesInFairValueOfWarrantLiabilityDetail" xlink:type="simple" />
  <roleRef roleURI="http://www.galenabiopharma.com/role/WarrantsFairValueOfWarrantsIsEstimatedUsingBlackScholesOptionPricingModelDetail" xlink:href="gale-20150930.xsd#WarrantsFairValueOfWarrantsIsEstimatedUsingBlackScholesOptionPricingModelDetail" xlink:type="simple" />
  <roleRef roleURI="http://www.galenabiopharma.com/role/WarrantsScheduleOfWarrantActivityDetail" xlink:href="gale-20150930.xsd#WarrantsScheduleOfWarrantActivityDetail" xlink:type="simple" />
  <roleRef roleURI="http://www.galenabiopharma.com/role/WarrantsTables" xlink:href="gale-20150930.xsd#WarrantsTables" xlink:type="simple" />
  <roleRef roleURI="http://www.galenabiopharma.com/role/WarrantsWarrantsClassifiedAsEquityDetails" xlink:href="gale-20150930.xsd#WarrantsWarrantsClassifiedAsEquityDetails" xlink:type="simple" />
  <calculationLink xlink:role="http://www.galenabiopharma.com/role/AccruedExpensesAndOtherCurrentLiabilities" xlink:type="extended" />
  <calculationLink xlink:role="http://www.galenabiopharma.com/role/AccruedExpensesAndOtherCurrentLiabilitiesDetails" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_1d834322-984c-3ee2-a4a0-2dc90b007763" xlink:type="locator" />
    <loc xlink:href="gale-20150930.xsd#gale_ContractResearchPayable" xlink:label="loc_gale_ContractResearchPayable_c30e2344-3447-c5b8-6835-36aef383625e" xlink:type="locator" />
    <calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_1d834322-984c-3ee2-a4a0-2dc90b007763" xlink:to="loc_gale_ContractResearchPayable_c30e2344-3447-c5b8-6835-36aef383625e" xlink:type="arc" />
    <loc xlink:href="gale-20150930.xsd#gale_FutureMilestonePayment" xlink:label="loc_gale_FutureMilestonePayment_382f14b8-2774-f5dd-d258-36aef3aa6efe" xlink:type="locator" />
    <calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_1d834322-984c-3ee2-a4a0-2dc90b007763" xlink:to="loc_gale_FutureMilestonePayment_382f14b8-2774-f5dd-d258-36aef3aa6efe" xlink:type="arc" />
    <loc xlink:href="gale-20150930.xsd#gale_CreditMemosAcquisitionChannelInventoryCurrent" xlink:label="loc_gale_CreditMemosAcquisitionChannelInventoryCurrent_c607fef0-6470-11e4-a349-22000a1e8102" xlink:type="locator" />
    <calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_1d834322-984c-3ee2-a4a0-2dc90b007763" xlink:to="loc_gale_CreditMemosAcquisitionChannelInventoryCurrent_c607fef0-6470-11e4-a349-22000a1e8102" xlink:type="arc" />
    <loc xlink:href="gale-20150930.xsd#gale_PatientAssistanceProgramCurrent" xlink:label="loc_gale_PatientAssistanceProgramCurrent_6bfb7f90-9a12-d9d8-2b93-36aef3d2168e" xlink:type="locator" />
    <calculationArc order="4" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_1d834322-984c-3ee2-a4a0-2dc90b007763" xlink:to="loc_gale_PatientAssistanceProgramCurrent_6bfb7f90-9a12-d9d8-2b93-36aef3d2168e" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_d69c5cc5-fc70-31a7-c2b1-924eb363b75b" xlink:type="locator" />
    <calculationArc order="5" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_1d834322-984c-3ee2-a4a0-2dc90b007763" xlink:to="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_d69c5cc5-fc70-31a7-c2b1-924eb363b75b" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:label="loc_us-gaap_AccruedProfessionalFeesCurrent_28c626c7-9023-e30f-2e48-0f4dd115d912" xlink:type="locator" />
    <calculationArc order="6" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_1d834322-984c-3ee2-a4a0-2dc90b007763" xlink:to="loc_us-gaap_AccruedProfessionalFeesCurrent_28c626c7-9023-e30f-2e48-0f4dd115d912" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AccruedRoyaltiesCurrent" xlink:label="loc_us-gaap_AccruedRoyaltiesCurrent_839b6add-8ba5-8eb9-6911-0eee956b66c8" xlink:type="locator" />
    <calculationArc order="7" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_1d834322-984c-3ee2-a4a0-2dc90b007763" xlink:to="loc_us-gaap_AccruedRoyaltiesCurrent_839b6add-8ba5-8eb9-6911-0eee956b66c8" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_InterestPayableCurrent" xlink:label="loc_us-gaap_InterestPayableCurrent_bb772f62-f5a6-bab7-e2c1-84f314d9b18f" xlink:type="locator" />
    <calculationArc order="8" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_1d834322-984c-3ee2-a4a0-2dc90b007763" xlink:to="loc_us-gaap_InterestPayableCurrent_bb772f62-f5a6-bab7-e2c1-84f314d9b18f" xlink:type="arc" />
    <loc xlink:href="gale-20150930.xsd#gale_AccruedInventoryPurchasesCurrent" xlink:label="loc_gale_AccruedInventoryPurchasesCurrent_1157FDED3C533A684802FE56EC7359BD" xlink:type="locator" />
    <calculationArc order="9" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_1d834322-984c-3ee2-a4a0-2dc90b007763" xlink:to="loc_gale_AccruedInventoryPurchasesCurrent_1157FDED3C533A684802FE56EC7359BD" xlink:type="arc" />
  </calculationLink>
  <calculationLink xlink:role="http://www.galenabiopharma.com/role/AccruedExpensesAndOtherCurrentLiabilitiesTables" xlink:type="extended" />
  <calculationLink xlink:role="http://www.galenabiopharma.com/role/BusinessAndBasisOfPresentation" xlink:type="extended" />
  <calculationLink xlink:role="http://www.galenabiopharma.com/role/BusinessAndBasisOfPresentationAdditionalInformationDetail" xlink:type="extended" />
  <calculationLink xlink:role="http://www.galenabiopharma.com/role/BusinessAndBasisOfPresentationPolicies" xlink:type="extended" />
  <calculationLink xlink:role="http://www.galenabiopharma.com/role/BusinessCombinations" xlink:type="extended" />
  <calculationLink xlink:role="http://www.galenabiopharma.com/role/BusinessCombinationsDetails" xlink:type="extended" />
  <calculationLink xlink:role="http://www.galenabiopharma.com/role/BusinessCombinationsTables" xlink:type="extended" />
  <calculationLink xlink:role="http://www.galenabiopharma.com/role/CondensedConsolidatedBalanceSheets" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_Assets" xlink:label="loc_us-gaap_Assets_b517a4f1-4597-b094-2608-75af660328e1" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaap_AssetsCurrent_67f49e84-05fd-4b0b-ae5a-e9913b97cea2" xlink:type="locator" />
    <calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_b517a4f1-4597-b094-2608-75af660328e1" xlink:to="loc_us-gaap_AssetsCurrent_67f49e84-05fd-4b0b-ae5a-e9913b97cea2" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_999960f8-6702-f7e9-88df-fcb8021751b2" xlink:type="locator" />
    <calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_67f49e84-05fd-4b0b-ae5a-e9913b97cea2" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_999960f8-6702-f7e9-88df-fcb8021751b2" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue_59dbb0ce-8e17-487b-ae40-e3a584ab7a36" xlink:type="locator" />
    <calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_67f49e84-05fd-4b0b-ae5a-e9913b97cea2" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue_59dbb0ce-8e17-487b-ae40-e3a584ab7a36" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_3227d5e9-cb9d-fda7-e599-c6fb89b5e07a" xlink:type="locator" />
    <calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_67f49e84-05fd-4b0b-ae5a-e9913b97cea2" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_3227d5e9-cb9d-fda7-e599-c6fb89b5e07a" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent" xlink:label="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent_744f4a4f-e553-b1fb-4b48-322a49225564" xlink:type="locator" />
    <calculationArc order="4" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_67f49e84-05fd-4b0b-ae5a-e9913b97cea2" xlink:to="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent_744f4a4f-e553-b1fb-4b48-322a49225564" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_dc301a2a-78b3-2f7c-72b2-6d5ec18f9327" xlink:type="locator" />
    <calculationArc order="5" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_67f49e84-05fd-4b0b-ae5a-e9913b97cea2" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_dc301a2a-78b3-2f7c-72b2-6d5ec18f9327" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_InventoryNet" xlink:label="loc_us-gaap_InventoryNet_a00a52e0-8d97-7156-7079-2c628ca1666f" xlink:type="locator" />
    <calculationArc order="6" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_67f49e84-05fd-4b0b-ae5a-e9913b97cea2" xlink:to="loc_us-gaap_InventoryNet_a00a52e0-8d97-7156-7079-2c628ca1666f" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_a1eaafaf-055b-e423-85ef-4424fb2ef4e4" xlink:type="locator" />
    <calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_b517a4f1-4597-b094-2608-75af660328e1" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_a1eaafaf-055b-e423-85ef-4424fb2ef4e4" xlink:type="arc" />
    <loc xlink:href="gale-20150930.xsd#gale_InProcessResearchDevelopment" xlink:label="loc_gale_InProcessResearchDevelopment_1b17581d-51a2-b3bc-44d6-36aef38b22b9" xlink:type="locator" />
    <calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_b517a4f1-4597-b094-2608-75af660328e1" xlink:to="loc_gale_InProcessResearchDevelopment_1b17581d-51a2-b3bc-44d6-36aef38b22b9" xlink:type="arc" />
    <loc xlink:href="gale-20150930.xsd#gale_SalesAndDistributionsRights" xlink:label="loc_gale_SalesAndDistributionsRights_0f09d8a4-c43c-d798-bdef-36aef3c509ef" xlink:type="locator" />
    <calculationArc order="4" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_b517a4f1-4597-b094-2608-75af660328e1" xlink:to="loc_gale_SalesAndDistributionsRights_0f09d8a4-c43c-d798-bdef-36aef3c509ef" xlink:type="arc" />
    <loc xlink:href="gale-20150930.xsd#gale_SalesAndDistributionsRightsZuplenz" xlink:label="loc_gale_SalesAndDistributionsRightsZuplenz_57cf43da-6457-11e4-a349-22000a1e8102" xlink:type="locator" />
    <calculationArc order="5" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_b517a4f1-4597-b094-2608-75af660328e1" xlink:to="loc_gale_SalesAndDistributionsRightsZuplenz_57cf43da-6457-11e4-a349-22000a1e8102" xlink:type="arc" />
    <loc xlink:href="gale-20150930.xsd#gale_GALE401rights" xlink:label="loc_gale_GALE401rights_3ef739be-0bee-34dc-69c0-36aef3c444cf" xlink:type="locator" />
    <calculationArc order="6" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_b517a4f1-4597-b094-2608-75af660328e1" xlink:to="loc_gale_GALE401rights_3ef739be-0bee-34dc-69c0-36aef3c444cf" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_Goodwill" xlink:label="loc_us-gaap_Goodwill_d1288432-0516-3188-e96b-2bc623375a5a" xlink:type="locator" />
    <calculationArc order="7" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_b517a4f1-4597-b094-2608-75af660328e1" xlink:to="loc_us-gaap_Goodwill_d1288432-0516-3188-e96b-2bc623375a5a" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DepositsAssetsNoncurrent" xlink:label="loc_us-gaap_DepositsAssetsNoncurrent_d38e3ea0-c47e-8d3f-d1c1-10b307bfbf64" xlink:type="locator" />
    <calculationArc order="8" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_b517a4f1-4597-b094-2608-75af660328e1" xlink:to="loc_us-gaap_DepositsAssetsNoncurrent_d38e3ea0-c47e-8d3f-d1c1-10b307bfbf64" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_ae9fd5e7-8741-dfbd-241e-1460ec6c786e" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaap_Liabilities_16ce0436-3b82-55c5-d896-5cba4c9023bd" xlink:type="locator" />
    <calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_ae9fd5e7-8741-dfbd-241e-1460ec6c786e" xlink:to="loc_us-gaap_Liabilities_16ce0436-3b82-55c5-d896-5cba4c9023bd" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaap_LiabilitiesCurrent_1477e02d-b6d8-3df6-e715-8364fedce6d9" xlink:type="locator" />
    <calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_16ce0436-3b82-55c5-d896-5cba4c9023bd" xlink:to="loc_us-gaap_LiabilitiesCurrent_1477e02d-b6d8-3df6-e715-8364fedce6d9" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="loc_us-gaap_AccountsPayableCurrent_bd7b63fa-09ae-1100-16fe-5ac027208548" xlink:type="locator" />
    <calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_1477e02d-b6d8-3df6-e715-8364fedce6d9" xlink:to="loc_us-gaap_AccountsPayableCurrent_bd7b63fa-09ae-1100-16fe-5ac027208548" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_1d834322-984c-3ee2-a4a0-2dc90b007763" xlink:type="locator" />
    <calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_1477e02d-b6d8-3df6-e715-8364fedce6d9" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_1d834322-984c-3ee2-a4a0-2dc90b007763" xlink:type="arc" />
    <loc xlink:href="gale-20150930.xsd#gale_FairValueOfWarrantsPotentiallySettleableInCash" xlink:label="loc_gale_FairValueOfWarrantsPotentiallySettleableInCash_aa7fcc1c-b1c3-0bc9-16a4-36aef3d4e0cc" xlink:type="locator" />
    <calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_1477e02d-b6d8-3df6-e715-8364fedce6d9" xlink:to="loc_gale_FairValueOfWarrantsPotentiallySettleableInCash_aa7fcc1c-b1c3-0bc9-16a4-36aef3d4e0cc" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LongTermDebtCurrent" xlink:label="loc_us-gaap_LongTermDebtCurrent_0601d697-1537-c3cb-caaf-11141ac92b39" xlink:type="locator" />
    <calculationArc order="4" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_1477e02d-b6d8-3df6-e715-8364fedce6d9" xlink:to="loc_us-gaap_LongTermDebtCurrent_0601d697-1537-c3cb-caaf-11141ac92b39" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent" xlink:label="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent_453469bb-c529-2b89-38e2-1ea12ded5b78" xlink:type="locator" />
    <calculationArc order="5" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_1477e02d-b6d8-3df6-e715-8364fedce6d9" xlink:to="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent_453469bb-c529-2b89-38e2-1ea12ded5b78" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNetNoncurrent" xlink:label="loc_us-gaap_DeferredTaxAssetsLiabilitiesNetNoncurrent_17dd34ae-bdb5-d249-f1b5-084376fff348" xlink:type="locator" />
    <calculationArc order="2" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_16ce0436-3b82-55c5-d896-5cba4c9023bd" xlink:to="loc_us-gaap_DeferredTaxAssetsLiabilitiesNetNoncurrent_17dd34ae-bdb5-d249-f1b5-084376fff348" xlink:type="arc" />
    <loc xlink:href="gale-20150930.xsd#gale_ContingentPurchasePriceConsiderationNetOfCurrentPortion" xlink:label="loc_gale_ContingentPurchasePriceConsiderationNetOfCurrentPortion_f1e0e921-cfc7-a57a-5c75-36aef3d5be11" xlink:type="locator" />
    <calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_16ce0436-3b82-55c5-d896-5cba4c9023bd" xlink:to="loc_gale_ContingentPurchasePriceConsiderationNetOfCurrentPortion_f1e0e921-cfc7-a57a-5c75-36aef3d5be11" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LongTermDebtNoncurrent" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_89b83a57-ffbc-fc48-170d-f8b25d163e54" xlink:type="locator" />
    <calculationArc order="4" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_16ce0436-3b82-55c5-d896-5cba4c9023bd" xlink:to="loc_us-gaap_LongTermDebtNoncurrent_89b83a57-ffbc-fc48-170d-f8b25d163e54" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_26e56c7a-24ab-e869-809a-0509ccbe86d9" xlink:type="locator" />
    <calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_ae9fd5e7-8741-dfbd-241e-1460ec6c786e" xlink:to="loc_us-gaap_StockholdersEquity_26e56c7a-24ab-e869-809a-0509ccbe86d9" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PreferredStockValue" xlink:label="loc_us-gaap_PreferredStockValue_9fd7dfd7-596e-4c7f-4077-abbf8130d157" xlink:type="locator" />
    <calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_26e56c7a-24ab-e869-809a-0509ccbe86d9" xlink:to="loc_us-gaap_PreferredStockValue_9fd7dfd7-596e-4c7f-4077-abbf8130d157" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaap_CommonStockValue_ffd09989-75a8-4713-beb0-21bebb3561d6" xlink:type="locator" />
    <calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_26e56c7a-24ab-e869-809a-0509ccbe86d9" xlink:to="loc_us-gaap_CommonStockValue_ffd09989-75a8-4713-beb0-21bebb3561d6" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock_3c55800a-0ae8-71c7-e1d1-5e4859c50246" xlink:type="locator" />
    <calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_26e56c7a-24ab-e869-809a-0509ccbe86d9" xlink:to="loc_us-gaap_AdditionalPaidInCapitalCommonStock_3c55800a-0ae8-71c7-e1d1-5e4859c50246" xlink:type="arc" />
    <loc xlink:href="gale-20150930.xsd#gale_DeficitAccumulatedDuringDevelopmentalStage" xlink:label="loc_gale_DeficitAccumulatedDuringDevelopmentalStage_85633807-18f7-72ee-eb13-36aef39d8fa0" xlink:type="locator" />
    <calculationArc order="4" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_26e56c7a-24ab-e869-809a-0509ccbe86d9" xlink:to="loc_gale_DeficitAccumulatedDuringDevelopmentalStage_85633807-18f7-72ee-eb13-36aef39d8fa0" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_TreasuryStockValue" xlink:label="loc_us-gaap_TreasuryStockValue_719740e5-b138-f870-281f-ac4786e101c2" xlink:type="locator" />
    <calculationArc order="5" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_26e56c7a-24ab-e869-809a-0509ccbe86d9" xlink:to="loc_us-gaap_TreasuryStockValue_719740e5-b138-f870-281f-ac4786e101c2" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="loc_us-gaap_CommitmentsAndContingencies_a7bb915d-e645-20d7-7b2e-623731454f45" xlink:type="locator" />
    <calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_ae9fd5e7-8741-dfbd-241e-1460ec6c786e" xlink:to="loc_us-gaap_CommitmentsAndContingencies_a7bb915d-e645-20d7-7b2e-623731454f45" xlink:type="arc" />
  </calculationLink>
  <calculationLink xlink:role="http://www.galenabiopharma.com/role/CondensedConsolidatedBalanceSheetsParenthetical" xlink:type="extended" />
  <calculationLink xlink:role="http://www.galenabiopharma.com/role/CondensedConsolidatedStatementOfStockholdersEquityCondensedConsolidatedStatementOfStockholdersEquity" xlink:type="extended" />
  <calculationLink xlink:role="http://www.galenabiopharma.com/role/CondensedConsolidatedStatementsOfCashFlows" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:label="loc_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_46b895b2-8ff5-9e37-d4c3-5b75649cbcba" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_6d7b73b6-0db7-23f7-377e-417fa8fc8e27" xlink:type="locator" />
    <calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_46b895b2-8ff5-9e37-d4c3-5b75649cbcba" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_6d7b73b6-0db7-23f7-377e-417fa8fc8e27" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_bdec3780-88f3-c634-f85d-cb36bba63bd2" xlink:type="locator" />
    <calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_6d7b73b6-0db7-23f7-377e-417fa8fc8e27" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_bdec3780-88f3-c634-f85d-cb36bba63bd2" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised_29d765d3-9bf3-69a0-f67a-85487c765b79" xlink:type="locator" />
    <calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_6d7b73b6-0db7-23f7-377e-417fa8fc8e27" xlink:to="loc_us-gaap_ProceedsFromStockOptionsExercised_29d765d3-9bf3-69a0-f67a-85487c765b79" xlink:type="arc" />
    <loc xlink:href="gale-20150930.xsd#gale_NetProceedsFromExerciseOfCommonStockWarrants" xlink:label="loc_gale_NetProceedsFromExerciseOfCommonStockWarrants_59d54f92-5751-9336-8cc7-36aef3ce858c" xlink:type="locator" />
    <calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_6d7b73b6-0db7-23f7-377e-417fa8fc8e27" xlink:to="loc_gale_NetProceedsFromExerciseOfCommonStockWarrants_59d54f92-5751-9336-8cc7-36aef3ce858c" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:label="loc_us-gaap_ProceedsFromIssuanceOrSaleOfEquity_46f27a16-fc41-aca3-91c1-4e39fa4c2ce6" xlink:type="locator" />
    <calculationArc order="4" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_6d7b73b6-0db7-23f7-377e-417fa8fc8e27" xlink:to="loc_us-gaap_ProceedsFromIssuanceOrSaleOfEquity_46f27a16-fc41-aca3-91c1-4e39fa4c2ce6" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RepaymentsOfLongTermDebt" xlink:label="loc_us-gaap_RepaymentsOfLongTermDebt_555855ee-67fc-e384-4c0f-c30d34ed47e5" xlink:type="locator" />
    <calculationArc order="5" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_6d7b73b6-0db7-23f7-377e-417fa8fc8e27" xlink:to="loc_us-gaap_RepaymentsOfLongTermDebt_555855ee-67fc-e384-4c0f-c30d34ed47e5" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_fb013d5f-7e0c-1a40-5a42-42bd8c3a1d51" xlink:type="locator" />
    <calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_46b895b2-8ff5-9e37-d4c3-5b75649cbcba" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_fb013d5f-7e0c-1a40-5a42-42bd8c3a1d51" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations_f47d1996-b77d-36f7-28c4-5d2058bf9b25" xlink:type="locator" />
    <calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_fb013d5f-7e0c-1a40-5a42-42bd8c3a1d51" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations_f47d1996-b77d-36f7-28c4-5d2058bf9b25" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncreaseDecreaseInRestrictedCash" xlink:label="loc_us-gaap_IncreaseDecreaseInRestrictedCash_bad4ac90-fa65-6575-9822-984531b2f63c" xlink:type="locator" />
    <calculationArc order="1" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations_f47d1996-b77d-36f7-28c4-5d2058bf9b25" xlink:to="loc_us-gaap_IncreaseDecreaseInRestrictedCash_bad4ac90-fa65-6575-9822-984531b2f63c" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PaymentsToAcquireBusinessesGross" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesGross_731c2d9f-8aec-0326-36d0-f4e24cd26053" xlink:type="locator" />
    <calculationArc order="2" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations_f47d1996-b77d-36f7-28c4-5d2058bf9b25" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesGross_731c2d9f-8aec-0326-36d0-f4e24cd26053" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_37181af6-e562-cefc-f2b6-8490ea2c3e04" xlink:type="locator" />
    <calculationArc order="3" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations_f47d1996-b77d-36f7-28c4-5d2058bf9b25" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_37181af6-e562-cefc-f2b6-8490ea2c3e04" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations" xlink:label="loc_us-gaap_CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations_584e529e-1ccd-eb17-0baa-f2c2deccb0b5" xlink:type="locator" />
    <calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_fb013d5f-7e0c-1a40-5a42-42bd8c3a1d51" xlink:to="loc_us-gaap_CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations_584e529e-1ccd-eb17-0baa-f2c2deccb0b5" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_b6b5c2f7-2ab7-a264-6d06-119dda52768c" xlink:type="locator" />
    <calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_46b895b2-8ff5-9e37-d4c3-5b75649cbcba" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_b6b5c2f7-2ab7-a264-6d06-119dda52768c" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations" xlink:label="loc_us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations_c4b06a2b-216d-f847-e7b3-26aa9fc68538" xlink:type="locator" />
    <calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_b6b5c2f7-2ab7-a264-6d06-119dda52768c" xlink:to="loc_us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations_c4b06a2b-216d-f847-e7b3-26aa9fc68538" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax_31578d71-898a-6267-3f3d-6ee457dbc36f" xlink:type="locator" />
    <calculationArc order="1" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations_c4b06a2b-216d-f847-e7b3-26aa9fc68538" xlink:to="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax_31578d71-898a-6267-3f3d-6ee457dbc36f" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf" xlink:label="loc_us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf_49c9546b-a1ac-5daa-7bad-69ce674d13ea" xlink:type="locator" />
    <calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations_c4b06a2b-216d-f847-e7b3-26aa9fc68538" xlink:to="loc_us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf_49c9546b-a1ac-5daa-7bad-69ce674d13ea" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncreaseDecreaseInAssetsHeldForSale" xlink:label="loc_us-gaap_IncreaseDecreaseInAssetsHeldForSale_0a6b1f54-8792-7a56-31cc-2843a0947f44" xlink:type="locator" />
    <calculationArc order="3" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations_c4b06a2b-216d-f847-e7b3-26aa9fc68538" xlink:to="loc_us-gaap_IncreaseDecreaseInAssetsHeldForSale_0a6b1f54-8792-7a56-31cc-2843a0947f44" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_32645c9d-8ff4-9939-6e7f-1f133b2a6c08" xlink:type="locator" />
    <calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_b6b5c2f7-2ab7-a264-6d06-119dda52768c" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_32645c9d-8ff4-9939-6e7f-1f133b2a6c08" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_5255d790-6d37-d507-f92b-3f845ba62745" xlink:type="locator" />
    <calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_32645c9d-8ff4-9939-6e7f-1f133b2a6c08" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_5255d790-6d37-d507-f92b-3f845ba62745" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_76f611bf-6cac-2837-6d7c-3028d488fc3b" xlink:type="locator" />
    <calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_32645c9d-8ff4-9939-6e7f-1f133b2a6c08" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_76f611bf-6cac-2837-6d7c-3028d488fc3b" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaap_ShareBasedCompensation_aa7a0bc5-86c6-13a8-3676-9960bad8007f" xlink:type="locator" />
    <calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_32645c9d-8ff4-9939-6e7f-1f133b2a6c08" xlink:to="loc_us-gaap_ShareBasedCompensation_aa7a0bc5-86c6-13a8-3676-9960bad8007f" xlink:type="arc" />
    <loc xlink:href="gale-20150930.xsd#gale_ChangeInFairValueOfCommonStockWarrantsIssuedInConnectionWithVariousEquityFinancings" xlink:label="loc_gale_ChangeInFairValueOfCommonStockWarrantsIssuedInConnectionWithVariousEquityFinancings_dae75ce7-425a-7119-0dd6-36aef384b473" xlink:type="locator" />
    <calculationArc order="4" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_32645c9d-8ff4-9939-6e7f-1f133b2a6c08" xlink:to="loc_gale_ChangeInFairValueOfCommonStockWarrantsIssuedInConnectionWithVariousEquityFinancings_dae75ce7-425a-7119-0dd6-36aef384b473" xlink:type="arc" />
    <loc xlink:href="gale-20150930.xsd#gale_ChangeInFairValueOfContingentPurchaseConsideration" xlink:label="loc_gale_ChangeInFairValueOfContingentPurchaseConsideration_30c404fa-c20d-e897-c0b6-36aef387c11b" xlink:type="locator" />
    <calculationArc order="5" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_32645c9d-8ff4-9939-6e7f-1f133b2a6c08" xlink:to="loc_gale_ChangeInFairValueOfContingentPurchaseConsideration_30c404fa-c20d-e897-c0b6-36aef387c11b" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_07d730ea-b32b-956c-677e-cf5b73c388b0" xlink:type="locator" />
    <calculationArc order="6" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_32645c9d-8ff4-9939-6e7f-1f133b2a6c08" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_07d730ea-b32b-956c-677e-cf5b73c388b0" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable_b9fb8522-752c-3209-8cca-60e64f420ad5" xlink:type="locator" />
    <calculationArc order="7" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_32645c9d-8ff4-9939-6e7f-1f133b2a6c08" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayable_b9fb8522-752c-3209-8cca-60e64f420ad5" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_5cb9a7e8-dd26-27c7-9313-c478703eadea" xlink:type="locator" />
    <calculationArc order="8" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_32645c9d-8ff4-9939-6e7f-1f133b2a6c08" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_5cb9a7e8-dd26-27c7-9313-c478703eadea" xlink:type="arc" />
  </calculationLink>
  <calculationLink xlink:role="http://www.galenabiopharma.com/role/CondensedConsolidatedStatementsOfComprehensiveLoss" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_faecc408-4bea-6e13-83bd-71b4c2ddf64c" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_5255d790-6d37-d507-f92b-3f845ba62745" xlink:type="locator" />
    <calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_faecc408-4bea-6e13-83bd-71b4c2ddf64c" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_5255d790-6d37-d507-f92b-3f845ba62745" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaap_OperatingIncomeLoss_72b2c986-6e1a-bdde-cc72-888b0df562b9" xlink:type="locator" />
    <calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_5255d790-6d37-d507-f92b-3f845ba62745" xlink:to="loc_us-gaap_OperatingIncomeLoss_72b2c986-6e1a-bdde-cc72-888b0df562b9" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SalesRevenueNet" xlink:label="loc_us-gaap_SalesRevenueNet_0863786b-6bf9-966f-db7b-d5636f830397" xlink:type="locator" />
    <calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_72b2c986-6e1a-bdde-cc72-888b0df562b9" xlink:to="loc_us-gaap_SalesRevenueNet_0863786b-6bf9-966f-db7b-d5636f830397" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CostsAndExpenses" xlink:label="loc_us-gaap_CostsAndExpenses_f5487d97-18cc-be7a-d1d1-ec68e0b0a9f3" xlink:type="locator" />
    <calculationArc order="2" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_72b2c986-6e1a-bdde-cc72-888b0df562b9" xlink:to="loc_us-gaap_CostsAndExpenses_f5487d97-18cc-be7a-d1d1-ec68e0b0a9f3" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CostOfRevenue" xlink:label="loc_us-gaap_CostOfRevenue_ba3cee0f-0b78-d604-d45b-dd6d9f2c2132" xlink:type="locator" />
    <calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_f5487d97-18cc-be7a-d1d1-ec68e0b0a9f3" xlink:to="loc_us-gaap_CostOfRevenue_ba3cee0f-0b78-d604-d45b-dd6d9f2c2132" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_7d1bc05d-33ee-c009-4533-b70ee0a74dc9" xlink:type="locator" />
    <calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_f5487d97-18cc-be7a-d1d1-ec68e0b0a9f3" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_7d1bc05d-33ee-c009-4533-b70ee0a74dc9" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_581512af-7ae6-1b38-5ef5-f123bd81ccb9" xlink:type="locator" />
    <calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_f5487d97-18cc-be7a-d1d1-ec68e0b0a9f3" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpense_581512af-7ae6-1b38-5ef5-f123bd81ccb9" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AmortizationOfIntangibleAssets" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets_c1b76359-2bf3-ac34-0e0e-8614c806c9a0" xlink:type="locator" />
    <calculationArc order="4" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_f5487d97-18cc-be7a-d1d1-ec68e0b0a9f3" xlink:to="loc_us-gaap_AmortizationOfIntangibleAssets_c1b76359-2bf3-ac34-0e0e-8614c806c9a0" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OtherOperatingIncomeExpenseNet" xlink:label="loc_us-gaap_OtherOperatingIncomeExpenseNet_99cc4179-c5f2-7860-2937-70c2f8f826bc" xlink:type="locator" />
    <calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_5255d790-6d37-d507-f92b-3f845ba62745" xlink:to="loc_us-gaap_OtherOperatingIncomeExpenseNet_99cc4179-c5f2-7860-2937-70c2f8f826bc" xlink:type="arc" />
    <loc xlink:href="gale-20150930.xsd#gale_LossOnWarrantExchange" xlink:label="loc_gale_LossOnWarrantExchange_a362a907-2b45-0c69-51a9-36aef3a302f1" xlink:type="locator" />
    <calculationArc order="1" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherOperatingIncomeExpenseNet_99cc4179-c5f2-7860-2937-70c2f8f826bc" xlink:to="loc_gale_LossOnWarrantExchange_a362a907-2b45-0c69-51a9-36aef3a302f1" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_InterestIncomeExpenseNet" xlink:label="loc_us-gaap_InterestIncomeExpenseNet_a12c4ccc-a50c-b165-5045-f74bbea2c47f" xlink:type="locator" />
    <calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherOperatingIncomeExpenseNet_99cc4179-c5f2-7860-2937-70c2f8f826bc" xlink:to="loc_us-gaap_InterestIncomeExpenseNet_a12c4ccc-a50c-b165-5045-f74bbea2c47f" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_27b74f5e-bc16-8d0b-2d8b-f8fb77af5bf6" xlink:type="locator" />
    <calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherOperatingIncomeExpenseNet_99cc4179-c5f2-7860-2937-70c2f8f826bc" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_27b74f5e-bc16-8d0b-2d8b-f8fb77af5bf6" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax_31578d71-898a-6267-3f3d-6ee457dbc36f" xlink:type="locator" />
    <calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_faecc408-4bea-6e13-83bd-71b4c2ddf64c" xlink:to="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax_31578d71-898a-6267-3f3d-6ee457dbc36f" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EarningsPerShareBasic" xlink:label="loc_us-gaap_EarningsPerShareBasic_ff703a61-adfc-9c6b-101d-59051209f285" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsPerBasicAndDilutedShare" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsPerBasicAndDilutedShare_4310cab8-5cf4-77f7-fcd5-0e9645d8973f" xlink:type="locator" />
    <calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EarningsPerShareBasic_ff703a61-adfc-9c6b-101d-59051209f285" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsPerBasicAndDilutedShare_4310cab8-5cf4-77f7-fcd5-0e9645d8973f" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicAndDilutedShare" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicAndDilutedShare_8ee928b6-4383-414a-0460-a9ca6d964404" xlink:type="locator" />
    <calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EarningsPerShareBasic_ff703a61-adfc-9c6b-101d-59051209f285" xlink:to="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicAndDilutedShare_8ee928b6-4383-414a-0460-a9ca6d964404" xlink:type="arc" />
  </calculationLink>
  <calculationLink xlink:role="http://www.galenabiopharma.com/role/DiscontinuedOperationsAssetsHeldForSaleCarryingAmountsOfAssetsAndLiabilitiesDetails" xlink:type="extended" />
  <calculationLink xlink:role="http://www.galenabiopharma.com/role/DiscontinuedOperationsAssetsHeldForSaleComponentsAttributableToCommercialBusinessDetails" xlink:type="extended" />
  <calculationLink xlink:role="http://www.galenabiopharma.com/role/DiscontinuedOperationsAssetsHeldForSaleDetails" xlink:type="extended" />
  <calculationLink xlink:role="http://www.galenabiopharma.com/role/DiscontinuedOperationsAssetsHeldForSaleNotes" xlink:type="extended" />
  <calculationLink xlink:role="http://www.galenabiopharma.com/role/DiscontinuedOperationsAssetsHeldForSaleSignificantOperatingNonCashAndCapitalExpendituresDetails" xlink:type="extended" />
  <calculationLink xlink:role="http://www.galenabiopharma.com/role/DiscontinuedOperationsAssetsHeldForSaleTables" xlink:type="extended" />
  <calculationLink xlink:role="http://www.galenabiopharma.com/role/DocumentAndEntityInformation" xlink:type="extended" />
  <calculationLink xlink:role="http://www.galenabiopharma.com/role/FairValueMeasurements" xlink:type="extended" />
  <calculationLink xlink:role="http://www.galenabiopharma.com/role/FairValueMeasurementsContingentPurchasePriceConsiderationMeasuredAtEstimatedFairValueOnRecurringBasisDetail" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EquityFairValueDisclosure" xlink:label="loc_us-gaap_EquityFairValueDisclosure_302a6e98-c762-716f-8178-ceed50d9741b" xlink:type="locator" />
    <loc xlink:href="gale-20150930.xsd#gale_FairValueOfWarrantsPotentiallySettleableInCash" xlink:label="loc_gale_FairValueOfWarrantsPotentiallySettleableInCash_aa7fcc1c-b1c3-0bc9-16a4-36aef3d4e0cc" xlink:type="locator" />
    <calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EquityFairValueDisclosure_302a6e98-c762-716f-8178-ceed50d9741b" xlink:to="loc_gale_FairValueOfWarrantsPotentiallySettleableInCash_aa7fcc1c-b1c3-0bc9-16a4-36aef3d4e0cc" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ContingentConsiderationClassifiedAsEquityFairValueDisclosure" xlink:label="loc_us-gaap_ContingentConsiderationClassifiedAsEquityFairValueDisclosure_397f7477-1aa4-42ae-c7e8-4b8ec1fcc54c" xlink:type="locator" />
    <calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EquityFairValueDisclosure_302a6e98-c762-716f-8178-ceed50d9741b" xlink:to="loc_us-gaap_ContingentConsiderationClassifiedAsEquityFairValueDisclosure_397f7477-1aa4-42ae-c7e8-4b8ec1fcc54c" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AssetsFairValueDisclosure" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_8b55b75a-d66d-1dbb-a26a-c58c1cb8c8b0" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_1b16e3b5-4267-805c-bc8d-0fbc8ca9b0da" xlink:type="locator" />
    <calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsFairValueDisclosure_8b55b75a-d66d-1dbb-a26a-c58c1cb8c8b0" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_1b16e3b5-4267-805c-bc8d-0fbc8ca9b0da" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AssetsHeldForSaleLongLivedFairValueDisclosure" xlink:label="loc_us-gaap_AssetsHeldForSaleLongLivedFairValueDisclosure_86c70b34-73b4-abf0-060e-396e6f4dc54f" xlink:type="locator" />
    <calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsFairValueDisclosure_8b55b75a-d66d-1dbb-a26a-c58c1cb8c8b0" xlink:to="loc_us-gaap_AssetsHeldForSaleLongLivedFairValueDisclosure_86c70b34-73b4-abf0-060e-396e6f4dc54f" xlink:type="arc" />
  </calculationLink>
  <calculationLink xlink:role="http://www.galenabiopharma.com/role/FairValueMeasurementsReconciliationOfLevel3LiabilitiesDetail" xlink:type="extended" />
  <calculationLink xlink:role="http://www.galenabiopharma.com/role/FairValueMeasurementsTables" xlink:type="extended" />
  <calculationLink xlink:role="http://www.galenabiopharma.com/role/LegalProceedingsCommitmentsAndContingenciesDetailsDetails" xlink:type="extended" />
  <calculationLink xlink:role="http://www.galenabiopharma.com/role/LegalProceedingsCommitmentsAndContingenciesNotes" xlink:type="extended" />
  <calculationLink xlink:role="http://www.galenabiopharma.com/role/LicenseAgreements" xlink:type="extended" />
  <calculationLink xlink:role="http://www.galenabiopharma.com/role/LicenseAgreementsAdditionalInformationDetail" xlink:type="extended" />
  <calculationLink xlink:role="http://www.galenabiopharma.com/role/LongTermDebt" xlink:type="extended" />
  <calculationLink xlink:role="http://www.galenabiopharma.com/role/LongTermDebtDetails" xlink:type="extended" />
  <calculationLink xlink:role="http://www.galenabiopharma.com/role/NetLossPerShare" xlink:type="extended" />
  <calculationLink xlink:role="http://www.galenabiopharma.com/role/NetLossPerShareCommonSharesExcludedFromNetLossDetail" xlink:type="extended" />
  <calculationLink xlink:role="http://www.galenabiopharma.com/role/NetLossPerShareTables" xlink:type="extended" />
  <calculationLink xlink:role="http://www.galenabiopharma.com/role/OtherIncomeExpenseNotes" xlink:type="extended" />
  <calculationLink xlink:role="http://www.galenabiopharma.com/role/OtherIncomeExpenseTableDetails" xlink:type="extended" />
  <calculationLink xlink:role="http://www.galenabiopharma.com/role/OtherIncomeExpenseTables" xlink:type="extended" />
  <calculationLink xlink:role="http://www.galenabiopharma.com/role/SignificantCustomersAndConcentrationOfCreditRiskDetails" xlink:type="extended" />
  <calculationLink xlink:role="http://www.galenabiopharma.com/role/SignificantCustomersAndConcentrationOfCreditRiskNotes" xlink:type="extended" />
  <calculationLink xlink:role="http://www.galenabiopharma.com/role/SignificantCustomersAndConcentrationOfCreditRiskSignificantCustomersAndConcentrationOfCreditRiskTables" xlink:type="extended" />
  <calculationLink xlink:role="http://www.galenabiopharma.com/role/StockBasedCompensation" xlink:type="extended" />
  <calculationLink xlink:role="http://www.galenabiopharma.com/role/StockBasedCompensationAdditionalInformationDetail" xlink:type="extended" />
  <calculationLink xlink:role="http://www.galenabiopharma.com/role/StockBasedCompensationAllocatedStockBasedCompensationDetails" xlink:type="extended" />
  <calculationLink xlink:role="http://www.galenabiopharma.com/role/StockBasedCompensationAssumptionsForOptionGrantsIssuedDetail" xlink:type="extended" />
  <calculationLink xlink:role="http://www.galenabiopharma.com/role/StockBasedCompensationStockOptionActivityDetail" xlink:type="extended" />
  <calculationLink xlink:role="http://www.galenabiopharma.com/role/StockBasedCompensationTables" xlink:type="extended" />
  <calculationLink xlink:role="http://www.galenabiopharma.com/role/StockholdersEquity" xlink:type="extended" />
  <calculationLink xlink:role="http://www.galenabiopharma.com/role/StockholdersEquityAdditionalInformationDetail" xlink:type="extended" />
  <calculationLink xlink:role="http://www.galenabiopharma.com/role/StockholdersEquityCommonStockAreReservedForFutureIssuanceDetail" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_a51b337f-fe8a-e677-aa85-f24cc1bc3ff0" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="loc_us-gaap_ClassOfWarrantOrRightOutstanding_e04c7e47-0e17-b87c-b6be-bac174a68406" xlink:type="locator" />
    <calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_a51b337f-fe8a-e677-aa85-f24cc1bc3ff0" xlink:to="loc_us-gaap_ClassOfWarrantOrRightOutstanding_e04c7e47-0e17-b87c-b6be-bac174a68406" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_b392c6a6-07f0-050a-e07d-ef62a880a291" xlink:type="locator" />
    <calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_a51b337f-fe8a-e677-aa85-f24cc1bc3ff0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_b392c6a6-07f0-050a-e07d-ef62a880a291" xlink:type="arc" />
    <loc xlink:href="gale-20150930.xsd#gale_OptionsReservedForFutureIssuanceUnderCompaniesIncentivePlan" xlink:label="loc_gale_OptionsReservedForFutureIssuanceUnderCompaniesIncentivePlan_e869d365-5f39-2489-9730-36aef3a6a861" xlink:type="locator" />
    <calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_a51b337f-fe8a-e677-aa85-f24cc1bc3ff0" xlink:to="loc_gale_OptionsReservedForFutureIssuanceUnderCompaniesIncentivePlan_e869d365-5f39-2489-9730-36aef3a6a861" xlink:type="arc" />
    <loc xlink:href="gale-20150930.xsd#gale_CommonStockCapitalSharesReservedForFutureIssuanceOfEmployeeStockPurchasePlan" xlink:label="loc_gale_CommonStockCapitalSharesReservedForFutureIssuanceOfEmployeeStockPurchasePlan_cca78d49-9821-d11e-1e65-36aef3ba77c1" xlink:type="locator" />
    <calculationArc order="4" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_a51b337f-fe8a-e677-aa85-f24cc1bc3ff0" xlink:to="loc_gale_CommonStockCapitalSharesReservedForFutureIssuanceOfEmployeeStockPurchasePlan_cca78d49-9821-d11e-1e65-36aef3ba77c1" xlink:type="arc" />
  </calculationLink>
  <calculationLink xlink:role="http://www.galenabiopharma.com/role/StockholdersEquityTables" xlink:type="extended" />
  <calculationLink xlink:role="http://www.galenabiopharma.com/role/SubsequentEvents" xlink:type="extended" />
  <calculationLink xlink:role="http://www.galenabiopharma.com/role/Warrants" xlink:type="extended" />
  <calculationLink xlink:role="http://www.galenabiopharma.com/role/WarrantsChangesInFairValueOfWarrantLiabilityDetail" xlink:type="extended" />
  <calculationLink xlink:role="http://www.galenabiopharma.com/role/WarrantsFairValueOfWarrantsIsEstimatedUsingBlackScholesOptionPricingModelDetail" xlink:type="extended" />
  <calculationLink xlink:role="http://www.galenabiopharma.com/role/WarrantsScheduleOfWarrantActivityDetail" xlink:type="extended" />
  <calculationLink xlink:role="http://www.galenabiopharma.com/role/WarrantsTables" xlink:type="extended" />
  <calculationLink xlink:role="http://www.galenabiopharma.com/role/WarrantsWarrantsClassifiedAsEquityDetails" xlink:type="extended" />
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>10
<FILENAME>gale-20150930_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!--XBRL Document Created with Wdesk from Workiva-->
<!-- -->
<linkbase xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
  <roleRef roleURI="http://www.galenabiopharma.com/role/AccruedExpensesAndOtherCurrentLiabilities" xlink:href="gale-20150930.xsd#AccruedExpensesAndOtherCurrentLiabilities" xlink:type="simple" />
  <roleRef roleURI="http://www.galenabiopharma.com/role/AccruedExpensesAndOtherCurrentLiabilitiesDetails" xlink:href="gale-20150930.xsd#AccruedExpensesAndOtherCurrentLiabilitiesDetails" xlink:type="simple" />
  <roleRef roleURI="http://www.galenabiopharma.com/role/AccruedExpensesAndOtherCurrentLiabilitiesTables" xlink:href="gale-20150930.xsd#AccruedExpensesAndOtherCurrentLiabilitiesTables" xlink:type="simple" />
  <roleRef roleURI="http://www.galenabiopharma.com/role/BusinessAndBasisOfPresentation" xlink:href="gale-20150930.xsd#BusinessAndBasisOfPresentation" xlink:type="simple" />
  <roleRef roleURI="http://www.galenabiopharma.com/role/BusinessAndBasisOfPresentationAdditionalInformationDetail" xlink:href="gale-20150930.xsd#BusinessAndBasisOfPresentationAdditionalInformationDetail" xlink:type="simple" />
  <roleRef roleURI="http://www.galenabiopharma.com/role/BusinessAndBasisOfPresentationPolicies" xlink:href="gale-20150930.xsd#BusinessAndBasisOfPresentationPolicies" xlink:type="simple" />
  <roleRef roleURI="http://www.galenabiopharma.com/role/BusinessCombinations" xlink:href="gale-20150930.xsd#BusinessCombinations" xlink:type="simple" />
  <roleRef roleURI="http://www.galenabiopharma.com/role/BusinessCombinationsDetails" xlink:href="gale-20150930.xsd#BusinessCombinationsDetails" xlink:type="simple" />
  <roleRef roleURI="http://www.galenabiopharma.com/role/BusinessCombinationsTables" xlink:href="gale-20150930.xsd#BusinessCombinationsTables" xlink:type="simple" />
  <roleRef roleURI="http://www.galenabiopharma.com/role/CondensedConsolidatedBalanceSheets" xlink:href="gale-20150930.xsd#CondensedConsolidatedBalanceSheets" xlink:type="simple" />
  <roleRef roleURI="http://www.galenabiopharma.com/role/CondensedConsolidatedBalanceSheetsParenthetical" xlink:href="gale-20150930.xsd#CondensedConsolidatedBalanceSheetsParenthetical" xlink:type="simple" />
  <roleRef roleURI="http://www.galenabiopharma.com/role/CondensedConsolidatedStatementOfStockholdersEquityCondensedConsolidatedStatementOfStockholdersEquity" xlink:href="gale-20150930.xsd#CondensedConsolidatedStatementOfStockholdersEquityCondensedConsolidatedStatementOfStockholdersEquity" xlink:type="simple" />
  <roleRef roleURI="http://www.galenabiopharma.com/role/CondensedConsolidatedStatementsOfCashFlows" xlink:href="gale-20150930.xsd#CondensedConsolidatedStatementsOfCashFlows" xlink:type="simple" />
  <roleRef roleURI="http://www.galenabiopharma.com/role/CondensedConsolidatedStatementsOfComprehensiveLoss" xlink:href="gale-20150930.xsd#CondensedConsolidatedStatementsOfComprehensiveLoss" xlink:type="simple" />
  <roleRef roleURI="http://www.galenabiopharma.com/role/DiscontinuedOperationsAssetsHeldForSaleCarryingAmountsOfAssetsAndLiabilitiesDetails" xlink:href="gale-20150930.xsd#DiscontinuedOperationsAssetsHeldForSaleCarryingAmountsOfAssetsAndLiabilitiesDetails" xlink:type="simple" />
  <roleRef roleURI="http://www.galenabiopharma.com/role/DiscontinuedOperationsAssetsHeldForSaleComponentsAttributableToCommercialBusinessDetails" xlink:href="gale-20150930.xsd#DiscontinuedOperationsAssetsHeldForSaleComponentsAttributableToCommercialBusinessDetails" xlink:type="simple" />
  <roleRef roleURI="http://www.galenabiopharma.com/role/DiscontinuedOperationsAssetsHeldForSaleDetails" xlink:href="gale-20150930.xsd#DiscontinuedOperationsAssetsHeldForSaleDetails" xlink:type="simple" />
  <roleRef roleURI="http://www.galenabiopharma.com/role/DiscontinuedOperationsAssetsHeldForSaleNotes" xlink:href="gale-20150930.xsd#DiscontinuedOperationsAssetsHeldForSaleNotes" xlink:type="simple" />
  <roleRef roleURI="http://www.galenabiopharma.com/role/DiscontinuedOperationsAssetsHeldForSaleSignificantOperatingNonCashAndCapitalExpendituresDetails" xlink:href="gale-20150930.xsd#DiscontinuedOperationsAssetsHeldForSaleSignificantOperatingNonCashAndCapitalExpendituresDetails" xlink:type="simple" />
  <roleRef roleURI="http://www.galenabiopharma.com/role/DiscontinuedOperationsAssetsHeldForSaleTables" xlink:href="gale-20150930.xsd#DiscontinuedOperationsAssetsHeldForSaleTables" xlink:type="simple" />
  <roleRef roleURI="http://www.galenabiopharma.com/role/DocumentAndEntityInformation" xlink:href="gale-20150930.xsd#DocumentAndEntityInformation" xlink:type="simple" />
  <roleRef roleURI="http://www.galenabiopharma.com/role/FairValueMeasurements" xlink:href="gale-20150930.xsd#FairValueMeasurements" xlink:type="simple" />
  <roleRef roleURI="http://www.galenabiopharma.com/role/FairValueMeasurementsContingentPurchasePriceConsiderationMeasuredAtEstimatedFairValueOnRecurringBasisDetail" xlink:href="gale-20150930.xsd#FairValueMeasurementsContingentPurchasePriceConsiderationMeasuredAtEstimatedFairValueOnRecurringBasisDetail" xlink:type="simple" />
  <roleRef roleURI="http://www.galenabiopharma.com/role/FairValueMeasurementsReconciliationOfLevel3LiabilitiesDetail" xlink:href="gale-20150930.xsd#FairValueMeasurementsReconciliationOfLevel3LiabilitiesDetail" xlink:type="simple" />
  <roleRef roleURI="http://www.galenabiopharma.com/role/FairValueMeasurementsTables" xlink:href="gale-20150930.xsd#FairValueMeasurementsTables" xlink:type="simple" />
  <roleRef roleURI="http://www.galenabiopharma.com/role/LegalProceedingsCommitmentsAndContingenciesDetailsDetails" xlink:href="gale-20150930.xsd#LegalProceedingsCommitmentsAndContingenciesDetailsDetails" xlink:type="simple" />
  <roleRef roleURI="http://www.galenabiopharma.com/role/LegalProceedingsCommitmentsAndContingenciesNotes" xlink:href="gale-20150930.xsd#LegalProceedingsCommitmentsAndContingenciesNotes" xlink:type="simple" />
  <roleRef roleURI="http://www.galenabiopharma.com/role/LicenseAgreements" xlink:href="gale-20150930.xsd#LicenseAgreements" xlink:type="simple" />
  <roleRef roleURI="http://www.galenabiopharma.com/role/LicenseAgreementsAdditionalInformationDetail" xlink:href="gale-20150930.xsd#LicenseAgreementsAdditionalInformationDetail" xlink:type="simple" />
  <roleRef roleURI="http://www.galenabiopharma.com/role/LongTermDebt" xlink:href="gale-20150930.xsd#LongTermDebt" xlink:type="simple" />
  <roleRef roleURI="http://www.galenabiopharma.com/role/LongTermDebtDetails" xlink:href="gale-20150930.xsd#LongTermDebtDetails" xlink:type="simple" />
  <roleRef roleURI="http://www.galenabiopharma.com/role/NetLossPerShare" xlink:href="gale-20150930.xsd#NetLossPerShare" xlink:type="simple" />
  <roleRef roleURI="http://www.galenabiopharma.com/role/NetLossPerShareCommonSharesExcludedFromNetLossDetail" xlink:href="gale-20150930.xsd#NetLossPerShareCommonSharesExcludedFromNetLossDetail" xlink:type="simple" />
  <roleRef roleURI="http://www.galenabiopharma.com/role/NetLossPerShareTables" xlink:href="gale-20150930.xsd#NetLossPerShareTables" xlink:type="simple" />
  <roleRef roleURI="http://www.galenabiopharma.com/role/OtherIncomeExpenseNotes" xlink:href="gale-20150930.xsd#OtherIncomeExpenseNotes" xlink:type="simple" />
  <roleRef roleURI="http://www.galenabiopharma.com/role/OtherIncomeExpenseTableDetails" xlink:href="gale-20150930.xsd#OtherIncomeExpenseTableDetails" xlink:type="simple" />
  <roleRef roleURI="http://www.galenabiopharma.com/role/OtherIncomeExpenseTables" xlink:href="gale-20150930.xsd#OtherIncomeExpenseTables" xlink:type="simple" />
  <roleRef roleURI="http://www.galenabiopharma.com/role/SignificantCustomersAndConcentrationOfCreditRiskDetails" xlink:href="gale-20150930.xsd#SignificantCustomersAndConcentrationOfCreditRiskDetails" xlink:type="simple" />
  <roleRef roleURI="http://www.galenabiopharma.com/role/SignificantCustomersAndConcentrationOfCreditRiskNotes" xlink:href="gale-20150930.xsd#SignificantCustomersAndConcentrationOfCreditRiskNotes" xlink:type="simple" />
  <roleRef roleURI="http://www.galenabiopharma.com/role/SignificantCustomersAndConcentrationOfCreditRiskSignificantCustomersAndConcentrationOfCreditRiskTables" xlink:href="gale-20150930.xsd#SignificantCustomersAndConcentrationOfCreditRiskSignificantCustomersAndConcentrationOfCreditRiskTables" xlink:type="simple" />
  <roleRef roleURI="http://www.galenabiopharma.com/role/StockBasedCompensation" xlink:href="gale-20150930.xsd#StockBasedCompensation" xlink:type="simple" />
  <roleRef roleURI="http://www.galenabiopharma.com/role/StockBasedCompensationAdditionalInformationDetail" xlink:href="gale-20150930.xsd#StockBasedCompensationAdditionalInformationDetail" xlink:type="simple" />
  <roleRef roleURI="http://www.galenabiopharma.com/role/StockBasedCompensationAllocatedStockBasedCompensationDetails" xlink:href="gale-20150930.xsd#StockBasedCompensationAllocatedStockBasedCompensationDetails" xlink:type="simple" />
  <roleRef roleURI="http://www.galenabiopharma.com/role/StockBasedCompensationAssumptionsForOptionGrantsIssuedDetail" xlink:href="gale-20150930.xsd#StockBasedCompensationAssumptionsForOptionGrantsIssuedDetail" xlink:type="simple" />
  <roleRef roleURI="http://www.galenabiopharma.com/role/StockBasedCompensationStockOptionActivityDetail" xlink:href="gale-20150930.xsd#StockBasedCompensationStockOptionActivityDetail" xlink:type="simple" />
  <roleRef roleURI="http://www.galenabiopharma.com/role/StockBasedCompensationTables" xlink:href="gale-20150930.xsd#StockBasedCompensationTables" xlink:type="simple" />
  <roleRef roleURI="http://www.galenabiopharma.com/role/StockholdersEquity" xlink:href="gale-20150930.xsd#StockholdersEquity" xlink:type="simple" />
  <roleRef roleURI="http://www.galenabiopharma.com/role/StockholdersEquityAdditionalInformationDetail" xlink:href="gale-20150930.xsd#StockholdersEquityAdditionalInformationDetail" xlink:type="simple" />
  <roleRef roleURI="http://www.galenabiopharma.com/role/StockholdersEquityCommonStockAreReservedForFutureIssuanceDetail" xlink:href="gale-20150930.xsd#StockholdersEquityCommonStockAreReservedForFutureIssuanceDetail" xlink:type="simple" />
  <roleRef roleURI="http://www.galenabiopharma.com/role/StockholdersEquityTables" xlink:href="gale-20150930.xsd#StockholdersEquityTables" xlink:type="simple" />
  <roleRef roleURI="http://www.galenabiopharma.com/role/SubsequentEvents" xlink:href="gale-20150930.xsd#SubsequentEvents" xlink:type="simple" />
  <roleRef roleURI="http://www.galenabiopharma.com/role/Warrants" xlink:href="gale-20150930.xsd#Warrants" xlink:type="simple" />
  <roleRef roleURI="http://www.galenabiopharma.com/role/WarrantsChangesInFairValueOfWarrantLiabilityDetail" xlink:href="gale-20150930.xsd#WarrantsChangesInFairValueOfWarrantLiabilityDetail" xlink:type="simple" />
  <roleRef roleURI="http://www.galenabiopharma.com/role/WarrantsFairValueOfWarrantsIsEstimatedUsingBlackScholesOptionPricingModelDetail" xlink:href="gale-20150930.xsd#WarrantsFairValueOfWarrantsIsEstimatedUsingBlackScholesOptionPricingModelDetail" xlink:type="simple" />
  <roleRef roleURI="http://www.galenabiopharma.com/role/WarrantsScheduleOfWarrantActivityDetail" xlink:href="gale-20150930.xsd#WarrantsScheduleOfWarrantActivityDetail" xlink:type="simple" />
  <roleRef roleURI="http://www.galenabiopharma.com/role/WarrantsTables" xlink:href="gale-20150930.xsd#WarrantsTables" xlink:type="simple" />
  <roleRef roleURI="http://www.galenabiopharma.com/role/WarrantsWarrantsClassifiedAsEquityDetails" xlink:href="gale-20150930.xsd#WarrantsWarrantsClassifiedAsEquityDetails" xlink:type="simple" />
  <arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" xlink:type="simple" />
  <arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" xlink:type="simple" />
  <arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" xlink:type="simple" />
  <arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" xlink:type="simple" />
  <arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" xlink:type="simple" />
  <definitionLink xlink:role="http://www.galenabiopharma.com/role/AccruedExpensesAndOtherCurrentLiabilities" xlink:type="extended" />
  <definitionLink xlink:role="http://www.galenabiopharma.com/role/AccruedExpensesAndOtherCurrentLiabilitiesDetails" xlink:type="extended" />
  <definitionLink xlink:role="http://www.galenabiopharma.com/role/AccruedExpensesAndOtherCurrentLiabilitiesTables" xlink:type="extended" />
  <definitionLink xlink:role="http://www.galenabiopharma.com/role/BusinessAndBasisOfPresentation" xlink:type="extended" />
  <definitionLink xlink:role="http://www.galenabiopharma.com/role/BusinessAndBasisOfPresentationAdditionalInformationDetail" xlink:type="extended">
    <loc xlink:href="gale-20150930.xsd#gale_ScheduleOfSummaryOfSignificantAccountingPoliciesLineItems" xlink:label="loc_gale_ScheduleOfSummaryOfSignificantAccountingPoliciesLineItems_E3D0066C4A9F53F30EDADECE1E81384E" xlink:type="locator" />
    <loc xlink:href="gale-20150930.xsd#gale_ScheduleOfSummaryOfSignificantAccountingPoliciesTable" xlink:label="loc_gale_ScheduleOfSummaryOfSignificantAccountingPoliciesTable_15E05D38C24332DBC547DECE1E80DFE9" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_gale_ScheduleOfSummaryOfSignificantAccountingPoliciesLineItems_E3D0066C4A9F53F30EDADECE1E81384E" xlink:to="loc_gale_ScheduleOfSummaryOfSignificantAccountingPoliciesTable_15E05D38C24332DBC547DECE1E80DFE9" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RangeAxis" xlink:label="loc_us-gaap_RangeAxis_7EEDE4D2940E921B7995DECE1E81E2BB" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_gale_ScheduleOfSummaryOfSignificantAccountingPoliciesTable_15E05D38C24332DBC547DECE1E80DFE9" xlink:to="loc_us-gaap_RangeAxis_7EEDE4D2940E921B7995DECE1E81E2BB" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaap_RangeMember_32DBEE5FF85A5B622F1DDECE1E81E8E4_default" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RangeAxis_7EEDE4D2940E921B7995DECE1E81E2BB" xlink:to="loc_us-gaap_RangeMember_32DBEE5FF85A5B622F1DDECE1E81E8E4_default" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaap_RangeMember_32DBEE5FF85A5B622F1DDECE1E81E8E4" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RangeAxis_7EEDE4D2940E921B7995DECE1E81E2BB" xlink:to="loc_us-gaap_RangeMember_32DBEE5FF85A5B622F1DDECE1E81E8E4" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_MinimumMember" xlink:label="loc_us-gaap_MinimumMember_AB9F14BBAE3607F76A3FDECE1E8190FC" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RangeMember_32DBEE5FF85A5B622F1DDECE1E81E8E4" xlink:to="loc_us-gaap_MinimumMember_AB9F14BBAE3607F76A3FDECE1E8190FC" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_MaximumMember" xlink:label="loc_us-gaap_MaximumMember_DE28EEEDB767537287E5DECE1E81F378" xlink:type="locator" />
    <definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RangeMember_32DBEE5FF85A5B622F1DDECE1E81E8E4" xlink:to="loc_us-gaap_MaximumMember_DE28EEEDB767537287E5DECE1E81F378" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_1DB980BDFCFEA1260C80DECE1E810547" xlink:type="locator" />
    <definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_gale_ScheduleOfSummaryOfSignificantAccountingPoliciesTable_15E05D38C24332DBC547DECE1E80DFE9" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_1DB980BDFCFEA1260C80DECE1E810547" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_22614AB42CEC081C2A5EDECE1E8119E5_default" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_1DB980BDFCFEA1260C80DECE1E810547" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_22614AB42CEC081C2A5EDECE1E8119E5_default" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_22614AB42CEC081C2A5EDECE1E8119E5" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_1DB980BDFCFEA1260C80DECE1E810547" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_22614AB42CEC081C2A5EDECE1E8119E5" xlink:type="arc" />
    <loc xlink:href="gale-20150930.xsd#gale_EquipmentFurnitureAndFixturesMember" xlink:label="loc_gale_EquipmentFurnitureAndFixturesMember_B777E9E80CD82CC887D7DECE1E81389D" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_22614AB42CEC081C2A5EDECE1E8119E5" xlink:to="loc_gale_EquipmentFurnitureAndFixturesMember_B777E9E80CD82CC887D7DECE1E81389D" xlink:type="arc" />
    <loc xlink:href="gale-20150930.xsd#gale_NumberofPatientsDiagnosedWithBreastCancerPatientsAnnuallyAtHighRiskofDiseaseRecurrence" xlink:label="loc_gale_NumberofPatientsDiagnosedWithBreastCancerPatientsAnnuallyAtHighRiskofDiseaseRecurrence_37EAB06DA03CBE2EC5FBDECE1E86A9E4" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gale_ScheduleOfSummaryOfSignificantAccountingPoliciesLineItems_E3D0066C4A9F53F30EDADECE1E81384E" xlink:to="loc_gale_NumberofPatientsDiagnosedWithBreastCancerPatientsAnnuallyAtHighRiskofDiseaseRecurrence_37EAB06DA03CBE2EC5FBDECE1E86A9E4" xlink:type="arc" />
    <loc xlink:href="gale-20150930.xsd#gale_NumberofPatientsDiagnosedWithBreastCancerPatientsAnnually" xlink:label="loc_gale_NumberofPatientsDiagnosedWithBreastCancerPatientsAnnually_FB93284E5CCB84EDBEB5DECE1E87F265" xlink:type="locator" />
    <definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gale_ScheduleOfSummaryOfSignificantAccountingPoliciesLineItems_E3D0066C4A9F53F30EDADECE1E81384E" xlink:to="loc_gale_NumberofPatientsDiagnosedWithBreastCancerPatientsAnnually_FB93284E5CCB84EDBEB5DECE1E87F265" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivable" xlink:label="loc_us-gaap_AllowanceForDoubtfulAccountsReceivable_58C3EFB14EB81C9C1E10DECE1E872BEE" xlink:type="locator" />
    <definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gale_ScheduleOfSummaryOfSignificantAccountingPoliciesLineItems_E3D0066C4A9F53F30EDADECE1E81384E" xlink:to="loc_us-gaap_AllowanceForDoubtfulAccountsReceivable_58C3EFB14EB81C9C1E10DECE1E872BEE" xlink:type="arc" />
    <loc xlink:href="gale-20150930.xsd#gale_MaximumMaturityPeriodToConsiderAllHighlyLiquidDebtInstrumentsAsCashAndCashEquivalents" xlink:label="loc_gale_MaximumMaturityPeriodToConsiderAllHighlyLiquidDebtInstrumentsAsCashAndCashEquivalents_0432E498B77DC7321941DECE1E87D006" xlink:type="locator" />
    <definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gale_ScheduleOfSummaryOfSignificantAccountingPoliciesLineItems_E3D0066C4A9F53F30EDADECE1E81384E" xlink:to="loc_gale_MaximumMaturityPeriodToConsiderAllHighlyLiquidDebtInstrumentsAsCashAndCashEquivalents_0432E498B77DC7321941DECE1E87D006" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_InventoryNet" xlink:label="loc_us-gaap_InventoryNet_246B7BC308E3C6EB648CDECE1E87FE5D" xlink:type="locator" />
    <definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gale_ScheduleOfSummaryOfSignificantAccountingPoliciesLineItems_E3D0066C4A9F53F30EDADECE1E81384E" xlink:to="loc_us-gaap_InventoryNet_246B7BC308E3C6EB648CDECE1E87FE5D" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_InventoryWorkInProcess" xlink:label="loc_us-gaap_InventoryWorkInProcess_5D4E23F4AB38BBC34391DECE1E8740A5" xlink:type="locator" />
    <definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gale_ScheduleOfSummaryOfSignificantAccountingPoliciesLineItems_E3D0066C4A9F53F30EDADECE1E81384E" xlink:to="loc_us-gaap_InventoryWorkInProcess_5D4E23F4AB38BBC34391DECE1E8740A5" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_InventoryFinishedGoods" xlink:label="loc_us-gaap_InventoryFinishedGoods_9D7B83ACF144DA8A1EB5DECE1E876B50" xlink:type="locator" />
    <definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gale_ScheduleOfSummaryOfSignificantAccountingPoliciesLineItems_E3D0066C4A9F53F30EDADECE1E81384E" xlink:to="loc_us-gaap_InventoryFinishedGoods_9D7B83ACF144DA8A1EB5DECE1E876B50" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_0BB6017A68A1FAFE6C10DECE1E87CB8B" xlink:type="locator" />
    <definitionArc order="8" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gale_ScheduleOfSummaryOfSignificantAccountingPoliciesLineItems_E3D0066C4A9F53F30EDADECE1E81384E" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_0BB6017A68A1FAFE6C10DECE1E87CB8B" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SalesDiscountsServices" xlink:label="loc_us-gaap_SalesDiscountsServices_870A8B3B3EE560B538A1DECE1E87A20A" xlink:type="locator" />
    <definitionArc order="9" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gale_ScheduleOfSummaryOfSignificantAccountingPoliciesLineItems_E3D0066C4A9F53F30EDADECE1E81384E" xlink:to="loc_us-gaap_SalesDiscountsServices_870A8B3B3EE560B538A1DECE1E87A20A" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AmortizationOfIntangibleAssets" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets_90A6C2DF78480C960857DECE1E87AA80" xlink:type="locator" />
    <definitionArc order="10" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gale_ScheduleOfSummaryOfSignificantAccountingPoliciesLineItems_E3D0066C4A9F53F30EDADECE1E81384E" xlink:to="loc_us-gaap_AmortizationOfIntangibleAssets_90A6C2DF78480C960857DECE1E87AA80" xlink:type="arc" />
  </definitionLink>
  <definitionLink xlink:role="http://www.galenabiopharma.com/role/BusinessAndBasisOfPresentationPolicies" xlink:type="extended" />
  <definitionLink xlink:role="http://www.galenabiopharma.com/role/BusinessCombinations" xlink:type="extended" />
  <definitionLink xlink:role="http://www.galenabiopharma.com/role/BusinessCombinationsDetails" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_BusinessAcquisitionLineItems" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_385F4649A184F137C5E8DDA4F7BACC26" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_6F08A45F81B05E3AE47ADDA4F7B4EA07" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_385F4649A184F137C5E8DDA4F7BACC26" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_6F08A45F81B05E3AE47ADDA4F7B4EA07" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_CBD5049D12CDEF883134DDA4F7B44B73" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_6F08A45F81B05E3AE47ADDA4F7B4EA07" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_CBD5049D12CDEF883134DDA4F7B44B73" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_704A499BFE5CC43D9EFDDDA4F7B41FDF_default" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_CBD5049D12CDEF883134DDA4F7B44B73" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_704A499BFE5CC43D9EFDDDA4F7B41FDF_default" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_704A499BFE5CC43D9EFDDDA4F7B41FDF" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_CBD5049D12CDEF883134DDA4F7B44B73" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_704A499BFE5CC43D9EFDDDA4F7B41FDF" xlink:type="arc" />
    <loc xlink:href="gale-20150930.xsd#gale_ZuplenzMember" xlink:label="loc_gale_ZuplenzMember_1C2B9692676B9B5875A5DDA4F7B472FC" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_704A499BFE5CC43D9EFDDDA4F7B41FDF" xlink:to="loc_gale_ZuplenzMember_1C2B9692676B9B5875A5DDA4F7B472FC" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_B239485301743F47B4F1DDA4F7B521B8" xlink:type="locator" />
    <definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_6F08A45F81B05E3AE47ADDA4F7B4EA07" xlink:to="loc_us-gaap_StatementClassOfStockAxis_B239485301743F47B4F1DDA4F7B521B8" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_883F86DF8D3C063709C3DDA4F7B58F93_default" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_B239485301743F47B4F1DDA4F7B521B8" xlink:to="loc_us-gaap_ClassOfStockDomain_883F86DF8D3C063709C3DDA4F7B58F93_default" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_883F86DF8D3C063709C3DDA4F7B58F93" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_B239485301743F47B4F1DDA4F7B521B8" xlink:to="loc_us-gaap_ClassOfStockDomain_883F86DF8D3C063709C3DDA4F7B58F93" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember_77C30CDFE372B7D5B5EFDDA4F7BAA798" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_883F86DF8D3C063709C3DDA4F7B58F93" xlink:to="loc_us-gaap_CommonStockMember_77C30CDFE372B7D5B5EFDDA4F7BAA798" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_972D3D20690609802907DDA4F7BA3E40" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_385F4649A184F137C5E8DDA4F7BACC26" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_972D3D20690609802907DDA4F7BA3E40" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_BusinessAcquisitionEquityInterestIssuedOrIssuableValueAssigned" xlink:label="loc_us-gaap_BusinessAcquisitionEquityInterestIssuedOrIssuableValueAssigned_3CCE5A0FBF680E6D4A14DDA4F7BA568E" xlink:type="locator" />
    <definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_385F4649A184F137C5E8DDA4F7BACC26" xlink:to="loc_us-gaap_BusinessAcquisitionEquityInterestIssuedOrIssuableValueAssigned_3CCE5A0FBF680E6D4A14DDA4F7BA568E" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred_F2CD3D864867AFBCFB9ADDA4F7BA2407" xlink:type="locator" />
    <definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_385F4649A184F137C5E8DDA4F7BACC26" xlink:to="loc_us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred_F2CD3D864867AFBCFB9ADDA4F7BA2407" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_BusinessCombinationConsiderationTransferredOther1" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferredOther1_AB376670F37E4E6FE961DDA4F7BAA121" xlink:type="locator" />
    <definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_385F4649A184F137C5E8DDA4F7BACC26" xlink:to="loc_us-gaap_BusinessCombinationConsiderationTransferredOther1_AB376670F37E4E6FE961DDA4F7BAA121" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_BusinessCombinationConsiderationTransferred1" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferred1_A53C9821ACB207EE160DDDA4F7BAC1B9" xlink:type="locator" />
    <definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_385F4649A184F137C5E8DDA4F7BACC26" xlink:to="loc_us-gaap_BusinessCombinationConsiderationTransferred1_A53C9821ACB207EE160DDDA4F7BAC1B9" xlink:type="arc" />
    <loc xlink:href="gale-20150930.xsd#gale_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedRights" xlink:label="loc_gale_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedRights_CD83B96F201E6F5C3F9BDDA4F7BBF567" xlink:type="locator" />
    <definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_385F4649A184F137C5E8DDA4F7BACC26" xlink:to="loc_gale_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedRights_CD83B96F201E6F5C3F9BDDA4F7BBF567" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_Goodwill" xlink:label="loc_us-gaap_Goodwill_B74D8577439916B3015FDDA4F7BB8A07" xlink:type="locator" />
    <definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_385F4649A184F137C5E8DDA4F7BACC26" xlink:to="loc_us-gaap_Goodwill_B74D8577439916B3015FDDA4F7BB8A07" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueOfAssetsAcquired" xlink:label="loc_us-gaap_FairValueOfAssetsAcquired_2C5397D3C347296B9BE5DDA4F7BB0910" xlink:type="locator" />
    <definitionArc order="8" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_385F4649A184F137C5E8DDA4F7BACC26" xlink:to="loc_us-gaap_FairValueOfAssetsAcquired_2C5397D3C347296B9BE5DDA4F7BB0910" xlink:type="arc" />
  </definitionLink>
  <definitionLink xlink:role="http://www.galenabiopharma.com/role/BusinessCombinationsTables" xlink:type="extended" />
  <definitionLink xlink:role="http://www.galenabiopharma.com/role/CondensedConsolidatedBalanceSheets" xlink:type="extended" />
  <definitionLink xlink:role="http://www.galenabiopharma.com/role/CondensedConsolidatedBalanceSheetsParenthetical" xlink:type="extended" />
  <definitionLink xlink:role="http://www.galenabiopharma.com/role/CondensedConsolidatedStatementOfStockholdersEquityCondensedConsolidatedStatementOfStockholdersEquity" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_95E1CD636ACC56FFB51496FEC3A9B2B7" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_A6BC268507DB5D6C801EEF1E351A33EC" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_95E1CD636ACC56FFB51496FEC3A9B2B7" xlink:to="loc_us-gaap_StatementTable_A6BC268507DB5D6C801EEF1E351A33EC" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_6A5FD0AC8FD65A53A7F956A80E3C9436" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_A6BC268507DB5D6C801EEF1E351A33EC" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_6A5FD0AC8FD65A53A7F956A80E3C9436" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_D2419D4A4ADE8AE7CEDAF4C7DD222A4D_AC07C473F17259308476173B2BB2AAFF" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_6A5FD0AC8FD65A53A7F956A80E3C9436" xlink:to="loc_us-gaap_EquityComponentDomain_D2419D4A4ADE8AE7CEDAF4C7DD222A4D_AC07C473F17259308476173B2BB2AAFF" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_B45758336F5B5E4CB688B8729BE9EF77" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_6A5FD0AC8FD65A53A7F956A80E3C9436" xlink:to="loc_us-gaap_EquityComponentDomain_B45758336F5B5E4CB688B8729BE9EF77" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember_741D613D4B1057D0A21E22B248287B1E" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_B45758336F5B5E4CB688B8729BE9EF77" xlink:to="loc_us-gaap_CommonStockMember_741D613D4B1057D0A21E22B248287B1E" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_E762029C2994514EB347BC5CB7FB969E" xlink:type="locator" />
    <definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_B45758336F5B5E4CB688B8729BE9EF77" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_E762029C2994514EB347BC5CB7FB969E" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="loc_us-gaap_RetainedEarningsMember_82B720A3DC9755A0B0BFA416B85E6692" xlink:type="locator" />
    <definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_B45758336F5B5E4CB688B8729BE9EF77" xlink:to="loc_us-gaap_RetainedEarningsMember_82B720A3DC9755A0B0BFA416B85E6692" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_TreasuryStockMember" xlink:label="loc_us-gaap_TreasuryStockMember_0846AD51934054C8AA55F67F85B00ED0" xlink:type="locator" />
    <definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_B45758336F5B5E4CB688B8729BE9EF77" xlink:to="loc_us-gaap_TreasuryStockMember_0846AD51934054C8AA55F67F85B00ED0" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_78BA6500FAF1599585AFC9BE3BE5BB0D" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_95E1CD636ACC56FFB51496FEC3A9B2B7" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_78BA6500FAF1599585AFC9BE3BE5BB0D" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SharesOutstanding" xlink:label="loc_us-gaap_SharesOutstanding_C1133C86FBA659CDA15C89A3DDB2C6DB" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_78BA6500FAF1599585AFC9BE3BE5BB0D" xlink:to="loc_us-gaap_SharesOutstanding_C1133C86FBA659CDA15C89A3DDB2C6DB" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_332CCB7DF16E5C5C82B63FD0AB91B7CE" xlink:type="locator" />
    <definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_78BA6500FAF1599585AFC9BE3BE5BB0D" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_332CCB7DF16E5C5C82B63FD0AB91B7CE" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesOther" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesOther_438DF48CEC095297BB69520E60FDCC40" xlink:type="locator" />
    <definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_78BA6500FAF1599585AFC9BE3BE5BB0D" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesOther_438DF48CEC095297BB69520E60FDCC40" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueOther" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueOther_9C4B48EDD3A75F08B118E7B1BABFE048" xlink:type="locator" />
    <definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_78BA6500FAF1599585AFC9BE3BE5BB0D" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueOther_9C4B48EDD3A75F08B118E7B1BABFE048" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_CE99E2A4BD0F5CA9A9535415BF4872AA" xlink:type="locator" />
    <definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_78BA6500FAF1599585AFC9BE3BE5BB0D" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_CE99E2A4BD0F5CA9A9535415BF4872AA" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_5B6A408D17D75B8CADF4804740C4D94C" xlink:type="locator" />
    <definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_78BA6500FAF1599585AFC9BE3BE5BB0D" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_5B6A408D17D75B8CADF4804740C4D94C" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_B812C9F4CDF857E5B1BA7099A500A36D" xlink:type="locator" />
    <definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_78BA6500FAF1599585AFC9BE3BE5BB0D" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_B812C9F4CDF857E5B1BA7099A500A36D" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_1416CAF360EC54199A44A2E277456BE7" xlink:type="locator" />
    <definitionArc order="8" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_78BA6500FAF1599585AFC9BE3BE5BB0D" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_1416CAF360EC54199A44A2E277456BE7" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalTaxEffectFromShareBasedCompensation" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalTaxEffectFromShareBasedCompensation_6A82047EC62A5E8B9FDDDA3C18F4B8DE" xlink:type="locator" />
    <definitionArc order="9" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_78BA6500FAF1599585AFC9BE3BE5BB0D" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalTaxEffectFromShareBasedCompensation_6A82047EC62A5E8B9FDDDA3C18F4B8DE" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_FC5F2601BAFA5E7A99E560BC00244D09" xlink:type="locator" />
    <definitionArc order="10" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_78BA6500FAF1599585AFC9BE3BE5BB0D" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_FC5F2601BAFA5E7A99E560BC00244D09" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_12B9F9D3550A59B98F239BCCD652AF6E" xlink:type="locator" />
    <definitionArc order="11" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_78BA6500FAF1599585AFC9BE3BE5BB0D" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_12B9F9D3550A59B98F239BCCD652AF6E" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_35219881DB6451E8820F475A55CDB1DE" xlink:type="locator" />
    <definitionArc order="12" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_78BA6500FAF1599585AFC9BE3BE5BB0D" xlink:to="loc_us-gaap_NetIncomeLoss_35219881DB6451E8820F475A55CDB1DE" xlink:type="arc" />
  </definitionLink>
  <definitionLink xlink:role="http://www.galenabiopharma.com/role/CondensedConsolidatedStatementsOfCashFlows" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_B9483F2F1F272C9C9D19DECFB1456D53" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_833B465F01FBA6E9A439DECFB144B6B8" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_B9483F2F1F272C9C9D19DECFB1456D53" xlink:to="loc_us-gaap_StatementTable_833B465F01FBA6E9A439DECFB144B6B8" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_644B76335F8D3E5177F6DECFB144BE9D" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_833B465F01FBA6E9A439DECFB144B6B8" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_644B76335F8D3E5177F6DECFB144BE9D" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_A1F176C14C1F6400B642DECFB145A390_default" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_644B76335F8D3E5177F6DECFB144BE9D" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_A1F176C14C1F6400B642DECFB145A390_default" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_A1F176C14C1F6400B642DECFB145A390" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_644B76335F8D3E5177F6DECFB144BE9D" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_A1F176C14C1F6400B642DECFB145A390" xlink:type="arc" />
    <loc xlink:href="gale-20150930.xsd#gale_AbstralMember" xlink:label="loc_gale_AbstralMember_8A6D9A18639A5E0E8194DECFB1453685" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_A1F176C14C1F6400B642DECFB145A390" xlink:to="loc_gale_AbstralMember_8A6D9A18639A5E0E8194DECFB1453685" xlink:type="arc" />
    <loc xlink:href="gale-20150930.xsd#gale_ZuplenzMember" xlink:label="loc_gale_ZuplenzMember_9E4577B7245ACFF4F031DECFB145075B" xlink:type="locator" />
    <definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_A1F176C14C1F6400B642DECFB145A390" xlink:to="loc_gale_ZuplenzMember_9E4577B7245ACFF4F031DECFB145075B" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_2C747EC46E27FF3C82E4DEE7D083E8BE" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_B9483F2F1F272C9C9D19DECFB1456D53" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_2C747EC46E27FF3C82E4DEE7D083E8BE" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_CCBDF903615CD281FE68DECFB145C274" xlink:type="locator" />
    <definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_B9483F2F1F272C9C9D19DECFB1456D53" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_CCBDF903615CD281FE68DECFB145C274" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_039E85029DD12E1B3B27DECFB145E917" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_CCBDF903615CD281FE68DECFB145C274" xlink:to="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_039E85029DD12E1B3B27DECFB145E917" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_191924000600F93A7B0BDECFB14AA4E5" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_039E85029DD12E1B3B27DECFB145E917" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_191924000600F93A7B0BDECFB14AA4E5" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaap_ShareBasedCompensation_7937A84F98D9E00D3068DECFB14A0EBE" xlink:type="locator" />
    <definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_039E85029DD12E1B3B27DECFB145E917" xlink:to="loc_us-gaap_ShareBasedCompensation_7937A84F98D9E00D3068DECFB14A0EBE" xlink:type="arc" />
    <loc xlink:href="gale-20150930.xsd#gale_ChangeInFairValueOfCommonStockWarrantsIssuedInConnectionWithVariousEquityFinancings" xlink:label="loc_gale_ChangeInFairValueOfCommonStockWarrantsIssuedInConnectionWithVariousEquityFinancings_C00AE340FF13CB57B40ADECFB14AF7CD" xlink:type="locator" />
    <definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_039E85029DD12E1B3B27DECFB145E917" xlink:to="loc_gale_ChangeInFairValueOfCommonStockWarrantsIssuedInConnectionWithVariousEquityFinancings_C00AE340FF13CB57B40ADECFB14AF7CD" xlink:type="arc" />
    <loc xlink:href="gale-20150930.xsd#gale_ChangeInFairValueOfContingentPurchaseConsideration" xlink:label="loc_gale_ChangeInFairValueOfContingentPurchaseConsideration_51BDE794020ABC65AD49DECFB14A1D20" xlink:type="locator" />
    <definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_039E85029DD12E1B3B27DECFB145E917" xlink:to="loc_gale_ChangeInFairValueOfContingentPurchaseConsideration_51BDE794020ABC65AD49DECFB14A1D20" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_1D39042AA97DC69BCC7ADECFB14A3BA1" xlink:type="locator" />
    <definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_CCBDF903615CD281FE68DECFB145C274" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_1D39042AA97DC69BCC7ADECFB14A3BA1" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_3D08D946986C5D996324DECFB14A26A8" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_1D39042AA97DC69BCC7ADECFB14A3BA1" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_3D08D946986C5D996324DECFB14A26A8" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable_A8B17C08F5B70E1A6AE2DECFB14A6D89" xlink:type="locator" />
    <definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_1D39042AA97DC69BCC7ADECFB14A3BA1" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayable_A8B17C08F5B70E1A6AE2DECFB14A6D89" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_4B5D1FE388FCEAB2254EDECFB14A3D24" xlink:type="locator" />
    <definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_1D39042AA97DC69BCC7ADECFB14A3BA1" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_4B5D1FE388FCEAB2254EDECFB14A3D24" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_C1221DE2F9CE10E36A72DECFB14B97BF" xlink:type="locator" />
    <definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_CCBDF903615CD281FE68DECFB145C274" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_C1221DE2F9CE10E36A72DECFB14B97BF" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax_FA3BCABD7563768C44D9DECFB14B5119" xlink:type="locator" />
    <definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_CCBDF903615CD281FE68DECFB145C274" xlink:to="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax_FA3BCABD7563768C44D9DECFB14B5119" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf" xlink:label="loc_us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf_82FA9E7246F7C650875FDECFB14B6CB7" xlink:type="locator" />
    <definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_CCBDF903615CD281FE68DECFB145C274" xlink:to="loc_us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf_82FA9E7246F7C650875FDECFB14B6CB7" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncreaseDecreaseInAssetsHeldForSale" xlink:label="loc_us-gaap_IncreaseDecreaseInAssetsHeldForSale_288E177A66ED957134BCDECFB14B2A62" xlink:type="locator" />
    <definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_CCBDF903615CD281FE68DECFB145C274" xlink:to="loc_us-gaap_IncreaseDecreaseInAssetsHeldForSale_288E177A66ED957134BCDECFB14B2A62" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations" xlink:label="loc_us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations_602F51B5546404D04884DECFB14B7E01" xlink:type="locator" />
    <definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_CCBDF903615CD281FE68DECFB145C274" xlink:to="loc_us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations_602F51B5546404D04884DECFB14B7E01" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_EBB9D03F28E25991181EDECFB14B5B64" xlink:type="locator" />
    <definitionArc order="8" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_CCBDF903615CD281FE68DECFB145C274" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_EBB9D03F28E25991181EDECFB14B5B64" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_4CB41BFA6BB6F341DB4BDECFB14BECE8" xlink:type="locator" />
    <definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_B9483F2F1F272C9C9D19DECFB1456D53" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_4CB41BFA6BB6F341DB4BDECFB14BECE8" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncreaseDecreaseInRestrictedCash" xlink:label="loc_us-gaap_IncreaseDecreaseInRestrictedCash_04BF2D4B5A813AC3D0A9DECFB14BE5D8" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_4CB41BFA6BB6F341DB4BDECFB14BECE8" xlink:to="loc_us-gaap_IncreaseDecreaseInRestrictedCash_04BF2D4B5A813AC3D0A9DECFB14BE5D8" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PaymentsToAcquireBusinessesGross" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesGross_48037E80F39D51C412AFDECFB14B9E92" xlink:type="locator" />
    <definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_4CB41BFA6BB6F341DB4BDECFB14BECE8" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesGross_48037E80F39D51C412AFDECFB14B9E92" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_0449D7BED612BC79F610DECFB14B433D" xlink:type="locator" />
    <definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_4CB41BFA6BB6F341DB4BDECFB14BECE8" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_0449D7BED612BC79F610DECFB14B433D" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations_DA98DEC5EB1396AEDD29DECFB14BD84D" xlink:type="locator" />
    <definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_4CB41BFA6BB6F341DB4BDECFB14BECE8" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations_DA98DEC5EB1396AEDD29DECFB14BD84D" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations" xlink:label="loc_us-gaap_CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations_8068DA8B834324BF1EE5DECFB14B9063" xlink:type="locator" />
    <definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_4CB41BFA6BB6F341DB4BDECFB14BECE8" xlink:to="loc_us-gaap_CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations_8068DA8B834324BF1EE5DECFB14B9063" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_4EC0E8788B1398A00E34DECFB14BD887" xlink:type="locator" />
    <definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_4CB41BFA6BB6F341DB4BDECFB14BECE8" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_4EC0E8788B1398A00E34DECFB14BD887" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_BA0A395456D450B07560DECFB14B5949" xlink:type="locator" />
    <definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_B9483F2F1F272C9C9D19DECFB1456D53" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_BA0A395456D450B07560DECFB14B5949" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_F6308569703CE949A25EDECFB14B1D60" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_BA0A395456D450B07560DECFB14B5949" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_F6308569703CE949A25EDECFB14B1D60" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised_0DA6D5B1965516F8CB88DECFB14BAF76" xlink:type="locator" />
    <definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_BA0A395456D450B07560DECFB14B5949" xlink:to="loc_us-gaap_ProceedsFromStockOptionsExercised_0DA6D5B1965516F8CB88DECFB14BAF76" xlink:type="arc" />
    <loc xlink:href="gale-20150930.xsd#gale_NetProceedsFromExerciseOfCommonStockWarrants" xlink:label="loc_gale_NetProceedsFromExerciseOfCommonStockWarrants_C8468E49C33E89FD8EEFDECFB14B2093" xlink:type="locator" />
    <definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_BA0A395456D450B07560DECFB14B5949" xlink:to="loc_gale_NetProceedsFromExerciseOfCommonStockWarrants_C8468E49C33E89FD8EEFDECFB14B2093" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:label="loc_us-gaap_ProceedsFromIssuanceOrSaleOfEquity_FC385DCA7D7E8A1E0BF3DECFB14CAC15" xlink:type="locator" />
    <definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_BA0A395456D450B07560DECFB14B5949" xlink:to="loc_us-gaap_ProceedsFromIssuanceOrSaleOfEquity_FC385DCA7D7E8A1E0BF3DECFB14CAC15" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RepaymentsOfLongTermDebt" xlink:label="loc_us-gaap_RepaymentsOfLongTermDebt_E769B039C1E90123DA56DECFB14CD014" xlink:type="locator" />
    <definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_BA0A395456D450B07560DECFB14B5949" xlink:to="loc_us-gaap_RepaymentsOfLongTermDebt_E769B039C1E90123DA56DECFB14CD014" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_109FF286CA2D47B266F7DECFB14C8998" xlink:type="locator" />
    <definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_BA0A395456D450B07560DECFB14B5949" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_109FF286CA2D47B266F7DECFB14C8998" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:label="loc_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_58C6A6246259D5256F97DECFB14C9380" xlink:type="locator" />
    <definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_B9483F2F1F272C9C9D19DECFB1456D53" xlink:to="loc_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_58C6A6246259D5256F97DECFB14C9380" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_9AA3081D60D23029C22EDECFB14C7D36" xlink:type="locator" />
    <definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_B9483F2F1F272C9C9D19DECFB1456D53" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_9AA3081D60D23029C22EDECFB14C7D36" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract_D55855D8687C632F9753DECFB14CBC22" xlink:type="locator" />
    <definitionArc order="8" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_B9483F2F1F272C9C9D19DECFB1456D53" xlink:to="loc_us-gaap_SupplementalCashFlowInformationAbstract_D55855D8687C632F9753DECFB14CBC22" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ProceedsFromInterestReceived" xlink:label="loc_us-gaap_ProceedsFromInterestReceived_67C228FC9C83E985B811DECFB14C1E99" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_D55855D8687C632F9753DECFB14CBC22" xlink:to="loc_us-gaap_ProceedsFromInterestReceived_67C228FC9C83E985B811DECFB14C1E99" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_InterestPaid" xlink:label="loc_us-gaap_InterestPaid_E6F1BE03E0558F4A26B8DECFB14C88E8" xlink:type="locator" />
    <definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_D55855D8687C632F9753DECFB14CBC22" xlink:to="loc_us-gaap_InterestPaid_E6F1BE03E0558F4A26B8DECFB14C88E8" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:label="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_4217351EF9E0882536DBDECFB14CBB48" xlink:type="locator" />
    <definitionArc order="9" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_B9483F2F1F272C9C9D19DECFB1456D53" xlink:to="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_4217351EF9E0882536DBDECFB14CBB48" xlink:type="arc" />
    <loc xlink:href="gale-20150930.xsd#gale_FairValueOfWarrantsIssuedInConnectionWithCommonStockRecordedAsCostOfEquity" xlink:label="loc_gale_FairValueOfWarrantsIssuedInConnectionWithCommonStockRecordedAsCostOfEquity_0C874305ED8A314B8C3CDECFB14CDC62" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_4217351EF9E0882536DBDECFB14CBB48" xlink:to="loc_gale_FairValueOfWarrantsIssuedInConnectionWithCommonStockRecordedAsCostOfEquity_0C874305ED8A314B8C3CDECFB14CDC62" xlink:type="arc" />
    <loc xlink:href="gale-20150930.xsd#gale_ReclassificationOfWarrantLiabilityUponExercise" xlink:label="loc_gale_ReclassificationOfWarrantLiabilityUponExercise_1DABF2C73AD23FB0425DDECFB14CEE6D" xlink:type="locator" />
    <definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_4217351EF9E0882536DBDECFB14CBB48" xlink:to="loc_gale_ReclassificationOfWarrantLiabilityUponExercise_1DABF2C73AD23FB0425DDECFB14CEE6D" xlink:type="arc" />
  </definitionLink>
  <definitionLink xlink:role="http://www.galenabiopharma.com/role/CondensedConsolidatedStatementsOfComprehensiveLoss" xlink:type="extended" />
  <definitionLink xlink:role="http://www.galenabiopharma.com/role/DiscontinuedOperationsAssetsHeldForSaleCarryingAmountsOfAssetsAndLiabilitiesDetails" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_19FEB59144560D59EE7EDEEC4A0AA37D" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_FC15CC0F9741C9F74764DEEC4A096745" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_19FEB59144560D59EE7EDEEC4A0AA37D" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_FC15CC0F9741C9F74764DEEC4A096745" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_20A9AC555EE4629F93A8DEEC4A09B0CF" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_FC15CC0F9741C9F74764DEEC4A096745" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_20A9AC555EE4629F93A8DEEC4A09B0CF" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_BEF614D9F375A46839B3DEEC4A09FFF9_default" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_20A9AC555EE4629F93A8DEEC4A09B0CF" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_BEF614D9F375A46839B3DEEC4A09FFF9_default" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_BEF614D9F375A46839B3DEEC4A09FFF9" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_20A9AC555EE4629F93A8DEEC4A09B0CF" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_BEF614D9F375A46839B3DEEC4A09FFF9" xlink:type="arc" />
    <loc xlink:href="gale-20150930.xsd#gale_AbstralRightsNetMember" xlink:label="loc_gale_AbstralRightsNetMember_482C82163038D52DDD05DEEC4A093416" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_BEF614D9F375A46839B3DEEC4A09FFF9" xlink:to="loc_gale_AbstralRightsNetMember_482C82163038D52DDD05DEEC4A093416" xlink:type="arc" />
    <loc xlink:href="gale-20150930.xsd#gale_ZuplenzRightsMember" xlink:label="loc_gale_ZuplenzRightsMember_9490DD5E45FAC34163FEDEEC4A09B1A5" xlink:type="locator" />
    <definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_BEF614D9F375A46839B3DEEC4A09FFF9" xlink:to="loc_gale_ZuplenzRightsMember_9490DD5E45FAC34163FEDEEC4A09B1A5" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_C86EA01710B89EB8AB03DEEC4A09B585" xlink:type="locator" />
    <definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_FC15CC0F9741C9F74764DEEC4A096745" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_C86EA01710B89EB8AB03DEEC4A09B585" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_57CC94EFBE5F0F4F58ACDEEC4A0AC884_default" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_C86EA01710B89EB8AB03DEEC4A09B585" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_57CC94EFBE5F0F4F58ACDEEC4A0AC884_default" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_57CC94EFBE5F0F4F58ACDEEC4A0AC884" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_C86EA01710B89EB8AB03DEEC4A09B585" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_57CC94EFBE5F0F4F58ACDEEC4A0AC884" xlink:type="arc" />
    <loc xlink:href="gale-20150930.xsd#gale_CommercialBusinessSegmentMember" xlink:label="loc_gale_CommercialBusinessSegmentMember_E4F761483B293455ECEDDEEC4A0ABD2B" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_57CC94EFBE5F0F4F58ACDEEC4A0AC884" xlink:to="loc_gale_CommercialBusinessSegmentMember_E4F761483B293455ECEDDEEC4A0ABD2B" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet_4FD7CF3002F7A4F639CDDEEC4A0A7042" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_19FEB59144560D59EE7EDEEC4A0AA37D" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet_4FD7CF3002F7A4F639CDDEEC4A0A7042" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationInventory1" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationInventory1_7E46B7E821CB2CE9E89DDEEC4A0AF3A2" xlink:type="locator" />
    <definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_19FEB59144560D59EE7EDEEC4A0AA37D" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationInventory1_7E46B7E821CB2CE9E89DDEEC4A0AF3A2" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationPrepaidAndOtherAssets" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationPrepaidAndOtherAssets_0FE48BA816BA4C5C3B67DEEC4A0A89CF" xlink:type="locator" />
    <definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_19FEB59144560D59EE7EDEEC4A0AA37D" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationPrepaidAndOtherAssets_0FE48BA816BA4C5C3B67DEEC4A0A89CF" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment_4352A88CA1BA59081E6CDEEC4A0AA7D3" xlink:type="locator" />
    <definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_19FEB59144560D59EE7EDEEC4A0AA37D" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment_4352A88CA1BA59081E6CDEEC4A0AA7D3" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationIntangibleAssets" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationIntangibleAssets_D9D805C1D49B79575DDADEEC4A0AA6C0" xlink:type="locator" />
    <definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_19FEB59144560D59EE7EDEEC4A0AA37D" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationIntangibleAssets_D9D805C1D49B79575DDADEEC4A0AA6C0" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationGoodwill1" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationGoodwill1_F2CB2F46037470F44488DEEC4A0AE6E3" xlink:type="locator" />
    <definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_19FEB59144560D59EE7EDEEC4A0AA37D" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationGoodwill1_F2CB2F46037470F44488DEEC4A0AE6E3" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf" xlink:label="loc_us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf_F6C144410DFBAF842540DEEC4A0A77DE" xlink:type="locator" />
    <definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_19FEB59144560D59EE7EDEEC4A0AA37D" xlink:to="loc_us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf_F6C144410DFBAF842540DEEC4A0A77DE" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation" xlink:label="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation_93C1F3505B10D3F0085EDEEC4A0A316F" xlink:type="locator" />
    <definitionArc order="8" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_19FEB59144560D59EE7EDEEC4A0AA37D" xlink:to="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation_93C1F3505B10D3F0085EDEEC4A0A316F" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsPayable" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsPayable_FCA9E4778F5ADBCCB9C4DEEC4A0A8DBD" xlink:type="locator" />
    <definitionArc order="9" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_19FEB59144560D59EE7EDEEC4A0AA37D" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsPayable_FCA9E4778F5ADBCCB9C4DEEC4A0A8DBD" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationAccruedLiabilities" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccruedLiabilities_304CC3A6592EE03399ADDEEC4A0B16D5" xlink:type="locator" />
    <definitionArc order="10" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_19FEB59144560D59EE7EDEEC4A0AA37D" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccruedLiabilities_304CC3A6592EE03399ADDEEC4A0B16D5" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent" xlink:label="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent_EA7D78C4DAE1B507088ADEEC4A0B84DB" xlink:type="locator" />
    <definitionArc order="11" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_19FEB59144560D59EE7EDEEC4A0AA37D" xlink:to="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent_EA7D78C4DAE1B507088ADEEC4A0B84DB" xlink:type="arc" />
  </definitionLink>
  <definitionLink xlink:role="http://www.galenabiopharma.com/role/DiscontinuedOperationsAssetsHeldForSaleComponentsAttributableToCommercialBusinessDetails" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_F9FFB630AF0A6AEF3AB8DEEC49FFF0CB" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_A5A9E9134263448B8F8BDEEC49FE1BA4" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_F9FFB630AF0A6AEF3AB8DEEC49FFF0CB" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_A5A9E9134263448B8F8BDEEC49FE1BA4" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_727ADB20A747B92528BADEEC49FFAB24" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_A5A9E9134263448B8F8BDEEC49FE1BA4" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_727ADB20A747B92528BADEEC49FFAB24" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_70112B153683DC1B4D3EDEEC49FF25B0_default" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_727ADB20A747B92528BADEEC49FFAB24" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_70112B153683DC1B4D3EDEEC49FF25B0_default" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_70112B153683DC1B4D3EDEEC49FF25B0" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_727ADB20A747B92528BADEEC49FFAB24" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_70112B153683DC1B4D3EDEEC49FF25B0" xlink:type="arc" />
    <loc xlink:href="gale-20150930.xsd#gale_CommercialBusinessSegmentMember" xlink:label="loc_gale_CommercialBusinessSegmentMember_C89D44B1584D99ACB076DEEC49FFFB81" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_70112B153683DC1B4D3EDEEC49FF25B0" xlink:to="loc_gale_CommercialBusinessSegmentMember_C89D44B1584D99ACB076DEEC49FFFB81" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue_CC616752004DA59003A4DEEC49FFB7B6" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_F9FFB630AF0A6AEF3AB8DEEC49FFF0CB" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue_CC616752004DA59003A4DEEC49FFB7B6" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold_3BCEFF9E3D4F05E37760DEEC49FFC5D3" xlink:type="locator" />
    <definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_F9FFB630AF0A6AEF3AB8DEEC49FFF0CB" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold_3BCEFF9E3D4F05E37760DEEC49FFC5D3" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationDepreciationAndAmortization" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationDepreciationAndAmortization_4BD28650B2139C53A933DEEC49FF1213" xlink:type="locator" />
    <definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_F9FFB630AF0A6AEF3AB8DEEC49FFF0CB" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationDepreciationAndAmortization_4BD28650B2139C53A933DEEC49FF1213" xlink:type="arc" />
    <loc xlink:href="gale-20150930.xsd#gale_DisposalGroupIncludingDiscontinuedOperationResearchandDevelopment" xlink:label="loc_gale_DisposalGroupIncludingDiscontinuedOperationResearchandDevelopment_C7ACB6287A7CADB121B3DEEC49FFAEF5" xlink:type="locator" />
    <definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_F9FFB630AF0A6AEF3AB8DEEC49FFF0CB" xlink:to="loc_gale_DisposalGroupIncludingDiscontinuedOperationResearchandDevelopment_C7ACB6287A7CADB121B3DEEC49FFAEF5" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense_3AD8218AD57A05895EA4DEEC49FFB04F" xlink:type="locator" />
    <definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_F9FFB630AF0A6AEF3AB8DEEC49FFF0CB" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense_3AD8218AD57A05895EA4DEEC49FFB04F" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss_C9666852FFFF8307EC44DEEC49FF8464" xlink:type="locator" />
    <definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_F9FFB630AF0A6AEF3AB8DEEC49FFF0CB" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss_C9666852FFFF8307EC44DEEC49FF8464" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf" xlink:label="loc_us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf_BBF74757825E2D5DE94EDEEC4A008E13" xlink:type="locator" />
    <definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_F9FFB630AF0A6AEF3AB8DEEC49FFF0CB" xlink:to="loc_us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf_BBF74757825E2D5DE94EDEEC4A008E13" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax_2958BA8BEB955B3AA903DEEC4A0068A5" xlink:type="locator" />
    <definitionArc order="8" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_F9FFB630AF0A6AEF3AB8DEEC49FFF0CB" xlink:to="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax_2958BA8BEB955B3AA903DEEC4A0068A5" xlink:type="arc" />
  </definitionLink>
  <definitionLink xlink:role="http://www.galenabiopharma.com/role/DiscontinuedOperationsAssetsHeldForSaleDetails" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_569D6B5878E22F15E5CBDE41403D3F67" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_451F1883DC4F0A1FA83ADE41403D5C89" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_569D6B5878E22F15E5CBDE41403D3F67" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_451F1883DC4F0A1FA83ADE41403D5C89" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_76AF4C4BAA6E5822E91EDE41403D1E92" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_451F1883DC4F0A1FA83ADE41403D5C89" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_76AF4C4BAA6E5822E91EDE41403D1E92" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_F8341F029CFD80DC372ADE41403D754D_default" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_76AF4C4BAA6E5822E91EDE41403D1E92" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_F8341F029CFD80DC372ADE41403D754D_default" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_F8341F029CFD80DC372ADE41403D754D" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_76AF4C4BAA6E5822E91EDE41403D1E92" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_F8341F029CFD80DC372ADE41403D754D" xlink:type="arc" />
    <loc xlink:href="gale-20150930.xsd#gale_CommercialBusinessSegmentMember" xlink:label="loc_gale_CommercialBusinessSegmentMember_1E64CFF3A3883CE43115DE4240ED96E1" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_F8341F029CFD80DC372ADE41403D754D" xlink:to="loc_gale_CommercialBusinessSegmentMember_1E64CFF3A3883CE43115DE4240ED96E1" xlink:type="arc" />
    <loc xlink:href="gale-20150930.xsd#gale_PercentageofCancerPatientsAffectedbyInadequatelyControlledBreakthroughCancerPainBTcP" xlink:label="loc_gale_PercentageofCancerPatientsAffectedbyInadequatelyControlledBreakthroughCancerPainBTcP_1610805B548208DECA69DE31303140A3" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_569D6B5878E22F15E5CBDE41403D3F67" xlink:to="loc_gale_PercentageofCancerPatientsAffectedbyInadequatelyControlledBreakthroughCancerPainBTcP_1610805B548208DECA69DE31303140A3" xlink:type="arc" />
    <loc xlink:href="gale-20150930.xsd#gale_DisposalGroupIncludingDiscontinuedOperationContingentLiabilityFromDivestitureAgreement" xlink:label="loc_gale_DisposalGroupIncludingDiscontinuedOperationContingentLiabilityFromDivestitureAgreement_A509B516526B0795943DDE3607C6CBF0" xlink:type="locator" />
    <definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_569D6B5878E22F15E5CBDE41403D3F67" xlink:to="loc_gale_DisposalGroupIncludingDiscontinuedOperationContingentLiabilityFromDivestitureAgreement_A509B516526B0795943DDE3607C6CBF0" xlink:type="arc" />
    <loc xlink:href="gale-20150930.xsd#gale_DisposalGroupIncludingDiscontinuedOperationContingentLiabilityPercentageofConsideration" xlink:label="loc_gale_DisposalGroupIncludingDiscontinuedOperationContingentLiabilityPercentageofConsideration_050D407A24ACA9B69030DE3742C076A4" xlink:type="locator" />
    <definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_569D6B5878E22F15E5CBDE41403D3F67" xlink:to="loc_gale_DisposalGroupIncludingDiscontinuedOperationContingentLiabilityPercentageofConsideration_050D407A24ACA9B69030DE3742C076A4" xlink:type="arc" />
    <loc xlink:href="gale-20150930.xsd#gale_DisposalGroupIncludingDiscontinuedOperationContingentRetentionFees" xlink:label="loc_gale_DisposalGroupIncludingDiscontinuedOperationContingentRetentionFees_256AAFBCF1AB90F132D7DE3AFA131820" xlink:type="locator" />
    <definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_569D6B5878E22F15E5CBDE41403D3F67" xlink:to="loc_gale_DisposalGroupIncludingDiscontinuedOperationContingentRetentionFees_256AAFBCF1AB90F132D7DE3AFA131820" xlink:type="arc" />
    <loc xlink:href="gale-20150930.xsd#gale_DisposalGroupIncludingDiscontinuedOperationContingentRetentionFeesPercentageofConsiderationReceived" xlink:label="loc_gale_DisposalGroupIncludingDiscontinuedOperationContingentRetentionFeesPercentageofConsiderationReceived_06B6ACEABD039AD13920DE3BE45C787A" xlink:type="locator" />
    <definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_569D6B5878E22F15E5CBDE41403D3F67" xlink:to="loc_gale_DisposalGroupIncludingDiscontinuedOperationContingentRetentionFeesPercentageofConsiderationReceived_06B6ACEABD039AD13920DE3BE45C787A" xlink:type="arc" />
  </definitionLink>
  <definitionLink xlink:role="http://www.galenabiopharma.com/role/DiscontinuedOperationsAssetsHeldForSaleNotes" xlink:type="extended" />
  <definitionLink xlink:role="http://www.galenabiopharma.com/role/DiscontinuedOperationsAssetsHeldForSaleSignificantOperatingNonCashAndCapitalExpendituresDetails" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_009063029D01C6E5A358DEEC49F80CA4" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_18459779389FFE7A38BBDEEC49F8FA2E" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_009063029D01C6E5A358DEEC49F80CA4" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_18459779389FFE7A38BBDEEC49F8FA2E" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_71BAB3D817A2D367CCC0DEEC49F8BD9C" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_18459779389FFE7A38BBDEEC49F8FA2E" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_71BAB3D817A2D367CCC0DEEC49F8BD9C" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_B3B551D1663C6A001460DEEC49F8D756_default" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_71BAB3D817A2D367CCC0DEEC49F8BD9C" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_B3B551D1663C6A001460DEEC49F8D756_default" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_B3B551D1663C6A001460DEEC49F8D756" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_71BAB3D817A2D367CCC0DEEC49F8BD9C" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_B3B551D1663C6A001460DEEC49F8D756" xlink:type="arc" />
    <loc xlink:href="gale-20150930.xsd#gale_CommercialBusinessSegmentMember" xlink:label="loc_gale_CommercialBusinessSegmentMember_55B03EF9A0D34B99CEA9DEEC49F8D9E2" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_B3B551D1663C6A001460DEEC49F8D756" xlink:to="loc_gale_CommercialBusinessSegmentMember_55B03EF9A0D34B99CEA9DEEC49F8D9E2" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf" xlink:label="loc_us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf_15750ABD82480B132C83DEEC49F8F89A" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_009063029D01C6E5A358DEEC49F80CA4" xlink:to="loc_us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf_15750ABD82480B132C83DEEC49F8F89A" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_85E019D9BED9B2D8FC6BDEEC49F93BA0" xlink:type="locator" />
    <definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_009063029D01C6E5A358DEEC49F80CA4" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_85E019D9BED9B2D8FC6BDEEC49F93BA0" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_5853A0B6E5AEECEB045FDEEC49F95842" xlink:type="locator" />
    <definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_009063029D01C6E5A358DEEC49F80CA4" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_5853A0B6E5AEECEB045FDEEC49F95842" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaap_ShareBasedCompensation_252706E93CE4197E00AEDEEC49F95FEA" xlink:type="locator" />
    <definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_009063029D01C6E5A358DEEC49F80CA4" xlink:to="loc_us-gaap_ShareBasedCompensation_252706E93CE4197E00AEDEEC49F95FEA" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_FD7484B9528DAD9F738DDEEC49F966AF" xlink:type="locator" />
    <definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_009063029D01C6E5A358DEEC49F80CA4" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_FD7484B9528DAD9F738DDEEC49F966AF" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PaymentsToAcquireIntangibleAssets" xlink:label="loc_us-gaap_PaymentsToAcquireIntangibleAssets_DD9A4B47496B79F29297DEEC49F9E14C" xlink:type="locator" />
    <definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_009063029D01C6E5A358DEEC49F80CA4" xlink:to="loc_us-gaap_PaymentsToAcquireIntangibleAssets_DD9A4B47496B79F29297DEEC49F9E14C" xlink:type="arc" />
  </definitionLink>
  <definitionLink xlink:role="http://www.galenabiopharma.com/role/DiscontinuedOperationsAssetsHeldForSaleTables" xlink:type="extended" />
  <definitionLink xlink:role="http://www.galenabiopharma.com/role/DocumentAndEntityInformation" xlink:type="extended" />
  <definitionLink xlink:role="http://www.galenabiopharma.com/role/FairValueMeasurements" xlink:type="extended" />
  <definitionLink xlink:role="http://www.galenabiopharma.com/role/FairValueMeasurementsContingentPurchasePriceConsiderationMeasuredAtEstimatedFairValueOnRecurringBasisDetail" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_015D165105D49F68C2BEDE2E96A98100" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_4AB702C16D27DBD020BCDE2E96A8A9D9" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_015D165105D49F68C2BEDE2E96A98100" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_4AB702C16D27DBD020BCDE2E96A8A9D9" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_5BA3BCB52AFC27D6549CDE2E96A8FBE5" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_4AB702C16D27DBD020BCDE2E96A8A9D9" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_5BA3BCB52AFC27D6549CDE2E96A8FBE5" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_61A49F9B33DFC2934716DE2E96A828B9_default" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_5BA3BCB52AFC27D6549CDE2E96A8FBE5" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_61A49F9B33DFC2934716DE2E96A828B9_default" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_61A49F9B33DFC2934716DE2E96A828B9" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_5BA3BCB52AFC27D6549CDE2E96A8FBE5" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_61A49F9B33DFC2934716DE2E96A828B9" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_64D4AB9390D99192CE53DE2E96A87419" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_61A49F9B33DFC2934716DE2E96A828B9" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_64D4AB9390D99192CE53DE2E96A87419" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_791612FFB3622194C72FDE2E96A8A87E" xlink:type="locator" />
    <definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_4AB702C16D27DBD020BCDE2E96A8A9D9" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_791612FFB3622194C72FDE2E96A8A87E" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_BCA95E15E1BA23F08F46DE2E96A9A744_default" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_791612FFB3622194C72FDE2E96A8A87E" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_BCA95E15E1BA23F08F46DE2E96A9A744_default" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_BCA95E15E1BA23F08F46DE2E96A9A744" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_791612FFB3622194C72FDE2E96A8A87E" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_BCA95E15E1BA23F08F46DE2E96A9A744" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_23A16F2D875BD766ACFCDE2E96A922BE" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_BCA95E15E1BA23F08F46DE2E96A9A744" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_23A16F2D875BD766ACFCDE2E96A922BE" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_77D3A81799656DE2BA57DE2E96A948C9" xlink:type="locator" />
    <definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_BCA95E15E1BA23F08F46DE2E96A9A744" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_77D3A81799656DE2BA57DE2E96A948C9" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_EA39C871679161840737DE2E96A9984A" xlink:type="locator" />
    <definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_BCA95E15E1BA23F08F46DE2E96A9A744" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_EA39C871679161840737DE2E96A9984A" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AssetsFairValueDisclosureAbstract" xlink:label="loc_us-gaap_AssetsFairValueDisclosureAbstract_7923F28012FE74B2780FDE2E96A9D43F" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_015D165105D49F68C2BEDE2E96A98100" xlink:to="loc_us-gaap_AssetsFairValueDisclosureAbstract_7923F28012FE74B2780FDE2E96A9D43F" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_19E2AE8B72EBD4583D37DE2E96A9CF67" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_7923F28012FE74B2780FDE2E96A9D43F" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_19E2AE8B72EBD4583D37DE2E96A9CF67" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AssetsHeldForSaleLongLivedFairValueDisclosure" xlink:label="loc_us-gaap_AssetsHeldForSaleLongLivedFairValueDisclosure_599926F81E6602430E03DE8DC74EDF12" xlink:type="locator" />
    <definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_7923F28012FE74B2780FDE2E96A9D43F" xlink:to="loc_us-gaap_AssetsHeldForSaleLongLivedFairValueDisclosure_599926F81E6602430E03DE8DC74EDF12" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AssetsFairValueDisclosure" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_63E636F74E44A33EBD1EDE2E96A9D563" xlink:type="locator" />
    <definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_7923F28012FE74B2780FDE2E96A9D43F" xlink:to="loc_us-gaap_AssetsFairValueDisclosure_63E636F74E44A33EBD1EDE2E96A9D563" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_A3189E1C4DDFE85E92BEDE2E96A99679" xlink:type="locator" />
    <definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_015D165105D49F68C2BEDE2E96A98100" xlink:to="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_A3189E1C4DDFE85E92BEDE2E96A99679" xlink:type="arc" />
    <loc xlink:href="gale-20150930.xsd#gale_FairValueOfWarrantsPotentiallySettleableInCash" xlink:label="loc_gale_FairValueOfWarrantsPotentiallySettleableInCash_15520E39EB89B2E2D725DE2E96A94A23" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_A3189E1C4DDFE85E92BEDE2E96A99679" xlink:to="loc_gale_FairValueOfWarrantsPotentiallySettleableInCash_15520E39EB89B2E2D725DE2E96A94A23" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ContingentConsiderationClassifiedAsEquityFairValueDisclosure" xlink:label="loc_us-gaap_ContingentConsiderationClassifiedAsEquityFairValueDisclosure_43557360DA03F5BC66A1DE2E96A99934" xlink:type="locator" />
    <definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_A3189E1C4DDFE85E92BEDE2E96A99679" xlink:to="loc_us-gaap_ContingentConsiderationClassifiedAsEquityFairValueDisclosure_43557360DA03F5BC66A1DE2E96A99934" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EquityFairValueDisclosure" xlink:label="loc_us-gaap_EquityFairValueDisclosure_B7614D69893C26129F79DE2E96A99F52" xlink:type="locator" />
    <definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_A3189E1C4DDFE85E92BEDE2E96A99679" xlink:to="loc_us-gaap_EquityFairValueDisclosure_B7614D69893C26129F79DE2E96A99F52" xlink:type="arc" />
  </definitionLink>
  <definitionLink xlink:role="http://www.galenabiopharma.com/role/FairValueMeasurementsReconciliationOfLevel3LiabilitiesDetail" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_3EF3B05B81EB5E81A4F5A5661ADC2BD5" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_A9BA8A2B547B584DAE2EDF4B620FEE72" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_3EF3B05B81EB5E81A4F5A5661ADC2BD5" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_A9BA8A2B547B584DAE2EDF4B620FEE72" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_6CB47389BFD65B98A38F1D34FB41659C" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_A9BA8A2B547B584DAE2EDF4B620FEE72" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_6CB47389BFD65B98A38F1D34FB41659C" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_223C2B3003966E47DEA0D437A872452A_AC07C473F17259308476173B2BB2AAFF" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_6CB47389BFD65B98A38F1D34FB41659C" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_223C2B3003966E47DEA0D437A872452A_AC07C473F17259308476173B2BB2AAFF" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_49CB70EF30915C6380BFF140D00395B1" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_6CB47389BFD65B98A38F1D34FB41659C" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_49CB70EF30915C6380BFF140D00395B1" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_133CB0C8DA1E5151BC4219141709A7B2" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_49CB70EF30915C6380BFF140D00395B1" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_133CB0C8DA1E5151BC4219141709A7B2" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_5167F35552D65AEA82C99B28771B20C5" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_3EF3B05B81EB5E81A4F5A5661ADC2BD5" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_5167F35552D65AEA82C99B28771B20C5" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ContingentConsiderationClassifiedAsEquityFairValueDisclosure" xlink:label="loc_us-gaap_ContingentConsiderationClassifiedAsEquityFairValueDisclosure_BBAF05F480715029A90EE878CAAFE417" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_5167F35552D65AEA82C99B28771B20C5" xlink:to="loc_us-gaap_ContingentConsiderationClassifiedAsEquityFairValueDisclosure_BBAF05F480715029A90EE878CAAFE417" xlink:type="arc" />
    <loc xlink:href="gale-20150930.xsd#gale_ChangeInFairValueOfContingentPurchasePriceConsideration" xlink:label="loc_gale_ChangeInFairValueOfContingentPurchasePriceConsideration_FCB5AA01EBCF538282492BC5FD52C0A7" xlink:type="locator" />
    <definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_5167F35552D65AEA82C99B28771B20C5" xlink:to="loc_gale_ChangeInFairValueOfContingentPurchasePriceConsideration_FCB5AA01EBCF538282492BC5FD52C0A7" xlink:type="arc" />
  </definitionLink>
  <definitionLink xlink:role="http://www.galenabiopharma.com/role/FairValueMeasurementsTables" xlink:type="extended" />
  <definitionLink xlink:role="http://www.galenabiopharma.com/role/LegalProceedingsCommitmentsAndContingenciesDetailsDetails" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LossContingenciesLineItems" xlink:label="loc_us-gaap_LossContingenciesLineItems_6881254A72F6558D85367A58CBCC3CBC" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LossContingenciesTable" xlink:label="loc_us-gaap_LossContingenciesTable_3AED1A50BF2557D2907B534997404A12" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_LossContingenciesLineItems_6881254A72F6558D85367A58CBCC3CBC" xlink:to="loc_us-gaap_LossContingenciesTable_3AED1A50BF2557D2907B534997404A12" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_3743D6F23405565DA07CE89BBFDCF74E" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LossContingenciesTable_3AED1A50BF2557D2907B534997404A12" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_3743D6F23405565DA07CE89BBFDCF74E" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_96E1BB622E8D709E3796FE181A16ECCD_AC07C473F17259308476173B2BB2AAFF" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_3743D6F23405565DA07CE89BBFDCF74E" xlink:to="loc_us-gaap_EquityComponentDomain_96E1BB622E8D709E3796FE181A16ECCD_AC07C473F17259308476173B2BB2AAFF" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_518B1DA052BA5C40A83A163D1A5FD0E3" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_3743D6F23405565DA07CE89BBFDCF74E" xlink:to="loc_us-gaap_EquityComponentDomain_518B1DA052BA5C40A83A163D1A5FD0E3" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember_54CA866B9AF458FEA8FE3A21AB554B63" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_518B1DA052BA5C40A83A163D1A5FD0E3" xlink:to="loc_us-gaap_CommonStockMember_54CA866B9AF458FEA8FE3A21AB554B63" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_7714894A77C956D0B8CD63645B6D23CC" xlink:type="locator" />
    <definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_518B1DA052BA5C40A83A163D1A5FD0E3" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_7714894A77C956D0B8CD63645B6D23CC" xlink:type="arc" />
    <loc xlink:href="gale-20150930.xsd#gale_LossContingencyPercentageofLegalFeesPaid" xlink:label="loc_gale_LossContingencyPercentageofLegalFeesPaid_C6DFE5D985B95F488F2C408C10139CB4" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_6881254A72F6558D85367A58CBCC3CBC" xlink:to="loc_gale_LossContingencyPercentageofLegalFeesPaid_C6DFE5D985B95F488F2C408C10139CB4" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PaymentsToAcquireBusinessesGross" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesGross_A7D69C84C8495A8E9CD1EB8AA32200DA" xlink:type="locator" />
    <definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_6881254A72F6558D85367A58CBCC3CBC" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesGross_A7D69C84C8495A8E9CD1EB8AA32200DA" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesOther" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesOther_A02A18BAD98151CF9CB2D475FFD8C6F9" xlink:type="locator" />
    <definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_6881254A72F6558D85367A58CBCC3CBC" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesOther_A02A18BAD98151CF9CB2D475FFD8C6F9" xlink:type="arc" />
    <loc xlink:href="gale-20150930.xsd#gale_ClosingPriceOfCommonStock" xlink:label="loc_gale_ClosingPriceOfCommonStock_B69272A20FC45A0AB31AC230BC330389" xlink:type="locator" />
    <definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_6881254A72F6558D85367A58CBCC3CBC" xlink:to="loc_gale_ClosingPriceOfCommonStock_B69272A20FC45A0AB31AC230BC330389" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueOther" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueOther_7A3BA6FE38C45EB4A2ECA337299A4CFB" xlink:type="locator" />
    <definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_6881254A72F6558D85367A58CBCC3CBC" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueOther_7A3BA6FE38C45EB4A2ECA337299A4CFB" xlink:type="arc" />
  </definitionLink>
  <definitionLink xlink:role="http://www.galenabiopharma.com/role/LegalProceedingsCommitmentsAndContingenciesNotes" xlink:type="extended" />
  <definitionLink xlink:role="http://www.galenabiopharma.com/role/LicenseAgreements" xlink:type="extended" />
  <definitionLink xlink:role="http://www.galenabiopharma.com/role/LicenseAgreementsAdditionalInformationDetail" xlink:type="extended">
    <loc xlink:href="gale-20150930.xsd#gale_LicenseAndCollaborationAgreementsLineItems" xlink:label="loc_gale_LicenseAndCollaborationAgreementsLineItems_A1A30BAFE7E75E44A6D7FF1B540D29B1" xlink:type="locator" />
    <loc xlink:href="gale-20150930.xsd#gale_LicenseAndCollaborationAgreementsTable" xlink:label="loc_gale_LicenseAndCollaborationAgreementsTable_1407CD18B82257ED80BC8D7D81E70E25" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_gale_LicenseAndCollaborationAgreementsLineItems_A1A30BAFE7E75E44A6D7FF1B540D29B1" xlink:to="loc_gale_LicenseAndCollaborationAgreementsTable_1407CD18B82257ED80BC8D7D81E70E25" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_17D1957E06885DE5BF407D4B24E20CCB" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_gale_LicenseAndCollaborationAgreementsTable_1407CD18B82257ED80BC8D7D81E70E25" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_17D1957E06885DE5BF407D4B24E20CCB" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_A24017C57FEC4E7B92BBFE42BF99C0A9_AC07C473F17259308476173B2BB2AAFF" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_17D1957E06885DE5BF407D4B24E20CCB" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_A24017C57FEC4E7B92BBFE42BF99C0A9_AC07C473F17259308476173B2BB2AAFF" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_11BDCBD96D895E10B9426D449139D0BE" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_17D1957E06885DE5BF407D4B24E20CCB" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_11BDCBD96D895E10B9426D449139D0BE" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DistributionRightsMember" xlink:label="loc_us-gaap_DistributionRightsMember_EC5E2FB2A47A58759DB708E1A3F0F426" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_11BDCBD96D895E10B9426D449139D0BE" xlink:to="loc_us-gaap_DistributionRightsMember_EC5E2FB2A47A58759DB708E1A3F0F426" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RangeAxis" xlink:label="loc_us-gaap_RangeAxis_07C41D0A23B95B38A623FCBED4519819" xlink:type="locator" />
    <definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_gale_LicenseAndCollaborationAgreementsTable_1407CD18B82257ED80BC8D7D81E70E25" xlink:to="loc_us-gaap_RangeAxis_07C41D0A23B95B38A623FCBED4519819" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaap_RangeMember_6C45E2F1EB469A380F3FFE4255882AA1_AC07C473F17259308476173B2BB2AAFF" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RangeAxis_07C41D0A23B95B38A623FCBED4519819" xlink:to="loc_us-gaap_RangeMember_6C45E2F1EB469A380F3FFE4255882AA1_AC07C473F17259308476173B2BB2AAFF" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaap_RangeMember_86838B90571D5D63BF2D772D68D9ED21" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RangeAxis_07C41D0A23B95B38A623FCBED4519819" xlink:to="loc_us-gaap_RangeMember_86838B90571D5D63BF2D772D68D9ED21" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_MinimumMember" xlink:label="loc_us-gaap_MinimumMember_2D6AE4C845DA5A888B3A37E823C1F6CE" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RangeMember_86838B90571D5D63BF2D772D68D9ED21" xlink:to="loc_us-gaap_MinimumMember_2D6AE4C845DA5A888B3A37E823C1F6CE" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_MaximumMember" xlink:label="loc_us-gaap_MaximumMember_273DB4F6F06E5B46A55A09A1C8482CCD" xlink:type="locator" />
    <definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RangeMember_86838B90571D5D63BF2D772D68D9ED21" xlink:to="loc_us-gaap_MaximumMember_273DB4F6F06E5B46A55A09A1C8482CCD" xlink:type="arc" />
    <loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_00510618FB495E31A4749049ACBF71D3" xlink:type="locator" />
    <definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_gale_LicenseAndCollaborationAgreementsTable_1407CD18B82257ED80BC8D7D81E70E25" xlink:to="loc_dei_LegalEntityAxis_00510618FB495E31A4749049ACBF71D3" xlink:type="arc" />
    <loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_2439CD40296C074937EBFE4041A56A82_AC07C473F17259308476173B2BB2AAFF" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_00510618FB495E31A4749049ACBF71D3" xlink:to="loc_dei_EntityDomain_2439CD40296C074937EBFE4041A56A82_AC07C473F17259308476173B2BB2AAFF" xlink:type="arc" />
    <loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_8A5D031D4BD55B7E8302FEB743CC3A7F" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_00510618FB495E31A4749049ACBF71D3" xlink:to="loc_dei_EntityDomain_8A5D031D4BD55B7E8302FEB743CC3A7F" xlink:type="arc" />
    <loc xlink:href="gale-20150930.xsd#gale_MDAndersonCancerCenterMember" xlink:label="loc_gale_MDAndersonCancerCenterMember_BBD250A0E81F5B47B560EEA58D8CD138" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_8A5D031D4BD55B7E8302FEB743CC3A7F" xlink:to="loc_gale_MDAndersonCancerCenterMember_BBD250A0E81F5B47B560EEA58D8CD138" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_440B474C034B5D3FB78A4BD1F29724D4" xlink:type="locator" />
    <definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_gale_LicenseAndCollaborationAgreementsTable_1407CD18B82257ED80BC8D7D81E70E25" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_440B474C034B5D3FB78A4BD1F29724D4" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_FBB62248FBD98728EA76FE4041A6DB73_AC07C473F17259308476173B2BB2AAFF" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_440B474C034B5D3FB78A4BD1F29724D4" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_FBB62248FBD98728EA76FE4041A6DB73_AC07C473F17259308476173B2BB2AAFF" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_F2E35DF556645CECBA4AA3EDCA6E1F77" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_440B474C034B5D3FB78A4BD1F29724D4" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_F2E35DF556645CECBA4AA3EDCA6E1F77" xlink:type="arc" />
    <loc xlink:href="gale-20150930.xsd#gale_OrexoMember" xlink:label="loc_gale_OrexoMember_55C6E426DE4259049BADCFC77638F7C4" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_F2E35DF556645CECBA4AA3EDCA6E1F77" xlink:to="loc_gale_OrexoMember_55C6E426DE4259049BADCFC77638F7C4" xlink:type="arc" />
    <loc xlink:href="gale-20150930.xsd#gale_AnnualMaintenanceFee" xlink:label="loc_gale_AnnualMaintenanceFee_9F2399AD70365C25BA4A666752C487DE" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gale_LicenseAndCollaborationAgreementsLineItems_A1A30BAFE7E75E44A6D7FF1B540D29B1" xlink:to="loc_gale_AnnualMaintenanceFee_9F2399AD70365C25BA4A666752C487DE" xlink:type="arc" />
    <loc xlink:href="gale-20150930.xsd#gale_FutureMilestonePayment" xlink:label="loc_gale_FutureMilestonePayment_699EFB6C61CF5284BA715B6B27AE6D75" xlink:type="locator" />
    <definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gale_LicenseAndCollaborationAgreementsLineItems_A1A30BAFE7E75E44A6D7FF1B540D29B1" xlink:to="loc_gale_FutureMilestonePayment_699EFB6C61CF5284BA715B6B27AE6D75" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_D95DC56649BE56AC9A2F0DCCFEC343DE" xlink:type="locator" />
    <definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gale_LicenseAndCollaborationAgreementsLineItems_A1A30BAFE7E75E44A6D7FF1B540D29B1" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_D95DC56649BE56AC9A2F0DCCFEC343DE" xlink:type="arc" />
    <loc xlink:href="gale-20150930.xsd#gale_BusinessAcquisitionCashHeldByAcquiredEntity" xlink:label="loc_gale_BusinessAcquisitionCashHeldByAcquiredEntity_BD6B8E7A3FE556BC8F570864A56ABE29" xlink:type="locator" />
    <definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gale_LicenseAndCollaborationAgreementsLineItems_A1A30BAFE7E75E44A6D7FF1B540D29B1" xlink:to="loc_gale_BusinessAcquisitionCashHeldByAcquiredEntity_BD6B8E7A3FE556BC8F570864A56ABE29" xlink:type="arc" />
    <loc xlink:href="gale-20150930.xsd#gale_EstimatedYearOfPatentExpiration" xlink:label="loc_gale_EstimatedYearOfPatentExpiration_F4F6DBA59D495818879856FE3CF08CFB" xlink:type="locator" />
    <definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gale_LicenseAndCollaborationAgreementsLineItems_A1A30BAFE7E75E44A6D7FF1B540D29B1" xlink:to="loc_gale_EstimatedYearOfPatentExpiration_F4F6DBA59D495818879856FE3CF08CFB" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PaymentsToAcquireBusinessesGross" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesGross_DFB4925335D15FA0BD971DB2653A89F2" xlink:type="locator" />
    <definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gale_LicenseAndCollaborationAgreementsLineItems_A1A30BAFE7E75E44A6D7FF1B540D29B1" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesGross_DFB4925335D15FA0BD971DB2653A89F2" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FinitelivedIntangibleAssetsAcquired1" xlink:label="loc_us-gaap_FinitelivedIntangibleAssetsAcquired1_FFDDE9FB55D65C25ABE8069E1E8170E2" xlink:type="locator" />
    <definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gale_LicenseAndCollaborationAgreementsLineItems_A1A30BAFE7E75E44A6D7FF1B540D29B1" xlink:to="loc_us-gaap_FinitelivedIntangibleAssetsAcquired1_FFDDE9FB55D65C25ABE8069E1E8170E2" xlink:type="arc" />
    <loc xlink:href="gale-20150930.xsd#gale_FinitelivedIntangibleAssetsAcquiredContingentConsideration" xlink:label="loc_gale_FinitelivedIntangibleAssetsAcquiredContingentConsideration_EDB91DFFD2F65BA69D686AD3D06B0404" xlink:type="locator" />
    <definitionArc order="8" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gale_LicenseAndCollaborationAgreementsLineItems_A1A30BAFE7E75E44A6D7FF1B540D29B1" xlink:to="loc_gale_FinitelivedIntangibleAssetsAcquiredContingentConsideration_EDB91DFFD2F65BA69D686AD3D06B0404" xlink:type="arc" />
    <loc xlink:href="gale-20150930.xsd#gale_FinitelivedIntangibleAssetsAcquiredContingentConsiderationPaymentPeriod" xlink:label="loc_gale_FinitelivedIntangibleAssetsAcquiredContingentConsiderationPaymentPeriod_A940960D9F0E56CE9D378F3745DD5096" xlink:type="locator" />
    <definitionArc order="9" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gale_LicenseAndCollaborationAgreementsLineItems_A1A30BAFE7E75E44A6D7FF1B540D29B1" xlink:to="loc_gale_FinitelivedIntangibleAssetsAcquiredContingentConsiderationPaymentPeriod_A940960D9F0E56CE9D378F3745DD5096" xlink:type="arc" />
    <loc xlink:href="gale-20150930.xsd#gale_ContractualObligationPotentialPaymentsfromNetSales" xlink:label="loc_gale_ContractualObligationPotentialPaymentsfromNetSales_DF500A08BF2B53E6908F6889E84E494C" xlink:type="locator" />
    <definitionArc order="10" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gale_LicenseAndCollaborationAgreementsLineItems_A1A30BAFE7E75E44A6D7FF1B540D29B1" xlink:to="loc_gale_ContractualObligationPotentialPaymentsfromNetSales_DF500A08BF2B53E6908F6889E84E494C" xlink:type="arc" />
    <loc xlink:href="gale-20150930.xsd#gale_ContractualObligationNetSalesThreshold" xlink:label="loc_gale_ContractualObligationNetSalesThreshold_0B146E09A4EE5A1780D7887ADF09FCBE" xlink:type="locator" />
    <definitionArc order="11" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gale_LicenseAndCollaborationAgreementsLineItems_A1A30BAFE7E75E44A6D7FF1B540D29B1" xlink:to="loc_gale_ContractualObligationNetSalesThreshold_0B146E09A4EE5A1780D7887ADF09FCBE" xlink:type="arc" />
  </definitionLink>
  <definitionLink xlink:role="http://www.galenabiopharma.com/role/LongTermDebt" xlink:type="extended" />
  <definitionLink xlink:role="http://www.galenabiopharma.com/role/LongTermDebtDetails" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="loc_us-gaap_DebtInstrumentLineItems_F95425BAA00A5691819F40D1EDD9F667" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DebtInstrumentTable" xlink:label="loc_us-gaap_DebtInstrumentTable_E28798D4D44B5AA7AB8AE05E6B2010A6" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DebtInstrumentLineItems_F95425BAA00A5691819F40D1EDD9F667" xlink:to="loc_us-gaap_DebtInstrumentTable_E28798D4D44B5AA7AB8AE05E6B2010A6" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_AB783BD086125355A63B91DDBD2DA3C7" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_E28798D4D44B5AA7AB8AE05E6B2010A6" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_AB783BD086125355A63B91DDBD2DA3C7" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_7DDD0E60B7A10868F1F4D437A7F6BAE4_AC07C473F17259308476173B2BB2AAFF" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_AB783BD086125355A63B91DDBD2DA3C7" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_7DDD0E60B7A10868F1F4D437A7F6BAE4_AC07C473F17259308476173B2BB2AAFF" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_22657301DC305B93836C4964DDA68425" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_AB783BD086125355A63B91DDBD2DA3C7" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_22657301DC305B93836C4964DDA68425" xlink:type="arc" />
    <loc xlink:href="gale-20150930.xsd#gale_FirstTrancheMember" xlink:label="loc_gale_FirstTrancheMember_BC0F7CD64CC750B0BBCFDBCB93898CF8" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_22657301DC305B93836C4964DDA68425" xlink:to="loc_gale_FirstTrancheMember_BC0F7CD64CC750B0BBCFDBCB93898CF8" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RangeAxis" xlink:label="loc_us-gaap_RangeAxis_7D751EE34F08506896FBB610769941FC" xlink:type="locator" />
    <definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_E28798D4D44B5AA7AB8AE05E6B2010A6" xlink:to="loc_us-gaap_RangeAxis_7D751EE34F08506896FBB610769941FC" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaap_RangeMember_5E688BADBFCC29A91442D437A7F79168_AC07C473F17259308476173B2BB2AAFF" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RangeAxis_7D751EE34F08506896FBB610769941FC" xlink:to="loc_us-gaap_RangeMember_5E688BADBFCC29A91442D437A7F79168_AC07C473F17259308476173B2BB2AAFF" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaap_RangeMember_16CB697124B75C6A9F9C10E1FC8DEA1F" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RangeAxis_7D751EE34F08506896FBB610769941FC" xlink:to="loc_us-gaap_RangeMember_16CB697124B75C6A9F9C10E1FC8DEA1F" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_MaximumMember" xlink:label="loc_us-gaap_MaximumMember_3509D84954F65169BF5BCC5A0A2A2E5D" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RangeMember_16CB697124B75C6A9F9C10E1FC8DEA1F" xlink:to="loc_us-gaap_MaximumMember_3509D84954F65169BF5BCC5A0A2A2E5D" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DebtInstrumentCarryingAmount" xlink:label="loc_us-gaap_DebtInstrumentCarryingAmount_F3CD4F58522E540987470253C35E6C20" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_F95425BAA00A5691819F40D1EDD9F667" xlink:to="loc_us-gaap_DebtInstrumentCarryingAmount_F3CD4F58522E540987470253C35E6C20" xlink:type="arc" />
    <loc xlink:href="gale-20150930.xsd#gale_DebtInstrumentTermInterestOnly" xlink:label="loc_gale_DebtInstrumentTermInterestOnly_B0C6C2AA9F9955E1BC93F0AC559AC979" xlink:type="locator" />
    <definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_F95425BAA00A5691819F40D1EDD9F667" xlink:to="loc_gale_DebtInstrumentTermInterestOnly_B0C6C2AA9F9955E1BC93F0AC559AC979" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_32FD2D4C122A523EB1C9F619A647E4CB" xlink:type="locator" />
    <definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_F95425BAA00A5691819F40D1EDD9F667" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_32FD2D4C122A523EB1C9F619A647E4CB" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DebtInstrumentTerm" xlink:label="loc_us-gaap_DebtInstrumentTerm_5C2F43DB556050F8BC578FDCA7E82D89" xlink:type="locator" />
    <definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_F95425BAA00A5691819F40D1EDD9F667" xlink:to="loc_us-gaap_DebtInstrumentTerm_5C2F43DB556050F8BC578FDCA7E82D89" xlink:type="arc" />
    <loc xlink:href="gale-20150930.xsd#gale_DebtInstrumentCashFacilityFee" xlink:label="loc_gale_DebtInstrumentCashFacilityFee_4E00F91A8D5D50F5BB80FCF67734B2CF" xlink:type="locator" />
    <definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_F95425BAA00A5691819F40D1EDD9F667" xlink:to="loc_gale_DebtInstrumentCashFacilityFee_4E00F91A8D5D50F5BB80FCF67734B2CF" xlink:type="arc" />
    <loc xlink:href="gale-20150930.xsd#gale_DebtInstrumentCashFinalPayment" xlink:label="loc_gale_DebtInstrumentCashFinalPayment_20BFDB6A4E54528E95205F4AF76ACE4F" xlink:type="locator" />
    <definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_F95425BAA00A5691819F40D1EDD9F667" xlink:to="loc_gale_DebtInstrumentCashFinalPayment_20BFDB6A4E54528E95205F4AF76ACE4F" xlink:type="arc" />
    <loc xlink:href="gale-20150930.xsd#gale_ClassofWarrantorRightTerm" xlink:label="loc_gale_ClassofWarrantorRightTerm_B40565F7C1B35180B4F189324DFCE0F0" xlink:type="locator" />
    <definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_F95425BAA00A5691819F40D1EDD9F667" xlink:to="loc_gale_ClassofWarrantorRightTerm_B40565F7C1B35180B4F189324DFCE0F0" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_9C1B37C661CA57B8A8944B4B9AD658B7" xlink:type="locator" />
    <definitionArc order="8" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_F95425BAA00A5691819F40D1EDD9F667" xlink:to="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_9C1B37C661CA57B8A8944B4B9AD658B7" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_66A6153F2F4350BEB2BC8162D273B610" xlink:type="locator" />
    <definitionArc order="9" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_F95425BAA00A5691819F40D1EDD9F667" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_66A6153F2F4350BEB2BC8162D273B610" xlink:type="arc" />
    <loc xlink:href="gale-20150930.xsd#gale_ClassofWarrantorRightAverageMarketPriceUsedForExercisePrice" xlink:label="loc_gale_ClassofWarrantorRightAverageMarketPriceUsedForExercisePrice_6AC26DE8E7CC59C297E00274799FDC46" xlink:type="locator" />
    <definitionArc order="10" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_F95425BAA00A5691819F40D1EDD9F667" xlink:to="loc_gale_ClassofWarrantorRightAverageMarketPriceUsedForExercisePrice_6AC26DE8E7CC59C297E00274799FDC46" xlink:type="arc" />
  </definitionLink>
  <definitionLink xlink:role="http://www.galenabiopharma.com/role/NetLossPerShare" xlink:type="extended" />
  <definitionLink xlink:role="http://www.galenabiopharma.com/role/NetLossPerShareCommonSharesExcludedFromNetLossDetail" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_6FAE955DB9A65DEB96F48F7F0F294834" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_CBC38946F2515C55AF4E42F972A3CBA9" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_6FAE955DB9A65DEB96F48F7F0F294834" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_CBC38946F2515C55AF4E42F972A3CBA9" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_C41A0062997252D5997C28B8BF94285E" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_CBC38946F2515C55AF4E42F972A3CBA9" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_C41A0062997252D5997C28B8BF94285E" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_77A7B9B397606869E672D437A88CB82C_AC07C473F17259308476173B2BB2AAFF" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_C41A0062997252D5997C28B8BF94285E" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_77A7B9B397606869E672D437A88CB82C_AC07C473F17259308476173B2BB2AAFF" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_3BAA3882512A5279B2B9A73007196498" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_C41A0062997252D5997C28B8BF94285E" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_3BAA3882512A5279B2B9A73007196498" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaap_WarrantMember_881B9DE545065F758DF94B61DFC47F87" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_3BAA3882512A5279B2B9A73007196498" xlink:to="loc_us-gaap_WarrantMember_881B9DE545065F758DF94B61DFC47F87" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaap_EmployeeStockOptionMember_2C23C19222825046BC8461D75EFDF8D5" xlink:type="locator" />
    <definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_3BAA3882512A5279B2B9A73007196498" xlink:to="loc_us-gaap_EmployeeStockOptionMember_2C23C19222825046BC8461D75EFDF8D5" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_5EB68F801D285689A867CC7B20D34414" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_6FAE955DB9A65DEB96F48F7F0F294834" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_5EB68F801D285689A867CC7B20D34414" xlink:type="arc" />
  </definitionLink>
  <definitionLink xlink:role="http://www.galenabiopharma.com/role/NetLossPerShareTables" xlink:type="extended" />
  <definitionLink xlink:role="http://www.galenabiopharma.com/role/OtherIncomeExpenseNotes" xlink:type="extended" />
  <definitionLink xlink:role="http://www.galenabiopharma.com/role/OtherIncomeExpenseTableDetails" xlink:type="extended" />
  <definitionLink xlink:role="http://www.galenabiopharma.com/role/OtherIncomeExpenseTables" xlink:type="extended" />
  <definitionLink xlink:role="http://www.galenabiopharma.com/role/SignificantCustomersAndConcentrationOfCreditRiskDetails" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ConcentrationRiskLineItems" xlink:label="loc_us-gaap_ConcentrationRiskLineItems_1B176FB11DAE0F13B24DDDA4F6B250BF" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ConcentrationRiskTable" xlink:label="loc_us-gaap_ConcentrationRiskTable_18524F7D8249571191F7DDA4F6B13BB1" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_1B176FB11DAE0F13B24DDDA4F6B250BF" xlink:to="loc_us-gaap_ConcentrationRiskTable_18524F7D8249571191F7DDA4F6B13BB1" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ConcentrationRiskByTypeAxis" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis_E239AE7869AAF28B2E5EDDA4F6B2CD49" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ConcentrationRiskTable_18524F7D8249571191F7DDA4F6B13BB1" xlink:to="loc_us-gaap_ConcentrationRiskByTypeAxis_E239AE7869AAF28B2E5EDDA4F6B2CD49" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_6F45A306D259EDBF334BDDA4F6B2E38D_default" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_E239AE7869AAF28B2E5EDDA4F6B2CD49" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_6F45A306D259EDBF334BDDA4F6B2E38D_default" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_6F45A306D259EDBF334BDDA4F6B2E38D" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_E239AE7869AAF28B2E5EDDA4F6B2CD49" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_6F45A306D259EDBF334BDDA4F6B2E38D" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ProductConcentrationRiskMember" xlink:label="loc_us-gaap_ProductConcentrationRiskMember_771FE295753DBECF55EBDDA4F6B214A9" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_6F45A306D259EDBF334BDDA4F6B2E38D" xlink:to="loc_us-gaap_ProductConcentrationRiskMember_771FE295753DBECF55EBDDA4F6B214A9" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_96B7BC682629372E3B7CDDA4F6B2DCB8" xlink:type="locator" />
    <definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ConcentrationRiskTable_18524F7D8249571191F7DDA4F6B13BB1" xlink:to="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_96B7BC682629372E3B7CDDA4F6B2DCB8" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_2738C2CE32664508F48BDDA4F6B22356_default" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_96B7BC682629372E3B7CDDA4F6B2DCB8" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_2738C2CE32664508F48BDDA4F6B22356_default" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_2738C2CE32664508F48BDDA4F6B22356" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_96B7BC682629372E3B7CDDA4F6B2DCB8" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_2738C2CE32664508F48BDDA4F6B22356" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SalesRevenueGoodsNetMember" xlink:label="loc_us-gaap_SalesRevenueGoodsNetMember_C12C86465A92747D92D4DDA4F6B2F635" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_2738C2CE32664508F48BDDA4F6B22356" xlink:to="loc_us-gaap_SalesRevenueGoodsNetMember_C12C86465A92747D92D4DDA4F6B2F635" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AccountsReceivableMember" xlink:label="loc_us-gaap_AccountsReceivableMember_16F0468584931AD4C438DDA4F6B2824B" xlink:type="locator" />
    <definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_2738C2CE32664508F48BDDA4F6B22356" xlink:to="loc_us-gaap_AccountsReceivableMember_16F0468584931AD4C438DDA4F6B2824B" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_MajorCustomersAxis" xlink:label="loc_us-gaap_MajorCustomersAxis_CB15BE011D8DDBBFF3AEDDA4F6B2F951" xlink:type="locator" />
    <definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ConcentrationRiskTable_18524F7D8249571191F7DDA4F6B13BB1" xlink:to="loc_us-gaap_MajorCustomersAxis_CB15BE011D8DDBBFF3AEDDA4F6B2F951" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NameOfMajorCustomerDomain" xlink:label="loc_us-gaap_NameOfMajorCustomerDomain_3575FECE6A3E9890F098DDA4F6B20B22_default" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_MajorCustomersAxis_CB15BE011D8DDBBFF3AEDDA4F6B2F951" xlink:to="loc_us-gaap_NameOfMajorCustomerDomain_3575FECE6A3E9890F098DDA4F6B20B22_default" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NameOfMajorCustomerDomain" xlink:label="loc_us-gaap_NameOfMajorCustomerDomain_3575FECE6A3E9890F098DDA4F6B20B22" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_MajorCustomersAxis_CB15BE011D8DDBBFF3AEDDA4F6B2F951" xlink:to="loc_us-gaap_NameOfMajorCustomerDomain_3575FECE6A3E9890F098DDA4F6B20B22" xlink:type="arc" />
    <loc xlink:href="gale-20150930.xsd#gale_CustomerOneMember" xlink:label="loc_gale_CustomerOneMember_3267EA7B0D9FCCABCA03DDA4F6B2F5DF" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NameOfMajorCustomerDomain_3575FECE6A3E9890F098DDA4F6B20B22" xlink:to="loc_gale_CustomerOneMember_3267EA7B0D9FCCABCA03DDA4F6B2F5DF" xlink:type="arc" />
    <loc xlink:href="gale-20150930.xsd#gale_CustomerTwoMember" xlink:label="loc_gale_CustomerTwoMember_3F480FEB91BB968C4D50DDA4F6B29FE7" xlink:type="locator" />
    <definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NameOfMajorCustomerDomain_3575FECE6A3E9890F098DDA4F6B20B22" xlink:to="loc_gale_CustomerTwoMember_3F480FEB91BB968C4D50DDA4F6B29FE7" xlink:type="arc" />
    <loc xlink:href="gale-20150930.xsd#gale_CustomerThreeMember" xlink:label="loc_gale_CustomerThreeMember_D212B944EB4D767ADDA5DDA4F6B2C5EE" xlink:type="locator" />
    <definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NameOfMajorCustomerDomain_3575FECE6A3E9890F098DDA4F6B20B22" xlink:to="loc_gale_CustomerThreeMember_D212B944EB4D767ADDA5DDA4F6B2C5EE" xlink:type="arc" />
    <loc xlink:href="gale-20150930.xsd#gale_CustomerFourMember" xlink:label="loc_gale_CustomerFourMember_12B1E9413A01C721DCD6DDA4F6B27643" xlink:type="locator" />
    <definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NameOfMajorCustomerDomain_3575FECE6A3E9890F098DDA4F6B20B22" xlink:to="loc_gale_CustomerFourMember_12B1E9413A01C721DCD6DDA4F6B27643" xlink:type="arc" />
    <loc xlink:href="gale-20150930.xsd#gale_CustomerFiveMember" xlink:label="loc_gale_CustomerFiveMember_78CE2BEA53DFC8972C32DDA4F6B23094" xlink:type="locator" />
    <definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NameOfMajorCustomerDomain_3575FECE6A3E9890F098DDA4F6B20B22" xlink:to="loc_gale_CustomerFiveMember_78CE2BEA53DFC8972C32DDA4F6B23094" xlink:type="arc" />
    <loc xlink:href="gale-20150930.xsd#gale_NumberofCommericalProducts" xlink:label="loc_gale_NumberofCommericalProducts_1DC2AE2B5CE1C69759B9DDA4F6B395C6" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_1B176FB11DAE0F13B24DDDA4F6B250BF" xlink:to="loc_gale_NumberofCommericalProducts_1DC2AE2B5CE1C69759B9DDA4F6B395C6" xlink:type="arc" />
    <loc xlink:href="gale-20150930.xsd#gale_NumberofDosingStrengths" xlink:label="loc_gale_NumberofDosingStrengths_47E691350972938543FBDDA4F6B3FE11" xlink:type="locator" />
    <definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_1B176FB11DAE0F13B24DDDA4F6B250BF" xlink:to="loc_gale_NumberofDosingStrengths_47E691350972938543FBDDA4F6B3FE11" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ConcentrationRiskPercentage1" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1_E813DD073E063DB48A4CDDA4F6B361AE" xlink:type="locator" />
    <definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_1B176FB11DAE0F13B24DDDA4F6B250BF" xlink:to="loc_us-gaap_ConcentrationRiskPercentage1_E813DD073E063DB48A4CDDA4F6B361AE" xlink:type="arc" />
    <loc xlink:href="gale-20150930.xsd#gale_NumberofTopPerformingPharmacies" xlink:label="loc_gale_NumberofTopPerformingPharmacies_AEB60E827799BA355D13DDA4F6B3B84C" xlink:type="locator" />
    <definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_1B176FB11DAE0F13B24DDDA4F6B250BF" xlink:to="loc_gale_NumberofTopPerformingPharmacies_AEB60E827799BA355D13DDA4F6B3B84C" xlink:type="arc" />
  </definitionLink>
  <definitionLink xlink:role="http://www.galenabiopharma.com/role/SignificantCustomersAndConcentrationOfCreditRiskNotes" xlink:type="extended" />
  <definitionLink xlink:role="http://www.galenabiopharma.com/role/SignificantCustomersAndConcentrationOfCreditRiskSignificantCustomersAndConcentrationOfCreditRiskTables" xlink:type="extended" />
  <definitionLink xlink:role="http://www.galenabiopharma.com/role/StockBasedCompensation" xlink:type="extended" />
  <definitionLink xlink:role="http://www.galenabiopharma.com/role/StockBasedCompensationAdditionalInformationDetail" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_DC6DDF098889592993B5B8CCA32AE32D" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_06411BEA1AFA543D9CC450269CD8B444" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_DC6DDF098889592993B5B8CCA32AE32D" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_06411BEA1AFA543D9CC450269CD8B444" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_TitleOfIndividualAxis" xlink:label="loc_us-gaap_TitleOfIndividualAxis_33BE35F37E255CB7B815AA694F203FA7" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_06411BEA1AFA543D9CC450269CD8B444" xlink:to="loc_us-gaap_TitleOfIndividualAxis_33BE35F37E255CB7B815AA694F203FA7" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_6F050AFBAC92696EC99ED437A8DB21B0_AC07C473F17259308476173B2BB2AAFF" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TitleOfIndividualAxis_33BE35F37E255CB7B815AA694F203FA7" xlink:to="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_6F050AFBAC92696EC99ED437A8DB21B0_AC07C473F17259308476173B2BB2AAFF" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_C58E07D700515604BFD9AE0670F7D314" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TitleOfIndividualAxis_33BE35F37E255CB7B815AA694F203FA7" xlink:to="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_C58E07D700515604BFD9AE0670F7D314" xlink:type="arc" />
    <loc xlink:href="gale-20150930.xsd#gale_TwoZeroZeroSevenIncentivePlanMember" xlink:label="loc_gale_TwoZeroZeroSevenIncentivePlanMember_DEF2DBDC343A5723A9217E4149D690E0" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_C58E07D700515604BFD9AE0670F7D314" xlink:to="loc_gale_TwoZeroZeroSevenIncentivePlanMember_DEF2DBDC343A5723A9217E4149D690E0" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RangeAxis" xlink:label="loc_us-gaap_RangeAxis_435F5640CDAF59CEB284949B196D64C5" xlink:type="locator" />
    <definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_06411BEA1AFA543D9CC450269CD8B444" xlink:to="loc_us-gaap_RangeAxis_435F5640CDAF59CEB284949B196D64C5" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaap_RangeMember_2A123C802E857727D52BD437A8DBDF54_AC07C473F17259308476173B2BB2AAFF" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RangeAxis_435F5640CDAF59CEB284949B196D64C5" xlink:to="loc_us-gaap_RangeMember_2A123C802E857727D52BD437A8DBDF54_AC07C473F17259308476173B2BB2AAFF" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaap_RangeMember_9D7A4F680C215D97994EE5D559DDAEB8" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RangeAxis_435F5640CDAF59CEB284949B196D64C5" xlink:to="loc_us-gaap_RangeMember_9D7A4F680C215D97994EE5D559DDAEB8" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_MinimumMember" xlink:label="loc_us-gaap_MinimumMember_37D0532F63AA5944A8710C1D7E3CB576" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RangeMember_9D7A4F680C215D97994EE5D559DDAEB8" xlink:to="loc_us-gaap_MinimumMember_37D0532F63AA5944A8710C1D7E3CB576" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_MaximumMember" xlink:label="loc_us-gaap_MaximumMember_A885F0020E0B54A5B3A1FA1771D679A7" xlink:type="locator" />
    <definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RangeMember_9D7A4F680C215D97994EE5D559DDAEB8" xlink:to="loc_us-gaap_MaximumMember_A885F0020E0B54A5B3A1FA1771D679A7" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_EA3E148C2B405549A7AD2903616E6907" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_DC6DDF098889592993B5B8CCA32AE32D" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_EA3E148C2B405549A7AD2903616E6907" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" xlink:label="loc_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_5F8F8B5C9D3453D09A248EFD1FBE4084" xlink:type="locator" />
    <definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_DC6DDF098889592993B5B8CCA32AE32D" xlink:to="loc_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_5F8F8B5C9D3453D09A248EFD1FBE4084" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_B79F848AC0B05F01A46D196D4DD7111F" xlink:type="locator" />
    <definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_DC6DDF098889592993B5B8CCA32AE32D" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_B79F848AC0B05F01A46D196D4DD7111F" xlink:type="arc" />
    <loc xlink:href="gale-20150930.xsd#gale_EstimatedAnnualizedForfeitureRateForOptionsGrantedToEmployees" xlink:label="loc_gale_EstimatedAnnualizedForfeitureRateForOptionsGrantedToEmployees_D56BE84CD78A502BA2A102DE94349F22" xlink:type="locator" />
    <definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_DC6DDF098889592993B5B8CCA32AE32D" xlink:to="loc_gale_EstimatedAnnualizedForfeitureRateForOptionsGrantedToEmployees_D56BE84CD78A502BA2A102DE94349F22" xlink:type="arc" />
    <loc xlink:href="gale-20150930.xsd#gale_EstimatedAnnualizedForfeitureRateForOptionsGrantedToSeniorManagement" xlink:label="loc_gale_EstimatedAnnualizedForfeitureRateForOptionsGrantedToSeniorManagement_84B98741EBD15A4299BA200A87AF2CFB" xlink:type="locator" />
    <definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_DC6DDF098889592993B5B8CCA32AE32D" xlink:to="loc_gale_EstimatedAnnualizedForfeitureRateForOptionsGrantedToSeniorManagement_84B98741EBD15A4299BA200A87AF2CFB" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_53E10FBD2E2C5BB1A59D80D733F50A74" xlink:type="locator" />
    <definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_DC6DDF098889592993B5B8CCA32AE32D" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_53E10FBD2E2C5BB1A59D80D733F50A74" xlink:type="arc" />
    <loc xlink:href="gale-20150930.xsd#gale_EmployeeServiceShareBasedCompensationUnrecognizedCompensationCosts" xlink:label="loc_gale_EmployeeServiceShareBasedCompensationUnrecognizedCompensationCosts_98CC170389905E46A996A449CE894C33" xlink:type="locator" />
    <definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_DC6DDF098889592993B5B8CCA32AE32D" xlink:to="loc_gale_EmployeeServiceShareBasedCompensationUnrecognizedCompensationCosts_98CC170389905E46A996A449CE894C33" xlink:type="arc" />
    <loc xlink:href="gale-20150930.xsd#gale_EmployeeServiceShareBasedCompensationUnrecognizedCompensationCostsWeightedAveragePeriodOfRecognition" xlink:label="loc_gale_EmployeeServiceShareBasedCompensationUnrecognizedCompensationCostsWeightedAveragePeriodOfRecognition_50A604EBA87F5F26A0A6D03513AE274D" xlink:type="locator" />
    <definitionArc order="8" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_DC6DDF098889592993B5B8CCA32AE32D" xlink:to="loc_gale_EmployeeServiceShareBasedCompensationUnrecognizedCompensationCostsWeightedAveragePeriodOfRecognition_50A604EBA87F5F26A0A6D03513AE274D" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_F8B04BEF31D95360AC1CEA7334B480D6" xlink:type="locator" />
    <definitionArc order="9" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_DC6DDF098889592993B5B8CCA32AE32D" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_F8B04BEF31D95360AC1CEA7334B480D6" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_0BC111709A2955AC986E18429B7B174A" xlink:type="locator" />
    <definitionArc order="10" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_DC6DDF098889592993B5B8CCA32AE32D" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_0BC111709A2955AC986E18429B7B174A" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_E34FF3AB87C35B079B102FBEF0B94B69" xlink:type="locator" />
    <definitionArc order="11" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_DC6DDF098889592993B5B8CCA32AE32D" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_E34FF3AB87C35B079B102FBEF0B94B69" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_9FDF9E7EA2B35D2B836B8171CA498E44" xlink:type="locator" />
    <definitionArc order="12" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_DC6DDF098889592993B5B8CCA32AE32D" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_9FDF9E7EA2B35D2B836B8171CA498E44" xlink:type="arc" />
    <loc xlink:href="gale-20150930.xsd#gale_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationPeriod" xlink:label="loc_gale_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationPeriod_9189AFD346F8509DA048D0A56B24F723" xlink:type="locator" />
    <definitionArc order="13" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_DC6DDF098889592993B5B8CCA32AE32D" xlink:to="loc_gale_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationPeriod_9189AFD346F8509DA048D0A56B24F723" xlink:type="arc" />
    <loc xlink:href="gale-20150930.xsd#gale_ClosingPriceOfCommonStock" xlink:label="loc_gale_ClosingPriceOfCommonStock_4365423020E75EF6A9FF49FB57F76B21" xlink:type="locator" />
    <definitionArc order="14" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_DC6DDF098889592993B5B8CCA32AE32D" xlink:to="loc_gale_ClosingPriceOfCommonStock_4365423020E75EF6A9FF49FB57F76B21" xlink:type="arc" />
  </definitionLink>
  <definitionLink xlink:role="http://www.galenabiopharma.com/role/StockBasedCompensationAllocatedStockBasedCompensationDetails" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_3247C7FA00BABB8D2859DE2E960E7E93" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_58038B07C615F3A01862DE2E960E98C7" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_3247C7FA00BABB8D2859DE2E960E7E93" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_58038B07C615F3A01862DE2E960E98C7" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementOperatingActivitiesSegmentAxis" xlink:label="loc_us-gaap_StatementOperatingActivitiesSegmentAxis_96372A821FAAB008C74BDE996948FAFF" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_58038B07C615F3A01862DE2E960E98C7" xlink:to="loc_us-gaap_StatementOperatingActivitiesSegmentAxis_96372A821FAAB008C74BDE996948FAFF" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SegmentOperatingActivitiesDomain" xlink:label="loc_us-gaap_SegmentOperatingActivitiesDomain_D222B235E27D8B2C40B4DE9A00540134_default" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementOperatingActivitiesSegmentAxis_96372A821FAAB008C74BDE996948FAFF" xlink:to="loc_us-gaap_SegmentOperatingActivitiesDomain_D222B235E27D8B2C40B4DE9A00540134_default" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SegmentOperatingActivitiesDomain" xlink:label="loc_us-gaap_SegmentOperatingActivitiesDomain_D222B235E27D8B2C40B4DE9A00540134" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementOperatingActivitiesSegmentAxis_96372A821FAAB008C74BDE996948FAFF" xlink:to="loc_us-gaap_SegmentOperatingActivitiesDomain_D222B235E27D8B2C40B4DE9A00540134" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SegmentContinuingOperationsMember" xlink:label="loc_us-gaap_SegmentContinuingOperationsMember_A671B6A51A35E4090E45DE9998C7A897" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentOperatingActivitiesDomain_D222B235E27D8B2C40B4DE9A00540134" xlink:to="loc_us-gaap_SegmentContinuingOperationsMember_A671B6A51A35E4090E45DE9998C7A897" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SegmentDiscontinuedOperationsMember" xlink:label="loc_us-gaap_SegmentDiscontinuedOperationsMember_704B607CEF48AEFE6A78DE99BAD3BDD8" xlink:type="locator" />
    <definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentOperatingActivitiesDomain_D222B235E27D8B2C40B4DE9A00540134" xlink:to="loc_us-gaap_SegmentDiscontinuedOperationsMember_704B607CEF48AEFE6A78DE99BAD3BDD8" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_045CF77143E5AA828CF6DE98972C0600" xlink:type="locator" />
    <definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_58038B07C615F3A01862DE2E960E98C7" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_045CF77143E5AA828CF6DE98972C0600" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_61BFEB9BC70041E93ABDDE98972C7A2A_default" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_045CF77143E5AA828CF6DE98972C0600" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_61BFEB9BC70041E93ABDDE98972C7A2A_default" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_61BFEB9BC70041E93ABDDE98972C7A2A" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_045CF77143E5AA828CF6DE98972C0600" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_61BFEB9BC70041E93ABDDE98972C7A2A" xlink:type="arc" />
    <loc xlink:href="gale-20150930.xsd#gale_CommercialBusinessSegmentMember" xlink:label="loc_gale_CommercialBusinessSegmentMember_288AC595A4A5CEA32630DE9897EBEDB5" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_61BFEB9BC70041E93ABDDE98972C7A2A" xlink:to="loc_gale_CommercialBusinessSegmentMember_288AC595A4A5CEA32630DE9897EBEDB5" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_6631E6125C52C1F92F51DE2E960EB27E" xlink:type="locator" />
    <definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_58038B07C615F3A01862DE2E960E98C7" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_6631E6125C52C1F92F51DE2E960EB27E" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_82EAA293D0C9A62741DADE2E960EDB69_default" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_6631E6125C52C1F92F51DE2E960EB27E" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_82EAA293D0C9A62741DADE2E960EDB69_default" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_82EAA293D0C9A62741DADE2E960EDB69" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_6631E6125C52C1F92F51DE2E960EB27E" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_82EAA293D0C9A62741DADE2E960EDB69" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_0FFBEA2204A216E06A6BDE2E960E9BEE" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_82EAA293D0C9A62741DADE2E960EDB69" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_0FFBEA2204A216E06A6BDE2E960E9BEE" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_2CC4A3F44FBD501622CADE2E960E1F5F" xlink:type="locator" />
    <definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_82EAA293D0C9A62741DADE2E960EDB69" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_2CC4A3F44FBD501622CADE2E960E1F5F" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_414715582751F6861173DE2E960E1047" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_3247C7FA00BABB8D2859DE2E960E7E93" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_414715582751F6861173DE2E960E1047" xlink:type="arc" />
  </definitionLink>
  <definitionLink xlink:role="http://www.galenabiopharma.com/role/StockBasedCompensationAssumptionsForOptionGrantsIssuedDetail" xlink:type="extended" />
  <definitionLink xlink:role="http://www.galenabiopharma.com/role/StockBasedCompensationStockOptionActivityDetail" xlink:type="extended" />
  <definitionLink xlink:role="http://www.galenabiopharma.com/role/StockBasedCompensationTables" xlink:type="extended" />
  <definitionLink xlink:role="http://www.galenabiopharma.com/role/StockholdersEquity" xlink:type="extended" />
  <definitionLink xlink:role="http://www.galenabiopharma.com/role/StockholdersEquityAdditionalInformationDetail" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ClassOfStockLineItems" xlink:label="loc_us-gaap_ClassOfStockLineItems_D44EDB4BDB5C56C78BAFB8E7AF60F739" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_296A971608965B448E6974FA1BBF315C" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ClassOfStockLineItems_D44EDB4BDB5C56C78BAFB8E7AF60F739" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_296A971608965B448E6974FA1BBF315C" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_0D57436B5EF7593BB7C99DD5807C8E0D" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_296A971608965B448E6974FA1BBF315C" xlink:to="loc_dei_LegalEntityAxis_0D57436B5EF7593BB7C99DD5807C8E0D" xlink:type="arc" />
    <loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_565CD3F6E001F7376BEBFE43427E28C8_AC07C473F17259308476173B2BB2AAFF" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_0D57436B5EF7593BB7C99DD5807C8E0D" xlink:to="loc_dei_EntityDomain_565CD3F6E001F7376BEBFE43427E28C8_AC07C473F17259308476173B2BB2AAFF" xlink:type="arc" />
    <loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_6ED96AA52B205D28BE8F0FC0B04FE6D9" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_0D57436B5EF7593BB7C99DD5807C8E0D" xlink:to="loc_dei_EntityDomain_6ED96AA52B205D28BE8F0FC0B04FE6D9" xlink:type="arc" />
    <loc xlink:href="gale-20150930.xsd#gale_LincolnParkCapitalLLCMember" xlink:label="loc_gale_LincolnParkCapitalLLCMember_E7FE8EA1C6E65581958491F205454870" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_6ED96AA52B205D28BE8F0FC0B04FE6D9" xlink:to="loc_gale_LincolnParkCapitalLLCMember_E7FE8EA1C6E65581958491F205454870" xlink:type="arc" />
    <loc xlink:href="gale-20150930.xsd#gale_MLVCo.LLCandMaximGroupLLCMember" xlink:label="loc_gale_MLVCo.LLCandMaximGroupLLCMember_186D461599F2534FAAFABDB19D8F8875" xlink:type="locator" />
    <definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_6ED96AA52B205D28BE8F0FC0B04FE6D9" xlink:to="loc_gale_MLVCo.LLCandMaximGroupLLCMember_186D461599F2534FAAFABDB19D8F8875" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_5946413637FA5BA28FA53AC691FF1979" xlink:type="locator" />
    <definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_296A971608965B448E6974FA1BBF315C" xlink:to="loc_us-gaap_StatementClassOfStockAxis_5946413637FA5BA28FA53AC691FF1979" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_736E82FEDC64B671B42CFE43427EFB83_AC07C473F17259308476173B2BB2AAFF" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_5946413637FA5BA28FA53AC691FF1979" xlink:to="loc_us-gaap_ClassOfStockDomain_736E82FEDC64B671B42CFE43427EFB83_AC07C473F17259308476173B2BB2AAFF" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_4FAC2440DF065BEE8FA26503F59838FB" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_5946413637FA5BA28FA53AC691FF1979" xlink:to="loc_us-gaap_ClassOfStockDomain_4FAC2440DF065BEE8FA26503F59838FB" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember_D58E23A7938E5EEC90DE63D31C5C4E93" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_4FAC2440DF065BEE8FA26503F59838FB" xlink:to="loc_us-gaap_CommonStockMember_D58E23A7938E5EEC90DE63D31C5C4E93" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaap_WarrantMember_45A8948C830E5CE2870BDC2CA9DC48C5" xlink:type="locator" />
    <definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_4FAC2440DF065BEE8FA26503F59838FB" xlink:to="loc_us-gaap_WarrantMember_45A8948C830E5CE2870BDC2CA9DC48C5" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_152EE2A8DEB054D1A001C2488E3FA05B" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_D44EDB4BDB5C56C78BAFB8E7AF60F739" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_152EE2A8DEB054D1A001C2488E3FA05B" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_97DF3539700558108AE5C1067B01937E" xlink:type="locator" />
    <definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_D44EDB4BDB5C56C78BAFB8E7AF60F739" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_97DF3539700558108AE5C1067B01937E" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_860C5EF2C76257A4BC077D779616D6A6" xlink:type="locator" />
    <definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_D44EDB4BDB5C56C78BAFB8E7AF60F739" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_860C5EF2C76257A4BC077D779616D6A6" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_47E96CB05444557A8688836F7E09458C" xlink:type="locator" />
    <definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_D44EDB4BDB5C56C78BAFB8E7AF60F739" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_47E96CB05444557A8688836F7E09458C" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:label="loc_us-gaap_ProceedsFromIssuanceOrSaleOfEquity_EAE1DE5F61245A839B7E586A7EC1C4F1" xlink:type="locator" />
    <definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_D44EDB4BDB5C56C78BAFB8E7AF60F739" xlink:to="loc_us-gaap_ProceedsFromIssuanceOrSaleOfEquity_EAE1DE5F61245A839B7E586A7EC1C4F1" xlink:type="arc" />
    <loc xlink:href="gale-20150930.xsd#gale_PurchaseAgreementTerm" xlink:label="loc_gale_PurchaseAgreementTerm_B98B7B075BFB51539FA090FD26B9A240" xlink:type="locator" />
    <definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_D44EDB4BDB5C56C78BAFB8E7AF60F739" xlink:to="loc_gale_PurchaseAgreementTerm_B98B7B075BFB51539FA090FD26B9A240" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets_5084DDF9E0AD5ACB8697847F3085F3E3" xlink:type="locator" />
    <definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_D44EDB4BDB5C56C78BAFB8E7AF60F739" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets_5084DDF9E0AD5ACB8697847F3085F3E3" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SharePrice" xlink:label="loc_us-gaap_SharePrice_4FC045C1EAAD5BF0A68070982CE11241" xlink:type="locator" />
    <definitionArc order="8" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_D44EDB4BDB5C56C78BAFB8E7AF60F739" xlink:to="loc_us-gaap_SharePrice_4FC045C1EAAD5BF0A68070982CE11241" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_415EBD02E2BF540FAAB2FDEB230D74BE" xlink:type="locator" />
    <definitionArc order="9" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_D44EDB4BDB5C56C78BAFB8E7AF60F739" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_415EBD02E2BF540FAAB2FDEB230D74BE" xlink:type="arc" />
    <loc xlink:href="gale-20150930.xsd#gale_AtMarketIssuanceSalesAgreementsPercentofGrossProceeds" xlink:label="loc_gale_AtMarketIssuanceSalesAgreementsPercentofGrossProceeds_250BC34514A058C7884EA78A38AA0EB5" xlink:type="locator" />
    <definitionArc order="10" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_D44EDB4BDB5C56C78BAFB8E7AF60F739" xlink:to="loc_gale_AtMarketIssuanceSalesAgreementsPercentofGrossProceeds_250BC34514A058C7884EA78A38AA0EB5" xlink:type="arc" />
    <loc xlink:href="gale-20150930.xsd#gale_AtMarketIssuanceSalesAgreementsMaximumGrossProceeds" xlink:label="loc_gale_AtMarketIssuanceSalesAgreementsMaximumGrossProceeds_124033EFCB3F5D289F6A6BAB4CFC7F7C" xlink:type="locator" />
    <definitionArc order="11" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_D44EDB4BDB5C56C78BAFB8E7AF60F739" xlink:to="loc_gale_AtMarketIssuanceSalesAgreementsMaximumGrossProceeds_124033EFCB3F5D289F6A6BAB4CFC7F7C" xlink:type="arc" />
    <loc xlink:href="gale-20150930.xsd#gale_NumberofSharesPerUnit" xlink:label="loc_gale_NumberofSharesPerUnit_D5E01A04C9135579881492BB50250F82" xlink:type="locator" />
    <definitionArc order="12" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_D44EDB4BDB5C56C78BAFB8E7AF60F739" xlink:to="loc_gale_NumberofSharesPerUnit_D5E01A04C9135579881492BB50250F82" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_72947B2F9CF25E719769969DED859FEF" xlink:type="locator" />
    <definitionArc order="13" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_D44EDB4BDB5C56C78BAFB8E7AF60F739" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_72947B2F9CF25E719769969DED859FEF" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_69AF91CA144F599CB72AC910751F58B0" xlink:type="locator" />
    <definitionArc order="14" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_D44EDB4BDB5C56C78BAFB8E7AF60F739" xlink:to="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_69AF91CA144F599CB72AC910751F58B0" xlink:type="arc" />
    <loc xlink:href="gale-20150930.xsd#gale_StockIssuedDuringPeriodSharesOverallotmentOption" xlink:label="loc_gale_StockIssuedDuringPeriodSharesOverallotmentOption_7C658606B8B25E99AED0727C7AFB317E" xlink:type="locator" />
    <definitionArc order="15" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_D44EDB4BDB5C56C78BAFB8E7AF60F739" xlink:to="loc_gale_StockIssuedDuringPeriodSharesOverallotmentOption_7C658606B8B25E99AED0727C7AFB317E" xlink:type="arc" />
    <loc xlink:href="gale-20150930.xsd#gale_ProceedsFromIssuanceorSaleofEquityNetUnderwritingDiscountsCommissionsandOfferingExpenses" xlink:label="loc_gale_ProceedsFromIssuanceorSaleofEquityNetUnderwritingDiscountsCommissionsandOfferingExpenses_3B1AD7F42360559380EFA1BCE1026A36" xlink:type="locator" />
    <definitionArc order="16" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_D44EDB4BDB5C56C78BAFB8E7AF60F739" xlink:to="loc_gale_ProceedsFromIssuanceorSaleofEquityNetUnderwritingDiscountsCommissionsandOfferingExpenses_3B1AD7F42360559380EFA1BCE1026A36" xlink:type="arc" />
  </definitionLink>
  <definitionLink xlink:role="http://www.galenabiopharma.com/role/StockholdersEquityCommonStockAreReservedForFutureIssuanceDetail" xlink:type="extended" />
  <definitionLink xlink:role="http://www.galenabiopharma.com/role/StockholdersEquityTables" xlink:type="extended" />
  <definitionLink xlink:role="http://www.galenabiopharma.com/role/SubsequentEvents" xlink:type="extended" />
  <definitionLink xlink:role="http://www.galenabiopharma.com/role/Warrants" xlink:type="extended" />
  <definitionLink xlink:role="http://www.galenabiopharma.com/role/WarrantsChangesInFairValueOfWarrantLiabilityDetail" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ClassOfWarrantOrRightLineItems" xlink:label="loc_us-gaap_ClassOfWarrantOrRightLineItems_5F5C140FFDF55602B4C16D7CA221772D" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ClassOfWarrantOrRightTable" xlink:label="loc_us-gaap_ClassOfWarrantOrRightTable_C43ED20E54A056BFBB81A2BE41C35A6A" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_5F5C140FFDF55602B4C16D7CA221772D" xlink:to="loc_us-gaap_ClassOfWarrantOrRightTable_C43ED20E54A056BFBB81A2BE41C35A6A" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis_3B25AA97C7DC5396966F3635F6C05407" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_C43ED20E54A056BFBB81A2BE41C35A6A" xlink:to="loc_us-gaap_ClassOfWarrantOrRightAxis_3B25AA97C7DC5396966F3635F6C05407" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_A86DEEBC0A72C201241FD437A7C8451E_AC07C473F17259308476173B2BB2AAFF" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_3B25AA97C7DC5396966F3635F6C05407" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_A86DEEBC0A72C201241FD437A7C8451E_AC07C473F17259308476173B2BB2AAFF" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_0AE86FC5411A5EC79A3205437FE3E963" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_3B25AA97C7DC5396966F3635F6C05407" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_0AE86FC5411A5EC79A3205437FE3E963" xlink:type="arc" />
    <loc xlink:href="gale-20150930.xsd#gale_MarchTwoThousandFifteenWarrantsMember" xlink:label="loc_gale_MarchTwoThousandFifteenWarrantsMember_9A4EE72B79D353CBBE8A74025B078856" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_0AE86FC5411A5EC79A3205437FE3E963" xlink:to="loc_gale_MarchTwoThousandFifteenWarrantsMember_9A4EE72B79D353CBBE8A74025B078856" xlink:type="arc" />
    <loc xlink:href="gale-20150930.xsd#gale_SeptemberTwoThousandThirteenWarrantMember" xlink:label="loc_gale_SeptemberTwoThousandThirteenWarrantMember_FF7927BE99FB53B481606E724880504B" xlink:type="locator" />
    <definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_0AE86FC5411A5EC79A3205437FE3E963" xlink:to="loc_gale_SeptemberTwoThousandThirteenWarrantMember_FF7927BE99FB53B481606E724880504B" xlink:type="arc" />
    <loc xlink:href="gale-20150930.xsd#gale_DecemberTwoThousandTwelveWarrantMember" xlink:label="loc_gale_DecemberTwoThousandTwelveWarrantMember_0AE9DA1BF1215CEAB9DC6AF23D72491A" xlink:type="locator" />
    <definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_0AE86FC5411A5EC79A3205437FE3E963" xlink:to="loc_gale_DecemberTwoThousandTwelveWarrantMember_0AE9DA1BF1215CEAB9DC6AF23D72491A" xlink:type="arc" />
    <loc xlink:href="gale-20150930.xsd#gale_AprilTwoThousandElevenWarrantMember" xlink:label="loc_gale_AprilTwoThousandElevenWarrantMember_68FC82B6E643559CA8DF3F903675EE11" xlink:type="locator" />
    <definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_0AE86FC5411A5EC79A3205437FE3E963" xlink:to="loc_gale_AprilTwoThousandElevenWarrantMember_68FC82B6E643559CA8DF3F903675EE11" xlink:type="arc" />
    <loc xlink:href="gale-20150930.xsd#gale_MarchTwoThousandElevenWarrantMember" xlink:label="loc_gale_MarchTwoThousandElevenWarrantMember_FE4730851ED954118A6CBAF93C8E6B73" xlink:type="locator" />
    <definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_0AE86FC5411A5EC79A3205437FE3E963" xlink:to="loc_gale_MarchTwoThousandElevenWarrantMember_FE4730851ED954118A6CBAF93C8E6B73" xlink:type="arc" />
    <loc xlink:href="gale-20150930.xsd#gale_MarchTwoThousandTenWarrantMember" xlink:label="loc_gale_MarchTwoThousandTenWarrantMember_70CDBEC41A5754D4B72AF32BE6CDBD3E" xlink:type="locator" />
    <definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_0AE86FC5411A5EC79A3205437FE3E963" xlink:to="loc_gale_MarchTwoThousandTenWarrantMember_70CDBEC41A5754D4B72AF32BE6CDBD3E" xlink:type="arc" />
    <loc xlink:href="gale-20150930.xsd#gale_FairValueofWarrantsGranted" xlink:label="loc_gale_FairValueofWarrantsGranted_D947E9AF3B7E5536843C00908B4B0B17" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_5F5C140FFDF55602B4C16D7CA221772D" xlink:to="loc_gale_FairValueofWarrantsGranted_D947E9AF3B7E5536843C00908B4B0B17" xlink:type="arc" />
    <loc xlink:href="gale-20150930.xsd#gale_ClassofWarrantorRightFairValueRollForward" xlink:label="loc_gale_ClassofWarrantorRightFairValueRollForward_11C1085806F95A178540C0BC1C9C1211" xlink:type="locator" />
    <definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_5F5C140FFDF55602B4C16D7CA221772D" xlink:to="loc_gale_ClassofWarrantorRightFairValueRollForward_11C1085806F95A178540C0BC1C9C1211" xlink:type="arc" />
    <loc xlink:href="gale-20150930.xsd#gale_FairValueOfWarrantsLiabilities" xlink:label="loc_gale_FairValueOfWarrantsLiabilities_74188ADE7C3954659289680BE1842EFB" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gale_ClassofWarrantorRightFairValueRollForward_11C1085806F95A178540C0BC1C9C1211" xlink:to="loc_gale_FairValueOfWarrantsLiabilities_74188ADE7C3954659289680BE1842EFB" xlink:type="arc" />
    <loc xlink:href="gale-20150930.xsd#gale_ChangeInFairValueOfWarrantLiabilities" xlink:label="loc_gale_ChangeInFairValueOfWarrantLiabilities_416ADAF925C95248BAB77422AC2AC8F3" xlink:type="locator" />
    <definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gale_ClassofWarrantorRightFairValueRollForward_11C1085806F95A178540C0BC1C9C1211" xlink:to="loc_gale_ChangeInFairValueOfWarrantLiabilities_416ADAF925C95248BAB77422AC2AC8F3" xlink:type="arc" />
  </definitionLink>
  <definitionLink xlink:role="http://www.galenabiopharma.com/role/WarrantsFairValueOfWarrantsIsEstimatedUsingBlackScholesOptionPricingModelDetail" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ClassOfWarrantOrRightLineItems" xlink:label="loc_us-gaap_ClassOfWarrantOrRightLineItems_C121BA8C84EC59C2A3C06DB318D8949D" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ClassOfWarrantOrRightTable" xlink:label="loc_us-gaap_ClassOfWarrantOrRightTable_114E4FA8849650D681CB20363268188E" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_C121BA8C84EC59C2A3C06DB318D8949D" xlink:to="loc_us-gaap_ClassOfWarrantOrRightTable_114E4FA8849650D681CB20363268188E" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis_0433F05B798B51E9B23B373C1F3DAB56" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_114E4FA8849650D681CB20363268188E" xlink:to="loc_us-gaap_ClassOfWarrantOrRightAxis_0433F05B798B51E9B23B373C1F3DAB56" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_B907C51D213C374CBEBCD437A828CEA7_AC07C473F17259308476173B2BB2AAFF" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_0433F05B798B51E9B23B373C1F3DAB56" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_B907C51D213C374CBEBCD437A828CEA7_AC07C473F17259308476173B2BB2AAFF" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_E576EE5D20D85792B4EAC03AD0D4D409" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_0433F05B798B51E9B23B373C1F3DAB56" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_E576EE5D20D85792B4EAC03AD0D4D409" xlink:type="arc" />
    <loc xlink:href="gale-20150930.xsd#gale_MarchTwoThousandFifteenWarrantsMember" xlink:label="loc_gale_MarchTwoThousandFifteenWarrantsMember_B17936AD4F015617AB01F4F6FFDC8E9C" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_E576EE5D20D85792B4EAC03AD0D4D409" xlink:to="loc_gale_MarchTwoThousandFifteenWarrantsMember_B17936AD4F015617AB01F4F6FFDC8E9C" xlink:type="arc" />
    <loc xlink:href="gale-20150930.xsd#gale_SeptemberTwoThousandThirteenWarrantMember" xlink:label="loc_gale_SeptemberTwoThousandThirteenWarrantMember_9E33C5147C655D05B5CD4DDDBB74D6F5" xlink:type="locator" />
    <definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_E576EE5D20D85792B4EAC03AD0D4D409" xlink:to="loc_gale_SeptemberTwoThousandThirteenWarrantMember_9E33C5147C655D05B5CD4DDDBB74D6F5" xlink:type="arc" />
    <loc xlink:href="gale-20150930.xsd#gale_DecemberTwoThousandTwelveWarrantMember" xlink:label="loc_gale_DecemberTwoThousandTwelveWarrantMember_0DFD86551E715FEC8284FB5AE9DB8170" xlink:type="locator" />
    <definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_E576EE5D20D85792B4EAC03AD0D4D409" xlink:to="loc_gale_DecemberTwoThousandTwelveWarrantMember_0DFD86551E715FEC8284FB5AE9DB8170" xlink:type="arc" />
    <loc xlink:href="gale-20150930.xsd#gale_AprilTwoThousandElevenWarrantMember" xlink:label="loc_gale_AprilTwoThousandElevenWarrantMember_1C7D1053CEF05CD8A6636377C8EFBE70" xlink:type="locator" />
    <definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_E576EE5D20D85792B4EAC03AD0D4D409" xlink:to="loc_gale_AprilTwoThousandElevenWarrantMember_1C7D1053CEF05CD8A6636377C8EFBE70" xlink:type="arc" />
    <loc xlink:href="gale-20150930.xsd#gale_MarchTwoThousandElevenWarrantMember" xlink:label="loc_gale_MarchTwoThousandElevenWarrantMember_11045D5FB51F53BB965F4AC4061DD41D" xlink:type="locator" />
    <definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_E576EE5D20D85792B4EAC03AD0D4D409" xlink:to="loc_gale_MarchTwoThousandElevenWarrantMember_11045D5FB51F53BB965F4AC4061DD41D" xlink:type="arc" />
    <loc xlink:href="gale-20150930.xsd#gale_MarchTwoThousandTenWarrantMember" xlink:label="loc_gale_MarchTwoThousandTenWarrantMember_D9EAEE4601285187B949338D6C961939" xlink:type="locator" />
    <definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_E576EE5D20D85792B4EAC03AD0D4D409" xlink:to="loc_gale_MarchTwoThousandTenWarrantMember_D9EAEE4601285187B949338D6C961939" xlink:type="arc" />
    <loc xlink:href="gale-20150930.xsd#gale_WarrantStrikePrice" xlink:label="loc_gale_WarrantStrikePrice_83F260DD775A54A4B83E6ED81B881D04" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_C121BA8C84EC59C2A3C06DB318D8949D" xlink:to="loc_gale_WarrantStrikePrice_83F260DD775A54A4B83E6ED81B881D04" xlink:type="arc" />
    <loc xlink:href="gale-20150930.xsd#gale_FairValueOfWarrantLiabilityAssumptionsExpectedTerm" xlink:label="loc_gale_FairValueOfWarrantLiabilityAssumptionsExpectedTerm_D26D3166082D56DE82200C1725E60E6B" xlink:type="locator" />
    <definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_C121BA8C84EC59C2A3C06DB318D8949D" xlink:to="loc_gale_FairValueOfWarrantLiabilityAssumptionsExpectedTerm_D26D3166082D56DE82200C1725E60E6B" xlink:type="arc" />
    <loc xlink:href="gale-20150930.xsd#gale_WarrantsFairValueAssumptionsExpectedVolatility" xlink:label="loc_gale_WarrantsFairValueAssumptionsExpectedVolatility_9489EF344DF95F18BB68857A669FBA12" xlink:type="locator" />
    <definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_C121BA8C84EC59C2A3C06DB318D8949D" xlink:to="loc_gale_WarrantsFairValueAssumptionsExpectedVolatility_9489EF344DF95F18BB68857A669FBA12" xlink:type="arc" />
    <loc xlink:href="gale-20150930.xsd#gale_WarrantsFairValueAssumptionsRiskFreeInterestRate" xlink:label="loc_gale_WarrantsFairValueAssumptionsRiskFreeInterestRate_4C8670C04EDA5B99BDE0BB8FF00C738C" xlink:type="locator" />
    <definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_C121BA8C84EC59C2A3C06DB318D8949D" xlink:to="loc_gale_WarrantsFairValueAssumptionsRiskFreeInterestRate_4C8670C04EDA5B99BDE0BB8FF00C738C" xlink:type="arc" />
  </definitionLink>
  <definitionLink xlink:role="http://www.galenabiopharma.com/role/WarrantsScheduleOfWarrantActivityDetail" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ClassOfWarrantOrRightLineItems" xlink:label="loc_us-gaap_ClassOfWarrantOrRightLineItems_F628DEAC97C65E7BB91A36012AAE27F3" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ClassOfWarrantOrRightTable" xlink:label="loc_us-gaap_ClassOfWarrantOrRightTable_D14D72E05535596E93F123C255140C55" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_F628DEAC97C65E7BB91A36012AAE27F3" xlink:to="loc_us-gaap_ClassOfWarrantOrRightTable_D14D72E05535596E93F123C255140C55" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis_6BB6AC842BE25B4CA4CD3CB04A97CC63" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_D14D72E05535596E93F123C255140C55" xlink:to="loc_us-gaap_ClassOfWarrantOrRightAxis_6BB6AC842BE25B4CA4CD3CB04A97CC63" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_C19E9C9355FD8FEACD49E0E750CF1744_AC07C473F17259308476173B2BB2AAFF" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_6BB6AC842BE25B4CA4CD3CB04A97CC63" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_C19E9C9355FD8FEACD49E0E750CF1744_AC07C473F17259308476173B2BB2AAFF" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_AB41C36ABE5650A096D59969576DF387" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_6BB6AC842BE25B4CA4CD3CB04A97CC63" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_AB41C36ABE5650A096D59969576DF387" xlink:type="arc" />
    <loc xlink:href="gale-20150930.xsd#gale_MarchTwoThousandFifteenWarrantsMember" xlink:label="loc_gale_MarchTwoThousandFifteenWarrantsMember_FC9627910C605B1F8A36C5D667DD2A70" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_AB41C36ABE5650A096D59969576DF387" xlink:to="loc_gale_MarchTwoThousandFifteenWarrantsMember_FC9627910C605B1F8A36C5D667DD2A70" xlink:type="arc" />
    <loc xlink:href="gale-20150930.xsd#gale_SeptemberTwoThousandThirteenWarrantMember" xlink:label="loc_gale_SeptemberTwoThousandThirteenWarrantMember_82573F54B9B75520AE81EC3D7D518498" xlink:type="locator" />
    <definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_AB41C36ABE5650A096D59969576DF387" xlink:to="loc_gale_SeptemberTwoThousandThirteenWarrantMember_82573F54B9B75520AE81EC3D7D518498" xlink:type="arc" />
    <loc xlink:href="gale-20150930.xsd#gale_DecemberTwoThousandTwelveWarrantMember" xlink:label="loc_gale_DecemberTwoThousandTwelveWarrantMember_2DAD7F3A11035445B72769327C204BE5" xlink:type="locator" />
    <definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_AB41C36ABE5650A096D59969576DF387" xlink:to="loc_gale_DecemberTwoThousandTwelveWarrantMember_2DAD7F3A11035445B72769327C204BE5" xlink:type="arc" />
    <loc xlink:href="gale-20150930.xsd#gale_AprilTwoThousandElevenWarrantMember" xlink:label="loc_gale_AprilTwoThousandElevenWarrantMember_C34172721CDA52F0973A4AE6511959E7" xlink:type="locator" />
    <definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_AB41C36ABE5650A096D59969576DF387" xlink:to="loc_gale_AprilTwoThousandElevenWarrantMember_C34172721CDA52F0973A4AE6511959E7" xlink:type="arc" />
    <loc xlink:href="gale-20150930.xsd#gale_MarchTwoThousandElevenWarrantMember" xlink:label="loc_gale_MarchTwoThousandElevenWarrantMember_22AF70E1FAC450488CEE2B2CF420B566" xlink:type="locator" />
    <definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_AB41C36ABE5650A096D59969576DF387" xlink:to="loc_gale_MarchTwoThousandElevenWarrantMember_22AF70E1FAC450488CEE2B2CF420B566" xlink:type="arc" />
    <loc xlink:href="gale-20150930.xsd#gale_MarchTwoThousandTenWarrantMember" xlink:label="loc_gale_MarchTwoThousandTenWarrantMember_12D141098E75531EA41293EABEBF1B1F" xlink:type="locator" />
    <definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_AB41C36ABE5650A096D59969576DF387" xlink:to="loc_gale_MarchTwoThousandTenWarrantMember_12D141098E75531EA41293EABEBF1B1F" xlink:type="arc" />
    <loc xlink:href="gale-20150930.xsd#gale_ConsultantWarrantsMember" xlink:label="loc_gale_ConsultantWarrantsMember_D66191DD568E52F4AB95D554037CEDA1" xlink:type="locator" />
    <definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_AB41C36ABE5650A096D59969576DF387" xlink:to="loc_gale_ConsultantWarrantsMember_D66191DD568E52F4AB95D554037CEDA1" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RangeAxis" xlink:label="loc_us-gaap_RangeAxis_95625F6055A855369C9235BF2953A60C" xlink:type="locator" />
    <definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_D14D72E05535596E93F123C255140C55" xlink:to="loc_us-gaap_RangeAxis_95625F6055A855369C9235BF2953A60C" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaap_RangeMember_0AE072BEC049F6F211B7E0E750D062CB_AC07C473F17259308476173B2BB2AAFF" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RangeAxis_95625F6055A855369C9235BF2953A60C" xlink:to="loc_us-gaap_RangeMember_0AE072BEC049F6F211B7E0E750D062CB_AC07C473F17259308476173B2BB2AAFF" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaap_RangeMember_51D1C7D5631C5CE691EB6FB7F34BF69E" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RangeAxis_95625F6055A855369C9235BF2953A60C" xlink:to="loc_us-gaap_RangeMember_51D1C7D5631C5CE691EB6FB7F34BF69E" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_MinimumMember" xlink:label="loc_us-gaap_MinimumMember_2902E1CFD66B570C9C1C930AA627E6FC" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RangeMember_51D1C7D5631C5CE691EB6FB7F34BF69E" xlink:to="loc_us-gaap_MinimumMember_2902E1CFD66B570C9C1C930AA627E6FC" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_MaximumMember" xlink:label="loc_us-gaap_MaximumMember_7F9A83F1F6955C0FA864259E4F32441B" xlink:type="locator" />
    <definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RangeMember_51D1C7D5631C5CE691EB6FB7F34BF69E" xlink:to="loc_us-gaap_MaximumMember_7F9A83F1F6955C0FA864259E4F32441B" xlink:type="arc" />
    <loc xlink:href="gale-20150930.xsd#gale_ClassofWarrantorRightOutstandingRollForward" xlink:label="loc_gale_ClassofWarrantorRightOutstandingRollForward_63F072EBFC4A53E4A2BF695DF9E8B51E" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_F628DEAC97C65E7BB91A36012AAE27F3" xlink:to="loc_gale_ClassofWarrantorRightOutstandingRollForward_63F072EBFC4A53E4A2BF695DF9E8B51E" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="loc_us-gaap_ClassOfWarrantOrRightOutstanding_D87C55071BD2522C82ED829456A5E41F" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gale_ClassofWarrantorRightOutstandingRollForward_63F072EBFC4A53E4A2BF695DF9E8B51E" xlink:to="loc_us-gaap_ClassOfWarrantOrRightOutstanding_D87C55071BD2522C82ED829456A5E41F" xlink:type="arc" />
    <loc xlink:href="gale-20150930.xsd#gale_ClassofWarrantorRightGranted" xlink:label="loc_gale_ClassofWarrantorRightGranted_CEE334D934A9544099F95320BCC4EA9D" xlink:type="locator" />
    <definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gale_ClassofWarrantorRightOutstandingRollForward_63F072EBFC4A53E4A2BF695DF9E8B51E" xlink:to="loc_gale_ClassofWarrantorRightGranted_CEE334D934A9544099F95320BCC4EA9D" xlink:type="arc" />
    <loc xlink:href="gale-20150930.xsd#gale_ClassofWarrantorRightExpired" xlink:label="loc_gale_ClassofWarrantorRightExpired_1F24F330076051E4B4ADAABC07A3860E" xlink:type="locator" />
    <definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gale_ClassofWarrantorRightOutstandingRollForward_63F072EBFC4A53E4A2BF695DF9E8B51E" xlink:to="loc_gale_ClassofWarrantorRightExpired_1F24F330076051E4B4ADAABC07A3860E" xlink:type="arc" />
    <loc xlink:href="gale-20150930.xsd#gale_ClassOfWarrantsOrRightsExpirationDate" xlink:label="loc_gale_ClassOfWarrantsOrRightsExpirationDate_35F665F4D9DF51858872826FE354D16B" xlink:type="locator" />
    <definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gale_ClassofWarrantorRightOutstandingRollForward_63F072EBFC4A53E4A2BF695DF9E8B51E" xlink:to="loc_gale_ClassOfWarrantsOrRightsExpirationDate_35F665F4D9DF51858872826FE354D16B" xlink:type="arc" />
  </definitionLink>
  <definitionLink xlink:role="http://www.galenabiopharma.com/role/WarrantsTables" xlink:type="extended" />
  <definitionLink xlink:role="http://www.galenabiopharma.com/role/WarrantsWarrantsClassifiedAsEquityDetails" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ClassOfWarrantOrRightLineItems" xlink:label="loc_us-gaap_ClassOfWarrantOrRightLineItems_DB58599E319D58FE8EC2AE5638300372" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ClassOfWarrantOrRightTable" xlink:label="loc_us-gaap_ClassOfWarrantOrRightTable_592E9E4B6F8352F7A979234F3F1DA31E" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_DB58599E319D58FE8EC2AE5638300372" xlink:to="loc_us-gaap_ClassOfWarrantOrRightTable_592E9E4B6F8352F7A979234F3F1DA31E" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis_39D712EE149A51BEA21D77C1F937A5FA" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_592E9E4B6F8352F7A979234F3F1DA31E" xlink:to="loc_us-gaap_ClassOfWarrantOrRightAxis_39D712EE149A51BEA21D77C1F937A5FA" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_8FA8D14C175D21A6DBB7D437A7E99FBF_AC07C473F17259308476173B2BB2AAFF" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_39D712EE149A51BEA21D77C1F937A5FA" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_8FA8D14C175D21A6DBB7D437A7E99FBF_AC07C473F17259308476173B2BB2AAFF" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_7B0BE6C79B205D22A122788A812583D0" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_39D712EE149A51BEA21D77C1F937A5FA" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_7B0BE6C79B205D22A122788A812583D0" xlink:type="arc" />
    <loc xlink:href="gale-20150930.xsd#gale_WarrantsGrantedNumberofShares" xlink:label="loc_gale_WarrantsGrantedNumberofShares_BDCCFC16B566583A870D337F57207073" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_DB58599E319D58FE8EC2AE5638300372" xlink:to="loc_gale_WarrantsGrantedNumberofShares_BDCCFC16B566583A870D337F57207073" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_AA4B42EE198950058C5CBE34B418BBB3" xlink:type="locator" />
    <definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_DB58599E319D58FE8EC2AE5638300372" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_AA4B42EE198950058C5CBE34B418BBB3" xlink:type="arc" />
    <loc xlink:href="gale-20150930.xsd#gale_NumberofDaysAveragedforExercisePrice" xlink:label="loc_gale_NumberofDaysAveragedforExercisePrice_D1523E5DAA86550EB48CCF886BC75938" xlink:type="locator" />
    <definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_DB58599E319D58FE8EC2AE5638300372" xlink:to="loc_gale_NumberofDaysAveragedforExercisePrice_D1523E5DAA86550EB48CCF886BC75938" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueAssumptionsExpectedVolatilityRate" xlink:label="loc_us-gaap_FairValueAssumptionsExpectedVolatilityRate_99DCBEB5321058A4A1357CA5930F7903" xlink:type="locator" />
    <definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_DB58599E319D58FE8EC2AE5638300372" xlink:to="loc_us-gaap_FairValueAssumptionsExpectedVolatilityRate_99DCBEB5321058A4A1357CA5930F7903" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueAssumptionsExpectedTerm" xlink:label="loc_us-gaap_FairValueAssumptionsExpectedTerm_AE830C2FEDA156329D68C0EE91EA3CAB" xlink:type="locator" />
    <definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_DB58599E319D58FE8EC2AE5638300372" xlink:to="loc_us-gaap_FairValueAssumptionsExpectedTerm_AE830C2FEDA156329D68C0EE91EA3CAB" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueAssumptionsRiskFreeInterestRate" xlink:label="loc_us-gaap_FairValueAssumptionsRiskFreeInterestRate_CF12D9A3C76C582E8207B2E5D23E591B" xlink:type="locator" />
    <definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_DB58599E319D58FE8EC2AE5638300372" xlink:to="loc_us-gaap_FairValueAssumptionsRiskFreeInterestRate_CF12D9A3C76C582E8207B2E5D23E591B" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueAssumptionsExpectedDividendRate" xlink:label="loc_us-gaap_FairValueAssumptionsExpectedDividendRate_047D1751A15757EF869FC08BE49E4A23" xlink:type="locator" />
    <definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_DB58599E319D58FE8EC2AE5638300372" xlink:to="loc_us-gaap_FairValueAssumptionsExpectedDividendRate_047D1751A15757EF869FC08BE49E4A23" xlink:type="arc" />
    <loc xlink:href="gale-20150930.xsd#gale_FairValueofWarrantsGrantedperShare" xlink:label="loc_gale_FairValueofWarrantsGrantedperShare_6C4F538BBA435D49A418AB43423C5F9C" xlink:type="locator" />
    <definitionArc order="8" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_DB58599E319D58FE8EC2AE5638300372" xlink:to="loc_gale_FairValueofWarrantsGrantedperShare_6C4F538BBA435D49A418AB43423C5F9C" xlink:type="arc" />
  </definitionLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>11
<FILENAME>gale-20150930_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!--XBRL Document Created with Wdesk from Workiva-->
<!-- -->
<link:linkbase xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" xlink:type="simple" />
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:label id="lab_us-gaap_WarrantsAndRightsNoteDisclosureAbstract_975849BA693F549CBA1DD437A84B7541_label_en-US" xlink:label="lab_us-gaap_WarrantsAndRightsNoteDisclosureAbstract_D4A0992CF7115602A765B8EAFFFA9660" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Warrants and Rights Note Disclosure [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_WarrantsAndRightsNoteDisclosureAbstract" xlink:label="loc_us-gaap_WarrantsAndRightsNoteDisclosureAbstract_D4A0992CF7115602A765B8EAFFFA9660" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WarrantsAndRightsNoteDisclosureAbstract_D4A0992CF7115602A765B8EAFFFA9660" xlink:to="lab_us-gaap_WarrantsAndRightsNoteDisclosureAbstract_D4A0992CF7115602A765B8EAFFFA9660" xlink:type="arc" />
    <link:label id="lab_us-gaap_OptionIndexedToIssuersEquityDescriptionTextBlock_DD01C7B7151EA391BB08D437A84BC6B7_terseLabel_en-US" xlink:label="lab_us-gaap_OptionIndexedToIssuersEquityDescriptionTextBlock_869547BC42365ED38D7F6C0CB21897B3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Warrants</link:label>
    <link:label id="lab_us-gaap_OptionIndexedToIssuersEquityDescriptionTextBlock_DD01C7B7151EA391BB08D437A84BC6B7_label_en-US" xlink:label="lab_us-gaap_OptionIndexedToIssuersEquityDescriptionTextBlock_869547BC42365ED38D7F6C0CB21897B3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Option Indexed to Issuer's Equity, Description [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OptionIndexedToIssuersEquityDescriptionTextBlock" xlink:label="loc_us-gaap_OptionIndexedToIssuersEquityDescriptionTextBlock_869547BC42365ED38D7F6C0CB21897B3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OptionIndexedToIssuersEquityDescriptionTextBlock_869547BC42365ED38D7F6C0CB21897B3" xlink:to="lab_us-gaap_OptionIndexedToIssuersEquityDescriptionTextBlock_869547BC42365ED38D7F6C0CB21897B3" xlink:type="arc" />
    <link:label id="lab_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_9C46BC855C4EABB43937DE2B9C46F48F_label_en-US" xlink:label="lab_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_9C46BC855C4EABB43937DE2B9C46F48F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Discontinued Operations and Disposal Groups [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract" xlink:label="loc_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_9C46BC855C4EABB43937DE2B9C46F48F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_9C46BC855C4EABB43937DE2B9C46F48F" xlink:to="lab_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_9C46BC855C4EABB43937DE2B9C46F48F" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock_2DC4308F867BA3E7591FDE2DC105D75E_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock_2DC4308F867BA3E7591FDE2DC105D75E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Disposal Groups, Including Discontinued Operations, Income Statement, Balance Sheet and Additional Disclosures</link:label>
    <link:label id="lab_us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock_2DC4308F867BA3E7591FDE2DC105D75E_label_en-US" xlink:label="lab_us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock_2DC4308F867BA3E7591FDE2DC105D75E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Disposal Groups, Including Discontinued Operations, Income Statement, Balance Sheet and Additional Disclosures [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock" xlink:label="loc_us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock_2DC4308F867BA3E7591FDE2DC105D75E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock_2DC4308F867BA3E7591FDE2DC105D75E" xlink:to="lab_us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock_2DC4308F867BA3E7591FDE2DC105D75E" xlink:type="arc" />
    <link:label id="lab_us-gaap_BusinessCombinationsAbstract_82A902F47B2876F846B9DDA4F7C4A699_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationsAbstract_82A902F47B2876F846B9DDA4F7C4A699" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combinations [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_BusinessCombinationsAbstract" xlink:label="loc_us-gaap_BusinessCombinationsAbstract_82A902F47B2876F846B9DDA4F7C4A699" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationsAbstract_82A902F47B2876F846B9DDA4F7C4A699" xlink:to="lab_us-gaap_BusinessCombinationsAbstract_82A902F47B2876F846B9DDA4F7C4A699" xlink:type="arc" />
    <link:label id="lab_us-gaap_BusinessCombinationDisclosureTextBlock_9D05AD0BAD83E894DC3EDDA4F7C4A0B2_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationDisclosureTextBlock_9D05AD0BAD83E894DC3EDDA4F7C4A0B2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Business Combinations</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationDisclosureTextBlock_9D05AD0BAD83E894DC3EDDA4F7C4A0B2_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationDisclosureTextBlock_9D05AD0BAD83E894DC3EDDA4F7C4A0B2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination Disclosure [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_BusinessCombinationDisclosureTextBlock" xlink:label="loc_us-gaap_BusinessCombinationDisclosureTextBlock_9D05AD0BAD83E894DC3EDDA4F7C4A0B2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationDisclosureTextBlock_9D05AD0BAD83E894DC3EDDA4F7C4A0B2" xlink:to="lab_us-gaap_BusinessCombinationDisclosureTextBlock_9D05AD0BAD83E894DC3EDDA4F7C4A0B2" xlink:type="arc" />
    <link:label id="lab_us-gaap_DebtDisclosureAbstract_4A12A959034597E05B8ED437A7D02A7F_label_en-US" xlink:label="lab_us-gaap_DebtDisclosureAbstract_BB2D9517DAF057EEA1F856389E0081EE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Disclosure [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="loc_us-gaap_DebtDisclosureAbstract_BB2D9517DAF057EEA1F856389E0081EE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtDisclosureAbstract_BB2D9517DAF057EEA1F856389E0081EE" xlink:to="lab_us-gaap_DebtDisclosureAbstract_BB2D9517DAF057EEA1F856389E0081EE" xlink:type="arc" />
    <link:label id="lab_us-gaap_DebtDisclosureTextBlock_B9F72BF7B750AB5928ACD437A7D0C657_terseLabel_en-US" xlink:label="lab_us-gaap_DebtDisclosureTextBlock_B06B4130CF8C56B789C3A5682B3C1285" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Long-term Debt</link:label>
    <link:label id="lab_us-gaap_DebtDisclosureTextBlock_B9F72BF7B750AB5928ACD437A7D0C657_label_en-US" xlink:label="lab_us-gaap_DebtDisclosureTextBlock_B06B4130CF8C56B789C3A5682B3C1285" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Disclosure [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DebtDisclosureTextBlock" xlink:label="loc_us-gaap_DebtDisclosureTextBlock_B06B4130CF8C56B789C3A5682B3C1285" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtDisclosureTextBlock_B06B4130CF8C56B789C3A5682B3C1285" xlink:to="lab_us-gaap_DebtDisclosureTextBlock_B06B4130CF8C56B789C3A5682B3C1285" xlink:type="arc" />
    <link:label id="lab_us-gaap_EquityAbstract_FA16D521C7FF951ADCE7D437A8A91616_label_en-US" xlink:label="lab_us-gaap_EquityAbstract_9D5A136EDA8D559DB1518DEF68DD28E5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaap_EquityAbstract_9D5A136EDA8D559DB1518DEF68DD28E5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityAbstract_9D5A136EDA8D559DB1518DEF68DD28E5" xlink:to="lab_us-gaap_EquityAbstract_9D5A136EDA8D559DB1518DEF68DD28E5" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_6DFCB6F6DC371FE37789D437A8A932FD_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_F8807505106456C7B2DDC34B8D5D4986" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stockholders' Equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_6DFCB6F6DC371FE37789D437A8A932FD_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_F8807505106456C7B2DDC34B8D5D4986" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stockholders' Equity Note Disclosure [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_F8807505106456C7B2DDC34B8D5D4986" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_F8807505106456C7B2DDC34B8D5D4986" xlink:to="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_F8807505106456C7B2DDC34B8D5D4986" xlink:type="arc" />
    <link:label id="lab_us-gaap_PayablesAndAccrualsAbstract_621E0E258FFE156652C3D437A8800D1B_label_en-US" xlink:label="lab_us-gaap_PayablesAndAccrualsAbstract_6A47FAB1DA10524F8A19FBA902CFFAE3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payables and Accruals [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="loc_us-gaap_PayablesAndAccrualsAbstract_6A47FAB1DA10524F8A19FBA902CFFAE3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_6A47FAB1DA10524F8A19FBA902CFFAE3" xlink:to="lab_us-gaap_PayablesAndAccrualsAbstract_6A47FAB1DA10524F8A19FBA902CFFAE3" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock_E4BB2197AFC60E9737C0D437A8809BBD_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock_1250C83D638D5F8EAF6A9E0A89BF7ECC" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accrued Expenses and Other Current Liabilities</link:label>
    <link:label id="lab_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock_E4BB2197AFC60E9737C0D437A8809BBD_label_en-US" xlink:label="lab_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock_1250C83D638D5F8EAF6A9E0A89BF7ECC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounts Payable, Accrued Liabilities, and Other Liabilities Disclosure, Current [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" xlink:label="loc_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock_1250C83D638D5F8EAF6A9E0A89BF7ECC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock_1250C83D638D5F8EAF6A9E0A89BF7ECC" xlink:to="lab_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock_1250C83D638D5F8EAF6A9E0A89BF7ECC" xlink:type="arc" />
    <link:label id="lab_us-gaap_DebtInstrumentTable_3C7D5ECD4F6692ACEE28D437A7F6E74C_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentTable_E28798D4D44B5AA7AB8AE05E6B2010A6" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Long-term Debt Instruments [Table]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentTable_3C7D5ECD4F6692ACEE28D437A7F6E74C_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentTable_E28798D4D44B5AA7AB8AE05E6B2010A6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Long-term Debt Instruments [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DebtInstrumentTable" xlink:label="loc_us-gaap_DebtInstrumentTable_E28798D4D44B5AA7AB8AE05E6B2010A6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentTable_E28798D4D44B5AA7AB8AE05E6B2010A6" xlink:to="lab_us-gaap_DebtInstrumentTable_E28798D4D44B5AA7AB8AE05E6B2010A6" xlink:type="arc" />
    <link:label id="lab_us-gaap_LongtermDebtTypeAxis_8E62A004E50F3A73BB61D437A7F61F7D_terseLabel_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeAxis_AB783BD086125355A63B91DDBD2DA3C7" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Long-term Debt, Type [Axis]</link:label>
    <link:label id="lab_us-gaap_LongtermDebtTypeAxis_8E62A004E50F3A73BB61D437A7F61F7D_label_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeAxis_AB783BD086125355A63B91DDBD2DA3C7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-term Debt, Type [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_AB783BD086125355A63B91DDBD2DA3C7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_AB783BD086125355A63B91DDBD2DA3C7" xlink:to="lab_us-gaap_LongtermDebtTypeAxis_AB783BD086125355A63B91DDBD2DA3C7" xlink:type="arc" />
    <link:label id="lab_us-gaap_LongtermDebtTypeDomain_7DDD0E60B7A10868F1F4D437A7F6BAE4_terseLabel_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeDomain_22657301DC305B93836C4964DDA68425" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Long-term Debt, Type [Domain]</link:label>
    <link:label id="lab_us-gaap_LongtermDebtTypeDomain_7DDD0E60B7A10868F1F4D437A7F6BAE4_label_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeDomain_22657301DC305B93836C4964DDA68425" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-term Debt, Type [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_22657301DC305B93836C4964DDA68425" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_22657301DC305B93836C4964DDA68425" xlink:to="lab_us-gaap_LongtermDebtTypeDomain_22657301DC305B93836C4964DDA68425" xlink:type="arc" />
    <link:label id="lab_gale_FirstTrancheMember_344BEF29263512FC37ECD437A7F62E6D_terseLabel_en-US" xlink:label="lab_gale_FirstTrancheMember_BC0F7CD64CC750B0BBCFDBCB93898CF8" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">First Tranche [Member]</link:label>
    <link:label id="lab_gale_FirstTrancheMember_344BEF29263512FC37ECD437A7F62E6D_label_en-US" xlink:label="lab_gale_FirstTrancheMember_BC0F7CD64CC750B0BBCFDBCB93898CF8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">First Tranche [Member]</link:label>
    <link:label id="lab_gale_FirstTrancheMember_344BEF29263512FC37ECD437A7F62E6D_documentation_en-US" xlink:label="lab_gale_FirstTrancheMember_BC0F7CD64CC750B0BBCFDBCB93898CF8" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">First Tranche [Member]</link:label>
    <link:loc xlink:href="gale-20150930.xsd#gale_FirstTrancheMember" xlink:label="loc_gale_FirstTrancheMember_BC0F7CD64CC750B0BBCFDBCB93898CF8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_FirstTrancheMember_BC0F7CD64CC750B0BBCFDBCB93898CF8" xlink:to="lab_gale_FirstTrancheMember_BC0F7CD64CC750B0BBCFDBCB93898CF8" xlink:type="arc" />
    <link:label id="lab_us-gaap_RangeAxis_1F37E46B6D06172F51DAD437A7F650FB_terseLabel_en-US" xlink:label="lab_us-gaap_RangeAxis_7D751EE34F08506896FBB610769941FC" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Range [Axis]</link:label>
    <link:label id="lab_us-gaap_RangeAxis_1F37E46B6D06172F51DAD437A7F650FB_label_en-US" xlink:label="lab_us-gaap_RangeAxis_7D751EE34F08506896FBB610769941FC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Range [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RangeAxis" xlink:label="loc_us-gaap_RangeAxis_7D751EE34F08506896FBB610769941FC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RangeAxis_7D751EE34F08506896FBB610769941FC" xlink:to="lab_us-gaap_RangeAxis_7D751EE34F08506896FBB610769941FC" xlink:type="arc" />
    <link:label id="lab_us-gaap_RangeMember_5E688BADBFCC29A91442D437A7F79168_terseLabel_en-US" xlink:label="lab_us-gaap_RangeMember_16CB697124B75C6A9F9C10E1FC8DEA1F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Range [Domain]</link:label>
    <link:label id="lab_us-gaap_RangeMember_5E688BADBFCC29A91442D437A7F79168_label_en-US" xlink:label="lab_us-gaap_RangeMember_16CB697124B75C6A9F9C10E1FC8DEA1F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Range [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaap_RangeMember_16CB697124B75C6A9F9C10E1FC8DEA1F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RangeMember_16CB697124B75C6A9F9C10E1FC8DEA1F" xlink:to="lab_us-gaap_RangeMember_16CB697124B75C6A9F9C10E1FC8DEA1F" xlink:type="arc" />
    <link:label id="lab_us-gaap_MaximumMember_7F935F5FBFEF23849EE2D437A7F7B8D6_terseLabel_en-US" xlink:label="lab_us-gaap_MaximumMember_3509D84954F65169BF5BCC5A0A2A2E5D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Maximum [Member]</link:label>
    <link:label id="lab_us-gaap_MaximumMember_7F935F5FBFEF23849EE2D437A7F7B8D6_label_en-US" xlink:label="lab_us-gaap_MaximumMember_3509D84954F65169BF5BCC5A0A2A2E5D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Maximum [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_MaximumMember" xlink:label="loc_us-gaap_MaximumMember_3509D84954F65169BF5BCC5A0A2A2E5D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MaximumMember_3509D84954F65169BF5BCC5A0A2A2E5D" xlink:to="lab_us-gaap_MaximumMember_3509D84954F65169BF5BCC5A0A2A2E5D" xlink:type="arc" />
    <link:label id="lab_us-gaap_DebtInstrumentLineItems_0D600B759081C0FB34D2D437A7F703C4_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentLineItems_F95425BAA00A5691819F40D1EDD9F667" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Instrument [Line Items]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentLineItems_0D600B759081C0FB34D2D437A7F703C4_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentLineItems_F95425BAA00A5691819F40D1EDD9F667" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="loc_us-gaap_DebtInstrumentLineItems_F95425BAA00A5691819F40D1EDD9F667" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentLineItems_F95425BAA00A5691819F40D1EDD9F667" xlink:to="lab_us-gaap_DebtInstrumentLineItems_F95425BAA00A5691819F40D1EDD9F667" xlink:type="arc" />
    <link:label id="lab_us-gaap_DebtInstrumentCarryingAmount_0156303EA843A34CBF28D437A7F7CAB6_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentCarryingAmount_F3CD4F58522E540987470253C35E6C20" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Loan, amount</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentCarryingAmount_0156303EA843A34CBF28D437A7F7CAB6_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentCarryingAmount_F3CD4F58522E540987470253C35E6C20" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-term Debt, Gross</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DebtInstrumentCarryingAmount" xlink:label="loc_us-gaap_DebtInstrumentCarryingAmount_F3CD4F58522E540987470253C35E6C20" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentCarryingAmount_F3CD4F58522E540987470253C35E6C20" xlink:to="lab_us-gaap_DebtInstrumentCarryingAmount_F3CD4F58522E540987470253C35E6C20" xlink:type="arc" />
    <link:label id="lab_gale_DebtInstrumentTermInterestOnly_D087E374FFFC07E653B6D437A7F79E78_terseLabel_en-US" xlink:label="lab_gale_DebtInstrumentTermInterestOnly_B0C6C2AA9F9955E1BC93F0AC559AC979" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Term for interest only payments</link:label>
    <link:label id="lab_gale_DebtInstrumentTermInterestOnly_D087E374FFFC07E653B6D437A7F79E78_label_en-US" xlink:label="lab_gale_DebtInstrumentTermInterestOnly_B0C6C2AA9F9955E1BC93F0AC559AC979" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Term, Interest Only</link:label>
    <link:label id="lab_gale_DebtInstrumentTermInterestOnly_D087E374FFFC07E653B6D437A7F79E78_documentation_en-US" xlink:label="lab_gale_DebtInstrumentTermInterestOnly_B0C6C2AA9F9955E1BC93F0AC559AC979" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Debt Instrument, Term, Interest Only</link:label>
    <link:loc xlink:href="gale-20150930.xsd#gale_DebtInstrumentTermInterestOnly" xlink:label="loc_gale_DebtInstrumentTermInterestOnly_B0C6C2AA9F9955E1BC93F0AC559AC979" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_DebtInstrumentTermInterestOnly_B0C6C2AA9F9955E1BC93F0AC559AC979" xlink:to="lab_gale_DebtInstrumentTermInterestOnly_B0C6C2AA9F9955E1BC93F0AC559AC979" xlink:type="arc" />
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_93413ADA0246CDAEF4C0D437A7F770EF_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_32FD2D4C122A523EB1C9F619A647E4CB" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Interest payments at the fixed coupon rate</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_93413ADA0246CDAEF4C0D437A7F770EF_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_32FD2D4C122A523EB1C9F619A647E4CB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Interest Rate, Stated Percentage</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_32FD2D4C122A523EB1C9F619A647E4CB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_32FD2D4C122A523EB1C9F619A647E4CB" xlink:to="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_32FD2D4C122A523EB1C9F619A647E4CB" xlink:type="arc" />
    <link:label id="lab_us-gaap_DebtInstrumentTerm_DD611BF32F2D570191D6D437A7F780B2_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentTerm_5C2F43DB556050F8BC578FDCA7E82D89" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Term for principal and interest payments</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentTerm_DD611BF32F2D570191D6D437A7F780B2_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentTerm_5C2F43DB556050F8BC578FDCA7E82D89" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Term</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DebtInstrumentTerm" xlink:label="loc_us-gaap_DebtInstrumentTerm_5C2F43DB556050F8BC578FDCA7E82D89" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentTerm_5C2F43DB556050F8BC578FDCA7E82D89" xlink:to="lab_us-gaap_DebtInstrumentTerm_5C2F43DB556050F8BC578FDCA7E82D89" xlink:type="arc" />
    <link:label id="lab_gale_DebtInstrumentCashFacilityFee_74EADE7D491B0173A25FD437A7F7E396_terseLabel_en-US" xlink:label="lab_gale_DebtInstrumentCashFacilityFee_4E00F91A8D5D50F5BB80FCF67734B2CF" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash facility fee percentage</link:label>
    <link:label id="lab_gale_DebtInstrumentCashFacilityFee_74EADE7D491B0173A25FD437A7F7E396_label_en-US" xlink:label="lab_gale_DebtInstrumentCashFacilityFee_4E00F91A8D5D50F5BB80FCF67734B2CF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Cash Facility Fee</link:label>
    <link:label id="lab_gale_DebtInstrumentCashFacilityFee_74EADE7D491B0173A25FD437A7F7E396_documentation_en-US" xlink:label="lab_gale_DebtInstrumentCashFacilityFee_4E00F91A8D5D50F5BB80FCF67734B2CF" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Debt Instrument, Cash Facility Fee</link:label>
    <link:loc xlink:href="gale-20150930.xsd#gale_DebtInstrumentCashFacilityFee" xlink:label="loc_gale_DebtInstrumentCashFacilityFee_4E00F91A8D5D50F5BB80FCF67734B2CF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_DebtInstrumentCashFacilityFee_4E00F91A8D5D50F5BB80FCF67734B2CF" xlink:to="lab_gale_DebtInstrumentCashFacilityFee_4E00F91A8D5D50F5BB80FCF67734B2CF" xlink:type="arc" />
    <link:label id="lab_gale_DebtInstrumentCashFinalPayment_9C57256B864F37E7FEE3D437A7F7F26A_terseLabel_en-US" xlink:label="lab_gale_DebtInstrumentCashFinalPayment_20BFDB6A4E54528E95205F4AF76ACE4F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash final payment percentage</link:label>
    <link:label id="lab_gale_DebtInstrumentCashFinalPayment_9C57256B864F37E7FEE3D437A7F7F26A_label_en-US" xlink:label="lab_gale_DebtInstrumentCashFinalPayment_20BFDB6A4E54528E95205F4AF76ACE4F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Cash Final Payment</link:label>
    <link:label id="lab_gale_DebtInstrumentCashFinalPayment_9C57256B864F37E7FEE3D437A7F7F26A_documentation_en-US" xlink:label="lab_gale_DebtInstrumentCashFinalPayment_20BFDB6A4E54528E95205F4AF76ACE4F" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Debt Instrument, Cash Final Payment</link:label>
    <link:loc xlink:href="gale-20150930.xsd#gale_DebtInstrumentCashFinalPayment" xlink:label="loc_gale_DebtInstrumentCashFinalPayment_20BFDB6A4E54528E95205F4AF76ACE4F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_DebtInstrumentCashFinalPayment_20BFDB6A4E54528E95205F4AF76ACE4F" xlink:to="lab_gale_DebtInstrumentCashFinalPayment_20BFDB6A4E54528E95205F4AF76ACE4F" xlink:type="arc" />
    <link:label id="lab_gale_ClassofWarrantorRightTerm_A6C9B310D0355EB4AF10D437A7F7FF0A_terseLabel_en-US" xlink:label="lab_gale_ClassofWarrantorRightTerm_B40565F7C1B35180B4F189324DFCE0F0" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Warrant term</link:label>
    <link:label id="lab_gale_ClassofWarrantorRightTerm_A6C9B310D0355EB4AF10D437A7F7FF0A_label_en-US" xlink:label="lab_gale_ClassofWarrantorRightTerm_B40565F7C1B35180B4F189324DFCE0F0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right, Term</link:label>
    <link:label id="lab_gale_ClassofWarrantorRightTerm_A6C9B310D0355EB4AF10D437A7F7FF0A_documentation_en-US" xlink:label="lab_gale_ClassofWarrantorRightTerm_B40565F7C1B35180B4F189324DFCE0F0" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right, Term</link:label>
    <link:loc xlink:href="gale-20150930.xsd#gale_ClassofWarrantorRightTerm" xlink:label="loc_gale_ClassofWarrantorRightTerm_B40565F7C1B35180B4F189324DFCE0F0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_ClassofWarrantorRightTerm_B40565F7C1B35180B4F189324DFCE0F0" xlink:to="lab_gale_ClassofWarrantorRightTerm_B40565F7C1B35180B4F189324DFCE0F0" xlink:type="arc" />
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_B76919DDC8B091500A93D437A7F7C4F0_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_9C1B37C661CA57B8A8944B4B9AD658B7" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of shares availabe from warrants</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_B76919DDC8B091500A93D437A7F7C4F0_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_9C1B37C661CA57B8A8944B4B9AD658B7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right, Number of Securities Called by Warrants or Rights</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_9C1B37C661CA57B8A8944B4B9AD658B7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_9C1B37C661CA57B8A8944B4B9AD658B7" xlink:to="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_9C1B37C661CA57B8A8944B4B9AD658B7" xlink:type="arc" />
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_8267AECCFC44464305F0D437A7F7FFB7_verboseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_66A6153F2F4350BEB2BC8162D273B610" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Exercise price (usd per share)</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_8267AECCFC44464305F0D437A7F7FFB7_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_66A6153F2F4350BEB2BC8162D273B610" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right, Exercise Price of Warrants or Rights</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_66A6153F2F4350BEB2BC8162D273B610" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_66A6153F2F4350BEB2BC8162D273B610" xlink:to="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_66A6153F2F4350BEB2BC8162D273B610" xlink:type="arc" />
    <link:label id="lab_gale_ClassofWarrantorRightAverageMarketPriceUsedForExercisePrice_80802391D1721CCE9B9DD437A7F7460F_terseLabel_en-US" xlink:label="lab_gale_ClassofWarrantorRightAverageMarketPriceUsedForExercisePrice_6AC26DE8E7CC59C297E00274799FDC46" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Duration of average market price used for warrant exercise price</link:label>
    <link:label id="lab_gale_ClassofWarrantorRightAverageMarketPriceUsedForExercisePrice_80802391D1721CCE9B9DD437A7F7460F_label_en-US" xlink:label="lab_gale_ClassofWarrantorRightAverageMarketPriceUsedForExercisePrice_6AC26DE8E7CC59C297E00274799FDC46" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right, Average Market Price Used For Exercise Price</link:label>
    <link:label id="lab_gale_ClassofWarrantorRightAverageMarketPriceUsedForExercisePrice_80802391D1721CCE9B9DD437A7F7460F_documentation_en-US" xlink:label="lab_gale_ClassofWarrantorRightAverageMarketPriceUsedForExercisePrice_6AC26DE8E7CC59C297E00274799FDC46" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right, Average Market Price Used For Exercise Price</link:label>
    <link:loc xlink:href="gale-20150930.xsd#gale_ClassofWarrantorRightAverageMarketPriceUsedForExercisePrice" xlink:label="loc_gale_ClassofWarrantorRightAverageMarketPriceUsedForExercisePrice_6AC26DE8E7CC59C297E00274799FDC46" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_ClassofWarrantorRightAverageMarketPriceUsedForExercisePrice_6AC26DE8E7CC59C297E00274799FDC46" xlink:to="lab_gale_ClassofWarrantorRightAverageMarketPriceUsedForExercisePrice_6AC26DE8E7CC59C297E00274799FDC46" xlink:type="arc" />
    <link:label id="lab_us-gaap_EarningsPerShareAbstract_C0710CDC6629A30F2620D437A7DE6990_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareAbstract_ACFCAE677C105C409F5F46F115B8769A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings Per Share [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="loc_us-gaap_EarningsPerShareAbstract_ACFCAE677C105C409F5F46F115B8769A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareAbstract_ACFCAE677C105C409F5F46F115B8769A" xlink:to="lab_us-gaap_EarningsPerShareAbstract_ACFCAE677C105C409F5F46F115B8769A" xlink:type="arc" />
    <link:label id="lab_us-gaap_EarningsPerShareTextBlock_66A4135E89F0B058EED1D437A7DE1BE1_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareTextBlock_FB60AD35A804511DB77C64EF5E36900A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net Loss Per Share</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareTextBlock_66A4135E89F0B058EED1D437A7DE1BE1_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareTextBlock_FB60AD35A804511DB77C64EF5E36900A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings Per Share [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EarningsPerShareTextBlock" xlink:label="loc_us-gaap_EarningsPerShareTextBlock_FB60AD35A804511DB77C64EF5E36900A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareTextBlock_FB60AD35A804511DB77C64EF5E36900A" xlink:to="lab_us-gaap_EarningsPerShareTextBlock_FB60AD35A804511DB77C64EF5E36900A" xlink:type="arc" />
    <link:label id="lab_us-gaap_RisksAndUncertaintiesAbstract_78C74653EE809D2E3442DDA4F6B770DE_label_en-US" xlink:label="lab_us-gaap_RisksAndUncertaintiesAbstract_78C74653EE809D2E3442DDA4F6B770DE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Risks and Uncertainties [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RisksAndUncertaintiesAbstract" xlink:label="loc_us-gaap_RisksAndUncertaintiesAbstract_78C74653EE809D2E3442DDA4F6B770DE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RisksAndUncertaintiesAbstract_78C74653EE809D2E3442DDA4F6B770DE" xlink:to="lab_us-gaap_RisksAndUncertaintiesAbstract_78C74653EE809D2E3442DDA4F6B770DE" xlink:type="arc" />
    <link:label id="lab_us-gaap_ConcentrationRiskDisclosureTextBlock_604D6D9CC6A908578692DDA4F6B70152_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskDisclosureTextBlock_604D6D9CC6A908578692DDA4F6B70152" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Significant Customer and Concentration of Credit Risk</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskDisclosureTextBlock_604D6D9CC6A908578692DDA4F6B70152_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskDisclosureTextBlock_604D6D9CC6A908578692DDA4F6B70152" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Concentration Risk Disclosure [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ConcentrationRiskDisclosureTextBlock" xlink:label="loc_us-gaap_ConcentrationRiskDisclosureTextBlock_604D6D9CC6A908578692DDA4F6B70152" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskDisclosureTextBlock_604D6D9CC6A908578692DDA4F6B70152" xlink:to="lab_us-gaap_ConcentrationRiskDisclosureTextBlock_604D6D9CC6A908578692DDA4F6B70152" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfStockByClassTable_EFDF607BC7BBEA58F366FE43427E9A0A_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfStockByClassTable_296A971608965B448E6974FA1BBF315C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Stock by Class [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfStockByClassTable_EFDF607BC7BBEA58F366FE43427E9A0A_label_en-US" xlink:label="lab_us-gaap_ScheduleOfStockByClassTable_296A971608965B448E6974FA1BBF315C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Stock by Class [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_296A971608965B448E6974FA1BBF315C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_296A971608965B448E6974FA1BBF315C" xlink:to="lab_us-gaap_ScheduleOfStockByClassTable_296A971608965B448E6974FA1BBF315C" xlink:type="arc" />
    <link:label id="lab_dei_LegalEntityAxis_D9D6108FCBA2B4E1E997FE43427E346F_terseLabel_en-US" xlink:label="lab_dei_LegalEntityAxis_0D57436B5EF7593BB7C99DD5807C8E0D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Legal Entity [Axis]</link:label>
    <link:label id="lab_dei_LegalEntityAxis_D9D6108FCBA2B4E1E997FE43427E346F_label_en-US" xlink:label="lab_dei_LegalEntityAxis_0D57436B5EF7593BB7C99DD5807C8E0D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Legal Entity [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_0D57436B5EF7593BB7C99DD5807C8E0D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LegalEntityAxis_0D57436B5EF7593BB7C99DD5807C8E0D" xlink:to="lab_dei_LegalEntityAxis_0D57436B5EF7593BB7C99DD5807C8E0D" xlink:type="arc" />
    <link:label id="lab_dei_EntityDomain_565CD3F6E001F7376BEBFE43427E28C8_terseLabel_en-US" xlink:label="lab_dei_EntityDomain_6ED96AA52B205D28BE8F0FC0B04FE6D9" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity [Domain]</link:label>
    <link:label id="lab_dei_EntityDomain_565CD3F6E001F7376BEBFE43427E28C8_label_en-US" xlink:label="lab_dei_EntityDomain_6ED96AA52B205D28BE8F0FC0B04FE6D9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_6ED96AA52B205D28BE8F0FC0B04FE6D9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityDomain_6ED96AA52B205D28BE8F0FC0B04FE6D9" xlink:to="lab_dei_EntityDomain_6ED96AA52B205D28BE8F0FC0B04FE6D9" xlink:type="arc" />
    <link:label id="lab_gale_LincolnParkCapitalLLCMember_1728A5C3981DBA376340FE43427E51CD_terseLabel_en-US" xlink:label="lab_gale_LincolnParkCapitalLLCMember_E7FE8EA1C6E65581958491F205454870" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Lincoln Park Capital, LLC [Member]</link:label>
    <link:label id="lab_gale_LincolnParkCapitalLLCMember_1728A5C3981DBA376340FE43427E51CD_label_en-US" xlink:label="lab_gale_LincolnParkCapitalLLCMember_E7FE8EA1C6E65581958491F205454870" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lincoln Park Capital, LLC [Member]</link:label>
    <link:label id="lab_gale_LincolnParkCapitalLLCMember_1728A5C3981DBA376340FE43427E51CD_documentation_en-US" xlink:label="lab_gale_LincolnParkCapitalLLCMember_E7FE8EA1C6E65581958491F205454870" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Lincoln Park Capital, LLC [Member]</link:label>
    <link:loc xlink:href="gale-20150930.xsd#gale_LincolnParkCapitalLLCMember" xlink:label="loc_gale_LincolnParkCapitalLLCMember_E7FE8EA1C6E65581958491F205454870" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_LincolnParkCapitalLLCMember_E7FE8EA1C6E65581958491F205454870" xlink:to="lab_gale_LincolnParkCapitalLLCMember_E7FE8EA1C6E65581958491F205454870" xlink:type="arc" />
    <link:label id="lab_gale_MLVCo.LLCandMaximGroupLLCMember_40A9216BF4C93C416B1CFE43427E4268_terseLabel_en-US" xlink:label="lab_gale_MLVCo.LLCandMaximGroupLLCMember_186D461599F2534FAAFABDB19D8F8875" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">MLV &amp; Co. LLC and Maxim Group LLC [Member]</link:label>
    <link:label id="lab_gale_MLVCo.LLCandMaximGroupLLCMember_40A9216BF4C93C416B1CFE43427E4268_label_en-US" xlink:label="lab_gale_MLVCo.LLCandMaximGroupLLCMember_186D461599F2534FAAFABDB19D8F8875" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">MLV &amp; Co. LLC and Maxim Group LLC [Member]</link:label>
    <link:label id="lab_gale_MLVCo.LLCandMaximGroupLLCMember_40A9216BF4C93C416B1CFE43427E4268_documentation_en-US" xlink:label="lab_gale_MLVCo.LLCandMaximGroupLLCMember_186D461599F2534FAAFABDB19D8F8875" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">MLV &amp; Co. LLC and Maxim Group LLC [Member]</link:label>
    <link:loc xlink:href="gale-20150930.xsd#gale_MLVCo.LLCandMaximGroupLLCMember" xlink:label="loc_gale_MLVCo.LLCandMaximGroupLLCMember_186D461599F2534FAAFABDB19D8F8875" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_MLVCo.LLCandMaximGroupLLCMember_186D461599F2534FAAFABDB19D8F8875" xlink:to="lab_gale_MLVCo.LLCandMaximGroupLLCMember_186D461599F2534FAAFABDB19D8F8875" xlink:type="arc" />
    <link:label id="lab_us-gaap_StatementClassOfStockAxis_F9E7C0C8518DD44E2E77FE43427E2179_terseLabel_en-US" xlink:label="lab_us-gaap_StatementClassOfStockAxis_5946413637FA5BA28FA53AC691FF1979" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Class of Stock [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementClassOfStockAxis_F9E7C0C8518DD44E2E77FE43427E2179_label_en-US" xlink:label="lab_us-gaap_StatementClassOfStockAxis_5946413637FA5BA28FA53AC691FF1979" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Stock [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_5946413637FA5BA28FA53AC691FF1979" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementClassOfStockAxis_5946413637FA5BA28FA53AC691FF1979" xlink:to="lab_us-gaap_StatementClassOfStockAxis_5946413637FA5BA28FA53AC691FF1979" xlink:type="arc" />
    <link:label id="lab_us-gaap_ClassOfStockDomain_736E82FEDC64B671B42CFE43427EFB83_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfStockDomain_4FAC2440DF065BEE8FA26503F59838FB" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Class of Stock [Domain]</link:label>
    <link:label id="lab_us-gaap_ClassOfStockDomain_736E82FEDC64B671B42CFE43427EFB83_label_en-US" xlink:label="lab_us-gaap_ClassOfStockDomain_4FAC2440DF065BEE8FA26503F59838FB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Stock [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_4FAC2440DF065BEE8FA26503F59838FB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfStockDomain_4FAC2440DF065BEE8FA26503F59838FB" xlink:to="lab_us-gaap_ClassOfStockDomain_4FAC2440DF065BEE8FA26503F59838FB" xlink:type="arc" />
    <link:label id="lab_us-gaap_CommonStockMember_D3EFBAB58A62B30D7352FE43427E01A1_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockMember_D58E23A7938E5EEC90DE63D31C5C4E93" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common Stock [Member]</link:label>
    <link:label id="lab_us-gaap_CommonStockMember_D3EFBAB58A62B30D7352FE43427E01A1_label_en-US" xlink:label="lab_us-gaap_CommonStockMember_D58E23A7938E5EEC90DE63D31C5C4E93" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember_D58E23A7938E5EEC90DE63D31C5C4E93" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockMember_D58E23A7938E5EEC90DE63D31C5C4E93" xlink:to="lab_us-gaap_CommonStockMember_D58E23A7938E5EEC90DE63D31C5C4E93" xlink:type="arc" />
    <link:label id="lab_us-gaap_WarrantMember_D037335C9BCA1FD4C110FE43427E22D5_terseLabel_en-US" xlink:label="lab_us-gaap_WarrantMember_45A8948C830E5CE2870BDC2CA9DC48C5" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Warrants to purchase common stock [Member]</link:label>
    <link:label id="lab_us-gaap_WarrantMember_D037335C9BCA1FD4C110FE43427E22D5_label_en-US" xlink:label="lab_us-gaap_WarrantMember_45A8948C830E5CE2870BDC2CA9DC48C5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Warrant [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaap_WarrantMember_45A8948C830E5CE2870BDC2CA9DC48C5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WarrantMember_45A8948C830E5CE2870BDC2CA9DC48C5" xlink:to="lab_us-gaap_WarrantMember_45A8948C830E5CE2870BDC2CA9DC48C5" xlink:type="arc" />
    <link:label id="lab_us-gaap_ClassOfStockLineItems_87EF746C8B346D0FBB7DFE43427ECEB5_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfStockLineItems_D44EDB4BDB5C56C78BAFB8E7AF60F739" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Class of Stock [Line Items]</link:label>
    <link:label id="lab_us-gaap_ClassOfStockLineItems_87EF746C8B346D0FBB7DFE43427ECEB5_label_en-US" xlink:label="lab_us-gaap_ClassOfStockLineItems_D44EDB4BDB5C56C78BAFB8E7AF60F739" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Stock [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ClassOfStockLineItems" xlink:label="loc_us-gaap_ClassOfStockLineItems_D44EDB4BDB5C56C78BAFB8E7AF60F739" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfStockLineItems_D44EDB4BDB5C56C78BAFB8E7AF60F739" xlink:to="lab_us-gaap_ClassOfStockLineItems_D44EDB4BDB5C56C78BAFB8E7AF60F739" xlink:type="arc" />
    <link:label id="lab_us-gaap_PreferredStockSharesAuthorized_584662C57827E421254DFE43427E7F42_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized_152EE2A8DEB054D1A001C2488E3FA05B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Preferred stock, shares authorized</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesAuthorized_584662C57827E421254DFE43427E7F42_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized_152EE2A8DEB054D1A001C2488E3FA05B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred Stock, Shares Authorized</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_152EE2A8DEB054D1A001C2488E3FA05B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesAuthorized_152EE2A8DEB054D1A001C2488E3FA05B" xlink:to="lab_us-gaap_PreferredStockSharesAuthorized_152EE2A8DEB054D1A001C2488E3FA05B" xlink:type="arc" />
    <link:label id="lab_us-gaap_PreferredStockParOrStatedValuePerShare_8E7138333CA594AA85D3FE43427FD092_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare_97DF3539700558108AE5C1067B01937E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Preferred stock, par value (usd per share)</link:label>
    <link:label id="lab_us-gaap_PreferredStockParOrStatedValuePerShare_8E7138333CA594AA85D3FE43427FD092_label_en-US" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare_97DF3539700558108AE5C1067B01937E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_97DF3539700558108AE5C1067B01937E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockParOrStatedValuePerShare_97DF3539700558108AE5C1067B01937E" xlink:to="lab_us-gaap_PreferredStockParOrStatedValuePerShare_97DF3539700558108AE5C1067B01937E" xlink:type="arc" />
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_B07011C96386E25EAF54FE43427F4E56_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized_860C5EF2C76257A4BC077D779616D6A6" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock, shares authorized</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_B07011C96386E25EAF54FE43427F4E56_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized_860C5EF2C76257A4BC077D779616D6A6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Shares Authorized</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_860C5EF2C76257A4BC077D779616D6A6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesAuthorized_860C5EF2C76257A4BC077D779616D6A6" xlink:to="lab_us-gaap_CommonStockSharesAuthorized_860C5EF2C76257A4BC077D779616D6A6" xlink:type="arc" />
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_D7F6014F65214D748614FE43427FB9AE_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare_47E96CB05444557A8688836F7E09458C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock, par value (usd per share)</link:label>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_D7F6014F65214D748614FE43427FB9AE_label_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare_47E96CB05444557A8688836F7E09458C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_47E96CB05444557A8688836F7E09458C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockParOrStatedValuePerShare_47E96CB05444557A8688836F7E09458C" xlink:to="lab_us-gaap_CommonStockParOrStatedValuePerShare_47E96CB05444557A8688836F7E09458C" xlink:type="arc" />
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOrSaleOfEquity_0BA25A562550FF6405BEFE43427FB0A5_verboseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOrSaleOfEquity_EAE1DE5F61245A839B7E586A7EC1C4F1" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from Issuance or Sale of Equity</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOrSaleOfEquity_0BA25A562550FF6405BEFE43427FB0A5_label_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOrSaleOfEquity_EAE1DE5F61245A839B7E586A7EC1C4F1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from Issuance or Sale of Equity</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:label="loc_us-gaap_ProceedsFromIssuanceOrSaleOfEquity_EAE1DE5F61245A839B7E586A7EC1C4F1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOrSaleOfEquity_EAE1DE5F61245A839B7E586A7EC1C4F1" xlink:to="lab_us-gaap_ProceedsFromIssuanceOrSaleOfEquity_EAE1DE5F61245A839B7E586A7EC1C4F1" xlink:type="arc" />
    <link:label id="lab_gale_PurchaseAgreementTerm_6C6A97330F9737F296A3FE43427F2F65_terseLabel_en-US" xlink:label="lab_gale_PurchaseAgreementTerm_B98B7B075BFB51539FA090FD26B9A240" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Purchase Agreement Term</link:label>
    <link:label id="lab_gale_PurchaseAgreementTerm_6C6A97330F9737F296A3FE43427F2F65_label_en-US" xlink:label="lab_gale_PurchaseAgreementTerm_B98B7B075BFB51539FA090FD26B9A240" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Purchase Agreement Term</link:label>
    <link:label id="lab_gale_PurchaseAgreementTerm_6C6A97330F9737F296A3FE43427F2F65_documentation_en-US" xlink:label="lab_gale_PurchaseAgreementTerm_B98B7B075BFB51539FA090FD26B9A240" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Purchase Agreement Term</link:label>
    <link:loc xlink:href="gale-20150930.xsd#gale_PurchaseAgreementTerm" xlink:label="loc_gale_PurchaseAgreementTerm_B98B7B075BFB51539FA090FD26B9A240" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_PurchaseAgreementTerm_B98B7B075BFB51539FA090FD26B9A240" xlink:to="lab_gale_PurchaseAgreementTerm_B98B7B075BFB51539FA090FD26B9A240" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets_30EBAE1575F34EA5209BFE43427F99D1_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets_5084DDF9E0AD5ACB8697847F3085F3E3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Shares, Purchase of Assets</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets_30EBAE1575F34EA5209BFE43427F99D1_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets_5084DDF9E0AD5ACB8697847F3085F3E3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Shares, Purchase of Assets</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets_5084DDF9E0AD5ACB8697847F3085F3E3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets_5084DDF9E0AD5ACB8697847F3085F3E3" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets_5084DDF9E0AD5ACB8697847F3085F3E3" xlink:type="arc" />
    <link:label id="lab_us-gaap_SharePrice_5B2F29C921DE81A57454FE43427F3423_terseLabel_en-US" xlink:label="lab_us-gaap_SharePrice_4FC045C1EAAD5BF0A68070982CE11241" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share Price</link:label>
    <link:label id="lab_us-gaap_SharePrice_5B2F29C921DE81A57454FE43427F3423_label_en-US" xlink:label="lab_us-gaap_SharePrice_4FC045C1EAAD5BF0A68070982CE11241" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share Price</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SharePrice" xlink:label="loc_us-gaap_SharePrice_4FC045C1EAAD5BF0A68070982CE11241" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharePrice_4FC045C1EAAD5BF0A68070982CE11241" xlink:to="lab_us-gaap_SharePrice_4FC045C1EAAD5BF0A68070982CE11241" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_B123B2FAEF5218EAD460FE43427FB4D1_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_415EBD02E2BF540FAAB2FDEB230D74BE" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Issuance of common stock, shares</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_B123B2FAEF5218EAD460FE43427FB4D1_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_415EBD02E2BF540FAAB2FDEB230D74BE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Shares, New Issues</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_415EBD02E2BF540FAAB2FDEB230D74BE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_415EBD02E2BF540FAAB2FDEB230D74BE" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_415EBD02E2BF540FAAB2FDEB230D74BE" xlink:type="arc" />
    <link:label id="lab_gale_AtMarketIssuanceSalesAgreementsPercentofGrossProceeds_D8E9FDD675F9AFF6C0AEFE43427F44F4_terseLabel_en-US" xlink:label="lab_gale_AtMarketIssuanceSalesAgreementsPercentofGrossProceeds_250BC34514A058C7884EA78A38AA0EB5" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">At Market Issuance Sales Agreements, Percent of Gross Proceeds</link:label>
    <link:label id="lab_gale_AtMarketIssuanceSalesAgreementsPercentofGrossProceeds_D8E9FDD675F9AFF6C0AEFE43427F44F4_label_en-US" xlink:label="lab_gale_AtMarketIssuanceSalesAgreementsPercentofGrossProceeds_250BC34514A058C7884EA78A38AA0EB5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">At Market Issuance Sales Agreements, Percent of Gross Proceeds</link:label>
    <link:label id="lab_gale_AtMarketIssuanceSalesAgreementsPercentofGrossProceeds_D8E9FDD675F9AFF6C0AEFE43427F44F4_documentation_en-US" xlink:label="lab_gale_AtMarketIssuanceSalesAgreementsPercentofGrossProceeds_250BC34514A058C7884EA78A38AA0EB5" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">At Market Issuance Sales Agreements, Percent of Gross Proceeds</link:label>
    <link:loc xlink:href="gale-20150930.xsd#gale_AtMarketIssuanceSalesAgreementsPercentofGrossProceeds" xlink:label="loc_gale_AtMarketIssuanceSalesAgreementsPercentofGrossProceeds_250BC34514A058C7884EA78A38AA0EB5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_AtMarketIssuanceSalesAgreementsPercentofGrossProceeds_250BC34514A058C7884EA78A38AA0EB5" xlink:to="lab_gale_AtMarketIssuanceSalesAgreementsPercentofGrossProceeds_250BC34514A058C7884EA78A38AA0EB5" xlink:type="arc" />
    <link:label id="lab_gale_AtMarketIssuanceSalesAgreementsMaximumGrossProceeds_F3F585B8BB48E41A204BFE43427F5D99_terseLabel_en-US" xlink:label="lab_gale_AtMarketIssuanceSalesAgreementsMaximumGrossProceeds_124033EFCB3F5D289F6A6BAB4CFC7F7C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">At Market Issuance Sales Agreements, Maximum Gross Proceeds</link:label>
    <link:label id="lab_gale_AtMarketIssuanceSalesAgreementsMaximumGrossProceeds_F3F585B8BB48E41A204BFE43427F5D99_label_en-US" xlink:label="lab_gale_AtMarketIssuanceSalesAgreementsMaximumGrossProceeds_124033EFCB3F5D289F6A6BAB4CFC7F7C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">At Market Issuance Sales Agreements, Maximum Gross Proceeds</link:label>
    <link:label id="lab_gale_AtMarketIssuanceSalesAgreementsMaximumGrossProceeds_F3F585B8BB48E41A204BFE43427F5D99_documentation_en-US" xlink:label="lab_gale_AtMarketIssuanceSalesAgreementsMaximumGrossProceeds_124033EFCB3F5D289F6A6BAB4CFC7F7C" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">At Market Issuance Sales Agreements, Maximum Gross Proceeds</link:label>
    <link:loc xlink:href="gale-20150930.xsd#gale_AtMarketIssuanceSalesAgreementsMaximumGrossProceeds" xlink:label="loc_gale_AtMarketIssuanceSalesAgreementsMaximumGrossProceeds_124033EFCB3F5D289F6A6BAB4CFC7F7C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_AtMarketIssuanceSalesAgreementsMaximumGrossProceeds_124033EFCB3F5D289F6A6BAB4CFC7F7C" xlink:to="lab_gale_AtMarketIssuanceSalesAgreementsMaximumGrossProceeds_124033EFCB3F5D289F6A6BAB4CFC7F7C" xlink:type="arc" />
    <link:label id="lab_gale_NumberofSharesPerUnit_3A2879CA1992AC099432FE43427FB3E2_terseLabel_en-US" xlink:label="lab_gale_NumberofSharesPerUnit_D5E01A04C9135579881492BB50250F82" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of Shares Per Unit</link:label>
    <link:label id="lab_gale_NumberofSharesPerUnit_3A2879CA1992AC099432FE43427FB3E2_label_en-US" xlink:label="lab_gale_NumberofSharesPerUnit_D5E01A04C9135579881492BB50250F82" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number of Shares Per Unit</link:label>
    <link:label id="lab_gale_NumberofSharesPerUnit_3A2879CA1992AC099432FE43427FB3E2_documentation_en-US" xlink:label="lab_gale_NumberofSharesPerUnit_D5E01A04C9135579881492BB50250F82" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Number of Shares Per Unit</link:label>
    <link:loc xlink:href="gale-20150930.xsd#gale_NumberofSharesPerUnit" xlink:label="loc_gale_NumberofSharesPerUnit_D5E01A04C9135579881492BB50250F82" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_NumberofSharesPerUnit_D5E01A04C9135579881492BB50250F82" xlink:to="lab_gale_NumberofSharesPerUnit_D5E01A04C9135579881492BB50250F82" xlink:type="arc" />
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_71C756F5DDA65BE21C9AFE43427F572F_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_72947B2F9CF25E719769969DED859FEF" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right, Exercise Price of Warrants or Rights</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_72947B2F9CF25E719769969DED859FEF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_72947B2F9CF25E719769969DED859FEF" xlink:to="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_72947B2F9CF25E719769969DED859FEF" xlink:type="arc" />
    <link:label id="lab_gale_StockIssuedDuringPeriodSharesOverallotmentOption_C532A919FFA015EA5B66FE43427FDBD6_terseLabel_en-US" xlink:label="lab_gale_StockIssuedDuringPeriodSharesOverallotmentOption_7C658606B8B25E99AED0727C7AFB317E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Shares, Overallotment Option</link:label>
    <link:label id="lab_gale_StockIssuedDuringPeriodSharesOverallotmentOption_C532A919FFA015EA5B66FE43427FDBD6_label_en-US" xlink:label="lab_gale_StockIssuedDuringPeriodSharesOverallotmentOption_7C658606B8B25E99AED0727C7AFB317E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Shares, Overallotment Option</link:label>
    <link:label id="lab_gale_StockIssuedDuringPeriodSharesOverallotmentOption_C532A919FFA015EA5B66FE43427FDBD6_documentation_en-US" xlink:label="lab_gale_StockIssuedDuringPeriodSharesOverallotmentOption_7C658606B8B25E99AED0727C7AFB317E" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Shares, Overallotment Option</link:label>
    <link:loc xlink:href="gale-20150930.xsd#gale_StockIssuedDuringPeriodSharesOverallotmentOption" xlink:label="loc_gale_StockIssuedDuringPeriodSharesOverallotmentOption_7C658606B8B25E99AED0727C7AFB317E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_StockIssuedDuringPeriodSharesOverallotmentOption_7C658606B8B25E99AED0727C7AFB317E" xlink:to="lab_gale_StockIssuedDuringPeriodSharesOverallotmentOption_7C658606B8B25E99AED0727C7AFB317E" xlink:type="arc" />
    <link:label id="lab_gale_ProceedsFromIssuanceorSaleofEquityNetUnderwritingDiscountsCommissionsandOfferingExpenses_DCA08018F366F445267AFE434280861F_terseLabel_en-US" xlink:label="lab_gale_ProceedsFromIssuanceorSaleofEquityNetUnderwritingDiscountsCommissionsandOfferingExpenses_3B1AD7F42360559380EFA1BCE1026A36" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds From Issuance or Sale of Equity, Net Underwriting Discounts, Commissions and Offering Expenses</link:label>
    <link:label id="lab_gale_ProceedsFromIssuanceorSaleofEquityNetUnderwritingDiscountsCommissionsandOfferingExpenses_DCA08018F366F445267AFE434280861F_label_en-US" xlink:label="lab_gale_ProceedsFromIssuanceorSaleofEquityNetUnderwritingDiscountsCommissionsandOfferingExpenses_3B1AD7F42360559380EFA1BCE1026A36" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds From Issuance or Sale of Equity, Net Underwriting Discounts, Commissions and Offering Expenses</link:label>
    <link:label id="lab_gale_ProceedsFromIssuanceorSaleofEquityNetUnderwritingDiscountsCommissionsandOfferingExpenses_DCA08018F366F445267AFE434280861F_documentation_en-US" xlink:label="lab_gale_ProceedsFromIssuanceorSaleofEquityNetUnderwritingDiscountsCommissionsandOfferingExpenses_3B1AD7F42360559380EFA1BCE1026A36" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Proceeds From Issuance or Sale of Equity, Net Underwriting Discounts, Commissions and Offering Expenses</link:label>
    <link:loc xlink:href="gale-20150930.xsd#gale_ProceedsFromIssuanceorSaleofEquityNetUnderwritingDiscountsCommissionsandOfferingExpenses" xlink:label="loc_gale_ProceedsFromIssuanceorSaleofEquityNetUnderwritingDiscountsCommissionsandOfferingExpenses_3B1AD7F42360559380EFA1BCE1026A36" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_ProceedsFromIssuanceorSaleofEquityNetUnderwritingDiscountsCommissionsandOfferingExpenses_3B1AD7F42360559380EFA1BCE1026A36" xlink:to="lab_gale_ProceedsFromIssuanceorSaleofEquityNetUnderwritingDiscountsCommissionsandOfferingExpenses_3B1AD7F42360559380EFA1BCE1026A36" xlink:type="arc" />
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_B618A651F1C6B444336BDE2E96DF3E90_label_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract_B618A651F1C6B444336BDE2E96DF3E90" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_B618A651F1C6B444336BDE2E96DF3E90" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_B618A651F1C6B444336BDE2E96DF3E90" xlink:to="lab_us-gaap_StatementOfFinancialPositionAbstract_B618A651F1C6B444336BDE2E96DF3E90" xlink:type="arc" />
    <link:label id="lab_us-gaap_AssetsAbstract_E6385B952618B104D879DE2E96DF6791_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsAbstract_E6385B952618B104D879DE2E96DF6791" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">ASSETS</link:label>
    <link:label id="lab_us-gaap_AssetsAbstract_E6385B952618B104D879DE2E96DF6791_label_en-US" xlink:label="lab_us-gaap_AssetsAbstract_E6385B952618B104D879DE2E96DF6791" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AssetsAbstract" xlink:label="loc_us-gaap_AssetsAbstract_E6385B952618B104D879DE2E96DF6791" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsAbstract_E6385B952618B104D879DE2E96DF6791" xlink:to="lab_us-gaap_AssetsAbstract_E6385B952618B104D879DE2E96DF6791" xlink:type="arc" />
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_03731BC327C70B8BFC31DE2E96DF7695_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract_03731BC327C70B8BFC31DE2E96DF7695" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Current assets:</link:label>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_03731BC327C70B8BFC31DE2E96DF7695_label_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract_03731BC327C70B8BFC31DE2E96DF7695" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets, Current [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="loc_us-gaap_AssetsCurrentAbstract_03731BC327C70B8BFC31DE2E96DF7695" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrentAbstract_03731BC327C70B8BFC31DE2E96DF7695" xlink:to="lab_us-gaap_AssetsCurrentAbstract_03731BC327C70B8BFC31DE2E96DF7695" xlink:type="arc" />
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_C79807E0A720064525ADDE2E96DF07D5_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_C79807E0A720064525ADDE2E96DF07D5" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_C79807E0A720064525ADDE2E96DF07D5_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_C79807E0A720064525ADDE2E96DF07D5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash and Cash Equivalents, at Carrying Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_C79807E0A720064525ADDE2E96DF07D5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_C79807E0A720064525ADDE2E96DF07D5" xlink:to="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_C79807E0A720064525ADDE2E96DF07D5" xlink:type="arc" />
    <link:label id="lab_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue_A568757A89F9C62DCEBBDE2E96DFFE5B_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue_A568757A89F9C62DCEBBDE2E96DFFE5B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restricted cash</link:label>
    <link:label id="lab_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue_A568757A89F9C62DCEBBDE2E96DFFE5B_label_en-US" xlink:label="lab_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue_A568757A89F9C62DCEBBDE2E96DFFE5B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restricted Cash and Cash Equivalents, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue_A568757A89F9C62DCEBBDE2E96DFFE5B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue_A568757A89F9C62DCEBBDE2E96DFFE5B" xlink:to="lab_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue_A568757A89F9C62DCEBBDE2E96DFFE5B" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrent_A384CE9D094FB444A524DE2E96E074A7_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent_A384CE9D094FB444A524DE2E96E074A7" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accounts receivable, net</link:label>
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrent_A384CE9D094FB444A524DE2E96E074A7_label_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent_A384CE9D094FB444A524DE2E96E074A7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounts Receivable, Net, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_A384CE9D094FB444A524DE2E96E074A7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsReceivableNetCurrent_A384CE9D094FB444A524DE2E96E074A7" xlink:to="lab_us-gaap_AccountsReceivableNetCurrent_A384CE9D094FB444A524DE2E96E074A7" xlink:type="arc" />
    <link:label id="lab_us-gaap_InventoryNet_F066F4593A58D13E0F15DE2E96E00514_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryNet_F066F4593A58D13E0F15DE2E96E00514" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Inventories</link:label>
    <link:label id="lab_us-gaap_InventoryNet_F066F4593A58D13E0F15DE2E96E00514_label_en-US" xlink:label="lab_us-gaap_InventoryNet_F066F4593A58D13E0F15DE2E96E00514" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Inventory, Net</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_InventoryNet" xlink:label="loc_us-gaap_InventoryNet_F066F4593A58D13E0F15DE2E96E00514" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryNet_F066F4593A58D13E0F15DE2E96E00514" xlink:to="lab_us-gaap_InventoryNet_F066F4593A58D13E0F15DE2E96E00514" xlink:type="arc" />
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_964BE8F671CC1B2DF0B0DE2E96E07206_terseLabel_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_964BE8F671CC1B2DF0B0DE2E96E07206" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Prepaid expenses and other current assets</link:label>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_964BE8F671CC1B2DF0B0DE2E96E07206_label_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_964BE8F671CC1B2DF0B0DE2E96E07206" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Prepaid Expense and Other Assets, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_964BE8F671CC1B2DF0B0DE2E96E07206" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_964BE8F671CC1B2DF0B0DE2E96E07206" xlink:to="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_964BE8F671CC1B2DF0B0DE2E96E07206" xlink:type="arc" />
    <link:label id="lab_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent_0AB1C73ADCC7CBF1A2C0DE7039B5AF00_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent_0AB1C73ADCC7CBF1A2C0DE7039B5AF00" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Current assets held for sale, net</link:label>
    <link:label id="lab_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent_0AB1C73ADCC7CBF1A2C0DE7039B5AF00_label_en-US" xlink:label="lab_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent_0AB1C73ADCC7CBF1A2C0DE7039B5AF00" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Assets, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent" xlink:label="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent_0AB1C73ADCC7CBF1A2C0DE7039B5AF00" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent_0AB1C73ADCC7CBF1A2C0DE7039B5AF00" xlink:to="lab_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent_0AB1C73ADCC7CBF1A2C0DE7039B5AF00" xlink:type="arc" />
    <link:label id="lab_us-gaap_AssetsCurrent_81C7131D3F76CF4712D7DE2E96E01E50_totalLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrent_81C7131D3F76CF4712D7DE2E96E01E50" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total current assets</link:label>
    <link:label id="lab_us-gaap_AssetsCurrent_81C7131D3F76CF4712D7DE2E96E01E50_label_en-US" xlink:label="lab_us-gaap_AssetsCurrent_81C7131D3F76CF4712D7DE2E96E01E50" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaap_AssetsCurrent_81C7131D3F76CF4712D7DE2E96E01E50" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrent_81C7131D3F76CF4712D7DE2E96E01E50" xlink:to="lab_us-gaap_AssetsCurrent_81C7131D3F76CF4712D7DE2E96E01E50" xlink:type="arc" />
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_41AFCA7E094D88232509DE2E96E002A9_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet_41AFCA7E094D88232509DE2E96E002A9" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equipment and furnishings, net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_41AFCA7E094D88232509DE2E96E002A9_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet_41AFCA7E094D88232509DE2E96E002A9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment, Net</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_41AFCA7E094D88232509DE2E96E002A9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet_41AFCA7E094D88232509DE2E96E002A9" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentNet_41AFCA7E094D88232509DE2E96E002A9" xlink:type="arc" />
    <link:label id="lab_gale_InProcessResearchDevelopment_10572EECD387BCFC19D9DE2E96E0CE15_terseLabel_en-US" xlink:label="lab_gale_InProcessResearchDevelopment_10572EECD387BCFC19D9DE2E96E0CE15" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">In-process research and development</link:label>
    <link:label id="lab_gale_InProcessResearchDevelopment_10572EECD387BCFC19D9DE2E96E0CE15_label_en-US" xlink:label="lab_gale_InProcessResearchDevelopment_10572EECD387BCFC19D9DE2E96E0CE15" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">In Process Research Development</link:label>
    <link:label id="lab_gale_InProcessResearchDevelopment_10572EECD387BCFC19D9DE2E96E0CE15_documentation_en-US" xlink:label="lab_gale_InProcessResearchDevelopment_10572EECD387BCFC19D9DE2E96E0CE15" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">In-process research and development.</link:label>
    <link:loc xlink:href="gale-20150930.xsd#gale_InProcessResearchDevelopment" xlink:label="loc_gale_InProcessResearchDevelopment_10572EECD387BCFC19D9DE2E96E0CE15" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_InProcessResearchDevelopment_10572EECD387BCFC19D9DE2E96E0CE15" xlink:to="lab_gale_InProcessResearchDevelopment_10572EECD387BCFC19D9DE2E96E0CE15" xlink:type="arc" />
    <link:label id="lab_gale_SalesAndDistributionsRights_6B6562BF508999E05C6BDE2E96E06737_terseLabel_en-US" xlink:label="lab_gale_SalesAndDistributionsRights_6B6562BF508999E05C6BDE2E96E06737" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Abstral rights, net</link:label>
    <link:label id="lab_gale_SalesAndDistributionsRights_6B6562BF508999E05C6BDE2E96E06737_label_en-US" xlink:label="lab_gale_SalesAndDistributionsRights_6B6562BF508999E05C6BDE2E96E06737" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sales And Distributions Rights</link:label>
    <link:label id="lab_gale_SalesAndDistributionsRights_6B6562BF508999E05C6BDE2E96E06737_documentation_en-US" xlink:label="lab_gale_SalesAndDistributionsRights_6B6562BF508999E05C6BDE2E96E06737" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Sales And Distributions Rights</link:label>
    <link:loc xlink:href="gale-20150930.xsd#gale_SalesAndDistributionsRights" xlink:label="loc_gale_SalesAndDistributionsRights_6B6562BF508999E05C6BDE2E96E06737" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_SalesAndDistributionsRights_6B6562BF508999E05C6BDE2E96E06737" xlink:to="lab_gale_SalesAndDistributionsRights_6B6562BF508999E05C6BDE2E96E06737" xlink:type="arc" />
    <link:label id="lab_gale_SalesAndDistributionsRightsZuplenz_5B63855DE96A47ADCDD8DE2E96E0809F_terseLabel_en-US" xlink:label="lab_gale_SalesAndDistributionsRightsZuplenz_5B63855DE96A47ADCDD8DE2E96E0809F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Zuplenz rights</link:label>
    <link:label id="lab_gale_SalesAndDistributionsRightsZuplenz_5B63855DE96A47ADCDD8DE2E96E0809F_label_en-US" xlink:label="lab_gale_SalesAndDistributionsRightsZuplenz_5B63855DE96A47ADCDD8DE2E96E0809F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sales And Distributions Rights, Zuplenz</link:label>
    <link:label id="lab_gale_SalesAndDistributionsRightsZuplenz_5B63855DE96A47ADCDD8DE2E96E0809F_documentation_en-US" xlink:label="lab_gale_SalesAndDistributionsRightsZuplenz_5B63855DE96A47ADCDD8DE2E96E0809F" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Sales And Distributions Rights, Zuplenz</link:label>
    <link:loc xlink:href="gale-20150930.xsd#gale_SalesAndDistributionsRightsZuplenz" xlink:label="loc_gale_SalesAndDistributionsRightsZuplenz_5B63855DE96A47ADCDD8DE2E96E0809F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_SalesAndDistributionsRightsZuplenz_5B63855DE96A47ADCDD8DE2E96E0809F" xlink:to="lab_gale_SalesAndDistributionsRightsZuplenz_5B63855DE96A47ADCDD8DE2E96E0809F" xlink:type="arc" />
    <link:label id="lab_gale_GALE401rights_4CAB1C51D926CC3BA46BDE2E96E09765_terseLabel_en-US" xlink:label="lab_gale_GALE401rights_4CAB1C51D926CC3BA46BDE2E96E09765" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">GALE-401 rights</link:label>
    <link:label id="lab_gale_GALE401rights_4CAB1C51D926CC3BA46BDE2E96E09765_label_en-US" xlink:label="lab_gale_GALE401rights_4CAB1C51D926CC3BA46BDE2E96E09765" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">GALE-401 rights</link:label>
    <link:label id="lab_gale_GALE401rights_4CAB1C51D926CC3BA46BDE2E96E09765_documentation_en-US" xlink:label="lab_gale_GALE401rights_4CAB1C51D926CC3BA46BDE2E96E09765" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">GALE-401 rights</link:label>
    <link:loc xlink:href="gale-20150930.xsd#gale_GALE401rights" xlink:label="loc_gale_GALE401rights_4CAB1C51D926CC3BA46BDE2E96E09765" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_GALE401rights_4CAB1C51D926CC3BA46BDE2E96E09765" xlink:to="lab_gale_GALE401rights_4CAB1C51D926CC3BA46BDE2E96E09765" xlink:type="arc" />
    <link:label id="lab_us-gaap_Goodwill_8F8925EFFDD30EAEC809DE2E96E01B5B_terseLabel_en-US" xlink:label="lab_us-gaap_Goodwill_8F8925EFFDD30EAEC809DE2E96E01B5B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Goodwill</link:label>
    <link:label id="lab_us-gaap_Goodwill_8F8925EFFDD30EAEC809DE2E96E01B5B_label_en-US" xlink:label="lab_us-gaap_Goodwill_8F8925EFFDD30EAEC809DE2E96E01B5B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Goodwill</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_Goodwill" xlink:label="loc_us-gaap_Goodwill_8F8925EFFDD30EAEC809DE2E96E01B5B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Goodwill_8F8925EFFDD30EAEC809DE2E96E01B5B" xlink:to="lab_us-gaap_Goodwill_8F8925EFFDD30EAEC809DE2E96E01B5B" xlink:type="arc" />
    <link:label id="lab_us-gaap_DepositsAssetsNoncurrent_7AA5933270246261924BDE2E96E0D516_terseLabel_en-US" xlink:label="lab_us-gaap_DepositsAssetsNoncurrent_7AA5933270246261924BDE2E96E0D516" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deposits and other assets</link:label>
    <link:label id="lab_us-gaap_DepositsAssetsNoncurrent_7AA5933270246261924BDE2E96E0D516_label_en-US" xlink:label="lab_us-gaap_DepositsAssetsNoncurrent_7AA5933270246261924BDE2E96E0D516" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deposits Assets, Noncurrent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DepositsAssetsNoncurrent" xlink:label="loc_us-gaap_DepositsAssetsNoncurrent_7AA5933270246261924BDE2E96E0D516" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DepositsAssetsNoncurrent_7AA5933270246261924BDE2E96E0D516" xlink:to="lab_us-gaap_DepositsAssetsNoncurrent_7AA5933270246261924BDE2E96E0D516" xlink:type="arc" />
    <link:label id="lab_us-gaap_Assets_95E7C6E589F7C9309C92DE2E96E06FD8_totalLabel_en-US" xlink:label="lab_us-gaap_Assets_95E7C6E589F7C9309C92DE2E96E06FD8" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total assets</link:label>
    <link:label id="lab_us-gaap_Assets_95E7C6E589F7C9309C92DE2E96E06FD8_label_en-US" xlink:label="lab_us-gaap_Assets_95E7C6E589F7C9309C92DE2E96E06FD8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_Assets" xlink:label="loc_us-gaap_Assets_95E7C6E589F7C9309C92DE2E96E06FD8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Assets_95E7C6E589F7C9309C92DE2E96E06FD8" xlink:to="lab_us-gaap_Assets_95E7C6E589F7C9309C92DE2E96E06FD8" xlink:type="arc" />
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_564A69E00E07D01EF701DE2E96E03F9F_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_564A69E00E07D01EF701DE2E96E03F9F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">LIABILITIES AND STOCKHOLDERS' EQUITY</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_564A69E00E07D01EF701DE2E96E03F9F_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_564A69E00E07D01EF701DE2E96E03F9F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities and Equity [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_564A69E00E07D01EF701DE2E96E03F9F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_564A69E00E07D01EF701DE2E96E03F9F" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_564A69E00E07D01EF701DE2E96E03F9F" xlink:type="arc" />
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_80597E87019B335097D1DE2E96E090E3_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract_80597E87019B335097D1DE2E96E090E3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Current liabilities:</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_80597E87019B335097D1DE2E96E090E3_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract_80597E87019B335097D1DE2E96E090E3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities, Current [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_80597E87019B335097D1DE2E96E090E3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_80597E87019B335097D1DE2E96E090E3" xlink:to="lab_us-gaap_LiabilitiesCurrentAbstract_80597E87019B335097D1DE2E96E090E3" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccountsPayableCurrent_A0AC4C5EF4FADD3C8BA1DE2E96E07117_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent_A0AC4C5EF4FADD3C8BA1DE2E96E07117" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_A0AC4C5EF4FADD3C8BA1DE2E96E07117_label_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent_A0AC4C5EF4FADD3C8BA1DE2E96E07117" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounts Payable, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="loc_us-gaap_AccountsPayableCurrent_A0AC4C5EF4FADD3C8BA1DE2E96E07117" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableCurrent_A0AC4C5EF4FADD3C8BA1DE2E96E07117" xlink:to="lab_us-gaap_AccountsPayableCurrent_A0AC4C5EF4FADD3C8BA1DE2E96E07117" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_5D8C964BD71F42DF60ABDE2E96E0E6CE_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent_5D8C964BD71F42DF60ABDE2E96E0E6CE" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accrued expenses and other current liabilities</link:label>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_5D8C964BD71F42DF60ABDE2E96E0E6CE_label_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent_5D8C964BD71F42DF60ABDE2E96E0E6CE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accrued Liabilities, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_5D8C964BD71F42DF60ABDE2E96E0E6CE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_5D8C964BD71F42DF60ABDE2E96E0E6CE" xlink:to="lab_us-gaap_AccruedLiabilitiesCurrent_5D8C964BD71F42DF60ABDE2E96E0E6CE" xlink:type="arc" />
    <link:label id="lab_gale_FairValueOfWarrantsPotentiallySettleableInCash_1ECB52357A63D3948566DE2E96E012AA_terseLabel_en-US" xlink:label="lab_gale_FairValueOfWarrantsPotentiallySettleableInCash_1ECB52357A63D3948566DE2E96E012AA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair value of warrants potentially settleable in cash</link:label>
    <link:label id="lab_gale_FairValueOfWarrantsPotentiallySettleableInCash_1ECB52357A63D3948566DE2E96E012AA_label_en-US" xlink:label="lab_gale_FairValueOfWarrantsPotentiallySettleableInCash_1ECB52357A63D3948566DE2E96E012AA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Of Warrants Potentially Settleable In Cash</link:label>
    <link:label id="lab_gale_FairValueOfWarrantsPotentiallySettleableInCash_1ECB52357A63D3948566DE2E96E012AA_documentation_en-US" xlink:label="lab_gale_FairValueOfWarrantsPotentiallySettleableInCash_1ECB52357A63D3948566DE2E96E012AA" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Fair value of warrants potentially settleable in cash.</link:label>
    <link:loc xlink:href="gale-20150930.xsd#gale_FairValueOfWarrantsPotentiallySettleableInCash" xlink:label="loc_gale_FairValueOfWarrantsPotentiallySettleableInCash_1ECB52357A63D3948566DE2E96E012AA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_FairValueOfWarrantsPotentiallySettleableInCash_1ECB52357A63D3948566DE2E96E012AA" xlink:to="lab_gale_FairValueOfWarrantsPotentiallySettleableInCash_1ECB52357A63D3948566DE2E96E012AA" xlink:type="arc" />
    <link:label id="lab_us-gaap_LongTermDebtCurrent_9E15B5141027F1C2BFB2DE2E96E0B3E1_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtCurrent_9E15B5141027F1C2BFB2DE2E96E0B3E1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Current portion of long-term debt</link:label>
    <link:label id="lab_us-gaap_LongTermDebtCurrent_9E15B5141027F1C2BFB2DE2E96E0B3E1_label_en-US" xlink:label="lab_us-gaap_LongTermDebtCurrent_9E15B5141027F1C2BFB2DE2E96E0B3E1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-term Debt, Current Maturities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LongTermDebtCurrent" xlink:label="loc_us-gaap_LongTermDebtCurrent_9E15B5141027F1C2BFB2DE2E96E0B3E1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtCurrent_9E15B5141027F1C2BFB2DE2E96E0B3E1" xlink:to="lab_us-gaap_LongTermDebtCurrent_9E15B5141027F1C2BFB2DE2E96E0B3E1" xlink:type="arc" />
    <link:label id="lab_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent_56B8D880591FB70C284FDE710C2D0EA0_verboseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent_56B8D880591FB70C284FDE710C2D0EA0" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Current liabilities held for sale</link:label>
    <link:label id="lab_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent_56B8D880591FB70C284FDE710C2D0EA0_label_en-US" xlink:label="lab_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent_56B8D880591FB70C284FDE710C2D0EA0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Liabilities, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent" xlink:label="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent_56B8D880591FB70C284FDE710C2D0EA0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent_56B8D880591FB70C284FDE710C2D0EA0" xlink:to="lab_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent_56B8D880591FB70C284FDE710C2D0EA0" xlink:type="arc" />
    <link:label id="lab_us-gaap_LiabilitiesCurrent_DDEBC82A2BC0FB0D2EE4DE2E96E15C25_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent_DDEBC82A2BC0FB0D2EE4DE2E96E15C25" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total current liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_DDEBC82A2BC0FB0D2EE4DE2E96E15C25_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent_DDEBC82A2BC0FB0D2EE4DE2E96E15C25" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaap_LiabilitiesCurrent_DDEBC82A2BC0FB0D2EE4DE2E96E15C25" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrent_DDEBC82A2BC0FB0D2EE4DE2E96E15C25" xlink:to="lab_us-gaap_LiabilitiesCurrent_DDEBC82A2BC0FB0D2EE4DE2E96E15C25" xlink:type="arc" />
    <link:label id="lab_us-gaap_DeferredTaxAssetsLiabilitiesNetNoncurrent_DD4CC87C645E8D74DE51DE2E96E19FEB_negatedLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsLiabilitiesNetNoncurrent_DD4CC87C645E8D74DE51DE2E96E19FEB" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Deferred tax liability</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsLiabilitiesNetNoncurrent_DD4CC87C645E8D74DE51DE2E96E19FEB_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsLiabilitiesNetNoncurrent_DD4CC87C645E8D74DE51DE2E96E19FEB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Net, Noncurrent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNetNoncurrent" xlink:label="loc_us-gaap_DeferredTaxAssetsLiabilitiesNetNoncurrent_DD4CC87C645E8D74DE51DE2E96E19FEB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsLiabilitiesNetNoncurrent_DD4CC87C645E8D74DE51DE2E96E19FEB" xlink:to="lab_us-gaap_DeferredTaxAssetsLiabilitiesNetNoncurrent_DD4CC87C645E8D74DE51DE2E96E19FEB" xlink:type="arc" />
    <link:label id="lab_gale_ContingentPurchasePriceConsiderationNetOfCurrentPortion_6CCE974CBDA8358AD17BDE2E96E1D468_terseLabel_en-US" xlink:label="lab_gale_ContingentPurchasePriceConsiderationNetOfCurrentPortion_6CCE974CBDA8358AD17BDE2E96E1D468" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred tax liability</link:label>
    <link:label id="lab_gale_ContingentPurchasePriceConsiderationNetOfCurrentPortion_6CCE974CBDA8358AD17BDE2E96E1D468_label_en-US" xlink:label="lab_gale_ContingentPurchasePriceConsiderationNetOfCurrentPortion_6CCE974CBDA8358AD17BDE2E96E1D468" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Contingent Purchase Price Consideration Net Of Current Portion</link:label>
    <link:label id="lab_gale_ContingentPurchasePriceConsiderationNetOfCurrentPortion_6CCE974CBDA8358AD17BDE2E96E1D468_documentation_en-US" xlink:label="lab_gale_ContingentPurchasePriceConsiderationNetOfCurrentPortion_6CCE974CBDA8358AD17BDE2E96E1D468" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Contingent purchase price consideration, net of current portion.</link:label>
    <link:loc xlink:href="gale-20150930.xsd#gale_ContingentPurchasePriceConsiderationNetOfCurrentPortion" xlink:label="loc_gale_ContingentPurchasePriceConsiderationNetOfCurrentPortion_6CCE974CBDA8358AD17BDE2E96E1D468" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_ContingentPurchasePriceConsiderationNetOfCurrentPortion_6CCE974CBDA8358AD17BDE2E96E1D468" xlink:to="lab_gale_ContingentPurchasePriceConsiderationNetOfCurrentPortion_6CCE974CBDA8358AD17BDE2E96E1D468" xlink:type="arc" />
    <link:label id="lab_us-gaap_LongTermDebtNoncurrent_79589E9A6845BAFCF5AADE2E96E1F857_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtNoncurrent_79589E9A6845BAFCF5AADE2E96E1F857" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Long-term debt, net of current portion</link:label>
    <link:label id="lab_us-gaap_LongTermDebtNoncurrent_79589E9A6845BAFCF5AADE2E96E1F857_label_en-US" xlink:label="lab_us-gaap_LongTermDebtNoncurrent_79589E9A6845BAFCF5AADE2E96E1F857" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-term Debt, Excluding Current Maturities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LongTermDebtNoncurrent" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_79589E9A6845BAFCF5AADE2E96E1F857" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtNoncurrent_79589E9A6845BAFCF5AADE2E96E1F857" xlink:to="lab_us-gaap_LongTermDebtNoncurrent_79589E9A6845BAFCF5AADE2E96E1F857" xlink:type="arc" />
    <link:label id="lab_us-gaap_Liabilities_DFD7D03B72DF31F81617DE2E96E12FAF_totalLabel_en-US" xlink:label="lab_us-gaap_Liabilities_DFD7D03B72DF31F81617DE2E96E12FAF" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total liabilities</link:label>
    <link:label id="lab_us-gaap_Liabilities_DFD7D03B72DF31F81617DE2E96E12FAF_label_en-US" xlink:label="lab_us-gaap_Liabilities_DFD7D03B72DF31F81617DE2E96E12FAF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaap_Liabilities_DFD7D03B72DF31F81617DE2E96E12FAF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Liabilities_DFD7D03B72DF31F81617DE2E96E12FAF" xlink:to="lab_us-gaap_Liabilities_DFD7D03B72DF31F81617DE2E96E12FAF" xlink:type="arc" />
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_45664A8220B6180A1200DE2E96E12DAC_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies_45664A8220B6180A1200DE2E96E12DAC" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Commitments and contingencies</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_45664A8220B6180A1200DE2E96E12DAC_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies_45664A8220B6180A1200DE2E96E12DAC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Commitments and Contingencies</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="loc_us-gaap_CommitmentsAndContingencies_45664A8220B6180A1200DE2E96E12DAC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingencies_45664A8220B6180A1200DE2E96E12DAC" xlink:to="lab_us-gaap_CommitmentsAndContingencies_45664A8220B6180A1200DE2E96E12DAC" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_DE16B15C5F76BB809846DE2E96E108CA_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract_DE16B15C5F76BB809846DE2E96E108CA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stockholders' equity:</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_DE16B15C5F76BB809846DE2E96E108CA_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract_DE16B15C5F76BB809846DE2E96E108CA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stockholders' Equity Attributable to Parent [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="loc_us-gaap_StockholdersEquityAbstract_DE16B15C5F76BB809846DE2E96E108CA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityAbstract_DE16B15C5F76BB809846DE2E96E108CA" xlink:to="lab_us-gaap_StockholdersEquityAbstract_DE16B15C5F76BB809846DE2E96E108CA" xlink:type="arc" />
    <link:label id="lab_us-gaap_PreferredStockValue_065C9E55B606BA43FA86DE2E96E1B1BE_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockValue_065C9E55B606BA43FA86DE2E96E1B1BE" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Preferred stock, $0.0001 par value; 5,000,000 shares authorized; no shares issued and outstanding</link:label>
    <link:label id="lab_us-gaap_PreferredStockValue_065C9E55B606BA43FA86DE2E96E1B1BE_label_en-US" xlink:label="lab_us-gaap_PreferredStockValue_065C9E55B606BA43FA86DE2E96E1B1BE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred Stock, Value, Issued</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PreferredStockValue" xlink:label="loc_us-gaap_PreferredStockValue_065C9E55B606BA43FA86DE2E96E1B1BE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockValue_065C9E55B606BA43FA86DE2E96E1B1BE" xlink:to="lab_us-gaap_PreferredStockValue_065C9E55B606BA43FA86DE2E96E1B1BE" xlink:type="arc" />
    <link:label id="lab_us-gaap_CommonStockValue_6267593E3731052E4A8ADE2E96E1AE84_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockValue_6267593E3731052E4A8ADE2E96E1AE84" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock, $0.0001 par value; 275,000,000 shares authorized, 162,575,446 shares issued and 161,900,446 shares outstanding at September 30, 2015; 200,000,000 shares authorized, 130,146,341 shares issued and 129,471,341 shares outstanding at December 31, 2014</link:label>
    <link:label id="lab_us-gaap_CommonStockValue_6267593E3731052E4A8ADE2E96E1AE84_label_en-US" xlink:label="lab_us-gaap_CommonStockValue_6267593E3731052E4A8ADE2E96E1AE84" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Value, Issued</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaap_CommonStockValue_6267593E3731052E4A8ADE2E96E1AE84" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockValue_6267593E3731052E4A8ADE2E96E1AE84" xlink:to="lab_us-gaap_CommonStockValue_6267593E3731052E4A8ADE2E96E1AE84" xlink:type="arc" />
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalCommonStock_B07D9656ECAB75D8D8E1DE2E96E1017D_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalCommonStock_B07D9656ECAB75D8D8E1DE2E96E1017D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Additional paid-in capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalCommonStock_B07D9656ECAB75D8D8E1DE2E96E1017D_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalCommonStock_B07D9656ECAB75D8D8E1DE2E96E1017D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Additional Paid in Capital, Common Stock</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock_B07D9656ECAB75D8D8E1DE2E96E1017D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalCommonStock_B07D9656ECAB75D8D8E1DE2E96E1017D" xlink:to="lab_us-gaap_AdditionalPaidInCapitalCommonStock_B07D9656ECAB75D8D8E1DE2E96E1017D" xlink:type="arc" />
    <link:label id="lab_gale_DeficitAccumulatedDuringDevelopmentalStage_A2CB610CF173D57B3AD1DE2E96E1EAA4_negatedLabel_en-US" xlink:label="lab_gale_DeficitAccumulatedDuringDevelopmentalStage_A2CB610CF173D57B3AD1DE2E96E1EAA4" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Accumulated deficit</link:label>
    <link:label id="lab_gale_DeficitAccumulatedDuringDevelopmentalStage_A2CB610CF173D57B3AD1DE2E96E1EAA4_label_en-US" xlink:label="lab_gale_DeficitAccumulatedDuringDevelopmentalStage_A2CB610CF173D57B3AD1DE2E96E1EAA4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deficit Accumulated During Developmental Stage</link:label>
    <link:label id="lab_gale_DeficitAccumulatedDuringDevelopmentalStage_A2CB610CF173D57B3AD1DE2E96E1EAA4_documentation_en-US" xlink:label="lab_gale_DeficitAccumulatedDuringDevelopmentalStage_A2CB610CF173D57B3AD1DE2E96E1EAA4" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Deficit accumulated during the developmental stage.</link:label>
    <link:loc xlink:href="gale-20150930.xsd#gale_DeficitAccumulatedDuringDevelopmentalStage" xlink:label="loc_gale_DeficitAccumulatedDuringDevelopmentalStage_A2CB610CF173D57B3AD1DE2E96E1EAA4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_DeficitAccumulatedDuringDevelopmentalStage_A2CB610CF173D57B3AD1DE2E96E1EAA4" xlink:to="lab_gale_DeficitAccumulatedDuringDevelopmentalStage_A2CB610CF173D57B3AD1DE2E96E1EAA4" xlink:type="arc" />
    <link:label id="lab_us-gaap_TreasuryStockValue_215286116C7D59B844C4DE2E96E1C30D_negatedLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockValue_215286116C7D59B844C4DE2E96E1C30D" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Less treasury shares at cost, 675,000 shares</link:label>
    <link:label id="lab_us-gaap_TreasuryStockValue_215286116C7D59B844C4DE2E96E1C30D_label_en-US" xlink:label="lab_us-gaap_TreasuryStockValue_215286116C7D59B844C4DE2E96E1C30D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Treasury Stock, Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_TreasuryStockValue" xlink:label="loc_us-gaap_TreasuryStockValue_215286116C7D59B844C4DE2E96E1C30D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockValue_215286116C7D59B844C4DE2E96E1C30D" xlink:to="lab_us-gaap_TreasuryStockValue_215286116C7D59B844C4DE2E96E1C30D" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockholdersEquity_C2C9FB3D73A9559DC4FADE2E96E1238D_totalLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity_C2C9FB3D73A9559DC4FADE2E96E1238D" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total stockholders&#8217; equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_C2C9FB3D73A9559DC4FADE2E96E1238D_label_en-US" xlink:label="lab_us-gaap_StockholdersEquity_C2C9FB3D73A9559DC4FADE2E96E1238D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stockholders' Equity Attributable to Parent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_C2C9FB3D73A9559DC4FADE2E96E1238D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquity_C2C9FB3D73A9559DC4FADE2E96E1238D" xlink:to="lab_us-gaap_StockholdersEquity_C2C9FB3D73A9559DC4FADE2E96E1238D" xlink:type="arc" />
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_AAD9A74B33B6BB271CD8DE2E96E15405_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity_AAD9A74B33B6BB271CD8DE2E96E15405" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total liabilities and stockholders' equity</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_AAD9A74B33B6BB271CD8DE2E96E15405_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity_AAD9A74B33B6BB271CD8DE2E96E15405" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities and Equity</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_AAD9A74B33B6BB271CD8DE2E96E15405" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_AAD9A74B33B6BB271CD8DE2E96E15405" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquity_AAD9A74B33B6BB271CD8DE2E96E15405" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueDisclosuresAbstract_CB1D5874696A61C15B50D437A87251FF_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresAbstract_DD826697906E56F9980FA5314B5C8BDB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Disclosures [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_DD826697906E56F9980FA5314B5C8BDB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_DD826697906E56F9980FA5314B5C8BDB" xlink:to="lab_us-gaap_FairValueDisclosuresAbstract_DD826697906E56F9980FA5314B5C8BDB" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_C3771F3B7C92A0A34571D437A872D417_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_A9BA8A2B547B584DAE2EDF4B620FEE72" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table]</link:label>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_C3771F3B7C92A0A34571D437A872D417_label_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_A9BA8A2B547B584DAE2EDF4B620FEE72" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_A9BA8A2B547B584DAE2EDF4B620FEE72" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_A9BA8A2B547B584DAE2EDF4B620FEE72" xlink:to="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_A9BA8A2B547B584DAE2EDF4B620FEE72" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_50F199DD81B6E1D30235D437A872E164_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_6CB47389BFD65B98A38F1D34FB41659C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value, Hierarchy [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_50F199DD81B6E1D30235D437A872E164_label_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_6CB47389BFD65B98A38F1D34FB41659C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Hierarchy [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_6CB47389BFD65B98A38F1D34FB41659C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_6CB47389BFD65B98A38F1D34FB41659C" xlink:to="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_6CB47389BFD65B98A38F1D34FB41659C" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_223C2B3003966E47DEA0D437A872452A_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_49CB70EF30915C6380BFF140D00395B1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value, Measurements, Fair Value Hierarchy [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_223C2B3003966E47DEA0D437A872452A_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_49CB70EF30915C6380BFF140D00395B1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Hierarchy [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_49CB70EF30915C6380BFF140D00395B1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_49CB70EF30915C6380BFF140D00395B1" xlink:to="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_49CB70EF30915C6380BFF140D00395B1" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_99DE9C09C6C48635C392D437A87270E6_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member_133CB0C8DA1E5151BC4219141709A7B2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Unobservable Inputs (Level 3) [Member]</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_99DE9C09C6C48635C392D437A87270E6_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member_133CB0C8DA1E5151BC4219141709A7B2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Inputs, Level 3 [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_133CB0C8DA1E5151BC4219141709A7B2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel3Member_133CB0C8DA1E5151BC4219141709A7B2" xlink:to="lab_us-gaap_FairValueInputsLevel3Member_133CB0C8DA1E5151BC4219141709A7B2" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_4FE1C73B3B7D50EF19EDD437A872FA40_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_3EF3B05B81EB5E81A4F5A5661ADC2BD5" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]</link:label>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_4FE1C73B3B7D50EF19EDD437A872FA40_label_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_3EF3B05B81EB5E81A4F5A5661ADC2BD5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_3EF3B05B81EB5E81A4F5A5661ADC2BD5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_3EF3B05B81EB5E81A4F5A5661ADC2BD5" xlink:to="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_3EF3B05B81EB5E81A4F5A5661ADC2BD5" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_8732F40A98F7FAE472E9D437A873940D_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_5167F35552D65AEA82C99B28771B20C5" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_8732F40A98F7FAE472E9D437A873940D_label_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_5167F35552D65AEA82C99B28771B20C5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_5167F35552D65AEA82C99B28771B20C5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_5167F35552D65AEA82C99B28771B20C5" xlink:to="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_5167F35552D65AEA82C99B28771B20C5" xlink:type="arc" />
    <link:label id="lab_us-gaap_ContingentConsiderationClassifiedAsEquityFairValueDisclosure_4B6A38AFB00B6807218BD437A873FFC7_periodStartLabel_en-US" xlink:label="lab_us-gaap_ContingentConsiderationClassifiedAsEquityFairValueDisclosure_BBAF05F480715029A90EE878CAAFE417" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Beginning Balance Liabilities</link:label>
    <link:label id="lab_us-gaap_ContingentConsiderationClassifiedAsEquityFairValueDisclosure_4B6A38AFB00B6807218BD437A873FFC7_label_en-US" xlink:label="lab_us-gaap_ContingentConsiderationClassifiedAsEquityFairValueDisclosure_BBAF05F480715029A90EE878CAAFE417" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Contingent Consideration Classified as Equity, Fair Value Disclosure</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ContingentConsiderationClassifiedAsEquityFairValueDisclosure" xlink:label="loc_us-gaap_ContingentConsiderationClassifiedAsEquityFairValueDisclosure_BBAF05F480715029A90EE878CAAFE417" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContingentConsiderationClassifiedAsEquityFairValueDisclosure_BBAF05F480715029A90EE878CAAFE417" xlink:to="lab_us-gaap_ContingentConsiderationClassifiedAsEquityFairValueDisclosure_BBAF05F480715029A90EE878CAAFE417" xlink:type="arc" />
    <link:label id="lab_gale_ChangeInFairValueOfContingentPurchasePriceConsideration_52A656B53F048EF2759DD437A873559B_negatedLabel_en-US" xlink:label="lab_gale_ChangeInFairValueOfContingentPurchasePriceConsideration_FCB5AA01EBCF538282492BC5FD52C0A7" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Change in the estimated fair value of the contingent purchase price consideration</link:label>
    <link:label id="lab_gale_ChangeInFairValueOfContingentPurchasePriceConsideration_52A656B53F048EF2759DD437A873559B_label_en-US" xlink:label="lab_gale_ChangeInFairValueOfContingentPurchasePriceConsideration_FCB5AA01EBCF538282492BC5FD52C0A7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Change In Fair Value Of Contingent Purchase Price Consideration</link:label>
    <link:label id="lab_gale_ChangeInFairValueOfContingentPurchasePriceConsideration_52A656B53F048EF2759DD437A873559B_documentation_en-US" xlink:label="lab_gale_ChangeInFairValueOfContingentPurchasePriceConsideration_FCB5AA01EBCF538282492BC5FD52C0A7" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Change in the fair value of contingent purchase price consideration.</link:label>
    <link:loc xlink:href="gale-20150930.xsd#gale_ChangeInFairValueOfContingentPurchasePriceConsideration" xlink:label="loc_gale_ChangeInFairValueOfContingentPurchasePriceConsideration_FCB5AA01EBCF538282492BC5FD52C0A7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_ChangeInFairValueOfContingentPurchasePriceConsideration_FCB5AA01EBCF538282492BC5FD52C0A7" xlink:to="lab_gale_ChangeInFairValueOfContingentPurchasePriceConsideration_FCB5AA01EBCF538282492BC5FD52C0A7" xlink:type="arc" />
    <link:label id="lab_us-gaap_ContingentConsiderationClassifiedAsEquityFairValueDisclosure_C2A70710A33627C03919D437A8731411_periodEndLabel_en-US" xlink:label="lab_us-gaap_ContingentConsiderationClassifiedAsEquityFairValueDisclosure_5FDF7D85609653C9A9B4CA5DDB5FCB48" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Ending Balance Liabilities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ContingentConsiderationClassifiedAsEquityFairValueDisclosure" xlink:label="loc_us-gaap_ContingentConsiderationClassifiedAsEquityFairValueDisclosure_5FDF7D85609653C9A9B4CA5DDB5FCB48" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContingentConsiderationClassifiedAsEquityFairValueDisclosure_5FDF7D85609653C9A9B4CA5DDB5FCB48" xlink:to="lab_us-gaap_ContingentConsiderationClassifiedAsEquityFairValueDisclosure_5FDF7D85609653C9A9B4CA5DDB5FCB48" xlink:type="arc" />
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightTable_45FEC658F8CCAD46500BE0E750CF7963_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightTable_D14D72E05535596E93F123C255140C55" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right [Table]</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightTable_45FEC658F8CCAD46500BE0E750CF7963_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightTable_D14D72E05535596E93F123C255140C55" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ClassOfWarrantOrRightTable" xlink:label="loc_us-gaap_ClassOfWarrantOrRightTable_D14D72E05535596E93F123C255140C55" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_D14D72E05535596E93F123C255140C55" xlink:to="lab_us-gaap_ClassOfWarrantOrRightTable_D14D72E05535596E93F123C255140C55" xlink:type="arc" />
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightAxis_2041866F3E51CF45815AE0E750CF7A7E_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightAxis_6BB6AC842BE25B4CA4CD3CB04A97CC63" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right [Axis]</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightAxis_2041866F3E51CF45815AE0E750CF7A7E_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightAxis_6BB6AC842BE25B4CA4CD3CB04A97CC63" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis_6BB6AC842BE25B4CA4CD3CB04A97CC63" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_6BB6AC842BE25B4CA4CD3CB04A97CC63" xlink:to="lab_us-gaap_ClassOfWarrantOrRightAxis_6BB6AC842BE25B4CA4CD3CB04A97CC63" xlink:type="arc" />
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightDomain_C19E9C9355FD8FEACD49E0E750CF1744_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightDomain_AB41C36ABE5650A096D59969576DF387" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right [Domain]</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightDomain_C19E9C9355FD8FEACD49E0E750CF1744_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightDomain_AB41C36ABE5650A096D59969576DF387" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_AB41C36ABE5650A096D59969576DF387" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_AB41C36ABE5650A096D59969576DF387" xlink:to="lab_us-gaap_ClassOfWarrantOrRightDomain_AB41C36ABE5650A096D59969576DF387" xlink:type="arc" />
    <link:label id="lab_gale_MarchTwoThousandFifteenWarrantsMember_ED5049CB8BD0B0B399DEE0E750CF75F8_terseLabel_en-US" xlink:label="lab_gale_MarchTwoThousandFifteenWarrantsMember_FC9627910C605B1F8A36C5D667DD2A70" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">March 2015 Warrants [Member]</link:label>
    <link:label id="lab_gale_MarchTwoThousandFifteenWarrantsMember_ED5049CB8BD0B0B399DEE0E750CF75F8_label_en-US" xlink:label="lab_gale_MarchTwoThousandFifteenWarrantsMember_FC9627910C605B1F8A36C5D667DD2A70" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">March Two Thousand Fifteen Warrants [Member]</link:label>
    <link:label id="lab_gale_MarchTwoThousandFifteenWarrantsMember_ED5049CB8BD0B0B399DEE0E750CF75F8_documentation_en-US" xlink:label="lab_gale_MarchTwoThousandFifteenWarrantsMember_FC9627910C605B1F8A36C5D667DD2A70" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">March Two Thousand Fifteen Warrants [Member]</link:label>
    <link:loc xlink:href="gale-20150930.xsd#gale_MarchTwoThousandFifteenWarrantsMember" xlink:label="loc_gale_MarchTwoThousandFifteenWarrantsMember_FC9627910C605B1F8A36C5D667DD2A70" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_MarchTwoThousandFifteenWarrantsMember_FC9627910C605B1F8A36C5D667DD2A70" xlink:to="lab_gale_MarchTwoThousandFifteenWarrantsMember_FC9627910C605B1F8A36C5D667DD2A70" xlink:type="arc" />
    <link:label id="lab_gale_SeptemberTwoThousandThirteenWarrantMember_DFFE9BE094F9505C3315E0E750CF6BE7_terseLabel_en-US" xlink:label="lab_gale_SeptemberTwoThousandThirteenWarrantMember_82573F54B9B75520AE81EC3D7D518498" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">September 2013 Warrant [Member]</link:label>
    <link:label id="lab_gale_SeptemberTwoThousandThirteenWarrantMember_DFFE9BE094F9505C3315E0E750CF6BE7_label_en-US" xlink:label="lab_gale_SeptemberTwoThousandThirteenWarrantMember_82573F54B9B75520AE81EC3D7D518498" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">September Two Thousand Thirteen Warrant [Member]</link:label>
    <link:label id="lab_gale_SeptemberTwoThousandThirteenWarrantMember_DFFE9BE094F9505C3315E0E750CF6BE7_documentation_en-US" xlink:label="lab_gale_SeptemberTwoThousandThirteenWarrantMember_82573F54B9B75520AE81EC3D7D518498" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">September Two Thousand Thirteen Warrant [Member]</link:label>
    <link:loc xlink:href="gale-20150930.xsd#gale_SeptemberTwoThousandThirteenWarrantMember" xlink:label="loc_gale_SeptemberTwoThousandThirteenWarrantMember_82573F54B9B75520AE81EC3D7D518498" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_SeptemberTwoThousandThirteenWarrantMember_82573F54B9B75520AE81EC3D7D518498" xlink:to="lab_gale_SeptemberTwoThousandThirteenWarrantMember_82573F54B9B75520AE81EC3D7D518498" xlink:type="arc" />
    <link:label id="lab_gale_DecemberTwoThousandTwelveWarrantMember_45A1F646FB1246FD60BEE0E750CFC2C9_terseLabel_en-US" xlink:label="lab_gale_DecemberTwoThousandTwelveWarrantMember_2DAD7F3A11035445B72769327C204BE5" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">December 2012 Warrants [Member]</link:label>
    <link:label id="lab_gale_DecemberTwoThousandTwelveWarrantMember_45A1F646FB1246FD60BEE0E750CFC2C9_label_en-US" xlink:label="lab_gale_DecemberTwoThousandTwelveWarrantMember_2DAD7F3A11035445B72769327C204BE5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">December Two Thousand Twelve Warrant [Member]</link:label>
    <link:label id="lab_gale_DecemberTwoThousandTwelveWarrantMember_45A1F646FB1246FD60BEE0E750CFC2C9_documentation_en-US" xlink:label="lab_gale_DecemberTwoThousandTwelveWarrantMember_2DAD7F3A11035445B72769327C204BE5" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">December Two Thousand Twelve Warrant [Member]</link:label>
    <link:loc xlink:href="gale-20150930.xsd#gale_DecemberTwoThousandTwelveWarrantMember" xlink:label="loc_gale_DecemberTwoThousandTwelveWarrantMember_2DAD7F3A11035445B72769327C204BE5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_DecemberTwoThousandTwelveWarrantMember_2DAD7F3A11035445B72769327C204BE5" xlink:to="lab_gale_DecemberTwoThousandTwelveWarrantMember_2DAD7F3A11035445B72769327C204BE5" xlink:type="arc" />
    <link:label id="lab_gale_AprilTwoThousandElevenWarrantMember_720BCFDC80F34394AF5DE0E750CFE992_terseLabel_en-US" xlink:label="lab_gale_AprilTwoThousandElevenWarrantMember_C34172721CDA52F0973A4AE6511959E7" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">April 2011 Warrants [Member]</link:label>
    <link:label id="lab_gale_AprilTwoThousandElevenWarrantMember_720BCFDC80F34394AF5DE0E750CFE992_label_en-US" xlink:label="lab_gale_AprilTwoThousandElevenWarrantMember_C34172721CDA52F0973A4AE6511959E7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">April Two Thousand Eleven Warrant [Member]</link:label>
    <link:label id="lab_gale_AprilTwoThousandElevenWarrantMember_720BCFDC80F34394AF5DE0E750CFE992_documentation_en-US" xlink:label="lab_gale_AprilTwoThousandElevenWarrantMember_C34172721CDA52F0973A4AE6511959E7" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">April Two Thousand Eleven Warrant [Member]</link:label>
    <link:loc xlink:href="gale-20150930.xsd#gale_AprilTwoThousandElevenWarrantMember" xlink:label="loc_gale_AprilTwoThousandElevenWarrantMember_C34172721CDA52F0973A4AE6511959E7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_AprilTwoThousandElevenWarrantMember_C34172721CDA52F0973A4AE6511959E7" xlink:to="lab_gale_AprilTwoThousandElevenWarrantMember_C34172721CDA52F0973A4AE6511959E7" xlink:type="arc" />
    <link:label id="lab_gale_MarchTwoThousandElevenWarrantMember_FA35227ED3EF2AECF34FE0E750CFA90C_terseLabel_en-US" xlink:label="lab_gale_MarchTwoThousandElevenWarrantMember_22AF70E1FAC450488CEE2B2CF420B566" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">March 2011 Warrants [Member]</link:label>
    <link:label id="lab_gale_MarchTwoThousandElevenWarrantMember_FA35227ED3EF2AECF34FE0E750CFA90C_label_en-US" xlink:label="lab_gale_MarchTwoThousandElevenWarrantMember_22AF70E1FAC450488CEE2B2CF420B566" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">March Two Thousand Eleven Warrant [Member]</link:label>
    <link:label id="lab_gale_MarchTwoThousandElevenWarrantMember_FA35227ED3EF2AECF34FE0E750CFA90C_documentation_en-US" xlink:label="lab_gale_MarchTwoThousandElevenWarrantMember_22AF70E1FAC450488CEE2B2CF420B566" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">March Two Thousand Eleven Warrant [Member]</link:label>
    <link:loc xlink:href="gale-20150930.xsd#gale_MarchTwoThousandElevenWarrantMember" xlink:label="loc_gale_MarchTwoThousandElevenWarrantMember_22AF70E1FAC450488CEE2B2CF420B566" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_MarchTwoThousandElevenWarrantMember_22AF70E1FAC450488CEE2B2CF420B566" xlink:to="lab_gale_MarchTwoThousandElevenWarrantMember_22AF70E1FAC450488CEE2B2CF420B566" xlink:type="arc" />
    <link:label id="lab_gale_MarchTwoThousandTenWarrantMember_B58706C50A7FDFC2EB6DE0E750CFF97A_terseLabel_en-US" xlink:label="lab_gale_MarchTwoThousandTenWarrantMember_12D141098E75531EA41293EABEBF1B1F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">March 2010 Warrants [Member]</link:label>
    <link:label id="lab_gale_MarchTwoThousandTenWarrantMember_B58706C50A7FDFC2EB6DE0E750CFF97A_label_en-US" xlink:label="lab_gale_MarchTwoThousandTenWarrantMember_12D141098E75531EA41293EABEBF1B1F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">March Two Thousand Ten Warrant [Member]</link:label>
    <link:label id="lab_gale_MarchTwoThousandTenWarrantMember_B58706C50A7FDFC2EB6DE0E750CFF97A_documentation_en-US" xlink:label="lab_gale_MarchTwoThousandTenWarrantMember_12D141098E75531EA41293EABEBF1B1F" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">March Two Thousand Ten Warrant [Member]</link:label>
    <link:loc xlink:href="gale-20150930.xsd#gale_MarchTwoThousandTenWarrantMember" xlink:label="loc_gale_MarchTwoThousandTenWarrantMember_12D141098E75531EA41293EABEBF1B1F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_MarchTwoThousandTenWarrantMember_12D141098E75531EA41293EABEBF1B1F" xlink:to="lab_gale_MarchTwoThousandTenWarrantMember_12D141098E75531EA41293EABEBF1B1F" xlink:type="arc" />
    <link:label id="lab_gale_ConsultantWarrantsMember_76D9DD15EA8EA2778126E0E750CFD95B_terseLabel_en-US" xlink:label="lab_gale_ConsultantWarrantsMember_D66191DD568E52F4AB95D554037CEDA1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Consultant Warrants [Member]</link:label>
    <link:label id="lab_gale_ConsultantWarrantsMember_76D9DD15EA8EA2778126E0E750CFD95B_label_en-US" xlink:label="lab_gale_ConsultantWarrantsMember_D66191DD568E52F4AB95D554037CEDA1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Consultant Warrants [Member]</link:label>
    <link:label id="lab_gale_ConsultantWarrantsMember_76D9DD15EA8EA2778126E0E750CFD95B_documentation_en-US" xlink:label="lab_gale_ConsultantWarrantsMember_D66191DD568E52F4AB95D554037CEDA1" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Consultant Warrants [Member]</link:label>
    <link:loc xlink:href="gale-20150930.xsd#gale_ConsultantWarrantsMember" xlink:label="loc_gale_ConsultantWarrantsMember_D66191DD568E52F4AB95D554037CEDA1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_ConsultantWarrantsMember_D66191DD568E52F4AB95D554037CEDA1" xlink:to="lab_gale_ConsultantWarrantsMember_D66191DD568E52F4AB95D554037CEDA1" xlink:type="arc" />
    <link:label id="lab_us-gaap_MinimumMember_D4A40A4D953FC7D8893CE0E750D0C458_terseLabel_en-US" xlink:label="lab_us-gaap_MinimumMember_2902E1CFD66B570C9C1C930AA627E6FC" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Minimum [Member]</link:label>
    <link:label id="lab_us-gaap_MinimumMember_D4A40A4D953FC7D8893CE0E750D0C458_label_en-US" xlink:label="lab_us-gaap_MinimumMember_2902E1CFD66B570C9C1C930AA627E6FC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Minimum [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_MinimumMember" xlink:label="loc_us-gaap_MinimumMember_2902E1CFD66B570C9C1C930AA627E6FC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MinimumMember_2902E1CFD66B570C9C1C930AA627E6FC" xlink:to="lab_us-gaap_MinimumMember_2902E1CFD66B570C9C1C930AA627E6FC" xlink:type="arc" />
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightLineItems_16A6FF46AFA034A48119E0E750D0871D_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightLineItems_F628DEAC97C65E7BB91A36012AAE27F3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right [Line Items]</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightLineItems_16A6FF46AFA034A48119E0E750D0871D_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightLineItems_F628DEAC97C65E7BB91A36012AAE27F3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ClassOfWarrantOrRightLineItems" xlink:label="loc_us-gaap_ClassOfWarrantOrRightLineItems_F628DEAC97C65E7BB91A36012AAE27F3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_F628DEAC97C65E7BB91A36012AAE27F3" xlink:to="lab_us-gaap_ClassOfWarrantOrRightLineItems_F628DEAC97C65E7BB91A36012AAE27F3" xlink:type="arc" />
    <link:label id="lab_gale_ClassofWarrantorRightOutstandingRollForward_81F9DAFE56A4C6C4D19BE0E750D0976B_terseLabel_en-US" xlink:label="lab_gale_ClassofWarrantorRightOutstandingRollForward_63F072EBFC4A53E4A2BF695DF9E8B51E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right, Outstanding [Roll Forward]</link:label>
    <link:label id="lab_gale_ClassofWarrantorRightOutstandingRollForward_81F9DAFE56A4C6C4D19BE0E750D0976B_label_en-US" xlink:label="lab_gale_ClassofWarrantorRightOutstandingRollForward_63F072EBFC4A53E4A2BF695DF9E8B51E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right, Outstanding [Roll Forward]</link:label>
    <link:label id="lab_gale_ClassofWarrantorRightOutstandingRollForward_81F9DAFE56A4C6C4D19BE0E750D0976B_documentation_en-US" xlink:label="lab_gale_ClassofWarrantorRightOutstandingRollForward_63F072EBFC4A53E4A2BF695DF9E8B51E" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right, Outstanding [Roll Forward]</link:label>
    <link:loc xlink:href="gale-20150930.xsd#gale_ClassofWarrantorRightOutstandingRollForward" xlink:label="loc_gale_ClassofWarrantorRightOutstandingRollForward_63F072EBFC4A53E4A2BF695DF9E8B51E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_ClassofWarrantorRightOutstandingRollForward_63F072EBFC4A53E4A2BF695DF9E8B51E" xlink:to="lab_gale_ClassofWarrantorRightOutstandingRollForward_63F072EBFC4A53E4A2BF695DF9E8B51E" xlink:type="arc" />
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightOutstanding_ECD543A45F35CAB69103E0E750D01D13_periodStartLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightOutstanding_D87C55071BD2522C82ED829456A5E41F" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Warrants outstanding , Beginning balance</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightOutstanding_ECD543A45F35CAB69103E0E750D01D13_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightOutstanding_D87C55071BD2522C82ED829456A5E41F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right, Outstanding</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="loc_us-gaap_ClassOfWarrantOrRightOutstanding_D87C55071BD2522C82ED829456A5E41F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightOutstanding_D87C55071BD2522C82ED829456A5E41F" xlink:to="lab_us-gaap_ClassOfWarrantOrRightOutstanding_D87C55071BD2522C82ED829456A5E41F" xlink:type="arc" />
    <link:label id="lab_gale_ClassofWarrantorRightGranted_9A314EBCE8131E0F095AE0E750D0B2C7_terseLabel_en-US" xlink:label="lab_gale_ClassofWarrantorRightGranted_CEE334D934A9544099F95320BCC4EA9D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Granted</link:label>
    <link:label id="lab_gale_ClassofWarrantorRightGranted_9A314EBCE8131E0F095AE0E750D0B2C7_label_en-US" xlink:label="lab_gale_ClassofWarrantorRightGranted_CEE334D934A9544099F95320BCC4EA9D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right Granted</link:label>
    <link:label id="lab_gale_ClassofWarrantorRightGranted_9A314EBCE8131E0F095AE0E750D0B2C7_documentation_en-US" xlink:label="lab_gale_ClassofWarrantorRightGranted_CEE334D934A9544099F95320BCC4EA9D" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right Granted</link:label>
    <link:loc xlink:href="gale-20150930.xsd#gale_ClassofWarrantorRightGranted" xlink:label="loc_gale_ClassofWarrantorRightGranted_CEE334D934A9544099F95320BCC4EA9D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_ClassofWarrantorRightGranted_CEE334D934A9544099F95320BCC4EA9D" xlink:to="lab_gale_ClassofWarrantorRightGranted_CEE334D934A9544099F95320BCC4EA9D" xlink:type="arc" />
    <link:label id="lab_gale_ClassofWarrantorRightExpired_C138AB45DF312823F8B3E0ED92D252E8_terseLabel_en-US" xlink:label="lab_gale_ClassofWarrantorRightExpired_1F24F330076051E4B4ADAABC07A3860E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right, Expired</link:label>
    <link:label id="lab_gale_ClassofWarrantorRightExpired_C138AB45DF312823F8B3E0ED92D252E8_label_en-US" xlink:label="lab_gale_ClassofWarrantorRightExpired_1F24F330076051E4B4ADAABC07A3860E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right, Expired</link:label>
    <link:label id="lab_gale_ClassofWarrantorRightExpired_C138AB45DF312823F8B3E0ED92D252E8_documentation_en-US" xlink:label="lab_gale_ClassofWarrantorRightExpired_1F24F330076051E4B4ADAABC07A3860E" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right, Expired</link:label>
    <link:loc xlink:href="gale-20150930.xsd#gale_ClassofWarrantorRightExpired" xlink:label="loc_gale_ClassofWarrantorRightExpired_1F24F330076051E4B4ADAABC07A3860E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_ClassofWarrantorRightExpired_1F24F330076051E4B4ADAABC07A3860E" xlink:to="lab_gale_ClassofWarrantorRightExpired_1F24F330076051E4B4ADAABC07A3860E" xlink:type="arc" />
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightOutstanding_6672AC4EC982E71C1D1FE0E750D020FD_periodEndLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightOutstanding_3273D635B91554559C901C3AF1BD7C79" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Warrants outstanding , Ending balance</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="loc_us-gaap_ClassOfWarrantOrRightOutstanding_3273D635B91554559C901C3AF1BD7C79" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightOutstanding_3273D635B91554559C901C3AF1BD7C79" xlink:to="lab_us-gaap_ClassOfWarrantOrRightOutstanding_3273D635B91554559C901C3AF1BD7C79" xlink:type="arc" />
    <link:label id="lab_gale_ClassOfWarrantsOrRightsExpirationDate_1DED05DF4FFD197BC55BE0E750D083E9_terseLabel_en-US" xlink:label="lab_gale_ClassOfWarrantsOrRightsExpirationDate_35F665F4D9DF51858872826FE354D16B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Expiration</link:label>
    <link:label id="lab_gale_ClassOfWarrantsOrRightsExpirationDate_1DED05DF4FFD197BC55BE0E750D083E9_label_en-US" xlink:label="lab_gale_ClassOfWarrantsOrRightsExpirationDate_35F665F4D9DF51858872826FE354D16B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class Of Warrants Or Rights Expiration Date</link:label>
    <link:label id="lab_gale_ClassOfWarrantsOrRightsExpirationDate_1DED05DF4FFD197BC55BE0E750D083E9_documentation_en-US" xlink:label="lab_gale_ClassOfWarrantsOrRightsExpirationDate_35F665F4D9DF51858872826FE354D16B" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Class Of Warrants Or Rights Expiration Date</link:label>
    <link:loc xlink:href="gale-20150930.xsd#gale_ClassOfWarrantsOrRightsExpirationDate" xlink:label="loc_gale_ClassOfWarrantsOrRightsExpirationDate_35F665F4D9DF51858872826FE354D16B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_ClassOfWarrantsOrRightsExpirationDate_35F665F4D9DF51858872826FE354D16B" xlink:to="lab_gale_ClassOfWarrantsOrRightsExpirationDate_35F665F4D9DF51858872826FE354D16B" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccountingPoliciesAbstract_0CC448C45B32DF4E99DFDECE1E7F9227_label_en-US" xlink:label="lab_us-gaap_AccountingPoliciesAbstract_0CC448C45B32DF4E99DFDECE1E7F9227" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_0CC448C45B32DF4E99DFDECE1E7F9227" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0CC448C45B32DF4E99DFDECE1E7F9227" xlink:to="lab_us-gaap_AccountingPoliciesAbstract_0CC448C45B32DF4E99DFDECE1E7F9227" xlink:type="arc" />
    <link:label id="lab_gale_ScheduleOfSummaryOfSignificantAccountingPoliciesTable_15E05D38C24332DBC547DECE1E80DFE9_terseLabel_en-US" xlink:label="lab_gale_ScheduleOfSummaryOfSignificantAccountingPoliciesTable_15E05D38C24332DBC547DECE1E80DFE9" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule Of Summary Of Significant Accounting Policies [Table]</link:label>
    <link:label id="lab_gale_ScheduleOfSummaryOfSignificantAccountingPoliciesTable_15E05D38C24332DBC547DECE1E80DFE9_label_en-US" xlink:label="lab_gale_ScheduleOfSummaryOfSignificantAccountingPoliciesTable_15E05D38C24332DBC547DECE1E80DFE9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule Of Summary Of Significant Accounting Policies [Table]</link:label>
    <link:label id="lab_gale_ScheduleOfSummaryOfSignificantAccountingPoliciesTable_15E05D38C24332DBC547DECE1E80DFE9_documentation_en-US" xlink:label="lab_gale_ScheduleOfSummaryOfSignificantAccountingPoliciesTable_15E05D38C24332DBC547DECE1E80DFE9" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Schedule Of Summary Of Significant Accounting Policies [Table]</link:label>
    <link:loc xlink:href="gale-20150930.xsd#gale_ScheduleOfSummaryOfSignificantAccountingPoliciesTable" xlink:label="loc_gale_ScheduleOfSummaryOfSignificantAccountingPoliciesTable_15E05D38C24332DBC547DECE1E80DFE9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_ScheduleOfSummaryOfSignificantAccountingPoliciesTable_15E05D38C24332DBC547DECE1E80DFE9" xlink:to="lab_gale_ScheduleOfSummaryOfSignificantAccountingPoliciesTable_15E05D38C24332DBC547DECE1E80DFE9" xlink:type="arc" />
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_1DB980BDFCFEA1260C80DECE1E810547_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_1DB980BDFCFEA1260C80DECE1E810547" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment, Type [Axis]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_1DB980BDFCFEA1260C80DECE1E810547_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_1DB980BDFCFEA1260C80DECE1E810547" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment, Type [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_1DB980BDFCFEA1260C80DECE1E810547" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_1DB980BDFCFEA1260C80DECE1E810547" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_1DB980BDFCFEA1260C80DECE1E810547" xlink:type="arc" />
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain_22614AB42CEC081C2A5EDECE1E8119E5_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain_22614AB42CEC081C2A5EDECE1E8119E5" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment, Type [Domain]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain_22614AB42CEC081C2A5EDECE1E8119E5_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain_22614AB42CEC081C2A5EDECE1E8119E5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment, Type [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_22614AB42CEC081C2A5EDECE1E8119E5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_22614AB42CEC081C2A5EDECE1E8119E5" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain_22614AB42CEC081C2A5EDECE1E8119E5" xlink:type="arc" />
    <link:label id="lab_gale_EquipmentFurnitureAndFixturesMember_B777E9E80CD82CC887D7DECE1E81389D_terseLabel_en-US" xlink:label="lab_gale_EquipmentFurnitureAndFixturesMember_B777E9E80CD82CC887D7DECE1E81389D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equipment and Furnishings [Member]</link:label>
    <link:label id="lab_gale_EquipmentFurnitureAndFixturesMember_B777E9E80CD82CC887D7DECE1E81389D_label_en-US" xlink:label="lab_gale_EquipmentFurnitureAndFixturesMember_B777E9E80CD82CC887D7DECE1E81389D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equipment Furniture And Fixtures [Member]</link:label>
    <link:label id="lab_gale_EquipmentFurnitureAndFixturesMember_B777E9E80CD82CC887D7DECE1E81389D_documentation_en-US" xlink:label="lab_gale_EquipmentFurnitureAndFixturesMember_B777E9E80CD82CC887D7DECE1E81389D" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Equipment Furniture And Fixtures [Member]</link:label>
    <link:loc xlink:href="gale-20150930.xsd#gale_EquipmentFurnitureAndFixturesMember" xlink:label="loc_gale_EquipmentFurnitureAndFixturesMember_B777E9E80CD82CC887D7DECE1E81389D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_EquipmentFurnitureAndFixturesMember_B777E9E80CD82CC887D7DECE1E81389D" xlink:to="lab_gale_EquipmentFurnitureAndFixturesMember_B777E9E80CD82CC887D7DECE1E81389D" xlink:type="arc" />
    <link:label id="lab_gale_ScheduleOfSummaryOfSignificantAccountingPoliciesLineItems_E3D0066C4A9F53F30EDADECE1E81384E_terseLabel_en-US" xlink:label="lab_gale_ScheduleOfSummaryOfSignificantAccountingPoliciesLineItems_E3D0066C4A9F53F30EDADECE1E81384E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule Of Summary Of Significant Accounting Policies [Line Items]</link:label>
    <link:label id="lab_gale_ScheduleOfSummaryOfSignificantAccountingPoliciesLineItems_E3D0066C4A9F53F30EDADECE1E81384E_label_en-US" xlink:label="lab_gale_ScheduleOfSummaryOfSignificantAccountingPoliciesLineItems_E3D0066C4A9F53F30EDADECE1E81384E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule Of Summary Of Significant Accounting Policies [Line Items]</link:label>
    <link:label id="lab_gale_ScheduleOfSummaryOfSignificantAccountingPoliciesLineItems_E3D0066C4A9F53F30EDADECE1E81384E_documentation_en-US" xlink:label="lab_gale_ScheduleOfSummaryOfSignificantAccountingPoliciesLineItems_E3D0066C4A9F53F30EDADECE1E81384E" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Schedule Of Summary Of Significant Accounting Policies [Line Items]</link:label>
    <link:loc xlink:href="gale-20150930.xsd#gale_ScheduleOfSummaryOfSignificantAccountingPoliciesLineItems" xlink:label="loc_gale_ScheduleOfSummaryOfSignificantAccountingPoliciesLineItems_E3D0066C4A9F53F30EDADECE1E81384E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_ScheduleOfSummaryOfSignificantAccountingPoliciesLineItems_E3D0066C4A9F53F30EDADECE1E81384E" xlink:to="lab_gale_ScheduleOfSummaryOfSignificantAccountingPoliciesLineItems_E3D0066C4A9F53F30EDADECE1E81384E" xlink:type="arc" />
    <link:label id="lab_gale_NumberofPatientsDiagnosedWithBreastCancerPatientsAnnuallyAtHighRiskofDiseaseRecurrence_37EAB06DA03CBE2EC5FBDECE1E86A9E4_terseLabel_en-US" xlink:label="lab_gale_NumberofPatientsDiagnosedWithBreastCancerPatientsAnnuallyAtHighRiskofDiseaseRecurrence_37EAB06DA03CBE2EC5FBDECE1E86A9E4" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of Patients Diagnosed With Breast Cancer Patients Annually At High Risk of Disease Recurrence</link:label>
    <link:label id="lab_gale_NumberofPatientsDiagnosedWithBreastCancerPatientsAnnuallyAtHighRiskofDiseaseRecurrence_37EAB06DA03CBE2EC5FBDECE1E86A9E4_label_en-US" xlink:label="lab_gale_NumberofPatientsDiagnosedWithBreastCancerPatientsAnnuallyAtHighRiskofDiseaseRecurrence_37EAB06DA03CBE2EC5FBDECE1E86A9E4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number of Patients Diagnosed With Breast Cancer Patients Annually At High Risk of Disease Recurrence</link:label>
    <link:label id="lab_gale_NumberofPatientsDiagnosedWithBreastCancerPatientsAnnuallyAtHighRiskofDiseaseRecurrence_37EAB06DA03CBE2EC5FBDECE1E86A9E4_documentation_en-US" xlink:label="lab_gale_NumberofPatientsDiagnosedWithBreastCancerPatientsAnnuallyAtHighRiskofDiseaseRecurrence_37EAB06DA03CBE2EC5FBDECE1E86A9E4" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Number of Patients Diagnosed With Breast Cancer Patients Annually At High Risk of Disease Recurrence</link:label>
    <link:loc xlink:href="gale-20150930.xsd#gale_NumberofPatientsDiagnosedWithBreastCancerPatientsAnnuallyAtHighRiskofDiseaseRecurrence" xlink:label="loc_gale_NumberofPatientsDiagnosedWithBreastCancerPatientsAnnuallyAtHighRiskofDiseaseRecurrence_37EAB06DA03CBE2EC5FBDECE1E86A9E4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_NumberofPatientsDiagnosedWithBreastCancerPatientsAnnuallyAtHighRiskofDiseaseRecurrence_37EAB06DA03CBE2EC5FBDECE1E86A9E4" xlink:to="lab_gale_NumberofPatientsDiagnosedWithBreastCancerPatientsAnnuallyAtHighRiskofDiseaseRecurrence_37EAB06DA03CBE2EC5FBDECE1E86A9E4" xlink:type="arc" />
    <link:label id="lab_gale_NumberofPatientsDiagnosedWithBreastCancerPatientsAnnually_FB93284E5CCB84EDBEB5DECE1E87F265_terseLabel_en-US" xlink:label="lab_gale_NumberofPatientsDiagnosedWithBreastCancerPatientsAnnually_FB93284E5CCB84EDBEB5DECE1E87F265" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of Patients Diagnosed With Breast Cancer Patients Annually</link:label>
    <link:label id="lab_gale_NumberofPatientsDiagnosedWithBreastCancerPatientsAnnually_FB93284E5CCB84EDBEB5DECE1E87F265_label_en-US" xlink:label="lab_gale_NumberofPatientsDiagnosedWithBreastCancerPatientsAnnually_FB93284E5CCB84EDBEB5DECE1E87F265" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number of Patients Diagnosed With Breast Cancer Patients Annually</link:label>
    <link:label id="lab_gale_NumberofPatientsDiagnosedWithBreastCancerPatientsAnnually_FB93284E5CCB84EDBEB5DECE1E87F265_documentation_en-US" xlink:label="lab_gale_NumberofPatientsDiagnosedWithBreastCancerPatientsAnnually_FB93284E5CCB84EDBEB5DECE1E87F265" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Number of Patients Diagnosed With Breast Cancer Patients Annually</link:label>
    <link:loc xlink:href="gale-20150930.xsd#gale_NumberofPatientsDiagnosedWithBreastCancerPatientsAnnually" xlink:label="loc_gale_NumberofPatientsDiagnosedWithBreastCancerPatientsAnnually_FB93284E5CCB84EDBEB5DECE1E87F265" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_NumberofPatientsDiagnosedWithBreastCancerPatientsAnnually_FB93284E5CCB84EDBEB5DECE1E87F265" xlink:to="lab_gale_NumberofPatientsDiagnosedWithBreastCancerPatientsAnnually_FB93284E5CCB84EDBEB5DECE1E87F265" xlink:type="arc" />
    <link:label id="lab_us-gaap_AllowanceForDoubtfulAccountsReceivable_58C3EFB14EB81C9C1E10DECE1E872BEE_terseLabel_en-US" xlink:label="lab_us-gaap_AllowanceForDoubtfulAccountsReceivable_58C3EFB14EB81C9C1E10DECE1E872BEE" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Allowance for doubtful accounts</link:label>
    <link:label id="lab_us-gaap_AllowanceForDoubtfulAccountsReceivable_58C3EFB14EB81C9C1E10DECE1E872BEE_label_en-US" xlink:label="lab_us-gaap_AllowanceForDoubtfulAccountsReceivable_58C3EFB14EB81C9C1E10DECE1E872BEE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Allowance for Doubtful Accounts Receivable</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivable" xlink:label="loc_us-gaap_AllowanceForDoubtfulAccountsReceivable_58C3EFB14EB81C9C1E10DECE1E872BEE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllowanceForDoubtfulAccountsReceivable_58C3EFB14EB81C9C1E10DECE1E872BEE" xlink:to="lab_us-gaap_AllowanceForDoubtfulAccountsReceivable_58C3EFB14EB81C9C1E10DECE1E872BEE" xlink:type="arc" />
    <link:label id="lab_gale_MaximumMaturityPeriodToConsiderAllHighlyLiquidDebtInstrumentsAsCashAndCashEquivalents_0432E498B77DC7321941DECE1E87D006_terseLabel_en-US" xlink:label="lab_gale_MaximumMaturityPeriodToConsiderAllHighlyLiquidDebtInstrumentsAsCashAndCashEquivalents_0432E498B77DC7321941DECE1E87D006" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Highly-liquid debt instruments maturity days</link:label>
    <link:label id="lab_gale_MaximumMaturityPeriodToConsiderAllHighlyLiquidDebtInstrumentsAsCashAndCashEquivalents_0432E498B77DC7321941DECE1E87D006_label_en-US" xlink:label="lab_gale_MaximumMaturityPeriodToConsiderAllHighlyLiquidDebtInstrumentsAsCashAndCashEquivalents_0432E498B77DC7321941DECE1E87D006" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Maximum Maturity Period To Consider All Highly Liquid Debt Instruments As Cash And Cash Equivalents</link:label>
    <link:label id="lab_gale_MaximumMaturityPeriodToConsiderAllHighlyLiquidDebtInstrumentsAsCashAndCashEquivalents_0432E498B77DC7321941DECE1E87D006_documentation_en-US" xlink:label="lab_gale_MaximumMaturityPeriodToConsiderAllHighlyLiquidDebtInstrumentsAsCashAndCashEquivalents_0432E498B77DC7321941DECE1E87D006" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Maximum Maturity Period To Consider All Highly Liquid Debt Instruments As Cash And Cash Equivalents</link:label>
    <link:loc xlink:href="gale-20150930.xsd#gale_MaximumMaturityPeriodToConsiderAllHighlyLiquidDebtInstrumentsAsCashAndCashEquivalents" xlink:label="loc_gale_MaximumMaturityPeriodToConsiderAllHighlyLiquidDebtInstrumentsAsCashAndCashEquivalents_0432E498B77DC7321941DECE1E87D006" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_MaximumMaturityPeriodToConsiderAllHighlyLiquidDebtInstrumentsAsCashAndCashEquivalents_0432E498B77DC7321941DECE1E87D006" xlink:to="lab_gale_MaximumMaturityPeriodToConsiderAllHighlyLiquidDebtInstrumentsAsCashAndCashEquivalents_0432E498B77DC7321941DECE1E87D006" xlink:type="arc" />
    <link:label id="lab_us-gaap_InventoryWorkInProcess_5D4E23F4AB38BBC34391DECE1E8740A5_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryWorkInProcess_5D4E23F4AB38BBC34391DECE1E8740A5" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Inventories, work-in-process</link:label>
    <link:label id="lab_us-gaap_InventoryWorkInProcess_5D4E23F4AB38BBC34391DECE1E8740A5_label_en-US" xlink:label="lab_us-gaap_InventoryWorkInProcess_5D4E23F4AB38BBC34391DECE1E8740A5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Inventory, Work in Process, Gross</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_InventoryWorkInProcess" xlink:label="loc_us-gaap_InventoryWorkInProcess_5D4E23F4AB38BBC34391DECE1E8740A5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryWorkInProcess_5D4E23F4AB38BBC34391DECE1E8740A5" xlink:to="lab_us-gaap_InventoryWorkInProcess_5D4E23F4AB38BBC34391DECE1E8740A5" xlink:type="arc" />
    <link:label id="lab_us-gaap_InventoryFinishedGoods_9D7B83ACF144DA8A1EB5DECE1E876B50_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryFinishedGoods_9D7B83ACF144DA8A1EB5DECE1E876B50" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Inventories, finished goods</link:label>
    <link:label id="lab_us-gaap_InventoryFinishedGoods_9D7B83ACF144DA8A1EB5DECE1E876B50_label_en-US" xlink:label="lab_us-gaap_InventoryFinishedGoods_9D7B83ACF144DA8A1EB5DECE1E876B50" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Inventory, Finished Goods, Gross</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_InventoryFinishedGoods" xlink:label="loc_us-gaap_InventoryFinishedGoods_9D7B83ACF144DA8A1EB5DECE1E876B50" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryFinishedGoods_9D7B83ACF144DA8A1EB5DECE1E876B50" xlink:to="lab_us-gaap_InventoryFinishedGoods_9D7B83ACF144DA8A1EB5DECE1E876B50" xlink:type="arc" />
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife_0BB6017A68A1FAFE6C10DECE1E87CB8B_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife_0BB6017A68A1FAFE6C10DECE1E87CB8B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Estimated useful lives</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife_0BB6017A68A1FAFE6C10DECE1E87CB8B_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife_0BB6017A68A1FAFE6C10DECE1E87CB8B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment, Useful Life</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_0BB6017A68A1FAFE6C10DECE1E87CB8B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_0BB6017A68A1FAFE6C10DECE1E87CB8B" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife_0BB6017A68A1FAFE6C10DECE1E87CB8B" xlink:type="arc" />
    <link:label id="lab_us-gaap_SalesDiscountsServices_870A8B3B3EE560B538A1DECE1E87A20A_terseLabel_en-US" xlink:label="lab_us-gaap_SalesDiscountsServices_870A8B3B3EE560B538A1DECE1E87A20A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Prompyt pay discount, percent of gross sales</link:label>
    <link:label id="lab_us-gaap_SalesDiscountsServices_870A8B3B3EE560B538A1DECE1E87A20A_label_en-US" xlink:label="lab_us-gaap_SalesDiscountsServices_870A8B3B3EE560B538A1DECE1E87A20A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sales Discounts, Services</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SalesDiscountsServices" xlink:label="loc_us-gaap_SalesDiscountsServices_870A8B3B3EE560B538A1DECE1E87A20A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SalesDiscountsServices_870A8B3B3EE560B538A1DECE1E87A20A" xlink:to="lab_us-gaap_SalesDiscountsServices_870A8B3B3EE560B538A1DECE1E87A20A" xlink:type="arc" />
    <link:label id="lab_us-gaap_AmortizationOfIntangibleAssets_90A6C2DF78480C960857DECE1E87AA80_terseLabel_en-US" xlink:label="lab_us-gaap_AmortizationOfIntangibleAssets_90A6C2DF78480C960857DECE1E87AA80" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amortization of certain acquired intangible assets</link:label>
    <link:label id="lab_us-gaap_AmortizationOfIntangibleAssets_90A6C2DF78480C960857DECE1E87AA80_label_en-US" xlink:label="lab_us-gaap_AmortizationOfIntangibleAssets_90A6C2DF78480C960857DECE1E87AA80" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Amortization of Intangible Assets</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AmortizationOfIntangibleAssets" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets_90A6C2DF78480C960857DECE1E87AA80" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AmortizationOfIntangibleAssets_90A6C2DF78480C960857DECE1E87AA80" xlink:to="lab_us-gaap_AmortizationOfIntangibleAssets_90A6C2DF78480C960857DECE1E87AA80" xlink:type="arc" />
    <link:label id="lab_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock_E8EDEF544114304620C4DDA4F6B50953_terseLabel_en-US" xlink:label="lab_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock_E8EDEF544114304620C4DDA4F6B50953" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedules of Concentration of Risk, by Risk Factor [Table Text Block]</link:label>
    <link:label id="lab_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock_E8EDEF544114304620C4DDA4F6B50953_label_en-US" xlink:label="lab_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock_E8EDEF544114304620C4DDA4F6B50953" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedules of Concentration of Risk, by Risk Factor [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock" xlink:label="loc_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock_E8EDEF544114304620C4DDA4F6B50953" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock_E8EDEF544114304620C4DDA4F6B50953" xlink:to="lab_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock_E8EDEF544114304620C4DDA4F6B50953" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_18459779389FFE7A38BBDEEC49F8FA2E_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_18459779389FFE7A38BBDEEC49F8FA2E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Table]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_18459779389FFE7A38BBDEEC49F8FA2E_label_en-US" xlink:label="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_18459779389FFE7A38BBDEEC49F8FA2E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_18459779389FFE7A38BBDEEC49F8FA2E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_18459779389FFE7A38BBDEEC49F8FA2E" xlink:to="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_18459779389FFE7A38BBDEEC49F8FA2E" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_71BAB3D817A2D367CCC0DEEC49F8BD9C_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_71BAB3D817A2D367CCC0DEEC49F8BD9C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disposal Group Name [Axis]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_71BAB3D817A2D367CCC0DEEC49F8BD9C_label_en-US" xlink:label="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_71BAB3D817A2D367CCC0DEEC49F8BD9C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disposal Group Name [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_71BAB3D817A2D367CCC0DEEC49F8BD9C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_71BAB3D817A2D367CCC0DEEC49F8BD9C" xlink:to="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_71BAB3D817A2D367CCC0DEEC49F8BD9C" xlink:type="arc" />
    <link:label id="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_B3B551D1663C6A001460DEEC49F8D756_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_B3B551D1663C6A001460DEEC49F8D756" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disposal Groups, Including Discontinued Operations, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_B3B551D1663C6A001460DEEC49F8D756_label_en-US" xlink:label="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_B3B551D1663C6A001460DEEC49F8D756" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disposal Groups, Including Discontinued Operations, Name [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_B3B551D1663C6A001460DEEC49F8D756" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_B3B551D1663C6A001460DEEC49F8D756" xlink:to="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_B3B551D1663C6A001460DEEC49F8D756" xlink:type="arc" />
    <link:label id="lab_gale_CommercialBusinessSegmentMember_55B03EF9A0D34B99CEA9DEEC49F8D9E2_terseLabel_en-US" xlink:label="lab_gale_CommercialBusinessSegmentMember_55B03EF9A0D34B99CEA9DEEC49F8D9E2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Commercial Business Segment [Member]</link:label>
    <link:label id="lab_gale_CommercialBusinessSegmentMember_55B03EF9A0D34B99CEA9DEEC49F8D9E2_label_en-US" xlink:label="lab_gale_CommercialBusinessSegmentMember_55B03EF9A0D34B99CEA9DEEC49F8D9E2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Commercial Business Segment [Member]</link:label>
    <link:label id="lab_gale_CommercialBusinessSegmentMember_55B03EF9A0D34B99CEA9DEEC49F8D9E2_documentation_en-US" xlink:label="lab_gale_CommercialBusinessSegmentMember_55B03EF9A0D34B99CEA9DEEC49F8D9E2" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Commercial Business Segment [Member]</link:label>
    <link:loc xlink:href="gale-20150930.xsd#gale_CommercialBusinessSegmentMember" xlink:label="loc_gale_CommercialBusinessSegmentMember_55B03EF9A0D34B99CEA9DEEC49F8D9E2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_CommercialBusinessSegmentMember_55B03EF9A0D34B99CEA9DEEC49F8D9E2" xlink:to="lab_gale_CommercialBusinessSegmentMember_55B03EF9A0D34B99CEA9DEEC49F8D9E2" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_009063029D01C6E5A358DEEC49F80CA4_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_009063029D01C6E5A358DEEC49F80CA4" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_009063029D01C6E5A358DEEC49F80CA4_label_en-US" xlink:label="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_009063029D01C6E5A358DEEC49F80CA4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_009063029D01C6E5A358DEEC49F80CA4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_009063029D01C6E5A358DEEC49F80CA4" xlink:to="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_009063029D01C6E5A358DEEC49F80CA4" xlink:type="arc" />
    <link:label id="lab_us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf_15750ABD82480B132C83DEEC49F8F89A_verboseLabel_en-US" xlink:label="lab_us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf_15750ABD82480B132C83DEEC49F8F89A" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Impairment of assets held for sale</link:label>
    <link:label id="lab_us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf_15750ABD82480B132C83DEEC49F8F89A_label_en-US" xlink:label="lab_us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf_15750ABD82480B132C83DEEC49F8F89A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Impairment of Long-Lived Assets to be Disposed of</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf" xlink:label="loc_us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf_15750ABD82480B132C83DEEC49F8F89A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf_15750ABD82480B132C83DEEC49F8F89A" xlink:to="lab_us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf_15750ABD82480B132C83DEEC49F8F89A" xlink:type="arc" />
    <link:label id="lab_us-gaap_DepreciationDepletionAndAmortization_85E019D9BED9B2D8FC6BDEEC49F93BA0_terseLabel_en-US" xlink:label="lab_us-gaap_DepreciationDepletionAndAmortization_85E019D9BED9B2D8FC6BDEEC49F93BA0" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Depreciation and amortization expense</link:label>
    <link:label id="lab_us-gaap_DepreciationDepletionAndAmortization_85E019D9BED9B2D8FC6BDEEC49F93BA0_label_en-US" xlink:label="lab_us-gaap_DepreciationDepletionAndAmortization_85E019D9BED9B2D8FC6BDEEC49F93BA0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Depreciation, Depletion and Amortization</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_85E019D9BED9B2D8FC6BDEEC49F93BA0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DepreciationDepletionAndAmortization_85E019D9BED9B2D8FC6BDEEC49F93BA0" xlink:to="lab_us-gaap_DepreciationDepletionAndAmortization_85E019D9BED9B2D8FC6BDEEC49F93BA0" xlink:type="arc" />
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_5853A0B6E5AEECEB045FDEEC49F95842_terseLabel_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense_5853A0B6E5AEECEB045FDEEC49F95842" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Allocated share based compensation expense</link:label>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_5853A0B6E5AEECEB045FDEEC49F95842_label_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense_5853A0B6E5AEECEB045FDEEC49F95842" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Allocated Share-based Compensation Expense</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_5853A0B6E5AEECEB045FDEEC49F95842" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllocatedShareBasedCompensationExpense_5853A0B6E5AEECEB045FDEEC49F95842" xlink:to="lab_us-gaap_AllocatedShareBasedCompensationExpense_5853A0B6E5AEECEB045FDEEC49F95842" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensation_252706E93CE4197E00AEDEEC49F95FEA_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation_252706E93CE4197E00AEDEEC49F95FEA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-cash stock-based compensation</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensation_252706E93CE4197E00AEDEEC49F95FEA_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation_252706E93CE4197E00AEDEEC49F95FEA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaap_ShareBasedCompensation_252706E93CE4197E00AEDEEC49F95FEA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensation_252706E93CE4197E00AEDEEC49F95FEA" xlink:to="lab_us-gaap_ShareBasedCompensation_252706E93CE4197E00AEDEEC49F95FEA" xlink:type="arc" />
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_FD7484B9528DAD9F738DDEEC49F966AF_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_FD7484B9528DAD9F738DDEEC49F966AF" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Purchases of property and equipment</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_FD7484B9528DAD9F738DDEEC49F966AF_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_FD7484B9528DAD9F738DDEEC49F966AF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments to Acquire Property, Plant, and Equipment</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_FD7484B9528DAD9F738DDEEC49F966AF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_FD7484B9528DAD9F738DDEEC49F966AF" xlink:to="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_FD7484B9528DAD9F738DDEEC49F966AF" xlink:type="arc" />
    <link:label id="lab_us-gaap_PaymentsToAcquireIntangibleAssets_DD9A4B47496B79F29297DEEC49F9E14C_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireIntangibleAssets_DD9A4B47496B79F29297DEEC49F9E14C" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Cash paid for acquisition of Zuplenz rights</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireIntangibleAssets_DD9A4B47496B79F29297DEEC49F9E14C_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireIntangibleAssets_DD9A4B47496B79F29297DEEC49F9E14C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments to Acquire Intangible Assets</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PaymentsToAcquireIntangibleAssets" xlink:label="loc_us-gaap_PaymentsToAcquireIntangibleAssets_DD9A4B47496B79F29297DEEC49F9E14C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireIntangibleAssets_DD9A4B47496B79F29297DEEC49F9E14C" xlink:to="lab_us-gaap_PaymentsToAcquireIntangibleAssets_DD9A4B47496B79F29297DEEC49F9E14C" xlink:type="arc" />
    <link:label id="lab_gale_PercentageofCancerPatientsAffectedbyInadequatelyControlledBreakthroughCancerPainBTcP_1610805B548208DECA69DE31303140A3_terseLabel_en-US" xlink:label="lab_gale_PercentageofCancerPatientsAffectedbyInadequatelyControlledBreakthroughCancerPainBTcP_1610805B548208DECA69DE31303140A3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Percentage of cancer patients affected by inadequately controlled breakthrough cancer pain (BTcP) (in percent)</link:label>
    <link:label id="lab_gale_PercentageofCancerPatientsAffectedbyInadequatelyControlledBreakthroughCancerPainBTcP_1610805B548208DECA69DE31303140A3_label_en-US" xlink:label="lab_gale_PercentageofCancerPatientsAffectedbyInadequatelyControlledBreakthroughCancerPainBTcP_1610805B548208DECA69DE31303140A3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Percentage of Cancer Patients Affected by Inadequately Controlled Breakthrough Cancer Pain (BTcP)</link:label>
    <link:label id="lab_gale_PercentageofCancerPatientsAffectedbyInadequatelyControlledBreakthroughCancerPainBTcP_1610805B548208DECA69DE31303140A3_documentation_en-US" xlink:label="lab_gale_PercentageofCancerPatientsAffectedbyInadequatelyControlledBreakthroughCancerPainBTcP_1610805B548208DECA69DE31303140A3" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Percentage of Cancer Patients Affected by Inadequately Controlled Breakthrough Cancer Pain (BTcP)</link:label>
    <link:loc xlink:href="gale-20150930.xsd#gale_PercentageofCancerPatientsAffectedbyInadequatelyControlledBreakthroughCancerPainBTcP" xlink:label="loc_gale_PercentageofCancerPatientsAffectedbyInadequatelyControlledBreakthroughCancerPainBTcP_1610805B548208DECA69DE31303140A3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_PercentageofCancerPatientsAffectedbyInadequatelyControlledBreakthroughCancerPainBTcP_1610805B548208DECA69DE31303140A3" xlink:to="lab_gale_PercentageofCancerPatientsAffectedbyInadequatelyControlledBreakthroughCancerPainBTcP_1610805B548208DECA69DE31303140A3" xlink:type="arc" />
    <link:label id="lab_gale_DisposalGroupIncludingDiscontinuedOperationContingentLiabilityFromDivestitureAgreement_A509B516526B0795943DDE3607C6CBF0_terseLabel_en-US" xlink:label="lab_gale_DisposalGroupIncludingDiscontinuedOperationContingentLiabilityFromDivestitureAgreement_A509B516526B0795943DDE3607C6CBF0" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Success fee contingently due to third party</link:label>
    <link:label id="lab_gale_DisposalGroupIncludingDiscontinuedOperationContingentLiabilityFromDivestitureAgreement_A509B516526B0795943DDE3607C6CBF0_label_en-US" xlink:label="lab_gale_DisposalGroupIncludingDiscontinuedOperationContingentLiabilityFromDivestitureAgreement_A509B516526B0795943DDE3607C6CBF0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Contingent Liability From Divestiture Agreement</link:label>
    <link:label id="lab_gale_DisposalGroupIncludingDiscontinuedOperationContingentLiabilityFromDivestitureAgreement_A509B516526B0795943DDE3607C6CBF0_documentation_en-US" xlink:label="lab_gale_DisposalGroupIncludingDiscontinuedOperationContingentLiabilityFromDivestitureAgreement_A509B516526B0795943DDE3607C6CBF0" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Contingent Liability From Divestiture Agreement</link:label>
    <link:loc xlink:href="gale-20150930.xsd#gale_DisposalGroupIncludingDiscontinuedOperationContingentLiabilityFromDivestitureAgreement" xlink:label="loc_gale_DisposalGroupIncludingDiscontinuedOperationContingentLiabilityFromDivestitureAgreement_A509B516526B0795943DDE3607C6CBF0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_DisposalGroupIncludingDiscontinuedOperationContingentLiabilityFromDivestitureAgreement_A509B516526B0795943DDE3607C6CBF0" xlink:to="lab_gale_DisposalGroupIncludingDiscontinuedOperationContingentLiabilityFromDivestitureAgreement_A509B516526B0795943DDE3607C6CBF0" xlink:type="arc" />
    <link:label id="lab_gale_DisposalGroupIncludingDiscontinuedOperationContingentLiabilityPercentageofConsideration_050D407A24ACA9B69030DE3742C076A4_terseLabel_en-US" xlink:label="lab_gale_DisposalGroupIncludingDiscontinuedOperationContingentLiabilityPercentageofConsideration_050D407A24ACA9B69030DE3742C076A4" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Success fee, as a percentage of consideration received, contingently due to third party (percent)</link:label>
    <link:label id="lab_gale_DisposalGroupIncludingDiscontinuedOperationContingentLiabilityPercentageofConsideration_050D407A24ACA9B69030DE3742C076A4_label_en-US" xlink:label="lab_gale_DisposalGroupIncludingDiscontinuedOperationContingentLiabilityPercentageofConsideration_050D407A24ACA9B69030DE3742C076A4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Contingent Liability, Percentage of Consideration</link:label>
    <link:label id="lab_gale_DisposalGroupIncludingDiscontinuedOperationContingentLiabilityPercentageofConsideration_050D407A24ACA9B69030DE3742C076A4_documentation_en-US" xlink:label="lab_gale_DisposalGroupIncludingDiscontinuedOperationContingentLiabilityPercentageofConsideration_050D407A24ACA9B69030DE3742C076A4" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Contingent Liability, Percentage of Consideration</link:label>
    <link:loc xlink:href="gale-20150930.xsd#gale_DisposalGroupIncludingDiscontinuedOperationContingentLiabilityPercentageofConsideration" xlink:label="loc_gale_DisposalGroupIncludingDiscontinuedOperationContingentLiabilityPercentageofConsideration_050D407A24ACA9B69030DE3742C076A4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_DisposalGroupIncludingDiscontinuedOperationContingentLiabilityPercentageofConsideration_050D407A24ACA9B69030DE3742C076A4" xlink:to="lab_gale_DisposalGroupIncludingDiscontinuedOperationContingentLiabilityPercentageofConsideration_050D407A24ACA9B69030DE3742C076A4" xlink:type="arc" />
    <link:label id="lab_gale_DisposalGroupIncludingDiscontinuedOperationContingentRetentionFees_256AAFBCF1AB90F132D7DE3AFA131820_terseLabel_en-US" xlink:label="lab_gale_DisposalGroupIncludingDiscontinuedOperationContingentRetentionFees_256AAFBCF1AB90F132D7DE3AFA131820" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Retention fees contingently due</link:label>
    <link:label id="lab_gale_DisposalGroupIncludingDiscontinuedOperationContingentRetentionFees_256AAFBCF1AB90F132D7DE3AFA131820_label_en-US" xlink:label="lab_gale_DisposalGroupIncludingDiscontinuedOperationContingentRetentionFees_256AAFBCF1AB90F132D7DE3AFA131820" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Contingent Retention Fees</link:label>
    <link:label id="lab_gale_DisposalGroupIncludingDiscontinuedOperationContingentRetentionFees_256AAFBCF1AB90F132D7DE3AFA131820_documentation_en-US" xlink:label="lab_gale_DisposalGroupIncludingDiscontinuedOperationContingentRetentionFees_256AAFBCF1AB90F132D7DE3AFA131820" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Contingent Retention Fees</link:label>
    <link:loc xlink:href="gale-20150930.xsd#gale_DisposalGroupIncludingDiscontinuedOperationContingentRetentionFees" xlink:label="loc_gale_DisposalGroupIncludingDiscontinuedOperationContingentRetentionFees_256AAFBCF1AB90F132D7DE3AFA131820" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_DisposalGroupIncludingDiscontinuedOperationContingentRetentionFees_256AAFBCF1AB90F132D7DE3AFA131820" xlink:to="lab_gale_DisposalGroupIncludingDiscontinuedOperationContingentRetentionFees_256AAFBCF1AB90F132D7DE3AFA131820" xlink:type="arc" />
    <link:label id="lab_gale_DisposalGroupIncludingDiscontinuedOperationContingentRetentionFeesPercentageofConsiderationReceived_06B6ACEABD039AD13920DE3BE45C787A_terseLabel_en-US" xlink:label="lab_gale_DisposalGroupIncludingDiscontinuedOperationContingentRetentionFeesPercentageofConsiderationReceived_06B6ACEABD039AD13920DE3BE45C787A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Retention fees contingently due (as percentage of consideration received)</link:label>
    <link:label id="lab_gale_DisposalGroupIncludingDiscontinuedOperationContingentRetentionFeesPercentageofConsiderationReceived_06B6ACEABD039AD13920DE3BE45C787A_label_en-US" xlink:label="lab_gale_DisposalGroupIncludingDiscontinuedOperationContingentRetentionFeesPercentageofConsiderationReceived_06B6ACEABD039AD13920DE3BE45C787A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Contingent Retention Fees, Percentage of Consideration Received</link:label>
    <link:label id="lab_gale_DisposalGroupIncludingDiscontinuedOperationContingentRetentionFeesPercentageofConsiderationReceived_06B6ACEABD039AD13920DE3BE45C787A_documentation_en-US" xlink:label="lab_gale_DisposalGroupIncludingDiscontinuedOperationContingentRetentionFeesPercentageofConsiderationReceived_06B6ACEABD039AD13920DE3BE45C787A" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Contingent Retention Fees, Percentage of Consideration Received</link:label>
    <link:loc xlink:href="gale-20150930.xsd#gale_DisposalGroupIncludingDiscontinuedOperationContingentRetentionFeesPercentageofConsiderationReceived" xlink:label="loc_gale_DisposalGroupIncludingDiscontinuedOperationContingentRetentionFeesPercentageofConsiderationReceived_06B6ACEABD039AD13920DE3BE45C787A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_DisposalGroupIncludingDiscontinuedOperationContingentRetentionFeesPercentageofConsiderationReceived_06B6ACEABD039AD13920DE3BE45C787A" xlink:to="lab_gale_DisposalGroupIncludingDiscontinuedOperationContingentRetentionFeesPercentageofConsiderationReceived_06B6ACEABD039AD13920DE3BE45C787A" xlink:type="arc" />
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_8D530DC217A50DD0ED7FD437A88D7750_label_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_43232B93821D5DE5AC435109B5FB03EE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Goodwill and Intangible Assets Disclosure [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_43232B93821D5DE5AC435109B5FB03EE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_43232B93821D5DE5AC435109B5FB03EE" xlink:to="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_43232B93821D5DE5AC435109B5FB03EE" xlink:type="arc" />
    <link:label id="lab_us-gaap_IntangibleAssetsDisclosureTextBlock_8BDD75E7B7B2217DB2DAD437A88DFEA1_terseLabel_en-US" xlink:label="lab_us-gaap_IntangibleAssetsDisclosureTextBlock_9DF71E876FFE592E96713725B2402BDD" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">License Agreements</link:label>
    <link:label id="lab_us-gaap_IntangibleAssetsDisclosureTextBlock_8BDD75E7B7B2217DB2DAD437A88DFEA1_label_en-US" xlink:label="lab_us-gaap_IntangibleAssetsDisclosureTextBlock_9DF71E876FFE592E96713725B2402BDD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Intangible Assets Disclosure [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IntangibleAssetsDisclosureTextBlock" xlink:label="loc_us-gaap_IntangibleAssetsDisclosureTextBlock_9DF71E876FFE592E96713725B2402BDD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IntangibleAssetsDisclosureTextBlock_9DF71E876FFE592E96713725B2402BDD" xlink:to="lab_us-gaap_IntangibleAssetsDisclosureTextBlock_9DF71E876FFE592E96713725B2402BDD" xlink:type="arc" />
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_B495BDF3128D48F2715ED437A7B1CDDE_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_AEC6D393004158DC833CECE51DD086D8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of Compensation Related Costs, Share-based Payments [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_AEC6D393004158DC833CECE51DD086D8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_AEC6D393004158DC833CECE51DD086D8" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_AEC6D393004158DC833CECE51DD086D8" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_6603FC8348047067E67CD437A7B1656C_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_BE9F4563DEDF516596A6CC55BF540024" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_6603FC8348047067E67CD437A7B1656C_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_BE9F4563DEDF516596A6CC55BF540024" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_BE9F4563DEDF516596A6CC55BF540024" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_BE9F4563DEDF516596A6CC55BF540024" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_BE9F4563DEDF516596A6CC55BF540024" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_058898DC007A22153BE1D437A7B1CE37_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_7EAFDBD961CC56B2A4D7703F0EF872D5" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Total Number of Shares, outstanding Beginning Balance</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_058898DC007A22153BE1D437A7B1CE37_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_7EAFDBD961CC56B2A4D7703F0EF872D5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_7EAFDBD961CC56B2A4D7703F0EF872D5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_7EAFDBD961CC56B2A4D7703F0EF872D5" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_7EAFDBD961CC56B2A4D7703F0EF872D5" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_85E6513E9BE5DC7F4354D437A7B13D52_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_D789EBB437A15E6A8A0F07C198B66724" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Stock options activity, Total Number of Shares, Granted</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_85E6513E9BE5DC7F4354D437A7B13D52_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_D789EBB437A15E6A8A0F07C198B66724" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_D789EBB437A15E6A8A0F07C198B66724" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_D789EBB437A15E6A8A0F07C198B66724" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_D789EBB437A15E6A8A0F07C198B66724" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_4895442FE72824E10575D437A7B15C3D_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_97A137D33137541AAE7027DF7075110F" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Stock options activity, Total Number of Shares, Exercised</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_4895442FE72824E10575D437A7B15C3D_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_97A137D33137541AAE7027DF7075110F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_97A137D33137541AAE7027DF7075110F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_97A137D33137541AAE7027DF7075110F" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_97A137D33137541AAE7027DF7075110F" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_50F0496096AAEE40B281D437A7B10CC9_negatedLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_3AB8A646DE035CF3B8E6D38429ABB01A" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Stock options activity, Total Number of Shares, Cancelled</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_50F0496096AAEE40B281D437A7B10CC9_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_3AB8A646DE035CF3B8E6D38429ABB01A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_3AB8A646DE035CF3B8E6D38429ABB01A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_3AB8A646DE035CF3B8E6D38429ABB01A" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_3AB8A646DE035CF3B8E6D38429ABB01A" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_FDAE06F734811FEF8262D437A7B11B66_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_C209B77C139151BEB9EBA45B7AD3AF23" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Total Number of Shares, outstanding Ending Balance</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_C209B77C139151BEB9EBA45B7AD3AF23" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_C209B77C139151BEB9EBA45B7AD3AF23" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_C209B77C139151BEB9EBA45B7AD3AF23" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_E081E39EBDE6B994009FD437A7B1DADD_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_B35C935CB3685F989E08915A1F42205A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Total Number of Shares, exercisable</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_E081E39EBDE6B994009FD437A7B1DADD_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_B35C935CB3685F989E08915A1F42205A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_B35C935CB3685F989E08915A1F42205A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_B35C935CB3685F989E08915A1F42205A" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_B35C935CB3685F989E08915A1F42205A" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_47A4C21DA76054F33C7ED437A7B1E289_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_9E9E4A416C915890B663AB7E7F8C7F22" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_47A4C21DA76054F33C7ED437A7B1E289_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_9E9E4A416C915890B663AB7E7F8C7F22" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_9E9E4A416C915890B663AB7E7F8C7F22" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_9E9E4A416C915890B663AB7E7F8C7F22" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_9E9E4A416C915890B663AB7E7F8C7F22" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_47F12BC0C42303C1FB4AD437A7B116F7_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_B46DE5D07A685CABAC241E16F0F89CBC" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Stock options activity, Weighted Average Exercise Price, Beginning balance</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_47F12BC0C42303C1FB4AD437A7B116F7_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_B46DE5D07A685CABAC241E16F0F89CBC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_B46DE5D07A685CABAC241E16F0F89CBC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_B46DE5D07A685CABAC241E16F0F89CBC" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_B46DE5D07A685CABAC241E16F0F89CBC" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_66B6C8785F219B89A23ED437A7B74C38_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_F04E8AA0341358E2965037B01CC5AF0E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock options activity, Weighted Average Exercise Price, Granted</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_66B6C8785F219B89A23ED437A7B74C38_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_F04E8AA0341358E2965037B01CC5AF0E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_F04E8AA0341358E2965037B01CC5AF0E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_F04E8AA0341358E2965037B01CC5AF0E" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_F04E8AA0341358E2965037B01CC5AF0E" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_5357EEBD59B1B2D9D380D437A7B789C8_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_3D31A99BC5855C3A956D97F1A9A2E902" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock options activity, Weighted Average Exercise Price, Exercised</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_5357EEBD59B1B2D9D380D437A7B789C8_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_3D31A99BC5855C3A956D97F1A9A2E902" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_3D31A99BC5855C3A956D97F1A9A2E902" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_3D31A99BC5855C3A956D97F1A9A2E902" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_3D31A99BC5855C3A956D97F1A9A2E902" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_60CDCF098857AFBD4E21D437A7B7F052_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_9549DFBB8DAF54D1A149F8F09EB8C6DA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock options activity, Weighted Average Exercise Price, Cancelled</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_60CDCF098857AFBD4E21D437A7B7F052_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_9549DFBB8DAF54D1A149F8F09EB8C6DA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_9549DFBB8DAF54D1A149F8F09EB8C6DA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_9549DFBB8DAF54D1A149F8F09EB8C6DA" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_9549DFBB8DAF54D1A149F8F09EB8C6DA" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_540306261DFD310EAA7BD437A7B7DF9A_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_3541EF341C055C71A213E9D023ABEEFB" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Stock options activity, Weighted Average Exercise Price, Ending balance</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_3541EF341C055C71A213E9D023ABEEFB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_3541EF341C055C71A213E9D023ABEEFB" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_3541EF341C055C71A213E9D023ABEEFB" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_7E6E5EAABE0264A5C7B5D437A7B72138_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_C32500CCC6F6585EBE708B74525F0878" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock options activity, Weighted Average Exercise Price, exercisable</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_7E6E5EAABE0264A5C7B5D437A7B72138_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_C32500CCC6F6585EBE708B74525F0878" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_C32500CCC6F6585EBE708B74525F0878" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_C32500CCC6F6585EBE708B74525F0878" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_C32500CCC6F6585EBE708B74525F0878" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_2EAFD0796FB8A72A3D7AD437A7B7B010_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_86545D61ED835E14A0C5A04AA855F470" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Stock options activity, Aggregate Intrinsic Value, Beginning balance</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_2EAFD0796FB8A72A3D7AD437A7B7B010_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_86545D61ED835E14A0C5A04AA855F470" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_86545D61ED835E14A0C5A04AA855F470" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_86545D61ED835E14A0C5A04AA855F470" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_86545D61ED835E14A0C5A04AA855F470" xlink:type="arc" />
    <link:label id="lab_gale_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateAggregateIntrinsicValue_D2685925FAEA9E3D6993D437A7B7DDF9_terseLabel_en-US" xlink:label="lab_gale_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateAggregateIntrinsicValue_35A6D6D48AA753489BD5B34591B6D30B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock options activity, Aggregate Intrinsic Value, Granted</link:label>
    <link:label id="lab_gale_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateAggregateIntrinsicValue_D2685925FAEA9E3D6993D437A7B7DDF9_label_en-US" xlink:label="lab_gale_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateAggregateIntrinsicValue_35A6D6D48AA753489BD5B34591B6D30B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Grant Date Aggregate Intrinsic Value</link:label>
    <link:label id="lab_gale_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateAggregateIntrinsicValue_D2685925FAEA9E3D6993D437A7B7DDF9_documentation_en-US" xlink:label="lab_gale_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateAggregateIntrinsicValue_35A6D6D48AA753489BD5B34591B6D30B" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Grant Date Aggregate Intrinsic Value</link:label>
    <link:loc xlink:href="gale-20150930.xsd#gale_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateAggregateIntrinsicValue" xlink:label="loc_gale_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateAggregateIntrinsicValue_35A6D6D48AA753489BD5B34591B6D30B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateAggregateIntrinsicValue_35A6D6D48AA753489BD5B34591B6D30B" xlink:to="lab_gale_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateAggregateIntrinsicValue_35A6D6D48AA753489BD5B34591B6D30B" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_1A66E3888A03A0357819D437A7B7AE07_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_CEA5F7BC139D59B1B9E1B9082CD5914E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock options activity, Aggregate Intrinsic Value, Exercised</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_1A66E3888A03A0357819D437A7B7AE07_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_CEA5F7BC139D59B1B9E1B9082CD5914E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_CEA5F7BC139D59B1B9E1B9082CD5914E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_CEA5F7BC139D59B1B9E1B9082CD5914E" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_CEA5F7BC139D59B1B9E1B9082CD5914E" xlink:type="arc" />
    <link:label id="lab_gale_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpiredInPeriodIntrinsicValue_29B83A35DEBDCCB59A34D437A7B7D659_terseLabel_en-US" xlink:label="lab_gale_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpiredInPeriodIntrinsicValue_D6677C0C6BDD506D95043BEC85861A11" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock options activity, Aggregate Intrinsic Value, Cancelled</link:label>
    <link:label id="lab_gale_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpiredInPeriodIntrinsicValue_29B83A35DEBDCCB59A34D437A7B7D659_label_en-US" xlink:label="lab_gale_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpiredInPeriodIntrinsicValue_D6677C0C6BDD506D95043BEC85861A11" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award Options Expired In Period Intrinsic Value</link:label>
    <link:label id="lab_gale_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpiredInPeriodIntrinsicValue_29B83A35DEBDCCB59A34D437A7B7D659_documentation_en-US" xlink:label="lab_gale_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpiredInPeriodIntrinsicValue_D6677C0C6BDD506D95043BEC85861A11" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award Options Expired In Period Intrinsic Value</link:label>
    <link:loc xlink:href="gale-20150930.xsd#gale_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpiredInPeriodIntrinsicValue" xlink:label="loc_gale_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpiredInPeriodIntrinsicValue_D6677C0C6BDD506D95043BEC85861A11" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpiredInPeriodIntrinsicValue_D6677C0C6BDD506D95043BEC85861A11" xlink:to="lab_gale_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpiredInPeriodIntrinsicValue_D6677C0C6BDD506D95043BEC85861A11" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_CEE84ADD94F0CA22BA6BD437A7B7318B_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_647715719BA654359888DE039AFA6460" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Stock options activity, Aggregate Intrinsic Value, Ending balance</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_647715719BA654359888DE039AFA6460" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_647715719BA654359888DE039AFA6460" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_647715719BA654359888DE039AFA6460" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_A183061B65EE564792CCD437A7B7A0FE_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_AF35D74F49015E3B88036EE1FCBA7516" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock options activity, Aggregate Intrinsic Value, exercisable</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_A183061B65EE564792CCD437A7B7A0FE_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_AF35D74F49015E3B88036EE1FCBA7516" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Aggregate Intrinsic Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_AF35D74F49015E3B88036EE1FCBA7516" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_AF35D74F49015E3B88036EE1FCBA7516" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_AF35D74F49015E3B88036EE1FCBA7516" xlink:type="arc" />
    <link:label id="lab_gale_DocumentDocumentAndEntityInformationAbstract_1A7CB92A6197C44B7482D437A8A7A07B_label_en-US" xlink:label="lab_gale_DocumentDocumentAndEntityInformationAbstract_F4AB2074FF1A53929E383C0F35D4CAD0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Document And Entity Information [Abstract]</link:label>
    <link:label id="lab_gale_DocumentDocumentAndEntityInformationAbstract_1A7CB92A6197C44B7482D437A8A7A07B_documentation_en-US" xlink:label="lab_gale_DocumentDocumentAndEntityInformationAbstract_F4AB2074FF1A53929E383C0F35D4CAD0" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Document Document and Entity Information [Abstract]</link:label>
    <link:loc xlink:href="gale-20150930.xsd#gale_DocumentDocumentAndEntityInformationAbstract" xlink:label="loc_gale_DocumentDocumentAndEntityInformationAbstract_F4AB2074FF1A53929E383C0F35D4CAD0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_DocumentDocumentAndEntityInformationAbstract_F4AB2074FF1A53929E383C0F35D4CAD0" xlink:to="lab_gale_DocumentDocumentAndEntityInformationAbstract_F4AB2074FF1A53929E383C0F35D4CAD0" xlink:type="arc" />
    <link:label id="lab_dei_EntityRegistrantName_4CA8E64EE750940F2A67D437A8A74CEF_terseLabel_en-US" xlink:label="lab_dei_EntityRegistrantName_228D3D2CEBC354B4A5B31D90B77DC96E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:label id="lab_dei_EntityRegistrantName_4CA8E64EE750940F2A67D437A8A74CEF_label_en-US" xlink:label="lab_dei_EntityRegistrantName_228D3D2CEBC354B4A5B31D90B77DC96E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityRegistrantName" xlink:label="loc_dei_EntityRegistrantName_228D3D2CEBC354B4A5B31D90B77DC96E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName_228D3D2CEBC354B4A5B31D90B77DC96E" xlink:to="lab_dei_EntityRegistrantName_228D3D2CEBC354B4A5B31D90B77DC96E" xlink:type="arc" />
    <link:label id="lab_dei_TradingSymbol_54C35470A8E06442AAEDD437A8A7766A_terseLabel_en-US" xlink:label="lab_dei_TradingSymbol_4418748DCE2053F7BD95797A5E3BA651" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Trading Symbol</link:label>
    <link:label id="lab_dei_TradingSymbol_54C35470A8E06442AAEDD437A8A7766A_label_en-US" xlink:label="lab_dei_TradingSymbol_4418748DCE2053F7BD95797A5E3BA651" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Symbol</link:label>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_TradingSymbol" xlink:label="loc_dei_TradingSymbol_4418748DCE2053F7BD95797A5E3BA651" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol_4418748DCE2053F7BD95797A5E3BA651" xlink:to="lab_dei_TradingSymbol_4418748DCE2053F7BD95797A5E3BA651" xlink:type="arc" />
    <link:label id="lab_dei_EntityCentralIndexKey_DBD5FEB02F10CAD2F579D437A8A71BE1_terseLabel_en-US" xlink:label="lab_dei_EntityCentralIndexKey_BD1C6A555D0A5ECE8A9F6DCA972582FA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:label id="lab_dei_EntityCentralIndexKey_DBD5FEB02F10CAD2F579D437A8A71BE1_label_en-US" xlink:label="lab_dei_EntityCentralIndexKey_BD1C6A555D0A5ECE8A9F6DCA972582FA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityCentralIndexKey" xlink:label="loc_dei_EntityCentralIndexKey_BD1C6A555D0A5ECE8A9F6DCA972582FA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey_BD1C6A555D0A5ECE8A9F6DCA972582FA" xlink:to="lab_dei_EntityCentralIndexKey_BD1C6A555D0A5ECE8A9F6DCA972582FA" xlink:type="arc" />
    <link:label id="lab_dei_CurrentFiscalYearEndDate_E656564C8CD0B2FC44D0D437A8A7C9EE_terseLabel_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate_02E20553FDA353B18B05DC78148D54E3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_E656564C8CD0B2FC44D0D437A8A7C9EE_label_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate_02E20553FDA353B18B05DC78148D54E3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_dei_CurrentFiscalYearEndDate_02E20553FDA353B18B05DC78148D54E3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CurrentFiscalYearEndDate_02E20553FDA353B18B05DC78148D54E3" xlink:to="lab_dei_CurrentFiscalYearEndDate_02E20553FDA353B18B05DC78148D54E3" xlink:type="arc" />
    <link:label id="lab_dei_EntityFilerCategory_2BE0217543B78868C0EDD437A8A77BF4_terseLabel_en-US" xlink:label="lab_dei_EntityFilerCategory_011B554AD0705831A21B7E7BB34400C0" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Filer Category</link:label>
    <link:label id="lab_dei_EntityFilerCategory_2BE0217543B78868C0EDD437A8A77BF4_label_en-US" xlink:label="lab_dei_EntityFilerCategory_011B554AD0705831A21B7E7BB34400C0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Filer Category</link:label>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityFilerCategory" xlink:label="loc_dei_EntityFilerCategory_011B554AD0705831A21B7E7BB34400C0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFilerCategory_011B554AD0705831A21B7E7BB34400C0" xlink:to="lab_dei_EntityFilerCategory_011B554AD0705831A21B7E7BB34400C0" xlink:type="arc" />
    <link:label id="lab_dei_DocumentType_557B6A2194C36C4ED775D437A8A7A0CC_terseLabel_en-US" xlink:label="lab_dei_DocumentType_5DD25AE17D75573595C96E7571A782A9" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Type</link:label>
    <link:label id="lab_dei_DocumentType_557B6A2194C36C4ED775D437A8A7A0CC_label_en-US" xlink:label="lab_dei_DocumentType_5DD25AE17D75573595C96E7571A782A9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentType" xlink:label="loc_dei_DocumentType_5DD25AE17D75573595C96E7571A782A9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType_5DD25AE17D75573595C96E7571A782A9" xlink:to="lab_dei_DocumentType_5DD25AE17D75573595C96E7571A782A9" xlink:type="arc" />
    <link:label id="lab_dei_DocumentPeriodEndDate_17AA5E2297C8E9D574AFD437A8A79E97_terseLabel_en-US" xlink:label="lab_dei_DocumentPeriodEndDate_3779F411D8725251B8D53961797CA49B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Period End Date</link:label>
    <link:label id="lab_dei_DocumentPeriodEndDate_17AA5E2297C8E9D574AFD437A8A79E97_label_en-US" xlink:label="lab_dei_DocumentPeriodEndDate_3779F411D8725251B8D53961797CA49B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_dei_DocumentPeriodEndDate_3779F411D8725251B8D53961797CA49B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate_3779F411D8725251B8D53961797CA49B" xlink:to="lab_dei_DocumentPeriodEndDate_3779F411D8725251B8D53961797CA49B" xlink:type="arc" />
    <link:label id="lab_dei_DocumentFiscalYearFocus_E47DFC2985FBAE329324D437A8A7E12D_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus_53CE1B3CF6455FF5B966E4FB5B26E6C7" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalYearFocus_E47DFC2985FBAE329324D437A8A7E12D_label_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus_53CE1B3CF6455FF5B966E4FB5B26E6C7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_dei_DocumentFiscalYearFocus_53CE1B3CF6455FF5B966E4FB5B26E6C7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalYearFocus_53CE1B3CF6455FF5B966E4FB5B26E6C7" xlink:to="lab_dei_DocumentFiscalYearFocus_53CE1B3CF6455FF5B966E4FB5B26E6C7" xlink:type="arc" />
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_B3020BE0F39B1A8098E0D437A8A8362F_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus_F4D2B238BD175F758476B17B4EAE9246" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_B3020BE0F39B1A8098E0D437A8A8362F_label_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus_F4D2B238BD175F758476B17B4EAE9246" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_dei_DocumentFiscalPeriodFocus_F4D2B238BD175F758476B17B4EAE9246" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalPeriodFocus_F4D2B238BD175F758476B17B4EAE9246" xlink:to="lab_dei_DocumentFiscalPeriodFocus_F4D2B238BD175F758476B17B4EAE9246" xlink:type="arc" />
    <link:label id="lab_dei_AmendmentFlag_1F6856A920B1B65D3F81D437A8A82BC4_terseLabel_en-US" xlink:label="lab_dei_AmendmentFlag_232E45EB97EE52759EE26AFA89226E99" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amendment Flag</link:label>
    <link:label id="lab_dei_AmendmentFlag_1F6856A920B1B65D3F81D437A8A82BC4_label_en-US" xlink:label="lab_dei_AmendmentFlag_232E45EB97EE52759EE26AFA89226E99" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_AmendmentFlag" xlink:label="loc_dei_AmendmentFlag_232E45EB97EE52759EE26AFA89226E99" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag_232E45EB97EE52759EE26AFA89226E99" xlink:to="lab_dei_AmendmentFlag_232E45EB97EE52759EE26AFA89226E99" xlink:type="arc" />
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_F310A2BE8F73DDBC578DD437A8A82598_terseLabel_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding_F3A13396DEFA5C3CA0F2A2541F78D308" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_F310A2BE8F73DDBC578DD437A8A82598_label_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding_F3A13396DEFA5C3CA0F2A2541F78D308" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_F3A13396DEFA5C3CA0F2A2541F78D308" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCommonStockSharesOutstanding_F3A13396DEFA5C3CA0F2A2541F78D308" xlink:to="lab_dei_EntityCommonStockSharesOutstanding_F3A13396DEFA5C3CA0F2A2541F78D308" xlink:type="arc" />
    <link:label id="lab_gale_ScheduleOfWarrantActivityTableTableTextBlock_3042C6FDEEF6926E125DD437A87F3644_terseLabel_en-US" xlink:label="lab_gale_ScheduleOfWarrantActivityTableTableTextBlock_4D933A19475450C78B811AA126ACCCA5" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Warrant Activity</link:label>
    <link:label id="lab_gale_ScheduleOfWarrantActivityTableTableTextBlock_3042C6FDEEF6926E125DD437A87F3644_label_en-US" xlink:label="lab_gale_ScheduleOfWarrantActivityTableTableTextBlock_4D933A19475450C78B811AA126ACCCA5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule Of Warrant Activity Table [Table Text Block]</link:label>
    <link:label id="lab_gale_ScheduleOfWarrantActivityTableTableTextBlock_3042C6FDEEF6926E125DD437A87F3644_documentation_en-US" xlink:label="lab_gale_ScheduleOfWarrantActivityTableTableTextBlock_4D933A19475450C78B811AA126ACCCA5" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Schedule Of Warrant Activity Table</link:label>
    <link:loc xlink:href="gale-20150930.xsd#gale_ScheduleOfWarrantActivityTableTableTextBlock" xlink:label="loc_gale_ScheduleOfWarrantActivityTableTableTextBlock_4D933A19475450C78B811AA126ACCCA5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_ScheduleOfWarrantActivityTableTableTextBlock_4D933A19475450C78B811AA126ACCCA5" xlink:to="lab_gale_ScheduleOfWarrantActivityTableTableTextBlock_4D933A19475450C78B811AA126ACCCA5" xlink:type="arc" />
    <link:label id="lab_gale_ScheduleOfWarrantValuationAssumptionsTableTextBlock_503F7D8A16AE9B9708D1D437A87F06D6_terseLabel_en-US" xlink:label="lab_gale_ScheduleOfWarrantValuationAssumptionsTableTextBlock_A98BAA24B3B05D8FA2349373440A5DE4" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value of Warrants is Estimated Using Black-Scholes Option Pricing Model</link:label>
    <link:label id="lab_gale_ScheduleOfWarrantValuationAssumptionsTableTextBlock_503F7D8A16AE9B9708D1D437A87F06D6_label_en-US" xlink:label="lab_gale_ScheduleOfWarrantValuationAssumptionsTableTextBlock_A98BAA24B3B05D8FA2349373440A5DE4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule Of Warrant Valuation Assumptions Table [Text Block]</link:label>
    <link:label id="lab_gale_ScheduleOfWarrantValuationAssumptionsTableTextBlock_503F7D8A16AE9B9708D1D437A87F06D6_documentation_en-US" xlink:label="lab_gale_ScheduleOfWarrantValuationAssumptionsTableTextBlock_A98BAA24B3B05D8FA2349373440A5DE4" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Schedule Of Warrant Valuation Assumptions Table [Text Block]</link:label>
    <link:loc xlink:href="gale-20150930.xsd#gale_ScheduleOfWarrantValuationAssumptionsTableTextBlock" xlink:label="loc_gale_ScheduleOfWarrantValuationAssumptionsTableTextBlock_A98BAA24B3B05D8FA2349373440A5DE4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_ScheduleOfWarrantValuationAssumptionsTableTextBlock_A98BAA24B3B05D8FA2349373440A5DE4" xlink:to="lab_gale_ScheduleOfWarrantValuationAssumptionsTableTextBlock_A98BAA24B3B05D8FA2349373440A5DE4" xlink:type="arc" />
    <link:label id="lab_gale_ChangesInFairValueOfWarrantLiabilityTableTextBlock_D2B3A8B610D957DA7415D437A87FC997_terseLabel_en-US" xlink:label="lab_gale_ChangesInFairValueOfWarrantLiabilityTableTextBlock_3CCAC7598F405A5C8BAA1363345EBA15" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Changes in Fair Value of Warrant Liability</link:label>
    <link:label id="lab_gale_ChangesInFairValueOfWarrantLiabilityTableTextBlock_D2B3A8B610D957DA7415D437A87FC997_label_en-US" xlink:label="lab_gale_ChangesInFairValueOfWarrantLiabilityTableTextBlock_3CCAC7598F405A5C8BAA1363345EBA15" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Changes In Fair Value Of Warrant Liability Table [Text Block]</link:label>
    <link:label id="lab_gale_ChangesInFairValueOfWarrantLiabilityTableTextBlock_D2B3A8B610D957DA7415D437A87FC997_documentation_en-US" xlink:label="lab_gale_ChangesInFairValueOfWarrantLiabilityTableTextBlock_3CCAC7598F405A5C8BAA1363345EBA15" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Changes In Fair Value Of Warrant Liability Table [Text Block]</link:label>
    <link:loc xlink:href="gale-20150930.xsd#gale_ChangesInFairValueOfWarrantLiabilityTableTextBlock" xlink:label="loc_gale_ChangesInFairValueOfWarrantLiabilityTableTextBlock_3CCAC7598F405A5C8BAA1363345EBA15" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_ChangesInFairValueOfWarrantLiabilityTableTextBlock_3CCAC7598F405A5C8BAA1363345EBA15" xlink:to="lab_gale_ChangesInFairValueOfWarrantLiabilityTableTextBlock_3CCAC7598F405A5C8BAA1363345EBA15" xlink:type="arc" />
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue_CC616752004DA59003A4DEEC49FFB7B6_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue_CC616752004DA59003A4DEEC49FFB7B6" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net revenue</link:label>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue_CC616752004DA59003A4DEEC49FFB7B6_label_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue_CC616752004DA59003A4DEEC49FFB7B6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Revenue</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue_CC616752004DA59003A4DEEC49FFB7B6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue_CC616752004DA59003A4DEEC49FFB7B6" xlink:to="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue_CC616752004DA59003A4DEEC49FFB7B6" xlink:type="arc" />
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold_3BCEFF9E3D4F05E37760DEEC49FFC5D3_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold_3BCEFF9E3D4F05E37760DEEC49FFC5D3" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Cost of revenue</link:label>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold_3BCEFF9E3D4F05E37760DEEC49FFC5D3_label_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold_3BCEFF9E3D4F05E37760DEEC49FFC5D3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Costs of Goods Sold</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold_3BCEFF9E3D4F05E37760DEEC49FFC5D3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold_3BCEFF9E3D4F05E37760DEEC49FFC5D3" xlink:to="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold_3BCEFF9E3D4F05E37760DEEC49FFC5D3" xlink:type="arc" />
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationDepreciationAndAmortization_4BD28650B2139C53A933DEEC49FF1213_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationDepreciationAndAmortization_4BD28650B2139C53A933DEEC49FF1213" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Amortization of certain acquired intangible assets</link:label>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationDepreciationAndAmortization_4BD28650B2139C53A933DEEC49FF1213_label_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationDepreciationAndAmortization_4BD28650B2139C53A933DEEC49FF1213" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Depreciation and Amortization</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationDepreciationAndAmortization" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationDepreciationAndAmortization_4BD28650B2139C53A933DEEC49FF1213" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationDepreciationAndAmortization_4BD28650B2139C53A933DEEC49FF1213" xlink:to="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationDepreciationAndAmortization_4BD28650B2139C53A933DEEC49FF1213" xlink:type="arc" />
    <link:label id="lab_gale_DisposalGroupIncludingDiscontinuedOperationResearchandDevelopment_C7ACB6287A7CADB121B3DEEC49FFAEF5_negatedTerseLabel_en-US" xlink:label="lab_gale_DisposalGroupIncludingDiscontinuedOperationResearchandDevelopment_C7ACB6287A7CADB121B3DEEC49FFAEF5" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Research and development</link:label>
    <link:label id="lab_gale_DisposalGroupIncludingDiscontinuedOperationResearchandDevelopment_C7ACB6287A7CADB121B3DEEC49FFAEF5_label_en-US" xlink:label="lab_gale_DisposalGroupIncludingDiscontinuedOperationResearchandDevelopment_C7ACB6287A7CADB121B3DEEC49FFAEF5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Research and Development</link:label>
    <link:label id="lab_gale_DisposalGroupIncludingDiscontinuedOperationResearchandDevelopment_C7ACB6287A7CADB121B3DEEC49FFAEF5_documentation_en-US" xlink:label="lab_gale_DisposalGroupIncludingDiscontinuedOperationResearchandDevelopment_C7ACB6287A7CADB121B3DEEC49FFAEF5" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Research and Development</link:label>
    <link:loc xlink:href="gale-20150930.xsd#gale_DisposalGroupIncludingDiscontinuedOperationResearchandDevelopment" xlink:label="loc_gale_DisposalGroupIncludingDiscontinuedOperationResearchandDevelopment_C7ACB6287A7CADB121B3DEEC49FFAEF5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_DisposalGroupIncludingDiscontinuedOperationResearchandDevelopment_C7ACB6287A7CADB121B3DEEC49FFAEF5" xlink:to="lab_gale_DisposalGroupIncludingDiscontinuedOperationResearchandDevelopment_C7ACB6287A7CADB121B3DEEC49FFAEF5" xlink:type="arc" />
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense_3AD8218AD57A05895EA4DEEC49FFB04F_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense_3AD8218AD57A05895EA4DEEC49FFB04F" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Selling, general, and administrative</link:label>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense_3AD8218AD57A05895EA4DEEC49FFB04F_label_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense_3AD8218AD57A05895EA4DEEC49FFB04F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disposal Group, Including Discontinued Operation, General and Administrative Expense</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense_3AD8218AD57A05895EA4DEEC49FFB04F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense_3AD8218AD57A05895EA4DEEC49FFB04F" xlink:to="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense_3AD8218AD57A05895EA4DEEC49FFB04F" xlink:type="arc" />
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss_C9666852FFFF8307EC44DEEC49FF8464_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss_C9666852FFFF8307EC44DEEC49FF8464" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-operating income (expense)</link:label>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss_C9666852FFFF8307EC44DEEC49FF8464_label_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss_C9666852FFFF8307EC44DEEC49FF8464" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Operating Income (Loss)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss_C9666852FFFF8307EC44DEEC49FF8464" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss_C9666852FFFF8307EC44DEEC49FF8464" xlink:to="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss_C9666852FFFF8307EC44DEEC49FF8464" xlink:type="arc" />
    <link:label id="lab_us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf_BBF74757825E2D5DE94EDEEC4A008E13_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf_BBF74757825E2D5DE94EDEEC4A008E13" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Impairment charge from classification as assets held for sale</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf" xlink:label="loc_us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf_BBF74757825E2D5DE94EDEEC4A008E13" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf_BBF74757825E2D5DE94EDEEC4A008E13" xlink:to="lab_us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf_BBF74757825E2D5DE94EDEEC4A008E13" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax_2958BA8BEB955B3AA903DEEC4A0068A5_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax_2958BA8BEB955B3AA903DEEC4A0068A5" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Loss from discontinued operations</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax_2958BA8BEB955B3AA903DEEC4A0068A5_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax_2958BA8BEB955B3AA903DEEC4A0068A5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income (Loss) from Discontinued Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax_2958BA8BEB955B3AA903DEEC4A0068A5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax_2958BA8BEB955B3AA903DEEC4A0068A5" xlink:to="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax_2958BA8BEB955B3AA903DEEC4A0068A5" xlink:type="arc" />
    <link:label id="lab_us-gaap_DiscontinuedOperationsPolicyTextBlock_B6F69B79F5E77C7735FFDED66804DC09_terseLabel_en-US" xlink:label="lab_us-gaap_DiscontinuedOperationsPolicyTextBlock_B6F69B79F5E77C7735FFDED66804DC09" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Discontinued Operations</link:label>
    <link:label id="lab_us-gaap_DiscontinuedOperationsPolicyTextBlock_B6F69B79F5E77C7735FFDED66804DC09_label_en-US" xlink:label="lab_us-gaap_DiscontinuedOperationsPolicyTextBlock_B6F69B79F5E77C7735FFDED66804DC09" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Discontinued Operations, Policy [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DiscontinuedOperationsPolicyTextBlock" xlink:label="loc_us-gaap_DiscontinuedOperationsPolicyTextBlock_B6F69B79F5E77C7735FFDED66804DC09" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DiscontinuedOperationsPolicyTextBlock_B6F69B79F5E77C7735FFDED66804DC09" xlink:to="lab_us-gaap_DiscontinuedOperationsPolicyTextBlock_B6F69B79F5E77C7735FFDED66804DC09" xlink:type="arc" />
    <link:label id="lab_us-gaap_UseOfEstimates_8A4B01E6BA9F13F0E3FADECFB122AC2A_terseLabel_en-US" xlink:label="lab_us-gaap_UseOfEstimates_8A4B01E6BA9F13F0E3FADECFB122AC2A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Uses of Estimates in Preparation of Financial Statements</link:label>
    <link:label id="lab_us-gaap_UseOfEstimates_8A4B01E6BA9F13F0E3FADECFB122AC2A_label_en-US" xlink:label="lab_us-gaap_UseOfEstimates_8A4B01E6BA9F13F0E3FADECFB122AC2A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Use of Estimates, Policy [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_UseOfEstimates" xlink:label="loc_us-gaap_UseOfEstimates_8A4B01E6BA9F13F0E3FADECFB122AC2A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UseOfEstimates_8A4B01E6BA9F13F0E3FADECFB122AC2A" xlink:to="lab_us-gaap_UseOfEstimates_8A4B01E6BA9F13F0E3FADECFB122AC2A" xlink:type="arc" />
    <link:label id="lab_us-gaap_ConsolidationPolicyTextBlock_D088711B4DEDA355DEE2DECFB122F8EF_terseLabel_en-US" xlink:label="lab_us-gaap_ConsolidationPolicyTextBlock_D088711B4DEDA355DEE2DECFB122F8EF" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Principles of Consolidation</link:label>
    <link:label id="lab_us-gaap_ConsolidationPolicyTextBlock_D088711B4DEDA355DEE2DECFB122F8EF_label_en-US" xlink:label="lab_us-gaap_ConsolidationPolicyTextBlock_D088711B4DEDA355DEE2DECFB122F8EF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Consolidation, Policy [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ConsolidationPolicyTextBlock" xlink:label="loc_us-gaap_ConsolidationPolicyTextBlock_D088711B4DEDA355DEE2DECFB122F8EF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConsolidationPolicyTextBlock_D088711B4DEDA355DEE2DECFB122F8EF" xlink:to="lab_us-gaap_ConsolidationPolicyTextBlock_D088711B4DEDA355DEE2DECFB122F8EF" xlink:type="arc" />
    <link:label id="lab_us-gaap_PriorPeriodReclassificationAdjustmentDescription_392D96B1EE4E0748DD1FDECFB122A610_terseLabel_en-US" xlink:label="lab_us-gaap_PriorPeriodReclassificationAdjustmentDescription_392D96B1EE4E0748DD1FDECFB122A610" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Reclassifications</link:label>
    <link:label id="lab_us-gaap_PriorPeriodReclassificationAdjustmentDescription_392D96B1EE4E0748DD1FDECFB122A610_label_en-US" xlink:label="lab_us-gaap_PriorPeriodReclassificationAdjustmentDescription_392D96B1EE4E0748DD1FDECFB122A610" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Reclassification, Policy [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PriorPeriodReclassificationAdjustmentDescription" xlink:label="loc_us-gaap_PriorPeriodReclassificationAdjustmentDescription_392D96B1EE4E0748DD1FDECFB122A610" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PriorPeriodReclassificationAdjustmentDescription_392D96B1EE4E0748DD1FDECFB122A610" xlink:to="lab_us-gaap_PriorPeriodReclassificationAdjustmentDescription_392D96B1EE4E0748DD1FDECFB122A610" xlink:type="arc" />
    <link:label id="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock_40F2042873CC519C5388DECFB1238ED9_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock_40F2042873CC519C5388DECFB1238ED9" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash and Cash Equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock_40F2042873CC519C5388DECFB1238ED9_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock_40F2042873CC519C5388DECFB1238ED9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash and Cash Equivalents, Policy [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock_40F2042873CC519C5388DECFB1238ED9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock_40F2042873CC519C5388DECFB1238ED9" xlink:to="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock_40F2042873CC519C5388DECFB1238ED9" xlink:type="arc" />
    <link:label id="lab_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_786C97EC54BED2BE0A33DECFB123AE59_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_786C97EC54BED2BE0A33DECFB123AE59" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restricted Cash</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_786C97EC54BED2BE0A33DECFB123AE59_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_786C97EC54BED2BE0A33DECFB123AE59" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash and Cash Equivalents, Restricted Cash and Cash Equivalents, Policy [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:label="loc_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_786C97EC54BED2BE0A33DECFB123AE59" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_786C97EC54BED2BE0A33DECFB123AE59" xlink:to="lab_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_786C97EC54BED2BE0A33DECFB123AE59" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy_E5C06E833C74D361F4A8DECFB1232E6A_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy_E5C06E833C74D361F4A8DECFB1232E6A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value of Financial Instruments</link:label>
    <link:label id="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy_E5C06E833C74D361F4A8DECFB1232E6A_label_en-US" xlink:label="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy_E5C06E833C74D361F4A8DECFB1232E6A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value of Financial Instruments, Policy [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:label="loc_us-gaap_FairValueOfFinancialInstrumentsPolicy_E5C06E833C74D361F4A8DECFB1232E6A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueOfFinancialInstrumentsPolicy_E5C06E833C74D361F4A8DECFB1232E6A" xlink:to="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy_E5C06E833C74D361F4A8DECFB1232E6A" xlink:type="arc" />
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_C0B75EACE3D5F20B92E0DECFB128FFFD_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_C0B75EACE3D5F20B92E0DECFB128FFFD" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equipment and Furnishings</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_C0B75EACE3D5F20B92E0DECFB128FFFD_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_C0B75EACE3D5F20B92E0DECFB128FFFD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment, Policy [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_C0B75EACE3D5F20B92E0DECFB128FFFD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_C0B75EACE3D5F20B92E0DECFB128FFFD" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_C0B75EACE3D5F20B92E0DECFB128FFFD" xlink:type="arc" />
    <link:label id="lab_us-gaap_TradeAndOtherAccountsReceivablePolicy_8BB58919340DC490ACC8DECFB123C804_terseLabel_en-US" xlink:label="lab_us-gaap_TradeAndOtherAccountsReceivablePolicy_8BB58919340DC490ACC8DECFB123C804" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accounts Receivable</link:label>
    <link:label id="lab_us-gaap_TradeAndOtherAccountsReceivablePolicy_8BB58919340DC490ACC8DECFB123C804_label_en-US" xlink:label="lab_us-gaap_TradeAndOtherAccountsReceivablePolicy_8BB58919340DC490ACC8DECFB123C804" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trade and Other Accounts Receivable, Policy [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_TradeAndOtherAccountsReceivablePolicy" xlink:label="loc_us-gaap_TradeAndOtherAccountsReceivablePolicy_8BB58919340DC490ACC8DECFB123C804" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TradeAndOtherAccountsReceivablePolicy_8BB58919340DC490ACC8DECFB123C804" xlink:to="lab_us-gaap_TradeAndOtherAccountsReceivablePolicy_8BB58919340DC490ACC8DECFB123C804" xlink:type="arc" />
    <link:label id="lab_us-gaap_InventoryPolicyTextBlock_3028A38651AF1AF3AE33DECFB123A899_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryPolicyTextBlock_3028A38651AF1AF3AE33DECFB123A899" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Inventories</link:label>
    <link:label id="lab_us-gaap_InventoryPolicyTextBlock_3028A38651AF1AF3AE33DECFB123A899_label_en-US" xlink:label="lab_us-gaap_InventoryPolicyTextBlock_3028A38651AF1AF3AE33DECFB123A899" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Inventory, Policy [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_InventoryPolicyTextBlock" xlink:label="loc_us-gaap_InventoryPolicyTextBlock_3028A38651AF1AF3AE33DECFB123A899" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryPolicyTextBlock_3028A38651AF1AF3AE33DECFB123A899" xlink:to="lab_us-gaap_InventoryPolicyTextBlock_3028A38651AF1AF3AE33DECFB123A899" xlink:type="arc" />
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock_7E02276B3B298D1EF2B4DECFB1284ED6_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock_7E02276B3B298D1EF2B4DECFB1284ED6" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Goodwill and Intangible Assets</link:label>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock_7E02276B3B298D1EF2B4DECFB1284ED6_label_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock_7E02276B3B298D1EF2B4DECFB1284ED6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Goodwill and Intangible Assets, Policy [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock_7E02276B3B298D1EF2B4DECFB1284ED6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock_7E02276B3B298D1EF2B4DECFB1284ED6" xlink:to="lab_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock_7E02276B3B298D1EF2B4DECFB1284ED6" xlink:type="arc" />
    <link:label id="lab_us-gaap_RevenueRecognitionPolicyTextBlock_D17F1C1B467AF8EE020FDECFB12859B5_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueRecognitionPolicyTextBlock_D17F1C1B467AF8EE020FDECFB12859B5" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Revenue Recognition</link:label>
    <link:label id="lab_us-gaap_RevenueRecognitionPolicyTextBlock_D17F1C1B467AF8EE020FDECFB12859B5_label_en-US" xlink:label="lab_us-gaap_RevenueRecognitionPolicyTextBlock_D17F1C1B467AF8EE020FDECFB12859B5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue Recognition, Policy [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RevenueRecognitionPolicyTextBlock" xlink:label="loc_us-gaap_RevenueRecognitionPolicyTextBlock_D17F1C1B467AF8EE020FDECFB12859B5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueRecognitionPolicyTextBlock_D17F1C1B467AF8EE020FDECFB12859B5" xlink:to="lab_us-gaap_RevenueRecognitionPolicyTextBlock_D17F1C1B467AF8EE020FDECFB12859B5" xlink:type="arc" />
    <link:label id="lab_us-gaap_BusinessCombinationsPolicy_E4F624C8F4FB1303D4B0DECFB1292E3B_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationsPolicy_E4F624C8F4FB1303D4B0DECFB1292E3B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Acquisitions and In-Licensing</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationsPolicy_E4F624C8F4FB1303D4B0DECFB1292E3B_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationsPolicy_E4F624C8F4FB1303D4B0DECFB1292E3B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combinations Policy [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_BusinessCombinationsPolicy" xlink:label="loc_us-gaap_BusinessCombinationsPolicy_E4F624C8F4FB1303D4B0DECFB1292E3B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationsPolicy_E4F624C8F4FB1303D4B0DECFB1292E3B" xlink:to="lab_us-gaap_BusinessCombinationsPolicy_E4F624C8F4FB1303D4B0DECFB1292E3B" xlink:type="arc" />
    <link:label id="lab_gale_ContingentConsiderationPolicyPolicyTextBlock_1BDE6CC519E7B49A0E82DECFB12968B2_terseLabel_en-US" xlink:label="lab_gale_ContingentConsiderationPolicyPolicyTextBlock_1BDE6CC519E7B49A0E82DECFB12968B2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Contingent Consideration</link:label>
    <link:label id="lab_gale_ContingentConsiderationPolicyPolicyTextBlock_1BDE6CC519E7B49A0E82DECFB12968B2_label_en-US" xlink:label="lab_gale_ContingentConsiderationPolicyPolicyTextBlock_1BDE6CC519E7B49A0E82DECFB12968B2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Contingent Consideration Policy [Policy Text Block]</link:label>
    <link:label id="lab_gale_ContingentConsiderationPolicyPolicyTextBlock_1BDE6CC519E7B49A0E82DECFB12968B2_documentation_en-US" xlink:label="lab_gale_ContingentConsiderationPolicyPolicyTextBlock_1BDE6CC519E7B49A0E82DECFB12968B2" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Contingent Consideration Policy [Text Block]</link:label>
    <link:loc xlink:href="gale-20150930.xsd#gale_ContingentConsiderationPolicyPolicyTextBlock" xlink:label="loc_gale_ContingentConsiderationPolicyPolicyTextBlock_1BDE6CC519E7B49A0E82DECFB12968B2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_ContingentConsiderationPolicyPolicyTextBlock_1BDE6CC519E7B49A0E82DECFB12968B2" xlink:to="lab_gale_ContingentConsiderationPolicyPolicyTextBlock_1BDE6CC519E7B49A0E82DECFB12968B2" xlink:type="arc" />
    <link:label id="lab_gale_PatentsAndPatentApplicationCostsPolicyPolicyTextBlock_64CA5D2BF4643AC48883DECFB12992AF_terseLabel_en-US" xlink:label="lab_gale_PatentsAndPatentApplicationCostsPolicyPolicyTextBlock_64CA5D2BF4643AC48883DECFB12992AF" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Patents and Patent Application Costs</link:label>
    <link:label id="lab_gale_PatentsAndPatentApplicationCostsPolicyPolicyTextBlock_64CA5D2BF4643AC48883DECFB12992AF_label_en-US" xlink:label="lab_gale_PatentsAndPatentApplicationCostsPolicyPolicyTextBlock_64CA5D2BF4643AC48883DECFB12992AF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Patents And Patent Application Costs Policy [Policy Text Block]</link:label>
    <link:label id="lab_gale_PatentsAndPatentApplicationCostsPolicyPolicyTextBlock_64CA5D2BF4643AC48883DECFB12992AF_documentation_en-US" xlink:label="lab_gale_PatentsAndPatentApplicationCostsPolicyPolicyTextBlock_64CA5D2BF4643AC48883DECFB12992AF" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Patents and Patent Application Costs [Policy Text Block]</link:label>
    <link:loc xlink:href="gale-20150930.xsd#gale_PatentsAndPatentApplicationCostsPolicyPolicyTextBlock" xlink:label="loc_gale_PatentsAndPatentApplicationCostsPolicyPolicyTextBlock_64CA5D2BF4643AC48883DECFB12992AF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_PatentsAndPatentApplicationCostsPolicyPolicyTextBlock_64CA5D2BF4643AC48883DECFB12992AF" xlink:to="lab_gale_PatentsAndPatentApplicationCostsPolicyPolicyTextBlock_64CA5D2BF4643AC48883DECFB12992AF" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_F9F56AFA835075C096D8DECFB12913BB_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_F9F56AFA835075C096D8DECFB12913BB" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based Compensation</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_F9F56AFA835075C096D8DECFB12913BB_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_F9F56AFA835075C096D8DECFB12913BB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation, Option and Incentive Plans Policy [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:label="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_F9F56AFA835075C096D8DECFB12913BB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_F9F56AFA835075C096D8DECFB12913BB" xlink:to="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_F9F56AFA835075C096D8DECFB12913BB" xlink:type="arc" />
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpensePolicy_09E495847AE91343B0B1DECFB129EC3E_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpensePolicy_09E495847AE91343B0B1DECFB129EC3E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Research and Development Expenses</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpensePolicy_09E495847AE91343B0B1DECFB129EC3E_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpensePolicy_09E495847AE91343B0B1DECFB129EC3E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research and Development Expense, Policy [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpensePolicy_09E495847AE91343B0B1DECFB129EC3E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpensePolicy_09E495847AE91343B0B1DECFB129EC3E" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpensePolicy_09E495847AE91343B0B1DECFB129EC3E" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeTaxPolicyTextBlock_B347044DEACA81933944DECFB129C52F_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxPolicyTextBlock_B347044DEACA81933944DECFB129C52F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxPolicyTextBlock_B347044DEACA81933944DECFB129C52F_label_en-US" xlink:label="lab_us-gaap_IncomeTaxPolicyTextBlock_B347044DEACA81933944DECFB129C52F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax, Policy [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="loc_us-gaap_IncomeTaxPolicyTextBlock_B347044DEACA81933944DECFB129C52F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxPolicyTextBlock_B347044DEACA81933944DECFB129C52F" xlink:to="lab_us-gaap_IncomeTaxPolicyTextBlock_B347044DEACA81933944DECFB129C52F" xlink:type="arc" />
    <link:label id="lab_us-gaap_ConcentrationRiskCreditRisk_56ED59ABE0E4D009C6CCDECFB12968B7_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskCreditRisk_56ED59ABE0E4D009C6CCDECFB12968B7" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Concentrations of Credit Risk</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskCreditRisk_56ED59ABE0E4D009C6CCDECFB12968B7_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskCreditRisk_56ED59ABE0E4D009C6CCDECFB12968B7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Concentration Risk, Credit Risk, Policy [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ConcentrationRiskCreditRisk" xlink:label="loc_us-gaap_ConcentrationRiskCreditRisk_56ED59ABE0E4D009C6CCDECFB12968B7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskCreditRisk_56ED59ABE0E4D009C6CCDECFB12968B7" xlink:to="lab_us-gaap_ConcentrationRiskCreditRisk_56ED59ABE0E4D009C6CCDECFB12968B7" xlink:type="arc" />
    <link:label id="lab_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_28CBF990831CAC72C8F2DECFB1297C05_terseLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_28CBF990831CAC72C8F2DECFB1297C05" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Comprehensive Loss</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_28CBF990831CAC72C8F2DECFB1297C05_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_28CBF990831CAC72C8F2DECFB1297C05" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Comprehensive Income, Policy [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:label="loc_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_28CBF990831CAC72C8F2DECFB1297C05" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_28CBF990831CAC72C8F2DECFB1297C05" xlink:to="lab_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_28CBF990831CAC72C8F2DECFB1297C05" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_8F108C4D19F371579383DECFB129A424_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_8F108C4D19F371579383DECFB129A424" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value Measurement</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_8F108C4D19F371579383DECFB129A424_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_8F108C4D19F371579383DECFB129A424" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Measurement, Policy [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:label="loc_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_8F108C4D19F371579383DECFB129A424" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_8F108C4D19F371579383DECFB129A424" xlink:to="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_8F108C4D19F371579383DECFB129A424" xlink:type="arc" />
    <link:label id="lab_us-gaap_EarningsPerSharePolicyTextBlock_BAB912465CE0C6963EE2DECFB1292DD1_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerSharePolicyTextBlock_BAB912465CE0C6963EE2DECFB1292DD1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Earnings per Share</link:label>
    <link:label id="lab_us-gaap_EarningsPerSharePolicyTextBlock_BAB912465CE0C6963EE2DECFB1292DD1_label_en-US" xlink:label="lab_us-gaap_EarningsPerSharePolicyTextBlock_BAB912465CE0C6963EE2DECFB1292DD1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings Per Share, Policy [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="loc_us-gaap_EarningsPerSharePolicyTextBlock_BAB912465CE0C6963EE2DECFB1292DD1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerSharePolicyTextBlock_BAB912465CE0C6963EE2DECFB1292DD1" xlink:to="lab_us-gaap_EarningsPerSharePolicyTextBlock_BAB912465CE0C6963EE2DECFB1292DD1" xlink:type="arc" />
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_E9112EFF020FF314BB93DEE1943CC7C1_terseLabel_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_E9112EFF020FF314BB93DEE1943CC7C1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Effect of Recent Accounting Pronouncements</link:label>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_E9112EFF020FF314BB93DEE1943CC7C1_label_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_E9112EFF020FF314BB93DEE1943CC7C1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">New Accounting Pronouncements, Policy [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_E9112EFF020FF314BB93DEE1943CC7C1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_E9112EFF020FF314BB93DEE1943CC7C1" xlink:to="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_E9112EFF020FF314BB93DEE1943CC7C1" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_DCAFD8BA33BF4698CF17D437A875D574_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_86113A6CCDFC5879B8224142BA8F5E63" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Allocated Stock-based Compensation Expense</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_DCAFD8BA33BF4698CF17D437A875D574_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_86113A6CCDFC5879B8224142BA8F5E63" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_86113A6CCDFC5879B8224142BA8F5E63" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_86113A6CCDFC5879B8224142BA8F5E63" xlink:to="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_86113A6CCDFC5879B8224142BA8F5E63" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_C61B4286DC8D89C48C20D437A87AB5C0_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_F74E972664355CBAA55BDE734673E68F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Assumptions for Option Grants Issued</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_C61B4286DC8D89C48C20D437A87AB5C0_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_F74E972664355CBAA55BDE734673E68F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_F74E972664355CBAA55BDE734673E68F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_F74E972664355CBAA55BDE734673E68F" xlink:to="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_F74E972664355CBAA55BDE734673E68F" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_425E118923AF26BD393AD437A87B4687_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_8E7F32656FEB5696876FC448E8257AC3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock Option Activity</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_425E118923AF26BD393AD437A87B4687_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_8E7F32656FEB5696876FC448E8257AC3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Share-based Compensation, Stock Options, Activity [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_8E7F32656FEB5696876FC448E8257AC3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_8E7F32656FEB5696876FC448E8257AC3" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_8E7F32656FEB5696876FC448E8257AC3" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_40E1BC40660E7F36A115D437A81CFBFC_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_8FAA9A305A5C5FCEB6DC9D8460AB670D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Accrued Expenses and Other Current Liabilities</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_40E1BC40660E7F36A115D437A81CFBFC_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_8FAA9A305A5C5FCEB6DC9D8460AB670D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Accrued Liabilities [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_8FAA9A305A5C5FCEB6DC9D8460AB670D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_8FAA9A305A5C5FCEB6DC9D8460AB670D" xlink:to="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_8FAA9A305A5C5FCEB6DC9D8460AB670D" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherIncomeAndExpensesAbstract_C6C2112EB0AB6AA42962D437A81D8F4A_label_en-US" xlink:label="lab_us-gaap_OtherIncomeAndExpensesAbstract_D89813F97EB75A248FF9B087AC656C92" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Income and Expenses [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OtherIncomeAndExpensesAbstract" xlink:label="loc_us-gaap_OtherIncomeAndExpensesAbstract_D89813F97EB75A248FF9B087AC656C92" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherIncomeAndExpensesAbstract_D89813F97EB75A248FF9B087AC656C92" xlink:to="lab_us-gaap_OtherIncomeAndExpensesAbstract_D89813F97EB75A248FF9B087AC656C92" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock_81C34FA38AB4D8939E78D437A81D4DB9_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock_95C1AAEC53485BC38D8EFC5975C918FC" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Other Income (Expense)</link:label>
    <link:label id="lab_us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock_81C34FA38AB4D8939E78D437A81D4DB9_label_en-US" xlink:label="lab_us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock_95C1AAEC53485BC38D8EFC5975C918FC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Other Nonoperating Income (Expense) [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock_95C1AAEC53485BC38D8EFC5975C918FC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock_95C1AAEC53485BC38D8EFC5975C918FC" xlink:to="lab_us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock_95C1AAEC53485BC38D8EFC5975C918FC" xlink:type="arc" />
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightOutstanding_91D76E92C226E4558117D437A7EC4321_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightOutstanding_BBD3F5C119945EC3971AFD379FB2238F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Warrants outstanding</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="loc_us-gaap_ClassOfWarrantOrRightOutstanding_BBD3F5C119945EC3971AFD379FB2238F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightOutstanding_BBD3F5C119945EC3971AFD379FB2238F" xlink:to="lab_us-gaap_ClassOfWarrantOrRightOutstanding_BBD3F5C119945EC3971AFD379FB2238F" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_3DD50C95F5A0442CAE00D437A7EC7FDE_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_FAFE5950FFFF5656A31C4DABD0768509" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Stock options outstanding</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_FAFE5950FFFF5656A31C4DABD0768509" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_FAFE5950FFFF5656A31C4DABD0768509" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_FAFE5950FFFF5656A31C4DABD0768509" xlink:type="arc" />
    <link:label id="lab_gale_OptionsReservedForFutureIssuanceUnderCompaniesIncentivePlan_F68C8B82F9383138DEFBD437A7ECDF36_terseLabel_en-US" xlink:label="lab_gale_OptionsReservedForFutureIssuanceUnderCompaniesIncentivePlan_E2016511C1B55CB580C61CB731F1EFE1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Options reserved for future issuance under the Company's 2007 Incentive Plan</link:label>
    <link:label id="lab_gale_OptionsReservedForFutureIssuanceUnderCompaniesIncentivePlan_F68C8B82F9383138DEFBD437A7ECDF36_label_en-US" xlink:label="lab_gale_OptionsReservedForFutureIssuanceUnderCompaniesIncentivePlan_E2016511C1B55CB580C61CB731F1EFE1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Options Reserved For Future Issuance Under Companies Incentive Plan</link:label>
    <link:label id="lab_gale_OptionsReservedForFutureIssuanceUnderCompaniesIncentivePlan_F68C8B82F9383138DEFBD437A7ECDF36_documentation_en-US" xlink:label="lab_gale_OptionsReservedForFutureIssuanceUnderCompaniesIncentivePlan_E2016511C1B55CB580C61CB731F1EFE1" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Options reserved for future issuance under the Company's 2007 Incentive Plan.</link:label>
    <link:loc xlink:href="gale-20150930.xsd#gale_OptionsReservedForFutureIssuanceUnderCompaniesIncentivePlan" xlink:label="loc_gale_OptionsReservedForFutureIssuanceUnderCompaniesIncentivePlan_E2016511C1B55CB580C61CB731F1EFE1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_OptionsReservedForFutureIssuanceUnderCompaniesIncentivePlan_E2016511C1B55CB580C61CB731F1EFE1" xlink:to="lab_gale_OptionsReservedForFutureIssuanceUnderCompaniesIncentivePlan_E2016511C1B55CB580C61CB731F1EFE1" xlink:type="arc" />
    <link:label id="lab_gale_CommonStockCapitalSharesReservedForFutureIssuanceOfEmployeeStockPurchasePlan_44EB5312A3238A28789DD437A7EC19F1_terseLabel_en-US" xlink:label="lab_gale_CommonStockCapitalSharesReservedForFutureIssuanceOfEmployeeStockPurchasePlan_8D5AF98C88C157D4A90FF8C64816AC25" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Shares reserved for future issuance under the Employee Stock Purchase Plan</link:label>
    <link:label id="lab_gale_CommonStockCapitalSharesReservedForFutureIssuanceOfEmployeeStockPurchasePlan_44EB5312A3238A28789DD437A7EC19F1_label_en-US" xlink:label="lab_gale_CommonStockCapitalSharesReservedForFutureIssuanceOfEmployeeStockPurchasePlan_8D5AF98C88C157D4A90FF8C64816AC25" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock Capital Shares Reserved For Future Issuance Of Employee Stock Purchase Plan</link:label>
    <link:label id="lab_gale_CommonStockCapitalSharesReservedForFutureIssuanceOfEmployeeStockPurchasePlan_44EB5312A3238A28789DD437A7EC19F1_documentation_en-US" xlink:label="lab_gale_CommonStockCapitalSharesReservedForFutureIssuanceOfEmployeeStockPurchasePlan_8D5AF98C88C157D4A90FF8C64816AC25" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Common Stock Capital Shares Reserved For Future Issuance Of Employee Stock Purchase Plan</link:label>
    <link:loc xlink:href="gale-20150930.xsd#gale_CommonStockCapitalSharesReservedForFutureIssuanceOfEmployeeStockPurchasePlan" xlink:label="loc_gale_CommonStockCapitalSharesReservedForFutureIssuanceOfEmployeeStockPurchasePlan_8D5AF98C88C157D4A90FF8C64816AC25" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_CommonStockCapitalSharesReservedForFutureIssuanceOfEmployeeStockPurchasePlan_8D5AF98C88C157D4A90FF8C64816AC25" xlink:to="lab_gale_CommonStockCapitalSharesReservedForFutureIssuanceOfEmployeeStockPurchasePlan_8D5AF98C88C157D4A90FF8C64816AC25" xlink:type="arc" />
    <link:label id="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_F91D996E7D16E9BA7706D437A7EC5593_totalLabel_en-US" xlink:label="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_186688B81FC25B07824423EFBC1B7C1C" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total reserved for future issuance</link:label>
    <link:label id="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_F91D996E7D16E9BA7706D437A7EC5593_label_en-US" xlink:label="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_186688B81FC25B07824423EFBC1B7C1C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Capital Shares Reserved for Future Issuance</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_186688B81FC25B07824423EFBC1B7C1C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_186688B81FC25B07824423EFBC1B7C1C" xlink:to="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_186688B81FC25B07824423EFBC1B7C1C" xlink:type="arc" />
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_42EF57CD448739DAC6C0DECFB1445E4C_label_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract_42EF57CD448739DAC6C0DECFB1445E4C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract_42EF57CD448739DAC6C0DECFB1445E4C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_42EF57CD448739DAC6C0DECFB1445E4C" xlink:to="lab_us-gaap_StatementOfCashFlowsAbstract_42EF57CD448739DAC6C0DECFB1445E4C" xlink:type="arc" />
    <link:label id="lab_us-gaap_StatementTable_833B465F01FBA6E9A439DECFB144B6B8_terseLabel_en-US" xlink:label="lab_us-gaap_StatementTable_833B465F01FBA6E9A439DECFB144B6B8" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statement [Table]</link:label>
    <link:label id="lab_us-gaap_StatementTable_833B465F01FBA6E9A439DECFB144B6B8_label_en-US" xlink:label="lab_us-gaap_StatementTable_833B465F01FBA6E9A439DECFB144B6B8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_833B465F01FBA6E9A439DECFB144B6B8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementTable_833B465F01FBA6E9A439DECFB144B6B8" xlink:to="lab_us-gaap_StatementTable_833B465F01FBA6E9A439DECFB144B6B8" xlink:type="arc" />
    <link:label id="lab_us-gaap_BusinessAcquisitionAxis_644B76335F8D3E5177F6DECFB144BE9D_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAxis_644B76335F8D3E5177F6DECFB144BE9D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Business Acquisition [Axis]</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionAxis_644B76335F8D3E5177F6DECFB144BE9D_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAxis_644B76335F8D3E5177F6DECFB144BE9D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Acquisition [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_644B76335F8D3E5177F6DECFB144BE9D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_644B76335F8D3E5177F6DECFB144BE9D" xlink:to="lab_us-gaap_BusinessAcquisitionAxis_644B76335F8D3E5177F6DECFB144BE9D" xlink:type="arc" />
    <link:label id="lab_us-gaap_BusinessAcquisitionAcquireeDomain_A1F176C14C1F6400B642DECFB145A390_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAcquireeDomain_A1F176C14C1F6400B642DECFB145A390" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Business Acquisition, Acquiree [Domain]</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionAcquireeDomain_A1F176C14C1F6400B642DECFB145A390_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAcquireeDomain_A1F176C14C1F6400B642DECFB145A390" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Acquisition, Acquiree [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_A1F176C14C1F6400B642DECFB145A390" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_A1F176C14C1F6400B642DECFB145A390" xlink:to="lab_us-gaap_BusinessAcquisitionAcquireeDomain_A1F176C14C1F6400B642DECFB145A390" xlink:type="arc" />
    <link:label id="lab_gale_AbstralMember_8A6D9A18639A5E0E8194DECFB1453685_terseLabel_en-US" xlink:label="lab_gale_AbstralMember_8A6D9A18639A5E0E8194DECFB1453685" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Abstral [Member]</link:label>
    <link:label id="lab_gale_AbstralMember_8A6D9A18639A5E0E8194DECFB1453685_label_en-US" xlink:label="lab_gale_AbstralMember_8A6D9A18639A5E0E8194DECFB1453685" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Abstral [Member]</link:label>
    <link:label id="lab_gale_AbstralMember_8A6D9A18639A5E0E8194DECFB1453685_documentation_en-US" xlink:label="lab_gale_AbstralMember_8A6D9A18639A5E0E8194DECFB1453685" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Abstral [Member]</link:label>
    <link:loc xlink:href="gale-20150930.xsd#gale_AbstralMember" xlink:label="loc_gale_AbstralMember_8A6D9A18639A5E0E8194DECFB1453685" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_AbstralMember_8A6D9A18639A5E0E8194DECFB1453685" xlink:to="lab_gale_AbstralMember_8A6D9A18639A5E0E8194DECFB1453685" xlink:type="arc" />
    <link:label id="lab_gale_ZuplenzMember_9E4577B7245ACFF4F031DECFB145075B_terseLabel_en-US" xlink:label="lab_gale_ZuplenzMember_9E4577B7245ACFF4F031DECFB145075B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Zuplenz [Member]</link:label>
    <link:label id="lab_gale_ZuplenzMember_9E4577B7245ACFF4F031DECFB145075B_label_en-US" xlink:label="lab_gale_ZuplenzMember_9E4577B7245ACFF4F031DECFB145075B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Zuplenz [Member]</link:label>
    <link:label id="lab_gale_ZuplenzMember_9E4577B7245ACFF4F031DECFB145075B_documentation_en-US" xlink:label="lab_gale_ZuplenzMember_9E4577B7245ACFF4F031DECFB145075B" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Zuplenz [Member]</link:label>
    <link:loc xlink:href="gale-20150930.xsd#gale_ZuplenzMember" xlink:label="loc_gale_ZuplenzMember_9E4577B7245ACFF4F031DECFB145075B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_ZuplenzMember_9E4577B7245ACFF4F031DECFB145075B" xlink:to="lab_gale_ZuplenzMember_9E4577B7245ACFF4F031DECFB145075B" xlink:type="arc" />
    <link:label id="lab_us-gaap_StatementLineItems_B9483F2F1F272C9C9D19DECFB1456D53_terseLabel_en-US" xlink:label="lab_us-gaap_StatementLineItems_B9483F2F1F272C9C9D19DECFB1456D53" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:label id="lab_us-gaap_StatementLineItems_B9483F2F1F272C9C9D19DECFB1456D53_label_en-US" xlink:label="lab_us-gaap_StatementLineItems_B9483F2F1F272C9C9D19DECFB1456D53" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_B9483F2F1F272C9C9D19DECFB1456D53" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementLineItems_B9483F2F1F272C9C9D19DECFB1456D53" xlink:to="lab_us-gaap_StatementLineItems_B9483F2F1F272C9C9D19DECFB1456D53" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_2C747EC46E27FF3C82E4DEE7D083E8BE_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_2C747EC46E27FF3C82E4DEE7D083E8BE" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net loss from continuing operations</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_2C747EC46E27FF3C82E4DEE7D083E8BE_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_2C747EC46E27FF3C82E4DEE7D083E8BE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income (Loss) from Continuing Operations, Including Portion Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_2C747EC46E27FF3C82E4DEE7D083E8BE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_2C747EC46E27FF3C82E4DEE7D083E8BE" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_2C747EC46E27FF3C82E4DEE7D083E8BE" xlink:type="arc" />
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_CCBDF903615CD281FE68DECFB145C274_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_CCBDF903615CD281FE68DECFB145C274" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash flows from operating activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_CCBDF903615CD281FE68DECFB145C274_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_CCBDF903615CD281FE68DECFB145C274" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_CCBDF903615CD281FE68DECFB145C274" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_CCBDF903615CD281FE68DECFB145C274" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_CCBDF903615CD281FE68DECFB145C274" xlink:type="arc" />
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_039E85029DD12E1B3B27DECFB145E917_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_039E85029DD12E1B3B27DECFB145E917" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Adjustment to reconcile net loss to net cash used in operating activities:</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_039E85029DD12E1B3B27DECFB145E917_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_039E85029DD12E1B3B27DECFB145E917" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_039E85029DD12E1B3B27DECFB145E917" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_039E85029DD12E1B3B27DECFB145E917" xlink:to="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_039E85029DD12E1B3B27DECFB145E917" xlink:type="arc" />
    <link:label id="lab_gale_ChangeInFairValueOfCommonStockWarrantsIssuedInConnectionWithVariousEquityFinancings_C00AE340FF13CB57B40ADECFB14AF7CD_negatedTerseLabel_en-US" xlink:label="lab_gale_ChangeInFairValueOfCommonStockWarrantsIssuedInConnectionWithVariousEquityFinancings_C00AE340FF13CB57B40ADECFB14AF7CD" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Change in fair value of common stock warrants</link:label>
    <link:label id="lab_gale_ChangeInFairValueOfCommonStockWarrantsIssuedInConnectionWithVariousEquityFinancings_C00AE340FF13CB57B40ADECFB14AF7CD_label_en-US" xlink:label="lab_gale_ChangeInFairValueOfCommonStockWarrantsIssuedInConnectionWithVariousEquityFinancings_C00AE340FF13CB57B40ADECFB14AF7CD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Change In Fair Value Of Common Stock Warrants Issued In Connection With Various Equity Financings</link:label>
    <link:label id="lab_gale_ChangeInFairValueOfCommonStockWarrantsIssuedInConnectionWithVariousEquityFinancings_C00AE340FF13CB57B40ADECFB14AF7CD_documentation_en-US" xlink:label="lab_gale_ChangeInFairValueOfCommonStockWarrantsIssuedInConnectionWithVariousEquityFinancings_C00AE340FF13CB57B40ADECFB14AF7CD" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Change in fair value of common stock warrants issued in connection with various equity financings.</link:label>
    <link:loc xlink:href="gale-20150930.xsd#gale_ChangeInFairValueOfCommonStockWarrantsIssuedInConnectionWithVariousEquityFinancings" xlink:label="loc_gale_ChangeInFairValueOfCommonStockWarrantsIssuedInConnectionWithVariousEquityFinancings_C00AE340FF13CB57B40ADECFB14AF7CD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_ChangeInFairValueOfCommonStockWarrantsIssuedInConnectionWithVariousEquityFinancings_C00AE340FF13CB57B40ADECFB14AF7CD" xlink:to="lab_gale_ChangeInFairValueOfCommonStockWarrantsIssuedInConnectionWithVariousEquityFinancings_C00AE340FF13CB57B40ADECFB14AF7CD" xlink:type="arc" />
    <link:label id="lab_gale_ChangeInFairValueOfContingentPurchaseConsideration_51BDE794020ABC65AD49DECFB14A1D20_negatedTerseLabel_en-US" xlink:label="lab_gale_ChangeInFairValueOfContingentPurchaseConsideration_51BDE794020ABC65AD49DECFB14A1D20" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Change in fair value of contingent consideration</link:label>
    <link:label id="lab_gale_ChangeInFairValueOfContingentPurchaseConsideration_51BDE794020ABC65AD49DECFB14A1D20_label_en-US" xlink:label="lab_gale_ChangeInFairValueOfContingentPurchaseConsideration_51BDE794020ABC65AD49DECFB14A1D20" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Change In Fair Value Of Contingent Purchase Consideration</link:label>
    <link:label id="lab_gale_ChangeInFairValueOfContingentPurchaseConsideration_51BDE794020ABC65AD49DECFB14A1D20_documentation_en-US" xlink:label="lab_gale_ChangeInFairValueOfContingentPurchaseConsideration_51BDE794020ABC65AD49DECFB14A1D20" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Change in fair value of contingent purchase consideration.</link:label>
    <link:loc xlink:href="gale-20150930.xsd#gale_ChangeInFairValueOfContingentPurchaseConsideration" xlink:label="loc_gale_ChangeInFairValueOfContingentPurchaseConsideration_51BDE794020ABC65AD49DECFB14A1D20" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_ChangeInFairValueOfContingentPurchaseConsideration_51BDE794020ABC65AD49DECFB14A1D20" xlink:to="lab_gale_ChangeInFairValueOfContingentPurchaseConsideration_51BDE794020ABC65AD49DECFB14A1D20" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_1D39042AA97DC69BCC7ADECFB14A3BA1_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_1D39042AA97DC69BCC7ADECFB14A3BA1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Changes in operating assets and liabilities:</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_1D39042AA97DC69BCC7ADECFB14A3BA1_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_1D39042AA97DC69BCC7ADECFB14A3BA1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Operating Capital [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_1D39042AA97DC69BCC7ADECFB14A3BA1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_1D39042AA97DC69BCC7ADECFB14A3BA1" xlink:to="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_1D39042AA97DC69BCC7ADECFB14A3BA1" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_3D08D946986C5D996324DECFB14A26A8_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_3D08D946986C5D996324DECFB14A26A8" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Prepaid expenses and other assets</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_3D08D946986C5D996324DECFB14A26A8_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_3D08D946986C5D996324DECFB14A26A8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Prepaid Expense and Other Assets</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_3D08D946986C5D996324DECFB14A26A8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_3D08D946986C5D996324DECFB14A26A8" xlink:to="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_3D08D946986C5D996324DECFB14A26A8" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayable_A8B17C08F5B70E1A6AE2DECFB14A6D89_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayable_A8B17C08F5B70E1A6AE2DECFB14A6D89" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayable_A8B17C08F5B70E1A6AE2DECFB14A6D89_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayable_A8B17C08F5B70E1A6AE2DECFB14A6D89" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Accounts Payable</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable_A8B17C08F5B70E1A6AE2DECFB14A6D89" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsPayable_A8B17C08F5B70E1A6AE2DECFB14A6D89" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsPayable_A8B17C08F5B70E1A6AE2DECFB14A6D89" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities_4B5D1FE388FCEAB2254EDECFB14A3D24_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities_4B5D1FE388FCEAB2254EDECFB14A3D24" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accrued expenses and other current liabilities</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities_4B5D1FE388FCEAB2254EDECFB14A3D24_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities_4B5D1FE388FCEAB2254EDECFB14A3D24" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Accrued Liabilities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_4B5D1FE388FCEAB2254EDECFB14A3D24" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_4B5D1FE388FCEAB2254EDECFB14A3D24" xlink:to="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities_4B5D1FE388FCEAB2254EDECFB14A3D24" xlink:type="arc" />
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_C1221DE2F9CE10E36A72DECFB14B97BF_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_C1221DE2F9CE10E36A72DECFB14B97BF" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net cash used in continuing operating activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_C1221DE2F9CE10E36A72DECFB14B97BF_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_C1221DE2F9CE10E36A72DECFB14B97BF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities, Continuing Operations</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_C1221DE2F9CE10E36A72DECFB14B97BF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_C1221DE2F9CE10E36A72DECFB14B97BF" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_C1221DE2F9CE10E36A72DECFB14B97BF" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax_FA3BCABD7563768C44D9DECFB14B5119_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax_FA3BCABD7563768C44D9DECFB14B5119" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Net loss from discontinued operations</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax_FA3BCABD7563768C44D9DECFB14B5119" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax_FA3BCABD7563768C44D9DECFB14B5119" xlink:to="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax_FA3BCABD7563768C44D9DECFB14B5119" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncreaseDecreaseInAssetsHeldForSale_288E177A66ED957134BCDECFB14B2A62_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAssetsHeldForSale_288E177A66ED957134BCDECFB14B2A62" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Changes in operating assets and liabilities attributable to discontinued operations</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAssetsHeldForSale_288E177A66ED957134BCDECFB14B2A62_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAssetsHeldForSale_288E177A66ED957134BCDECFB14B2A62" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Assets Held-for-sale</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncreaseDecreaseInAssetsHeldForSale" xlink:label="loc_us-gaap_IncreaseDecreaseInAssetsHeldForSale_288E177A66ED957134BCDECFB14B2A62" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAssetsHeldForSale_288E177A66ED957134BCDECFB14B2A62" xlink:to="lab_us-gaap_IncreaseDecreaseInAssetsHeldForSale_288E177A66ED957134BCDECFB14B2A62" xlink:type="arc" />
    <link:label id="lab_us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations_602F51B5546404D04884DECFB14B7E01_totalLabel_en-US" xlink:label="lab_us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations_602F51B5546404D04884DECFB14B7E01" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net cash used in discontinued operating activities</link:label>
    <link:label id="lab_us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations_602F51B5546404D04884DECFB14B7E01_label_en-US" xlink:label="lab_us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations_602F51B5546404D04884DECFB14B7E01" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash Provided by (Used in) Operating Activities, Discontinued Operations</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations" xlink:label="loc_us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations_602F51B5546404D04884DECFB14B7E01" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations_602F51B5546404D04884DECFB14B7E01" xlink:to="lab_us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations_602F51B5546404D04884DECFB14B7E01" xlink:type="arc" />
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_EBB9D03F28E25991181EDECFB14B5B64_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_EBB9D03F28E25991181EDECFB14B5B64" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net cash used in operating activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_EBB9D03F28E25991181EDECFB14B5B64_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_EBB9D03F28E25991181EDECFB14B5B64" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_EBB9D03F28E25991181EDECFB14B5B64" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_EBB9D03F28E25991181EDECFB14B5B64" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_EBB9D03F28E25991181EDECFB14B5B64" xlink:type="arc" />
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_4CB41BFA6BB6F341DB4BDECFB14BECE8_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_4CB41BFA6BB6F341DB4BDECFB14BECE8" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash flows from investing activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_4CB41BFA6BB6F341DB4BDECFB14BECE8_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_4CB41BFA6BB6F341DB4BDECFB14BECE8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_4CB41BFA6BB6F341DB4BDECFB14BECE8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_4CB41BFA6BB6F341DB4BDECFB14BECE8" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_4CB41BFA6BB6F341DB4BDECFB14BECE8" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncreaseDecreaseInRestrictedCash_04BF2D4B5A813AC3D0A9DECFB14BE5D8_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInRestrictedCash_04BF2D4B5A813AC3D0A9DECFB14BE5D8" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Change in restricted cash</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInRestrictedCash_04BF2D4B5A813AC3D0A9DECFB14BE5D8_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInRestrictedCash_04BF2D4B5A813AC3D0A9DECFB14BE5D8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Restricted Cash</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncreaseDecreaseInRestrictedCash" xlink:label="loc_us-gaap_IncreaseDecreaseInRestrictedCash_04BF2D4B5A813AC3D0A9DECFB14BE5D8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInRestrictedCash_04BF2D4B5A813AC3D0A9DECFB14BE5D8" xlink:to="lab_us-gaap_IncreaseDecreaseInRestrictedCash_04BF2D4B5A813AC3D0A9DECFB14BE5D8" xlink:type="arc" />
    <link:label id="lab_us-gaap_PaymentsToAcquireBusinessesGross_48037E80F39D51C412AFDECFB14B9E92_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireBusinessesGross_48037E80F39D51C412AFDECFB14B9E92" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Cash paid for acquisition of GALE-401 rights</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireBusinessesGross_48037E80F39D51C412AFDECFB14B9E92_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireBusinessesGross_48037E80F39D51C412AFDECFB14B9E92" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments to Acquire Businesses, Gross</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PaymentsToAcquireBusinessesGross" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesGross_48037E80F39D51C412AFDECFB14B9E92" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireBusinessesGross_48037E80F39D51C412AFDECFB14B9E92" xlink:to="lab_us-gaap_PaymentsToAcquireBusinessesGross_48037E80F39D51C412AFDECFB14B9E92" xlink:type="arc" />
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_0449D7BED612BC79F610DECFB14B433D_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_0449D7BED612BC79F610DECFB14B433D" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Cash paid for purchase of equipment and furnishings</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_0449D7BED612BC79F610DECFB14B433D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_0449D7BED612BC79F610DECFB14B433D" xlink:to="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_0449D7BED612BC79F610DECFB14B433D" xlink:type="arc" />
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations_DA98DEC5EB1396AEDD29DECFB14BD84D_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations_DA98DEC5EB1396AEDD29DECFB14BD84D" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net cash used in continuing investing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations_DA98DEC5EB1396AEDD29DECFB14BD84D_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations_DA98DEC5EB1396AEDD29DECFB14BD84D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities, Continuing Operations</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations_DA98DEC5EB1396AEDD29DECFB14BD84D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations_DA98DEC5EB1396AEDD29DECFB14BD84D" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations_DA98DEC5EB1396AEDD29DECFB14BD84D" xlink:type="arc" />
    <link:label id="lab_us-gaap_CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations_8068DA8B834324BF1EE5DECFB14B9063_terseLabel_en-US" xlink:label="lab_us-gaap_CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations_8068DA8B834324BF1EE5DECFB14B9063" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net cash used in discontinued investing activities</link:label>
    <link:label id="lab_us-gaap_CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations_8068DA8B834324BF1EE5DECFB14B9063_label_en-US" xlink:label="lab_us-gaap_CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations_8068DA8B834324BF1EE5DECFB14B9063" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash Provided by (Used in) Investing Activities, Discontinued Operations</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations" xlink:label="loc_us-gaap_CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations_8068DA8B834324BF1EE5DECFB14B9063" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations_8068DA8B834324BF1EE5DECFB14B9063" xlink:to="lab_us-gaap_CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations_8068DA8B834324BF1EE5DECFB14B9063" xlink:type="arc" />
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_4EC0E8788B1398A00E34DECFB14BD887_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_4EC0E8788B1398A00E34DECFB14BD887" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net cash used in investing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_4EC0E8788B1398A00E34DECFB14BD887_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_4EC0E8788B1398A00E34DECFB14BD887" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_4EC0E8788B1398A00E34DECFB14BD887" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_4EC0E8788B1398A00E34DECFB14BD887" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_4EC0E8788B1398A00E34DECFB14BD887" xlink:type="arc" />
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_BA0A395456D450B07560DECFB14B5949_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_BA0A395456D450B07560DECFB14B5949" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash flows from financing activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_BA0A395456D450B07560DECFB14B5949_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_BA0A395456D450B07560DECFB14B5949" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_BA0A395456D450B07560DECFB14B5949" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_BA0A395456D450B07560DECFB14B5949" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_BA0A395456D450B07560DECFB14B5949" xlink:type="arc" />
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfCommonStock_F6308569703CE949A25EDECFB14B1D60_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfCommonStock_F6308569703CE949A25EDECFB14B1D60" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net proceeds from issuance of common stock</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfCommonStock_F6308569703CE949A25EDECFB14B1D60_label_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfCommonStock_F6308569703CE949A25EDECFB14B1D60" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from Issuance of Common Stock</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_F6308569703CE949A25EDECFB14B1D60" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_F6308569703CE949A25EDECFB14B1D60" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfCommonStock_F6308569703CE949A25EDECFB14B1D60" xlink:type="arc" />
    <link:label id="lab_us-gaap_ProceedsFromStockOptionsExercised_0DA6D5B1965516F8CB88DECFB14BAF76_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromStockOptionsExercised_0DA6D5B1965516F8CB88DECFB14BAF76" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net proceeds from exercise of stock options</link:label>
    <link:label id="lab_us-gaap_ProceedsFromStockOptionsExercised_0DA6D5B1965516F8CB88DECFB14BAF76_label_en-US" xlink:label="lab_us-gaap_ProceedsFromStockOptionsExercised_0DA6D5B1965516F8CB88DECFB14BAF76" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from Stock Options Exercised</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised_0DA6D5B1965516F8CB88DECFB14BAF76" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromStockOptionsExercised_0DA6D5B1965516F8CB88DECFB14BAF76" xlink:to="lab_us-gaap_ProceedsFromStockOptionsExercised_0DA6D5B1965516F8CB88DECFB14BAF76" xlink:type="arc" />
    <link:label id="lab_gale_NetProceedsFromExerciseOfCommonStockWarrants_C8468E49C33E89FD8EEFDECFB14B2093_terseLabel_en-US" xlink:label="lab_gale_NetProceedsFromExerciseOfCommonStockWarrants_C8468E49C33E89FD8EEFDECFB14B2093" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from exercise of warrants</link:label>
    <link:label id="lab_gale_NetProceedsFromExerciseOfCommonStockWarrants_C8468E49C33E89FD8EEFDECFB14B2093_label_en-US" xlink:label="lab_gale_NetProceedsFromExerciseOfCommonStockWarrants_C8468E49C33E89FD8EEFDECFB14B2093" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Proceeds From Exercise Of Common Stock Warrants</link:label>
    <link:label id="lab_gale_NetProceedsFromExerciseOfCommonStockWarrants_C8468E49C33E89FD8EEFDECFB14B2093_documentation_en-US" xlink:label="lab_gale_NetProceedsFromExerciseOfCommonStockWarrants_C8468E49C33E89FD8EEFDECFB14B2093" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Net proceeds from exercise of common stock warrants.</link:label>
    <link:loc xlink:href="gale-20150930.xsd#gale_NetProceedsFromExerciseOfCommonStockWarrants" xlink:label="loc_gale_NetProceedsFromExerciseOfCommonStockWarrants_C8468E49C33E89FD8EEFDECFB14B2093" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_NetProceedsFromExerciseOfCommonStockWarrants_C8468E49C33E89FD8EEFDECFB14B2093" xlink:to="lab_gale_NetProceedsFromExerciseOfCommonStockWarrants_C8468E49C33E89FD8EEFDECFB14B2093" xlink:type="arc" />
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOrSaleOfEquity_FC385DCA7D7E8A1E0BF3DECFB14CAC15_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOrSaleOfEquity_FC385DCA7D7E8A1E0BF3DECFB14CAC15" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from common stock issued in connection with ESPP</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:label="loc_us-gaap_ProceedsFromIssuanceOrSaleOfEquity_FC385DCA7D7E8A1E0BF3DECFB14CAC15" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOrSaleOfEquity_FC385DCA7D7E8A1E0BF3DECFB14CAC15" xlink:to="lab_us-gaap_ProceedsFromIssuanceOrSaleOfEquity_FC385DCA7D7E8A1E0BF3DECFB14CAC15" xlink:type="arc" />
    <link:label id="lab_us-gaap_RepaymentsOfLongTermDebt_E769B039C1E90123DA56DECFB14CD014_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_RepaymentsOfLongTermDebt_E769B039C1E90123DA56DECFB14CD014" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Principle payments on long-term debt</link:label>
    <link:label id="lab_us-gaap_RepaymentsOfLongTermDebt_E769B039C1E90123DA56DECFB14CD014_label_en-US" xlink:label="lab_us-gaap_RepaymentsOfLongTermDebt_E769B039C1E90123DA56DECFB14CD014" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Repayments of Long-term Debt</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RepaymentsOfLongTermDebt" xlink:label="loc_us-gaap_RepaymentsOfLongTermDebt_E769B039C1E90123DA56DECFB14CD014" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RepaymentsOfLongTermDebt_E769B039C1E90123DA56DECFB14CD014" xlink:to="lab_us-gaap_RepaymentsOfLongTermDebt_E769B039C1E90123DA56DECFB14CD014" xlink:type="arc" />
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_109FF286CA2D47B266F7DECFB14C8998_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_109FF286CA2D47B266F7DECFB14C8998" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net cash provided by financing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_109FF286CA2D47B266F7DECFB14C8998_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_109FF286CA2D47B266F7DECFB14C8998" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_109FF286CA2D47B266F7DECFB14C8998" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_109FF286CA2D47B266F7DECFB14C8998" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_109FF286CA2D47B266F7DECFB14C8998" xlink:type="arc" />
    <link:label id="lab_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_58C6A6246259D5256F97DECFB14C9380_totalLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_58C6A6246259D5256F97DECFB14C9380" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net increase (decrease) in cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_58C6A6246259D5256F97DECFB14C9380_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_58C6A6246259D5256F97DECFB14C9380" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash and Cash Equivalents, Period Increase (Decrease)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:label="loc_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_58C6A6246259D5256F97DECFB14C9380" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_58C6A6246259D5256F97DECFB14C9380" xlink:to="lab_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_58C6A6246259D5256F97DECFB14C9380" xlink:type="arc" />
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_9AA3081D60D23029C22EDECFB14C7D36_periodStartLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_9AA3081D60D23029C22EDECFB14C7D36" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Cash and cash equivalents at the beginning of period</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_9AA3081D60D23029C22EDECFB14C7D36" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_9AA3081D60D23029C22EDECFB14C7D36" xlink:to="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_9AA3081D60D23029C22EDECFB14C7D36" xlink:type="arc" />
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_3827AA13C33134EF838DDECFB14C2E6A_periodEndLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_3827AA13C33134EF838DDECFB14C2E6A" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Cash and cash equivalents at end of period</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_3827AA13C33134EF838DDECFB14C2E6A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_3827AA13C33134EF838DDECFB14C2E6A" xlink:to="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_3827AA13C33134EF838DDECFB14C2E6A" xlink:type="arc" />
    <link:label id="lab_us-gaap_SupplementalCashFlowInformationAbstract_D55855D8687C632F9753DECFB14CBC22_terseLabel_en-US" xlink:label="lab_us-gaap_SupplementalCashFlowInformationAbstract_D55855D8687C632F9753DECFB14CBC22" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Supplemental disclosure of cash flow information:</link:label>
    <link:label id="lab_us-gaap_SupplementalCashFlowInformationAbstract_D55855D8687C632F9753DECFB14CBC22_label_en-US" xlink:label="lab_us-gaap_SupplementalCashFlowInformationAbstract_D55855D8687C632F9753DECFB14CBC22" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Supplemental Cash Flow Information [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract_D55855D8687C632F9753DECFB14CBC22" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_D55855D8687C632F9753DECFB14CBC22" xlink:to="lab_us-gaap_SupplementalCashFlowInformationAbstract_D55855D8687C632F9753DECFB14CBC22" xlink:type="arc" />
    <link:label id="lab_us-gaap_ProceedsFromInterestReceived_67C228FC9C83E985B811DECFB14C1E99_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromInterestReceived_67C228FC9C83E985B811DECFB14C1E99" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash received during the periods for interest</link:label>
    <link:label id="lab_us-gaap_ProceedsFromInterestReceived_67C228FC9C83E985B811DECFB14C1E99_label_en-US" xlink:label="lab_us-gaap_ProceedsFromInterestReceived_67C228FC9C83E985B811DECFB14C1E99" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from Interest Received</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ProceedsFromInterestReceived" xlink:label="loc_us-gaap_ProceedsFromInterestReceived_67C228FC9C83E985B811DECFB14C1E99" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromInterestReceived_67C228FC9C83E985B811DECFB14C1E99" xlink:to="lab_us-gaap_ProceedsFromInterestReceived_67C228FC9C83E985B811DECFB14C1E99" xlink:type="arc" />
    <link:label id="lab_us-gaap_InterestPaid_E6F1BE03E0558F4A26B8DECFB14C88E8_terseLabel_en-US" xlink:label="lab_us-gaap_InterestPaid_E6F1BE03E0558F4A26B8DECFB14C88E8" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash paid during the periods for interest</link:label>
    <link:label id="lab_us-gaap_InterestPaid_E6F1BE03E0558F4A26B8DECFB14C88E8_label_en-US" xlink:label="lab_us-gaap_InterestPaid_E6F1BE03E0558F4A26B8DECFB14C88E8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Interest Paid</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_InterestPaid" xlink:label="loc_us-gaap_InterestPaid_E6F1BE03E0558F4A26B8DECFB14C88E8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestPaid_E6F1BE03E0558F4A26B8DECFB14C88E8" xlink:to="lab_us-gaap_InterestPaid_E6F1BE03E0558F4A26B8DECFB14C88E8" xlink:type="arc" />
    <link:label id="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_4217351EF9E0882536DBDECFB14CBB48_terseLabel_en-US" xlink:label="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_4217351EF9E0882536DBDECFB14CBB48" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Supplemental disclosure of non-cash investing and financing activities:</link:label>
    <link:label id="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_4217351EF9E0882536DBDECFB14CBB48_label_en-US" xlink:label="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_4217351EF9E0882536DBDECFB14CBB48" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:label="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_4217351EF9E0882536DBDECFB14CBB48" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_4217351EF9E0882536DBDECFB14CBB48" xlink:to="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_4217351EF9E0882536DBDECFB14CBB48" xlink:type="arc" />
    <link:label id="lab_gale_FairValueOfWarrantsIssuedInConnectionWithCommonStockRecordedAsCostOfEquity_0C874305ED8A314B8C3CDECFB14CDC62_terseLabel_en-US" xlink:label="lab_gale_FairValueOfWarrantsIssuedInConnectionWithCommonStockRecordedAsCostOfEquity_0C874305ED8A314B8C3CDECFB14CDC62" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair value of warrants issued in connection with common stock recorded as cost of equity</link:label>
    <link:label id="lab_gale_FairValueOfWarrantsIssuedInConnectionWithCommonStockRecordedAsCostOfEquity_0C874305ED8A314B8C3CDECFB14CDC62_label_en-US" xlink:label="lab_gale_FairValueOfWarrantsIssuedInConnectionWithCommonStockRecordedAsCostOfEquity_0C874305ED8A314B8C3CDECFB14CDC62" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Of Warrants Issued In Connection With Common Stock Recorded As Cost Of Equity</link:label>
    <link:label id="lab_gale_FairValueOfWarrantsIssuedInConnectionWithCommonStockRecordedAsCostOfEquity_0C874305ED8A314B8C3CDECFB14CDC62_documentation_en-US" xlink:label="lab_gale_FairValueOfWarrantsIssuedInConnectionWithCommonStockRecordedAsCostOfEquity_0C874305ED8A314B8C3CDECFB14CDC62" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Fair value of warrants issued in connection with common stock recorded as a cost of equity.</link:label>
    <link:loc xlink:href="gale-20150930.xsd#gale_FairValueOfWarrantsIssuedInConnectionWithCommonStockRecordedAsCostOfEquity" xlink:label="loc_gale_FairValueOfWarrantsIssuedInConnectionWithCommonStockRecordedAsCostOfEquity_0C874305ED8A314B8C3CDECFB14CDC62" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_FairValueOfWarrantsIssuedInConnectionWithCommonStockRecordedAsCostOfEquity_0C874305ED8A314B8C3CDECFB14CDC62" xlink:to="lab_gale_FairValueOfWarrantsIssuedInConnectionWithCommonStockRecordedAsCostOfEquity_0C874305ED8A314B8C3CDECFB14CDC62" xlink:type="arc" />
    <link:label id="lab_gale_ReclassificationOfWarrantLiabilityUponExercise_1DABF2C73AD23FB0425DDECFB14CEE6D_negatedTerseLabel_en-US" xlink:label="lab_gale_ReclassificationOfWarrantLiabilityUponExercise_1DABF2C73AD23FB0425DDECFB14CEE6D" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Reclassification of warrant liabilities upon exercise</link:label>
    <link:label id="lab_gale_ReclassificationOfWarrantLiabilityUponExercise_1DABF2C73AD23FB0425DDECFB14CEE6D_label_en-US" xlink:label="lab_gale_ReclassificationOfWarrantLiabilityUponExercise_1DABF2C73AD23FB0425DDECFB14CEE6D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Reclassification Of Warrant Liability Upon Exercise</link:label>
    <link:label id="lab_gale_ReclassificationOfWarrantLiabilityUponExercise_1DABF2C73AD23FB0425DDECFB14CEE6D_documentation_en-US" xlink:label="lab_gale_ReclassificationOfWarrantLiabilityUponExercise_1DABF2C73AD23FB0425DDECFB14CEE6D" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Reclassification of warrant liability upon exercise.</link:label>
    <link:loc xlink:href="gale-20150930.xsd#gale_ReclassificationOfWarrantLiabilityUponExercise" xlink:label="loc_gale_ReclassificationOfWarrantLiabilityUponExercise_1DABF2C73AD23FB0425DDECFB14CEE6D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_ReclassificationOfWarrantLiabilityUponExercise_1DABF2C73AD23FB0425DDECFB14CEE6D" xlink:to="lab_gale_ReclassificationOfWarrantLiabilityUponExercise_1DABF2C73AD23FB0425DDECFB14CEE6D" xlink:type="arc" />
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_20A9AC555EE4629F93A8DEEC4A09B0CF_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_20A9AC555EE4629F93A8DEEC4A09B0CF" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets by Major Class [Axis]</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_20A9AC555EE4629F93A8DEEC4A09B0CF_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_20A9AC555EE4629F93A8DEEC4A09B0CF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets by Major Class [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_20A9AC555EE4629F93A8DEEC4A09B0CF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_20A9AC555EE4629F93A8DEEC4A09B0CF" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_20A9AC555EE4629F93A8DEEC4A09B0CF" xlink:type="arc" />
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_BEF614D9F375A46839B3DEEC4A09FFF9_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_BEF614D9F375A46839B3DEEC4A09FFF9" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets, Major Class Name [Domain]</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_BEF614D9F375A46839B3DEEC4A09FFF9_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_BEF614D9F375A46839B3DEEC4A09FFF9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets, Major Class Name [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_BEF614D9F375A46839B3DEEC4A09FFF9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_BEF614D9F375A46839B3DEEC4A09FFF9" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_BEF614D9F375A46839B3DEEC4A09FFF9" xlink:type="arc" />
    <link:label id="lab_gale_AbstralRightsNetMember_482C82163038D52DDD05DEEC4A093416_terseLabel_en-US" xlink:label="lab_gale_AbstralRightsNetMember_482C82163038D52DDD05DEEC4A093416" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Abstral Rights, Net [Member]</link:label>
    <link:label id="lab_gale_AbstralRightsNetMember_482C82163038D52DDD05DEEC4A093416_label_en-US" xlink:label="lab_gale_AbstralRightsNetMember_482C82163038D52DDD05DEEC4A093416" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Abstral Rights, Net [Member]</link:label>
    <link:label id="lab_gale_AbstralRightsNetMember_482C82163038D52DDD05DEEC4A093416_documentation_en-US" xlink:label="lab_gale_AbstralRightsNetMember_482C82163038D52DDD05DEEC4A093416" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Abstral Rights, Net [Member]</link:label>
    <link:loc xlink:href="gale-20150930.xsd#gale_AbstralRightsNetMember" xlink:label="loc_gale_AbstralRightsNetMember_482C82163038D52DDD05DEEC4A093416" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_AbstralRightsNetMember_482C82163038D52DDD05DEEC4A093416" xlink:to="lab_gale_AbstralRightsNetMember_482C82163038D52DDD05DEEC4A093416" xlink:type="arc" />
    <link:label id="lab_gale_ZuplenzRightsMember_9490DD5E45FAC34163FEDEEC4A09B1A5_terseLabel_en-US" xlink:label="lab_gale_ZuplenzRightsMember_9490DD5E45FAC34163FEDEEC4A09B1A5" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Zuplenz Rights [Member]</link:label>
    <link:label id="lab_gale_ZuplenzRightsMember_9490DD5E45FAC34163FEDEEC4A09B1A5_label_en-US" xlink:label="lab_gale_ZuplenzRightsMember_9490DD5E45FAC34163FEDEEC4A09B1A5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Zuplenz Rights [Member]</link:label>
    <link:label id="lab_gale_ZuplenzRightsMember_9490DD5E45FAC34163FEDEEC4A09B1A5_documentation_en-US" xlink:label="lab_gale_ZuplenzRightsMember_9490DD5E45FAC34163FEDEEC4A09B1A5" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Zuplenz Rights [Member]</link:label>
    <link:loc xlink:href="gale-20150930.xsd#gale_ZuplenzRightsMember" xlink:label="loc_gale_ZuplenzRightsMember_9490DD5E45FAC34163FEDEEC4A09B1A5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_ZuplenzRightsMember_9490DD5E45FAC34163FEDEEC4A09B1A5" xlink:to="lab_gale_ZuplenzRightsMember_9490DD5E45FAC34163FEDEEC4A09B1A5" xlink:type="arc" />
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet_4FD7CF3002F7A4F639CDDEEC4A0A7042_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet_4FD7CF3002F7A4F639CDDEEC4A0A7042" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accounts receivable</link:label>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet_4FD7CF3002F7A4F639CDDEEC4A0A7042_label_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet_4FD7CF3002F7A4F639CDDEEC4A0A7042" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Accounts, Notes and Loans Receivable, Net</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet_4FD7CF3002F7A4F639CDDEEC4A0A7042" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet_4FD7CF3002F7A4F639CDDEEC4A0A7042" xlink:to="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet_4FD7CF3002F7A4F639CDDEEC4A0A7042" xlink:type="arc" />
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationInventory1_7E46B7E821CB2CE9E89DDEEC4A0AF3A2_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationInventory1_7E46B7E821CB2CE9E89DDEEC4A0AF3A2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Inventories</link:label>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationInventory1_7E46B7E821CB2CE9E89DDEEC4A0AF3A2_label_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationInventory1_7E46B7E821CB2CE9E89DDEEC4A0AF3A2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Inventory</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationInventory1" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationInventory1_7E46B7E821CB2CE9E89DDEEC4A0AF3A2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationInventory1_7E46B7E821CB2CE9E89DDEEC4A0AF3A2" xlink:to="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationInventory1_7E46B7E821CB2CE9E89DDEEC4A0AF3A2" xlink:type="arc" />
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationPrepaidAndOtherAssets_0FE48BA816BA4C5C3B67DEEC4A0A89CF_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationPrepaidAndOtherAssets_0FE48BA816BA4C5C3B67DEEC4A0A89CF" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Prepaid Expenses</link:label>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationPrepaidAndOtherAssets_0FE48BA816BA4C5C3B67DEEC4A0A89CF_label_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationPrepaidAndOtherAssets_0FE48BA816BA4C5C3B67DEEC4A0A89CF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Prepaid and Other Assets</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationPrepaidAndOtherAssets" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationPrepaidAndOtherAssets_0FE48BA816BA4C5C3B67DEEC4A0A89CF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationPrepaidAndOtherAssets_0FE48BA816BA4C5C3B67DEEC4A0A89CF" xlink:to="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationPrepaidAndOtherAssets_0FE48BA816BA4C5C3B67DEEC4A0A89CF" xlink:type="arc" />
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment_4352A88CA1BA59081E6CDEEC4A0AA7D3_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment_4352A88CA1BA59081E6CDEEC4A0AA7D3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equipment and furnishings, net</link:label>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment_4352A88CA1BA59081E6CDEEC4A0AA7D3_label_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment_4352A88CA1BA59081E6CDEEC4A0AA7D3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Property, Plant and Equipment</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment_4352A88CA1BA59081E6CDEEC4A0AA7D3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment_4352A88CA1BA59081E6CDEEC4A0AA7D3" xlink:to="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment_4352A88CA1BA59081E6CDEEC4A0AA7D3" xlink:type="arc" />
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationIntangibleAssets_D9D805C1D49B79575DDADEEC4A0AA6C0_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationIntangibleAssets_D9D805C1D49B79575DDADEEC4A0AA6C0" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Rights</link:label>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationIntangibleAssets_D9D805C1D49B79575DDADEEC4A0AA6C0_label_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationIntangibleAssets_D9D805C1D49B79575DDADEEC4A0AA6C0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Intangible Assets</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationIntangibleAssets" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationIntangibleAssets_D9D805C1D49B79575DDADEEC4A0AA6C0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationIntangibleAssets_D9D805C1D49B79575DDADEEC4A0AA6C0" xlink:to="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationIntangibleAssets_D9D805C1D49B79575DDADEEC4A0AA6C0" xlink:type="arc" />
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationGoodwill1_F2CB2F46037470F44488DEEC4A0AE6E3_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationGoodwill1_F2CB2F46037470F44488DEEC4A0AE6E3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Goodwill</link:label>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationGoodwill1_F2CB2F46037470F44488DEEC4A0AE6E3_label_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationGoodwill1_F2CB2F46037470F44488DEEC4A0AE6E3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Goodwill</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationGoodwill1" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationGoodwill1_F2CB2F46037470F44488DEEC4A0AE6E3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationGoodwill1_F2CB2F46037470F44488DEEC4A0AE6E3" xlink:to="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationGoodwill1_F2CB2F46037470F44488DEEC4A0AE6E3" xlink:type="arc" />
    <link:label id="lab_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation_93C1F3505B10D3F0085EDEEC4A0A316F_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation_93C1F3505B10D3F0085EDEEC4A0A316F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Assets held for sale, net</link:label>
    <link:label id="lab_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation_93C1F3505B10D3F0085EDEEC4A0A316F_label_en-US" xlink:label="lab_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation_93C1F3505B10D3F0085EDEEC4A0A316F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Assets</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation" xlink:label="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation_93C1F3505B10D3F0085EDEEC4A0A316F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation_93C1F3505B10D3F0085EDEEC4A0A316F" xlink:to="lab_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation_93C1F3505B10D3F0085EDEEC4A0A316F" xlink:type="arc" />
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsPayable_FCA9E4778F5ADBCCB9C4DEEC4A0A8DBD_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsPayable_FCA9E4778F5ADBCCB9C4DEEC4A0A8DBD" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsPayable_FCA9E4778F5ADBCCB9C4DEEC4A0A8DBD_label_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsPayable_FCA9E4778F5ADBCCB9C4DEEC4A0A8DBD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Accounts Payable</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsPayable" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsPayable_FCA9E4778F5ADBCCB9C4DEEC4A0A8DBD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsPayable_FCA9E4778F5ADBCCB9C4DEEC4A0A8DBD" xlink:to="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsPayable_FCA9E4778F5ADBCCB9C4DEEC4A0A8DBD" xlink:type="arc" />
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccruedLiabilities_304CC3A6592EE03399ADDEEC4A0B16D5_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccruedLiabilities_304CC3A6592EE03399ADDEEC4A0B16D5" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accrued expenses and other current liabilities</link:label>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccruedLiabilities_304CC3A6592EE03399ADDEEC4A0B16D5_label_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccruedLiabilities_304CC3A6592EE03399ADDEEC4A0B16D5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Accrued Liabilities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationAccruedLiabilities" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccruedLiabilities_304CC3A6592EE03399ADDEEC4A0B16D5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccruedLiabilities_304CC3A6592EE03399ADDEEC4A0B16D5" xlink:to="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccruedLiabilities_304CC3A6592EE03399ADDEEC4A0B16D5" xlink:type="arc" />
    <link:label id="lab_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent_EA7D78C4DAE1B507088ADEEC4A0B84DB_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent_EA7D78C4DAE1B507088ADEEC4A0B84DB" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Total current liabilities held for sale</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent" xlink:label="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent_EA7D78C4DAE1B507088ADEEC4A0B84DB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent_EA7D78C4DAE1B507088ADEEC4A0B84DB" xlink:to="lab_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent_EA7D78C4DAE1B507088ADEEC4A0B84DB" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_B3D17458A6C41B65D40AD437A88C7E03_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_CBC38946F2515C55AF4E42F972A3CBA9" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_B3D17458A6C41B65D40AD437A88C7E03_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_CBC38946F2515C55AF4E42F972A3CBA9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_CBC38946F2515C55AF4E42F972A3CBA9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_CBC38946F2515C55AF4E42F972A3CBA9" xlink:to="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_CBC38946F2515C55AF4E42F972A3CBA9" xlink:type="arc" />
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_CCC94C44A8B29856D498D437A88C6BEF_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_C41A0062997252D5997C28B8BF94285E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Antidilutive Securities [Axis]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_CCC94C44A8B29856D498D437A88C6BEF_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_C41A0062997252D5997C28B8BF94285E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Antidilutive Securities [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_C41A0062997252D5997C28B8BF94285E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_C41A0062997252D5997C28B8BF94285E" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_C41A0062997252D5997C28B8BF94285E" xlink:type="arc" />
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesNameDomain_77A7B9B397606869E672D437A88CB82C_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesNameDomain_3BAA3882512A5279B2B9A73007196498" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Antidilutive Securities, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesNameDomain_77A7B9B397606869E672D437A88CB82C_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesNameDomain_3BAA3882512A5279B2B9A73007196498" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Antidilutive Securities, Name [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_3BAA3882512A5279B2B9A73007196498" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_3BAA3882512A5279B2B9A73007196498" xlink:to="lab_us-gaap_AntidilutiveSecuritiesNameDomain_3BAA3882512A5279B2B9A73007196498" xlink:type="arc" />
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_88F4589C60050099EBA8D437A88C957B_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember_2C23C19222825046BC8461D75EFDF8D5" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Options to purchase common stock [Member]</link:label>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_88F4589C60050099EBA8D437A88C957B_label_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember_2C23C19222825046BC8461D75EFDF8D5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Employee Stock Option [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaap_EmployeeStockOptionMember_2C23C19222825046BC8461D75EFDF8D5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeStockOptionMember_2C23C19222825046BC8461D75EFDF8D5" xlink:to="lab_us-gaap_EmployeeStockOptionMember_2C23C19222825046BC8461D75EFDF8D5" xlink:type="arc" />
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_06DA4490C0DB35B9C367D437A88C1488_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_6FAE955DB9A65DEB96F48F7F0F294834" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_06DA4490C0DB35B9C367D437A88C1488_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_6FAE955DB9A65DEB96F48F7F0F294834" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_6FAE955DB9A65DEB96F48F7F0F294834" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_6FAE955DB9A65DEB96F48F7F0F294834" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_6FAE955DB9A65DEB96F48F7F0F294834" xlink:type="arc" />
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_F0B349432B509407FBDED437A88C7745_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_5EB68F801D285689A867CC7B20D34414" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Shares of common stock issuable upon the exercise which were excluded from the computation of diluted earnings per share</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_F0B349432B509407FBDED437A88C7745_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_5EB68F801D285689A867CC7B20D34414" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_5EB68F801D285689A867CC7B20D34414" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_5EB68F801D285689A867CC7B20D34414" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_5EB68F801D285689A867CC7B20D34414" xlink:type="arc" />
    <link:label id="lab_us-gaap_FinancialInstrumentsDisclosureTextBlock_2E36AF168428E573E3ACD437A8565EA1_terseLabel_en-US" xlink:label="lab_us-gaap_FinancialInstrumentsDisclosureTextBlock_56417954780E5286A409B0F761015C1D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value Measurements</link:label>
    <link:label id="lab_us-gaap_FinancialInstrumentsDisclosureTextBlock_2E36AF168428E573E3ACD437A8565EA1_label_en-US" xlink:label="lab_us-gaap_FinancialInstrumentsDisclosureTextBlock_56417954780E5286A409B0F761015C1D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Financial Instruments Disclosure [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FinancialInstrumentsDisclosureTextBlock" xlink:label="loc_us-gaap_FinancialInstrumentsDisclosureTextBlock_56417954780E5286A409B0F761015C1D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinancialInstrumentsDisclosureTextBlock_56417954780E5286A409B0F761015C1D" xlink:to="lab_us-gaap_FinancialInstrumentsDisclosureTextBlock_56417954780E5286A409B0F761015C1D" xlink:type="arc" />
    <link:label id="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock_45FC27D1DF784CB824E2DE2A19830533_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock_45FC27D1DF784CB824E2DE2A19830533" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Discontinued Operations,Assets Held for Sale</link:label>
    <link:label id="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock_45FC27D1DF784CB824E2DE2A19830533_label_en-US" xlink:label="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock_45FC27D1DF784CB824E2DE2A19830533" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disposal Groups, Including Discontinued Operations, Disclosure [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock_45FC27D1DF784CB824E2DE2A19830533" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock_45FC27D1DF784CB824E2DE2A19830533" xlink:to="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock_45FC27D1DF784CB824E2DE2A19830533" xlink:type="arc" />
    <link:label id="lab_gale_CommonStockAreReservedForFutureIssuanceTableTextBlock_E26D2C25CAFDC8FA57EDD437A7F96185_terseLabel_en-US" xlink:label="lab_gale_CommonStockAreReservedForFutureIssuanceTableTextBlock_866FC528352655519CA3C725F062C282" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common Stock are Reserved for Future Issuance</link:label>
    <link:label id="lab_gale_CommonStockAreReservedForFutureIssuanceTableTextBlock_E26D2C25CAFDC8FA57EDD437A7F96185_label_en-US" xlink:label="lab_gale_CommonStockAreReservedForFutureIssuanceTableTextBlock_866FC528352655519CA3C725F062C282" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock Are Reserved For Future Issuance Table [Text Block]</link:label>
    <link:label id="lab_gale_CommonStockAreReservedForFutureIssuanceTableTextBlock_E26D2C25CAFDC8FA57EDD437A7F96185_documentation_en-US" xlink:label="lab_gale_CommonStockAreReservedForFutureIssuanceTableTextBlock_866FC528352655519CA3C725F062C282" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Common stock are reserved for future issuance.</link:label>
    <link:loc xlink:href="gale-20150930.xsd#gale_CommonStockAreReservedForFutureIssuanceTableTextBlock" xlink:label="loc_gale_CommonStockAreReservedForFutureIssuanceTableTextBlock_866FC528352655519CA3C725F062C282" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_CommonStockAreReservedForFutureIssuanceTableTextBlock_866FC528352655519CA3C725F062C282" xlink:to="lab_gale_CommonStockAreReservedForFutureIssuanceTableTextBlock_866FC528352655519CA3C725F062C282" xlink:type="arc" />
    <link:label id="lab_us-gaap_SubsequentEventsAbstract_0BA28247B42A24F9FB65D437A849EBB3_label_en-US" xlink:label="lab_us-gaap_SubsequentEventsAbstract_B7AB548C3D1B5586B849D52C55F8F3AB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Subsequent Events [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="loc_us-gaap_SubsequentEventsAbstract_B7AB548C3D1B5586B849D52C55F8F3AB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventsAbstract_B7AB548C3D1B5586B849D52C55F8F3AB" xlink:to="lab_us-gaap_SubsequentEventsAbstract_B7AB548C3D1B5586B849D52C55F8F3AB" xlink:type="arc" />
    <link:label id="lab_us-gaap_SubsequentEventsTextBlock_83CA0294D0A1B790B4CDD437A849421E_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventsTextBlock_60484E44A92A5B7AACB4C60FD30552A1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Subsequent Events</link:label>
    <link:label id="lab_us-gaap_SubsequentEventsTextBlock_83CA0294D0A1B790B4CDD437A849421E_label_en-US" xlink:label="lab_us-gaap_SubsequentEventsTextBlock_60484E44A92A5B7AACB4C60FD30552A1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Subsequent Events [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="loc_us-gaap_SubsequentEventsTextBlock_60484E44A92A5B7AACB4C60FD30552A1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventsTextBlock_60484E44A92A5B7AACB4C60FD30552A1" xlink:to="lab_us-gaap_SubsequentEventsTextBlock_60484E44A92A5B7AACB4C60FD30552A1" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_F5773B746C19551646A9D437A8D6B994_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_06411BEA1AFA543D9CC450269CD8B444" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_F5773B746C19551646A9D437A8D6B994_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_06411BEA1AFA543D9CC450269CD8B444" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_06411BEA1AFA543D9CC450269CD8B444" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_06411BEA1AFA543D9CC450269CD8B444" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_06411BEA1AFA543D9CC450269CD8B444" xlink:type="arc" />
    <link:label id="lab_us-gaap_TitleOfIndividualAxis_37D04CB02900ECF2D83ED437A8DB9889_terseLabel_en-US" xlink:label="lab_us-gaap_TitleOfIndividualAxis_33BE35F37E255CB7B815AA694F203FA7" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Title of Individual [Axis]</link:label>
    <link:label id="lab_us-gaap_TitleOfIndividualAxis_37D04CB02900ECF2D83ED437A8DB9889_label_en-US" xlink:label="lab_us-gaap_TitleOfIndividualAxis_33BE35F37E255CB7B815AA694F203FA7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Title of Individual [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_TitleOfIndividualAxis" xlink:label="loc_us-gaap_TitleOfIndividualAxis_33BE35F37E255CB7B815AA694F203FA7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TitleOfIndividualAxis_33BE35F37E255CB7B815AA694F203FA7" xlink:to="lab_us-gaap_TitleOfIndividualAxis_33BE35F37E255CB7B815AA694F203FA7" xlink:type="arc" />
    <link:label id="lab_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_6F050AFBAC92696EC99ED437A8DB21B0_terseLabel_en-US" xlink:label="lab_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_C58E07D700515604BFD9AE0670F7D314" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Title of Individual with Relationship to Entity [Domain]</link:label>
    <link:label id="lab_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_6F050AFBAC92696EC99ED437A8DB21B0_label_en-US" xlink:label="lab_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_C58E07D700515604BFD9AE0670F7D314" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Relationship to Entity [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_C58E07D700515604BFD9AE0670F7D314" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_C58E07D700515604BFD9AE0670F7D314" xlink:to="lab_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_C58E07D700515604BFD9AE0670F7D314" xlink:type="arc" />
    <link:label id="lab_gale_TwoZeroZeroSevenIncentivePlanMember_3569BBBCD6F77F0A850FD437A8DB403D_terseLabel_en-US" xlink:label="lab_gale_TwoZeroZeroSevenIncentivePlanMember_DEF2DBDC343A5723A9217E4149D690E0" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2007 Incentive Plan [Member]</link:label>
    <link:label id="lab_gale_TwoZeroZeroSevenIncentivePlanMember_3569BBBCD6F77F0A850FD437A8DB403D_label_en-US" xlink:label="lab_gale_TwoZeroZeroSevenIncentivePlanMember_DEF2DBDC343A5723A9217E4149D690E0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Two Zero Zero Seven Incentive Plan [Member]</link:label>
    <link:label id="lab_gale_TwoZeroZeroSevenIncentivePlanMember_3569BBBCD6F77F0A850FD437A8DB403D_documentation_en-US" xlink:label="lab_gale_TwoZeroZeroSevenIncentivePlanMember_DEF2DBDC343A5723A9217E4149D690E0" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Two Zero Zero Seven Incentive Plan [Member]</link:label>
    <link:loc xlink:href="gale-20150930.xsd#gale_TwoZeroZeroSevenIncentivePlanMember" xlink:label="loc_gale_TwoZeroZeroSevenIncentivePlanMember_DEF2DBDC343A5723A9217E4149D690E0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_TwoZeroZeroSevenIncentivePlanMember_DEF2DBDC343A5723A9217E4149D690E0" xlink:to="lab_gale_TwoZeroZeroSevenIncentivePlanMember_DEF2DBDC343A5723A9217E4149D690E0" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_F8132D3BBDE0A1C182A9D437A8DCBCDA_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_DC6DDF098889592993B5B8CCA32AE32D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_F8132D3BBDE0A1C182A9D437A8DCBCDA_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_DC6DDF098889592993B5B8CCA32AE32D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_DC6DDF098889592993B5B8CCA32AE32D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_DC6DDF098889592993B5B8CCA32AE32D" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_DC6DDF098889592993B5B8CCA32AE32D" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_BE4413B284B13F58F217D437A8DC87F8_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_EA3E148C2B405549A7AD2903616E6907" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted average exercise price, granted</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_BE4413B284B13F58F217D437A8DC87F8_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_EA3E148C2B405549A7AD2903616E6907" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_EA3E148C2B405549A7AD2903616E6907" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_EA3E148C2B405549A7AD2903616E6907" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_EA3E148C2B405549A7AD2903616E6907" xlink:type="arc" />
    <link:label id="lab_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_BE28FE045B3C540A4BE9D437A8DC3E77_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_5F8F8B5C9D3453D09A248EFD1FBE4084" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Averages contractual term</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_BE28FE045B3C540A4BE9D437A8DC3E77_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_5F8F8B5C9D3453D09A248EFD1FBE4084" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Outstanding Options, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" xlink:label="loc_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_5F8F8B5C9D3453D09A248EFD1FBE4084" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_5F8F8B5C9D3453D09A248EFD1FBE4084" xlink:to="lab_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_5F8F8B5C9D3453D09A248EFD1FBE4084" xlink:type="arc" />
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_D525A51C046B26DD5DBBD437A8DC5227_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_B79F848AC0B05F01A46D196D4DD7111F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Average vesting term</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_D525A51C046B26DD5DBBD437A8DC5227_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_B79F848AC0B05F01A46D196D4DD7111F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_B79F848AC0B05F01A46D196D4DD7111F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_B79F848AC0B05F01A46D196D4DD7111F" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_B79F848AC0B05F01A46D196D4DD7111F" xlink:type="arc" />
    <link:label id="lab_gale_EstimatedAnnualizedForfeitureRateForOptionsGrantedToEmployees_C0F7985F4677193B9DD5D437A8DC3F38_terseLabel_en-US" xlink:label="lab_gale_EstimatedAnnualizedForfeitureRateForOptionsGrantedToEmployees_D56BE84CD78A502BA2A102DE94349F22" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Estimated annualized forfeiture rate for options granted to employees</link:label>
    <link:label id="lab_gale_EstimatedAnnualizedForfeitureRateForOptionsGrantedToEmployees_C0F7985F4677193B9DD5D437A8DC3F38_label_en-US" xlink:label="lab_gale_EstimatedAnnualizedForfeitureRateForOptionsGrantedToEmployees_D56BE84CD78A502BA2A102DE94349F22" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Estimated Annualized Forfeiture Rate For Options Granted To Employees</link:label>
    <link:label id="lab_gale_EstimatedAnnualizedForfeitureRateForOptionsGrantedToEmployees_C0F7985F4677193B9DD5D437A8DC3F38_documentation_en-US" xlink:label="lab_gale_EstimatedAnnualizedForfeitureRateForOptionsGrantedToEmployees_D56BE84CD78A502BA2A102DE94349F22" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Estimated annualized forfeiture rate for options granted to employees.</link:label>
    <link:loc xlink:href="gale-20150930.xsd#gale_EstimatedAnnualizedForfeitureRateForOptionsGrantedToEmployees" xlink:label="loc_gale_EstimatedAnnualizedForfeitureRateForOptionsGrantedToEmployees_D56BE84CD78A502BA2A102DE94349F22" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_EstimatedAnnualizedForfeitureRateForOptionsGrantedToEmployees_D56BE84CD78A502BA2A102DE94349F22" xlink:to="lab_gale_EstimatedAnnualizedForfeitureRateForOptionsGrantedToEmployees_D56BE84CD78A502BA2A102DE94349F22" xlink:type="arc" />
    <link:label id="lab_gale_EstimatedAnnualizedForfeitureRateForOptionsGrantedToSeniorManagement_F0BBDB53FCEE3DEB2C4ED437A8DC2E25_terseLabel_en-US" xlink:label="lab_gale_EstimatedAnnualizedForfeitureRateForOptionsGrantedToSeniorManagement_84B98741EBD15A4299BA200A87AF2CFB" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Estimated annualized forfeiture rate for options granted to senior management</link:label>
    <link:label id="lab_gale_EstimatedAnnualizedForfeitureRateForOptionsGrantedToSeniorManagement_F0BBDB53FCEE3DEB2C4ED437A8DC2E25_label_en-US" xlink:label="lab_gale_EstimatedAnnualizedForfeitureRateForOptionsGrantedToSeniorManagement_84B98741EBD15A4299BA200A87AF2CFB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Estimated Annualized Forfeiture Rate For Options Granted To Senior Management</link:label>
    <link:label id="lab_gale_EstimatedAnnualizedForfeitureRateForOptionsGrantedToSeniorManagement_F0BBDB53FCEE3DEB2C4ED437A8DC2E25_documentation_en-US" xlink:label="lab_gale_EstimatedAnnualizedForfeitureRateForOptionsGrantedToSeniorManagement_84B98741EBD15A4299BA200A87AF2CFB" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Estimated annualized forfeiture rate for options granted to senior management.</link:label>
    <link:loc xlink:href="gale-20150930.xsd#gale_EstimatedAnnualizedForfeitureRateForOptionsGrantedToSeniorManagement" xlink:label="loc_gale_EstimatedAnnualizedForfeitureRateForOptionsGrantedToSeniorManagement_84B98741EBD15A4299BA200A87AF2CFB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_EstimatedAnnualizedForfeitureRateForOptionsGrantedToSeniorManagement_84B98741EBD15A4299BA200A87AF2CFB" xlink:to="lab_gale_EstimatedAnnualizedForfeitureRateForOptionsGrantedToSeniorManagement_84B98741EBD15A4299BA200A87AF2CFB" xlink:type="arc" />
    <link:label id="lab_gale_EmployeeServiceShareBasedCompensationUnrecognizedCompensationCosts_28C93D262968539CB4E4D437A8DC65F4_terseLabel_en-US" xlink:label="lab_gale_EmployeeServiceShareBasedCompensationUnrecognizedCompensationCosts_98CC170389905E46A996A449CE894C33" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Unrecognized compensation cost</link:label>
    <link:label id="lab_gale_EmployeeServiceShareBasedCompensationUnrecognizedCompensationCosts_28C93D262968539CB4E4D437A8DC65F4_label_en-US" xlink:label="lab_gale_EmployeeServiceShareBasedCompensationUnrecognizedCompensationCosts_98CC170389905E46A996A449CE894C33" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Employee Service Share Based Compensation Unrecognized Compensation Costs</link:label>
    <link:label id="lab_gale_EmployeeServiceShareBasedCompensationUnrecognizedCompensationCosts_28C93D262968539CB4E4D437A8DC65F4_documentation_en-US" xlink:label="lab_gale_EmployeeServiceShareBasedCompensationUnrecognizedCompensationCosts_98CC170389905E46A996A449CE894C33" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Employee Service Share Based Compensation Unrecognized Compensation Costs</link:label>
    <link:loc xlink:href="gale-20150930.xsd#gale_EmployeeServiceShareBasedCompensationUnrecognizedCompensationCosts" xlink:label="loc_gale_EmployeeServiceShareBasedCompensationUnrecognizedCompensationCosts_98CC170389905E46A996A449CE894C33" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_EmployeeServiceShareBasedCompensationUnrecognizedCompensationCosts_98CC170389905E46A996A449CE894C33" xlink:to="lab_gale_EmployeeServiceShareBasedCompensationUnrecognizedCompensationCosts_98CC170389905E46A996A449CE894C33" xlink:type="arc" />
    <link:label id="lab_gale_EmployeeServiceShareBasedCompensationUnrecognizedCompensationCostsWeightedAveragePeriodOfRecognition_B994D0ACC9831D52EAC8D437A8DCA77E_terseLabel_en-US" xlink:label="lab_gale_EmployeeServiceShareBasedCompensationUnrecognizedCompensationCostsWeightedAveragePeriodOfRecognition_50A604EBA87F5F26A0A6D03513AE274D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating expenses weighted average period</link:label>
    <link:label id="lab_gale_EmployeeServiceShareBasedCompensationUnrecognizedCompensationCostsWeightedAveragePeriodOfRecognition_B994D0ACC9831D52EAC8D437A8DCA77E_label_en-US" xlink:label="lab_gale_EmployeeServiceShareBasedCompensationUnrecognizedCompensationCostsWeightedAveragePeriodOfRecognition_50A604EBA87F5F26A0A6D03513AE274D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Employee Service Share Based Compensation Unrecognized Compensation Costs Weighted Average Period Of Recognition</link:label>
    <link:label id="lab_gale_EmployeeServiceShareBasedCompensationUnrecognizedCompensationCostsWeightedAveragePeriodOfRecognition_B994D0ACC9831D52EAC8D437A8DCA77E_documentation_en-US" xlink:label="lab_gale_EmployeeServiceShareBasedCompensationUnrecognizedCompensationCostsWeightedAveragePeriodOfRecognition_50A604EBA87F5F26A0A6D03513AE274D" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Employee Service Share Based Compensation Unrecognized Compensation Costs Weighted Average Period Of Recognition</link:label>
    <link:loc xlink:href="gale-20150930.xsd#gale_EmployeeServiceShareBasedCompensationUnrecognizedCompensationCostsWeightedAveragePeriodOfRecognition" xlink:label="loc_gale_EmployeeServiceShareBasedCompensationUnrecognizedCompensationCostsWeightedAveragePeriodOfRecognition_50A604EBA87F5F26A0A6D03513AE274D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_EmployeeServiceShareBasedCompensationUnrecognizedCompensationCostsWeightedAveragePeriodOfRecognition_50A604EBA87F5F26A0A6D03513AE274D" xlink:to="lab_gale_EmployeeServiceShareBasedCompensationUnrecognizedCompensationCostsWeightedAveragePeriodOfRecognition_50A604EBA87F5F26A0A6D03513AE274D" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_D83DA58C9D71F19CC97CD437A8DC1A22_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_F8B04BEF31D95360AC1CEA7334B480D6" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Shares of common stock reserved for issuance</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_D83DA58C9D71F19CC97CD437A8DC1A22_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_F8B04BEF31D95360AC1CEA7334B480D6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_F8B04BEF31D95360AC1CEA7334B480D6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_F8B04BEF31D95360AC1CEA7334B480D6" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_F8B04BEF31D95360AC1CEA7334B480D6" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_4BC086F6995BE30F4760D437A8DC338E_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_0BC111709A2955AC986E18429B7B174A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Shares subject to outstanding common stock options granted</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_0BC111709A2955AC986E18429B7B174A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_0BC111709A2955AC986E18429B7B174A" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_0BC111709A2955AC986E18429B7B174A" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_5CFC4C385EC772873318D437A8DDE591_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_E34FF3AB87C35B079B102FBEF0B94B69" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Shares available for future grants</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_5CFC4C385EC772873318D437A8DDE591_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_E34FF3AB87C35B079B102FBEF0B94B69" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_E34FF3AB87C35B079B102FBEF0B94B69" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_E34FF3AB87C35B079B102FBEF0B94B69" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_E34FF3AB87C35B079B102FBEF0B94B69" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_585608EB1707B23625B1D437A8DDBF4F_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_9FDF9E7EA2B35D2B836B8171CA498E44" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Vesting periods of options granted</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_585608EB1707B23625B1D437A8DDBF4F_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_9FDF9E7EA2B35D2B836B8171CA498E44" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_9FDF9E7EA2B35D2B836B8171CA498E44" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_9FDF9E7EA2B35D2B836B8171CA498E44" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_9FDF9E7EA2B35D2B836B8171CA498E44" xlink:type="arc" />
    <link:label id="lab_gale_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationPeriod_3F36D59DE615DB878371D437A8DDBDB0_terseLabel_en-US" xlink:label="lab_gale_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationPeriod_9189AFD346F8509DA048D0A56B24F723" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Options expire from date of grant</link:label>
    <link:label id="lab_gale_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationPeriod_3F36D59DE615DB878371D437A8DDBDB0_label_en-US" xlink:label="lab_gale_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationPeriod_9189AFD346F8509DA048D0A56B24F723" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award Expiration Period</link:label>
    <link:label id="lab_gale_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationPeriod_3F36D59DE615DB878371D437A8DDBDB0_documentation_en-US" xlink:label="lab_gale_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationPeriod_9189AFD346F8509DA048D0A56B24F723" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award Expiration Period</link:label>
    <link:loc xlink:href="gale-20150930.xsd#gale_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationPeriod" xlink:label="loc_gale_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationPeriod_9189AFD346F8509DA048D0A56B24F723" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationPeriod_9189AFD346F8509DA048D0A56B24F723" xlink:to="lab_gale_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationPeriod_9189AFD346F8509DA048D0A56B24F723" xlink:type="arc" />
    <link:label id="lab_gale_ClosingPriceOfCommonStock_456D30DB02DB7D85B7ABD437A8DD3088_terseLabel_en-US" xlink:label="lab_gale_ClosingPriceOfCommonStock_4365423020E75EF6A9FF49FB57F76B21" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Closing price of the Company's common stock</link:label>
    <link:label id="lab_gale_ClosingPriceOfCommonStock_456D30DB02DB7D85B7ABD437A8DD3088_label_en-US" xlink:label="lab_gale_ClosingPriceOfCommonStock_4365423020E75EF6A9FF49FB57F76B21" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Closing Price Of Common Stock</link:label>
    <link:label id="lab_gale_ClosingPriceOfCommonStock_456D30DB02DB7D85B7ABD437A8DD3088_documentation_en-US" xlink:label="lab_gale_ClosingPriceOfCommonStock_4365423020E75EF6A9FF49FB57F76B21" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Closing price of common stock.</link:label>
    <link:loc xlink:href="gale-20150930.xsd#gale_ClosingPriceOfCommonStock" xlink:label="loc_gale_ClosingPriceOfCommonStock_4365423020E75EF6A9FF49FB57F76B21" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_ClosingPriceOfCommonStock_4365423020E75EF6A9FF49FB57F76B21" xlink:to="lab_gale_ClosingPriceOfCommonStock_4365423020E75EF6A9FF49FB57F76B21" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherIncomeAndOtherExpenseDisclosureTextBlock_40A3F8C4BF1C5E9D54AFD437A87D2D0D_terseLabel_en-US" xlink:label="lab_us-gaap_OtherIncomeAndOtherExpenseDisclosureTextBlock_31707E64DDB15720917C6AC082354C8D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other Income (Expense)</link:label>
    <link:label id="lab_us-gaap_OtherIncomeAndOtherExpenseDisclosureTextBlock_40A3F8C4BF1C5E9D54AFD437A87D2D0D_label_en-US" xlink:label="lab_us-gaap_OtherIncomeAndOtherExpenseDisclosureTextBlock_31707E64DDB15720917C6AC082354C8D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Income and Other Expense Disclosure [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OtherIncomeAndOtherExpenseDisclosureTextBlock" xlink:label="loc_us-gaap_OtherIncomeAndOtherExpenseDisclosureTextBlock_31707E64DDB15720917C6AC082354C8D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherIncomeAndOtherExpenseDisclosureTextBlock_31707E64DDB15720917C6AC082354C8D" xlink:to="lab_us-gaap_OtherIncomeAndOtherExpenseDisclosureTextBlock_31707E64DDB15720917C6AC082354C8D" xlink:type="arc" />
    <link:label id="lab_gale_FairValueofWarrantsGranted_530C1847E8E6FDC36EFCD437A7C9A974_terseLabel_en-US" xlink:label="lab_gale_FairValueofWarrantsGranted_D947E9AF3B7E5536843C00908B4B0B17" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value of Warrants Granted</link:label>
    <link:label id="lab_gale_FairValueofWarrantsGranted_530C1847E8E6FDC36EFCD437A7C9A974_label_en-US" xlink:label="lab_gale_FairValueofWarrantsGranted_D947E9AF3B7E5536843C00908B4B0B17" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value of Warrants Granted</link:label>
    <link:label id="lab_gale_FairValueofWarrantsGranted_530C1847E8E6FDC36EFCD437A7C9A974_documentation_en-US" xlink:label="lab_gale_FairValueofWarrantsGranted_D947E9AF3B7E5536843C00908B4B0B17" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Fair Value of Warrants Granted</link:label>
    <link:loc xlink:href="gale-20150930.xsd#gale_FairValueofWarrantsGranted" xlink:label="loc_gale_FairValueofWarrantsGranted_D947E9AF3B7E5536843C00908B4B0B17" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_FairValueofWarrantsGranted_D947E9AF3B7E5536843C00908B4B0B17" xlink:to="lab_gale_FairValueofWarrantsGranted_D947E9AF3B7E5536843C00908B4B0B17" xlink:type="arc" />
    <link:label id="lab_gale_ClassofWarrantorRightFairValueRollForward_5C2205A92295D257BC36D437A7C908D3_terseLabel_en-US" xlink:label="lab_gale_ClassofWarrantorRightFairValueRollForward_11C1085806F95A178540C0BC1C9C1211" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right, Fair Value [Roll Forward]</link:label>
    <link:label id="lab_gale_ClassofWarrantorRightFairValueRollForward_5C2205A92295D257BC36D437A7C908D3_label_en-US" xlink:label="lab_gale_ClassofWarrantorRightFairValueRollForward_11C1085806F95A178540C0BC1C9C1211" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right, Fair Value [Roll Forward]</link:label>
    <link:label id="lab_gale_ClassofWarrantorRightFairValueRollForward_5C2205A92295D257BC36D437A7C908D3_documentation_en-US" xlink:label="lab_gale_ClassofWarrantorRightFairValueRollForward_11C1085806F95A178540C0BC1C9C1211" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right, Fair Value [Roll Forward]</link:label>
    <link:loc xlink:href="gale-20150930.xsd#gale_ClassofWarrantorRightFairValueRollForward" xlink:label="loc_gale_ClassofWarrantorRightFairValueRollForward_11C1085806F95A178540C0BC1C9C1211" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_ClassofWarrantorRightFairValueRollForward_11C1085806F95A178540C0BC1C9C1211" xlink:to="lab_gale_ClassofWarrantorRightFairValueRollForward_11C1085806F95A178540C0BC1C9C1211" xlink:type="arc" />
    <link:label id="lab_gale_FairValueOfWarrantsLiabilities_D1935D80FC4CB2D6D301D437A7C98F2C_periodStartLabel_en-US" xlink:label="lab_gale_FairValueOfWarrantsLiabilities_74188ADE7C3954659289680BE1842EFB" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Warrant liability, Beginning balance</link:label>
    <link:label id="lab_gale_FairValueOfWarrantsLiabilities_D1935D80FC4CB2D6D301D437A7C98F2C_label_en-US" xlink:label="lab_gale_FairValueOfWarrantsLiabilities_74188ADE7C3954659289680BE1842EFB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Of Warrants Liabilities</link:label>
    <link:label id="lab_gale_FairValueOfWarrantsLiabilities_D1935D80FC4CB2D6D301D437A7C98F2C_documentation_en-US" xlink:label="lab_gale_FairValueOfWarrantsLiabilities_74188ADE7C3954659289680BE1842EFB" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Fair value of warrant liabilities as of the balance sheet date.</link:label>
    <link:loc xlink:href="gale-20150930.xsd#gale_FairValueOfWarrantsLiabilities" xlink:label="loc_gale_FairValueOfWarrantsLiabilities_74188ADE7C3954659289680BE1842EFB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_FairValueOfWarrantsLiabilities_74188ADE7C3954659289680BE1842EFB" xlink:to="lab_gale_FairValueOfWarrantsLiabilities_74188ADE7C3954659289680BE1842EFB" xlink:type="arc" />
    <link:label id="lab_gale_ChangeInFairValueOfWarrantLiabilities_4B88DAEBF47F831DFC7ED437A7C9A1C1_terseLabel_en-US" xlink:label="lab_gale_ChangeInFairValueOfWarrantLiabilities_416ADAF925C95248BAB77422AC2AC8F3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Change in fair value of warrants</link:label>
    <link:label id="lab_gale_ChangeInFairValueOfWarrantLiabilities_4B88DAEBF47F831DFC7ED437A7C9A1C1_label_en-US" xlink:label="lab_gale_ChangeInFairValueOfWarrantLiabilities_416ADAF925C95248BAB77422AC2AC8F3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Change In Fair Value Of Warrant Liabilities</link:label>
    <link:label id="lab_gale_ChangeInFairValueOfWarrantLiabilities_4B88DAEBF47F831DFC7ED437A7C9A1C1_documentation_en-US" xlink:label="lab_gale_ChangeInFairValueOfWarrantLiabilities_416ADAF925C95248BAB77422AC2AC8F3" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Change In Fair Value Of Warrant Liabilities</link:label>
    <link:loc xlink:href="gale-20150930.xsd#gale_ChangeInFairValueOfWarrantLiabilities" xlink:label="loc_gale_ChangeInFairValueOfWarrantLiabilities_416ADAF925C95248BAB77422AC2AC8F3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_ChangeInFairValueOfWarrantLiabilities_416ADAF925C95248BAB77422AC2AC8F3" xlink:to="lab_gale_ChangeInFairValueOfWarrantLiabilities_416ADAF925C95248BAB77422AC2AC8F3" xlink:type="arc" />
    <link:label id="lab_gale_FairValueOfWarrantsLiabilities_1932CB80608B4590B137D437A7C98499_periodEndLabel_en-US" xlink:label="lab_gale_FairValueOfWarrantsLiabilities_4A179EA7BB8E57D7A77669B142497ED2" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Warrant liability, Ending balance</link:label>
    <link:loc xlink:href="gale-20150930.xsd#gale_FairValueOfWarrantsLiabilities" xlink:label="loc_gale_FairValueOfWarrantsLiabilities_4A179EA7BB8E57D7A77669B142497ED2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_FairValueOfWarrantsLiabilities_4A179EA7BB8E57D7A77669B142497ED2" xlink:to="lab_gale_FairValueOfWarrantsLiabilities_4A179EA7BB8E57D7A77669B142497ED2" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_2E720D1EBFAA606C5441D437A7A41D0C_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_D966421A5D5D59A19B2CF1F4E79DC5CC" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Contingent Purchase Price Consideration, Measured at Estimated Fair Value on Recurring Basis</link:label>
    <link:label id="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_2E720D1EBFAA606C5441D437A7A41D0C_label_en-US" xlink:label="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_D966421A5D5D59A19B2CF1F4E79DC5CC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_D966421A5D5D59A19B2CF1F4E79DC5CC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_D966421A5D5D59A19B2CF1F4E79DC5CC" xlink:to="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_D966421A5D5D59A19B2CF1F4E79DC5CC" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_A77CB4B9645BA7DDE892D437A7A4313D_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_DC3A60B96B06516AB0D516893FA077A0" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Reconciliation of Level 3 Liabilities</link:label>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_A77CB4B9645BA7DDE892D437A7A4313D_label_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_DC3A60B96B06516AB0D516893FA077A0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_DC3A60B96B06516AB0D516893FA077A0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_DC3A60B96B06516AB0D516893FA077A0" xlink:to="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_DC3A60B96B06516AB0D516893FA077A0" xlink:type="arc" />
    <link:label id="lab_gale_ChangeInFairValueOfContingentPurchasePriceConsideration_327343672781E47286E0E0E460E7EC54_negatedTerseLabel_en-US" xlink:label="lab_gale_ChangeInFairValueOfContingentPurchasePriceConsideration_15747043B507542CA45F8C16C4E60052" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Change in fair value of the contingent purchase price liability</link:label>
    <link:loc xlink:href="gale-20150930.xsd#gale_ChangeInFairValueOfContingentPurchasePriceConsideration" xlink:label="loc_gale_ChangeInFairValueOfContingentPurchasePriceConsideration_15747043B507542CA45F8C16C4E60052" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_ChangeInFairValueOfContingentPurchasePriceConsideration_15747043B507542CA45F8C16C4E60052" xlink:to="lab_gale_ChangeInFairValueOfContingentPurchasePriceConsideration_15747043B507542CA45F8C16C4E60052" xlink:type="arc" />
    <link:label id="lab_gale_MiscellaneousOtherIncomeExpense_75B2257EFEAF1FACB457E0E460E73208_terseLabel_en-US" xlink:label="lab_gale_MiscellaneousOtherIncomeExpense_4385694D25FF52958D276045ECBC3AC9" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Miscellaneous other income (expense)</link:label>
    <link:label id="lab_gale_MiscellaneousOtherIncomeExpense_75B2257EFEAF1FACB457E0E460E73208_label_en-US" xlink:label="lab_gale_MiscellaneousOtherIncomeExpense_4385694D25FF52958D276045ECBC3AC9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Miscellaneous Other Income Expense</link:label>
    <link:label id="lab_gale_MiscellaneousOtherIncomeExpense_75B2257EFEAF1FACB457E0E460E73208_documentation_en-US" xlink:label="lab_gale_MiscellaneousOtherIncomeExpense_4385694D25FF52958D276045ECBC3AC9" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Miscellaneous other income (expense).</link:label>
    <link:loc xlink:href="gale-20150930.xsd#gale_MiscellaneousOtherIncomeExpense" xlink:label="loc_gale_MiscellaneousOtherIncomeExpense_4385694D25FF52958D276045ECBC3AC9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_MiscellaneousOtherIncomeExpense_4385694D25FF52958D276045ECBC3AC9" xlink:to="lab_gale_MiscellaneousOtherIncomeExpense_4385694D25FF52958D276045ECBC3AC9" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_37CC78385D5C023D4353E0E460E892F7_terseLabel_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense_BD6B9C26CA70554CB57A7C0C18D7A5C4" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other income (expense)</link:label>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_37CC78385D5C023D4353E0E460E892F7_label_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense_BD6B9C26CA70554CB57A7C0C18D7A5C4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Nonoperating Income (Expense)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_BD6B9C26CA70554CB57A7C0C18D7A5C4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpense_BD6B9C26CA70554CB57A7C0C18D7A5C4" xlink:to="lab_us-gaap_OtherNonoperatingIncomeExpense_BD6B9C26CA70554CB57A7C0C18D7A5C4" xlink:type="arc" />
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_3BBD9A1752532EEADD11F4C7DD21B903_label_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract_DDBAEB77D6FD58BEA1CE21530CB08832" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_DDBAEB77D6FD58BEA1CE21530CB08832" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_DDBAEB77D6FD58BEA1CE21530CB08832" xlink:to="lab_us-gaap_StatementOfStockholdersEquityAbstract_DDBAEB77D6FD58BEA1CE21530CB08832" xlink:type="arc" />
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_B08724EAD7C5BC93EFA8F4C7DD223A2E_terseLabel_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis_6A5FD0AC8FD65A53A7F956A80E3C9436" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_B08724EAD7C5BC93EFA8F4C7DD223A2E_label_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis_6A5FD0AC8FD65A53A7F956A80E3C9436" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_6A5FD0AC8FD65A53A7F956A80E3C9436" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_6A5FD0AC8FD65A53A7F956A80E3C9436" xlink:to="lab_us-gaap_StatementEquityComponentsAxis_6A5FD0AC8FD65A53A7F956A80E3C9436" xlink:type="arc" />
    <link:label id="lab_us-gaap_EquityComponentDomain_D2419D4A4ADE8AE7CEDAF4C7DD222A4D_terseLabel_en-US" xlink:label="lab_us-gaap_EquityComponentDomain_B45758336F5B5E4CB688B8729BE9EF77" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:label id="lab_us-gaap_EquityComponentDomain_D2419D4A4ADE8AE7CEDAF4C7DD222A4D_label_en-US" xlink:label="lab_us-gaap_EquityComponentDomain_B45758336F5B5E4CB688B8729BE9EF77" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_B45758336F5B5E4CB688B8729BE9EF77" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityComponentDomain_B45758336F5B5E4CB688B8729BE9EF77" xlink:to="lab_us-gaap_EquityComponentDomain_B45758336F5B5E4CB688B8729BE9EF77" xlink:type="arc" />
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_4DDC85CEE30ECDDD60D7F4C7DD23A126_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember_E762029C2994514EB347BC5CB7FB969E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Additional Paid-in Capital [Member]</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_4DDC85CEE30ECDDD60D7F4C7DD23A126_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember_E762029C2994514EB347BC5CB7FB969E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Additional Paid-in Capital [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_E762029C2994514EB347BC5CB7FB969E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalMember_E762029C2994514EB347BC5CB7FB969E" xlink:to="lab_us-gaap_AdditionalPaidInCapitalMember_E762029C2994514EB347BC5CB7FB969E" xlink:type="arc" />
    <link:label id="lab_us-gaap_RetainedEarningsMember_A4663AE632B686D22AB6F4C7DD230214_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember_82B720A3DC9755A0B0BFA416B85E6692" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accumulated Deficit [Member]</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsMember_A4663AE632B686D22AB6F4C7DD230214_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember_82B720A3DC9755A0B0BFA416B85E6692" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Retained Earnings [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="loc_us-gaap_RetainedEarningsMember_82B720A3DC9755A0B0BFA416B85E6692" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsMember_82B720A3DC9755A0B0BFA416B85E6692" xlink:to="lab_us-gaap_RetainedEarningsMember_82B720A3DC9755A0B0BFA416B85E6692" xlink:type="arc" />
    <link:label id="lab_us-gaap_TreasuryStockMember_07763747FFC2EC7CFDBAF4C7DD232A48_terseLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockMember_0846AD51934054C8AA55F67F85B00ED0" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Treasury Stock [Member]</link:label>
    <link:label id="lab_us-gaap_TreasuryStockMember_07763747FFC2EC7CFDBAF4C7DD232A48_label_en-US" xlink:label="lab_us-gaap_TreasuryStockMember_0846AD51934054C8AA55F67F85B00ED0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Treasury Stock [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_TreasuryStockMember" xlink:label="loc_us-gaap_TreasuryStockMember_0846AD51934054C8AA55F67F85B00ED0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockMember_0846AD51934054C8AA55F67F85B00ED0" xlink:to="lab_us-gaap_TreasuryStockMember_0846AD51934054C8AA55F67F85B00ED0" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_7971EE13A7179A82F680F4C7DD239878_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_78BA6500FAF1599585AFC9BE3BE5BB0D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_7971EE13A7179A82F680F4C7DD239878_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_78BA6500FAF1599585AFC9BE3BE5BB0D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_78BA6500FAF1599585AFC9BE3BE5BB0D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_78BA6500FAF1599585AFC9BE3BE5BB0D" xlink:to="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_78BA6500FAF1599585AFC9BE3BE5BB0D" xlink:type="arc" />
    <link:label id="lab_us-gaap_SharesOutstanding_A1046F45C0540B35AB49F4C7DD23800A_periodStartLabel_en-US" xlink:label="lab_us-gaap_SharesOutstanding_C1133C86FBA659CDA15C89A3DDB2C6DB" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Beginning balance, shares</link:label>
    <link:label id="lab_us-gaap_SharesOutstanding_A1046F45C0540B35AB49F4C7DD23800A_label_en-US" xlink:label="lab_us-gaap_SharesOutstanding_C1133C86FBA659CDA15C89A3DDB2C6DB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Shares, Outstanding</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SharesOutstanding" xlink:label="loc_us-gaap_SharesOutstanding_C1133C86FBA659CDA15C89A3DDB2C6DB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharesOutstanding_C1133C86FBA659CDA15C89A3DDB2C6DB" xlink:to="lab_us-gaap_SharesOutstanding_C1133C86FBA659CDA15C89A3DDB2C6DB" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_7BA66963451080F54E19F4C7DD23A26A_periodStartLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_332CCB7DF16E5C5C82B63FD0AB91B7CE" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Beginning balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_7BA66963451080F54E19F4C7DD23A26A_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_332CCB7DF16E5C5C82B63FD0AB91B7CE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_332CCB7DF16E5C5C82B63FD0AB91B7CE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_332CCB7DF16E5C5C82B63FD0AB91B7CE" xlink:to="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_332CCB7DF16E5C5C82B63FD0AB91B7CE" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesOther_31924CAC393D0065F4B4F4C7DD2359E7_verboseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesOther_438DF48CEC095297BB69520E60FDCC40" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Issuance of common stock, shares</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesOther_31924CAC393D0065F4B4F4C7DD2359E7_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesOther_438DF48CEC095297BB69520E60FDCC40" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Shares, Other</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesOther" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesOther_438DF48CEC095297BB69520E60FDCC40" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesOther_438DF48CEC095297BB69520E60FDCC40" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesOther_438DF48CEC095297BB69520E60FDCC40" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueOther_1CFBE7751DCCCD375D59F4C7DD23DCDF_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueOther_9C4B48EDD3A75F08B118E7B1BABFE048" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Issuance of common stock</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueOther_1CFBE7751DCCCD375D59F4C7DD23DCDF_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueOther_9C4B48EDD3A75F08B118E7B1BABFE048" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Value, Other</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueOther" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueOther_9C4B48EDD3A75F08B118E7B1BABFE048" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueOther_9C4B48EDD3A75F08B118E7B1BABFE048" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueOther_9C4B48EDD3A75F08B118E7B1BABFE048" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_07D0BD308DAC4496A63CF4C7DD249F64_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_CE99E2A4BD0F5CA9A9535415BF4872AA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Issuance of common stock upon exercise of warrants, shares</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_07D0BD308DAC4496A63CF4C7DD249F64_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_CE99E2A4BD0F5CA9A9535415BF4872AA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Shares, Conversion of Convertible Securities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_CE99E2A4BD0F5CA9A9535415BF4872AA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_CE99E2A4BD0F5CA9A9535415BF4872AA" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_CE99E2A4BD0F5CA9A9535415BF4872AA" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_E0BEA1A19015FE2E7970F4C7DD241F0D_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_5B6A408D17D75B8CADF4804740C4D94C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock warrants issued in connection with March 2015 common stock offering</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_E0BEA1A19015FE2E7970F4C7DD241F0D_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_5B6A408D17D75B8CADF4804740C4D94C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Value, Conversion of Convertible Securities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_5B6A408D17D75B8CADF4804740C4D94C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_5B6A408D17D75B8CADF4804740C4D94C" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_5B6A408D17D75B8CADF4804740C4D94C" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_9004479B47C6447F9E9FF4C7DD244392_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_B812C9F4CDF857E5B1BA7099A500A36D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Issuance of common stock in connection with employee stock purchase plan, shares</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_9004479B47C6447F9E9FF4C7DD244392_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_B812C9F4CDF857E5B1BA7099A500A36D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Shares, Employee Stock Purchase Plans</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_B812C9F4CDF857E5B1BA7099A500A36D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_B812C9F4CDF857E5B1BA7099A500A36D" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_B812C9F4CDF857E5B1BA7099A500A36D" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_3545F072C8962C1E16F1F4C7DD2480AA_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_1416CAF360EC54199A44A2E277456BE7" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Issuance of common stock in connection with employee stock purchase plan</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_3545F072C8962C1E16F1F4C7DD2480AA_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_1416CAF360EC54199A44A2E277456BE7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Value, Employee Stock Purchase Plan</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_1416CAF360EC54199A44A2E277456BE7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_1416CAF360EC54199A44A2E277456BE7" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_1416CAF360EC54199A44A2E277456BE7" xlink:type="arc" />
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalTaxEffectFromShareBasedCompensation_8F416EF764F0C878C539F4C7DD24BAAB_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalTaxEffectFromShareBasedCompensation_6A82047EC62A5E8B9FDDDA3C18F4B8DE" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock-based compensation for directors and employees</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalTaxEffectFromShareBasedCompensation_8F416EF764F0C878C539F4C7DD24BAAB_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalTaxEffectFromShareBasedCompensation_6A82047EC62A5E8B9FDDDA3C18F4B8DE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustments to Additional Paid in Capital, Income Tax Benefit from Share-based Compensation</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalTaxEffectFromShareBasedCompensation" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalTaxEffectFromShareBasedCompensation_6A82047EC62A5E8B9FDDDA3C18F4B8DE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalTaxEffectFromShareBasedCompensation_6A82047EC62A5E8B9FDDDA3C18F4B8DE" xlink:to="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalTaxEffectFromShareBasedCompensation_6A82047EC62A5E8B9FDDDA3C18F4B8DE" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_673E64906356BB784F7BF4C7DD2A8575_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_FC5F2601BAFA5E7A99E560BC00244D09" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_FC5F2601BAFA5E7A99E560BC00244D09" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_FC5F2601BAFA5E7A99E560BC00244D09" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_FC5F2601BAFA5E7A99E560BC00244D09" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_553E63F6AFCA0A7A0F64F4C7DD2A1567_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_12B9F9D3550A59B98F239BCCD652AF6E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Value, Stock Options Exercised</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_553E63F6AFCA0A7A0F64F4C7DD2A1567_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_12B9F9D3550A59B98F239BCCD652AF6E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Value, Stock Options Exercised</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_12B9F9D3550A59B98F239BCCD652AF6E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_12B9F9D3550A59B98F239BCCD652AF6E" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_12B9F9D3550A59B98F239BCCD652AF6E" xlink:type="arc" />
    <link:label id="lab_us-gaap_NetIncomeLoss_229E2BFA0BBA0AA6DC68F4C7DD2A8C04_terseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss_35219881DB6451E8820F475A55CDB1DE" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net loss</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_229E2BFA0BBA0AA6DC68F4C7DD2A8C04_label_en-US" xlink:label="lab_us-gaap_NetIncomeLoss_35219881DB6451E8820F475A55CDB1DE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Income (Loss) Attributable to Parent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_35219881DB6451E8820F475A55CDB1DE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLoss_35219881DB6451E8820F475A55CDB1DE" xlink:to="lab_us-gaap_NetIncomeLoss_35219881DB6451E8820F475A55CDB1DE" xlink:type="arc" />
    <link:label id="lab_us-gaap_SharesOutstanding_83C6B0B411EBF7AAAB15F4C7DD2A3771_periodEndLabel_en-US" xlink:label="lab_us-gaap_SharesOutstanding_726D137F3EB85063931D7FE3A3402A57" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Ending balance, shares</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SharesOutstanding" xlink:label="loc_us-gaap_SharesOutstanding_726D137F3EB85063931D7FE3A3402A57" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharesOutstanding_726D137F3EB85063931D7FE3A3402A57" xlink:to="lab_us-gaap_SharesOutstanding_726D137F3EB85063931D7FE3A3402A57" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_5DF53F9D54740D4228AEF4C7DD2A8DD8_periodEndLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_9AECD271B98252CFAD1C5B6255F6D596" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Ending balance</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_9AECD271B98252CFAD1C5B6255F6D596" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_9AECD271B98252CFAD1C5B6255F6D596" xlink:to="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_9AECD271B98252CFAD1C5B6255F6D596" xlink:type="arc" />
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_BFA03AEB2D266D67125FD437A80B4D42_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_934314CF4FC75956867732DC183D748B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_934314CF4FC75956867732DC183D748B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_934314CF4FC75956867732DC183D748B" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_934314CF4FC75956867732DC183D748B" xlink:type="arc" />
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_C71E375B0673379F8A72D437A80BF0E3_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_A03EFA9B1A1D5E328F8B4B3DC1489133" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Legal Proceedings, Commitments and Contingencies</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_C71E375B0673379F8A72D437A80BF0E3_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_A03EFA9B1A1D5E328F8B4B3DC1489133" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Commitments and Contingencies Disclosure [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_A03EFA9B1A1D5E328F8B4B3DC1489133" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_A03EFA9B1A1D5E328F8B4B3DC1489133" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_A03EFA9B1A1D5E328F8B4B3DC1489133" xlink:type="arc" />
    <link:label id="lab_us-gaap_ConcentrationRiskTable_18524F7D8249571191F7DDA4F6B13BB1_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskTable_18524F7D8249571191F7DDA4F6B13BB1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Concentration Risk [Table]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskTable_18524F7D8249571191F7DDA4F6B13BB1_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskTable_18524F7D8249571191F7DDA4F6B13BB1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Concentration Risk [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ConcentrationRiskTable" xlink:label="loc_us-gaap_ConcentrationRiskTable_18524F7D8249571191F7DDA4F6B13BB1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskTable_18524F7D8249571191F7DDA4F6B13BB1" xlink:to="lab_us-gaap_ConcentrationRiskTable_18524F7D8249571191F7DDA4F6B13BB1" xlink:type="arc" />
    <link:label id="lab_us-gaap_ConcentrationRiskByTypeAxis_E239AE7869AAF28B2E5EDDA4F6B2CD49_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByTypeAxis_E239AE7869AAF28B2E5EDDA4F6B2CD49" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Concentration Risk Type [Axis]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskByTypeAxis_E239AE7869AAF28B2E5EDDA4F6B2CD49_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByTypeAxis_E239AE7869AAF28B2E5EDDA4F6B2CD49" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Concentration Risk Type [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ConcentrationRiskByTypeAxis" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis_E239AE7869AAF28B2E5EDDA4F6B2CD49" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_E239AE7869AAF28B2E5EDDA4F6B2CD49" xlink:to="lab_us-gaap_ConcentrationRiskByTypeAxis_E239AE7869AAF28B2E5EDDA4F6B2CD49" xlink:type="arc" />
    <link:label id="lab_us-gaap_ConcentrationRiskTypeDomain_6F45A306D259EDBF334BDDA4F6B2E38D_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskTypeDomain_6F45A306D259EDBF334BDDA4F6B2E38D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Concentration Risk Type [Domain]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskTypeDomain_6F45A306D259EDBF334BDDA4F6B2E38D_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskTypeDomain_6F45A306D259EDBF334BDDA4F6B2E38D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Concentration Risk Type [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_6F45A306D259EDBF334BDDA4F6B2E38D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_6F45A306D259EDBF334BDDA4F6B2E38D" xlink:to="lab_us-gaap_ConcentrationRiskTypeDomain_6F45A306D259EDBF334BDDA4F6B2E38D" xlink:type="arc" />
    <link:label id="lab_us-gaap_ProductConcentrationRiskMember_771FE295753DBECF55EBDDA4F6B214A9_terseLabel_en-US" xlink:label="lab_us-gaap_ProductConcentrationRiskMember_771FE295753DBECF55EBDDA4F6B214A9" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Product Concentration Risk [Member]</link:label>
    <link:label id="lab_us-gaap_ProductConcentrationRiskMember_771FE295753DBECF55EBDDA4F6B214A9_label_en-US" xlink:label="lab_us-gaap_ProductConcentrationRiskMember_771FE295753DBECF55EBDDA4F6B214A9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Product Concentration Risk [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ProductConcentrationRiskMember" xlink:label="loc_us-gaap_ProductConcentrationRiskMember_771FE295753DBECF55EBDDA4F6B214A9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProductConcentrationRiskMember_771FE295753DBECF55EBDDA4F6B214A9" xlink:to="lab_us-gaap_ProductConcentrationRiskMember_771FE295753DBECF55EBDDA4F6B214A9" xlink:type="arc" />
    <link:label id="lab_us-gaap_ConcentrationRiskByBenchmarkAxis_96B7BC682629372E3B7CDDA4F6B2DCB8_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByBenchmarkAxis_96B7BC682629372E3B7CDDA4F6B2DCB8" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Concentration Risk Benchmark [Axis]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskByBenchmarkAxis_96B7BC682629372E3B7CDDA4F6B2DCB8_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByBenchmarkAxis_96B7BC682629372E3B7CDDA4F6B2DCB8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Concentration Risk Benchmark [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_96B7BC682629372E3B7CDDA4F6B2DCB8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_96B7BC682629372E3B7CDDA4F6B2DCB8" xlink:to="lab_us-gaap_ConcentrationRiskByBenchmarkAxis_96B7BC682629372E3B7CDDA4F6B2DCB8" xlink:type="arc" />
    <link:label id="lab_us-gaap_ConcentrationRiskBenchmarkDomain_2738C2CE32664508F48BDDA4F6B22356_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskBenchmarkDomain_2738C2CE32664508F48BDDA4F6B22356" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Concentration Risk Benchmark [Domain]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskBenchmarkDomain_2738C2CE32664508F48BDDA4F6B22356_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskBenchmarkDomain_2738C2CE32664508F48BDDA4F6B22356" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Concentration Risk Benchmark [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_2738C2CE32664508F48BDDA4F6B22356" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_2738C2CE32664508F48BDDA4F6B22356" xlink:to="lab_us-gaap_ConcentrationRiskBenchmarkDomain_2738C2CE32664508F48BDDA4F6B22356" xlink:type="arc" />
    <link:label id="lab_us-gaap_SalesRevenueGoodsNetMember_C12C86465A92747D92D4DDA4F6B2F635_terseLabel_en-US" xlink:label="lab_us-gaap_SalesRevenueGoodsNetMember_C12C86465A92747D92D4DDA4F6B2F635" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Sales Revenue, Product Line [Member]</link:label>
    <link:label id="lab_us-gaap_SalesRevenueGoodsNetMember_C12C86465A92747D92D4DDA4F6B2F635_label_en-US" xlink:label="lab_us-gaap_SalesRevenueGoodsNetMember_C12C86465A92747D92D4DDA4F6B2F635" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sales Revenue, Goods, Net [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SalesRevenueGoodsNetMember" xlink:label="loc_us-gaap_SalesRevenueGoodsNetMember_C12C86465A92747D92D4DDA4F6B2F635" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SalesRevenueGoodsNetMember_C12C86465A92747D92D4DDA4F6B2F635" xlink:to="lab_us-gaap_SalesRevenueGoodsNetMember_C12C86465A92747D92D4DDA4F6B2F635" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccountsReceivableMember_16F0468584931AD4C438DDA4F6B2824B_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsReceivableMember_16F0468584931AD4C438DDA4F6B2824B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accounts Receivable [Member]</link:label>
    <link:label id="lab_us-gaap_AccountsReceivableMember_16F0468584931AD4C438DDA4F6B2824B_label_en-US" xlink:label="lab_us-gaap_AccountsReceivableMember_16F0468584931AD4C438DDA4F6B2824B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounts Receivable [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AccountsReceivableMember" xlink:label="loc_us-gaap_AccountsReceivableMember_16F0468584931AD4C438DDA4F6B2824B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsReceivableMember_16F0468584931AD4C438DDA4F6B2824B" xlink:to="lab_us-gaap_AccountsReceivableMember_16F0468584931AD4C438DDA4F6B2824B" xlink:type="arc" />
    <link:label id="lab_us-gaap_MajorCustomersAxis_CB15BE011D8DDBBFF3AEDDA4F6B2F951_terseLabel_en-US" xlink:label="lab_us-gaap_MajorCustomersAxis_CB15BE011D8DDBBFF3AEDDA4F6B2F951" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Major Customers [Axis]</link:label>
    <link:label id="lab_us-gaap_MajorCustomersAxis_CB15BE011D8DDBBFF3AEDDA4F6B2F951_label_en-US" xlink:label="lab_us-gaap_MajorCustomersAxis_CB15BE011D8DDBBFF3AEDDA4F6B2F951" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Customer [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_MajorCustomersAxis" xlink:label="loc_us-gaap_MajorCustomersAxis_CB15BE011D8DDBBFF3AEDDA4F6B2F951" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MajorCustomersAxis_CB15BE011D8DDBBFF3AEDDA4F6B2F951" xlink:to="lab_us-gaap_MajorCustomersAxis_CB15BE011D8DDBBFF3AEDDA4F6B2F951" xlink:type="arc" />
    <link:label id="lab_us-gaap_NameOfMajorCustomerDomain_3575FECE6A3E9890F098DDA4F6B20B22_terseLabel_en-US" xlink:label="lab_us-gaap_NameOfMajorCustomerDomain_3575FECE6A3E9890F098DDA4F6B20B22" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Name of Major Customer [Domain]</link:label>
    <link:label id="lab_us-gaap_NameOfMajorCustomerDomain_3575FECE6A3E9890F098DDA4F6B20B22_label_en-US" xlink:label="lab_us-gaap_NameOfMajorCustomerDomain_3575FECE6A3E9890F098DDA4F6B20B22" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Customer [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NameOfMajorCustomerDomain" xlink:label="loc_us-gaap_NameOfMajorCustomerDomain_3575FECE6A3E9890F098DDA4F6B20B22" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NameOfMajorCustomerDomain_3575FECE6A3E9890F098DDA4F6B20B22" xlink:to="lab_us-gaap_NameOfMajorCustomerDomain_3575FECE6A3E9890F098DDA4F6B20B22" xlink:type="arc" />
    <link:label id="lab_gale_CustomerOneMember_3267EA7B0D9FCCABCA03DDA4F6B2F5DF_terseLabel_en-US" xlink:label="lab_gale_CustomerOneMember_3267EA7B0D9FCCABCA03DDA4F6B2F5DF" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Customer A [Member]</link:label>
    <link:label id="lab_gale_CustomerOneMember_3267EA7B0D9FCCABCA03DDA4F6B2F5DF_label_en-US" xlink:label="lab_gale_CustomerOneMember_3267EA7B0D9FCCABCA03DDA4F6B2F5DF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Customer One [Member]</link:label>
    <link:label id="lab_gale_CustomerOneMember_3267EA7B0D9FCCABCA03DDA4F6B2F5DF_documentation_en-US" xlink:label="lab_gale_CustomerOneMember_3267EA7B0D9FCCABCA03DDA4F6B2F5DF" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Customer One [Member]</link:label>
    <link:loc xlink:href="gale-20150930.xsd#gale_CustomerOneMember" xlink:label="loc_gale_CustomerOneMember_3267EA7B0D9FCCABCA03DDA4F6B2F5DF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_CustomerOneMember_3267EA7B0D9FCCABCA03DDA4F6B2F5DF" xlink:to="lab_gale_CustomerOneMember_3267EA7B0D9FCCABCA03DDA4F6B2F5DF" xlink:type="arc" />
    <link:label id="lab_gale_CustomerTwoMember_3F480FEB91BB968C4D50DDA4F6B29FE7_terseLabel_en-US" xlink:label="lab_gale_CustomerTwoMember_3F480FEB91BB968C4D50DDA4F6B29FE7" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Customer B [Member]</link:label>
    <link:label id="lab_gale_CustomerTwoMember_3F480FEB91BB968C4D50DDA4F6B29FE7_label_en-US" xlink:label="lab_gale_CustomerTwoMember_3F480FEB91BB968C4D50DDA4F6B29FE7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Customer Two [Member]</link:label>
    <link:label id="lab_gale_CustomerTwoMember_3F480FEB91BB968C4D50DDA4F6B29FE7_documentation_en-US" xlink:label="lab_gale_CustomerTwoMember_3F480FEB91BB968C4D50DDA4F6B29FE7" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Customer Two [Member]</link:label>
    <link:loc xlink:href="gale-20150930.xsd#gale_CustomerTwoMember" xlink:label="loc_gale_CustomerTwoMember_3F480FEB91BB968C4D50DDA4F6B29FE7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_CustomerTwoMember_3F480FEB91BB968C4D50DDA4F6B29FE7" xlink:to="lab_gale_CustomerTwoMember_3F480FEB91BB968C4D50DDA4F6B29FE7" xlink:type="arc" />
    <link:label id="lab_gale_CustomerThreeMember_D212B944EB4D767ADDA5DDA4F6B2C5EE_terseLabel_en-US" xlink:label="lab_gale_CustomerThreeMember_D212B944EB4D767ADDA5DDA4F6B2C5EE" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Customer C [Member]</link:label>
    <link:label id="lab_gale_CustomerThreeMember_D212B944EB4D767ADDA5DDA4F6B2C5EE_label_en-US" xlink:label="lab_gale_CustomerThreeMember_D212B944EB4D767ADDA5DDA4F6B2C5EE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Customer Three [Member]</link:label>
    <link:label id="lab_gale_CustomerThreeMember_D212B944EB4D767ADDA5DDA4F6B2C5EE_documentation_en-US" xlink:label="lab_gale_CustomerThreeMember_D212B944EB4D767ADDA5DDA4F6B2C5EE" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Customer Three [Member]</link:label>
    <link:loc xlink:href="gale-20150930.xsd#gale_CustomerThreeMember" xlink:label="loc_gale_CustomerThreeMember_D212B944EB4D767ADDA5DDA4F6B2C5EE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_CustomerThreeMember_D212B944EB4D767ADDA5DDA4F6B2C5EE" xlink:to="lab_gale_CustomerThreeMember_D212B944EB4D767ADDA5DDA4F6B2C5EE" xlink:type="arc" />
    <link:label id="lab_gale_CustomerFourMember_12B1E9413A01C721DCD6DDA4F6B27643_terseLabel_en-US" xlink:label="lab_gale_CustomerFourMember_12B1E9413A01C721DCD6DDA4F6B27643" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Customer D [Member]</link:label>
    <link:label id="lab_gale_CustomerFourMember_12B1E9413A01C721DCD6DDA4F6B27643_label_en-US" xlink:label="lab_gale_CustomerFourMember_12B1E9413A01C721DCD6DDA4F6B27643" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Customer Four [Member]</link:label>
    <link:label id="lab_gale_CustomerFourMember_12B1E9413A01C721DCD6DDA4F6B27643_documentation_en-US" xlink:label="lab_gale_CustomerFourMember_12B1E9413A01C721DCD6DDA4F6B27643" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Customer Four [Member]</link:label>
    <link:loc xlink:href="gale-20150930.xsd#gale_CustomerFourMember" xlink:label="loc_gale_CustomerFourMember_12B1E9413A01C721DCD6DDA4F6B27643" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_CustomerFourMember_12B1E9413A01C721DCD6DDA4F6B27643" xlink:to="lab_gale_CustomerFourMember_12B1E9413A01C721DCD6DDA4F6B27643" xlink:type="arc" />
    <link:label id="lab_gale_CustomerFiveMember_78CE2BEA53DFC8972C32DDA4F6B23094_terseLabel_en-US" xlink:label="lab_gale_CustomerFiveMember_78CE2BEA53DFC8972C32DDA4F6B23094" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Customer E [Member]</link:label>
    <link:label id="lab_gale_CustomerFiveMember_78CE2BEA53DFC8972C32DDA4F6B23094_label_en-US" xlink:label="lab_gale_CustomerFiveMember_78CE2BEA53DFC8972C32DDA4F6B23094" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Customer Five [Member]</link:label>
    <link:label id="lab_gale_CustomerFiveMember_78CE2BEA53DFC8972C32DDA4F6B23094_documentation_en-US" xlink:label="lab_gale_CustomerFiveMember_78CE2BEA53DFC8972C32DDA4F6B23094" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Customer Five [Member]</link:label>
    <link:loc xlink:href="gale-20150930.xsd#gale_CustomerFiveMember" xlink:label="loc_gale_CustomerFiveMember_78CE2BEA53DFC8972C32DDA4F6B23094" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_CustomerFiveMember_78CE2BEA53DFC8972C32DDA4F6B23094" xlink:to="lab_gale_CustomerFiveMember_78CE2BEA53DFC8972C32DDA4F6B23094" xlink:type="arc" />
    <link:label id="lab_us-gaap_ConcentrationRiskLineItems_1B176FB11DAE0F13B24DDDA4F6B250BF_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskLineItems_1B176FB11DAE0F13B24DDDA4F6B250BF" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Concentration Risk [Line Items]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskLineItems_1B176FB11DAE0F13B24DDDA4F6B250BF_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskLineItems_1B176FB11DAE0F13B24DDDA4F6B250BF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Concentration Risk [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ConcentrationRiskLineItems" xlink:label="loc_us-gaap_ConcentrationRiskLineItems_1B176FB11DAE0F13B24DDDA4F6B250BF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_1B176FB11DAE0F13B24DDDA4F6B250BF" xlink:to="lab_us-gaap_ConcentrationRiskLineItems_1B176FB11DAE0F13B24DDDA4F6B250BF" xlink:type="arc" />
    <link:label id="lab_gale_NumberofCommericalProducts_1DC2AE2B5CE1C69759B9DDA4F6B395C6_terseLabel_en-US" xlink:label="lab_gale_NumberofCommericalProducts_1DC2AE2B5CE1C69759B9DDA4F6B395C6" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of Commerical Products</link:label>
    <link:label id="lab_gale_NumberofCommericalProducts_1DC2AE2B5CE1C69759B9DDA4F6B395C6_label_en-US" xlink:label="lab_gale_NumberofCommericalProducts_1DC2AE2B5CE1C69759B9DDA4F6B395C6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number of Commerical Products</link:label>
    <link:label id="lab_gale_NumberofCommericalProducts_1DC2AE2B5CE1C69759B9DDA4F6B395C6_documentation_en-US" xlink:label="lab_gale_NumberofCommericalProducts_1DC2AE2B5CE1C69759B9DDA4F6B395C6" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Number of Commerical Products</link:label>
    <link:loc xlink:href="gale-20150930.xsd#gale_NumberofCommericalProducts" xlink:label="loc_gale_NumberofCommericalProducts_1DC2AE2B5CE1C69759B9DDA4F6B395C6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_NumberofCommericalProducts_1DC2AE2B5CE1C69759B9DDA4F6B395C6" xlink:to="lab_gale_NumberofCommericalProducts_1DC2AE2B5CE1C69759B9DDA4F6B395C6" xlink:type="arc" />
    <link:label id="lab_gale_NumberofDosingStrengths_47E691350972938543FBDDA4F6B3FE11_terseLabel_en-US" xlink:label="lab_gale_NumberofDosingStrengths_47E691350972938543FBDDA4F6B3FE11" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of Dosing Strengths</link:label>
    <link:label id="lab_gale_NumberofDosingStrengths_47E691350972938543FBDDA4F6B3FE11_label_en-US" xlink:label="lab_gale_NumberofDosingStrengths_47E691350972938543FBDDA4F6B3FE11" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number of Dosing Strengths</link:label>
    <link:label id="lab_gale_NumberofDosingStrengths_47E691350972938543FBDDA4F6B3FE11_documentation_en-US" xlink:label="lab_gale_NumberofDosingStrengths_47E691350972938543FBDDA4F6B3FE11" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Number of Dosing Strengths</link:label>
    <link:loc xlink:href="gale-20150930.xsd#gale_NumberofDosingStrengths" xlink:label="loc_gale_NumberofDosingStrengths_47E691350972938543FBDDA4F6B3FE11" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_NumberofDosingStrengths_47E691350972938543FBDDA4F6B3FE11" xlink:to="lab_gale_NumberofDosingStrengths_47E691350972938543FBDDA4F6B3FE11" xlink:type="arc" />
    <link:label id="lab_us-gaap_ConcentrationRiskPercentage1_E813DD073E063DB48A4CDDA4F6B361AE_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskPercentage1_E813DD073E063DB48A4CDDA4F6B361AE" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Concentration Risk, Percentage</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskPercentage1_E813DD073E063DB48A4CDDA4F6B361AE_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskPercentage1_E813DD073E063DB48A4CDDA4F6B361AE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Concentration Risk, Percentage</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ConcentrationRiskPercentage1" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1_E813DD073E063DB48A4CDDA4F6B361AE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskPercentage1_E813DD073E063DB48A4CDDA4F6B361AE" xlink:to="lab_us-gaap_ConcentrationRiskPercentage1_E813DD073E063DB48A4CDDA4F6B361AE" xlink:type="arc" />
    <link:label id="lab_gale_NumberofTopPerformingPharmacies_AEB60E827799BA355D13DDA4F6B3B84C_terseLabel_en-US" xlink:label="lab_gale_NumberofTopPerformingPharmacies_AEB60E827799BA355D13DDA4F6B3B84C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of Top Performing Pharmacies</link:label>
    <link:label id="lab_gale_NumberofTopPerformingPharmacies_AEB60E827799BA355D13DDA4F6B3B84C_label_en-US" xlink:label="lab_gale_NumberofTopPerformingPharmacies_AEB60E827799BA355D13DDA4F6B3B84C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number of Top Performing Pharmacies</link:label>
    <link:label id="lab_gale_NumberofTopPerformingPharmacies_AEB60E827799BA355D13DDA4F6B3B84C_documentation_en-US" xlink:label="lab_gale_NumberofTopPerformingPharmacies_AEB60E827799BA355D13DDA4F6B3B84C" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Number of Top Performing Pharmacies</link:label>
    <link:loc xlink:href="gale-20150930.xsd#gale_NumberofTopPerformingPharmacies" xlink:label="loc_gale_NumberofTopPerformingPharmacies_AEB60E827799BA355D13DDA4F6B3B84C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_NumberofTopPerformingPharmacies_AEB60E827799BA355D13DDA4F6B3B84C" xlink:to="lab_gale_NumberofTopPerformingPharmacies_AEB60E827799BA355D13DDA4F6B3B84C" xlink:type="arc" />
    <link:label id="lab_gale_ScheduleOfEarningPerShareToCommonShareholdersTableTextBlock_38607CC23D1657E20E20D437A8882E24_terseLabel_en-US" xlink:label="lab_gale_ScheduleOfEarningPerShareToCommonShareholdersTableTextBlock_DC8799C90CD35F8880EF12E841FE4E5C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common Shares Excluded from Net Loss</link:label>
    <link:label id="lab_gale_ScheduleOfEarningPerShareToCommonShareholdersTableTextBlock_38607CC23D1657E20E20D437A8882E24_label_en-US" xlink:label="lab_gale_ScheduleOfEarningPerShareToCommonShareholdersTableTextBlock_DC8799C90CD35F8880EF12E841FE4E5C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule Of Earning Per Share To Common Shareholders Table [Text Block]</link:label>
    <link:label id="lab_gale_ScheduleOfEarningPerShareToCommonShareholdersTableTextBlock_38607CC23D1657E20E20D437A8882E24_documentation_en-US" xlink:label="lab_gale_ScheduleOfEarningPerShareToCommonShareholdersTableTextBlock_DC8799C90CD35F8880EF12E841FE4E5C" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Schedule Of Earning Per Share To Common Shareholders Table [Text Block]</link:label>
    <link:loc xlink:href="gale-20150930.xsd#gale_ScheduleOfEarningPerShareToCommonShareholdersTableTextBlock" xlink:label="loc_gale_ScheduleOfEarningPerShareToCommonShareholdersTableTextBlock_DC8799C90CD35F8880EF12E841FE4E5C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_ScheduleOfEarningPerShareToCommonShareholdersTableTextBlock_DC8799C90CD35F8880EF12E841FE4E5C" xlink:to="lab_gale_ScheduleOfEarningPerShareToCommonShareholdersTableTextBlock_DC8799C90CD35F8880EF12E841FE4E5C" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_44390EFB9260CACE1B14D437A83C46C9_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_D5F78D0ABCA551039C0C6C10BC3089E4" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Risk free interest rate</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_44390EFB9260CACE1B14D437A83C46C9_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_D5F78D0ABCA551039C0C6C10BC3089E4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_D5F78D0ABCA551039C0C6C10BC3089E4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_D5F78D0ABCA551039C0C6C10BC3089E4" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_D5F78D0ABCA551039C0C6C10BC3089E4" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_EE4FF02E3E334E121F2FD437A83C43BB_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_BE2FB88FB980520A8FE35CA5E44BD566" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Volatility</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_EE4FF02E3E334E121F2FD437A83C43BB_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_BE2FB88FB980520A8FE35CA5E44BD566" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_BE2FB88FB980520A8FE35CA5E44BD566" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_BE2FB88FB980520A8FE35CA5E44BD566" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_BE2FB88FB980520A8FE35CA5E44BD566" xlink:type="arc" />
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_5B2D63BCB3FF18ABFCAAD437A83CCC56_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_EE538F6247D153118B0AFDDBC25C7CD5" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Expected lives (years)</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_5B2D63BCB3FF18ABFCAAD437A83CCC56_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_EE538F6247D153118B0AFDDBC25C7CD5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_EE538F6247D153118B0AFDDBC25C7CD5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_EE538F6247D153118B0AFDDBC25C7CD5" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_EE538F6247D153118B0AFDDBC25C7CD5" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_817A40DEB6ADAB0A6E8CD437A83C035D_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_501B10773B3D5946A7C1989C84659FBD" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Expected dividend yield</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_817A40DEB6ADAB0A6E8CD437A83C035D_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_501B10773B3D5946A7C1989C84659FBD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_501B10773B3D5946A7C1989C84659FBD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_501B10773B3D5946A7C1989C84659FBD" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_501B10773B3D5946A7C1989C84659FBD" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_6F08A45F81B05E3AE47ADDA4F7B4EA07_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_6F08A45F81B05E3AE47ADDA4F7B4EA07" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Business Acquisitions, by Acquisition [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_6F08A45F81B05E3AE47ADDA4F7B4EA07_label_en-US" xlink:label="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_6F08A45F81B05E3AE47ADDA4F7B4EA07" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Business Acquisitions, by Acquisition [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_6F08A45F81B05E3AE47ADDA4F7B4EA07" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_6F08A45F81B05E3AE47ADDA4F7B4EA07" xlink:to="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_6F08A45F81B05E3AE47ADDA4F7B4EA07" xlink:type="arc" />
    <link:label id="lab_us-gaap_BusinessAcquisitionLineItems_385F4649A184F137C5E8DDA4F7BACC26_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionLineItems_385F4649A184F137C5E8DDA4F7BACC26" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Business Acquisition [Line Items]</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionLineItems_385F4649A184F137C5E8DDA4F7BACC26_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionLineItems_385F4649A184F137C5E8DDA4F7BACC26" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Acquisition [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_BusinessAcquisitionLineItems" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_385F4649A184F137C5E8DDA4F7BACC26" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_385F4649A184F137C5E8DDA4F7BACC26" xlink:to="lab_us-gaap_BusinessAcquisitionLineItems_385F4649A184F137C5E8DDA4F7BACC26" xlink:type="arc" />
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_972D3D20690609802907DDA4F7BA3E40_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_972D3D20690609802907DDA4F7BA3E40" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_972D3D20690609802907DDA4F7BA3E40_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_972D3D20690609802907DDA4F7BA3E40" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Cash and Equivalents</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_972D3D20690609802907DDA4F7BA3E40" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_972D3D20690609802907DDA4F7BA3E40" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_972D3D20690609802907DDA4F7BA3E40" xlink:type="arc" />
    <link:label id="lab_us-gaap_BusinessAcquisitionEquityInterestIssuedOrIssuableValueAssigned_3CCE5A0FBF680E6D4A14DDA4F7BA568E_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionEquityInterestIssuedOrIssuableValueAssigned_3CCE5A0FBF680E6D4A14DDA4F7BA568E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionEquityInterestIssuedOrIssuableValueAssigned_3CCE5A0FBF680E6D4A14DDA4F7BA568E_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionEquityInterestIssuedOrIssuableValueAssigned_3CCE5A0FBF680E6D4A14DDA4F7BA568E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Acquisition, Equity Interest Issued or Issuable, Value Assigned</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_BusinessAcquisitionEquityInterestIssuedOrIssuableValueAssigned" xlink:label="loc_us-gaap_BusinessAcquisitionEquityInterestIssuedOrIssuableValueAssigned_3CCE5A0FBF680E6D4A14DDA4F7BA568E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionEquityInterestIssuedOrIssuableValueAssigned_3CCE5A0FBF680E6D4A14DDA4F7BA568E" xlink:to="lab_us-gaap_BusinessAcquisitionEquityInterestIssuedOrIssuableValueAssigned_3CCE5A0FBF680E6D4A14DDA4F7BA568E" xlink:type="arc" />
    <link:label id="lab_us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred_F2CD3D864867AFBCFB9ADDA4F7BA2407_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred_F2CD3D864867AFBCFB9ADDA4F7BA2407" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Contingent consideration</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred_F2CD3D864867AFBCFB9ADDA4F7BA2407_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred_F2CD3D864867AFBCFB9ADDA4F7BA2407" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination, Consideration Transferred, Liabilities Incurred</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred_F2CD3D864867AFBCFB9ADDA4F7BA2407" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred_F2CD3D864867AFBCFB9ADDA4F7BA2407" xlink:to="lab_us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred_F2CD3D864867AFBCFB9ADDA4F7BA2407" xlink:type="arc" />
    <link:label id="lab_us-gaap_BusinessCombinationConsiderationTransferredOther1_AB376670F37E4E6FE961DDA4F7BAA121_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationConsiderationTransferredOther1_AB376670F37E4E6FE961DDA4F7BAA121" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Credit memos for expiring channel inventory</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationConsiderationTransferredOther1_AB376670F37E4E6FE961DDA4F7BAA121_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationConsiderationTransferredOther1_AB376670F37E4E6FE961DDA4F7BAA121" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination, Consideration Transferred, Other</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_BusinessCombinationConsiderationTransferredOther1" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferredOther1_AB376670F37E4E6FE961DDA4F7BAA121" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationConsiderationTransferredOther1_AB376670F37E4E6FE961DDA4F7BAA121" xlink:to="lab_us-gaap_BusinessCombinationConsiderationTransferredOther1_AB376670F37E4E6FE961DDA4F7BAA121" xlink:type="arc" />
    <link:label id="lab_us-gaap_BusinessCombinationConsiderationTransferred1_A53C9821ACB207EE160DDDA4F7BAC1B9_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationConsiderationTransferred1_A53C9821ACB207EE160DDDA4F7BAC1B9" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Total consideration</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationConsiderationTransferred1_A53C9821ACB207EE160DDDA4F7BAC1B9_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationConsiderationTransferred1_A53C9821ACB207EE160DDDA4F7BAC1B9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination, Consideration Transferred</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_BusinessCombinationConsiderationTransferred1" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferred1_A53C9821ACB207EE160DDDA4F7BAC1B9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationConsiderationTransferred1_A53C9821ACB207EE160DDDA4F7BAC1B9" xlink:to="lab_us-gaap_BusinessCombinationConsiderationTransferred1_A53C9821ACB207EE160DDDA4F7BAC1B9" xlink:type="arc" />
    <link:label id="lab_gale_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedRights_CD83B96F201E6F5C3F9BDDA4F7BBF567_terseLabel_en-US" xlink:label="lab_gale_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedRights_CD83B96F201E6F5C3F9BDDA4F7BBF567" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Zuplenz rights</link:label>
    <link:label id="lab_gale_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedRights_CD83B96F201E6F5C3F9BDDA4F7BBF567_label_en-US" xlink:label="lab_gale_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedRights_CD83B96F201E6F5C3F9BDDA4F7BBF567" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Rights</link:label>
    <link:label id="lab_gale_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedRights_CD83B96F201E6F5C3F9BDDA4F7BBF567_documentation_en-US" xlink:label="lab_gale_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedRights_CD83B96F201E6F5C3F9BDDA4F7BBF567" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Rights</link:label>
    <link:loc xlink:href="gale-20150930.xsd#gale_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedRights" xlink:label="loc_gale_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedRights_CD83B96F201E6F5C3F9BDDA4F7BBF567" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedRights_CD83B96F201E6F5C3F9BDDA4F7BBF567" xlink:to="lab_gale_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedRights_CD83B96F201E6F5C3F9BDDA4F7BBF567" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueOfAssetsAcquired_2C5397D3C347296B9BE5DDA4F7BB0910_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueOfAssetsAcquired_2C5397D3C347296B9BE5DDA4F7BB0910" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair value of assets acquired</link:label>
    <link:label id="lab_us-gaap_FairValueOfAssetsAcquired_2C5397D3C347296B9BE5DDA4F7BB0910_label_en-US" xlink:label="lab_us-gaap_FairValueOfAssetsAcquired_2C5397D3C347296B9BE5DDA4F7BB0910" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value of Assets Acquired</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueOfAssetsAcquired" xlink:label="loc_us-gaap_FairValueOfAssetsAcquired_2C5397D3C347296B9BE5DDA4F7BB0910" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueOfAssetsAcquired_2C5397D3C347296B9BE5DDA4F7BB0910" xlink:to="lab_us-gaap_FairValueOfAssetsAcquired_2C5397D3C347296B9BE5DDA4F7BB0910" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_4AB702C16D27DBD020BCDE2E96A8A9D9_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_4AB702C16D27DBD020BCDE2E96A8A9D9" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value Measurements, Recurring and Nonrecurring [Table]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_4AB702C16D27DBD020BCDE2E96A8A9D9_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_4AB702C16D27DBD020BCDE2E96A8A9D9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Measurements, Recurring and Nonrecurring [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_4AB702C16D27DBD020BCDE2E96A8A9D9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_4AB702C16D27DBD020BCDE2E96A8A9D9" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_4AB702C16D27DBD020BCDE2E96A8A9D9" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueByMeasurementFrequencyAxis_5BA3BCB52AFC27D6549CDE2E96A8FBE5_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByMeasurementFrequencyAxis_5BA3BCB52AFC27D6549CDE2E96A8FBE5" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Measurement Frequency [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByMeasurementFrequencyAxis_5BA3BCB52AFC27D6549CDE2E96A8FBE5_label_en-US" xlink:label="lab_us-gaap_FairValueByMeasurementFrequencyAxis_5BA3BCB52AFC27D6549CDE2E96A8FBE5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Measurement Frequency [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_5BA3BCB52AFC27D6549CDE2E96A8FBE5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_5BA3BCB52AFC27D6549CDE2E96A8FBE5" xlink:to="lab_us-gaap_FairValueByMeasurementFrequencyAxis_5BA3BCB52AFC27D6549CDE2E96A8FBE5" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueMeasurementFrequencyDomain_61A49F9B33DFC2934716DE2E96A828B9_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementFrequencyDomain_61A49F9B33DFC2934716DE2E96A828B9" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value, Measurement Frequency [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementFrequencyDomain_61A49F9B33DFC2934716DE2E96A828B9_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementFrequencyDomain_61A49F9B33DFC2934716DE2E96A828B9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Measurement Frequency [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_61A49F9B33DFC2934716DE2E96A828B9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_61A49F9B33DFC2934716DE2E96A828B9" xlink:to="lab_us-gaap_FairValueMeasurementFrequencyDomain_61A49F9B33DFC2934716DE2E96A828B9" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueMeasurementsRecurringMember_64D4AB9390D99192CE53DE2E96A87419_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsRecurringMember_64D4AB9390D99192CE53DE2E96A87419" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value, Measurements, Recurring [Member]</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsRecurringMember_64D4AB9390D99192CE53DE2E96A87419_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsRecurringMember_64D4AB9390D99192CE53DE2E96A87419" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Measurements, Recurring [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_64D4AB9390D99192CE53DE2E96A87419" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsRecurringMember_64D4AB9390D99192CE53DE2E96A87419" xlink:to="lab_us-gaap_FairValueMeasurementsRecurringMember_64D4AB9390D99192CE53DE2E96A87419" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_23A16F2D875BD766ACFCDE2E96A922BE_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member_23A16F2D875BD766ACFCDE2E96A922BE" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Quoted Prices in Active Markets (Level 1) [Member]</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_23A16F2D875BD766ACFCDE2E96A922BE_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member_23A16F2D875BD766ACFCDE2E96A922BE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Inputs, Level 1 [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_23A16F2D875BD766ACFCDE2E96A922BE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel1Member_23A16F2D875BD766ACFCDE2E96A922BE" xlink:to="lab_us-gaap_FairValueInputsLevel1Member_23A16F2D875BD766ACFCDE2E96A922BE" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_77D3A81799656DE2BA57DE2E96A948C9_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member_77D3A81799656DE2BA57DE2E96A948C9" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Significant Other Observable Inputs (Level 2) [Member]</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_77D3A81799656DE2BA57DE2E96A948C9_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member_77D3A81799656DE2BA57DE2E96A948C9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Inputs, Level 2 [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_77D3A81799656DE2BA57DE2E96A948C9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel2Member_77D3A81799656DE2BA57DE2E96A948C9" xlink:to="lab_us-gaap_FairValueInputsLevel2Member_77D3A81799656DE2BA57DE2E96A948C9" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_015D165105D49F68C2BEDE2E96A98100_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_015D165105D49F68C2BEDE2E96A98100" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_015D165105D49F68C2BEDE2E96A98100_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_015D165105D49F68C2BEDE2E96A98100" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_015D165105D49F68C2BEDE2E96A98100" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_015D165105D49F68C2BEDE2E96A98100" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_015D165105D49F68C2BEDE2E96A98100" xlink:type="arc" />
    <link:label id="lab_us-gaap_AssetsFairValueDisclosureAbstract_7923F28012FE74B2780FDE2E96A9D43F_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosureAbstract_7923F28012FE74B2780FDE2E96A9D43F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Assets:</link:label>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosureAbstract_7923F28012FE74B2780FDE2E96A9D43F_label_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosureAbstract_7923F28012FE74B2780FDE2E96A9D43F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets, Fair Value Disclosure [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AssetsFairValueDisclosureAbstract" xlink:label="loc_us-gaap_AssetsFairValueDisclosureAbstract_7923F28012FE74B2780FDE2E96A9D43F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_7923F28012FE74B2780FDE2E96A9D43F" xlink:to="lab_us-gaap_AssetsFairValueDisclosureAbstract_7923F28012FE74B2780FDE2E96A9D43F" xlink:type="arc" />
    <link:label id="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure_19E2AE8B72EBD4583D37DE2E96A9CF67_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure_19E2AE8B72EBD4583D37DE2E96A9CF67" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure_19E2AE8B72EBD4583D37DE2E96A9CF67_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure_19E2AE8B72EBD4583D37DE2E96A9CF67" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash and Cash Equivalents, Fair Value Disclosure</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_19E2AE8B72EBD4583D37DE2E96A9CF67" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_19E2AE8B72EBD4583D37DE2E96A9CF67" xlink:to="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure_19E2AE8B72EBD4583D37DE2E96A9CF67" xlink:type="arc" />
    <link:label id="lab_us-gaap_AssetsHeldForSaleLongLivedFairValueDisclosure_599926F81E6602430E03DE8DC74EDF12_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsHeldForSaleLongLivedFairValueDisclosure_599926F81E6602430E03DE8DC74EDF12" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Assets held for sale</link:label>
    <link:label id="lab_us-gaap_AssetsHeldForSaleLongLivedFairValueDisclosure_599926F81E6602430E03DE8DC74EDF12_label_en-US" xlink:label="lab_us-gaap_AssetsHeldForSaleLongLivedFairValueDisclosure_599926F81E6602430E03DE8DC74EDF12" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets Held-for-sale, Long Lived, Fair Value Disclosure</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AssetsHeldForSaleLongLivedFairValueDisclosure" xlink:label="loc_us-gaap_AssetsHeldForSaleLongLivedFairValueDisclosure_599926F81E6602430E03DE8DC74EDF12" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsHeldForSaleLongLivedFairValueDisclosure_599926F81E6602430E03DE8DC74EDF12" xlink:to="lab_us-gaap_AssetsHeldForSaleLongLivedFairValueDisclosure_599926F81E6602430E03DE8DC74EDF12" xlink:type="arc" />
    <link:label id="lab_us-gaap_AssetsFairValueDisclosure_63E636F74E44A33EBD1EDE2E96A9D563_totalLabel_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosure_63E636F74E44A33EBD1EDE2E96A9D563" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total assets</link:label>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosure_63E636F74E44A33EBD1EDE2E96A9D563_label_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosure_63E636F74E44A33EBD1EDE2E96A9D563" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets, Fair Value Disclosure</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AssetsFairValueDisclosure" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_63E636F74E44A33EBD1EDE2E96A9D563" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsFairValueDisclosure_63E636F74E44A33EBD1EDE2E96A9D563" xlink:to="lab_us-gaap_AssetsFairValueDisclosure_63E636F74E44A33EBD1EDE2E96A9D563" xlink:type="arc" />
    <link:label id="lab_us-gaap_LiabilitiesFairValueDisclosureAbstract_A3189E1C4DDFE85E92BEDE2E96A99679_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesFairValueDisclosureAbstract_A3189E1C4DDFE85E92BEDE2E96A99679" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Liabilities:</link:label>
    <link:label id="lab_us-gaap_LiabilitiesFairValueDisclosureAbstract_A3189E1C4DDFE85E92BEDE2E96A99679_label_en-US" xlink:label="lab_us-gaap_LiabilitiesFairValueDisclosureAbstract_A3189E1C4DDFE85E92BEDE2E96A99679" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities, Fair Value Disclosure [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_A3189E1C4DDFE85E92BEDE2E96A99679" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_A3189E1C4DDFE85E92BEDE2E96A99679" xlink:to="lab_us-gaap_LiabilitiesFairValueDisclosureAbstract_A3189E1C4DDFE85E92BEDE2E96A99679" xlink:type="arc" />
    <link:label id="lab_gale_FairValueOfWarrantsPotentiallySettleableInCash_15520E39EB89B2E2D725DE2E96A94A23_verboseLabel_en-US" xlink:label="lab_gale_FairValueOfWarrantsPotentiallySettleableInCash_15520E39EB89B2E2D725DE2E96A94A23" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Warrants potentially settleable in cash</link:label>
    <link:loc xlink:href="gale-20150930.xsd#gale_FairValueOfWarrantsPotentiallySettleableInCash" xlink:label="loc_gale_FairValueOfWarrantsPotentiallySettleableInCash_15520E39EB89B2E2D725DE2E96A94A23" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_FairValueOfWarrantsPotentiallySettleableInCash_15520E39EB89B2E2D725DE2E96A94A23" xlink:to="lab_gale_FairValueOfWarrantsPotentiallySettleableInCash_15520E39EB89B2E2D725DE2E96A94A23" xlink:type="arc" />
    <link:label id="lab_us-gaap_ContingentConsiderationClassifiedAsEquityFairValueDisclosure_43557360DA03F5BC66A1DE2E96A99934_terseLabel_en-US" xlink:label="lab_us-gaap_ContingentConsiderationClassifiedAsEquityFairValueDisclosure_43557360DA03F5BC66A1DE2E96A99934" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Contingent purchase price consideration</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ContingentConsiderationClassifiedAsEquityFairValueDisclosure" xlink:label="loc_us-gaap_ContingentConsiderationClassifiedAsEquityFairValueDisclosure_43557360DA03F5BC66A1DE2E96A99934" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContingentConsiderationClassifiedAsEquityFairValueDisclosure_43557360DA03F5BC66A1DE2E96A99934" xlink:to="lab_us-gaap_ContingentConsiderationClassifiedAsEquityFairValueDisclosure_43557360DA03F5BC66A1DE2E96A99934" xlink:type="arc" />
    <link:label id="lab_us-gaap_EquityFairValueDisclosure_B7614D69893C26129F79DE2E96A99F52_totalLabel_en-US" xlink:label="lab_us-gaap_EquityFairValueDisclosure_B7614D69893C26129F79DE2E96A99F52" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total liabilities</link:label>
    <link:label id="lab_us-gaap_EquityFairValueDisclosure_B7614D69893C26129F79DE2E96A99F52_label_en-US" xlink:label="lab_us-gaap_EquityFairValueDisclosure_B7614D69893C26129F79DE2E96A99F52" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity, Fair Value Disclosure</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EquityFairValueDisclosure" xlink:label="loc_us-gaap_EquityFairValueDisclosure_B7614D69893C26129F79DE2E96A99F52" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityFairValueDisclosure_B7614D69893C26129F79DE2E96A99F52" xlink:to="lab_us-gaap_EquityFairValueDisclosure_B7614D69893C26129F79DE2E96A99F52" xlink:type="arc" />
    <link:label id="lab_gale_LicenseAndCollaborationAgreementsTable_F781F9580A1B4A067993FE4041A56BFE_terseLabel_en-US" xlink:label="lab_gale_LicenseAndCollaborationAgreementsTable_1407CD18B82257ED80BC8D7D81E70E25" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">License And Collaboration Agreements [Table]</link:label>
    <link:label id="lab_gale_LicenseAndCollaborationAgreementsTable_F781F9580A1B4A067993FE4041A56BFE_label_en-US" xlink:label="lab_gale_LicenseAndCollaborationAgreementsTable_1407CD18B82257ED80BC8D7D81E70E25" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">License And Collaboration Agreements [Table]</link:label>
    <link:label id="lab_gale_LicenseAndCollaborationAgreementsTable_F781F9580A1B4A067993FE4041A56BFE_documentation_en-US" xlink:label="lab_gale_LicenseAndCollaborationAgreementsTable_1407CD18B82257ED80BC8D7D81E70E25" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">License And Collaboration Agreements [Table]</link:label>
    <link:loc xlink:href="gale-20150930.xsd#gale_LicenseAndCollaborationAgreementsTable" xlink:label="loc_gale_LicenseAndCollaborationAgreementsTable_1407CD18B82257ED80BC8D7D81E70E25" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_LicenseAndCollaborationAgreementsTable_1407CD18B82257ED80BC8D7D81E70E25" xlink:to="lab_gale_LicenseAndCollaborationAgreementsTable_1407CD18B82257ED80BC8D7D81E70E25" xlink:type="arc" />
    <link:label id="lab_us-gaap_DistributionRightsMember_09B64E25799A64DA97A0FE42BE410425_terseLabel_en-US" xlink:label="lab_us-gaap_DistributionRightsMember_EC5E2FB2A47A58759DB708E1A3F0F426" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Distribution Rights [Member]</link:label>
    <link:label id="lab_us-gaap_DistributionRightsMember_09B64E25799A64DA97A0FE42BE410425_label_en-US" xlink:label="lab_us-gaap_DistributionRightsMember_EC5E2FB2A47A58759DB708E1A3F0F426" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Distribution Rights [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DistributionRightsMember" xlink:label="loc_us-gaap_DistributionRightsMember_EC5E2FB2A47A58759DB708E1A3F0F426" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DistributionRightsMember_EC5E2FB2A47A58759DB708E1A3F0F426" xlink:to="lab_us-gaap_DistributionRightsMember_EC5E2FB2A47A58759DB708E1A3F0F426" xlink:type="arc" />
    <link:label id="lab_gale_MDAndersonCancerCenterMember_098161B1A1370BF63639FE4041A6B049_terseLabel_en-US" xlink:label="lab_gale_MDAndersonCancerCenterMember_BBD250A0E81F5B47B560EEA58D8CD138" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">M D Anderson Cancer Center [Member]</link:label>
    <link:label id="lab_gale_MDAndersonCancerCenterMember_098161B1A1370BF63639FE4041A6B049_label_en-US" xlink:label="lab_gale_MDAndersonCancerCenterMember_BBD250A0E81F5B47B560EEA58D8CD138" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">M D Anderson Cancer Center [Member]</link:label>
    <link:label id="lab_gale_MDAndersonCancerCenterMember_098161B1A1370BF63639FE4041A6B049_documentation_en-US" xlink:label="lab_gale_MDAndersonCancerCenterMember_BBD250A0E81F5B47B560EEA58D8CD138" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">M D Anderson Cancer Center [Member]</link:label>
    <link:loc xlink:href="gale-20150930.xsd#gale_MDAndersonCancerCenterMember" xlink:label="loc_gale_MDAndersonCancerCenterMember_BBD250A0E81F5B47B560EEA58D8CD138" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_MDAndersonCancerCenterMember_BBD250A0E81F5B47B560EEA58D8CD138" xlink:to="lab_gale_MDAndersonCancerCenterMember_BBD250A0E81F5B47B560EEA58D8CD138" xlink:type="arc" />
    <link:label id="lab_gale_OrexoMember_AE2DC51ADFCE36B13F30FE4041A6712C_terseLabel_en-US" xlink:label="lab_gale_OrexoMember_55C6E426DE4259049BADCFC77638F7C4" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Orexo [Member]</link:label>
    <link:label id="lab_gale_OrexoMember_AE2DC51ADFCE36B13F30FE4041A6712C_label_en-US" xlink:label="lab_gale_OrexoMember_55C6E426DE4259049BADCFC77638F7C4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Orexo [Member]</link:label>
    <link:label id="lab_gale_OrexoMember_AE2DC51ADFCE36B13F30FE4041A6712C_documentation_en-US" xlink:label="lab_gale_OrexoMember_55C6E426DE4259049BADCFC77638F7C4" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Orexo [Member]</link:label>
    <link:loc xlink:href="gale-20150930.xsd#gale_OrexoMember" xlink:label="loc_gale_OrexoMember_55C6E426DE4259049BADCFC77638F7C4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_OrexoMember_55C6E426DE4259049BADCFC77638F7C4" xlink:to="lab_gale_OrexoMember_55C6E426DE4259049BADCFC77638F7C4" xlink:type="arc" />
    <link:label id="lab_gale_LicenseAndCollaborationAgreementsLineItems_ACFE1C5668A46140E176FE4041A6DC53_terseLabel_en-US" xlink:label="lab_gale_LicenseAndCollaborationAgreementsLineItems_A1A30BAFE7E75E44A6D7FF1B540D29B1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">License And Collaboration Agreements [Line Items]</link:label>
    <link:label id="lab_gale_LicenseAndCollaborationAgreementsLineItems_ACFE1C5668A46140E176FE4041A6DC53_label_en-US" xlink:label="lab_gale_LicenseAndCollaborationAgreementsLineItems_A1A30BAFE7E75E44A6D7FF1B540D29B1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">License And Collaboration Agreements [Line Items]</link:label>
    <link:label id="lab_gale_LicenseAndCollaborationAgreementsLineItems_ACFE1C5668A46140E176FE4041A6DC53_documentation_en-US" xlink:label="lab_gale_LicenseAndCollaborationAgreementsLineItems_A1A30BAFE7E75E44A6D7FF1B540D29B1" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">License And Collaboration Agreements [Line Items]</link:label>
    <link:loc xlink:href="gale-20150930.xsd#gale_LicenseAndCollaborationAgreementsLineItems" xlink:label="loc_gale_LicenseAndCollaborationAgreementsLineItems_A1A30BAFE7E75E44A6D7FF1B540D29B1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_LicenseAndCollaborationAgreementsLineItems_A1A30BAFE7E75E44A6D7FF1B540D29B1" xlink:to="lab_gale_LicenseAndCollaborationAgreementsLineItems_A1A30BAFE7E75E44A6D7FF1B540D29B1" xlink:type="arc" />
    <link:label id="lab_gale_AnnualMaintenanceFee_96449DF6B945C53F0001FE4041A6F0DE_terseLabel_en-US" xlink:label="lab_gale_AnnualMaintenanceFee_9F2399AD70365C25BA4A666752C487DE" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Annual maintenance fee</link:label>
    <link:label id="lab_gale_AnnualMaintenanceFee_96449DF6B945C53F0001FE4041A6F0DE_label_en-US" xlink:label="lab_gale_AnnualMaintenanceFee_9F2399AD70365C25BA4A666752C487DE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Annual Maintenance Fee</link:label>
    <link:label id="lab_gale_AnnualMaintenanceFee_96449DF6B945C53F0001FE4041A6F0DE_documentation_en-US" xlink:label="lab_gale_AnnualMaintenanceFee_9F2399AD70365C25BA4A666752C487DE" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Annual Maintenance Fee</link:label>
    <link:loc xlink:href="gale-20150930.xsd#gale_AnnualMaintenanceFee" xlink:label="loc_gale_AnnualMaintenanceFee_9F2399AD70365C25BA4A666752C487DE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_AnnualMaintenanceFee_9F2399AD70365C25BA4A666752C487DE" xlink:to="lab_gale_AnnualMaintenanceFee_9F2399AD70365C25BA4A666752C487DE" xlink:type="arc" />
    <link:label id="lab_gale_FutureMilestonePayment_DF1E4ADA5FD324854E5EFE4041A6D78A_terseLabel_en-US" xlink:label="lab_gale_FutureMilestonePayment_699EFB6C61CF5284BA715B6B27AE6D75" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Milestone payment for Phase 3</link:label>
    <link:label id="lab_gale_FutureMilestonePayment_DF1E4ADA5FD324854E5EFE4041A6D78A_label_en-US" xlink:label="lab_gale_FutureMilestonePayment_699EFB6C61CF5284BA715B6B27AE6D75" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Future Milestone Payment</link:label>
    <link:label id="lab_gale_FutureMilestonePayment_DF1E4ADA5FD324854E5EFE4041A6D78A_documentation_en-US" xlink:label="lab_gale_FutureMilestonePayment_699EFB6C61CF5284BA715B6B27AE6D75" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Future Milestone Payment</link:label>
    <link:loc xlink:href="gale-20150930.xsd#gale_FutureMilestonePayment" xlink:label="loc_gale_FutureMilestonePayment_699EFB6C61CF5284BA715B6B27AE6D75" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_FutureMilestonePayment_699EFB6C61CF5284BA715B6B27AE6D75" xlink:to="lab_gale_FutureMilestonePayment_699EFB6C61CF5284BA715B6B27AE6D75" xlink:type="arc" />
    <link:label id="lab_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_36545A68A5275BF94ABDFE4041A66725_terseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_D95DC56649BE56AC9A2F0DCCFEC343DE" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash paid for acquisition of Abstral rights</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_36545A68A5275BF94ABDFE4041A66725_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_D95DC56649BE56AC9A2F0DCCFEC343DE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments to Acquire Businesses, Net of Cash Acquired</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_D95DC56649BE56AC9A2F0DCCFEC343DE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_D95DC56649BE56AC9A2F0DCCFEC343DE" xlink:to="lab_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_D95DC56649BE56AC9A2F0DCCFEC343DE" xlink:type="arc" />
    <link:label id="lab_gale_BusinessAcquisitionCashHeldByAcquiredEntity_426AAE939EE328565A46FE4041A63E7F_terseLabel_en-US" xlink:label="lab_gale_BusinessAcquisitionCashHeldByAcquiredEntity_BD6B8E7A3FE556BC8F570864A56ABE29" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Remaining cash held of Abstral rights</link:label>
    <link:label id="lab_gale_BusinessAcquisitionCashHeldByAcquiredEntity_426AAE939EE328565A46FE4041A63E7F_label_en-US" xlink:label="lab_gale_BusinessAcquisitionCashHeldByAcquiredEntity_BD6B8E7A3FE556BC8F570864A56ABE29" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Acquisition Cash Held By Acquired Entity</link:label>
    <link:label id="lab_gale_BusinessAcquisitionCashHeldByAcquiredEntity_426AAE939EE328565A46FE4041A63E7F_documentation_en-US" xlink:label="lab_gale_BusinessAcquisitionCashHeldByAcquiredEntity_BD6B8E7A3FE556BC8F570864A56ABE29" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Business Acquisition Cash Held By Acquired Entity</link:label>
    <link:loc xlink:href="gale-20150930.xsd#gale_BusinessAcquisitionCashHeldByAcquiredEntity" xlink:label="loc_gale_BusinessAcquisitionCashHeldByAcquiredEntity_BD6B8E7A3FE556BC8F570864A56ABE29" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_BusinessAcquisitionCashHeldByAcquiredEntity_BD6B8E7A3FE556BC8F570864A56ABE29" xlink:to="lab_gale_BusinessAcquisitionCashHeldByAcquiredEntity_BD6B8E7A3FE556BC8F570864A56ABE29" xlink:type="arc" />
    <link:label id="lab_gale_EstimatedYearOfPatentExpiration_85AEE263DCA0135F0DB0FE4041A609EE_terseLabel_en-US" xlink:label="lab_gale_EstimatedYearOfPatentExpiration_F4F6DBA59D495818879856FE3CF08CFB" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Estimated year of licensed patents expiration</link:label>
    <link:label id="lab_gale_EstimatedYearOfPatentExpiration_85AEE263DCA0135F0DB0FE4041A609EE_label_en-US" xlink:label="lab_gale_EstimatedYearOfPatentExpiration_F4F6DBA59D495818879856FE3CF08CFB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Estimated Year Of Patent Expiration</link:label>
    <link:label id="lab_gale_EstimatedYearOfPatentExpiration_85AEE263DCA0135F0DB0FE4041A609EE_documentation_en-US" xlink:label="lab_gale_EstimatedYearOfPatentExpiration_F4F6DBA59D495818879856FE3CF08CFB" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Estimated Year Of Patent Expiration</link:label>
    <link:loc xlink:href="gale-20150930.xsd#gale_EstimatedYearOfPatentExpiration" xlink:label="loc_gale_EstimatedYearOfPatentExpiration_F4F6DBA59D495818879856FE3CF08CFB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_EstimatedYearOfPatentExpiration_F4F6DBA59D495818879856FE3CF08CFB" xlink:to="lab_gale_EstimatedYearOfPatentExpiration_F4F6DBA59D495818879856FE3CF08CFB" xlink:type="arc" />
    <link:label id="lab_us-gaap_PaymentsToAcquireBusinessesGross_30D90A8BE620C9BCF481FE4041A7EA18_terseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireBusinessesGross_DFB4925335D15FA0BD971DB2653A89F2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Payments to Acquire Businesses, Gross</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PaymentsToAcquireBusinessesGross" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesGross_DFB4925335D15FA0BD971DB2653A89F2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireBusinessesGross_DFB4925335D15FA0BD971DB2653A89F2" xlink:to="lab_us-gaap_PaymentsToAcquireBusinessesGross_DFB4925335D15FA0BD971DB2653A89F2" xlink:type="arc" />
    <link:label id="lab_us-gaap_FinitelivedIntangibleAssetsAcquired1_A9EFC5BA77392814E61BFE42BDCED0D8_terseLabel_en-US" xlink:label="lab_us-gaap_FinitelivedIntangibleAssetsAcquired1_FFDDE9FB55D65C25ABE8069E1E8170E2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Finite-lived Intangible Assets Acquired</link:label>
    <link:label id="lab_us-gaap_FinitelivedIntangibleAssetsAcquired1_A9EFC5BA77392814E61BFE42BDCED0D8_label_en-US" xlink:label="lab_us-gaap_FinitelivedIntangibleAssetsAcquired1_FFDDE9FB55D65C25ABE8069E1E8170E2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-lived Intangible Assets Acquired</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FinitelivedIntangibleAssetsAcquired1" xlink:label="loc_us-gaap_FinitelivedIntangibleAssetsAcquired1_FFDDE9FB55D65C25ABE8069E1E8170E2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinitelivedIntangibleAssetsAcquired1_FFDDE9FB55D65C25ABE8069E1E8170E2" xlink:to="lab_us-gaap_FinitelivedIntangibleAssetsAcquired1_FFDDE9FB55D65C25ABE8069E1E8170E2" xlink:type="arc" />
    <link:label id="lab_gale_FinitelivedIntangibleAssetsAcquiredContingentConsideration_B890EC9BA3C943F9C7FEFE42BDE28EC1_terseLabel_en-US" xlink:label="lab_gale_FinitelivedIntangibleAssetsAcquiredContingentConsideration_EDB91DFFD2F65BA69D686AD3D06B0404" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Finite-lived Intangible Assets Acquired, Contingent Consideration</link:label>
    <link:label id="lab_gale_FinitelivedIntangibleAssetsAcquiredContingentConsideration_B890EC9BA3C943F9C7FEFE42BDE28EC1_label_en-US" xlink:label="lab_gale_FinitelivedIntangibleAssetsAcquiredContingentConsideration_EDB91DFFD2F65BA69D686AD3D06B0404" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-lived Intangible Assets Acquired, Contingent Consideration</link:label>
    <link:label id="lab_gale_FinitelivedIntangibleAssetsAcquiredContingentConsideration_B890EC9BA3C943F9C7FEFE42BDE28EC1_documentation_en-US" xlink:label="lab_gale_FinitelivedIntangibleAssetsAcquiredContingentConsideration_EDB91DFFD2F65BA69D686AD3D06B0404" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Finite-lived Intangible Assets Acquired, Contingent Consideration</link:label>
    <link:loc xlink:href="gale-20150930.xsd#gale_FinitelivedIntangibleAssetsAcquiredContingentConsideration" xlink:label="loc_gale_FinitelivedIntangibleAssetsAcquiredContingentConsideration_EDB91DFFD2F65BA69D686AD3D06B0404" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_FinitelivedIntangibleAssetsAcquiredContingentConsideration_EDB91DFFD2F65BA69D686AD3D06B0404" xlink:to="lab_gale_FinitelivedIntangibleAssetsAcquiredContingentConsideration_EDB91DFFD2F65BA69D686AD3D06B0404" xlink:type="arc" />
    <link:label id="lab_gale_FinitelivedIntangibleAssetsAcquiredContingentConsiderationPaymentPeriod_B75B4CEF66068DE21429FE42BDF50DA8_terseLabel_en-US" xlink:label="lab_gale_FinitelivedIntangibleAssetsAcquiredContingentConsiderationPaymentPeriod_A940960D9F0E56CE9D378F3745DD5096" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Finite-lived Intangible Assets Acquired, Contingent Consideration, Payment Period</link:label>
    <link:label id="lab_gale_FinitelivedIntangibleAssetsAcquiredContingentConsiderationPaymentPeriod_B75B4CEF66068DE21429FE42BDF50DA8_label_en-US" xlink:label="lab_gale_FinitelivedIntangibleAssetsAcquiredContingentConsiderationPaymentPeriod_A940960D9F0E56CE9D378F3745DD5096" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-lived Intangible Assets Acquired, Contingent Consideration, Payment Period</link:label>
    <link:label id="lab_gale_FinitelivedIntangibleAssetsAcquiredContingentConsiderationPaymentPeriod_B75B4CEF66068DE21429FE42BDF50DA8_documentation_en-US" xlink:label="lab_gale_FinitelivedIntangibleAssetsAcquiredContingentConsiderationPaymentPeriod_A940960D9F0E56CE9D378F3745DD5096" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Finite-lived Intangible Assets Acquired, Contingent Consideration, Payment Period</link:label>
    <link:loc xlink:href="gale-20150930.xsd#gale_FinitelivedIntangibleAssetsAcquiredContingentConsiderationPaymentPeriod" xlink:label="loc_gale_FinitelivedIntangibleAssetsAcquiredContingentConsiderationPaymentPeriod_A940960D9F0E56CE9D378F3745DD5096" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_FinitelivedIntangibleAssetsAcquiredContingentConsiderationPaymentPeriod_A940960D9F0E56CE9D378F3745DD5096" xlink:to="lab_gale_FinitelivedIntangibleAssetsAcquiredContingentConsiderationPaymentPeriod_A940960D9F0E56CE9D378F3745DD5096" xlink:type="arc" />
    <link:label id="lab_gale_ContractualObligationPotentialPaymentsfromNetSales_C1D3ADB1D732AA85120AFE40D63865DA_terseLabel_en-US" xlink:label="lab_gale_ContractualObligationPotentialPaymentsfromNetSales_DF500A08BF2B53E6908F6889E84E494C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Contractual Obligation, Potential Payments from Net Sales</link:label>
    <link:label id="lab_gale_ContractualObligationPotentialPaymentsfromNetSales_C1D3ADB1D732AA85120AFE40D63865DA_label_en-US" xlink:label="lab_gale_ContractualObligationPotentialPaymentsfromNetSales_DF500A08BF2B53E6908F6889E84E494C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Contractual Obligation, Potential Payments from Net Sales</link:label>
    <link:label id="lab_gale_ContractualObligationPotentialPaymentsfromNetSales_C1D3ADB1D732AA85120AFE40D63865DA_documentation_en-US" xlink:label="lab_gale_ContractualObligationPotentialPaymentsfromNetSales_DF500A08BF2B53E6908F6889E84E494C" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Contractual Obligation, Potential Payments from Net Sales</link:label>
    <link:loc xlink:href="gale-20150930.xsd#gale_ContractualObligationPotentialPaymentsfromNetSales" xlink:label="loc_gale_ContractualObligationPotentialPaymentsfromNetSales_DF500A08BF2B53E6908F6889E84E494C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_ContractualObligationPotentialPaymentsfromNetSales_DF500A08BF2B53E6908F6889E84E494C" xlink:to="lab_gale_ContractualObligationPotentialPaymentsfromNetSales_DF500A08BF2B53E6908F6889E84E494C" xlink:type="arc" />
    <link:label id="lab_gale_ContractualObligationNetSalesThreshold_6249554A14ECB0FED920FE422689E569_terseLabel_en-US" xlink:label="lab_gale_ContractualObligationNetSalesThreshold_0B146E09A4EE5A1780D7887ADF09FCBE" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Contractual Obligation, Net Sales Threshold</link:label>
    <link:label id="lab_gale_ContractualObligationNetSalesThreshold_6249554A14ECB0FED920FE422689E569_label_en-US" xlink:label="lab_gale_ContractualObligationNetSalesThreshold_0B146E09A4EE5A1780D7887ADF09FCBE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Contractual Obligation, Net Sales Threshold</link:label>
    <link:label id="lab_gale_ContractualObligationNetSalesThreshold_6249554A14ECB0FED920FE422689E569_documentation_en-US" xlink:label="lab_gale_ContractualObligationNetSalesThreshold_0B146E09A4EE5A1780D7887ADF09FCBE" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Contractual Obligation, Net Sales Threshold</link:label>
    <link:loc xlink:href="gale-20150930.xsd#gale_ContractualObligationNetSalesThreshold" xlink:label="loc_gale_ContractualObligationNetSalesThreshold_0B146E09A4EE5A1780D7887ADF09FCBE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_ContractualObligationNetSalesThreshold_0B146E09A4EE5A1780D7887ADF09FCBE" xlink:to="lab_gale_ContractualObligationNetSalesThreshold_0B146E09A4EE5A1780D7887ADF09FCBE" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_58038B07C615F3A01862DE2E960E98C7_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_58038B07C615F3A01862DE2E960E98C7" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_58038B07C615F3A01862DE2E960E98C7_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_58038B07C615F3A01862DE2E960E98C7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_58038B07C615F3A01862DE2E960E98C7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_58038B07C615F3A01862DE2E960E98C7" xlink:to="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_58038B07C615F3A01862DE2E960E98C7" xlink:type="arc" />
    <link:label id="lab_us-gaap_StatementOperatingActivitiesSegmentAxis_96372A821FAAB008C74BDE996948FAFF_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOperatingActivitiesSegmentAxis_96372A821FAAB008C74BDE996948FAFF" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating Activities [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementOperatingActivitiesSegmentAxis_96372A821FAAB008C74BDE996948FAFF_label_en-US" xlink:label="lab_us-gaap_StatementOperatingActivitiesSegmentAxis_96372A821FAAB008C74BDE996948FAFF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Activities [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementOperatingActivitiesSegmentAxis" xlink:label="loc_us-gaap_StatementOperatingActivitiesSegmentAxis_96372A821FAAB008C74BDE996948FAFF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOperatingActivitiesSegmentAxis_96372A821FAAB008C74BDE996948FAFF" xlink:to="lab_us-gaap_StatementOperatingActivitiesSegmentAxis_96372A821FAAB008C74BDE996948FAFF" xlink:type="arc" />
    <link:label id="lab_us-gaap_SegmentOperatingActivitiesDomain_D222B235E27D8B2C40B4DE9A00540134_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentOperatingActivitiesDomain_D222B235E27D8B2C40B4DE9A00540134" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating Activities [Domain]</link:label>
    <link:label id="lab_us-gaap_SegmentOperatingActivitiesDomain_D222B235E27D8B2C40B4DE9A00540134_label_en-US" xlink:label="lab_us-gaap_SegmentOperatingActivitiesDomain_D222B235E27D8B2C40B4DE9A00540134" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Activities [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SegmentOperatingActivitiesDomain" xlink:label="loc_us-gaap_SegmentOperatingActivitiesDomain_D222B235E27D8B2C40B4DE9A00540134" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentOperatingActivitiesDomain_D222B235E27D8B2C40B4DE9A00540134" xlink:to="lab_us-gaap_SegmentOperatingActivitiesDomain_D222B235E27D8B2C40B4DE9A00540134" xlink:type="arc" />
    <link:label id="lab_us-gaap_SegmentContinuingOperationsMember_A671B6A51A35E4090E45DE9998C7A897_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentContinuingOperationsMember_A671B6A51A35E4090E45DE9998C7A897" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Continuing Operations [Member]</link:label>
    <link:label id="lab_us-gaap_SegmentContinuingOperationsMember_A671B6A51A35E4090E45DE9998C7A897_label_en-US" xlink:label="lab_us-gaap_SegmentContinuingOperationsMember_A671B6A51A35E4090E45DE9998C7A897" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Continuing Operations [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SegmentContinuingOperationsMember" xlink:label="loc_us-gaap_SegmentContinuingOperationsMember_A671B6A51A35E4090E45DE9998C7A897" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentContinuingOperationsMember_A671B6A51A35E4090E45DE9998C7A897" xlink:to="lab_us-gaap_SegmentContinuingOperationsMember_A671B6A51A35E4090E45DE9998C7A897" xlink:type="arc" />
    <link:label id="lab_us-gaap_SegmentDiscontinuedOperationsMember_704B607CEF48AEFE6A78DE99BAD3BDD8_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentDiscontinuedOperationsMember_704B607CEF48AEFE6A78DE99BAD3BDD8" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Discontinued Operations [Member]</link:label>
    <link:label id="lab_us-gaap_SegmentDiscontinuedOperationsMember_704B607CEF48AEFE6A78DE99BAD3BDD8_label_en-US" xlink:label="lab_us-gaap_SegmentDiscontinuedOperationsMember_704B607CEF48AEFE6A78DE99BAD3BDD8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Discontinued Operations [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SegmentDiscontinuedOperationsMember" xlink:label="loc_us-gaap_SegmentDiscontinuedOperationsMember_704B607CEF48AEFE6A78DE99BAD3BDD8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentDiscontinuedOperationsMember_704B607CEF48AEFE6A78DE99BAD3BDD8" xlink:to="lab_us-gaap_SegmentDiscontinuedOperationsMember_704B607CEF48AEFE6A78DE99BAD3BDD8" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_6631E6125C52C1F92F51DE2E960EB27E_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis_6631E6125C52C1F92F51DE2E960EB27E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs, by Report Line [Axis]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_6631E6125C52C1F92F51DE2E960EB27E_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis_6631E6125C52C1F92F51DE2E960EB27E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Statement Location [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_6631E6125C52C1F92F51DE2E960EB27E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_6631E6125C52C1F92F51DE2E960EB27E" xlink:to="lab_us-gaap_IncomeStatementLocationAxis_6631E6125C52C1F92F51DE2E960EB27E" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_82EAA293D0C9A62741DADE2E960EDB69_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain_82EAA293D0C9A62741DADE2E960EDB69" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Employee Service Share-based Compensation, Allocation of Recognized Period Costs, Report Line [Domain]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_82EAA293D0C9A62741DADE2E960EDB69_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain_82EAA293D0C9A62741DADE2E960EDB69" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Statement Location [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_82EAA293D0C9A62741DADE2E960EDB69" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_82EAA293D0C9A62741DADE2E960EDB69" xlink:to="lab_us-gaap_IncomeStatementLocationDomain_82EAA293D0C9A62741DADE2E960EDB69" xlink:type="arc" />
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_0FFBEA2204A216E06A6BDE2E960E9BEE_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember_0FFBEA2204A216E06A6BDE2E960E9BEE" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Research and Development [Member]</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_0FFBEA2204A216E06A6BDE2E960E9BEE_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember_0FFBEA2204A216E06A6BDE2E960E9BEE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research and Development Expense [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_0FFBEA2204A216E06A6BDE2E960E9BEE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpenseMember_0FFBEA2204A216E06A6BDE2E960E9BEE" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpenseMember_0FFBEA2204A216E06A6BDE2E960E9BEE" xlink:type="arc" />
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember_2CC4A3F44FBD501622CADE2E960E1F5F_terseLabel_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember_2CC4A3F44FBD501622CADE2E960E1F5F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Selling, General and Administrative [Member]</link:label>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember_2CC4A3F44FBD501622CADE2E960E1F5F_label_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember_2CC4A3F44FBD501622CADE2E960E1F5F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Selling, General and Administrative Expenses [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_2CC4A3F44FBD501622CADE2E960E1F5F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_2CC4A3F44FBD501622CADE2E960E1F5F" xlink:to="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember_2CC4A3F44FBD501622CADE2E960E1F5F" xlink:type="arc" />
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_3247C7FA00BABB8D2859DE2E960E7E93_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_3247C7FA00BABB8D2859DE2E960E7E93" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_3247C7FA00BABB8D2859DE2E960E7E93_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_3247C7FA00BABB8D2859DE2E960E7E93" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_3247C7FA00BABB8D2859DE2E960E7E93" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_3247C7FA00BABB8D2859DE2E960E7E93" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_3247C7FA00BABB8D2859DE2E960E7E93" xlink:type="arc" />
    <link:label id="lab_gale_WarrantsGrantedNumberofShares_F6DB130979048F1148DED437A7E9DB87_terseLabel_en-US" xlink:label="lab_gale_WarrantsGrantedNumberofShares_BDCCFC16B566583A870D337F57207073" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Warrants Granted, Number of Shares</link:label>
    <link:label id="lab_gale_WarrantsGrantedNumberofShares_F6DB130979048F1148DED437A7E9DB87_label_en-US" xlink:label="lab_gale_WarrantsGrantedNumberofShares_BDCCFC16B566583A870D337F57207073" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Warrants Granted, Number of Shares</link:label>
    <link:label id="lab_gale_WarrantsGrantedNumberofShares_F6DB130979048F1148DED437A7E9DB87_documentation_en-US" xlink:label="lab_gale_WarrantsGrantedNumberofShares_BDCCFC16B566583A870D337F57207073" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Warrants Granted, Number of Shares</link:label>
    <link:loc xlink:href="gale-20150930.xsd#gale_WarrantsGrantedNumberofShares" xlink:label="loc_gale_WarrantsGrantedNumberofShares_BDCCFC16B566583A870D337F57207073" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_WarrantsGrantedNumberofShares_BDCCFC16B566583A870D337F57207073" xlink:to="lab_gale_WarrantsGrantedNumberofShares_BDCCFC16B566583A870D337F57207073" xlink:type="arc" />
    <link:label id="lab_gale_NumberofDaysAveragedforExercisePrice_725047590530D94B4061D437A7E9C894_terseLabel_en-US" xlink:label="lab_gale_NumberofDaysAveragedforExercisePrice_D1523E5DAA86550EB48CCF886BC75938" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of Days Averaged for Exercise Price</link:label>
    <link:label id="lab_gale_NumberofDaysAveragedforExercisePrice_725047590530D94B4061D437A7E9C894_label_en-US" xlink:label="lab_gale_NumberofDaysAveragedforExercisePrice_D1523E5DAA86550EB48CCF886BC75938" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number of Days Averaged for Exercise Price</link:label>
    <link:label id="lab_gale_NumberofDaysAveragedforExercisePrice_725047590530D94B4061D437A7E9C894_documentation_en-US" xlink:label="lab_gale_NumberofDaysAveragedforExercisePrice_D1523E5DAA86550EB48CCF886BC75938" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Exercise price is based on the average closing price over this many trading days up to the date of the grant.</link:label>
    <link:loc xlink:href="gale-20150930.xsd#gale_NumberofDaysAveragedforExercisePrice" xlink:label="loc_gale_NumberofDaysAveragedforExercisePrice_D1523E5DAA86550EB48CCF886BC75938" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_NumberofDaysAveragedforExercisePrice_D1523E5DAA86550EB48CCF886BC75938" xlink:to="lab_gale_NumberofDaysAveragedforExercisePrice_D1523E5DAA86550EB48CCF886BC75938" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueAssumptionsExpectedVolatilityRate_134F67F090598FCEF02DD437A7E94204_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssumptionsExpectedVolatilityRate_99DCBEB5321058A4A1357CA5930F7903" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value Assumptions, Expected Volatility Rate</link:label>
    <link:label id="lab_us-gaap_FairValueAssumptionsExpectedVolatilityRate_134F67F090598FCEF02DD437A7E94204_label_en-US" xlink:label="lab_us-gaap_FairValueAssumptionsExpectedVolatilityRate_99DCBEB5321058A4A1357CA5930F7903" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Assumptions, Expected Volatility Rate</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueAssumptionsExpectedVolatilityRate" xlink:label="loc_us-gaap_FairValueAssumptionsExpectedVolatilityRate_99DCBEB5321058A4A1357CA5930F7903" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssumptionsExpectedVolatilityRate_99DCBEB5321058A4A1357CA5930F7903" xlink:to="lab_us-gaap_FairValueAssumptionsExpectedVolatilityRate_99DCBEB5321058A4A1357CA5930F7903" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueAssumptionsExpectedTerm_42B8DA61EF1157678E57D437A7E902DD_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssumptionsExpectedTerm_AE830C2FEDA156329D68C0EE91EA3CAB" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value Assumptions, Expected Term</link:label>
    <link:label id="lab_us-gaap_FairValueAssumptionsExpectedTerm_42B8DA61EF1157678E57D437A7E902DD_label_en-US" xlink:label="lab_us-gaap_FairValueAssumptionsExpectedTerm_AE830C2FEDA156329D68C0EE91EA3CAB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Assumptions, Expected Term</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueAssumptionsExpectedTerm" xlink:label="loc_us-gaap_FairValueAssumptionsExpectedTerm_AE830C2FEDA156329D68C0EE91EA3CAB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssumptionsExpectedTerm_AE830C2FEDA156329D68C0EE91EA3CAB" xlink:to="lab_us-gaap_FairValueAssumptionsExpectedTerm_AE830C2FEDA156329D68C0EE91EA3CAB" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueAssumptionsRiskFreeInterestRate_1631E9287B0D99238808D437A7E9A891_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssumptionsRiskFreeInterestRate_CF12D9A3C76C582E8207B2E5D23E591B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value Assumptions, Risk Free Interest Rate</link:label>
    <link:label id="lab_us-gaap_FairValueAssumptionsRiskFreeInterestRate_1631E9287B0D99238808D437A7E9A891_label_en-US" xlink:label="lab_us-gaap_FairValueAssumptionsRiskFreeInterestRate_CF12D9A3C76C582E8207B2E5D23E591B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Assumptions, Risk Free Interest Rate</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueAssumptionsRiskFreeInterestRate" xlink:label="loc_us-gaap_FairValueAssumptionsRiskFreeInterestRate_CF12D9A3C76C582E8207B2E5D23E591B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssumptionsRiskFreeInterestRate_CF12D9A3C76C582E8207B2E5D23E591B" xlink:to="lab_us-gaap_FairValueAssumptionsRiskFreeInterestRate_CF12D9A3C76C582E8207B2E5D23E591B" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueAssumptionsExpectedDividendRate_5BA27794F9C31EF2FDB6D437A7E930E1_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssumptionsExpectedDividendRate_047D1751A15757EF869FC08BE49E4A23" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value Assumptions, Expected Dividend Rate</link:label>
    <link:label id="lab_us-gaap_FairValueAssumptionsExpectedDividendRate_5BA27794F9C31EF2FDB6D437A7E930E1_label_en-US" xlink:label="lab_us-gaap_FairValueAssumptionsExpectedDividendRate_047D1751A15757EF869FC08BE49E4A23" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Assumptions, Expected Dividend Rate</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueAssumptionsExpectedDividendRate" xlink:label="loc_us-gaap_FairValueAssumptionsExpectedDividendRate_047D1751A15757EF869FC08BE49E4A23" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssumptionsExpectedDividendRate_047D1751A15757EF869FC08BE49E4A23" xlink:to="lab_us-gaap_FairValueAssumptionsExpectedDividendRate_047D1751A15757EF869FC08BE49E4A23" xlink:type="arc" />
    <link:label id="lab_gale_FairValueofWarrantsGrantedperShare_B4516424B2F6E7114559D437A7E96687_terseLabel_en-US" xlink:label="lab_gale_FairValueofWarrantsGrantedperShare_6C4F538BBA435D49A418AB43423C5F9C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value of Warrants Granted, per Share</link:label>
    <link:label id="lab_gale_FairValueofWarrantsGrantedperShare_B4516424B2F6E7114559D437A7E96687_label_en-US" xlink:label="lab_gale_FairValueofWarrantsGrantedperShare_6C4F538BBA435D49A418AB43423C5F9C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value of Warrants Granted, per Share</link:label>
    <link:label id="lab_gale_FairValueofWarrantsGrantedperShare_B4516424B2F6E7114559D437A7E96687_documentation_en-US" xlink:label="lab_gale_FairValueofWarrantsGrantedperShare_6C4F538BBA435D49A418AB43423C5F9C" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Fair Value of Warrants Granted, per Share</link:label>
    <link:loc xlink:href="gale-20150930.xsd#gale_FairValueofWarrantsGrantedperShare" xlink:label="loc_gale_FairValueofWarrantsGrantedperShare_6C4F538BBA435D49A418AB43423C5F9C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_FairValueofWarrantsGrantedperShare_6C4F538BBA435D49A418AB43423C5F9C" xlink:to="lab_gale_FairValueofWarrantsGrantedperShare_6C4F538BBA435D49A418AB43423C5F9C" xlink:type="arc" />
    <link:label id="lab_gale_WarrantStrikePrice_FBFA498BFCC6E0C8E8D4D437A829C272_terseLabel_en-US" xlink:label="lab_gale_WarrantStrikePrice_83F260DD775A54A4B83E6ED81B881D04" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Strike price</link:label>
    <link:label id="lab_gale_WarrantStrikePrice_FBFA498BFCC6E0C8E8D4D437A829C272_label_en-US" xlink:label="lab_gale_WarrantStrikePrice_83F260DD775A54A4B83E6ED81B881D04" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Warrant Strike Price</link:label>
    <link:label id="lab_gale_WarrantStrikePrice_FBFA498BFCC6E0C8E8D4D437A829C272_documentation_en-US" xlink:label="lab_gale_WarrantStrikePrice_83F260DD775A54A4B83E6ED81B881D04" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Warrant Strike Price</link:label>
    <link:loc xlink:href="gale-20150930.xsd#gale_WarrantStrikePrice" xlink:label="loc_gale_WarrantStrikePrice_83F260DD775A54A4B83E6ED81B881D04" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_WarrantStrikePrice_83F260DD775A54A4B83E6ED81B881D04" xlink:to="lab_gale_WarrantStrikePrice_83F260DD775A54A4B83E6ED81B881D04" xlink:type="arc" />
    <link:label id="lab_gale_FairValueOfWarrantLiabilityAssumptionsExpectedTerm_AFFD74EB3F8CB8F5C8ABD437A8291577_terseLabel_en-US" xlink:label="lab_gale_FairValueOfWarrantLiabilityAssumptionsExpectedTerm_D26D3166082D56DE82200C1725E60E6B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Expected term (years)</link:label>
    <link:label id="lab_gale_FairValueOfWarrantLiabilityAssumptionsExpectedTerm_AFFD74EB3F8CB8F5C8ABD437A8291577_label_en-US" xlink:label="lab_gale_FairValueOfWarrantLiabilityAssumptionsExpectedTerm_D26D3166082D56DE82200C1725E60E6B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Of Warrant Liability Assumptions Expected Term</link:label>
    <link:label id="lab_gale_FairValueOfWarrantLiabilityAssumptionsExpectedTerm_AFFD74EB3F8CB8F5C8ABD437A8291577_documentation_en-US" xlink:label="lab_gale_FairValueOfWarrantLiabilityAssumptionsExpectedTerm_D26D3166082D56DE82200C1725E60E6B" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Fair Value of Warrant Liability Assumptions Expected Term</link:label>
    <link:loc xlink:href="gale-20150930.xsd#gale_FairValueOfWarrantLiabilityAssumptionsExpectedTerm" xlink:label="loc_gale_FairValueOfWarrantLiabilityAssumptionsExpectedTerm_D26D3166082D56DE82200C1725E60E6B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_FairValueOfWarrantLiabilityAssumptionsExpectedTerm_D26D3166082D56DE82200C1725E60E6B" xlink:to="lab_gale_FairValueOfWarrantLiabilityAssumptionsExpectedTerm_D26D3166082D56DE82200C1725E60E6B" xlink:type="arc" />
    <link:label id="lab_gale_WarrantsFairValueAssumptionsExpectedVolatility_DCBFC30ABDD75F226672D437A8298759_terseLabel_en-US" xlink:label="lab_gale_WarrantsFairValueAssumptionsExpectedVolatility_9489EF344DF95F18BB68857A669FBA12" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Volatility %</link:label>
    <link:label id="lab_gale_WarrantsFairValueAssumptionsExpectedVolatility_DCBFC30ABDD75F226672D437A8298759_label_en-US" xlink:label="lab_gale_WarrantsFairValueAssumptionsExpectedVolatility_9489EF344DF95F18BB68857A669FBA12" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Warrants Fair Value Assumptions Expected Volatility</link:label>
    <link:label id="lab_gale_WarrantsFairValueAssumptionsExpectedVolatility_DCBFC30ABDD75F226672D437A8298759_documentation_en-US" xlink:label="lab_gale_WarrantsFairValueAssumptionsExpectedVolatility_9489EF344DF95F18BB68857A669FBA12" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Warrants Fair Value Assumptions Expected Volatility</link:label>
    <link:loc xlink:href="gale-20150930.xsd#gale_WarrantsFairValueAssumptionsExpectedVolatility" xlink:label="loc_gale_WarrantsFairValueAssumptionsExpectedVolatility_9489EF344DF95F18BB68857A669FBA12" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_WarrantsFairValueAssumptionsExpectedVolatility_9489EF344DF95F18BB68857A669FBA12" xlink:to="lab_gale_WarrantsFairValueAssumptionsExpectedVolatility_9489EF344DF95F18BB68857A669FBA12" xlink:type="arc" />
    <link:label id="lab_gale_WarrantsFairValueAssumptionsRiskFreeInterestRate_D1E53385B2E589E8563FD437A82EB7A5_terseLabel_en-US" xlink:label="lab_gale_WarrantsFairValueAssumptionsRiskFreeInterestRate_4C8670C04EDA5B99BDE0BB8FF00C738C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Risk-free rate %</link:label>
    <link:label id="lab_gale_WarrantsFairValueAssumptionsRiskFreeInterestRate_D1E53385B2E589E8563FD437A82EB7A5_label_en-US" xlink:label="lab_gale_WarrantsFairValueAssumptionsRiskFreeInterestRate_4C8670C04EDA5B99BDE0BB8FF00C738C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Warrants Fair Value Assumptions Risk Free Interest Rate</link:label>
    <link:label id="lab_gale_WarrantsFairValueAssumptionsRiskFreeInterestRate_D1E53385B2E589E8563FD437A82EB7A5_documentation_en-US" xlink:label="lab_gale_WarrantsFairValueAssumptionsRiskFreeInterestRate_4C8670C04EDA5B99BDE0BB8FF00C738C" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Warrants Fair Value Assumptions Risk Free Interest Rate</link:label>
    <link:loc xlink:href="gale-20150930.xsd#gale_WarrantsFairValueAssumptionsRiskFreeInterestRate" xlink:label="loc_gale_WarrantsFairValueAssumptionsRiskFreeInterestRate_4C8670C04EDA5B99BDE0BB8FF00C738C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_WarrantsFairValueAssumptionsRiskFreeInterestRate_4C8670C04EDA5B99BDE0BB8FF00C738C" xlink:to="lab_gale_WarrantsFairValueAssumptionsRiskFreeInterestRate_4C8670C04EDA5B99BDE0BB8FF00C738C" xlink:type="arc" />
    <link:label id="lab_gale_ContractResearchPayable_62877174DC00BFEE4684FE434294DED2_terseLabel_en-US" xlink:label="lab_gale_ContractResearchPayable_C92529FA2389510B93D9E6C2713ED965" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Clinical trial costs</link:label>
    <link:label id="lab_gale_ContractResearchPayable_62877174DC00BFEE4684FE434294DED2_label_en-US" xlink:label="lab_gale_ContractResearchPayable_C92529FA2389510B93D9E6C2713ED965" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Contract Research Payable</link:label>
    <link:label id="lab_gale_ContractResearchPayable_62877174DC00BFEE4684FE434294DED2_documentation_en-US" xlink:label="lab_gale_ContractResearchPayable_C92529FA2389510B93D9E6C2713ED965" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Contract Research Payable</link:label>
    <link:loc xlink:href="gale-20150930.xsd#gale_ContractResearchPayable" xlink:label="loc_gale_ContractResearchPayable_C92529FA2389510B93D9E6C2713ED965" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_ContractResearchPayable_C92529FA2389510B93D9E6C2713ED965" xlink:to="lab_gale_ContractResearchPayable_C92529FA2389510B93D9E6C2713ED965" xlink:type="arc" />
    <link:label id="lab_gale_CreditMemosAcquisitionChannelInventoryCurrent_FBBEFCCD4689C5D390AAFE434295DD2A_terseLabel_en-US" xlink:label="lab_gale_CreditMemosAcquisitionChannelInventoryCurrent_9711CFEC30285B319B591C13112C32FE" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Credit memos for expiring Zuplenz channel inventory</link:label>
    <link:label id="lab_gale_CreditMemosAcquisitionChannelInventoryCurrent_FBBEFCCD4689C5D390AAFE434295DD2A_label_en-US" xlink:label="lab_gale_CreditMemosAcquisitionChannelInventoryCurrent_9711CFEC30285B319B591C13112C32FE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Credit Memos Acquisition Channel Inventory, Current</link:label>
    <link:label id="lab_gale_CreditMemosAcquisitionChannelInventoryCurrent_FBBEFCCD4689C5D390AAFE434295DD2A_documentation_en-US" xlink:label="lab_gale_CreditMemosAcquisitionChannelInventoryCurrent_9711CFEC30285B319B591C13112C32FE" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Credit Memos Acquisition Channel Inventory, Current</link:label>
    <link:loc xlink:href="gale-20150930.xsd#gale_CreditMemosAcquisitionChannelInventoryCurrent" xlink:label="loc_gale_CreditMemosAcquisitionChannelInventoryCurrent_9711CFEC30285B319B591C13112C32FE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_CreditMemosAcquisitionChannelInventoryCurrent_9711CFEC30285B319B591C13112C32FE" xlink:to="lab_gale_CreditMemosAcquisitionChannelInventoryCurrent_9711CFEC30285B319B591C13112C32FE" xlink:type="arc" />
    <link:label id="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent_C3639E272396BAB26AC6FE4342951107_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent_AFC5342BB342577C9D28D9E318BC0DA3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Compensation and related benefits</link:label>
    <link:label id="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent_C3639E272396BAB26AC6FE4342951107_label_en-US" xlink:label="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent_AFC5342BB342577C9D28D9E318BC0DA3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Employee-related Liabilities, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_AFC5342BB342577C9D28D9E318BC0DA3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_AFC5342BB342577C9D28D9E318BC0DA3" xlink:to="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent_AFC5342BB342577C9D28D9E318BC0DA3" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccruedProfessionalFeesCurrent_10AFE3D57EBF9AEA7E0BFE434295E278_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedProfessionalFeesCurrent_A0FFFFA774FE53B486B3B22239FF658C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Professional fees</link:label>
    <link:label id="lab_us-gaap_AccruedProfessionalFeesCurrent_10AFE3D57EBF9AEA7E0BFE434295E278_label_en-US" xlink:label="lab_us-gaap_AccruedProfessionalFeesCurrent_A0FFFFA774FE53B486B3B22239FF658C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accrued Professional Fees, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:label="loc_us-gaap_AccruedProfessionalFeesCurrent_A0FFFFA774FE53B486B3B22239FF658C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedProfessionalFeesCurrent_A0FFFFA774FE53B486B3B22239FF658C" xlink:to="lab_us-gaap_AccruedProfessionalFeesCurrent_A0FFFFA774FE53B486B3B22239FF658C" xlink:type="arc" />
    <link:label id="lab_gale_PatientAssistanceProgramCurrent_E5D5B0E7682A14492FA0FE4342958BBF_terseLabel_en-US" xlink:label="lab_gale_PatientAssistanceProgramCurrent_16395329048C5972853C8B81384D2A6B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Patient assistance programs and rebates</link:label>
    <link:label id="lab_gale_PatientAssistanceProgramCurrent_E5D5B0E7682A14492FA0FE4342958BBF_label_en-US" xlink:label="lab_gale_PatientAssistanceProgramCurrent_16395329048C5972853C8B81384D2A6B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Patient Assistance Program, Current</link:label>
    <link:label id="lab_gale_PatientAssistanceProgramCurrent_E5D5B0E7682A14492FA0FE4342958BBF_documentation_en-US" xlink:label="lab_gale_PatientAssistanceProgramCurrent_16395329048C5972853C8B81384D2A6B" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Patient Assistance Program, Current</link:label>
    <link:loc xlink:href="gale-20150930.xsd#gale_PatientAssistanceProgramCurrent" xlink:label="loc_gale_PatientAssistanceProgramCurrent_16395329048C5972853C8B81384D2A6B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_PatientAssistanceProgramCurrent_16395329048C5972853C8B81384D2A6B" xlink:to="lab_gale_PatientAssistanceProgramCurrent_16395329048C5972853C8B81384D2A6B" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccruedRoyaltiesCurrent_380DA7AD4E89A5A42128FE4342952E34_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedRoyaltiesCurrent_641A5DF37E3054D2A136AD690B3F461F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Royalties</link:label>
    <link:label id="lab_us-gaap_AccruedRoyaltiesCurrent_380DA7AD4E89A5A42128FE4342952E34_label_en-US" xlink:label="lab_us-gaap_AccruedRoyaltiesCurrent_641A5DF37E3054D2A136AD690B3F461F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accrued Royalties, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AccruedRoyaltiesCurrent" xlink:label="loc_us-gaap_AccruedRoyaltiesCurrent_641A5DF37E3054D2A136AD690B3F461F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedRoyaltiesCurrent_641A5DF37E3054D2A136AD690B3F461F" xlink:to="lab_us-gaap_AccruedRoyaltiesCurrent_641A5DF37E3054D2A136AD690B3F461F" xlink:type="arc" />
    <link:label id="lab_gale_AccruedInventoryPurchasesCurrent_7C6FD3F809FC0AF6A5EDFE56F7AC5B07_terseLabel_en-US" xlink:label="lab_gale_AccruedInventoryPurchasesCurrent_8A884B824F1B59F6909DEF3F3901A374" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Inventory purchases</link:label>
    <link:label id="lab_gale_AccruedInventoryPurchasesCurrent_7C6FD3F809FC0AF6A5EDFE56F7AC5B07_label_en-US" xlink:label="lab_gale_AccruedInventoryPurchasesCurrent_8A884B824F1B59F6909DEF3F3901A374" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accrued Inventory Purchases, Current</link:label>
    <link:label id="lab_gale_AccruedInventoryPurchasesCurrent_7C6FD3F809FC0AF6A5EDFE56F7AC5B07_documentation_en-US" xlink:label="lab_gale_AccruedInventoryPurchasesCurrent_8A884B824F1B59F6909DEF3F3901A374" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Accrued Inventory Purchases, Current</link:label>
    <link:loc xlink:href="gale-20150930.xsd#gale_AccruedInventoryPurchasesCurrent" xlink:label="loc_gale_AccruedInventoryPurchasesCurrent_8A884B824F1B59F6909DEF3F3901A374" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_AccruedInventoryPurchasesCurrent_8A884B824F1B59F6909DEF3F3901A374" xlink:to="lab_gale_AccruedInventoryPurchasesCurrent_8A884B824F1B59F6909DEF3F3901A374" xlink:type="arc" />
    <link:label id="lab_gale_FutureMilestonePayment_EEAB95E87828F9E90B76FE4342955DF8_verboseLabel_en-US" xlink:label="lab_gale_FutureMilestonePayment_A1E859A7C4445938BB8F76D1D8E54E9E" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Zuplenz milestone payments</link:label>
    <link:loc xlink:href="gale-20150930.xsd#gale_FutureMilestonePayment" xlink:label="loc_gale_FutureMilestonePayment_A1E859A7C4445938BB8F76D1D8E54E9E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_FutureMilestonePayment_A1E859A7C4445938BB8F76D1D8E54E9E" xlink:to="lab_gale_FutureMilestonePayment_A1E859A7C4445938BB8F76D1D8E54E9E" xlink:type="arc" />
    <link:label id="lab_us-gaap_InterestPayableCurrent_C1EC3A7337A75E6D57E5FE434295002C_terseLabel_en-US" xlink:label="lab_us-gaap_InterestPayableCurrent_7DCCCAD638A25E97AB3F62260A22E05A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Interest expense</link:label>
    <link:label id="lab_us-gaap_InterestPayableCurrent_C1EC3A7337A75E6D57E5FE434295002C_label_en-US" xlink:label="lab_us-gaap_InterestPayableCurrent_7DCCCAD638A25E97AB3F62260A22E05A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Interest Payable, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_InterestPayableCurrent" xlink:label="loc_us-gaap_InterestPayableCurrent_7DCCCAD638A25E97AB3F62260A22E05A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestPayableCurrent_7DCCCAD638A25E97AB3F62260A22E05A" xlink:to="lab_us-gaap_InterestPayableCurrent_7DCCCAD638A25E97AB3F62260A22E05A" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_B50BF38B2DBAD70D429EFE4342957EC3_totalLabel_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent_C74288A03AE45D9FB37CE83437D77A40" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Accrued expenses and other current liabilities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_C74288A03AE45D9FB37CE83437D77A40" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_C74288A03AE45D9FB37CE83437D77A40" xlink:to="lab_us-gaap_AccruedLiabilitiesCurrent_C74288A03AE45D9FB37CE83437D77A40" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock_EBA2A7344EABA801D8CADDA4F7BD311F_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock_EBA2A7344EABA801D8CADDA4F7BD311F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Purchase Price Consideration</link:label>
    <link:label id="lab_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock_EBA2A7344EABA801D8CADDA4F7BD311F_label_en-US" xlink:label="lab_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock_EBA2A7344EABA801D8CADDA4F7BD311F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Recognized Identified Assets Acquired and Liabilities Assumed [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock_EBA2A7344EABA801D8CADDA4F7BD311F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock_EBA2A7344EABA801D8CADDA4F7BD311F" xlink:to="lab_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock_EBA2A7344EABA801D8CADDA4F7BD311F" xlink:type="arc" />
    <link:label id="lab_us-gaap_LossContingenciesTable_C6F07DECA4C67BB1B216FE181A15FE33_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingenciesTable_3AED1A50BF2557D2907B534997404A12" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Loss Contingencies [Table]</link:label>
    <link:label id="lab_us-gaap_LossContingenciesTable_C6F07DECA4C67BB1B216FE181A15FE33_label_en-US" xlink:label="lab_us-gaap_LossContingenciesTable_3AED1A50BF2557D2907B534997404A12" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Loss Contingencies [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LossContingenciesTable" xlink:label="loc_us-gaap_LossContingenciesTable_3AED1A50BF2557D2907B534997404A12" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingenciesTable_3AED1A50BF2557D2907B534997404A12" xlink:to="lab_us-gaap_LossContingenciesTable_3AED1A50BF2557D2907B534997404A12" xlink:type="arc" />
    <link:label id="lab_us-gaap_LossContingenciesLineItems_DF915E0B58705FA19550FE181A16EEA3_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingenciesLineItems_6881254A72F6558D85367A58CBCC3CBC" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Loss Contingencies [Line Items]</link:label>
    <link:label id="lab_us-gaap_LossContingenciesLineItems_DF915E0B58705FA19550FE181A16EEA3_label_en-US" xlink:label="lab_us-gaap_LossContingenciesLineItems_6881254A72F6558D85367A58CBCC3CBC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Loss Contingencies [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LossContingenciesLineItems" xlink:label="loc_us-gaap_LossContingenciesLineItems_6881254A72F6558D85367A58CBCC3CBC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingenciesLineItems_6881254A72F6558D85367A58CBCC3CBC" xlink:to="lab_us-gaap_LossContingenciesLineItems_6881254A72F6558D85367A58CBCC3CBC" xlink:type="arc" />
    <link:label id="lab_gale_LossContingencyPercentageofLegalFeesPaid_F00BF5D58304DFD240FBFE1ACD23940C_terseLabel_en-US" xlink:label="lab_gale_LossContingencyPercentageofLegalFeesPaid_C6DFE5D985B95F488F2C408C10139CB4" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Percentage of legal fees obligated to pay</link:label>
    <link:label id="lab_gale_LossContingencyPercentageofLegalFeesPaid_F00BF5D58304DFD240FBFE1ACD23940C_label_en-US" xlink:label="lab_gale_LossContingencyPercentageofLegalFeesPaid_C6DFE5D985B95F488F2C408C10139CB4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Loss Contingency, Percentage of Legal Fees Paid</link:label>
    <link:label id="lab_gale_LossContingencyPercentageofLegalFeesPaid_F00BF5D58304DFD240FBFE1ACD23940C_documentation_en-US" xlink:label="lab_gale_LossContingencyPercentageofLegalFeesPaid_C6DFE5D985B95F488F2C408C10139CB4" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Loss Contingency, Percentage of Legal Fees Paid</link:label>
    <link:loc xlink:href="gale-20150930.xsd#gale_LossContingencyPercentageofLegalFeesPaid" xlink:label="loc_gale_LossContingencyPercentageofLegalFeesPaid_C6DFE5D985B95F488F2C408C10139CB4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_LossContingencyPercentageofLegalFeesPaid_C6DFE5D985B95F488F2C408C10139CB4" xlink:to="lab_gale_LossContingencyPercentageofLegalFeesPaid_C6DFE5D985B95F488F2C408C10139CB4" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesOther_E94B3EFD1B990E792272FE181A164182_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesOther_A02A18BAD98151CF9CB2D475FFD8C6F9" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Issuance of common stock for milestone payment, other</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesOther" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesOther_A02A18BAD98151CF9CB2D475FFD8C6F9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesOther_A02A18BAD98151CF9CB2D475FFD8C6F9" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesOther_A02A18BAD98151CF9CB2D475FFD8C6F9" xlink:type="arc" />
    <link:label id="lab_us-gaap_PreferredStockSharesIssued_B08F220960165EED5E0CD437A80E3D24_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesIssued_217151036E1450E5AD491C8F4C1D4974" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Preferred stock, shares issued</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesIssued_B08F220960165EED5E0CD437A80E3D24_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesIssued_217151036E1450E5AD491C8F4C1D4974" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred Stock, Shares Issued</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="loc_us-gaap_PreferredStockSharesIssued_217151036E1450E5AD491C8F4C1D4974" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesIssued_217151036E1450E5AD491C8F4C1D4974" xlink:to="lab_us-gaap_PreferredStockSharesIssued_217151036E1450E5AD491C8F4C1D4974" xlink:type="arc" />
    <link:label id="lab_us-gaap_PreferredStockSharesOutstanding_783BCA75A335436C5B1BD437A80F37CA_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesOutstanding_15EB80215B105F48B72F8201A6DD11CD" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Preferred stock, shares outstanding</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesOutstanding_783BCA75A335436C5B1BD437A80F37CA_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesOutstanding_15EB80215B105F48B72F8201A6DD11CD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred Stock, Shares Outstanding</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding_15EB80215B105F48B72F8201A6DD11CD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesOutstanding_15EB80215B105F48B72F8201A6DD11CD" xlink:to="lab_us-gaap_PreferredStockSharesOutstanding_15EB80215B105F48B72F8201A6DD11CD" xlink:type="arc" />
    <link:label id="lab_us-gaap_CommonStockSharesIssued_580032C848AD83EA93B7D437A80F2380_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued_A2E5EBC8B5CA5D4999B1D8F9269550D8" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock, shares issued</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_580032C848AD83EA93B7D437A80F2380_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued_A2E5EBC8B5CA5D4999B1D8F9269550D8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Shares, Issued</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaap_CommonStockSharesIssued_A2E5EBC8B5CA5D4999B1D8F9269550D8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesIssued_A2E5EBC8B5CA5D4999B1D8F9269550D8" xlink:to="lab_us-gaap_CommonStockSharesIssued_A2E5EBC8B5CA5D4999B1D8F9269550D8" xlink:type="arc" />
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_279343300353C4A61A71D437A80F09A9_verboseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding_BEA88C7670435DC1A1E9B4A9FA4BC95E" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Common stock, shares outstanding</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_279343300353C4A61A71D437A80F09A9_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding_BEA88C7670435DC1A1E9B4A9FA4BC95E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Shares, Outstanding</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_BEA88C7670435DC1A1E9B4A9FA4BC95E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesOutstanding_BEA88C7670435DC1A1E9B4A9FA4BC95E" xlink:to="lab_us-gaap_CommonStockSharesOutstanding_BEA88C7670435DC1A1E9B4A9FA4BC95E" xlink:type="arc" />
    <link:label id="lab_us-gaap_TreasuryStockShares_6335DDA8410976B89C7AD437A80F0980_terseLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockShares_5450E33B182C5A508CD61581838D29DD" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Treasury stock, shares</link:label>
    <link:label id="lab_us-gaap_TreasuryStockShares_6335DDA8410976B89C7AD437A80F0980_label_en-US" xlink:label="lab_us-gaap_TreasuryStockShares_5450E33B182C5A508CD61581838D29DD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Treasury Stock, Shares</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_TreasuryStockShares" xlink:label="loc_us-gaap_TreasuryStockShares_5450E33B182C5A508CD61581838D29DD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockShares_5450E33B182C5A508CD61581838D29DD" xlink:to="lab_us-gaap_TreasuryStockShares_5450E33B182C5A508CD61581838D29DD" xlink:type="arc" />
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_6B727E90505BA66A3072D437A7AB98D6_terseLabel_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_4292DCDA5727557FBC910DEE5F96735F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock Based Compensation</link:label>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_6B727E90505BA66A3072D437A7AB98D6_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_4292DCDA5727557FBC910DEE5F96735F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of Compensation Related Costs, Share-based Payments [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_4292DCDA5727557FBC910DEE5F96735F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_4292DCDA5727557FBC910DEE5F96735F" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_4292DCDA5727557FBC910DEE5F96735F" xlink:type="arc" />
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock_3F6734EDF6D3993EAE67D437A8AB46E5_terseLabel_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock_CF8C245BA3D45C1BB6C2285E3D6DEF42" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Business and Basis of Presentation</link:label>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock_3F6734EDF6D3993EAE67D437A8AB46E5_label_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock_CF8C245BA3D45C1BB6C2285E3D6DEF42" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements Disclosure and Significant Accounting Policies [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock_CF8C245BA3D45C1BB6C2285E3D6DEF42" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock_CF8C245BA3D45C1BB6C2285E3D6DEF42" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock_CF8C245BA3D45C1BB6C2285E3D6DEF42" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeStatementAbstract_4F7484249900195CCF72DECFB16D4B26_label_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract_4F7484249900195CCF72DECFB16D4B26" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:label="loc_us-gaap_IncomeStatementAbstract_4F7484249900195CCF72DECFB16D4B26" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementAbstract_4F7484249900195CCF72DECFB16D4B26" xlink:to="lab_us-gaap_IncomeStatementAbstract_4F7484249900195CCF72DECFB16D4B26" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_5F6B819DA0807A49A31EDECFB16D4E80_totalLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_5F6B819DA0807A49A31EDECFB16D4E80" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Income (Loss) from Continuing Operations, Including Portion Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_5F6B819DA0807A49A31EDECFB16D4E80" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_5F6B819DA0807A49A31EDECFB16D4E80" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_5F6B819DA0807A49A31EDECFB16D4E80" xlink:type="arc" />
    <link:label id="lab_us-gaap_SalesRevenueNet_4ED930C40F728C1F0329DECFB16D8D0B_terseLabel_en-US" xlink:label="lab_us-gaap_SalesRevenueNet_4ED930C40F728C1F0329DECFB16D8D0B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net revenue</link:label>
    <link:label id="lab_us-gaap_SalesRevenueNet_4ED930C40F728C1F0329DECFB16D8D0B_label_en-US" xlink:label="lab_us-gaap_SalesRevenueNet_4ED930C40F728C1F0329DECFB16D8D0B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue, Net</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SalesRevenueNet" xlink:label="loc_us-gaap_SalesRevenueNet_4ED930C40F728C1F0329DECFB16D8D0B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SalesRevenueNet_4ED930C40F728C1F0329DECFB16D8D0B" xlink:to="lab_us-gaap_SalesRevenueNet_4ED930C40F728C1F0329DECFB16D8D0B" xlink:type="arc" />
    <link:label id="lab_us-gaap_OperatingExpensesAbstract_0C5D62A368BDA98DD540DECFB16DEC5D_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingExpensesAbstract_0C5D62A368BDA98DD540DECFB16DEC5D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Costs and expenses:</link:label>
    <link:label id="lab_us-gaap_OperatingExpensesAbstract_0C5D62A368BDA98DD540DECFB16DEC5D_label_en-US" xlink:label="lab_us-gaap_OperatingExpensesAbstract_0C5D62A368BDA98DD540DECFB16DEC5D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Expenses [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="loc_us-gaap_OperatingExpensesAbstract_0C5D62A368BDA98DD540DECFB16DEC5D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpensesAbstract_0C5D62A368BDA98DD540DECFB16DEC5D" xlink:to="lab_us-gaap_OperatingExpensesAbstract_0C5D62A368BDA98DD540DECFB16DEC5D" xlink:type="arc" />
    <link:label id="lab_us-gaap_CostOfRevenue_E6E287D026F776B4EA61DECFB16D85AD_terseLabel_en-US" xlink:label="lab_us-gaap_CostOfRevenue_E6E287D026F776B4EA61DECFB16D85AD" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cost of revenue (excluding amortization of certain acquired intangible assets)</link:label>
    <link:label id="lab_us-gaap_CostOfRevenue_E6E287D026F776B4EA61DECFB16D85AD_label_en-US" xlink:label="lab_us-gaap_CostOfRevenue_E6E287D026F776B4EA61DECFB16D85AD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cost of Revenue</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CostOfRevenue" xlink:label="loc_us-gaap_CostOfRevenue_E6E287D026F776B4EA61DECFB16D85AD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostOfRevenue_E6E287D026F776B4EA61DECFB16D85AD" xlink:to="lab_us-gaap_CostOfRevenue_E6E287D026F776B4EA61DECFB16D85AD" xlink:type="arc" />
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_90A4CFF321AD1BDC04F7DECFB16DE2A1_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense_90A4CFF321AD1BDC04F7DECFB16DE2A1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Research and development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_90A4CFF321AD1BDC04F7DECFB16DE2A1_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense_90A4CFF321AD1BDC04F7DECFB16DE2A1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research and Development Expense</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_90A4CFF321AD1BDC04F7DECFB16DE2A1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpense_90A4CFF321AD1BDC04F7DECFB16DE2A1" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpense_90A4CFF321AD1BDC04F7DECFB16DE2A1" xlink:type="arc" />
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpense_33CFA4273F606FBCB59ADECFB16D4A4E_terseLabel_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpense_33CFA4273F606FBCB59ADECFB16D4A4E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">General and administrative</link:label>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpense_33CFA4273F606FBCB59ADECFB16D4A4E_label_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpense_33CFA4273F606FBCB59ADECFB16D4A4E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Selling, General and Administrative Expense</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_33CFA4273F606FBCB59ADECFB16D4A4E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SellingGeneralAndAdministrativeExpense_33CFA4273F606FBCB59ADECFB16D4A4E" xlink:to="lab_us-gaap_SellingGeneralAndAdministrativeExpense_33CFA4273F606FBCB59ADECFB16D4A4E" xlink:type="arc" />
    <link:label id="lab_us-gaap_CostsAndExpenses_CCC2FD56C120084EEED8DECFB16D4596_totalLabel_en-US" xlink:label="lab_us-gaap_CostsAndExpenses_CCC2FD56C120084EEED8DECFB16D4596" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total operating expenses</link:label>
    <link:label id="lab_us-gaap_CostsAndExpenses_CCC2FD56C120084EEED8DECFB16D4596_label_en-US" xlink:label="lab_us-gaap_CostsAndExpenses_CCC2FD56C120084EEED8DECFB16D4596" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Costs and Expenses</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CostsAndExpenses" xlink:label="loc_us-gaap_CostsAndExpenses_CCC2FD56C120084EEED8DECFB16D4596" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostsAndExpenses_CCC2FD56C120084EEED8DECFB16D4596" xlink:to="lab_us-gaap_CostsAndExpenses_CCC2FD56C120084EEED8DECFB16D4596" xlink:type="arc" />
    <link:label id="lab_us-gaap_OperatingIncomeLoss_92FAFF7EC1A4AEDA9CE6DECFB16DC8FD_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss_92FAFF7EC1A4AEDA9CE6DECFB16DC8FD" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Operating loss</link:label>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_92FAFF7EC1A4AEDA9CE6DECFB16DC8FD_label_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss_92FAFF7EC1A4AEDA9CE6DECFB16DC8FD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Income (Loss)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaap_OperatingIncomeLoss_92FAFF7EC1A4AEDA9CE6DECFB16DC8FD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingIncomeLoss_92FAFF7EC1A4AEDA9CE6DECFB16DC8FD" xlink:to="lab_us-gaap_OperatingIncomeLoss_92FAFF7EC1A4AEDA9CE6DECFB16DC8FD" xlink:type="arc" />
    <link:label id="lab_us-gaap_NonoperatingIncomeExpenseAbstract_43B2E5B9B94B4A6BC189DECFB16D593B_terseLabel_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpenseAbstract_43B2E5B9B94B4A6BC189DECFB16D593B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other income (expense):</link:label>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpenseAbstract_43B2E5B9B94B4A6BC189DECFB16D593B_label_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpenseAbstract_43B2E5B9B94B4A6BC189DECFB16D593B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Nonoperating Income (Expense) [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NonoperatingIncomeExpenseAbstract" xlink:label="loc_us-gaap_NonoperatingIncomeExpenseAbstract_43B2E5B9B94B4A6BC189DECFB16D593B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_43B2E5B9B94B4A6BC189DECFB16D593B" xlink:to="lab_us-gaap_NonoperatingIncomeExpenseAbstract_43B2E5B9B94B4A6BC189DECFB16D593B" xlink:type="arc" />
    <link:label id="lab_gale_LossOnWarrantExchange_55DBDDDB23B1FBB49CFADECFB16D0AF5_negatedTerseLabel_en-US" xlink:label="lab_gale_LossOnWarrantExchange_55DBDDDB23B1FBB49CFADECFB16D0AF5" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Change in fair value of warrants potentially settleable in cash</link:label>
    <link:label id="lab_gale_LossOnWarrantExchange_55DBDDDB23B1FBB49CFADECFB16D0AF5_label_en-US" xlink:label="lab_gale_LossOnWarrantExchange_55DBDDDB23B1FBB49CFADECFB16D0AF5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Loss on Warrant Exchange</link:label>
    <link:label id="lab_gale_LossOnWarrantExchange_55DBDDDB23B1FBB49CFADECFB16D0AF5_documentation_en-US" xlink:label="lab_gale_LossOnWarrantExchange_55DBDDDB23B1FBB49CFADECFB16D0AF5" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Loss on warrant exchange.</link:label>
    <link:loc xlink:href="gale-20150930.xsd#gale_LossOnWarrantExchange" xlink:label="loc_gale_LossOnWarrantExchange_55DBDDDB23B1FBB49CFADECFB16D0AF5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_LossOnWarrantExchange_55DBDDDB23B1FBB49CFADECFB16D0AF5" xlink:to="lab_gale_LossOnWarrantExchange_55DBDDDB23B1FBB49CFADECFB16D0AF5" xlink:type="arc" />
    <link:label id="lab_us-gaap_InterestIncomeExpenseNet_B1306893D66AE66020C4DECFB16E5212_terseLabel_en-US" xlink:label="lab_us-gaap_InterestIncomeExpenseNet_B1306893D66AE66020C4DECFB16E5212" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Interest income (expense), net</link:label>
    <link:label id="lab_us-gaap_InterestIncomeExpenseNet_B1306893D66AE66020C4DECFB16E5212_label_en-US" xlink:label="lab_us-gaap_InterestIncomeExpenseNet_B1306893D66AE66020C4DECFB16E5212" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Interest Income (Expense), Net</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_InterestIncomeExpenseNet" xlink:label="loc_us-gaap_InterestIncomeExpenseNet_B1306893D66AE66020C4DECFB16E5212" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestIncomeExpenseNet_B1306893D66AE66020C4DECFB16E5212" xlink:to="lab_us-gaap_InterestIncomeExpenseNet_B1306893D66AE66020C4DECFB16E5212" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherOperatingIncomeExpenseNet_C7C20D11B58D33269798DECFB16EA466_totalLabel_en-US" xlink:label="lab_us-gaap_OtherOperatingIncomeExpenseNet_C7C20D11B58D33269798DECFB16EA466" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total non-operating income (expense), net</link:label>
    <link:label id="lab_us-gaap_OtherOperatingIncomeExpenseNet_C7C20D11B58D33269798DECFB16EA466_label_en-US" xlink:label="lab_us-gaap_OtherOperatingIncomeExpenseNet_C7C20D11B58D33269798DECFB16EA466" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Operating Income (Expense), Net</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OtherOperatingIncomeExpenseNet" xlink:label="loc_us-gaap_OtherOperatingIncomeExpenseNet_C7C20D11B58D33269798DECFB16EA466" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherOperatingIncomeExpenseNet_C7C20D11B58D33269798DECFB16EA466" xlink:to="lab_us-gaap_OtherOperatingIncomeExpenseNet_C7C20D11B58D33269798DECFB16EA466" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax_AC17C1159252F48B9D12DECFB16E20AF_verboseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax_AC17C1159252F48B9D12DECFB16E20AF" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Loss from discontinued operations, including $8,071 impairment charge from classification as held for sale for three and nine months ended September 30, 2015</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax_AC17C1159252F48B9D12DECFB16E20AF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax_AC17C1159252F48B9D12DECFB16E20AF" xlink:to="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax_AC17C1159252F48B9D12DECFB16E20AF" xlink:type="arc" />
    <link:label id="lab_us-gaap_NetIncomeLoss_60E83E4092E1FF8F56B0DECFB16EDFA9_totalLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss_60E83E4092E1FF8F56B0DECFB16EDFA9" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net loss</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_60E83E4092E1FF8F56B0DECFB16EDFA9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLoss_60E83E4092E1FF8F56B0DECFB16EDFA9" xlink:to="lab_us-gaap_NetIncomeLoss_60E83E4092E1FF8F56B0DECFB16EDFA9" xlink:type="arc" />
    <link:label id="lab_us-gaap_EarningsPerShareBasicAndDilutedAbstract_C6B39BDDD850502AAB65DECFB16EFACD_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasicAndDilutedAbstract_C6B39BDDD850502AAB65DECFB16EFACD" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net loss per common share:</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasicAndDilutedAbstract_C6B39BDDD850502AAB65DECFB16EFACD_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasicAndDilutedAbstract_C6B39BDDD850502AAB65DECFB16EFACD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings Per Share, Basic and Diluted [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EarningsPerShareBasicAndDilutedAbstract" xlink:label="loc_us-gaap_EarningsPerShareBasicAndDilutedAbstract_C6B39BDDD850502AAB65DECFB16EFACD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasicAndDilutedAbstract_C6B39BDDD850502AAB65DECFB16EFACD" xlink:to="lab_us-gaap_EarningsPerShareBasicAndDilutedAbstract_C6B39BDDD850502AAB65DECFB16EFACD" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsPerBasicAndDilutedShare_D7B05E990B402D59796EDECFB16EDD33_verboseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsPerBasicAndDilutedShare_D7B05E990B402D59796EDECFB16EDD33" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Basic and diluted net loss per share, continuing operations (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsPerBasicAndDilutedShare_D7B05E990B402D59796EDECFB16EDD33_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsPerBasicAndDilutedShare_D7B05E990B402D59796EDECFB16EDD33" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income (Loss) from Continuing Operations, Per Basic and Diluted Share</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsPerBasicAndDilutedShare" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsPerBasicAndDilutedShare_D7B05E990B402D59796EDECFB16EDD33" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsPerBasicAndDilutedShare_D7B05E990B402D59796EDECFB16EDD33" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsPerBasicAndDilutedShare_D7B05E990B402D59796EDECFB16EDD33" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicAndDilutedShare_053F272E208D0D2BA240DECFB16E5E9B_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicAndDilutedShare_053F272E208D0D2BA240DECFB16E5E9B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Basic and diluted net loss per share, discontinued operations (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicAndDilutedShare_053F272E208D0D2BA240DECFB16E5E9B_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicAndDilutedShare_053F272E208D0D2BA240DECFB16E5E9B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income (Loss) from Discontinued Operations and Disposal of Discontinued Operations, Net of Tax, Per Basic and Diluted Share</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicAndDilutedShare" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicAndDilutedShare_053F272E208D0D2BA240DECFB16E5E9B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicAndDilutedShare_053F272E208D0D2BA240DECFB16E5E9B" xlink:to="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicAndDilutedShare_053F272E208D0D2BA240DECFB16E5E9B" xlink:type="arc" />
    <link:label id="lab_us-gaap_EarningsPerShareBasic_8D3F6C54DD32ADDCB205DECFB16E7854_totalLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic_8D3F6C54DD32ADDCB205DECFB16E7854" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Basic net loss per share (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_8D3F6C54DD32ADDCB205DECFB16E7854_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic_8D3F6C54DD32ADDCB205DECFB16E7854" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings Per Share, Basic</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EarningsPerShareBasic" xlink:label="loc_us-gaap_EarningsPerShareBasic_8D3F6C54DD32ADDCB205DECFB16E7854" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasic_8D3F6C54DD32ADDCB205DECFB16E7854" xlink:to="lab_us-gaap_EarningsPerShareBasic_8D3F6C54DD32ADDCB205DECFB16E7854" xlink:type="arc" />
    <link:label id="lab_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_C85DC6396288CA68593EDECFB16EAC0F_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_C85DC6396288CA68593EDECFB16EAC0F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted-average common shares outstanding: basic and diluted</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_C85DC6396288CA68593EDECFB16EAC0F_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_C85DC6396288CA68593EDECFB16EAC0F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic and Diluted</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:label="loc_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_C85DC6396288CA68593EDECFB16EAC0F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_C85DC6396288CA68593EDECFB16EAC0F" xlink:to="lab_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_C85DC6396288CA68593EDECFB16EAC0F" xlink:type="arc" />
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>12
<FILENAME>gale-20150930_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!--XBRL Document Created with Wdesk from Workiva-->
<!-- -->
<linkbase xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
  <roleRef roleURI="http://www.galenabiopharma.com/role/AccruedExpensesAndOtherCurrentLiabilities" xlink:href="gale-20150930.xsd#AccruedExpensesAndOtherCurrentLiabilities" xlink:type="simple" />
  <roleRef roleURI="http://www.galenabiopharma.com/role/AccruedExpensesAndOtherCurrentLiabilitiesDetails" xlink:href="gale-20150930.xsd#AccruedExpensesAndOtherCurrentLiabilitiesDetails" xlink:type="simple" />
  <roleRef roleURI="http://www.galenabiopharma.com/role/AccruedExpensesAndOtherCurrentLiabilitiesTables" xlink:href="gale-20150930.xsd#AccruedExpensesAndOtherCurrentLiabilitiesTables" xlink:type="simple" />
  <roleRef roleURI="http://www.galenabiopharma.com/role/BusinessAndBasisOfPresentation" xlink:href="gale-20150930.xsd#BusinessAndBasisOfPresentation" xlink:type="simple" />
  <roleRef roleURI="http://www.galenabiopharma.com/role/BusinessAndBasisOfPresentationAdditionalInformationDetail" xlink:href="gale-20150930.xsd#BusinessAndBasisOfPresentationAdditionalInformationDetail" xlink:type="simple" />
  <roleRef roleURI="http://www.galenabiopharma.com/role/BusinessAndBasisOfPresentationPolicies" xlink:href="gale-20150930.xsd#BusinessAndBasisOfPresentationPolicies" xlink:type="simple" />
  <roleRef roleURI="http://www.galenabiopharma.com/role/BusinessCombinations" xlink:href="gale-20150930.xsd#BusinessCombinations" xlink:type="simple" />
  <roleRef roleURI="http://www.galenabiopharma.com/role/BusinessCombinationsDetails" xlink:href="gale-20150930.xsd#BusinessCombinationsDetails" xlink:type="simple" />
  <roleRef roleURI="http://www.galenabiopharma.com/role/BusinessCombinationsTables" xlink:href="gale-20150930.xsd#BusinessCombinationsTables" xlink:type="simple" />
  <roleRef roleURI="http://www.galenabiopharma.com/role/CondensedConsolidatedBalanceSheets" xlink:href="gale-20150930.xsd#CondensedConsolidatedBalanceSheets" xlink:type="simple" />
  <roleRef roleURI="http://www.galenabiopharma.com/role/CondensedConsolidatedBalanceSheetsParenthetical" xlink:href="gale-20150930.xsd#CondensedConsolidatedBalanceSheetsParenthetical" xlink:type="simple" />
  <roleRef roleURI="http://www.galenabiopharma.com/role/CondensedConsolidatedStatementOfStockholdersEquityCondensedConsolidatedStatementOfStockholdersEquity" xlink:href="gale-20150930.xsd#CondensedConsolidatedStatementOfStockholdersEquityCondensedConsolidatedStatementOfStockholdersEquity" xlink:type="simple" />
  <roleRef roleURI="http://www.galenabiopharma.com/role/CondensedConsolidatedStatementsOfCashFlows" xlink:href="gale-20150930.xsd#CondensedConsolidatedStatementsOfCashFlows" xlink:type="simple" />
  <roleRef roleURI="http://www.galenabiopharma.com/role/CondensedConsolidatedStatementsOfComprehensiveLoss" xlink:href="gale-20150930.xsd#CondensedConsolidatedStatementsOfComprehensiveLoss" xlink:type="simple" />
  <roleRef roleURI="http://www.galenabiopharma.com/role/DiscontinuedOperationsAssetsHeldForSaleCarryingAmountsOfAssetsAndLiabilitiesDetails" xlink:href="gale-20150930.xsd#DiscontinuedOperationsAssetsHeldForSaleCarryingAmountsOfAssetsAndLiabilitiesDetails" xlink:type="simple" />
  <roleRef roleURI="http://www.galenabiopharma.com/role/DiscontinuedOperationsAssetsHeldForSaleComponentsAttributableToCommercialBusinessDetails" xlink:href="gale-20150930.xsd#DiscontinuedOperationsAssetsHeldForSaleComponentsAttributableToCommercialBusinessDetails" xlink:type="simple" />
  <roleRef roleURI="http://www.galenabiopharma.com/role/DiscontinuedOperationsAssetsHeldForSaleDetails" xlink:href="gale-20150930.xsd#DiscontinuedOperationsAssetsHeldForSaleDetails" xlink:type="simple" />
  <roleRef roleURI="http://www.galenabiopharma.com/role/DiscontinuedOperationsAssetsHeldForSaleNotes" xlink:href="gale-20150930.xsd#DiscontinuedOperationsAssetsHeldForSaleNotes" xlink:type="simple" />
  <roleRef roleURI="http://www.galenabiopharma.com/role/DiscontinuedOperationsAssetsHeldForSaleSignificantOperatingNonCashAndCapitalExpendituresDetails" xlink:href="gale-20150930.xsd#DiscontinuedOperationsAssetsHeldForSaleSignificantOperatingNonCashAndCapitalExpendituresDetails" xlink:type="simple" />
  <roleRef roleURI="http://www.galenabiopharma.com/role/DiscontinuedOperationsAssetsHeldForSaleTables" xlink:href="gale-20150930.xsd#DiscontinuedOperationsAssetsHeldForSaleTables" xlink:type="simple" />
  <roleRef roleURI="http://www.galenabiopharma.com/role/DocumentAndEntityInformation" xlink:href="gale-20150930.xsd#DocumentAndEntityInformation" xlink:type="simple" />
  <roleRef roleURI="http://www.galenabiopharma.com/role/FairValueMeasurements" xlink:href="gale-20150930.xsd#FairValueMeasurements" xlink:type="simple" />
  <roleRef roleURI="http://www.galenabiopharma.com/role/FairValueMeasurementsContingentPurchasePriceConsiderationMeasuredAtEstimatedFairValueOnRecurringBasisDetail" xlink:href="gale-20150930.xsd#FairValueMeasurementsContingentPurchasePriceConsiderationMeasuredAtEstimatedFairValueOnRecurringBasisDetail" xlink:type="simple" />
  <roleRef roleURI="http://www.galenabiopharma.com/role/FairValueMeasurementsReconciliationOfLevel3LiabilitiesDetail" xlink:href="gale-20150930.xsd#FairValueMeasurementsReconciliationOfLevel3LiabilitiesDetail" xlink:type="simple" />
  <roleRef roleURI="http://www.galenabiopharma.com/role/FairValueMeasurementsTables" xlink:href="gale-20150930.xsd#FairValueMeasurementsTables" xlink:type="simple" />
  <roleRef roleURI="http://www.galenabiopharma.com/role/LegalProceedingsCommitmentsAndContingenciesDetailsDetails" xlink:href="gale-20150930.xsd#LegalProceedingsCommitmentsAndContingenciesDetailsDetails" xlink:type="simple" />
  <roleRef roleURI="http://www.galenabiopharma.com/role/LegalProceedingsCommitmentsAndContingenciesNotes" xlink:href="gale-20150930.xsd#LegalProceedingsCommitmentsAndContingenciesNotes" xlink:type="simple" />
  <roleRef roleURI="http://www.galenabiopharma.com/role/LicenseAgreements" xlink:href="gale-20150930.xsd#LicenseAgreements" xlink:type="simple" />
  <roleRef roleURI="http://www.galenabiopharma.com/role/LicenseAgreementsAdditionalInformationDetail" xlink:href="gale-20150930.xsd#LicenseAgreementsAdditionalInformationDetail" xlink:type="simple" />
  <roleRef roleURI="http://www.galenabiopharma.com/role/LongTermDebt" xlink:href="gale-20150930.xsd#LongTermDebt" xlink:type="simple" />
  <roleRef roleURI="http://www.galenabiopharma.com/role/LongTermDebtDetails" xlink:href="gale-20150930.xsd#LongTermDebtDetails" xlink:type="simple" />
  <roleRef roleURI="http://www.galenabiopharma.com/role/NetLossPerShare" xlink:href="gale-20150930.xsd#NetLossPerShare" xlink:type="simple" />
  <roleRef roleURI="http://www.galenabiopharma.com/role/NetLossPerShareCommonSharesExcludedFromNetLossDetail" xlink:href="gale-20150930.xsd#NetLossPerShareCommonSharesExcludedFromNetLossDetail" xlink:type="simple" />
  <roleRef roleURI="http://www.galenabiopharma.com/role/NetLossPerShareTables" xlink:href="gale-20150930.xsd#NetLossPerShareTables" xlink:type="simple" />
  <roleRef roleURI="http://www.galenabiopharma.com/role/OtherIncomeExpenseNotes" xlink:href="gale-20150930.xsd#OtherIncomeExpenseNotes" xlink:type="simple" />
  <roleRef roleURI="http://www.galenabiopharma.com/role/OtherIncomeExpenseTableDetails" xlink:href="gale-20150930.xsd#OtherIncomeExpenseTableDetails" xlink:type="simple" />
  <roleRef roleURI="http://www.galenabiopharma.com/role/OtherIncomeExpenseTables" xlink:href="gale-20150930.xsd#OtherIncomeExpenseTables" xlink:type="simple" />
  <roleRef roleURI="http://www.galenabiopharma.com/role/SignificantCustomersAndConcentrationOfCreditRiskDetails" xlink:href="gale-20150930.xsd#SignificantCustomersAndConcentrationOfCreditRiskDetails" xlink:type="simple" />
  <roleRef roleURI="http://www.galenabiopharma.com/role/SignificantCustomersAndConcentrationOfCreditRiskNotes" xlink:href="gale-20150930.xsd#SignificantCustomersAndConcentrationOfCreditRiskNotes" xlink:type="simple" />
  <roleRef roleURI="http://www.galenabiopharma.com/role/SignificantCustomersAndConcentrationOfCreditRiskSignificantCustomersAndConcentrationOfCreditRiskTables" xlink:href="gale-20150930.xsd#SignificantCustomersAndConcentrationOfCreditRiskSignificantCustomersAndConcentrationOfCreditRiskTables" xlink:type="simple" />
  <roleRef roleURI="http://www.galenabiopharma.com/role/StockBasedCompensation" xlink:href="gale-20150930.xsd#StockBasedCompensation" xlink:type="simple" />
  <roleRef roleURI="http://www.galenabiopharma.com/role/StockBasedCompensationAdditionalInformationDetail" xlink:href="gale-20150930.xsd#StockBasedCompensationAdditionalInformationDetail" xlink:type="simple" />
  <roleRef roleURI="http://www.galenabiopharma.com/role/StockBasedCompensationAllocatedStockBasedCompensationDetails" xlink:href="gale-20150930.xsd#StockBasedCompensationAllocatedStockBasedCompensationDetails" xlink:type="simple" />
  <roleRef roleURI="http://www.galenabiopharma.com/role/StockBasedCompensationAssumptionsForOptionGrantsIssuedDetail" xlink:href="gale-20150930.xsd#StockBasedCompensationAssumptionsForOptionGrantsIssuedDetail" xlink:type="simple" />
  <roleRef roleURI="http://www.galenabiopharma.com/role/StockBasedCompensationStockOptionActivityDetail" xlink:href="gale-20150930.xsd#StockBasedCompensationStockOptionActivityDetail" xlink:type="simple" />
  <roleRef roleURI="http://www.galenabiopharma.com/role/StockBasedCompensationTables" xlink:href="gale-20150930.xsd#StockBasedCompensationTables" xlink:type="simple" />
  <roleRef roleURI="http://www.galenabiopharma.com/role/StockholdersEquity" xlink:href="gale-20150930.xsd#StockholdersEquity" xlink:type="simple" />
  <roleRef roleURI="http://www.galenabiopharma.com/role/StockholdersEquityAdditionalInformationDetail" xlink:href="gale-20150930.xsd#StockholdersEquityAdditionalInformationDetail" xlink:type="simple" />
  <roleRef roleURI="http://www.galenabiopharma.com/role/StockholdersEquityCommonStockAreReservedForFutureIssuanceDetail" xlink:href="gale-20150930.xsd#StockholdersEquityCommonStockAreReservedForFutureIssuanceDetail" xlink:type="simple" />
  <roleRef roleURI="http://www.galenabiopharma.com/role/StockholdersEquityTables" xlink:href="gale-20150930.xsd#StockholdersEquityTables" xlink:type="simple" />
  <roleRef roleURI="http://www.galenabiopharma.com/role/SubsequentEvents" xlink:href="gale-20150930.xsd#SubsequentEvents" xlink:type="simple" />
  <roleRef roleURI="http://www.galenabiopharma.com/role/Warrants" xlink:href="gale-20150930.xsd#Warrants" xlink:type="simple" />
  <roleRef roleURI="http://www.galenabiopharma.com/role/WarrantsChangesInFairValueOfWarrantLiabilityDetail" xlink:href="gale-20150930.xsd#WarrantsChangesInFairValueOfWarrantLiabilityDetail" xlink:type="simple" />
  <roleRef roleURI="http://www.galenabiopharma.com/role/WarrantsFairValueOfWarrantsIsEstimatedUsingBlackScholesOptionPricingModelDetail" xlink:href="gale-20150930.xsd#WarrantsFairValueOfWarrantsIsEstimatedUsingBlackScholesOptionPricingModelDetail" xlink:type="simple" />
  <roleRef roleURI="http://www.galenabiopharma.com/role/WarrantsScheduleOfWarrantActivityDetail" xlink:href="gale-20150930.xsd#WarrantsScheduleOfWarrantActivityDetail" xlink:type="simple" />
  <roleRef roleURI="http://www.galenabiopharma.com/role/WarrantsTables" xlink:href="gale-20150930.xsd#WarrantsTables" xlink:type="simple" />
  <roleRef roleURI="http://www.galenabiopharma.com/role/WarrantsWarrantsClassifiedAsEquityDetails" xlink:href="gale-20150930.xsd#WarrantsWarrantsClassifiedAsEquityDetails" xlink:type="simple" />
  <roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" xlink:type="simple" />
  <roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" xlink:type="simple" />
  <roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" xlink:type="simple" />
  <roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" xlink:type="simple" />
  <roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" xlink:type="simple" />
  <roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" xlink:type="simple" />
  <roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" xlink:type="simple" />
  <presentationLink xlink:role="http://www.galenabiopharma.com/role/AccruedExpensesAndOtherCurrentLiabilities" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="loc_us-gaap_PayablesAndAccrualsAbstract_6A47FAB1DA10524F8A19FBA902CFFAE3" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" xlink:label="loc_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock_1250C83D638D5F8EAF6A9E0A89BF7ECC" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_6A47FAB1DA10524F8A19FBA902CFFAE3" xlink:to="loc_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock_1250C83D638D5F8EAF6A9E0A89BF7ECC" xlink:type="arc" />
  </presentationLink>
  <presentationLink xlink:role="http://www.galenabiopharma.com/role/AccruedExpensesAndOtherCurrentLiabilitiesDetails" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="loc_us-gaap_PayablesAndAccrualsAbstract_F8DEBA7F524A59F2B2C4716EC59D9247" xlink:type="locator" />
    <loc xlink:href="gale-20150930.xsd#gale_ContractResearchPayable" xlink:label="loc_gale_ContractResearchPayable_C92529FA2389510B93D9E6C2713ED965" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_F8DEBA7F524A59F2B2C4716EC59D9247" xlink:to="loc_gale_ContractResearchPayable_C92529FA2389510B93D9E6C2713ED965" xlink:type="arc" />
    <loc xlink:href="gale-20150930.xsd#gale_CreditMemosAcquisitionChannelInventoryCurrent" xlink:label="loc_gale_CreditMemosAcquisitionChannelInventoryCurrent_9711CFEC30285B319B591C13112C32FE" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_F8DEBA7F524A59F2B2C4716EC59D9247" xlink:to="loc_gale_CreditMemosAcquisitionChannelInventoryCurrent_9711CFEC30285B319B591C13112C32FE" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_AFC5342BB342577C9D28D9E318BC0DA3" xlink:type="locator" />
    <presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_F8DEBA7F524A59F2B2C4716EC59D9247" xlink:to="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_AFC5342BB342577C9D28D9E318BC0DA3" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:label="loc_us-gaap_AccruedProfessionalFeesCurrent_A0FFFFA774FE53B486B3B22239FF658C" xlink:type="locator" />
    <presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_F8DEBA7F524A59F2B2C4716EC59D9247" xlink:to="loc_us-gaap_AccruedProfessionalFeesCurrent_A0FFFFA774FE53B486B3B22239FF658C" xlink:type="arc" />
    <loc xlink:href="gale-20150930.xsd#gale_PatientAssistanceProgramCurrent" xlink:label="loc_gale_PatientAssistanceProgramCurrent_16395329048C5972853C8B81384D2A6B" xlink:type="locator" />
    <presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_F8DEBA7F524A59F2B2C4716EC59D9247" xlink:to="loc_gale_PatientAssistanceProgramCurrent_16395329048C5972853C8B81384D2A6B" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AccruedRoyaltiesCurrent" xlink:label="loc_us-gaap_AccruedRoyaltiesCurrent_641A5DF37E3054D2A136AD690B3F461F" xlink:type="locator" />
    <presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_F8DEBA7F524A59F2B2C4716EC59D9247" xlink:to="loc_us-gaap_AccruedRoyaltiesCurrent_641A5DF37E3054D2A136AD690B3F461F" xlink:type="arc" />
    <loc xlink:href="gale-20150930.xsd#gale_AccruedInventoryPurchasesCurrent" xlink:label="loc_gale_AccruedInventoryPurchasesCurrent_8A884B824F1B59F6909DEF3F3901A374" xlink:type="locator" />
    <presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_F8DEBA7F524A59F2B2C4716EC59D9247" xlink:to="loc_gale_AccruedInventoryPurchasesCurrent_8A884B824F1B59F6909DEF3F3901A374" xlink:type="arc" />
    <loc xlink:href="gale-20150930.xsd#gale_FutureMilestonePayment" xlink:label="loc_gale_FutureMilestonePayment_A1E859A7C4445938BB8F76D1D8E54E9E" xlink:type="locator" />
    <presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_F8DEBA7F524A59F2B2C4716EC59D9247" xlink:to="loc_gale_FutureMilestonePayment_A1E859A7C4445938BB8F76D1D8E54E9E" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_InterestPayableCurrent" xlink:label="loc_us-gaap_InterestPayableCurrent_7DCCCAD638A25E97AB3F62260A22E05A" xlink:type="locator" />
    <presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_F8DEBA7F524A59F2B2C4716EC59D9247" xlink:to="loc_us-gaap_InterestPayableCurrent_7DCCCAD638A25E97AB3F62260A22E05A" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_C74288A03AE45D9FB37CE83437D77A40" xlink:type="locator" />
    <presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_F8DEBA7F524A59F2B2C4716EC59D9247" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_C74288A03AE45D9FB37CE83437D77A40" xlink:type="arc" />
  </presentationLink>
  <presentationLink xlink:role="http://www.galenabiopharma.com/role/AccruedExpensesAndOtherCurrentLiabilitiesTables" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="loc_us-gaap_PayablesAndAccrualsAbstract_3853ACCD0E6252C6B88C0DDABA5E7636" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_8FAA9A305A5C5FCEB6DC9D8460AB670D" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_3853ACCD0E6252C6B88C0DDABA5E7636" xlink:to="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_8FAA9A305A5C5FCEB6DC9D8460AB670D" xlink:type="arc" />
  </presentationLink>
  <presentationLink xlink:role="http://www.galenabiopharma.com/role/BusinessAndBasisOfPresentation" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_8904DC6EE81653A7AC3FE5CD7B28FF06" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock_CF8C245BA3D45C1BB6C2285E3D6DEF42" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_8904DC6EE81653A7AC3FE5CD7B28FF06" xlink:to="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock_CF8C245BA3D45C1BB6C2285E3D6DEF42" xlink:type="arc" />
  </presentationLink>
  <presentationLink xlink:role="http://www.galenabiopharma.com/role/BusinessAndBasisOfPresentationAdditionalInformationDetail" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_0CC448C45B32DF4E99DFDECE1E7F9227" xlink:type="locator" />
    <loc xlink:href="gale-20150930.xsd#gale_ScheduleOfSummaryOfSignificantAccountingPoliciesTable" xlink:label="loc_gale_ScheduleOfSummaryOfSignificantAccountingPoliciesTable_15E05D38C24332DBC547DECE1E80DFE9" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0CC448C45B32DF4E99DFDECE1E7F9227" xlink:to="loc_gale_ScheduleOfSummaryOfSignificantAccountingPoliciesTable_15E05D38C24332DBC547DECE1E80DFE9" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RangeAxis" xlink:label="loc_us-gaap_RangeAxis_7EEDE4D2940E921B7995DECE1E81E2BB" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gale_ScheduleOfSummaryOfSignificantAccountingPoliciesTable_15E05D38C24332DBC547DECE1E80DFE9" xlink:to="loc_us-gaap_RangeAxis_7EEDE4D2940E921B7995DECE1E81E2BB" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaap_RangeMember_32DBEE5FF85A5B622F1DDECE1E81E8E4" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RangeAxis_7EEDE4D2940E921B7995DECE1E81E2BB" xlink:to="loc_us-gaap_RangeMember_32DBEE5FF85A5B622F1DDECE1E81E8E4" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_MinimumMember" xlink:label="loc_us-gaap_MinimumMember_AB9F14BBAE3607F76A3FDECE1E8190FC" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RangeMember_32DBEE5FF85A5B622F1DDECE1E81E8E4" xlink:to="loc_us-gaap_MinimumMember_AB9F14BBAE3607F76A3FDECE1E8190FC" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_MaximumMember" xlink:label="loc_us-gaap_MaximumMember_DE28EEEDB767537287E5DECE1E81F378" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RangeMember_32DBEE5FF85A5B622F1DDECE1E81E8E4" xlink:to="loc_us-gaap_MaximumMember_DE28EEEDB767537287E5DECE1E81F378" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_1DB980BDFCFEA1260C80DECE1E810547" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gale_ScheduleOfSummaryOfSignificantAccountingPoliciesTable_15E05D38C24332DBC547DECE1E80DFE9" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_1DB980BDFCFEA1260C80DECE1E810547" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_22614AB42CEC081C2A5EDECE1E8119E5" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_1DB980BDFCFEA1260C80DECE1E810547" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_22614AB42CEC081C2A5EDECE1E8119E5" xlink:type="arc" />
    <loc xlink:href="gale-20150930.xsd#gale_EquipmentFurnitureAndFixturesMember" xlink:label="loc_gale_EquipmentFurnitureAndFixturesMember_B777E9E80CD82CC887D7DECE1E81389D" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_22614AB42CEC081C2A5EDECE1E8119E5" xlink:to="loc_gale_EquipmentFurnitureAndFixturesMember_B777E9E80CD82CC887D7DECE1E81389D" xlink:type="arc" />
    <loc xlink:href="gale-20150930.xsd#gale_ScheduleOfSummaryOfSignificantAccountingPoliciesLineItems" xlink:label="loc_gale_ScheduleOfSummaryOfSignificantAccountingPoliciesLineItems_E3D0066C4A9F53F30EDADECE1E81384E" xlink:type="locator" />
    <presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gale_ScheduleOfSummaryOfSignificantAccountingPoliciesTable_15E05D38C24332DBC547DECE1E80DFE9" xlink:to="loc_gale_ScheduleOfSummaryOfSignificantAccountingPoliciesLineItems_E3D0066C4A9F53F30EDADECE1E81384E" xlink:type="arc" />
    <loc xlink:href="gale-20150930.xsd#gale_NumberofPatientsDiagnosedWithBreastCancerPatientsAnnuallyAtHighRiskofDiseaseRecurrence" xlink:label="loc_gale_NumberofPatientsDiagnosedWithBreastCancerPatientsAnnuallyAtHighRiskofDiseaseRecurrence_37EAB06DA03CBE2EC5FBDECE1E86A9E4" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gale_ScheduleOfSummaryOfSignificantAccountingPoliciesLineItems_E3D0066C4A9F53F30EDADECE1E81384E" xlink:to="loc_gale_NumberofPatientsDiagnosedWithBreastCancerPatientsAnnuallyAtHighRiskofDiseaseRecurrence_37EAB06DA03CBE2EC5FBDECE1E86A9E4" xlink:type="arc" />
    <loc xlink:href="gale-20150930.xsd#gale_NumberofPatientsDiagnosedWithBreastCancerPatientsAnnually" xlink:label="loc_gale_NumberofPatientsDiagnosedWithBreastCancerPatientsAnnually_FB93284E5CCB84EDBEB5DECE1E87F265" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gale_ScheduleOfSummaryOfSignificantAccountingPoliciesLineItems_E3D0066C4A9F53F30EDADECE1E81384E" xlink:to="loc_gale_NumberofPatientsDiagnosedWithBreastCancerPatientsAnnually_FB93284E5CCB84EDBEB5DECE1E87F265" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivable" xlink:label="loc_us-gaap_AllowanceForDoubtfulAccountsReceivable_58C3EFB14EB81C9C1E10DECE1E872BEE" xlink:type="locator" />
    <presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gale_ScheduleOfSummaryOfSignificantAccountingPoliciesLineItems_E3D0066C4A9F53F30EDADECE1E81384E" xlink:to="loc_us-gaap_AllowanceForDoubtfulAccountsReceivable_58C3EFB14EB81C9C1E10DECE1E872BEE" xlink:type="arc" />
    <loc xlink:href="gale-20150930.xsd#gale_MaximumMaturityPeriodToConsiderAllHighlyLiquidDebtInstrumentsAsCashAndCashEquivalents" xlink:label="loc_gale_MaximumMaturityPeriodToConsiderAllHighlyLiquidDebtInstrumentsAsCashAndCashEquivalents_0432E498B77DC7321941DECE1E87D006" xlink:type="locator" />
    <presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gale_ScheduleOfSummaryOfSignificantAccountingPoliciesLineItems_E3D0066C4A9F53F30EDADECE1E81384E" xlink:to="loc_gale_MaximumMaturityPeriodToConsiderAllHighlyLiquidDebtInstrumentsAsCashAndCashEquivalents_0432E498B77DC7321941DECE1E87D006" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_InventoryNet" xlink:label="loc_us-gaap_InventoryNet_246B7BC308E3C6EB648CDECE1E87FE5D" xlink:type="locator" />
    <presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gale_ScheduleOfSummaryOfSignificantAccountingPoliciesLineItems_E3D0066C4A9F53F30EDADECE1E81384E" xlink:to="loc_us-gaap_InventoryNet_246B7BC308E3C6EB648CDECE1E87FE5D" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_InventoryWorkInProcess" xlink:label="loc_us-gaap_InventoryWorkInProcess_5D4E23F4AB38BBC34391DECE1E8740A5" xlink:type="locator" />
    <presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gale_ScheduleOfSummaryOfSignificantAccountingPoliciesLineItems_E3D0066C4A9F53F30EDADECE1E81384E" xlink:to="loc_us-gaap_InventoryWorkInProcess_5D4E23F4AB38BBC34391DECE1E8740A5" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_InventoryFinishedGoods" xlink:label="loc_us-gaap_InventoryFinishedGoods_9D7B83ACF144DA8A1EB5DECE1E876B50" xlink:type="locator" />
    <presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gale_ScheduleOfSummaryOfSignificantAccountingPoliciesLineItems_E3D0066C4A9F53F30EDADECE1E81384E" xlink:to="loc_us-gaap_InventoryFinishedGoods_9D7B83ACF144DA8A1EB5DECE1E876B50" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_0BB6017A68A1FAFE6C10DECE1E87CB8B" xlink:type="locator" />
    <presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gale_ScheduleOfSummaryOfSignificantAccountingPoliciesLineItems_E3D0066C4A9F53F30EDADECE1E81384E" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_0BB6017A68A1FAFE6C10DECE1E87CB8B" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SalesDiscountsServices" xlink:label="loc_us-gaap_SalesDiscountsServices_870A8B3B3EE560B538A1DECE1E87A20A" xlink:type="locator" />
    <presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gale_ScheduleOfSummaryOfSignificantAccountingPoliciesLineItems_E3D0066C4A9F53F30EDADECE1E81384E" xlink:to="loc_us-gaap_SalesDiscountsServices_870A8B3B3EE560B538A1DECE1E87A20A" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AmortizationOfIntangibleAssets" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets_90A6C2DF78480C960857DECE1E87AA80" xlink:type="locator" />
    <presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gale_ScheduleOfSummaryOfSignificantAccountingPoliciesLineItems_E3D0066C4A9F53F30EDADECE1E81384E" xlink:to="loc_us-gaap_AmortizationOfIntangibleAssets_90A6C2DF78480C960857DECE1E87AA80" xlink:type="arc" />
  </presentationLink>
  <presentationLink xlink:role="http://www.galenabiopharma.com/role/BusinessAndBasisOfPresentationPolicies" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_D662AA768049F0D29A6EDECFB12208DC" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DiscontinuedOperationsPolicyTextBlock" xlink:label="loc_us-gaap_DiscontinuedOperationsPolicyTextBlock_B6F69B79F5E77C7735FFDED66804DC09" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_D662AA768049F0D29A6EDECFB12208DC" xlink:to="loc_us-gaap_DiscontinuedOperationsPolicyTextBlock_B6F69B79F5E77C7735FFDED66804DC09" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_UseOfEstimates" xlink:label="loc_us-gaap_UseOfEstimates_8A4B01E6BA9F13F0E3FADECFB122AC2A" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_D662AA768049F0D29A6EDECFB12208DC" xlink:to="loc_us-gaap_UseOfEstimates_8A4B01E6BA9F13F0E3FADECFB122AC2A" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ConsolidationPolicyTextBlock" xlink:label="loc_us-gaap_ConsolidationPolicyTextBlock_D088711B4DEDA355DEE2DECFB122F8EF" xlink:type="locator" />
    <presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_D662AA768049F0D29A6EDECFB12208DC" xlink:to="loc_us-gaap_ConsolidationPolicyTextBlock_D088711B4DEDA355DEE2DECFB122F8EF" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PriorPeriodReclassificationAdjustmentDescription" xlink:label="loc_us-gaap_PriorPeriodReclassificationAdjustmentDescription_392D96B1EE4E0748DD1FDECFB122A610" xlink:type="locator" />
    <presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_D662AA768049F0D29A6EDECFB12208DC" xlink:to="loc_us-gaap_PriorPeriodReclassificationAdjustmentDescription_392D96B1EE4E0748DD1FDECFB122A610" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock_40F2042873CC519C5388DECFB1238ED9" xlink:type="locator" />
    <presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_D662AA768049F0D29A6EDECFB12208DC" xlink:to="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock_40F2042873CC519C5388DECFB1238ED9" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:label="loc_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_786C97EC54BED2BE0A33DECFB123AE59" xlink:type="locator" />
    <presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_D662AA768049F0D29A6EDECFB12208DC" xlink:to="loc_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_786C97EC54BED2BE0A33DECFB123AE59" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:label="loc_us-gaap_FairValueOfFinancialInstrumentsPolicy_E5C06E833C74D361F4A8DECFB1232E6A" xlink:type="locator" />
    <presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_D662AA768049F0D29A6EDECFB12208DC" xlink:to="loc_us-gaap_FairValueOfFinancialInstrumentsPolicy_E5C06E833C74D361F4A8DECFB1232E6A" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_C0B75EACE3D5F20B92E0DECFB128FFFD" xlink:type="locator" />
    <presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_D662AA768049F0D29A6EDECFB12208DC" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_C0B75EACE3D5F20B92E0DECFB128FFFD" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_TradeAndOtherAccountsReceivablePolicy" xlink:label="loc_us-gaap_TradeAndOtherAccountsReceivablePolicy_8BB58919340DC490ACC8DECFB123C804" xlink:type="locator" />
    <presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_D662AA768049F0D29A6EDECFB12208DC" xlink:to="loc_us-gaap_TradeAndOtherAccountsReceivablePolicy_8BB58919340DC490ACC8DECFB123C804" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_InventoryPolicyTextBlock" xlink:label="loc_us-gaap_InventoryPolicyTextBlock_3028A38651AF1AF3AE33DECFB123A899" xlink:type="locator" />
    <presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_D662AA768049F0D29A6EDECFB12208DC" xlink:to="loc_us-gaap_InventoryPolicyTextBlock_3028A38651AF1AF3AE33DECFB123A899" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock_7E02276B3B298D1EF2B4DECFB1284ED6" xlink:type="locator" />
    <presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_D662AA768049F0D29A6EDECFB12208DC" xlink:to="loc_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock_7E02276B3B298D1EF2B4DECFB1284ED6" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RevenueRecognitionPolicyTextBlock" xlink:label="loc_us-gaap_RevenueRecognitionPolicyTextBlock_D17F1C1B467AF8EE020FDECFB12859B5" xlink:type="locator" />
    <presentationArc order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_D662AA768049F0D29A6EDECFB12208DC" xlink:to="loc_us-gaap_RevenueRecognitionPolicyTextBlock_D17F1C1B467AF8EE020FDECFB12859B5" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_BusinessCombinationsPolicy" xlink:label="loc_us-gaap_BusinessCombinationsPolicy_E4F624C8F4FB1303D4B0DECFB1292E3B" xlink:type="locator" />
    <presentationArc order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_D662AA768049F0D29A6EDECFB12208DC" xlink:to="loc_us-gaap_BusinessCombinationsPolicy_E4F624C8F4FB1303D4B0DECFB1292E3B" xlink:type="arc" />
    <loc xlink:href="gale-20150930.xsd#gale_ContingentConsiderationPolicyPolicyTextBlock" xlink:label="loc_gale_ContingentConsiderationPolicyPolicyTextBlock_1BDE6CC519E7B49A0E82DECFB12968B2" xlink:type="locator" />
    <presentationArc order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_D662AA768049F0D29A6EDECFB12208DC" xlink:to="loc_gale_ContingentConsiderationPolicyPolicyTextBlock_1BDE6CC519E7B49A0E82DECFB12968B2" xlink:type="arc" />
    <loc xlink:href="gale-20150930.xsd#gale_PatentsAndPatentApplicationCostsPolicyPolicyTextBlock" xlink:label="loc_gale_PatentsAndPatentApplicationCostsPolicyPolicyTextBlock_64CA5D2BF4643AC48883DECFB12992AF" xlink:type="locator" />
    <presentationArc order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_D662AA768049F0D29A6EDECFB12208DC" xlink:to="loc_gale_PatentsAndPatentApplicationCostsPolicyPolicyTextBlock_64CA5D2BF4643AC48883DECFB12992AF" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:label="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_F9F56AFA835075C096D8DECFB12913BB" xlink:type="locator" />
    <presentationArc order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_D662AA768049F0D29A6EDECFB12208DC" xlink:to="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_F9F56AFA835075C096D8DECFB12913BB" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpensePolicy_09E495847AE91343B0B1DECFB129EC3E" xlink:type="locator" />
    <presentationArc order="17" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_D662AA768049F0D29A6EDECFB12208DC" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpensePolicy_09E495847AE91343B0B1DECFB129EC3E" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="loc_us-gaap_IncomeTaxPolicyTextBlock_B347044DEACA81933944DECFB129C52F" xlink:type="locator" />
    <presentationArc order="18" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_D662AA768049F0D29A6EDECFB12208DC" xlink:to="loc_us-gaap_IncomeTaxPolicyTextBlock_B347044DEACA81933944DECFB129C52F" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ConcentrationRiskCreditRisk" xlink:label="loc_us-gaap_ConcentrationRiskCreditRisk_56ED59ABE0E4D009C6CCDECFB12968B7" xlink:type="locator" />
    <presentationArc order="19" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_D662AA768049F0D29A6EDECFB12208DC" xlink:to="loc_us-gaap_ConcentrationRiskCreditRisk_56ED59ABE0E4D009C6CCDECFB12968B7" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:label="loc_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_28CBF990831CAC72C8F2DECFB1297C05" xlink:type="locator" />
    <presentationArc order="20" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_D662AA768049F0D29A6EDECFB12208DC" xlink:to="loc_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_28CBF990831CAC72C8F2DECFB1297C05" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:label="loc_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_8F108C4D19F371579383DECFB129A424" xlink:type="locator" />
    <presentationArc order="21" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_D662AA768049F0D29A6EDECFB12208DC" xlink:to="loc_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_8F108C4D19F371579383DECFB129A424" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="loc_us-gaap_EarningsPerSharePolicyTextBlock_BAB912465CE0C6963EE2DECFB1292DD1" xlink:type="locator" />
    <presentationArc order="22" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_D662AA768049F0D29A6EDECFB12208DC" xlink:to="loc_us-gaap_EarningsPerSharePolicyTextBlock_BAB912465CE0C6963EE2DECFB1292DD1" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_E9112EFF020FF314BB93DEE1943CC7C1" xlink:type="locator" />
    <presentationArc order="23" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_D662AA768049F0D29A6EDECFB12208DC" xlink:to="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_E9112EFF020FF314BB93DEE1943CC7C1" xlink:type="arc" />
  </presentationLink>
  <presentationLink xlink:role="http://www.galenabiopharma.com/role/BusinessCombinations" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_BusinessCombinationsAbstract" xlink:label="loc_us-gaap_BusinessCombinationsAbstract_82A902F47B2876F846B9DDA4F7C4A699" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_BusinessCombinationDisclosureTextBlock" xlink:label="loc_us-gaap_BusinessCombinationDisclosureTextBlock_9D05AD0BAD83E894DC3EDDA4F7C4A0B2" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationsAbstract_82A902F47B2876F846B9DDA4F7C4A699" xlink:to="loc_us-gaap_BusinessCombinationDisclosureTextBlock_9D05AD0BAD83E894DC3EDDA4F7C4A0B2" xlink:type="arc" />
  </presentationLink>
  <presentationLink xlink:role="http://www.galenabiopharma.com/role/BusinessCombinationsDetails" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_BusinessCombinationsAbstract" xlink:label="loc_us-gaap_BusinessCombinationsAbstract_26B5311FB587019D39FCDDA4F7B4C4A4" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_6F08A45F81B05E3AE47ADDA4F7B4EA07" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationsAbstract_26B5311FB587019D39FCDDA4F7B4C4A4" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_6F08A45F81B05E3AE47ADDA4F7B4EA07" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_CBD5049D12CDEF883134DDA4F7B44B73" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_6F08A45F81B05E3AE47ADDA4F7B4EA07" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_CBD5049D12CDEF883134DDA4F7B44B73" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_704A499BFE5CC43D9EFDDDA4F7B41FDF" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_CBD5049D12CDEF883134DDA4F7B44B73" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_704A499BFE5CC43D9EFDDDA4F7B41FDF" xlink:type="arc" />
    <loc xlink:href="gale-20150930.xsd#gale_ZuplenzMember" xlink:label="loc_gale_ZuplenzMember_1C2B9692676B9B5875A5DDA4F7B472FC" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_704A499BFE5CC43D9EFDDDA4F7B41FDF" xlink:to="loc_gale_ZuplenzMember_1C2B9692676B9B5875A5DDA4F7B472FC" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_B239485301743F47B4F1DDA4F7B521B8" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_6F08A45F81B05E3AE47ADDA4F7B4EA07" xlink:to="loc_us-gaap_StatementClassOfStockAxis_B239485301743F47B4F1DDA4F7B521B8" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_883F86DF8D3C063709C3DDA4F7B58F93" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_B239485301743F47B4F1DDA4F7B521B8" xlink:to="loc_us-gaap_ClassOfStockDomain_883F86DF8D3C063709C3DDA4F7B58F93" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember_77C30CDFE372B7D5B5EFDDA4F7BAA798" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_883F86DF8D3C063709C3DDA4F7B58F93" xlink:to="loc_us-gaap_CommonStockMember_77C30CDFE372B7D5B5EFDDA4F7BAA798" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_BusinessAcquisitionLineItems" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_385F4649A184F137C5E8DDA4F7BACC26" xlink:type="locator" />
    <presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_6F08A45F81B05E3AE47ADDA4F7B4EA07" xlink:to="loc_us-gaap_BusinessAcquisitionLineItems_385F4649A184F137C5E8DDA4F7BACC26" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_972D3D20690609802907DDA4F7BA3E40" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_385F4649A184F137C5E8DDA4F7BACC26" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_972D3D20690609802907DDA4F7BA3E40" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_BusinessAcquisitionEquityInterestIssuedOrIssuableValueAssigned" xlink:label="loc_us-gaap_BusinessAcquisitionEquityInterestIssuedOrIssuableValueAssigned_3CCE5A0FBF680E6D4A14DDA4F7BA568E" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_385F4649A184F137C5E8DDA4F7BACC26" xlink:to="loc_us-gaap_BusinessAcquisitionEquityInterestIssuedOrIssuableValueAssigned_3CCE5A0FBF680E6D4A14DDA4F7BA568E" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred_F2CD3D864867AFBCFB9ADDA4F7BA2407" xlink:type="locator" />
    <presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_385F4649A184F137C5E8DDA4F7BACC26" xlink:to="loc_us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred_F2CD3D864867AFBCFB9ADDA4F7BA2407" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_BusinessCombinationConsiderationTransferredOther1" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferredOther1_AB376670F37E4E6FE961DDA4F7BAA121" xlink:type="locator" />
    <presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_385F4649A184F137C5E8DDA4F7BACC26" xlink:to="loc_us-gaap_BusinessCombinationConsiderationTransferredOther1_AB376670F37E4E6FE961DDA4F7BAA121" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_BusinessCombinationConsiderationTransferred1" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferred1_A53C9821ACB207EE160DDDA4F7BAC1B9" xlink:type="locator" />
    <presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_385F4649A184F137C5E8DDA4F7BACC26" xlink:to="loc_us-gaap_BusinessCombinationConsiderationTransferred1_A53C9821ACB207EE160DDDA4F7BAC1B9" xlink:type="arc" />
    <loc xlink:href="gale-20150930.xsd#gale_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedRights" xlink:label="loc_gale_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedRights_CD83B96F201E6F5C3F9BDDA4F7BBF567" xlink:type="locator" />
    <presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_385F4649A184F137C5E8DDA4F7BACC26" xlink:to="loc_gale_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedRights_CD83B96F201E6F5C3F9BDDA4F7BBF567" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_Goodwill" xlink:label="loc_us-gaap_Goodwill_B74D8577439916B3015FDDA4F7BB8A07" xlink:type="locator" />
    <presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_385F4649A184F137C5E8DDA4F7BACC26" xlink:to="loc_us-gaap_Goodwill_B74D8577439916B3015FDDA4F7BB8A07" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueOfAssetsAcquired" xlink:label="loc_us-gaap_FairValueOfAssetsAcquired_2C5397D3C347296B9BE5DDA4F7BB0910" xlink:type="locator" />
    <presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_385F4649A184F137C5E8DDA4F7BACC26" xlink:to="loc_us-gaap_FairValueOfAssetsAcquired_2C5397D3C347296B9BE5DDA4F7BB0910" xlink:type="arc" />
  </presentationLink>
  <presentationLink xlink:role="http://www.galenabiopharma.com/role/BusinessCombinationsTables" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_BusinessCombinationsAbstract" xlink:label="loc_us-gaap_BusinessCombinationsAbstract_A06DB7A0169AB241B4B5DDA4F7BDC250" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock_EBA2A7344EABA801D8CADDA4F7BD311F" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationsAbstract_A06DB7A0169AB241B4B5DDA4F7BDC250" xlink:to="loc_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock_EBA2A7344EABA801D8CADDA4F7BD311F" xlink:type="arc" />
  </presentationLink>
  <presentationLink xlink:role="http://www.galenabiopharma.com/role/CondensedConsolidatedBalanceSheets" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_B618A651F1C6B444336BDE2E96DF3E90" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AssetsAbstract" xlink:label="loc_us-gaap_AssetsAbstract_E6385B952618B104D879DE2E96DF6791" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_B618A651F1C6B444336BDE2E96DF3E90" xlink:to="loc_us-gaap_AssetsAbstract_E6385B952618B104D879DE2E96DF6791" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="loc_us-gaap_AssetsCurrentAbstract_03731BC327C70B8BFC31DE2E96DF7695" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_E6385B952618B104D879DE2E96DF6791" xlink:to="loc_us-gaap_AssetsCurrentAbstract_03731BC327C70B8BFC31DE2E96DF7695" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_C79807E0A720064525ADDE2E96DF07D5" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_03731BC327C70B8BFC31DE2E96DF7695" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_C79807E0A720064525ADDE2E96DF07D5" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue_A568757A89F9C62DCEBBDE2E96DFFE5B" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_03731BC327C70B8BFC31DE2E96DF7695" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue_A568757A89F9C62DCEBBDE2E96DFFE5B" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_A384CE9D094FB444A524DE2E96E074A7" xlink:type="locator" />
    <presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_03731BC327C70B8BFC31DE2E96DF7695" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_A384CE9D094FB444A524DE2E96E074A7" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_InventoryNet" xlink:label="loc_us-gaap_InventoryNet_F066F4593A58D13E0F15DE2E96E00514" xlink:type="locator" />
    <presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_03731BC327C70B8BFC31DE2E96DF7695" xlink:to="loc_us-gaap_InventoryNet_F066F4593A58D13E0F15DE2E96E00514" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_964BE8F671CC1B2DF0B0DE2E96E07206" xlink:type="locator" />
    <presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_03731BC327C70B8BFC31DE2E96DF7695" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_964BE8F671CC1B2DF0B0DE2E96E07206" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent" xlink:label="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent_0AB1C73ADCC7CBF1A2C0DE7039B5AF00" xlink:type="locator" />
    <presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_03731BC327C70B8BFC31DE2E96DF7695" xlink:to="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent_0AB1C73ADCC7CBF1A2C0DE7039B5AF00" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaap_AssetsCurrent_81C7131D3F76CF4712D7DE2E96E01E50" xlink:type="locator" />
    <presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_03731BC327C70B8BFC31DE2E96DF7695" xlink:to="loc_us-gaap_AssetsCurrent_81C7131D3F76CF4712D7DE2E96E01E50" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_41AFCA7E094D88232509DE2E96E002A9" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_E6385B952618B104D879DE2E96DF6791" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_41AFCA7E094D88232509DE2E96E002A9" xlink:type="arc" />
    <loc xlink:href="gale-20150930.xsd#gale_InProcessResearchDevelopment" xlink:label="loc_gale_InProcessResearchDevelopment_10572EECD387BCFC19D9DE2E96E0CE15" xlink:type="locator" />
    <presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_E6385B952618B104D879DE2E96DF6791" xlink:to="loc_gale_InProcessResearchDevelopment_10572EECD387BCFC19D9DE2E96E0CE15" xlink:type="arc" />
    <loc xlink:href="gale-20150930.xsd#gale_SalesAndDistributionsRights" xlink:label="loc_gale_SalesAndDistributionsRights_6B6562BF508999E05C6BDE2E96E06737" xlink:type="locator" />
    <presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_E6385B952618B104D879DE2E96DF6791" xlink:to="loc_gale_SalesAndDistributionsRights_6B6562BF508999E05C6BDE2E96E06737" xlink:type="arc" />
    <loc xlink:href="gale-20150930.xsd#gale_SalesAndDistributionsRightsZuplenz" xlink:label="loc_gale_SalesAndDistributionsRightsZuplenz_5B63855DE96A47ADCDD8DE2E96E0809F" xlink:type="locator" />
    <presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_E6385B952618B104D879DE2E96DF6791" xlink:to="loc_gale_SalesAndDistributionsRightsZuplenz_5B63855DE96A47ADCDD8DE2E96E0809F" xlink:type="arc" />
    <loc xlink:href="gale-20150930.xsd#gale_GALE401rights" xlink:label="loc_gale_GALE401rights_4CAB1C51D926CC3BA46BDE2E96E09765" xlink:type="locator" />
    <presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_E6385B952618B104D879DE2E96DF6791" xlink:to="loc_gale_GALE401rights_4CAB1C51D926CC3BA46BDE2E96E09765" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_Goodwill" xlink:label="loc_us-gaap_Goodwill_8F8925EFFDD30EAEC809DE2E96E01B5B" xlink:type="locator" />
    <presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_E6385B952618B104D879DE2E96DF6791" xlink:to="loc_us-gaap_Goodwill_8F8925EFFDD30EAEC809DE2E96E01B5B" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DepositsAssetsNoncurrent" xlink:label="loc_us-gaap_DepositsAssetsNoncurrent_7AA5933270246261924BDE2E96E0D516" xlink:type="locator" />
    <presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_E6385B952618B104D879DE2E96DF6791" xlink:to="loc_us-gaap_DepositsAssetsNoncurrent_7AA5933270246261924BDE2E96E0D516" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_Assets" xlink:label="loc_us-gaap_Assets_95E7C6E589F7C9309C92DE2E96E06FD8" xlink:type="locator" />
    <presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_E6385B952618B104D879DE2E96DF6791" xlink:to="loc_us-gaap_Assets_95E7C6E589F7C9309C92DE2E96E06FD8" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_564A69E00E07D01EF701DE2E96E03F9F" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_B618A651F1C6B444336BDE2E96DF3E90" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_564A69E00E07D01EF701DE2E96E03F9F" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_80597E87019B335097D1DE2E96E090E3" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_564A69E00E07D01EF701DE2E96E03F9F" xlink:to="loc_us-gaap_LiabilitiesCurrentAbstract_80597E87019B335097D1DE2E96E090E3" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="loc_us-gaap_AccountsPayableCurrent_A0AC4C5EF4FADD3C8BA1DE2E96E07117" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_80597E87019B335097D1DE2E96E090E3" xlink:to="loc_us-gaap_AccountsPayableCurrent_A0AC4C5EF4FADD3C8BA1DE2E96E07117" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_5D8C964BD71F42DF60ABDE2E96E0E6CE" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_80597E87019B335097D1DE2E96E090E3" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_5D8C964BD71F42DF60ABDE2E96E0E6CE" xlink:type="arc" />
    <loc xlink:href="gale-20150930.xsd#gale_FairValueOfWarrantsPotentiallySettleableInCash" xlink:label="loc_gale_FairValueOfWarrantsPotentiallySettleableInCash_1ECB52357A63D3948566DE2E96E012AA" xlink:type="locator" />
    <presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_80597E87019B335097D1DE2E96E090E3" xlink:to="loc_gale_FairValueOfWarrantsPotentiallySettleableInCash_1ECB52357A63D3948566DE2E96E012AA" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LongTermDebtCurrent" xlink:label="loc_us-gaap_LongTermDebtCurrent_9E15B5141027F1C2BFB2DE2E96E0B3E1" xlink:type="locator" />
    <presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_80597E87019B335097D1DE2E96E090E3" xlink:to="loc_us-gaap_LongTermDebtCurrent_9E15B5141027F1C2BFB2DE2E96E0B3E1" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent" xlink:label="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent_56B8D880591FB70C284FDE710C2D0EA0" xlink:type="locator" />
    <presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_80597E87019B335097D1DE2E96E090E3" xlink:to="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent_56B8D880591FB70C284FDE710C2D0EA0" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaap_LiabilitiesCurrent_DDEBC82A2BC0FB0D2EE4DE2E96E15C25" xlink:type="locator" />
    <presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_80597E87019B335097D1DE2E96E090E3" xlink:to="loc_us-gaap_LiabilitiesCurrent_DDEBC82A2BC0FB0D2EE4DE2E96E15C25" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNetNoncurrent" xlink:label="loc_us-gaap_DeferredTaxAssetsLiabilitiesNetNoncurrent_DD4CC87C645E8D74DE51DE2E96E19FEB" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_564A69E00E07D01EF701DE2E96E03F9F" xlink:to="loc_us-gaap_DeferredTaxAssetsLiabilitiesNetNoncurrent_DD4CC87C645E8D74DE51DE2E96E19FEB" xlink:type="arc" />
    <loc xlink:href="gale-20150930.xsd#gale_ContingentPurchasePriceConsiderationNetOfCurrentPortion" xlink:label="loc_gale_ContingentPurchasePriceConsiderationNetOfCurrentPortion_6CCE974CBDA8358AD17BDE2E96E1D468" xlink:type="locator" />
    <presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_564A69E00E07D01EF701DE2E96E03F9F" xlink:to="loc_gale_ContingentPurchasePriceConsiderationNetOfCurrentPortion_6CCE974CBDA8358AD17BDE2E96E1D468" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LongTermDebtNoncurrent" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_79589E9A6845BAFCF5AADE2E96E1F857" xlink:type="locator" />
    <presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_564A69E00E07D01EF701DE2E96E03F9F" xlink:to="loc_us-gaap_LongTermDebtNoncurrent_79589E9A6845BAFCF5AADE2E96E1F857" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaap_Liabilities_DFD7D03B72DF31F81617DE2E96E12FAF" xlink:type="locator" />
    <presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_564A69E00E07D01EF701DE2E96E03F9F" xlink:to="loc_us-gaap_Liabilities_DFD7D03B72DF31F81617DE2E96E12FAF" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="loc_us-gaap_CommitmentsAndContingencies_45664A8220B6180A1200DE2E96E12DAC" xlink:type="locator" />
    <presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_564A69E00E07D01EF701DE2E96E03F9F" xlink:to="loc_us-gaap_CommitmentsAndContingencies_45664A8220B6180A1200DE2E96E12DAC" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="loc_us-gaap_StockholdersEquityAbstract_DE16B15C5F76BB809846DE2E96E108CA" xlink:type="locator" />
    <presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_564A69E00E07D01EF701DE2E96E03F9F" xlink:to="loc_us-gaap_StockholdersEquityAbstract_DE16B15C5F76BB809846DE2E96E108CA" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PreferredStockValue" xlink:label="loc_us-gaap_PreferredStockValue_065C9E55B606BA43FA86DE2E96E1B1BE" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_DE16B15C5F76BB809846DE2E96E108CA" xlink:to="loc_us-gaap_PreferredStockValue_065C9E55B606BA43FA86DE2E96E1B1BE" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaap_CommonStockValue_6267593E3731052E4A8ADE2E96E1AE84" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_DE16B15C5F76BB809846DE2E96E108CA" xlink:to="loc_us-gaap_CommonStockValue_6267593E3731052E4A8ADE2E96E1AE84" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock_B07D9656ECAB75D8D8E1DE2E96E1017D" xlink:type="locator" />
    <presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_DE16B15C5F76BB809846DE2E96E108CA" xlink:to="loc_us-gaap_AdditionalPaidInCapitalCommonStock_B07D9656ECAB75D8D8E1DE2E96E1017D" xlink:type="arc" />
    <loc xlink:href="gale-20150930.xsd#gale_DeficitAccumulatedDuringDevelopmentalStage" xlink:label="loc_gale_DeficitAccumulatedDuringDevelopmentalStage_A2CB610CF173D57B3AD1DE2E96E1EAA4" xlink:type="locator" />
    <presentationArc order="4" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_DE16B15C5F76BB809846DE2E96E108CA" xlink:to="loc_gale_DeficitAccumulatedDuringDevelopmentalStage_A2CB610CF173D57B3AD1DE2E96E1EAA4" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_TreasuryStockValue" xlink:label="loc_us-gaap_TreasuryStockValue_215286116C7D59B844C4DE2E96E1C30D" xlink:type="locator" />
    <presentationArc order="5" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_DE16B15C5F76BB809846DE2E96E108CA" xlink:to="loc_us-gaap_TreasuryStockValue_215286116C7D59B844C4DE2E96E1C30D" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_C2C9FB3D73A9559DC4FADE2E96E1238D" xlink:type="locator" />
    <presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_DE16B15C5F76BB809846DE2E96E108CA" xlink:to="loc_us-gaap_StockholdersEquity_C2C9FB3D73A9559DC4FADE2E96E1238D" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_AAD9A74B33B6BB271CD8DE2E96E15405" xlink:type="locator" />
    <presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_564A69E00E07D01EF701DE2E96E03F9F" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquity_AAD9A74B33B6BB271CD8DE2E96E15405" xlink:type="arc" />
  </presentationLink>
  <presentationLink xlink:role="http://www.galenabiopharma.com/role/CondensedConsolidatedBalanceSheetsParenthetical" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_2D38A5F904A85F5887BCCF09FFF460E3" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_470A7C09AF0F5CFFA5EEEEEA9E5FD9C0" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_2D38A5F904A85F5887BCCF09FFF460E3" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_470A7C09AF0F5CFFA5EEEEEA9E5FD9C0" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_2E1F3BE980075A5782D4FAD33D0442C4" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_2D38A5F904A85F5887BCCF09FFF460E3" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_2E1F3BE980075A5782D4FAD33D0442C4" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="loc_us-gaap_PreferredStockSharesIssued_217151036E1450E5AD491C8F4C1D4974" xlink:type="locator" />
    <presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_2D38A5F904A85F5887BCCF09FFF460E3" xlink:to="loc_us-gaap_PreferredStockSharesIssued_217151036E1450E5AD491C8F4C1D4974" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding_15EB80215B105F48B72F8201A6DD11CD" xlink:type="locator" />
    <presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_2D38A5F904A85F5887BCCF09FFF460E3" xlink:to="loc_us-gaap_PreferredStockSharesOutstanding_15EB80215B105F48B72F8201A6DD11CD" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_BA66A026452355C5BAE54823DE2C8350" xlink:type="locator" />
    <presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_2D38A5F904A85F5887BCCF09FFF460E3" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_BA66A026452355C5BAE54823DE2C8350" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_CB165C9736E45DB5A94AE17C32DE0F89" xlink:type="locator" />
    <presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_2D38A5F904A85F5887BCCF09FFF460E3" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_CB165C9736E45DB5A94AE17C32DE0F89" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaap_CommonStockSharesIssued_A2E5EBC8B5CA5D4999B1D8F9269550D8" xlink:type="locator" />
    <presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_2D38A5F904A85F5887BCCF09FFF460E3" xlink:to="loc_us-gaap_CommonStockSharesIssued_A2E5EBC8B5CA5D4999B1D8F9269550D8" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_BEA88C7670435DC1A1E9B4A9FA4BC95E" xlink:type="locator" />
    <presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_2D38A5F904A85F5887BCCF09FFF460E3" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_BEA88C7670435DC1A1E9B4A9FA4BC95E" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_TreasuryStockShares" xlink:label="loc_us-gaap_TreasuryStockShares_5450E33B182C5A508CD61581838D29DD" xlink:type="locator" />
    <presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_2D38A5F904A85F5887BCCF09FFF460E3" xlink:to="loc_us-gaap_TreasuryStockShares_5450E33B182C5A508CD61581838D29DD" xlink:type="arc" />
  </presentationLink>
  <presentationLink xlink:role="http://www.galenabiopharma.com/role/CondensedConsolidatedStatementOfStockholdersEquityCondensedConsolidatedStatementOfStockholdersEquity" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_DDBAEB77D6FD58BEA1CE21530CB08832" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_A6BC268507DB5D6C801EEF1E351A33EC" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_DDBAEB77D6FD58BEA1CE21530CB08832" xlink:to="loc_us-gaap_StatementTable_A6BC268507DB5D6C801EEF1E351A33EC" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_6A5FD0AC8FD65A53A7F956A80E3C9436" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_A6BC268507DB5D6C801EEF1E351A33EC" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_6A5FD0AC8FD65A53A7F956A80E3C9436" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_B45758336F5B5E4CB688B8729BE9EF77" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_6A5FD0AC8FD65A53A7F956A80E3C9436" xlink:to="loc_us-gaap_EquityComponentDomain_B45758336F5B5E4CB688B8729BE9EF77" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember_741D613D4B1057D0A21E22B248287B1E" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_B45758336F5B5E4CB688B8729BE9EF77" xlink:to="loc_us-gaap_CommonStockMember_741D613D4B1057D0A21E22B248287B1E" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_E762029C2994514EB347BC5CB7FB969E" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_B45758336F5B5E4CB688B8729BE9EF77" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_E762029C2994514EB347BC5CB7FB969E" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="loc_us-gaap_RetainedEarningsMember_82B720A3DC9755A0B0BFA416B85E6692" xlink:type="locator" />
    <presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_B45758336F5B5E4CB688B8729BE9EF77" xlink:to="loc_us-gaap_RetainedEarningsMember_82B720A3DC9755A0B0BFA416B85E6692" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_TreasuryStockMember" xlink:label="loc_us-gaap_TreasuryStockMember_0846AD51934054C8AA55F67F85B00ED0" xlink:type="locator" />
    <presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_B45758336F5B5E4CB688B8729BE9EF77" xlink:to="loc_us-gaap_TreasuryStockMember_0846AD51934054C8AA55F67F85B00ED0" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_95E1CD636ACC56FFB51496FEC3A9B2B7" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_A6BC268507DB5D6C801EEF1E351A33EC" xlink:to="loc_us-gaap_StatementLineItems_95E1CD636ACC56FFB51496FEC3A9B2B7" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_78BA6500FAF1599585AFC9BE3BE5BB0D" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_95E1CD636ACC56FFB51496FEC3A9B2B7" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_78BA6500FAF1599585AFC9BE3BE5BB0D" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SharesOutstanding" xlink:label="loc_us-gaap_SharesOutstanding_C1133C86FBA659CDA15C89A3DDB2C6DB" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_78BA6500FAF1599585AFC9BE3BE5BB0D" xlink:to="loc_us-gaap_SharesOutstanding_C1133C86FBA659CDA15C89A3DDB2C6DB" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_332CCB7DF16E5C5C82B63FD0AB91B7CE" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_78BA6500FAF1599585AFC9BE3BE5BB0D" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_332CCB7DF16E5C5C82B63FD0AB91B7CE" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesOther" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesOther_438DF48CEC095297BB69520E60FDCC40" xlink:type="locator" />
    <presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_78BA6500FAF1599585AFC9BE3BE5BB0D" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesOther_438DF48CEC095297BB69520E60FDCC40" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueOther" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueOther_9C4B48EDD3A75F08B118E7B1BABFE048" xlink:type="locator" />
    <presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_78BA6500FAF1599585AFC9BE3BE5BB0D" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueOther_9C4B48EDD3A75F08B118E7B1BABFE048" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_CE99E2A4BD0F5CA9A9535415BF4872AA" xlink:type="locator" />
    <presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_78BA6500FAF1599585AFC9BE3BE5BB0D" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_CE99E2A4BD0F5CA9A9535415BF4872AA" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_5B6A408D17D75B8CADF4804740C4D94C" xlink:type="locator" />
    <presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_78BA6500FAF1599585AFC9BE3BE5BB0D" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_5B6A408D17D75B8CADF4804740C4D94C" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_B812C9F4CDF857E5B1BA7099A500A36D" xlink:type="locator" />
    <presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_78BA6500FAF1599585AFC9BE3BE5BB0D" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_B812C9F4CDF857E5B1BA7099A500A36D" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_1416CAF360EC54199A44A2E277456BE7" xlink:type="locator" />
    <presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_78BA6500FAF1599585AFC9BE3BE5BB0D" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_1416CAF360EC54199A44A2E277456BE7" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalTaxEffectFromShareBasedCompensation" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalTaxEffectFromShareBasedCompensation_6A82047EC62A5E8B9FDDDA3C18F4B8DE" xlink:type="locator" />
    <presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_78BA6500FAF1599585AFC9BE3BE5BB0D" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalTaxEffectFromShareBasedCompensation_6A82047EC62A5E8B9FDDDA3C18F4B8DE" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_FC5F2601BAFA5E7A99E560BC00244D09" xlink:type="locator" />
    <presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_78BA6500FAF1599585AFC9BE3BE5BB0D" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_FC5F2601BAFA5E7A99E560BC00244D09" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_12B9F9D3550A59B98F239BCCD652AF6E" xlink:type="locator" />
    <presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_78BA6500FAF1599585AFC9BE3BE5BB0D" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_12B9F9D3550A59B98F239BCCD652AF6E" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_35219881DB6451E8820F475A55CDB1DE" xlink:type="locator" />
    <presentationArc order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_78BA6500FAF1599585AFC9BE3BE5BB0D" xlink:to="loc_us-gaap_NetIncomeLoss_35219881DB6451E8820F475A55CDB1DE" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SharesOutstanding" xlink:label="loc_us-gaap_SharesOutstanding_726D137F3EB85063931D7FE3A3402A57" xlink:type="locator" />
    <presentationArc order="13" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_78BA6500FAF1599585AFC9BE3BE5BB0D" xlink:to="loc_us-gaap_SharesOutstanding_726D137F3EB85063931D7FE3A3402A57" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_9AECD271B98252CFAD1C5B6255F6D596" xlink:type="locator" />
    <presentationArc order="14" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_78BA6500FAF1599585AFC9BE3BE5BB0D" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_9AECD271B98252CFAD1C5B6255F6D596" xlink:type="arc" />
  </presentationLink>
  <presentationLink xlink:role="http://www.galenabiopharma.com/role/CondensedConsolidatedStatementsOfCashFlows" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract_42EF57CD448739DAC6C0DECFB1445E4C" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_833B465F01FBA6E9A439DECFB144B6B8" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_42EF57CD448739DAC6C0DECFB1445E4C" xlink:to="loc_us-gaap_StatementTable_833B465F01FBA6E9A439DECFB144B6B8" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_644B76335F8D3E5177F6DECFB144BE9D" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_833B465F01FBA6E9A439DECFB144B6B8" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_644B76335F8D3E5177F6DECFB144BE9D" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_A1F176C14C1F6400B642DECFB145A390" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_644B76335F8D3E5177F6DECFB144BE9D" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_A1F176C14C1F6400B642DECFB145A390" xlink:type="arc" />
    <loc xlink:href="gale-20150930.xsd#gale_AbstralMember" xlink:label="loc_gale_AbstralMember_8A6D9A18639A5E0E8194DECFB1453685" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_A1F176C14C1F6400B642DECFB145A390" xlink:to="loc_gale_AbstralMember_8A6D9A18639A5E0E8194DECFB1453685" xlink:type="arc" />
    <loc xlink:href="gale-20150930.xsd#gale_ZuplenzMember" xlink:label="loc_gale_ZuplenzMember_9E4577B7245ACFF4F031DECFB145075B" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_A1F176C14C1F6400B642DECFB145A390" xlink:to="loc_gale_ZuplenzMember_9E4577B7245ACFF4F031DECFB145075B" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_B9483F2F1F272C9C9D19DECFB1456D53" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_833B465F01FBA6E9A439DECFB144B6B8" xlink:to="loc_us-gaap_StatementLineItems_B9483F2F1F272C9C9D19DECFB1456D53" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_2C747EC46E27FF3C82E4DEE7D083E8BE" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_B9483F2F1F272C9C9D19DECFB1456D53" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_2C747EC46E27FF3C82E4DEE7D083E8BE" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_CCBDF903615CD281FE68DECFB145C274" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_B9483F2F1F272C9C9D19DECFB1456D53" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_CCBDF903615CD281FE68DECFB145C274" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_039E85029DD12E1B3B27DECFB145E917" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_CCBDF903615CD281FE68DECFB145C274" xlink:to="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_039E85029DD12E1B3B27DECFB145E917" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_191924000600F93A7B0BDECFB14AA4E5" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_039E85029DD12E1B3B27DECFB145E917" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_191924000600F93A7B0BDECFB14AA4E5" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaap_ShareBasedCompensation_7937A84F98D9E00D3068DECFB14A0EBE" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_039E85029DD12E1B3B27DECFB145E917" xlink:to="loc_us-gaap_ShareBasedCompensation_7937A84F98D9E00D3068DECFB14A0EBE" xlink:type="arc" />
    <loc xlink:href="gale-20150930.xsd#gale_ChangeInFairValueOfCommonStockWarrantsIssuedInConnectionWithVariousEquityFinancings" xlink:label="loc_gale_ChangeInFairValueOfCommonStockWarrantsIssuedInConnectionWithVariousEquityFinancings_C00AE340FF13CB57B40ADECFB14AF7CD" xlink:type="locator" />
    <presentationArc order="3" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_039E85029DD12E1B3B27DECFB145E917" xlink:to="loc_gale_ChangeInFairValueOfCommonStockWarrantsIssuedInConnectionWithVariousEquityFinancings_C00AE340FF13CB57B40ADECFB14AF7CD" xlink:type="arc" />
    <loc xlink:href="gale-20150930.xsd#gale_ChangeInFairValueOfContingentPurchaseConsideration" xlink:label="loc_gale_ChangeInFairValueOfContingentPurchaseConsideration_51BDE794020ABC65AD49DECFB14A1D20" xlink:type="locator" />
    <presentationArc order="4" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_039E85029DD12E1B3B27DECFB145E917" xlink:to="loc_gale_ChangeInFairValueOfContingentPurchaseConsideration_51BDE794020ABC65AD49DECFB14A1D20" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_1D39042AA97DC69BCC7ADECFB14A3BA1" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_CCBDF903615CD281FE68DECFB145C274" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_1D39042AA97DC69BCC7ADECFB14A3BA1" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_3D08D946986C5D996324DECFB14A26A8" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_1D39042AA97DC69BCC7ADECFB14A3BA1" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_3D08D946986C5D996324DECFB14A26A8" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable_A8B17C08F5B70E1A6AE2DECFB14A6D89" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_1D39042AA97DC69BCC7ADECFB14A3BA1" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayable_A8B17C08F5B70E1A6AE2DECFB14A6D89" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_4B5D1FE388FCEAB2254EDECFB14A3D24" xlink:type="locator" />
    <presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_1D39042AA97DC69BCC7ADECFB14A3BA1" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_4B5D1FE388FCEAB2254EDECFB14A3D24" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_C1221DE2F9CE10E36A72DECFB14B97BF" xlink:type="locator" />
    <presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_CCBDF903615CD281FE68DECFB145C274" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_C1221DE2F9CE10E36A72DECFB14B97BF" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax_FA3BCABD7563768C44D9DECFB14B5119" xlink:type="locator" />
    <presentationArc order="4" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_CCBDF903615CD281FE68DECFB145C274" xlink:to="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax_FA3BCABD7563768C44D9DECFB14B5119" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf" xlink:label="loc_us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf_82FA9E7246F7C650875FDECFB14B6CB7" xlink:type="locator" />
    <presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_CCBDF903615CD281FE68DECFB145C274" xlink:to="loc_us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf_82FA9E7246F7C650875FDECFB14B6CB7" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncreaseDecreaseInAssetsHeldForSale" xlink:label="loc_us-gaap_IncreaseDecreaseInAssetsHeldForSale_288E177A66ED957134BCDECFB14B2A62" xlink:type="locator" />
    <presentationArc order="6" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_CCBDF903615CD281FE68DECFB145C274" xlink:to="loc_us-gaap_IncreaseDecreaseInAssetsHeldForSale_288E177A66ED957134BCDECFB14B2A62" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations" xlink:label="loc_us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations_602F51B5546404D04884DECFB14B7E01" xlink:type="locator" />
    <presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_CCBDF903615CD281FE68DECFB145C274" xlink:to="loc_us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations_602F51B5546404D04884DECFB14B7E01" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_EBB9D03F28E25991181EDECFB14B5B64" xlink:type="locator" />
    <presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_CCBDF903615CD281FE68DECFB145C274" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_EBB9D03F28E25991181EDECFB14B5B64" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_4CB41BFA6BB6F341DB4BDECFB14BECE8" xlink:type="locator" />
    <presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_B9483F2F1F272C9C9D19DECFB1456D53" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_4CB41BFA6BB6F341DB4BDECFB14BECE8" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncreaseDecreaseInRestrictedCash" xlink:label="loc_us-gaap_IncreaseDecreaseInRestrictedCash_04BF2D4B5A813AC3D0A9DECFB14BE5D8" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_4CB41BFA6BB6F341DB4BDECFB14BECE8" xlink:to="loc_us-gaap_IncreaseDecreaseInRestrictedCash_04BF2D4B5A813AC3D0A9DECFB14BE5D8" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PaymentsToAcquireBusinessesGross" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesGross_48037E80F39D51C412AFDECFB14B9E92" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_4CB41BFA6BB6F341DB4BDECFB14BECE8" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesGross_48037E80F39D51C412AFDECFB14B9E92" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_0449D7BED612BC79F610DECFB14B433D" xlink:type="locator" />
    <presentationArc order="3" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_4CB41BFA6BB6F341DB4BDECFB14BECE8" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_0449D7BED612BC79F610DECFB14B433D" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations_DA98DEC5EB1396AEDD29DECFB14BD84D" xlink:type="locator" />
    <presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_4CB41BFA6BB6F341DB4BDECFB14BECE8" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations_DA98DEC5EB1396AEDD29DECFB14BD84D" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations" xlink:label="loc_us-gaap_CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations_8068DA8B834324BF1EE5DECFB14B9063" xlink:type="locator" />
    <presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_4CB41BFA6BB6F341DB4BDECFB14BECE8" xlink:to="loc_us-gaap_CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations_8068DA8B834324BF1EE5DECFB14B9063" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_4EC0E8788B1398A00E34DECFB14BD887" xlink:type="locator" />
    <presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_4CB41BFA6BB6F341DB4BDECFB14BECE8" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_4EC0E8788B1398A00E34DECFB14BD887" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_BA0A395456D450B07560DECFB14B5949" xlink:type="locator" />
    <presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_B9483F2F1F272C9C9D19DECFB1456D53" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_BA0A395456D450B07560DECFB14B5949" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_F6308569703CE949A25EDECFB14B1D60" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_BA0A395456D450B07560DECFB14B5949" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_F6308569703CE949A25EDECFB14B1D60" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised_0DA6D5B1965516F8CB88DECFB14BAF76" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_BA0A395456D450B07560DECFB14B5949" xlink:to="loc_us-gaap_ProceedsFromStockOptionsExercised_0DA6D5B1965516F8CB88DECFB14BAF76" xlink:type="arc" />
    <loc xlink:href="gale-20150930.xsd#gale_NetProceedsFromExerciseOfCommonStockWarrants" xlink:label="loc_gale_NetProceedsFromExerciseOfCommonStockWarrants_C8468E49C33E89FD8EEFDECFB14B2093" xlink:type="locator" />
    <presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_BA0A395456D450B07560DECFB14B5949" xlink:to="loc_gale_NetProceedsFromExerciseOfCommonStockWarrants_C8468E49C33E89FD8EEFDECFB14B2093" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:label="loc_us-gaap_ProceedsFromIssuanceOrSaleOfEquity_FC385DCA7D7E8A1E0BF3DECFB14CAC15" xlink:type="locator" />
    <presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_BA0A395456D450B07560DECFB14B5949" xlink:to="loc_us-gaap_ProceedsFromIssuanceOrSaleOfEquity_FC385DCA7D7E8A1E0BF3DECFB14CAC15" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RepaymentsOfLongTermDebt" xlink:label="loc_us-gaap_RepaymentsOfLongTermDebt_E769B039C1E90123DA56DECFB14CD014" xlink:type="locator" />
    <presentationArc order="5" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_BA0A395456D450B07560DECFB14B5949" xlink:to="loc_us-gaap_RepaymentsOfLongTermDebt_E769B039C1E90123DA56DECFB14CD014" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_109FF286CA2D47B266F7DECFB14C8998" xlink:type="locator" />
    <presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_BA0A395456D450B07560DECFB14B5949" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_109FF286CA2D47B266F7DECFB14C8998" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:label="loc_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_58C6A6246259D5256F97DECFB14C9380" xlink:type="locator" />
    <presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_B9483F2F1F272C9C9D19DECFB1456D53" xlink:to="loc_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_58C6A6246259D5256F97DECFB14C9380" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_9AA3081D60D23029C22EDECFB14C7D36" xlink:type="locator" />
    <presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_B9483F2F1F272C9C9D19DECFB1456D53" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_9AA3081D60D23029C22EDECFB14C7D36" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_3827AA13C33134EF838DDECFB14C2E6A" xlink:type="locator" />
    <presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_B9483F2F1F272C9C9D19DECFB1456D53" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_3827AA13C33134EF838DDECFB14C2E6A" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract_D55855D8687C632F9753DECFB14CBC22" xlink:type="locator" />
    <presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_B9483F2F1F272C9C9D19DECFB1456D53" xlink:to="loc_us-gaap_SupplementalCashFlowInformationAbstract_D55855D8687C632F9753DECFB14CBC22" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ProceedsFromInterestReceived" xlink:label="loc_us-gaap_ProceedsFromInterestReceived_67C228FC9C83E985B811DECFB14C1E99" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_D55855D8687C632F9753DECFB14CBC22" xlink:to="loc_us-gaap_ProceedsFromInterestReceived_67C228FC9C83E985B811DECFB14C1E99" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_InterestPaid" xlink:label="loc_us-gaap_InterestPaid_E6F1BE03E0558F4A26B8DECFB14C88E8" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_D55855D8687C632F9753DECFB14CBC22" xlink:to="loc_us-gaap_InterestPaid_E6F1BE03E0558F4A26B8DECFB14C88E8" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:label="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_4217351EF9E0882536DBDECFB14CBB48" xlink:type="locator" />
    <presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_B9483F2F1F272C9C9D19DECFB1456D53" xlink:to="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_4217351EF9E0882536DBDECFB14CBB48" xlink:type="arc" />
    <loc xlink:href="gale-20150930.xsd#gale_FairValueOfWarrantsIssuedInConnectionWithCommonStockRecordedAsCostOfEquity" xlink:label="loc_gale_FairValueOfWarrantsIssuedInConnectionWithCommonStockRecordedAsCostOfEquity_0C874305ED8A314B8C3CDECFB14CDC62" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_4217351EF9E0882536DBDECFB14CBB48" xlink:to="loc_gale_FairValueOfWarrantsIssuedInConnectionWithCommonStockRecordedAsCostOfEquity_0C874305ED8A314B8C3CDECFB14CDC62" xlink:type="arc" />
    <loc xlink:href="gale-20150930.xsd#gale_ReclassificationOfWarrantLiabilityUponExercise" xlink:label="loc_gale_ReclassificationOfWarrantLiabilityUponExercise_1DABF2C73AD23FB0425DDECFB14CEE6D" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_4217351EF9E0882536DBDECFB14CBB48" xlink:to="loc_gale_ReclassificationOfWarrantLiabilityUponExercise_1DABF2C73AD23FB0425DDECFB14CEE6D" xlink:type="arc" />
  </presentationLink>
  <presentationLink xlink:role="http://www.galenabiopharma.com/role/CondensedConsolidatedStatementsOfComprehensiveLoss" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:label="loc_us-gaap_IncomeStatementAbstract_4F7484249900195CCF72DECFB16D4B26" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_5F6B819DA0807A49A31EDECFB16D4E80" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_4F7484249900195CCF72DECFB16D4B26" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_5F6B819DA0807A49A31EDECFB16D4E80" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SalesRevenueNet" xlink:label="loc_us-gaap_SalesRevenueNet_4ED930C40F728C1F0329DECFB16D8D0B" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_4F7484249900195CCF72DECFB16D4B26" xlink:to="loc_us-gaap_SalesRevenueNet_4ED930C40F728C1F0329DECFB16D8D0B" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="loc_us-gaap_OperatingExpensesAbstract_0C5D62A368BDA98DD540DECFB16DEC5D" xlink:type="locator" />
    <presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_4F7484249900195CCF72DECFB16D4B26" xlink:to="loc_us-gaap_OperatingExpensesAbstract_0C5D62A368BDA98DD540DECFB16DEC5D" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CostOfRevenue" xlink:label="loc_us-gaap_CostOfRevenue_E6E287D026F776B4EA61DECFB16D85AD" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_0C5D62A368BDA98DD540DECFB16DEC5D" xlink:to="loc_us-gaap_CostOfRevenue_E6E287D026F776B4EA61DECFB16D85AD" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_90A4CFF321AD1BDC04F7DECFB16DE2A1" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_0C5D62A368BDA98DD540DECFB16DEC5D" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_90A4CFF321AD1BDC04F7DECFB16DE2A1" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_33CFA4273F606FBCB59ADECFB16D4A4E" xlink:type="locator" />
    <presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_0C5D62A368BDA98DD540DECFB16DEC5D" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpense_33CFA4273F606FBCB59ADECFB16D4A4E" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AmortizationOfIntangibleAssets" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets_8F1AAC277D1DD36D6383DECFB16D756D" xlink:type="locator" />
    <presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_0C5D62A368BDA98DD540DECFB16DEC5D" xlink:to="loc_us-gaap_AmortizationOfIntangibleAssets_8F1AAC277D1DD36D6383DECFB16D756D" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CostsAndExpenses" xlink:label="loc_us-gaap_CostsAndExpenses_CCC2FD56C120084EEED8DECFB16D4596" xlink:type="locator" />
    <presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_0C5D62A368BDA98DD540DECFB16DEC5D" xlink:to="loc_us-gaap_CostsAndExpenses_CCC2FD56C120084EEED8DECFB16D4596" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaap_OperatingIncomeLoss_92FAFF7EC1A4AEDA9CE6DECFB16DC8FD" xlink:type="locator" />
    <presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_0C5D62A368BDA98DD540DECFB16DEC5D" xlink:to="loc_us-gaap_OperatingIncomeLoss_92FAFF7EC1A4AEDA9CE6DECFB16DC8FD" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NonoperatingIncomeExpenseAbstract" xlink:label="loc_us-gaap_NonoperatingIncomeExpenseAbstract_43B2E5B9B94B4A6BC189DECFB16D593B" xlink:type="locator" />
    <presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_4F7484249900195CCF72DECFB16D4B26" xlink:to="loc_us-gaap_NonoperatingIncomeExpenseAbstract_43B2E5B9B94B4A6BC189DECFB16D593B" xlink:type="arc" />
    <loc xlink:href="gale-20150930.xsd#gale_LossOnWarrantExchange" xlink:label="loc_gale_LossOnWarrantExchange_55DBDDDB23B1FBB49CFADECFB16D0AF5" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_43B2E5B9B94B4A6BC189DECFB16D593B" xlink:to="loc_gale_LossOnWarrantExchange_55DBDDDB23B1FBB49CFADECFB16D0AF5" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_InterestIncomeExpenseNet" xlink:label="loc_us-gaap_InterestIncomeExpenseNet_B1306893D66AE66020C4DECFB16E5212" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_43B2E5B9B94B4A6BC189DECFB16D593B" xlink:to="loc_us-gaap_InterestIncomeExpenseNet_B1306893D66AE66020C4DECFB16E5212" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_22F075DF5A06F587A707DECFB16E32A0" xlink:type="locator" />
    <presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_43B2E5B9B94B4A6BC189DECFB16D593B" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_22F075DF5A06F587A707DECFB16E32A0" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OtherOperatingIncomeExpenseNet" xlink:label="loc_us-gaap_OtherOperatingIncomeExpenseNet_C7C20D11B58D33269798DECFB16EA466" xlink:type="locator" />
    <presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_43B2E5B9B94B4A6BC189DECFB16D593B" xlink:to="loc_us-gaap_OtherOperatingIncomeExpenseNet_C7C20D11B58D33269798DECFB16EA466" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax_AC17C1159252F48B9D12DECFB16E20AF" xlink:type="locator" />
    <presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_4F7484249900195CCF72DECFB16D4B26" xlink:to="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax_AC17C1159252F48B9D12DECFB16E20AF" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_60E83E4092E1FF8F56B0DECFB16EDFA9" xlink:type="locator" />
    <presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_4F7484249900195CCF72DECFB16D4B26" xlink:to="loc_us-gaap_NetIncomeLoss_60E83E4092E1FF8F56B0DECFB16EDFA9" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EarningsPerShareBasicAndDilutedAbstract" xlink:label="loc_us-gaap_EarningsPerShareBasicAndDilutedAbstract_C6B39BDDD850502AAB65DECFB16EFACD" xlink:type="locator" />
    <presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_4F7484249900195CCF72DECFB16D4B26" xlink:to="loc_us-gaap_EarningsPerShareBasicAndDilutedAbstract_C6B39BDDD850502AAB65DECFB16EFACD" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsPerBasicAndDilutedShare" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsPerBasicAndDilutedShare_D7B05E990B402D59796EDECFB16EDD33" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareBasicAndDilutedAbstract_C6B39BDDD850502AAB65DECFB16EFACD" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsPerBasicAndDilutedShare_D7B05E990B402D59796EDECFB16EDD33" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicAndDilutedShare" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicAndDilutedShare_053F272E208D0D2BA240DECFB16E5E9B" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareBasicAndDilutedAbstract_C6B39BDDD850502AAB65DECFB16EFACD" xlink:to="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicAndDilutedShare_053F272E208D0D2BA240DECFB16E5E9B" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EarningsPerShareBasic" xlink:label="loc_us-gaap_EarningsPerShareBasic_8D3F6C54DD32ADDCB205DECFB16E7854" xlink:type="locator" />
    <presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_4F7484249900195CCF72DECFB16D4B26" xlink:to="loc_us-gaap_EarningsPerShareBasic_8D3F6C54DD32ADDCB205DECFB16E7854" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:label="loc_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_C85DC6396288CA68593EDECFB16EAC0F" xlink:type="locator" />
    <presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_4F7484249900195CCF72DECFB16D4B26" xlink:to="loc_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_C85DC6396288CA68593EDECFB16EAC0F" xlink:type="arc" />
  </presentationLink>
  <presentationLink xlink:role="http://www.galenabiopharma.com/role/DiscontinuedOperationsAssetsHeldForSaleCarryingAmountsOfAssetsAndLiabilitiesDetails" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract" xlink:label="loc_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_CDF8FFF971370FD6502FDEEC4A098398" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_FC15CC0F9741C9F74764DEEC4A096745" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_CDF8FFF971370FD6502FDEEC4A098398" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_FC15CC0F9741C9F74764DEEC4A096745" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_20A9AC555EE4629F93A8DEEC4A09B0CF" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_FC15CC0F9741C9F74764DEEC4A096745" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_20A9AC555EE4629F93A8DEEC4A09B0CF" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_BEF614D9F375A46839B3DEEC4A09FFF9" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_20A9AC555EE4629F93A8DEEC4A09B0CF" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_BEF614D9F375A46839B3DEEC4A09FFF9" xlink:type="arc" />
    <loc xlink:href="gale-20150930.xsd#gale_AbstralRightsNetMember" xlink:label="loc_gale_AbstralRightsNetMember_482C82163038D52DDD05DEEC4A093416" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_BEF614D9F375A46839B3DEEC4A09FFF9" xlink:to="loc_gale_AbstralRightsNetMember_482C82163038D52DDD05DEEC4A093416" xlink:type="arc" />
    <loc xlink:href="gale-20150930.xsd#gale_ZuplenzRightsMember" xlink:label="loc_gale_ZuplenzRightsMember_9490DD5E45FAC34163FEDEEC4A09B1A5" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_BEF614D9F375A46839B3DEEC4A09FFF9" xlink:to="loc_gale_ZuplenzRightsMember_9490DD5E45FAC34163FEDEEC4A09B1A5" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_C86EA01710B89EB8AB03DEEC4A09B585" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_FC15CC0F9741C9F74764DEEC4A096745" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_C86EA01710B89EB8AB03DEEC4A09B585" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_57CC94EFBE5F0F4F58ACDEEC4A0AC884" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_C86EA01710B89EB8AB03DEEC4A09B585" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_57CC94EFBE5F0F4F58ACDEEC4A0AC884" xlink:type="arc" />
    <loc xlink:href="gale-20150930.xsd#gale_CommercialBusinessSegmentMember" xlink:label="loc_gale_CommercialBusinessSegmentMember_E4F761483B293455ECEDDEEC4A0ABD2B" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_57CC94EFBE5F0F4F58ACDEEC4A0AC884" xlink:to="loc_gale_CommercialBusinessSegmentMember_E4F761483B293455ECEDDEEC4A0ABD2B" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_19FEB59144560D59EE7EDEEC4A0AA37D" xlink:type="locator" />
    <presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_FC15CC0F9741C9F74764DEEC4A096745" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_19FEB59144560D59EE7EDEEC4A0AA37D" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet_4FD7CF3002F7A4F639CDDEEC4A0A7042" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_19FEB59144560D59EE7EDEEC4A0AA37D" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet_4FD7CF3002F7A4F639CDDEEC4A0A7042" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationInventory1" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationInventory1_7E46B7E821CB2CE9E89DDEEC4A0AF3A2" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_19FEB59144560D59EE7EDEEC4A0AA37D" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationInventory1_7E46B7E821CB2CE9E89DDEEC4A0AF3A2" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationPrepaidAndOtherAssets" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationPrepaidAndOtherAssets_0FE48BA816BA4C5C3B67DEEC4A0A89CF" xlink:type="locator" />
    <presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_19FEB59144560D59EE7EDEEC4A0AA37D" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationPrepaidAndOtherAssets_0FE48BA816BA4C5C3B67DEEC4A0A89CF" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment_4352A88CA1BA59081E6CDEEC4A0AA7D3" xlink:type="locator" />
    <presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_19FEB59144560D59EE7EDEEC4A0AA37D" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment_4352A88CA1BA59081E6CDEEC4A0AA7D3" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationIntangibleAssets" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationIntangibleAssets_D9D805C1D49B79575DDADEEC4A0AA6C0" xlink:type="locator" />
    <presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_19FEB59144560D59EE7EDEEC4A0AA37D" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationIntangibleAssets_D9D805C1D49B79575DDADEEC4A0AA6C0" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationGoodwill1" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationGoodwill1_F2CB2F46037470F44488DEEC4A0AE6E3" xlink:type="locator" />
    <presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_19FEB59144560D59EE7EDEEC4A0AA37D" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationGoodwill1_F2CB2F46037470F44488DEEC4A0AE6E3" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf" xlink:label="loc_us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf_F6C144410DFBAF842540DEEC4A0A77DE" xlink:type="locator" />
    <presentationArc order="7" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_19FEB59144560D59EE7EDEEC4A0AA37D" xlink:to="loc_us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf_F6C144410DFBAF842540DEEC4A0A77DE" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation" xlink:label="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation_93C1F3505B10D3F0085EDEEC4A0A316F" xlink:type="locator" />
    <presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_19FEB59144560D59EE7EDEEC4A0AA37D" xlink:to="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation_93C1F3505B10D3F0085EDEEC4A0A316F" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsPayable" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsPayable_FCA9E4778F5ADBCCB9C4DEEC4A0A8DBD" xlink:type="locator" />
    <presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_19FEB59144560D59EE7EDEEC4A0AA37D" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsPayable_FCA9E4778F5ADBCCB9C4DEEC4A0A8DBD" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationAccruedLiabilities" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccruedLiabilities_304CC3A6592EE03399ADDEEC4A0B16D5" xlink:type="locator" />
    <presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_19FEB59144560D59EE7EDEEC4A0AA37D" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccruedLiabilities_304CC3A6592EE03399ADDEEC4A0B16D5" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent" xlink:label="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent_EA7D78C4DAE1B507088ADEEC4A0B84DB" xlink:type="locator" />
    <presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_19FEB59144560D59EE7EDEEC4A0AA37D" xlink:to="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent_EA7D78C4DAE1B507088ADEEC4A0B84DB" xlink:type="arc" />
  </presentationLink>
  <presentationLink xlink:role="http://www.galenabiopharma.com/role/DiscontinuedOperationsAssetsHeldForSaleComponentsAttributableToCommercialBusinessDetails" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract" xlink:label="loc_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_68B67F16B5EDB2BB5855DEEC49FE345B" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_A5A9E9134263448B8F8BDEEC49FE1BA4" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_68B67F16B5EDB2BB5855DEEC49FE345B" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_A5A9E9134263448B8F8BDEEC49FE1BA4" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_727ADB20A747B92528BADEEC49FFAB24" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_A5A9E9134263448B8F8BDEEC49FE1BA4" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_727ADB20A747B92528BADEEC49FFAB24" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_70112B153683DC1B4D3EDEEC49FF25B0" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_727ADB20A747B92528BADEEC49FFAB24" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_70112B153683DC1B4D3EDEEC49FF25B0" xlink:type="arc" />
    <loc xlink:href="gale-20150930.xsd#gale_CommercialBusinessSegmentMember" xlink:label="loc_gale_CommercialBusinessSegmentMember_C89D44B1584D99ACB076DEEC49FFFB81" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_70112B153683DC1B4D3EDEEC49FF25B0" xlink:to="loc_gale_CommercialBusinessSegmentMember_C89D44B1584D99ACB076DEEC49FFFB81" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_F9FFB630AF0A6AEF3AB8DEEC49FFF0CB" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_A5A9E9134263448B8F8BDEEC49FE1BA4" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_F9FFB630AF0A6AEF3AB8DEEC49FFF0CB" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue_CC616752004DA59003A4DEEC49FFB7B6" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_F9FFB630AF0A6AEF3AB8DEEC49FFF0CB" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue_CC616752004DA59003A4DEEC49FFB7B6" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold_3BCEFF9E3D4F05E37760DEEC49FFC5D3" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_F9FFB630AF0A6AEF3AB8DEEC49FFF0CB" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold_3BCEFF9E3D4F05E37760DEEC49FFC5D3" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationDepreciationAndAmortization" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationDepreciationAndAmortization_4BD28650B2139C53A933DEEC49FF1213" xlink:type="locator" />
    <presentationArc order="3" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_F9FFB630AF0A6AEF3AB8DEEC49FFF0CB" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationDepreciationAndAmortization_4BD28650B2139C53A933DEEC49FF1213" xlink:type="arc" />
    <loc xlink:href="gale-20150930.xsd#gale_DisposalGroupIncludingDiscontinuedOperationResearchandDevelopment" xlink:label="loc_gale_DisposalGroupIncludingDiscontinuedOperationResearchandDevelopment_C7ACB6287A7CADB121B3DEEC49FFAEF5" xlink:type="locator" />
    <presentationArc order="4" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_F9FFB630AF0A6AEF3AB8DEEC49FFF0CB" xlink:to="loc_gale_DisposalGroupIncludingDiscontinuedOperationResearchandDevelopment_C7ACB6287A7CADB121B3DEEC49FFAEF5" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense_3AD8218AD57A05895EA4DEEC49FFB04F" xlink:type="locator" />
    <presentationArc order="5" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_F9FFB630AF0A6AEF3AB8DEEC49FFF0CB" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense_3AD8218AD57A05895EA4DEEC49FFB04F" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss_C9666852FFFF8307EC44DEEC49FF8464" xlink:type="locator" />
    <presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_F9FFB630AF0A6AEF3AB8DEEC49FFF0CB" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss_C9666852FFFF8307EC44DEEC49FF8464" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf" xlink:label="loc_us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf_BBF74757825E2D5DE94EDEEC4A008E13" xlink:type="locator" />
    <presentationArc order="7" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_F9FFB630AF0A6AEF3AB8DEEC49FFF0CB" xlink:to="loc_us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf_BBF74757825E2D5DE94EDEEC4A008E13" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax_2958BA8BEB955B3AA903DEEC4A0068A5" xlink:type="locator" />
    <presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_F9FFB630AF0A6AEF3AB8DEEC49FFF0CB" xlink:to="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax_2958BA8BEB955B3AA903DEEC4A0068A5" xlink:type="arc" />
  </presentationLink>
  <presentationLink xlink:role="http://www.galenabiopharma.com/role/DiscontinuedOperationsAssetsHeldForSaleDetails" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract" xlink:label="loc_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_1EF74126BCD060616523DE2B9B4F4CFC" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_451F1883DC4F0A1FA83ADE41403D5C89" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_1EF74126BCD060616523DE2B9B4F4CFC" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_451F1883DC4F0A1FA83ADE41403D5C89" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_76AF4C4BAA6E5822E91EDE41403D1E92" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_451F1883DC4F0A1FA83ADE41403D5C89" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_76AF4C4BAA6E5822E91EDE41403D1E92" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_F8341F029CFD80DC372ADE41403D754D" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_76AF4C4BAA6E5822E91EDE41403D1E92" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_F8341F029CFD80DC372ADE41403D754D" xlink:type="arc" />
    <loc xlink:href="gale-20150930.xsd#gale_CommercialBusinessSegmentMember" xlink:label="loc_gale_CommercialBusinessSegmentMember_1E64CFF3A3883CE43115DE4240ED96E1" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_F8341F029CFD80DC372ADE41403D754D" xlink:to="loc_gale_CommercialBusinessSegmentMember_1E64CFF3A3883CE43115DE4240ED96E1" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_569D6B5878E22F15E5CBDE41403D3F67" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_451F1883DC4F0A1FA83ADE41403D5C89" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_569D6B5878E22F15E5CBDE41403D3F67" xlink:type="arc" />
    <loc xlink:href="gale-20150930.xsd#gale_PercentageofCancerPatientsAffectedbyInadequatelyControlledBreakthroughCancerPainBTcP" xlink:label="loc_gale_PercentageofCancerPatientsAffectedbyInadequatelyControlledBreakthroughCancerPainBTcP_1610805B548208DECA69DE31303140A3" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_569D6B5878E22F15E5CBDE41403D3F67" xlink:to="loc_gale_PercentageofCancerPatientsAffectedbyInadequatelyControlledBreakthroughCancerPainBTcP_1610805B548208DECA69DE31303140A3" xlink:type="arc" />
    <loc xlink:href="gale-20150930.xsd#gale_DisposalGroupIncludingDiscontinuedOperationContingentLiabilityFromDivestitureAgreement" xlink:label="loc_gale_DisposalGroupIncludingDiscontinuedOperationContingentLiabilityFromDivestitureAgreement_A509B516526B0795943DDE3607C6CBF0" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_569D6B5878E22F15E5CBDE41403D3F67" xlink:to="loc_gale_DisposalGroupIncludingDiscontinuedOperationContingentLiabilityFromDivestitureAgreement_A509B516526B0795943DDE3607C6CBF0" xlink:type="arc" />
    <loc xlink:href="gale-20150930.xsd#gale_DisposalGroupIncludingDiscontinuedOperationContingentLiabilityPercentageofConsideration" xlink:label="loc_gale_DisposalGroupIncludingDiscontinuedOperationContingentLiabilityPercentageofConsideration_050D407A24ACA9B69030DE3742C076A4" xlink:type="locator" />
    <presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_569D6B5878E22F15E5CBDE41403D3F67" xlink:to="loc_gale_DisposalGroupIncludingDiscontinuedOperationContingentLiabilityPercentageofConsideration_050D407A24ACA9B69030DE3742C076A4" xlink:type="arc" />
    <loc xlink:href="gale-20150930.xsd#gale_DisposalGroupIncludingDiscontinuedOperationContingentRetentionFees" xlink:label="loc_gale_DisposalGroupIncludingDiscontinuedOperationContingentRetentionFees_256AAFBCF1AB90F132D7DE3AFA131820" xlink:type="locator" />
    <presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_569D6B5878E22F15E5CBDE41403D3F67" xlink:to="loc_gale_DisposalGroupIncludingDiscontinuedOperationContingentRetentionFees_256AAFBCF1AB90F132D7DE3AFA131820" xlink:type="arc" />
    <loc xlink:href="gale-20150930.xsd#gale_DisposalGroupIncludingDiscontinuedOperationContingentRetentionFeesPercentageofConsiderationReceived" xlink:label="loc_gale_DisposalGroupIncludingDiscontinuedOperationContingentRetentionFeesPercentageofConsiderationReceived_06B6ACEABD039AD13920DE3BE45C787A" xlink:type="locator" />
    <presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_569D6B5878E22F15E5CBDE41403D3F67" xlink:to="loc_gale_DisposalGroupIncludingDiscontinuedOperationContingentRetentionFeesPercentageofConsiderationReceived_06B6ACEABD039AD13920DE3BE45C787A" xlink:type="arc" />
  </presentationLink>
  <presentationLink xlink:role="http://www.galenabiopharma.com/role/DiscontinuedOperationsAssetsHeldForSaleNotes" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract" xlink:label="loc_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_049B70DB1B6863D0C304DE2E669E817C" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock_45FC27D1DF784CB824E2DE2A19830533" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_049B70DB1B6863D0C304DE2E669E817C" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock_45FC27D1DF784CB824E2DE2A19830533" xlink:type="arc" />
  </presentationLink>
  <presentationLink xlink:role="http://www.galenabiopharma.com/role/DiscontinuedOperationsAssetsHeldForSaleSignificantOperatingNonCashAndCapitalExpendituresDetails" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract" xlink:label="loc_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_0B2DBE9435D71B63655FDEEC49F85209" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_18459779389FFE7A38BBDEEC49F8FA2E" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_0B2DBE9435D71B63655FDEEC49F85209" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_18459779389FFE7A38BBDEEC49F8FA2E" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_71BAB3D817A2D367CCC0DEEC49F8BD9C" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_18459779389FFE7A38BBDEEC49F8FA2E" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_71BAB3D817A2D367CCC0DEEC49F8BD9C" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_B3B551D1663C6A001460DEEC49F8D756" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_71BAB3D817A2D367CCC0DEEC49F8BD9C" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_B3B551D1663C6A001460DEEC49F8D756" xlink:type="arc" />
    <loc xlink:href="gale-20150930.xsd#gale_CommercialBusinessSegmentMember" xlink:label="loc_gale_CommercialBusinessSegmentMember_55B03EF9A0D34B99CEA9DEEC49F8D9E2" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_B3B551D1663C6A001460DEEC49F8D756" xlink:to="loc_gale_CommercialBusinessSegmentMember_55B03EF9A0D34B99CEA9DEEC49F8D9E2" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_009063029D01C6E5A358DEEC49F80CA4" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_18459779389FFE7A38BBDEEC49F8FA2E" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_009063029D01C6E5A358DEEC49F80CA4" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf" xlink:label="loc_us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf_15750ABD82480B132C83DEEC49F8F89A" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_009063029D01C6E5A358DEEC49F80CA4" xlink:to="loc_us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf_15750ABD82480B132C83DEEC49F8F89A" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_85E019D9BED9B2D8FC6BDEEC49F93BA0" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_009063029D01C6E5A358DEEC49F80CA4" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_85E019D9BED9B2D8FC6BDEEC49F93BA0" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_5853A0B6E5AEECEB045FDEEC49F95842" xlink:type="locator" />
    <presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_009063029D01C6E5A358DEEC49F80CA4" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_5853A0B6E5AEECEB045FDEEC49F95842" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaap_ShareBasedCompensation_252706E93CE4197E00AEDEEC49F95FEA" xlink:type="locator" />
    <presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_009063029D01C6E5A358DEEC49F80CA4" xlink:to="loc_us-gaap_ShareBasedCompensation_252706E93CE4197E00AEDEEC49F95FEA" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_FD7484B9528DAD9F738DDEEC49F966AF" xlink:type="locator" />
    <presentationArc order="5" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_009063029D01C6E5A358DEEC49F80CA4" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_FD7484B9528DAD9F738DDEEC49F966AF" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PaymentsToAcquireIntangibleAssets" xlink:label="loc_us-gaap_PaymentsToAcquireIntangibleAssets_DD9A4B47496B79F29297DEEC49F9E14C" xlink:type="locator" />
    <presentationArc order="6" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_009063029D01C6E5A358DEEC49F80CA4" xlink:to="loc_us-gaap_PaymentsToAcquireIntangibleAssets_DD9A4B47496B79F29297DEEC49F9E14C" xlink:type="arc" />
  </presentationLink>
  <presentationLink xlink:role="http://www.galenabiopharma.com/role/DiscontinuedOperationsAssetsHeldForSaleTables" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract" xlink:label="loc_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_9C46BC855C4EABB43937DE2B9C46F48F" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock" xlink:label="loc_us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock_2DC4308F867BA3E7591FDE2DC105D75E" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_9C46BC855C4EABB43937DE2B9C46F48F" xlink:to="loc_us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock_2DC4308F867BA3E7591FDE2DC105D75E" xlink:type="arc" />
  </presentationLink>
  <presentationLink xlink:role="http://www.galenabiopharma.com/role/DocumentAndEntityInformation" xlink:type="extended">
    <loc xlink:href="gale-20150930.xsd#gale_DocumentDocumentAndEntityInformationAbstract" xlink:label="loc_gale_DocumentDocumentAndEntityInformationAbstract_F4AB2074FF1A53929E383C0F35D4CAD0" xlink:type="locator" />
    <loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityRegistrantName" xlink:label="loc_dei_EntityRegistrantName_228D3D2CEBC354B4A5B31D90B77DC96E" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gale_DocumentDocumentAndEntityInformationAbstract_F4AB2074FF1A53929E383C0F35D4CAD0" xlink:to="loc_dei_EntityRegistrantName_228D3D2CEBC354B4A5B31D90B77DC96E" xlink:type="arc" />
    <loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_TradingSymbol" xlink:label="loc_dei_TradingSymbol_4418748DCE2053F7BD95797A5E3BA651" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gale_DocumentDocumentAndEntityInformationAbstract_F4AB2074FF1A53929E383C0F35D4CAD0" xlink:to="loc_dei_TradingSymbol_4418748DCE2053F7BD95797A5E3BA651" xlink:type="arc" />
    <loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityCentralIndexKey" xlink:label="loc_dei_EntityCentralIndexKey_BD1C6A555D0A5ECE8A9F6DCA972582FA" xlink:type="locator" />
    <presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gale_DocumentDocumentAndEntityInformationAbstract_F4AB2074FF1A53929E383C0F35D4CAD0" xlink:to="loc_dei_EntityCentralIndexKey_BD1C6A555D0A5ECE8A9F6DCA972582FA" xlink:type="arc" />
    <loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_dei_CurrentFiscalYearEndDate_02E20553FDA353B18B05DC78148D54E3" xlink:type="locator" />
    <presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gale_DocumentDocumentAndEntityInformationAbstract_F4AB2074FF1A53929E383C0F35D4CAD0" xlink:to="loc_dei_CurrentFiscalYearEndDate_02E20553FDA353B18B05DC78148D54E3" xlink:type="arc" />
    <loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityFilerCategory" xlink:label="loc_dei_EntityFilerCategory_011B554AD0705831A21B7E7BB34400C0" xlink:type="locator" />
    <presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gale_DocumentDocumentAndEntityInformationAbstract_F4AB2074FF1A53929E383C0F35D4CAD0" xlink:to="loc_dei_EntityFilerCategory_011B554AD0705831A21B7E7BB34400C0" xlink:type="arc" />
    <loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentType" xlink:label="loc_dei_DocumentType_5DD25AE17D75573595C96E7571A782A9" xlink:type="locator" />
    <presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gale_DocumentDocumentAndEntityInformationAbstract_F4AB2074FF1A53929E383C0F35D4CAD0" xlink:to="loc_dei_DocumentType_5DD25AE17D75573595C96E7571A782A9" xlink:type="arc" />
    <loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_dei_DocumentPeriodEndDate_3779F411D8725251B8D53961797CA49B" xlink:type="locator" />
    <presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gale_DocumentDocumentAndEntityInformationAbstract_F4AB2074FF1A53929E383C0F35D4CAD0" xlink:to="loc_dei_DocumentPeriodEndDate_3779F411D8725251B8D53961797CA49B" xlink:type="arc" />
    <loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_dei_DocumentFiscalYearFocus_53CE1B3CF6455FF5B966E4FB5B26E6C7" xlink:type="locator" />
    <presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gale_DocumentDocumentAndEntityInformationAbstract_F4AB2074FF1A53929E383C0F35D4CAD0" xlink:to="loc_dei_DocumentFiscalYearFocus_53CE1B3CF6455FF5B966E4FB5B26E6C7" xlink:type="arc" />
    <loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_dei_DocumentFiscalPeriodFocus_F4D2B238BD175F758476B17B4EAE9246" xlink:type="locator" />
    <presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gale_DocumentDocumentAndEntityInformationAbstract_F4AB2074FF1A53929E383C0F35D4CAD0" xlink:to="loc_dei_DocumentFiscalPeriodFocus_F4D2B238BD175F758476B17B4EAE9246" xlink:type="arc" />
    <loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_AmendmentFlag" xlink:label="loc_dei_AmendmentFlag_232E45EB97EE52759EE26AFA89226E99" xlink:type="locator" />
    <presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gale_DocumentDocumentAndEntityInformationAbstract_F4AB2074FF1A53929E383C0F35D4CAD0" xlink:to="loc_dei_AmendmentFlag_232E45EB97EE52759EE26AFA89226E99" xlink:type="arc" />
    <loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_F3A13396DEFA5C3CA0F2A2541F78D308" xlink:type="locator" />
    <presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gale_DocumentDocumentAndEntityInformationAbstract_F4AB2074FF1A53929E383C0F35D4CAD0" xlink:to="loc_dei_EntityCommonStockSharesOutstanding_F3A13396DEFA5C3CA0F2A2541F78D308" xlink:type="arc" />
  </presentationLink>
  <presentationLink xlink:role="http://www.galenabiopharma.com/role/FairValueMeasurements" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_D7921F93E70A5E2E8BE2D8D1599D2C5D" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FinancialInstrumentsDisclosureTextBlock" xlink:label="loc_us-gaap_FinancialInstrumentsDisclosureTextBlock_56417954780E5286A409B0F761015C1D" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_D7921F93E70A5E2E8BE2D8D1599D2C5D" xlink:to="loc_us-gaap_FinancialInstrumentsDisclosureTextBlock_56417954780E5286A409B0F761015C1D" xlink:type="arc" />
  </presentationLink>
  <presentationLink xlink:role="http://www.galenabiopharma.com/role/FairValueMeasurementsContingentPurchasePriceConsiderationMeasuredAtEstimatedFairValueOnRecurringBasisDetail" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_CBE72336659C9F365BF8DE2E96A8D581" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_4AB702C16D27DBD020BCDE2E96A8A9D9" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_CBE72336659C9F365BF8DE2E96A8D581" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_4AB702C16D27DBD020BCDE2E96A8A9D9" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_5BA3BCB52AFC27D6549CDE2E96A8FBE5" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_4AB702C16D27DBD020BCDE2E96A8A9D9" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_5BA3BCB52AFC27D6549CDE2E96A8FBE5" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_61A49F9B33DFC2934716DE2E96A828B9" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_5BA3BCB52AFC27D6549CDE2E96A8FBE5" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_61A49F9B33DFC2934716DE2E96A828B9" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_64D4AB9390D99192CE53DE2E96A87419" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_61A49F9B33DFC2934716DE2E96A828B9" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_64D4AB9390D99192CE53DE2E96A87419" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_791612FFB3622194C72FDE2E96A8A87E" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_4AB702C16D27DBD020BCDE2E96A8A9D9" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_791612FFB3622194C72FDE2E96A8A87E" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_BCA95E15E1BA23F08F46DE2E96A9A744" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_791612FFB3622194C72FDE2E96A8A87E" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_BCA95E15E1BA23F08F46DE2E96A9A744" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_23A16F2D875BD766ACFCDE2E96A922BE" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_BCA95E15E1BA23F08F46DE2E96A9A744" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_23A16F2D875BD766ACFCDE2E96A922BE" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_77D3A81799656DE2BA57DE2E96A948C9" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_BCA95E15E1BA23F08F46DE2E96A9A744" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_77D3A81799656DE2BA57DE2E96A948C9" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_EA39C871679161840737DE2E96A9984A" xlink:type="locator" />
    <presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_BCA95E15E1BA23F08F46DE2E96A9A744" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_EA39C871679161840737DE2E96A9984A" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_015D165105D49F68C2BEDE2E96A98100" xlink:type="locator" />
    <presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_4AB702C16D27DBD020BCDE2E96A8A9D9" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_015D165105D49F68C2BEDE2E96A98100" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AssetsFairValueDisclosureAbstract" xlink:label="loc_us-gaap_AssetsFairValueDisclosureAbstract_7923F28012FE74B2780FDE2E96A9D43F" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_015D165105D49F68C2BEDE2E96A98100" xlink:to="loc_us-gaap_AssetsFairValueDisclosureAbstract_7923F28012FE74B2780FDE2E96A9D43F" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_19E2AE8B72EBD4583D37DE2E96A9CF67" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_7923F28012FE74B2780FDE2E96A9D43F" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_19E2AE8B72EBD4583D37DE2E96A9CF67" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AssetsHeldForSaleLongLivedFairValueDisclosure" xlink:label="loc_us-gaap_AssetsHeldForSaleLongLivedFairValueDisclosure_599926F81E6602430E03DE8DC74EDF12" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_7923F28012FE74B2780FDE2E96A9D43F" xlink:to="loc_us-gaap_AssetsHeldForSaleLongLivedFairValueDisclosure_599926F81E6602430E03DE8DC74EDF12" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AssetsFairValueDisclosure" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_63E636F74E44A33EBD1EDE2E96A9D563" xlink:type="locator" />
    <presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_7923F28012FE74B2780FDE2E96A9D43F" xlink:to="loc_us-gaap_AssetsFairValueDisclosure_63E636F74E44A33EBD1EDE2E96A9D563" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_A3189E1C4DDFE85E92BEDE2E96A99679" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_015D165105D49F68C2BEDE2E96A98100" xlink:to="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_A3189E1C4DDFE85E92BEDE2E96A99679" xlink:type="arc" />
    <loc xlink:href="gale-20150930.xsd#gale_FairValueOfWarrantsPotentiallySettleableInCash" xlink:label="loc_gale_FairValueOfWarrantsPotentiallySettleableInCash_15520E39EB89B2E2D725DE2E96A94A23" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_A3189E1C4DDFE85E92BEDE2E96A99679" xlink:to="loc_gale_FairValueOfWarrantsPotentiallySettleableInCash_15520E39EB89B2E2D725DE2E96A94A23" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ContingentConsiderationClassifiedAsEquityFairValueDisclosure" xlink:label="loc_us-gaap_ContingentConsiderationClassifiedAsEquityFairValueDisclosure_43557360DA03F5BC66A1DE2E96A99934" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_A3189E1C4DDFE85E92BEDE2E96A99679" xlink:to="loc_us-gaap_ContingentConsiderationClassifiedAsEquityFairValueDisclosure_43557360DA03F5BC66A1DE2E96A99934" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EquityFairValueDisclosure" xlink:label="loc_us-gaap_EquityFairValueDisclosure_B7614D69893C26129F79DE2E96A99F52" xlink:type="locator" />
    <presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_A3189E1C4DDFE85E92BEDE2E96A99679" xlink:to="loc_us-gaap_EquityFairValueDisclosure_B7614D69893C26129F79DE2E96A99F52" xlink:type="arc" />
  </presentationLink>
  <presentationLink xlink:role="http://www.galenabiopharma.com/role/FairValueMeasurementsReconciliationOfLevel3LiabilitiesDetail" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_DD826697906E56F9980FA5314B5C8BDB" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_A9BA8A2B547B584DAE2EDF4B620FEE72" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_DD826697906E56F9980FA5314B5C8BDB" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_A9BA8A2B547B584DAE2EDF4B620FEE72" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_6CB47389BFD65B98A38F1D34FB41659C" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_A9BA8A2B547B584DAE2EDF4B620FEE72" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_6CB47389BFD65B98A38F1D34FB41659C" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_49CB70EF30915C6380BFF140D00395B1" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_6CB47389BFD65B98A38F1D34FB41659C" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_49CB70EF30915C6380BFF140D00395B1" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_133CB0C8DA1E5151BC4219141709A7B2" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_49CB70EF30915C6380BFF140D00395B1" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_133CB0C8DA1E5151BC4219141709A7B2" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_3EF3B05B81EB5E81A4F5A5661ADC2BD5" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_A9BA8A2B547B584DAE2EDF4B620FEE72" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_3EF3B05B81EB5E81A4F5A5661ADC2BD5" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_5167F35552D65AEA82C99B28771B20C5" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_3EF3B05B81EB5E81A4F5A5661ADC2BD5" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_5167F35552D65AEA82C99B28771B20C5" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ContingentConsiderationClassifiedAsEquityFairValueDisclosure" xlink:label="loc_us-gaap_ContingentConsiderationClassifiedAsEquityFairValueDisclosure_BBAF05F480715029A90EE878CAAFE417" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_5167F35552D65AEA82C99B28771B20C5" xlink:to="loc_us-gaap_ContingentConsiderationClassifiedAsEquityFairValueDisclosure_BBAF05F480715029A90EE878CAAFE417" xlink:type="arc" />
    <loc xlink:href="gale-20150930.xsd#gale_ChangeInFairValueOfContingentPurchasePriceConsideration" xlink:label="loc_gale_ChangeInFairValueOfContingentPurchasePriceConsideration_FCB5AA01EBCF538282492BC5FD52C0A7" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_5167F35552D65AEA82C99B28771B20C5" xlink:to="loc_gale_ChangeInFairValueOfContingentPurchasePriceConsideration_FCB5AA01EBCF538282492BC5FD52C0A7" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ContingentConsiderationClassifiedAsEquityFairValueDisclosure" xlink:label="loc_us-gaap_ContingentConsiderationClassifiedAsEquityFairValueDisclosure_5FDF7D85609653C9A9B4CA5DDB5FCB48" xlink:type="locator" />
    <presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_5167F35552D65AEA82C99B28771B20C5" xlink:to="loc_us-gaap_ContingentConsiderationClassifiedAsEquityFairValueDisclosure_5FDF7D85609653C9A9B4CA5DDB5FCB48" xlink:type="arc" />
  </presentationLink>
  <presentationLink xlink:role="http://www.galenabiopharma.com/role/FairValueMeasurementsTables" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_C90DB1F3ACCE55999A2CDD2A2CDFABD0" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_D966421A5D5D59A19B2CF1F4E79DC5CC" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_C90DB1F3ACCE55999A2CDD2A2CDFABD0" xlink:to="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_D966421A5D5D59A19B2CF1F4E79DC5CC" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_DC3A60B96B06516AB0D516893FA077A0" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_C90DB1F3ACCE55999A2CDD2A2CDFABD0" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_DC3A60B96B06516AB0D516893FA077A0" xlink:type="arc" />
  </presentationLink>
  <presentationLink xlink:role="http://www.galenabiopharma.com/role/LegalProceedingsCommitmentsAndContingenciesDetailsDetails" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_50C4A84E33635900A035E1B326D2ADEF" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LossContingenciesTable" xlink:label="loc_us-gaap_LossContingenciesTable_3AED1A50BF2557D2907B534997404A12" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_50C4A84E33635900A035E1B326D2ADEF" xlink:to="loc_us-gaap_LossContingenciesTable_3AED1A50BF2557D2907B534997404A12" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_3743D6F23405565DA07CE89BBFDCF74E" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_3AED1A50BF2557D2907B534997404A12" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_3743D6F23405565DA07CE89BBFDCF74E" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_518B1DA052BA5C40A83A163D1A5FD0E3" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_3743D6F23405565DA07CE89BBFDCF74E" xlink:to="loc_us-gaap_EquityComponentDomain_518B1DA052BA5C40A83A163D1A5FD0E3" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember_54CA866B9AF458FEA8FE3A21AB554B63" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_518B1DA052BA5C40A83A163D1A5FD0E3" xlink:to="loc_us-gaap_CommonStockMember_54CA866B9AF458FEA8FE3A21AB554B63" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_7714894A77C956D0B8CD63645B6D23CC" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_518B1DA052BA5C40A83A163D1A5FD0E3" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_7714894A77C956D0B8CD63645B6D23CC" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LossContingenciesLineItems" xlink:label="loc_us-gaap_LossContingenciesLineItems_6881254A72F6558D85367A58CBCC3CBC" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_3AED1A50BF2557D2907B534997404A12" xlink:to="loc_us-gaap_LossContingenciesLineItems_6881254A72F6558D85367A58CBCC3CBC" xlink:type="arc" />
    <loc xlink:href="gale-20150930.xsd#gale_LossContingencyPercentageofLegalFeesPaid" xlink:label="loc_gale_LossContingencyPercentageofLegalFeesPaid_C6DFE5D985B95F488F2C408C10139CB4" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_6881254A72F6558D85367A58CBCC3CBC" xlink:to="loc_gale_LossContingencyPercentageofLegalFeesPaid_C6DFE5D985B95F488F2C408C10139CB4" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PaymentsToAcquireBusinessesGross" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesGross_A7D69C84C8495A8E9CD1EB8AA32200DA" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_6881254A72F6558D85367A58CBCC3CBC" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesGross_A7D69C84C8495A8E9CD1EB8AA32200DA" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesOther" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesOther_A02A18BAD98151CF9CB2D475FFD8C6F9" xlink:type="locator" />
    <presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_6881254A72F6558D85367A58CBCC3CBC" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesOther_A02A18BAD98151CF9CB2D475FFD8C6F9" xlink:type="arc" />
    <loc xlink:href="gale-20150930.xsd#gale_ClosingPriceOfCommonStock" xlink:label="loc_gale_ClosingPriceOfCommonStock_B69272A20FC45A0AB31AC230BC330389" xlink:type="locator" />
    <presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_6881254A72F6558D85367A58CBCC3CBC" xlink:to="loc_gale_ClosingPriceOfCommonStock_B69272A20FC45A0AB31AC230BC330389" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueOther" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueOther_7A3BA6FE38C45EB4A2ECA337299A4CFB" xlink:type="locator" />
    <presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_6881254A72F6558D85367A58CBCC3CBC" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueOther_7A3BA6FE38C45EB4A2ECA337299A4CFB" xlink:type="arc" />
  </presentationLink>
  <presentationLink xlink:role="http://www.galenabiopharma.com/role/LegalProceedingsCommitmentsAndContingenciesNotes" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_934314CF4FC75956867732DC183D748B" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_A03EFA9B1A1D5E328F8B4B3DC1489133" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_934314CF4FC75956867732DC183D748B" xlink:to="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_A03EFA9B1A1D5E328F8B4B3DC1489133" xlink:type="arc" />
  </presentationLink>
  <presentationLink xlink:role="http://www.galenabiopharma.com/role/LicenseAgreements" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_43232B93821D5DE5AC435109B5FB03EE" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IntangibleAssetsDisclosureTextBlock" xlink:label="loc_us-gaap_IntangibleAssetsDisclosureTextBlock_9DF71E876FFE592E96713725B2402BDD" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_43232B93821D5DE5AC435109B5FB03EE" xlink:to="loc_us-gaap_IntangibleAssetsDisclosureTextBlock_9DF71E876FFE592E96713725B2402BDD" xlink:type="arc" />
  </presentationLink>
  <presentationLink xlink:role="http://www.galenabiopharma.com/role/LicenseAgreementsAdditionalInformationDetail" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_50077C38F19B549BB855C5D44CCA4E5D" xlink:type="locator" />
    <loc xlink:href="gale-20150930.xsd#gale_LicenseAndCollaborationAgreementsTable" xlink:label="loc_gale_LicenseAndCollaborationAgreementsTable_1407CD18B82257ED80BC8D7D81E70E25" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_50077C38F19B549BB855C5D44CCA4E5D" xlink:to="loc_gale_LicenseAndCollaborationAgreementsTable_1407CD18B82257ED80BC8D7D81E70E25" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_17D1957E06885DE5BF407D4B24E20CCB" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gale_LicenseAndCollaborationAgreementsTable_1407CD18B82257ED80BC8D7D81E70E25" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_17D1957E06885DE5BF407D4B24E20CCB" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_11BDCBD96D895E10B9426D449139D0BE" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_17D1957E06885DE5BF407D4B24E20CCB" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_11BDCBD96D895E10B9426D449139D0BE" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DistributionRightsMember" xlink:label="loc_us-gaap_DistributionRightsMember_EC5E2FB2A47A58759DB708E1A3F0F426" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_11BDCBD96D895E10B9426D449139D0BE" xlink:to="loc_us-gaap_DistributionRightsMember_EC5E2FB2A47A58759DB708E1A3F0F426" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RangeAxis" xlink:label="loc_us-gaap_RangeAxis_07C41D0A23B95B38A623FCBED4519819" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gale_LicenseAndCollaborationAgreementsTable_1407CD18B82257ED80BC8D7D81E70E25" xlink:to="loc_us-gaap_RangeAxis_07C41D0A23B95B38A623FCBED4519819" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaap_RangeMember_86838B90571D5D63BF2D772D68D9ED21" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RangeAxis_07C41D0A23B95B38A623FCBED4519819" xlink:to="loc_us-gaap_RangeMember_86838B90571D5D63BF2D772D68D9ED21" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_MinimumMember" xlink:label="loc_us-gaap_MinimumMember_2D6AE4C845DA5A888B3A37E823C1F6CE" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RangeMember_86838B90571D5D63BF2D772D68D9ED21" xlink:to="loc_us-gaap_MinimumMember_2D6AE4C845DA5A888B3A37E823C1F6CE" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_MaximumMember" xlink:label="loc_us-gaap_MaximumMember_273DB4F6F06E5B46A55A09A1C8482CCD" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RangeMember_86838B90571D5D63BF2D772D68D9ED21" xlink:to="loc_us-gaap_MaximumMember_273DB4F6F06E5B46A55A09A1C8482CCD" xlink:type="arc" />
    <loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_00510618FB495E31A4749049ACBF71D3" xlink:type="locator" />
    <presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gale_LicenseAndCollaborationAgreementsTable_1407CD18B82257ED80BC8D7D81E70E25" xlink:to="loc_dei_LegalEntityAxis_00510618FB495E31A4749049ACBF71D3" xlink:type="arc" />
    <loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_8A5D031D4BD55B7E8302FEB743CC3A7F" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_00510618FB495E31A4749049ACBF71D3" xlink:to="loc_dei_EntityDomain_8A5D031D4BD55B7E8302FEB743CC3A7F" xlink:type="arc" />
    <loc xlink:href="gale-20150930.xsd#gale_MDAndersonCancerCenterMember" xlink:label="loc_gale_MDAndersonCancerCenterMember_BBD250A0E81F5B47B560EEA58D8CD138" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_8A5D031D4BD55B7E8302FEB743CC3A7F" xlink:to="loc_gale_MDAndersonCancerCenterMember_BBD250A0E81F5B47B560EEA58D8CD138" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_440B474C034B5D3FB78A4BD1F29724D4" xlink:type="locator" />
    <presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gale_LicenseAndCollaborationAgreementsTable_1407CD18B82257ED80BC8D7D81E70E25" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_440B474C034B5D3FB78A4BD1F29724D4" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_F2E35DF556645CECBA4AA3EDCA6E1F77" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_440B474C034B5D3FB78A4BD1F29724D4" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_F2E35DF556645CECBA4AA3EDCA6E1F77" xlink:type="arc" />
    <loc xlink:href="gale-20150930.xsd#gale_OrexoMember" xlink:label="loc_gale_OrexoMember_55C6E426DE4259049BADCFC77638F7C4" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_F2E35DF556645CECBA4AA3EDCA6E1F77" xlink:to="loc_gale_OrexoMember_55C6E426DE4259049BADCFC77638F7C4" xlink:type="arc" />
    <loc xlink:href="gale-20150930.xsd#gale_LicenseAndCollaborationAgreementsLineItems" xlink:label="loc_gale_LicenseAndCollaborationAgreementsLineItems_A1A30BAFE7E75E44A6D7FF1B540D29B1" xlink:type="locator" />
    <presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gale_LicenseAndCollaborationAgreementsTable_1407CD18B82257ED80BC8D7D81E70E25" xlink:to="loc_gale_LicenseAndCollaborationAgreementsLineItems_A1A30BAFE7E75E44A6D7FF1B540D29B1" xlink:type="arc" />
    <loc xlink:href="gale-20150930.xsd#gale_AnnualMaintenanceFee" xlink:label="loc_gale_AnnualMaintenanceFee_9F2399AD70365C25BA4A666752C487DE" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gale_LicenseAndCollaborationAgreementsLineItems_A1A30BAFE7E75E44A6D7FF1B540D29B1" xlink:to="loc_gale_AnnualMaintenanceFee_9F2399AD70365C25BA4A666752C487DE" xlink:type="arc" />
    <loc xlink:href="gale-20150930.xsd#gale_FutureMilestonePayment" xlink:label="loc_gale_FutureMilestonePayment_699EFB6C61CF5284BA715B6B27AE6D75" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gale_LicenseAndCollaborationAgreementsLineItems_A1A30BAFE7E75E44A6D7FF1B540D29B1" xlink:to="loc_gale_FutureMilestonePayment_699EFB6C61CF5284BA715B6B27AE6D75" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_D95DC56649BE56AC9A2F0DCCFEC343DE" xlink:type="locator" />
    <presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gale_LicenseAndCollaborationAgreementsLineItems_A1A30BAFE7E75E44A6D7FF1B540D29B1" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_D95DC56649BE56AC9A2F0DCCFEC343DE" xlink:type="arc" />
    <loc xlink:href="gale-20150930.xsd#gale_BusinessAcquisitionCashHeldByAcquiredEntity" xlink:label="loc_gale_BusinessAcquisitionCashHeldByAcquiredEntity_BD6B8E7A3FE556BC8F570864A56ABE29" xlink:type="locator" />
    <presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gale_LicenseAndCollaborationAgreementsLineItems_A1A30BAFE7E75E44A6D7FF1B540D29B1" xlink:to="loc_gale_BusinessAcquisitionCashHeldByAcquiredEntity_BD6B8E7A3FE556BC8F570864A56ABE29" xlink:type="arc" />
    <loc xlink:href="gale-20150930.xsd#gale_EstimatedYearOfPatentExpiration" xlink:label="loc_gale_EstimatedYearOfPatentExpiration_F4F6DBA59D495818879856FE3CF08CFB" xlink:type="locator" />
    <presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gale_LicenseAndCollaborationAgreementsLineItems_A1A30BAFE7E75E44A6D7FF1B540D29B1" xlink:to="loc_gale_EstimatedYearOfPatentExpiration_F4F6DBA59D495818879856FE3CF08CFB" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PaymentsToAcquireBusinessesGross" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesGross_DFB4925335D15FA0BD971DB2653A89F2" xlink:type="locator" />
    <presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gale_LicenseAndCollaborationAgreementsLineItems_A1A30BAFE7E75E44A6D7FF1B540D29B1" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesGross_DFB4925335D15FA0BD971DB2653A89F2" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FinitelivedIntangibleAssetsAcquired1" xlink:label="loc_us-gaap_FinitelivedIntangibleAssetsAcquired1_FFDDE9FB55D65C25ABE8069E1E8170E2" xlink:type="locator" />
    <presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gale_LicenseAndCollaborationAgreementsLineItems_A1A30BAFE7E75E44A6D7FF1B540D29B1" xlink:to="loc_us-gaap_FinitelivedIntangibleAssetsAcquired1_FFDDE9FB55D65C25ABE8069E1E8170E2" xlink:type="arc" />
    <loc xlink:href="gale-20150930.xsd#gale_FinitelivedIntangibleAssetsAcquiredContingentConsideration" xlink:label="loc_gale_FinitelivedIntangibleAssetsAcquiredContingentConsideration_EDB91DFFD2F65BA69D686AD3D06B0404" xlink:type="locator" />
    <presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gale_LicenseAndCollaborationAgreementsLineItems_A1A30BAFE7E75E44A6D7FF1B540D29B1" xlink:to="loc_gale_FinitelivedIntangibleAssetsAcquiredContingentConsideration_EDB91DFFD2F65BA69D686AD3D06B0404" xlink:type="arc" />
    <loc xlink:href="gale-20150930.xsd#gale_FinitelivedIntangibleAssetsAcquiredContingentConsiderationPaymentPeriod" xlink:label="loc_gale_FinitelivedIntangibleAssetsAcquiredContingentConsiderationPaymentPeriod_A940960D9F0E56CE9D378F3745DD5096" xlink:type="locator" />
    <presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gale_LicenseAndCollaborationAgreementsLineItems_A1A30BAFE7E75E44A6D7FF1B540D29B1" xlink:to="loc_gale_FinitelivedIntangibleAssetsAcquiredContingentConsiderationPaymentPeriod_A940960D9F0E56CE9D378F3745DD5096" xlink:type="arc" />
    <loc xlink:href="gale-20150930.xsd#gale_ContractualObligationPotentialPaymentsfromNetSales" xlink:label="loc_gale_ContractualObligationPotentialPaymentsfromNetSales_DF500A08BF2B53E6908F6889E84E494C" xlink:type="locator" />
    <presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gale_LicenseAndCollaborationAgreementsLineItems_A1A30BAFE7E75E44A6D7FF1B540D29B1" xlink:to="loc_gale_ContractualObligationPotentialPaymentsfromNetSales_DF500A08BF2B53E6908F6889E84E494C" xlink:type="arc" />
    <loc xlink:href="gale-20150930.xsd#gale_ContractualObligationNetSalesThreshold" xlink:label="loc_gale_ContractualObligationNetSalesThreshold_0B146E09A4EE5A1780D7887ADF09FCBE" xlink:type="locator" />
    <presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gale_LicenseAndCollaborationAgreementsLineItems_A1A30BAFE7E75E44A6D7FF1B540D29B1" xlink:to="loc_gale_ContractualObligationNetSalesThreshold_0B146E09A4EE5A1780D7887ADF09FCBE" xlink:type="arc" />
  </presentationLink>
  <presentationLink xlink:role="http://www.galenabiopharma.com/role/LongTermDebt" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="loc_us-gaap_DebtDisclosureAbstract_BB2D9517DAF057EEA1F856389E0081EE" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DebtDisclosureTextBlock" xlink:label="loc_us-gaap_DebtDisclosureTextBlock_B06B4130CF8C56B789C3A5682B3C1285" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_BB2D9517DAF057EEA1F856389E0081EE" xlink:to="loc_us-gaap_DebtDisclosureTextBlock_B06B4130CF8C56B789C3A5682B3C1285" xlink:type="arc" />
  </presentationLink>
  <presentationLink xlink:role="http://www.galenabiopharma.com/role/LongTermDebtDetails" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="loc_us-gaap_DebtDisclosureAbstract_0ACB540EE43D5F5FBCACA8B3AA9BFCB9" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DebtInstrumentTable" xlink:label="loc_us-gaap_DebtInstrumentTable_E28798D4D44B5AA7AB8AE05E6B2010A6" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_0ACB540EE43D5F5FBCACA8B3AA9BFCB9" xlink:to="loc_us-gaap_DebtInstrumentTable_E28798D4D44B5AA7AB8AE05E6B2010A6" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_AB783BD086125355A63B91DDBD2DA3C7" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_E28798D4D44B5AA7AB8AE05E6B2010A6" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_AB783BD086125355A63B91DDBD2DA3C7" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_22657301DC305B93836C4964DDA68425" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_AB783BD086125355A63B91DDBD2DA3C7" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_22657301DC305B93836C4964DDA68425" xlink:type="arc" />
    <loc xlink:href="gale-20150930.xsd#gale_FirstTrancheMember" xlink:label="loc_gale_FirstTrancheMember_BC0F7CD64CC750B0BBCFDBCB93898CF8" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_22657301DC305B93836C4964DDA68425" xlink:to="loc_gale_FirstTrancheMember_BC0F7CD64CC750B0BBCFDBCB93898CF8" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RangeAxis" xlink:label="loc_us-gaap_RangeAxis_7D751EE34F08506896FBB610769941FC" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_E28798D4D44B5AA7AB8AE05E6B2010A6" xlink:to="loc_us-gaap_RangeAxis_7D751EE34F08506896FBB610769941FC" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaap_RangeMember_16CB697124B75C6A9F9C10E1FC8DEA1F" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RangeAxis_7D751EE34F08506896FBB610769941FC" xlink:to="loc_us-gaap_RangeMember_16CB697124B75C6A9F9C10E1FC8DEA1F" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_MaximumMember" xlink:label="loc_us-gaap_MaximumMember_3509D84954F65169BF5BCC5A0A2A2E5D" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RangeMember_16CB697124B75C6A9F9C10E1FC8DEA1F" xlink:to="loc_us-gaap_MaximumMember_3509D84954F65169BF5BCC5A0A2A2E5D" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="loc_us-gaap_DebtInstrumentLineItems_F95425BAA00A5691819F40D1EDD9F667" xlink:type="locator" />
    <presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_E28798D4D44B5AA7AB8AE05E6B2010A6" xlink:to="loc_us-gaap_DebtInstrumentLineItems_F95425BAA00A5691819F40D1EDD9F667" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DebtInstrumentCarryingAmount" xlink:label="loc_us-gaap_DebtInstrumentCarryingAmount_F3CD4F58522E540987470253C35E6C20" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_F95425BAA00A5691819F40D1EDD9F667" xlink:to="loc_us-gaap_DebtInstrumentCarryingAmount_F3CD4F58522E540987470253C35E6C20" xlink:type="arc" />
    <loc xlink:href="gale-20150930.xsd#gale_DebtInstrumentTermInterestOnly" xlink:label="loc_gale_DebtInstrumentTermInterestOnly_B0C6C2AA9F9955E1BC93F0AC559AC979" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_F95425BAA00A5691819F40D1EDD9F667" xlink:to="loc_gale_DebtInstrumentTermInterestOnly_B0C6C2AA9F9955E1BC93F0AC559AC979" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_32FD2D4C122A523EB1C9F619A647E4CB" xlink:type="locator" />
    <presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_F95425BAA00A5691819F40D1EDD9F667" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_32FD2D4C122A523EB1C9F619A647E4CB" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DebtInstrumentTerm" xlink:label="loc_us-gaap_DebtInstrumentTerm_5C2F43DB556050F8BC578FDCA7E82D89" xlink:type="locator" />
    <presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_F95425BAA00A5691819F40D1EDD9F667" xlink:to="loc_us-gaap_DebtInstrumentTerm_5C2F43DB556050F8BC578FDCA7E82D89" xlink:type="arc" />
    <loc xlink:href="gale-20150930.xsd#gale_DebtInstrumentCashFacilityFee" xlink:label="loc_gale_DebtInstrumentCashFacilityFee_4E00F91A8D5D50F5BB80FCF67734B2CF" xlink:type="locator" />
    <presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_F95425BAA00A5691819F40D1EDD9F667" xlink:to="loc_gale_DebtInstrumentCashFacilityFee_4E00F91A8D5D50F5BB80FCF67734B2CF" xlink:type="arc" />
    <loc xlink:href="gale-20150930.xsd#gale_DebtInstrumentCashFinalPayment" xlink:label="loc_gale_DebtInstrumentCashFinalPayment_20BFDB6A4E54528E95205F4AF76ACE4F" xlink:type="locator" />
    <presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_F95425BAA00A5691819F40D1EDD9F667" xlink:to="loc_gale_DebtInstrumentCashFinalPayment_20BFDB6A4E54528E95205F4AF76ACE4F" xlink:type="arc" />
    <loc xlink:href="gale-20150930.xsd#gale_ClassofWarrantorRightTerm" xlink:label="loc_gale_ClassofWarrantorRightTerm_B40565F7C1B35180B4F189324DFCE0F0" xlink:type="locator" />
    <presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_F95425BAA00A5691819F40D1EDD9F667" xlink:to="loc_gale_ClassofWarrantorRightTerm_B40565F7C1B35180B4F189324DFCE0F0" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_9C1B37C661CA57B8A8944B4B9AD658B7" xlink:type="locator" />
    <presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_F95425BAA00A5691819F40D1EDD9F667" xlink:to="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_9C1B37C661CA57B8A8944B4B9AD658B7" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_66A6153F2F4350BEB2BC8162D273B610" xlink:type="locator" />
    <presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_F95425BAA00A5691819F40D1EDD9F667" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_66A6153F2F4350BEB2BC8162D273B610" xlink:type="arc" />
    <loc xlink:href="gale-20150930.xsd#gale_ClassofWarrantorRightAverageMarketPriceUsedForExercisePrice" xlink:label="loc_gale_ClassofWarrantorRightAverageMarketPriceUsedForExercisePrice_6AC26DE8E7CC59C297E00274799FDC46" xlink:type="locator" />
    <presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_F95425BAA00A5691819F40D1EDD9F667" xlink:to="loc_gale_ClassofWarrantorRightAverageMarketPriceUsedForExercisePrice_6AC26DE8E7CC59C297E00274799FDC46" xlink:type="arc" />
  </presentationLink>
  <presentationLink xlink:role="http://www.galenabiopharma.com/role/NetLossPerShare" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="loc_us-gaap_EarningsPerShareAbstract_ACFCAE677C105C409F5F46F115B8769A" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EarningsPerShareTextBlock" xlink:label="loc_us-gaap_EarningsPerShareTextBlock_FB60AD35A804511DB77C64EF5E36900A" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_ACFCAE677C105C409F5F46F115B8769A" xlink:to="loc_us-gaap_EarningsPerShareTextBlock_FB60AD35A804511DB77C64EF5E36900A" xlink:type="arc" />
  </presentationLink>
  <presentationLink xlink:role="http://www.galenabiopharma.com/role/NetLossPerShareCommonSharesExcludedFromNetLossDetail" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="loc_us-gaap_EarningsPerShareAbstract_5CB962E21B385B3D9381FB1826B106D3" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_CBC38946F2515C55AF4E42F972A3CBA9" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_5CB962E21B385B3D9381FB1826B106D3" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_CBC38946F2515C55AF4E42F972A3CBA9" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_C41A0062997252D5997C28B8BF94285E" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_CBC38946F2515C55AF4E42F972A3CBA9" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_C41A0062997252D5997C28B8BF94285E" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_3BAA3882512A5279B2B9A73007196498" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_C41A0062997252D5997C28B8BF94285E" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_3BAA3882512A5279B2B9A73007196498" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaap_WarrantMember_881B9DE545065F758DF94B61DFC47F87" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_3BAA3882512A5279B2B9A73007196498" xlink:to="loc_us-gaap_WarrantMember_881B9DE545065F758DF94B61DFC47F87" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaap_EmployeeStockOptionMember_2C23C19222825046BC8461D75EFDF8D5" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_3BAA3882512A5279B2B9A73007196498" xlink:to="loc_us-gaap_EmployeeStockOptionMember_2C23C19222825046BC8461D75EFDF8D5" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_6FAE955DB9A65DEB96F48F7F0F294834" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_CBC38946F2515C55AF4E42F972A3CBA9" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_6FAE955DB9A65DEB96F48F7F0F294834" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_5EB68F801D285689A867CC7B20D34414" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_6FAE955DB9A65DEB96F48F7F0F294834" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_5EB68F801D285689A867CC7B20D34414" xlink:type="arc" />
  </presentationLink>
  <presentationLink xlink:role="http://www.galenabiopharma.com/role/NetLossPerShareTables" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="loc_us-gaap_EarningsPerShareAbstract_E69F69D60B875C88B464E6DDB82747BC" xlink:type="locator" />
    <loc xlink:href="gale-20150930.xsd#gale_ScheduleOfEarningPerShareToCommonShareholdersTableTextBlock" xlink:label="loc_gale_ScheduleOfEarningPerShareToCommonShareholdersTableTextBlock_DC8799C90CD35F8880EF12E841FE4E5C" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_E69F69D60B875C88B464E6DDB82747BC" xlink:to="loc_gale_ScheduleOfEarningPerShareToCommonShareholdersTableTextBlock_DC8799C90CD35F8880EF12E841FE4E5C" xlink:type="arc" />
  </presentationLink>
  <presentationLink xlink:role="http://www.galenabiopharma.com/role/OtherIncomeExpenseNotes" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OtherIncomeAndExpensesAbstract" xlink:label="loc_us-gaap_OtherIncomeAndExpensesAbstract_870D887214E15E0FBA0E8E3999377D91" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OtherIncomeAndOtherExpenseDisclosureTextBlock" xlink:label="loc_us-gaap_OtherIncomeAndOtherExpenseDisclosureTextBlock_31707E64DDB15720917C6AC082354C8D" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherIncomeAndExpensesAbstract_870D887214E15E0FBA0E8E3999377D91" xlink:to="loc_us-gaap_OtherIncomeAndOtherExpenseDisclosureTextBlock_31707E64DDB15720917C6AC082354C8D" xlink:type="arc" />
  </presentationLink>
  <presentationLink xlink:role="http://www.galenabiopharma.com/role/OtherIncomeExpenseTableDetails" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OtherIncomeAndExpensesAbstract" xlink:label="loc_us-gaap_OtherIncomeAndExpensesAbstract_F30B8C21422B56F689ECE0982D15A3DC" xlink:type="locator" />
    <loc xlink:href="gale-20150930.xsd#gale_ChangeInFairValueOfContingentPurchasePriceConsideration" xlink:label="loc_gale_ChangeInFairValueOfContingentPurchasePriceConsideration_15747043B507542CA45F8C16C4E60052" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherIncomeAndExpensesAbstract_F30B8C21422B56F689ECE0982D15A3DC" xlink:to="loc_gale_ChangeInFairValueOfContingentPurchasePriceConsideration_15747043B507542CA45F8C16C4E60052" xlink:type="arc" />
    <loc xlink:href="gale-20150930.xsd#gale_MiscellaneousOtherIncomeExpense" xlink:label="loc_gale_MiscellaneousOtherIncomeExpense_4385694D25FF52958D276045ECBC3AC9" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherIncomeAndExpensesAbstract_F30B8C21422B56F689ECE0982D15A3DC" xlink:to="loc_gale_MiscellaneousOtherIncomeExpense_4385694D25FF52958D276045ECBC3AC9" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_BD6B9C26CA70554CB57A7C0C18D7A5C4" xlink:type="locator" />
    <presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherIncomeAndExpensesAbstract_F30B8C21422B56F689ECE0982D15A3DC" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_BD6B9C26CA70554CB57A7C0C18D7A5C4" xlink:type="arc" />
  </presentationLink>
  <presentationLink xlink:role="http://www.galenabiopharma.com/role/OtherIncomeExpenseTables" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OtherIncomeAndExpensesAbstract" xlink:label="loc_us-gaap_OtherIncomeAndExpensesAbstract_D89813F97EB75A248FF9B087AC656C92" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock_95C1AAEC53485BC38D8EFC5975C918FC" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherIncomeAndExpensesAbstract_D89813F97EB75A248FF9B087AC656C92" xlink:to="loc_us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock_95C1AAEC53485BC38D8EFC5975C918FC" xlink:type="arc" />
  </presentationLink>
  <presentationLink xlink:role="http://www.galenabiopharma.com/role/SignificantCustomersAndConcentrationOfCreditRiskDetails" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RisksAndUncertaintiesAbstract" xlink:label="loc_us-gaap_RisksAndUncertaintiesAbstract_0BFA2D99E937CE66248DDDA4F6B14FE3" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ConcentrationRiskTable" xlink:label="loc_us-gaap_ConcentrationRiskTable_18524F7D8249571191F7DDA4F6B13BB1" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RisksAndUncertaintiesAbstract_0BFA2D99E937CE66248DDDA4F6B14FE3" xlink:to="loc_us-gaap_ConcentrationRiskTable_18524F7D8249571191F7DDA4F6B13BB1" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ConcentrationRiskByTypeAxis" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis_E239AE7869AAF28B2E5EDDA4F6B2CD49" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTable_18524F7D8249571191F7DDA4F6B13BB1" xlink:to="loc_us-gaap_ConcentrationRiskByTypeAxis_E239AE7869AAF28B2E5EDDA4F6B2CD49" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_6F45A306D259EDBF334BDDA4F6B2E38D" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_E239AE7869AAF28B2E5EDDA4F6B2CD49" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_6F45A306D259EDBF334BDDA4F6B2E38D" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ProductConcentrationRiskMember" xlink:label="loc_us-gaap_ProductConcentrationRiskMember_771FE295753DBECF55EBDDA4F6B214A9" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_6F45A306D259EDBF334BDDA4F6B2E38D" xlink:to="loc_us-gaap_ProductConcentrationRiskMember_771FE295753DBECF55EBDDA4F6B214A9" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_96B7BC682629372E3B7CDDA4F6B2DCB8" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTable_18524F7D8249571191F7DDA4F6B13BB1" xlink:to="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_96B7BC682629372E3B7CDDA4F6B2DCB8" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_2738C2CE32664508F48BDDA4F6B22356" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_96B7BC682629372E3B7CDDA4F6B2DCB8" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_2738C2CE32664508F48BDDA4F6B22356" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SalesRevenueGoodsNetMember" xlink:label="loc_us-gaap_SalesRevenueGoodsNetMember_C12C86465A92747D92D4DDA4F6B2F635" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_2738C2CE32664508F48BDDA4F6B22356" xlink:to="loc_us-gaap_SalesRevenueGoodsNetMember_C12C86465A92747D92D4DDA4F6B2F635" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AccountsReceivableMember" xlink:label="loc_us-gaap_AccountsReceivableMember_16F0468584931AD4C438DDA4F6B2824B" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_2738C2CE32664508F48BDDA4F6B22356" xlink:to="loc_us-gaap_AccountsReceivableMember_16F0468584931AD4C438DDA4F6B2824B" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_MajorCustomersAxis" xlink:label="loc_us-gaap_MajorCustomersAxis_CB15BE011D8DDBBFF3AEDDA4F6B2F951" xlink:type="locator" />
    <presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTable_18524F7D8249571191F7DDA4F6B13BB1" xlink:to="loc_us-gaap_MajorCustomersAxis_CB15BE011D8DDBBFF3AEDDA4F6B2F951" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NameOfMajorCustomerDomain" xlink:label="loc_us-gaap_NameOfMajorCustomerDomain_3575FECE6A3E9890F098DDA4F6B20B22" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MajorCustomersAxis_CB15BE011D8DDBBFF3AEDDA4F6B2F951" xlink:to="loc_us-gaap_NameOfMajorCustomerDomain_3575FECE6A3E9890F098DDA4F6B20B22" xlink:type="arc" />
    <loc xlink:href="gale-20150930.xsd#gale_CustomerOneMember" xlink:label="loc_gale_CustomerOneMember_3267EA7B0D9FCCABCA03DDA4F6B2F5DF" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NameOfMajorCustomerDomain_3575FECE6A3E9890F098DDA4F6B20B22" xlink:to="loc_gale_CustomerOneMember_3267EA7B0D9FCCABCA03DDA4F6B2F5DF" xlink:type="arc" />
    <loc xlink:href="gale-20150930.xsd#gale_CustomerTwoMember" xlink:label="loc_gale_CustomerTwoMember_3F480FEB91BB968C4D50DDA4F6B29FE7" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NameOfMajorCustomerDomain_3575FECE6A3E9890F098DDA4F6B20B22" xlink:to="loc_gale_CustomerTwoMember_3F480FEB91BB968C4D50DDA4F6B29FE7" xlink:type="arc" />
    <loc xlink:href="gale-20150930.xsd#gale_CustomerThreeMember" xlink:label="loc_gale_CustomerThreeMember_D212B944EB4D767ADDA5DDA4F6B2C5EE" xlink:type="locator" />
    <presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NameOfMajorCustomerDomain_3575FECE6A3E9890F098DDA4F6B20B22" xlink:to="loc_gale_CustomerThreeMember_D212B944EB4D767ADDA5DDA4F6B2C5EE" xlink:type="arc" />
    <loc xlink:href="gale-20150930.xsd#gale_CustomerFourMember" xlink:label="loc_gale_CustomerFourMember_12B1E9413A01C721DCD6DDA4F6B27643" xlink:type="locator" />
    <presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NameOfMajorCustomerDomain_3575FECE6A3E9890F098DDA4F6B20B22" xlink:to="loc_gale_CustomerFourMember_12B1E9413A01C721DCD6DDA4F6B27643" xlink:type="arc" />
    <loc xlink:href="gale-20150930.xsd#gale_CustomerFiveMember" xlink:label="loc_gale_CustomerFiveMember_78CE2BEA53DFC8972C32DDA4F6B23094" xlink:type="locator" />
    <presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NameOfMajorCustomerDomain_3575FECE6A3E9890F098DDA4F6B20B22" xlink:to="loc_gale_CustomerFiveMember_78CE2BEA53DFC8972C32DDA4F6B23094" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ConcentrationRiskLineItems" xlink:label="loc_us-gaap_ConcentrationRiskLineItems_1B176FB11DAE0F13B24DDDA4F6B250BF" xlink:type="locator" />
    <presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTable_18524F7D8249571191F7DDA4F6B13BB1" xlink:to="loc_us-gaap_ConcentrationRiskLineItems_1B176FB11DAE0F13B24DDDA4F6B250BF" xlink:type="arc" />
    <loc xlink:href="gale-20150930.xsd#gale_NumberofCommericalProducts" xlink:label="loc_gale_NumberofCommericalProducts_1DC2AE2B5CE1C69759B9DDA4F6B395C6" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_1B176FB11DAE0F13B24DDDA4F6B250BF" xlink:to="loc_gale_NumberofCommericalProducts_1DC2AE2B5CE1C69759B9DDA4F6B395C6" xlink:type="arc" />
    <loc xlink:href="gale-20150930.xsd#gale_NumberofDosingStrengths" xlink:label="loc_gale_NumberofDosingStrengths_47E691350972938543FBDDA4F6B3FE11" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_1B176FB11DAE0F13B24DDDA4F6B250BF" xlink:to="loc_gale_NumberofDosingStrengths_47E691350972938543FBDDA4F6B3FE11" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ConcentrationRiskPercentage1" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1_E813DD073E063DB48A4CDDA4F6B361AE" xlink:type="locator" />
    <presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_1B176FB11DAE0F13B24DDDA4F6B250BF" xlink:to="loc_us-gaap_ConcentrationRiskPercentage1_E813DD073E063DB48A4CDDA4F6B361AE" xlink:type="arc" />
    <loc xlink:href="gale-20150930.xsd#gale_NumberofTopPerformingPharmacies" xlink:label="loc_gale_NumberofTopPerformingPharmacies_AEB60E827799BA355D13DDA4F6B3B84C" xlink:type="locator" />
    <presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_1B176FB11DAE0F13B24DDDA4F6B250BF" xlink:to="loc_gale_NumberofTopPerformingPharmacies_AEB60E827799BA355D13DDA4F6B3B84C" xlink:type="arc" />
  </presentationLink>
  <presentationLink xlink:role="http://www.galenabiopharma.com/role/SignificantCustomersAndConcentrationOfCreditRiskNotes" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RisksAndUncertaintiesAbstract" xlink:label="loc_us-gaap_RisksAndUncertaintiesAbstract_78C74653EE809D2E3442DDA4F6B770DE" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ConcentrationRiskDisclosureTextBlock" xlink:label="loc_us-gaap_ConcentrationRiskDisclosureTextBlock_604D6D9CC6A908578692DDA4F6B70152" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RisksAndUncertaintiesAbstract_78C74653EE809D2E3442DDA4F6B770DE" xlink:to="loc_us-gaap_ConcentrationRiskDisclosureTextBlock_604D6D9CC6A908578692DDA4F6B70152" xlink:type="arc" />
  </presentationLink>
  <presentationLink xlink:role="http://www.galenabiopharma.com/role/SignificantCustomersAndConcentrationOfCreditRiskSignificantCustomersAndConcentrationOfCreditRiskTables" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RisksAndUncertaintiesAbstract" xlink:label="loc_us-gaap_RisksAndUncertaintiesAbstract_98A0733C534DE11A47F5DDA4F6B5D2F7" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock" xlink:label="loc_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock_E8EDEF544114304620C4DDA4F6B50953" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RisksAndUncertaintiesAbstract_98A0733C534DE11A47F5DDA4F6B5D2F7" xlink:to="loc_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock_E8EDEF544114304620C4DDA4F6B50953" xlink:type="arc" />
  </presentationLink>
  <presentationLink xlink:role="http://www.galenabiopharma.com/role/StockBasedCompensation" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_BB2900E856AD58AE80FC957E3D7C7824" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_4292DCDA5727557FBC910DEE5F96735F" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_BB2900E856AD58AE80FC957E3D7C7824" xlink:to="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_4292DCDA5727557FBC910DEE5F96735F" xlink:type="arc" />
  </presentationLink>
  <presentationLink xlink:role="http://www.galenabiopharma.com/role/StockBasedCompensationAdditionalInformationDetail" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_1EBD69F8C1F05D63B35487ED0E4B6E41" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_06411BEA1AFA543D9CC450269CD8B444" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_1EBD69F8C1F05D63B35487ED0E4B6E41" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_06411BEA1AFA543D9CC450269CD8B444" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_TitleOfIndividualAxis" xlink:label="loc_us-gaap_TitleOfIndividualAxis_33BE35F37E255CB7B815AA694F203FA7" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_06411BEA1AFA543D9CC450269CD8B444" xlink:to="loc_us-gaap_TitleOfIndividualAxis_33BE35F37E255CB7B815AA694F203FA7" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_C58E07D700515604BFD9AE0670F7D314" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TitleOfIndividualAxis_33BE35F37E255CB7B815AA694F203FA7" xlink:to="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_C58E07D700515604BFD9AE0670F7D314" xlink:type="arc" />
    <loc xlink:href="gale-20150930.xsd#gale_TwoZeroZeroSevenIncentivePlanMember" xlink:label="loc_gale_TwoZeroZeroSevenIncentivePlanMember_DEF2DBDC343A5723A9217E4149D690E0" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_C58E07D700515604BFD9AE0670F7D314" xlink:to="loc_gale_TwoZeroZeroSevenIncentivePlanMember_DEF2DBDC343A5723A9217E4149D690E0" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RangeAxis" xlink:label="loc_us-gaap_RangeAxis_435F5640CDAF59CEB284949B196D64C5" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_06411BEA1AFA543D9CC450269CD8B444" xlink:to="loc_us-gaap_RangeAxis_435F5640CDAF59CEB284949B196D64C5" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaap_RangeMember_9D7A4F680C215D97994EE5D559DDAEB8" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RangeAxis_435F5640CDAF59CEB284949B196D64C5" xlink:to="loc_us-gaap_RangeMember_9D7A4F680C215D97994EE5D559DDAEB8" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_MinimumMember" xlink:label="loc_us-gaap_MinimumMember_37D0532F63AA5944A8710C1D7E3CB576" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RangeMember_9D7A4F680C215D97994EE5D559DDAEB8" xlink:to="loc_us-gaap_MinimumMember_37D0532F63AA5944A8710C1D7E3CB576" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_MaximumMember" xlink:label="loc_us-gaap_MaximumMember_A885F0020E0B54A5B3A1FA1771D679A7" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RangeMember_9D7A4F680C215D97994EE5D559DDAEB8" xlink:to="loc_us-gaap_MaximumMember_A885F0020E0B54A5B3A1FA1771D679A7" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_DC6DDF098889592993B5B8CCA32AE32D" xlink:type="locator" />
    <presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_06411BEA1AFA543D9CC450269CD8B444" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_DC6DDF098889592993B5B8CCA32AE32D" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_EA3E148C2B405549A7AD2903616E6907" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_DC6DDF098889592993B5B8CCA32AE32D" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_EA3E148C2B405549A7AD2903616E6907" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" xlink:label="loc_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_5F8F8B5C9D3453D09A248EFD1FBE4084" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_DC6DDF098889592993B5B8CCA32AE32D" xlink:to="loc_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_5F8F8B5C9D3453D09A248EFD1FBE4084" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_B79F848AC0B05F01A46D196D4DD7111F" xlink:type="locator" />
    <presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_DC6DDF098889592993B5B8CCA32AE32D" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_B79F848AC0B05F01A46D196D4DD7111F" xlink:type="arc" />
    <loc xlink:href="gale-20150930.xsd#gale_EstimatedAnnualizedForfeitureRateForOptionsGrantedToEmployees" xlink:label="loc_gale_EstimatedAnnualizedForfeitureRateForOptionsGrantedToEmployees_D56BE84CD78A502BA2A102DE94349F22" xlink:type="locator" />
    <presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_DC6DDF098889592993B5B8CCA32AE32D" xlink:to="loc_gale_EstimatedAnnualizedForfeitureRateForOptionsGrantedToEmployees_D56BE84CD78A502BA2A102DE94349F22" xlink:type="arc" />
    <loc xlink:href="gale-20150930.xsd#gale_EstimatedAnnualizedForfeitureRateForOptionsGrantedToSeniorManagement" xlink:label="loc_gale_EstimatedAnnualizedForfeitureRateForOptionsGrantedToSeniorManagement_84B98741EBD15A4299BA200A87AF2CFB" xlink:type="locator" />
    <presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_DC6DDF098889592993B5B8CCA32AE32D" xlink:to="loc_gale_EstimatedAnnualizedForfeitureRateForOptionsGrantedToSeniorManagement_84B98741EBD15A4299BA200A87AF2CFB" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_53E10FBD2E2C5BB1A59D80D733F50A74" xlink:type="locator" />
    <presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_DC6DDF098889592993B5B8CCA32AE32D" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_53E10FBD2E2C5BB1A59D80D733F50A74" xlink:type="arc" />
    <loc xlink:href="gale-20150930.xsd#gale_EmployeeServiceShareBasedCompensationUnrecognizedCompensationCosts" xlink:label="loc_gale_EmployeeServiceShareBasedCompensationUnrecognizedCompensationCosts_98CC170389905E46A996A449CE894C33" xlink:type="locator" />
    <presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_DC6DDF098889592993B5B8CCA32AE32D" xlink:to="loc_gale_EmployeeServiceShareBasedCompensationUnrecognizedCompensationCosts_98CC170389905E46A996A449CE894C33" xlink:type="arc" />
    <loc xlink:href="gale-20150930.xsd#gale_EmployeeServiceShareBasedCompensationUnrecognizedCompensationCostsWeightedAveragePeriodOfRecognition" xlink:label="loc_gale_EmployeeServiceShareBasedCompensationUnrecognizedCompensationCostsWeightedAveragePeriodOfRecognition_50A604EBA87F5F26A0A6D03513AE274D" xlink:type="locator" />
    <presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_DC6DDF098889592993B5B8CCA32AE32D" xlink:to="loc_gale_EmployeeServiceShareBasedCompensationUnrecognizedCompensationCostsWeightedAveragePeriodOfRecognition_50A604EBA87F5F26A0A6D03513AE274D" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_F8B04BEF31D95360AC1CEA7334B480D6" xlink:type="locator" />
    <presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_DC6DDF098889592993B5B8CCA32AE32D" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_F8B04BEF31D95360AC1CEA7334B480D6" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_0BC111709A2955AC986E18429B7B174A" xlink:type="locator" />
    <presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_DC6DDF098889592993B5B8CCA32AE32D" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_0BC111709A2955AC986E18429B7B174A" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_E34FF3AB87C35B079B102FBEF0B94B69" xlink:type="locator" />
    <presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_DC6DDF098889592993B5B8CCA32AE32D" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_E34FF3AB87C35B079B102FBEF0B94B69" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_9FDF9E7EA2B35D2B836B8171CA498E44" xlink:type="locator" />
    <presentationArc order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_DC6DDF098889592993B5B8CCA32AE32D" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_9FDF9E7EA2B35D2B836B8171CA498E44" xlink:type="arc" />
    <loc xlink:href="gale-20150930.xsd#gale_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationPeriod" xlink:label="loc_gale_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationPeriod_9189AFD346F8509DA048D0A56B24F723" xlink:type="locator" />
    <presentationArc order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_DC6DDF098889592993B5B8CCA32AE32D" xlink:to="loc_gale_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationPeriod_9189AFD346F8509DA048D0A56B24F723" xlink:type="arc" />
    <loc xlink:href="gale-20150930.xsd#gale_ClosingPriceOfCommonStock" xlink:label="loc_gale_ClosingPriceOfCommonStock_4365423020E75EF6A9FF49FB57F76B21" xlink:type="locator" />
    <presentationArc order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_DC6DDF098889592993B5B8CCA32AE32D" xlink:to="loc_gale_ClosingPriceOfCommonStock_4365423020E75EF6A9FF49FB57F76B21" xlink:type="arc" />
  </presentationLink>
  <presentationLink xlink:role="http://www.galenabiopharma.com/role/StockBasedCompensationAllocatedStockBasedCompensationDetails" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_1E77A7DA8E5DF918D72EDE2E960EB9E8" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_58038B07C615F3A01862DE2E960E98C7" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_1E77A7DA8E5DF918D72EDE2E960EB9E8" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_58038B07C615F3A01862DE2E960E98C7" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementOperatingActivitiesSegmentAxis" xlink:label="loc_us-gaap_StatementOperatingActivitiesSegmentAxis_96372A821FAAB008C74BDE996948FAFF" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_58038B07C615F3A01862DE2E960E98C7" xlink:to="loc_us-gaap_StatementOperatingActivitiesSegmentAxis_96372A821FAAB008C74BDE996948FAFF" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SegmentOperatingActivitiesDomain" xlink:label="loc_us-gaap_SegmentOperatingActivitiesDomain_D222B235E27D8B2C40B4DE9A00540134" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOperatingActivitiesSegmentAxis_96372A821FAAB008C74BDE996948FAFF" xlink:to="loc_us-gaap_SegmentOperatingActivitiesDomain_D222B235E27D8B2C40B4DE9A00540134" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SegmentContinuingOperationsMember" xlink:label="loc_us-gaap_SegmentContinuingOperationsMember_A671B6A51A35E4090E45DE9998C7A897" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentOperatingActivitiesDomain_D222B235E27D8B2C40B4DE9A00540134" xlink:to="loc_us-gaap_SegmentContinuingOperationsMember_A671B6A51A35E4090E45DE9998C7A897" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SegmentDiscontinuedOperationsMember" xlink:label="loc_us-gaap_SegmentDiscontinuedOperationsMember_704B607CEF48AEFE6A78DE99BAD3BDD8" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentOperatingActivitiesDomain_D222B235E27D8B2C40B4DE9A00540134" xlink:to="loc_us-gaap_SegmentDiscontinuedOperationsMember_704B607CEF48AEFE6A78DE99BAD3BDD8" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_045CF77143E5AA828CF6DE98972C0600" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_58038B07C615F3A01862DE2E960E98C7" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_045CF77143E5AA828CF6DE98972C0600" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_61BFEB9BC70041E93ABDDE98972C7A2A" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_045CF77143E5AA828CF6DE98972C0600" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_61BFEB9BC70041E93ABDDE98972C7A2A" xlink:type="arc" />
    <loc xlink:href="gale-20150930.xsd#gale_CommercialBusinessSegmentMember" xlink:label="loc_gale_CommercialBusinessSegmentMember_288AC595A4A5CEA32630DE9897EBEDB5" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_61BFEB9BC70041E93ABDDE98972C7A2A" xlink:to="loc_gale_CommercialBusinessSegmentMember_288AC595A4A5CEA32630DE9897EBEDB5" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_6631E6125C52C1F92F51DE2E960EB27E" xlink:type="locator" />
    <presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_58038B07C615F3A01862DE2E960E98C7" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_6631E6125C52C1F92F51DE2E960EB27E" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_82EAA293D0C9A62741DADE2E960EDB69" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_6631E6125C52C1F92F51DE2E960EB27E" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_82EAA293D0C9A62741DADE2E960EDB69" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_0FFBEA2204A216E06A6BDE2E960E9BEE" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_82EAA293D0C9A62741DADE2E960EDB69" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_0FFBEA2204A216E06A6BDE2E960E9BEE" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_2CC4A3F44FBD501622CADE2E960E1F5F" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_82EAA293D0C9A62741DADE2E960EDB69" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_2CC4A3F44FBD501622CADE2E960E1F5F" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_3247C7FA00BABB8D2859DE2E960E7E93" xlink:type="locator" />
    <presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_58038B07C615F3A01862DE2E960E98C7" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_3247C7FA00BABB8D2859DE2E960E7E93" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_414715582751F6861173DE2E960E1047" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_3247C7FA00BABB8D2859DE2E960E7E93" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_414715582751F6861173DE2E960E1047" xlink:type="arc" />
  </presentationLink>
  <presentationLink xlink:role="http://www.galenabiopharma.com/role/StockBasedCompensationAssumptionsForOptionGrantsIssuedDetail" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_48BAF6D3D1D55C6AA00E9E6CCCE19338" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_D5F78D0ABCA551039C0C6C10BC3089E4" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_48BAF6D3D1D55C6AA00E9E6CCCE19338" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_D5F78D0ABCA551039C0C6C10BC3089E4" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_BE2FB88FB980520A8FE35CA5E44BD566" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_48BAF6D3D1D55C6AA00E9E6CCCE19338" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_BE2FB88FB980520A8FE35CA5E44BD566" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_EE538F6247D153118B0AFDDBC25C7CD5" xlink:type="locator" />
    <presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_48BAF6D3D1D55C6AA00E9E6CCCE19338" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_EE538F6247D153118B0AFDDBC25C7CD5" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_501B10773B3D5946A7C1989C84659FBD" xlink:type="locator" />
    <presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_48BAF6D3D1D55C6AA00E9E6CCCE19338" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_501B10773B3D5946A7C1989C84659FBD" xlink:type="arc" />
  </presentationLink>
  <presentationLink xlink:role="http://www.galenabiopharma.com/role/StockBasedCompensationStockOptionActivityDetail" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_AEC6D393004158DC833CECE51DD086D8" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_BE9F4563DEDF516596A6CC55BF540024" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_AEC6D393004158DC833CECE51DD086D8" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_BE9F4563DEDF516596A6CC55BF540024" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_7EAFDBD961CC56B2A4D7703F0EF872D5" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_BE9F4563DEDF516596A6CC55BF540024" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_7EAFDBD961CC56B2A4D7703F0EF872D5" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_D789EBB437A15E6A8A0F07C198B66724" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_BE9F4563DEDF516596A6CC55BF540024" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_D789EBB437A15E6A8A0F07C198B66724" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_97A137D33137541AAE7027DF7075110F" xlink:type="locator" />
    <presentationArc order="3" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_BE9F4563DEDF516596A6CC55BF540024" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_97A137D33137541AAE7027DF7075110F" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_3AB8A646DE035CF3B8E6D38429ABB01A" xlink:type="locator" />
    <presentationArc order="4" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_BE9F4563DEDF516596A6CC55BF540024" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_3AB8A646DE035CF3B8E6D38429ABB01A" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_C209B77C139151BEB9EBA45B7AD3AF23" xlink:type="locator" />
    <presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_BE9F4563DEDF516596A6CC55BF540024" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_C209B77C139151BEB9EBA45B7AD3AF23" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_B35C935CB3685F989E08915A1F42205A" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_AEC6D393004158DC833CECE51DD086D8" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_B35C935CB3685F989E08915A1F42205A" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_9E9E4A416C915890B663AB7E7F8C7F22" xlink:type="locator" />
    <presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_AEC6D393004158DC833CECE51DD086D8" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_9E9E4A416C915890B663AB7E7F8C7F22" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_B46DE5D07A685CABAC241E16F0F89CBC" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_9E9E4A416C915890B663AB7E7F8C7F22" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_B46DE5D07A685CABAC241E16F0F89CBC" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_F04E8AA0341358E2965037B01CC5AF0E" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_9E9E4A416C915890B663AB7E7F8C7F22" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_F04E8AA0341358E2965037B01CC5AF0E" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_3D31A99BC5855C3A956D97F1A9A2E902" xlink:type="locator" />
    <presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_9E9E4A416C915890B663AB7E7F8C7F22" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_3D31A99BC5855C3A956D97F1A9A2E902" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_9549DFBB8DAF54D1A149F8F09EB8C6DA" xlink:type="locator" />
    <presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_9E9E4A416C915890B663AB7E7F8C7F22" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_9549DFBB8DAF54D1A149F8F09EB8C6DA" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_3541EF341C055C71A213E9D023ABEEFB" xlink:type="locator" />
    <presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_9E9E4A416C915890B663AB7E7F8C7F22" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_3541EF341C055C71A213E9D023ABEEFB" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_C32500CCC6F6585EBE708B74525F0878" xlink:type="locator" />
    <presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_AEC6D393004158DC833CECE51DD086D8" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_C32500CCC6F6585EBE708B74525F0878" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_86545D61ED835E14A0C5A04AA855F470" xlink:type="locator" />
    <presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_AEC6D393004158DC833CECE51DD086D8" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_86545D61ED835E14A0C5A04AA855F470" xlink:type="arc" />
    <loc xlink:href="gale-20150930.xsd#gale_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateAggregateIntrinsicValue" xlink:label="loc_gale_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateAggregateIntrinsicValue_35A6D6D48AA753489BD5B34591B6D30B" xlink:type="locator" />
    <presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_AEC6D393004158DC833CECE51DD086D8" xlink:to="loc_gale_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateAggregateIntrinsicValue_35A6D6D48AA753489BD5B34591B6D30B" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_CEA5F7BC139D59B1B9E1B9082CD5914E" xlink:type="locator" />
    <presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_AEC6D393004158DC833CECE51DD086D8" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_CEA5F7BC139D59B1B9E1B9082CD5914E" xlink:type="arc" />
    <loc xlink:href="gale-20150930.xsd#gale_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpiredInPeriodIntrinsicValue" xlink:label="loc_gale_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpiredInPeriodIntrinsicValue_D6677C0C6BDD506D95043BEC85861A11" xlink:type="locator" />
    <presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_AEC6D393004158DC833CECE51DD086D8" xlink:to="loc_gale_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpiredInPeriodIntrinsicValue_D6677C0C6BDD506D95043BEC85861A11" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_647715719BA654359888DE039AFA6460" xlink:type="locator" />
    <presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_AEC6D393004158DC833CECE51DD086D8" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_647715719BA654359888DE039AFA6460" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_AF35D74F49015E3B88036EE1FCBA7516" xlink:type="locator" />
    <presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_AEC6D393004158DC833CECE51DD086D8" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_AF35D74F49015E3B88036EE1FCBA7516" xlink:type="arc" />
  </presentationLink>
  <presentationLink xlink:role="http://www.galenabiopharma.com/role/StockBasedCompensationTables" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_E0AD5E81BC875E5892BB188DF3B2261F" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_86113A6CCDFC5879B8224142BA8F5E63" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_E0AD5E81BC875E5892BB188DF3B2261F" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_86113A6CCDFC5879B8224142BA8F5E63" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_F74E972664355CBAA55BDE734673E68F" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_E0AD5E81BC875E5892BB188DF3B2261F" xlink:to="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_F74E972664355CBAA55BDE734673E68F" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_8E7F32656FEB5696876FC448E8257AC3" xlink:type="locator" />
    <presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_E0AD5E81BC875E5892BB188DF3B2261F" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_8E7F32656FEB5696876FC448E8257AC3" xlink:type="arc" />
  </presentationLink>
  <presentationLink xlink:role="http://www.galenabiopharma.com/role/StockholdersEquity" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaap_EquityAbstract_9D5A136EDA8D559DB1518DEF68DD28E5" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_F8807505106456C7B2DDC34B8D5D4986" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_9D5A136EDA8D559DB1518DEF68DD28E5" xlink:to="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_F8807505106456C7B2DDC34B8D5D4986" xlink:type="arc" />
  </presentationLink>
  <presentationLink xlink:role="http://www.galenabiopharma.com/role/StockholdersEquityAdditionalInformationDetail" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaap_EquityAbstract_61AE98E7D04B5280AC6440D9CF381502" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_296A971608965B448E6974FA1BBF315C" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_61AE98E7D04B5280AC6440D9CF381502" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_296A971608965B448E6974FA1BBF315C" xlink:type="arc" />
    <loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_0D57436B5EF7593BB7C99DD5807C8E0D" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_296A971608965B448E6974FA1BBF315C" xlink:to="loc_dei_LegalEntityAxis_0D57436B5EF7593BB7C99DD5807C8E0D" xlink:type="arc" />
    <loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_6ED96AA52B205D28BE8F0FC0B04FE6D9" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_0D57436B5EF7593BB7C99DD5807C8E0D" xlink:to="loc_dei_EntityDomain_6ED96AA52B205D28BE8F0FC0B04FE6D9" xlink:type="arc" />
    <loc xlink:href="gale-20150930.xsd#gale_LincolnParkCapitalLLCMember" xlink:label="loc_gale_LincolnParkCapitalLLCMember_E7FE8EA1C6E65581958491F205454870" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_6ED96AA52B205D28BE8F0FC0B04FE6D9" xlink:to="loc_gale_LincolnParkCapitalLLCMember_E7FE8EA1C6E65581958491F205454870" xlink:type="arc" />
    <loc xlink:href="gale-20150930.xsd#gale_MLVCo.LLCandMaximGroupLLCMember" xlink:label="loc_gale_MLVCo.LLCandMaximGroupLLCMember_186D461599F2534FAAFABDB19D8F8875" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_6ED96AA52B205D28BE8F0FC0B04FE6D9" xlink:to="loc_gale_MLVCo.LLCandMaximGroupLLCMember_186D461599F2534FAAFABDB19D8F8875" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_5946413637FA5BA28FA53AC691FF1979" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_296A971608965B448E6974FA1BBF315C" xlink:to="loc_us-gaap_StatementClassOfStockAxis_5946413637FA5BA28FA53AC691FF1979" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_4FAC2440DF065BEE8FA26503F59838FB" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_5946413637FA5BA28FA53AC691FF1979" xlink:to="loc_us-gaap_ClassOfStockDomain_4FAC2440DF065BEE8FA26503F59838FB" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember_D58E23A7938E5EEC90DE63D31C5C4E93" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_4FAC2440DF065BEE8FA26503F59838FB" xlink:to="loc_us-gaap_CommonStockMember_D58E23A7938E5EEC90DE63D31C5C4E93" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaap_WarrantMember_45A8948C830E5CE2870BDC2CA9DC48C5" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_4FAC2440DF065BEE8FA26503F59838FB" xlink:to="loc_us-gaap_WarrantMember_45A8948C830E5CE2870BDC2CA9DC48C5" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ClassOfStockLineItems" xlink:label="loc_us-gaap_ClassOfStockLineItems_D44EDB4BDB5C56C78BAFB8E7AF60F739" xlink:type="locator" />
    <presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_296A971608965B448E6974FA1BBF315C" xlink:to="loc_us-gaap_ClassOfStockLineItems_D44EDB4BDB5C56C78BAFB8E7AF60F739" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_152EE2A8DEB054D1A001C2488E3FA05B" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_D44EDB4BDB5C56C78BAFB8E7AF60F739" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_152EE2A8DEB054D1A001C2488E3FA05B" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_97DF3539700558108AE5C1067B01937E" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_D44EDB4BDB5C56C78BAFB8E7AF60F739" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_97DF3539700558108AE5C1067B01937E" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_860C5EF2C76257A4BC077D779616D6A6" xlink:type="locator" />
    <presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_D44EDB4BDB5C56C78BAFB8E7AF60F739" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_860C5EF2C76257A4BC077D779616D6A6" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_47E96CB05444557A8688836F7E09458C" xlink:type="locator" />
    <presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_D44EDB4BDB5C56C78BAFB8E7AF60F739" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_47E96CB05444557A8688836F7E09458C" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:label="loc_us-gaap_ProceedsFromIssuanceOrSaleOfEquity_EAE1DE5F61245A839B7E586A7EC1C4F1" xlink:type="locator" />
    <presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_D44EDB4BDB5C56C78BAFB8E7AF60F739" xlink:to="loc_us-gaap_ProceedsFromIssuanceOrSaleOfEquity_EAE1DE5F61245A839B7E586A7EC1C4F1" xlink:type="arc" />
    <loc xlink:href="gale-20150930.xsd#gale_PurchaseAgreementTerm" xlink:label="loc_gale_PurchaseAgreementTerm_B98B7B075BFB51539FA090FD26B9A240" xlink:type="locator" />
    <presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_D44EDB4BDB5C56C78BAFB8E7AF60F739" xlink:to="loc_gale_PurchaseAgreementTerm_B98B7B075BFB51539FA090FD26B9A240" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets_5084DDF9E0AD5ACB8697847F3085F3E3" xlink:type="locator" />
    <presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_D44EDB4BDB5C56C78BAFB8E7AF60F739" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets_5084DDF9E0AD5ACB8697847F3085F3E3" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SharePrice" xlink:label="loc_us-gaap_SharePrice_4FC045C1EAAD5BF0A68070982CE11241" xlink:type="locator" />
    <presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_D44EDB4BDB5C56C78BAFB8E7AF60F739" xlink:to="loc_us-gaap_SharePrice_4FC045C1EAAD5BF0A68070982CE11241" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_415EBD02E2BF540FAAB2FDEB230D74BE" xlink:type="locator" />
    <presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_D44EDB4BDB5C56C78BAFB8E7AF60F739" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_415EBD02E2BF540FAAB2FDEB230D74BE" xlink:type="arc" />
    <loc xlink:href="gale-20150930.xsd#gale_AtMarketIssuanceSalesAgreementsPercentofGrossProceeds" xlink:label="loc_gale_AtMarketIssuanceSalesAgreementsPercentofGrossProceeds_250BC34514A058C7884EA78A38AA0EB5" xlink:type="locator" />
    <presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_D44EDB4BDB5C56C78BAFB8E7AF60F739" xlink:to="loc_gale_AtMarketIssuanceSalesAgreementsPercentofGrossProceeds_250BC34514A058C7884EA78A38AA0EB5" xlink:type="arc" />
    <loc xlink:href="gale-20150930.xsd#gale_AtMarketIssuanceSalesAgreementsMaximumGrossProceeds" xlink:label="loc_gale_AtMarketIssuanceSalesAgreementsMaximumGrossProceeds_124033EFCB3F5D289F6A6BAB4CFC7F7C" xlink:type="locator" />
    <presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_D44EDB4BDB5C56C78BAFB8E7AF60F739" xlink:to="loc_gale_AtMarketIssuanceSalesAgreementsMaximumGrossProceeds_124033EFCB3F5D289F6A6BAB4CFC7F7C" xlink:type="arc" />
    <loc xlink:href="gale-20150930.xsd#gale_NumberofSharesPerUnit" xlink:label="loc_gale_NumberofSharesPerUnit_D5E01A04C9135579881492BB50250F82" xlink:type="locator" />
    <presentationArc order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_D44EDB4BDB5C56C78BAFB8E7AF60F739" xlink:to="loc_gale_NumberofSharesPerUnit_D5E01A04C9135579881492BB50250F82" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_72947B2F9CF25E719769969DED859FEF" xlink:type="locator" />
    <presentationArc order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_D44EDB4BDB5C56C78BAFB8E7AF60F739" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_72947B2F9CF25E719769969DED859FEF" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_69AF91CA144F599CB72AC910751F58B0" xlink:type="locator" />
    <presentationArc order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_D44EDB4BDB5C56C78BAFB8E7AF60F739" xlink:to="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_69AF91CA144F599CB72AC910751F58B0" xlink:type="arc" />
    <loc xlink:href="gale-20150930.xsd#gale_StockIssuedDuringPeriodSharesOverallotmentOption" xlink:label="loc_gale_StockIssuedDuringPeriodSharesOverallotmentOption_7C658606B8B25E99AED0727C7AFB317E" xlink:type="locator" />
    <presentationArc order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_D44EDB4BDB5C56C78BAFB8E7AF60F739" xlink:to="loc_gale_StockIssuedDuringPeriodSharesOverallotmentOption_7C658606B8B25E99AED0727C7AFB317E" xlink:type="arc" />
    <loc xlink:href="gale-20150930.xsd#gale_ProceedsFromIssuanceorSaleofEquityNetUnderwritingDiscountsCommissionsandOfferingExpenses" xlink:label="loc_gale_ProceedsFromIssuanceorSaleofEquityNetUnderwritingDiscountsCommissionsandOfferingExpenses_3B1AD7F42360559380EFA1BCE1026A36" xlink:type="locator" />
    <presentationArc order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_D44EDB4BDB5C56C78BAFB8E7AF60F739" xlink:to="loc_gale_ProceedsFromIssuanceorSaleofEquityNetUnderwritingDiscountsCommissionsandOfferingExpenses_3B1AD7F42360559380EFA1BCE1026A36" xlink:type="arc" />
  </presentationLink>
  <presentationLink xlink:role="http://www.galenabiopharma.com/role/StockholdersEquityCommonStockAreReservedForFutureIssuanceDetail" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaap_EquityAbstract_4D1DEE7F08985C51AD674795C9EA1E22" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="loc_us-gaap_ClassOfWarrantOrRightOutstanding_BBD3F5C119945EC3971AFD379FB2238F" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_4D1DEE7F08985C51AD674795C9EA1E22" xlink:to="loc_us-gaap_ClassOfWarrantOrRightOutstanding_BBD3F5C119945EC3971AFD379FB2238F" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_FAFE5950FFFF5656A31C4DABD0768509" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_4D1DEE7F08985C51AD674795C9EA1E22" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_FAFE5950FFFF5656A31C4DABD0768509" xlink:type="arc" />
    <loc xlink:href="gale-20150930.xsd#gale_OptionsReservedForFutureIssuanceUnderCompaniesIncentivePlan" xlink:label="loc_gale_OptionsReservedForFutureIssuanceUnderCompaniesIncentivePlan_E2016511C1B55CB580C61CB731F1EFE1" xlink:type="locator" />
    <presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_4D1DEE7F08985C51AD674795C9EA1E22" xlink:to="loc_gale_OptionsReservedForFutureIssuanceUnderCompaniesIncentivePlan_E2016511C1B55CB580C61CB731F1EFE1" xlink:type="arc" />
    <loc xlink:href="gale-20150930.xsd#gale_CommonStockCapitalSharesReservedForFutureIssuanceOfEmployeeStockPurchasePlan" xlink:label="loc_gale_CommonStockCapitalSharesReservedForFutureIssuanceOfEmployeeStockPurchasePlan_8D5AF98C88C157D4A90FF8C64816AC25" xlink:type="locator" />
    <presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_4D1DEE7F08985C51AD674795C9EA1E22" xlink:to="loc_gale_CommonStockCapitalSharesReservedForFutureIssuanceOfEmployeeStockPurchasePlan_8D5AF98C88C157D4A90FF8C64816AC25" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_186688B81FC25B07824423EFBC1B7C1C" xlink:type="locator" />
    <presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_4D1DEE7F08985C51AD674795C9EA1E22" xlink:to="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_186688B81FC25B07824423EFBC1B7C1C" xlink:type="arc" />
  </presentationLink>
  <presentationLink xlink:role="http://www.galenabiopharma.com/role/StockholdersEquityTables" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaap_EquityAbstract_AC476B84C55A58969640CFCBE0CC5275" xlink:type="locator" />
    <loc xlink:href="gale-20150930.xsd#gale_CommonStockAreReservedForFutureIssuanceTableTextBlock" xlink:label="loc_gale_CommonStockAreReservedForFutureIssuanceTableTextBlock_866FC528352655519CA3C725F062C282" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_AC476B84C55A58969640CFCBE0CC5275" xlink:to="loc_gale_CommonStockAreReservedForFutureIssuanceTableTextBlock_866FC528352655519CA3C725F062C282" xlink:type="arc" />
  </presentationLink>
  <presentationLink xlink:role="http://www.galenabiopharma.com/role/SubsequentEvents" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="loc_us-gaap_SubsequentEventsAbstract_B7AB548C3D1B5586B849D52C55F8F3AB" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="loc_us-gaap_SubsequentEventsTextBlock_60484E44A92A5B7AACB4C60FD30552A1" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventsAbstract_B7AB548C3D1B5586B849D52C55F8F3AB" xlink:to="loc_us-gaap_SubsequentEventsTextBlock_60484E44A92A5B7AACB4C60FD30552A1" xlink:type="arc" />
  </presentationLink>
  <presentationLink xlink:role="http://www.galenabiopharma.com/role/Warrants" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_WarrantsAndRightsNoteDisclosureAbstract" xlink:label="loc_us-gaap_WarrantsAndRightsNoteDisclosureAbstract_D4A0992CF7115602A765B8EAFFFA9660" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OptionIndexedToIssuersEquityDescriptionTextBlock" xlink:label="loc_us-gaap_OptionIndexedToIssuersEquityDescriptionTextBlock_869547BC42365ED38D7F6C0CB21897B3" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WarrantsAndRightsNoteDisclosureAbstract_D4A0992CF7115602A765B8EAFFFA9660" xlink:to="loc_us-gaap_OptionIndexedToIssuersEquityDescriptionTextBlock_869547BC42365ED38D7F6C0CB21897B3" xlink:type="arc" />
  </presentationLink>
  <presentationLink xlink:role="http://www.galenabiopharma.com/role/WarrantsChangesInFairValueOfWarrantLiabilityDetail" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaap_EquityAbstract_C18FF260436354DA933D35D3168C4315" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ClassOfWarrantOrRightTable" xlink:label="loc_us-gaap_ClassOfWarrantOrRightTable_C43ED20E54A056BFBB81A2BE41C35A6A" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_C18FF260436354DA933D35D3168C4315" xlink:to="loc_us-gaap_ClassOfWarrantOrRightTable_C43ED20E54A056BFBB81A2BE41C35A6A" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis_3B25AA97C7DC5396966F3635F6C05407" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_C43ED20E54A056BFBB81A2BE41C35A6A" xlink:to="loc_us-gaap_ClassOfWarrantOrRightAxis_3B25AA97C7DC5396966F3635F6C05407" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_0AE86FC5411A5EC79A3205437FE3E963" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_3B25AA97C7DC5396966F3635F6C05407" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_0AE86FC5411A5EC79A3205437FE3E963" xlink:type="arc" />
    <loc xlink:href="gale-20150930.xsd#gale_MarchTwoThousandFifteenWarrantsMember" xlink:label="loc_gale_MarchTwoThousandFifteenWarrantsMember_9A4EE72B79D353CBBE8A74025B078856" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_0AE86FC5411A5EC79A3205437FE3E963" xlink:to="loc_gale_MarchTwoThousandFifteenWarrantsMember_9A4EE72B79D353CBBE8A74025B078856" xlink:type="arc" />
    <loc xlink:href="gale-20150930.xsd#gale_SeptemberTwoThousandThirteenWarrantMember" xlink:label="loc_gale_SeptemberTwoThousandThirteenWarrantMember_FF7927BE99FB53B481606E724880504B" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_0AE86FC5411A5EC79A3205437FE3E963" xlink:to="loc_gale_SeptemberTwoThousandThirteenWarrantMember_FF7927BE99FB53B481606E724880504B" xlink:type="arc" />
    <loc xlink:href="gale-20150930.xsd#gale_DecemberTwoThousandTwelveWarrantMember" xlink:label="loc_gale_DecemberTwoThousandTwelveWarrantMember_0AE9DA1BF1215CEAB9DC6AF23D72491A" xlink:type="locator" />
    <presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_0AE86FC5411A5EC79A3205437FE3E963" xlink:to="loc_gale_DecemberTwoThousandTwelveWarrantMember_0AE9DA1BF1215CEAB9DC6AF23D72491A" xlink:type="arc" />
    <loc xlink:href="gale-20150930.xsd#gale_AprilTwoThousandElevenWarrantMember" xlink:label="loc_gale_AprilTwoThousandElevenWarrantMember_68FC82B6E643559CA8DF3F903675EE11" xlink:type="locator" />
    <presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_0AE86FC5411A5EC79A3205437FE3E963" xlink:to="loc_gale_AprilTwoThousandElevenWarrantMember_68FC82B6E643559CA8DF3F903675EE11" xlink:type="arc" />
    <loc xlink:href="gale-20150930.xsd#gale_MarchTwoThousandElevenWarrantMember" xlink:label="loc_gale_MarchTwoThousandElevenWarrantMember_FE4730851ED954118A6CBAF93C8E6B73" xlink:type="locator" />
    <presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_0AE86FC5411A5EC79A3205437FE3E963" xlink:to="loc_gale_MarchTwoThousandElevenWarrantMember_FE4730851ED954118A6CBAF93C8E6B73" xlink:type="arc" />
    <loc xlink:href="gale-20150930.xsd#gale_MarchTwoThousandTenWarrantMember" xlink:label="loc_gale_MarchTwoThousandTenWarrantMember_70CDBEC41A5754D4B72AF32BE6CDBD3E" xlink:type="locator" />
    <presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_0AE86FC5411A5EC79A3205437FE3E963" xlink:to="loc_gale_MarchTwoThousandTenWarrantMember_70CDBEC41A5754D4B72AF32BE6CDBD3E" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ClassOfWarrantOrRightLineItems" xlink:label="loc_us-gaap_ClassOfWarrantOrRightLineItems_5F5C140FFDF55602B4C16D7CA221772D" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_C43ED20E54A056BFBB81A2BE41C35A6A" xlink:to="loc_us-gaap_ClassOfWarrantOrRightLineItems_5F5C140FFDF55602B4C16D7CA221772D" xlink:type="arc" />
    <loc xlink:href="gale-20150930.xsd#gale_FairValueofWarrantsGranted" xlink:label="loc_gale_FairValueofWarrantsGranted_D947E9AF3B7E5536843C00908B4B0B17" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_5F5C140FFDF55602B4C16D7CA221772D" xlink:to="loc_gale_FairValueofWarrantsGranted_D947E9AF3B7E5536843C00908B4B0B17" xlink:type="arc" />
    <loc xlink:href="gale-20150930.xsd#gale_ClassofWarrantorRightFairValueRollForward" xlink:label="loc_gale_ClassofWarrantorRightFairValueRollForward_11C1085806F95A178540C0BC1C9C1211" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_5F5C140FFDF55602B4C16D7CA221772D" xlink:to="loc_gale_ClassofWarrantorRightFairValueRollForward_11C1085806F95A178540C0BC1C9C1211" xlink:type="arc" />
    <loc xlink:href="gale-20150930.xsd#gale_FairValueOfWarrantsLiabilities" xlink:label="loc_gale_FairValueOfWarrantsLiabilities_74188ADE7C3954659289680BE1842EFB" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gale_ClassofWarrantorRightFairValueRollForward_11C1085806F95A178540C0BC1C9C1211" xlink:to="loc_gale_FairValueOfWarrantsLiabilities_74188ADE7C3954659289680BE1842EFB" xlink:type="arc" />
    <loc xlink:href="gale-20150930.xsd#gale_ChangeInFairValueOfWarrantLiabilities" xlink:label="loc_gale_ChangeInFairValueOfWarrantLiabilities_416ADAF925C95248BAB77422AC2AC8F3" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gale_ClassofWarrantorRightFairValueRollForward_11C1085806F95A178540C0BC1C9C1211" xlink:to="loc_gale_ChangeInFairValueOfWarrantLiabilities_416ADAF925C95248BAB77422AC2AC8F3" xlink:type="arc" />
    <loc xlink:href="gale-20150930.xsd#gale_FairValueOfWarrantsLiabilities" xlink:label="loc_gale_FairValueOfWarrantsLiabilities_4A179EA7BB8E57D7A77669B142497ED2" xlink:type="locator" />
    <presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gale_ClassofWarrantorRightFairValueRollForward_11C1085806F95A178540C0BC1C9C1211" xlink:to="loc_gale_FairValueOfWarrantsLiabilities_4A179EA7BB8E57D7A77669B142497ED2" xlink:type="arc" />
  </presentationLink>
  <presentationLink xlink:role="http://www.galenabiopharma.com/role/WarrantsFairValueOfWarrantsIsEstimatedUsingBlackScholesOptionPricingModelDetail" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_WarrantsAndRightsNoteDisclosureAbstract" xlink:label="loc_us-gaap_WarrantsAndRightsNoteDisclosureAbstract_E1666F05E24957AAAF73A95A25C219B7" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ClassOfWarrantOrRightTable" xlink:label="loc_us-gaap_ClassOfWarrantOrRightTable_114E4FA8849650D681CB20363268188E" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WarrantsAndRightsNoteDisclosureAbstract_E1666F05E24957AAAF73A95A25C219B7" xlink:to="loc_us-gaap_ClassOfWarrantOrRightTable_114E4FA8849650D681CB20363268188E" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis_0433F05B798B51E9B23B373C1F3DAB56" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_114E4FA8849650D681CB20363268188E" xlink:to="loc_us-gaap_ClassOfWarrantOrRightAxis_0433F05B798B51E9B23B373C1F3DAB56" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_E576EE5D20D85792B4EAC03AD0D4D409" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_0433F05B798B51E9B23B373C1F3DAB56" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_E576EE5D20D85792B4EAC03AD0D4D409" xlink:type="arc" />
    <loc xlink:href="gale-20150930.xsd#gale_MarchTwoThousandFifteenWarrantsMember" xlink:label="loc_gale_MarchTwoThousandFifteenWarrantsMember_B17936AD4F015617AB01F4F6FFDC8E9C" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_E576EE5D20D85792B4EAC03AD0D4D409" xlink:to="loc_gale_MarchTwoThousandFifteenWarrantsMember_B17936AD4F015617AB01F4F6FFDC8E9C" xlink:type="arc" />
    <loc xlink:href="gale-20150930.xsd#gale_SeptemberTwoThousandThirteenWarrantMember" xlink:label="loc_gale_SeptemberTwoThousandThirteenWarrantMember_9E33C5147C655D05B5CD4DDDBB74D6F5" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_E576EE5D20D85792B4EAC03AD0D4D409" xlink:to="loc_gale_SeptemberTwoThousandThirteenWarrantMember_9E33C5147C655D05B5CD4DDDBB74D6F5" xlink:type="arc" />
    <loc xlink:href="gale-20150930.xsd#gale_DecemberTwoThousandTwelveWarrantMember" xlink:label="loc_gale_DecemberTwoThousandTwelveWarrantMember_0DFD86551E715FEC8284FB5AE9DB8170" xlink:type="locator" />
    <presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_E576EE5D20D85792B4EAC03AD0D4D409" xlink:to="loc_gale_DecemberTwoThousandTwelveWarrantMember_0DFD86551E715FEC8284FB5AE9DB8170" xlink:type="arc" />
    <loc xlink:href="gale-20150930.xsd#gale_AprilTwoThousandElevenWarrantMember" xlink:label="loc_gale_AprilTwoThousandElevenWarrantMember_1C7D1053CEF05CD8A6636377C8EFBE70" xlink:type="locator" />
    <presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_E576EE5D20D85792B4EAC03AD0D4D409" xlink:to="loc_gale_AprilTwoThousandElevenWarrantMember_1C7D1053CEF05CD8A6636377C8EFBE70" xlink:type="arc" />
    <loc xlink:href="gale-20150930.xsd#gale_MarchTwoThousandElevenWarrantMember" xlink:label="loc_gale_MarchTwoThousandElevenWarrantMember_11045D5FB51F53BB965F4AC4061DD41D" xlink:type="locator" />
    <presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_E576EE5D20D85792B4EAC03AD0D4D409" xlink:to="loc_gale_MarchTwoThousandElevenWarrantMember_11045D5FB51F53BB965F4AC4061DD41D" xlink:type="arc" />
    <loc xlink:href="gale-20150930.xsd#gale_MarchTwoThousandTenWarrantMember" xlink:label="loc_gale_MarchTwoThousandTenWarrantMember_D9EAEE4601285187B949338D6C961939" xlink:type="locator" />
    <presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_E576EE5D20D85792B4EAC03AD0D4D409" xlink:to="loc_gale_MarchTwoThousandTenWarrantMember_D9EAEE4601285187B949338D6C961939" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ClassOfWarrantOrRightLineItems" xlink:label="loc_us-gaap_ClassOfWarrantOrRightLineItems_C121BA8C84EC59C2A3C06DB318D8949D" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_114E4FA8849650D681CB20363268188E" xlink:to="loc_us-gaap_ClassOfWarrantOrRightLineItems_C121BA8C84EC59C2A3C06DB318D8949D" xlink:type="arc" />
    <loc xlink:href="gale-20150930.xsd#gale_WarrantStrikePrice" xlink:label="loc_gale_WarrantStrikePrice_83F260DD775A54A4B83E6ED81B881D04" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_C121BA8C84EC59C2A3C06DB318D8949D" xlink:to="loc_gale_WarrantStrikePrice_83F260DD775A54A4B83E6ED81B881D04" xlink:type="arc" />
    <loc xlink:href="gale-20150930.xsd#gale_FairValueOfWarrantLiabilityAssumptionsExpectedTerm" xlink:label="loc_gale_FairValueOfWarrantLiabilityAssumptionsExpectedTerm_D26D3166082D56DE82200C1725E60E6B" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_C121BA8C84EC59C2A3C06DB318D8949D" xlink:to="loc_gale_FairValueOfWarrantLiabilityAssumptionsExpectedTerm_D26D3166082D56DE82200C1725E60E6B" xlink:type="arc" />
    <loc xlink:href="gale-20150930.xsd#gale_WarrantsFairValueAssumptionsExpectedVolatility" xlink:label="loc_gale_WarrantsFairValueAssumptionsExpectedVolatility_9489EF344DF95F18BB68857A669FBA12" xlink:type="locator" />
    <presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_C121BA8C84EC59C2A3C06DB318D8949D" xlink:to="loc_gale_WarrantsFairValueAssumptionsExpectedVolatility_9489EF344DF95F18BB68857A669FBA12" xlink:type="arc" />
    <loc xlink:href="gale-20150930.xsd#gale_WarrantsFairValueAssumptionsRiskFreeInterestRate" xlink:label="loc_gale_WarrantsFairValueAssumptionsRiskFreeInterestRate_4C8670C04EDA5B99BDE0BB8FF00C738C" xlink:type="locator" />
    <presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_C121BA8C84EC59C2A3C06DB318D8949D" xlink:to="loc_gale_WarrantsFairValueAssumptionsRiskFreeInterestRate_4C8670C04EDA5B99BDE0BB8FF00C738C" xlink:type="arc" />
  </presentationLink>
  <presentationLink xlink:role="http://www.galenabiopharma.com/role/WarrantsScheduleOfWarrantActivityDetail" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_WarrantsAndRightsNoteDisclosureAbstract" xlink:label="loc_us-gaap_WarrantsAndRightsNoteDisclosureAbstract_E5857422337051669EA6692D50FB25DC" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ClassOfWarrantOrRightTable" xlink:label="loc_us-gaap_ClassOfWarrantOrRightTable_D14D72E05535596E93F123C255140C55" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WarrantsAndRightsNoteDisclosureAbstract_E5857422337051669EA6692D50FB25DC" xlink:to="loc_us-gaap_ClassOfWarrantOrRightTable_D14D72E05535596E93F123C255140C55" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis_6BB6AC842BE25B4CA4CD3CB04A97CC63" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_D14D72E05535596E93F123C255140C55" xlink:to="loc_us-gaap_ClassOfWarrantOrRightAxis_6BB6AC842BE25B4CA4CD3CB04A97CC63" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_AB41C36ABE5650A096D59969576DF387" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_6BB6AC842BE25B4CA4CD3CB04A97CC63" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_AB41C36ABE5650A096D59969576DF387" xlink:type="arc" />
    <loc xlink:href="gale-20150930.xsd#gale_MarchTwoThousandFifteenWarrantsMember" xlink:label="loc_gale_MarchTwoThousandFifteenWarrantsMember_FC9627910C605B1F8A36C5D667DD2A70" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_AB41C36ABE5650A096D59969576DF387" xlink:to="loc_gale_MarchTwoThousandFifteenWarrantsMember_FC9627910C605B1F8A36C5D667DD2A70" xlink:type="arc" />
    <loc xlink:href="gale-20150930.xsd#gale_SeptemberTwoThousandThirteenWarrantMember" xlink:label="loc_gale_SeptemberTwoThousandThirteenWarrantMember_82573F54B9B75520AE81EC3D7D518498" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_AB41C36ABE5650A096D59969576DF387" xlink:to="loc_gale_SeptemberTwoThousandThirteenWarrantMember_82573F54B9B75520AE81EC3D7D518498" xlink:type="arc" />
    <loc xlink:href="gale-20150930.xsd#gale_DecemberTwoThousandTwelveWarrantMember" xlink:label="loc_gale_DecemberTwoThousandTwelveWarrantMember_2DAD7F3A11035445B72769327C204BE5" xlink:type="locator" />
    <presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_AB41C36ABE5650A096D59969576DF387" xlink:to="loc_gale_DecemberTwoThousandTwelveWarrantMember_2DAD7F3A11035445B72769327C204BE5" xlink:type="arc" />
    <loc xlink:href="gale-20150930.xsd#gale_AprilTwoThousandElevenWarrantMember" xlink:label="loc_gale_AprilTwoThousandElevenWarrantMember_C34172721CDA52F0973A4AE6511959E7" xlink:type="locator" />
    <presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_AB41C36ABE5650A096D59969576DF387" xlink:to="loc_gale_AprilTwoThousandElevenWarrantMember_C34172721CDA52F0973A4AE6511959E7" xlink:type="arc" />
    <loc xlink:href="gale-20150930.xsd#gale_MarchTwoThousandElevenWarrantMember" xlink:label="loc_gale_MarchTwoThousandElevenWarrantMember_22AF70E1FAC450488CEE2B2CF420B566" xlink:type="locator" />
    <presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_AB41C36ABE5650A096D59969576DF387" xlink:to="loc_gale_MarchTwoThousandElevenWarrantMember_22AF70E1FAC450488CEE2B2CF420B566" xlink:type="arc" />
    <loc xlink:href="gale-20150930.xsd#gale_MarchTwoThousandTenWarrantMember" xlink:label="loc_gale_MarchTwoThousandTenWarrantMember_12D141098E75531EA41293EABEBF1B1F" xlink:type="locator" />
    <presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_AB41C36ABE5650A096D59969576DF387" xlink:to="loc_gale_MarchTwoThousandTenWarrantMember_12D141098E75531EA41293EABEBF1B1F" xlink:type="arc" />
    <loc xlink:href="gale-20150930.xsd#gale_ConsultantWarrantsMember" xlink:label="loc_gale_ConsultantWarrantsMember_D66191DD568E52F4AB95D554037CEDA1" xlink:type="locator" />
    <presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_AB41C36ABE5650A096D59969576DF387" xlink:to="loc_gale_ConsultantWarrantsMember_D66191DD568E52F4AB95D554037CEDA1" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RangeAxis" xlink:label="loc_us-gaap_RangeAxis_95625F6055A855369C9235BF2953A60C" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_D14D72E05535596E93F123C255140C55" xlink:to="loc_us-gaap_RangeAxis_95625F6055A855369C9235BF2953A60C" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaap_RangeMember_51D1C7D5631C5CE691EB6FB7F34BF69E" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RangeAxis_95625F6055A855369C9235BF2953A60C" xlink:to="loc_us-gaap_RangeMember_51D1C7D5631C5CE691EB6FB7F34BF69E" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_MinimumMember" xlink:label="loc_us-gaap_MinimumMember_2902E1CFD66B570C9C1C930AA627E6FC" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RangeMember_51D1C7D5631C5CE691EB6FB7F34BF69E" xlink:to="loc_us-gaap_MinimumMember_2902E1CFD66B570C9C1C930AA627E6FC" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_MaximumMember" xlink:label="loc_us-gaap_MaximumMember_7F9A83F1F6955C0FA864259E4F32441B" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RangeMember_51D1C7D5631C5CE691EB6FB7F34BF69E" xlink:to="loc_us-gaap_MaximumMember_7F9A83F1F6955C0FA864259E4F32441B" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ClassOfWarrantOrRightLineItems" xlink:label="loc_us-gaap_ClassOfWarrantOrRightLineItems_F628DEAC97C65E7BB91A36012AAE27F3" xlink:type="locator" />
    <presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_D14D72E05535596E93F123C255140C55" xlink:to="loc_us-gaap_ClassOfWarrantOrRightLineItems_F628DEAC97C65E7BB91A36012AAE27F3" xlink:type="arc" />
    <loc xlink:href="gale-20150930.xsd#gale_ClassofWarrantorRightOutstandingRollForward" xlink:label="loc_gale_ClassofWarrantorRightOutstandingRollForward_63F072EBFC4A53E4A2BF695DF9E8B51E" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_F628DEAC97C65E7BB91A36012AAE27F3" xlink:to="loc_gale_ClassofWarrantorRightOutstandingRollForward_63F072EBFC4A53E4A2BF695DF9E8B51E" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="loc_us-gaap_ClassOfWarrantOrRightOutstanding_D87C55071BD2522C82ED829456A5E41F" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gale_ClassofWarrantorRightOutstandingRollForward_63F072EBFC4A53E4A2BF695DF9E8B51E" xlink:to="loc_us-gaap_ClassOfWarrantOrRightOutstanding_D87C55071BD2522C82ED829456A5E41F" xlink:type="arc" />
    <loc xlink:href="gale-20150930.xsd#gale_ClassofWarrantorRightGranted" xlink:label="loc_gale_ClassofWarrantorRightGranted_CEE334D934A9544099F95320BCC4EA9D" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gale_ClassofWarrantorRightOutstandingRollForward_63F072EBFC4A53E4A2BF695DF9E8B51E" xlink:to="loc_gale_ClassofWarrantorRightGranted_CEE334D934A9544099F95320BCC4EA9D" xlink:type="arc" />
    <loc xlink:href="gale-20150930.xsd#gale_ClassofWarrantorRightExpired" xlink:label="loc_gale_ClassofWarrantorRightExpired_1F24F330076051E4B4ADAABC07A3860E" xlink:type="locator" />
    <presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gale_ClassofWarrantorRightOutstandingRollForward_63F072EBFC4A53E4A2BF695DF9E8B51E" xlink:to="loc_gale_ClassofWarrantorRightExpired_1F24F330076051E4B4ADAABC07A3860E" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="loc_us-gaap_ClassOfWarrantOrRightOutstanding_3273D635B91554559C901C3AF1BD7C79" xlink:type="locator" />
    <presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gale_ClassofWarrantorRightOutstandingRollForward_63F072EBFC4A53E4A2BF695DF9E8B51E" xlink:to="loc_us-gaap_ClassOfWarrantOrRightOutstanding_3273D635B91554559C901C3AF1BD7C79" xlink:type="arc" />
    <loc xlink:href="gale-20150930.xsd#gale_ClassOfWarrantsOrRightsExpirationDate" xlink:label="loc_gale_ClassOfWarrantsOrRightsExpirationDate_35F665F4D9DF51858872826FE354D16B" xlink:type="locator" />
    <presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gale_ClassofWarrantorRightOutstandingRollForward_63F072EBFC4A53E4A2BF695DF9E8B51E" xlink:to="loc_gale_ClassOfWarrantsOrRightsExpirationDate_35F665F4D9DF51858872826FE354D16B" xlink:type="arc" />
  </presentationLink>
  <presentationLink xlink:role="http://www.galenabiopharma.com/role/WarrantsTables" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_WarrantsAndRightsNoteDisclosureAbstract" xlink:label="loc_us-gaap_WarrantsAndRightsNoteDisclosureAbstract_79EDE473889E5376B1FD83CF4613FFC4" xlink:type="locator" />
    <loc xlink:href="gale-20150930.xsd#gale_ScheduleOfWarrantActivityTableTableTextBlock" xlink:label="loc_gale_ScheduleOfWarrantActivityTableTableTextBlock_4D933A19475450C78B811AA126ACCCA5" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WarrantsAndRightsNoteDisclosureAbstract_79EDE473889E5376B1FD83CF4613FFC4" xlink:to="loc_gale_ScheduleOfWarrantActivityTableTableTextBlock_4D933A19475450C78B811AA126ACCCA5" xlink:type="arc" />
    <loc xlink:href="gale-20150930.xsd#gale_ScheduleOfWarrantValuationAssumptionsTableTextBlock" xlink:label="loc_gale_ScheduleOfWarrantValuationAssumptionsTableTextBlock_A98BAA24B3B05D8FA2349373440A5DE4" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WarrantsAndRightsNoteDisclosureAbstract_79EDE473889E5376B1FD83CF4613FFC4" xlink:to="loc_gale_ScheduleOfWarrantValuationAssumptionsTableTextBlock_A98BAA24B3B05D8FA2349373440A5DE4" xlink:type="arc" />
    <loc xlink:href="gale-20150930.xsd#gale_ChangesInFairValueOfWarrantLiabilityTableTextBlock" xlink:label="loc_gale_ChangesInFairValueOfWarrantLiabilityTableTextBlock_3CCAC7598F405A5C8BAA1363345EBA15" xlink:type="locator" />
    <presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WarrantsAndRightsNoteDisclosureAbstract_79EDE473889E5376B1FD83CF4613FFC4" xlink:to="loc_gale_ChangesInFairValueOfWarrantLiabilityTableTextBlock_3CCAC7598F405A5C8BAA1363345EBA15" xlink:type="arc" />
  </presentationLink>
  <presentationLink xlink:role="http://www.galenabiopharma.com/role/WarrantsWarrantsClassifiedAsEquityDetails" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_WarrantsAndRightsNoteDisclosureAbstract" xlink:label="loc_us-gaap_WarrantsAndRightsNoteDisclosureAbstract_2429E0DD3266551980C801C10639C4FF" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ClassOfWarrantOrRightTable" xlink:label="loc_us-gaap_ClassOfWarrantOrRightTable_592E9E4B6F8352F7A979234F3F1DA31E" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WarrantsAndRightsNoteDisclosureAbstract_2429E0DD3266551980C801C10639C4FF" xlink:to="loc_us-gaap_ClassOfWarrantOrRightTable_592E9E4B6F8352F7A979234F3F1DA31E" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis_39D712EE149A51BEA21D77C1F937A5FA" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_592E9E4B6F8352F7A979234F3F1DA31E" xlink:to="loc_us-gaap_ClassOfWarrantOrRightAxis_39D712EE149A51BEA21D77C1F937A5FA" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_7B0BE6C79B205D22A122788A812583D0" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_39D712EE149A51BEA21D77C1F937A5FA" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_7B0BE6C79B205D22A122788A812583D0" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ClassOfWarrantOrRightLineItems" xlink:label="loc_us-gaap_ClassOfWarrantOrRightLineItems_DB58599E319D58FE8EC2AE5638300372" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_592E9E4B6F8352F7A979234F3F1DA31E" xlink:to="loc_us-gaap_ClassOfWarrantOrRightLineItems_DB58599E319D58FE8EC2AE5638300372" xlink:type="arc" />
    <loc xlink:href="gale-20150930.xsd#gale_WarrantsGrantedNumberofShares" xlink:label="loc_gale_WarrantsGrantedNumberofShares_BDCCFC16B566583A870D337F57207073" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_DB58599E319D58FE8EC2AE5638300372" xlink:to="loc_gale_WarrantsGrantedNumberofShares_BDCCFC16B566583A870D337F57207073" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_AA4B42EE198950058C5CBE34B418BBB3" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_DB58599E319D58FE8EC2AE5638300372" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_AA4B42EE198950058C5CBE34B418BBB3" xlink:type="arc" />
    <loc xlink:href="gale-20150930.xsd#gale_NumberofDaysAveragedforExercisePrice" xlink:label="loc_gale_NumberofDaysAveragedforExercisePrice_D1523E5DAA86550EB48CCF886BC75938" xlink:type="locator" />
    <presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_DB58599E319D58FE8EC2AE5638300372" xlink:to="loc_gale_NumberofDaysAveragedforExercisePrice_D1523E5DAA86550EB48CCF886BC75938" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueAssumptionsExpectedVolatilityRate" xlink:label="loc_us-gaap_FairValueAssumptionsExpectedVolatilityRate_99DCBEB5321058A4A1357CA5930F7903" xlink:type="locator" />
    <presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_DB58599E319D58FE8EC2AE5638300372" xlink:to="loc_us-gaap_FairValueAssumptionsExpectedVolatilityRate_99DCBEB5321058A4A1357CA5930F7903" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueAssumptionsExpectedTerm" xlink:label="loc_us-gaap_FairValueAssumptionsExpectedTerm_AE830C2FEDA156329D68C0EE91EA3CAB" xlink:type="locator" />
    <presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_DB58599E319D58FE8EC2AE5638300372" xlink:to="loc_us-gaap_FairValueAssumptionsExpectedTerm_AE830C2FEDA156329D68C0EE91EA3CAB" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueAssumptionsRiskFreeInterestRate" xlink:label="loc_us-gaap_FairValueAssumptionsRiskFreeInterestRate_CF12D9A3C76C582E8207B2E5D23E591B" xlink:type="locator" />
    <presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_DB58599E319D58FE8EC2AE5638300372" xlink:to="loc_us-gaap_FairValueAssumptionsRiskFreeInterestRate_CF12D9A3C76C582E8207B2E5D23E591B" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueAssumptionsExpectedDividendRate" xlink:label="loc_us-gaap_FairValueAssumptionsExpectedDividendRate_047D1751A15757EF869FC08BE49E4A23" xlink:type="locator" />
    <presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_DB58599E319D58FE8EC2AE5638300372" xlink:to="loc_us-gaap_FairValueAssumptionsExpectedDividendRate_047D1751A15757EF869FC08BE49E4A23" xlink:type="arc" />
    <loc xlink:href="gale-20150930.xsd#gale_FairValueofWarrantsGrantedperShare" xlink:label="loc_gale_FairValueofWarrantsGrantedperShare_6C4F538BBA435D49A418AB43423C5F9C" xlink:type="locator" />
    <presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_DB58599E319D58FE8EC2AE5638300372" xlink:to="loc_gale_FairValueofWarrantsGrantedperShare_6C4F538BBA435D49A418AB43423C5F9C" xlink:type="arc" />
  </presentationLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>13
<FILENAME>logo-vertical.jpg
<TEXT>
begin 644 logo-vertical.jpg
MB5!.1PT*&@H    -24A$4@   ?0   &0" 8   !8LY+&    &71%6'13;V9T
M=V%R90!!9&]B92!);6%G95)E861Y<<EE/   4X])1$%4>-KLG?E[(\=YYZMA
M97\-_,ORFN<)QE<2)YO!))O=)'ZR!./(DJR+M Y;LJT!)8^L>TA9IV-GP,2.
M-))E<BSYT&$!E*S1+7*DD2Q9<8C9W/8F ]FQX\0'D>?AN;\(^P<$M55] %W5
M57T #: ;_'ZD'H! -X[N1G_K6_6^;Q$"
M
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MD#__K]/[7OC)&A/=-5/,3>&V(]8=X6Y'L-OW:=NMT]8=[_CYC4]EV;JYUOH
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MKO^%UW/F7.3-IBOZG;;G'E=UEPOW;6$W-,*NZX*/$C@GZ[DJ(MZ@ 0X=W>T
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M$O(FS8G.6^&.50[=(X)!X]RJ+GCW8ZK> (V+%SY3MX%SFH(RJBYVZ#D $'0
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M MU4/$Z\Z[D_%]&]7EOL*75]WZ9W#G1B%I1QN7TJIZ_AO ( @@Y /\5\9JG
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M3Y75HOZM3[M$735&+OY-FR$CXIL!8^JZP+=>!,ZIW7G!4^;5+>+(00< @@Y
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M]5N>UHCZ#8ZHJ]/1@@+GFA$"Y[I(=Z-:-^]I0-2W[CZ[KG?G+A&7Z[<C* X
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M?_]L1T[=X]C-]VFPAML[A5Z/CWR%':-FT7;GO%%WD#GXNDO,>9K:>N!L:NY
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MC?&%UY@H\S%K.YB-: O.U"U'3RK;QS\66J#&[_W+K%G!S>I2+Z@=LRVTO(?
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MNK>A5/W:K?6;]N*L[[KO64]Z????;B%NTIK7G>L$7"_FYM]-;PE8YM(AY@!
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M:Y=;]=YKI-E4I(]IG+1B/77N>C-$P%QP65E7-+Q84.9C7\NQQW(1Q!QCYP!
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MNN5^9VQQE4K!JH+FY-QU&G+"%W.]^LXW9T6W3<FD1LSYL\?9YT.)5P @Z "
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MK$U;:U85:Q>DOS%V#@ $'0#08U&OD+!5VY1!<TTQ(.[L>V0Q7\($+ ! T $
M_1%U[M*KH3=P!\U13Y>[6] ;<.< 0- ! /TE>#S=*^KUW=?OE-WW ==]3, "
M  0= -!GE\Z%=RKB9JI MX++G6,"%@ @Z "  8BZOI*<&GG\/,=NLO:?\W#G
M $#0 0"#$_4*<<_,YD]5X\XQ 0L $'0 0 )$G;OT6HCUY'6<@C((A , @@X
M2 A!07)5Q6.\H$P5[AP "#H (#DNO6Z+N@YY_#QK"SK<.0 0= ! PD2=N_#Y
MD [=<>=5[#D (.@ @.2).D\]JRB>4A64P00L $#0 0 )9EX2\)HB):V&"5@
M@* # )+MTN69V:J*=5:QIP" H , DB_J==(N.O,6]@@ $'0 0'I%G;OP:!.Y
M
M
M
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M#ETU" !@KY&UG<UDBH7=N0@V<#@!
M
M
M
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M^7TEB;)&I/(A2H;6B7I<E9N"U3UP_5A-Z'FKT@?=>#H_?JIB.<ZX>5J8(YJ
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M]6%?ZWXG_88W&I=[>=VT)VXY2/2%A@
M
M                                                   8$OZ_  ,
4XT7\[_IA+3      245.1*Y"8((!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>14
<FILENAME>pipelineimageq32015.jpg
<TEXT>
begin 644 pipelineimageq32015.jpg
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M5&!48%1@5&!48%1@5&!48%1@5&!48/>IP#@PN/NLJQ'IJ,"HP*C J,"HP*C
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M5&!48%1@5&!48%1@5&!48%1@5&#WJ< X,+C[K*L1Z:C J,"HP*C J,"HP*C
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M>G_>__KHUN+H[H?V_NLRXH_&\:--VC/C*ILZF8S]VIO&E3A'MQT<9R-7XR2
MU7:3_D?Y^,["R03]>PT_S!];;9=?2ORZI_[M=F-_4ISJRZ.;U[7[_?NK)@Z<
M56.'A%/2:1R5YY'-=1\_[G_RKA?<1Z=SWR[.(GA^7)K+::S]RN,-X-T'?D%X
MN#G3HFZ>+^%.+JY\V0OHM&+@7-IT[W][A9@XPLMC[=FH></@"]1;W_<Y7=)5
M]V7Y2-S\\NDO>]].>AZP48%1@5&!W:,"'-SCGB2T3W[^6SK(5[^6\:OKM^)#
M\I9QBPA^S:.]^/4?GI[RDO=JS.6^__N*O]?-G>]\\ROJDE8I5A:KGQF<O<87
M1PZ$L2-0/R =?,B/)YZL2ZNGI*U031Q(?'#\Z$3[P,>^,AT6!S(?<H_K:,[E
M!,1T=.,5V5$L=O;S@K,J:/Q0=<<'O'#ZXM?]RR@W0'[R0VZN7TJW<KD+ER%7
M>^W;/J$A7[ZY!)P#IUMY",GJ.KG[K:^RT3K^Q_]XC=8?GZ5O>->G% -Y<)#X
MAE>[A.:<.<GV,]JHP*C ,5,!;EE0MRU8]7#(]W^ZW?L+;N5]GQ\=MOH^S26\
MI\PK><X09VSQ<(BOQ;V9^*[  2AN0=2_%^RJ]^A=>5G<:OV.[_.=_0[W=X_X
M[^FS7_J.TN/)FV]YSCTU9IU5V^3]_;A:]Q4K/6?V\]#,NJ_@Y^,A$R^*AS#L
M3>WXLCV<\72G:F7G^,"!<8GZ5^/'RW][\O],KWK+_^F!2(<>YJLOV!?D-C:T
MW\1[Q#W^]66ZW1<'K'F8TKWC0"\/4^*)P]S*;*N-!]!4XZJ-/XA;B7TGW@_W
MAL9!_G6-]^ 3[<13A]=Q(=L5^Z'%S96EM$TO(_XUE_+^UYMT8AMXGDK/0V:.
M3CLLMTTXSAX/;ND;VS;'EF@<N.;2>-IK8C^<L_!I?QDG-3SF6'H(R2X_,*@,
M5A:<#<)]];@'P+K&@;_^H" V'(FNQD&W.BB(C,N;N,\!EYMQJN=%SK_?],./
M_+(]-8TS'.IR,>SYPO2>#WUQ.O<-SL!TRRWO ;FPY_32:GR![%M]$>YE8SPJ
M,"HP*K"W5> 3<5_9OO%A5^TT<;8UC9V[:IQM4/=S1<:->3G[A)TW+@E9_55V
MW6<&]\'BBPE__ ATB^M<.LYV.7O<VV.^67B=65)^JW]O?#[T[<WO_6P[,,A]
MK6A')]Z>F_&ZSY95FZW.SW..,\J4)Q7704$$?&'^R[]]ZI9H..C'3C*-,]_?
M^.Y/-]QKXOXH=:]<#A9L[R$DZ];)IC7C'D#\L9ZXM(*S-2]YT7-.E_S]<[5X
MZN;P33 &HP*C L=*!?B"]= GOE&OT74.M_*^O\G[-/?NKGU];D?Q7W'&#N]/
MGSSH6_KAGQ]3^K;I^TV/'>/M5V!'W^'XSE4'!6'A\LMJ7%U5;9/W]^-ZW7,V
M&;?H^//+7UCA\S31>\?!S]7;@E1N>U-_7&P/!\99O'60Y-9_>=F)/[:G]WWT
M2WHOZ+>_<\45@EPA0OM&W!*@#NPR/_R(W]&IG3\NA]VDW?I^S]%]#?_FEE?2
MK<S8/AX?^YKUH_8F7+N;[5->_%Z]]_)48O;!./F)?31^J.4J2JX&NNN_O.1H
MI;4K]D/[ "ZUO_<;-WWP"!S<P_M_XHJ9:U[Y8CKIZ_YW^@N=Y-#S;S(^0W=@
M^\<__=4">OTX&[8.O+XAKG"MXUWLSW-/3$YL\T-(?O]8>3[%+C\PR/WUCH@O
M>23&D>0?_/B7NCQX]8M=7Y5U1]PO'/=VJM8?Y"L9]SKBP""-Z[4/BH>,U#T*
MN3Z\?CDH^Q_&P<<=M?Z&HMC6BNIQ_65,/_V9+V7H]6,\*C J,"JPMU=@]3V]
M?S)PO4^?HSN=_AZWF6\)L5H[;C*]^@2O5?["<'"1AT+U]_"HRU"QX>%6ZQH/
MR.H;&+Z \AFP7]R'EG9TXJW[YI:/=9\MI=NDYY?&NO2V+JW;!%^V//6LOL!Q
M0^_7/.5O2A7W^-NGC:GKNH>08+!NG6Q:,\X.>ECL9/[9Y2[4\N(6)'Q)Y/(=
MVMY\?R<58"Q&!8[A"G"U#0\NXMV2 WD\[(,SL+\6M^@YJK;Z'K#N?1_\)N_3
M]_JWE\<]O6_5KM3AO9/[U_''0ZM>^+H/Z?8/\&[Z?@-FM&4%=N8[W'?C05=]
MV]YZW_3]_;A:]SHH^* X*'@Y'Q3D1Z_;_</S=89:G^?>,#Z^; _OC2L%N677
M76]YY7;0CX-27$G '^]/]W[X*W2 NK\?*@?_GO#/-UN[JMBWW*3Q,%/:@__S
M]=HVV$YXT-W><&#PJ7%%#\=T^L;!JM<^]6]T;SP>K,J/-URAL[-M5^R'EN_S
MQ _Z9SCMJ6+?\;#I<U\ZI,0;]8^(VPIQ2SRN;+I^W _]9"?S@_DV(DGC^A[!
M]&O?^M&"HK]E$K<[JJM,,>)!3M6XG/C8>'#M+C\PR W+^P^%2NBH>D[U76U?
M^.I\HTB>5LF]COI6-V%'QI.D.".%+Q#<J+R^0/3V;, [:JOW&^"4X]7V@S@K
MH]KI3KODY&CWD?&/':G11@5&!48%]M8*;.4SX&=YCRAJ](RXQ0)/T5W7?O[+
M;6\_L>XSXXIQSUE^P>4S@)V3Y[_FP.F#<<G9=^(,\P^_ZA]%S6?$NK9Z[SR^
MP-3!N^_GT]:.3KQ;^6Q9%]>.9/T!S-.O?!Z!Y2;]?*G?4>MW3#APRP[W]MK-
MXYY1JP\AP7;=.MFT9L^(AXW5TS]?]=:/3]S0FE][[W;K*^OA(_BI7U,9CS8J
M,"JPZRO [7!>$_ORF[:MO.]O^C[-;1"N>Y<GZP<)?C#@M@(\:("'(/!>Q26#
M'XW;]'#VX*;O-YOFMS?8[\QWN*U^Y]GT_?VX6/=L5X^+IX'604'.O+]]W/OX
MZWEO^[UA&^AS/#YM#T]]R0'3R^)>T->YRO[3'U_B/'K@9WW?YS+??__[ZT_7
MN\M3IOY'4M[+N'_TNO:=E:<8K]JP+9PI?GP]VUE.$P<<#VGW6_[9+WZMIZ+S
M3 .NV.!R^:W<KF65?W>?L__Y\<]^LQW(^M,X:_ %KSUPI]/:%?NAY;PN(R:^
MG=UGY"J<_WS>.Z<'W?5:HNT/V)6?K?9_&)>=5^M_8+MT/%BDO\T=/]#O.U\U
M7Q#UQ]9#2+8]\K4(X]B9_&;-@;2/?^Z;S3FG<G,C\FJ\$5SZXKYV'!EG"[)#
MPA= SNBKO_[>(Y>/FY:O:_W9)*?==S[E'=OSG7.^U*VP_0IE!^6E;_"-3]%S
M8UV>G,B#3Q[SG'=,[_C 08LS5#@%=[11@5&!48%1@4D[VG69[T_C=A,OBC,_
MJO$P#<Y"^-+7O[_V:;KK/C/ <%"0QOT"ZU8/_8=N7,1;+A8]OW;V-_J]3'Q8
M5_O&=_P+*%\,-HF77RJYQ(H?C%:?(MS?DJ+\T/=G-&[E\X(G-A]\R$^T8\&O
MHSPIKBXGYL>P=[_P/M.OX]XFW+C_+O\\/PVZ]\D.]64N?FZ)?A%/+G[S 9_M
MU1ISKR5^,:7Q><Q-_G_TT_ER,>3KULDF-3M+G)E9!P5YV-@_/>:UT*KU]Q?B
MC,;11@5&!7;/"FSR/LT/&Q>,>\9R]@<_]O!@*-J93G\JW?>))Q#3N.T$!P8W
M>;\1<"R.M0IL^OY^7*W[N\>/4/40,RY5O4U</KHW'O0YIC>,3;>'>@C*.>.L
MM!?&P2<.0'$U ]_#G_"@F^JL+@[4L;]5]Y<F!P[:O3P>;%H'KXOG2_&4VMJW
MVUZN/!R/2Y9I[%/6 49B9U^+QCX>!Y#VQL;5*I?*^_B1__9^W-]*;7;5?FCY
M:@\>^=0W2K13_8M>]V'M^]:#^7:&A/W]6UWO,H)R)=*+N^\Z_<%0?G#_9G[?
MZ/UP=2SW3J=QUN CXQD:QV0[7AP87'=I$$\GYDV9,Q?X8O<O=[^V;E!_TCB+
MC\L'ZFR.U[WC$^W45>Z%=+=;7T6_)#[QP3?3%PM. ;_3S:XX7?A\^ZVMXU>^
M\8,FY\;%[SGPBWJA<T/W=9AWQ246</)%Y6I7N,CTR/M=7U]H6?&L,'[!Y(V'
M^&G]ER7.<OS]\Y]57]2.K<=.M^3&8%1@5&!4X'A4@5>^^>.Z#R AW?S:EXJ;
M1W]O>O]'OZQ[W?W[W]] D7[HDU^;;GO_YVUS^>BZSXQ3=:?<\S[+@4$>8O'W
M=_R+EG5_6GX3QH![Z-TY/B>XV2\W ;[;K:[<U'7FS*;Q<B^BK\<E Q>(LUO8
MD>2FRJ^.&UWS.?# O[UFX^\'._-Y\=]O_MATOSLXQR?%PT:>^8KWZW*:.]WT
MBKH<EYTW;NFQO7:CJU]"GYGHW_2>S[2'L*S:L^/&@3MVO&]PM3^<GA5^^K9N
MG6Q2LW[=<$G*OJ<ZV<0O\U>,2SGJ'H?XZ^UZ_V,\*C J</ROP";OTQ>)_?87
M_,?ME!3?!WC*/#_._R+.(O]5W%Z@6OU@O\G[S;KWJ^(;_:ZO0/^^O97W]^-B
MW7-2R5V[SW[N*WC?.UQUFV+\XZ-?L_&5<=N0[.6"3;>'A]SCVNW9 _N>^F33
MT^+L02YMY7WA!/&]F_;M[_U$W]]_^),C=-]![GO'B43WO^/5XL&?!TR__>V1
MTZ/N?X-I_PN>7?N4MW_ "[9YOD&_6KBE0AT8O&L\Y9C;I.'O+K>X4MMGXH$F
M6SE3NN?='<?L$Q^15]SPI&[N_7VUN 5-_6C+#]#;NY<?]X;DA_)U[=.?_[:>
M_KZK]D/+!V?7T;874]GMJ.=SXE_BH/ KGG"G=N+!46$N$R>MW3-.$J/QX\;9
MSG2:Z2I_?,%VS.J%K_V0'@B(GFVS]FVYFNG^CWJU3HA U[?+7_*\T[,?^5<2
M'1L/(3E>'!CL"U!CSH3@EYKG_K_;ZA'EMXB#=OSUC3/S'O$4_X*(_%FO^("^
ML'##>KX8]O=)XL:DR%8;9R9RVC%?('FT^7M?<M]X\^"2Y'WB!L<'3Q>/1U7W
MC:<J\\3C1__##;61\(ME_6I9=D][Z0'M26E?C%\EJO$FQ=\S7_Z^Z3^>]?82
MCWY48%1@5&"OJP!/IWQ)/(V8]W6^*#P]+B,]+)X&=M*3^#X>G,W]]__O5=L<
M%-Q>H=[Q@<^W2QHX4,;#1_AAB<MXZ\R],\:9)NL:!Z!X\AA_?>.A6)SY3=N9
M>-_SH2^T>V,][-[7TP--^/'H*W$?W)_'V7EU&4SYW)G/B^?%@[UXXC._*'+P
MCAM!]XU+H?_K!>_N16W,#E[_^?7:^*%M>^V5;_EX.Z/OIG&0<_7 X#K<)C7C
MQS+^SAL_K+'>#HC/8F[2O%_L6/67*6]O':[S/V2C J,"QZ\*;/(^S9>Z-\6#
MD*YUE8OI/>'-S[[']-T?_BSN'77*]D6+]\S_B1\T:)N\WQR_JK+G1[/I^_MQ
ML>ZO>>6+M@,^K!$^4^M,G7X-]6>S]_(QWGH%-MT>N&KP>8^Z[73*DY]4]QF\
MPXTO'_M0A[4#4WA^XO/?W0)X[+/?'L\A.)ON,W>;ZU]VNOEU+C6=,+[7UU4E
M[+^L/O2T@7/POOBAFA..N%J"_9!'W/?Z"Y,?_N07<=#H#0O9GCJY\\VOM-W4
M.'C&$\?[*S![XWI"="^K\4O?^!$]''97[H?R0SS?*=AO_,3G#RY7.]U_YHO?
MB1/ /CRQ'>VH<0ES7<:\:LL9@4]\_KN:^#I_NG^[ES8G0:S>J[4,__?C7]5!
M;XYM'1L/(?%A]O)^/.NY+("G +WY@,_H++T*CWLF<2KQ]>.)BS_I[E/% TYN
M<H]GZ"E%]6L@MD]ZX;NG__?T]:=><O3_S@]Z43OK$!_L>-S_4:^*TX\_5BX7
M_1O>]2G]<LE#3OK&?0XY:/B?SWUG$V-#K-6(Z\1QQL5HHP*C J,">WL%'OI?
M;YP>]J0WQ9/F?ZI2U$'!SW_ED.F>#WOY=C\HU]6-F_(^\07O:@>1^/6?#]H[
M/?"%$_?)H9WE#/M.%[O@V;:!/^ QKY%-W8.07X!?$9>?K%Y^NVF\CWGV.R;.
MZ.. )XT?G=[YP<]/M_B[9R_.>*F =N;S@EAO?J]GZLQU?K7M&[]X<\;EZD,!
MRN9/+GU^?>%FSJ5Z'_WT]B^[X,MW/42,AY!P"<]6VE9KQAF6]_C7E^DI;/"R
M+? D-^XU>,.[/ZT=(+YJ7,H\VJC J,#N68%-WZ?Y<>CQL4_-E3HTWL.Y8HA+
MLGAOO4.<]=,_;'"K[S>[9_5VWZAWYOW]V%[WUXX#T*,=.Q78='O@Z>2<,7Q
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M!48%1@7VQ@J, X-[XUH?.8\*C J,"NSE%?CY+W\]\3?:J,"HP*C J,"HP*C
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M_\0QX]'9VGC8JQ7.L9>4ONK7NU$:@KL"Z!17 LULSO*O^J$/<.5O<X%%+T2
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M98FN,ID5VL#0P\-"ZR7&0=#JEV1KT %Q ,3.?SD63^&[/M3B+[/"Q!RHJ)2
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M36@:Y]7K[$O&Z=<^)5>29M4\?-?Z,_>,%J>#)4C%0DW<DB.ZPA=USU ZY1G
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MMZ)!&8_IMO4+K5)2+V.9@0*@Y8SOK4.9?O M6WJ&"_\IDT6J<ZPZ P 3"^<
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M"^VOB2G$NBDU=:^A#,S;)I-OZX#K6%U3SR=(\1]69L!LHEED(->/3-H?51'
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MS>74MP-U+> &PO)O:D>*-"")7ERK+KT [KN6ZKL.[0DXW-8[%X:NK2%0-:-
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MVUX8)*Q"6 Y>(#UO$R.X,,'"NIO=-6TV-I.R+;+VBNPP7*19L89#$.!(ZT@
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MEE/\L%=#C4Q]E=<R;&CQ9H"OV'4M;"RKE@ND:]$]WH''3ACU]P<!;6/WPL5
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MU@\>,1K__2?CJ:^QR0;6?"N ?2T8!!QK]5\)D%7\P\.P3;)RSA3+R<U.Q#1
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M+B$0F72CUMC9I=G% ?BLBP8)X=[\X.* LNV>H855O^%DA=:\"J/>^1/7N12
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MO\7/G(A3.I/0O#DS;RX>:[+/7U*9[_]O+>Y9W_C;23CJ#_E'AQTQ:8WO257
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M1(TD<_W0.YO)HW,),K:I,_-^W2(++/AS'8(>'0:C/L#;7Y<.Q5"\IC\60?#
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M#XWC5_W*8BT#N--;=H5OH?T3<ZWKZA]:(-A1_OR%61-$FO"GU]6:!:#20NQ
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MGOX85BX:.6269.0<Z & @YMQE92I5H&\SI5HB813B=BK$ZN:.=8<8QKWELE
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MUB63O?^TZ25/321')9=1OXB,.;C:.$:N'^NDGXZ1B!CAEIE'#-7FODO-;*F
M>__8EHLGCE7$>MT/QP>M8\X1/&9>%7>)V35-U+Y.+.<Q80=6\\##XW:E;W=T
MS">!DE3.XF'3 D@82?23F@1HQLH<@]0$\ /UPT1M^ BTUZ*]H\_[0(\'Z:7.
M#(DSTU>LGA%@V#(FJ'X=WX[6)P^BI+4)?;>5:_Q;4WE,8,?W^\<J,Q?Y&-P$
M>E)U++PDI$GG@;R))U:E9"A["7/DW*9.;WU-)ZNL2>*/_*I^CB1PUZ-ZKWYA
M.=:XA%_GN91ZMZXVM_]P/#0PCP6@.69=Y'PHO@1NE1.5R%#2"C;RP+!D&JUF
MX\M'RL1*QAG$-&\()4)1MWE;RZ5:%\+355Y$YH?)1QG_-ER]2V8#4;>_4)VS
MA,MMY@G=?UEV4>"*77SP]XK0JR&^>KF3#]F(47[8Q!*E)V,>74U+9V@IK"N#
MWI \/MJM%]9S[*&F"?[W:_)Q/JBME/UZ,3=9S9P2P'YE#8"WHU71 \S1U$?K
MT#>P$F([<D):]?,FL=6,I6FOS#6JF;^\(2;VZ^+8!LPCXR;4)%:VG]*A$0UF
MQ<YSSR3@SKGOTK<<][<6OT6/?7.'9UJ1M2-5V)$WA//1)2_<!!EQ4%),_2*C
M3MT8Y75'3:(W(.:V=;G:'6O])+[U7,J2&O#YB[?=+MX5#VWV5J/%G%I>PQ<
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M0^R1].MG'H/I,(WG9 /)[;\,$,IGO)4-MF[-4)$<X/-:Q.PPMX7L-7J:.!.
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M25BR'8'"D.8X?-+<AG!G&%W-LIQ"'7:#M_-7#"L>POC'!9'/7AQ6^5X]Q^9
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M N3U5VSFD@R*X!V*><K$VG)A9>,;4PCC321!EIQ%CIB08^Q%1V>?#:J<8G*
M.<Y?7Z>F,J F=L U0Y@5K%RU3LNCR_IE*ON,#?0"6M?YBR;Y@YTV,(4OM#38
MF29K:479Q7OCL0YOFPUN+03_(P4#G]=*[I&@1BSVCJ$'!_[-X_SC ?_X[E91
MX:^5Z@_R!ZWQ 7I<!",6SSM/B3\KA+3D%5OP(0AOQU/YLW]P:\.]0P!6"R!B
M\!6*23H>YP]X*;&SK=;9/E&WC#$)KVQX_88>X$/G. QHO,' U<) ;(%6#ZB
M]CGA"VB?P0MCLI7A..9>F.45(SP=?Z^[54-.A+T [!G+R'8Z,7?L64Q%253Y
M8\O"8]+V,80O7%??O]$5W)"V1^,82K#B)45A4%9!)+:U&%EF9C"^\E=K@&NL
M^0@37@G=$G\-2Z9.]'9?D@.NSG@%%)TF<_Z,)\[$:INV+UG,#_.W!I \.P9P
MM60/-0Y5SG SROT#PRJW3M,#_[:/33 A=_[!6F70\!L?P<Q<JT_\XSN-H6.'
MVN,:9-(ANN?:IDT$ Y/8[+.LXK_N':YSH^< M(B5%[(884)<,=6$N?[@>5T+
ML\A;-_SC[R!_&";&D3^C(4X$1#IC!I?L['.*;2R!$$H.7?",,L[(X=L/"S!7
M0O?ZXB>Q'>8BLG 0IT;@<#[PB;G]>(DUZ7%= <>&ZB!_T-HPB^@U.Q?.]^HK
M:Y/&BZ\ *F=0(#:^DA-['/(790*;PK< [(PO^(@7HW@+P8C?O.6S".PSQBLI
M^":=Q\97_BHVQX]#-2A'[++M:]/Y[-X8&U<L1M>]U+'(_WJ7(6ST\?4KI_:O
M^_T GSP,F?T05PY,1_R:S+D()HLD%TT+!7'Q!ZDQ" L?CSI#$/AA+@L#A#;C
MVQX.^_,U*BX+)!]^0C[BGWAM6MP '$NO0?T!QDZ#&+$X,NSPG2,!26'_61JH
MYO+8.8G-@:Y]PVM\Y:]CP5@-J0TT=P8^)'\.K$P=<^$--].4/QA9Q+&\<KOB
M95/W)*9!Q$GPDOAOY<^J&A>_<Q$SG(YPVGWW=E-KZ_SA<XTE >0>PVVBP8:&
M77#E7S(L@B_; _\S0S"5ON*!M99ON.S=)\A+^1LK*Y^  51.>^HYT9LL<1%)
MKK.MRK]TAG=4K:,/-7HSV"YRSLE#YCVV7>EP;?\M-)X(VE>ML>WC13/R%-^'
M^#5_>.VU0+\N/\X<CX;@G8):!/+A'9#;E!<PR*P[RA]$,T;CY+=C"9@\VXEH
MXMM.S&MX!= QQEW'$MO.9Q,X)JDLAT3$E_'V')ULP71\653EK_SW6K KRJ#6
M\(V/[YSQ:5MC.N;P]EK3QPD1553A!NQ6F 16:RE/301B'FO>:"C6'-4X<"]\
MW!N7\# DMLOX(A!F#;-BPJ%B;5YFAW@D6,A>?SM'CM\4+9\8R@D8N&P6FLP5
M!_B1 \<5O#&U#B#!AP%=JX(O4M13 F>?8RTR,4O')I_=&,;N*'\VB"S@X_PU
M1];9L9FK5.7N\J/$<(^8RT>,-4E$LF@'V [K(>^4*7ICQF*!'9A7@!+/;39I
M>5%50LJ_NEY(B"/'_^$%D\2AE+]>A_H1FQT=!D@<@R>3^&NS[F5GM>9K/&M$
MZ'J&/VZ2Q(/]I'5<6):SZC,W2=/4Y"A^XE&;8X@DL*'$3[755CY+GIAJ<5-,
M(Q>^_HG1MF4:O.2HU&PA?*^Q958>G48^)J/@>SV>B3/]"F<>&^=UG=AO<AT;
MJW0:X6K4N6W_#9^,CO+9<:P\8&JU-:H8FU13^W$N2U?K:/\&EE,LW&R:: ?5
M4,I"*N0?U@R7TB8UR?4"*(6IK:TI^:!%26SCFI?]',><VU(7WB3C%,Y,#_%S
M_+(:]UI#FY6(:MP$-9_OK14_>ZS\7::TY"!_,?W0-21=%6?Q7?*/W*2YM^8<
M656X=&+T>JIC.AEYQ672,,LTL5T+F8MGO?\E2+#.:=88Y'Q-Q[6%IYT55_#P
M)(!C?T!H5\EK^<49HWA'U"/#:YYQ@F8<F[&F+*#6,GD\^MGB)3?58*D8RRU4
MPVX,$E?RL1*LN8(,8'Z6C6M:N0$1^OGUTSRY#WK91=-T[E=\,' =MR$;!++P
MI1D:QX>?-<?HLLB,$K]%=E#S=E;Y6%&-;H.D8<77W.JC^T^R@_Q5 L8UK7D2
M$9[U_B4"\"SI,,9+L96@TV+<D1&ZM;4RDI&KB<"OZ;ZVU0=5UW*03?.)MJGL
M]XJ<#K@&:V@KP8J7S/Y!1#_B/9@W(\YH80W/E#^I+6N+BJT1TQ11>2BV"L_7
M3S> I^9;X^+U$UP9SS&N@/6F.KJV!I??'G>_YD22#M3^A\7(U>J]1ZRA?I?-
M1,?^#W+=ZY^NL5P-^.26X5A>3UI6/6+:>O_7,B!T/O/Z:9LA*QURRV3?8?KG
ME?&K?ZQ*Q-!.#N:1CK-USJ?B@%AMM2^9NI&_K!0K'5-N/&U\Q=@R$<8Z*'QT
M0^[6!DQJ3!Q>ZS!*'%Y44,-XC6\E&+GN!8DL]V^[6.,_=F_ZCF.E/%S P?UG
MQ(!EMK+B=RRF%U7QK,C*GQ/04F1:W02_^OYO^[7'>[<5WT32.'ZLXF/-:V1K
M3ILI^5O-36 71JS35:91HQ&..#2VUU(V'N/5WM*:9SP(+*UX(*:15S7GVB.=
M*M<K9RO2$\^ZGDG69@XR,678@+*M.-:X)*]%7KK_Y"BOA"/R 2G]T5(=8T':
M^]RC.IC/$P4=?(3S-3WX]Y_Y*W]F:](IQY6+2_Z,74]X<IOBL,SX%LK"L?6\
M>];2X[5/2BN6CN/*UP^8M!6M>4V<BX$O^:KNE9O@ %\$\S6=_VUB6\<#E%FW
MPVN>=8QPZMJ4;<4UHYMER)J@%+G7"WAP_Q\NTO%Q_QG?K-/<!H<!M,@Y:W\-
M[5Y&N\D]F#G7]?(;PBNO;6$._OTGSBRU8L1&S3%5;T&=.BVS_S8^C+_^'2!<
MPIX9D>!7L@Z\>O,6PD8^'5[;F='JB=K#6M/ '\^'(H,)WLE(;!V'8LOUC_WZ
M_B71!E\Q%MF\M*8!?>!+\[,;)[OE-SWSV/+YQ\_-'DH/Q^D8A*+MDMQAFD$#
M2GQ5, -_57*^#=[7"?\B]3]$*P#SC?%Z\1W"'  $-&2T(O0/S$ITNR^+V(US
M.1GSP\%5F/7%L-J.FZ]%PVDSM)]<V/6'>.0.7\,A-UZ"7E?SJA_4&C>KU^M9
M]).Y[(_R=XD!4K%"-C@*(WE".;QI![_S+8L.:B@R0&SJ7DH'W'8U]S+MOQ53
MW]S5#]M)SO"CM@DV('U-C\/#X/*U%4.O>[[?,/8]9Q03'6*V>;V@#U7A(7D$
M1>M\,-08+*K#N%H"(*WC[_EAW_;IQWH2F$P3HS$X[7@Z@$.R*^))G)@9PJ!<
M^EHQ_PYMA"([H(VG]_P[X:4G<MJQ/?.K\G<@GP,P2YUD1&[7?S0TTV'O=3J
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M^(M,=R<G%S]\X_3OT'-<#U^_=_XJ2K7HDT-[V^UF_'XOIR5W7%HJ=26]S=.
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M[?YR=NW:Q8,'>N&I7;N>'(EE+SC1[Y?K"DB8T^N%)]"Z5O<E/[MBR#J#  !
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M^^NR4T40D^NXO;>[OMP0P3W&"B)%P<>DO\L/@QLJ"%(/=(7P,:CV=^^F0"C
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M.%'3VI>6P) %EW_K!//UEE(]>;H4OWQ+SKI\<'UT >%745!X\L%,N4&F_$A
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M\4N#7V2.4CT%N2J1HK /]0H_GY]F&;NU[,%14F72H&5>@;0NJX@6,(6PK)]
M[8M3YX\U828=IR2*P.KZ2]=X^U?^L4T8N'?(SA^7N@@T0"YFPR,ES=QCZ.Q^
MS9ME@.*?D5=!7]>/*'U5XM_9D7^M187EE$+M?S#@'$(*>;E^Q.K[#YLJ;E$0
M=&63W/B1TU3HB!\K[+LZ5YBD-SOP*'P9+YV+CMHUZ6PG+R+0%7!(A*UKW)?(
ML2@\"H((M1*EB\NBU+HT&_]2.5K %1-$<S->R1:5U^IO^^6^J+CQ00-O__&I
MJ<I_4F7GG=0JR&FL^E=V#$K+9_#!3"*X281A 8Y(8YH?VS6W<B&\[E6I=3.+
M#VO9U[</IT@MA*IP71Q4$<_^9:6JJ1\+AAR4OTB$#^O#WK+ZO$$[]MTMJ92G
M!*GU4L_C:GD;I&.E#"=)X65M*(5 =@'"6>/$+P(^<U!LGI]3%%05A"\*H?'H
M,#JJA^GT.*XW.OJ+/:QS'3%:'D\F ,7$-QF3-W*H-8J*'%.\$Q_?2)S7CXRG
MHI_CVZG8>**=B&"-RR/%^S/M'-3UT./,9[R@A*_/&L3PH2IW9^SB>X 7[40<
MWY(LBL3*IPC*EPJ99WN5 /UB=[%0\/J,0=EJ&Z!T9^PD5,,_WTBLLMW^_GU;
M[RC\J8J7^)M 5;V+R,4@O'82!G]=.P3O^X< U;_[.SU.K.M($5 &>TI]&-9G
M#.[I;RB"\_J6XAN/Y1N))=8.09<']0W$8E!!$+R_@*1V#.IG@L)5$?&V=A?>
M?-S^L;ESFT>(M5/O\??92;@[=T'P??W@W>_Y I*W^S,&-?>G"^[>W=V\^)3Q
MGWIZV;_[]MO:;;K??_,MT^^>OGAVKR>)^;*=/5] TCL&'UP\+X/7E^OZ I(?
M^MQGC=>]L7_MU5=W=_3-TI_7<\0J8>[NO+3L7R;0EU_VX\0_]K)2\&.4"$EW
M3DKX(]6VPN C=3FV8+8,;!G8,K!E8,O EH$M UL&M@RL&="["-X_\'99;^6J
MKS<7JY5UJ2*E0(/*SVGQYE)O D53[S/7HDW@&%#9&44N%WB,CUO\^WT>[R5Y
M4Z.3BU;!ZTR,%#X,<FF(H38RY3V<=()T_%(88A,0;@Z!D=Z;Q3YR_*D1/FMD
MTY2(TY?.ZG":.OR*QT ZU[&(<; H"10XJBDX%M9SUJ*Q*=/7.B3"QM>!7#1
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M1U[6^$V=%GW2X!?IU+[T)27@)P[_FR&:[^^9'SZO*83?JE^ ?_G[&\KF?<O
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MHJ$SX)?"CX#CMN$7DA>0^P58)%L<"6^#)2<NDNPDNH=/TF>R0+) LD"R0+)
MLD"R0++ H;) T7/P 4<-O>_2F[>\:=KEV]M<>Q/>@?5F(HUH.S'?,N>@?D0O
M;JG/>0S:J Q\ EW*)6L8HA\L;F@Z8U!>; (86_-J1K"2EM8ZSH+>8W"6 "2
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M?^DM6U[/RQN>@WQKGE?S<BON<^29@Y(&\0>#:,0 =\!5RD= $ $#Y!J"@D!
M-H0KZEQ!D=)2J[Z-TF[B6;85MP(("I/Q 4NHMK[JZ+6!C BLH??;]5_B','I
M:3Q7"3O<FA-U6 !A .2LH_@A;T%"#[NPC5A).[Z%>=F#@]-\,X;7H+H19?GD
M5*Y]H).3) ""<_T#_05JRBH&_ D-;*X (E8Z&_I$)<Z[V4*\P^T$#NPV0"B>
M-1CU=S#.GC[FM!5X%:2]JY^3!3UEU4UAKBH9'C:0:SC8Q$3D+;@2;TG*KL07
MXL1UJ[)=1"96W2#C'\5D. UF:TYQ^5JNUR 7OOPS]:7PH>?K4% GC?X[_,S]
M;/PAR+T3QMG2@# M6KX,GP;'&T+6/"B>IPPDD.\"R_F/?R"1-X3HY?#/X'-A
MP%WSNA@B'87/AR,]ADST3_XY^;B D]?*F^ 7PBM@74_"DGD[_"-8]%Q8<B+5
M:RO7=EU *E>]Z)?PBRVW_Q_G(?H6^&18]E%[+X$3)0LD"R0+) LD"R0+) LD
M"R0+) LD"R0+_!Y8H AP:;@?7OL\15>=Y]U7G,9/+KO.?;T #!;/)^P#Y/O,
M^_ZJ*'Z[_-4;-KFW?_!_&N5%<$Z% A/%>Z+K-FZ95R7P[55KSW ?>-NSW6,?
M=L]&G8*;K'GU4]PK_N)1[KW_?:X+@%:C7IGB%F: $-?=*9^7/=.O"QZ%]RF<
MRRCO/IW+^&8 5$58EN??Z(-/<-^[^#?S^MC3-FOU6+P/U]^\U>W<6_"5/0_Q
M+JF9!PX.#WS@5YLVOX:S[,8KE4XW.SMKWH+8,P8?:8S)XWPM\AO4T7\6G$-1
MB>5=B*)' P.@)<\_%'/O+>C!06T@+E% HF^F3%][>$Q]#A2DFLK0?J-S,N8I
M"'*B<P;)9P Y)LLV8G8.L\68- **3=.[&_4X##JP05<G\(B>D#KG#+*I):M/
M>?UR1]E-34Y%4##T/\GX0N 1=,P_4.+8" PQYT1!@,)=N3P'NSN[@ 1W>5 P
M )K-U"\$!V\#%%14XAKG#,I;4/6W B?U#PVRAV>3.VIX2*"B]7\C)FB @ROI
M'G"0P,3NQ%6KY.W(5N)+LM6K5]?E,2AO06*/2,] 05(D,+'?&6"7A_N#9^:@
MTN]H32":OA)Y!OP4^&QX;_175'X,+H[E05R+!8H]$?;/N-^2INVWHFZ?-#Z/
M(1?KND)IE?1,^%7A6D!=$1@\)90K^7PA?P;Y/RM<*\OSY1X%GP=K7FI']_G5
M\,-@T6GP2V !G.^&-2>>"SL4G^2 Z!*DM\&GPOK-+9!3;2=*%D@62!9(%D@6
M2!9(%D@62!9(%D@62!;X/;! $1S3<'46WY[H?W]TI?NG?_OFO.J%P-Z\RG"A
M("6_))C&#WYZ#=&,+P8# KX(5/24TQF >SN#3RH77OK;J-I(IV>J[I6 @P^^
M[XC[V^<\HN$]*('!_BYWVEN?Y>1)^+$S+VCH:)[RAHQT V!<,5IQ+(_I;01E
MV;9#OC:>BO/6]NN)J1GWK>]=[O[\R5IJXX'S5(*07'*M.^'8([P"GXMMTXZ5
MQ?L0O2ECW5),OW?1;]QO;]S"&8J#QW5E;F1R:O>5U;9V>?\9HM?4T@+N9F1
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M>GM+.6\VKS^ A@"283> )^ IRWA/P5F^VL6'$!C1 X+R%!30%UEG!K*IF*,
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M1(Q>]OWDCX,CG1 RQY 6^[V9ZYNB4$J3!9(%YEM ZS-*]#LP4;) LD"R0++
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MM@A\,D#-6X&MQ ($N>!O1'QOLRK^8&2 .S@'5LU+, *"5!;T)0K,!_BG9F9
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M*G".7Y2.IG3CHC6^\'$D\@K;$RU6]R.$/QD4> 4PD/!9I+^"_Q2^'MX7+4=
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MJ> UR;UBD?)4E"R0+'!["VBQD#<U-^7CNW?G/_S9S[.-VR;J,S/3KE:=R>N
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M-=5;FUMKK0#\[9T=,]T]?=/=O7V @G@+#O;/=%1ZJQT=%GG8-36SG=4 /6&
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M-=G/IB$%PWJ"OAH,G7172I*IC[?.:$T:VO0)'=H0U"3V5F&HUP0:MJ904$\
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MV&)E+AR@T:/I<]DH","*)F?]JR;H:F(:AI=5UKHS;2L-[4H '7D3>0=.:T.
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MT$\+<IJK[Y\G&'WKO="_&H"ITQ<"I9SC1<-HD#7]< \EU.@3 $G 5YB+KPI
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MIA'[,4F,U)58:4O 2'DY@/=T( RRL#Y;YE32)OA5P%)BU>, JJH?\85CJ\8
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M1_AI#U#GT9$XGDU=:0,(9)W!6:>!S4B$]N9L0N+0]<-=B8MWS6L_Z^"@ *$
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MU?!Y4;C'Y[,\J.=%)04"I3'RG/<^>,.@:DS8G*.MHZ).$3]>!5$*,*A^'M&
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MGY?B5: <2.#<D #^2.-XLR]H98FFA?\H@)%T."P)5'NI$YS.81]M@GPEOW
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M-$C-4=1<BCRK-H% LP!M:'5/^J[$&T;#\W5!05 0-@B1U12_9#W2DG,W'L$
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M@+[L:L+&(_J.!XLW;3(% 04SC9CIS#!DC4&/SN:]M%;K S(%6(?X8THQ;ZS
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MNS3F:&<YBK4@*6H3;R/^==[LXVZ M&ZB65K85ZX58MWCCXK()Z:Y?CK07.8
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MP8W]\_E!?W'S\T:0<6/.&H/#H;G3B;,;,4?>$G.S!2MC\&G P*<! ]V9^"E
M0J_WS</ITYR='F8WS5UC<)@_N?1$_',Z,;&=Y^G@L<>&]SQ:4XE7W1OG$?Q;
MNP/YX_GE11AF%P$'S\/O=.(3NL7+*<Y?WX@6^'D1%+S!L@:YSE.9(C!%8(K
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M_7!>@\\^"BJ6YQ^V=^FUQU:7OO!MSUSX$AN=HMQW.UY::1NJ*)3=A>6@FO3
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M_< >\**"=M2;G5< 0M XBH!Z 0K!2R(/Y%0 ,F"U JPA SJC3?MC'?JZ4;^
M@J/X'!5Y@,+2<?7%]>B3HX(E <*R,K&6ZBK&U;_@780 *(ML.29;$(0&0*\@
M;^4[C[JVBO*X_YP"5EOW/2CV-)8N@=P!\*":]UTR <$*@7U<C;A0 P=S5-S1
M?;K3&JQCO"YH8%Z/8S\9@U2!L25VR%0"K"NEVH\$@Y"P& K_J$QFX&K-& 0=
M3-\!!-%B(1..I6D /V4M6Y>%2"AWHGK("0I2R8L?KWZJB 1":QS/F/)7YAF,
MOK6SZL#:5-(%11Q"K( V7+PD% "0^OPO_I6=JX@@J%T6*,D\@S%4U'P;W4*1
MJ0+)^+.?]7]M;COK+0L*"IQX$019JGE*A03JS!+TR&'%SC%(NBQW.Q9,9S)C
M4#I9]]0M\._XR9.9Z&V>>0:Q'?W!B1/4 1L!"JX/@-2!D)(QN%06'M&,@XL+
MW97=>K<]JQ/OY.@._CUJ%WEDM^>VCLWUHPY#W#U@56+(S9ZDZ-QXV./+!GLO
M(].S^G_W]8/!Y4$@6'R$.H<27WGEQ/T'^G2-:@</<F.*D5Y<5._GA[Q3?X7%
MGX;_(^SU_SFX@5(4Q_2QX])@</5$>7/Q,53\[:;*?'U-U-6[?*)FH_@RB@?K
MX9>SYW;)(@Y6<0<%@+/<2(#RA?#^5L&>6V1,[0MF7$'A^;# 8*/?IG!K.SC+
M7IG-]&=4R)+@D;%K]/)6.(_]OT1&;O2'%)X!WP _'GX@]*<HO> ,BI=2=R9@
M\,%<WQLW^>%3.!Z6/GDM-HF-#Q^,[Q;_9LSKF*]B]I>UR@>Y+]]&&T;\KFQT
MIL^*;7Z%_W43ZO=]!/H(]!'H(]!'H(_ 1W$$S&_HJ8] 'X%'1 1:IN#"ENFI
M5_[^:UY[\]TG[MBY:_=P=7U]BFRZJ?6UT=343)+8!!0<XILY_"RW ('DC0$^
MA]^2:&>F7KY'VI>)0VNCP[8 AP([C7S%Q;( 8\W.PT" PB8!_*5\ 04#0A;
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M$[*FU)8,Q6(WTMD,R30,*(C_9.VQ5P:WR29L!O3/T&6''&?8<</TP"CK\R4
MGF41'W4!JQB:2]4: &.&[$X^AZ;L'(6M)\XMB.L<T]_,4QAPUR'*,$:PC7'8
M58D;MWD&,XQ862CS#+*;I;RVM@I.R++!X^=@AA0#_04"3+]\[,G##XB3]:O
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MG+6QCG+=Z'..60)/GV8%DBVL;-QM09]'\0K(3<HZQV!6)6:.0<G=5J"_;KZ
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M9EBL!%0O&8. @RAS]?7O_[(H2;(%9P$%ZQR#JRNKS!=(&\.)IYF;$  P=!J
M$!H*+*H/8)CS[WCDUZY]LMZAR*PV0N(A<Q,RM^!I4PRA.?;QSU;W;3[!K$J,
M+$N6=*,*$,[3?HKAQ'/SS"U8,P9/8APRR75P$E^C^:Y;I#QB./'4<)$O^C+'
MH,.)UY>8@_#X\>'\XM*(14?4 R[D4Y&SYSK04]DY!N_P302[VSOF&-PUZ!Q*
M[+>.PXF7+[EDE&1!-A\<Y3%\.,?%63G,O(AKEZ5#S"\XF-M?0,%3],OAQ%>R
M ,FA P$%NZNHBX>ZQRWWP/B[JS9=V)W?<X?IPM/IV-]=V*[TWOL(]!'H(]!'
MX*&( -_K_O@L\;U^XJ&P=S]M^*?%CX=]KGPOS._CO6@K1SX=M!_(R<:G<G (
M_AGXW\.->(;(RL'^&O/36_/_6^N9]_Z)3S\-9#RSU/VOO125Q\$?@#]2@.#]
M[^4C2\-K_5C8>\[[XT+<][C]$/(^^5CX3^ SW>\?HM!7/*(CX/><[/OFEN_X
MH1=^W+.^XI_]Q>CD\>[O;[][L'+//9FDG@P77Z=\[V*K!B\6]>[RH9X:6_@'
M3(.U""J6>W#R-BQ0AR\F52V:;5/V>O)C)2%7"K&EO8;4Q)MMH"0B07&*L"<#
MS!"U@#+-0DZ@6HM_-%6O[6FV_U2WET;-6^]>PI'P48Z;7D :VC9\H2$,U+2,
M525UTW]K=,2.8FF/F\0EI]!TQH:0*N=9Y76C_F3W/-3L)'+$.?DUI7!ZW_2J
M@WBD\3$[ECX&%'']IKM/W+)A5.^U_\6;=E*BD]EK55-Z*+T'<PI.5!W4G:!1
MB5'3*_MV/3TW.Z^9G$93K_WUFW;RM/2EB&<;T79ETK$-&$ZY=C<IV>3'^NW\
M8@QA_//V/\8&BY-B(;HHQI]5VC/@N<:<2;O6NN>_YS0^/_PTZ"ORM8N>D\>"
MB5KVXI?XQP";F,H&5_PGCLT/;8Q9'4W/SHSF8!9)6%L # 047%G>[G[G:E8?
MGM^R/CNW9<1P4C \\KIFG+NOP%TXT$?W2=OFKG[GW2L_#-!C@E;\)H-/0<A[
MEY0^+J,CC#.W8.K5;\>"9 4IJS$"[4HZ'Y(@;/S/G'X;^BB4^TB@+8[8B^25
MX @*M@MA61N>@/X<2BS%?YEK$$WJ_29;7\_<@.,Y!A6D+_;/[[(ZMZ"U5;^"
MEIYCK;/? JZ :=C#)SYL<DASRFFPT?-/AF#*NB>&L0/.F-'"B@H&QC^-+A1B
M/Z* K,>D[*$#V 8P-\5U:HN/T+/80LU32Q_4V[-E]HI=<U/_ZIW'UOAC-WT%
MJA-0=([! @A6^\XQV,!!]#L!/7KH4.+FOV8(>N]WSC$XJJL7VR[8YPTQ6&,[
M,VO"9-%3NE#VRH$,9B$30,-ZUT2XRB4_,#Y4H[*;X\G=O>#@!C (H#>Q6(GM
M<0/2-P(,+"I4CJ]5Z4?LL2+QRO TF8?E9O*ON<XQJ+X/YF"+JN68.RQ[_HK:
M*=<6'S%S<';K5OK/:T20MKI*,6B@?V79NE#T.H82:Q=!]B=H6^S().Q. @P"
MQ(_*2T"98U Y <(E]->[;=$KV8."A,7>]IW>6P487-ZU:]0F)5K;3?L1+1P9
MK([V="M[.09%<RBQM>U>$R]-=YEC\)8KZ-:A0X,#!\H<@TXR>-555RG/5Q@T
M\?WAX84D0O(&[IV>^@CT$>@CT$>@C\!#%@&?6\PX.QM]!0W_$[X:WCP<T@Q"
MZ<_*;KSU1Y2?W_%\A..&^RC<>A]M#Z;I%I3EGBZ>"'BM/US7^\&<Y?M1EGOJ
M(W"^$<@+ \*CK=NWDW7$J]>6K0R16O.%E??$-=[%A3?:JQAO%^7=2OMY.<D^
M+QL<MIJ(^1Z2=0M$ #8:U5>..E]43/\J[1S04,TKA%5Q.M]E!*"J4GE=KP8+
MW-3 D@;$:!4[5)>71$RI7*D #S&H<_YOV(^3R5Y4O>9?$[6'GE/IN:XB5]_S
M/)VB5T_'7EKA^8*;"1(@85W@))I:_ZI:$?>48[))H3:VC:18E0%F7_V+_%0A
M)>U'+([[H4G_0^F_EZ#KEI;(>$%F<62J5W&I0&2T:?R+5FUFE^ZSM9CK@\WJ
M7G>>8P%I(U$#$I.QI$7^8X5=T[=?BNL- X0JLIYH&NS3^)2BFIZQF9"+OI:*
M'?;&(143=3FW7+\83'NSD_/ ?T/VTL=FH/K2E)81HKG$/U5IJ&&I( 6"&_[;
M+5EUM."9:+X!8<9#HT8@7O1I;.F3B_2"7B;FW-_.^;8^-S?'_(&+#!E>9#[!
MG2M;68UX86EI?<O\%E8?!M"I8 ^@8#/3 JK;>Q' &\? F&*0SK4G"%=!006#
M+K+WG(IH!>NP7$2%QVAF.#'@'"!7R1BD%5 MEG,>GG<*I4<U/AFV&]MF)]*7
MA(2;*>>?C, Q*!BP+MAC!>XHVQ=S#HDI_DF#SAWI<: R$#J''DMM.'$<>[])
M 03I9$!!,6+N -,@TU?!.5% #T/1$>,3^+.FEDO_^7L*71D9#1H![2B @KA0
MB.30X43*7#X)4 X'.,S"'FE3I1)@(J5IL]8\I_2)NX]SU+8VR#+$'D!@J0N4
M. $*:F?($&"!1\NE3QE2W,T@Y\W6,?]D]@6H#$K<0$%6#=$+P.,8^,-$Z:OS
M"P(PLH+P3+=:ONPRK%@_=8Y!9$D#I&W&3,+JWQ6)R8'K5E;XW<%V,@$S3)CN
MI8K:"@JZYV%_#!RZHO&0J2_\H#A.0E"04K(%<="9$:"C!@JZWT(/UNLJQ?S,
M90@QU60("@^Z C$6R!94/PN0U(Q!/^$*W',2F?F%]%^94R<=0DRFWL)Q,PF'
MZXM+K%A\/%^[+D!R9\L81/^N>+A[.#_:%OUM.P;=W7?>2;9IU]UV>\P/=XQV
M=3Q9DIB*_]TH3(""Y@7,L0#)HR[;&WU!P<,WW# \Q<K2ES..>![_IZX8= ?T
M R@(-CB\Z@ AN(J\0>W5#0&_J(@[IZ<^ GT$^@CT$>@C\!&+P!OQY(_B#\ \
M/F3^NCWLOQ@6-/P_\*OAGOH(]!'H(_!(BH#?B[XGN%]G".+:'),XS3 !TSSO
MB3/,_^1\6 (?X"I-#N$&@JA8&P18"F&KO$0!%N4%IAQ-Z*-497U1C$SI K5J
MMX.">2%3_.FK-$WX;[9BT0UM!4ND6$"5-.E060XP5_I5ZN[EOYY;5:$I\LT_
M8 ,UY7Q4#E7]- #6%!E;-AJ*H)JV8S+VW6BOMD8#"8_A>"I-Z%A /6#09 <F
M]=4M>!+RFSJJ 2Q3K_UZ!E968]NW+X W=:,3TW.\;Y;S;6+8:O!6_&^ K_:J
M]"T%_:N4*&\TC>. W?2OZ92&G%N+%A*<1K5I3Q/%UA_K8[[JX .#G*IH"D6=
M*^L0WN:$HX(#1[;(U_,O]1NV!, 3G^*OG:?(@V?38LUACK-KBUPH0'6Z7\^_
M>J%'53ZVTR_[J(8XU(9_ZH*I1)]2BT-&WM;S0(WF;MIL/&AJV@2OV='<ECEX
MGOD$661D?GYMZ]+B^MR6+>N @H-9P!Y$,X0W.FX@8E:R(\NAYV?8&O ' (4K
MAOD*8('X90CQQDT=8>5!XJ+E<&(Q-.XB8 V;@ZHQ=)9\-H^3,0BT5" M_33_
MUF"_$"!78H,\P%^=3Y!/LA>%_R5NBO+50<)D760$$$X$L>B8X8Q\B9%V<WNX
M5\_4.S<.(69<;S%(N/D*-* 5]W/]$#*\TN_HQ8Z:&P0 UY&Q206@G>V:[L3]
MV L*FC$8L(_&H1EUIG@U<EBRW? 8#!-YIS!D@1!LQ*9('S*)/_K(VNY=UDQ8
M*@?TOV8-CNO6 D"6\T A_0<@;K>E%36FR3P#L.,^*0;9!N@K,O9[ -S'5('3
M#/.MM[-]B,U2**"@XXEGLAAQ 025X0ZTC_B:[;@=Q]T7%"SNYKS7VW#B+$RB
MS:" ZI$I. 582* RA+B= ..*:2M'0T8*.X1X"X_X#"_67U;VHX<9)LSAT.S
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M6_A T//<&R!W 3 #"K8AQ?&/F!F#N3RU/SF[F"YV&<*K-65<I7@\]+CJQS_
M[7K)&(RB&ZPUN][#97Y!ZP'N'"+L2L<2^&CDG&\PM,F_?JFO?2GWID.(J1 $
MDT0* P:60^5+.\&B:FK 8C(D".* >)@UZ,+&'&D3:*\.42[ L,H-5$IFH<>
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M-2\-XRR>DN"6%UO>/K)GD_<B0:J4@^V4EQ%!!# 6ZZW0%D<<"B@UN;RF(E!
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MC\8_L@C.HL\<@[2!YC7_W%%^V>NO4<'YDLOHG9(OH56 /L'$ <L/!PVL^BQ
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MH](-+YIR_72H(A.5"_NYVXJU Y=MXY8-^082EB\%1 E:>8Z?L6=</*];Q$J
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M[QR&&VZRO6\^,K#Y2(9NXWQ@L<%;K1T[QHW9?^;9<&44[[NI3!&8(C!%8(K
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MQ-]!P;%?<.2Z1K:K4(/C2V<#0<WFTQ>_@VE7/_>,@?9;(CX7]&X)&$/Y;/)
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MA5[E+1RZ>>K= ZO8[[:+E<^:WEH.*ZGYXHJL[] 6UF33?M[VY&B%MJX1%<'
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M,C;/M5NQC2LZ#C_W*! ";G/.J='-0GEQN\9$4]E%A7IU+K$M7IP%+ SRN%!
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M.3"[6C/0[$2D_+>01T_J@)>1;^ @ITZ?%H#$8N!A]Q<&P,8-LQX[2%:8G6V
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M6'5>++L1NZY@P#[ 0.J"@OX%5OFY.Q+3YC*$[DJ\.EIC$$5S04%W(Y;4NCX
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MZQ%^:^OC5_SPF]#G0'^UM;V(X^9" G[6*N37-[^7A^$_0!\&74KY!S#IAY,
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MI [HX7I]/$*X7I_9>V%4!]E^:BI9LOOB@&W :PAJMX.".B<X*'5Y%)+]YAE
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MS')4E^>2N!8B!;;%O@J*3 HT4S  (7T">66W?(@O->?8WY.< @""QJGS@@*
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M)/^Q,;H)":V >XR]9?[!&O_;%&#!P 4MP,-FBYU&8*NU!9/M9\:@0"5I?,N
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M8'J 88)WSAFF  ;F..=Y*>*<FP4HF%>LR_9G.C%9>.!?E3%(+]-]X3(W$+.
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M&!C.#4EX]H  V"H$0%:;WV?9D9B,+1! L_V4+=Z@9 !E0&!1L!8%H'P!\WI
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M@")\@<ZCA4;H+UF).>7QC&6^UG%&!T87\&I$X^7C6T3W(=+Y3&0ICR7#5B(
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M-+/SZWOGE\CR"] #XN=28N*J!.1BJ;# '1@>R,)4@&PX(*(%(0,F 4";$H$
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M1+*2F=FQJ%Y$# (.PNQBV@#H@ 3#+Q$M. LH6/887%];9[] QEA./,W>A "
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MGN.( HP'8/8:G&W7[63?0!*0 #ZF_F(6 UEF.8@,.HVTF1[ /9011>CH.NU
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MF]:(0>&ELVPTN,$>@P_#L^<A0:>'1OMI;S8'VGWL-[CN<F+ P8/P/$#_<]'
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MGTSY4HA>1?UIZE??@.&-C/UOU*^DOH)J$1C[3]0W4%]$[1>C]=Y,?1OUSO[
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MP>3! X,'MGM@*RCXVC>05N+*,GL)KNS:O;ZZ9Q<1@WO7%]AT;669T+>Y^4U
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MS;&G(*2M@%REZ8Y&"Y)ZN)X_1ECAR.7$B_Y/'1$@9O,D'[$JMXFLQ%=B^;"
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M/BCXXZ_ZV5_; !1< 01<7#52</?Z;B(%%XT47 I0,!*-$ 4&0!?[Z464G 8
M/9' 0["!%N%QO3*B[3+:""JL[1B7C$# -L+E1&Y,X@'[=*)C$89GT!MR?8G
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MPM O+R!=+"4V\L^HP)%5>A%$B(TLE%7:[KBV-JK+BNVWN(28B$&C!A%Q=;3
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MBWO7*KQ9A_H/AUCU[-TK!]&T^>"Y"V<(W2I*.^OXM*<+G@[ 2S?H_E!JO\T
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M$O/^!_T*4+#8%WSR XIIFOL.RE-(;=,'*(=]P(0%%(RCDE-O7ML0 'WPA#!
M0)V!"UURC'[4"PIZC%* 7_<SK#U@D-$.@!!;Y!>49(_#X/)2%+Q.'(WA  B#
M1]KX41C6ZE.ZH&?ZFI$E:&T&?:\/95P#NY&*$FV1!E%$)Z;5P2.*$R!;TKIT
MV ]>BB(R44F1([UC&\57TF!R?%(#L(X_8G[F!?OFFI?<?^'J-X3L0C<![M2A
M,"1DJ4?LRRS'\IF(Q"-FQ3@;#^8Q^ A=M-\]!@$%8^- 9$T123B1&4E(,+X
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M5CU(Q_-A.9^,J":>]>B*IU(>?7S^T3P,** /DU%0P:E">DC*AZ0*8OG0!$V
M:8JIZI$EPA,3\R$Q6 6=0F:0R0.+OZI1CH.U0"EWUU=E^9@-GJ)BY8?*M"E
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M^,"A0QNS<SRH\>PPOSG5S(&"^/#C3SR9^%#D,UUT^( 5O1SM )^@D8]=,5"
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MT.(@0&',RQXCU\8E:S'GU5Y&B!T4$)3'.[57]!DV$AR8^Q]60!"2'K\,P'R
M?XH1%+0D..@'>0LFN,ZRXED 02<W&W,)0 RZ,7SSN938-\_C],^Q2^#5JV0@
MF0<\;.?A)^>><]E&&]&"I!YF8\'0[V&!V,)V,<'!J[PIB1HL_L=^LQ(#^EV^
MS % T('4#_17RM1H.?70-;T,B+B\TO&;E7@72XC/-X\"!^Z*ZYA1@I6; $+L
MW+V7.3V"__G[N[J/G06SC#(K,2?V'#K4/. A+UM2G. S^PC1DO2]%63P!???
M.;I 9F('#^"!HW 2-#@Z=G?3WLOY,>CB<R>Y=\3K  SNB,LP&#%X8/# X('!
M X,'!@\,'A@\,'@@/;"XR/(I'QUY4 %8 %"(YPO.XD$C'AZEI#<?T*6D"$K8
M3:DT'#M\P;;C]:B 3J8#4U.Q+"WX!8BDA:"@ X 2/ @+"M#GF(5V "P<*#,)
M4$ST2XK^?+S*)8Z=3D3DDU$%JKK)A:R87LS+9U5)0TPJ"E+)/*VV%#8/@H+T
MP^;#8TS$IW#L 'B2I?+$ [./]7;8ZW#J$&PM?HQ^SB  V9%6<HI 2.>+[.(5
M[?PD@ *E,_9"HC_Y(0G!X"X )=U2P#" Y]&00+<Z/,D9Q",__!PG^LMX(>20
MA;G"Z'23'XYI'8+^Z9!?]6-\3*<R%G:YLM]7Y;@<4TMBG:8MH[+LQYKB"T>C
MN)36D\DYW4P40D \[]$.L++1[9"VE=Z(RM!<]"=F@>+P=P$997&9K$X6Z)CV
M7@5_XYD[0"_O@^[^Q?:,G'*7.RV->14[Y0?T&B,8_@2XC%%#4&<MH%+>RR6#
M;9$@:^B/2$6:N \VYPF %J\QCBD34% >@3;>=$$?0HHM\H>!''W_1\B@M$XS
M[J90IXBXOMH;]I?W?P)X^DTSC+9T(:Z@G!<+^"HN#]R!7]GG>]J"M=H0=B7*
MCX"<,WV"@EA=/W/4GO<'@&#H!R"47X"0/"=Q_W5["8I5"@K"%4N+1=BT)>@C
M.4E&##I#(PL+@*C]DC*)HC]N0?4X*R+W .*43?$MQD%@<$2U;2K@L3E78JX5
M%,S;A<[@"Z!48F];EQ%[;W-G8W]&"/I1/!-@GH!AP">AWV6[WC7](BAHR:7$
M,:](-$+47T0!*@?FX <3S S$T-<.Q4<D(3:&KQR"<!9^]ACL[2_HY'A3^*'4
M*XGS12RC=TI\_JT7,+$A_7"@@46=D7^JSFC!! ==0#Q'!X?4KZ^2S3T&*R@8
M.KEI0GY//3 @0""1A"XEIMW]\6$9,5@@2XPY8G'P3UU]K!LG8+ 1(AP3,>A^
M@N-<2CP:7TG:Q:7%YLKE*Q44+/HOH]]D([4($G*ZO"*&V+*C(&_^"ZV1@[M6
M5H$$+R0H6/23VZM+6%,E/ PH>%NSK]EDGT&C!04/W]><:?8=!-X[?;IY]J&#
MW$IITP-<@@X</(($P,&&XPONO#/V&5Q]TYM&=]UUU]B(0:,%64FLK0$*<D0*
M+O9S;8<4;KVA#!X8/#!X8/# X('! X,'!@\,'A@\L-,\8'21C\0)9N732#Q9
M%$-YJJL/%?7H@YX/C'F>4 (]%?JBN55 T/&2BWA]3"G\/FY6.2'4^!:8 0>D
MH%K$8:+4XQ;]\=SJ<#QH<Q3MT+0 IU!6'M#H\2&TDTJSR// 2%A%0!WTR$1,
MD#-2\9-*#[D<S#L>EXO0,,IN@(,057"07"(;JE(@O.4Q._77WG0?JMU3$6D)
MO"*Q6R((?;$U+/ D?55%A%FA7W2F&# ]'1%UA3GF+Y)A 9 !62F(1QCM=-6/
M,? '38E(K/S!F"\:PY6*0[1@ FP1!XR;(OFGNPWPXTJDFA  .%,N%Y3E\GG!
MF!0=Q2P>K,5K<K+!UKWTIEWZ5 RPI"N9=.K'?]'H@1OA7V?HK>5<*?D*#ZH
MBA"0;-,E407(5=67'(*'3CTCV<)^=\C+8BL?@=$-E3=EN:'0&/8DP"9=O=)!
M%C.M8CBVXPFH&6.PRZ]<P+D ZKMW"/VAB6,5(2C(:=]_H9[.Z%=%@((27;ML
MX0^@$3KYA:<0'^-Y!1.P$M70(6%#N4&DQUSHTZ\,!I] 8&*S*I=CVPQ*;*G\
M4F3$H"WD\<*UJ@84A73&7H<8$#=5^@]CX1>E!$CS_@<4E"X 1(:"5*'48CXM
M1:;_:*9^[LO^^]>]!6.@"B@N*)<_@_Z2.<@$%.7)+M! ?H.6VV4S$X>$,60L
MSMND\?W?74V(W0\Q"F">>8W3,.\VEA;+$WHBL0DG=8DPG=DO>"A1^5RLRXGM
M([*PX]\L240F$8V%7T(*4B(SL=&%[!9(SVRS 8]ZU%"3D!!Y&!<T] /^58"P
MLP<@L!8PR4Y_ 12)7"QOGN+F2LO284'!>AK'M:N1>(0(P:N1\\0<QK/S&1&H
M/C,2+[">F';B_"PE[I?',O&(PXU+B3W.+RZ%_;Q$/XB@W0'<N;]@K"7V0(+B
M2^PS"#+8$C38N)38[L5=NX)_\VSR[Z7/C@(*@@L^1*[BMGF6Q&?.1 ;B]]IF
M*;&'0X<.!3_7.?4?L3>3CWB\<-==T7^W)Z7<R_%8/:E_I^OY+3[V[^1;;,J@
M?O# X('! X,'!@\,'A@\,'A@\,#@@>H!GJ]\ /&!SB>/B!6RHYQ[C >4\BI;
MTF1OGD6/'(IA8*N @G6(&<60A-(6A$3]B;ED0VQ&%H.H(I!*:9#[2!$5?H]V
M0P>L@M:DT9H@X52TA)H&02I-0C"PF-*APWD*LV8I*<SE-0"NZ&3 PF!@=DDH
M)6I4G %RT4ZAZA+XH,HC RB&RR[1JVJ/LA8!"DI-T9MZ!.ATC")#@G+2-=F'
M?H94%4>:W00!!84X _35;HI 5X)=<6J717 0=*6<A)>0DOPAHUXEYU'\AQYM
M*EHQ*5KZ.DT,^VGKPY 8YCM9^1"/G, CJVJ.Q2@.D @*XCLNN?Z0Q_'JL_!?
MC.10)9$FQ/ DK47I.&W&V13EZ+/43[^1DSG]4 %!3C#\)*"6H%,,"A9*BV#]
MBBA/. 0 6Q-HE*6^C!D"YP_W< J7/BO&=&UI\O[U\5^,JPYQZOU;KW^UDV,F
M ($N 4Q(BH]0%*"H(A17:H=L*Y(2SLAFT#@>-AKM%ZF&ZV >8TS]I81^M_@3
MH +V95Q 2N1MFH!'>@MR)3[G==8.YUQD%/TIT/E;@T3;@J@W@S*WZ4@Z8K_
M+S^<^R-0B8"./Z0:>NI:WZQ@@23JT*R(,NV 5D3%6F17_08_AH5MQ?PPB8$J
M.\ZY0EMHF*-[(%::1!@5(&)G+?RI7QNX8T@^(D89D8&@:"5"T PK'2CH_H*(
MX>;5M^E!;9'?I":QJ'A&3BI'53$D#_,F"I'](:QX(6P3=*S HP"@>Q!*"G-$
M"MILC2 &B=L@,['["UI]PSC&9 A>W(B8XDP^LC&:Q7:R"AL@2"'2D S#GL<^
M@_":B(0 0I>^&DA(]YH?"/2-1A7X,TUQ\J-?WW+NF E'K&@/_1S@\:TR[_N:
MY".N)/:'Y<'SOB:_+<==;JRN-2(&!01)-N)$_(!J;5L;HN8C=-!CX?<H0.C^
M@M:J?ZJY-+IR^5(L(Y[B:$9B\#^*^8>SA:_;7;L$!2^,5MI=)"+9U4Z?QYQS
M7)O1N9%U# IX?G26Y"./C)K]#;^\'"!2D+(Q/H!Y!R,SL?L+6G%QS/_4R69T
MZN3)6$;\[A,G1HOWWQ_]D7RDT" B[LUC(2U?_*SMG=[RII^^[\.*;Z>^YY9;
M,Q@P>&#PP."!P0//A =^"2&?1]WZ[[IG0O(@8_# X('! X,'WN\>8$G5;1>O
M;KYJ@<BGA]9BQSH?G'RPB(>+>@BP1S!$C().&Q:>RZ(1/ 5L08"@2X[[#)>E
MLLA4^VQ$._A][BU8@#".;,66T,@SH7+!J29++G, 0JB+W@!]. O1$46%$$"S
M_N1\5E2\)?5,["R]W03*.'2%93(W6S42"^,[D=KBLDH*\_"9-GB,;<*6*DG
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ML'HFW1.:SKZ>C)CMA#A&MM)!4<:W]E<A$^9KTTW&K_5>WN+MZ^BI--?BW^*
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MTFKPTHEC7HK\.?8%&5S+]@+'@PS.=#M3*-T[9HHUK1VM!UH/M!YH/=!ZH/5
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M<J*^P/E(9V*R%.1CNC!U(R)UM=&"=G#KM.(1PP/S6 0'IG4&"7LS8I#P-\(
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M;OCML']#O"/I\2C[+S@>Z0Y3\;VS[$?9_O)AR#Z6OMZ7O2>7)Q;^(%A]#KX
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M]>KZ+,KKHK7JK%D3X\1YIZIL4^L,^N0XCCK=CQ'+@]]1'_PP!MQ#WP_#)8)
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MWH^]/TO^TGOONX<[4\@G<MN\7Q?RA_&M\%_"_DP+'GT9]C[[7[#@T##\'5B
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MB=6IQ(LHGNA86[9T.)_U]9;S5.+ERY>'O/56QQ,R&RR/_=UGG17;<Z(Q?5S
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M#V?WW^G\N[!_R''[*%B@0N#F:OA(Z>(L^(!;&<!GCQ_ F^!%N>^1V)2>+/,
M>7,T_#-YQ(/O;<Y-Y;=Q:L_X@RF5.Z<T3&?WE"X'W7T(+9^"'P3_(_P\V-]>
M_?BG\/&DGT.YSS O/X@1/N"]&?XO6)^=!1\IW9;ORL'&WIT;IOL#ZL%DIM:?
M2L74[['G^2K88[NUL7^//C[/_3%\,/(YZ7]@QQ38FX[\OOYA;O!9;#HJMI3C
MGJY/6]=ZX$[I@28H^+'/?:=ZV_O_FX L 4%O-[Y&YS=+]Z+N\ _3:,!")3/Q
MTQYY$B_OO5%]V8]V5I=OF/B;FE-S'_^0!*H9Q;=EQX'JP6<N[O*2A0-E."(0
M9W?+I6#[4)X2;-VA(@;+5&7[77GMQ%>\&3'87%_0?DU2YI\OO+)ZS=LNN46$
MX$\]ZJ18M[#9?R:4O3$64/#[/[CRL@]\^O-?9THK6-D8B6R='LSR=L1/"<'5
MHP!T);''A/&UZP/2(4WY]=?$7^7\RUQ'P%Z:QHLN :L)24XY.!_(A/*"?S&-
M.+>G ;SDC,K+X""F- :WIPI87]!(0:/SQ/RB1YI&+#C(-&*C$2-:+H&0,30=
M$Q*'#!F*.=[&Y=VU,8&93*078 S[ ^!IM ?8@NA8FD:<6\I1X@[1.+]&NEK
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MW[GL\BO>^ZG/?G,>(4U,OZ6EI^H'<.L#."!,SZM@/% \+@3!$#I8YY8/0#/
MP3*-&'E.P,0Y(#00[,]N@8YUY;EKASQVT)[D4]2@\HF\Z8XQ?@8'K2P 7E<_
M:".@('F4\S1BRBQGB'4*H\&(P4A\@G[EK0V0*&8*VTGYW@#5W*%O5[_[#!_V
M*>WZA@P9D7;F;K8=HAUPT>,$NN-4HS\U&*(7]FE)JIO0G_RH09/U]Q*"FH#$
M:AQYP4 B^L0QT4>T7QR58H*& IY\,1J4UQB,.@UTK4$S%+L%2;)>L)'HPA@W
MOLE$"9J-.(V"+DP5!*Q<YI.(P7J$.MJ='AS@((,D/Q@E*%I'.&$2[LLX7TP[
M!G5D(C%(WPCH(+&'=40+TEWYD0 %"0\$]?.8(N**L4PN @'P)8KU"%'L5OVJ
MZVZ'B0V$9F4@T7),(>9,6*Z94#Q;<)#:  O)2JRNS@'M)V*0\?2>D7[V]P%@
M'VL,0B$OC#AN1F+ 03,3W\R:@^.U&8KW=6970_7^_?NX#NDZN#?DJSG<;^H]
M5>]>*BFRQB#YB.?5KC$X9RZ9B;%+7:XM.+;3(%#3C8 79_W^7?JF;=NZ^D<!
MPA<M75*[QN#BI4OK+9OQ&^ @H0"=9<NK>M/&C9V!OA6&DM75*L1\8KK4EP(C
M!L^L=K/.X#J.9<N:-:XQZ*(TG4M=9_"""SIKUZY--EL_0\@[S[&DCS+XH8#!
MMS:4_RKEI\%^#UX,OP_^*OQAN-AY&>5"@GLGP0*$KX5]:3D4O9?&?)M(%QO[
M-\*?G2+D0VXA7Y"DQ?!?12E]-/N<T6CS2GX,_*74+2Z1)MB9J]M-ZX'6 ZT'
M[M0>\)[X>OC9\"[X;^%"_G'$>^W#X66EDNTB^!<:^Z7HO=FVEY:*O'TDVR?
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M^\$,,.L$;+@'O D6\#L4G4RCW\D-A^IT.]J\QDZ#M\+ZJ*76 ZT'6@_<*3S
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M;D&I?V?S^N;FZ\N:GQ?^2]BJ,OBJ^B_#I_8T%06))[\[&!W:(0.'#!PR<,C
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M[.<^MU/$6@X[!C>[5S1^[;77MJ^\HE')&=#6O_\B^R2/?5U^DC$<?!\R<,C
M(0.'#!PR<,C (0.'#!PR\).> ;Y,\#G[3W[QK_U//__S/_]7=Q]^L/G_WOV
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MMNY]_4B46H(&J+O]P!^ :8'3]=L4L[8I?]@>+F+K#U^8^6B?(!M6-N\<4Y[
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MAZPH<_3^(1WQ)JZV;O]+!F+(>AR+$X%UR3T? 8P$#9^H-&'N80^@4)OAQOB
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MK[/<9OW%, <CUC%M!V T'O+A,V2YWF*#9'"7;UL93YR)U3;MOF0Q7^?/V#J
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M).#TV(L@H1&GK1U?\F)C.UG"EXP_" 8>NW!Y4 =LK#%OA,R!-A\^,Z[S-Y\
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MUBL./ R9<76NK>B#"1R#;>V@O*IKO&,&TI&AT\R6PN2ZH =C0Q^"1\B4M>*
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M#X1QS&K=R$0*KU.$A0VDM[.E#[[89)/XT)LD!.:1$KT44(4'^ZD-/ :+W!A
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M=32<L^Q <Y\M@NE#%UO7M3IAAFLNN?"X[B&\#*I_IA,'?Z'2V.!:Q8?=[G6
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M<*(51)RF)_=?$0R%B0F21:=U]V#B^M/'S5YUV!CZY*C84[Q<YE=@Q[H2,9:
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MD#5L#0@??2Z&\O7FI#>2XIHC3!Z%*6JGL,]V>B#>TK$#HDI*6G\1D!J2Z7-
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MHO=KYN'2<HM>([YQ'9'#UVH3.V]WO^#X#FV2?N.S\E9W]S@"_/;\]Q _@R=
MOUZ_8[@17J)2K]2&Y^/UM"/WUI7*S^9T/D(@7SKS=?JL1)X._2W=YVSJ\A9Q
MGAS\</U>^GEM_*6Z:.'(6]Q_1Z_W[I/]W'0:_8O<9]ELK=>M>R*;?1NIN^A
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MIC,Q'@GK:=DPBK5[X6 !0RP*:H%@G2&/A3A<<$!7,89CJZJ%QYU[,M1+5"A
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M)-^JS[^C+]LE;%I?6ZOOFN3A:5GGZ$+)AW^+Z?G^13;6**!S^4P:@4*F:?J
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M,\:'E.#2)2?X1',"+)><E"Q@^%;VXV^2-/0K!XT1^]+C;_%0-_4#YNP  $
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MNO]_A%\"&/]F(;K8![/S"JM]6/.%_:P'NDBIE6\>MI(9\S+(#3!9V?. TBK
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M6A3)17PA9]#P]4+^;+MW0>6O[5H_MCJO'6JY8Z9IQ2#?+8M)[(+N=; 2@C'
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M7N0:M<OF-YJ8;N!DV)S,FKHJC=@@,EGV'Z0UGD8QZBFT<V@LZ @"Q1_-3VV
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MY]L9(O MZCTC"\E#:&)H=>6;UCJ^:]TMO?"#X3UA^;$M+8CM*VP9F9GA9X[
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M.[[^JHN"1QT6C%SU,JL],'^7 /J3;GMA\">] KO]/0-[!O8,[!G8,[!G8,_
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M?*)0D_6MQ#QCD+<2(Z+,VCX%0BD>;QVYG=C;WWW;/]=-P]!Y*S%%0;UU1*5
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MJT4]J"CHXF!.!^I68>5$;R,^WKC%B4$I2YB>4X,N&D*+JZ-0F%.$=[7JM_7
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M!Q/@ N"6C[$ ,,JXMJ!3AP'_+,?4X@*"T8_(OT#\0*  )(?P'F%Z16D"!36
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MA)3B;F,$P+V<T=B:_,8>BJ0F98U!HP)!!Y%/DI098$@= >X-9U 084!'(0P
MK#I=-_9R&K'3B:VW53 Q]4H5 H3^1Q2@G2 3D2PLY,@_IA&[QF" AB!X\PE5
MC'Y$!?90/<Y%(R@HN>8@XN@DVS#1@11"?S3RU.#-2*$0,2OQB.L/)B)BL'8*
ML7L"A*7LW4I@@F,49+(2R]XXJ=^"9:,&C[FNH/5,(QZH+9MT!(!P=I8U!OTC
M*S&OLI0B!+U-6U<-UH?J6&,09-!IQ$XG]J9),OD(F&!B\,!JRY;J 6[4+VTE
M#PE1@WOW[ G]%VW'+TPGCC9>#N\@8G!75>_")T0,!N^D'D[R9B5>0Y2NM'MN
MT/T9 FPVZ ]Y]2;8*[J?-K$C'^NO/(ME'UBY(N*:T;['PU?!*^EKJ7A(KOP$
M6V^BSR;=R.#_7U;PG6RYI*J7Y'T!S*?#VNL%\Q3XO?"CX6VP=0+:+;4>:#W0
M>N!<>& +2EX'S\#^MO@!V,\IRX^ 9V _0W\?_BEXY><^56><7L:(/P%[KW$J
M^KP+\#/U3'W?,=0)R7L>=?6#0JMUGL[]^N^7+"M[.WPS?#(2H"U4Y#Y#Q?6E
M,F^]C=L&?R/\/V"!H]^ "VGOU;#?V<?@?X:WPZ7_\RG_,7PR\J9&NU?>W-P3
M7ZB/^_GJQ?#/P8[M][> VT;XJ; V?@/\+/BOX+M+KT# 'S+?>7<%[Z+_TVCW
M/>+YD+X#?AWL,>R&_QWV7#P2MNU1\&'XGM#%"'L?X]@2M_T!VC^>[2WP/\%/
M@'?"OE_UW0&XI=8#K0?6B <*.*@Y3W_BEX15[9J#:^3DG"4S"CCH\$PK?BQ@
M1_6)VUES$'3/*8PB?'X19@JL.+YH(_)/< 10C#(O!5T(, Y1T4"GU/+@" 35
MEWP$2 21'+D'(", R,.ESY<28H[9%8P,8KIN1+FA32 R^O7Z"USF-0;1XB 1
M+0@0%_W"^C@ 43KJLMUA5AH^IA GT2(?H!KK*CJB7,BE"ATW!HSQTQ3AL,FQ
M_0\P-4 ? ,JPB1=SK6@;%2$7989U&C" 8-_QI^G,@4G:7R"1P#NR2P"F1E*/
M;$S<>@9 2H5CQKB+*6P2GSA%54 S'8O;@2&F1^<(01W*?^08:H@*+/8800@P
MB$XB"!ECB20EF(]^UQ8<ZBY'#(89<2DH2XJ3"'+,-\2$H0T9J9@!PN%FL299
MR1#)2A824#C$'&*$ V)6#Y.-P_Z(%ARN>VL,+LPO,)V8-J8?#[(V(0!@T)QW
MELJSKWR91MP0.^"XVF1];6(3,$"ZU4.L+3AGB"'481OZ>56]$8/61U9B^@(9
M-MT,$([1?HQD(YTQUA;,$8-'&1P2]/47XZ8[UC2"4%U^,QZH)YAJG-88'#PR
M6R]-L@;A[&P]-C'9)>F(<H!#7 H98%_"4MDU!@^DNZ)Z7<,:@QNKYN!MMQDY
MVQRXY99Z:M.F;OP$SLMGNCX:,=6:DS._EW41%[>&0:PO6'6V5_4\X" WU,W8
M[MWUCDLN:7;-D-"8_4MA!:'8HG9-)1[1,*Z;,TY?RH@_"?_V&1_Y[@TX2_?7
MP]^3Q;Z3[56YW+_A//7H-;W2V2M<S] _GX?W8>S^??M6"PQ* I1/AGTP\D;>
MXRD/&A1;:CW0>J#UP%GU@-^Y?PL++EP#?S_,U]YQM(,]08\?@]\#_R5\MNDQ
M=U/!Y?07N/S(W90[7]W_'L7//@WE_X;,<T\@Y_?<W\"_#GN.RG>)$65^#_T=
M_(/P[; D6.4Y-]KR7^";X'--/X/"%\+>JGT=?!U<2.#+8_IS^"]@S^W[X%.A
M"^CT!_ S3J5S[G,_ME\.?Q3^=*Y;;<.];MCZ9[G1'_)>"7L3^$2XW(/X(_>K
M8.]+7@2_ %Z-'DGE)/RVU1K[Z@1*?2:X,M=Y#^;[]A_A;X=Y'/ ^/,ZGH+H@
M_J_ J]&I'NMJLFU=ZX'6 _?  RTX> ^<=R\570D.>A@"@X)"@?;D<#XW@&M^
MCKMFGZ"A()Z1?1'U9[U?-#E2<!E2,X1/ F@S<L]B%Z!0<)!HO9 '31-@3(,[
M+FA((D'!5!;D*]%YEIV6K)U&!]:L+6BOT)^F$M.# 0>I1(<6!-#7TR_<&(DZ
MD(\TOF%7DL^@I3N%. 83CPBF.;]3G1# 6RX+X&& -M#-J<0]*N7 &>EGD]&!
MH=]OS>/THX>(O\C:$1#)(OU8!Y#4PJX)"/P65B$6@!W2_58Z&)QR*&=Q\$2.
MAZG$<,TB@D8#TB=<#2[$/E_=3AV6TN"TYWUKF5K>TTFT7[-@)5F)F4[L\HG1
MELURB"!OD&(.LT-%(S5Y;<&(&*P6N+8BPTC(*]2ABSL1(.@ 06F:L46/F3G
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MKX-],/H:^'ZP]!9X7Y32K_?>0'\9_$Y86>F3\#.C5%47Y*T;Z_\G_)?N0&^
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MLT)<AIK(WG'Z!0A#/UL;L_Y8[]"NAA=*1-FED9.\24@,VPLD+ZI2OV1'P)(
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MD+2.":N>Q[+68!G@$':NV\ Q@?H(PD]M9&7!1/7BOGRLUEQP0=PL7]#OTQL
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M$^LW+JS?L'[!J<1C(\3Z@= (AAG51^)BU^LS]JA,W^RM\P?2YCJ L:Z@77H
MH3M2K-?']Z;A<XP@V$-M;YU!ZQ *^0@(9''!D.-E$'8=OPP.6AU176X',LAA
M1)YK"RY%XA'T"Q NT:HPFHP8!+0+_<I9*\@&^L),83LISSJ!D?A#^_.:A+9
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MDN>;[H<!#X9OAGT@/1D]B$8_3?:<K-,]:.-RBDB26]CJHY9:#[0>:#UPK_!
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M9;1D'1%>&!TV\3(HBN-_!ONBS+ F"$D1@C9+"=0+3-+^3B<&H ,E8MKU4!?
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M(?JAE.G,0T:"(I_6&@S,;I%7UQ@D53!:B$3L94EFB&2K:4:<CAQK#0HFX\\
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M682C3_A?_8QCMN*"83H&!Y2."?M-0"(^5^K,2HQ8'(<%NYN$) E$1?:IF**
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MW,THL85\4 8X.,>'!U&#.E>JFZ/'F@K0[^A1-@""-B3]0'^9!NJ)I(>JP0E
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M OS@.2/^^\$9GJ)\3*&>V@"Q GQA7P+<H-+&(L->"0^+=L2CC?K\?)> NSQ
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M"VE$6_.H84ZI=? 8/[67L=G:'1_9+$:EN\*V-'8891<]VWL&ID_=6XI6+RX
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MIJ8- 52 =$3$H T"(&A)F8@SH-&+_G(Z:K;%XY\8'PZ/3M7#@8D$*A:(33F
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M2,CZMXKIISFOGC'_^;1^B<>O*K7N^^,N==*[:7?^96+0^MU@-,6K+GBY^?>
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MD[W6<H5[>K*2F*>.7/>(L#\SC8/S_B^UZNZ__P9T$3QG(A7;#,:YT2=Q^L2
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M8M8S38]!WL]TGRT\%1NNX.&)@5<](%R?Q:?]X4Q1U EU9_B<LX]I]JG9GM+
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M7U[QC8<;=U3:9OX!(7C^+J0Z\SP>;E38;C_L6]N'Q#GR@QW>H,MGY.HYU[J
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MB*U@4_J#S_?/]I,N5MW@ =F]]]?\7*"S<2^Z C@RX>#SOE3_O/_MX*Q]MDB
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M9=.>$AR\$8AV8ZO6(3+A Y?>R#HVJ%<O!U_>OO^\OXKA97S %WS(0D]?)$:
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M/O#P<B[6Q0"HX1!@WU.G=4LN[U\AUNX!W.ZIX]B =MKR<5L;1S2PJ+8>%XD
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M[<1QC1P[ JP!7OFN^@&4 5NUE'._QC1)@/P"$4'\93,^X]3%SO&A:SU@@>N
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M/OBH[KNI[KV+[(_T\>7'J,:D_WC=[,@:/4@;9'RTDTT?W92I.S'OZ-<4,7]
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M+LQE>)GN0GRE<[^?-@/YQP^^U7IOO ?^O+[5&RZ>C<G&)=].S+7Q^=ID;GW
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MX>'03]9=#JV#N0]T>\4;%?'F10$VA!R^,[6?<!FQ@8\W-K5>?QX,_TQ- 89
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MQ$\@QOM_/\PYUU^8H O?VAB$BLE0JJ/F190QA+&DCQ%[4<REWR+'6\<)U(3
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M7]B43----:5>MBW3X&UL=JTDVL:([*:1\Y.,G;Z,@M=LD'>. []SA#%XSA5
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M@K_XQ8&FH%2'O];C)RPTN&/PHX_^ZO3!3W_J_?LZ$IC^6/D46O@=..R-P>_
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M*]#-076T7OWA&P_^L?H@K_%6TN/I^5&?.ZB.QU6:9$I2'0/U/-+\RS:9\\>
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M^7.]<$T;'2B/ &'9%Q0,3-"(08FJQ!)88-AWQWVC!L^ZKJ#]I!&/$"=HU&
MA*=.$2\8,8/-!K:2+54B)I>8&L6C/:,&66,09- T8M.)[PNN)HJ/B D&;6>[
M?7OS:#?Q%K"SDSHD1 T>.G@P[-^P&[^03LQ(-%.)]^]O>OOQ"1&#07L9@=+Y
MFWV]CII_Q;55#U0/5 ]4#U0/5 ]4#U0/5 ]4#UQ;#_B0$$2QSW7UP'!MW5*M
M5P_\P_5 %QQ\_!8C!YN-_91*ZM\X&%4&"=(V_NXC ([!(>0&'U%-1@S2*0&.
M (JQ[QJ# 'D!YB%B.C%+$?8;,WD#D$I*B!9,$8,D" ,J E81LB0 :&1AM@2(
MZ.</FOF7I,L,4K2>0-^ 7]Y88Y#47=2)]R%K.C'X7ZPOF-4ZD*,%F0,:(P(0
M0Y'"BYT 2?2#0*$1A*D)J)5FL&.)&$S\*44X(AC#'[B 2@XIU5D5(<V+6W6S
M$Y0B\0347 ^PZW] /8#"%C>%B$ B:!O5)3C/ -P"KC/J#_)]BO<JJ0?*0S@7
M'L&$@&8""-VFM08%^Z"5G"H<(&^418[SSQ&$V*3*"/9*NC&H7ZPM:+3?$A&#
M1@JN-$N<_A)36\(2:Q8"'F;M7"*QAF$&""E6TJ,:<2HPHH:4!TPJL;YB0CC%
M-0LG(EJ0KEACL"4*<&EQB?4"QR/M&#=P##-DU!]:(H78J$$C!HTPC!1A4H?U
M=5RK (:&%B+2ZP,$*B=9E=A48FUYF(N/-%8E[KG&(-=X/P#"7@\HL%D@G5B=
M340,GHU(0:L2CYQI>@8-]J?;=E:$D'1B0<9^RQJ#S5QK.G%4(V8KD&FT8(H8
M?  P\ ' 0"L3GP D]/W>U!P[QM&QIK>Q=8W!ICT^<G_,SW1B?-M&L.#AP\W=
M]Z14X@EKXQQB?LL[D=_5- <"-^TM @Y&YC/IQ'N<%B\$'1HU&$0/_+P("JZS
MJ$'_VFNK'J@>J!ZH'J@>J!ZH'J@>J!ZH'E@?'J!28@4&U\=;46=1/7#E'NB"
M@ZPY^(*I?G_3XE**["J%-; B$!&@0;$H/!<0G:@8,()$!WQT, !0!XI"9)\1
M?4;H ?0I&Z"8.X;PA0)0C!PQ:"1>&DH 7,A'Y)U 8Y)W7.VLY<<V@7P"D1+"
M I+T,H:A7EY;,*TOF.2=5TP"^RO.@<.(%F0.2(7]DKZ;P4 !P0 *C2!<U9"W
M1SEML)ODL_TXQB=&6 H.=F4%".,L50#0)_#G_,."2!J:48]>QU+AD"1O_)W3
M!J0C*]>H/'M2;Y9?\UX5KT?\8V:T" FVVAYK#I;(/]3$_ 7_M"&H5R@B!.VD
MJ0+$#[:TMF!$^QDQ*% )8#<*H%>B!D,@OT2 7[:/!:R,I[4%&5<'BPQF^T-?
M32 D&2 X;"G-6% 15_4B6A  <$3 CQ: 8(0 #B7*WJ2((/]A!V-LVD6 0%DE
M@4+YF-JJ]\K(0E.)&U*)2^NSKN#D-/YSK<&(&,1^7A-PBF(C,P""LZ80#^AT
MB*:X0'K;N;9/(9+35"(N$8.GLOQ*NP'[1@UN*N;2=LOP<//6K<"$6]NQ(\S9
MB$%>QD<.Q_P7=R3_[=K5-%*S&UK5;FKV>[Q_OVG$340,[MNG;,C'B^/KJ/EG
M^D@V@R\_ 5J/Y_Y(GG?573U0/5 ]\/'H ;\S/A'J?&U^/)[F53TG[]%N@/)M
MVE757955#U0/5 ]4#U0/5 _\ _# 6G!PI@$<)!K,&RO P54@23F=% DH]@>@
M!6B7(@8!WPP+I $&QA;A7)'8M0(91VDL^V>98-?U Y"S  AA=T8+FJ9KA%\"
M]^#E01T5SD1]@GMIW^(C1@D*"*K7?77(%N!?7ENP1!$&!D@:L4B>48,:T:Z@
M9,PC1PPFL"Y N9B_:PNZQF THR)M&1 <Q:YX'C,BZ-&YI7'GEE"_X X9@4"C
M %6E#;=&,@K\,2?[1:-:@O;BKJR DT81RCM0:$2G<CDMUR%% DM4'N7\Y^UP
M_49]I0\'$8)1? 29! C&*$=Y34$.8ZX]P,:RMF":$RG!\L)GX1$6'O37(?XG
MJX'9N<:@58DI%;Q""C!19Z$KZ11H-H90%0*9 (H R5VLSXC!%"%HR& 4)FD%
M!+6/2N0721].Z<$"?U%\I*N L3[]HGNF$&,][%O1F&HC%!3Q!-#2(W*0,4%
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MQ*83ARSK#+*-P+WEM#[@&&L-VN?OQ5CI13RFRC)PR0T\8)7RKF280$$C_ZQ
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M<,[E$YC4CT#OA'P/_@1Z)G2A-L/ #T+OALY!AR%]IN^ZK<SEF^A\%O3_00]
M^N=G(:\UO_=_#CH(J<OWX7.@M>U)=/B=^1%(/J^1ET+J*.TQ["C_Y-SQ%VS?
MDO=_F*UC7A/_&_+[^M>A+= /0(ZM?9^_G+X_@NZ&!)\/09[#VO.DJ[;J@>J!
MZH'J@>J!2_=  0=!_38\\5'S+YQDS4%!P0#@6'.0FX:(=A,4M)5UUM)1ZC*%
M&'G3D"5Q1!K(()&&_$_K#@8HA[Q8W\I0&@@1P"I5-09NX5Y%X60L"HT$0&A/
MZN,5H,[F[8Q'5"GN5"6VX$@4'4DLV!=@Y)$XVV>+#33XE&PCRLXHP4*Y+S8(
MBJ2Q"0E>$U#:F7Z 4 R 7Z*#<Q/\BW'T"P;JOS U-.G]F)A<NL,%1&1J8=^(
MO\@$%K,,(6Z!^0_*1D0>H!Q"@FYVDF8<>NQ+OE I &:*+8PY+P,.RLF_7EIK
M$%[\+>>*T8@TTX<+Q:1((PY ST&CT"#7%K20B#<Z""7Y'/G'.H%R#EKRF8#B
M6+.$>*PM2)$1^V6*U&#N9(P<](;&4L06'\F[#;BAV*&5A%/8U&+BQ7C8IS?L
M6WA$AHGN'3J#R7ZR92KQ0E+3F\A 8,^(P7,L0DB58H96-=<:% R,5&)'SI[U
M?[, *-@&(#@= *-#Y\Z<"?D9RA)WJQ+WV]DVI1)[@P>T<NH4V<6G A143M#1
MK85'XJ?[-56)-Y)&+,ES].A1'C*.-L>.'NU%Q"!/&4<X?V\&#U-X1)[K=^YL
M=NUB1Z(M[B:*$DI'S.'FM \D&* @V][M99 M 9&AI]-U37?]J[[2]DP4;,Y*
MWL_VMR^@T!OPYT'?"?T2Y/':]O6=CM>S_]K.L0^?CT3S >%"-'N)!OFS"3#T
MS]CZY_5LZ)50^7-Y'?O=YH.2S8<C'SQ+.UAVV!8>N_R,>S7T^+QE4UOU0/5
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MWH7>+%&#$E=DSZK$MA/<MFZ,1QS>XC7S/^$UNR78FK&1D=[FK5M;:0SY01G
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MH'J@>N!J>D!P\#?^X)V]K_BBIVV\;F;\J0=/+_P)B$LSP9IG@(+>'W5;Z_J
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M (3TMZT6(Y*0C8 ?MYB*$#%H*]6)<]1@R-LKD&CBL#KEM*"($8,RJ",E)SL
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M]006E8\B)72TW**JUSG9;RHRU48(/&1M0M867##$D#;!-NSSJOFRGJ#1@CP
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M09A:@"N\$&5'1T3F"<X!_\&2@<)(YR4*#_PK10PR&A\X)5J+#R!D0H%;R!:
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MVH6"C_1&U)[ 88"'O!@QB)U2H3CD2J29!N@(^X)Z3(E#X!XC]B#7&(R(0;J
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M#2\\N1'IE_;R/,(9N(1B*/RC,PJ,+ $4RD<X8)@?)>Q/A8*!-M89--0N= P
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M*;YT1^3<0!PVP4$:$78!"J(ZHO14DEJLE2>0@93R@HD#!8%AH%F $6OTJR"
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MQ)-YC<%@YF6&LPP@$%"0_^"%9T@1AIT48M.(1X@3#%#1BB.G3C7SLPD([&=
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MQ RV_>FV)4"0*_XT(.,LH&!:8]!TXI4YUB \=:HW/3O7?R#6&C1BD$LASEZ
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M14ONUT=K6 *P@VWU6U;@+@>RGT)51T]1G;>KKM_5-@9'HG/^K5$=P^BJ/I&
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MQ*XQ:%5BN?%LR/==;)">J78Z[*ZUWV]FH]^JQ(*"KI!WTN(CO5,A/]_.MWU
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MA]?6%[1S]=>@>?V%\R66T2<E0*F[$@LF#F>I+5 QZHS\@W=:T8(%#OH)6J2
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M?'/*;ZGB'&_C>*!?7T6@H";-/\G=Q/$\>F#TP.B!T0.C!T8/C!X8/3!Z8/3
MD^<!!QK^+G=<N=A G"=/^ZCIBGK@>W[H/PX_?/M_&ZY=VK1KW_;-+Q!4$.GR
M)AL=9>28H!67A2P9#2;U 6:S)D!AP$);,OBD1< O>".CP7B,HP%$&O 6 ([J
MR# @I<3"C+X@9I2XD0G72M2*DIR&R@G Q=,8U9QMDE8:(/@%<$3XEEQ1HV"@
M ?*:P;GR86I-E!$QC*2U2&/1SZDP!>5@JOSHAYR)J_Z:D4ME&M-*/PFH%>@D
M'UD@(MHB&,UD_"A9$Z"P;Z!14ZEI21?J7X! !>2C%SYL;/S5SJ%[P9^";+U*
M%M +U*4;W4[.M0$([;0IOFH.L&%G%TUHU",#E6B*CRJ;-M:GCT;[9:OA7EGG
MU*FJI>AWB3]?).Q[2KV E,C; K-H*6W(E?B<]UD[['.3T?270+Q$_1K85XVL
MZ]:7;41B1@9R,)-_7/M/H!(!L9$&Z3^5F(/R(K! -NK0+,/U9I&8BLM<9&?]
MAA_#8ELSGP9Q3)>=:^[0>6WHHVL@]C8!]=)_$3NI^;;T:P-/#!]/,<I$!H*B
MM0A!=U@)OZ"@ZPMB!S=?WY8'R1"1"B#+IB:95+Q13HBSJJB2AW[S+F!]00DO
MQ#;?#QUX% !T#4*;PIQ(0;-3EQX%B5MA9V+7%Y3\P%A'9PA>7,DT8J,8B6R<
M;,)V=A4V0)!$Q""1M5YGG4%XW8B$ $*GOAI(2/$97PB4328=^'.;XN)'O[[E
MVCHW')'0'OV<X/&CLN0'@LU'!/[\Q_1@-M$RR6_.>J<;J^L,$8,"@J=/G;(C
M\ ,HDI>&9>(&#1WT3(I^S@*$KB\H=?T;AN.3DR>.9QKQ!L[N2 S^1W+_X<H)
M%N[8(2AX=+)MNH.-2'9,%Q["G"/<F\F1B;0*"OC0Y$$V'WE@,NP:^,]A-Y&"
MI)75W9BW9W!G8M<7E'!Q^G_XT# Y?.A0IA&_[ZZ[)LMWW)'R;#[2VB BS^:!
M2*N#[[JYRZ<\2W_&-'I@],#H@=$#HP=&#XP>&#TP>F#TP%/D@3XX<'3M;W.
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M^5@%[PQ0:-E,/UD,X!( #_T%!JX)(&R0*;^M>8"X@OP$Z00, QQ&G)5)L8_
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M+^@9;^!K?10QGKE*:SE,=CVPH<Q&#Q9 %S$6"4X*))VO/]9:&>!O3:(RE-J
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M)?4_[<J/): U19B),M2%CZNP5/"?/@M8&:!NOANE?PY*:E%XI2]2T[U^K8J
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M>+GGW7,,ZT$[!R Z[$+DP&,^O6[NXL=;W@B"7VSY1<ZO:?FK^?3\.>/T[Y^
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M-4B3QE_3B\_S GUPXQ'DL!@<OA3QE!^+DA? PP!ML#N%S]D$X&>M^Z)Q8(G
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MQYX^/&/0.P8E4KE/Z6<GGR;NB8WU3"XH><:@/MH!F \[!T$<]1(2YUUQ](Y
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MCIW],I:B5*+;_OXV$_VT@7=ZB8YKIGBCOGR< 5CGE,6]N'/-L=@UFO9BV2:
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M?Y_SQ%E@\S6NX,B,U\'K<U>'\C_A,YYD?)#T>1\&M8!3_]%7SHR&O-'S^NH
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M]SCH(#LO/A\2)1]B%Y&CK+R8T?C@'/+@PT^MWRCE, MP7&@\55]A9D!(H8/
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MQW2L$[']E'Z>"VMT@+?<6)3X.HZ((H,(V\]N'6.O"<O*I=>A6"Q)?Q7/T/=
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MG3\C<E[ YCI;U@/&]ARG_[&6#+)^6>3TE1WQZ$,+![R9-SZY1CYS 62<I2:
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M3,'4AZ?#)"#&6WPP7E0%'!P\A?>YG5Q0#"=$)COGR"8ZY&?@PVVQ@([ %'W
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MV"1IB.V8*+[B<HZ'/*[,*UGG]A(<^[$6)G:?7L[P!W9PRQ\-6>=7PSBS9CD
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MV+:I5=OSC!J6+!;#.1[GW'A;E<?8):?_G[)W ?I_.ZOZ?LDY(>?DY)X0 DE
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MSKZ (ISW-?R>1WQ8X\<;&H2&?7EYA!L7)E0#_#R.IV@E'25!J@]G=-&OB-/
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MU^&DI[M6>Q/^&)B>42OW;!:J$[P-Q /^V6Y)[^&>_/8VO@R9XT9@^1\=XT;
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M[K7>_XZ7'85P#J:6KA?Z\,5Q/#JN[N<_!6 #9VX=+;T?HC>]?P%21RR1X$7
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M@ZF_]H+Y'+6_^>AN#?=CMD=T(5Q?.[S'_T;Q/*SS4=2-JX/BF/-<N'_&<>%
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M_%SXXZO&1+OTQV[1XM1QUA\+\QX]FQ9KUNZE8L&[6V5Z]K<?:Y5A4EI.C32
MH^]Z F(9/<9>Y[[%!U&\<$73.^G._9F9G/TEG;S > ]/1.CCXRX?F*7O\.%T
MA#.[2WU)6SM@=*)'S;BB:ZV)PEI?=.(@_.FOA% (/[4Y0NJM0H NW^(= +CM
MR3%1_%S?K:N]/<>"><:YY/;B+KG^G?[;)^(F7/G*]?Y->N?M8\Z#U\6'PV:$
MM6X?8NE:W_T4% &SYGQ$VFO2R4X]DAI31;BL?9V-NT+<O@+PO9";<\:GZT0R
M7O%,4; 1L%#J/1W?1:S@LRY^Z^]YG<GG3%%[S5(5P>:9(]1>UL>5WPX8*?#T
MS MB:8!;TG,DE)Z!IP90C=;U7J3F4M.(] HM^Q^?_A$#2^@2%C59^[XYE#MX
MCW_J2*\>:BS\\3:;E,T]69ZDG1\12GV@/H=]P!^OS%Z>_.3,G/[4WZAIRK-@
M'<&1G>/O&3"Y%' <8+QXE?3D2VR_W4OH#)'B_\Y:7)>?_!:GSK5_FS]>5R^0
MC[[Y+CBQ61NJ _KN3R\Y 9YS?/'U07Y%E)X&) [?L:E%EJ9I$(Y.&1,D6=T<
MU!' KF5ZF*Z_^H0/%QOA\37U\8V7UI\-AW9LG\/E$T_1[75,Q]:<R:*Q&(VL
M>Z7/#-N. :_;_\[XX$=\!IFS<J+Q[Q[C'[8^1VK-RR02YN%/RP@XZEI.HSOG
M/F=$[ ':G"],7:=_ $;7S]>%/SDX%[Y%;,7RP[=!X^8\4_],*Q.>@O27XLF?
M_2<Y.&=3'_VT[SQ+^5(*;?H4#W':_DQ-VD)1J65&5VM]="9GHQ'0,C7MV;;C
MI<]?>9<Y#X 5'+?!$<2KEJE/S#O/6,N.*QWJGH4=F.>5!)P??_9LT<&1#<!*
M@EG-OEVD_'@A7T]. R<0HOO@$!>#D6]_]XSC. "877'L777J.R^M\_E#F__]
MZ$ K_$8TXY6M[9W\L7;\![BM F8Q(U\_"C8^YUP^P"F6=/0)7;TH+\#6AV,0
M]IQSP(!P[1N,$61WW_J<^?SBM 6-NZ><NPD7H_YY_ACB?S\Z5KYE)U6$\_C0
M!S%[Q_,,VS=8,2>9=D]6D%AU3+^W?VV69=8Y6LG=2@GSIS^N)8R,A)?ZF%WU
MV"3KN6>)LEBJQ3D9JW^*F:7XNN_V%+:/K,OJ3SV=I:2W^FL=EY"3@LGC,[AD
MO5D^KOP^#R#MP%IV:DDN8(YS>'WZ( <_"L%JHT78@S6@]410OGW(CP\#T!B!
MGFE[T<JTS7-O72>YT"=OL7A:[5G\548+/CE4"%,^,842[DG@/4U]IP?9?,RL
MOOL<BBU]2MJ/9O@SFA]C-H"_J(?0OJ'I'"0-,/4'/UI@J!6%:!DI?/B7__X#
M+>Q(VB/:B(<5+]9T8FK.VI. ^&"D;#0W'_WTT3Y+&IY]F3X8TV&C&\W-UT_&
M.D.R"U4UG.HCFA119S*;T'W)25GA'OZ!83F'_,;7O>/VG^OUIOD=?'U3\!?T
MX[+_X4^^5?']>P<O"AQF_#R-B\DILP[&X8/\+OUEWK^H-_5X$Y#Q"OTQCX?U
MW7I?]=JWW/ZW-^:/;[Q,;_+]5GUW(,WB33W>P.P@IK^GLL:W_?*CMV_6&W0_
MHS_L\8'1!/-+>D/QU:]YBW]$VKV;^C,M/@OPOZ;O!'SU3[SE]KWZ3L"WSW</
MDGN/_K#(_ZSOKOS#/_KP[5%^KZ"/X0;<?E"_$_"K_]%;;C^@-SOY'8'_6+^K
M\*^_X;';G](;JF/%;R"BPVBO_F_A^?V('?QX,2/W3K--TK_4@==^&\A^TNSQ
M3][Z2O2,CL^FN?(#SF[*:",4GV@L73"C'I'<UA:YX(!2/R_J7T;DQ3_C_:*U
MN.OZHNU=>I)5##Z[T1O?;H#6U_HYD_%IJY>)PL?SG+32-A $.;(>!Y]]V!P]
M^<ZY+P(HWI@U(%1+%/_C-M+$^['\DYL\TZ5_THY<  .CP/3O("HV%ED!\>0Z
MWN)S@LK?K;-2)N;BF!\@KXYSUF?BE.-<?#+JP]MIH,]=G%%*S-[<,'.M@';M
ML[443Z]S_PMSSDPNT9W&N4]+GWJNF?[M^R;:B)S]MMIZ4*D-SI=[GK_C^$MK
M\R-N'V,@]W^*6G:OX3$N$?'83_D<8#!D'!]&D#Z)$/D?Q^9]9FW:5P&&RTI#
MYZ5.V'G^K&<SJ>.\V^S@A9]V)8[0?OZ+1>UN_<&G/"XRAK\+@ MV]6^%[++,
M@U_*-1_^Y-0/JZ9)):2LG_^1,ZX%VZ'T+WQPZ1\KJ]*G0]\XDHRI=XDYG+X#
M\7VJN&8TV>Z^3AW &G850/:^GQ9(O:GI\\_:P-'U^L)/EJOA([7Z-X1('77B
MA ,L ?<!(*\S7FTC[^W?/J'.3@E>ZZ#9IKX%UDF M4Z_UO/\[S@0=]1@=H>\
MUNXS!9VG?CSXOB083[,^CF4M; [5^X'YOB8 (,7M8YTK??._TTF+RB*OU?^&
MEEAXWK8IIWYQK3-\IGI+G;'%@91<L8+F_A)O;_<YYO9(TGTZ?!A/7!^N2=D6
MUUQ;"GNX_ +:BGEG7Q+M530$YT:L/CFLN(OQ]95SI4JN*3/Q,1*99-:S([CC
M/=<IPMKU)S@^<)?24^6(K]QTI+)&IE R2BP/PP=C7$FSMWVM@:5B_ #CE>=W
M8B &%!Z;K-9]<C[U\7#VM61#UKG0[K]CRO@S,YG S"B=\)2=^ X(PY.C@7F-
M59]]<R".\P9*8+C*=S4&+!=<=-%FY=-'+A@2&@O5_BNPG_]B]O/E/B]2ZG-=
M?44S!BSNYS(RKN;[M_)QCUSNS@AWTAS?$P!G 03%=3BY_?RS+W[F;J'YG GD
MV<MZZP*R>A:L@=!V(C'J-?$>Q;KLP7-E,2/]"-']4]QI8!;(\U?*E=_"B('C
M>B"M,<=:\10 E:K%LT\$XX[Z$/ G[BBBJ<?U.L E'Y]9;W[1%!Q3/0  0 !)
M1$%4%JB!!O<<VM0YZR._3XC=[/KO:WR.[=6_W-?(K>>/:CK7.+&NW2_]76?U
M%5^+4+L3T.3GW-O$4&#5^VKR". C;D<'O@L-U[BLUWT!ZI!TDQIR)M^FI;]3
MKK/P^UQ&&#]]R$%7.$B(4M#$BMB24GSHSJ2?DU=BK!#6.JS-=1G'[9LJ*1,M
M >& 7_V[5!^]0S"X";C^77YJUMBU+ZD_B)P1*;WJ+SD%\EDQS5:R3P>;Y\QZ
M^;X.&C+AC/!8CU.OHC\XL&.4I24U>R@>7@/LP:1 YUT?S>2,-+_NF>=^6@[E
MJ*_^BQIZ-+9[BD9GZROTQO<]^=27_^B;;[\Z?_6WA%J@3@@JC1D2GOGBT&+6
M++#2+X3-5W0X,:^-A- 4=:U9ODCOMKU2;]*]Y7'^PN_^^5UCYPY7B\-XN/ZL
M';1J XY<^;G9Q![4FWO\M>!'GGS*;PPN022FD-L[_E^@W_7W"N'?H%Z]CW?=
MII2A4_%!?;<AFKS)]UY]]Z-M K@^H3X_L91* ??O..>K].8D_X^CW^#-49=+
MC]G@_WGZXR(?K4.\^?T?NCVF-P^M8D_YKLL?^<)7V=7//_;$[8_]^,->@V$\
MI+-\U^_ZZ-L+](=3>'C^U1]ZDWJ@GM=G++D-U_N:>^R^3 /PDH-(N/RY%\ZY
M8G+L?>;&.$NZI)Z#60DOD%X)Y7:I#5Y>G+P*W*UO@:.FG\FIO^E73[8@%QS-
M?@X?^'7,+M.;.F9FY,P"&BLU"=T3"U17@33:<^:++VV6#X"CQ?+I1MJ7FN2K
ME;X<GEP7=.I7R[U=81]@US0]9[%VV7<\N3]7V>7#/)O<9TZ?ZB#]XYQ(V(]6
M[A^-(.8"7MK;C@UC_'_8>WWA1V?WZ?!%+;VL6@ Q\U/+-P>) 5Z\X5L?IP_4
MC!FZQ;E8/Q-R=\>T+.&C5O^'9.6U:,^L/5[K X'DIV1[JJA/*GRU_#\RAR\L
MVW\10R':)?!5:XYU^LA1%]IZ\#M<O6F!Z=7R >C.LQ;>;N:5K^QHX<NC4*?N
M_?HUS&?.:7-?YIYAWOR(13JX=,U)4XSC8JV9#*W6LM:VCT&P4E[/?\+M SOG
M8T0[B>XR[OVVKUIG ^[4M_+$XG-[<XY:J>"T2Q++\9.=YZ? Y,H29!(]$Y'4
MFJG/WYC.V8S2!7/1RCF(C,>>V?Z#,DOPGAGI>B66?U%V/CXB4,?4[WH_:V"(
M,MI3+3=P;:[\J7_2!ZDIR?;/@8265_L_GW\%)C9P38@S8L;N3U]W^WHT9<&&
M796S+SUC[HLZN.JG#[NGL!ER,,+[7N6>Y:AS_XP<]TJ@;_SP@TT_?,3#K/6G
MEA5H ?F9K#4"[:7]-[8%1)_^$=/:N%5+>WWL<U"A7J>DZ"X_G$@O 0@>K1]L
M\M9>G@13TKCAC+(3X1,9C\9JC^"*)8@Z@U37IR-[-#3/%MCFR?7,",1/E9B3
MGT4-.%H?U6H_>U_-P6M=+6 R7"_]<_V46#X^C*<J6!M=!LU!L/?5H>F?UKM\
M/7$^*4S"NUE;1MGTA,7)SSI1K05>_[M\U*</NZ=%4X610O@?BF+QNO[WS]#M
MWS0N-IH=*M?Z2BOO_N5AR7J1E+SPI3!G=GUMSF?.,0QVP$7@..?F%Y0T,)<:
MNLN8O_-P?0]==:^O9XI ^!%8YY,/QUUZWU>B04[_;"36#1T2QPAV= =RJIZU
MW%P+Y.)<]_/<_;.?_VWFRI?0X0O9(EE/RUD:UL7R:K $#A\(M$:D <&?0JQ8
M:NSG;I[#!._P#=WUM45_/_\(38S%JD_=UMPK?.QS3=WQ[TKGV@$N6\OGV+)+
MRV<"IM'S9:=KZ>0(;@,3Z3/CKV"ETZ"4$5F?B45HUZIPSX'X:%49".MZUNPS
M"%=V\F=/#[#Z43Y+?#3K6MU18&%94U0OTTUTOF>SZ $!VG%Z#;^9.<<6UFK^
M_3AC]B*.Z]M -ZNW5LR!M%3/#"9:XZDU1UI9%JL#A?IX\8%"\YQU/:<D&(KU
MK/<^_Q(:K8![C;]^G?MXU-9@?5@>OE-/>W'M0Z ><U^>KOX4LNOI4VO&K&K.
M,V>H+C9%'V(-V/JKQ+@"9R-LXLC1-*0Y)>;[-"VT"/"/&W;&QTC_ZMC%R)B"
M_4Y]-]PC3^X?VZW3UK=!@N?WB>)5L6!\THF TU(A<JXY3TVMO4_O@_V"?IQY
M-SM:+C$JGD;V4?W%X<?X(R+L$1E],);6GC<,?V'^PG ?N"1!86,_?*Z#-<7A
M^]M_5S]NMU_7&X(IG;Y:SV N-_W(\7VW_^7S7N[U>_7&X%>]]JVWU^D[+9\I
MQ7_]H_/[#4GR^PO#T$;Z+]%?3_X//N$%?E.0_(^^\W'_16AC!KAJ*=_[FG^:
MXA?>./?*&/<E N?5 ,.?+JJ8/GV+S ]Z(PFF"SD$SF9?X>$CXB^8T8D&= 7H
MJU[$Z&8'*U(\(_O;?Q7(IRL==-#Z3'VMCA\YH@.',J(S\FP:G8B62V$]RXE8
M?W@]2^OWQPL.:<%3!_:N..L<C,,EX!+JP:HYA32E1E4R+[UEX$[_!$ *G/NG
M>N:,I_);GFKG\U][5A!H??M[1(!K<%_Z_+<8488K>^4#.#0>'(V#UG=F*.&;
M,/Q,9Q/=?^KK8U7BC AN 1-30T&?/7ZW%F 4XN=T.%53@_\O@"&#RU2(9[CX
M.4=C><Z4<;E6J7^TCW,(%@2>X0CGY13UE+7C6J8?)J:$2PU>ZXLM\,0TZBL_
M'4,"@[PT!L0N7]<$Y'.>(2 QIG@I9V[QI^<FS-G!M51D<]3A&*J+^\?YIS_$
MK3"<77_ZM_@!^&K^\$9X7"PZ_UA4TC6\X:(AGW=N?^*DI W*2)]I[JD"W!L/
M9O=5P9F-5[A?/X82S(TPK9=BILBN54#GRK>NX_G?--^_*;KZ=^<&C'UY@&@S
M<YWG[[BW?09\M*FS&0Z(.P6UI1<'/0#B^@"57!0:.VQ8P#5'J,IY?G6Z!HZ:
M+J*X,0L@5\:&4%]'>GG+@L[)X[J9>&TQ^C('\WWM.6 *,[&>QS$R1WU))RP#
MA,\?\P/H&/&!:?*PAH(YOT+8T =?)T&W6K;Y^JF:YEFV?V-58!*Z:EI'UF+]
M^'K,NQ8X'Y^9S3E&'[W4&(3B.17@Z9]K^@!MV<7 .N.J+>JL=V$+BX_Q&L&$
MAO:$H$SDH.?Y \9]I58/7FSXPKFFE>[P@R3M_PX @EXF73FG3NW 1+.)KPLV
M)%"1R6KUP.EVD"<+_[WOX5X41#?7MMFD#W7G>TR)\5/EI6&^TG,FX@,-I \
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M6<,0JO/5K8AE*Z(^[\Q7!JS86/K%XQ@%9)B?_="O@=VMM?) 1.22AB/E7(^
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M/./7R4.W';W32?/O*4UV)KO?6',BY!FHK-@YS872W6C014WQ25X$8<5Y963
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MTE.F@1/<R<A@+]5!UI'BP+DW^1OQLU)C!FI2S=L?FM8TDIC 6_$(7F'TQB?
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MH.S]4VZJ>%^#RS>EO76>8'_UR] \+_8Z?<K=#:TY\]O=!5O-W6QMN?7<[:H
M]0@];:]^T6C[TD>U[_<\NY=D>?;]/"H7,)>B\0%5_0D7AIH8!UCW]ZICO(FZ
MY=Y-9-)S-F7?^&N"9[.]W[ZF]S.D/SFROQ_K<P["^T'PQ6ASA07;KZ^4M[U4
M3]NK7S3:*MT7B*?W.0'Z<T2B/0)("V4@WZWV"U3? 6$N<P3F",P1F"/PHH_
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MJN+'GV:P1\&NGU4E*0X?+87O:)+Q5:['K@^3T%M4B0GGW]M5.3=>H]J7K]$
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MV8CRM%G](SJ?U"4K\K4M];]1.TAI)^VE3]WSI47>2^)-Z+/1JW/FU[%5&^]
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MRG)K?5'.<&+^G,I92\?/JL3W$1R[!E(P10Q6]?H-&QBNG02H(04WUI>P>_/
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M%$V\4:L2=R[:M$F+IG X$)*75_5FTENW;NULWDPJYRLA64ZDH/SANV Q D;
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MQ>K)5:M7,Z?@BJG1\1730\-#FE-P9HA%&=2.)L?+(H8KL3<E1^0>9)UJ!*O
M%B,M',(F_5=5-4&UE$\B+3XB9BN1<=& *HI-8TZ]9*^,S#91(<]3F!JE/5FS
MB6[5?^SQJ;D&&_M,GD'&$4E&?F]/ET ][)(%QMEM*D16GN\P1^A%L_E#<PV6
MR#U8O<B%XV,A#PS933GR*_6C)8O;TNDD>T7 ::X_E2MR+GE"S=Q +%P2_:<&
M"J[8X;_\A5QC\0]2,<<@""H/$D@K_C;-A!D9_(<Z;36EN05G-*]@=)_:B+_[
M:,5A)%8U8>$1I3'3.0]1I)OF&:PA$#OT3W[,,:AM1*--I_D!^_H4ZJ;_4YHQ
MLE/HT_";EA0M)U_#_4P*:O)!K4"<>LKV,>%?6I58+&'PA")1(06U^(@BY#3'
M8-/_[/R"NO(4$:=) ^F'*0@'Q-;I/RW5@_5DA]6)@[1+I*"6)YX\/!']#U!?
MOJEN6958::2&4(L5BK4ZL<A!Z$8J#M=:FU@+D:@2"XY$_UI]!%&]F&&P.ZIF
M$RD8BX^H_]&(-HV^]G?VA?T8<PTF'GIO+$1R_YXHIJE,"K86'PE2<%TZKOZ=
M:7[!G>NA!EEXY([H/JU*7%4;JTL@!86)2$$M/K*5Q4<VD][%1\5,@UNT0:Z^
M&@"NZL2$F2EG>7P&.,O#%7MA!(R $3 "1L (& $C8 0>= CH>5Q:(@9'7O7+
MKWOTS[[\97_9I[=[7BS2:TG:J&)YC5'A<67!RD=F+D7DPI&MMKQ+[X&M# YZ
M$7-LS3%8Y,X1?LS)X#7V-/6[H'NY;\V'-<>-!2N?ALQ6_Z7U,^''+,;S>INW
M6WPZWO;$S68MM&['\=H_7OGQ&BC'N^/NN^]]YP?^[!,LY3K)/()38^.K)E>M
M63TQ-CX^/;)BY=3(Z,A,W^#0S' B!8G6BR&EZK[I@D235GZ)!!33D_ULMBG:
M+]\GHA#*1O9LQ%41#,B*P%!'L'41,1AU4COTK,*FK504G^1%.ZJ(&1& [--+
MU%5>L'RRAT@3WY;RFA8BVB[9P.[D_I,?U-5Q))).I%VKS6S?'*?&PFH!#Y&#
MZG^NK[E/K7C<^!8'39N)ITM^B>Q+9&'N2^WK;LLV]1_.T!Q6_"<[1_=!TD43
M?)#96R+3<IZ&J&*YH/\B!R.<+,IU'*7-(!;#1A&"I?U>AL>JOF($1>R)'!0:
MJ5SUFN&QC<TT0UQ9L3CJI:JR2&TFDE$-J7IJ1R1?20?12(A@694X]:-2V< '
MEM6&94\DH6Q+9*%(01&)DQ.3L0A)V*BG+&I+Y&")("0 $;*0"D/*4_O)CVKB
ML%CPE!=MI@9FHP@/<=9A 0\=@FEK10SFN@</'A1)F%<ESFT>X,H=J>L1(@:U
M#C'Q@VSW01R.-RL@!RFH=4?V[H4@E-^K,E&8EB9FK>AZU9HU-0&#U<Q:VF72
M/44,KHN(P7R)8'[']NV55B7>2'IZ(_5N(8%,PI$>NI3]&ZIJW^55O1E_67BD
MNB)'#%(ECKG<,V2S',3$X'(X"_;!"!@!(V $C( 1, )&X,&*0"$&]7:J\5@C
M_^,%/_XUS_R1YU]_8-\^WIT.5U.3DPP1U%BZ_ X5FPQ7F<"=PN;5C#P:;6K%
MN,1<G>G*ZF;2=FH4&[VWI4".5'&63%%)J94:366Y^3#,C9?61+S-FH1]>>E0
MEZ4V6Z7+_IPBO*2-1$Z$7\5(!X!).3ZE0](\;*4M<K,MA?C;[)1# :"HVY M
MT6K*4T')EV&;TU._LR%=N6;TI34=Y4E\:%L2$)%Y_C1RY&^[8KP<9COR<TI]
M-@T%?FI9PLE3 VF'SZ97\K.Y:C7^JV)TJP12*I5^"WYJ-,YK;KK$D26"J(5?
M.24Z#;G%M&%QW%F7&[^B\W*-JF+C),>AW6PCO\*GW+Y(I9;,[F0KU4W)<D3L
MY:3*-"*V",O61E7MSR*3*M!(E,V%C[:;XYO%..S#(/DN;-0>WR<^>^I.;R^1
M@ ,S0T-#TR(%QU>NS*L/KY@:$3$X,@HI."A2D%GF(+-@_$1,*9W/=_)%;B95
MET(B\JG+(<XM4Y;J\-'8T*ZPX3\LEZ1U8L(^HN)2$;7BJY((QFB#@IX@S))U
MX*2V0]1N(N@B7[U$F?*I$.DT1UY*)^?3$-321#-$.(79-?9I2#&]0B3F]AJ3
MG%"C(B+#1GFIGCS%)ONBH<21GP\_U2DM4*;C%P.7)-K*=>1:[%/4U.GI+?,O
M)M(M>LLD(5U2/Q.8[.1AU]FOU$%/7YJ_,/;D(W/O]<XA_LIQR R).?!RFEW(
MOPQVJA>$8)KCCMYG_<W'$$VD=)KQKI<QQ)')1\EGDKSHB\\Z#2'6@>2V%#48
M_V4U577[^[LB$K/4\(&SA*".!Y'MK W[.5]E4)?S^J><Q7C:Q.#@D$R&( $/
M*^*.0<=U1 _*?F!XN+&G1BU"<(B%?%16^J%"0_QI"#'GJ,XCB:OAT;'&7J3C
MWNI^:$.M2LR9RWYJNS*G[V4=F>G6!)[C:]<V]N)(JQT[JO4;-H0]EU&S3;#1
M*!,ZB1B$F(PR>,78JC^*ZBVM_;CGJ6 9B+ARBQ$P D; "!@!(V $C( 1, )G
M'P&]0'1'!@>G&2[6T4JF8CA82*##,#^D<'IB6E0UL1=!*NBU+$0E4#QB>4A2
MEMY*>-&*=)@J";E1FHDZT4"N(I-4,;6I"A(%VS%R2_24FB5#;TQ!*,&LL)_:
M58$J%&(O&H%<RKFQJ^X@S(K7JAV=*[^1%B'5Y*=$'%Z3EYW!+A]V2LF/+.%]
MI NI@[NEG%JX)C(DB+<XT*A;[./0HBU9A9_R-Y&1J0?!E:7;'/>L_Z4KMM2+
MRHD(RV8ZST2/J3AJJ*F&P"4-EF&GI,J"<&F35SE?7D5A5)KU2:W*[](*.]3#
ME]0:)7-PT3[:'$CBF,1B%>_B\FBN/_E'??E,'IU -#$T-9_3R$\]%3\ .A.L
MR0%V(Q$ORODUO#D_R=6(# NN"]=TOG3%B4!LVZ@DV96C#;>HJ YTW>J<A&G@
MG[NJ.@H=$L<G1S@V70LSK<-G5R,6==US'5,CF$2UK?/&M</05$5O,5_:]/#0
M\/2HA@VO6*7AP].CH^,SK$C,-(/]!$T%*:BAN$&^\:76>=>Q2QO0Z3\<50\(
MW#)#=+M=MM3#A+QB$_9D< DQQ#;RHT*;J<6\EV*&VC+OGH;LAGUJJ]5_C&ZD
MW8CUHT[S]92_T7^.'DS]"&I$1" )+<:!#<>2F#-6J5 YXW/Q'\:-1F>TK3O:
MAJT&P::Y )-]\D]689..D1[BL$&JV^FE?9JG.$7[B8@;R$2BH%2[$1W(B&6U
M*?\XQQHBW)4K(@4UE#B717F>BU#S$M)N']N(!.ST-(3<=(>!OUK0@B;*4&*1
MA,E_]:&2&-:K13VFTS$WA."T^LN3"JHJX8'B)45P*FI0(D>(\HOC4@ZI#A=4
M7)[L%W\I8<Y 5K%6_>:[2%HBS!1M.$7K2K<(P9:]:D+SB=RC&9&"JYFDJP
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M$>AKP @\0!$HI. #U'V[;02,@!$P D; "!@!(V $C( 1, )&P @8 2-@!(R
M$3 "1L (& $C8 2,@!$P D; "!@!(V $C( 1, )&P @8 2-@!(R $3 "1L (
M& $C8 2,@!$P D; "!@!(V $C( 1, )&P @8 2-@!(R $3 "1L (& $C8 2,
M@!$P D; "!@!(V $C( 1, )&P @8 2-@!(R $3 "1L (& $C8 2,@!$P D;
M"!@!(V $C( 1, )&P @8 2-@!(R $3 "1L (& $C8 2,@!$P D; "!@!(V $
MC( 1, )&P @8 2-@!(R $3 "1L (& $C8 2,@!$P D; "!@!(V $C( 1, )&
MP @8 2-@!(R $3 "1L (& $C8 2,@!$P D; "!@!(V $C( 1, )&P @8 2-@
M!(R $3 "1L (& $C8 2,@!$P D; "!@!(V $C( 1, )&P @8 2-@!(R $3 "
M1L (& $C8 2,@!$P D; "!@!(V $C( 1, )&P @8 2-@!(R $3 "1L (& $C
M8 2,@!$P D; "!@!(V $C( 1, )&P @8 2-@!(R $3 "1L (& $C8 2,@!$P
M D; "!@!(V $C( 1, )&P @8 2-@!(R $3 "1L (& $C8 2,@!$P D; "!@!
M(V $C( 1, )&P @8 2-@!(R $3 "1L (& $C8 2,@!$P D; "!@!(V $C( 1
M, )&P @8 2-@!(R $3 "1L (& $C8 2,@!$P D; "!@!(V $C( 1, )&P @8
M 2-@!(R $3 "1L (& $C8 2,@!$P D; "!@!(V $C( 1, )&P @8 2-@!(R
M$3 "1L (& $C8 2,@!$P D; "!@!(V $C( 1, )&P @8 2-@!(R $3 "1L (
M& $C8 2,@!$P D; "!@!(V $C( 1, )&P @8 2-@!(R $3 "1L (& $C8 2,
M@!$P D; "!@!(V $C( 1, )&P @8 2-@!(R $3 "1L (& $C8 2,@!$P D;
M"!@!(V $C( 1, )&P @8 2-@!(R $3 "1L (& $C8 2,@!$P D; "!@!(V $
MC( 1, )&P @8 2-@!(R $3 "1L (& $C8 2,@!$P D; "!@!(V $C( 1, )&
MP @8 2-@!(R $3 "1L (& $C8 2,@!$P D; "!@!(V $C( 1, )&P @8 2-@
M!(R $3 "1L (& $C8 2,@!$P D; "!@!(V $C( 1, )&P @8 2-@!(R $3 "
M1L (& $C8 2,@!$P D; "!@!(V $C( 1, )&P @8 2-@!(R $3 "1L (& $C
M8 2,@!$P D; "!@!(V $C( 1, )&P @8 2-@!(R $3 "1L (& $C8 2,@!$P
M D; "!@!(V $C( 1, )&P @8 2-@!(R $3 "1L (& $C8 2,@!$P D; "!@!
M(V $C( 1, )&P @8 2-@!(R $3 "1L (& $C8 2,@!$P D; "!@!(V $C( 1
M, )&P @8 2-@!(R $3 "1L (& $C8 2,@!$P D; "!@!(V $C( 1, )&P @8
M 2-@!(R $3 "1L (& $C8 2,@!$P D; "!@!(V $C( 1, )&P @8 2-@!(R
M$3 "1L (& $C8 2,@!$P D; "!@!(V $C( 1, )&P @8 2-@!(R $3 "1L (
M& $C8 2,@!$P D; "!@!(V $C( 1, )&P @8 2-@!(R $3 "1L (& $C8 2,
M@!$P D; "!@!(V $C( 1, )&P @8 2-@!(R $3 "1L (& $C8 2,@!$P D;
M"!@!(V $C( 1, )&P @8 2-@!(R $3 "1L (& $C8 2,@!$P D; "!@!(V $
MC( 1, )&P @8 2-@!(R $3 "1L (& $C8 2,@!$P D; "!@!(V $C( 1, )&
MP @8 2-@!(R $3 "1L (& $C8 2,@!$P D; "!@!(V $C( 1, )&P @8 2-@
M!(R $3 "1L (& $C8 2,@!$P D; "!@!(V $C( 1, )&P @8 2-@!(R $3 "
M1L (& $C8 2,@!$P D; "!@!(V $C( 1, )&P @8 2-@!(R $3 "1L (& $C
M8 2,@!$P D; "!@!(V $C( 1, )&P @8 2-@!(R $3 "1L (& $C8 2,@!$P
M D; "!@!(V $C( 1, )&P @8 2-@!(R $3 "1L (& $C8 2,@!$P D; "!@!
M(V $C( 1, )&P @8 2-@!(R $3 "1L (& $C8 2,@!$P D; "!@!(V $C( 1
M, )&P @8 2-@!(R $3 "1L (& $C8 2,@!$P D; "!@!(V $C( 1, )&P @8
M 2-@!(R $3 "1L (& $C8 2,@!$P D; "!@!(V $C( 1, )&P @8 2-@!(R
M$3 "1L (& $C8 2,@!$P D; "!@!(V $C( 1, )&P @8 2-@!(R $3 "1L (
M& $C8 2,@!$P D; "!@!(V $C( 1, )&P @8 2-@!(R $3 "1L (& $C8 2,
M@!$P D; "!@!(V $C( 1, )&P @8 2-@!(R $3 "1L (& $C8 2,@!$P D;
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M.3BO, ,C9ZTB(+#H"40]1 V[7GS[O4VYO&K8N3@/:E@0" A   (0@  $LA'
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M0. P@63=)N</[U&_N73-II?KEPDM00 "$(  !"   0A   (0@  $(  !"$
M A"   0@  $(0  "$(  !"   0A   (0@  $(  !"$   A"   0@T( $_@5.
3_GDD4I8$O     !)14Y$KD)@@@$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>15
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.0.814</span><table class="report" border="0" cellspacing="2" id="idm139922633451728">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Warrants (Fair Value of Warrants is Estimated Using Black-Scholes Option Pricing Model) (Detail) - $ / shares<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2015</div></th>
<th class="th"><div>Dec. 31, 2014</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=gale_MarchTwoThousandFifteenWarrantsMember', window );">March 2015 Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_WarrantStrikePrice', window );">Strike price</a></td>
<td class="nump">$ 2.08<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_FairValueOfWarrantLiabilityAssumptionsExpectedTerm', window );">Expected term (years)</a></td>
<td class="text">4 years 5 months 19 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_WarrantsFairValueAssumptionsExpectedVolatility', window );">Volatility %</a></td>
<td class="nump">74.99%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_WarrantsFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free rate %</a></td>
<td class="nump">1.25%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=gale_SeptemberTwoThousandThirteenWarrantMember', window );">September 2013 Warrant [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_WarrantStrikePrice', window );">Strike price</a></td>
<td class="nump">$ 2.50<span></span>
</td>
<td class="nump">$ 2.50<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_FairValueOfWarrantLiabilityAssumptionsExpectedTerm', window );">Expected term (years)</a></td>
<td class="text">2 years 11 months 19 days<span></span>
</td>
<td class="text">3 years 8 months 19 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_WarrantsFairValueAssumptionsExpectedVolatility', window );">Volatility %</a></td>
<td class="nump">76.85%<span></span>
</td>
<td class="nump">75.60%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_WarrantsFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free rate %</a></td>
<td class="nump">0.91%<span></span>
</td>
<td class="nump">1.30%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=gale_DecemberTwoThousandTwelveWarrantMember', window );">December 2012 Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_WarrantStrikePrice', window );">Strike price</a></td>
<td class="nump">$ 1.83<span></span>
</td>
<td class="nump">$ 1.90<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_FairValueOfWarrantLiabilityAssumptionsExpectedTerm', window );">Expected term (years)</a></td>
<td class="text">2 years 2 months 23 days<span></span>
</td>
<td class="text">2 years 11 months 23 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_WarrantsFairValueAssumptionsExpectedVolatility', window );">Volatility %</a></td>
<td class="nump">75.45%<span></span>
</td>
<td class="nump">76.85%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_WarrantsFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free rate %</a></td>
<td class="nump">0.70%<span></span>
</td>
<td class="nump">1.09%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=gale_AprilTwoThousandElevenWarrantMember', window );">April 2011 Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_WarrantStrikePrice', window );">Strike price</a></td>
<td class="nump">$ 0.65<span></span>
</td>
<td class="nump">$ 0.65<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_FairValueOfWarrantLiabilityAssumptionsExpectedTerm', window );">Expected term (years)</a></td>
<td class="text">1 year 6 months 22 days<span></span>
</td>
<td class="text">2 years 3 months 22 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_WarrantsFairValueAssumptionsExpectedVolatility', window );">Volatility %</a></td>
<td class="nump">69.48%<span></span>
</td>
<td class="nump">78.24%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_WarrantsFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free rate %</a></td>
<td class="nump">0.50%<span></span>
</td>
<td class="nump">0.80%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=gale_MarchTwoThousandElevenWarrantMember', window );">March 2011 Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_WarrantStrikePrice', window );">Strike price</a></td>
<td class="nump">$ 0.65<span></span>
</td>
<td class="nump">$ 0.65<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_FairValueOfWarrantLiabilityAssumptionsExpectedTerm', window );">Expected term (years)</a></td>
<td class="text">5 months 5 days<span></span>
</td>
<td class="text">1 year 2 months 5 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_WarrantsFairValueAssumptionsExpectedVolatility', window );">Volatility %</a></td>
<td class="nump">72.42%<span></span>
</td>
<td class="nump">77.38%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_WarrantsFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free rate %</a></td>
<td class="nump">0.06%<span></span>
</td>
<td class="nump">0.32%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=gale_MarchTwoThousandTenWarrantMember', window );">March 2010 Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_WarrantStrikePrice', window );">Strike price</a></td>
<td class="nump">$ 2.02<span></span>
</td>
<td class="nump">$ 2.15<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_FairValueOfWarrantLiabilityAssumptionsExpectedTerm', window );">Expected term (years)</a></td>
<td class="text">5 months 27 days<span></span>
</td>
<td class="text">1 year 2 months 27 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_WarrantsFairValueAssumptionsExpectedVolatility', window );">Volatility %</a></td>
<td class="nump">68.33%<span></span>
</td>
<td class="nump">77.12%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_WarrantsFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free rate %</a></td>
<td class="nump">0.08%<span></span>
</td>
<td class="nump">0.35%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gale_FairValueOfWarrantLiabilityAssumptionsExpectedTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair Value of Warrant Liability Assumptions Expected Term</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gale_FairValueOfWarrantLiabilityAssumptionsExpectedTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gale_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gale_WarrantStrikePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Warrant Strike Price</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gale_WarrantStrikePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gale_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gale_WarrantsFairValueAssumptionsExpectedVolatility">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Warrants Fair Value Assumptions Expected Volatility</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gale_WarrantsFairValueAssumptionsExpectedVolatility</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gale_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gale_WarrantsFairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Warrants Fair Value Assumptions Risk Free Interest Rate</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gale_WarrantsFairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gale_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=gale_MarchTwoThousandFifteenWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=gale_MarchTwoThousandFifteenWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=gale_SeptemberTwoThousandThirteenWarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=gale_SeptemberTwoThousandThirteenWarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=gale_DecemberTwoThousandTwelveWarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=gale_DecemberTwoThousandTwelveWarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=gale_AprilTwoThousandElevenWarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=gale_AprilTwoThousandElevenWarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=gale_MarchTwoThousandElevenWarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=gale_MarchTwoThousandElevenWarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=gale_MarchTwoThousandTenWarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=gale_MarchTwoThousandTenWarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.0.814</span><table class="report" border="0" cellspacing="2" id="idm139922638106768">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>License Agreements (Additional Information) (Detail) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2015</div></th>
<th class="th"><div>Sep. 30, 2014</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_LicenseAndCollaborationAgreementsLineItems', window );"><strong>License And Collaboration Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireBusinessesGross', window );">Payments to Acquire Businesses, Gross</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 2,315,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=gale_MDAndersonCancerCenterMember', window );">M D Anderson Cancer Center [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_LicenseAndCollaborationAgreementsLineItems', window );"><strong>License And Collaboration Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_AnnualMaintenanceFee', window );">Annual maintenance fee</a></td>
<td class="nump">200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_FutureMilestonePayment', window );">Milestone payment for Phase 3</a></td>
<td class="nump">$ 200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gale_AnnualMaintenanceFee">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Annual Maintenance Fee</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gale_AnnualMaintenanceFee</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gale_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gale_FutureMilestonePayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Future Milestone Payment</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gale_FutureMilestonePayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gale_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gale_LicenseAndCollaborationAgreementsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>License And Collaboration Agreements [Line Items]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gale_LicenseAndCollaborationAgreementsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gale_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireBusinessesGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of business during the period. The cash portion only of the acquisition price.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Glossary Investing Activities<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6516133<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 230<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 13<br><br><br><br> -Subparagraph (b)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3213-108585<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireBusinessesGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=gale_MDAndersonCancerCenterMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=gale_MDAndersonCancerCenterMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>17
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
M4$L#!!0````(`+".:4>\#5@"[P$``"T@```3````6T-O;G1E;G1?5'EP97-=
M+GAM;,W:S4[C,!`'\%>I<ETUKC_*+HAR`:Z`M+R`-YDV5N/8LDTI;[]V"FBW
MZJ[XJO2_-$W'GIEDDM^IY_=/GN)D:_LA+JHN)7_&6&PZLCK6SM.0(TL7K$[Y
M-*R8U\U:KXB)V>R$-6Y(-*1I*CFJB_/;#85@6II<[@(E]Z+2WO>FT<FX@6V&
M=B_KU"V7IJ'6-0\V;ZE3+DW?<KR:W.F0;K3-*=BV9V-@]\GK$F=?4S#Z0+J-
M'5&R?1W34T_Q4/U=Y*7R%2WU0Y_>5?CYWM6!^G%-[(Q_+G6]S5EB_FU1Y6A\
M4X7]C?_KS-@R-#^L_MI1SC]X+7LW<6/[JZ`?S5Z!S='&5(ZUU68X-*I'%]:_
MG%M_Y6-"Y:I::J<^Y(4AF0-/25Y\EZ.1Y=2?JOWRI#0NT)L*EH5'?"DZ':C]
MF4*>[^%WX\\%Q^NCS'7\_J^AC\'(QL,1D7A7'P*D#PG2AP+I8P[2QPE(']]!
M^O@!TL<I2!]\AM((BJ@<A52.8BI'096CJ,I16.4HKG(46#F*K`)%5H$BJT"1
M5:#(*E!D%2BR"A19!8JL`D56@2*K1)%5HL@J4625*+)*%%DEBJP215:)(JM$
MD56BR*I09%4HLBH4616*K`I%5H4BJT*15:'(JE!D52BRSE%DG:/(.G^5E8W_
M$KCX#5!+`P04````"`"PCFE'2'4%[L4````K`@``"P```%]R96QS+RYR96QS
MK9++;L)`#$5_)9I]<4HE%A%AQ88=0OR`.^,\E,QXY#$B_?N.V(#"0ZW$TJ][
MCZZ\#JFL#C2B]AQ2U\=43'X,J<K]VG2JL0)(MB./:<&10IXV+!XUE])"1#M@
M2[`LRQ7(K8[9K.?:Q<[51G;NTQ1'E):T-M,(9Y;AFWE89.D\^(GT%V-NFM[2
MENW)4]`'_K,-`\]YEE<>QW8OG*\M"_V/Z'D4X$G1H>)%]2-F`Q+M*;V"^GH`
MA3&^.R6:E((C-Z."N[_8_`)02P,$%`````@`L(YI1[>K)I[H`0``V1\``!H`
M``!X;"]?<F5L<R]W;W)K8F]O:RYX;6PN<F5L<\79S6Z;0!B%X5NQN(`,W\\X
MB15GE4VV36\`V6-CQ0;$3-7F[D.]J-PD'&5AZ6Q`@/3-NT"/T/#0Y7KU(QV;
M<NB[W!Z&O/AS.G9Y-=U?5VTIPRJ$O&G3J<DW_9"ZZ>FN'T]-F2['?1B:S6NS
M3T'K>AG&RSG5X\/'V8OG[;H:G[=2+7XVXSZ5=?6['U]SFU+)X7R2FVF!Z?';
MD+ZS?+_;'3;IJ=_\.J6N?%$1_BU0A?D@G0]22I#-!QDER.>#G!(4YX,B)6@Y
M'[2D!-W.!]U2@N[F@^XH0??S0?>4(*F!C#4G"6'-T5H`U\+Q6@#8PA%;`-G"
M,5L`VL)16P#;PG%;`-S"D5L`W<*Q6P#>PM%;@=[*T5N!WDKZUD8?VQR]%>BM
M'+T5Z*T<O17HK1R]%>BM'+T5Z*T<O17HK1R]%>BM'+T-Z&T<O0WH;1R]#>AM
MI+T2M%G"T=N`WL;1VX#>QM';@-[&T=N`WL;1VX#>QM';@-[&T=N!WL[1VX'>
MSM';@=[.T=N!WD[:ZT:;W1R]'>CM'+T=Z.T<O1WH[1R]'>CM'+T=Z.T<O2/0
M.W+TCD#OR-$[`KTC1^]XH7=NFS%M7\IXZ/;YVC7_#8=%%WCG\G9,UT\Y3X4-
M%UJ7::44SL>KOS7GJ7]#PJ>_^(_O4$L#!!0````(`+".:4?##MS83@,``&@-
M```0````9&]C4')O<',O87!P+GAM;+U746_:,!#^*Q8O:Z6UH7146T4CI<"T
M2A308.VS<0ZPZMC4YR"Z7[]+`A1:DS8\K"^U+_?=^;[[?`DMC?7KH34+L$X"
MLE6B-%Z3\:8V=VYQ'00HYI!P/"<734^GQB;<T=;.`C.=2@$=(]($M`L:]?I5
M`"L'.H;X;+$-6@M;699HL5!2<">-#N^EL`;-U+'N2H!J!6\=<@1%'H%(K70O
M8;WPV37E/B/!%;0I5SCE"J'P>C7F/FV3++A^"8I=3^HG_+,8FPYWL(O:?U!$
MGW,+,27=B[XUYCZ_7JA.E6';<ZYG$._ZOG^XX>(!+&:57C3.Z_2WI6!C+V(#
MCZ6>#;FT&+:6[GH)PAF[;M/2'=NEV(BLZ?@PIO-AC4TX0K:\J2VYE5R[&D/Y
ME[:-6I&VL.9KM4!GPT=CGW`.X+`5;(WY<M=W=RV_A<U&[D&K?<]@6UFXIFVO
M[LPREDX!#J9#;MU_HB*O:4-$<\U$4>@F!.,Z9EWM2([L3A>IJ'F[E&Q7[4&_
MT^V/NAU&J]&@=]>)QK2YC7I1O]UE1V`NJV!&8_IWW^T?@6D>@;GR8FY3E!H0
M<]YN.4ID9LJ&%I#(Y,Z+^4DB8`]<I<#N@6-J(6,>O;Z1$#8%:LF*FH]0Y!FX
M.5C63JWU8GI&S\X<V(1U8.(_0@]F7-$QC0#(=(E?&<V41+K\)/[6C9P13W.C
M8KK/7UCW.26->!T?N;7\4$%YE(PI*BH;8U358845A=YI81)@)VL.3ME)WSC`
M4R^D#X[U##5D2,A\L/D)H&M#L5@TLU!"?T>B,'0;=-:#`4V^_*S$5H0(ARI,
M)PC/:7:9NLN#D4N%TZA7$0X[&?,)S9+J`FHT/MWI31(_ZYN6EWL=ZOT:54D"
M97G>:Z#<O[3+C>]'].]'.8:*GTA=9&$G'7!<J@-G.]CS=G[B:IC?0'6*ZCJY
M]`_F_4'S02&E(^?2/Y']0HSB6&;4\0J8+!4);>0?AZ_R'=&[-DX59,U<6UGT
M`6:'[E?4!YCBXPF9U.P5_@%FNVHKCBBGDMI5PH'WHD5*&;\`2C"(:5(5D_6H
M(B9_4F4(Y'>:9/?I(;!1`>T^^5;849OROQ9+A\<W_R`HQ33]P[\<<W$$9F_X
MO_MB??-]&NS_K@K_`5!+`P04````"`"PCFE'D4TKLS\!``!I`P``$0```&1O
M8U!R;W!S+V-O<F4N>&ULS9--3\,P#(;_"NJ]2[-I3$1=#X`X,0F)(1"WD'A;
M6/.AQ%/7?T^6=2T#+KMQJVN_CU_'22D<$];#D[<./"H(5WM=F\"$FV<;1,<(
M"6(#FH=1K#`QN;)><XRA7Q/'Q9:O@8R+XIIH0"XY<G(`YJXG9E4I!1,>.%K?
MX:7H\6[GZP23@D`-&@P&0D>49-6+V1K;F)(,^JJ,CFL><&&E6BF0M^U0]CL5
M.R-X'8YRD'W[]/=/#RE#LJYR'U1?U33-J)FDNC@P)6^+Q^=T-KDR`;D1$%5!
M,6P=S+-3Y]?)W?WR(:O&!9WFE.;%S9+.V'3"QK/WPV1G_@;#NAOBWSH^&4S;
M184U7+C;I)%IN>DS@20$X95#9<U%N(3Y)DZPL/OX!(&7@SIANFQ;:!OK9:C2
M_1JBP\N)*UM;WQY3/Z*S5U5]`5!+`P04````"`"PCFE'F5R<(Q`&``"<)P``
M$P```'AL+W1H96UE+W1H96UE,2YX;6SM6EMSVC@4?N^OT'AG]FT+QC:!MK03
M<VEVV[29A.U.'X416(UL>621A'^_1S80RY8-[9)-NIL\!"SI^\Y%1^?H.'GS
M[BYBZ(:(E/)X8-DOV]:[MR_>X%<R)!%!,!FGK_#`"J5,7K5::0##.'W)$Q+#
MW(*+"$MX%,O67.!;&B\CUNJTV]U6A&ELH1A'9&!]7BQH0-!445IO7R"TY1\S
M^!7+5(UEHP$35T$FN8BT\OELQ?S:WCYES^DZ'3*!;C`;6"!_SF^GY$Y:B.%4
MPL3`:F<_5FO'T=)(@(+)?90%NDGVH],5"#(-.SJ=6,YV?/;$[9^,RMIT-&T:
MX./Q>#BVR]*+<!P$X%&[GL*=]&R_I$$)M*-IT&38]MJND::JC5-/T_=]W^N;
M:)P*C5M/TVMWW=..B<:MT'@-OO%/A\.NB<:KT'3K:28G_:YKI.D6:$)&X^MZ
M$A6UY4#3(`!8<';6S-(#EEXI^G64&MD=N]U!7/!8[CF)$?[&Q036:=(9EC1&
M<IV0!0X`-\313%!\KT&VBN#"DM)<D-;/*;50&@B:R('U1X(AQ=RO_?67N\FD
M,WJ=?3K.:Y1_::L!I^V[F\^3_'/HY)^GD]=-0LYPO"P)\?LC6V&')VX[$W(Z
M'&="?,_V]I&E)3+/[_D*ZTX\9Q]6EK!=S\_DGHQR([O=]EA]]D]';B/7J<"S
M(M>41B1%G\@MNN01.+5)#3(3/PB=AIAJ4!P"I`DQEJ&&^+3&K!'@$WVWO@C(
MWXV(]ZMOFCU7H5A)VH3X$$8:XIQSYG/1;/L'I4;1]E6\W*.76!4!EQC?-*HU
M+,76>)7`\:V</!T3$LV4"P9!AI<D)A*I.7Y-2!/^*Z7:_IS30/"4+R3Z2I&/
M:;,CIW0FS>@S&L%&KQMUAVC2/'K^!?F<-0H<D1L=`F<;LT8AA&F[\!ZO)(Z:
MK<(1*T(^8ADV&G*U%H&V<:F$8%H2QM%X3M*T$?Q9K#63/F#([,V1=<[6D0X1
MDEXW0CYBSHN0$;\>ACA*FNVB<5@$_9Y>PTG!Z(++9OVX?H;5,VPLCO='U!=*
MY`\FIS_I,C0'HYI9";V$5FJ?JH<T/J@>,@H%\;D>/N5Z>`HWEL:\4*Z">P'_
MT=HWPJOX@L`Y?RY]SZ7ON?0]H=*W-R-]9\'3BUO>1FY;Q/NN,=K7-"XH8U=R
MS<C'5*^3*=@YG\#L_6@^GO'M^MDDA*^:62TC%I!+@;-!)+C\B\KP*L0)Z&1;
M)0G+5--E-XH2GD(;;NE3]4J5U^6ON2BX/%ODZ:^A=#XLS_D\7^>TS0LS0[=R
M2^JVE+ZU)CA*]+',<$X>RPP[9SR2';9WH!TU^_9==N0CI3!3ET.X&D*^`VVZ
MG=PZ.)Z8D;D*TU*0;\/YZ<5X&N(YV02Y?9A7;>?8T='[Y\%1L*/O/)8=QXCR
MHB'NH8:8S\-#AWE[7YAGE<90-!1M;*PD+$:W8+C7\2P4X&1@+:`'@Z]1`O)2
M56`Q6\8#*Y"B?$R,1>APYY=<7^/1DN/;IF6U;J\I=QEM(E(YPFF8$V>KRMYE
ML<%5'<]56_*POFH]M!5.S_Y9K<B?#!%.%@L22&.4%Z9*HO,94[[G*TG$53B_
M13.V$I<8O./FQW%.4[@2=K8/`C*YNSFI>F4Q9Z;RWRT,"2Q;B%D2XDU=[=7G
MFYRN>B)V^I=WP6#R_7#)1P_E.^=?]%U#KG[VW>/Z;I,[2$R<><41`71%`B.5
M'`86%S+D4.Z2D`83`<V4R43P`H)DIAR`F/H+O?(,N2D5SJT^.7]%+(.&3E[2
M)1(4BK`,!2$7<N/O[Y-J=XS7^BR!;814,F35%\I#B<$],W)#V%0E\Z[:)@N%
MV^)4S;L:OB9@2\-Z;ITM)__;7M0]M!<]1O.CF>`>LX=SFWJXPD6L_UC6'ODR
MWSEPVSK>`U[F$RQ#I'[!?8J*@!&K8KZZKT_Y)9P[M'OQ@2";_-;;I/;=X`Q\
MU*M:I60K$3]+!WP?D@9CC%OT-%^/%&*MIK&MQMHQ#'F`6/,,H68XWX=%FAHS
MU8NL.8T*;T'50.4_V]0-:/8--!R1!5XQF;8VH^1."CS<_N\-L,+$CN'MB[\!
M4$L#!!0````(`+".:4?6&H]Z30(``'P*```-````>&PO<W1Y;&5S+GAM;,U6
M6VO;,!3^*T(9HX41VRE-:6L;1B$PV,J@>>A;D6W9%NCBR7+F]-=/%U^20)8V
M34O]HJ-/1]_Y='3LX[!6:XH?2HP5:!GE=01+I:H;SZO3$C-43T6%N5[)A61(
MZ:DLO+J2&&6UV<2H-_/]N<<0X3`.><,63-4@%0U7$;P8(.#VWXD,1_#I[.N?
M1JC;+\"-DV^3B?]T?KN+G]F%<P@<QX\L@L'\$GHO)YWZ^MG+;%=WZ.>OI/\?
M^0[UE:'VNA3%82[XF*D9=$`<UL]@A:CV#XQ[*JB00.FKT!HLPA'#SN,.49)(
M8L`<,4+7#IX9P-Y>Y\<(%]+&=A%VXTS],9(LD@CZW?/R<,G(;@=S/$+I]O$T
M$(<54@I+OM`3T-G+=:4/QP7'3J3U.^!=2+0.9I<;&^R@XR9"9E@.D0/80W%(
M<:[T!DF*THQ*5$:Z4$HP;60$%8(C:BC['9VA:5-,Z8-Y5Q[S+>XV!\['W+$/
M@5'1FSH1G3F6@4VJM\GFN#=IC^,%;3X$T+M15='U=TH*SK`3ZZ"%Z&:'Z(,]
M]'&(>E90"DF>M;\IA%0#6$*PPE*1=!/Y*U&UQ*WJ*MAK\WT*CSWR>VHZ?=9&
M-;H$/SH]1P>WT'W#$BP7]L/X>DD75X>OS+Z=<$?FQU;-$1).D!S3VCZMM/GG
ME?8^-76*:K]^HS*O:PP;W6>K]PPH2!I"%>&]!&3^%NZ-;+K5%L:^HSFS=FPY
M=E6A1/\*;D719!G.44/5;[(2RBY&<+1_&OG!?/!:#A01'.U?.",-N[8*QO_-
M^!]02P,$%`````@`L(YI1_?P@GZ1!```'!$```\```!X;"]W;W)K8F]O:RYX
M;6R5EUUSVC@4AO^*QC>;SG07_$633.D,`;J;&4(R)9->"UN`)K)%)3E)^^OW
MV$!Y7003KK!L_%@?SSDZ^FRO7[5YGFO]S-X*5=IKTP]6SJVO.QV;K43![3]Z
M+4IZMM"FX(Z:9MG1BX7,Q$AG52%*UXFZW5['",6=U*5=R;4-MC3['II=&\%S
MNQ+"%6H#*[@L@R^?[?5"*O$DC"4PX^OUE!>B'[RI@"ENW3B73N3](*&F?A6M
M&Z9:WU12U8VTFP:=&K8;ZH-AF<[%!O:XDO;[]D'`<K'@E7*/U-G==_M!&"51
MU-LPZK\]2?%J$5C?8#QS\D4\\GD_Z`:,5TY_E<H),^)._&MTM9;EDE@!6TAC
MW:P>;O//0I:RD+_J?E/+KO3K?]K(7[IT7,TRHY5JWJH?-"_1%^SO.]1')[/6
M'QV??ZM7HA_TN@1\D5;.I9+N9S]HKI6H1]+Y8RC-].^O6-E,SFZ)&2]S-BX=
M4=AMN5D\FIJZ#_3GV[SYL+F6=&%N\W`S50@:WD]'X^EL/&)T-;N?W(X&C]2X
M&4P&T^&8`2@"4'0N*`90#*#XW:#9(_W<C:<`2@"4G`M*`90"*#T7U`-0#T"]
M0]!-964IK&U6[89;:9E>L`<C+"TE=P#Z!*!/AZ"O7!KVQ%4EV)W@MC*BEL$"
MX!(`EX>`09:92I`Z;Q3V5FQZ=.]6PK!A90R`K@!T=0B:Z'+Y-P53P49BCB,(
MNRA>U_.F6')%@]>9$#F%H/W(AKHHI&N&@N:%+8<]$L^<SIY76N64&/YBXQ\5
MA0.^C^J&'G>_<V-X>_Y"M#3T:-I\LUY$FD7J=SV-!Z&'@H8>0S<3?EMFNA#L
M8KL6']C%5#MA/R`)#0T]BD[I:J+)K`<"SE;<"'P;M0P]7DYHTZ`OL\'2B`.3
M0G0Q],@XDC:CI"C+6JC[M3";[>8C&U@KVBBT,O1H.:OF5ORHZL0V?OFS'VAB
MZ%'Q9'1%74QEZ&;D<?-(?+$+RO%*8*\B=#/RN'DRTJ((4:T,Z]'4I_FN2VA+
MA.Y&'G=WOGM?1FDCC[3'Q-_"$(761AYKC_GOZ14J''D4/@P`+P9=CLYU.;I$
M%+H<>5P^K>,5HM#LZ)39--]S66[ZQ"Y&PG&I6@.,T>SX'+.'S;`1A6;''K./
MHKX)FL,,46AV[#'[9)#$K>*A53UXW&YO2/Y)0L5CC^(GMZ88*X<8%8\]BOMC
M=I!304R+R!&%BL<>Q?VHNF,4?#/<>V/4//9HOD\`,RK_\TJ)VLWM739`%&H>
M>S3?H\"'/0Q1J'GLT7R/&JYXN20-9,GV5*S\4//$H_D>]?MJ2"<3*Q>2-,-I
M3U#SY%AQX<UW`Z4T:IZ@YLFQ!.Y'65L5B$+-DS/*CZU;B&J5R6<E].8)HM#V
MY/T)O4G$%(J(0MN3=R;TG>O40A3:GGAL/RQO(`(55IH)VIYX;#^Y/R28U!.T
M/?'8?A*58KF2HNVIQ_;3J!!1:'OJL?TT"LN5%&U/H^W9=7]<I1,[;5IY?9BW
MS6?H-)S5)WSZV53E25K7='7[CD[]_:`^FM,IO%)J2/?NRXGFS0%V0]Z=Z;_\
M#U!+`P04````"`"PCFE'ZP]06T\"``#U!P``&````'AL+W=O<FMS:&5E=',O
M<VAE970Q+GAM;'U5VY*C(!#]%<L/&`2\)%/&JB1;6[L/6S4U#[O/Q)!HC8H+
M),[^_0(:QP&<%X'VG#[=0-/YP/B;J"B5P7O;=&(75E+VSP"(LJ(M$4^LIYWZ
M<V&\)5(M^16(GE-R-J2V`2B*4M"2N@N+W-A>>)&SFVSJCK[P0-S:EO!_!]JP
M81?"\&%XK:^5U`90Y&#FG>N6=J)F7<#I91?NX?,1QAIB$+]K.HC%/-#!GQA[
MTXN?YUT8Z1AH0TNI71`UW.F1-HWVI)3_3DX_-#5Q.7]X_V[25>&?B*!'UORI
MS[)2T49A<*87<FOD*QM^T"F'1#LL62/,-RAO0K+V00F#EKR/8]V9<1C_)&BB
M^0EH(J"9@/"7!#P1\$P8MPZ,D9F\OA%)BIRS(>#C8?1$GSE\QFKG2FTT&V7^
MJ<R$LMZ+*`=W[69"'$8$6B#@C`#*]RR`?`('Y-#19X&CB\!^`>S-`!LZ7M!C
M/SWVTF-#CQ?TQ-H`%Y'Z!1*O0.+0,TO`16S\`JE7('7H6TM@1"0&T8U'B+=1
MG*W(9%Z9S)&!]E7Q0%;NRL8KL7'YUF4Y>"`KMV7KE=BZ_-B2\$`2OX1^('PU
M%;D>4KNJ/)AL166E<J'K86.K0.?D4;2:C;>`]Q"Y.O8%FS#ILLJC%15_%4/L
MJ"!HJW@P:$7%7^S0K66$K>=HPGRJEA1NHS1+[)L&%J]L2_G5=!\1E.S6F6:W
ML,X=;F_Z`/B`%WE/KO07X=>Z$\&)2?76FQ?YPIBD*J+H2<52J1X\+QIZD7J:
MJ3D?N]*XD*Q_--FYTQ?_`5!+`P04````"`"PCFE'69X'XN\#```C$P``&```
M`'AL+W=O<FMS:&5E=',O<VAE970R+GAM;(6838^;2!"&_PKR?0-5_04CCZ78
M4;1[B!3EL'MF[/;8"A@'F''R[Y>O<:"J.G.Q`;]%/TTW#VW6MZK^WIR\;Z.?
M97%I'E>GMKT^Q'&S/_DR;SY45W_I?CE6=9FWW6[]'#?7VN>'H:@L8DP2&Y?Y
M^;+:K(=C7^O-NGIIB_/%?ZVCYJ4L\_K7UA?5[7$%J[<#W\[/I[8_$&_6\;WN
M<"[]I3E7EZCVQ\?51WC8*>PC0^+?L[\UL^VHAW^JJN_]SC^'QU72,_C"[]O^
M%'GW]>IWOBCZ,W4M_YA.^KO-OG"^_7;VST-W._RGO/&[JOCO?&A/'6VRB@[^
MF+\4[;?J]K>?^F#Z$^ZKHAD^H_U+TU;E6\DJ*O.?X_?Y,GS?QE_29"J3"W`J
MP'L!Z#\6J*E`D8)X)!OZ]2EO\\VZKFY1/0[&->_''!Y4=^7V_<'A0@V_=3UK
MNJ.O&]3K^+4_SQ39CA&<1Y:)G9`P]TC<M7^'0!$"AWHUK[=RO1+KU5"OY_6.
M=&*,N"%R&2)*IT`[PE.HK$ED%BVR:,Z2$I8Q8F:MZ`0("<]T=Y[,840.PSDR
MPF%8&P".C/Y."*%R,HD522PC40DAL;P1E[)KPE/H$E`RBQ-9'&<AK6P=:\5H
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ME^5*2O8G<G]JZD_D9E0NR>A0"3%TJ`)CA;)!D1M44X.BX,;$*(KS3FI)$UAH
M<H-R&BY':U*Z4I12UD"`1I8H<HEJZG/D=@2#=!X+*:TS#-#("D6^<M54Z5/&
M+<8`#;LX/*:5QM!,EH6,7,B:KJ2E#!7@GS-+$EG&:-G#)?2?`&6!(A>HH0*=
M,FXQTK0O0B8TRK([D;N3#M\6A25E9C+#9IV0,U:YP%("97\B]R>]][?(S8@F
M<PF[/D(.3/='+_!O4G:HX@XUU*&*R_$OE;+)]VYLR2,[5'&'TM7N5G$[*M1`
M'S%2K+N,(1[9HHI;E,Z-[929SU1I\2?%A,5?/'N=<<V?_9>\?CY?FNBI:MNJ
M'-Y?'*NJ]=TIDP]=YTX^/]QW"G]L^TW7;=?C.YQQIZVN;Z^D[N_%-O\#4$L#
M!!0````(`+".:4?ZT=0>)`(``!H'```8````>&PO=V]R:W-H965T<R]S:&5E
M=#,N>&ULC95=CZ,@%(;_BO$'%/Q`:V--MMU,=B\VF<S%[C6UM)I!<8#6V7^_
M@-:UR$RG%^7K?<]Y#AC(>\9?146(]-X;VHJM7TG9;0`0944:+%:L(ZU:.3'>
M8*F&_`Q$QPD^&E-#00AA`AI<MWZ1F[EG7N3L(FG=DF?NB4O38/YW1RCKMW[@
MWR9>ZG,E]00H<C#YCG5#6E&SUN/DM/6_!9M]IA5&\+LFO9CU/<U^8.Q5#WX>
MMS[4"(224NH(6#57LB>4ZD`J\=L8\W]*;9SW;]&?3+6*_H`%V3/ZIS[*2L%"
MWSN2$[Y0^<+Z'V0L`>F`):/"_'OE14C6W"R^U^#WH:U;T_;#2I*.-K<A'`WA
M9`CB3PW1:(@L`QC(3%W?L<1%SEGO\>$L.JR//-A$:N=*/6DVRJRIRH2:O18H
MS<%5QQDENT$2SB3AO6+O4*!)`E3^"2)T0H3&'\TAUFY_Y/1'QA_/_9E5Q"!9
M&TEK)'`%(0RL2A[*[FAB)TV\H$F@13-(T"P-@N9GX3S6W?$@)P]:\EAE[]#7
M=N>A[(XF<=(D2QKK<]HEBZK#U+T_#B6$G^U0ZF1*ETR1Q90N,@5)D$$8QXG%
MY%`&,(`P_6B?UDZF]9(IMIC6#J80I6C)Y%#"+%;:CY@R)U.V9$(64[;(E)BS
MLX`>R@8:,+O&.GPFOS`_UZWP#DRJ&]'<6R?&)%$AX4I%J]1#-0TH.4G=356?
M#W?W,)"LN[U$TW-8_`-02P,$%`````@`L(YI1Q6CIL@'!```51(``!@```!X
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MEA+:HAC^T\G+ETXF84HV5[*SEV/[A+>/6?NXLX]']B9"N>X1TR%%ASQHJ7`V
M&$HJB:@=0PD+"DWYPF$B`L,K4ZPR13)C9@I`L_::9@:IV?2(&H6I3(RT;"ED
M(J%07B@$UFA<+)02$&O)JS*L*D-52:3*T%EL@@+>4DBJ&*\VA8P=E6<OBD(@
M3!SSHBPKRE)1,1)ER2S6%S$212&(%-E8*"6TEH!D44K&(IJIX(25E5!9*.)-
M0F9Y8'0Q%">,P3AE#/:%M+8E<GM\1&]//>-AIDL`30]2M!F8Z1TC46UL&4H;
MG,0=0STD%B>'H4""F2EG8'O/,P@JS6)I@EE49;$TAA():94,I2.#I3%4,MK)
MILKX=@62*DNP,DEO'1S,EH$4U44ALOTPS(.:::'`]U"@3=3B)CHPDTH45F)5
ME#(1K41*^:4'HHQB("")9K3Q7104U098FV+B`8WWX"W'"1T#EL>Y\^488WT,
MY[>KF78(?)<'VN8M;O,#,WD<`1L)C?4QG`;<7W<<%L="$'T,)ZQ6<PO(-WPP
M9*.U<RGBNRO0]FIQ>QV89!QK]!B1"N`QDB$6`XL3Q&-S-R_?9(%V68N[[,"T
M/6L2MXDF?X#5SICAQZ09#DAOF?$WTS<%WWE%1`7CUZN!F58\X"?;@<*KB;<K
M'A-XNYK!9OJ+X!\*!'THL/BA0#`M6H-51@GRBL>@?@>5_B[46"6#*NFKPCO&
M2CFOQFAC$OR&$H[>F7-7G;JO%76P+]^*IKVI1Z/W+R+/HGWG1N,;6&Z!&=_!
M\J7_WO'I?KVZIB?W9UJ=+D4=O):-?]/OWL>/9=DXKR!Z]+&?77JXGV3NV+2'
MQA]7_5>/_J0IKQ\?<>Y?DM;_`E!+`P04````"`"PCFE'GF6XZQ0#``!:#```
M&````'AL+W=O<FMS:&5E=',O<VAE970U+GAM;(5737.;,!#]*XSO"5I]`1G;
M,XT33WOH3*:']DQLV68"R`4Y3O]]Q8<)2&OG8D"\M_MV)3WD^5E7;_5!*1-\
M%'E9+V8'8XX/85AO#JI(ZWM]5*5]L]-5D1K[6.W#^EBI=-N2BCRDA,BP2+-R
MMIRW8R_5<JY/)L]*]5(%]:DHTNK?H\KU>3&#V67@5[8_F&8@7,[#@;?-"E76
MF2Z#2NT6LV_PL`;90%K$[TR=Z]%]T(A_U?JM>?BQ7<Q(HT'E:F.:$*F]O*N5
MRO,FDLW\MP_ZF;,ACN\OT==MN5;^:UJKE<[_9%MSL&K)+-BJ77K*S2]]_J[Z
M&D03<*/SNOT--J?:Z.)"F05%^M%=L[*]GKLW,>EI.('V!#H0X#:!]00V$"B]
M2>`]@0\$)F\21$\0GQF2FP39$^0G@;?-[YK5MOHI->ER7NES4'7KXY@VRQ`>
MI)W,33/8SEW[SC:[MJ/ORSB>A^]-G![RV$'H&)),(2L?DI`IY`F!P!3RC$#H
M%+)&(&R`A+;2H5R*EDM;/A_SN5-+!Q$MI&PAP`APR3C@F1B:B?F9A-/8#A*-
M,K&("+>W/@J<KCSY$"HDBR*GOS[LCH+@L3,/:P3'8I[@U7.T>MZ&8./J)<X7
M*%_XW7.J60EOGIBM)I:QP!-)-)'T$[GK7WJ)>,1!.G*D/YG.+.%QKBS?"%4;
M^6K=Y1)Y60B>(48SQ%X&(,Y6?HR]%'=`:.)V)/8ZXGK"EX$F@A-4<(((=A;T
M*O'R4`9LM(TF>9HO$>:4!,E$7:\D_JHDB6N%MT%3,5=L&Q`QS!4#OB\`=<VC
M1XEKJ*D<W%;!]U4@W)7C.RM+B+NZ5B@,2'Q%$.Z^X-LO$-=_`3%@<+O#?#57
MO@.`6R%P3TKL+1ON[P3.*75:^/PU;JH(-U?PW16(NWO!]U>05$2"\RO[$W"'
M!=]B@41N`Q#[I!Q<ST=@(-P9\S$T$8F0;B]]W!T52>0NDS4&1+Z'X>C(=4SW
MZF=:[;.R#EZUL:>W]HRUT]HH&Y+<V[8>[$%_>,C5SC2WD;VONJ-O]V#T\7*2
M'_Y.+/\#4$L#!!0````(`+".:4>?%-H=E`0``!@7```8````>&PO=V]R:W-H
M965T<R]S:&5E=#8N>&UL?9A)D^(X$(7_"L&=1LJ4MPJ*B(*)CI[#1'3T8>;L
M`K%$VYBQ3='S[\<+15&93WW!MGB27FKYM"RN5?VS.7C?3GZ5Q:EYGA[:]OPT
MGS>;@R_SYDMU]J?NGUU5EWG;?=;[>7.N?;X=,I7%G(R)YV5^/$V7BR'M>[U<
M5)>V.)[\]WK27,HRK_];^:*Z/D_M]#WAQW%_:/N$^7(QO^?;'DM_:H[5:5+[
MW?/TQ3ZMW2`9%'\?_;5Y>)_TYE^KZF?_\>?V>6IZ#[[PF[8O(N\>;W[MBZ(O
MJ:OYWUNA'W7V&1_?WTO_.H3;V7_-&[^NBG^.V_;0N373R=;O\DO1_JBNW_PM
MAJ@O<%,5S?`[V5R:MBK?LTPG9?YK?!Y/P_,Z_I.:6S:<@6X9Z)[A7@_.P+<,
M_)'!#9&.SH:X_LC;?+FHJ^ND'COCG/=];I^X:[E-GS@TU/!?%UG3I;XMK4D7
M\[>^H)MF-6KH47-7S+O2[U40JF)%*CM]KF"M%7&*:V`8!`_YW:<@,A'$J$D&
MS6G0S"BUD1%6D(R,3;`=!^VXH0Q^M&,-+B""!40Z'FM%/*,F>C#*QHE@@,8%
MC,302`R,B,Y;Q:H2RRR=:!&G2:"/$V@E`5986$E4+5DJQYK6S"S;Q&$O*?22
M`B\BXE6JZXG%F%QK391A'QGTD8&!%N$">I:AZ6]`*+&<_T;'0D*T1B)V@2ZV
M`1A9Y8;E/+YI/C>L2Z4;K8H"76PAM5XL*2_.2"\$!E,4J:;1,G)QJ*,PXBQ@
MW`.5;GX8=%22DAQW4)<FC@.6,.:L`Y;4VN$T'F*32#X`61QSR`^FID785,-'
M,S$UB95VM"K`38O!:0$Y20T?347*].@!["076($MAJ<%]"2YHEB`QLBX1/H!
M,N:,`H8P02U`*,F5Q0*&<C=.50M!G>70#,,PM8"F%!B!A&E*@*8D%P9"-#6A
M'14&)6E06HID19J!<K<#)#/BT!I"F)2D26GE\K`B@,I43CLD"BTAA#E)@),D
M.4F0?VI7BE0<AX8$AB0!2)*$)&GZS2*UAT(J-@^\^.P'0Y(`).7ZL"*-OZZS
MY+1#JLC9P`Z&,"@IUK..`ZPE##<"<&,)-]+4<HG3,6E9R`P&&P&PL00;:6!)
MPVN@<>P"E"6,-,J`&;EIOHE^BPDML=VB&3@4,88C`SC*,;YB#4>61[DU$%%H
M6C(&*`.`L@0H(SIF1G("R3(3.L!BAC)@*$N&LL:C<VDD.0%DUCD;V/YRX$@-
M.,J2HZP)V1U48]5`$*0V=!1E3%(&)&5)4M:,[)"M3_E:YI(D#0UHC%(&*%7'
M%49G\%0>HM=`UAT17,@09BD#E@8;&;.4`4N=9"EK2.J`@"8T13%)&9#429(R
MHJ3<L0)1S`&2,B8I@\UAZ+CD,/\<X)^3_+N)DD^DI4PN4PX0,#$4V`HXS$`'
M&.@B69-5AF9]57)8S1\N'$M?[X>+V&:RJ2ZGMK_:>TB]7_:^4']A*=)7]FD]
M7ME^%+-<G/.]_RNO]\=3,WFMVK8JATO+756UOK-IOG1-<?#Y]OY1^%W;OR;=
M>SU>W(X?;75^OX>^7X8O_P=02P,$%`````@`L(YI1\P<#M.?`0``L0,``!@`
M``!X;"]W;W)K<VAE971S+W-H965T-RYX;6Q]4]MNW"`0_17$!P0OZURT\EK*
M)JK:ATI1'MIGUA[;*,`X@-?IWQ?PVG%;JR_`#'/.G!F&8D3[YCH`3SZT,NY(
M.^_[`V.NZD`+=X,]F'#3H-7"!].VS/461)U`6C&>97=,"VEH623?BRT+'+R2
M!EXL<8/6POXZ@<+Q2'=T=KS*MO/1P<J"+;A::C!.HB$6FB-]W!U.>8Q(`3\D
MC&YU)E'[&?$M&M_J(\VB!%!0^<@@PG:!)U`J$H7$[U?.SY01N#[/[%]2M4']
M63AX0O53UKX+8C-*:FC$H/PKCE_A6L)M)*Q0N;22:G`>]0RA1(N/:9<F[>-T
MLY]AVP!^!?`%\)`EX5.B)/-9>%$6%D=BI];V(K[@[L!#(ZKH3'6GNR#4!>^E
MW.5W!;M$HFO,:8KAZY@E@@7V)07?2G'B_\#Y-GR_J7"?X/L_%-YO$^2;!'DB
MR/];XE;,PU])V*JG&FR;1L>1"@>3!G7E7:;SD:<W^0POBUZT\%W85AI'SNC#
MRZ;^-X@>@I3LYI:2+OR?Q5#0^'B\#V<[C=1D>.SG#[+\TO(W4$L#!!0````(
M`+".:4<K(+CGH`$``+$#```8````>&PO=V]R:W-H965T<R]S:&5E=#@N>&UL
M?5/;;MP@$/T5Q`<$+^OM9>6UE$U4M0^5HCRTSZP]ME&`<0"OT[\O8*]CI59?
M@!GFG#DS#,6(]L5U`)Z\:67<B7;>]T?&7-6!%NX.>S#AID&KA0^F;9GK+8@Z
M@;1B/,L^,2VDH661?$^V+'#P2AIXLL0-6@O[YPP*QQ/=T9OC6;:=CPY6%FS!
MU5*#<1(-L="<Z/WN>,YC1`KX)6%TJS.)VB^(+]'X49]H%B6`@LI'!A&V*SR`
M4I$H)'Z=.=]31N#Z?&/_EJH-ZB_"P0.JW[+V71";45)#(P;EGW'\#G,)ATA8
MH7)I)=7@/.H;A!(MWJ9=FK2/T\T^GV';`#X#^`+XDB7A4Z(D\U%X41861V*G
MUO8BON#NR$,CJNA,=:>[(-0%[[7<Y5\+=HU$<\QYBN'KF"6"!?8E!=]*<>;_
MP/DV?+^I<)_@^W7V0[9-D&\2Y(D@_V^)&S&'CT6R54\UV#:-CB,5#B8-ZLJ[
M3.<]3V_R'EX6O6CAI["M-(Y<T(>73?UO$#T$*=G=@9(N_)_%4-#X>/P<SG8:
MJ<GPV-\^R/)+R[]02P,$%`````@`L(YI1WS0M=B?`0``L0,``!@```!X;"]W
M;W)K<VAE971S+W-H965T.2YX;6Q]4\%NW"`0_17$!P0OZVVJE==2-E'5'BI%
M.;1GUA[;*,`X@-?IWQ>PUW%;JQ=@AGEOW@Q#,:)]=1V`)^]:&7>BG??]D3%7
M=:"%N\,>3+AIT&KA@VE;YGH+HDX@K1C/LD],"VEH623?LRT+'+R2!IXM<8/6
MPOXZ@\+Q1'?TYGB1;>>C@Y4%6W"UU&"<1$,L-"?ZL#N>\QB1`GY(&-WJ3*+V
M"^)K-+[5)YI%":"@\I%!A.T*CZ!4)`J)WV;.CY01N#[?V+^D:H/ZBW#PB.JG
MK'T7Q&:4U-"(0?D7'+_"7,(A$E:H7%I)-3B/^@:A1(OW:9<F[>-TD]_/L&T`
MGP%\`7S.DO`I49+Y)+PH"XLCL5-K>Q%?<'?DH1%5=*:ZTUT0ZH+W6NX.O&#7
M2#3'G*<8OHY9(EA@7U+PK11G_@^<;\/WFPKW";[_0^%^FR#?),@30?[?$K=B
M\K^2L%5/-=@VC8XC%0XF#>K*NTSG`T]O\A%>%KUHX;NPK32.7-"'ETW];Q`]
M!"G9W8&2+OR?Q5#0^'B\#V<[C=1D>.QO'V3YI>5O4$L#!!0````(`+".:4>U
MBK43H`$``+$#```9````>&PO=V]R:W-H965T<R]S:&5E=#$P+GAM;'U346_;
M(!#^*X@?4!R2-%/D6&HZ5=O#I*H/VS.QSS8J<"[@N/OW`^RX[F;M!;CCON^^
M.XY\0/OJ6@!/WK4R[D1;[[LC8ZYL00MWAQV8<%.CU<('TS;,=19$E4!:,9YE
M]TP+:6B1)]^S+7+LO9(&GBUQO=;"_CZ#PN%$-_3F>)%-ZZ.#%3F;<9748)Q$
M0RS4)_JP.9YW,2(%_)0PN,691.T7Q-=H?*].-(L20$'I(X,(VQ4>0:E(%!*_
M39P?*2-P>;ZQ/Z5J@_J+</"(ZI>L?!O$9I144(M>^1<<OL%4PCX2EJA<6DG9
M.X_Z!J%$B_=QER;MPWC##Q-L'<`G`)\!7[(D?$R49'X57A2YQ8'8L;6=B"^X
M.?+0B#(Z4]WI+@AUP7LM-OM]SJZ1:(HYCS%\&3-'L,`^I^!K*<[\'SA?AV]7
M%6X3?/M)X?TZP6Z58)<(=O\M<2WF\%<2MNBI!MNDT7&DQ-ZD05UXY^E\X.E-
M/L*+O!,-_!"VD<:1"_KPLJG_-:*'("6[VU/2AO\S&PIJ'X^'<+;C2(V&Q^[V
M0>9?6OP!4$L#!!0````(`+".:4=7'4(1H@$``+$#```9````>&PO=V]R:W-H
M965T<R]S:&5E=#$Q+GAM;&U3P6[<(!#]%<0'!"^[FZ0KKZ5LJJ@]5(IR:,^L
M/;91@'$`K]._+V"OXZ2^`#/,>_-F&/(![:MK`3QYU\JX(VV][PZ,N;(%+=P-
M=F#"38U6"Q],VS#761!5`FG%>);=,BVDH46>?,^VR+'W2AIXML3U6@O[]P0*
MAR/=T*OC13:MCPY6Y&S&55*#<1(-L5`?Z</F<-K%B!3P6\+@%F<2M9\17Z/Q
MLSK2+$H`!:6/#")L%W@$I2)12/PV<7ZDC,#E^<K^E*H-ZL_"P2.J/[+R;1";
M45)!+7KE7W#X`5,)^TA8HG)I)67O/.HKA!(MWL==FK0/X\W^;H*M`_@$X#/@
M/DO"QT1)YG?A19%;'(@=6]N)^(*;`P^-**,SU9WN@E`7O)=BL[_/V24233&G
M,88O8^8(%MCG%'PMQ8G_!^?K\.VJPFV";S\I_+9.L%LEV"6"W9+@-OM2XEK,
MUR+9HJ<:;)-&QY$2>Y,&=>&=I_.!IS?Y""_R3C3P2]A&&D?.Z,/+IO[7B!Z"
ME.QF3TD;_L]L**A]/-Z%LQU':C0\=M</,O_2XA]02P,$%`````@`L(YI1Q,_
MU#J?`0``L0,``!D```!X;"]W;W)K<VAE971S+W-H965T,3(N>&UL?5/!;MP@
M$/T5Q`<$FW72:N6UE$U5M8=*40[MF;7'-@HP+N!U^O<%['7<UNH%F&'>FS?#
M4$YH7UT/X,F;5L:=:._]<&3,U3UHX>YP`!-N6K1:^&#:CKG!@F@22"O&L^R!
M:2$-K<KD>[95B:-7TL"S)6[46MA?9U`XG6A.;XX7V?4^.EA5LA772`W&233$
M0GNBC_GQ7,2(%/!=PN0V9Q*U7Q!?H_&U.=$L2@`%M8\,(FQ7>`*E(E%(_'/A
M?$\9@=OSC?USJC:HOP@'3ZA^R,;W06Q&20.M&)5_P>D++"7<1\(:E4LKJ4?G
M4=\@E&CQ-N_2I'V:;WB^P/8!?`'P%?`Q2\+G1$GF)^%%55J<B)U;.XCX@OF1
MAT;4T9GJ3G=!J`O>:Y4_\))=(]$2<YYC^#9FC6"!?4W!]U*<^3]PO@\_["H\
M)/CA#X6'?8)BEZ!(!,5_2]R+*?Y*PC8]U6"[-#J.U#B:-*@;[SJ=CSR]R7MX
M50ZB@V_"=M(X<D$?7C;UOT7T$*1D=_>4].'_K(:"UL?CAW"V\TC-AL?A]D'6
M7UK]!E!+`P04````"`"PCFE'=:0`6:`!``"Q`P``&0```'AL+W=O<FMS:&5E
M=',O<VAE970Q,RYX;6Q]4\%NXR`0_17$!Q3'<9)5Y%AJNEJUAY6J'G;/Q![;
MJ,!X`<?=OU_`CNNVUEZ`&>:]>3,,^8#FU;8`CKPIJ>V)MLYU1\9LV8+B]@X[
MT/ZF1J.X\Z9IF.T,\"J"E&1IDNR9XD+3(H^^9U/DV#LI-#P;8GNEN/E[!HG#
MB6[HS?$BFM8%!RMR-N,JH4!;@9H8J$_T?G,\9R$B!OP2,-C%F03M%\378#Q5
M)YH$"2"A=(&!^^T*#R!E(/*)_TR<[RD#<'F^L?^(U7KU%V[A`>5O4;G6BTTH
MJ:#FO70O.#S"5,(N$)8H;5Q)V5N'Z@:A1/&W<1<Z[L-XDQTFV#H@G0#I#/B6
M1.%CHBCS.W>\R`T.Q(RM[7AXP<TQ]8TH@S/6'>^\4.N]UV*SW^7L&HBFF/,8
MDRYCY@CFV><4Z5J*<_H%GJ[#MZL*MQ&^_:!POTZ0K1)DD2#[;XEK,8=/2=BB
MIPI,$T?'DA)['0=UX9VG\SZ-;_(>7N0=;^`G-XW0EES0^9>-_:\1'7@IR=V.
MDM;_G]F04+MP//BS&4=J-!QVMP\R_]+B'U!+`P04````"`"PCFE'M:#S4J$!
M``"Q`P``&0```'AL+W=O<FMS:&5E=',O<VAE970Q-"YX;6Q]4\%NXR`0_17$
M!Q3'<9MNY%AJNJK:PTI5#]TSL<<V*C`NX+C[]P7LN.ZNM1=@AGEOW@Q#/J!Y
MLRV`(Q]*:GN@K7/=GC%;MJ"XO<(.M+^IT2CNO&D:9CL#O(H@)5F:)#=,<:%I
MD4??LRER[)T4&IX-L;U2W/PY@L3A0#?TXG@13>N"@Q4YFW&54*"M0$T,U`=Z
MM]D?LQ`1`UX%#'9Q)D'["?$M&$_5@29!`D@H76#@?CO#/4@9B'SB]XGS*V4`
M+L\7]H=8K5=_XA;N4?X6E6N]V(22"FK>2_>"PR-,)5P'PA*EC2LI>^M072"4
M*/XQ[D+'?1AO=MD$6P>D$R"=`;=)%#XFBC)_<L>+W.!`S-C:CH<7W.Q3WX@R
M.&/=\<X+M=Y[+C8WMSD[!Z(IYCC&I,N8.8)Y]CE%NI;BF/X#3]?AVU6%VPC?
M?E/X8YT@6R7((D'VWQ)78G;)7TG8HJ<*3!-'QY(2>QT'=>&=I_,NC6_R%5[D
M'6_@%S>-T):<T/F7C?VO$1UX*<G5-26M_S^S(:%VX;CS9S..U&@X["X?9/ZE
MQ2=02P,$%`````@`L(YI1Y*,?)*A`0``L0,``!D```!X;"]W;W)K<VAE971S
M+W-H965T,34N>&UL=5/;;MP@$/T5Q`<$W]*M5EY+V515^U`IRD/[S-IC&P48
M%_`Z_?L"]CI.ZKX`,\PY<V88R@G-B^T!''E54ML3[9T;CHS9N@?%[1T.H/U-
MBT9QYTW3,3L8X$T$*<FR)/G$%!>:5F7T/9FJQ-%)H>')$#LJQ<V?,TB<3C2E
M-\>SZ'H7'*PJV8IKA`)M!6IBH#W1A_1X+D)$#/@I8+*;,PG:+X@OP?C>G&@2
M)("$V@4&[K<K/(*4@<@G_KUPOJ4,P.WYQOXU5NO57[B%1Y2_1.-Z+S:AI(&6
MC](]X_0-EA+N`V&-TL:5U*-UJ&X02A1_G7>AXS[--_EA@>T#L@60K8#/210^
M)XHROW#'J]+@1,S<VH&'%TR/F6]$'9RQ[GCGA5KOO5;I(2W9-1`M,><Y)MO&
MK!',LZ\ILKT4Y^P?>+8/SW<5YA&>OU/X'X)BEZ"(!,4[@OQ#B7LQQ8<D;--3
M!::+HV-)C:..@[KQKM/YD,4W>0NORH%W\(.;3FA++NC\R\;^MX@.O)3D[IZ2
MWO^?U9#0NG`\^+.91VHV'`ZW#[+^TNHO4$L#!!0````(`+".:4?L_(=SH`$`
M`+$#```9````>&PO=V]R:W-H965T<R]S:&5E=#$V+GAM;'U346_;(!#^*X@?
M4!R2-%/D6&HZ5=O#I*H/VS.QSS8J<"[@N/OW`^RX[F;M!;CCON^^.XY\0/OJ
M6@!/WK4R[D1;[[LC8ZYL00MWAQV8<%.CU<('TS;,=19$E4!:,9YE]TP+:6B1
M)]^S+7+LO9(&GBUQO=;"_CZ#PN%$-_3F>)%-ZZ.#%3F;<9748)Q$0RS4)_JP
M.9YW,2(%_)0PN,691.T7Q-=H?*].-(L20$'I(X,(VQ4>0:E(%!*_39P?*2-P
M>;ZQ/Z5J@_J+</"(ZI>L?!O$9I144(M>^1<<OL%4PCX2EJA<6DG9.X_Z!J%$
MB_=QER;MPWBSS2;8.H!/`#X#OB0`&Q,EF5^%%T5N<2!V;&TGX@MNCCPTHHS.
M5'>Z"T)=\%Z+S6&?LVLDFF+.8PQ?QLP1++#/*?A:BC/_!\[7X=M5A=L$WWY2
M>+].L%LEV"6"W7]+7(LY_)6$+7JJP39I=!PIL3=I4!?>>3H?>'J3C_`B[T0#
M/X1MI''D@CZ\;.I_C>@A2,GN]I2TX?_,AH+:Q^,AG.TX4J/AL;M]D/F7%G\`
M4$L#!!0````(`+".:4=%2W8\H0$``+$#```9````>&PO=V]R:W-H965T<R]S
M:&5E=#$W+GAM;'U346_;(!#^*X@?4!R2K%GD6&I:3=O#I*H/VS.QSS8J<"[@
MN/OW`^RXWF;M!;CCON^^.XY\0/OJ6@!/WK4R[D1;[[LC8ZYL00MWAQV8<%.C
MU<('TS;,=19$E4!:,9YEGY@6TM`B3[YG6^38>R4-/%OB>JV%_74&A<.);NC-
M\2*;UD<'*W(VXRJIP3B)AEBH3_1A<SSO8D0*^"%A<(LSB=HOB*_1^%:=:!8E
M@(+21P81MBL\@E*1*"1^FS@_4D;@\GQC_Y*J#>HOPL$CJI^R\FT0FU%202UZ
MY5]P^`I3"?M(6*)R:25E[SSJ&X02+=['79JT#^/-?CO!U@%\`O`9<,B2\#%1
MDODDO"ARBP.Q8VL[$5]P<^2A$65TIKK371#J@O=:;.X/.;M&HBGF/,;P9<P<
MP0+[G(*OI3CS?^!\';Y=5;A-\.T?"C^O$^Q6"7:)8/??$E=B#ME?2=BBIQIL
MDT;'D1)[DP9UX9VG\X&G-_D(+_).-/!=V$8:1R[HP\NF_M>('H*4[&Y/21O^
MSVPHJ'T\WH>S'4=J-#QVMP\R_]+B-U!+`P04````"`"PCFE'UPRKCJ$!``"Q
M`P``&0```'AL+W=O<FMS:&5E=',O<VAE970Q."YX;6QU4\%NW"`0_17D#P@V
MZTVCE==2-E75'"I%.21GUA[;*,"X@-?IWQ?PVG%2]P+,,._-FV$H1C1OM@-P
MY%U);8])YUQ_H-16'2AN;[`'[6\:-(H[;YJ6VMX`KR-(2<K2])8J+G12%M'W
M9,H"!R>%AB=#[*`4-W].('$\)EDR.YY%V[G@H&5!%UPM%&@K4!,#S3&YSPZG
M/$3$@!<!HUV=2=!^1GP+QF-]3-(@`214+C!POUW@`:0,1#[Q[ROG1\H`7)]G
M]A^Q6J_^S"T\H'P5M>N\V#0A-31\D.X9QY]P+6$?""N4-JZD&JQ#-4,2HOC[
MM`L=]W&ZV<^P;0"[`M@"N$NC\"E1E/F=.UX6!D=BIM;V/+Q@=F"^$55PQKKC
MG1=JO?=29G=902^!Z!ISFF+8.F:)H)Y]2<&V4IS8/W"V#=]M*MQ%^.Z3PO\0
MY)L$>23(/Q'LOI2X%9-_24)7/55@VC@ZEE0XZ#BH*^\RG?<LOLE'>%GTO(5?
MW+1"6W)&YU\V]K]!=."EI#?[A'3^_RR&A,:%XS=_-M-(38;#?OX@RR\M_P)0
M2P,$%`````@`L(YI1P>=(\N@`0``L0,``!D```!X;"]W;W)K<VAE971S+W-H
M965T,3DN>&UL?5/!;MP@$/T5Q`<$+[N;I"NOI6RJJ#U4BG)HSZP]ME&`<0"O
MT[\O8*_CM%8OP`SSWKP9AGQ`^^I:`$_>M3+N2%OONP-CKFQ!"W>#'9AP4Z/5
MP@?3-LQU%D250%HQGF6W3`MI:)$GW[,M<NR]D@:>+7&]UL+^/H'"X4@W].IX
MD4WKHX,5.9MQE=1@G$1#+-1'^K`YG'8Q(@7\E#"XQ9E$[6?$UVA\KXXTBQ)`
M0>DC@PC;!1Y!J4@4$K]-G!\I(W!YOK(_I6J#^K-P\(CJEZQ\&\1FE%10BU[Y
M%QR^P53"/A*6J%Q:2=D[C_H*H42+]W&7)NW#>,._3+!U`)\`?`;<9TGXF"C)
M_"J\*'*+`[%C:SL17W!SX*$1972FNM-=$.J"]U)L[O<YNT2B*>8TQO!ES!S!
M`ON<@J^E./%_X'P=OEU5N$WP[2>%M^L$NU6"72+8_;?$M9B[OY*P14\UV":-
MCB,E]B8-ZL([3^<#3V_R$5[DG6C@A["--(Z<T8>73?VO$3T$*=G-GI(V_)_9
M4%#[>+P+9SN.U&AX[*X?9/ZEQ1]02P,$%`````@`L(YI1SA%'J^@`@``6PL`
M`!D```!X;"]W;W)K<VAE971S+W-H965T,C`N>&UL=5;+;MLP$/P501\0B>MW
M(`NP4Q3MH4"00WNF;=H6(HDN2=OIWY>D;,6AAA<]J-F9I3B[V.(JU;L^"F&2
MCZ9N]3(]&G-ZSC*]/8J&ZR=Y$JW]LI>JX<:^JD.F3TKPG0]JZHSR?)HUO&K3
MLO!KKZHLY-G452M>5:+/3</5O[6HY769LO2^\%8=CL8M9&61]7&[JA&MKF2;
M*+%?IBOVO*:1@WC$[TI<]<-SXI+?2/GN7G[NEFGN<A"UV!I'P>WM(EY$73LF
MJ_SW1OJIZ0(?G^_LW_UV;?H;KL6+K/]4.W.TV>9ILA-[?J[-F[S^$+<]3!SA
M5M;:7Y/M61O9W$/2I.$?W;UJ_?W:?9G,;F$X@&X!U`?,<Y]X)^33_,8-+PLE
MKXGJ_NV)NR-DSV1_Q-8M^GW[;S91;5<O)9O/B^SBB&Z8=8>A1TR/R"Q[+T%(
M8DV#<,+A(YCAR(>/'M7',TPPA@1C3S#^LL5%L$6`6>189`)%)H"`!2(($_D5
M4R@R!02C0`1AQEAD!D5F@&`2B"#,%(O,H<@<$,P"$8298Y$%%%D`@O#@AQC;
ML+"(JVY403F@"(\>@B)GSR*5R@!%>/H0%#E^!LMUQ0A0A`:`H(@#&*YK-@(4
MH0<@*&("ALN?#6N;\M`&",1B/L`=@`W+F]C`!P@4\P%N`FQ8X<0&/D"@F`]P
M'V##(B<V\`$"Q7R`6P$;UCFQ@0\0*.8#W`T8*'4V\`$`4<0'A/L!@5*GT`<0
M%/$!X7Y`H-0I]`$$17Q`N!\0*'4*?0!!$1\0[@<$2IU"'T!0Z(/L8?AIA#KX
M&4\G6WEN_4CYL-K/D2ORP],GO"Q._"!^<76H6IULI+$CF!^4]E(:87/)GVPM
M'^VDV[_48F_<X\P^JV[VZUZ,/-U'V7Z>+O\#4$L#!!0````(`+".:4<?R=60
MJP$``!8$```9````>&PO=V]R:W-H965T<R]S:&5E=#(Q+GAM;'54S8[;(!!^
M%>0'6!R<]"=R+&VVJMI#I=4>VC.QQS9:8%S`\?;M"]CQ6BF]!!B^OS&0<D+S
M:GL`1]Z4U/:4]<X-1TIMW8/B]@$'T'ZG1:.X\TO343L8X$TD*4E9GG^@B@N=
M566L/9NJQ-%)H>'9$#LJQ<V?,TB<3MDNNQ5>1->[4*!525=>(Q1H*U`3`^TI
M>]P=SX>`B("?`B:[F9.0_8+X&A;?FU.6AP@@H79!@?OA"D\@91#RQK\7S7?+
M0-S.;^I?8[<^_85;>$+Y2S2N]V'SC#30\E&Z%YR^P=)"3%BCM/&7U*-UJ&Z4
MC"C^-H]"QW&:=S[E"RU-8`N!W1'H;!1C?N&.5Z7!B9CYTPX\G.#NR/R'J$,Q
M]AWW?%#KJ]>*L<\EO0:A!7.>,6R#V:T(ZM57"Y:R.+-_Z"Q-+Y()BT@OMNZ'
M/"VP3PKLH\!^ZU_D=RVF,/]I\I`T.20$V)U)"E/<F=#-P2DP7;R?EM0XZO@:
M-M7U"3RR>/#O\*H<>`<_N.F$MN2"SE^?>,@MH@,?)7_P67K_2->%A-:%Z4<_
M-_.]G1<.A]LK7/\*JK]02P,$%`````@`L(YI1R#"#G6C`0``L0,``!D```!X
M;"]W;W)K<VAE971S+W-H965T,C(N>&UL;5/!;MP@$/T5Y`\(7FRG[<IK*9NJ
M:@^5HAS:,VN/;11@7,#K].\+V.LXJ2_`#//>O!F&<D+S8GL`1UZ5U/:4],X-
M1TIMW8/B]@X'T/ZF1:.X\Z;IJ!T,\":"E*0L3>^IXD(G51E]3Z8J<712:'@R
MQ(Y*<?/W#!*G4W)(;HYGT?4N.&A5TA77"`7:"M3$0'M*'@['<QXB8L`O`9/=
MG$G0?D%\"<:/YI2D00)(J%U@X'Z[PB-(&8A\XC\+YUO*`-R>;^S?8K5>_85;
M>$3Y6S2N]V+3A#30\E&Z9YR^PU)"$0AKE#:NI!ZM0W6#)$3QUWD7.N[3?%-\
M66#[`+8`V`KXG$;A<Z(H\RMWO"H-3L3,K1UX>,'#D?E&U,$9ZXYW7JCUWFO%
MLKRDUT"TQ)SG&+:).:P1U+.O*=A>BC/[#\[VX=FNPBS"LVWV(MLGR'<)\DB0
MORNQ^%#B7LS]AR1TTU,%IHNC8TF-HXZ#NO&NT_G`XIN\A5?EP#OXR4TGM"47
M=/YE8_];1`=>2GI7)*3W_V<U)+0N'#_YLYE':C8<#K</LO[2ZA]02P,$%```
M``@`L(YI1[Y5!N6D`0``L0,``!D```!X;"]W;W)K<VAE971S+W-H965T,C,N
M>&UL;5/!;MP@$/T5Q`<$+W8VZ<IK*9LJ:@^5HAS:,VN/;13P.(#7Z=\7L-=Q
M4E^`&>:]>3,,^8CFU;8`CKQKU=DC;9WK#XS9L@4M[`WVT/F;&HT6SINF8;8W
M(*H(THKQ)-DS+61'BSSZGDV1X^"4[.#9$#MH+<S?$R@<CW1'KXX7V;0N.%B1
MLP5720V=E=@1`_61/NP.IRQ$Q(#?$D:[.I.@_8SX&HR?U9$F00(H*%U@$'Z[
MP",H%8A\XK>9\R-E`*[/5_:G6*U7?Q86'E']D95KO=B$D@IJ,2CW@N,/F$NX
M#80E*AM74@[6H;Y"*-'B?=IE%_=QNLGV,VP;P&<`7P#W210^)8HROPLGBMS@
M2,S4VEZ$%]P=N&]$&9RQ[GCGA5KOO10\O<O9)1#-,:<IAJ]B=DL$\^Q+"KZ5
MXL3_@_-M>+JI,(WP=)U]GVX39)L$623(/I5X_Z7$K9AO7Y*P54\UF":.CB4E
M#ET<U)5WF<X''M_D([S(>]'`+V$:V5ER1N=?-O:_1G3@I20WMY2T_O\LAH+:
MA>.=/YMII";#87_](,LO+?X!4$L#!!0````(`+".:4?Q)6V%O`$``'L$```9
M````>&PO=V]R:W-H965T<R]S:&5E=#(T+GAM;'54W6[;(!1^%>0'*#9QG"ER
M+#6=JNUB4M6+[9K8QS8J/R[@N'O[`79<+V,W`0[?WR'@<E+ZS?0`%GT(+LTI
MZ:T=CAB;N@=!S8,:0+J=5FE!K5OJ#IM!`VT"27!,TK3`@C*95&6HO>BJ5*/E
M3,*+1F84@NK?9^!J.B59<BN\LJZWOH"K$J^\A@F0ABF)-+2GY#$[G@N/"("?
M#":SF2.?_:+4FU]\;TY)ZB,`A]IZ!>J&*SP!YU[(&;\OFI^6GKB=W]2?0[<N
M_84:>%+\%VML[\*F"6J@I2.WKVKZ!DL+>R]8*V["+ZI'8Y6X41(DZ,<\,AG&
M:=XY'!9:G$`6`ED)7](0?#8*,;]22ZM2JPGI^6@'ZO_![$C<0=2^&/H.>RZH
M<=5K1?*TQ%<OM&#.,X9L,-F*P$Y]M2`QBS/YAT[B]%TTX2[0=UOWHH@+Y%&!
M/`CD?[68W;48P_PGY3YJLH\([.Y,8I@\;E)$38J(P/[.)(:Y/RZ\N1T"=!<>
M@4&U&F5X<IOJ^LX>2;A=G_"J'&@'/ZCNF#3HHJR[H^$FM4I9<%'2!]=P[[X$
MZX)#:_WTX.9Z?ASSPJKA]M37[TWU!U!+`P04````"`"PCFE'(NI:N;\!``![
M!```&0```'AL+W=O<FMS:&5E=',O<VAE970R-2YX;6QU5-UNFS`4?A6+!ZB)
M0T@7$:2F4[5=3*IZL5T[<`"K_J&V"=W;SS:$LM2]P?;Q]W..\7$Q*OUJ.@"+
MW@67YIATUO8'C$W5@:#F3O4@W4ZCM*#6+76+3:^!UH$D."9IFF-!F4S*(L2>
M=5FHP7(FX5DC,PA!]=\3<#4>DTUR#;RPMK,^@,L"+[R:"9"&*8DT-,?D87,X
MY1X1`+\9C&8U1S[WLU*O?O&S/B:I3P$X5-8K4#=<X!$X]T+.^&W6_+#TQ/7\
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M2>]<P9U["98%A\;ZZ=[-]=0<T\*J_MKJRWM3_@-02P,$%`````@`L(YI1QN-
M;EVE`0``L0,``!D```!X;"]W;W)K<VAE971S+W-H965T,C8N>&UL=5/!;MP@
M$/T5Q`<$F_5VJY774C91U1XJ13FT9]8>VRC@<0"OT[\O8*_C)NX%F&'>FS?#
MD(]H7FP+X,B;5IT]T=:Y_LB8+5O0PMYA#YV_J=%HX;QI&F9[`Z**(*T83Y(O
M3`O9T2*/OB=3Y#@X)3MX,L0.6@OSYPP*QQ--Z<WQ+)O6!0<K<K;@*JFALQ([
M8J`^T?OT>,Y"1`SX)6&TJS,)VB^(+\'X49UH$B2`@M(%!N&W*SR`4H'()WZ=
M.=]3!N#Z?&/_%JOUZB_"P@.JW[)RK1>;4%)!+0;EGG'\#G,)^T!8HK)Q)>5@
M'>H;A!(MWJ9==G$?IYO=889M`_@,X`O@:Q*%3XFBS$?A1)$;'(F96MN+\(+I
MD?M&E,$9ZXYW7JCUWFO!]UG.KH%HCCE/,7P5DRX1S+,O*?A6BC/_!.?;\-VF
MPEV$[];9#_\AR#8)LDB0_5/B_D.)GV/20_8A"5OU5(-IXNA84N+0Q4%=>9?I
MO.?Q3=[#B[P7#?P4II&=)1=T_F5C_VM$!UY*<K>GI/7_9S$4U"X<#_YLII&:
M#(?][8,LO[3X"U!+`P04````"`"PCFE'G8YB0J,!``"Q`P``&0```'AL+W=O
M<FMS:&5E=',O<VAE970R-RYX;6QM4]MNW"`0_17$!P0O>XM67DO95%7[4"G*
M0_O,VF,;!1@7\#K]^P+V.F[J%V"&.6?.#$,^H'US+8`G[UH9=Z:M]]V),5>V
MH(5[P`Y,N*G1:N&#:1OF.@NB2B"M&,^R`]-"&EKDR?=BBQQ[KZ2!%TM<K[6P
M?RZ@<#C3#;T[7F73^NA@1<YF7"4U&"?1$`OUF3YM3I==C$@!/R4,;G$F4?L5
M\2T:WZLSS:($4%#ZR"#"=H-G4"H2A<2_)\Z/E!&X/-_9OZ9J@_JK</",ZI>L
M?!O$9I144(M>^5<<OL%4PCX2EJA<6DG9.X_Z#J%$B_=QER;MPWBS/4ZP=0"?
M`'P&/&9)^)@HR?PBO"ARBP.Q8VL[$5]P<^*A$65TIKK371#J@O=6\/TA9[=(
M-,5<QAB^B-G,$2RPSRGX6HH+_P_.U^';587;!-\NLQ\/ZP2[58)=(MC]4^+Q
M4XEK,8^?DK!%3S78)HV.(R7V)@WJPCM/YQ-/;_(17N2=:."'L(TTCES1AY=-
M_:\1/00IV<.>DC;\G]E04/MX/(:S'4=J-#QV]P\R_]+B+U!+`P04````"`"P
MCFE'TN31'Z$!``"Q`P``&0```'AL+W=O<FMS:&5E=',O<VAE970R."YX;6QU
M4U%OVR`0_BN('U`<DG1=Y%AJ6DW;PZ2J#]LSL<\V*G`NX+C[]P/LN%;FO0!W
MW/?==\>1#VC?7`O@R8=6QAUIZWUW8,R5+6CA[K`#$VYJM%KX8-J&N<Z"J!)(
M*\:S[)YI(0TM\N1[L46.O5?2P(LEKM=:V#\G4#@<Z89>':^R:7UTL")G,ZZ2
M&HR3:(B%^D@?-X?3+D:D@%\2!K<XDZC]C/@6C1_5D691`B@H?6008;O`$R@5
MB4+B]XGS,V4$+L]7]F^IVJ#^+!P\H?HM*]\&L1DE%=2B5_X5A^\PE;"/A"4J
MEU92]LZCOD(HT>)CW*5)^S#>/&03;!W`)P"_`;`Q49+Y++PH<HL#L6-K.Q%?
M<'/@H1%E=*:ZTUT0ZH+W4O#]UYQ=(M$4<QIC^")F,T>PP#ZGX&LI3OP?.%^'
M;U<5;A-\N\S^\!^"W2K!+A'LEOGOLYL2UV)NBV2+GFJP31H=1TKL31K4A7>>
MSD>>WN0SO,@[T<!/81MI'#FC#R^;^E\C>@A2LKL])6WX/[.AH/;Q^"6<[3A2
MH^&QNWZ0^9<6?P%02P,$%`````@`L(YI1Q9$,(;P`0``^@4``!D```!X;"]W
M;W)K<VAE971S+W-H965T,CDN>&ULC53-CILP$'X5Q`.LP2201`1IDZIJ#Y56
M>VC/#ID$M#:FM@G;MZ]M"$N2.>2"[?'W,V/CR7NI/G0%8()/P1N]#2MCV@TA
MNJQ`,/TB6VCLSDDJP8Q=JC/1K0)V]"3!"8VBE`A6-V&1^]B;*G+9&5XW\*8"
MW0G!U+\=<-EOPSB\!M[K<V5<@!0YF7C'6D"C:]D$"D[;\#7>[./(03SB=PV]
MGLT#E_Q!R@^W^'G<AI'+`3B4QDDP.UQ@#YP[)>O\=Q3]\G3$^?RJ_MV7:],_
M,`U[R?_41U/9;*,P.,*)==R\R_X'C#4LG6`IN?;?H.RTD>)*"0/!/H>Q;OS8
M#SOI>J3A!#H2Z$28?'!",A*2.P(9,O-U?6.&%;F2?:"&RVB9N_-XD]B3*UW0
M'Y3?LY5I&[T4-*4YN3BA$;,;,'2&2;-;R/X1$D\(8A.8LJ!8%COZZ+"Z<WB$
M4-PA0>M,/#VYJ3/!!1:HP,(++&X$%G<'A6&6N,D2-5DB`BDND*("Z?-E9JA`
MAF1P?]D89H6;K%"3%2*PQ@76J,#Z^3+=(\;^^^B)0C%0%MWYD-E3$Z#.O@7I
MH)1=XSO>+#JUN5?JG^H7O,A;=H9?3)WK1@<':>R#]\_R)*4!FTOT8O^-RC;B
M:<'A9-PTLW,UM*9A861[[;13NR_^`U!+`P04````"`"PCFE'^?PH(IL!``"P
M`P``&0```'AL+W=O<FMS:&5E=',O<VAE970S,"YX;6Q]4]MNW"`0_17$!P1?
MXCI=>2TU6T7M0Z4H#^TS:X_7*,`XP*[3OR]@K^NLK+R8F>&<PYG!5".:5]L#
M./*NI+9[VCLW[!BS30^*VSL<0/N=#HWBSJ?FQ.Q@@+>1I"3+DN0+4UQH6E>Q
M]FSJ"L]."@W/AMBS4MS\?02)XYZF]%IX$:?>A0*K*[;P6J%`6X&:&.CV]%NZ
M.^0!$0&_!8QV%9/@_8CX&I*?[9XFP0)(:%Q0X'ZYP`&D#$+^X+=9\_^1@;B.
MK^I/L5OO_L@M'%#^$:WKO=F$DA8Z?I;N!<<?,+=0!,$&I8U?TIRM0W6E4*+X
M^[0*'==QVBG*F;9-R&9"MA#2^T\)^4S(;PAL<A;[^LX=KRN#(S'370P\7'FZ
MR_WDFE",@XI[OC/KJY<Z*].*78+0C'F<,-D:\Q%QV$`4"X1Y`XN+;--%%OGY
M!Q?9MD"^*9!'@?N50%[<=#%!R@C1$5(\?'VX:6035-XX8:OA#OP$O[@Y"6W)
M$9V_ISC-#M&!%TSN"DIZ_WR61$+G0ECZV$Q_U)0X'*[O8WFD]3]02P,$%```
M``@`L(YI1^/9<8^_`P``>Q0``!D```!X;"]W;W)K<VAE971S+W-H965T,S$N
M>&ULE5C;;IM`$/T5Y`\([,YR<>18:E)5[4.E*`_M,['7,0JP+N`X_?MRLVMV
M#H2\A-N9V3.S.<<#JY,I7LN]UI7SGJ5Y>;?85]7AUG7+S5YG<7EC#CJOG^Q,
MD<55?5F\N.6AT/&V#<I25WI>X&9QDB_6J_;>8[%>F6.5)KE^+)SRF&5Q\?=>
MI^9TMQ"+\XVGY&5?-3?<]<J]Q&V33.=E8G*GT+N[Q1=Q^Z!D`VD1OQ)]*J_.
MG8;\LS&OS<6/[=W":SCH5&^J)D5<'][T@T[3)E.]\I\^Z?\UF\#K\W/V;VVY
M-?WGN-0/)OV=;*M]S=9;.%N]BX]I]61.WW5?@]\DW)BT;/\ZFV-9F>P<LG"R
M^+T[)GE[/'5/(J\/PP&R#Y"7`*$F`Z@/("O`[9BU=7V-JWB]*LS)*;K-.,3-
MGHM;JCNW:6ZVC6J?U965]=VWM0QIY;XUB7K,?8>1UY@AX@$@_`O$K0E<6$C(
M0K;Q-&"A<`*"":A-H`8)?*N,#A.VF+S%B"`(A%4*1_D4$>:B(!<%N`0X@0\3
M^/.[$<`$`6`06MWH,/Y5G8$?V?L*0($O,)404@D!E0@GB&"""#1CB1,L88(E
M9Q!Y5C.6K$Z2@8BL;G"46*JKQ@[(-.:!].8!.L(6G,=7"B-OI/%B1-F"K43V
M/T&/N5[(]Y18VO+FL*G*L<;%)T0NL,K%')GW(/\#G0/8N-`%5KI`4F<]5G.4
MAE"C4A/8-X3/Z"C&QF?K2)**;#H<)J1'8]N%;4@`'[HJ?)@"VX<(Y\M?8`,1
MT0P#Z$$?.0"`30D!&Y)`CL0L@)N-AU>1V&@D-QHF?\E]!E4-8!-52VQ'4LR7
MOQR9$N0,^?<@W+B^GBG(D`CV(8E\B#67&PPC,@49$L$&)+D!,<5+[BR,QQ1D
MR`,[C^3.(\>\5&*SD,%\I4ML%A(,&TSI/6BR'5.0(1%L.1)9CJUPR;UD;!7L
M(Y+["%?XE(WTU<YV&L).0]XGIG=L#L1G%3"_@RD$#?!@IAG]82?L-(2<QNXM
M?>PTDY`AD9'W&NXT3.`T;^`!L(F^8+\A,/!$8UN-K8+0V\V(S@E;!:&YPM8Y
M\7<7MCM3D"$1;#B$#,?6.7$WF1CF"3L*<4=A6B<PG`P6ZJN>[3N$?8>6\_6N
ML&4H\!;$]*[XV&'OX"1D2`0;CT+&8S=6<4<!$SQ"C4[P"ON.XK[#Y-YCP@_8
M`!1GXUY])CK$+_IG7+PD>>D\FZHR6?M=:&=,I>N,WDU=V5['V\M%JG=5<QK6
MYT7W;:R[J,SA_*GO\KUQ_0]02P,$%`````@`L(YI1VYIM:TZ`@``00<``!D`
M``!X;"]W;W)K<VAE971S+W-H965T,S(N>&ULC57+CILP%/T5Q+[#TSPB@C0D
M4[6+2J-9M&N'.`$-QM1VPO3OZP<A!)S);+!].>?<EW6=]82^LPHA;GW@IF5K
MN^*\6SD.*RN$(7LB'6K%GP.A&')QI$>'=13!O2+AQO%=-W(PK%L[SY3ME>89
M.?&F;M$KM=@)8TC_%:@A_=KV[(OAK3Y67!J</'-&WK[&J&4U:2V*#FO[V5N]
MI!*A`+]KU+/)WI*Q[PAYEX>?^[7MRA!0@THN%:!8SFB#FD8*"<=_!\VK2TF<
M[B_JWU6V(OH=9&A#FC_UGE<B6->V]N@`3PU_(_T/-*0`I&!)&J:^5GEBG.`+
MQ;8P_-!KW:JUUW\2=Z"9"?Y`\$?"Z,=,"`9"<"6$GQ+"@1!^U0,8"&#FP=&Y
MJ\IM(8=Y1DEO4=WM#LI+Y:V`Z$TIC:H5ZI^H'1/6<^XG('/.4FC`%!KC3S!1
M?`O9+B'>B'!$`&,4OBF*PE_0_5L'FR4B2F8Q/!1Y^53D)LS`6*Q`\8.;8D5F
M@=`H$"J!\$9@5LI"8V*%:14F<&>8S1(#TGE+EI@HG=5C"?D&4G,^P)@/6.83
MWRE(9!2(OE[1V"@0&RHZOQ@:`Z:5B,"=^YD8O22/^[9-EE[NU#(U^D@-/F8-
M*])E3T$RN^7;!R`=BC,9$!C1HQK-S"K)J>6R(1/K./V??3E@9O;"6VT\@WTK
M7@L]W*_R>=;!(_H%Z;%NF;4C7(PU-7P.A'`D8G>?1/TJ\9Z-AP8=N-S&8D_U
MB-<'3KK+@S6^FOE_4$L#!!0````(`+".:4?7]Z>:^0$``-8%```9````>&PO
M=V]R:W-H965T<R]S:&5E=#,S+GAM;'V4VZZ<(!2&7\7X`!L53S-Q3#HV37O1
M9&=?M->,XF@VB`5FW'W[`CK60=H;.?W_6M\"H9@8?Q<=QM+[H&00)[^3<CP"
M(.H.4R1>V(@'M=(R3I%40WX%8N08-<9$"8B"(`44]8-?%F;NE9<%NTG2#_B5
M>^)&*>*_SYBPZ>2'_F/BK;]V4D^`L@"KK^DI'D3/!H_C]N1_"H]5IA5&\*/'
MD]CT/<U^8>Q=#[XU)S_0")C@6NH(2#5W7&%"=""5^-<2\V]*;=SV']&_F&H5
M_04)7#'RLV]DIV`#WVMPBVY$OK'I*UY*2'3`FA%AOEY]$Y+1A\7W*/J8VWXP
M[32OY,%B<QNBQ1"MAC#^KP$N!F@9P$QFZOJ,)"H+SB:/SV<Q(GWDX1&JG:OU
MI-DHLZ8J$VKV7D:'H`!W'6C1G&=-M-4\*RJ'(EDE0`&L%)&3(C)^N/&'"70'
M@,X`T`2(G\H(K3)F368T@]$D87:P*MF+TD.:N5%B)TKL0+'VZSQKDDV6@ZVI
M]IHPB`,W2>(D21PDT"))]EG"R-JY:B_*-YHGDM1)DCI(8HLDW26!F<6QER3_
M.)K,B9'M,&+[7\]VYY_!R/Y)]J(\S^T?'FRNX(BN^#OBUWX0WH5)=9O-G6L9
MDU@%#%Y439UZ9-<!P:W4W4SU^?SNS`/)QL<KNC[EY1]02P,$%`````@`L(YI
M1^<G<U90`@``Q@@``!D```!X;"]W;W)K<VAE971S+W-H965T,S0N>&ULE5;;
MKILP$/P5Q`?$V-Q"1)":5%7[4.GH/+3/3N($=`RFMA-._[ZV(31QEZI]`=O,
MSNRRC$TY"/FF:L9T\-[R3FW#6NM^@Y`ZUJRE:B5ZUIDG9R%;JLU47I#J):,G
M%]1R1*(H0RUMNK`JW=J+K$IQU;SIV(L,U+5MJ?RY8UP,VQ"']X77YE)KNX"J
M$LUQIZ9EG6I$%TAVWH8?\&:/<PMQB&\-&]3#.+#)'X1XLY,OIVT8V1P89T=M
M*:BYW=B><6Z9C/*/B?2WI@U\'-_9/[ER3?H'JMA>\._-2=<FVR@,3NQ,KUR_
MBN$SFVI(+>%1<.6NP?&JM&CO(6'0TO?QWG3N/HQ/\F@*@P/(%$#F`)S\-2">
M`F(O`(V9N;H^4DVK4HHAD&,S>FI[CC>Q>7-'N^A>E'MF*E-F]5:1(BW1S1)-
MF-V((4^8[!FSAS#YC$$FASD1`B9"'$'\1+"&"6*0('8$R1-!X57R)R:.(E@D
M`442@`![(A"&P"(I*)("!+$G`F$26"0#13*`P&\\A,E@D1P4R0&"W!.!,`N-
M7X,B:X#`;SR`P0N-+T"1`B#P&K\?,:G#=`Z#UR0K2`P+V>T%<F0$2!'?DB.H
M>-`BJR3W30FAEEXN7M@@,)"._S6"H(7/$</^QP2@2!<HX!T`Q_^^AV#8WQ@P
MK]_GW03R&HW7"];`L,LQ8&&\1`%[&&?_43#L4`S8#_L6G4#Y8\&^>]##B=/3
M"_M*Y:7I5'`0VAQ>[H@Y"Z&9X8M6IO3:_%3,$\[.V@YS,Y;C,3M.M.CO?PWS
MKTOU"U!+`P04````"`"PCFE'";(MQ2P"``#B!@``&0```'AL+W=O<FMS:&5E
M=',O<VAE970S-2YX;6R-5<V.FS`0?A7$`RS8_(1$!"E)5;6'2JL]M&>'3`):
M&U/;"=NWKVT(RX*CW4NPA^]G9AP/><?%JZP`E/?&:".W?J54NPD"65;`B'SB
M+33ZS9D+1I3>BDL@6P'D9$F,!C@,TX"1NO&+W,:>19'SJZ)U`\_"DU?&B/BW
M!\J[K8_\>^"EOE3*!((B#T;>J6;0R)HWGH#SUM^AS0%A`[&(WS5T<K+V3/)'
MSE_-YN=IZX<F!Z!0*B-!].,&!Z#4*&GGOX/HNZ<A3M=W]>^V7)W^D4@X</JG
M/JE*9QOZW@G.Y$K5"^]^P%!#8@1+3J7]]<JK5)S=*;['R%O_K!O[[/HW63C0
MW`0\$/!(&'W<A&@@1.^$V%;:9V;K^D84*7+!.T_TA]$2<^9H$^G.E29H&V7?
MZ<JDCMZ*"&5Y<#-"`V;?8_`$@T9$H-5'"^RRV.,%'7\T."P1:>9VB)Q%1)8?
M?2AB[1:(G0*Q%8BG`CB<=:''K"RFL9@9XK!$X`@E[CP29Q[)(H_U_#"2A4F\
MBE'J=DF=+NG2)73S5T[^ZNOMSIP"F:/=:%9GCTDF=6I,DJ79@X:NG4[KSQNZ
M7C0T<CN8<>"Z0>'2X\']0`_N(/IZ0Y'SCNT0_KS0`3/_Z\RK#2:C@X&XV)$J
MO9)?&V4NZ20ZCNV=G=JS^-Z,<SN2WF6*O"47^$7$I6ZD=^1*#S8[?LZ<*]!9
MAD_ZR"O]P1DW%,[*+%=Z+?H1W&\4;^]?E/&S5OP'4$L#!!0````(`+".:4?S
MREM-SP,```43```9````>&PO=V]R:W-H965T<R]S:&5E=#,V+GAM;)58VV[C
M.`S]%<,?4%N4Y4N1!IA))]L46&`P#[O/;J(TQMA6QG:;V;]?7]1L)%*NMP^-
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M\?<RO4E#3:,)H`EP);!HEL`U@2\E1)H0+24(31!+";$FQ$L)B28D2PFI)J1+
M"9DF9$L)PYQ/,Q=:E&":\K%@'O,N7Z\:=?&:J<K/^=!,[)X--;D?GHXE.+[L
M:Z;MG[ZO.<`J>!\L:<S7"0,&AIN8#<9`EIB81\I.9&*^+?"U)7R9B#\^13QA
M1)R:D!UA1)B09VK4\143]*F_YA_H_,-H@1OC%;0%3EO@HX7H=B2AE;`)(D9(
M/4)$./Y9:5N(VWV.,P*/Z,`C%+C(K,`G2'KC*+SKW3`K[F6PW:<P(VI!1RUP
MNJW:V@B4'AX+GD:Q-3J,@X2>F,7('8$,P[G)B>EAQGB85CJW\;+)60;;?0HS
MHD[HJ!,4-0<KZYL)D]S.3DHFG0"&&8(]81C$W)GNE`X\)0*WY9/"I+27C/:2
M$1:LEMM,F.QF..Q..#1M6'W(125$CNS%8*,Q1J5&7*19$CF<N58PAD?%0]N;
M7N="H[X<0LL<6LV`\,1L3X`2"'>AM;8\DZ@H<<3C4'Z&I9\S%`\6:Y9"G-VL
MJJ8SAUHS+-><HYU"M$SZ-@1P/BJ'&C,LQYQS.RJ!6E1$1,=_(X!1F,Z()W.H
M)\/RR;FKKAU:QI+E6P/FD!5&:88U%X\:9(PZ(]*SI8#17'8<,L0('>+"CBK#
M^B!FG(%#BP!K$1*]1PTR1-SAQJ%"@%7(EKRMQIC+^-R07'M&2H=<VTZ'=@!?
M7EW@D`0@)`%5EP89S3>[(0%'JP-N=73"`+S]B3D#<.PBP-&^0+6O0YS!T;[P
M/]H7'.T+"]IW"[@K@<_EU]&5@+L25S!N2C:G`-S1E)QH2FZ?OTA0YG#D:$M.
M;`XB=)QA.(-TB08WY^IS_BK_S)O7HFZ]%]7UA_3Q''U4JI.]U7YWX7LGF1^N
M-Z4\=L-ETE\WTU>:Z:93YX^/3M<O7^M_`5!+`P04````"`"PCFE'RE6:J.4!
M``!Q!0``&0```'AL+W=O<FMS:&5E=',O<VAE970S-RYX;6Q]5-V.G"`4?A7C
M`RR"HG;BF'2F:=J+)IN]:*\9Q=$LB`5FW+Y]`1WK*ML;@</W=U0H1B%?54NI
M#MXXZ]4Q;+4>#@"HJJ6<J"<QT-[L-$)RHLU27H$:)"6U(W$&4!2E@).N#\O"
MU9YE68B;9EU/GV6@;IP3^>=$F1B/(0P?A9?NVFI;`&4!%E[=<=JK3O2!I,TQ
M_`P/Y\PB'.!G1T>UF@<V^T6(5[OX7A_#R$:@C%;:*A`SW.F9,F:%C/'O6?.?
MI26NYP_UKZY;D_Y"%#T+]JNK=6O"1F%0TX;<F'X1XS<ZMX"M8"68<L^@NBDM
M^(,2!IR\36/7NW&<=O)HIOD):":@A0"3_Q+BF1!O"&!*YOKZ0C0I"RG&0$[?
M8B#VD\-#;-Y<98ON1;D]TYDRU7L9)[``=RLT8TX3!JTPZ#WB[$'@!0),@"4%
M\J9`CA^O^#"-_0*Q5R!V`LF[-C8A3Q,&.TP_A41QE&]:V:-RG$3^+(DW2^+)
M$F^R)#L7"&&^S;)'Y?C3!UFP-POV9$DV6?`^2X0P]-ND7IO48X,W-NG.!J/<
M;Y)Y33*/2;HQR78F28*R[;\(5J=C(%?Z@\AKUZO@(K0Y:.XX-$)H:A2C)R/6
MFOMO63#::#O-S%Q.5\*TT&)X7'#++5O^!5!+`P04````"`"PCFE'VGY*/.D#
M```W%@``&0```'AL+W=O<FMS:&5E=',O<VAE970S."YX;6R5F-]NHD`4QE^%
M\`"%^0?:J$EUL]F]V*3IQ>XUU5%)@7$!:_?M%T9J+?.=9KQ1P#/SG8'OQSG.
M[&3JEV:O=1N\E475S,-]VQ[NHZA9[W69-7?FH*ONEZVIRZSM3NM=U!QJG6WL
MH+*(>!PG49GE5;B8V6N/]6)FCFV15_JQ#IIC66;UOZ4NS&D>LO#]PE.^V[?]
MA6@QBR[C-GFIJR8W55#K[3Q\8/<KI?H0&_$[UZ?FZCCHDW\VYJ4_^;F9AW&?
M@R[TNNVGR+JO5[W21='/U"G_'2;]T.P'7A^_S_[=+K=+_SEK],H4?_)-N^^R
MC<-@H[?9L6B?S.F''M9@,UR;HK&?P?K8M*9\'Q(&9?9V_LXK^WTZ_Y).AF%X
M`!\&\,L`EGPY0`P#Q&A`=,[,KNM;UF:+66U.07U^&(>L?^;L7G1W;MU?M#?*
M_M:MK.FNOBZ$3&?1:S_1$+,\Q_"KF&04LG)#V"4BZA*X9,%1%DON*DQ&"FX(
MQPH"KE/8X>+3.B=X`@DGD'8"^6F"Z2C'<XRR,96-F2@98Q4%592KHN*1BG)4
MF.RHQ#()E$F`#!O))(X,%\0=2Z%("D3X2"1U1;B("9D)E)D`&8$GF,()IO[6
MZ-\("*+8PQQ#T/5:"6LP`E7F88XAR-,=#.+XP+C'HQN"?)4PEDP`)3E60D&*
MT,'T,H"OHE+%:#)U@T\P=@QPY_K$!4],4\+1#*/'$'N.55SX*$-B\AA"S[')
MY);E8$+9U,<E*"@EJA#FF`..%?&(.8:4,W^7<$P?!_0Y+N$N?2(65-'%\''$
MU=@E0Y"'2SA&CR/TQB[A;NG\8CD84(Z*Y]@E,&A*Z&"*.:`XH>X)YI.G-[@$
MP\<!?*Y+7/@21KPY.6:/(ZP<DTQ]32(P>0*1-S:)<"LHN1J!\12HAHX]@H(2
MPHL",RP`PPG5L!(=ZPTMJ\#H"9^F5;CHL90HC0*3)WS:5N'VK91','<"=:V.
M1]SJ2:\&PRE0\70\`H(2HJH)3+``!">2F`+#*6[H724F3_KTKM(ECQ/@20R>
M]&E>I=N\$A:1&#OIT[A*MW22B\%H2I^N%051#I'$?T[`;T*EBM&4-W2M$G,G
M?;I6Z7*7<NKA8>ZD3],JO9M6B:F3J&D=__>5;MTD__Q*C*9$==.QHELWY80H
M$PKSJP"_"?'"4YA-=4//JC!X"H$W(F*)@A*B0U>8/(6@HE+%4"EYPVJ)71J/
M3G.)@I)QIQE=[=.5NM[9_<LF6)MC9;=+KZY>]D@?N-WG^PA?S`[93O_*ZEU>
M-<&S:5M3VCV]K3&M[G*)[[I<]CK;7$X*O6W[P[0[KL_[FN>3UAS>MVDO>\6+
M_U!+`P04````"`"PCFE'>ELOEYX#``!"$P``&0```'AL+W=O<FMS:&5E=',O
M<VAE970S.2YX;6R5F,URVC`4A5_%XP?`^O%O!IA)Z'3:16<R6;1K!01X8EO4
M%B%]^]JR(2`?)<X&;//IWBOYZ"!I?E+U2[.74GMO95$U"W^O]>$N")KU7I:B
MF:F#K-I?MJHNA6YOZUW0'&HI-J91602,D#@H15[YR[EY]E@OY^JHB[R2C[77
M',M2U/\>9*%."Y_ZYP=/^6ZONP?!<AY<VFWR4E9-KBJOEMN%?T_O5CSM$$/\
MSN6IN;KVNN*?E7KI;GYN%C[I:I"%7.LNA&B_7N5*%D47J<W\=PCZGK-K>'U]
MCO[==+<M_UDT<J6*/_E&[]MJB>]MY%8<"_VD3C_DT(>H"[A616,^O?6QT:H\
M-_&]4KSUWWEEOD_]+RD9FN$&;&C`+@U8_&$#/C3@5H.@K\STZYO08CFOU<FK
M^Y=Q$-T[IW>\';EU]]`,E/FM[5G3/GU=\H3,@]<NT,`\]`R[8N@ML1H3/'EG
M@K:"2QD,E?'`1@&8E0(0$<[`84>Y:1]>EQAQ'""$`4(3@-_TD>$`$0P0C2M(
MN#74/9,9INI[.2,ISA+#+#'($EI9$.,8S`0F24"`V$J"F`0G26&2%`1(K22(
MR7"2#";)@"QB'*"S`S2#R'1A4,<DI!.D,4"WVHCLB?@Q=%L,G(KWE$U0$()2
M8A>#((<M4#QK*9BV(Z4A*+7]`T(.`Z#8`6@X09$(2D.[&`2Y7A-V$PKL)'(X
M!<560>,O*!<;`46S?*3<9"1*.DNY/2:(<LQEBAV#(CL821=`:6P7@R"'>U'L
M+!18RUBZ`$I3NQ@$.=X3PR;%R`3I(BC-K&(0E!%',=CN&+"[V!4"FQ1CTZ7+
ML+4P9"VV=`?H6I1D%MNN^QEU6PXV%X;,Q=8N@C)[,08AU]A@<V%HK6)K%T&9
M/:LA%#J*P3;%T')EI%T`9:/WA"#'OSW#AL>`X<6NP<4NQ=(O:!=["T/>,M)N
M-DF[GU"W2VOL+ARYBZU=!&6)50V$'/]J'+L+1XLI6[L(RFRK`U!('#[%L4]Q
MM)BRM0N@D-BS&D(.U7#'%@@X7NR8BQR[%/_"+HAC;^%3]D$<;H3L-1VDJ$N[
MV%WXE`T3@$)B6QV$7,.+W85/V5@!*"3VM(:0P^HX]BD^90,&H)",9C6"[%D=
M7!U9E++>F:.<QENK8V5.CJZ>7HZ+[IDY\GC'E_.#V,E?HM[E5>,]*ZU5:8XW
MMDIIV=9"9JUF]E)L+C>%W.KN,FFOZ_Z(I[_1ZG`^L;H<FRW_`U!+`P04````
M"`"PCFE'>0R.&%\#``#Q$```&0```'AL+W=O<FMS:&5E=',O<VAE970T,"YX
M;6R5F$UOHS`0AO\*XMZ"9\Q'JB12T]5J][!2U</NV4V<!!5P%IRF^^\7#$U)
M/):<2\!F/.^,/0_&F9]4\];NI=3!1U76[2+<:WUXB*)VO9>5:._50=;=DZUJ
M*J&[9K.+VD,CQ<8,JLH(XCB-*E'4X7)N^IZ;Y5P==5G4\KD)VF-5B>;?2I;J
MM`A9^-GQ4NSVNN^(EO/H/&Y35+)N"U4'C=PNPD?VL.+0FQB+WX4\M9/[H`_^
M5:FWOO%SLPCC/@99RK7N78CN\BZ?9%GVGCKEOZ/3+\U^X/3^T_MWDVX7_JMH
MY9,J_Q0;O>^BC<-@([?B6.H7=?HAQQR2WN%:E:WY#=;'5JOJ<T@85.)CN!:U
MN9Z&)UD^#J,'P#@`S@-@"'P0,F%^$UHLYXTZ!<TPMP?1+R%[@&XBUGVGR=L\
MZP)MN][W)8]G\^B]=S3:K`8;F-BPLT74>3]+`"6Q`FLX9S'M`,D8T3C`B0/,
M@';`20?<..`7$;"K)`>;S-C40Y(QS%):)B%E$BM.SAQQIJ2#E(@3K^(<;)))
MG`GF2*MDI$I&J/`KE<Q2F>6.5')2)"=$DBN1W!)A:9HZ:FM&RLPL&4P<D]'#
M20$0^U<7<S#$/.IK-$K\"HR1*#TR\"\Q1L/$T*/(1J-IL`YB&4T<HY"[+K+1
MZ&)*D+F6CV:.)1Z%-AI="+%T\IZ[5*+A9#:=F+B6CR:/93?4&LT5H\"R:LTF
MR[5\-%9LYE]G0',%L4>=C4;30"%)';$"31]0]%V7&MCTW;$D<PC1\`%XE-IH
M=)$1CQTU#32B8".*2>YP0?,'_(8%I,D"BBQK`6VR(`;7O-)@`;7M60MH[WMW
M+'5E1.,'U,YG+:"]];$\31Q"-*1@0XK.JJ8)A!L(1)I`]"$0;0)3<&2+-(#H
M`R!2`+J^`FG^T(<_M/E+F2L?Q^<F@9^KTI#&#V_`#VG\T`<_)#:VU/&R09H^
M]*$/;?I<V=#HH0]Z2*#G(@]I\I`BCSM<T.3A#>1QFCSN0QZWR7.\XSG-'??A
MCA/<.>:#T]AQ'^Q&H^GQZ5HEFAQ)*]GLS,F[#=;J6)N#_J3W?+I_-(?[Z,M\
M.3^(G?PEFEU1M\&KTMW!V!Q?MTIIV442WW>I[J78G!NEW.K^-NONF^%$/C2T
M.GS^P7#^EV/Y'U!+`P04````"`"PCFE'W[M#@0@"``!_!@``&0```'AL+W=O
M<FMS:&5E=',O<VAE970T,2YX;6Q]5<N.FS`4_17$!\38)CQ&!*F3JFH7E4:S
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M^W&<[F3I3(,)9":0A8#_3Z`S@08$-"7S=7UFAM65DF.DIH<Q,/?,\1.U)W=T
MF_Z@_#U;F;:[MSK%685N3FC&/$\8LL*0,L#L(4R^8)#-L`0A8!#B!>A*@.8$
M%J"@`/4"Z8=*\J"2";/UF-YC<$%PD<$^*>B3/OA0B@.?"5.N?,@F#<+L(5!2
MP%&V8)0M4'(11'G$4)S")AEHD@$F96`"8$@"F^2@20X(A(?ZB*'X'R8%:%(`
M)B0P@3`4-BE!DQ(02`,3"+.%35P/@C[;!)!X^&Z3AS<,;\JP&K1J%0.[\.],
M7=I>1P=I;-?QO>$LI>%6,=G8MZFQ?X-E(?C9N&ENYVKJC]/"R.'>[I=_3OT'
M4$L#!!0````(`+".:4?*!745M0(``*D*```9````>&PO=V]R:W-H965T<R]S
M:&5E=#0R+GAM;)56VVZC,!#]%<0'%(Q-(!%!RFVU^[!2U8?=9S=Q$E3`*7::
M[M^O;0@E]M"F+X"',\<SQV-[L@MO7L21,>F]5V4MYOY1RM,L",3VR"HJ'OB)
MU>K/GC<5E6K8'`)Q:AC=&:>J#*(PG`05+6H_SXSML<DS?I9E4;/'QA/GJJ+-
MOR4K^67N(_]J>"H.1ZD-09X%O=^NJ%@M"EY[#=O/_06:;5"B(0;QIV`7,?CV
M=/#/G+_HP:_=W`]U#*QD6ZDIJ'J]L14K2\VD9G[M2#_FU([#[RO[#Y.N"O^9
M"K;BY=]B)X\JVM#W=FQ/SZ5\XI>?K,LAUH1;7@KS]+9G(7EU=?&]BKZW[Z(V
M[TO[)PT[-]@AZARBWJ&?!W;`G0/^<""?.I#.@=P[0]PYQ-8,09N[46Y-)<VS
MAE^\IEWN$]55A6:Q6INM-IJE,/^4=D)9WW(2)5GPIHDZS++%1`/,Q(*L70CJ
M$8$*H(\B@J)81HY[=#O!RD5,4BN&+TDVGY+<A(E!L;#Q)S=BC1`0D(`8`GQ#
M,(4)8I`@=B/`H;5<+28QF-I@4FRIZ4*FEE9K%Q+%%LW&Q1`\HL<$3&<"I#-2
M.`E(D-PO:`H2I'<(VF+B89JV7"L7,YU:/&L7@\(469JZ($Q("*<T!5.:`BE%
M,($^0Z%#(;Q?5C1RKJ"OA5UWH&&R23I20`@\.18H`N;!(Q3PKD;X&]G"^QJ1
M.\JH`PVSC9/8JB,`I(K$WIP0"F-BE1*`PFDRIB]\X"#HQ"$C%/`F1Y-OZ`MO
M<Y3<HV_B'EFNO@`(.;>9"QK69:>N"XKCQ$HK&-S#%6L.I@,2WI:?:ZDE&5C[
M+FL1Z7O<LB_1;(4`^UIW9>;>_Z#/LQ,]L-^T.12U\)ZY5-V#N>/WG$NF8@\?
MU*H>5=_8#TJVE_HS4=]-VTFU`\E/U\:P[T[S_U!+`P04````"`"PCFE']8-Q
M&4`"``#>!P``&0```'AL+W=O<FMS:&5E=',O<VAE970T,RYX;6R-5=N.VR`0
M_17+'[#8^-:-'$N;2]4^5%KM0_M,'!);:XP+)-[^?0$[CD.FZ;X$&)]SF,,0
M)N^Y>)<5I<K[8$TKEWZE5+=`2)85940^\8ZV^LN!"T:47HHCDIV@9&])K$$X
M"%+$2-WZ16YCKZ+(^4DU=4M?A2=/C!'Q9T4;WB_]T+\$WNICI4P`%3F:>/N:
MT5;6O/4$/2S]EW"QS0S"`G[6M)>SN6=RWW'^;A;?]TL_,"G0AI;**!`]G.F:
M-HT1TAO_'C6O6QKB?'Y1_VK=ZNQW1-(U;W[5>U7I9`/?V],#.37JC???Z&@A
M,8(E;Z3]]<J35)Q=*+['R,<PUJT=^^%+%H\TF(!'`IX(TSXP(1H)T43`CW>(
M1T)\)40/"<E(2)P=T.#=GMR&*%+D@O>>&*K=$7.IPD6B:U.:H"V%_:;/3NKH
MN8BC)$=G(S1B5@,&SS!I=@O9W$/""8%T`E,6&,IBA>_H^':#]3TB_>+D\%^1
M[4.1FS0C\+`BRX_F+M-G6"`&!6(K$-^<=NJ<-H#!3D76D(Y;$@CC'-GVL<Z-
MH00TE``"SXXA`'-G",#$@6,(PH2.(0B#84,I:"@%!"+'$(2)'4,0QC&]@3#.
M;=A"F']4*`,-98"`<PU6`.:N0I_`;#Z!V3[&#(;0[/5B5!QMWY!>R4^M,O^_
M671J32_8O'Y.?!4NUB$0W^A6-G2>JWR1=^1(?Q!QK%OI[;C2;ZY]&0^<*ZI3
M#Y[T[:ITLYT6#3TH,\WT7`S]9U@HWEVZZ=32B[]02P,$%`````@`L(YI1RZO
M.4BN`@``_0H``!D```!X;"]W;W)K<VAE971S+W-H965T-#0N>&ULE5;;CILP
M$/T5Q`<$QERS(DC)5E7[4&FU#^VSDS@)6L"I[23;OZ]M"$M@+.V^!-N<.6<F
M]L%3W+AXDR?&E/?>U*U<^2>ESD]!('<GUE"YX&?6ZC<'+AJJ]%0<`WD6C.YM
M4%,')`S3H*%5ZY>%77L19<$OJJY:]B(\>6D:*OYM6,UO*Q_\^\)K=3PILQ"4
M13#$[:N&M;+BK2?88>6OX6E#8@.QB-\5N\G1V#/);SE_,Y.?^Y4?FAQ8S7;*
M4%#]N+)G5M>&22O_[4D_-$W@>'QG_V[+U>EOJ63/O/Y3[=5)9QOZWIX=Z*56
MK_SV@_4U)(9PQVMI?[W=12K>W$-\KZ'OW;-J[?/6O<G#/@P/('T`&0*BS";>
M"=DTOU%%RT+PFR>Z__9,S1;"$]%_Q,XLVKKM.YVHU*O7,HZ717`U1#UFTV'(
M"`,#(M#L@P3!)#9D%AXG(4X0H3E&EB!Z('!D$*,$L26('PC(I,@.L[28MBMR
M`3&NDJ`J":(2350PC$,D1452A""9B&"8%!?)4)$,(<@F(A@FQT5R5"1'"*8G
MK\-DHTV)<TAPE26JLIRKI.%$!<,XSI=Q..:B$*&8GK`>E(RJB=)<?Q\=9@"'
M8P'1BAP4J"/70#[O*,`]"1&213RM&`,YM@]PZ\+<NY'K!`#N2TB^4"WN.D`L
M-:\6`SE\![CQ`'%5FCDH<%M!_H5J<<\`9HA\6NUR=II)FH2A\S@3W#KD,]8A
M<^L`0)Z[Q7#O$,P[TX].#WH0"TD";C'<983,Q;+IMP<#N2Q"<"L2Q&493'40
MD.OF(;@5"7*-9K.=PN[1V<40C-J3AHFC[<*DM^.7UC9]H]6ATUL3V]Y\P,OB
M3(_L%Q7'JI7>EBO=)-E6YL"Y8CJ9<*'W\*1[T6%2LX,RPTR/1=>==1/%S_=F
M<^AXR_]02P,$%`````@`L(YI1QN!".[+`@``W0H``!D```!X;"]W;W)K<VAE
M971S+W-H965T-#4N>&UL=99-CYLP$(;_"N+>@,V7B0A2LE75'BJM]M">O8F3
MH`6<M9W-]M_7-H0E9GP)8%[/,S9^)U/=N'B39\94\-FUO=R$9Z4NZRB2^S/K
MJ%SQ"^OUFR,7'57Z49PB>1&,'NRDKHUP'.=11YL^K"L[]BSJBE]5V_3L603R
MVG54_-NQEM\V(0KO`R_-Z:S,0%17T33OT'2LEPWO`\&.FW"+UCN,C<0J_C3L
M)F?W@4G^E?,W\_#KL`ECDP-KV5Z9$%1?/M@3:UL329/?QZ!?3#-Q?G^/_L,N
M5Z?_2B5[XNW?YJ#..MLX#`[L2*^M>N&WGVQ<0V8"[GDK[6^POTK%N_N4,.CH
MYW!M>GN]#6](/$Z#)^!Q`IXF)(5-?`#9-+]31>M*\%L@AKV]4/,)T1KKC=B;
M0;MN^TXG*O7H1YT6215]F$"C9C=H\$R#)D6DHT\(#"%V>#$]S6(X0`+FF-@`
MR4..*1P@!0.D-D#Z$"!S%CEH,JOIK89DI2?-#*1D`"5W*-F"DN0$PY0<I.0`
MI7`H^8+R+2EA2`%""@!"'$BQA*`XS6`,`3$$P)0.ABPP""%"8$P)8LHEAL0.
MIEQ@\AQ[/HRQ.62E>'E.B<<IR.-&!*2*73L.HG)^B%;8L_$(].0680"T\/T@
M,NOZVOS5K#P\DF#SH@0@I2XI69+B5>$YLPAV.0)L3ER;CZ('$EZEGG*"8*<C
MP.K$M?HH<DC$MWNPVQ%@=^+:?10]'HC$=WAAQR/`\L2U/"3R?2/8\0BP/'$M
M#XE\&-CQ"+!\Z5I^%!7S;2M@#(8=CV,`@QS,*)J7%NS[_X2K`@:J0NE6A5'T
M4,%\_U\8+@H8*`JE6Q1&T7S7<N26XVC6?G1,G&R7)8,]O_:VJ9N-3IW<UC9R
MT9>\KB[TQ'Y3<6IZ&;QRI9L@VZH<.5=,YQ*O]&K/NM><'EIV5.:VT/=BZ+Z&
M!\4O]V9RZFCK_U!+`P04````"`"PCFE'D9'+PA("```Y!@``&0```'AL+W=O
M<FMS:&5E=',O<VAE970T-BYX;6R-54UOVS`,_2N&[ZO\F2R!8Z!.6FR'`44/
MVUEQZ`]4LEQ)B;M_/TEV',<RNEXBB7J/?"0C.ND8?Q,5@'0^*&G$SJVD;+<(
MB;P"BL4#:Z%1-P7C%$MUY"42+0=\,B1*4.!Y*T1QW;AI8FPO/$W869*Z@1?N
MB#.EF/_-@+!NY_KNU?!:EY74!I0F:.2=:@J-J%GC<"AV[J._?8HUP@!^U]")
MR=[1VH^,O>G#S]/.];0$()!+[0&KY0)[($0[4H'?!Y^WD)HXW5^]/YMLE?HC
M%K!GY$]]DI42Z[G."0I\)O*5=3]@2,$HS!D1YM?)ST(R>J6X#L4?_5HW9NWZ
MFU4TT)8)P4`(1L(89YD0#H3P1O@\0C00HJ]&B`="/(N`^MQ-Y0Y8XC3AK'-X
MW^T6ZS^5OXU5;W)M-*TP=ZIV0EDO:;2)$G31C@9,UF.""6:UOH<<;(@_(I`2
M,*H(EE1D@44/[@/L;<3J^TS#?YT\?>KD3F:X6*S0\,-IENM@V4&TZ"`R#J*[
M:L>S:O>8M<$T!A-ZLW+O;4R\F;?$QJPVLWK8D&_Q9CF?>#&?V,IG/8N1Q5](
MQ\;8Z=@8*QT;8J>#)@^#`B_-2!).SLZ-U*V=6,>I]QCHAS6S9_YV[R_8#VI*
M]D/MYCY-6ES"+\S+NA'.D4GUG,VC*QB3H*1[#TI[I>;X>"!02+U=JSWO1UM_
MD*R]#NKQ:Y'^`U!+`P04````"`"PCFE'!]?B&AD"``!F!@``&0```'AL+W=O
M<FMS:&5E=',O<VAE970T-RYX;6R-5=N.FS`0_17$!RSF#A%!VE!5[4.EU3ZT
MSPY,`EH;4]L)V[^O;0BYX)7R$MO#.6?.#/%0C(Q_B!9`.I^4]&+KME(.&\\3
M=0L4BQ<V0*^>'!BG6*HC/WIBX(`;0Z+$"Q!*/(J[WBT+$WOC9<%.DG0]O'%'
MG"C%_-\."!NWKN]>`N_=L94ZX)6%M_":CD(O.M8['`Y;]]7?5#[2$(/XW<$H
M;O:.-K]G[$,??C9;%VD/0*"66@*KY0P5$**55.:_L^@UIR;>[B_JWTVYROX>
M"Z@8^=,ULE5ND>LT<,`G(M_9^`/F&F(M6#,BS*]3GX1D]$)Q'8H_I[7KS3I.
M3S(TT^R$8"8$"V')8R>$,R&\$B)3Z>3,U/4-2UP6G(T.GU[&@/4[]S>AZERM
M@Z91YIFJ3*CHN8SRI/#.6FC&["9,<(/Q%X2GU)<4@2W%+EC1@_L$U1J19/8,
MH;6(T/##NR)2NT!D%8B,0'0GD#UT8<+$!M,;3!BN>E6M47X:AY'=3&PU$UO,
MY':!Q"J0/-^.U"J0/M&.=%5H$(3H`56M45D<(;N7S.HE6WF)T1<"N54@?[X;
M^L+;[@AZHA\SZ.[-^W[VV!`++,OSQ_^'=W-]*?"C&6O"J=FIE_JBW$27T?D:
MZ.O_$-_ID6K&PE6F+`9\A%^8'[M>.'LFU7`Q(^#`F`1E$KTH>ZT:^LN!P$'J
M;:KV?!J#TT&RX3+5ET]+^1]02P,$%`````@`L(YI1P'1PC[[`0``E04``!D`
M``!X;"]W;W)K<VAE971S+W-H965T-#@N>&ULC53-CILP$'X5BP=8C`U)%!&D
M#:NJ/51:[:$].V02T-J8M4W8OGUM0PB;N%(OV!Z^GYD!3SY(]:YK`(,^!6_U
M+JJ-Z;9QK*L:!--/LH/6OCE))9BQ1W6.=:>`'3U)\)A@O(H%:]JHR'WL516Y
M[`UO6GA52/=",/5G#UP.NRB)KH&WYEP;%XB+/)YYQT9`JQO9(@6G7?2<;,N-
M0WC`KP8&O=@CE_M!RG=W^''<1=BE`!PJXQ2872Y0`N=.R!I_3)HW2T=<[J_J
MWWRU-OL#TU!*_KLYFMHFBR-TA!/KN7F3PW>82LB<8"6Y]D]4]=I(<:5$2+#/
M<6U:OP[CFQ6=:&$"F0AD)LP^80*="/1&2'VE8V:^KA=F6)$K.2`U?HN.N4^>
M;*GM7.6"OE'^G:U,V^BER'"2QQ<G-&'V(X8L,#=$;-5G"Q*RV),'.OEJ4#XB
M5INP`PT603V??BF"A`72H$#J!=*%`"7XK@LC9NTQK<?<(<I'!*%)AC$.IY(%
M4\D>4LDP#0NL@@*K_V_&.BBP#F20WC5CQ&3+4C'^9Z6;H,\FX)/=^6P>6QKR
MB1>_NP!U]F-`HTKVK7$_UB(Z3YIGXJ[+77QO)]`X,&XR1=ZQ,_QDZMRT&AVD
ML9?17YF3E`9LEOC)-J*V,W(^<#@9MUW;O1K'QG@PLKL.P7D2%W\!4$L#!!0`
M```(`+".:4<MX!7;Z@$``&H%```9````>&PO=V]R:W-H965T<R]S:&5E=#0Y
M+GAM;(U476^;,!3]*X@?4(,A`2*"U+2:MH=)51^V9P<N'ZJ-J6U"]^]GFX32
M8$WC`=O7YYYSKL$WG[AXDRV`\CX8[>71;Y4:#@C)L@5&Y`,?H-<[-1>,*+T4
M#9*#`%+9)$81#H(]8J3K_2*WL1=1Y'Q4M.OA17AR9(R(/R>@?#KZH7\+O'9-
MJTP`%3E:\JJ.02\[WGL"ZJ/_&!Y.F4%8P*\.)KF:>\;[F?,WL_A1'?W`6``*
MI3(,1`\7>`)*#9$6?K]R?DJ:Q/7\QO[-5JO=GXF$)TY_=Y5JM=G`]RJHR4C5
M*Y^^P[6$G2$L.97V[96C5)S=4GR/D8]Y['H[3O-.&ES3W`GXFH"7!#P;GX6L
MS6>B2)$+/GEB/MJ!F"\8'K`^B-($;=UV3QN5.GHI=L$^1Q=#=,6<9@Q>8<(%
M@33[(H%=$B>\28_#P$T0.3U&EB#ZXC%Q$\1.@M@2Q%\(TKLB79C,+;)SBNPV
M!'&$W01[)\'^_\M,G`3)MH350<]ESIC$8GJ+R0+SN'52IT[JT`GO=-*-3OP/
MG<RIDSET\)W.%A-%]Y\-K2X#`]'8.R^]DH^][3"KZ-)6'K&]3)_P(A](`S^)
M:+I>>F>N])6T%Z?F7(&V$CSH/Z#5C6]94*B5F29Z+N9>,"\4'VZ=;6FOQ5]0
M2P,$%`````@`L(YI1SUOQ]%Y`P``BQ```!D```!X;"]W;W)K<VAE971S+W-H
M965T-3`N>&ULE9A-<YLP$(;_"L.]`4D(L,?V3/RA:0^=R>30GHDMVTP`N2#'
MZ;\O$L0?TF*KEX#$LZM7*VG7RN0DZO=FS[GT/LNB:J;^7LK#.`B:]9Z76?,D
M#KQJOVQ%76:R;=:[H#G4/-MHH[((<!C&09GEE3^;Z+Z7>C811UGD%7^IO>98
MEEG]=\X+<9KZR/_J>,UW>ZDZ@MDD.-MM\I)732XJK^;;J?^,Q@P3A6CB5\Y/
MS=6[I\2_"?&N&C\V4S]4&GC!UU*YR-K'!U_PHE">VI'_]$XO8RK#Z_<O[TQ/
MMY7_EC5\(8K?^4;N6[6A[VWX-CL6\E6<OO-^#E0Y7(NBT7^]];&1HOPR\;TR
M^^R>>:6?I^Y+&O9FL`'N#?#9X#P.;$!Z`W(QB.X:1+U!Y#H"[0VHZPAQ;Q!?
M#&(=_"Y8.M3+3&:S22U.7MWMCT.FMB$:Q^UBKE6G7CO]K0UVT_9^S"@BD^!#
M.>J9><?@*R9.;I&EC:!;@MD$22Y,T(H\*\60TCFV'.#;(18V$:>&SH=.5H^=
M,,`)A6="P)@3;4^N8QXFL(,(=!!I!]'-HD7&3#LFT4REF6]IF!BKLK*I$!9"
M02$4$$*-W4.M(9)X9.Z?#J)W(09X0O$(UAN#>F-+;T0P["`!'23N2Y>"#E(@
M8K$1L=0*!L+$W,DN$`,@2@;VZ@C4.P+T&NLR']FC$&3J=8&8#<5T0*ZJ%U`^
M"P'!J9G00EM,&)LGR(EB$)5$`WL"#21A9(DFV-2,K'%PA$S)#A"#H&3@V",P
M%S\C;`LVSWW/W`8&FX(=(/8`NA4,IUQ$'J?,>0_1^SEST6-PTNRGY>1I]=@3
M`SP-+15<*Q!4+$;FS",@PFEH;2\GC`%8N\&N?E;<ZH9+"[)K"[%DVV4#$3HR
M5;M0#*!(.I1[X.J"@/(2FI)C.\41*[D[40RBDC0:T`P7-)0XE/`>NE^>ETX4
M@ZC!*H[@(HJ`*HJ'C@5<U]#(O9)CN-1@H-1@XRS,,5`>2&(MN!O&("RB9.!D
M8;C:8+O:4#R03C&<_S'^C^C!&1D#&=F.GIT@4V2E)2>*/:(ZT<'5Q:GD]4[?
M<1MO+8Z55!.^ZCW?HY^QNG@9_7,T7B"@?XG&J^Z6?'$_FQRR'?^9U;N\:KPW
M(=OKGKZ4;860O!4?/K5+ON?9YMPH^%:JUZ1]K[N[<M>0XO!U]3___V'V#U!+
M`P04````"`"PCFE'JU-EYS8#``#G#0``&0```'AL+W=O<FMS:&5E=',O<VAE
M970U,2YX;6R-5TV3HC`0_2L4]QWR`0E8:M6(6+N'K9K:P^Z9T:C4`'$ACK/_
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MZNNE^R=$?1@<0/H`<@NXY8$#:!]`[P'^IP%^'^!/S1#T`<'4#*P/8/<`IHO?
M%4N7>IVJ=#FOY,6INO5Q2MMEB&>LF<QM.ZCG3O_7%+MN1M^7`:%S[[TEZC&K
M#D,&&,;'D+4-P6/$QD90?L=XC<B;4@(I71&+@(Q3Q#:"A8;.+TF2KTDV`$D`
M.Z%@S:F.I\.:(PX3^""!KPG\(0'V#:<=AFM,J3'?0L2-64EL%(*%!*"0P!9"
M#"&KP!:",>,&+`9@A/F&WG6'"D9D#)ED"0!CC%+8&@.M,<N:3PE,P$$"/GV6
M0Y`@!(H;&,4-+:,$,V:4U@9A1I!161L4DLA8^8D-8G@PX2-3$6@J`DP9>E>1
M/7L<FYL=`!'??"T!(!QPX_V6`*CHT8YNVQ3T&D6`+VZ^1Q&@&1DUCB$4-V<+
M!$7&ZDC`A$'TP-F#!H$M9YR8QC"X+4UC`(K@R'0&H"B-3&<`BN%'SL"&\HP)
M,&>A:8W8B7QF5B"&8)2;VW4-P3`-.#?M03@4!0^V&H;[#*:`P<@T2(%4W+1G
M@ZP5.8$G^91G;`GN?'A"ZUOUH)$4N_?%`,PR-8DI^9II@R=W6@RW6CREU^*)
MS1;"`=T6I`/:+80#^JTW^"@M1'70YX?:V<ISJ=I..1B]G5&>2?M1:XRO\"S&
MP/@:SY+N!'*G7\Y/Z4'\3*M#5M;.JU3-I[3^X-U+J42C'CTUZH_-J>OVD(N]
M:F]Y<U]UYY#N0<G3]5AU.]LM_P-02P,$%`````@`L(YI1U3++S38`@``*@L`
M`!D```!X;"]W;W)K<VAE971S+W-H965T-3(N>&ULC59-;Z,P$/TKB'N+C3'0
MB"`U7]H]K%3UL'LFB9.@`LZ"TW3__=J&$+`G32X!#^_-/(_'DTG.O/YH#HP)
MYZLLJF;J'H0X3CROV1Q8F37/_,@J^67'ZS(3<EGOO>98LVRK267A^0B%7IGE
ME9LFVO96IPD_B2*OV%OM-*>RS.I_,U;P\]3%[L7PGN\/0AF\-/%ZWC8O6=7D
MO')JMINZKWBRPE1!-.)WSL[-X-U1XM><?ZC%S^W414H#*]A&*!>9?'RR.2L*
MY4E&_MLYO<94Q.'[Q?M*;U?*7V<-F_/B3[X5!ZD6N<Z6[;)3(=[Y^0?K]J`5
M;GC1Z%]G<VH$+R\4URFSK_:95_IY;K_$J*/!!+\C^#VACP,32$<@5T+P+2'H
M",&C$6A'H(]&"#M">"6$.OEMLG2J%YG(TJ3F9Z=NZ^.8J3+$DU`>YD89]=GI
M;S+9C;1^II2@Q/M4CCK,K,7X`TP8C2$+&X+'B)6-(-$5XTF1O5(?4CKS+0?^
M.,3<1H2QH?.ND^5])RO`"85W0L"<$\TGPYRC"'80@`X"[2`89AN_&#MM,9'&
M5!H3H\@XE*4-0K`."NJ@@`XCQ*+%T$$(@@)#!H`);@@)02$A(,0XV$5H!<&$
MF$IL$(FC&)82@5(B2PHE9DXB*\I3;!X-@`EN"(E!(;$E)"`^[.`%=/#R>)FJ
MY@TU%W2_4&<=Z/M*G0,H9/8@9*4,*'D`A<Q6]5VL\;YO-%7\P,7H0".Y-#;5
MVB`RR.!8#-@W7[$/%(*5.]^*$\4WR@W#70V3^Y=PV8&&<2B]551P\\-V][-O
M6`<:71_KL@.@6^<,]S]L-T!*S+[3@8;5]$01,K4`*()H:.CQ!O_K):OW>@1K
MG`T_54+=U8&U'_->?347&/89GLPQ8%_@R;(=XJ[NT^28[=FOK-[G5>.LN9#3
MB)X9=IP+)M6C9ZG^(`?7?E&PG5"OD7ROVU&N70A^O$RF_7B<_@=02P,$%```
M``@`L(YI1X!^8NM*@0``^^8!`!0```!X;"]S:&%R9613=')I;F=S+GAM;.R]
MR7(;698@NN[^"K<P12=IZ4!@($!2455F%$E%,$L#4U1$6'?96S@!!^@IASO2
M!U+(52WZ$WI39MV;^H#W$>]3\DOZC'?P`824D5WYVG(AD03<[W#NN6<>_J$L
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MLG?5B@3_^3_]I[TG[4+@-7S8PK7FDS)OY[._G[0``*\N^?4T6C>_745IV5JY
MGF&^V0"FW57YXE,8W-$]"-[755G!90&L:!WI^W=7U^_NKJ\"^.WN_9N;JXN/
M\,>KBS<7[RZO@[L?KZ\_WL&-^NGN*CAZ<1R\")(L^/B0UR6,U]YUO##7Y*0/
M>Z*RC*OR9>OKJ'R@&[W`7^(_ULDCHGO5FN1##%<D62!RX*/-KV^+>!LERR#^
M#+2FA-WCF'GU`/BV\%:P?WW!0YPN`[B[00G+"(,LKEH7+:_@9/</>@W[V!IB
MM:J++"D?X!S*SA%OLL&VR!=Q609P;H!<"P;),GZ,TYS&Z;K/@Y/1."B2]4-[
M_A_R?/F4I"TR<!5O\S*I7.AT;X`WN1]B:1+=)VE2)7'[6.$N(P4O@VVTB^[3
M%M["]T4=[STN9_CFVZ^CI`@`3^HXR%?!4U0@[82Y\@I>3*(TW06P\"J-<6I$
MW2Z,T6UL\X+(-(R4YMEZ4,7%!D!_WX)YQ[Y]=-F/*7OV<Q6O8GAH&5319_-<
MBSZ^\59'F(2+7OC[Z%[$GLF1=B05(AF?P@*X):!JG"W:#R-_?UENHT7\C]]L
M$5>+Q_B;?PI:]!3IT$.>+N.B_`U=ZFK7OOE,LTJF62]&P]$(\'D;R<E^'TQ.
M9R%\AO^$M0=173WD1?*G>!D&X_DDG,$C)R=S_3HI2T0JW,5X/@[/X67GV]S2
MPR"J`B#Z5;RY!XQ3]@]3\G2]4\*3XY-Y.#T9=TTY.0]/3L?NMXTI@5#*C#W$
M\F*Y3/`0X<20F@T(=;<)G&#'!:HW=4K,<AFODD72PM<W2%`J$+/*NMB9[51P
MP"5@SYRAVR,T,=:4SCG^^5__34[R60PC:)0=./!U;.CH-D($?XBK!'CJ,;"E
M%\%W/>N^JP`B1'CA9KQ.L@BP&/DP4KW]LA@P$+F$@I$&$X.CNEP&6S@VFO/X
MV3=;F+,?]0^>R'_M"V?Q\/6@1_-^^>&CP2KWC0./]^XC_'A[_0Z.]OUK^.KM
M[8?K'^&YFY^O@S?O[PZ7.Z8'2_:MBP82=+Z)`XLN_8@ACQZ]R<OR.%@5^0;$
M+221-=[J]UN46`&U2A++TYKN^JWPE(L*9);[NB(^5.7!NSQ#\EKD:8J/W61`
MSD&N:1]'*<18^6.+>GXX5%"(LQBE>WPL6FZ2C#2-*GGLX58Y[P<6IU.WE"+S
M1`H0:7U+/#P1F,D8QVWB_Q`!B\'37?T:O%P!V9JX4][J7F,W/+(\&UB8'#0\
M(@KCR1*T`$85(`ZY@RF)P9079^'H=!PD&Z#W!6'B`NX2@(8&6*0@@B5`W5F3
MC!H"!_U2/11Q3.>;)5D<;/A*Q'@E.GA<<['O0(CH.D?]G,C10L@#WO+64;Z*
MRF3!:)BD-?*CS'V77@I%JJ`K8P$1',%Y+N$R1$6YA^X=-D,/L+]HCO:X![[^
M2XQR>+P<1(\P,1R?"S*/E+X,[IO;^5*ZB63S[N/[RW_^\?V;J^L/=[\)KG__
MT\W'_QI\]8N#X+R%.-8L<C!!IBO3PUM()@S^Y2VA8XO(.H+/K0@^ERSX]+_B
M2$!7+`'U/FOXU?Y5O(K7298ACMY'*8@.<>B(37NUW-:;S[X!S`(7!0@&C]%O
MQPA;7W2^)K$I^)</@(#!Z[P`\KAL,RA@Z30E*@,=C/S0YP]]+JBW\&O\.2X6
M2>E1[5Y!P'W;D'@1G9&DYUD6+XC$/2750_"6.!NAGC=QO@)!JT,<Z5UIQ]CQ
M9IOF.Z"8_,2VAJGP&+9P;%\*L2\=OU-/&@`]0*-&OD&>PH0>Z?HR*6#<O!!!
M0(9M2[RX8AGCTAWC`L&\9NGF?A>XS]U&.S98(CZ%(,,(6[J6,RUQ8VR[ZEQR
M<,-'=U47).W0DV'P,W+Q4.Z8#&K&;(UTS6I1QTW;:Y/U7WOV\<-DT(N['X/7
M;][_<KCL:?@C\^DN[M:F<7^H2U*T412$PP5A,`$F;I@.?(J_DR6L+OEJ6-D#
M9-/DL=O:<A6#,@Z*#@L)*.EM4`#]$W\@PDIK!R#9T%1E#Q8>*K,MNF[WX2^+
MM0'UTJQ,E@*][O?+!DC89H<[WF>,VF,;[+9PO6N>0OM\O0/9CQP]@DF+R%@1
M$.#298[\"V`"]\371`Y<5`L27>\]"XMG,;K3*KQ*\R<!89(]@G3_S"VP*%;L
MMQ73Z(01"-EH`4Q6S`,`^&<LJ_Z[AKK#BW&?S?=+L*MKHU]V)E\UPB$O-<]D
MQ=:5_6>",Y%M.U[J41XH?;3?="4.D0>VG4A[V_M:'W7RW_!9?*^4<GUW>]L>
M"%2[9`MW;,L\%F3_[!F[LCD-V.YC@M(WL.LNZ':]F!@Q<NF*D8M#W2J]_A?D
MK$`B@WLCV0+\MITRP=XQ8J2U?6_>U5N`%<()!'U$8Z":=<&XH>@&VS&^U&[W
M$?"^.'E$0RC+([ALGJ^D6YKTF5G,7?["%_<L.U.NZEPI)`>'7)8>MT8_!GJ(
MB@)%@=@3E63B59K4-KM^B!MV!3N;QS,\.;^E\=1EDJ&%&;>'VG.)P]RB4P#`
MTL7"Q2?$]K$T0?="O]FMQ]/P_*S!>]#`'Y/X*>CVFP='?_[7__D4AW_^U_\5
MP&]UJ;_E=:&_\IOX!]E78OP,):,HV\&'<,%@_N!>QUW$-5FF`WF$CB6ID/L`
MH\77'?N<N%@V&X1JE*J,!INHT.R#+Z&-,,W7.WRUB+8T.@B'#W"9HN6RP-UO
MHC_`RNIL`Q1@$R]I]@P)V##0M?];Z4V+WJ$50#W'Q:_0'PTS;8MD$Q5)ND,B
M)6/K/8"9DR5\LR[R)_QL"POE@;:H=)-L3]<4:#F()S7`_!&5%:!=`)7,&6F;
M/\$3N$/X(]ELZ@R4HUU9Q1N$#QSN(TE_/!!@,?FS%O$0A.^85!H".^QGFVSC
M%&U<)"FBB10&W=1I101WDRP'."!:!`9E1488>)I@PT*1:W?+<H"-3DJ+RAG<
M.R3#ZR+:E$'*I/A=7/\<??[S?__WX"B#^;?Q-MG4U>#N."1980JR`AZJ_#$9
MR@L(:/'-`1CA]D:P@4>TD(3!+0D-4[M`$%?@?[K49?Q(%EM4#\2UQX]/^"GD
M*.N<="!8,M[V*$!8`PBBM6(8$8O-/5`=2RU8XN5=PMT;!F;Y2<GKDWFBYKI0
M:GL$1(E8NP"2G@/FT5<,07Y?;#AX"`J,SH78>?UQ[Y%_*2;`^M[1&5WR&=TX
M9Y10=$-AKTSG.49;.,EH\>`?!.LY1-JJISSX%,.#..]+Q42$;(G*V3(J=@X^
M6FP/@Z>'A,>]AP<W8AG&4?`<=FC-A>L647@`87U6DQ&VZ[ZHY$;J'UZV[Q$6
M88#Q0"R5DC$^*M*$C-;,E%U(D8^/]<IR"^RAJ#?!8Q+)[=Z9?>79,'A/.K->
M9KI550W*(F\$%@'G"B/#UXN09LKKBDS>L-<-,Y4J1AV.T'@3?3*7W$R"NW2@
M%GFF_$616%J99Z+LY(3QJ:$Q"SB1(9VPN8N65/&AZ[.E@B0"[?H107X4P1*+
M`4!X'1>[8_(>X"J?'G*@3(]`V>*4'"`PUD,<I=7#SJ=*0"=`48+-H7LK@671
M6^@ZV<#"@48FRYKY/HI;P^!MSS<A<@^YF7)2BSB%^WN4+Q9`M;P/C_'A3;(H
M<CD!('`A8B90^27@^((U-R!'2A0PW@N!LP5<#$H8BQ`%GGS(D'W`'>%]/,7!
MIPS$*'@"EX@3L\Y`8J-+;^E*F0L&;`?8$WH6Y%XM$=,1PD`!*Y!3Y6+#;:);
M[5!W/8N0A!*Z_?#:0[V!L6#%69WFBUT%,(U@O\!$U_$`65Y&`">;+FYE%:'Y
M*S@J'GYX.[B\>WT<$I5XRHM/75S&0>G\*6LSFC*./R$ZLX&DJB*0F9!;FV-S
MCV,8_$0CZU89`D!>026/D/_"BP:O'3ZSQ&W#?CQ>$\%6X*[3`9;1*JZ(QZP2
M##""6>"2P`;@+)9%O2X)[U)<'.ZJRC^C81O/H]IM:0[D>;ES^2T]!WX)Q"PM
M!<^9]^H:`0+Q8_XI9F4$Y#^",:RC$HFR>BCR>OW``JJ52EH\F\"'9`ON.T(<
M=PK$:@GJ#4RSR9=$*9?`*>%6[X;!+S&AL:7`<;8&"!&/,LS;9S@E8U0_XS4L
M)/18;RC$X5FB!%,S"0V#=42V@O`Y#C?L7\Z^A8)4"7)$A+)6OJP7=&S+9`DR
M2LAB9"?KLMO@2P,#"GR10P!HY&Z@YK.E2_+C]8?),5JX5(9K+!LG,V=IKS*H
M*Y'B.,Q`6A3IP/AL_!E%<[@.<".+`-Z)$H,3.!]C3Y+!(0"52=,!*#R`Y$GY
M(!$QH,O05I=*M-E?::1:5K#TB,RAT+MR+L@+0&_*,8R8!$+9SF.T6*`HB+S=
M(T-,*T1]^X/@-M)0EN3+3[A>UNT,TKJ.<>225\#>Z)Z7#TA*6/3.C*Z-AXD*
MA\@$2;%0DL6\5*C\Y<=+(.MXG>%QD-&KX$J([FOTV-Z1"`"S'UV]!AS"/;\7
M/FB_>G]W#)QLO595$DX!5IPM=CAS4N;L_O+X!M(>DD]"XJL!4-0X9*J">,BF
M9T/S+Y!9@B[#5G4DDR!"H&88_/CF`FYS"L^F,5DQ`%\2H("R>5H/[90%!0_Q
M@=C^L28`*4&'(<S(0/MS(FS!QR#=;;8/S`T`8&_*8SIE@)&0(?1JP,?$2-89
M\"-TN=<8L,R\"8,?X.#R76@(&"X*QB4&2FC:NA6Z;DNB.S@R#>Y"%A$6-*>$
M\=#9KQ)(F`1DFI*X/=/A-45?P-YH#P!=EL$--X$1Y?:59OET)P8BQ<-&!P)W
M>!:FJ_(M`)6"YV'=1%U9/%%**@34DEO5%O!&\.49HBN1*%-+(;G]<'V'CN*C
MX#;PB.>'P*.>UT#3T]T@N`N0VX4@JB_C@819P6I>\3T6T9WNY1L000``%*F!
M*BM"A4[G.I#C4?5`;OC'0,7:8]Y4Z)(RC\Y/.6)O$)SP+T*C)O+Y*MY@L(0O
M-!OY$02GFF136-,ZR\4BBN__-+P;DMB(_`M)0/"0K/'\BJ3\)),D16-<OERP
M,M42GA`Q5G@1<U0'_ORO_[,M>Y'A@>16P/N')'[$G<&3&3)MP`XA-?(B/GST
M[OH*9%O`RAH0^4@E>"82\*8J&&2O8+T2`Q"B8CG(5P,4L`-E-D<B*H<!IFLH
M#PI)P"2":.XD;G]`FS?0(^1#A:*`ZT%\0FA&A++O&M0^-(QQL`/OFM?\D@__
MYL?+8/S;[R:_A2UDBUP8"NKK.?JSE*A'ZS6A"$HU1&*9#6+\#<H;6\6[(YU$
M:)11#CXG&,&Q8W)#+Y%*D=.IJ*K`P@32O8O)=Q?3X(B9;QK7GYA"*04D#LG/
M&$`8]8*X3+1!06N1X*DA$2@%&8I85E:R>OH9-(<*-9'Y[%M%6VMA`<#_M,45
M3OA;?)45`=[XP&R\&[=#7!%;.WQUH0.I@#ZD*9MZ!!X2,R9J%>'&=P8G`H,F
MB$KH65N(P0O5JRV,AP='X$=FMXLQ?L9.(7<M$::.:A[]R8JY*ZF5`8J1`)2\
M4#1LWF`$*9S4?6H5MJ5ACJ%1H'!YA#S(F)FII[SDJ%/-;RC;1W">I.7ID\<L
M1@"8F*KC]P2:(X=A"'3A)&]\"PF27Z6Z0MZ>7"F9<>DI-R]A:(S8@9KJOV<5
M<FEHE_4%6$I9U7]"@('8&!<H0<)S_]__&WP?8+1@ABKD=Q]R./#C+Y"G`04B
M"AU"48(!4;+PCXP0!57:%E#;O(97E@0`Y'7L#@?YJR*>$/G6+F\[;5L73&QO
M(#Z),C8)[2(UXA-P1VJ0LBYO[M@W@M%<]WGAP@0%RTB@K`:G#)"IJE$P>7=Y
M`\3!M6/XUAE97L-(8\TRB]V"O*X8;E%VVF4^/L1FOVIQ,(HW:O.(>J"5;.&(
M*[B^45JSQ"E3BQ0Q.$3&^CZXO#K[+7R.8LZQE5I@V2Q5$]U5L((T#(`C907C
MS#.VB1+`+F_X1#*$PF-$Y!GM9HF*\TSSHOLL)S%;Q*H":4V=&3:+JA^[ER+%
M;#Q%IL:BMK#&R^X.4(3IEGJW@$'8F(K`"+=3!"8*PT--AVSRJ(P9B:PB)TOI
M7WFZLR5:OQ8L5B,D2))F:UE@=\TH0W'O/%5SY%#,#C`\;HED<OR>*!R0YR<8
M%=XA2PV##:1N,K(O\CI=-F<<!IJ-8K%,O*$DZ-%*6;S5W0S0:HZND0:%;Y%T
ML1:SW(8&DRK:`":M8E"<^H?2ASLX!'%9O)6@Q"$ASC=[Y@"59(&.+%%'\#0N
M-J"9HDPM-_,.&&M<[5!^I]`Z`>133))&@+K2AG!X-@[/IU,CV)&_`"%#=*E!
M:B/'2*ND%#W\*5`LM#`W#!0@0(!TP^R#21\MU5J"4(6-E>'"!ZL\K^#FL\&3
M;^U+$-3^W3"!]SSI2S+#_2KR^%]-'`?^L=Q9ZWN<84"[1JZ<@L1-([%<9\@S
MZ^!1<(<D"ID9R'HYT.+@HH2C*>GUH[O;BV,R$5:6SI`8_CK/V:9P5=3KX,)3
MV(.CUU<7+*2R'I0)*0_Y3V0]:+6'8='P0:D\R[P&,6IP#^>%3$OA+/X.RTT!
MMN_R`L`@2!@"Z@`2%VPGNH[X]^NZ`+V,[_A-641QZI)T]+C5*5F^$%`JU)[.
MSAPJ:U%A<F]QX<);M+<;<3"OHRHO!D3"\P(?F@+\U9!N!FPZ=$I9"V[1.2Q?
MJ,3=6)&?OLOB=;1'X#3:$@O1OPV#BRG^-SGY+5ZFB\G\MR1P$_X<**,T[?MB
MST<`(R75_2SRP:K.)'JB(<<$1QQ:89QF[OBDYN<9B&R8SU)OT77#YAAQ(#LO
MJQS2]8IWA,X)9CTGU<:U+X0,HQB_05(#'VDP!@3PU2)*#M"3,WK7U+F<<#CT
M.>HJ@VBS34&(B)<'GC*]C;_"B,3E"C0F(F%)A$+>D_YL<6F5^Y[>6U0?D4C6
M;(=B.Z$Y7G9-&;OD58SJIM(;3)[,*(XZ!XU8K2@5^8ZSM9`R$MJN**(65O16
M7.8FB>:6W4SD-DLQ&Y_U+V+'F3KQ=*(+5-R`E(L3_`*+!.!)$-D"1@XB#@IZ
MZ&44DN?3W]:L1@3%YS[I#B@X-UC#D67*",F`YV*3&E093CX&WC+G0AKBW_XP
M0#92I4@L?KZXNKE[V1"Y10]]YUGT;L5*_#,,QY;7+/@%SD7P\BJX#$#DD%=E
MPW"`RC]=$5_HND0&8=3N=R@Z[_#7.<.RJ0,`6B,.B?#/9%N)..#;QB?NFF-E
M+QE9+0?$T$&2',"R\VU4EU':4!](;E(<!IP>7$S,-1HRM,QJ+,4A,:K.OEZY
MZ#TY_:CMD/?7;:WEK+F6GDIN(,\"T[RE;\!N9/TW<`$C/"$R#\(URY#77(%\
M_2%>+CD.XPUO,"_(Q_BF6@Y#O"/X-$E/M1H:.P)=(KB1').>B&&]@/NFH/+F
M<0(47"</R4?LH&]X35:``XL'#/5CT80,#H1P8MY6\]+1ZU>WQ\9Y,HC2[4-D
MG!B.T\+Q5/"(CN<?B1E:5Q_C8B`&9GCE:#(:G(UPWN6Q$]X0>AZEKEB'5[D;
M&'%T/3T_]G>-'P%4C@DS>PS($0UH;>[&[&RLYZ[%/``H#'ILXP[LW6`;1&5X
MR[A%84V=[A>CNS4"8/H"3)2,[3,P^`C_K+?.1J"@B1<=OG%6T['"B96.=Q/W
MH/O9M^KQO4=CA!*Q-&:NI9)FML-RD)$JU3@G:$WD6R>`=Z,W.6I)OX]=[ZM1
MTT7X2)#\V\!2>BJI=AV*82F69=74!-CH<&;C%.OD6PY=)4Y)(-Z24ZO>2,B,
M8QSF*T$6&':3F+,I:TS1$4NY>X#H!9'(%M+ES1NNN9"TM\^P\`V:1-'D9RV#
MH!>FJ"JN'TBCIZ"RF*.PXQ5&,BY`(82G-PD[[F'<!)V<%,.#40^.`-&'AAK^
MC6="VJ08:]DE8),I*3-)XF-9]+?*J0H=<M/@I$A-H>QPV'-)X2]HJ03UD2(P
MX:B6Z&\TO$+U5\D"$NLL6E%+]0OBW$^Y6%7AC[/9\/3;X&B,WH[-8@V,L41Y
M)*^WQ\$C@&XZ'<Z_-;=,V",_`.)M\%_2ZOM@.)J(!9P(B04$D'8BC%6NU7D8
M/4Q$S@_H2`T8C2=NR`)=3HSTQ)>`><.LK%*A:Z*)V!V*/UJ8T!<:H_6>DH2N
MT1&^22@^,I1*4$N4J.B`C^ZNKS\<JUR%GL(G-MUPD!%3#"%SZ/$K`G;LL@N(
M<!2?'$^&8\KU'$LIB">2<QRO4&C1U1@;)N-P<CZ2^1#4B"4.UC;F=ST!]V@!
M&0^G9.1'![!0,5#RJO:#D^%)XT'`LZAZ*,G2XJUI?!*.@1WQU\+]<4V>ZT$G
M?A)ICN4!ZPWSZ*U:NBHVC+$]TH9/)T"3DE6,]BWDA6-TRL&/":'XL1K[8XH/
M9UM[8V#7]988T)Q/[#DHCL*=`*%L@'?`AM,])%N"_9.53)L3E,')#&_#,+BJ
M8R-91Y1>:'W4Y6X#LL%&G-L4;XN9F.T%6S]BX0(-G0L145T*!U)F8T+#VOAS
M.G-.P?&Q\Y,86+2(EQ+8>G1S<X.'??/SL8U#8^>([YGC(R&W!Y!:@"5P:B0^
MP`J$#BWC^SK]Q')B7XR;`7E&NR3.8LB`<`GR6'^'%";Z'&6::>AZ%(?!+P^8
M[\;!4Y;^X_674.FD=.R9*!@B+$A<8O.GTNMT1P0179EFB<USJGQP$%X+LQFB
M"AFS3,B1H(RY&"\M?K;&_BDBNJVY"F?%8,8T5K%%[?LJEA:<I47<9S[Z%G=Z
M-D/\^PD3&ZHZXVMHV;*@>2Z187ZL'F)DR^2+IX+LKA)EQ'\+XW;P]L/;Z#OL
M([1`.WM(9UO`VD<^)[.O(9^SD_#L=`_Y[%A#BS).#R6A8V27!Y+043@^?8Z$
M3H9GSY/0CAW\>F2T8_!.4CJ?C+Z>E'9-4@9G!,UA\",@6L69"R:)[BC*4.-+
M.5S4:.7P"2<M77XX/D8OR^\B0*&"+``GY`BU?D(R_ODY>OC14UZDRR<<EQ/U
MR(_[[&1>4$86;>*E6:L-($(%MC'CVP3]2;=>O@?JOF\NAW:S."==-5XR6=L2
ME`:7"<?EZ^H0[L'KJXL!Q0`\QB8Z,'0,.N:.KQJJSV:'61VP.<`0+N4"MS4'
M.EQN0`1Z>_NN/*8\"$J[4(\86I^!OK%K#SE3BCFJ2/#$!6]UGN@Q2E*NMK)1
MUX"!X0W(5XX"Y4(\JDF56.+7(,4^THHY=J[`/+(TB1^-.9`D5%(=<-T43XJJ
ME-A-ED2>X6]:6Q$#5&(,)@88J2]Z$\'MJS>-%X\NX7-*T'G8;9'QE*BML0H,
M+TMT!BX7E(9X44F,M&88&55B&+S5@"K1_LC0FK"+\/S,1(Z7]3T&&0J[Y7A!
MFT)*<S(^X,(:$+/A$'G1BD(,,4"$Y'L&6$,$%^UCF3/,^<V8'`!1ID!>1%LZ
M1V)I`KO.P]<]2KB]S42D.0"(J&K=_O-WMU>@+O`ER#^!*`'WX#O]>[F#^Y0L
MCC6VF139C/.-48UE&Y1S@]7LK38N>`_X.48GX9%N*S5J.O;`$+.',Y"L`)M"
M$PF`YK_NEZW'97S6RACX*2-^236@RNZ+AQ1A<X^N\YS""5'9;-TBJ738,E'@
M31Q:2V:^'5#RDD2`DVXDV"8*8%3Z"N?O4#WJU#4=4GLAH5((V,D('C,:J(3+
M:W2.)%M16%0$2GB!=XBBLVCV$G8BT\Q.K;\K4V\K@L.=EGG^VSB6PDBVN!TS
MR%<D_Z'%#P4Y-$?E0-\W\KQ1=H$*ANIH$1*!(06ST>SH_OAH<NR^#%A%<[%!
M9X''3.@%8']`_SGIRXU4.QL`S[36T?+AA@[A]/$^@3`,2B1E#<*WE\9JZ93W
MTF(7N.@_`J]"N:^OR!*'\K!0J)JOS%*865@3M]EMUE8*)$FR'&V`JGMAN#3I
M$DD%IO1KT0<0.C\Q=,4(BR8"9U3A,8`7G'298LS/T0H3)[-=>@R:-IK5UWBL
M'Q&N8MOY;S5L(_L3/8Q)4:"JHQY_'+S'(>[RE&SPKY-T`]_#K)PKV=P*!3AB
M%IZ8)4""*@DU*"%%P,'`(>AMT*00&3=2I&%3)0;W8O0J2M=/"1NQMCFG=^/T
M'7,/>S)%<7=WCAFF*T&5HDH6<DYD)47WG5J(5Z;"8*F5Y/30X%OD7'`QB#/<
MQZS5;:-"7)2,\UN0Z.N(8Z`(!!1M30X%1GQ-M,0O[U`!L*:5Z\\++GE`)3S9
M97]T=WV)88-92M4?Q=H3?ZX<B$F$%AKO*3(594BEBB4%S'`V6N5EOFIRK)L[
M*RFRG#V+?YA(5]X>YS\\/>0H?P!K1"M8?0_\-XDPWO1B2SH2)^:&,I)^2!B3
M+?>/T"^7X6C?T-?#;S#PWE9(<.[T`+$0^-L"+A+3W'>P^6`\81R,*T%+I/D8
MQP7`!ZH8B19(%5?QNG6C7;M<FV1F]E4J4T^WBVZ@'0(!8(:`<V^Z<2XR.-)5
M#LXDM?<1+#;=D>SM(N3KB[M7P<=\"W1K,IH-0'7P+Y!78_/.KF;0!W!F2<ZP
MTSF-B4#`@![T?$G@ERFAC*E8K(9>BU+&Y8GH+NU?QY__]7^HJN0^RVA^R$6F
MLRB65*^"559+(K9:ZJ&4,'_$4.9*3@BY)V/`W,)6`7M@?UCO:(,"8:Q5@3;1
M)VL`YEL.5+/>B)[/TC1)KH*9B(,Q%?PA(<16CFD5@.$0;+?"@BV]TULTA@5`
M4>Q94>S"/M$BNY9#'ITZ]JI9NO46[#5B)$7K1%6S$8J,NAS_MDS(L8!@*1(Q
M`)$U'TF_`1B(6_94B)/K&>/1*SH<3,+-==3-"-&F>\QQ$!UDB7+Q+M+4+):O
MKE8',.-9OB"NBLI4>;"+1G^H7ZV!T?H2+DQ$;FT,8B?-78%NQRW,JZP#P<A8
M2H-^%2\1O;EU+K7:$8O6M!A5C0D)C'X`SW:UQ&%@:H'0+]=.+1`+?:V2P.6>
M2K+"B#LU3>"-)95)`5"4F,ML!6J0^G)0]I.,0@FK6BU]YR-`T1T%L3#7$^7'
M+T8B:W/+DXAKTZV#L#)@9&>>Y"GF6;P3`<L>H'AX^`<75L?C,K6':#[<=J-V
MO>=27<!!,I`9964DA.\#R>\J*;NRHD7:1`()V`Q8<OQ!104$*`6.=EEL<S+.
M+=`40>G56"F"RHW\K.5&+`&]<>!N#BTJ"N)'"AUSU35B5NJQ44</FKH)_]`"
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M9J+^`'(UO+\C$P;`(M]@4`NP@&7'6\MXD4J(EU2Q!.K%_FC096&<B`(^F&&3
M5W_?$'+WY$IK()!68="JA_=Y_HDO=`-])66RA9!$&"WBRH6A;"0)GU@VSVZ5
M%"45PXQ0A0<AAU<0V0!DK(RGD8N2G/`)N/,#1A_C&9FQAL$-'AFG1=A01T0H
M%UE*1F\:!:\PH!?@2^AA)NV4G&M2[TQU+]3?X6IMW1$K(EH?21+#S?#W)7/W
MS5;R^AI%%CONGTS1H.O=#]->NYZ./W/5-']&C*22^"Q:W:9&H.NE$$DD2A<<
MHN2"]+VJJ"%2@8/VX2ZAL3R&\EIQB?(L;)5)8XGF!7#=+)EC0]6"62A'*9$2
M01)B7)[U1N?S%F@FU%LJ9LK&PE6&?)[T^MABL*WT>*`0$#.YY3TJM4@UG/`+
M9G9&D<KG.LK0Y2KR<`.ZK>$1-QF`[9OY]$!5919,['RB+_GO?+EZX5Z:=2!#
MP+7<DQ!+-)*\GA\;0M06;3P[N3R8#PERF*3$4"DU=WTHYE)1CQ40*^S40]8'
MRG)JT27<RO,<S.Q&5XWR@8^/HE5A3'1)0I+*CUR%T8H,C,B:;"Z)$WGI\6ZQ
M!T59UU4I/>@@84<](5ZZ2-\X,8L:/:04GZ=@^_6721H42XK>#DHNZT0MN;B-
MH1BSL6Q#DR)7E!^$WY!:E.4>1<U]]&$RT&$C&:KX]*,:=>[0J#/P0&?E-4>_
MX==XU;Y%B)#E*#GF7]C_$&5EQ&4KS(J-GU!"I^]SC`VGY%TM$HV2E#4EB.K"
M:A-W"*DHP4Q&:DX5PB*28Q<?*>?=>`+Y\-4;2$M/-&Q"G0HF]8\&D]$4+K@5
M#4->LOV>$$8]3N2P7'`"Z'V]DV0Z*=*[8/5&;"9+979H7:=),,C<&(?M'G`=
MC\=T$/5FX_F>7"ACE'J1W[/R<?38@L)];.HV(A.W9G9KUT./"LM(+`'@6J,R
MS[1G!0L[N0GD5^W;8YJPWZ-'`5MC?6XP-UVWU4XC43"N5YM#1([3@9T$DH0-
MZBMI#)A'I3Y'6D>K#N16;'%LKS':C^V(YO$B:^4KK>:C@[.YGW18M)O"$UQ,
M1;_1T"NW/&"3M(NB)SQ,($5$.%ZBI-]KOE6<J:)/<'_DVLBZ?U/V797NN_4;
MYPJ1EWOI00'-=O&!IF)Y3TW%CO&W:2Q&.Y@)02A%D1N\P?2ODJM#_`\JXX'R
M?Y(!!<0O;"2!&.6\:F!/L5)VCMJ)J$B*+_,"':([!\]B%P)`*0IW8SR6)BND
M!KA];%QSA&G$TODJ99[LL`Z=6`W$+Z/)X`7@4!79+:,W-ZU+MAT_Q1T+;8:'
MK"+T"-B"/]NZ4)FM;SFN59=XU"HH\]`0<!J&N;X04<>`V)R?4+*;?_@;6`I7
MHCACX$@]BT,SK$OW[GWSI<VP?_9D1:+N,_6JRDD%#3R(*L$A`O.-<:I]0WP/
MY>_2",ZVVP$10ZX_U"G&H\JG2]&IT=N<9UBC,;89"R276R$^(_X@#A8G.\ZK
M%FK(8$D"C&3+YPYDLES",UDB`G'CT;3.,6'BKMW;.^)+:SF_U1W?THXOW1KV
M;*CM*7!/Y:XZ-E(R]]!:OE7#.N1`TNHK[FFQOO*Q$^A]Q?9YRH&H/31K''&U
M$L\VKV;8'65CEI5QDSA3&>\GLAURC#G&]M)MSX:'5,0/2,\>8Y*P,1&P,H(S
M_XZ1=JDR*&Z,A6`U<8$N)38!!,R%R:AHQR.:D.Z\*HEB.G(JL`N/(;`:G7A5
MDR7Q'H2[56)$N5;!-)T-ZYA@=!S:271/9"(D@4(2_SFF25PBA.5)I@:LWJ8>
M32,ZZ]2L_E+03NGZB\G1=G%W*<ZVT_%9B![6]I#<LL/]F&H,H3<6WH;WL(Q0
M:&K8B.NJJ2JKZJ02B9RQF4GVRG:D-/4:3TBY=$Z=+-G]CP%$VO8DI,K:IKF*
MX<VAL@ET%G$/&ALTX56)9TE$BFH/9<N=Z_,,LYS52:3`P7)[(3N<A.W#$"CJ
MU;:$+;*S&F))\"W1I$4U%A:Q\8PAO^_?D\F;C\K&]2:9@L?"!62L1=WO/)@V
M[`QFG64WD'KV+<@AI>]7312<C6:#V<A@%O_)R(6(*?V.7KE=:DIIG#<(KG6E
MP1#1\YV+$`P0%QX,#J$%RYQTR$<2352/`4Y#T=]\Q&R>L#74NXY&2[H;5Z60
M9\YD)9II9:$6]30%IV08!GC#B-%ULJ02&Y.9ZUAXA8D+@[L%R&IH!*)W!\A\
M\0&LQ9F&3>)N7^YB$'X\DBDNK[8(4][>PPD'IUN5]"E<B[@%@E4#SU.0`>^T
M]&E;QB>1<!^*H]'8Q5V<14(Q24`SK4!H>*+>39INO^E&<)$WV!'L@,K"<B-U
M+:HD%?N\=S71K4%E'UC#&-K$;ZICX02J7:M?7)R%G9T=+0/I81HW#N?MZR/M
M#/+$96H-3[/ZMNW00D^':)@3.3&D<@<I_19_QMH7Z#A7TD)#P%UYP#QU]4E)
MK:O>%2U--K\2<S\I3X,&0.SJ_L(<$C,%W6*CA!SI*Z`5VH7DQ3K*Q!V!Y3H_
MO"^//>.3A',.="<R<(4%I3@Z@ADBQ=IQ61AK+T!K2+V@<[_:MRY\&:>F5ZWU
M2+RA'$!)>0#LQN2(@I(U)_*?D>5(A`VW%(N3)TK$(`$*4>69^$BXS""N3I#/
M/:_(/MU@67*C]&IKB2>2!-Q7='@ID6:"[EWG"HEH?2X2\[W)_3<+_DCFZ,><
MB9STR?0P@\\'U8DT6IN"^BS>L\9$[<>%XA*KY<,QG!]/Q>1A`K&HMS`/%Q\9
MU%MY6E.'@G)1Q+$6L:J,;T:KL*@XC1/9E`O]UL<N;P58?B*-E^O820)PCYA+
M*7KC$QE`2_W'Z'/<#KIPN+JK_>7:"<N$02_=EN14[HD+NK)L&:,+%?,U."R'
MO[B/08]2*R:\991[Z\5L!B2Q`;$5-J1T^\"@+"-CG)Z,!N,1BQ).,"?NR86*
M)]O2*RB!:.!+]^8D?4S+IV.2&UU/C#C&>\X&;+M^X2R<H6N,NUT!4HY2WH10
M83P8?).X$2[*'6;EKC1.9DA'V475@*!T3P*K*<U,RW$L8(Y+Z:!;&7$(;J0M
MY[ETF\$8MNX1P(P;ALKU+GTO@[II2P$-^89I\SMU9Z&5P(PK+JB*"@$:(T;'
M?LF8YKAIJ-`C5EO(,R==C=!S:,.ZT<QJ!FO*PFA"8F,"JFT@`5421B)5V?"*
M_`%TOF:WC>X2/*;\)D@112XU;WJ!L`<`30-/]_$GUH0$J.-H[F*![7I'I1]N
M+D5H+K\WY41G54;I":@>+0D6?.:>H1H9DZ,V8BD_%4(<)M2<AR;(U1YJT-[-
MH_]#O5SCD,3%C0;.%([Z5L2?,=R+S@?S3D5:Q%S'-'HJ.>NQ:89$P1Y?PS/B
MI[C<2TIA0&A9CCZ3Y5!LQ!3^=]5!%R,_KM&4C'/VZ,9ZHA_4CQ7I>]*2&XWS
M]709GV=7V"1`TFFIO)&D6%'Z"7K&['$:]<<<ILV2Z6PZ?7"8,1?@$]<!Q[TF
ME#N'O1)`9NY$R6B-R745<4:/,-@+0:8YFP[&,:`<]/8!LW?):.[%SFF@&Q$V
MK^FX:A.^I=]%MT5K+@FPHTQA)[C0U-7(5_V=V7SBJ``I^3D)KZ.S5GG&1,ZQ
M\OV4PU/9)ZW^3J;#9"-LA`JTJJ5V%2]%RH3Q22>D^*5RK^VZI1XV@RG)D-T;
M-+FI"?FQ8%+9=L7S:]*HBKSRRSQFMR^=O_L`&:AW'"):VH0(]GQ;+S?P=^>E
M-9:H0+Z/1@^MQ<1*3FGT%_\$'B)>`-Z"(HDI%Q4_YU``\OT3<>;`SZ\Z6@^9
M]C;B>\K[8CY-@N6!1WSI65VI5SV;J9O&6"]*5>\<?B'9VYE6./7MN,H2L9&.
MK>LCA,&DMX':(6'$*PQPCAO9-R!K4_8OW\V;++B`6Y1*AH*Q;$ICO(N[G^B;
MP>@LA,'4Z-*7\T'*MPF$YYJ@E$)$190I^XL[$['LF@77Y"0B7<N9"G-LT#GD
MS4[>BZ49S>2=<SD@FP56/B0KPF3'`4@'*:5(N;^;C;1N7K[<WXYK<V+F4CY(
MU5@GHQ`#([HS3U`JT"+3*>;EV#U91FL*/"\=X'%2>5]""VV))`E)*.T2Z3'H
ML=#4YIP0V?1[E/%=E[XC((>";*&?7$"NVYY]?B03$/`GHTRX>R7;"@$=,1F1
M=P4#P6))C)?(*8D.590V9<XQWD:>LSTSN3Z$28W$U$#F?RY!B);YENN-@:2V
MKA-6;8P2A*JD9AQ*O3P3Z1*1,69)(GM']M#>G"%J8-O,A_-31!KN:C>SJ>_,
MCTH0#,0-SU7/WT:[/3?W73X4^)_C[>5D$5+J+\5B([AQ"6(K''91OA1;\GPT
M;US*\Z'[AZ/SJ(/$Y(8XP1-_0D"Y62IBG))PB@W9-_E;;:%`KU-=A1\N+FZU
M#J=\!PB;DBYE2I7[!)*LLERW2AV\(%?4UJ3N:*UF6057M3+-QAVX+!0NM/BR
MWF+Z/=:#XYK9VBU,1G(%<44UUV6B<<*VDK@^Q17L`=]VJJV@M-PU+N^0_>2=
M*Z7Z!^Q[?QD<C8\U^BZ);<HBOG=42N^*R+S[?8!)P8WGQ??-;87AQ-=^0ITS
M'+P^/?857C_8AAS7\-3),4D>"Z.?MAY2'>5+)J<8G]FQ:X91`'(D&!EBCL6I
M0+$):)4N::=1SU1#DZ0JF*.HB!8J<EPQE>`2&6G:CT`H/V#J/-$R(U@8"H>&
MKIQKKTMM<[R'9J=LAK'+N#/+N,R7)LCH@-5RPX"V?H<U+)0)_1%S%$W48;;T
MHA!=#E6`TET8!9M30D(;(9QL-.K#ZHN[9MZ:$W1YT$V4VL26E)=[V,J!7.59
MIC)WBE/ZL[DJC/Y->5]2`LF,-!W32*=\1G2><).CG54B[<!^<$3_:5+"RE^R
M6[8F=._YU-FS%G32/'^?QWI5'9W^";A\#`9=./'%R4:[.ZMUR^4JMD%#AV#6
MQ6B)<%[4:PR#/X`/XM:N/"[\DV?)8)'(R*4T[858C`#8EZI54[C.#U0P@)3B
M(O.Y)54QLG](">G/6ZK7E^[T!C825#G`U])O-D;8Z1?>]%RO8*'32V42%0;5
MV(.E\3'IW!4^$NO3\`*HM?G6DV6XZB'PD3ZB@MC"8#U92NQ_8@]1K.F^4Z"G
M2%,/$M(T7!2Y1U4U#9J28<"UC/EY&-D#^%\!)?7HO@0EK1="C%(RGZE<I?5W
MK(_#'9*S-!.)$K5TE1N>*KWFPE1BF9*`^+RP8<*B'[!-CN8Q,,,AF7XLS3D/
M&W6B9GOOT6R`%9WN$BIE3A*+>`!,>KB?RGZ_"ZXE"U<7<"F59##S'#LADN<:
M)[_A)K'V,N%D0_</F]$KX60H)ZHXH(/&WJ"D,/N#?#G;>(Y'S!B?=X=@L['`
M:/D8D["@[UHLI.4ZG6N<U&=&++&6/)MY/6PVC7>25-\Z7O<]C[FZ?6][^;YQ
M.X.KT-MR-F&_4M][#:M"Z/J8X%UJP];@Q8W;V1.8:<0P+T"/(JW4EU1Y48$]
ML7O2@.:+!DJE&Z<D=G+D2.0^]`"D$9WINT`#W^^+'".N*=8;T#,74[%6FWI#
M-1:3;%M+&((V%8JT/1CH=_S0F`Q3?ZQSJK94)&+^E,0!MBNR)L?J@&WTWG"D
MZ:P3&I!%5]?TEM^C!5"";VEA>E+=?CG3:#(OBMRO]2[63JJH)->EG4S&JYG2
M:MQUU%E[)5(B?97B%;2LF'#GGJ*$'2_U$SXL2^".?,F6PF:>R!J$.B:QWT3B
M;GK<CGWK=N\&*D;KO."@@*K#'`SG*<?(+QJ+/D-7CYBLQDY0]+TM&P6WIY&[
MAI>*D?!KL&)(][91!41`8(B=2CV17Z`YQK+U^):ZF/9#P\0K>1X%\MYJ2@C;
M>TN#FGS>/*QY'2^(&Y7KQTAEIG$=@H3=[7K).0B%GN?2KOPFD08Q)@UBTGHD
M>FG'79HE<-HL=]FQ(II>`\DBR4ZBAA@<^.W$GLDSCK-*K,J4]*?Q+Y$3XFNC
M)17$)F:Y$5W>"F%V3\%`=FJ(#==V=\&)1]496MT+6B^8K1><[$#O@^47[$@@
M[5<*,+E`K+L"P&QL3^@_PGE-QIM<U@MR$)#Q"9=N8W;4]D?1<5PFP;F*MH2$
M5.:0%(6"FTHLX\^PE7LX0W0XD"S&J3DP8%V6C=0<EJW$%_*KY\WTYN\)`[15
MQT)19FPZCP[O%"IKICVZY9%L6.M!98Q8<:EZTH9[IG^*2DWLYE8>5=G.`6AL
M=CR:^>D0'?F0[B#*U\EM:=`;EZJI?6:ERYC:\;AHRL4\-`S^/EF*R.M4WN,$
MC\*X)ET,X`P?-.E0YQS_UCZ_C08P.1U<J+`+)__HG4#?+'AQ-ASC34CITMFC
MAIM9K)D6,)-PBNFTL$XT3*$%Z<Y1+SM=X9*B8;/QD"\8!UF'#X3H9+>(Z)*T
MYXB8M4HN.834$\F]*BYE<,1&F;J$&<OCEZ!.8*H="_\=3N+?,U.^9::,1@]F
MRF^%*1\)TS_V*D50TG_PWDH^-TROY>G)<?"3*Q?YWTZ/)2GW9;NZSXM@.@GG
MXS/W%Q2Y^'_)Y?5/<7P:GHU8[L1_\N=':EZH>=J^Z&SS=!S(OPAFH_!D?-Z>
M649\8T_O9?#+@<("O#T/Y_.Q'<S]\_)`KC(/9V<3LT/^BS?8C5+[=CF9AI.3
M:7L]/*J++4T3X\G?'K*,S\.3TU/W%XLL7X$!^X;[RN.?A=,S"VWWK\,/?SX;
M.X>/?WWMX0,K'TU/6LN105U#0K+DV$'TH%!W&-2M.Z-P2&'$ZIXU64B4%S32
ME)T<@^XXI-[X(RXK?S+$OHI8H03#VKV\<,>`DAG;H"[#A9%JB`=-FY2.>MNB
MJGTFA9^(+;O8OQ^W7T72)$6-9&.97@_ETLN*Z!9\6XF">_'I:'X>F(D10SHV
MK^3@8T_&R<'"L,OFV$%FLVY:N38LTS14`(HO<V3BP5.,53>H'ZA?8F,`&(@.
M']9CQ,/;IZK[L7BV<F!#^N8(=ER6+WNS1$S.$J]8<T&/56YHO<BPC;*XE+;O
M"FHKJ7_%J>JY%>S5&*OZ`1$6V6K;]G9!4?)+FYZ"DS,%UB93#B5KOGW+&0S\
M%@V%(3']%KDOFRW0QV/W<0E(DL?=^ZK1>!J@;P2OYFWLP.`V\VIDHG#H/M+`
M\>DY(?SY_-3/LF12ROX.$^UZ?CZ!2SHZ&:'NL-).E<$*$YK&X7@R#L[@WXU)
M")=XS.EI,#O]4@"\"$[#Z017=Q:>G<V:T']C.HE=@8;7_!8_<YU2_:?HCX-Y
M_AC^<49PFQ)^TVZ63.JC(,VEB9N$\NV<#H%D'WC_>86U>#AJ,\;*OF&CSB'U
M(0L]"*>4XZAE`$SVR3T:[)YB;7F!SJ"*>@82.7HQ'ADUX`B?^.8-+.X;:;>!
MOYLL5=R@O>OCB7(`I[+@@&+!MIK#J%I7\IED;G)W:,.4L^')[-L@M`6R[G>`
M?,Z84G//N>T24FJ=`(@?;'PPE3%)YWXT-=GGY$"!>Y#%3IAZ)5OCZA!1PK!A
M^,'QC+\5YS=G@.T0-X4&S88S_9(J<IH,7OC62=.SPY44N9H%W&?$6)30(JF4
M'Q1>^'-\-@G'9W,N*6K"#_U\Q(KS,U%CMN4&X`PGPY/30/7,&(,"D&%@9?S!
M,L+>%H`R:U,4R[S7FL#D:AK:K.6]<-4M4ODF7G-+:U0_,:@TY*+<E?4.&!F-
MZHH?H3FD/&Z.L_^EPV[@%R[E+]Y*ZP7$,UBB%,M]E>3<(H++?+M%S-\DE<2P
M2'V3X$/O:U>8;,_A'<YK[XUG_42M/-N4/.6KE5%V'_,4K@87>`56B*728TS`
M3#'97-+X)9!$ZRZAPRUAU-GD]%D9QY\2[IA$W2V8M)1H#XG<(<CJARO0V:\2
M+OX*4*L+LFB@(9<'19.'R=K.R-@FVQ%60TY.1/:%>=Y3V.D.?P7<J`(+>LG)
MMF!YGOH)L8:?Q!"[0=:8_U`GW.28X>,V&?)W:D1D\S'<H/=%O,XSIP'Q!QAE
M%SP.>Y8?!FC^3P/I6(MYD-3GIZ2:06X;@"TU1S85LS`Y5;N!6XZB94K0-Q)S
M*B!23PY+>$S6>0&"`#5%6^&'FG'`_"G^A-8CP"6WDA.F`TF4`YSZ9D\,/5%8
MPBSV,Q@#U,[CT\WD%!*2:>C.BAK=`2>_F'X[C#XR`%OX.9V,\1?'T]DE5IQU
M",JZMNMEJQ=7Z9%GR/26(%E745X`@"?%4>>%%*.6'F]\&E3IE=-I(A-U[!N\
M,GF0`O--1RSI\^24]I$F#6[\(AF334.H94P61B'Z_"86VH%3UD2#^+,6&!IB
M!XP_6+`GA2S!\%T>F/M3&1]+$2>;^QIC+K5M<@>(5KGO<G0SYU(L<[Q6N8]+
MA3&AP<&6TG6\`>1?Y&P\<4HC9FBC543TRB!_:?TMMFI<(]\JM10"]F+D)G;J
MXT"<'LS-"-T:9\X&N!Y'Z7A1G5'Y"$QDCPD%`=A?7\*--_USX=E?&,I,I(W!
M]]`>&$&B:27:CU=GW6`OX,*'-`6<,)3U,2",U"B*!\F+@19QHW)Q1EJG%+#:
ME;[9$R+F#R4SMB@[[[OB<!N1P'#S<']7J\#M088Z6QFGQJ>WR&UFOGDU<6$&
MU.?=U46#0;Z'HR89<*J$"*CPYSRX>$41"O0'Q2?@/#U<A.1A>/A20Q?@\88D
MSR8K(P)*0;*F.'^QJ*+'Q.\A'KQ^H]-@Q`0_05.0%@S$#@L%BC&&:^QXF$H0
MJ[3(&V].2;?.APGC*1$3:7[C][XI;>^;BGO?2).]WEDM"X1Y><XOY(7OXJ?@
M=QBLO9.*#=S?&1U+"H)_PX4I6G,VRL7]/::CTJW%$:Z*>NW52"(8`A8H`,V2
M7F,18XI3H5>\;F/TUFM^*32RCBUU:)HG<0UHJE,`..YT@A.P=O;U>0XU0G-,
M&H!F8I*XBU@E%%_$=HD)UU7@DCCY$CV__6LS!^0UY=`N6V=4&ENB_1ITJAV!
MR,>*XH9>`^I.@&^)B&ENZ;:(_P#,:1$WB6$#1U%6@^G2L@ML=/VS%<<T1*E;
M1H!D&>D_A]@BK>N=FR=8\%H$NH_4K]DAF#K6E2G%@4OX78W-JF-2MTT)NON=
MD0M!&!Q*#;AMHHW[HLK&'"-K8;-%4C@WSUXFS12DQ2'R_5N)7:60G+_"<N"`
M$%[3[?.AIXJX1F;Q,9IBJ[!T+A?7;`A&QR66YMZ:)*2;KEVV63TDQ=(`F[@1
MIQ2;,%G/E5[DNRBM'/W?<^%3T5.G;)[4PQ32[RZ$NP</L<^1C&Y&Q#+']Z;@
MTI);1\:?(PPZ""6>TFEY)O-BK0)ZTMYMJH?NM%E#>PIV0+RQ(;A6B/`3XQ._
M."%UK^G9.B\(+S9F^T5K(]&@XZW4X@L>X&6'3AN59?)(C7G3G29C,>?.I$X!
M19GRZ3CU3FB[VL[1U,=409C91G-NBDLB"ZQ%T3+:Q"::CF_8&M,+L'P(^XJ1
M6(F1;J$)>&;YVN%+4O2HQ)'-3,/DFJ76S^U8$&/;.GGT,O#9/)%@`1+52NHL
M$<L8%FX0,W'L896/#JY7WN2H4C7J9<Z=/,3:&=H$,%6]1`8TGGT.-..<76^9
MP)$?\P0KV'RR\1S6]"^XTLB+T[25!R\TW"FMUJ@N=C*WI<7@=UM7[(<Z0BT[
M+SA:WB_WZ5A5/KC5RW#K\B)51[LQ2L9-)J6&[-<(4_@XO@>2ELG5)N,UIM?^
MKU!#-QQI7)I/<-K[6@?B@CG+>)-9?Q?(_'793$^6(/J2JD<WWBBEVBD%1G#.
M#JFPP!\#1TU0R=837H7"T;G+<Y+Q7-94TT!J^G#5*16ZS`)B)I([$7,]6Z-J
M7M5N*W5DD*@.^'E543%#*OGB+>7825-SX*QZHQS64F\[D9O(P]Q6JEA1,)SF
M*%!JGE*GUIKH.A9H?B!KKYH+.W%5`ML`+V&XG#BE3TPUX=S`5@M&->6ITD\T
MHRTW@[5S'L92'Q[,JXCF-`)'@MJUEDB<#$TK1<+QW)UYI;Y.V0&VEO64:C%B
MN>$8BRUS$<#F,U(:L-_NZ0Z"DK.\<%MHF0BN^-BLB$19M%9Z9`OT#'MD4Y]L
M:X/>FH'(0AP&+T9#>&*,:"5^-],'BYDQ1L)QYB2I$O[[3KA\6:,'4VP+6]N2
M$?\`A@>ZM2B[A?212HCB6J/'8T[$3(<@+HGV*_T`+J)*P_H1K"-FGV5S$D[N
MB.0K9S$1II5'FB!B(W:]VMI$8%]I">TK<Q.)_5/7"0N4O9>`,SJ8TAG`T6&P
M$(@A2(<?Z.2TZTA=B_\7G:?K5SFQ-8`O?%WW#::GIUEP"Z)6<,GM;[@WY0#U
M<C/(F-UC)SXD&NJU\9%$ATYR].;V\MAOZ-AF]`@M8S.S-?3S`%X6V+V86;\8
MEA\QX'/&^4W9`*9;C%'9"%:@\&M[:R*0*;`YG4O'2G(A-JM*FZT/$>9>W]3V
M,R%M@7L.4$4]>6(93(8SLZ%#=H/>IA<30`Z+$,WJ/8JO\^DXG$S&/3BF<-52
M_:+)H-W,"%"16_V9GV.WM?1/ZE"P$VVMD!H4;=5RC:79!C_&L9TYM\Y!M]G)
M\-R`))3D(2EL1@E\JBIZ92)1'*!P!E.AT1%B9:]2WH6G-8?4Y7'S2K:WSM*)
M^>FLB$!&6;//COV=F/T1Q]>E8==&;CUFIF67*ZR_8LUI,CSM0)?F^D.V)"^M
M=.L>KR%=%Y5$N`4W<E341:2TM*-DZD!5$T[$;UXY4;`>73ADN*.+CV\EC_[M
MFY^#_P(:XO<PVI"(!![GV^ASL@E^H'AC(APXW04*YN7Q,'A-`I)X7NBG&W_E
M7%.81EHWRW40OPGUY"A,L6X>.-P+2KU=_"PY^Y&81`1*\NKB8J;?6J<LM:'4
M$[<R'09U8N`[S14*0=.S)8+$7F./POFC,?>&S5$8E^F(XE<H\P+_C=)EF*/L
MP\__&KHMQ0]`:B!!4W>9'I*WMCQV,'Z/(]T[F8]O33$PZ4I`RODSUQ5!TPK)
M.R`2[VO#^$Z&B/-`*VD@JL*##490/;YET_M[I4QRD_!A8;(S[]103&?37>T.
M(Q9\0^#P.$["Z>PL/#\]H?9=I=?S15F0O!6\&`]G<V(6U.H+98<&AN)#T[-&
MN(FS*]T!1I]<8Q@8#>159,J$J+0%&8[/T#+8;GS%:`B\G*A;YZO[PBI&9VZ;
M5[P2'<O5D!BVA@)3'Z`I0"R*6U.+G&TV`G#4VMPU1IGK%YR&\]DT/#N9][%4
MV.QW^?YPDO!L,@_/)].>(89M)`G;2U2@:-'2[MVYLW<N"7=GK$9X30]9'%>_
M&H]^Q<4]"U<R]-MS:''4F4-?Q#M/1+7Y8-6-*4V?K<$Y>>7Y'>!3MD`Z$:P7
M)Z/AV1XYQL`,_]"@2!5&&R).4[@Q%9E]?4=Z-73#3\(M52B3[%LT-,2<=+`G
M*KBW%)^)%T<')>;&XRHGDW`*-_3.JT#N/C`>A^.SL^#]5LMG.JMH+M.2]DM'
MJ9N,1J=H`T,'!"BMF..$*#F9C14$!PZJ9?QEM;:#"HXXFYQ)1/K>T4Y.0E#I
MFB8`!4W?YW2R'S@Z@-+1#@JH,F]_]`)'$ZKPA(W%"@KO57I+F:@4*O<E(>+-
MXW>NC)G?\X5,[><F/A4^GMB/3<V\L?W,#-OUV<A^=FD::G`8+@=A6DC0";VW
M^-4..D>U?`K\<@K_CZ;C8`Z?C4_GP606G(*X=1;.3D8DM`(\0/4=C>8F+Z'Y
M3[Z^1C]2O.Q][&@"'/58?WB+ZP"X#-JSQ).SB=ZI:^O=4DC!^KVS./..X-1"
M_M0"=^[^^C-UB>?Z'32<@:P3IWQ@$K&I]TGEFC6RW<E5<[I(9-S3K?O[H;,*
M+]/--?R]V3=#Y^I=FNU12%&9.PS%O$:U+F)$89(Y-R)LW(30OP&A@_FA@_&A
M*#N*[6K5]7*;GTO8IK`H/V6=<EM,1\K/L6EYX/-Q\I3VY%RXE-HN9Z$9"<(J
M/`.LU^524Y']+NR<M7]!F9.VD+,IZGQ`'HC2-!LB5IJF'51>KN#:G>UYO2Y6
M^Y,.GVD*13FN%?>`I@HN1\*2C_O:7!D()J775_VY='4;5.-0><H<V<.._X,)
M]5U5))]44G\1D)R./T#.?P$Z(*5DC8;SF?T!CTPHR8*3R%&!/Y)N\B<8/#T9
MGN-_()&2%C,:GDSQO_/@YQSCGP@+O@U.3X;GY_AS/CR;X4^0!_'G_'QX<H9_
M3X8G$_S[;#B=PD\LOSQ8H99'4>_?PN`3?'XT/!_3C],1_9CQ#Z#,]`.'8M"W
MDS#^(Z$LX#T?=8`7,*$;O-/AZ03!>P;_`;L9#X%Q`!A.&I"=#><C%[)G^`C\
M/!U.S_CG>-(-T>F(?HS."7AG#,KIA'_@6!*MP6M[M+.Z&4P4V>A&*UBC*%53
M\M\DZFV:USEA:<U'N0@[T`\0SZ/"E@NH,!AE:4IU#?TUILG*S:^B`C/NVHH8
MJRE+D3$2W\@V1.D9#6H@A>A]J#7'^U-<Y&YZ!G$>J<,K`8AD`B-GI!03X8&-
MTV67Q%QKQ59>]X@,3(FS8)58:B;:X?YPTL")&XGF$^V8">E4ZA&V5>(/H>!?
M))82K]NCI?P'4S^60W]I[K$K!9*S5"?A;#ZBGZ,)YN3.)S-*7$8R>6:R6%][
M8'38"4NKH/2<=TNK\I5-M%QUCS0.IP"9H_'L%`76\7Q"/T;P_R0X.H$?YV>3
MKFUUIE>"9#,?G=.F3D:XD7%X1J1HSE_3[R<V/[M'RA.AZ[I7/NR4[OJ%..G)
M1_YZ=:V+5WVI;G6_['3N)XN1]P-]]FI_I!0L(Q22<523)[PL,70UH!W[BU*,
M_H+T(K'__=HY1G[A';J)!U?>H0K-K<;(YTATX!ZW!">7_BM]X*YXUJ#G4GU8
M)["IZ0EFK<4>KT,23UE>4@J[06_),#T9X7N2R6I\U?(U.F&_#9X5[?3@T5_V
M`ACQM&&=;,KUKBPJF.XGM+.#VKC/R!:-`1">V&V+J.%WCH_3]D.E!"&W':KK
M8FJF*?>$0D@#1#>!M)61Z54(]5)-/TC\Q24W;W-[B9J6BL^$40S:"S"F(]B?
M,=E8V]=>EWQ/EU*I\_3K]Q5U=OSU?46M?=)\ZS7X^[^ZA2C3\[^-%J+-[J'#
MOW?^?/A[Y\^_Y<Z?[KK;;4!],S*EFX@=F:Z*GH;M0>+V2>Z[2(?85\H>`\O^
MID[/-G,*-5T1!H1M-E6$CS3J6Q[LNF.P=SC9GN]I,M+X[6^]35)!C$<1^'R"
M\O`,?ST!K?D'[JO)W-M)?`$(G,"CYZ#'C\/1V3B8AB<G(U$K>L%N:K]+RW"G
M&AUH$*<D=,-H$_HYI1HYT_#L5-TS?2/V==1X@=%K^/\8-9;3,])30'-P.2S&
M!Q](%LR-MCBH95`&*KJZ\J#78ZY-/)#A)I1PX5X!N:U_K=/'0G4D5/J5"%'N
M^)8-7&@'(5N2_.686/BIT_/A>,2&K,F(_P;1_EMKNDD3["2OMAL42X,Y6E[F
M:%^9>U:>AN[/$[3_)WF^">J&(=B'GTM4#]/761P&&/GBL!O2T7507Q[`T6[B
M9:O*-)2<1=QM:[+6EV:5\=\`ZCYE?Y&]B4ONX/C(6X3P10516R<U<Y^U20IE
MJJ"Q=A2QQK)+KC.."]C$0/R65M/%(6KI%$42''4H%9<-XX#?]$0-6%V<V7AV
ML0=KIMU%%0:*4BJKZ"@KU#SY61*1,_,D&>0^RW>'`,-GO5V@Z-L&+[W35N9C
MQ#/&,6Q^QX5*?%L8D36QFZ7&D.89T$`4+/.F&="G(&2V,^5163RDNI38D\39
M*4R$D6!DW'@`68]+WGAC=;23LR*_:4-*HA-,N(H3$DB,ECS[EM;1O*>21^)(
MW&>]#P(H$LKT,@T<$$9DXFR>I55\_%5+VUN4W=QH$"-X:/\/;NYGML%B#Q:S
M0<D"Y6EGYTM_5&UQN^,@^X2RV/8/+Z99G.,!R&EKDN<:&4JWRQ<GX=F8XL+Q
MX3ISA%F/.R_8T^6T,[?>.@6[EC^WUI"<L_,\5<T*=MVW6[.[;2^S1RK#T^(:
M(F%3="H(&'2!]^ZZ&7<TF8>SO?'PF@'G!&%TQ'(L]@>(N%HT1Z"X,SIBNPM2
M;Q5-M':BA%.I',5!*.[`-DK3B1U9.UX`1P;,"Q-FC@,V6T-1!TWJS801;4RD
M."^1?)%B(L2YAL'/GHY8=O'SBG,>;!T04[#6(=*\1GU5^[(DJ,C4&76X1/*3
M<*D2$_J%E@Q*N97;8!F$B0VUAHAGM1#5JC68Q4?7ER(BOZL)SQ#I&/)'-QF,
MK,)_\(O@;7`A>'NM)E6J^QE<&)2\`:Z1@$ZRD$J(C8&<:`ZTVS7-^V?AC%QQ
M4W0J_B"PGH9SD,''P].IF789'$VQ8N%H2'7:IJ?!)2)TBE;<(ZS$-D,3_/#D
MA,3MYJQ=420<5H5N/ZY^"<M00YF#&SUOS\/Y9$++GD[(7G_&V&F@DABHD(18
M-F,%**##F<9HH)W3T8UVC`F^EP]404)>-5?OMPJ4MFU$GM&JWUW<75W\7E-0
M-"P][ZP4+#&RK9#2WIVSK5TLB-I3V_9G]WK/ZTXZ;0L'V3K:AG\3<<G=[]0$
MV#2><KE"Z31S))4,C_N*?7E/<S$3(?O]YMGN&0Y<Q_O.,`JVH,C-7^[S]OU5
ME+D^9YD*D]W50:T_$Z[/"!7CV3DY]/!>'\WPDC.)Z@X=Z7VK"<EW@#S4)/<6
M1B$BUTI,C(J,8I3,$WN.KSU<HXJ!A*2RG&[:<6)RIW3?I2NC6/L@C7^;9M1&
M7O1D/J(T:+/4K<X^Q)8:KR*\9WLF8/MM+0D-)'+C+3!O1!5<UONZTL0(]U))
M1J:&S;8DF<RP$'=.+W@5JZFDM=:D_QM:(_>WI91W6]_'I<]MFRCI.OJ9$:A:
M(ZLKPQ;17R((I,!<'YANS=/^0X[C5CZAF1$21F]S`[#[S9D]<H.T7%''A1-#
MU[-LSI6*EU8V4;XD#I[^DW8TPZ1@^9(R6Y^TX`(VAAR8>;MI&.[I<&+U2Y<C
MV>,<$BO*4:V.IZS[:9$:SL+S\Q,A4]-I>'(^Q_KPL^E)JR2C%,RQ25W-)W[(
M\R4)BEQ'$3!BG>#)2)7[PPI'MF9!A4(=\*AU:OF'CD15J:C"I7VZZH[]50NH
M2$6AI59_Z2JEHE'^TF3C/ZZRBDUO,]4V_`F_JI0*7AB3K>4LR5IU,-M66J+*
M/$:9:A8;09:2F1X6S3HLZ@.7HBOH\$YKU-$KZ=PL[R'^B[OL8WN.$A@RJU=<
M[,F#R-?4,5&P%C'"G:J-&"]/J]+(]\%#_H2VI%9!&U-,AE*7\>ZZ4R96A`1.
MO=26.NSAX0K?2'!-?6A1"7/2=-&BK%5X_U!GC3*\5,*H-"[N=W']<_0Y^/@V
M\)<HE8XTNU]:FP!7P>OAE(6HI81ONQ!;!)0(:X8AK")Z'U'DIRRA(@&L['T$
M?"^#M\!Z,8(8N2.LBI2E(KCD@EQ8:>7MU<7EI2D>A\/\&&>`Z?#B[Z+%)WSI
M-<+).I%Q*Q=<0%#/\"T*<JC.O8V7Z*B(G6IP/_[N-0W/!E,QP4K-1J#N3WF1
M`N%;ND4?(RYW)E6FR+9D;.AQFFSC;;*IJ\$=X!T0ZJ6FJ3Z2AXA>Q0^PL&>R
MSF08,2_RD$Z[JM*.SX9?NG[6T6JF0.//(XAIL+LAYRRR?<%&*B:E'I4I,.D2
M!(S^,U;#`*,>82TD/*QBB4T2>P[6;MTTJ9KW!!$0HH44244KN>6TL.#VP_7=
M];N/4MG<XJ%375R1NS4)NZN?,.,7%<1>$F[HE(QMJ@D11FYCX-P+6ZA)KI\K
M+!AZ7\6+ARQ/\S49\Z]-MTP.*F0NCHWE.PJ/=]<G_.<GH%!+O!^W5/]P08N!
MS5[F8?"F6@9'YHEC]R"=5'4G+,V.9E'6(BJ5E.VHL9>P0OTAMAFE_PS8&`5'
M=R#N/?`?W$X2C48"1*6""Y0&O3IL%3QNJKK=%]34<<%7V0ET1QS7%8@@_/KJ
M0G.6KVOL;@4(J'>TI*1FP\VTPUS("=^BN[#('>L286/.#JPL3`50[/8!->ZQ
M8@0:<NV1V@#P4-(\]APJ46;L5=^J/_GJYE)L$]0@(J%Z>2&E<MV7H#-(-M?'
M^#%JH$#)M:5@`"XLU2@NKV=.,WSA<=^4112GAYTH6D8BF'E#K_Y!0B[_%L]:
M=G7(,3-4_ZTT3`W]+1J"$4EU$G1E49I\$:]`GF]"#O4ES1,$@"F!QJ_XD&1E
M(L[P0G!R>XOWX4_()\M2-O%;K=F9.)'5CK0'O]KZFI;8F46'ILB44T8))LVE
M7FB:(]UQA(^P(<-2[2M'_DDT)GXM%0)B+8[+8BE57FM190K%M;19(-@@T7Q"
M?"P$$5-*:N^5<S4@(MY8*#?E;::)QP.<?'HWL4G#AIBQ8Y@)NUFQ6C0`VB40
MQBA\HN5TV@2"S@/@L]BC&FBC!=15,A!\'I(MTXZK8@A$>;EDRZ%7P18X`\LK
MWC.==,+P+D<9$:Q'U`#,Q?H4C<GP`"W^R+VF3@L1E822.U[VL"1_,$)A*I=N
M&?^D*5@[V$I+PKH8WERA6]":'!%;L7IX-@`4FA*2O/.MZO?1<HG:&]D."+**
M9.]MAV\D\.84C<S;*>]EN-,4/R3G<T[F?.PHB1L[NOQPK-C"Q17-210@0*'4
M_,/%F^O!"?8+=ZLO-\1Q$%*!`S0X@A1:^H:^_(:%8'X0K11HU879<E0-\B=$
M9\MCAF;60&H`ENKK1%P&,,)V$T9.W1YY\8!.#Y1TF9M/ZK2I?8\5P,O82=5#
M/2H8GY^/RFX^@4TP^;`0`)O[?+&#9S9PZD?7'X^'LB6TDDEPI#(WO?P4(T3H
MTT&BG/.Y_.`?A5N;JE<D>Y7D/T<E&H<*40PZY>>X_7ZH*X]*IWPY2M+M,5%F
M7@ZJ?("E*U%^3]'!L`:]5"EFSB57"@QOK^-VQ15SL8WDZ@C#JHEBS$);;O:M
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MAXYT+!6'N>J#V=*1#4B`V[BNXV,I(&\HK7/D(I*;?6RY"JM9@B1."7L=GXG_
M'M>[9@F+'!6XV9Q[(Z0PW%(+O%%@.5GKY>LJ3V.I`03HMTUR;N\$*K9)`TP*
M-+]I1VXD0XBL+H2E_I7`QB'?@*4IF8R8:&51NH[1D;2EL!\NS\RIY@#&))>@
M#!.;MTD61<ZA,8HLW*"O58O?!-<L8Q0Y8NUIQXT!F@=`*3?8W-'$A+&0C2P(
M4+WS#!#NV!D"2`4%;KF8P'TK-_6"")9)(3`"AEG\T<>;#Z^/S=V1VN^BPF$Z
M'47SE(G3JP#?X&C6:Y-.*D*$J1)_Q^1G%QQ]N'Y[=XPB,8>`Y*!Q;H;!?ZNW
M:9S]B6X=;!K6&L.ER8ZQDGH*^G9:(R=XG:2;L`>S">Q++"=H$%&1=TO<3F4@
M#+9"^1[91TZI(51T>Q-7.>B'*!F"U)`+A@U`":L7Z+1#=PW;&1_S#1??.;J\
M>?<SW%K09)/#7OC`+]")YMA>C>DYAM%T/7[['AZWP%'F:':/MXX.$@5:LVTB
M2;&T5>K>(BY\&+SKF)-NW%.N#(3J(ZC;!Q!PP&G$'"(&5#=;\"'0;LJZ6&,(
MG%F)F!L3J:@KU]L#,))]A)\D(>M6:PQ_Q1">MWF6P_$3]><TP9BLK"3#(CX@
MRA@#&BGW,"0JH8(S*WR&DVCDLI4JHMBK1O%(1%JG([UW$F2')M0@QBI[662Z
MN-_7Q3(F;"J?(C5(;$F"$6^I$SX%<"\3C=EBSKOUS7*.H`R+$1A@*JFY")SS
MB%YO$C+E)@+]B:V-`$9")E/&10X[@X%F@Q\_3@GNVXI<\56TSC.JO48$-B\^
MD;OX'I1T4]!<FG11"J0,A(:E#!ORD6Y_SRTD&*8;2N=&0;T#@?THS$U<B6:?
MQH](SQ=4]POD<S8Y:+:1\/P6KVYU*Y?:^7T9!XG*H;(`KIT5U<N$<\-P[DUW
M\6=N2"\&]-ZL$G/&?>'EH9-=XBH)%-@@00VCV6`"C]]RS*\QL]@<X#NSK,&@
M5Q;$>9Q1IW,:$H&!"=<8Q"AV%TR,WG+QV69<+WH=2ZF^UGD`J#=PDX<U5=DD
M2<=VFN_9(:T%$WEA[74I!04HD1=T8S62\+E+;0+L-T6G)4%3%%S8D;1!ITM"
ML'M5'[S:L\&+L^'8UINTJY5>!U%/L*D/'M_^DC5UNRAP2[.O8`:ZI26%*[A>
M+^,E8_&6PX#%+>U`W$-BC3SEIBDK`HRU2XA-`6TFS6+"GE;I:)-:,4>Z3-C5
M>5Y`_!"D%HQ#]5;KEMI4G;%_^5RGU!;(;_DIQ=?G>(=T&>01TJTTP4NN74V&
MDP+/Y^(7PC`43O%S4S^U`&D8S$AV!AXI8>NLTZI"S"QK)WU+X*E-PQ^DC=*X
M*&ZNS2,X<K$&EKX:;(&<QJ;3;4<(/7%Q#ZE,J#9YV%T/<Z.Y60-S^A0;EL&U
M5QCAM@F.EF>M2-]GBV@XNT/7;\P4'150G86-K:R5%VLL[5KSM)K&B,V&'IK5
M8<7D^@68]Y=B';(LQK0BUKP*#]>0TCN9F1E'O-\G++-CG(L@GJGA2W8;))ZT
MK1<GBHF%5/?=@X^(4_5V!2S>N/458"2R,SL.11#7SKTY:[@F\4$[\9EJY&R'
M07<L+(+\G89O\$L\CG.9->!42SBPGZ.%;QF5W[K/K5K`9XY9!N7*"@_B"D5L
MTL`)"U,\`C'S$!3$<8U2A3$F&>#FRF^YU'64HOB'%T_#92GH7-W?F>9\H>?`
MD#AW%Z;+A%0?EU9V+>#X(0U`8X/NN#%)URDE"23#'L.&CWO\C-&&90LVWG"K
M`EL0S9IM>M":7_/DH)`8L^",5\.L'?MZ6%_P_O7:0AK6SM0C?[W4#C4J^1.P
M,)D42QOBS]ET1LT2,W$_8#V9LV`^FZ$T1,E1>[J"RX+&X6A^`O^?GIQ:V88E
MM[H`4?<AH=Z_"*')R3B8G(Z,6JQ-)/"[\30\A56!H#:;3HT2(M;YLW`\&LO_
M)D1M?#JA?S<MD8(3:Z7RC#2_B<K.HPN.SL+1Z3@XYF(31%L:&_2?'Y^&9R/<
M1HBU9;H.RN]O\C6GI25B*>]W1AD&9[,O;=0^#Z<`SWEX>G;2V)?[E+\Y;.X^
MITCFTW`\/^^\;(`8>MU,!!.GF#=#8_?<(^I%7)B;&[NU_;ZHHE^?ZO%_).3\
MG6/&Q[))X_F<SFP^P222LW!RCM=L'HXG)U1%A:4>?O[H=$S5FB8G7+LIG)U.
M\9?S">:.7#0ZM9L&:NK`2FQLIJ#IT61$94M/1_3_^8Q&IPCVWBSWH_&<GIZ,
M\;&C*26U',WIKSL0M\@2N.:D][`KZ_WH))R?TC[@^M+*C^`BSTYY3Z/P?(95
MJ+#.ADU*:\70'XU/Y?[9WW[%2^W]04'SSZ3)'V$EK%-<./P^"><G8_YU/(>!
MY.-Y.)_B>>UE1VZG7KM_4P$#M&#I5"4].9KAE4;L/!3+.U"V7?;>A:WE*TU"
MP$#C>F=7>.47B34K1BYZPK,SQ/,IH,U=7ZT#M^#`K=L@8RLZLBDJJ_47CJ8,
M:ES`)8*+^!$%:/@>U0:OP`2,T8A/:1J.9O-V,L:=K:1T_=@5!MUZ8%^AH]:S
MGM[*]MB8FMFQ.,3]&ZQDJ5',"VG7Q=7&.XX2M2Q'7"0QD76$3A,*I6EQ7;6A
MI.R0?4VH)K<LB-,R?J),5B'`&3KA+/7NK`32-9TOX2\3+GO%'9])Y)>@7\UD
M96VM<-)E)7700).!U7(JOC+6*$`83#DA-/*L-T>WTM'[4&?BH3['`7KWVO70
M)(CL4/-:G\;X?]R\]M5FM5_7J@9@_37-:LW#_$DHS;4X]`AP)-\6>Y?U:XUC
MRIAM_6?YZCY[L;KRLB+;>7);`#_%CJ2E,FH*($>#LY6J_$[%6`MK@[V-(ULK
MS?$N:M9`;/9I0L/=)'5QB3+"2PKG\^J5DXQ6:^,0$U3?]TYEZ9V67>I$:DF'
MZ%J.:UPR`K235M4LM84]#:E:@+99Y3ZLG"IJJ!F`6L(W\M(!6`L%;^TAY2LJ
MBL]'WE&0;\^C3CV\YW&&0QZ5/B@8I"T[$19D$9U!110#?9&F;L=<^*657&AS
MU=0Y$YN*;V;1+5A\B'TAKG7/6@^P""`2,%=V0(>V.5Z[CB)VZHV232]#1S/]
M*LH/O;EUJ)+:1HK6M`\1,C$MVRMA.R:9C-.-FXN_U.KN]`L2I4<$>9N:]#[8
MJGJH5BL.>13?*7=7#+!1;("M28O:R9$B!URR3C*R,8(T*:[R\Q%<HAW)'^QN
MH]H2)(O&=@%#7I+SB4G\`^!C>F_*17$$_-S^E8\>V$>\TV1I@RBL=FSX!Z5=
MMZ_(!^E)&3-$GOF:@.1\9LU[TM8(%28^2KY(,B^9Y+AT2.4U,.3H2'.5$*0@
MADND$7<.XR0B]KD03(IM3F56%N@YQ/#H8MDZ9BH!_+/Z2RQ[N+%G]A6O6!QI
MVA\,[>NR1G$WWL;AAO:<K)7(^5",$:&GJ%#(@@0!?":B)T$@UC^$Y%7-`$GA
MEK<A1V:L=FK$E$*/22O?M-##MRR]MI:E@Q\DF/4:J,@:0024NB!0J1;!5U9]
M8K?N(:H"J&T,*,A%2C5YL7=NOX!X5:=:!LSR:!:\,``,%6DI#R;L354_9H@M
M8.S/TOS"G$X$B_<(=I]88:O%>)!*M\>FK4$KUXH>B`$(-1MT*B8%G%Z4[IH>
MRJAJ<%OJ1Y:B22)$LD0!5JN"-0!X/5FISD38EQ2+>L/.[U*#\V-W?#1K$SM0
M;6H8O(XX(*[J)*GP+JPDTF[OS.6!JJS7%'MDI&@LE!(_-;<C;#8TVT>@I)P+
M0L%2E6L>>`FP_O?@SC$*."77)<0K8P<&$IB:DZB-R4=@+^[P4L-YE![EE'AF
MU8GO6[-E6!*#HX*7-;Q/D1]H+\\W(%I76(VUXZUEO"`L3_Q*;*2(@\Q0<NJ%
MB$W?TSGM&4(NO-`1-2$0ODL\)#+9^SS_Q%1DZ..F5F%H(B21<XNX<MOP1*P"
MWC@[3@&AU%KT<U!+V<=8?/`J"/L5"RFA,WG(N6*2'6L8W*RD9Z.3<\#19@ZR
ME(S>FA:*NCC@BZ\XTTXKK!,DS<^,4^P)2^[%6W=$O&SB$:'-\/>EE"78TGWL
M]-DW[I]J^SXSZ7Z8]MKU-`<)E(T9*2.*HGEX=9L:@:Z70J0T+27C@?2]1J(:
MI^>S^W"7T%@>0WFMN)2P_TGI0*QUMG@!;*_7^"NG@C27/+K))%R72$+3Q>0M
MT$RHMU0BPAL+5WG\>=+;,+/8*E,NXQ4"8B:WC$LE,^3;T>(A_(*9G5'$@JNC
M#%VN(@\WH-L:GM-2$8#MFTEELM"12<3.)_IE#92YK'I#5:S;G->!#`'7(C74
MD$92C:V/#=%OBQ:CG5P>#?3@"@)<7\Y9'ZH`,?OBLQB]YE'!70<ZZ!)NY7D.
M9G:CJ^;@3A<?1;>M,^TWJ%+OBDKL>-'*\"++&:9U;%YZO-L&VW5Y1_UH"2#L
MJ$/%2Q?I&R=F4:.'E*[48[W^,DG#"_SH1BW;,LL=BC'[(6I39(I3LDDN6-S1
MH:BYCSY]P4E!2R:[L$;I4B2MP1NM8M%ZN+_`WE/LK]@MN?H(NI>T$9,"D;&T
MN_%2O.]]"\$P^"5F7[\<)>=_1^FN3!IE>1,WI*MMA['.)QK",</3L>.%01_\
M-R8QX!LI&K%P:FPT"C"9RNAMZFZBW9RI%ZC;9NFN7131TG8,%S%&5:?**^/U
MI9$!-<@%\=H-FQ;(-,K@`18^FG*V)FG'-4HY`&G;!:R5Z]*-0MGSG&UH28#R
M7F.3B'W6CVS!U+Z._9=>,S6A.)UMVRSW<P_9*?BWK\)68RU^[7CM,-<J;2^&
MBYW3`J/9BL@XTTTZR>&^XK9)SJG'P+\'%[8>`S>]^)IWZ&0N4O3*K3T+`X8/
M<U4/%@Q)M;;C.57A;"PUZS).B7"1J>ADC)`F\7/W0/)72:5F'1B.:*I!59V-
M:I.(0WFH^UC0VB,I<L^!G*%:2NE^`?19HVHYP)PV&6ZGCT.?.[3-AV!:HR89
M-?[`HF2M(;E*NOLQ%BFCW'NNH,QIM;]VTQ#'`_KU34,X84M[IWI=1/85U?J_
MN)-(5#8(RW]@)Y$&"G([$8-9_"<C%U7+XS9!K_S..8`'&!9ANAB7`=70^WM+
MDK^W)/E;;DG2[$+28:>WH4973JB1UB3]XA?4U-\=P63X5C>OPIQL(S,4SP_R
MA,7<0LM*K<W)QN\LN!\6**BFFY?6H4"."1(C^ET,::(AX*X]8*$$K_IWT;^B
M)7J**ZV%A,S`5`(CAYP-;+_L_L(<,C,5W6)9YF+,UMYZ%-1B%Y(7ZR@3LUR)
M10_>E\>>$B;)9`/=B0Q<!4C<Z1=FJ+@]6I)T`HT9=)B:1SK)U;YUX<LX-;UJ
M3>8:%TEEZZA_)OL0V$M)V>])279DTKLU:"[.,/G7<',@``G&NR(Q,=GOG`;+
M"?-8+DCNBW->;C$LG^5I>TXA#9E`@"0)]Q4=GKLGV_H1KI&1),,^4Z'YGJ[Q
MO;O@CV26><R92$JLG(<9?#ZH/Z71VM0I8WV&542*+Q6*3:R:#\=(#G@J*B-0
M>3()F@<-;5!OY6G;RV)1@'Y-\2[JLT<;I9;Q4$4`)[*5#/5;'[N\%7S*\J<T
M7G*U0GW>.6)4!.K2&[]%I:2B\<?H<YL@N=^U1%-'@/""Q@M55#5;;1FO8HKF
MJJ+/)+B02V,A`>8Q>ATPB-Z6GBZ]VM/XUKW&-EG#?S.2@EUKK7@'91$'1I,8
M<>;T9$1=15!JN;`A)K@G%RJ>&$VOH+"C?O3NS4FK!@WWA_UI`!@09R`);/.Q
MZQ<F)IU)'F(M2=2.['`,%DT(%<;HQY>.&[&CB&-6[@K^5#K(,02@%A)Q57#$
M>UAP4CX@B<+E.`$S7JW_`RYPQ*46(I,S@F=L,883_`A@QG+)F5+#SM#"4D!#
M[A2;%X_L"RTH9ERQVB)J.0:>COV2V<NQ;$85^7O)>6Y+!Q)Z`AU7V0A+)IC!
MFF(W&@W9T(**)0A;E;A[:4E)1R5+YKJF1CL%J*G_*J9>+>C5!BZ/92%M%$\'
M$/8`H&G\ZC[^Q)K7L-6L-4^(WZ3K'16TJ&X!H[G\WA1)G549_8H2?%@&D3XS
MC@9*/,S14+$2@<HKC50U=QZ:(%<+I4%[-T;Y#_5R+07"'!N!I,5@C=WX,T:!
MT/E(KS;VV#T!3WFB1(XGMDUNB[@2&0)U"'P-SXB?(I6Z3LGMCM;IZ#,9G^OJ
M`;@R-^^^ZJ"+D1^0I2S#W:,;I(:N`]^]VO>D)3<:]]CL].JP=_C5=.U`5I29
MOEC:*<@<I]&TS&$^TR+OX+!+XM<:,,D!>TG&"0(DGG>B9+3&ZE`5,5&/,-@+
MT66VQ-K`A3W+2PYVP6(37_0PL=+77H"-!K,0472+?1NEQZ$A6*/&]9RWYI(H
M'.S(Y,8K83`=#:I)@!S&T@QY<@FK`K/DYR2$IN2"("PVF>@8MA$\85.G[%-I
M&G)5TO%%ZNI;"_@J7HHP"^.3ZDKA`ON;[K2TV&9\%H=Z]\5A;6KN>U3;5N\>
M_<'7.'^<G6`F/8]PQWU`ZCE3U!E6@2K$^4`TQSJ50#9P7EICF4F4&=`V0^>%
MMYATJ=*H2>T,7>YJ8TM<X.?L>;/ED3B6[*N.UD.FOI?I()_ROL`PD\9TV!&W
M[XMKI<;,E.>?$,-_*Q7*C7W3"XY?2-HJ$";)%/->5?Y+B2BF5HM0(9.;U5JX
M$Z'VUC*BPYXJ.TV]*)"=35CT['M/"GY)Z'`9NF(HO$OEG74/W5%]/7XM<XR>
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MRD:;CO"V-2)"\%(Q$GX-5@SIWC8R'`0$3M(W-VJ(O)-9QE@?`]]2*70_-(SU
MU!,<2,&3PQ6R7AK4Y//F8;V^RJYWTK?89IQ2#FH&]6$@C5PO.9NTZ'FGF#&3
M!BFQ,(C)LR>VU!V]IGYGL]QEQXIH>C5K1](G`HX"L;!A"9=G''E6>$&L&?24
MG._X*:WO1D'<UQVIY<IU3\%`=FJ(#1>V<\%)32:[7,R]H/5,Z[W@9!V[#Y9?
ML".!M!^\:YHO)ALQ8%E+8>@_`N=R[RB<IG2*]O[TVY%H\(Y$/#M7T8:32TR_
MVTX4HUM`>Z,R[BA7<%)?;P<ITY:I\43P>9.^++?1(O[';[;2DO&;O_>2^GLO
MJ?^?]Y)J703)V%D%'^(%16E88^9MD6=Y+5U#VMD#![^)4:#<'8+S($UH`E].
MP/2?Z)O!Z"S$%@PB*3Y3S5:%6UR!%K>51#!39H'JH@77&/FU(V>',Y76$?)F
MIWBII1G-%'!@4=.6I2T?DA77:FU4:N`L7F!P?T"J9M*AFH)V[F_'=1JSR:9\
MT-Y:MNY#?PT'M+5II^`4=NKLR9JON%IX["85PNSW@(*]:;-\0]`^UU$WWT01
M@22G/;')DIM0)IG85&A\*]Z%KG`7BE85^KF&_84_I"PAS+HT)GIWK^3<--7I
MJ1,M#`2+)>.XA/!*FH+J;E*(E`,_Y;E[..2,'#*<86[*SF"9/+8J>71_F5,*
M*5EVUW7"I-RX%M"7TU5(BHIK;;F)>F**XG@YRGLSDZG4M)LTW,X8%;SKRI_N
M+910@FPIN=K'%,']-MKMN;GO\J'`_QQOKU.I^U)<IH(;ER"HP&$7Y4OA:_/1
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M<F\>2U00PD=JC9$JVS.5%ELUF*.HB"YBBCR+I'<'^M:QC'8?`J%E;5L)+3.V
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M:[KOU!"U9J"=!0MI8LG@]I=5,TQ`4MT`?U,1ZG!D#^!_!934H_L2E+1A0.+J
ME?D4E,L8;Q,)Y]N.(;DD0B*EI"Q=I<@/0Z]9LQ5_KZW'9,IVBG[`GF[ND*HP
MPR&9?BS-.=,UTEY#7'%ZSSV:#;`[T!W"3>H(2UR-J1;C%\P!Y?^Z4?><;LV6
M5-3KST#G*?04)[]!)XY[F7"RH?N'+=,A"2PH)ZHXH(/&WJ#D&?('^7*V\1R/
MF#$^[P[!9F-%9@.<Q47SKL5"6J[%PLBI9\*()7[$9\NI'.@``S6#.I.TRTX=
MF-43ZFAD^;PV9E.W(D2&E@DQFE+UJ^9<"*U&13KCR^O08LDXW.T7<^VXSUEN
MK5S953#LF9JH5U11BX^OPP'^>_9$W+(G`MD6(]];\40<B:?CV$LZYXIG[ZV[
MYX:-U/(TR.L_N<X@_UL0Q[D\PLMV,907P702SL=G[B_H9^+_+_84#<7O\9_\
MR54Y->73]Q?:)"T'\B^"V2@\&9^W9Y81W]C3>VF[C3_C(8&WY^%\/K:#N7]>
M'FA*GX>SLXG9(?_%&^Q&J7V[G$S#R<FTO1X>U<66=NG<OSED&9^')Z>G[B\6
M6;X"`_8-]Y7'/PNG9Q;:[E^''_Y\-G8.'__ZVL,?3\+1]*2U'!JTHU14H]JS
M>J0<4+22;WN*1#ML*C,2F([G[D.U%3=TJS=D*RD=OWN+\O4QDI](G7,Q=#_^
MO6("&]JVAS*]`"ZX]))'NCURK4S.O6=^-,<JL3(QGF+'YN7*MG.EN9+QM5O)
MF*_@I5B&G//KY:IWBX=X67,I^B\;LF]!!Y96=GP7E<=MOZ[8MQ^GSR'OB/CC
MTW."X/G\U,]NY/O#:HH)_3P_GV`M[I,1.BI6H`YQH-4JIKK>X\DX.(-_-R9S
M7((3IZ?![/1+:TMC?>CIY)S*Q)Z=S5H'XSBP?J/Y;_VR$5DS.741+3L?V#')
M[/,U"^HWXI5JOOR6DE8(L.3X>"I09LQ`RJ*.U^\QBA0/9H`M0?EAS!>E%UP#
MA%1#!06R=H<QC;-E&#1TGX33V5EX?GI"I3M*M^&LVMY,N^T7X^%L3HY!*O.!
M&UH7.7?=XE(E^-#TS+1'.<+WOW%VI3OXYAB%9/B4!O*BO;)8_(V.QPZ!*>%(
M)G70;:([&LY&'';>^2IM*K/^-TG5Q];OP]&94_Z.9/..Y=I<;<S7?XR+`=HM
M6UWZ2*-2@%,'.&>-$35X%0=0,`4R-@W/3N;&R]A<<K;\#C-_E.VY0W%_DG%X
M-H';-)GV##%L(TG87J("Y7^W=RV];>1(^#S[*_J0["I`IZ?5#SUV@06TMI,Q
MX"2&G60.P1Z<M6P8X\A>*YXDP/SXJ2H67\TBNR4YDXL/4<<2FV2SB\5Z?%6E
MHR_DIW-'%Z=$-6PNT0ZH+%:#)J<<CN/R`2?7NZYDMK#O`9W7'O6V16/(5]&#
MJM#1;?A9IA37S-_U^>+?_4_PV0'/Y`KM]*0I"[NI<M8[.=*$DN[PFI%#G#$9
MG*$%RV2NU\:+:?:^88TZ"HT]\\Q""@5>D-=/EQ/7OG6%$7387$)$B.*"C8#G
M>O>K*J]AAYYZWG*WP1C.@MDL>W.KXP"<672G:4LB[CEVEJHLIVBW0*$2!&O,
MP8LD68&4P4LPL%,=^LRSM9HQ]MA6,Q8AD[TU35Y-@P/(+,T0T8$;*T4!3JI!
MH!E?R^9JGJ;XJ6:Y9]SE9B)CEP*<76,>S-Y681T*\[T1+^#KRGYMD`IC^YWI
M5OJNM-_MF3P$2JCZ>H'YD,S/ZB6]L206"J$HR==P9-;P6=;C;`+?C:>3K&JS
M:56"#-&"U'*HK&7C)B_+B=$ENO_X9Q#S*!U,K-D(*YP\TQ=O<L*"<Z>1*3:@
M<_*VHF&5#*97"N;OO8N9]PJF=N6G=G$G[G_?4\)=936E[M+Y0,VZ`\U9"Y'2
M%_S`>;7%21/&'U^A_U,T%@4JP!=G##>191\8T69,<+8&J2H)-O:#J?L4I.[?
MM(3S)"/Y!B\MEO`8%Z1[EL6DM1=H4I&>H2""F-%TQ.D[FZ*9PN]S_("3G*2_
MLFAJ_)AG[V\PRR'Y))YFTZ:8S_$Z*68M7N$<Q>MD7C0S_+LJF@K_GA5U#5>,
MH7E^@1!90@0^A<XK;%\6\S%=IB5=6G4!<J8+=J66/E0\?N0J\_+.2V%Y@1+D
MY:V+:87+.X,/V*/C`G8;+$/36=FVF)3NRLZP"5RG13U3UW$EKVA=TJ6<T^+-
MU%+6E;I`7X'N8@/,Q%UJ=,[NH4(;SPE/B^Y!HW9M>(:0&)20*G[PKE.'QJ_=
M9Y3L%\H,5.7MI*1K6:'1:U*U9!G$[3DS9J(7WC(Z;$P=+2"DS.6CA7^R5I(+
MN2<LD%5GHW&K"MQ,*E7G!CZK;(3U2N:S2GHLT3:"96;*.3U44]94.6A&6V"B
M?J;_-\8`*FK9G%;&,P\,LI<PC.3<*]GB=<.FE`'^!19]"#FB16(+5ES':L(X
M67<2O@,'&R9F]NJ)J1Q0PH)#6:'#ZV]_3>&H:#H3(&8DA'F%5-'B?QO@62]5
M!@RES_L%F!IH.@<N.L[+V1ADEP8D*;6YHLMN0"*<4\RK?=1.B?2@MTJ5'R-3
M+"B(4ZU4Q'J,UU.JJ,]J/'6K`(4I$6T``[Y1EEY>JGVGA$.1B;(%YW[-Q->?
M/<CXART9!_!JK]Q%-P^PSQS0IT^I73V=BY/Z?"\"PBA7.KO\0`'D94^5A(('
M&0D#_)=S1JI6TWDQ+I4D4I7J;Y!>GMJSEU.6\^$+PD293?#HG.`!.?&.:<*V
M8W3&MRMT?*D!@D^9@_&;CJA???Q&Y\C2FI:?].F?O!E>&[0\JZBCPQ6\&;W-
MLU_Y_6<+?O\'V@RAW+0+8ZHY7($HL\+@!'78=SIR5`TTHG6/,U!U2.2I47A[
MR7F?ZGP"NVU<@/)Q8.PW(ZK%!F(=>?NFV1ZJNU1=?(167BRU!A)B0QNK.ZJD
MXBBU'\4KY4Z!:6@;`)M<:&7EN^'\J2J:=EW1^33KOB5E:F<TP^C`E'8;<!3)
MMW;O$*)4^BS*ZDT??&5+)'$IW<T@*N,P-YW]SO&C12(?EMY81(><X(S]3/%@
MD8]+5<1=V>W()D:9(+YHR#PB"Y^;<>5C"AG;<'9BI#'7FN;9KECM50KZ&\L.
MY=9,8[-\/M<E)VLXD4"N&D_SMFX&5MG*M0_]%^U#/Z6:?@-(28=,P-:ZN;^%
MG@Z-;3$Z6!>!DQN?UBG5S,`UM8$(;I#&$!IZ+$W[6)KVL33M8VG:Q]*TCZ5I
M'TO3/I:F[2M-.Z2ZJ2.-'%H\)Q#K_A)VXG5<0GH#Z@\[J?"_#@FX8:Y<.S7[
M<(1\AV#%0=';7Z@*W?-8%3I3=`[+S77OY2IT`90#-N^G^T_9AU=$$__-_LCB
MM;QTHR!^5RR[U6U5*[!R"";YNOL,6KEO\U[WW'S\_,9`;WR>O3O=ST9/D#:N
M'(TRVH]3;R+YIJ)0Y>^)2;:T./C!7.QBU)V;AC(&!5N3D+G8"QR(>8RO<^XM
M=.ZL36Q(1H^*)2(=,*E\F\\>=YD6T+N/GKU*H&=CS[+A@)N!<!]HT.T(([J3
M!J%0M]@2[E.Y>$BS(<.-EPO/EOGSR^'(LC:)#R<@(6`.?BQ1$.Z%AT:-!NS,
M8&ZUTIU`:1XH`]>`EIL"3#=FPQ)F4TK>EH1LAJ5_.[C-,#6Q#]X,>.C-ZE*5
MV-S'$UE^K)]-OHT5U84&FJ%G?:704L*I^*W(2H6'JP7\96'`<H%]!R=AJY8F
MCZFW.&M**:6?D;)6<`6-8%*@H"C_3G2)])TZU];%U5<2_"BD"VWEW3MG1=,&
M%FHS+9-)TD8XN:,$$D89F1_Q=$X=_PU?,EH"$4IU=AG,:%R49>ARI@ZHM*\N
M+Q+OH2W:L`?MGD1"Z?XVE:47:SYGVCG['0CK[".K/MH]&FQ8'S\ZNE^?6^QH
M(*;NW]O:Z-H-HS.MT?WW:P:!:=^XCT_M]E=%Y,R.E!=P70K'?`L#@-@<;75T
M<[;2`=O!;\M+>#O'"ONH3$QHDK[Z;/,8&B&#)&W>IUOP(=(9_<Y2N\RM/K)0
M^GJF)4K,7/+R3C"-'PH9@0RRT::W8FK,E=UG&"2\3Y.QZQ!P^%MD/*7,>%[?
M_&ZX4F!UWD,]G3Q!]!#)Y=+P5:)RNPYLD<803'J0X#Y]`BXPIQWMT;?"9JLG
M$2:AW!O'$E$'CBQTAR`;CSZFWNXPZQ-40_.N;\L%E>E&X91HL1BCQSF_CSGK
MI9I)GKU1%6@9J:O<!=$E?9%>TIPL6.]<G.Z^QNGR=G)`N@9V'JLR<H26G>M5
M=@S\!.0?,FF`4'6T%]W@0Q[8O&<$5(BUE_O'!7'4BX"(S>?5T?OL[V>?;O\%
MS0OJ`1^<F)GR=B2?9O&917B[Y+C>:TNA^#CJ',&G(4:@65AXNDD'TZ`A-/--
M]R\SBXT"13P>PH>6E7NB_%3"5,N4(6"K`Y_H5ACK?X@(:Y%%/`C2.A!Y>D'7
M<;1U"E:]Y1M)\#'7ZYW68T2H?)Y9[8,]8]W[V$._$6\E8/+`";!&$QE=PNA%
M#5\&F1P3T?_VTT\(+PX(203]Q=GB\M;V%L(`(E#!6&_0O$#7HNHMQ`0)",,H
MAT.!H"YC74G`Q"BKQ14SLYI$NRK[NW*P\SNUA5.B:Q]-KV4H]O3TWB,5>[V'
M5&19P$.BU3V6835701ETO6.#=VM2]G,1R\)F"]')W48-9\1H-1)Q/!?U$1>[
M'*AC"!(/ONT"ET.]L0HUV8JG`QL@/1\VCF>SGG8$KPYGC.#KX%L$J0O3K,.6
M>II:O\^J6AP]?)Q(0\+5"Q.:AF,C\#O\4B6EFIAAJN1\ZIYV!.\/5PTAZL(D
M!>T=8>G!EX;&6G%0?H8JW8HB#L*I(6I>F$4Y$;ZLP_O-U*KIH+E%FE$8A#2Y
M<3@DACU(DPO)P+*MX4A^ARFE=7,Z*K6S,Z+&1KCEYG*'T]$@4<@%I_>*07VP
M^`%CI"4=^QYLU!F[TQ5`1>D`SSP+2?Q`Z*YC'N`_XVKU/A"?1H$JZ==7EQ-O
MT($PYQ8:Z_#W$\'L"/RI#K=^;Z^2/2%V$X&%7^!Y8:RCTDS@V`@Y2^]$]C7R
M5^JRE!3%-,WGT>SEB8"'_FB&9UL8UZ*E2:-"N%&SN,9QK.1UKN,OV-QY8HM)
M*AL#UQ)/"2CVF1E`&@VP"!D3PV?<N(*%CYZ)"ZD&-&5<T:?+R^2R[-E8`R?C
M=532C&3(3AMJ1*H8$%(01TU$(/;!P5^4X0DTEDYNRP@"'H!(?$GX$S8DH?2#
M;V7,?K`=Y:-5BU+J",[&LB#5;1:1;[JM&K%9)'!@@W?;9SF..[HV.K!M-_)1
M$RUJOT"VQADJ/W[S.`%;X;,%'M#)/6["$K0_Q/=XY*9T]!^)TY`/L[5)#(NI
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MUJ;=F,BM73LR@5[;K(X/D1G:@Q,`]A<10MX;<9>FE-BB]O0JZ+H#-N(6P[P<
M<"YOW;D-$OPNW=M(P^\S>\\2\'W&<",:MQD@&NX9(:`'Z->AF`?HS2.1!^C/
MHXF'F%]`!`_0:>>M!\>Y'*)*887;0``C1K$T&O(ZEA!$BF\=$LBZI5MU`1,T
MP:2GMI2O/\@>E2\S9@I3J\W.,>E"D>6[1)TO53:!<I<(H;3^9,ZY_MK2+2"W
MENQ&_7&N,0FU-^0U"@^#=[UR`4#K7<!.IC="CEV#P*LKHCK]I][$JVP?;U[>
MK>$>VLMWV1X&M]W%50-5CX`*)B]7M$LOEJ&+N@O_(CG\6&46'&C9B<7[ZAW9
M[6;[@%T45#8/$4Y#Q`SVDNA<+>TMW*B@?I0H?TGE_ZY69^?+_]^?4;5*4L5O
MB*%^O%N>_6;JW>H.8.^._O/V?\?/*)"*$9[!4K2B@?54UZ!<NIP(H];O.?CQ
MZNZ<8CX#+G2RI``+S.FQ9(N!>_>&S;/1V=I!IRI.X.805K&_R_,0"[H1J3RW
MP:X+&^RZL%'41X>[@+UW"OB39?#>>-=@.X;ATN&^,-'2`95RR'0,'B=%DE#L
M<]"0PZ-/.#P:3Z$.DFU3Z[",-]21<^K77<?8F)QLY/"B$SDL#;\E;C<5ZRF)
M!QR?&YK7O?#=X)5M'*\;]1<DPFV#^2;C:G=]/U[4D!GEM8Y>)80UQZT>N'&K
MF[^H`0&AP?L8'A%J;_UYO?[\[S\!4$L!`A0#%`````@`L(YI1[P-6`+O`0``
M+2```!,``````````````(`!`````%M#;VYT96YT7U1Y<&5S72YX;6Q02P$"
M%`,4````"`"PCFE'2'4%[L4````K`@``"P``````````````@`$@`@``7W)E
M;',O+G)E;'-02P$"%`,4````"`"PCFE'MZLFGN@!``#9'P``&@``````````
M````@`$.`P``>&PO7W)E;',O=V]R:V)O;VLN>&UL+G)E;'-02P$"%`,4````
M"`"PCFE'PP[<V$X#``!H#0``$```````````````@`$N!0``9&]C4')O<',O
M87!P+GAM;%!+`0(4`Q0````(`+".:4>132NS/P$``&D#```1````````````
M``"``:H(``!D;V-0<F]P<R]C;W)E+GAM;%!+`0(4`Q0````(`+".:4>97)PC
M$`8``)PG```3``````````````"``1@*``!X;"]T:&5M92]T:&5M93$N>&UL
M4$L!`A0#%`````@`L(YI1]8:CWI-`@``?`H```T``````````````(`!61``
M`'AL+W-T>6QE<RYX;6Q02P$"%`,4````"`"PCFE']_""?I$$```<$0``#P``
M````````````@`'1$@``>&PO=V]R:V)O;VLN>&UL4$L!`A0#%`````@`L(YI
M1^L/4%M/`@``]0<``!@``````````````(`!CQ<``'AL+W=O<FMS:&5E=',O
M<VAE970Q+GAM;%!+`0(4`Q0````(`+".:4=9G@?B[P,``",3```8````````
M``````"``10:``!X;"]W;W)K<VAE971S+W-H965T,BYX;6Q02P$"%`,4````
M"`"PCFE'^M'4'B0"```:!P``&```````````````@`$Y'@``>&PO=V]R:W-H
M965T<R]S:&5E=#,N>&UL4$L!`A0#%`````@`L(YI1Q6CIL@'!```51(``!@`
M`````````````(`!DR```'AL+W=O<FMS:&5E=',O<VAE970T+GAM;%!+`0(4
M`Q0````(`+".:4>>9;CK%`,``%H,```8``````````````"``=`D``!X;"]W
M;W)K<VAE971S+W-H965T-2YX;6Q02P$"%`,4````"`"PCFE'GQ3:'90$```8
M%P``&```````````````@`$:*```>&PO=V]R:W-H965T<R]S:&5E=#8N>&UL
M4$L!`A0#%`````@`L(YI1\P<#M.?`0``L0,``!@``````````````(`!Y"P`
M`'AL+W=O<FMS:&5E=',O<VAE970W+GAM;%!+`0(4`Q0````(`+".:4<K(+CG
MH`$``+$#```8``````````````"``;DN``!X;"]W;W)K<VAE971S+W-H965T
M."YX;6Q02P$"%`,4````"`"PCFE'?-"UV)\!``"Q`P``&```````````````
M@`&/,```>&PO=V]R:W-H965T<R]S:&5E=#DN>&UL4$L!`A0#%`````@`L(YI
M1[6*M1.@`0``L0,``!D``````````````(`!9#(``'AL+W=O<FMS:&5E=',O
M<VAE970Q,"YX;6Q02P$"%`,4````"`"PCFE'5QU"$:(!``"Q`P``&0``````
M````````@`$[-```>&PO=V]R:W-H965T<R]S:&5E=#$Q+GAM;%!+`0(4`Q0`
M```(`+".:4<3/]0ZGP$``+$#```9``````````````"``10V``!X;"]W;W)K
M<VAE971S+W-H965T,3(N>&UL4$L!`A0#%`````@`L(YI1W6D`%F@`0``L0,`
M`!D``````````````(`!ZC<``'AL+W=O<FMS:&5E=',O<VAE970Q,RYX;6Q0
M2P$"%`,4````"`"PCFE'M:#S4J$!``"Q`P``&0``````````````@`'!.0``
M>&PO=V]R:W-H965T<R]S:&5E=#$T+GAM;%!+`0(4`Q0````(`+".:4>2C'R2
MH0$``+$#```9``````````````"``9D[``!X;"]W;W)K<VAE971S+W-H965T
M,34N>&UL4$L!`A0#%`````@`L(YI1^S\AW.@`0``L0,``!D`````````````
M`(`!<3T``'AL+W=O<FMS:&5E=',O<VAE970Q-BYX;6Q02P$"%`,4````"`"P
MCFE'14MV/*$!``"Q`P``&0``````````````@`%(/P``>&PO=V]R:W-H965T
M<R]S:&5E=#$W+GAM;%!+`0(4`Q0````(`+".:4?7#*N.H0$``+$#```9````
M``````````"``2!!``!X;"]W;W)K<VAE971S+W-H965T,3@N>&UL4$L!`A0#
M%`````@`L(YI1P>=(\N@`0``L0,``!D``````````````(`!^$(``'AL+W=O
M<FMS:&5E=',O<VAE970Q.2YX;6Q02P$"%`,4````"`"PCFE'.$4>KZ`"``!;
M"P``&0``````````````@`'/1```>&PO=V]R:W-H965T<R]S:&5E=#(P+GAM
M;%!+`0(4`Q0````(`+".:4<?R=60JP$``!8$```9``````````````"``:9'
M``!X;"]W;W)K<VAE971S+W-H965T,C$N>&UL4$L!`A0#%`````@`L(YI1R#"
M#G6C`0``L0,``!D``````````````(`!B$D``'AL+W=O<FMS:&5E=',O<VAE
M970R,BYX;6Q02P$"%`,4````"`"PCFE'OE4&Y:0!``"Q`P``&0``````````
M````@`%B2P``>&PO=V]R:W-H965T<R]S:&5E=#(S+GAM;%!+`0(4`Q0````(
M`+".:4?Q)6V%O`$``'L$```9``````````````"``3U-``!X;"]W;W)K<VAE
M971S+W-H965T,C0N>&UL4$L!`A0#%`````@`L(YI1R+J6KF_`0``>P0``!D`
M`````````````(`!,$\``'AL+W=O<FMS:&5E=',O<VAE970R-2YX;6Q02P$"
M%`,4````"`"PCFE'&XUN7:4!``"Q`P``&0``````````````@`$F40``>&PO
M=V]R:W-H965T<R]S:&5E=#(V+GAM;%!+`0(4`Q0````(`+".:4>=CF)"HP$`
M`+$#```9``````````````"``0)3``!X;"]W;W)K<VAE971S+W-H965T,C<N
M>&UL4$L!`A0#%`````@`L(YI1]+DT1^A`0``L0,``!D``````````````(`!
MW%0``'AL+W=O<FMS:&5E=',O<VAE970R."YX;6Q02P$"%`,4````"`"PCFE'
M%D0PAO`!``#Z!0``&0``````````````@`&T5@``>&PO=V]R:W-H965T<R]S
M:&5E=#(Y+GAM;%!+`0(4`Q0````(`+".:4?Y_"@BFP$``+`#```9````````
M``````"``=M8``!X;"]W;W)K<VAE971S+W-H965T,S`N>&UL4$L!`A0#%```
M``@`L(YI1^/9<8^_`P``>Q0``!D``````````````(`!K5H``'AL+W=O<FMS
M:&5E=',O<VAE970S,2YX;6Q02P$"%`,4````"`"PCFE';FFUK3H"``!!!P``
M&0``````````````@`&C7@``>&PO=V]R:W-H965T<R]S:&5E=#,R+GAM;%!+
M`0(4`Q0````(`+".:4?7]Z>:^0$``-8%```9``````````````"``11A``!X
M;"]W;W)K<VAE971S+W-H965T,S,N>&UL4$L!`A0#%`````@`L(YI1^<G<U90
M`@``Q@@``!D``````````````(`!1&,``'AL+W=O<FMS:&5E=',O<VAE970S
M-"YX;6Q02P$"%`,4````"`"PCFE'";(MQ2P"``#B!@``&0``````````````
M@`'+90``>&PO=V]R:W-H965T<R]S:&5E=#,U+GAM;%!+`0(4`Q0````(`+".
M:4?SREM-SP,```43```9``````````````"``2YH``!X;"]W;W)K<VAE971S
M+W-H965T,S8N>&UL4$L!`A0#%`````@`L(YI1\I5FJCE`0``<04``!D`````
M`````````(`!-&P``'AL+W=O<FMS:&5E=',O<VAE970S-RYX;6Q02P$"%`,4
M````"`"PCFE'VGY*/.D#```W%@``&0``````````````@`%0;@``>&PO=V]R
M:W-H965T<R]S:&5E=#,X+GAM;%!+`0(4`Q0````(`+".:4=Z6R^7G@,``$(3
M```9``````````````"``7!R``!X;"]W;W)K<VAE971S+W-H965T,SDN>&UL
M4$L!`A0#%`````@`L(YI1WD,CAA?`P``\1```!D``````````````(`!178`
M`'AL+W=O<FMS:&5E=',O<VAE970T,"YX;6Q02P$"%`,4````"`"PCFE'W[M#
M@0@"``!_!@``&0``````````````@`';>0``>&PO=V]R:W-H965T<R]S:&5E
M=#0Q+GAM;%!+`0(4`Q0````(`+".:4?*!745M0(``*D*```9````````````
M``"``1I\``!X;"]W;W)K<VAE971S+W-H965T-#(N>&UL4$L!`A0#%`````@`
ML(YI1_6#<1E``@``W@<``!D``````````````(`!!G\``'AL+W=O<FMS:&5E
M=',O<VAE970T,RYX;6Q02P$"%`,4````"`"PCFE'+J\Y2*X"``#]"@``&0``
M````````````@`%]@0``>&PO=V]R:W-H965T<R]S:&5E=#0T+GAM;%!+`0(4
M`Q0````(`+".:4<;@0CNRP(``-T*```9``````````````"``6*$``!X;"]W
M;W)K<VAE971S+W-H965T-#4N>&UL4$L!`A0#%`````@`L(YI1Y&1R\(2`@``
M.08``!D``````````````(`!9(<``'AL+W=O<FMS:&5E=',O<VAE970T-BYX
M;6Q02P$"%`,4````"`"PCFE'!]?B&AD"``!F!@``&0``````````````@`&M
MB0``>&PO=V]R:W-H965T<R]S:&5E=#0W+GAM;%!+`0(4`Q0````(`+".:4<!
MT<(^^P$``)4%```9``````````````"``?V+``!X;"]W;W)K<VAE971S+W-H
M965T-#@N>&UL4$L!`A0#%`````@`L(YI1RW@%=OJ`0``:@4``!D`````````
M`````(`!+XX``'AL+W=O<FMS:&5E=',O<VAE970T.2YX;6Q02P$"%`,4````
M"`"PCFE'/6_'T7D#``"+$```&0``````````````@`%0D```>&PO=V]R:W-H
M965T<R]S:&5E=#4P+GAM;%!+`0(4`Q0````(`+".:4>K4V7G-@,``.<-```9
M``````````````"``0"4``!X;"]W;W)K<VAE971S+W-H965T-3$N>&UL4$L!
M`A0#%`````@`L(YI1U3++S38`@``*@L``!D``````````````(`!;9<``'AL
M+W=O<FMS:&5E=',O<VAE970U,BYX;6Q02P$"%`,4````"`"PCFE'@'YBZTJ!
M``#[Y@$`%```````````````@`%\F@``>&PO<VAA<F5D4W1R:6YG<RYX;6Q0
52P4&`````#T`/0"=$```^!L!````
`
end

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.0.814</span><table class="report" border="0" cellspacing="2" id="idm139922633436944">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Other Income (Expense) Table (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2015</div></th>
<th class="th"><div>Sep. 30, 2014</div></th>
<th class="th"><div>Sep. 30, 2015</div></th>
<th class="th"><div>Sep. 30, 2014</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherIncomeAndExpensesAbstract', window );"><strong>Other Income and Expenses [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_ChangeInFairValueOfContingentPurchasePriceConsideration', window );">Change in fair value of the contingent purchase price liability</a></td>
<td class="nump">$ 307<span></span>
</td>
<td class="nump">$ 597<span></span>
</td>
<td class="nump">$ 69<span></span>
</td>
<td class="num">$ (59)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Other income (expense)</a></td>
<td class="nump">$ 307<span></span>
</td>
<td class="nump">$ 597<span></span>
</td>
<td class="nump">$ 69<span></span>
</td>
<td class="num">$ (59)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gale_ChangeInFairValueOfContingentPurchasePriceConsideration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Change in the fair value of contingent purchase price consideration.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gale_ChangeInFairValueOfContingentPurchasePriceConsideration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gale_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherIncomeAndExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherIncomeAndExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net amount of other income and expense amounts, the components of which are not separately disclosed on the income statement, resulting from ancillary business-related activities (that is, excluding major activities considered part of the normal operations of the business) also known as other nonoperating income (expense) recognized for the period. Such amounts may include: (a) dividends, (b) interest on securities, (c) net gains or losses on securities, (d) unusual costs, (e) gains or losses on foreign exchange transactions, and (f) miscellaneous other income and expense items.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 225<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 2<br><br><br><br> -Subparagraph (SX 210.5-03.9)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 03<br><br><br><br> -Paragraph 9<br><br><br><br> -Article 5<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.0.814</span><table class="report" border="0" cellspacing="2" id="idm139922644986944">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Accrued Expenses and Other Current Liabilities (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Sep. 30, 2015</div></th>
<th class="th"><div>Dec. 31, 2014</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_ContractResearchPayable', window );">Clinical trial costs</a></td>
<td class="nump">$ 5,179<span></span>
</td>
<td class="nump">$ 6,967<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeRelatedLiabilitiesCurrent', window );">Compensation and related benefits</a></td>
<td class="nump">992<span></span>
</td>
<td class="nump">1,040<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedProfessionalFeesCurrent', window );">Professional fees</a></td>
<td class="nump">1,121<span></span>
</td>
<td class="nump">821<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestPayableCurrent', window );">Interest expense</a></td>
<td class="nump">37<span></span>
</td>
<td class="nump">57<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued expenses and other current liabilities</a></td>
<td class="nump">$ 7,329<span></span>
</td>
<td class="nump">$ 8,885<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gale_ContractResearchPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contract Research Payable</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gale_ContractResearchPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gale_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.20)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 20<br><br><br><br> -Article 5<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedProfessionalFeesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 6<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6911-107765<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Glossary Current Liabilities<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6509677<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 8<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6935-107765<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.20)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 20<br><br><br><br> -Article 5<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedProfessionalFeesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeRelatedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.20)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 20<br><br><br><br> -Article 5<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeRelatedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of [accrued] interest payable on all forms of debt, including trade payables, that has been incurred and is unpaid. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Glossary Current Liabilities<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6509677<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.20)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 9<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e7018-107765<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 8<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6935-107765<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 20<br><br><br><br> -Article 5<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.0.814</span><table class="report" border="0" cellspacing="2" id="idm139922625872752">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock Based Compensation (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2015</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Disclosure of Compensation Related Costs, Share-based Payments [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock', window );">Schedule of Allocated Stock-based Compensation Expense</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">The following table summarizes the components of stock-based compensation expense in the condensed consolidated statements of comprehensive loss for the three and nine months ended </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">September&#160;30, 2015</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> and 2014, respectively (in thousands):</font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16" rowspan="1"></td></tr><tr><td width="41%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="12%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="12%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="12%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="12%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Three Months Ended September 30,</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Nine Months Ended September 30,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">2014</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">2014</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Research and development</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">83</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">92</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">253</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">438</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">General and administrative</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">492</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">990</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">1,081</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">3,440</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Total stock-based compensation from continuing operations</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">575</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">1,082</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">1,334</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">3,878</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Stock based compensation from discontinued operations</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">275</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">217</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">788</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">557</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">Assumptions for Option Grants Issued</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-indent:66px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">The company uses the Black-Scholes option-pricing model and the following weighted-average assumptions to determine the fair value of all its stock options granted:</font></div><div style="line-height:120%;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">&#160;</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12" rowspan="1"></td></tr><tr><td width="41%" rowspan="1" colspan="1"></td><td width="13%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="13%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="13%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="13%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Three Months Ended September 30,</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Nine Months Ended September 30,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">2014</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">2014</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Risk free interest rate</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">2.02</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">1.50</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">2.02</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">%</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Volatility</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">79.10</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">74.20</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">79.47</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">%</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Expected lives (years)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">0.00</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">6.12</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">6.09</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">6.15</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Expected dividend yield</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">%</font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Stock Option Activity</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">The following table summarizes option activity of the company:</font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="11" rowspan="1"></td></tr><tr><td width="56%" rowspan="1" colspan="1"></td><td width="13%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="12%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="12%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Total</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Number of</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Shares </font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">(In Thousands)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Weighted</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Average</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Exercise</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Price</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Aggregate</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Intrinsic</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Value</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">(In Thousands)</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Outstanding at January&#160;1, 2015</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">8,590</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">3.25</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Granted</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">3,682</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">1.73</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Exercised</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(39</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">0.79</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">37</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Cancelled</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(1,045</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">2.44</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">21</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Outstanding at September&#160;30, 2015</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">11,188</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">2.83</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">690</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Options exercisable at September&#160;30, 2015</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">6,622</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">3.32</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">618</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the allocation of equity-based compensation costs to a given line item on the balance sheet and income statement for the period. This may include the reporting line for the costs and the amount capitalized and expensed.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 718<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 2<br><br><br><br> -Subparagraph (h)(1)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 718<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (b)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5047-113901<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 718<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SAB TOPIC 14.F)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=27013229&amp;loc=d3e301413-122809<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Staff Accounting Bulletin (SAB)<br><br><br><br> -Number Topic 14<br><br><br><br> -Section F<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the number and weighted-average exercise prices (or conversion ratios) for share options (or share units) that were outstanding at the beginning and end of the year, vested and expected to vest, exercisable or convertible at the end of the year, and the number of share options or share units that were granted, exercised or converted, forfeited, and expired during the year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 718<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 2<br><br><br><br> -Subparagraph (c)(1)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 718<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 2<br><br><br><br> -Subparagraph (f)(2)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.0.814</span><table class="report" border="0" cellspacing="2" id="idm139922622235328">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Discontinued Operations, Assets Held for Sale - Carrying Amounts of Assets and LIabilities (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2015</div></th>
<th class="th"><div>Sep. 30, 2014</div></th>
<th class="th"><div>Sep. 30, 2015</div></th>
<th class="th"><div>Sep. 30, 2014</div></th>
<th class="th"><div>Dec. 31, 2014</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems', window );"><strong>Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf', window );">Impairment charge from classification as assets held for sale</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (8,071)<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent', window );">Total current liabilities held for sale</a></td>
<td class="nump">$ 7,697<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,697<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,169<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=gale_CommercialBusinessSegmentMember', window );">Commercial Business Segment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems', window );"><strong>Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet', window );">Accounts receivable</a></td>
<td class="nump">1,238<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,238<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,535<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationInventory1', window );">Inventories</a></td>
<td class="nump">1,318<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,318<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">655<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationPrepaidAndOtherAssets', window );">Prepaid Expenses</a></td>
<td class="nump">1,064<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,064<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,747<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment', window );">Equipment and furnishings, net</a></td>
<td class="nump">241<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">241<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">270<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationGoodwill1', window );">Goodwill</a></td>
<td class="nump">172<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">172<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">172<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf', window );">Impairment charge from classification as assets held for sale</a></td>
<td class="num">(8,071)<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="num">(8,071)<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation', window );">Assets held for sale, net</a></td>
<td class="nump">17,801<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">17,801<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">27,013<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsPayable', window );">Accounts payable</a></td>
<td class="nump">1,359<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,359<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">385<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccruedLiabilities', window );">Accrued expenses and other current liabilities</a></td>
<td class="nump">6,338<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,338<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,784<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent', window );">Total current liabilities held for sale</a></td>
<td class="nump">7,697<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,697<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,169<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=gale_AbstralRightsNetMember', window );">Abstral Rights, Net [Member] | Commercial Business Segment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems', window );"><strong>Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationIntangibleAssets', window );">Rights</a></td>
<td class="nump">13,738<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13,738<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14,533<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=gale_ZuplenzRightsMember', window );">Zuplenz Rights [Member] | Commercial Business Segment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems', window );"><strong>Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationIntangibleAssets', window );">Rights</a></td>
<td class="nump">$ 8,101<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8,101<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8,101<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount classified as assets attributable to disposal group held for sale or disposed of.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 205<br><br><br><br> -SubTopic 20<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 10<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6892542&amp;loc=d3e1107-107759<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount classified as accounts, notes and loans receivable attributable to disposal group held for sale or disposed of.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 205<br><br><br><br> -SubTopic 20<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (a)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6360339&amp;loc=d3e1361-107760<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount classified as accounts payable attributable to disposal group held for sale or disposed of.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 205<br><br><br><br> -SubTopic 20<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (a)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6360339&amp;loc=d3e1361-107760<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount classified as accrued liabilities attributable to disposal group held for sale or disposed of.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 205<br><br><br><br> -SubTopic 20<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (a)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6360339&amp;loc=d3e1361-107760<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupIncludingDiscontinuedOperationAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationGoodwill1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount classified as goodwill attributable to disposal group held for sale or disposed of.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 205<br><br><br><br> -SubTopic 20<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 10<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6892542&amp;loc=d3e1107-107759<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 205<br><br><br><br> -SubTopic 20<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (a)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6360339&amp;loc=d3e1361-107760<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 205<br><br><br><br> -SubTopic 20<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 2<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6360339&amp;loc=d3e1436-107760<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupIncludingDiscontinuedOperationGoodwill1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount classified as intangible assets, excluding goodwill, attributable to disposal group held for sale or disposed of.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 205<br><br><br><br> -SubTopic 20<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (a)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6360339&amp;loc=d3e1361-107760<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 205<br><br><br><br> -SubTopic 20<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 2<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6360339&amp;loc=d3e1436-107760<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 205<br><br><br><br> -SubTopic 20<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 10<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6892542&amp;loc=d3e1107-107759<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupIncludingDiscontinuedOperationIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationInventory1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount classified as inventory attributable to disposal group held for sale or disposed of.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 205<br><br><br><br> -SubTopic 20<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 2<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6360339&amp;loc=d3e1436-107760<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 205<br><br><br><br> -SubTopic 20<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (a)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6360339&amp;loc=d3e1361-107760<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 205<br><br><br><br> -SubTopic 20<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 10<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6892542&amp;loc=d3e1107-107759<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupIncludingDiscontinuedOperationInventory1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationPrepaidAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount classified as prepaid and other assets attributable to disposal group held for sale or disposed of.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 205<br><br><br><br> -SubTopic 20<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (a)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6360339&amp;loc=d3e1361-107760<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupIncludingDiscontinuedOperationPrepaidAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount classified as property, plant and equipment attributable to disposal group held for sale or disposed of.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 205<br><br><br><br> -SubTopic 20<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (a)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6360339&amp;loc=d3e1361-107760<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 205<br><br><br><br> -SubTopic 20<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 2<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6360339&amp;loc=d3e1436-107760<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 205<br><br><br><br> -SubTopic 20<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 10<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6892542&amp;loc=d3e1107-107759<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of write-downs for impairments recognized during the period for long-lived assets held for abandonment, exchange or sale.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 360<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 15<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=8077374&amp;loc=d3e2611-110228<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 230<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 28<br><br><br><br> -Subparagraph (b)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3602-108585<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount classified as liabilities attributable to disposal group held for sale or disposed of, expected to be disposed of within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 205<br><br><br><br> -SubTopic 20<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 10<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6892542&amp;loc=d3e1107-107759<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 205<br><br><br><br> -SubTopic 20<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (a)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6360339&amp;loc=d3e1361-107760<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=gale_CommercialBusinessSegmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=gale_CommercialBusinessSegmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=gale_AbstralRightsNetMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=gale_AbstralRightsNetMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=gale_ZuplenzRightsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=gale_ZuplenzRightsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.0.814</span><table class="report" border="0" cellspacing="2" id="idm139922625751360">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock Based Compensation (Allocated Stock-based Compensation) (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2015</div></th>
<th class="th"><div>Sep. 30, 2014</div></th>
<th class="th"><div>Sep. 30, 2015</div></th>
<th class="th"><div>Sep. 30, 2014</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and Development [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Allocated share based compensation expense</a></td>
<td class="nump">$ 83<span></span>
</td>
<td class="nump">$ 92<span></span>
</td>
<td class="nump">$ 253<span></span>
</td>
<td class="nump">$ 438<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember', window );">Selling, General and Administrative [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Allocated share based compensation expense</a></td>
<td class="nump">492<span></span>
</td>
<td class="nump">990<span></span>
</td>
<td class="nump">1,081<span></span>
</td>
<td class="nump">3,440<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=gale_CommercialBusinessSegmentMember', window );">Commercial Business Segment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Allocated share based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">788<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOperatingActivitiesSegmentAxis=us-gaap_SegmentContinuingOperationsMember', window );">Continuing Operations [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Allocated share based compensation expense</a></td>
<td class="nump">575<span></span>
</td>
<td class="nump">1,082<span></span>
</td>
<td class="nump">1,334<span></span>
</td>
<td class="nump">3,878<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOperatingActivitiesSegmentAxis=us-gaap_SegmentDiscontinuedOperationsMember', window );">Discontinued Operations [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Allocated share based compensation expense</a></td>
<td class="nump">$ 275<span></span>
</td>
<td class="nump">$ 217<span></span>
</td>
<td class="nump">$ 788<span></span>
</td>
<td class="nump">$ 557<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the expense recognized during the period arising from equity-based compensation arrangements (for example, shares of stock, unit, stock options or other equity instruments) with employees, directors and certain consultants qualifying for treatment as employees.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 718<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SAB TOPIC 14.F)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=27013229&amp;loc=d3e301413-122809<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 718<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (b)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5047-113901<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 718<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 2<br><br><br><br> -Subparagraph (h)(1)(i)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Staff Accounting Bulletin (SAB)<br><br><br><br> -Number Topic 14<br><br><br><br> -Section F<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=gale_CommercialBusinessSegmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=gale_CommercialBusinessSegmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOperatingActivitiesSegmentAxis=us-gaap_SegmentContinuingOperationsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOperatingActivitiesSegmentAxis=us-gaap_SegmentContinuingOperationsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOperatingActivitiesSegmentAxis=us-gaap_SegmentDiscontinuedOperationsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOperatingActivitiesSegmentAxis=us-gaap_SegmentDiscontinuedOperationsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.0.814</span><table class="report" border="0" cellspacing="2" id="idm139922633290736">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Stockholders' Equity (Common Stock are Reserved for Future Issuance) (Detail) - shares<br> shares in Thousands</strong></div></th>
<th class="th"><div>Sep. 30, 2015</div></th>
<th class="th"><div>Dec. 31, 2014</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrants outstanding</a></td>
<td class="nump">22,308<span></span>
</td>
<td class="nump">8,540<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Stock options outstanding</a></td>
<td class="nump">11,188<span></span>
</td>
<td class="nump">8,590<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_OptionsReservedForFutureIssuanceUnderCompaniesIncentivePlan', window );">Options reserved for future issuance under the Company's 2007 Incentive Plan</a></td>
<td class="nump">10,251<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_CommonStockCapitalSharesReservedForFutureIssuanceOfEmployeeStockPurchasePlan', window );">Shares reserved for future issuance under the Employee Stock Purchase Plan</a></td>
<td class="nump">528<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Total reserved for future issuance</a></td>
<td class="nump">44,275<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gale_CommonStockCapitalSharesReservedForFutureIssuanceOfEmployeeStockPurchasePlan">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Common Stock Capital Shares Reserved For Future Issuance Of Employee Stock Purchase Plan</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gale_CommonStockCapitalSharesReservedForFutureIssuanceOfEmployeeStockPurchasePlan</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gale_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gale_OptionsReservedForFutureIssuanceUnderCompaniesIncentivePlan">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Options reserved for future issuance under the Company's 2007 Incentive Plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gale_OptionsReservedForFutureIssuanceUnderCompaniesIncentivePlan</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gale_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 235<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.4-08.(i))<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 08<br><br><br><br> -Paragraph i<br><br><br><br> -Article 4<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate number of common shares reserved for future issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.29)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockCapitalSharesReservedForFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 718<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 2<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 718<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 2<br><br><br><br> -Subparagraph (c)(1)(i)-(ii)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.0.814</span><table class="report" border="0" cellspacing="2" id="idm139922636090992">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Discontinued Operations, Assets Held for Sale - Significant Operating Non-cash and Capital Expenditures (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2015</div></th>
<th class="th"><div>Sep. 30, 2014</div></th>
<th class="th"><div>Sep. 30, 2015</div></th>
<th class="th"><div>Sep. 30, 2014</div></th>
<th class="th"><div>Dec. 31, 2014</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems', window );"><strong>Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf', window );">Impairment of assets held for sale</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8,071<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation and amortization expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">304<span></span>
</td>
<td class="nump">340<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Non-cash stock-based compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,334<span></span>
</td>
<td class="nump">3,878<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchases of property and equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(81)<span></span>
</td>
<td class="num">(48)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=gale_CommercialBusinessSegmentMember', window );">Commercial Business Segment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems', window );"><strong>Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf', window );">Impairment of assets held for sale</a></td>
<td class="nump">$ 8,071<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">8,071<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation and amortization expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">858<span></span>
</td>
<td class="nump">319<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Allocated share based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">788<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Non-cash stock-based compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">557<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchases of property and equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(34)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireIntangibleAssets', window );">Cash paid for acquisition of Zuplenz rights</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (500)<span></span>
</td>
<td class="num">$ (3,056)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the expense recognized during the period arising from equity-based compensation arrangements (for example, shares of stock, unit, stock options or other equity instruments) with employees, directors and certain consultants qualifying for treatment as employees.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 718<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SAB TOPIC 14.F)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=27013229&amp;loc=d3e301413-122809<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 718<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (b)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5047-113901<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 718<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 2<br><br><br><br> -Subparagraph (h)(1)(i)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Staff Accounting Bulletin (SAB)<br><br><br><br> -Number Topic 14<br><br><br><br> -Section F<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationDepletionAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 230<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 28<br><br><br><br> -Subparagraph (b)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3602-108585<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationDepletionAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of write-downs for impairments recognized during the period for long-lived assets held for abandonment, exchange or sale.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 360<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 15<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=8077374&amp;loc=d3e2611-110228<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 230<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 28<br><br><br><br> -Subparagraph (b)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3602-108585<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow to acquire asset without physical form usually arising from contractual or other legal rights, excluding goodwill.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 230<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 13<br><br><br><br> -Subparagraph (c)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3213-108585<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Glossary Investing Activities<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6516133<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Glossary Investing Activities<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6516133<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 230<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 13<br><br><br><br> -Subparagraph (c)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3213-108585<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of noncash, equity-based employee remuneration. This may include the value of stock or unit options, amortization of restricted stock or units, and adjustment for officers' compensation. As noncash, this element is an add back when calculating net cash generated by operating activities using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 230<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 28<br><br><br><br> -Subparagraph (a)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3602-108585<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=gale_CommercialBusinessSegmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=gale_CommercialBusinessSegmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.0.814</span><table class="report" border="0" cellspacing="2" id="idm139922633648880">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss Per Share (Common Shares Excluded from Net Loss) (Detail) - shares<br> shares in Thousands</strong></div></th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2015</div></th>
<th class="th"><div>Sep. 30, 2014</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Shares of common stock issuable upon the exercise which were excluded from the computation of diluted earnings per share</a></td>
<td class="nump">33,496<span></span>
</td>
<td class="nump">17,534<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember', window );">Warrants to purchase common stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Shares of common stock issuable upon the exercise which were excluded from the computation of diluted earnings per share</a></td>
<td class="nump">22,308<span></span>
</td>
<td class="nump">8,540<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember', window );">Options to purchase common stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Shares of common stock issuable upon the exercise which were excluded from the computation of diluted earnings per share</a></td>
<td class="nump">11,188<span></span>
</td>
<td class="nump">8,994<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Glossary Antidilution<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6505113<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Glossary Diluted Earnings Per Share<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6510752<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Glossary Contingent Stock Agreement<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6508534<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 260<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (c)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.0.814</span><table class="report" border="0" cellspacing="2" id="idm139922790535600">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accrued Expenses and Other Current Liabilities<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2015</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock', window );">Accrued Expenses and Other Current Liabilities</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#00497f;font-weight:bold;">Accrued Expenses and Other Current Liabilities</font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:66px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Accrued expenses and other current liabilities consist of the following (in thousands):</font></div><div style="line-height:120%;text-indent:66px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8" rowspan="1"></td></tr><tr><td width="71%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="12%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="12%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">September&#160;30, 2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">December&#160;31, 2014</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Clinical trial costs</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">5,179</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">6,967</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Compensation and related benefits</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">992</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">1,040</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Professional fees</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">1,121</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">821</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Interest expense</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">37</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">57</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Accrued expenses and other current liabilities</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">7,329</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">8,885</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for accounts payable, accrued expenses, and other liabilities that are classified as current at the end of the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>28
<FILENAME>0001390478-15-000050-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001390478-15-000050-xbrl.zip
M4$L#!!0````(`(Z&:4<_Y2NKHD(!`+1V$@`1`!P`9V%L92TR,#$U,#DS,"YX
M;6Q55`D``YP505:<%4%6=7@+``$$)0X```0Y`0``[%U;<Z.XMG[>I^K\AYP\
M[W0DA`3JFLDN"<3LU$Y?DYG9O5^FB*TDG,'@`9Q.SJ\_2_AN8\?NV`XD=%6Z
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M-02X40$@+_K9BO)PIZ+"(#^Y#</^I,Y-F%^7@HQN5#`$[F1IK//*.N6=ZDI&
M#]65RCM5E8I,WZ[4$S^%^^.BYD9W869,]#F\.5>TJ"Q*AT6+V:+1.H(F>1$F
MG0GE'I8H^IV4I3'G_+2\.RF:=ZL*0K/X]-\?+BX[=[H73@M'3Q<^F4@#ANIO
M/YG.WN?EG:_ZYJCL_/U=23PSI4_&<_@=2'(\NFT&XN?C/.KU8\!T6K8SM'B=
M-"GT0W$4@=2!;^I^(=^N_+*K<1DPR5'Q6%X97XJZYN)-I+.C4I1YTS+FIG?^
MK^,S!&`(1[;C_G2Z6'G8R^E2-Z->^C"UTNY<QZ")K/#!.YP960VM$!XW,+TW
M6T,GW9GR_(2@:8?=2>GQM6F7XRLC#:W0V7FI,OM3IP!ZUU5I0P(50Q5@!#-Q
MTNKHSG-4$!@=V%_L)L"W3["U#_@P:YH`?V$"[`2^7XX^^=(4HP&^R-G&:-B[
M-QIC0]L8G=$M=;8'0SOF66.<D[VE<]HCST!G?XSBOC\N"VC59%GJKP$@\M)>
M/TW@SUP\1/FD%%SNI<EED7;^_*![USH[I,XGZM2W1M#AM>'%+G3^T(^C3E0,
MY3KJ1E!FF&2.A'^_%N+QV;C8$L:?3BN[&,ETNBQ4HR.7L=_:DAFBVXT*4'<8
M?PZC[GGBA?VH".-7RY*U>/?+F`,X[A\R#BT%#D:!5V(T6G?2-.,PRNFV'.>K
M3(?Y('M\W2-=@?)@8[W'!';+L?ZJBS!*=%>%61(EM_FK'>YJH&]P=K<CWNPY
MOOV(MWZ[B>.\O2UO_783K?@/)W"M(7]K*=OVIK]-\E]BG6=_KK\1SZ?L/<6Z
MI!E/)\D>1K_"27S.4FBF>/P<0^LBZ9J)T3?4E8]7CWU=F@&SE>"/R8U@`/:S
M&&0:2@?1@_EM9$NG/B5,;O6<!?D0/D2]0:]Y%F,#_1R?&06]WT!!:TW'%D)-
M]#LU67,*?F-.[05I'24MK?=*ZUD%OS%:+\9J01AEOX7Q0,O'R:__!$*$6>?N
M\4+?ZWB.FY,RYTE_4.1E`=(\IFZ&>LJ8-;`;'[G-)O,M&YK"A@.E^RTA:DV(
M6KJ7%0;E0[DV5B;*0:;_&IC7%*K),U,R_ZK-*PU1<MMH%JW"7D&A->`;;5SV
MX&KP0BC=DNUY)@OO-O)N^7^84*OE_P%==LO_^O#?:OF_4_Y;+?\/MR.F)6L3
MF7&(G3-M9%`[R]A&!LWB?QL9M)'!6^9_NS+2KHPTA?]^N7W&^B"^N;7=0C.W
MSDY.D'E=>>-U]F%Y=]KA;@Z%,#H+'^NKL[EM1W,:V`5K9C0PL5P7:7);Z*SG
MZ^MB?D-&$&5Y<96%"6B@>1:L"M=H(\4RL(.9@@,-ZBO:]O6R.ZSV.W0S)T[\
MT=71'Q<:^*E*N:;3\,/%;U[Z[N+""Y-NB?R7+!WTX>_FC"5@>[^`;305GP!W
MV`?!+WV8QG"U%W\(,]P(#P4J("=XIS/";X(*%GDSJX1->#-;?A>\&9[!8G],
M[[&[VHY<1$DGC9//8?;G:!?]9)HMOX3@Q6&>?[HIW\EI_KMGJ^W/&J7L*F]9
MJ=-ZG'D"R0G>AK\+Y7=\\-(/T?=M4O#5N;_165+VMS8:>O%H:/MCLN:6.';E
MU>@72_0SC!H3"H`>T#9S:+;\3K>JMQ/HX!-H_RM^XR"O&=.A!I'%LR/C9D^'
M>H06->$!-6MDD%9>I<UR*=MFE[MV*>?M''J1.33O3O".%UJ6'J".LM/?PRR#
MMC]E7Z/;NV(ZOK[NE."NOJ=7=^D@!P=[]5W']WI4H3E#/4FZ5P$>#?QFB)L<
M4FS+@4O=+Y94<A=EA=;)JZ7!QJ`;S829U+LE0^W)4+=4?5M#\L%L(YE5X2NF
MS%-8WYC9:..(EX@CFFXP(&.+XAD%JEC?OV*;L0'<1IN-9[J+5S[Z&\!M].AO
M[S3:>.'-.HKMR=+ZBL-:BU=`F=;!O''*++YGW9J86IF8`[]EWUJ+6EF+>H]^
M&XN^C7%O%ZY>^`%8#3C0/O.HQ0.P&C!AT3(&T<V,/AKXZ89M74$EX$8SH.(@
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MM;"(DEO1`5L6%9'.+X?`YZ@PNN9'N6DY2@:Z.ZH)45SS"+(A_"E]-L!_6%+5
MXF#%!5*!1TQ[>J+;B[13ZF>!2'$,ZOY%)Z"]6"1=T>V!'<X+H\M[K1[Z,%:Z
M@91:`WZ61EN@?X.$LEM"O0Y"U27CM>=CG)90#2;4EF_TU<;E?=6Y-D]I09F^
M^891VC=%1YI\I33:`/,;=&^TM4:OPQK5**O[UF9UKR>KJP6I[':IX/60JBZ!
M^&[6G[RA1J'X6Z34:O1O,);:C95J"?7BA*J+A?J!I8(VLWOIS*XNRP)V&XB_
MJIBI%J3Z@>6"UB*]M$6J41:W`XO4QD=UB(]J88U^X-E<:XU>VAK5);C>S4)E
M:XU>W!K5Q;TM$$H`D&X4#\Q3@4O=&62E-M5#)QYT=3?(TIZ7]OJ#HM3:IQL5
M9@GH,?^LL\N[,-/RL;J!.1*J7C].'[4NOZG[J6]::A[Y]JBH*6%7:JHEZB&(
MVMC7XP]"SK?\-GU%8M!:SCJ1LPZ6LT8)1VLYZT3.YISFOK]WHE9_`]N'C$]G
M>9IX8=+1F0<X==8<)JWY`/8:9/MEP6%>-E^SQBK#V$"^O-.Z*'<?=2,S@<+8
MK%3':3[(="X?X8]^FH=Q^6'P')J`20>SJWHU>_9EX%Y/9YTHC.4@CQ*=C[._
MYI!FQ<K(GM0V>7%XK=[>F&%Z^D%!2^*6Q`W(2];OK&Y)W)*X>;N26A*W)&[6
MPYK%LQ]:!K<,?LD<;?'TQY:/+1\WY>.!/C3;4K*EY#[7#/;_:<H@2J)"7T3W
MNGN>P!RYC:YC+?)<%Z#R#^'_IEEYF-N4AO\9]&.=_%]YI-OB$7;M=/BAZ;#%
M&(PX73$(:WG<SLV7#U_:F=;.M':F[>N8^&?Y-'%M7BN/AX/\41?M9'N9R58]
M#NU\>VV>K9UO[7Q[I?-M1_YM`$-93K;<[-')YVC8TZ%1UME(Z++`N*7QO9G&
M35-5+0_R[G@/T%SSY?FW\SFIJ?-QT#-J3^=X,.TPRE/;PL[[7R_]"EG^-B?-
M0E,SG?@Z27M1LKJ;)S#/][/8VOC>%.$&.JI4_7JT3[6:#)9,RSR^/ORZ2;MF
MXXX`RG8-;8,XO#T:,>FKOIG;'W`\--QAIS@)7.EAC!1'&%$92(Y<A\O`]9U`
M!7[`CL]NPCB'[I<:GW3I#;+,7(,Y&<;?=)BIX<K$!KTSI3"800?[7-)`2.Z[
M%L8!<JB#5<"=X[.3\01:U]-$%#_M#'J3$I_+F17`M7P#63PNF7!)@+FC*'4<
MCB5R0#&4H<!G@3H^^V(-Q5C9RPHYC*2;2F%Y$KK%%L,4A*".<)G$(D"!="Q.
M//>X].)5<DQZ69)B*.'FH^*YBEI8*.ZX'K4IX111S[/@@@O*\.WCN4AB94]+
M<EP]]C?IWN>^8Z/`"2PI*%7(I;XB+E&@`Q($-CH^P^CDRWS'INE)?\-]:V9S
M&GBS\Z2K'_ZE'S?HF-I`0ALI1V*/>N"=F<T4)L@)A')MJ>:=]LJ>%N4`5Y0F
MY3;>TKKFGP:%\0+&C\T)-<Q;[$^=@N#CHZ[N1#V8>G#]8S`CI,,\T(UR'2HP
ME1)SS#W,),/80DP*^_C(V(.RP;&SP`QSQ!Q*YH1>(]8"@B"*=>;!B-ZFV29Z
M)$0P3W@NYS;PA]L<>S;\92L79!=<'I^)3D?'QNCK[E'9^JQD<]TMB/)5WY9G
M?B7%Q["W$9FD8@$3#`<.I=CQ!?<I<X0$TR8)\NCQV2\0+R3AD8S2/NBA%_[]
M",*,=[,"S7<ZD>@J"XVR+A][UVF\$:\9MF"\D*LP%2P00&;&7*XLBEU'>""*
MN%##CN?:+GL<1FA),@CC#V$$?24F?`KT@A*>MSMU)>N(E%9@"^43I:@O'==A
M@EI((>"BY)+/L*YTDA8R_WXZ72GU#*;B0YC]J8OS/!^4$2%<S,5MILLP,1\=
MUPT!8)Y_SM*.UMT*.SIZ$+,:]<5O7OKNX@(P=\L6RX`2_EX&?L)F<+M,*$M8
M`0L<0BT'2<H]ASB!E))X'G:J<4^1;X]M8\6`K36?'4AOUJAFG)KM0B_6G)?R
M8%Y3[ON62RV;2JPX<-L!=3FV\L6,6L;1#7J'R&9:J08VU8MW9PYU/T^",,I^
M"^.!_G0S8\S&GY`QC9O,QTN31'=,?O![5-S]%H*#&N3JKT%I:`P;S>[W*D(-
M9^\,+\CL7'8889:TF;&KQA`C*A"6QNXAIM`2+S#!X-,FO-@#A`/KAZ[7CQ(0
M-Q!*E*T89:XE,"?498[M@B(H5HOZ.>&N]9+J,;GDK0E@!EGG+LPU7,DA*1@F
MEENS0\D`^Y*YRO'`:B#B6I+9W"'@I]V`8K:$GO(GP*^5;[?8GAI9ZLC`4S;X
M4P]&E$C?9E@X''$48$3$(C9V2&B?LZBSP=A]68./^)PJQGPD`D(Q=CF$6Y*Z
M@A&'>ZYE58R=LR7"92GW`W.M`2,N8T$00&AH4RQ](1!5+G<\SEPP8'@1YM8,
M/0A(^L18*D09H8Y%$:(V!%X!=WV?0'@/9HAX]M)80JQ?4YAKIZ3CN2ZDRY1;
MC"+'%4)B2U`N/(J8A?PEF%O/R0.BG"XCC]N3CY-?_QE!;6CQ\<(<J#'WPMZD
MS'G2ATRF+$`JHKM9Q7F.BVWB$(4EHYZ)S6TB+0ZDL62`[.#@BANYMHLHO([B
M\KV[K<D06):%;0]3A7V*7!M2'P8VS'<Y`KAT*3)YRO$NB[0C!+O\\/LJ9;@0
MGPGB@S^&^>!SW[4)4I9K$0PIJ>TN&P",ZJT,7W=*Q#/ZN/JNXWN]F3ZP]`B'
MF$0B`<XM@&@LL`B$[ZX'.8X@RX3'K.;L6/SJ^3;L\'Q%F6,%U$2K./!<Z3C$
M4Y#K\L`%AE0E=PU21?47[U?'K!8%#7`,*J$!!H?B,8\A9'N20Z*[%!!`1D.:
MI8^K37F!L5"^#2&N%5@T$)P[-J40"5);N80Y[M(L69_9O;@B+G6_6+(:=U$V
MPXZGR>%0,)XN%F9=6KB<R$`2R7UN^P%?#HHQ71](K=7)')I\!"=7#_UHZ$*K
ME[$/_/W=F179`&('Y#N(88LJ#X.N7,=''K)=Q2Q/&L-AH?%SC,TA-D`C<]^`
MG&J$.P'S?>8@BFP:^('+.2/@;R'X!K_CL>.Y1Z,'U,@>(H\I:#_P50"QA50>
M)!O81<+VD##+]3:QE%>"=DZ073XUJ2WH32.,*6X,8ZTLR5S7ACP923]0!/(L
MBL"7,LE'N.L^V!L%$M,HV_.15(H2'^PA8[Y9&B!(6A)#%(4]58)F)X@T"_2*
MD&'J!XBMA,-=\PB*0FKA$HDP9\JB3"+BC$T=P,9N@V`O1P93XVYQ"])H3P:>
M0S$D5`R[`;6`WMCQB(\:,M!;A``3Z$(J*2R(?"CGU`N0D(Y'J651H2#!E%8)
MW36/@9\UV.FX>#H2^AXRY5L]?$10YL^_YKH;I)EZ,#MZ1CGUG$*,/L@7ZX/X
MYL[(+SU>QK00T_O4<RR)+.%A&#/(@AW"Z/'99W#;LY+_F"A/X"G!Z^[6B;R+
MN:`"$8:$HHI8W,=2*,1LX""%D+3B0:]%W)FH:XTPSQ/YN1'%ZO4ZBX%ML;&C
M?$Z%)*ZD/O8\$;AF^=Q&>X3\B_G]!T9)^D0PR3SE@R>P!!.$(W![@8U='^)C
M5O4X'M(%]H30(W&>)_0A5EAL[-F^YSD>=UW(D6QNF:45Q0DD2L)152RM#_"M
M"1H@"R*\@$*""'X?7)\%$:WOVY8O(`MR1*W1/G/MR(/0SB1UMB*"JB#@S,(0
MZ''?10I+C]8:^W.6B1QP'4Q@9H/G,TM%DB%"N.",*B=0<WL`Z@]\NT4ACFU?
M*D'!N"$(>""#PS#JG(!M@]C7MII@W7YX&8CPP'(#B.9=VZ$6LH6E,"2UEJUL
MPFP<U'K<G[_F(UU&N%(>_"^I[3N<VF9?HLT5LJ7C^_N!?Z6SW@:QG25!+L^3
MDBB?,J*DY7';4K9E>0$D901B.^?;.FE,/[.BI'F4W);AW-Q>@^K-5>,QN(J*
M&,J?)^46XD$83_4/:O^/SLJ?2V-JSA.SIR6ZUY_C,%F_N0;ZH&!</0OB;XK]
M0"I?`DBEI,,#QR7SBVW33=OX'9W&X2OPS$">7O3"?E2$\7`;H#FU/KLOH]Q@
M4`PR/=ZE\^EF[DC2R1,NP%.II97$$L1#Q/>IRQC@4\3UN`-)M(6$3P,IJIPH
M)%PS)F6'DL_JX^EG=Q]U`=H<;D+^G&;+CS%'^ZU6Q_0PGK[AK+($)%;,=1QF
M,RXLGPH"J=;2Y@E&\2SP'Q)Q#QC7#:]C,PB3;,@0A:0\D*[G<")]UW(\+"1?
M>JK"Z-P3R%U@S$".\=<7/H>/X75<L4MRW3@IQV?_S]W5=;>9V^B_TM/[=DF"
M`,F>LQ<$/W9S3M/)9F9VSURZCC+C,QZ[M9RV[J]?0!^QY/>5+%F6+><F<>)$
M!D`2>$`"#X#$TU6?$"0/(7'_6%STF+N6:@Z*7"BLZS`BPA-DW&9GKR69MD"'
MGB1-$B"6*TGN4:E&D+1W4,%A0]I#QCKYZ^V[J^GMS:R^NIQ-?Y&?JG?U=P]K
M3M\M//397=Q<0%HD?%`3L7R.6-EP[#Y;29Q*9J*Z&DQ7*@:75RI;A=DJ\\75
MV:7HIG_>7^AD$NG9E`2O"P*8724`ME0;,"+#N-"(FZ5>$6>3V!J9WFE-[F1Z
M^]W5Y=T.T;"8WJ"T%E2NY"+;["V!-4RA&KVD^F#=^U&I'OZT5:D^:V=4/C__
M\MN72RW5KE]NM/?J?I:)>-[;LY_W/%O.B'\PMB""N$.#46_7#'OCQ5$P#(OC
MG$4?5]S@[H(]CS);#R'&$$VLD:)#F`5LB\4GD`2XI#XL,'!:+H8'*K/:%+>]
M)^[>G2Z?VNZ4`KH*$)G>7FB0_%IWNQWJG%(3YL;SZA,ETQ-G\'WVB)]\E+-*
M)C1QW#0(KVFU5OLX5CUPU3Y.;A4V7E^)GQNI[7YS*V18$FER74Y,Y0[:915D
MA7+/7CO/!D'+'[Q":Q9\SM58E*G+R;S^O`9//D[.)]IU^PTL5PDU%5>S%SA7
MK'R)OFGP:YX",&T(@/!LZ_6HC9^TH$O,<[8VF.O1]_,37;&U>$0^^E2B%3Q`
M`@L#8\#:)(777C'F07!U-CWI?(V;\-BK<:I<:QMOD#P;:C88Z`5J$-B#8;$:
M"5L=IA%O9S5.F*-Y(_!DUXB+;[94?<8VMKG%:K04[;#"C9X6>UYG-=[:V8@Y
M-PTCOO?B`[4D1V*Q&H%B'R`!@..<C:]70Y.;?URHD70(RMET\DG'I$RNIK,/
M^?'J9G)^_?/5Q;_7_[Y<3V^?4*)=6HC8>\38L:#-N8+3'+XQ0,N#%AK)?E8R
MAL,%?D[E_V^BMZF33XNG\GD#^'>?/\[_Q_9VAONK9JTU=131D62%M@DZ1%L-
M(#8P"4E?ZG_R[UU]-A,\+O:*D033_Z:9V;R/53^O7]]\GLR`_D?YAOQI/J!I
MNKCC_N%Z*>%.FV/U\A=CS5VO:C))R+:4>D?JP+(Y7(G,HXC++F\<#A+U,(V_
MGUQ=7-^\/[L2<VYS4AMOO:$E@B!;W7:4O"U[.0ZMUN9CZ0'3.-2,!RC^4.)[
M_3<7JM[EZ?3+;_,/TDFNY_I)#Y\LQJAAG[74T'02R\2F_`0(2?OL9;=X$XVK
M*9LP.R_PWGT],/LK])K&V+L$D1RJ^E7])^;$'%-)C9SQWI(DFC-[6/O>P=LT
MR'ZUB:1UMDXB3-;6!M:VAFH+9).#AZKUR!_L3^X]?ANVV%*[9R3$*HN(-1FQ
M.HY$&$/((.80[`$+0[CP-BWQE)J^B*:7"CV(;\62$L>@KQPY]0C-Q2@F@9_B
M>YM.Q23'K-@F3H49M31=@BPB-W$?U'H%[[@I]Y'L#SHA-WKD2N[9>Y+!U+U8
M`ZA&6Z)A!U!!$&J;PS!W0E[TF!7><B):];5A9,!H.9&WC*:$))[$@QH#3\>'
M'K?L.]<$G-GY$`+&C!S`]QS)4<^-C484_Q.^6:^Q1T@1AY&JTE-5-,C)24A%
M'Y.`#0$>OL?9KCB=@'+\(G'V$D)8/&F$CH9\+JT".!N3('<#90F]CK4W-K"`
MK-2(:$YW\TDR@ZEF?M]]GC.#[$V8D`&=7J[&;BOFT#,WWQS8:EW*,$S:73!N
MI0[N^21_&6L\<H61>^1L.'595]WX68R``KVKDN<E,H.[-./2RUMC8P_E8V_4
MHD954I,@B15:<,D4UWT+5DZZ[W7PD(@08:MVHXV.3Y#X)4JZ"P?!A;;6W#K*
M%]F`Z5DK-RAWEP=<7^3PI'0_M,ZY5^X48BV25%)J,0LXE%^HNF:U>7'0%>["
M2>E_2*TS&28PKCDEG\R"?3R[6BG''&QC&JR]I=/:]X>5.Z.63RD%0!9O3Q+7
MN50R<O"S;(-:!B\$)ZSXSE7.J=5D6RV2+`/Z!@G9-)N+RY5S'W*@Q)-:[\/+
MG'T.)D2!;ZD%=-DGJY"N8"^^6^X#IC*'J\]"QS+!U@)+2^@(7"23,!23<HN2
MO98,',BYD3-*9%]$Y)>(3I0+1><$9G3&P%E<5/>R@C62_L;#-]47B$Y[Z'XH
M@PM@%6!2BHT5$;HBT9*IV`#JMP8%9U:VQDGI?TATZIRMX\K6<T#1.#%)6`[)
M.@RVA@'1E3UQW?>+3CW[*E[*=4FX)!?A7(OH+'F(C7I!,<3<5AS$2>N_>RN.
MDZCL[.PF1OFH4]-G0L`N/E".PJ"0PI^4VH<'J2`X7(*SC2U)EF53-I**=B_'
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M8W9_M5A3G>!A+]L^D827C*E#%S?7*B7//&1T_C:W_:L%&TE-FV')2`$174FY
M>)MS0/+BC4P9W$N<J-V/:R1;#'>+N3DB%+^@;T*D4Q1JX0)^F,(^\Q[]R@(P
M?2K?CPO>J[QDK$5LE$.T34X75)30D@;7A9L>O@:2'"+M"S'$&MG2)"[%)Z=T
MN?H6YIV5+-0%FWCP`GI2JA^>@UN2!#Q)*),#C>R4%*UI8Z'+L3L:#@9X'KW_
MMJ!WV*5Y>;6<MHB<H;GJ3?#((;!W1D<PU4I04W_@CE9))!(\*OA2J!4%9H0+
M[R\N)]/;ZZO)6,?UL48354,>?.(@NT+6)G#JP9J>@^L!TO`!8VTTT;C<]WKI
M1"9O[,V,QFZ_&X^4*6GH+>(9D%Q()%`TM6RA61?[X,Y*#M7*;>7:#]Y9GFVP
MN"N!L0+A9!Q6QMA*,EQ-)A\$Z0^RH9WD>7<UF\\SG2[;+#:VJ3QF+K8`AJ-K
MXF10,'O2:R&&D(N-/0\GQH@-:>6:;YL@3Q5W*XF)"-<S>M^ZPQ!:%O.2J$"-
M;5]G`GNZN'^^%I>V=$_M7^<S'N4G3#2)UN<,V=8XOS>.2E,7,A57VG"&U1\H
MP,K*CPKQ%!FWA=7D3`5#O>C(/^N`/5B=O96Q`O%P:L$?'@Q4>AXA'QDG4IJN
M;,1L?$(L)O=,KE=)=`K55H>\X,[",63<9D@O!SM:RT`"1+D21]V@E$1((\YQ
MX`W3*K/"(Q(N";#/Q&>*XYXWS?QPO6S,S9>7_RWNX?+NSQ=__W+Q:9UG8IJG
MBLG$P>MO6KOS#_G(J['NJ>5VOM_`I0JT5G)E90@2G2B6PM$;P=>]S^I2TU<B
MSZ,(>6^#OR@1Z'PBF;;\+XE`1P=4[7T*2E=U:@JI5\R98RP8(0KDLJUG'N00
MU@2[4GNRCVS/I=$CV]&2]EF*^]%A-!)HH@!_O6LB\>L5W,:LZ(FJS!J#KC_7
ML[OIHK/KT^?]B6.3D>S$.Q$V!,'X2J82$U=N>IA2+FO$L;O\S*&$<\8JV9P_
MZA3@A]@._\<*5+=;F&F@19+L7@*Y'`GN(46!I#2#Y[G(=\;(V?Z(YH',:U+<
M"[EHE-K(I_6CHC1MJ3N[NIA,UYC-]H0D:EF/A5HR2B>8;8I5?+[D#4&^,\:P
M)TG%*B76`:+>Z[O&,C!#GA_.;B]F_N#SYUD5ZE_OWEV=?9)T^.QV<GDWXTZZ
MOKR<?.*;R=FOM[_<7'_Y^9?E_[RXXA_./^QR4M:7E$J/)68?JF`+45/?^&K3
M*1O>^L;C,Q67C7_'4&'%0"M'<6G9ZQL=VWB]*,.4\SHS]3_%YRX[<;_(3]?C
M>C'50?":<'TGLN@M@1;W7DT?O*K.;>3RWVZL6=LQN`J[$-G&4F4+,.8F<2TT
M0UF"@^M]Y&X7UPA$CJ7'ZUAJYB)^N-YNL&#%7"5@4E?6:XN2L1N3B@`7"F98
MWJ1-A"]KL07-VU?&G%$&2,D<_G+]#[OJI05;*<.R][:`:%;EL,1:0D4G7[LR
M:V6B)>G5Z$^Y%^+CY%RO#RX^7YS/>H2'I>D__NWZ:NG3]X[K`F9M*#5$-H0-
MNUZ<>%-R[0UK'=+^:>WXRB+L)]V]5N-]T5G_Z[SCE>_N_\DB]<W_/+OY=,_7
M/H=/CUZ^'$J$>5^!"0U2BXS0+3H6Y),#%BO9,V<VD+4ERRR)/9]-OV<PV7=?
MVQ:4;/S=XH/?B9>]$.!Y/KM'V1L]I=FC<>W=UXR!*$HL")8CHK-UY&W.K43&
MHVKR?`;[KWGQ_^*GS/ZD,P+RSW)0?Y8O=K7@"FLO1B_GOQ7;4.S&D(D\:@%[
MUHNB!S;[W;^F%W^ZNKC\S]]+#C#Y_>_^8T4U!9GSMH0Y)]M<QL6T=(5ZEY?7
MMZK07)<1'SV$<6;5@V'UE*V%+/FD5Z9,BZ:%*/#8NV1'1[D+@$YN>4.WKX3/
MJMLP4C_$,\57;%62SB(I,PE@9=>;3P2R@Z&,:`>$$#T=K-W"/7XO6^?7$=1_
MY&:*U6O8!()8$BMQLOBSF%.H'4./?C8VJ]*F:UCS1UI"NZ$R1U-T_]K4M:'@
M##2+OKWKXX[G*I@L*X6X5^KP;5?.YN5UW;,.=551@9T)3`J:<6$IE(LA0]4V
MXUU+?2-!\^LLZCY%EVM:BIK(7'P,#8O'[`UUR)JFZ0UMW:2ENZ<C>4$MG_2^
MLZIN;ZSD=H1<"$LS64"(27J=ZPUGDS:KB\^U>X]70;]V3&O3B8Y>6QT$BF8)
M/;*:J0D.[>3\1D6?<?<>M5Q^C52F%),0(3CH2*VF7M@$^5O)(I4Q9+-+BO#R
MNA[@DA)$?2G1)^B('GI,`4-4AC.7'`4\K47=^QUZ557NS`",+<W&4H'D_D&0
MDW>4)1O$C=[7W;,%O:*JNWK?%$L$9*C9=RQ44K=!_)+DN8':X*UA34OW\EH>
M['TI&%F[JI.#!+6C[%_9SU0#-/(YUF?ROM.O3]HCG>;_>WTIN<OEH!OZN&#1
MKS_4$<;(T*(@9K"IV42^0X@=+:R1X][?`(;H_+H%=M3R5:RSOSM?-9"D<!E<
M*1*>`0/8:!@MZR#K3-C-.$=8H(AOQT![QH!5ZZ3D0D\QUUX`B5..1C9'L04=
MZ!#C<>L$B&_7.MN\Z=K&090T._1JB!&5:5#RKU:R&$J?F=T&TUCW=DSS)!>\
M:B-?N8#>4#J4(^5[M`+U7:HQI&HBC3,/!B3SRC8Z'FKV:Z@Y,LGQL@11YT$D
M-#T4!`E1F2B,NQY*_K4/UU&A]JJ!V$L2T6TJWDGPTGDDIEAGFZTN0"H;?+/$
M^K=CH`-\<S1=!X]R:_(3):@GYD[,)(B'G>,V;AWG7]L!'1/4KSGH#D21M9+2
M".J%F`7/4\,NB:DDJAL<M$_I[=IGU]A%/F9,@@D;&`ECRKF#R3$4[MX9,..>
M)P*\'=,<'+M:-NQ[#5;+`\"E7"$Y`86.L?B"_C6`X<>+Z:_]9C)93M?Y.!CC
M_(*9!;9HK3+0:_VRDW!>@O(9=2?!WI1Q^Q@3=XGM8WJ^DH4.BV!62_D"<6'7
M$9K+J4!KQ4/S+@@VVC"BRNSB@T[(2`=$,=]+E)@>N;:(`@MS`J-SI[HAJQS$
M&[81[!+%3MA"NWIJ*%T"F$3SXG30`W(P#%UYB3.`[>.>6LRSBQ<Z(?,<[*U!
M,K&BG,T=`P:7V1AQ0C48L1FZ.IZH&@NGX(U>)MOPV"E@LP(7$7/G2,FTX*`8
MD\43U0T[Z>%=V*E;Z#!_W:QD&Z4:6UO"[FPVS3C;]1HXQW6NLE4CA3=FI`/\
MM<2OPI)Y6(GD^@J2HP/)N#R(KPYUPS`!8PR];0OME7ET[#WK;9G-!64;24AK
M.I;5.+"2I]D-SLB=@M-^@>S#2R(&7I*P%`!3<"S>B.1\56K1^#Q>E2I;:)=[
MCQ,RS\$Q+08;"W)42AYD"KD6)^E(8Q]RLV$\P3<FV6>STZ(W;[VV>Y>VP=62
MI%)][06;CRR_EIJAQ(Y-&_FI6#\VZ]Y&080//<:H,#.9%PORIWP^KQ-=#)Y=
MC//=KV>L%\%:S$U[@1"ZR3Z;T*,<7N`8<=@O$>.\(76[$$^2<RLCA=6KL:[,
M&5'\<&9;<M%F,6:=TS!LS7<0GR#GS9?)IQ5BIR>95'!8JMTZEP67U@I1'$`+
M`LS$UH'\@&(MBIT?BCHNQU.EW698:P0BA91S$^]D.69G@^TI,Z#I9`9<$T&I
M?)\L[0?9R9-92?/9I4XG?-J>=:`UB<G7G#&'$$W(LC$XLG-FA`@K+HHZ=Y/E
M(+&W#KKUC6P(+N;J!+,[K@X,=BU_,KV%X5&S!\C]=4#9A[,+I82>3WE?:?W9
MDWL,J9A4:M2*%WTVM.(BO+B"%B*%8>>V_/O_9^_:>N.ZD?1?&>0]6-Z*K%I@
M%V#Q,AL@,PDVWH=]U%B=C!:R--`EB.?7;]61;*N;I[MUZ5:K[8D?8LM6JU@D
MZ\:J[_,I+4N_5:07KV"3]M&FPK;;A#9#8;FB*'%*]MK*DGH>&X&532V^;`7_
M=WL]-5=>O[M<\[WO3OYHTW2)3@?,-P(_O>4YB[?)E;!5I4CTQ*DH-UI,IKGF
MQ[T24[6RSIT(_IK*^!RD?&;LNQNMT.^]O)B&>!XB<*P18#M\07%8`@5E<76*
MNJ'PY@%!ODIM&$=_'<6>GU^^5]JN^7][/RWR5&;6'R_OYB26M/9IT#HO\0#>
M_X1M&,E=6^_9^0A&V=AR0K'A"OL1,XI6Q]'Y9<T]:I6'4LPOB_/SLXO?_KRX
MT([JB1_RP]G%V?6-3DC\OO@TL;,-1MEZ+M:Q01>@ML`2]<9J:G3-NIP'A$HB
M\T9T]%D[]Y21%[_E][+P*1BXI[)<T=?TM7+'-"G__`LKYC:$IF)07[846!LB
MV^PD+(PN%2_*,CP"DXDRCUM)\^2AVW!F.(5F`V3EI&HV>QV2:B0QJ/+=Y0$D
MR-ET0"UMX%W=N1WRDIV!.'T.-0$GH"#A8VQ:3;50^Q"<A]4TXDUK9D>&B)"M
M)TR=.EBDW%THV<LUDUP1QD#5AW!(2S3K_O=NB9Q>+6:?0$=NP*,$\SHS)5=,
MXF$<R7<QO963])J62`Q."+DDXZ`;-CZ%9"9+E#I@]$/,!'`P2[29CWOGEDC]
M>J1>LW<6,M:,ALGT*FE'<!P'S=QCAAZ'8G9CB$KL$G,SN)3=!&Y`':-5W%F2
M?+F.D]>'BQKA4!$1%TK=]5I#!R!+A)D4:L,UR4N8_'#!$ARWCIYEAF*-8G6X
M5"8E)*3JO9W,4+!-HL<9ZK%#:NG8B.@-$M2D,Q70,=L4HE$B>LKRAQA'7YCP
M8*YPLW;W$&ZB]IIU%+V`I'0,3;(4YB0.T#4_W$XQ<T>DF=U8>86JP22!08\!
M`!M6\K9+?"ZY2BYQ!A03[1M1TNN9^03@>K*E!4>@=%JHR#82J&,``S/0Q/X>
M-^UHE?0L.X^04\SLR6>Q1YE,23#9>3E)*$K;AR42&4_/SF_UQ/^B(+[3PMH?
M:G,7IUK%TT^XO;G''6DG5Q>B@NM/`UCY@SY+/1D/Q8@)"35ZY]D!1&VY2UBM
MN#8@"F$.O<I*JK)R)G8A^NLIXTOY]F4_A3_.?\#2*6P?_G%^^7&QF.KZ=^@(
MVTJ<E%PR;&,W!;QLB+A!ZI$!C?-]R=9_VA*4O?K7CCQR1]8V$:R\?HCO8"/.
M533/!,C6J*6L2;R*Y%5SNP"K]8MCV84M+T$^VY(9-<0-H%!/V-EZDU,G#ZG.
M&0EQ&Q2/61EOW$@X*I&*:8YL%[>M/%3(OJ92.X/ULX`UUJYZJ7]MR0NM!#?)
M!%L-R9H,$J'K8Q17R0];AEQ:F]D&IP6^?6_#]?7BJ2#9KOO<R+7$+H#-0,U$
MKI*/L7)PQK'=Q(35XS3]U$<)LA&*TE'B8BEBE'2P1V+*X"O'*%_"-H2H"F1*
MCQ/D66TB/A;N41**Z`L4XW+K5+K'$FNA4H;.%IC:+49Y9OLK-HNU24T2O8=$
M6&M5J(5B<RLFA.PA6\QA)**#,%S_+6)];H#[4A/X>GG9,J6<0W/:EP;-30^#
ME7*QQJ'<C)'*E<)J8\HZI;T1U1Z,#J<A*E&B1=<ZB%EDIR_VH4?K(',>BA='
MI-.#<=Q@2M7DVL695,`@2:DD;C5A;,U@Y0&E_0`ZW3/)C_&HH"S*`@/9<>;0
MF`W59KK).!+0[O^^?BVT89:*!Z3F?$"(*`E/1CEK6H:-/8_\2=Y%.^=9WJYJ
M#V8*/2IA=`^V8E-<<U(`94`$E!#+^*%&>40Z/9@I#!(:9N3FDPG00B&#BM54
M"W"44&S@6;"*QG60X[IGUCF;3$03LRL,3AOP#4E>4KPNMHV]M6""G8N;'Z>'
M_UJ<*\:[XD__>'GQVX]GBOG^+5E)XF@5J-``);`A)U+L<ZS%HF1.87A4'O3\
M2`V^8=T?S(S:#A-CM6\M<.-<E*MCTCW);HR/U5^A[@]F;A6_.1%13)E+R#&)
MD;G3/4.K<=#].G/[=K9@SW8"Q!$%<?"M5%,`.16ZTU>6V+6,B>7.]?73KTOO
M^)N?\3>']\?01>`[2AH0J?EB6B?+7MN@P7?)C4)R@V%V20?:1X4_26V[5_O#
MPWH,:G?L.@%$IW8Y2\X?+$]JAU"3'2F^UYWS5U7[LPJ"N;-E-%R+OH)`")7$
M`B;C(Z7LS4P3T`X.V/HRW6X6O''B3`LU+2I*G\'LDZ=L[A=,U&F(+'>RM7,+
MGJ<$RS?EY.KJHWS0##/!W:3MALVLKF5EOTV]04F0"Y*WMMNHC'%E**.&E'"Y
MCO`HH7:QC+"I:&Y#X2:WS[%5-E^,49),D]E9604.]2`78CC8,C;,O-J66H52
MN!@%P6:]6+6Z"+)/<2QJ3W-`AUG&QBGC7D&\#L0JGI^B9/G&.$5*M>#)F>'"
M^(#6[649WU0-WW73B1T&3PT4&[)DK[-0AG+K!A]1PW^T$M^HZ@]7V&)&*V>X
MUL!`K5!SS&!=(/89ZC!0]17I_&"9F&1A4&,&0T;M8\H]1K4NQDD4XNLPG?4&
M=;Y?!976N5I%M4(YE"YB238ZRX1)&__'9L?#VX.OI3KF4J-8>G0(#0B5D,:'
MRI(6>$G.1IR-\0WAV%5_,%.,9(-/SB2,'EIU<NJS-164_56LPE`/_XIT?C!3
M;"/:',@HO;Q8&D2G5+`8399-<.,0UAO4^9X?:0JX1JW%$A&Z]]D$8[+'!)XS
MUR%GWJ\]^$2D]_Y*EK*HB[O_/[EYFCVVV&7+;5<'K+1Q&/0$2!(C>S^\07_O
MO`V/25?FY=OAPK8T?#J*6JN4X]P(O`>,DGTIW0/V8"6M&2%FQ*_N;ET_7UW^
M?G:Z..6/_W.MO(<_7/R^N%YN^)^O8CUY!ZLD:B&A\C=G#U#)-'W$06J]NT3#
M0K_W9@7,Y47R[G/E6[8X*A2J<REB;Q@">PMQ6GDW)4,9"@;?KS;][W?A,S,>
M.]IRKVCFW(V$@%A+)2ZM5:TZN,;0^M#.][WW-)[M9\N[SY5O:^,.3(&[3=Z2
MI,39X%3&TY7?,;H.6VYF:D0[6OD<".`24_OGO[R^_]MK^Q@(O67FRQ"5[C[6
MY&P`6;MX8VIR@<DU\=9YI1#SD,PHI`?+?HZP>UCN=C)Z<*9TN=`M5`13?.[,
MV91H/<=.=0-3H,)$[GF]=Q"$/_WZI<>YG$R\YQ]7/VS=1G^9I51.VZ7HY"\G
M?YQ]N/TPAB'+"BK=9TF2,V?'8+HGMK;:8KL<$E?3W%C')U3%':UMKWK:?D):
MCRP'(J<2,CB;F'NVT!3F);7NURC@CNGVU33PDP3T-R<7^C;PM/IQ0UM-M,!)
M5L<HL67AX)`I52\AVAS3[3"ULTVBEXN_)]CJY1*T"=13[8JR""Z`=JNDXFH+
MGKV),*,)T=L;5401]W%[+I]TLQY)>#F`-<W;6FT-',&!XV*2+6@2=P_+W=R?
M5I_<6ST&3\?F7GY3294J%*5];G(Q8O8-H<A%">(`L>&,+KSQ]HTJXXD8W,O1
M?B[&AR:7(@<YZH4\AR*608D!V"T!3'\9=HU'HHBM4-LK4;`U[-`R3[/R-6/C
M''V3J+!UBWU&%4>AA4U@VLNU8>L,:*MXTLFM(!&AQ(/)QU)[J)#FSH)[J^;Q
M69#9*YBRV8F)D$!`?LEOJ:(X34N!BC)@SLT<>TK^-?6QZ;VUU-H-^Q3!)D"T
M"+X"%VRMH_*B/&H,;__ROX;?CT'Y\2#F!EVT$+(/(-LH\6Y.DN3-#8:^LM]_
M@B*>[/>C0=^@U*E]P#8E4;2^F\@N2)*;>6;U8079\>VL_H5^/XN/]\D7S7'`
M.T?,5?)_4UAR8F/F(OW7]OO[X]Y8MFZHP`G.](@.;(CDFZE*_J>]F,;-YCRO
MZ_?W2;&Q[/>;98EZ>K#:F!<R10*=MP7JSA>:2PNT9'TLRGBT^Q?SF"NT:HV-
MP/*?K8F0"L4FT9";8U=X7?>_;\:,Y0N2.#.UEEL@:$@YN%))'+PUXEF71D=V
MY/XO/WPXNT.PUE>"J5CXV^+B_=EBW=3ZE]2N26SB8I`D-H%OA5SH%(NI.E[:
M:+73Y$]_7)_]^\79^7]\=W-UN_CN3__V?#FF".0!+;S<BHCL/(G.K"C0)0-9
M4FQQ*"ZMMAEOE^,>^_T>O_N.IT,QPZZTT?ORJM_>W%XM?KB^OM7>WZ?%1\YU
MP)#U);Z`[26':C,TI>P.K8<\YQ;#*G;=DV5<M\*?3ZY^NIJ:F4^GI[M/9<BM
MI9[E2I9)/233K9(&02+M.U;>4DEK(,DY".MJG1,ICIU=USK)7KZ2E=U9J<D9
M9R-6]%D1?[I2D1CG-!`GL<FMO<)*[K8RW][\_?+J[)^+TR?N17&109'64*LM
M)!=4TBF)Q%N2$"S%N?QA*K>8=2=L59[GR[U9\QS9*'1*\:PHU\3-4#!-PB5G
M)8.8DWNZ%GN5^[&57&/%S@1&<L`VX-25;FQ2YB`[']]%\!CB#B37._[D4V*4
M8L6UY,3+`G2?G:E>OR#7.!0_9X:LU4[RM.:4/Y3E>?)N/!T92@LMVUH2@-CZ
M3'(LT,I=!9=X:<;\L[Q19RK#1AT_1MZG5,!7A/8()M6:H`<1VNFH%@<YX!ZX
M%C-W%:V<>0>;E;S)DS]>\HWJ+A4AE@[5%J\&'6UJGF*P8@5[A+G+:*/(#9O5
M_0C)G]&I7@/9)CFU""PY12FDE1(G"5=!:!*3C$12ZTS&3"OW5LDV%D/$@9@(
M@4KM`"#A2`V9?8PV,T8>!W'6NODYR>XC),6>O#X[_32KH;'?V:]GB]-\?4>8
M\DWUG6,*25GY&ED'E;R$ISWZF+T)E'&<6EC2]O,5>CP[<[!>R)BJ\^"<%X<.
M/M?<C>D2C]@@7MR'38/"W\;.^&U/)FR-]XJ]90M0B&2RCU1#LQ(N]3@8DQAA
MI8+T+:GQ`-/%60P,!F540\`LV4)74$"%!DM:Z/K*]F?/"!IBP`/4+":\0"])
MTA?F[B4=N"L1':LROY:A@@(3OPX'`QEL,PB>0%*(XGKH'0=@HF]N9P[F9RM+
MV)YC9L7N=[TR21A,6!NSDE,.G=#?W,YL\[.%),\%EG-=(B1GV'"E+%ERRZ&V
M/@QM1%A]MOJ6U/CZ![S;"$X),26UEDT*T[N)I*M1&T?ZR-EXY/NS9PB9IBC2
MA@J)_=9^3*]CNKV9V"1QXB%WWJ<RKZ?*_R>*B77L>^MG,%NU(5?,#IVVV=%T
M-"I8A<,H;81&,!!7>JI71'BZ?!M)7#L:,.1;MQFR$:F45AP#`;785DO+.HGN
MS$[E@\WZH^`D9V9O32%`8SFUTCR)(:32PS@IKS-M.Q9OXY1$H$[6:XS1P)'!
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M`UIY0*+^U\7-7R\OWC\'YR;XFAHV9)UJ,U6".Z16(7!FK&D<)/T>S`KMT*,%
MV]5R-M5%32@Q94V0#4/$JC-NZ'LNP;$O?6[\94?+^<?E]9D8@>E;GKL9##X6
M!1U2E*7L'1*ABQA,["@I_XB*GE9$GQ?BF9)NTK/50@3GFGPR0!-BD%;$4[3@
MV<P!Q,5GB7HE/WYR^_+[\\5$*G5Q*G;GZN;LGVM(OK>1X9B20_0>IM?`V+F4
M9DLVWA9C<A@.O`^KIG"[4#M;Q5&!@^4L&3J2B$_:D1_8=JXM8@\2(P4WP(/X
M%6325]+LEFC`6D\EN=8D$P!7?4X&DZ6>Q'Z;&8H$;\+A5G%4YZ/Y7'QK'BU)
MG"J)<')T=SZJ(<<#E(F8F!=J]O%`9/G]>XUEQ!+=+#22^_'RY$)3G<79[R=_
M.U^(X3]^S$0T%)EL2$GR%^=30`ZUA0`Q]Q1I2!/$E"^'X3O5YVONU+'!+$KD
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MV/^?O&MK;NO(T?]EWK75`!I]>4E57V=3M3MQ>3);-?OFQ,Q$,[+DDI3L>G_]
M`B1M2VSJD#P2;=)YDBU3%NX-H-$?LB\^>A_*2@]%\;L&/42<?4Q_.3WP^?F#
M"%MJNQ@2V>0+6,!6UWK`4&GHM/B-\<E3U<.Y^8.4#*TG]&1)A\;)5[0K/=34
M>QOJ;N"-5S]?01$/:_U]>F7GYALNQ>!:TI6.I9:4:R<Y)+C[!)GJN*+=F[D:
MF9#DEU+.N3D,E^26;^1K"J%"S/IEJ1PD#5W#03Z_QOC:VCG#8\66FH/WT6:H
MN7IJ)O':=3H2C2CX9G;">P+:.3??D9S+5.=+BY306:D+R:RU4YWAH77EX^SD
MZPC:^?/B6OYTM93FN\OKR[M[_?[OB_7%_C=Q]/3:6XP0O9'"G4+)T$`UI#NV
MR(UM>/+S\^,=\OR2:CH_1Q+-9"KB2MUE[TTIM%)3Y]+:N.?`1)[=8SD5/9WA
M<>1]#1`=EI8CB&M)T>/7[D0ET#"O;)V?7>:<D)K.S9VZ+SU9V_311$>%CP&W
M4E.%ZNVX)H#8SV[/'$M/4E7]S^75%9Q_`]D3MA!S,3FB3:$$W[17ADVQ"K:L
MM8!G.,U'J1U![.?6+6;`;FVUI3L?%2C'A+H2.R?/>5RH_17%_OWU_9OK?US^
M=+58#0GM>#\D;G:_6"Y,W/S!_.$_W_SSYG8Y./P`?^LG]<JK%5KI7Q;W&T/G
MYZ#-@%G<I2$6ZWMTU@:G*0)A[QQJ'(X>L$RS.SN;4CU1M?[W;^^O%M?_MU+K
M&>H4$\H!!9:<U5'1[&QI*YTV':P:=!I@8PO?2:KTT0N$/Z"GNHZF-4)@*PE]
MD!QQF22JIT(E-ZXO)S__FNY,U'KNGIJ-<UZ;4*ZZ!LF[L.P2JJ=6RWZ8JC\-
M3_U=&+NY_?`-I)"P7+.\Q'/-G".;8O2:#]BCKW;`"/O.\>PVQF>Q'4/PYY9$
M.DHUE)1-3#$VHYCKN!9\]'7<IP($SXAESY7\I]45*]'^Q\W=DP_`SDH+@1)U
M!,?=R1D2"R8=P7'&,+568&BTSI/_%ND=6Q'GUEGPI@:#4"R+'WBD%AG7BDB&
M>.K!^@DKX@P[<021C(,.6>\;0C?HTUH1!7#<#'L!LQL\7T$;Y^865"$&W=)1
M4V93:_7+UR"B#:NP].,*II/0QJO;Q?LWEV]%BC_<_[JXW:=$/0=E<(5F?4$7
MN@*7AM!U])\A1L7=&Q>!@9\_F[95A$?6Q[FE4`6R*\6T`.(,3<J&4/U2'Z%'
M;]J0NX)QL^]V7E@?-_+'^P^O1*@J3GV!__[=4P\=STHGD0%<;""G.9,$*QM(
MYPI`MP1B'5O2.'\FYTDI?@&UG)NKU!)2SB@E1TPVAJPIUEHMUE,9TBNTLZOL
M%U?+:X6OWX1V/--Z`[LG1%-L[&$)$==9)]8D<AE(J8^(DPYG^\=:;L<0^[FE
M4=$A6^M%X*%7X[*E&-=BM\!A?&D!./ND.);8S["6J)BKOB^*"(S6HTFXLO;2
MFPU;9OG!N1,4^[E9>PJA(8NE<W9=\E7)CV!M[<%MV4D<,,YN+6T3>WMS>RV?
MUQW&2USA_.;N\N=]\(+P84-`LKB<%3O842BQD-A/;3Y4?1I"<<-E/_XJJ8#,
MOYD'6"5;:9E)[=^?IC9#JSXXUSJ:[+MAT+>F2VIM`G03U.(QJ!VQA!Y12]EZ
MRPI=8TK"%ED+F26U3.3Y26H!%$C_./1.2#=RTRV57='RE\\AV'RT!0C.FRGI
MQH.H???^ZN;#8O%Z<:5`-@_>:)4Y2"1>'S)Y@M*KYT206XF*AV#U43B5+07*
M!DS&3GJ>2_TD.G;DVIO3/H.73+$D1D,QQQ@H@]C-\`)H8_GS@<3_\<"PLW-4
M@4L.D#CW)&5KI)B:Z1PRM>$^\Z%L]\)L^P/"6(>20@**5:(P)Y."Y!Z`4OL0
MF]Q'&&NF\'B8X]0E^]5P'8W-VFXI(DE=A&DE^MH@H2TFRBV%H?LU0/Y^*<D>
M5PS8)'6UU2>,F3EB;L$$<5Y""E#+>&\G0=,>5P[?"FBQ:8Y<@>*2)4ZII!1#
M3(FKE,H8QC<I9R33KQ8/?0VF&%N3M9TE'TE2V(I$@6J2PR>-TVW.N2.[[;<"
M=`N66A$Q1O9BKH6B@6@1(YM>,)L1\'\3F_5+2?;(4.-4+/56O*O$W864&D%/
MKA9M(MH!$`D)[9PC]]._I[N[W]Z]7];*.@K^L^26]?+WR[>+Z[>O)=%\&E3R
M,P/VT:V.RS9$FSD&]@&#C1+9:S3>YIC-PPO/!X"8CQC8E[2]^=D3'!-*P-JS
MQ$:+3,Z%FK"TUG)PU0;,?_KNE?_[?F0.2)E3'_ZO&\GH-9?_,$?@P19Q$JDG
MNJ020;X&VWV2\CZ)'T'9CD#JF>Q^G#PF;B=/KR_O_B5>L7@(8WHH1Y%+"+ID
M47>$5[6C7L&99)S+GIS9;D*2&4QSM(VT1_Q\G`X_K"HM8M6)(E&0.K1&3(BM
M6R@D:7*Q6U+D$!]?8W[\M7O2,E5CYN*Q%M]J=X7)B!^2J0PU4>D$?FC,"BUA
M-RW?OWLOXM0H]L,OBOV[G*=<7=G]>),7J_;6XNT/OWP3=PK=Y.9"T^FEH@&!
MLLBS.9/1V=!IZ#(\D-[>@GI!\4[!1OK24H762^X8LI%R0T%'@A1I,6+8;/J=
M`BMG92E>\A.IB=$WH\N=EE.WBAUI:H+0S(E9BCTW\1+&U&M&3I)$)*^W'TEG
MF2N2E#`X-</VQ<5[AK=)F5/+''3G1U&DTZI`+,LX9XN)84"M"\8_KF2^AI"G
MHETHX%J$6%%.79,A9.CK:!=XB[V<"D-G93624KH(!*699"7UR>E3S+/&C57:
M2PGYTQ!=O[UY5U:<"9N?6?O$^2M%7+BY3O?WMY<__7:O*(D_WBB8M_S0[<W5
MU7(D;Y4!'KQT@TUQ/?<H!8'GU"FQ7>Y`8X<1S>:]U)^^$W'1XR+U.(Q\+5E-
M8IIG:UNUV1(U2>AK!(LA,`!'R[X,HTL7*/^G_U:%M6,;"301#CG)-E%$U%SB
MJ(,M=KF7P8UW%Q>.^)LUK%VK46+-)*>41*#(U4,@.;^Z9.DM9IO2L+GE`L-R
MT^RI">O5XG9Y92JQO5Y>_2:U]I85[KMO]J%:8T+GUI)GWT..:C;B2"EXVS9;
MDH]O]ND0D3Q![Q&YGKC#]E0,Y=R2`TD0<\]RT/LJ!7=*$F(@3G`-\82YGIXT
M,($[1&][-XHAW$,4TR\MDZZ?(3NI:WO:7$_HVK44C0[>Y"H.'SF3MM^U,+?1
MF<UU,(]U'8[+]?8TZR\+26Y^?/._!^<76'7[>"3Q9LZ8&S:ODR229/A8G1M2
MV`M%LYJ(;-/DO3A?9Y7)!F+3D5V.T;06(-6J3Z1TOTW)\HU3EO5DTT<.1AWG
MJ8TJ].QB:F5I0[E%B1<#G,:%<QL`#%^5K[.R(7U*)$D'%^NMCZ&&$M/*AD($
M=.-FIU.1]8YTM&<.8+E+89.#;3YUA6,3&_(FN<Y;7JV!\_9T&#LK(Z)H2V//
M/5"0?+_ZY/O*B'SFV(9[^I,2]E0DRL%WK"9:3Y*M=\2@K^W$BF*!ZFA,U,&9
M4V+LK*RH]X;5(3J*/>L$:A=36EE1U4/@5(3]0E5/RH5[[DF7IKL@R5%7'&^O
MNU"7JYNF,F&<Q_)+9X<O5`D9+KZ7(CER`^]22-AX)0GP%2A-2<*=F21V54<N
ME0@-2C5&5^BYYE:2,-GT,CGC[L]/$A,VP=C0BS$DU-'7X(V4C6M)I`B;,"2/
M*R8XJB1N%V_N%G6Q^OK]]"Z@/9)=;"XX1;N,<H#*<9-:+4ZS7.>S:WTHF'B(
M>-,$/9?\'2>D;ZJ<VO3Y&D=Q7B-1W!FV%8QD`V.>Y6QX:08FM\_LHX+0`O9>
MG.N&I:2*6B<U1F$F=#!;WD(ZWLW#U$Z7>6SLNCW2W8I1`D=HD1.::"2*^-!T
M':=M<4L6QNQ>G(_E/<B_+Z[>]IO;O[Z9X1`!=8ERZ4C`U*G5X,7SQ<BZJ[EM
MG@9Z0['Y-G4/JI[/Q0YE1&S1F5B<]9Q\DT)$7[HMN9"_P);:/.Y6QH%<K)^H
M?UR]NX9)G7KTOX=ZBBGH<N5<B3ES252CDU*QV&9C';>VTTY_WX?,HW"Z0X6M
M989$<OJ4SL&%K,OI28J<5KG6-"+B[]+?"S#Z>G%W?WNI4VWES=VOAV]A325'
MDW5C#S)S"EBE(NY.87DM^N&2!LTNSWI,T`;UJTN%U1F\YG98)+E'3]&V&@,;
MZRHDUH=&NN<40"Q0?IAH&`(27]J\A=M.R7QRIX3,W5@&ED,BZ?"?#M(X$A$W
MC"TQ#_.O%YN;DEZ8W!V=DI(<NZP[>#,QM)H52*;4;%S%Y,V6LHLW/?JER9V,
M/YYTY[LM/@,WJKH;#[W4#@0Y-[<EX3#/,(97XJ\'&T!JB5#R=<C-<\PI54HU
MIUBRI!DA#0;@AAOVS[_\`*IV"(Y*2=5W)E>9BVG9R\':;#8&(E88?-_2=KE-
M4+7,UV8]C`R]8TW)1@R&6S3)HI!;2L;N"]$PRL-/T?:0A%E43@VGDCX^@1R\
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MV61OQZ1/7#S"3`)_^.4`7(59XBZD':0(NLDW2$D8`NI-FISOU*L$BW%7X-/&
M,8?:HW-^5@UN0S9SLV))!76_K^E6H7492H"V99[LO+0Q&:5R(.%;#BG)*:%@
M+\M>M]BA%=O$X86)=QL9_*ES?E9V&).WW8!"DR3?HS5R5JSM,#"-_:[C:N/F
M^A_ZUJPN?KJ?%>/4CB2G6#X082PZ:$,1J80LX8["V)!8QNN'W(P4'$[AE/4K
M/$US'KA`Y*P+<U+,M4573)*R8$@P[";JT2$4ZF#?'#$:*4X5SB,%L80F<A1/
M#64)GU@CCL,DUFZ@>VPG8A:=4\),3*4[;-$ZRTG2;ENC]9!K+Y*5NT'=P/BT
M,)^@4ZI![6:\NKW1IYIO\X>_W2G\?K^\%F<6XTX_WU_^/J_7')RIIJ!MT`H3
M*!O@=(&!5&$@!<^X7,3"XX[__L2]&$^[[@!`3#LF8:I*690P=TFD"T+O17NX
M0Z)O;>!C\J3HYG?WS]-3M#60C]DW$YFH9Y^%EX316W)E+%XNV$+<AZ<MQ+T8
M3[NZ?_(A\CFJK3$@!/;0LBM2QN;>W3C['\!]69:VC30>[F(]!AMTI6QO68JA
M6JQ"P0;GN5?GMK0+R=%,/K<1?%3>=[EB9P@2'VTR64X=B>:8U[P7SB.ZPP5N
M0!`<G_5/L-+/\,ZN$=^XS.0:4\/0&NC2N61;3FE$+[T@!.)]&-U"W8LQM4-W
M%;`BZ*E0=-H_B9^&DJLMNHV*<`PYA,'OY:`OQ]2+."@;'S"RA-8F1Q[8PGK#
MYVMEMAS]<`:*D7J[EX?N2?%1F=_EH=67PC57/4V`,OI8ULP3Q;SE[8<*ZXC,
M?QZ1./ABIA=,%DB!&KA(!I`3:5G''C&F.C:Z+QSX08^??_^!E$V^L,'&J3BH
M+D9'2=<6N!5E('_-XU&'P6V\L)E-VJ[[%M:E(E214Y0XUH-O>2TT),#QH10$
M@X.;SR9M\N34H8V$DMXTRJ;IH].R(HU,KR/>TH6UB$,F]QS2/M71GRKH51-2
M2MWW-]>*0O,(I^;UXOZ-%+YO/P(Y[H*?E<)0XJF<$,):T&L:$Y`Z2,ZJ8$AC
MX#F$OP,VXDQTB%#DSCU)>:`7<KIRHQ$'*6Y<#3P2"(;=X]I\U]:&`_;%3&09
MKH"/U5A,;+K-7ENF3M(HJ<"H;QG1L&B.0.8.3[/B.);9`7HI2++-&JRD!D_&
MR='9QT1P>5%Q#"HGQPR04I4CP7!6)-`<2@*K]]Q)DO(\WLE?H',$AY&I\P52
MZ]X\_MR.]>M/UQ%02[4DA5#+$B$P2U(M%80)F4J+8P3CC?;1-#G/I7PRQ:K!
MZ<U(R\N=@3ERTW$6'2UTM:0![^*"XY>B?(<MM^3T*@VJ!&+NV$(.R:9F6[&^
M>#\DA[3I;T>E?#+;\VAR;+JY6PK.*"&8K63N1GO!DO`-P<(]3^0_;/W<G+$3
MWY(DJ+K@.GBV<AJ65K*8.3<V4E,.;3MO-J/')#W/)7TR_2G-9!U>)+"<00K!
M7CTA4:^V.AH2,\!E\^++T+[#TB4-0G;%<Y3#K<L9&#HEK-Q0_+:-T05Q`[#U
MN*1/GHODBD@9X/_)N];>N(X<^U<&^1YOO5C%6F`'8+V"`$[L=3RSR'X9=*RV
MTQA%"KJE)-Y?O^2U):OOO?W4;<FR)S.3AQV;/)=%'E;Q`0&`V3#JS(Q.-=4L
MI%`'SQS?:M`CUKZ?["]G[[NQ?*\OZ0USI.7\YA%@OOIN>4Q4=Y9MO+%$M7G@
MA#-E#)R$<DQR0@$'-\!2H+DF_"Z)[BG^KEX=5SEI#JHED-EPAAK)37O-AK]`
M&\YAG4SP[0M=GVA?8(W.Q9:IU*(]-C:#*K-U"A"SO:@'D=*J7OGJ3ICN"^H3
M['!*)FLK+Y_0;`O%9I]N0$4VW0&H748Z':9[KC/:Y_XM^1(\<G+$X5"IFBQG
MC(Y9K#.QD!V^:.%V/?9;$71_A9Z4M4"D;&W26K8R*-^L-3*H*-<68G-F$,0?
M%^`=WEDA4@B8*'.6@SH@FXK4*7G,%LO("A+]V!;S!/U+;1ISL47:<#@M4!RV
M_4>+8>*=!Q;3FT-^+,C+CP7M7>W8R]GRQ;*#Z:P;7WK3FK7S-?K[']O:Z&_+
MU+OHTM""CY5)++L;14RNFN?L9U/_5S>)]TX#V'["3:)/[]5Z79^42XXZ$"<2
MS$_(DPK>%"$IGKQS^&#Z=#^^HNNK7R^7B_^;GQWX77)4G(6BDX'WP.Z)DK>D
M(8'&P,?F;C:WZGZGFRBF-NG0%^A>LF_]!HKC5;;)8[(>V+`P8_9!!MY6B*69
MZ667=H_1-H^C*EV,*S&X5$IN!D+140;T!G*<H-K28+ANU/0*D/>0Z/X:;"O>
M:"RFU06380TX>TADE0_&EV+D[6-8O*%[#=Z':W#Y9CX_Z[H_;Z<FS]_,963?
MX77]B1-J]*"KS5`41,_91G&I`A'!R'I1VY-]LRSW$'K7HW_DPQJ1;=Q$T*60
M%"][BRI0,R,#>;290.C5ZEJBXXNW$LDN+[JS<O@E1I7563+<L["Q(-.$;+R<
MWT@AD1]<AF^2>DR8^XJ^J]>B:<X]94%*BZ",Y;`5#*EJV."9"P]`=\'U2BTF
MT*!K$7SQ=J2J_.,XW1\O_]#XK[/YXE_/Y\P[*C.2J_>?6,CS!5.>\PN.,?_.
ML]\75[/SY\_S"`.!NV4S(9J04X)HB7E>I9RI,2512,Q*TN"(N#CPK[LT>53%
MA^]3^7RV6KUXVWV3M;>I.]]J"-IZ8-))VH^C#:Y9D)M=$S%'9Y%)G/,X(,<?
MH]*#P@;_K7^8+?7:R/MO_5HG`F;I!'<9&L2J8B1JT`VWLUG5@1(6'U:)_3JW
M7"A,.,GH"$&:IK,OV4?/Q[FH,KAE-WZ+BS^-!A_'`TUZ:F4I,^<.EKP5^S,Q
MF!@U`5)6<<33.O?P7VZ7WC\\_V>^?,:ZSB[.?IC]M?BMR[EVZVY,8"((287N
MCEENMZ1K6X:3LML:/A(:^RBZ;PWQSCB*@;\BL-,MFOBS*<@IAJY7;1!MK(I3
M:="YMQ<W^S8D9UT=0:Q4:<3^PF5V'*"J%,5ZI[,4I[>8\N#>7)K7-FHP*M)]
M%=AUN]&,[)>73$X!0HE>9<-,EYT)Q5J&74/Z?N*/9^6#)XM="06#K54`>19'
MR"9%>>%BHDBE^9CTT-TA].7>*,D]1-Y:2R^)LY2.!2&%4<?(SLK)]8#44@^1
M-KU6O?N+_(_5_.WU^?/%V]V[@3?^&NG]Z_>_SS\YK]L?:-=+%O]Z*:E-6_PE
M?[7J,8]7LXMW\S6FT;F[Z]]N'-VGZR!G&FKIZ8@."!4Q^4PU<N#5`;)KW_S]
M)?R\!S2?-'ZR""TN1A%B:N)]0P`V>;#>(%MXL*85&YMK03-"]AX(O>)D]<.5
MVH=)\3=M!X?7+<@""1<#?TD/U359@U<\IL3GMA0UL/JHUJU^DR!'2KOK&91:
MJ,PG*@<::$XE]H*AQLPABC@?&B0!)BISC+BKN6R%DW%-LO;MLOL2Q]:TQ"*[
MOIQ6AL^*B@DY:6-&WHQB5^B'?9]!]88V;!7GGH)O!5O>8&H"FZ6$S1#65#B8
M8JSB&VG(7[3KD=:32;[CH1]U%N<4JZT!JO7D.7=()LNNUJA@N'8J])8AGU+P
MK15;VCFI(U5!.<@BK]=DI*^=>6-T`\@U!M\W\`,DOS-?A7^^_$G\SA_L%:4<
M\BK/ELOWBXMWW07P@:US&FHP4AI7%3BJ4<MH&SX`A<]L',[2,&KP`0X1;EK%
MMK$$'URT/N?D4P(3=,PA<&:#KI9LS;`GT/7FW-Q'L9_FW4C][^87\^7LO'L;
M^HW##_^"LZO%'T<7W5%M?$J(2%>"UA+:C'QR6G'=<**!T5GH<>3]Y)I*E:WY
MBI7!'H'`I@JL!"7A<.P*BI4:GY%[[.#<8^FRPXG9;)E-(7,(YX!C1[*)PUUN
MC;FTB_UW*N&C$1Y1E:V11-6,/AFR3(821X\B55BH-54OCV^#$(B]4KUC5)$'
ME#3C%$<JO/F'NZ?0P^L1FK0;1.:V,8-A5\84SIFHL^<_R`U[@#&L$Z1Q.>XA
MZI-Z-_;$\.E@';)K\<H8,%BJC\0TTYAAN2#TQN],B-ZNBW4@&5<4:Z4(1(HY
M!-,&9)X9'?_=\`')]MZXCQ:5EDM)*S[D)I]^RL<W<_ISMCSK_N^?'_KD7LZ7
MB\LSO3,!>KVXDFN6[R_.9"WL]>S\T]=\_>?E_\Z7W?]^8I)PP6;`OQ,?)$D_
M!JE,5%J>=J12M0&5&.56JS&EBM2:;9%3&??S+AR.4W(:](Y:Y[LA<JY?K_L&
MG"NID%-UTFH6,Z=[(3`LB'9]0_OM-M8)D#IJ"?#CP/?S-OBL9!3$1%'NB@Q1
M0I6L<Z76D+'I\I7#-R0(Z_"!SYP9-`+/835Z12A]*"[[8%76:P,SOU+XMEJ?
M\QR`G`U\@IDPNI@XL2T8%>>P,K\$OGCXMNS6WLO[V29L)WGE,Z=ZE4TPDY%&
M!I\:6A_&`'P6HCXQB%NV<C\6C-OML&$R"#E8SI&K=M$GFUO0U*)TY8S:(</H
MPE>&XRYWJ*I'X2?@"WV8JIL9),YA54ED'L4=?H80;C7%J,AK+,&UJD&#)>T\
MIVO,R8.I6/6X*3KSA<#X:K'Z=UO.Y[?E2$>Y19-RXG17&]^,K*0C"\QN5*:2
M=#+*C8*HC#H5BF-:?088;F>&LLY::1N:D<'&)@6?DG;5^ZA5PU%B_;5AN),>
M,DXQA*2-16!*C0V"+48*:"P@/"2_^4SAVVJ"+>1F?+6)DSKP.I%4DGJ="=$$
MLU:Z<L<$-3PY"'_LI'_Q=J\:Z,FN%S;!7K1739&LB6O`]">:E)BGAXI&-MC<
MA?VFE-KX?CO3Y%B<!.D_9HMS&=?<+I??\;^[8_[CJ0`GY[/L2W7&*?#@9'8(
M00HQR^@CLB.`:V5`GP3P/B33X+Y>]"*__H??]K"G'\<&F9-";ZJ"4'W2S#.S
M)H(BE3E^!"COC9D&ITTJG`J@_YDOWOW*U(O^F"]G[^8W]4(OEXLWNU_,UI:1
M14RJ2?$8YXBZA60"_WSTC6FYLOWQX9_:4^PS.T4P/TRS4Z`Y7WU_\>$Z\_7E
MU>R<_?=R<;%:O!EY?-QGP;?3ED*,*#_5<*93*103<BW9.4[(=PR*?PB=)@61
M'<';>5>5<_M;'K'801695Y_%!,$!)1<T1W&MJPO\GU$/YV!2X$;TF!2GSEO>
M_M+'];G+&@GD,VK9K?$)+:EU>T4<V01&^S$'9SU.Z^!&]'@LG$X>>95RR;JB
M(5$%+)&TS@'8,K4*H50W9I=:XS[OBY\KX#WGV_U@829[RW@/W>97'#!/3S[*
MA"5OHSS8*8T1.-N6ZKM-X44_T^Y4(.Y4<E*`7UQ?K:YF%V?=5(_-L>6V8N?.
M%HU8H;BH?)`)W8'05.#_>FMJ:-"OT?W;7ZO%?UXLSO_KFZOE]?R;O_W'8VFQ
ME:,UGSP$Y:,NT*"FBCFR+K+K39EAW;&/$R4.N]0X%5B;B.RVXBQ=$(LGLMD:
MJ+5P?I6U=\&X[%"W,<:/<#J@3D!D]P!H.]/'W)22M@&V'47LI=GK6I*>ZNAA
M-"6:W#$_&$*'4?V>8=WUQ:'(_@G29%N"8I")?S00214;TV#?UUVJ;Z:X-3E,
ML\\#S2V)4VHQ!*\XRXP$H7"Z"3&";]!*E,5ZF]`TS]`^;32E!H1_FXNSF_O_
MUY?RC^[D</3NW7+^CD/J?6)%SE+#Z1)*R/"5_6$,"IQUJA0%PU$S7D][P(]6
M\S"P5X>F=/M;\&YZUII3@9+R5LD(2JFG:K*-W3EGJNWW7]T=3A'B`4A/JN.T
M\(XD?E,"3-6&8"T0RB4_!J+"J4-MB5S6R8?-7L(=PG\GUG):B+>R[WNAJYT)
MR9D,I7!BE@F=DK$8',N*E[KBS=E%.,0'3Z?@$-BAWM]/V:/?KX?SV(S3)CF`
MP@:8R`346).F$/M+V.Y:X\"Q'J3.6`OY&C.!G-#%'*,W0,ZDF$RST$+URJ>P
MT0WI9^#WD^N7W7'@ET.>O*4Q::3&\^;M^<[B2%VSCLI8K9BCVP3!R8A.2Z"(
MZ<,W?W_I?]8_:%MZ>IQ$X,?$Y><U7.2I'2&YDMD4?6[HR$$NN5*-Q2;W$1?C
MOFQ<H&\O"9+TX%3?.%X8#A,$D(K)T1:KE$?&17WQD*R;"LH[>?,E9Z-`=G'+
MX"#4'DN2BG5[8RI/"):]&68OEKR:_S9;R+Q[6>^P9'"N9^=;83RB=]B%E)JC
M5K.R,B0;,T;#J/L846EK.K@G@'IR#+Z@3[.A:3G)0J.&(7-4`4,*9?R#7*:9
M$I1)-%;I_UE@L,>GZ;_H_^/BC,/\IY$(<F&_6N-2'6YW\M^/4N\ID]G#\P![
M&</>QS2Y,.&C``XP6U\+$/DJ;?1:[03\P34;HGWWFF#[-M7]MF\<,.$H!I]#
MLJ6F%$"8G3>I1E\K-E6,&7NTTE9)J[+K%R+?U>)0'>]6:DRNHTQ(;C:T7%!F
M'D6411[HO0UL+6%M7NNMCDQT&0_7IZ^;=11!9$;+_*Q<+V];<#[\2VP!;!,K
M-A*9%"9_?26C@7^:O^&?NFTEU>DP,:A2DJ^NBH8&G)O)CG<.+2B#,.L8)G=3
MC'MINS]P];??SR_?S^<?9FI>+]_\RJ>W.Y`/CUC+C7,>&YTM$5IJ,7DD+Y?:
M-M0:8:RRRFJKS9ZP;=9U?[Q^G/_9_=`Z/)_I<+6HJ<@V2L\'#31%1&"$,R6L
M(=!:D_MM01##:?2>@-Z",05^8RFRNOL8[72AI$T+K%3SF4TCH7)$AE(I>JQ(
MPC@+&(-[:'5.-JV,OZ4L'`*+3;8=&DZ6JO>D3%,R_']L!*T)_=+#SP>"8P>7
M@4Z`F"M"D?6KD*QJXB!2L]8G->8H=']NV]0P=--8']YG6I11^LI%IL10J*)L
MS^)3HHRR3MFQET!KI+P-84\L.L7VQ^'&K[YX.[*]X'33-VU)F%-6B9T;I%@2
MU>1#-D4IMI.UW<BW)V-0E'N(7OLC,LV<-8B<ARK^Q#+I+NF2<@DI9UV1=0UA
M]$/'_=7;/7MM.AU/=QJJZZKH8JR)>6C3L269Q>DAUBH+[49!T@I/#5)WHW(T
M1]T\&"4:6\%IUSBU:#4G],%560ID2K%MN`M69CSY?8QB/X%/K_J!IO)IIL3+
MV>+L^XN/[F/'#`AC?4/;0BB&#Y<Q,4O:ZS@_X?S%X7`UVI<.X]83MUZI4S'Q
MX<)J$0"T8^X>.39S[H,J.AI4^SXX9!LY_^&'#=CE>MFH*(O%BDLDMX.1="A,
M/&"PG*L_:O0H*4^GYX.<+&$@J6:O9!9R,IP"-]2A:JG;;=4.%N`]+&9;*=MF
MDP^%(ZZOQ?-7UU[)\PU9ITDI>=P>+@`:##C?*=,T&CS(%\;$+!S!,!^IP(0D
M@L*4=.;H:UTI:@P-^P30V-\%<N3-BK2M.E;`)"DW<J(=*K2"38_XA=-H/PW-
MU(GY4"+M"TKM;8NE!AFT9BR![%S?,<[W8`%/H]Z#F'Z0YTE="CLRRUDH9V(<
M&AID_L=4?1G.GIX<JE\OS\\X3([-SMXY_SA&G1503,V!M3DVG5(SI%M4G!L.
MEZH&!2.^>4V"@P7<5OP6BS51!<<LOH$C%YF-U2;569X"CBQT,DZ'^PEX.VSL
MY>6R>RBZNEHN?KF^DH>>UY<_7EZ(`LO+;M+;39?K8:A7/EI%%6TSL8?T,2$?
MMUJ)$KGJS3`>[H'Z,5(_%!`/<@Y;:.AD5*UE+@JU46DR=A<TY8`T,A<;O`V[
M3.4+0G7_4(8D,Z"9O<OV]>!=#+*@*'FVU**-&MF=^_6@^&I^-5M<S,_J;"E/
MCJM=^RXA8@V)8Z=O((4^3`8L:AN50T=A,*WO6]G*C2,1XDO%\_5R/EM=+]_O
M8Y=-:316D\R*@,A)>5`)0HPUU*J9;@W`M.B>K-O<%A23='WHUFHTXNJ8;YL,
MEF1VJ9,EM,<$Q<\9B`>)'^3EXIA<ED7S3NGHI36+L[G4K,EM<%1-A`@C&=V7
MBNK^\<.8YHQJ,J44P"A(,:82D`T66ZDT2(U[2[2_:!0/C!\4/`874E5=/:1*
MT;)3JYY2"`S;<)^Z`6D.^7KP/"1^Z,`>4TZW@,FY67(RPS.!EFWOV0]XS8/$
MCS4%/KPO'+B0%"LFC23;=RK81G(%0ZU0BC*3JHV]!ONP;B(C0APNY-;-H\V7
MYAI&*T4P21O,QI:*-EC^&'5MR=0D0AZQ"Z!54L4$SXQ"@98"':T20K7("5JE
M8:K9MXZA``?+MRWJR]+TQJ[@_]D[UQ^W;66!?VZ!_@^$VQ0)X'7TMN1-`OB)
MTX.>)DWVMNA'K4RO=2-+/J*4S=Z__@[EE[SV^DG9M#Q`D=I>BR:'\QN^AC,M
M6-B8JFH[($28J5MM4S5;>GTU_OV>]7OF5K<4\2;GC=5RF>_QM`U^D"8OI+IZ
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M:BF:;50^_!HDMWW_&V')4T#?5P90Y,W`'?G!4^/.'\$(\0=]))^CD1O>9G]C
M_O_1AJJ,D]O*KP_)[;/'88"D-\-,$@U54U[=\OK=^&$?AOR&98Z_OU@(_WQ=
M)?Y%@V\T\3VWRMR0W3`:^X.UA=P-P1)/9$C\D`Q`BN1;9I^C`4G@CX\389)@
M)DTRB.+L+S"'HP2FQ<F0$0IU[1->H[?\5X15[PL=)]G$YE=W-+[]6;646UVI
M$MYIXG^,/,(4A;@,6A@$T2,CKT$BR3!*X;D^>]-8^<6WT(>[=.?BQQP!G;<H
M8RX3`35[43G';I\3>!/00=)00!?SRLG?YPL-HQ@LQ>WLF20:\X*_+PK.)H?$
MHT$P_4YF5/A[-G:]V?O]L7KT^\D07D*;[J,8YJ@W'G2B.V:T,7LQJ;@;^`]A
M@S<F5ZEX_HJ;05Z5\'U%LRLD!C7(WJCS+[]-^HN7\=HBLLI``<:KI1(61:\M
M;?&@>N!S]HE_[]3/8?ODJ">V#]LG<SWE;M]+H\9TT,L\O3PWF(Y4]U&21*/;
MI5%8@Q$U/\3FWT^^O_11G`W-_).MU<R-^Q%49`#3H,;0[\-8O_<4U`^','%)
MUC^WV\QE6=CSZNJ5S;*:3@"FDE#'WPF+`K]/?IZDG"]"EFODEYMM\'B#-,Y)
MPA8P#9R7\1^>2S*;$I/IRH?M(579)(E:60ZM7*S<=ER;G*QF0(HN7:607"17
M$G([U),67$VZ2HD&%\%$,%]0M>8X]H.%1`$'%7%`'*X5AVS=(QT`2"52B53*
M!@!0J4A7*:12?BHWB$X:Y++\/KL*:;_=9VC^[;WK?7V(HS3L\S/5*&[\['F4
M#@9GT+?G)[@%':S__=SGH4K^[8:I&S\ME%)]P0OAA.R^V#%3Y<Y.WU<T6T)Y
M_R)LUVN;JFZ29@%"R[2\6/</6U.U?2SD8?([@48)&#'@N?N8>`%UX_>5,`II
MY>U<"*?0KN,,H3`92S<JH^5#RR=2:EK5M#9/Y]'FH<U#FX<VKTPV3]'J:/-*
M8//0K*%90[,V+</2A&VAH%%#HX9&#8W:^8V::FUV,$2CAD8-C1H:M8LR:C::
M-#1I:-+0I)7'I)E5W<:9FA"SMK];26F]1WI+,32F\3,8\;,XQWMHVR(0P19?
MID,DN8?S4K%+):6J.98H!LM"$WKZ(1T+R0AU\4%$$!%$!!%!1!`11`010400
M$40$$4%$$!%$!#>S9-@:EN@,[$1[QI,PUJL1F!_WOR*\,VG;KL`*[05I$*WJ
M6Z)_"0RR]:($RX)V80+"$1,YWLCQ:]44=QOB6`$N-&Y?"<HQ^KP1)DGD&7D^
MD&=K<VP_Y!EY1IXOB&=Q%[019\09<3[O[>.SPWPU2V9D%!D];,@US@XICKA(
M<P$TEY%6QQ8WII9]S,3+!9M"4^Z3(U/(@*##@-"/4I[(\9@@QM=[QVI7:9;I
MKI6J5BW%.9D(K^+2U5FP73635QK$#8TB&L5CMU6JAE*0-P+:1/3%0ZN&5NTL
M/E:V=;JE!UHUM&IHU="J%1ZI\H3;*6C3T*:A34.;5GR@2K1I:-/0IJ%-*X]-
M*\@+`BT:6C2T:&C1SC)+JUK6YJ32:-8.=REYF[C0_+7?7_/ZW=L'-Z"-R85=
M]EO(HSW^Q:_K?AQ,?3-^G[EFW/%R[T`(K2#ROG[XZ<<?WDV>C4:C*/R2P(?-
MF'ZFT/'?:+\7Q;TT26/Z&V.I&WIT^7&0=<@%^ID.WE=Z'>[=\:?^SUVG0OP^
M?.!ZR4VO4W=,IZNK[5;'[-7;MMY36KVN[M2[FE(WFI4/SSHH+^P[?T09^8,^
MDL_1R'W9JN8>#_R0W@QI9L1537FU=P=O`>#(WMY4TTPU_1"&CZ1AF6`4BJCZ
MY"U_MN$GP($W*3;+D)VYYY#_@1K$CZ#C"0W))Z#0]\C'P0`*"Q]6VG:T%,D-
M^1B2R<^K]L1#B"1#"JHU`HJ?0+X1HWWBAB3-5VP\J5@TK1B_ERZ^<II1U4V[
MZM17YV_'-SP-_801-R$N&<>^1TD290V?MZR`!OVBULS56!#'MV5,XZP]9!#%
MY"&.&(,V11ZE?5900W2;P!.!'X4%-.<U[X=*CHF9_E?>U$C7A4^SQH+U8SY+
MLB8"_H0-W3B+D.!EQA3J`#:R"JH+ZCN+FL![>9Q"P2ZC!<A%J9FK=YR.%PBT
MR5W?O$R!0T*_T]CSH4D352ZFS[6:LAKP7XSR9FVKD3OH]S7=3OS0"]+^Q`SQ
MJ3[,(((H&8&E)M$X`27,%)]KS=Q(T9@M]34\R:=]_,MN4(!T]*IEZE7;*`+O
M3#ILM>O#_EMH]CR:=+ZYZ9B_%5\7M6IK5M715CU4BFIF;76`JJYV]0R`/O^3
M'[^@)7D)K14;UY*'AY@^N$E!%)U)@$TP#`%1%8$"+`5#W&[D[$)(DZ)'3K-F
M%#=T3DQH$B5KVI*L-Z[5J77E=I9_93Z43!_9K@C\6S.:JN21QD7HQB^&4BMP
MS@'3A`%P0&"02;V$RV).!W_3]YD7I=Q:\-D$UR"?,:C(Y/U\%DR_CVG(0,W&
M[A-?J9'[I_QDNK8J%ZD6)R=85UE%5OW+RXP/LF5TEG"!KZ,)GTK%TU7VQ`@P
M^!]H^2,CKWW0[V&4PJ_UV9O&!31<>)_ML-)?VJ-4H'7YYO+W^4+#*!ZYP=).
MG,J_,R\XVV\A'@V"Z7?>5Y1*]IZ-76_V?O\]BD>_GPSA);1INH?E02^[8T8;
MLQ>WS_>D%I7*7RR:[VOI:Z^+[7`U*:O+^XIMO-JZ8[:\=S=]4#4/?7"OY_:[
M676V+?^7=Q)M`6PMRCCKI>0"Q+I9E![02^.BA-G,C+.`RVD'Z:A$%V^/W0;?
M>63X>[;*B=*$)3"@K=M%E.$B\RE.8`3+5M.J^IH=$<P55OAU7@D''=%3V6SF
M.EEL%0+OT??DI<%05:NJ+0S#JP;J&D?(CU/&EE:#SY>+V69`MI1O3Y;R\\CW
M]5L&,Q>E3GX+^=S)_T;)I\!=W:&088R5E%^EJIGB7!DP\,65C92339\=\>V.
MQD'T1"F9#+"?9GN8(IDM#YJFAN,JCJN'Z<Y==@BQ"4MA)G^K]]J5+U0-HZK5
M3WBK`U>RLY>'>!$>X@F8=R0,^8D53$7;W#T&Y.WR^>TGD+7W-/EW'_]!4S>-
M5J^GU2W3,#73=+HMJ]GJMNI=M6,ZG7KA_H/G],I;R#(W4<@<;)9DNZ(91P-+
M<HFU2*X67OYG>6:8^Y2!P!CC!U[W?NA.EC(^GPYY'+8^]P_*3G59XH_<A!OB
M13(9=WXN['K_37V6G8*3/GQM<HZ\G'=F<I#Y4EWX3]Z,J,M`1[-?I=Q/*Z;C
M*,Y.4,?0V(B?2"1#POT*W?[_IBP[4F;/4MS,G7W@XRB-LQ_BEB*K/4O@?Y.#
MZ.R4;QS3(86*P+(KB!BK;:;T.6F[H[(`[!-4`"K=#/N35\WQ&+Z9/=F.6,(.
M):W>4VRKJUE6NZ4`9NT6$*=VVWJOWNNTZ\U>J4F;"C4[39^\)CFYDDRP!6/6
M#/B9[\-PR?OUG@8^_0:B38:@TMQA=)RK:;:L")XRSPGJ#4,8[!Z>R-#]-@,E
MY7_*M'KB<>..N!,!5]WI5.B>AG3@3YR0[BF!XOQLLA1'HXDSZO37`*\4C'Z<
MN'Y8FTG(XU+A)]E9X3&%*1:\G/H@]#G=@%(:`X][87&0@B_X^.(-:3\-Z,=!
MUXU#$,`G&F=KM+MH.K3Q-\,H@,:RO?W9FUW':CD]PW0TW6RWU:9I-YVVJC7;
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MS8[=:MO-ENGH/45IE=9=QF<\8EHZ&KGQ$_=RF85_<Z?BG`<,"_F)YFARHDFS
M$\T5?3FZ:OM<>#_ZQ]`/YZK]<#3C2$<<[5#_%OM"_'"PGEA/K"?6\RK=[J1;
MYF&HI/4.*KE(C3//BF*6>B>1)&IE.;1RL9+9<>Y^2H>NS5FSSU$I)!?)E83<
M#O6D!5>3KE*BP44P$<R78F+RR.P+B0(.FV,A(0Z(0XEQR-8]T@&`5"*52*5L
M``"5FWVLD4JDLL14\K`U:9"`MDE'`;\L_/'[`/I#^/8E`B$>B$NXC[Z7MV=Y
MPS0*E>G'16#Q*OFW&Z;<74;=+Q=#Z:Z"%7"Y/PLQ5;A`K^(ZV)DA%B9CZ085
MA/A%B/6J4]]\NH3XRJAHB"_BF^&KZ,4G&$!\Y9I"(Z&70ZAU@N4&\HE\2B*X
MB^-3K8N[%8I\(I_(I^"3,!P^$4_$4U8\ZQK&`D,^D4]9^<1H?9B>LA#%XMFZ
M:%^49ITQ=HG8U:11511A"\JRD",?))<UA)6%C@(\!A`11`010400$40$$4%$
M$!%$!!%!1!`11`010400$40$]WLOX:1$H@/.$QVA=+^/_5C<&<JV&Y$R!HZ7
M?;PZ6*9E05DJI;NF$1)I1IK1R0AI15J15J05:45:D5:D%6E%6I%6I!5I15J1
M5J3U:%I?:[HMC3`7&E><-(L\T'B#/"//R//U\8Q7X_)E+(4>W2=#;E$)KLL"
MMUAOBZUBNYK9<Q'Z<[VC;HD!%!LM%/E#_N05H)S\B0SWB?RALR[B55"L3H0+
MX4*X"@JTB7`A7`A7,5$RD2UD"]G*E6'8F[-X(UP(%\)UZ,"E576EH!.[$O.%
M-RQWOV'I)GX4[J%A\YIO34%Y0GENEN$)4B0333E!J&<<%U#]GI<Q/T'GA^;B
MA@I4053!756P0[VY!M91`Z]'`W.!S;?-)L^IG\UQ[`>HG%>FG-*HWVR"J!:?
M2@O5#]4/U0_53R+U^\N-?<JX_ADWN$A&)917<+E=P[>)"S/9M=]?\_K=VP<W
MH(TOWI#VTX!^'/SMQK$;)DTO\;_YR=,=+VSR#U#7"B+OZX>??OSAW?JG_G*#
M--N4:S*6CL;\%5M^&/HWY/Q^IH/WE5Z'.\O_J?]SUZD0OP\?N%YR8]F.YMA=
MU=8ZBJGJ1M.P6YJM*9UN1W6LNEKY\*PK\F*]\T=`[!_TD7R.1N[+W9)[//!#
M>C.D6<^KFO+J-K,O?@B]FC0L"W1AW[[=8E\6A=P-*1FX?DR^@>`HB08D@4\>
M)\)DQ&>$LL0?N0GMDY2!@A(W).YX'$>P+(!/"?S/XQ^/HCX-R*.?#+,2!E$`
MJLG_X(?C-&&-C7JT21:+6CL"6N[LJ>&[U>S%GEVR!`IT9+YG^?M\H6$4C]Q@
MR5BH_#OS@C.NB$>#8/J=]Q6EDKT',^'-WN^ODX]^/QDV'*=F*Z9BV9IF0?ML
M\]5LB0K6+7#'C#9F+VZ?[[$OJABOM:3&6F.VPZ%#5C4H0'^U=4Q9MN+3!]5#
MGU-._8/80&P@-A`;*/X'\0;E:@R-@]<$^K9%P9:+O4<[5YQS.=ID?(8HX-HI
MJJ0XE3R'1DJ\93+?L3/)=$W(A.V:G%Z2%[MY@EJYWM%@U]7FR6H&I&R^=GN.
M2HDF%\E$,K?X7TC'`("YV3D<P40P2PQFYGBRD"C@L/EZ.N*`.)08AVQ=(QT`
M2"52B53*!@!0N=E5Y!*H+.\])*$'V5^2V/\Z.8>GYS1X+TH^Y^>\:@XD%.@O
MPK8+M^GB)FD6(+3GERV%2DVK";QJ>495.O_]RS.;.&$REFX.@R8/39Y8DV<6
M[Y"+)D^N61U:-;1JI;9J:LT6%X87K1I:-<FM&AJN'9S.)+%-2LT2%XP.$UNA
M^4'S@^8'S0^:'S0_:'ZD-S]:31$7+;3LYN?B;Q@(59WN]S'U^!W>A,8C\OH)
MA,KVR:BX\YWX@J^W%,J743.$Q3@J"T;R$2/=8'T5;&@U!]E`-I"-M6QHPG;,
MD0UDHTQLJ#536.0T9`/9*!,;2LW`<0/90#;6L^$@&P*VM"3:9C_17M=?4>`F
M?N`G3^15$5@)E:@LO-6-FB,,N*T26NA/<5OQ1:K8/GIU*71>[CA73B"MFEW\
M83,"B4`BD+L!:=8,!!*!1"`E`=)R:L;I4G8AD`@D`KEYA-1J1O$.2@@D`HE`
M[C9"VC6]^+M<5P<DNA;FR_CLLZ\W@YA2$O-\((5LN5XRA&I-$[9LO#K4Y*/J
M<H>X2X9(J3F;P\PA1`@10K0-HKJP>"4($4)TI1")"_J#$"%$5PJ1(LPK&"%"
MB*X5(F''7U<'T=[IBG-MP12U>>4X98I:55$$)J55CDQ*JUOES!=9^H28V$!L
MH.0-O/@S)HD29*H.YFR=9SE;I&Q5LY2MQ@$S)M3(4B11V3T(ZSGU%S-G8NXC
M2783Y,!6&C(Q<R:"B6!*""9FSD0<$`?Y<_0AE4@E4BD5`)@Y4X)K))@Y$X-S
M7UYP[A,D@RM+)*,+LD72S2?0_*#Y62U#K3EH?M#\H/E!\X.9D=#\H/E!\X/F
M!\T/FA\T/VA^BM_[4='\%+HY7=H]:$S,MH.0]%I=6%RQLF`D'S'2#=97P896
M<X3=`D0VD(URL:$+BQJ$;"`;96)#K:DX;B`;R,9:-K2=K\5="QOH4X;)IXH2
M6MVL6<5[+ZSJ3W';C5+$.+D@.B]WG"LGD)A\"H%$("4"TA8X)44@$4@$\D@@
MZS4=DT\AD`BD/$!N"?J`0&*NFR/%AKENMFV<ZA@<O:BQ#X>X:X%(<1`BA`@A
M.D)AE)J-(Q%"A!`=!Y$N;$F%$"%$UPH1YO\4L/VP6YJ.V>MW;Q_<@#:^>$/:
M3P/Z<3"-H?27&Z1NXD=AD[%T-.:OV!TO^`Y:W@HB[^N'GW[\X5W*;AY<=]QH
M>EZ4A@G[Y#[Q+\';.*7]WWWWGOMX^)0UP_['!+#(?=3QF1=$+(UI.XUC&B;S
MHD'X(9?P9SIX7^EU-$4U_]3_N>M4B-^'#UPON3$LLZEJEF,V[8YIF$U';W=:
MAM%5ZDJWI]AJY<.S'LN+?TL.C74=OG/&D`.[/"MDNH>F*(93G_[Q<?*3]U'0
MG_S&5+2$7X@)&33##?LD$RV9BI'D9+Q1?S8U+Y_<Q#*!CB+:>[C#U<Y5MXJL
M^JPO:+XOHJPOO&E?!(N^X%K-?);P,//P'3*(`AADP`B1UWX(GT0I_%R?O6E<
M0,N+Z;078L1=>$J>D1L_^.&DDFZ:1+,/)H-3]DD!67OL(Y/VU$^>,$2[E,PF
M<C?P0DXBY)UD8_S1I3(6>246*5&4+"6*\.DZ:A]JW[,RSI2/1R+_B6,O.^P\
MIVO#;(E+@B2Q#_]Z$3MO?&LI(CSL++TR!?T0+!JSJM:%G=1)H148=DC.411M
M$-J@]:*QJHY51QM4Y)RIS%.C:,1W^+(-\6R3+Z:!RZ,1W=.0#OR]YDFR'N8(
M%IGC8"@B7`:7Y:13,!QJ53&$N=V4!0]<J.^H/9_B:$`9@[$(END#NN64[\(O
M/P@G3]6$Q3HJ_3SP@NB[W*&LI*39R!FNMP[4G=_XD0)ER<RS`F>0SPO1A6UF
ME(4A^7"YW"'ILMDPD8T3+JV44HT\^[GT"9O@+!WJZ^/OI!^EW!OMF%/]%_MO
M^FN9!]R*_X"4O2+N8&.;H(\Y^2A"K@6;RGI5U\0=S1XL7&DT$A?3<LY<T'JB
M]93/>MI56V#X/[2>.TYA][WA5,PEI:7[3ZV4^2%EK!V-[OTP.R=FGZ`?O*<=
M[C(IFFVWM+;15CIMTVIIS6:]V>JTG9Y=5QQ3Z19^E^F$-V88O_VRTN='E[N/
MD_+1/U8ECY3T*<]$!)+L\\L\,87/X)\P(M_<V,]NDOCS3:PPF5P`BNE_4S_F
M3T3DGF;W@3BKW).@MI&#73M/UR[OTL])].YO2MR`160,\YHH'L&J#OYS@R?F
ML_]O[T^7&T>21&'T]XS9O`,L[]09R0[%XKYD=;49M=5D?Y7+I+*Z;<Z_$!`4
MT0D"+`0@I?KIK[M'8.,B41)`@92/35>*)!"+A^_A"QY&>IB6JW.SA%(RTL9?
M/H-+V.8`79^&P(_*I:B0/V-@G--[>-,2UKMKPP^:[ZQO,)S\8<.')/%K$8?V
M3"CX(W1M::&RI1/"A!L"^GBQ3)[T990N)9G:AHD#W[M'#`JE'=SXL%4'Y[T)
M`N?.]3Q:G94L`=`LY4E-6@U&LP@?.=-\X<'.E>7"!+=)QF<&&<!F#'/!U<&D
MT1U"VYH#>&?*FH;!G-:(Z)NL-P>0@T7H5;FRF?D79,294#.0,/C/!8`)X"U1
M&-&#3TI];??ZIV>3R[/3X:#?/N^->Z/>Z')X=M$=#D=G_>I37W>2&ZH_XKOO
MW0A(RS:16``](DOZ(P?'\MF\I67)J-/N_$)T8Z=TXRL7-"X@2B"V&0`&J-%S
M82T.<)+K".A/16$\QV59=VZ$"[8"T$5=O+"?BR@.L>Y])8)P37?[EP/"$?<J
M$ZQ!:'G(5XP0PW.0V3DT]<GDODGS7H'=S4$X>K1U,2==#&!U"S)2LU1@+?(>
M`!1^1[YGM#4Z;4?.]3^+`-B+>IBYK%+H5J2W!;%^A:4"SX;E/C3B%C1\=M8^
M'5QT)I?#P7E_#&H>?+@<#P9GD]Y%KW?>.F@:SJ!(N%(QY>9F(UPUV$C2V$9+
M;`HCHA"$SP:_0+Y:,\0W(MXH(_UTW.$O(`&!G'T;4V60WMTH)L:/@IAR=D%N
M8G@.4(M+-!`N`BJ&:(,0AREL$3J/^(^W1./MD+*(W<%\[D;$H/!Y6``8XQ(V
MDS=XGB*3+KMGHT[K=#"\N&CWS\^'I_UN[[)WVKGH7XQZEZU^Y?B\Y%!H5Z4W
M;%.BX7=Y`R?_)0S`/,=%J8:5`[B67GF0OTQ3JMB#M(&&5_98VB9>S)E*]T+L
M=/4O.),//A@$UF](]<(Z=8/%3(1ST;`^^';3NI(VJAUHQ?P._]QDL>SPVM>-
MKYW#_+?P+"C^V6NE0:O@F.V-EBHX[/?ITW8J,UT^^]8DOHE!J^II-T?#6GC"
M!:XRG:)215+K-O!`@](JE^.JN0NFI`-'ZHD[$:(+(SU;X.$N"3WX>^IZ:$^"
M-D;?*2F_8Y$24/?P%RN&[87P+9"_R`]!UB2N()D=)`G))6!V<1@U+="A192,
M>H?V*A8:PJGPBC7=C\GOA0U%^+Q9V9U0!7^)%LVEJ@Z;J>JEY/$<7'VA_5PF
M4KX=D@)E35P'<62E_D0+$5&CH["FTB&E3F6\%$A)Q:#.(7YJPC'8_T?SJKE$
M`J0,%B@#5,[/H;P!_"8?(;S>V`E.?X65WENWS0UHW;#0_O+*5\R)"4@K`H4/
M^0D\?`<@!JA0A,6=BSXQP"0'&)$"XU("7'Y$$@[?L:[O+7$32HDZ5.I($R$>
M`I/*KDGE']J[[9,G^]:]"<(@5BADY!2_%#<"32)B["@^0"T!QDWV$;Z@BU\A
MWJ-<L4%HS!5@AKX;R"@O<>"3NYTDDQ]$Y/(,'9(:]^63RHHN7X&+)N]0)BD&
MT%E(X`8&-!H@R$>`:12%7F9RJ@B^F&N'BP7'<2T]5P*(2&::$5#&V^A=AC>U
MU,8!D^GOT6R-003;LD$GE8,RV,3P#CZ=/H,&:^BBT\L07WIN2-'T&/Y((^"&
M@H1J\=(#+%0\:M3V(IVVXOKHA\^44'H08'9+J@9@>6C1Y:TR*R=R1T,6H-:`
MMVTO=LRCR8/DQR?W'&Q9W"2:"M['`';JM^_1%>_%F#N#2[^*K_^901[GI#7H
M9<$^]<B$@`C,:XE3AM*=7\>ATMO;`"1D]0HHD[P+@#!@_">#HM/0(_,)<W=T
M*JE1L'`PHB$EE\'\#W,Z5&V%Q`P\C_X+(#6]TTB0GI9R28-=-*8+9!,%H4H3
M5PVN>9DI`'NYF[GV+,4#&HB>%,XM[2Z40L'IX>56;@-X?%0L))5ON5'U&23K
M!&36&,`\>Y<\>X,6<'5Q!N(>W:]EVW5\)MM?2P)?T>88L6XDGYRICK1U\<.>
M"?]&:B<2Y?U91W!VQY:;N,_I_%"6&CH#QAK)L,A;<.18\Y7D,=!T\2+##!*$
M)_IY]&(N<CF&"GE#G`^%7<37@$7&*XH:F)7R)]+:-*E'8+ME+E3$-I!:4V1K
MH"[<S(QXBX'9>32VEE?!`K@W+3I]U<TC:7F<@Y%R2T8Q^70^J<+]PVQBR_L,
M,$T_@_Q&K;C33;1BL!Q_!-;DU#I*KB4ZK5_HR_1S^Y=CHJP-WHLC)*[<RV?%
M6PYZO:!O"%#G(S!3R0C3P1$V*2N9:49$.[$C<0O<Z7>PIH&8@Q!YV>7OR;2Y
M*<V3A2EA(C(8@)LLP)Q`5K``I85"[S-UA7A(A*P)=Z&!D1@>R?S`.&`8'&!R
M#28WF+3Z%G/8^\4Z`C4K@MUZQY9"=N;?Q%C[#+6;*%%K-T^?V?NP`#WY$PU_
MO._X&S!IB8JX49D5F<5+,&D/?\$5)JP?-4@?]G,=REN7=#D<Z3R,89.+A8>7
M620A\D`&^EV&<+K4RR#0+C@]A#-W?5SEZBB7Q4$:J6=07]B2[KD`N7%KKKV$
M=2-]P&G;`GT\6;HY!VWN"=QV[*7V_&/(U4@/EL)<KO&`PKD;&8664)4&,E?(
M^NX]70:N*8YF@(T8,+-Y<>E)^BZ.?!71]>#?8E\BY8UP'.`I8&^%R^JM&]KQ
M'(0<*,LJB;7!\T=W1D)(%`N`;QF/;"KI%J'\)Q@UMES6H9>P&F!W+F$^3ZV#
M&\E0?^HB6P)#49MV.6>)EM*$3Y&.7<L1K\&+2^/G^A8*IZ!V)&.=2QPM<<7\
M+0;A3%9D+L0-R")QEWGBKFG"H!:N02R*&DKM!01PI'_.$6M&=DF``"TN0T.Z
MAOT<DG)T&@3?42'*_`=P5N,:F1FUJ*V]ZVO"W+TGG\1K;B4?OV1""5426@C4
MJX,&'7DKO6"1,F!B64J+?O2,B-">F7"<W(,A$6#.XQ#-W-!)^0V9-<$4*#EA
M#A8L'>T-X*=42RNX%UYT#R_<ZT&N!?I6`DWN(%"`/67!D[3FU(3(+P3X[@VR
MW8_IZ.F(<V'")35S:A#GD3\$QC\VK'B!K"T178EO.0R<V-:B.Q-PZ(6&86YB
M#[4:=$E+W[YOXAUJ(@0R_TLC'SJ"O"D?_SL7W^6FK>L%H7##XKKHRDH8/>AQ
M=7*=O%%*0ITDC_4&O>88\Z/C@6#IK@/ZI'>O!;"17;'ON=^E=V\!VJ*XI0O1
M!%VU_VP.^I`+:)D@H$I=N%K379Z;PLY#*;"!2S*-$G-2C=S`:1@)#TAY0]%'
MH/_?D)9I,ES1`O><PO*-%J!U,R(\8Y.3TQ10/?'C-M8M2)/ZC7LK"^A/H<*N
MLD.97`/$OFNBI``@.OX:5Y@GZ2(M-HR#,C_L'%'"<@*"G6TJ&#>RX.?D;LGX
M+E4RQAWM6F`'CN(RP8BX#5P'Z3/Q+Z,K@X)UHI10]Y$&"R(`+05BSOI4=,07
M`AH43'(`74ZN3JW)U9GU+5B`EMP;M(HF!?P"WQ4-@MSO.[G&_"T6&$(0A`6%
MT*3YD#V"9DVVO:^:_VH\180Q`TB\4_B0WBE\\+6_//<S8B)\+:]!$?6--*)4
MH2KCC@&H#41(C!_,>?7U%0^ZUX#<;Y(E(J8C&LWUE0,1F>V)6"662'+T=,8.
M;.G(/<Z">I=>I0W>BO`>X:%LH']]F0<KM7+W#HGCL.`;-'*?"-(\!_#'7'H5
M3Z?$RFBME$^?L+5L[5*K#O?&B>A+$P""FD5REQ/=+Z31"$#5.-'/)[=>L)(C
M]_E["Z;PH#1;RBY.$B,L4VZR&4.7K+@T)8+NL6Q-7BG`B>7ILU!R^:B49I@A
MWH!3<H?AP>MI$TW5J[-L@T"(,&Y`1E51Z4##$V]-4VCKBQJQ8GOCO->>L3C-
MW@.I7T9)H2_):)A,4.C!C-"9QA$LLTGD%R(=H>Q;MQ9A2BS@=_F[4,2G2*V]
MXURZMEH#OR='A#\I`G8Y>!9,]1D(3S@RX!K!7.H0VZ>G<@Q/3\?=L_9EJW5Q
MT;\<]4:=\6`\G+1.^^W6V?CR_*##P`MPM'X'%E$A+\5(\.*$R),*P>!X'8$)
M5_A#0_,;/TAJ?Q1>=>G0`5OE/+OTU/H6WIP`?OJEI?35L/G:6FK:BB26Z,A'
M\T8KEE]=]?V,(N/QKRU(9](>CT;#[F0XONP`Z4S&@]&DW^WT+T:MSN3\?'+@
MI),#'2&OAIV%P*N8BBX+:0])FA,I)8L@TEY'$&`J":TH*M?YF`A[91<F-R(T
M*)!D#<%T"QH4'TD2P%83C_):SAPC45%BZ^>NA4=.610R2MZ26S)-,-).B[L`
MGO*_IQ8"7L82FJ!+U?5S.9S&K^F9"!J)GNHY9B59!Y+>O"GC91GDVOC<F,$U
M!XT`[P)BWRF>3F%0_3J9>R9$)U4\M'F6>X#2;N]UDETN"#,DW4`GI6&F:LX.
MR;U\@][LG&Z-FJ?.UH1%ZBMGE:IN16Q*5!?4A$(7U(1$?=%Z;:`UER0[[5EH
M6B",32\34MX%FU*/=,#TUNCZ;/E4?W&T4;(L2R`36P?//5U[ZTPFY[U6=]09
MM'K]0:\[.6V?75Y<CD=G[5:_V]]QW88=BZ`OFBU[V@XK0+):`92Q0$U(CX1'
MFEA!:?+3#<N')9L[<?+.(2N;!21A[K"B`P@OY3JN""FV9>)Y>=\>_)%YTLUX
M6>B+1.+RA>&'=AXN3[=1-J-G`8_/@1\^+V^OW^T-^H.ST7AX.NB/!_W)Y?ED
MW.E=3CJ=\XO>I'HMJ@J,W2I'+\!J1#*<6PB\0]74ZU%\X[-O?13WUH@4EB[&
MERX%E7B!\$VPN*USXY?B23[_`"O+,:HGV(J_GS66\FSQ(B9J%'JS>)@X$"8!
MQ&ELZW40AL&=N?J>NB'Z=#!X=R:KT=W^L]U"'[]7#6.D$)YWOP,`WQUKU0+_
M3OS4Y%;/6&#Y\[=7F[R\?$^FP@B<1E)"YX1\8NDMF8F3G+H_R*-%UV6A*4-2
M_GI&S5[_IRK4;-T`7+M`RQ^_6T4EB.QHQ!PCVO^5ALJG9IJY[S*UC]`1GZMY
M`2+Q4W";QF<,],WIDI<W,EA,<?<+X6I2U>0,W*("+*[@>+7N/A6VSK682NUE
MKF+Y_685^&DV0#5+$G:".TBR-I,,`L-ERU\`VND5L,R3>Y"@UAW=6>JLD;0>
M4[S`CQ7@UZC3:(\&%9R1FHE0IMY+4$OGF+$;H?*'IB":@:"MNEFMJ4HD7*?9
M6RVY70*#U#);8FDM60WI="I@DB<.*#O"Y"`95T@*_95C@E_0@1RLU-(B.GNJ
MR;#!$BA:"^GOGZ?YQG9?M=YTAI<Z5XA7IQB,\L4(W:=8%6`+CP>7W?%9=WC>
M/S\]/>T/6OU);]CJ7/3AC>JK@;R657&%1WI"<+/RH'WS]L6.G1.?%\8A%EA?
M$N9^E;+*,TU_=%@5.\OSOCZM[JDDHB6YS"W<Y`[;HX3MF6`Q_?Q<"B385`B;
MPG^)\F7G^U,F@3T4@^UY6D:<Z,BR5)#?8?DAX$[Z7EK.%UYP3V$0</(GR<?L
M^CN?<IG^JAE8L#"!003/]4LI1/018S,!P%G%0TSPF2=N$T%WR&3KI1KA`_??
M`#4=7I>OABBRZ=,*BP13Y4;I%;VYM3O8J[IZ+/T2DV'SR*+SC1,5+-$HC;\,
M2^MI]*$DVB26(B1%4UM+>21="K-,D4"M1\4-V!7F0X,T?IG(IWZK?])O-<%N
MR1&&WD=^&WH7Q@?O!'1=@%</ECN?2P<3-<"")4M5X[\(92Z7?3VZWIJ\:8.D
MUD3;O9AB#TO$F+^<RS.4E&.</IYI%F88#:=\?5$EUQZ(]JT(SXZU(R56223<
MJ2=`OEW9LX#\OO3N">HVE`82.-)K:$(\,0PK__)J>=.U=TP%'=;D&^!YF^)M
MN2/-T;L3A\DT9O>P#.'\,Z:+*9&%I`";<GV38D$+,@I:NJX',30*BJB'LZ@L
MA]SD:18"8DP`)E4[3/:M?UF/GZ:`JW;8Y$"6P53CJ#:L*=IH,V4ADDUC]&OK
M*SKF<Y4N_1L5MD`I3\A(B?(JGF/1RW\908YG#ELR7(:.SHCF3=S*1*`Z^-DI
MWG?D;CF,$K`4WI+$ID2ST/@??"QR;+PXNK#*GM]6TZY@Z%XCJ:,!NP>$/R+0
M!3&\[JCC]WN`/=4@O@XUMLGCOHTM52C)UEJJR(:?\]/X6,/#*W1W:.,SZ<":
M!FSI>>:97]^UWM%GM1!V\OGI5B"0U(WKZT6*.`J2+W2[$_KFSG6B&3P-@#`-
M$NBZ8*'D^^2/E6#L;-WY+EE9TX3!VB9G6S3:HL7\^J[7_NG1?@S%EA'FQ6>_
MU]GUA+Q!WF`=-[@G+59KUWDI7>[PL3;&A?XUJXUH*NXIN2+A1B4(YU&FV:$"
M]5'K31>D-Q4*E3T!H(QPC'"/(]PGU--?CF_,]5Z(A-U70,)56&[?X>LU<7:M
M@?>JC+"TSFB,H`>"H+UZ(2CCX!O$06:2C*"U1M"MF625?>4/JJW\UPW5<UZ3
M$]2_G^PK=#A^8PV,NY4#KC;(Q*W=ZRFDF:\Q7RL;;N/5M!3F:\S7F*\Q7]MK
MOM;IL\+&C(T9&S.V`V-LO>Z(&5L9C&U/+GQW1I"_895_DY0L<KT-;N5S_,B=
M>H<D5$VD)9I5CP#J4,BQ?I17.W6"B4N[+,:KJ<A,7$Q<3%QE%&!HM$9M)B\F
M+R:O*LBKV^CU6'KMPE*KD5]J9R;<MR"BBHX;4B6IZKYNT1%CVF76JZ0:C.P"
M1CI!C'EM+Z'>^KLI7L'I]1B@WYA7K#\L+53P^:"M#3[R?4`]E2#FG<P[Z\<[
MT>2KR%W)W).Y)W-/YIX'S3V[W=)2I9A[,O=D[LG<\\UPSVYC-"POGH6Y9^EN
MU`/VENHJK)O\I-A/5+M*L1[KGGA*,S1>,V(M#V%WG/6UX%=UH/,N/9^UP2^^
MS7UKRF1M4(]9V\Y86WNU5P:S-F9MS-J8M>TY:QN.=FCUU@:_F+4Q:V/6=N"L
MK=]GK:TRQ]W/5"9^W?,[6U@.:#5O=_[02G?7TS??V"I6IKG%X^UATHXN69L,
MW41-.B=)RSRA5#S/&G@Y$IO88CG<U28RV-X*FW<76Z"8;BW/[_F0;7A<`M#&
M3Q1OST'%W#L%B5;;!@Y5=&?HO%IWANZ^U-KGA>[G0O?DEJMVQD&ZW'Z]$W2X
M>P$CW`$A''<OJ`<2OD9:XBHL]Z;N<<T*<S,.EH>#=4(S[D%PL&C&K*YJN#&"
MO@T$K:@'`6R\3@'UNVM`X*KOUA3-0!</#AN3AR)Z2A&TW>4H[&'$=]K"O/,4
MWO`RD&88]THPK19C?ZHE;AZ8^L1$_5"D7K-5?1UYIF:FYOVCYGH2;+O9+Z\,
M5:D$RS3)-/DV:;*^0G2_:?+I9N\!6[=_#SP1N9X;W;^F6ZN>!%B!:?H&R8U=
M\4Q/)LEAW&R7IF4R)3$EO5U*ZC4[3$E,24Q))<BD7FGY*6^0DO@.<1MP7OQ8
M2#N2CN6YMU)91_=2A.J8?2%;`[#5;%7OGSR4_#!V.K+3\;F$-FBVJW<Z,J$Q
MH3&AM<9,:'7$%R:T`R.T\D)V#Y[0^&YLG=4&D[M`RXYU[TK/82<*7Y2Q4[)^
MLHSIB>F)Z8GIB>F)Z8GIB>FI[O2T/V7<"L71^HL*BZ/M\=*QKMM*1;9BT;6E
M,FN6$X>`T52=S<>Z'_.`ZGY(JONQLN47KS"M))+QMFZK8:W-:7[Q9-:=4!7L
MX3_;S34)KB]?[4*&EIJ)4#8M.,@0CQ+^XP?6V@)Y^9.+J$30(1U=<P^H;<\9
MA2D`F0K2X2^`.XF["7X$=#*8AT4@I76;AFGGBCQ:KC+M:N(%?(JR<?]+6<$=
M_#Y?>"[\G'O;]?&9:]?7K6WNW&A&+ZYY%*M$XOC?981_T]"A+FI(L[A2$;%D
M"_?<:;$(Y30(+0DC!_=`(D0[2A/6TK(533_%!<QE-`L<V':`/C>'AHCA6$)K
M<G668?^P/3II`P7<S5Q[9AEVJPP,_"@4=A0+S\("F+CX:`/,$[J&1\JGHTCZ
M%D5Z5,%=DX-+),VM5!&Q)+/C\N><!G%8V7[PF(6?[J:2#2CW1U7KWX80@$F=
M),2PG@PV8:[&4CU'T1>]Q`W^)<.@85U+6\1*YI'>FH$T]B5`UUH(%UB,4+-T
M*$6U91>A5,#\//-L0.4.?!H9:\F")`ST"D)7?3]9+8B`Q6PUN4H!)$G43DJ`
M\%20WRE,="N`Q0"RJED01B>TU<)8AK'D%X_H/1<(7$03WP<8P1'0A%/I1C%`
MDU91">:T^ZM:?3DXOZQ8`*BQ+&^*)XT*=C/:X68`I5SX92Y\(.LYX!/A&N+I
M"DT`/H9`/D&X=/IWKN=9\$L0PMF##8AS`($@L?F`Y:ZF$4,V&3H`X@%.>`$0
M&CP`2)/'(*<X*OT!Q$%"#R0N(O$CPVL\I3EFH$6L3,)*5*5+GU0DLW>J:#<0
MM=#6J,94ZC5&[7ZCM29R\N7D#L"/?:2:&Y_8<*%AHAT@'Y>>,$P@B",5`=$A
MRT]X!%!+A"(KE9GPW+6T<D.BZ*!Q`2_]Z&$MCMHQPNB&:N$K%'5BU2"')UU0
M+RO!G4YS3>?GEX.:5!9F)\Q.'F<GJ!K=W(3RIC)-J#-H]%NMBI@*.6"4,38S
M$YA49=1.PUNC8;J@]0H?[&)M&6[B"YU6:VA]\+'BFGLKK2^>\!N@:-I>3*RH
M`CVQW6B/1M5"1\77_P2.N<Q7"Q!;5L0R,"T\4I^K\%&!.=[IMZO=O$#+@7P0
MB`;3F#0Q[5C02J-PYJ[O*C"C(E1(I]FFTVX8VDL049>%NYE$<!B`@9IZC]93
M,$=;3H:VJW"NIO5W8UQKZ:'6^7+11D*JFX&D`;4V@@%L*:OQ!E9IB6LP)KLC
M+1F$*FCF#<`B3RI%]IL;Q`HL10,DZ3308$1Y;]3@_7*F4(-G1`IMM.(Y-E>W
M4#^IM<<"]UNADXWNE:+B^5R$\%SBET.KR[TUOL@<DW]^?YH]/IM-D^3>*=PP
MOZD&-NT7-K#I#^K=Q>05W^OLRT+KO4'NR'`05:!K4^CY6Q`);UMALKOV)3%U
M*@FFM5O9E38@:K>NHP\^:-R@3H-15EY*.#..;+E=9ASY,?YA7**UHX2)=M'6
M;ET7QLBMW<*^8&@(<PSF&%439N)2KAT%?/"CT/65:]=N97_'F,_:K>IYR@;7
M^-G&X?,YYXP7D?4WX<<BO,\847O#M4\=,K?WL,7`J-$?5U\2J#;M`KBZ0CUU
MAM)UJOJCXO8!*#M#P,-B;=UFIWHQ41MT8LY63\ZVO>/U=3215R715T/,-T&V
M+ZU",SHHP^(W'6'RFDI)3>5D8S`JK5CAH=`.^_G*DVPO)I57)8]V<]AEZF#J
M8.IX#4PZ%(JIS/E[6$I:<DE8FIKV!BIS'G6KKX![.'5EZMDNX*T*O^K(\U5)
MLM4<<E5J)K1#NC>I)3.OQ=5(/;6";FGMF&J!$O72S0]9!3_#C%#/*U$%KR#,
MJYXT=]1NM'KEW3EN"3?6R=GO].;\3IUF;[5(Q!OW,3%U[!X^M>2GI:G%>RN)
M.VUF#CMR0!^4\KL4??R4NC.E:'E=T/*<(,:,\43->P,>;%WOY?4A>BBTSAZU
M&FD(M<`V]JB587*,2@L$J052,`MB%L0L:)]8T&`'N5J'PH&X!V?>KC&%Z'+E
M^.IBWQR.&3-H##KE=7U_#&Z'0J?LM62O)7LM]9U]L\N)&,P>F#TP>UBK7[1+
M\Y$>"G?@YH\'M70J/9Y6WG>3LD2Z]:.N%YZ_H/&=@D&35-L&PV9EKR]>VHZ[
M/F*M?J!:.];=/W3?IZ2_E1<HW+_N:?=`0X]",7NAK%`N@C#2`R&H/TVNSB?_
M8YV)A1L)S_HH0FI25T7=\=V"KY*>#?_9;O97&?#+%UOLF;D9_RWY9RP\779_
M`1A`S1@<=SH%7,$F#M<RNI.RB"+4.'6NSS7MG[H=N@!Q1;.T@+\L8AMU0O#N
MW:P3S<.=59*___)SK$YNA%B\/W<5+C(.Y>?I6:[KS5?=[^8L4)&B8J.GB/I?
MQ#UVO5+?@!6=>K"^O_['O__;7_)CP<2N'TOGLVYB`ROZ$GBN?9^^06WAX,-7
M.?WUW>4Y8M[_=/_WV_D[RW7@"V%')]U6?W#9&UV<]\_'I^UAOW76.3^_.!\,
M1IW>>?OL\MU?EUAE_L`?*=>]3K*NY[0Y4;L3SJL_XKOOD0VXMAXV#U0K@ZIU
M4@%I393E2&6'[C7,Y?K6IP#0O]UI`!_$3I:$<J'TY"WV%8#'(AA)4.\*S=((
M#^.0,!C1%9C9=:RP285"OC?#%G_XM!+H]_)I#B>_OR#;G^N;3F6&1'#LV!>Q
MXT:T.)Q[;DU=7_@T$8BCB%JRT52&/G0W6YPIZTB<MKW0W6T?X(CT(OS1:UB+
M.,0>+=2GY')R=6I]"Q;`$#JM_DD'GOZBNPWJ?E$P]V6ZK*ML62?6AK-LT$2Y
M8;L#&A.A$=TWJ--+I!^Z^#-V%SC<<^C\4=I<IF9@;\+[+0SBA?J0])E9/U#&
M1IY"Z.-)?](9]B87@_99Z[S=/QM?C,XO.I-VO]\Y&XS[E1-Z%71LW/BM5F\\
M-#_JOEV@]'O.@T3=L"9*24"5_TXHY0HH90\4QFITW4T<>%#E5H`'+D2XW*#M
MOY1%77CD#9!G0"V+4.Q'V/?1CA5UN00>`,S/1@79IR\<>2N]@,C56K@+B;ML
M$(-<:B!Y'8B0NKBE/2-UXQU'VM0U&)]!GNI&IC</L2-@;+H7$#6F]#P+6P1A
M"[X[U!,`NMA_]"$E8XE%-RUK8EV'KIR:WB74J(3:GR["P(GM")GR)O[NJJS+
M\35L^^Z%/=Y>Y?`/"8^O$6%7:^J7`B,5+QZXP'N`S2ZBO']MV-/`A.'60OGE
M2OW1%,6R?^\=6U?Q-7;IQ;ZGW]!.C8#=NMB4,0JEB(@639\>ZLGF"P<5_4AZ
M][J3<8#).$`?4GP'M2*(;V9@&8+"3SV(?>OH])O]Y3AIX>WF6_P"?0HP#X!^
MYD$HJVHIU6]5T0@7VZ8#:TEW&KF2NI,9]"((+I#P$3;WQ&XNSR=:62'HJ@SL
M1UGCMBB`K^2Q;I44$<3QZQQ?A(D+L"8@P_\G2]`]P_6ZJF@KO,;)]W)H4LLO
M@NF-5DM!(\#EW\T"ZKTK/-BR<X]]0Z5["V#3@$Q^C@)/AEH+!3FR<`.7C,-0
M+.X3$(*=">J$<A5VNR9_!5)C'E.U>9N<'[PV1^<&XKT#SP(Y:],63L*[D6CU
M+JCIL%;7;5@?ND"NW<`TKW,]T]%J[MIAH'N=)D2'YU7``'/<2;=4,#:`9YAV
M<ZY2`<#16D82'$1)(,&TLS=)&31$4%2MQ1/$#?AG#@H6M=_.8RO0.YS2/+91
MN;5<D&2.BV8^&C:PMVSQ1]\^?+T\3F4?X5ORP?:$TFU9%;*Y!/7Q#>NKJ[Y;
M%VCF:[#BHC^ZD7NC/UYI/>+>.OIZ\?'J&"T<W8<NN`G%_*6=VEALOFPK_R]>
M>-+_UUL7FT!M\(@$J><?6Y^1=*X"C^(>+EUOWMC`]HG>G=B+,BZ=<'9LLXB-
M2[5]C#W&0:XB9<P#!\T?%+/`^*/@1OK`<^R9G`>&M>'!QS9,!-:_DH+>N@U`
M&4:7P-'9AT]_![$;"L?=[H6O^@5B)8&*3HS/`?M<KGO\RV=XO&D9O*"->RK(
M=H\BB3A(B*PRV3;I%-+13&/]%G'A3>O3FCF)U=\%B0DRQ_[3B5,0.-^))&5"
M-YL&==VW]2'0;L`$O\'.[^E*:)_)AU2N%`",A@/"C_A3MM4X`MZ.[0L_!GX`
MQU^P'V#W"Y@[0BOARTR$<\2+NE.-52W91-*>^6#]W]Q3[^(`R489LID">+3<
M2P2=2NX1,C%'#4E)/>RV$IEGNJI/47,$B0<B3?<&QS>OXQ!8(N*)NA-)]\F%
MZWD@6N/0+;9X!=0#M<`XM[7YNL"#$[:,":BP@IL04!D5!UB,00-0-#)>T"#3
MSK]1I-,F4A!D/[QF&\<=C(2*,H`I@)W!0/V3__[6)=1;8!=;T%_$38!=;35R
MW@7A=X7X>XU>HV1KN$+-*]*!`*A`HE%,8(VO\?[)EAJFV.G61DI:1\,L4E]W
M*]\R%\367F3CMGA]+S*.G\BPIWB3K<2)W-C:BYPYH+=Q)Y^</,6;G!_[0;>R
ME3^MF4`P*`"\=#8>B0]'B@]%%L8Q+[3U#.^[H79\K=\SN;AA>#RXF,9/[ALZ
MC;2YM<8$8;Q8(@SI_,PM'#6DIE_H=JUPK4;K*;#.&=V[VAC-Z0`?^<]1LPWF
M@><AA'.KM8$CHFE&9[]ZF,Q*ZL-*J+60)N(`Q:T`X:5=!Z1T@9TW<T.'G+E@
M'</YDLQ2:!KGO:+Z:?Q">TQ=:L(.IX\>W!R^%YB*N0NQ7-RS.R6T7`1H<N.C
MP@9R"L$T;%I?<MA/+`3P.KV=2E?<2/@4Z<B%U:F8S,-I[)$?:@XR.<+.\875
M)K8OODA<\<'ED^@FX)P0<!J%"4'!#<!>OTD\5PL0K2)9!AC',MW*,GA=ZCTO
MYD$,>P!&`,]5</L_;K4:K=9J_D4IKBY;J!EZ^U#-UN`R*C/VA.__A(^`8N]I
M)T=,L">[)I9&SZ;K<;PJD&*NB,'=H6>>F(\[!WU-:135TDZHP-<A,S'8(=.3
M!2A`P$=1KP>%2]6)V[Q>D-;.&`I).[3M"IS%3H(B`K!T0`0)_\8H"*$.D4CH
M88E];+HGT6Y+D,#HIYJ3>"&&D'LV\X(V+>N/S!V6XQV@Z>;7`@RD<%T%`^,U
M8C(-\@2M;,]!O,$7?JSG-6QG"HN%5?T9`S%3O]OL^OM)_.>EO`?5>,UO0AD9
M;T&!XZ#^)6$-P;V42GL7X=UK5_L0,7C*L!^*T4G>0[-*;ZL"?M2KCA^%%:RW
M6]$EP0.<$[E?O)B&.$W"(0WBD2M6FWH-XV`U#\#1T<UC<MH6608P*AK%+OZE
MX^=F**]",`I"*U.&]4MZG)QH3**Q''3WHF49V[,E3$;"!=4>1KP.,G>OIAT,
MC%+3S#`E]XFF2E*;51XW$96)F1@H@!F+#6'18C5;5!F2!HDU47"Q`#6A=P5%
M11)3AH2JUX)21[]#=)`I#OG=.`&LQ`\BO)I&KYSKKP=2J@(EFLO6./*06'C^
M!?">J<([DU33(''RT$4*.E65ME7)M@$3T7-3H[%@,VFVJ"U:'6*"6`1/T_V-
M*U.==#/;UJ\5K.\&&7^&EJ\!71&]U8QDSQ%]G33G?%^&)F.ZB>9AWGH`Y+E1
M"]D7^,[R&/EI_2"<"Z^0G]#&9]*!-?"Q.J-YYM=WK7?T62V$G7Q^>LB2%LYZ
MD2*.@N0+G1]#W]RY3C1[/QCEFDO9@!1BH>3[Y(\5Y2];>#X!-\TV&*TM)[=%
M"B\MYM=WO3%`Y]%,AF)6A'EU]-P7A^/GOME[[HO]P]WDTW*T.>-KA82XQ79A
MC%7'V1.`RDC'2/<<I#L'15OCG.Y-O75=TDW<+R\@:U-$YV$(5UV2>J,VJ5VB
MVM9+PF<WW,D\K`J6*Y5:!U4]9&+;&N[:IJ0\RU?DJ[6$$:<GMQN=+B<HLU[!
MY0N8/ZSG#_UN:?KXH?"'9^D:6^I]AZ6$?/#1U1R$KE3/,5K>:">R=J-;7M60
M@Z\9R%5+2W`/O%%*&_3+JYEXZ'3&%O;2(%]"N1"NDT;@Z!PMNN>UXS"D?%UR
M>%1!D/M-=^U&:\"M@-CLY$99&\ACV"NM%>2AD`=;75LW9$\"]'5"0ASZKIK!
MNA6%8+!ZN'WWB%YI+:D.7CUD,XS-L&?3V9!;)+`9]K+:-18MLSH1M]\4UNXV
MAGS1QQ876UP;Z*/7Z'=+ZQ1V*/3!)M<3*\$8(<2JW]:`&S7:+3:RV,BJD21C
M2F-*8S-K>9#?@L"Y<[W5&J&L.PZY`10;5FQ8,7&P555R^.!*K:5I&,QU)3EW
M:HK(6:;NU'*^<26JX2-94@>J.AZ-&JUA>;KC2X&88>V^!I8?L\%7(PG[1JDZ
MK1_2*<__\%Q(OFG9OGM:W1FC^T9UEHKAD+L6TR7U+S>#4H6/%<2N#U6WAXU1
MB7Z>QR"Y/53VF*KK1\"'(FS?%FUVAHU6N[1;1J;-JJWIUZ!D4U>J\U"QJMU3
M]:/E0UZWJD6M@5@;P#$FOF5,?''EFMT`\%4+U.1K'-:F2LV;=/VFY6L6XOZU
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M8=-!+]`]TS>U1^<F;:O'7EZ3MO:BO"9M[<$+N[1U6Z_0I>W9;^Y3E[;A6]CD
MFSC)76UR3U(*:F?^I,L=OD+KL]HT.OM&;;`_!M3[]\+'>*9"P[VR-'%&.$8X
M&N,3Z%TEX!MS/6[X6"9:<E]11K/=H%EI%ZB,9HQFS,T8S?:#FW&8Q)8.X$\R
MLD)Y*_VXGDD-M;D9V:]HXSV\BNLTVH-!Y;"K#3YQG$(]I2^S-F9MY6=Z#3K5
M]Q2I#3XQ:V/65A-49-96>1WOSKCZ[M"UP2=F;<S::H**S-HJSS]J=TISG]<?
MGVJ7M73`7K>S0%'(X],];V\D]^]HV"ZM4OLJ3E27KK\GA9I98W@SA-0IKW<W
M$Q(3TMLEI':C/RRM6BJ3$I/2VR6E<:?T>)$W1$@<V[!M?:)Y`*#XE^[+@PEF
M`!GA^I:P_XS=D%+2(N'?N)AMI9L!5$&K!]JOXZC3JM[O^P:I>X\(>7_EYZ'2
MY+#Z6V8F229))LDGD.2X^@J;3)-,DTR33U!==U!W^PW2)-_R%0?Y*I44H3VC
MNKB.O)5>L,!B)^P16G6N#DK37-\@X=6/QO97YNTY(77:I8DV)B0FI+=+2-TN
M$Q(3$A/2BPEIP!*)+_NJA^B5]#Q89L.ZD;X,A=<@JTLX<]=W5815(V^KZ>Y]
MH#Z27F,P+"T$D[TD[+EDSV496FEC6%[L#%,E4R5391G>RVZC/RRO"0>3)9,E
MDV4)9-EJC/O59_"]0;+DF[ZE*EJ!?V)Z$_@WV*L]F$OKR/3%?`JS>RM.H38G
M);%SM0ZR;[_I2,-FU&EWG@*<!P%R*"GG3"1,)"QL6-@P';&PJ6=]DQKY+G;&
M=C[,%\(-J>.;/1/AC;2F83`'P`NEW"D,0+EZ0IE\O&?W:M[>]_%(#>U#]8V,
M&JUANS37R$N!R/*TCEQA?P7M&Z7J"B3TLR%Y***=Z97IE:4P2V&F:J9JEL)[
M96`7T:AU4(;T[]@>G6SG#0W2JT&]+J">$\18,><E7:9J4_3V%8HH;PO/PRJF
M?-1N-P;#\H(QMH7BDW2:_4-+=N.7I]<P&V0V6'U^;F/0J\CB8R[(7)"Y('/!
M/>""[4&CQ<H@LT%F@_N,;\P&7YH:WQAT2RLISUSP^4D,/T<"(+7V^=S?N=UX
MKB]/9I(@V>ZT?OIE>7OTV?6!ET7O!P,`9'7NYN>X5A_=RDZ6_FTFK6G@`=_'
MM`DZ`VL12@4S*TL!+"DD"";)<BM@?R>V4#/+C>1<48Z_+19N)#R+TBT<-XIA
M!"N4GHBD8T7!)@>I=>3Z5C0+8EBDHX[?[P&\JCGJ#5C;>F`GN3$+H@[?61XC
M/ZD?A'/A%?A.&Y])!]8X8$O/,\_\^J[UCCX#:[&3SVM@^,V=PZE_DG?6UV`N
M5A2(.]>)9N\'HQQ+`W;EB862[Y,_5J"1K2I_Y9"RN=':*Z<M+BUH,;^^ZXUA
MZX^RT*($,*^.GOOB</S<-WO/?;%_N)O<DS2XVBG7Z7*[+[Q!K@"6#ZLN-G`U
M&>8@,2J!P:=C7,D%2+5K&5K=5L/JM-JEMTEAI&.D>PSIMO;+<-3[TZ/>@^E+
M0]M+I_/ZMZ;E5L>5=W$O,PZQ]OC$\<+U%-',VIBU[4,T9NVQJN:AF`>EW)W+
M12AMUV0N8LW17-O!UV1^M816:6RL.@!4K6OU2^N;>"@LI7[<X_!5(^8.M>0.
MW?*JI1\*=V`WT[8ET*/`_GYR+91$;^<<B\^]NA)2B\RD_3*RZLF8AJ/JVST?
M"L?:(^9T^(I.+;"-.=#+0=/O5U]B^U`X$#MIBH-\B4-[!HJ1P@NX18A18-$]
M>6ODG['[U*Z<;(R]#6/LJ%M:CL*S@F]KB1:<95!C9:>6&,.,A$MGLG?GI3AT
MAE'O"^'JH"%A@]ZB7+IT`I7F_\4+3_K_LF@/I=7^8'/K#9M;1_U6:3W9N?08
M.X=JJ2\QMSH4;M5MM/H#YE<U2)-,_O[+S[$ZN1%B\?[<58M`">\W`.E"??!M
M+T88G><2\SZG>7GXK1>H.)3?`!:G7F!__^M__/N__249[$*$/KRLOLCP:B9"
M^27P7/L^?=;"(>'#5SG]]=WE.291_$_W?[^=O[-<![X0=G1R/NA<#"]&_?/S
MT6E_U.I.!N/3RU'[XGPP;G<&[=Z[ORX=2A[`CR2:K3O3E;2[*@[5X&FKU1L/
MS8]W>LKKP'/T')]D9%'A.("=1<![$`FV3GKL[U_2XTZ6COFM>!$K_'M0V&W@
M)Y'2VKOO4%HJX#D@DP_'XN&Q``W@\W/0Z16>CN7Z]%[H"-^6UIT;S:S+R=6I
M-;DZL[X%"]>V.H.6E5B7G36R]"5[T!_QW?>88.O:>E<)`=)R"8N:Z0K:Y:Z`
MYK-.A8*=/@`E15".,=_W^AX`>^LZE"N<O"&B*'2O8YU<&@7IVWA?/@/JD*'"
M%R,X+DTSTCD1(!G$C;3\F')CP,;*SZFL((Y4!.<($S6M<]>CV6NVQF@F(NLN
MB#W'FL&SUK64?G[AEA.'E'D-@\**W<#!Y)1XGGSGP@?"O)61"8D]SUH$$9"1
M*SS8$8#`O94/@>E+^G3Q(6#9RE64'&.^H9D1$O$B\&DM\H<,;5?16@@H5K#0
M>=Q(3'<B#`505]-Z6*RMB*9'I,F#DN<I,N>B>]JY[(U!\%RV^^U1>S0^/6_U
M)^UN:]SNGI^=LLRI$^-FF<,RAV4.RYPR9$X]V,*><[3E*C&400L(`<R)$"DY
M9.]^$U+('VAU`B50T6Q\":Q^._9$XD+?3$?7TA8Q8`&\Y(;8W=>+%;ZDL?Q:
M`C9$[DDZ;UEU93)8C$N`Y_B)CK?GZ!)[6A:FW8(]E5459O#"JC"#X4_/JUW2
M[C_WQ5V_MYN%[GT(5*E5'EY6,J/_"B4S:E,@(P/=MUDH)<G^3\"]K(_P[$Q9
M%SZ*E4(9C6?X5AE':]A\M<9E6[@ZT/[T\*TW&E54[P?@4:>[[)U=K/W#F(5H
M4"],V''!LBZ+:DL%[AY6=NAT&MU6]4E);Z*H`P>E5!24\M:)=-3H]ZH/(WL3
M-/IT\7O`4O:S<<16+F2KMFQK0ZGM=J-=8H[O(W`[%*)DTXKI:UM).!Y7U/+F
M<,F+3<ZM;LB"2'C5H-::/B+5M6VN#:UVNXW>N+QHXF=#]%#(F,W+G8C/MTFL
M[6&C7UZB-A-K"0'_&R,E"_&4E\(-_RZ\6/[NBFO7<R-7JH]28.B_\]G_*NTX
MQ%`A#,52?_C!-:#`+:[G@[^((_@Y\&UXBP(XGA**.>H-VY>CRW%[<'G1/QT,
M3B=GW>%EOS,>M+JM\U'UH9B["YV96&$!3!CG@J$OU_+&]?&$=`D,'9CUN[R5
MGM6UO.PT*.8*7_#QOG.N[SLEW7>N8-.+%YO>H&9L<F,;C!=/AL%Q0IFXHO)Z
M0653<<Q.I3$[XW%SU.JW!J-.9P#[&_7+B^#IO3""9S38=4!-AP-J]BQ8@7O0
M%,9`3<`B56!;_K:SI1F%!"M$/5Q7X346]X>"`\TP\<I-6R;6;ZDY!:YVBR.-
MLG['>V14LN?DZF[!HN=@X7JR3L;WSCQFI\+#)(.&]3?AQR*\SVBH_?J-UVIA
M87)1@I>#9M`8]*MOJW2`?H?MF=<!\ZBSF?!O*!^/<I%4Y,ZII?$4E:5;5)82
M<UY74;C!_G+I9?@B=&VILYP<4UKA.8KJ8^&0KQSY77F']M*J\6\+J+=9682U
ME2VT%4M$UE.<9%5YP$O5:6H3NO4*"L^++V\.*U9PT.B/.J\/W-I@9,TO>:JX
MOEE_/Y3SP>CZ'$^O^=0;GW<FG?%IYZ+;[O>[9_"Q?WXVN.R>#R[/3KO]@ZV_
MD;G6K.>XL@XI97V)2[8[2U<<NRO,D5P[3:[.,CD^ZH`@S]75V'!R=&67%4E3
MC5PA#.LH]SX6[(`Q<S\?I_=Y9B%I7>+A+\J:NCYH&5@IP72HQHGREX%4V@$3
MXD-Y,C>$3@^%<A&$:)K`[SGK!#Y)8<_,SWC%J`L^-'2;Q"<-!$B@8'+?CRG)
M/U9T>9E_:.:"F0/&S[U>IZNLZS#X+GW@^W<^6%%1`#]@_J:'3C75-/>=+KG^
M:#6.!!#@Y.F]X/,O`M?A6D%O:K=&56(;;2[GU<I=5V2UJ*T_XP"A3;:BTI5?
MJ(3!7(3?384%8*%86L'.T`*^RV%%\U!`U%D/H@#();14YEFW,DF6($]"56L!
MA%@7Q#<SH+DP#$"YT#?Q5%A'P]ER1"00R7&,>4;J^+U\.7Q?`9;=];#,0S'V
M5^%(A!O*J2?M"&#CBQN"0X%+74O@`XDS!!T@=_B2`>1"H"KH+BC_3I?GH,(=
M@7&';#ZDTJ&?%RSMUF"O!&5!*%:Z]+Q0M`'>-T$(#SB6"R=D8\%S;,\"_%T+
M/F4ML[6FA2.@`-#%0XD4EQ^R[B1Q]TB&<V+PND4>MNO-RUN#0V*Q"`,06WFQ
MJL7-<[AEDR1X/OA&I2CH!%B(*T"4AUW"$D6!0AQY@^(*WOIG[-P@2NK=;H)7
M4H^H4`T')HH`+S21:9"N@K%C"%"/GXZ#,C$3SRF1&=<C0B],E'P$J:M2N7XM
M\3MZWD'J,V^2-O!G#$0*]I6$9V-8IH=`N:?7<&<>'%.Z;F?-BFAZ)]$`?'U>
M<";(#O!H:.;`D5XC>0;+2YET(5/U"<F;&'`0AS@`6!/I$15TLF%[E`!]*Q<K
MU=S*G4L":ZN;*AJP;7@H#U<\O/7NW4TPQG^<?\;*J$H;X.I&20FP=4!]PHX,
MR%.RT;6Q%L"E\7A=JMT%D`/2AVT`^U&-XB-P0->:U=Y3*:T8+&VEZ866GKZ8
M%JG#LG46+``()$>L($$7*#^1F*\CU.F`L)5^T$)^]0.V<@V'"7O%:EZPU8?M
MX<TV[6,FYWI#]?/T,E&B/_@J"F/2V/6K6QBIK<FD?W[9[IT.>NW^Y<5DW&YW
MQNW1I'MVWFU-AI/#B$S4'_'=0HF_G+D#.)+"T<H!<N4P7RQ_K+QZ0E0!K.:>
MN,9<ETY,31)S#W-M?+%J)H&C(0HORZE&5G<1:%>ZI.+DOER(>_,-(+LM%@@$
MLF]0#4%F]D/K-KK<6,8.0&#$I,OH']0,UG6",LWR112'FG@,I]6D`W!,:.39
MA/`02A>)8,UC:VIY;T$&P_9YI],['X_/1V?]B]/ST]ZH.S@_;5U<="Z[_?/#
MK<_-OAKVU;"OAGTU[*MA7PW[:MA7P[X:]M6PKX9]->RKJ0L/W&/V/5%T6K%2
MVIGQ"3B/U>[HXS\S?&HNM6P-)6C>R-CLT(6#<P4A0&8<&+MDCO7Q@7\&:?<N
MI**9]'234@7"`+\`/"J4QZ5P-6-9*"(;%7M1@W@M+6]I>.+!%@;K+#3CAL6Z
MX=R0`_8+B)!S91TJN@,TS\KT%FUP6GTQK>0;UA</5J'W=)&TE%_%Z)<[K)`=
M8*GZU%&U%`F\%FAW0O,6$6H>CUPL;[.M.Z)VJZ^93X(;.:%,RA_.EQLD,?-"
M5WW/.!XN=0'GBV>5KM21U(XAS[FTIRPISW_M.DK_E35[H(ZWH0R!8=W-7'M6
MP%L,)M+E_>\(HPJ,_/%M+`%3_K"E=(RHSL.IB+"47!TZ9`];_SEJMI$Y>L2'
M,P0%9AW>:/&@-0G;@S]`;]`2IT@KQL=HQ`-P1M,A0ZZ6F"8:>C[+9`ZY7L%=
M:C2A4N1U_2EF/!.RBNL@CK0^LM[[DM<8'M,1S)D#!L,6D?DA86#,(6D8!7=S
M%7GJI<!PFT3U/4TT+[4Y1/NEW2%Z.V_6L)O<\E=\CS=8EX76>X-<_L",L7)W
M15,ZJ`N1>'P?`R,/D87KZ<ZE`BMB\=P,-"Z54!AC!PE`7'2-L6\#]OT/N54S
MD'XA_VKV^8._?)NP\:\M5=>=;6VB'<0?M8.X=LLSM2#:6V=7,I4SE3]7QN3J
MR*1P_8R7J[4CB\]949GZLA9=7L8R)-QA$F82WFFYI;I31NV6Q867JKN%0H?I
MPX[+YU+X#L&Y#ZRQ-L`Z7)G"&,<8QQC'&,<8]S8PCDO4+96H6PK[?$W#MI8`
M*JU6U-[6P.QV&H-V:6WE#J7\$GMVF$$P@V`&P0R"&00SB$<B2K.L-.82S"68
M2S"78"[Q%"[!EU-/NIPJYF0\QZ?VTJ+YU37M?%42;0\;HU9Y_3">"\1#(6MV
M?Y?@_F92W94T97IE>F5Z97IE>F5Z??/TRJKPZUNX10P:'90E^RV(LB)P2V7[
MDIH%^=3T:C"QK-Y1=6G(4\,64:\$OHK98[_5Z+4K:KVWKA5471",[PKJ>U?`
MK(U96^W"'9BU,6MCUL:LK1:LK7(G%/,WYF_,WYB_':#3[JVR-HY-V;9J?U9>
MDK.G7UV@U`<!:P<XQCC&.,:XO0!<;8#%&/<6,(ZSIXN#_&.[)C"OZ26H)=PX
MV:$]:`P&I5FBAV)+LIN,&00SB*I<\<PEF$LPES@H+L%J!#,(9A#,(%B-X(NK
MRG#H+-BJ=^ESO&^<7+)VD$&C/^J4Y@9^Z[DE["<OP4_.E/HZ$7-,KTRO3*],
MKTRO3*]OD%Y9$WYUD[>(0(>89;V^\?=^IEK7$LRUBENOIZ.NTVUT>MV=P>E0
M.!J[^ID',0_:%^.(&1$S(F9$S(AV&];`/(AY$/,@YD&U\3P=,`O*>9A^CJAU
M];KG<W_G]N6YOCR926(T[4[KIPH5W>?L\CDKS;U3X!TM0'LZ1M<'MJ@_YP?U
M@W`NO`+QM/&9=&""K65+SS//_/JN]8X^`^+8R><U,/KFSJ6R/LD[ZVLP%RL<
M^<YUHAG\"7LR.`NXZ(F%DN^3/WY9QK]L47F?8H;#@[7NY"W<DK287]_UVC\]
M2AY%6C0O/ON]SJXGY`WR!NNXP:==&+R:FKE9(HY*D!LX!GVZT\SY.O`<S00=
MO!^@X+?W,3#R$%FXGNY<*CMT%\^-BWLT*_61FZS=)*?FP&Z#%)-A!8`WT+3E
M_%J&F<K?;3>L3JO=8].H_*MH1K["&/\3!Y%T,I!^P=!7E7W^X.?`_?!?6ZJ7
M.]O:Q([<6VE]%.%W^4COY]=8WM'O\E9Z5ON8J9RIO&)<NX(IW"D\!T!,X?HY
M`NC7CBP^7\-/MV1<UY>U?/`7<:0L0\(=)F$FX:I1[@\_V!_*J-VR#*5VMZ94
MSI]Z4E-*KOGWZM<[]<&]V@&.,8XQCC%N+P!7&V`QQKT%C..:?TO9\$+-+/EG
M[-X*#Q3RAQ5Y+KI1`D3V+G2D/6[TAL.RP'`HH2'LV6$&P0R"&00S"&80S""X
M;!=S">82S"682U0=AU[ZY=0AED`XE$;S=:C@4<,LG$<Q>^]X7[DFU/,!>"@,
MDR\6JKJ1V2F?JTW+R0-C@OO8[+0F'+(V*,GLD]DGJXEO2TU\C9(VM<`N9G;,
M[)C9,;-C9O<:GL0#CG^JNHW]6XRQXSLMQA_&'\8?QI_:PH?QIVP=J496(C>,
M9W/QX*S!?J,[*J^@?!VP@GU:->3]S(.8!^W4(U4'W&!.Q)R(.=$^<2+6AI@'
M,0]B'L3:T'YQ(KY^6RH_`-_!,B4,LXA#>R:4M!98D106Z"O7D;H>\7,\FR]M
M0?KBS*)7)<Y!8]"OJ.7,VPU[9'6`R6M'L2E,9$QD3&1,9$QD3&2L*-:-O#@?
M^^VVI*^%CX(#T'>1<MAIM+JE]>3AV'-VPU?DAF<^QWRNSG86,SMF=LSLF-G5
M@=F5&SG!;([9'+,Y9G.U8W,5NO7>(IO+.?Q^IF;UZY[?V<)R0,,>S2<SW<FY
MW6G]I#LYNSXPN.C]H`_X69W9L+]+_S;#`),YX.*]Y;B.Y0>1%87PSE2&%GXY
M=7WAVZ[P+-=741C/L3<&_!T%5A!:01Q9P=0R+>8``D(IZK:)L2J6$X?`(JP(
MYHAFH93DZ/1AL]8<EC)3EO31X[D"IA?OZDHNHN7&TBUJ+-TO?S*$`[:L;EH3
M\N("M#Q7`P!`@YN_EC>N[R,H$`"P:?PS@5G>(SR%H?"%PX.1JRR!^_-`[5#6
MD>O#/H,8WG+4\</E!AZBDVRJ<0E4,7ZB#K/=RHH$FWNGH+:T@,CS5(^?\X/Z
M03@77D$*M_&9=&#BQ98M/<\\\^N[UCOZ#(+&3CZO`<HW=PZ8]TG>65^#N5A1
M!N]<)YJ]'X^;HU:_-1AU.@/8WZC_4R(*09)Y8J'D^^2/7Y:E5[;$_`51*@%[
M:V\`M[ABHI7]^FXT^.E1V5J4\.;%]G/?Z^QDPJ?=K+W:;?9F7:74+J;5YG:_
ML8:ZEWB_^/='[Q=?8VD?]9WH_-$.7*^QN#\4'&B&B?G6XK5;:KYG<MT6QYV2
MZ^$'VIG_XE1X8$3(AO4WX<<BO,]HJ+U!X^0T'$[#>5U/3QVPHG:16P?,H\YF
MPK^A2BUH@4L5N7,1@>6=!6,EYCR8^)RJ4\41'`W&U3AJ-P,J0\KJV%ZU>,O:
M2D7:"D9B/L5)MA?76[4IVG]@=U][V$=BT.B/.J\/W-I@)-^:/>2XKL7B=GLO
M]FS-#V\[LN#^2"N4OH.C2&'/K%`N@A`'LA:P@,"Q8I6_$7+)/8*:J(#1@VM]
M/W1_<D>0D$[#<EQE`RFA>HIE!4^".,)X#FL>.-)K6KAXE3FGK#CG#,*.</%\
M@<O$*6PO=B0M,#<3+A36Z<I;7!8M&:`'*C&<8(,>=D`UMNY@5S\6TH8-!K`G
M?`Q_RSV*UUW"<F0DP[GKIW=BBU`JA*&&[53841`J``)L!T9*-F=-XP@@:.8P
M6[7,5E7S8=(S?__EYUB=W`BQ>'^9W&-^R*XQSV$F+\!C^@:(=>H%]O>__L>_
M_]M?DG=^"P+GSO6\B>]\\",P#UP`X(0ZZGT!-F7?IZ\19L"'KW+ZZ[O+<]0/
M_J?[O]_.WUFN`U_`#D^ZPTZW/SD=#5NMRWYK.!R?ML_.!N-6>]@:#R].!^_^
MNH3]3[BD6<<.5XAG26J-EFZ<*J,G_1'??>]&P)]M/6P"7$*2#+R6AN_*Z;[\
M"C(7W&L5)D<`3%W?C>2)Y]Y*_")=C>F?*``/\6I<S)%P_P7/7,<1?1L!KE,*
MCQ]3T4^\PG7G"V`=B&()]6<4'\,\EH>4WL"+8Q@/*""4?\;P-+SN`HNXI2MV
M7)GMAG8\5Q&JHTBM#MZLR_SX<W%OS<0M<"C;CD/@-TWKTM!3E+O:3]B3PG=A
M)<@5HADL#BC-`ZH#5>.&+OQQ[P#".:SXU@5T6]J.81B-=/L(%,^=NQ'1KF8.
M^I87-OO\B]V"SCL8KNI<*?:NNVC,X\H6[ST5G9;,F%%Z#6L0K#-8E7`O1M_<
M98-EDZM");X*8`@^'!XP5C<B-JKY]Y^Q2_)'8[")+`#>!QAT8_`4OP=]#A`7
M#A1DD%3J^<*9S^RA,_/E#<B_6W0P.3&<PCV>"$:+!'/7!@($_8!A7Q'L'6DC
MQ)!>0#$!::UU-B0!82DX#0&_.D89^P4Y;XD'L174#PG$<Q%^E\"DQ(+$_;^T
MVA=*3^,_:'@^_'P=!-^U`OBP)E</<V"/+9F"JA.`#`C7Z#=W;C3+Z4$6ZD%:
MZY%X1MH17E0%IFZHX!CO@83^!-4'SIJ.%P=4BIY`7=ZH_MK$\-SOTG-GL"`2
M5NE83>L#RBXTF](7'*V?Y'4/I;4E&N4>?_91_6@4%!W:*7SAHSUC2VU14`#B
M70!@E(O\B*B[:6M);T;_KO`5&B_4RUZU`Y?4.3.%+<+PGJ+\YF2_K'V8]KKN
M:?D#EZN69FP@AT(QX>C5S6,$>J)CZ>W9PK-CKZ@8-JW/>-1WKH(AW.EV^\@O
M86EY&LHW"2X!D%#S2]1*O8[K9`&D=21SS+.(#C(;`0`^:1Y&PPR6P%%88#IA
MHJZ@H>RM+)RT>#*9']/DB]B28IO*`4<EFE0ZN3;/M:I%O$TL`+O`WFT\8>;<
M**!%!W.9CL(,<%#ETC^LG,02ZJZ<'1*^QLY5MG>'O`5=%J12%PTT%8,5I8QE
MM1&I5;H.--YP+=>2`H=1$X=5:HYD4#0U6H>_8',)=#H8#N4BZ-SI?:YZ1'Z=
M7H",F&C?E[`X)<)[L#C]=<P?M_2XU9GN*ED]'F:1Z'V''HC])0>512Z;W*6J
MYA8WTD>/&5K3R,\#5;"W/5BTYO)K^-$C_I]Z8-X>$TT^+P#T8B""N73R;'N)
M+#+FMD$9P.?!IIAE7'4[UTL#1<F=Q.?5!OHUHF=I*,V;9V)5IT#!*.F7:RE1
MARCH!$&11K4@JT!YWF7X_5.=I=L[/@O^T@\DU[Z)'T_WC@[/A^>=?JLU/C]M
M]X>]R_'DO']VWAD,S_JGHV[WLG+OZ&NZ0C7<+`"<K-KQF:=K%!I@P?T+8)=/
M0D&K6.-^DHX"A"5#HC3Q@PB/W)6VUI0`BT$7`^EB.>X4GM,_7,OH#HF+5&]X
MZUHHEQ[/W%'Y.8WD`!5,:W8H3#2?3YQ<61X2"*9()FE(EK!1\M%]/1DQEY.K
M4VMR=9:1U;#7.FD#::6V\)H8\@H.=6*3!$2VB'`LG'&RDO8OUE%N6;!L2Z\V
M]\3Q*O&^'"6^$8M;?W3$G$.I8B\BX(L?=&\$>W"D$]N19L[9Z9AKFGL0<D:7
MR$R+W#D:C7[#^8>I"@2OP(^Z=Y;3+)?S;CJJ#.[E@QI]^Z`=*2U[A*7M:72)
M"#3A"'.O*>`,P.RJ&>R?@`B,3-P8LRDS4[11O-$8-I/``9)OBXPD?><F,BJF
M(]#'G&J?Z*A!<.?Y0V+Z*W.@Y,S);@A1&4!/3CJN,6N0W!/A"62]9K\D57-:
MJ<`;$0&*,S[DF[L4S3*:UGF21`A;ENE@13M.ZR2*E@3$)D'GU!AGEH3MUP+_
MG[%OTT*(46A7R")0KE95,#4Q\='"<`X2`VCT(<4L),K-6B`\`("""\2=;CA^
M5R58`B<P<?X)-K[F;\:QL.X=;8;[-JQ(&>(T?T<;K(?<ZL#NO'45809H9:"%
M3UWC"#$R04\&(,E;[[!=\ZS2[KS,N[)N/IJ(P(M7S2D9Y"^F_QD[-S@T*7EP
M.C)$5ZR60M,(K9(?KHKT><&[R5VS#Y+>$W>@&^)?=&.U"&4D]$QXRXZOX9GI
MI\A"BD'DWRBR-,0/,B1B,#E"XC^`96MD%^@EB(>:%:8R:NU>\Y?J:!86+V@>
M>R-CHMH%G?%#J@AH1C&Q`O#G/2R1SO*[']SY[#ZHVA*"P[A#CA7D:0C#$GQ-
M>H8J4GUI?;)S<K:'D="+N]-9S_](XF)B<N[/D8(%!:],8^!1ZYB7N!&836X%
M<5@4(1GK?*K)LLGV6#)0BL;,F@"0+6R5SME9^^+R\G("O_4GH\&DU^N>=R>7
MD\'E97<\F%1NJU2!ZR8HK]7JC8?F1QUO]/XZ\!P]Q^^N32@_N0'\?E**WL&R
MGDJ7/@&F(<(HT3.2*_JB[D,I<:8B@T<'1,(M/2(M/4%]"AT:S4VT2"UAC5S.
MHK:TM`SNA0<:SD+<ZT%`&4/%W$]"Q6!XE>KT>MHLU@#X7Q#?S("L;Z47+'0@
M##H6@_E<AHD1=X-R]V,Z;3H5>D5))]4:48/8JOP!3,V3#2M>("=!SSDPEF0!
M\`DM$WI2N^@1!G0W%<H;O!L)P,B!&7W[OK$LR)<GU$SLN]P$!+T"9.>8C@B#
MXBJ0BRGA2;6T)*U5D:QP7!3QF:J';E(9)MXF[!]\DS-KM=\-!;Y9'CI.0P0=
M!=7E5/_`FGHQJBH11A(%\U11",Q?K"!4'2JZ?(`*1%%$C'Z!NG]40#<XE]AW
M47T.*6(L"8Z4!7I9PFR#LZ%$I+X-7"?1&/,AJ09/?[%FP1T,%189A8LJ=H8T
M-AD+^2G=:?H\VCQ@_-AHHJ$4OS?QH+`CO.?'^&^Z/44R"Z[_"7HY7A@SHE6Z
M]`]KK%ARJ6"HE[:S$&T^R?COXD?Y*A\.HN+%ACR`*%C\\H"BLH@TK7RD=<$P
M:V'^XC46,3Z-@:.P&&W!D=V%HNP:EFTL1LV(12+',N&)SBO`\,D"24_0^\C.
M__`!VT-E7`"@.H)Q\!%L2##><20%YW"&>FYHG9%T+CCY/IY/SL[R_KUTV/^6
M/D@I&.AOPOZ.@UPB&6K=.3$M)LXMCIRPB(_HB$`'WD?IN+:+,=>@"#<+$_[W
MWRX+T]W-7'MFW>A^]?*'[8%:<0L63A!ZSIWKR`1:P".$]4?SJ@F,!9O:6^2>
M2SPAOO3<A5RX\S@ZN0(V!Z:LHW4')2FD4+^*7Z!'!E#$#*./P0P)@MPSU:)4
M-CXPSQE:2K#![%XIG4*1%\7&W3;A*(P,)39JI*^KDJ-L8)"Z-J8SX0Y\,N=F
M(GM%^F273*6LYK;G/SNM5J/5JL"_B`$B\V4E:M\VH74J4@]].SGP+Y1>T;6^
M?+VXNOCT#8.4M<:G&5PNGBD522N`*%X?;M9J4]7-C(VES6AH(OR%C&$7B2Q6
MB=#$X`#4MPHJ<"3MF0^VU`VYE?9`JI0N$)<B2-O=-4&0^>WU1E5N[V(ZU=H)
M</'0]2SM$FF-B3,0=]:WSL%:_D\R]O^[`\W.04$`*!G.A4WH`.AV%C2LWR/'
M.DJ?.&Y:.9:4CD.3$<>%R;+A,N:;L5PEY?><#9-:.F`3H(SX*A<Q2"X;<?7_
M`[XJK*.K(,9%XH=CDA/H53%XG*B/-A"+2TD[J8\*'H]2MVY([G=;"ZTT?I^L
MSG0%%*,AK<OS21),?A&'0`7`2A/IHZQ)WL8*S$8:L"MSX>^X"NCX.H:5F"7"
MQG([T/(9YP;M<Y;;/E#GM8[3W0NJRM#N7-K+7CERRG4>Q$!2OT$XWB\CX^3T
MPYGU,<6/WW7N!84)QM?*=5S4!D@KN15+^*J*EXTP4%XO:!@U2*L'.7RE&9^(
MJA]4**2W'3;"UD,!,\_I5;(E<@I/G?#4[&H;%,U#E_S]B0KJJ2!-NQ/Z6]R9
M#D`-Y316*Q#$ZSQC[9E@+%*7\"=]6&:%QE&@%X2+R#C10WC5T">L8W)(.Z:[
M%HRO,?=<.%/.CP)_NI1'4C`XLD4W]/V24[BTATF#4'MHO`"99\[R;"QYAX"4
M"L:OFUPIWU!R)5X+Z1L6X_#YCH>Q(MS1SLZ)>`/!)4FO3TH?"T$DO;1YD!11
MBTP20$D'B!4=$SWH%E0)NO35"0>Y0"0=MD"J#M(]7FVY4U>'&\X!T&_2E*ZK
MYF"J5EGM'G'NWCK.;1*K0#)O]GHFN1#HAO7!3IRY"\W4S\,F2';'*5X1_BZN
M@Q!)#A$*](RB6;?VG0<9>JJCYORPABTA[0)K$8B-ZQ>#E)81NF'$N+T;@9S2
M-DQ9-=?K/^L')9X#Z./D%/[.LALLQUYHB?!'<<Y&_DX9R%3^6(CLRGX1H*6)
M>P6;TR4_6;!`5D974HZ#CFP*<*&3,%SA9=2W`5VKO:?\[&=XVLGA:>H$66O@
M^WA&'GZ)CL00)"JZ2Z1'SL&CLZ_'"4/201<I+H5@,:,;Y;?)[Q<GO5:[D3K]
M4=XO>:0^PC&K964$5.??SZRC=_3C.^T%T0]>2UM@>#S,%J#K,;A#CIFI-\UT
M5EHT7B4:/YA)L(,M.:XFOV1[*&)0)3A)I&,J7.@N)`T&!>3"!$KEHCN`Q`"J
M*>WQN*76JR2`/0:]$`#SZ\"^AV?F@*='%]^.FV9+L!&\U?=S>E0B7RA$A!!^
MC13,G<_9U^)1@/Q1L="R:*/I<NH&?Q<*LT-"XQE:ZS"1J^\WDI6COP6_3%TG
MJV.B!\(YB8(3K$%@,C0<]\:-4J$,>(`W)"%&F<<R,YM1&N,24M:4VM@YLSWQ
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M.5`M*&XK,^F2N#@UHQH2US*IZZ+3_YP\;+)!,,#1(<T`+S\;^;UE,8):@Y-D
MAJ=`!&TXCC8-J[=&^N0:XS.)&$?9'IJ("`J?=7V4J487I/&S&.5&/D*Y84*_
MM*EJ8K_H]#;N$]UUH,?X3GJIG]\KY=:F%@8*FRD,!(NE.&J36&AJ<2218[AN
MW3E!R>2Y7&^)*5XU)>XFJ]UOF`"M?$RO<((%Q6WB)<E-[.K(^33&'IT0?X(.
M&>EZ$B@^TC0:NJNA)*#D>31B:5CRP9C%K@W4)V&JL4.D8C0[W*R^4FJ8),$N
M#Z"2=:2DM#X%J*!UCE_J%MS`=KK/4=K?#M/\"`KA9I;Y*6AF;D^-^>-&]LW7
MO#IXAO8'Y542>9[%H*(!,JCWUK=@`?QLT!KD7BTPRG$S_R$72J^,&PEHUUUX
MIL%*DO9"3B.S`D)'K87C]2+B(=4LT+]B*J0C0IT+2M>:OTTF7TR=K>0W8!X>
MN19%H@(C<81RAA%9MU+7YM*Q3,CL*0PK(&/#9+'DDD72984NW7\2@.PB@.P$
M0(F'"OZ4#K85#]!%BL6`_$SCSL=U)V3?,(Y(3;VZ*LF)T9CM]"G*UT;:O\^N
M?N_6CJMW2,GSZU=*1ACM_OZ]==0^3G)879E4*]+O':EC_:9(W_W%.NJL/&\2
M$XF%Y>_ST[#K=#AXO7M<S*.0NL^1T.YF<M#!4[UC"E.UT[2'E8>2D/>G3(XG
M=-0_SF=<)0"D7(\CRKDZIA<U?,`RBEQ%.Q4;ILJ1UC?#C`T*)3BIK'A!;G9A
MO))H*H*$W(A)6`!@$1D!HU-)0IF)'<!V&]@O<FMS.XJ4F6Y9IUYER[A*EW$6
M.&E7J*<L6]MDJXD#J9,'^,R?:`2G":>^4TA`S>L/8`&*,'4+^0*-RD96WL"=
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MR["399BKT<2<2C*^ID$0^:ASY]1WS*_30"@6C]!<`_6%5$VB#5POVSXHE5*U
MJ&"-F"@M$].<$/1Z=M>T+D0(@B[49HZIQ*I#<*/E[$93P@80V3-F$8Y<`'P%
M3"(YPN<PB2QRW62FF7D3D#H2&1Z9N8L'AO9<0!D',2`93LM"2KM-9:Q-R)V4
M8-7%03"S+?`=-V=QZP0]'1*?P)!*@!"K=])SK^9&A?G;@_PMN0]",_Y!!M<_
MP1N<*\1;=TIZODE7OTH])U_RUOOUO76!53_]C`:(>RW(7WKQ`W0ANMW&R3_`
M`"K/U'"RG"3.?6M),RA::JA6H9F5:-/)Z+(PNHNC-_-#/T.U>DR/ZFO&<K\-
M6W$":1B+*8V<5LU)WLW8`2TW8P<BR_$PE!WH2EE8<@'+HFO^NTY]>#9^9IA3
M;KN^Y]#1ZFW)4V\_"E<GGPG<'X#6?DCG6_`!L3Y4%\#\HOMSJ>S0I0>><G4R
MZ/0G[=/11;M]/NKW!\/):-1I]2:GE[W.^>7PHOHJ)55PBVTR__Y!Z2V<[[>#
MHO-94!NYDN+YW$3TW>DST-?<25@6B>^#ZQ;,_8'E?O4';K=:Y74$[KRT)7#G
MN:U]1[MN)<SKY'7R.GF=M5CGGG0<QRQ!=,&_G[D.R,)R[?\7M1E_C>Z--6XS
M_E&$]DS'$&QE/U30WI&QDK%R:8S,DME2=]_9RH!2NK5;%%,N4VY-*#?-I*P;
MC6`V9^T653;A,F$R86Y`-8J<+@3ZM9D<F!S>*CF0W5,[`F"J9*IDJJP;`0!5
MKM93>NU%,54R5>X(U<X"'[/(`-MJ1P48*?3YQQ3[:C%!U)\@'@!=;;#]6Q`)
M;UL@/>LZYEK8WV^H9<6)B>NQ;2FGTU=`N;4];<N'Z><XHB!36&@CJX"Q(33E
MN4[+,J%J$)I"-%:P^9D`IA.J+)@OZQ]5.4"K`,X2]KU2E/!KH=LJ$9<&X]H)
M%2;BC43<;8R'#]\N,?G6$=&8?)E\B7Q;W8?==TR^=42T`[/:F$(W4NA@!^8&
MTR?39TT`MW?TV1X.F#Z9/ID^:TJ?'1:?3)Y,GG4ESV'GX7MJIL\ZHAG3YUNA
MSU&CWV,*+85"]R0/;D?WJU0WPRD+LYX#ICJ26[O7:+5*,R@/A7+J1R3[)<(.
MA3HJB!A@$F$281)A$F$281)A$F$281)A$F$281)A$F$281)A$F$281)A?^\^
MW)34Z()S1U<H%S\6V(&Y+.QY+".R5`#7D1BK2$A[+DP/A91KA71O24(R-3,U
M<Y`14RM3*U,K4RM3*U,K4RM3*U,K4RM3*U,K4RM3*U,K4^N+J?6HTQW5!I@9
MQE4'S2HO-(Z9GIF>F9[?'CUS:EQ^C$+IT:=TR"T%3[N`ITX08UO7EQ2'KB-Q
MEQMM\2C8WHSV7`7^O%VI>\`$6&ZU4*8_IK_Z`K">]%=FN4^F/P[69?*JJ%8G
M$Q<3%Q-7184VF;B8N)BXJJF2R;3%M,6TE1NC-WJXBS<3%Q,7$]=S!5>GT6U5
M=&-WP/3%&9;;9UB*R`W\)V!8NO)'6U#N$)X/PW`'+9*M3FL'I9Y9+C#Z+8^1
MWJ#CI7EYHH)1D%%P6Q0\EW:*@4/&P+>#@;G"YH]IDZ^)GY-%Z'J,G&\,.6N#
M?HF"V*Z^E1:C'Z,?HQ^C7XW0[^\B=*5"_.N=L)',2%A?P.6\AC]'`C39=<_O
MS)V9`Y/G^O)D)@FL[4[KIU^(>%T?0!:]'PP`T$\%W"/$>Q!+_X<(0^%'"JC!
M5ZZ*K&!JW27?+8((5N`*S[NWE(PBV!^:+JYOV4+-&M;=S`6A*4)I>:ZX=CTW
MNC^Q/:&4.W6EDX[3L(3O6/+/>,/OS5+@U.WP$2\/HC_BN^_="'B:O7SHV6$(
ME1XB2*)G;XL/8'60WQ\BCK6$%P76(@:%5"@)O\_G@0\+".SOEDL=LX@"`]^7
M-EY+6'=N-#/D94U=7_@V"!B%#Z5:;3^71(2?NPTK[X_J-#)!D/H!VKDOTX'R
M7R)5IS^TFM:WF83UIIM`OO`P!R&^<"?A.4>"<C6'(W(L/XAP_]?XE"-_P#?P
M*8C#`B"8952*L7"2EE21.Q<1P'\JW-"Z%5XL$4F#+#,M=]:V#?H1/1R$2[P$
MD#9_OB*RI`"<N18>8*JTU$S*R')@IJ8U\>_A43N4B/@PD.N;OP%AH@?6A+^9
MM62BR%(NCH^_S0,@L%"B#K]F7EP@_(AN.B>9"<@+X*RD0_2)*9LT+>P<B`B'
M@5D!(1>AG,%C[BV(P$`IW'D`K]/*@[FTCN2/!0YS3-2Q>=4$I&QWL4+H"M\2
MBT48`$'B*N$?)&S8C",]3?0XPC3P0#G$'UQ_`6?SO@3>/2X!F\9/U#&?(U5R
M[Q1T\1801YY:\'-^4#\(Y\(KJ.MM?"8=F#1;RY:>9Y[Y]5WK'7T&1=U./J\!
MRC=W#AC_2=Y97X.Y6%'6[UPGFKT?CYNC5K\U&'4Z`]C?J/]3XB0&^\(3"R7?
M)W_\LGS+G2TQ?V>?V3*]M>;$%M?^M#08H/O3HU9=T8XR+[:?^UYKUQ/R!GF#
MO$'>8/D3<@V#U2I6S_;*=1]SRSU26N/%X8T/0Z[BVUB%&F()A1\8)<M#R=?`
MR!I?6F3>!2OQ*#T!JG6#Y-Y>7S!6K@_UV];:W-G*T.]6NT653;E,F4R9CT1`
MUHX&T`->NT4Q83)A[C+T,X,H7O,P.3`YO%5R(+NF=@3`5,E4R519-P+`R(?:
M+>JI5'FXF<"E7F1?1:'[7=_#R]=D>!LAG\LT6F4'-03H?Y;F+GP,%Q^"9@5`
M6RYW4"K4.LT2BQV\(BJ]?@6$5V9QI<&X=CH,LSQF>>6RO'[U*3',\NJEU3%7
M8ZYVT%RMW1R55PB?N1ISM9IS-69<6P2=U80WM9J#\LK!<FM)9C_,?IC],/MA
M]L/LA]E/[=E/I]DJKU[WH;.?O<\P*!5U+GXLI(TYO)CP;!W=`U#54WH:;UV5
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MWZ./J9*IDJFR5@3`G3-KD$;"G3.Y./?^%>?>03.X0ZEDM$>\J';Z!+,?9C^K
M8[2;8V8_S'Z8_3#[X<Y(S'Z8_3#[8?;#[(?9#[,?9C_5^W[:S'XJ=4X?K`^:
M&[-M`:1N<UA:7;%#(:/Z44SMA/6;H(U.<UQ:%B#3!M/&8=%&M[2J04P;3!N'
M1!OM9IOE!M,&T\9:VNALG1;W5FB#8\JX^5150!OVFX/JHQ=6\:<Z=V,M:ISL
M$77NKYP[3(+DYE-,D$R0-2+(48DJ*1,D$R03Y`L)<MCL<O,I)D@FR/H0Y"-%
M'Y@@N=?-"\'&O6X><YQVN3AZ5;*/1=Q;(:+6F(F(B8B)Z`4(TVJ.6!(Q$3$1
MO8R(NJ695$Q$3$1OE8BX_V<)[H?-;3J>A:_>,\)A<H!:Z;21[YHQZ`/8GTI=
MC\#N();^;28MF62\W&:A,D*I>+Z(W,!7E@BE=2T4/!#X5@0OV,$<$/;^OY3E
MSA>>6WS3]?'W:]<7^+9UYT8S>FGE45=2'73EPHI%:"WB:\^UO7LK"H4#S\'>
MZ9FF55BCYTYE;G66JXIK"^5<N#X0'*S"AZ'L*!8>Y?+0;/C(G2G>I4<.BQZD
MY?'^)<,`AHH7\!D?4+A!.9W":BP1T2.1.Y<X]JWP8MJT'A@.V(43=*Q[5WJ.
M%>.@KAX4"USA$N>!(SV<$F=I6-?2%O!8'L;63"C+#^`-J0`B,$"$@,'%P9?B
MWK*%FJ53J>:>H)P]$_Z-AN54N"&!3BZ=#QRUN-8X-0U"^@7.50+0_&BF`#\0
M2U;V^^+E9=7-L\+\+2K,ORHT7CR9=2=#1&?8H0=Z@+*."$."&-YSU/'[9Q]G
M16*"&R!E*Z^B`=+HA0V0.KT=-U\9[4N3&-X?[Z_&Z^3]\?ZJFV]/[HSKZP[A
M2M&%,:A2-*G$5MGUR5\!DHR5AX&5W)?J53L+,.4RY3X3%;EO%;<$8<*L(6%R
MWRHF!R:'^G?(8:IDJF2JK!4!'$3?*J;*W5/E/K2P_Q9$PML62$_S/L/VZY14
MN*/XJW\LQSPTK+\)/Q;A?8:4[0U1"'4HCKU]Y_IZP+L6E;.K`%JED9,:%T>=
M=N<I'/)Y\-L!1KU^#:]7SJXN#<:UD\K,^9CSE0FU3J._@X)HS/.8YS'/8YY7
M%Y[7Z@R9YQT`SV.VQFR-V9H98]"IOI`F,S5F:LS4F*GMKD3-X.$`0V9JS-28
MJ3%3VRNF5GTY5V9IS-*8I3%+VQE+ZS>Z(];42F%K3P\K.=CHD<M"#8VDOHGE
M*A5+YPG8]B;*/[5;C<YX4!8-'@HU<:0?4T<&F5)#?)A$F$281)A$F$281)A$
MF$281)A$F$281)A$F$281-B950?7<(WNP';D,SZC$LRK%9COGIXBO#6E/98"
M>Y!]$-N-[B/5OTHLLK41@H="VI4!B"4FT_&#='S4[I>7#?%2`.Y[OY'CTB#)
M],ST_$QZ'I37GICIF>F9Z?F5Z;F\!&TF9R9G)N?7S3Y^=6)^,R8STRC3Z/-$
M;N_5B90E+E-S!=1\B-0Z'I4G4P]=9G)RP4.E*9_2([,4@=`%@>`$,39R?$D1
MX[>;8[4M-`\IUZK=;@Q:XYV!\$TD7;T*V:ZRR3=:Q(V9(C/%E[I5&KU61=$(
MS!,Y%H^Y&G.U5XFQ&@UV9WHP5V.NQER-N5KEE2IWZ$YAGL8\C7D:\[3J"U4R
M3V.>QCR->=KA\+2*HB"8HS%'8X[&'.U5M+3&8/!P4VEF:\\/*?DY$K#]=<_O
M;&$YH'FN+T]FDCACN]/ZZ1>"HNL#IXO>#_J`OT\%XR-HMN]+UQ_QW?=N!-AF
M%P)E%&Q'*.5.7>E80EGRS]B-[NN]HST^#!KD@F!\D@-\6@35#GSEJFA-853,
M?8=??6E';N!;=VXTHZ=C+P+^;<%LMZXME;4(@UO7@>>CP(I5TYH`?\<WA.?=
M-RQX\Z.XMT84_M3%`Q?60H0T81"'UN^!\*VIZPO?AE$;UIVT;G`5,-[G'U-@
M?-:E_E%XUN^_GV6+A-D6<6C/A))6O,"/*P?Q8KBU1YU&>[1:/^+%`UMJ)D*`
M'0#!#N9S`)**`ON[)2(+P"%_R-!V85^+$"",#Y6_@O_L-'NK^;HO'A8.<.;:
M,Z1JX6F<B&:R@O5W5K.97CSFB0.8*D!(BQMIS47X74;9$2"R%LX*?@G"9(..
MB.@I_)OPMVE]@S]3;+V3H=1%)!P@$J0?.&>Q`-J!8?!=G`>_G@>.])!,'*GL
MT+W6=/@I@$?&#>M:@IJMA\Z5I0"JCN<+I#EE37%-R2+@5=N+D3:%=1MX(J(`
MQ6H0:MAO=GL_58%1\L<">!`BDPSGU2Q>R5OI5T#F]R`K5,,*7?7]9!I*:84&
M3RK@54V0*56`7_B(/B#(@,G#G]7MH-5L5;&#%7(Q9)K29B)O[H#J*F"T[>9X
M-:+HY:BUD*&6(K0_E=L/?&>%TD:C@9B'UK!0MN2`$"^`D:&@!]DJ]2'[082,
M)PED=J4RAP_CX6\JOOXG$"*R/.'\,U;1'#07_)0;%J:#QQ1,B;^%<A&$I"W`
M:MW`4<V'K0'S]U]^CM7)C1"+]Y^)JWT`'>F'=+X%'U`Q"9569\Z)0=(#WT"3
M.O6`*?_U/_[]W_Z2OAS>"-_]E\`GSH`WHME$'R:^\P6D+ZR0/GZ>IBK&%7PC
M<5OJW%6V%Z@XE/#T%5A,H#?9`-Z);0>QCWOZ`N/9`*1T<M2.4*?[*J>_OKL\
MQW#O_^G^[[?S=Y;KP!?"CDXFO<GEY>"T?WHV&?9[%^W3\7C<GHPN.V>GYX.+
MX?C=7Y>4QCQN?'/GH#)\DG?6UV`N-KM9'M(YJU`Q38I#J]4;#\V/=WK*Z\!S
M#+J>HM232A%&G0K0.9$.\\?P;#UZ?S3^2J$_D->;H/_Y%I5U>5>KA:]?ZI;^
MOH<6N^1A:G?!M%KV?!1LKT&5MM=OH`?[PCIU@P5PZ[EH6!]\NVD=)=4;.ZU?
M[F0C_=3^Q<K]$JM-OX`ZNNDG/6/^1Z,3YIX!378A_/O<0\<@#4#.7R?KM&5,
MOBK+/$K*KQM%F5+O@-+D!0N2`DC5^``:+@!FS71)THKP1N)+@8^8>G./KX9B
M0:.#%3=#D\=Q0F0-<_%/6&GLST'OGDN'9O>E!+%A%??4'OZB"M.CF)D"/PYP
M$]/`CA7,""HU*/%P6&B$FCE0%N':806N`[_<A,$=R2=8L!YH$7M"J])HG*%T
M!#D;`_G<!J&RKN\M@(Z?&VD1@&Z?Z!3N?![[TE+W"L0(F:@A:I91,A"(Y3@,
M)?RMM9*SXC'0OA;N0B).)Z8Y+62.5O?"`[/$=4YP8%BD/%$16BHV/$VP`CM`
M1B"TM=:/"_0#@%$R.2TNT."_1[,=%)\YR'L`%6SKDXS_+GZ8E?1&G5^L(Q_6
ML9`+=QY')U?'C=\FOU^<=%MM.FSSH=/,"%:/@">@-QD!?$$?`'L?8!<)KV%]
M(6N]FZTX"M&N)]<"JN`AH9MO7C>/=_13``;_)L!-`5W/M",!#P%@`D`P*$@N
MB_DUB//,9T$[-E@'XKIII?N`E=+ZS#QB>5WP8W`+&(2F&@P.VF\`J$D_:9#J
M]XV_`T\E@<K:A63S%L>]#J50"8JH9@D<\*5^WA+D#BW!02V4(/`^!EX;XD+U
M[)\(,<\T8G[((2:<4&G;WAV3+UU3J)<,^QR'&2-?RTW(E2'L69'ZKP7R83(U
MHKO`^B[OT9@0ZGW"%[4C$4C>$>%]CCMFO#=Q*,&XU_#@'-\`_H:C(/$#AYDC
M\T=GAU#$@_T84R_7<F]4T%T_EN0]1-;_"Q)@`\@=]D]$C,/#&7HN[M"G\0KD
M"8]*H0T?A5Z),)Y;MZXPLN8^W5?@-ZW/N!&1B)8"CX_B.4@ZVA`L!I@*S`"/
MV0V:,8@C_`'W/`_(-QM)K$-*/'0NOJ>B)YT,=YN#'DP:1/@+^F`ML)(R20ZH
MZ6OG*[%;+Y5\-IF2>-*I9,@$J#[\Y%F5@`;-P%L$_9&`)88G`.D;&=X?PYE&
M=+9WLP#DY2W:HRA5@>9!?DKA1;/[HJP$J74=@]07]X"H+BR+WH+3AA5X\+9R
MG1C^<%P%AP'KM#YN^*F!RHZ1"^;(;.F!]#@*;!N$:.'+8WQX[MIA8(X`Y&V#
M[%UD5Q&<+UY$H71,1%(H'!>ALP"DM!2,11@#3\Y\U&[(9L:-W$GKNQ_<X6RX
M1)P88&;6F%<#]I#9$3=(F+45HU/Q7Q+]F9HE.$BDB!2@.D2N(XT@1`<+2L&<
MFI2@3X/<%20MX;59#,8M.65BL*KO(W3%P@F!5GHC*9W>)QR9DYX&P)^"80W'
M>!3.?OMX<G9U>:R]%G=!^'V=NK:&&H,[?U5S4U)^1TK4+I`H$NB>]^\SA,LC
M4M/Z0VDWA]ZRA@2H)0KF1\467DQ),J>P.;A]V%=!:1.P)6!7A'I*3&5$RMK4
M]0"Y81:@[X@</DX8WR@B&0\7A[N+@A^N3:X;*[I?T!RH/`8Y_I7I0:"``C_V
ME"%1K<PF:P0(R-O@N[0`WC<G'A`'[2\,(G,?%,W"(+X!10P^WF;J_HH2K-V'
MP'F!52'D<:?`;T$;0/)%=S>^YX"J"0SIOFG]0Q(!9D)$^C<`(=+M4BVXJ*@I
MC5F/:["I"M8HZ+`-P]\>Y:NP!"T-&M8-_#=$AOV(AKB/!%[-36=N*X4(FVZG
MHKVLT5`+M]+K'1"/8E&%4-CC(ZZ7PKH%*\#[/-@]N@D")[:)03KH(`8N2YZ0
MM7INQBBTF((!#2=#=1*8D)%&P#1`%*!8^N^+KYUCO,-*W`\)8[`R>SGEFIGP
MA",1B32!&8`Y.M84]!1Z%N`8"A0\(`-#"]X1;LI]<3[-IUT?V!QH(IYW(A5J
M,JZ:X54@,*I;0;YP].5HS<Y<&R:.&>31,DR88,KVZ%W#^5!AM%T?YM:B)-G.
MK;!M]%Z@(5`0_%HZTTRN_T\C1<@LI'6K[[A>^C$3#\)!%1#F$UJE/@<=F"2J
MFJ'0UMXC/S$(R.>##F5C0+BAG2@)6N$VFN#9MS-0_5!PPN.."V=_;A2S2[RC
MNR)[`68_.K^\.J8]?S;*<O;3YZMC4'=O0'1'6F8[`:S8M^EVU55XV0K+*>B6
M*.7)F&F0\FV!#B,;6GXC'H+$S;N')JA16P`_T@E0(0%[`R\AK/_^?0)RTX-G
M/0PA0-$3N:!KF,W3>FBGVIHH(+ZEKV8`0(D*!4.D(X.V%9`*87VSO/OY8J;U
M+P#8[^HXN6<R`A]VAU^3ZG;C`_DU8*883LIH@P[>8$=A<-](505<%(Q+2C:A
MZ0I5).O.E*$U6CL-GH<L(NPTL%V-A[G])JH(3`*&CR*+0&L\`"Y)-YFT!X"N
M]A*E>AN,:*A/I<LGFC@Q?B;8Z(F!.SP+TT7!`H`*^Q&X[N>+_7HQ4M#&M"66
M:%Y&X<K4L\0KAW2M64#3NH2_D;^N./Z^?+VXNOCTS3HJ]4)TO2#_4OZE:T$O
MW,$6OI:_A8(RNX,M7)2_!1%Z]R<[6/I5^4M'6Z]A?0*CY\3Z$J#+"6CK5,M6
MXPPE6?E[<(=,Z0-R'+P)04Y%'',_3\RP^<01OH--&&7D6Q4\0/O_CC4K;.35
MN((56?[4W5:CU:HB[JW\(7L5+371<BL(**P*NM94@BJ[[$=.7:G"]V-RTP*5
MW_B!TIX.W.,?S:LF>5#1'X**KC4#+,=;1%=]-X!PPZ5QM0JI0VG)<7Z'ZL]4
M4J0B!CAE=\"KWLC"C3*Y=$';F[GR%G$Z]Z:/SB$,!].*MADH__+1IXOS8PMU
MLQC4N:/$V:U5Y=Q(B6^^<!&M[P,C@;<"SDDP/4'?M)688$?&R]RP[)F<)Y99
M@URS9":DFBJ"ZX2`E4*;E!D=@>S:9#T935J@U_C&A_6&1GLUT-%[>*_9[X?_
M/K/:__?GSO^%+?EV8,PLO'@%]9-T8EJ[N+DAAH=>-3(\M'$(5J>/_JY%POF/
MDDF,YI[ZU7^XGH?7":2$TTLJBS=-O.S:B876P*3S\Z1K'6F3U)/Q=ZVW)W8!
MV8WZF100J6>>;"\Q1T>?[>)IHFJL#/*$TJQ,Z1N>'^X<=@G(6CZ9#/H5Q/XE
M["*[U@?D^*.B:/%.53O`(]!7$1J!3E($6L]3&GBR^OJ_>&&QAFA!;_<\'0-A
M\$I[;).;':*QGU/:LE)R0Y+,(G,#NN%98!@B$`"A,9K2%/^:F\+P.->X#/"F
MB3[J.\*\IU59Z`Z&@PO"A)R7.2>B)F#\M9?=&3FIZ=U(KW!P>42$:/9KEX&)
M3!=K;QR7[OV.@"[HGBEY\E@[*0!,VF;$WPDT1SESU$`7L`V4N$*(`-I%B3ED
M-(B[O+M;$^5=D+X$DR>!$,M7D86PB)P/?&WX`5BL*HK_A1"SCOY;ANB@<BL(
M>L9!5+S8D/.&M8`?""];1/DHL&%/F\XPW%KGY(O7^HOUF\0+46G/?OX:`*X?
M/^$J`+`?2(7D-<8J4=`0G/?A6/[D*4%/)B$F*"I!#%MW"(71&:*C?UT?T!0-
M%%$,V"D@Y&JX#@`P$T;X)#IAZ=[$N!4IEMB-8NOH_.S#U;'&:1"+UR:D)+M.
M_"0,G23Q)#[P@RA&S]6GLP\@)_.WX<6[?K.\I2O_[)+?OK?1Z1'<@2:BUM[R
M$R-+-IQ<7*>7H7@GC.Q#^LX"J#0"%BR\6/LDS=S&SW2RC1?N%^OL?/1_X7MT
MA!UG?BU8M_:[D@Z2P+5I(>3(G>W(*7EBK^\UQ,X^Z"/Q$0RW@E05#,-P$X>O
MEO_BV@_($6L<;R'*B]A/552\AD,GW10C!S5SPF/4FHEQ;.O;1YTY$]TOB-,6
M&)F!X=)<!$<*.R>?&E[%*G2&4^1AK,/036@7Y:NI(M_6C%=A&(6M7:\("_*V
MZK`+*]NWQAI<LIEK>6@3!P]SSG!3Y+?%WTE.@9"]@U'A';KQUX#SI*(80CN(
M/6=Y1EC;F8DGR#`MR"7PT%)-[H[9SPE&`V(4[Y*@7I',)NA-.Q+P_CH2<T"F
MJ?0;#PR5/+Q&T)/2B90YAW=!G@;S!^:`K6&$?)@XK?%`)G-@,NAY->1Y!8JF
MQ#KI<&"=5KMG0$DI4GBE@IYIPN/R^7V_W1AWJ\C&2(PW"M;$XSL@!_"2;B)R
M$5:)[@&HL/!`0&!XV-+5/)@NL&RM<&F)24B1Q4#@E9),5%3X8AH$$3!:':6D
M>>3[!X&I@W20:QC0_?JN]4YSD86PD\\&",O032^?-R196)L@NZ[OP9WK1#-X
M;K1-`8UBA8#M'WYR[X6G5`AX+/*_<&<]ZN$^RU,<$Q_`X.%KZ&U**Z":^:)]
M[R*$5E]3&%O@LR:E]Q2"Q_<E?%]2[GW)+M9>[84)WY=4?E]2@6*T@[57>LFC
MHMBYSX+?I1^"#3HW,=1/GWCM;,-*KAT(_[6S.C6T=;B-L*[0UD3'4@B6)DA&
M:Z)`=U6TKZ.K+Y/C-"G:&(QT%W$9!#I\Z#R,;ZQ)(3;'.KH\GVC/NPX6\(U1
MWM`?T8F`T?PP+,8X_0L]=+K,T<FUYY(;)1%V)ODF\VQ1`800",%8$@WK'V`D
MR%`'75X(_?=%'`8+D\K\085">LV<;8YY8;%'X:1X@HFGOJP3[(\J.,',CM]6
M']I81(EU9-:1]UU'[EQG2O*DP$@*',;U;]&%<".B(#PA_U@0XD,ED7JW$F:=
M9.&D.UU.152&<2$_S''VXG40LK[LTI-^\^6->."J*+U?UM>(_[=A3;KXGT[O
M_Z)1/^D,_B]=.9(4W/)R83DYR"0#D9L/W6?)ANS@9!H3YP<AL^2'MXYT6:DT
MWS,_`<7_!;Z,T!>KX@4F@.DX39-LG7LY\3^O>^61:A3,5IFMO@6VFN.J_@;N
MN:J3/9$I:%5,OT'7))J;E<64VY4PY6*P!I7(2;AI&@W2S6G7P##I>XR@.`&,
M\G2MO>TX+[V-?\*(2=4=O,`.YZ[QGEY3%%#&WZ=!L:#`%PQJ00=JK&/&=4Q_
MRG%UKFF:0W`N,0@FL63.Y53B1=+1>7!^G$8\1U2BP+\QUBC=GYV[H;Y4_V@J
M-'R52HK0GJ$Q@7FCE`_KR1M7Z8@+NA;QD^S<9*))6ON,;CTFMJF8INN682DF
M@7=NF#YL;):BV;\R:WH;B,]]3W8PP4&L&S@R/[F.H&#[/)JG-=,(3B\7"D]Q
M[G?6./<+C$YS],I8``[RY#P@EGHL]?9?ZGW1%U9H2Q25[8:%3NO(0Z/A[Y/S
M#U?OEP(;3%#9IT)BS1>3K+4#A]??)^4+.Y.TY5O_`#&Q.[_C>?D[.=O!LC]<
M57`Y;=#*R#F0V\F5:C[(QOCCL!(C/(\UYG[&X)5[_'.@1>AR%`ZH6:@ZF/`;
M[6Y+G&^@9LR+3CFLD6$\9&D5G$4H3^B.-U#1":!'L!"Q$MY2``]%+22J"Z@R
M)Y-.JCV!\4>DE"XG,_XHBB'VGQ_?PV;<W@JT<8L%6A4"+?EJM:!5D62S7%X=
M^:H*(;TIT]&!.H/58#<@9$.Z'\#F$,B=*.\/+`L??7'G81,T=<<I5CC[7=-X
M$%*YE-\CI]E`\R!?%MQ8E:LEY008(U2A4[N9!!89O4FYQ=KY2G"?'TIQ@[4E
MW!Z$SK,K5.QA+?Y7JZ:C2V`ME1J8@E2V9U@&7M\^4AP]J0`F)SS)/CFZ//UR
MG%8<@%TL9B+-_,]E^N?2^_6()D4H*S@'](_N!<SJ!6YX8M*SX=VC3NMDU,(%
M.,>Y\G6-0L63-;7LK-,@7_CNZ*([/B[@'GV5(]9C4AXVI&$+&CC+7$^3M],<
M]'S>N05@.=F089XK`IBOLHC*!KR5EO&!M:TM8I#&MRX5.MQ42#!Q,#P435YD
MS(]5E<E5&E142CZ*I!_3.</)J5PU'MQ#LI^'5MV^+JB!1EG4ERJI^$B<)CJ/
M2U>73`*/<4Y$<ZP)10!?RVQT82&*@9;Y:D%I*+/QU+OHF*':0U3UG9YRH_MU
MH;/*I*HEL:P&VE@A26=AZ,!EC"FTW04YL0C&"ZH-$<]-F;I<-IDF$HI3U]4&
MTL-1\71*WBBDD_P)8C$!4TV.`I[3-_)Y,;JY`RQ\CCE4F-N2I<`TK8F'P;0W
M,XIZIK*B6/,#GI%3K#UMWS?PZ;FK*TW!N"[6"J&Z>5A@+.?;VX2'@!+IH5"X
MK<GNTCF'5X`EDB([T:S0X<[27*MGT;N)/]"0&AP5A0!(AS+E@))P/DS)R6IF
M8W<$D:GS28`O[2U-0\)T(964U\"Y[P*3/@0?1OWF\"?KJ-UJM:RY?0/&BT)7
M81`OCJU;`%VWVQS\E)*9,6'T`];10B<<`K.VFJV.29LC;I(!0RC-+J/`DV&6
MR)=5P/L-:Y)8&I<[^3I;1*%8"3RB-@O(>OR;!VIXOM@8+8AY$B$8_>_>!A5-
MJJ<H4NDC*E4])6TU2L-.EKX24X\)'%B,1F*B*%7PO\!*1'.7:BQK%+^`_WTU
MK.'HZN+BZW'B+,=2+7<Z+T*7@M3"QDA(++D2FE8T.CNYRK85G>9J([42[M-A
M'Q4LME55CO@=>=URB=^-3&!4F`_1:3<ZXRKVHW$+&3+*DIQL6\*U?(+Q-6:2
M5'!HS6Y%>;E8$<HH9`W+C7:QF4ZSBAX[Q<V`5!?13%'F3\7XU^XUVJ,J\$]O
MP3@N`/\RV3BI.(^].G2[,YYY[7?)RD44#(8DF2W2N6\ZZ=")0Y/0ZH)2[4XE
MIK"A4==N62<(H0ZI:,=Y.'TS]@I&U)@.6,4I\E4JW`K)=]RIDN<FVB!HH.ZM
M/$&-,RL8/7,7Q,/NLCN192!4T3*HUP=MMOQA<Y7ESV.97H=C[5@XW33]5-W/
M%U$P-]7CJ">#:1JVM/>LA$F81T?,KQ=DCU%EV\0.3>LS[T*N#:LJQ:`Q(5=H
M3^\&Z_C:TC$-&8X^?/B`S//#WX^SBM6ZAD&Q$(DF2*I.`(8BT`]HF&@Z@2%K
MK"A'7L?>=^V.W50-.T5AGTZ"[.+4@#$V+I6M^QGM(_%#@!J[8O)BY=V9BPTF
MJ%9Q9KVBPF]:?E`H29*OBFY7A`5Y?71^:V)M>O=DSF'EEG2)R[@4%<%!7,V8
MRF#CG\N%U$XN73Q>,RYL^&'J82P!@%IZK,;$&,<`UCWW9.)V29*X$S];*/R;
M)#"F?*095-'2K)KZ):,JB`8.\P\?3B6*?2UQ,^^,X;^!J6A=K(Z.[&<E-QK1
M&[T>D;DV++Z%55!1Y,/;Z+OGRLNONI7U)BM8H1N,T%4OYVX-T4Z?#='7,T3[
MO<9HN%-#=`V^[<!^ZQZ2,=IN#@_*&&TUVI7@X.L9HYWFZ#6,T36T585!NF::
M'1FE@TZE_/>I1NDZ0%1AF(ZJH?A]:7FV&Q6MBI6_K%G;?X-J'='%0JTWN9OC
MJ7UX3P\#+82/@5*>;K^4!G3"-V0K'9U]/>8^)C4SF#[XUM\$&#DAQ?+VJ"QD
M5G./,BKM/V-7UZY+FY@'H>?<X3&'N`>*AGG\[`NU@7TQER8^HX>=D9+4&0S#
M6YKQHXN5V;X4^L-B!-_O9\UT`)J3+'&]9$J7<C%FP'%UF\YD=2CEK,OSR0F5
MEKV5:2N61BXC)W4!3)<B9.;WV/T5-@?:0ZB3LGP9+#RAYLHZ^OCEDSJF/JG4
MGC6I+8?Y_Y[4W2O0-08?(NU7,A5)L]`8<2M<C^*"W7E24B2%X8>OQ_DXFSS$
M14P!)P[^+"V*]TG:W(82="7/E;=I/A?%,5"`":Z;VF1AQ(T)@';("P:?:6VA
M!*A([)4&,$KJ4\X%:(_Q?.G%HS/XGAKZSNX7Z.!#5#-56N%E4_07ERNG4VE'
MIFD=&0SAK4P#3MB%\JI;^9@TW3`16I0_Z>I*A^5K8>,J2E@DS1Y5?(TM?XS?
M6W?O23F&1DK-,!!SET@J*Q\<A"L]@1I8F)K"A#1%+47QF"`F)]!$J=^45`]`
M^`D5VF)!A$ZN94-<:[E#<@ZF0Z:ET\P-=\9"=QBQ]>7_^_G+N75DNF@'WP&?
M`%0_)Y^=>V"XKGV<]/2C@#B?YJ=P.!USG6/Q2<9M$M,-[P53JHJ.-+^(3-IB
M/O4#K&7@'!:P+^DUTK*KF.FQ_N6L*$H%5G65E5%2>\\GG_!51/V,UDH/%&OS
M:RRE&E`#(HRK6Q$%-DA;/6I1V*`X:6:)-<'BA#ITF^Z,%`)F6*:)=1.J&%OW
M-XR>6AM6ERG76(2'RLCCX7<J,"YQD)=69HYFM*[**C*G\86FBV=29-PT4Z<J
M^<*:@R0$V4?%^@G@"@[/0+8_S"H%^4FQ4<2`/*2U-_FCU)6>X8#.I9W%/C:M
M4[H?PWP#O.C":.,`]+*Y>3X-903MI9$4G3"B':OJ]EO]H^OCH\YQ_F4@=II+
MQ^O:2'U$]8!I,RP@2]&0N9[VI!:D_3BUCI2+X03&69YXWE]I7#]K^8K"86]<
MV_HJ;UUYAR=VEN:Q6)\74K]77I_S_3V]W66,G*<>1^M/L+'P6EA2^F$6]=QM
M-8CZ=4%^?6><Q/2:$PW3$]5QQO.%\(NY35G&$JC4('DQ4CKK9I>7YTI@/P<'
M-1D7M&]*;L+8=Q%^UUS&I$)A('1N5&,C`7^<7./"O'K*B?^SHPK^UM$4D`=.
MP3NVKF+,;;U!SOX-6:L)WO]_,9RD_Z^W#J?`=^`1B?'IQ]9GU*2O`H]R@"]=
M;PZ_`Z[]GZPSSQI$_C_Y[D`*1:X.P6^"YD*"DOJ<&^+0I$*T-,?0>9%6,Q%)
M*PR%_2"Q52"&8MRY.F%C@2:Q0?TU:WA)@X4#,DI?0>S1'*`7N71=_T7K8B+E
M6U>Y?`^\^X]U?-27`',CY`N%G3FDRMRM^YX?0/T3;"./*-D-"S<EF7]3;"E,
M5(0I.G)N+"=J+^!8Z%D"!9@,\VNIH]L6(C1EV;1NNXA#%>/)FEB.D%K/4N:^
M5G`I/,=0_A7&[V3),1<_[!F&6)$2Y.JRMD=7%V?8B<GW4#XF.3L`KAPO,%U5
M,$68&ICAK5]B\"EJ#2%5LIXBWT(@%%J9Y7Z^DYM^B0O\+2@P0V!&^1_3AFH:
M/+J9]-TL0/]B<(?)@BJ^5J[C"FQ3-EE0J%G#^N#;S<;2R,F/!=[J.P^/N-D/
MBZ._HY^;[_8`;P]#P5R]GM$JIZL0JUT_AN/+U'ZKY%K<.MJ*&BW8H$EJ?\,G
MH`ZKW='B5T9&(J._`R:"QT`2N\)$2V(M1-(WUTM<3,V?24^G(J+2:CH@H[#.
M]A=D^TOJ/^;Y4>P+T("U,P3GGJ]G2B)E(KI_&-5<0T_+'"::83"5&SAJ67//
MKH\3%5ZGZ=$M2IYU74ZN3JUOP0(T^4ZK?]*!IPMR#.:^3)=UE2WKQ-IPEMI)
MD1NV.Z`Q$1K8X01+,IAN.!=_QBX9]B^TVO<XO_Z5Z/`/$V%X86*'"$._D)![
M\-@K4,)34['SBVF`5UB%EFS;R&ZBKM#!6`\3GY>I7";1&26T;G..0D0[G'+-
M10L>4YC;>,R`'P"B`E%@(+BXT:4V,/A<?,\R=[5@!Q,@GIO(7'W!19=)AM<@
M5T'K>:Y=JNC21Y-!O^JYXMKU,AT!68D7*'3G81\^HC3J$K;I'>/6-]&@.E)F
M'3\Q833KED.Y^+'F,>AC]!%-LL"D'&/4;*>)10IC'7]/.96ZMY/C4D8X@B5T
M3>P[I6&C'9,"C(E^QT3_)2,"\K\E)`786BU=%P/6MM;#4Y&9H*?1O$G6ZFJA
M:W1!H`4,:?52]-/BU0C>;+Q,N3=5`PPGL/-P81S=,8Y^E;8'#(ZLYO4>X7(E
MSADH)8+*N6$G88HJ3/AAAB!ANB@=,0`H`HK?G/XTE3?HS45.<4JRF\+E#5%+
M5NP6K24#2#D?KU0#T"HQ,%Z!!?/2/(U7.KLSH69$G/0'*G<4F+H3K2$A;RI=
MXT@LD8&-)W7E'L^%M6!ECFLLD:6B,)YG]Y@"U(S0O7%]:N<7Q4DV5@71!)4$
M4HM[E?%7+!!#[@-SB0_G(+-S:.J3R7V3E/K)5?5`K62>W/EB<1O-%K%2_+WQ
MQ&=,U!0\T?]084,6Z[MGF52P#L\)C[=B8LO-1NB5KQ5EH[=_JCU4U$];HP3R
MN!G=7"=WQ.MNB3)-P#6U+'5^F](E,"-4VLG>=@EMPT5`B4\V!M%A$:S08=3;
M->I="C>T_BZ\6!8-Q@\9D]T%[Q=A2!Z5A&^EIDW2_E9001B0K1*8%^+0,F=L
M9"P-B\;!U]19/OUR(>[--S[B_0*!8'FFD%:6L&*R-Z8(%BSH1=93DE;NHG"'
M=>GJ7;Z.U,BN-RF/C\B&]%4@LY+0>0^]E54O?0,ZI_XH[<**0]]5,T"LJI&X
M..\TFY?B8\DPHK`]&ZNH&5D;8K<R_%X7EJ/HU2@4"$@=B#678&\[II";3AC/
MI8K%2DYC0&$7HW..,I](^3LEKV4%`*PDWQMSBRI8*Q5M.\ZN@3U]HN3(>9-"
M:ZE@]&@Y06+'<NRW('`H;X\:Y6'LQ(V+40`3.J&*J;\P.0)@B@&O\@1ID^X&
MDM4DCK]0-X$':0?J%@:Q8Z`ZE;G0VKK."S=U!5S0M-Q0,Y=HR8F'Y2-U,"]=
MP5$$X12=G:82YC2)U2>IYX9V/`=F9.X<]4UD?GQL)$]&,R6I@U[6M"Z%'6$A
MCVBMB0;OPDKH(H(*F9+S$+3+FQOJ/9_>BY@0HZ7M&"]1(]T^`B4IA1`%N@)&
M&BC]<+_L;7"5<GD&0\#,3=B;NV1;BZU;O/=4=$J&I%27]YU16CO\@;+?+T;?
M?%R#OLA.;[CF6&^;^J"CFA[KN!5*F0E3CF>96&030W:?:O5881?-]N2:[>7\
MA<]LW9FE+9N`BF,XA7N*_`:Z#.98"#F4OL.PKPCVCK0]TU9$18']'3TOMJ[[
M*BP%IR&HLK*^7Z&XAQ(/8BNH'Q*(C6EE++:D8#XI8(C_H$.B\_4Z"+YK>^U-
M*F.[6WI!U:&PIC7Z#7F),CW(V"@HX),BV<ZR*C!U0[",KN^!A/X$U<>-]/&*
MK(,SG'3:.4[7>'._2\^=8?MF%%;I6$WK`\HNS$G(MYI#_22O>RBM+=$H6#<+
MM!50/QH%18=V2C7(%F%@2^DDH5D8O@R:VB(_(NIN.F%);T;_KO1UPWQ!ZAW^
MF+H6,FNBH,Z9*99\(NL?IKVN>UK^P.6JI1FQ@+XIRT^KF\<(]$3',E<CPK-U
M(?H\2#\G$6P-5"JWVD=^"4O+TU"^27`)@(2:7Z)6IHFD>@&D=21SS*7`"W4"
M.-X_`@!\TCR6@MB3^0H+3"=,U!631+:T\.1V\G%-OH@M*;:I@O_(:%+IY)FY
MG_CBT?TD[%GC"3/G1@$M&FN0)*,P`ZPXH7WY))90=^7LD/`U=JZRO3OD+5-A
M:Y6Z:*"I&*PH92RKC4BMTG6@\89KN:8K2]+$L6!<_G*MX*Y?8!#SO>%0+H+.
MG=Z;\%<,P\FO$R\W,685:-^7L#A%$9N!OX[YXY8>MSK3726KQ\,L$KT)<\'&
MGXJ\N,F-Q128E<JYPC2WT"ZP2(?XZDB5G+UM8G*%OXX?E>7"84?MYDCNA$N"
M7HQ7[]+)L^TELLB8VP9E`)^G#MHW3W.]4$LFS*;&?]?3KQ$]2T-IWCP3JSH%
M"D9)OU"D@1\4=(*@2*-:D%6@/&^.&BU_,B:6'=]J:">F]=])O/(5QBN7?ZXG
MA3B,[$8A%Y&A%Z))I!@^36S_R#W6?^A$=9@.2Z70Y;$AC[0JBFGY>!U@*V.\
M::8.S.AI1#]F%J5IXA=TH$<,;)VB.[`@C!YI>:H&+,(]SDL6Y/Y9W1/-:9+:
M)[1T-ZG%FZ1BHX+LIH.9T1*XX%:2'G*.SGHF[I243Z#R+"3BA'4=WY,?-#&5
M]!)5$H[J)+8!YF32)-@<,TTBR_:`Z[@]IH.(Y_-"(84\E+&[9AA<ZWO.H]L5
M*%Q+$GFT7N\^EY29!<%C'KKV9VB#"=<J5*!+.;B)X1VD?:>3Z*F"C0'[/;HU
M8%M:7[X3'_'VZ7U2WAB;7>G$*\R[RU)5=4HI(@#VZ`+C#^]BFM9E6D"#UE$(
MT=(5D76\N@Z%3>_GDJTNJ>Y9)+S*[N:2P75:(,4_8)(!/(&5/K)?DJ+C5)5G
M@P5B[I2-RF\@1>J4=-#/OC'7(<&92'P'^C%D8];]7VH3J:RGK?_*D1#5]'$*
M4,"(:+EE7H5Y+\FKR&5*+&=6E",N.$MN>W&1U;=2YC[LY'<@:9^TJGQ4;_G7
M8I?H!463W@>]":?,"F"9P'5ISWRL5T%M,N]DH@_J<LC"NU?:(,E\/2!0B'G"
ML[/`P]1UJMBO&9*.LZ`ZJFE=,.)HN5@D\PRUA5M]%>T>;,'V.8DT,;F@F#A$
M#P$SB$0&3*PQX\5*)\K<R34+7:YJ-A68V$8%%323QZ*7VE>Q:3GYS`?2;*>6
M"AJI)*9AM"%FI&$N)'MY?N(M^Z]U%H'M&+V;&KZ!SKT!D)A6D1>VU\7@=69-
ME2KA_P`\]%3P.(D;E^*FO)CD\A$IV"^05J)"D,KP+DVG?T>:+#H@5>HY!*JS
MJ=215F_0/[+!CXD7"LE2DJFQZD[@@])DO"O4F),<DYD7TR>-S^07Z@Z;62`Y
M)@J;RW.MV"BR?[4_7*>;&\@`-NM6(]I;<8?0UJF"N6:(^22A/*V_>83>=<1\
MD&9U?4D0[`LAV)GAU3O(SK%RJ[#STR).KL-(I15[]/)EY>0R?UJ.)#+/>Y[L
MM.?]VUKJL3>N!:<\,0Y\FE4*>[:2D9;$]`-1._^,590F!^:F2M/\T2*@!-]<
M0E*:AJ2S[N8@OV>H^]Q*<F.R?WS726LB2IW!^F]KLEAXB:EV%JC*`[32_@AY
M:R<M;:8M78H1SE:JZU^1!9>JK"8XREB*J7&G3<GLFFX:4V#PM?3EU$W=)3`<
M^213%I[,YJ)N:.LLIF8"(0P4):.]H14=72759'22W*&6,.%+=!A&WVW0]PK3
MN4QK*93A<`"[8.EY5YR^GM4WJ52=4^4KDU"B_N3JS"3K#]NC1KX61ZGKW"@%
M<W#)RM[GMG-%D3*KSU%MD`I`>92O1@*P`:CD)DQK1:=YX<MWR\DU6.*3,J(D
M67Q"B3KJQ_-T))#!DH6XUV/<84J++A2%]5!![PON)9J]0!(GR<?,.]-([$O,
MQ!:4TY`56=.A1FG/*/1%B3`4E!.F@;MV?87@\9O0]*TNR.U,[J_)P%]%.8!F
M=L0`UD25R#1BD4V?:MD$:(7!(%B,&?4CDW]>;YZPQ^Q,I_>@#VXCYFB$T(=6
MU-7(=Z</"D_7UU=CU_<%S%T*?TB10*U'Q0W894A0JWF8@U1D9_U6_Z3?6J%G
M_761I'./E.OLV,#U,.DCNC=55;]HHB=I_PF`9%TD4*KB`BY75^E3GI?H4\X?
MLCYCH^0X`=UVWI([++D$`:.6^A%J[J"C%1++8#TQX_N%$A+&@/#)VTQ:?>9_
M6]'O=:(V@,D,H[%H*:9A';K2Y6T:GI3/FSG%?I\G5_8LH-((].X)VOGXP#QP
M,#Q^R?S(7EYGPJPO@1DD$9]):`)2@\FAS"%\CAOF*F^8W6.E7+)K$+Q)-SGO
M'IBXF[0,7+DH('?D0_2+49!YPL193'%R<@[J4F4FP%NKI\M*:_;+>NHU+@Y=
MUB$'L@RF&OW1:>F9X/`"W\',A!BO$_4U!3/^W2<9PS9LG=]_GBO)?&'*Q%2L
MT!;FSY>$3DV=]>8-%IA+C?WP\4'NL#]O([.^LMM7<T=%A005LI.IL(V/L0'D
M@C8I_@5G)$.L)9`*0!H"F-],"B?-_0*Z0M?#QA4Y6`1)>R^,8F<:R2;5Z0W8
MF1`J7?K9>JBGK$QKWPG^F%KUR2TJW2@).\I..0AOA&^BT!6VG?FLC@M!1:;$
M_DF")F9@V`3='(O(6!Y4!!F7E+^:Q\"#V&;N6'G=[(<.'4\&SY7.)8N",0GD
MNGP^=?;3F=^Z1)'2%X>4A4<1,,:A8YI0I#8EZ!`NV'JDE[B@K$2!;T+C06NB
M)CK-A"'G.8W(GEZRMXQ03[0+WZ`7V;/Y5Y+A<8'I4X7K2^,&VQ09G_Z>M$=,
M%[P'![['N/J-0KQO`ZW,DO=P29)HSH(W5)ZX`:E%.7CFQJAI_8,J<(6Q-)HU
M&>$:\U/G`*)\X@9`93!>P#RX;AF=Q`OS=-*TW%)V**5OBKE':;Z#X7RI8Q\G
MRGH^)K\6^6)A!=_]X,Z3SHW,]<7*TP\Z]F-5&)]Q;\=:Y`>=;/!-_*A<8?RV
MWK>0OQE&YYN^J$VZXSA8Q)@N^\4/\FE0+K2MTS`BB>G*V(M.US?4/US+Z$XF
M,8OP5AH!DN6Z+E=VU.&"*_47$P-KR^J6B:<CYT[KM4[:K9V[;W.5S1&.A3/.
M>1I6?*JTVKP/9I4<7XX2WXAKK3\Z$D6F0C\"7_S0(AI[SJ`BI2._L],Q!BX5
M<\@"5=?5T<R%(RR??YCF5VAI"@]%'LKMG1Q5!O?R09WSAE,@:"XX`2\@"'.O
MR6$,8';5##4F!&(N!C&7`[65/B%TLP1AD9/(-![,J%C'5](QIZDMF`6*X,[S
MAR2O4)D#I4Q1.K+[)/\*HSK2<4W.%))[+NADS7XIG#&7\B(B*AI$%;$HG(5:
M+A'+:%II.Q8,=$T'6_:28NR7#O[`2SU;F-);9DFZ?N4_8U^'S&J-E,Q7JL1%
M>1!8/SI)`)?8JXU*(X&Y'&"N3%KI=0T0'@#`<D#.^N-WLWBJIC7)7=";&-AU
M[R2NHY#:3!)QFK\W.=MRJTLO'_!%8]3KLR^$#*-JG;N^@>VF#H"<&KUI/IHH
M2$(F4S)0N93D?\;.#0Y-QEYZ7ZNET#3"E*<?6(6/S@O>3;I[^?(.M+([O/.!
MOY;C"=%;BJ_AF>FGZ-XI]JAT$,;ZBA\4`FBB=JDRZOD:V26*17P3I6O=7O,%
MCC'GK%C]X;$W,B::E"TO.(R+U@C\B=?L=):HW'$QULK3K,@!1C%D.1I*'?@I
M!67=!-=4I%=+)>G+ES0[#1Q-R^:3+92$^>ORWRYU]05>AZ[IM<Q+W&#;WX@,
ME(((R5@G8_7N@^ZROL"Z%+:N(?G55=\KMDHN"T4NDSJTI,ND?0V]^^SVI9A>
MD9<H]LHN3"7,$':1+^N*);]I4'PDJ="[6ADVKP\EF*WT<Z9\(K'OQ#^05D;4
M-[%W`3SE?U=)9`0&!;ISH^^B'RL-IIU*Q[C$8'RZ2Z.23>I@XLPW7@$NE]ZE
MX/.-)7;G,<GD*>AD:G,6MGZ=E!:3D.T$4B>E$A/*/T#QS_>Z"K+*^A'II.<L
MP3EGIN5>O@F%(_/F'-[F$^ZAXD#W(BJ]\BABTTSH!:$<"5U)K=OQ>YT53FG@
MI%OJ\L'/0M,"86QZF9`2$'5#H=FT'_EVZ,IQ<Q4SZ7SD[>^`*A5SYK.54-]"
M:>-$@.,/.IT0M21M6A6CA!-+#'A.YEA*5**T`?+;E?JOWXGJD6:U%Z8P_]3Z
M*FV*-\ZU[@L#/T#[K;+:QK6!K>L#;KO1`6.&<4E;$]"2/-,:*PV)=<%L!6X_
MN?J#?CEIC1J`#TDPTJ8^9A0=D3;N(<YQ3OT[\8Y/-SU>`+22[C^^=4$)>W3Q
MEYL*VP!BHEYA=DH@<M+10FF8"9GX5M:05\W<*4G[7%8M"3<*/Q<@-O^)Y?[2
M]A.;%):@N*U\3);V$Z@9%>R\EKF^[ECB8GT/-'3XZ+QX%*>-_-XRGPGH"(*L
M1B<'1'$=Q-'&UFJT-7(2D;/'6>M!QTJ4H5%6R9WH4@</8Z[1^/E\^9S'MF$8
M>J/8%(GRHC?L\QN%1H'UF_KN\WNE4!4"/DH+%!!3&`@62WYE4\7)%#Y-Q(9)
M7]=E:<QSUW#8/MVCB2GF>Z7=VK%;LS98\\J2<`+J=47NQ9O8U3<)Z9T#7L$E
M3:!A;VG#.%3>!,6V..2-7=/'[L'N=;B_Q7)?U&)KJZ5<\'R/O4UG?J2D3'+<
MC]>XSLM@.]WG.%O>#M/\*.X?8)F?@F9F;6G,'S>R;[Z:/F-T'XWI9R$5L2+R
M/(M5!/06JO<FAG?0&N1>+3#*<3/_(7>UD&0[I`VO<E4B_H5(F^]T9N*N3-V(
M.<5@ZE^Q[I2#91#P]3^:5TWKM\GDBR:L]#=@'AY=68BD(EQ1(:0(4AHA32H&
M6S[.8IISEV?ILL"*SR[LBP"R$P#1XE4,9*'`2L%[$B#BI*1&,E+>SYV0?3XS
M("D!>X).9[2ATJ>H.![2_GUR*8!.Z'7CZAWJ//*U*VU0(#")NO?64?LX*1CF
MRJS3+;YWI(Y-`E_Z[B_646?E>9,23"PL@!._*;;9S`T'KW>/B_=*Q:HBE,\+
M3_6.R6*VTVN@E8>2*X"G3$[%3/K'^1OH!("ZY`W=01^;`&C*W<?(644[%1NF
MRI'6MYG,HU""DQAN08D:FG43PN%=V49,0H-W$1D!DUK"J=C!J`U@OV0(Z2(%
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MP4_,-3K@_UER@40U)WX+$-WH0B+TBT9@N]_,?]`8!KS/<VT7T=5PQZ66M+K(
M829MBS>QV3+LPC)N`A,^K)=!][]!:DXE-^#3((BPPWQ>?7>S4-5"I4[--5!?
M2-6D)/"SR(]0*J5J4<$:,<$1YC(X(>CU[*YI78@0!%VHS9RDFAG*_"A:CO8P
M]8(!D3UC%N'(!<!7P"22(WP.D\CB(,U-O9DW`:DCD>&1F;MX8&C=!M$U1<TR
M64AA2*F,M64N"]U48@W"K*J=L;AUP`+-E\(0A]2LWDG/_86.3N9OS^%O?Q-`
M.R$9:/T'&5S_I`5R_@KQUIV2GF_"]]*6W\5N\-?WUH7IEIL<.'&O!?E++WZ`
M+D0Y:3CY!_2`YYD:3I:3Q+EOLQ:\ID@-FEF)-IV,+@NCDW^]F1_Z&:K58WI4
M7S.6^VW82GKQIHL49DPA?3=C![3<C!V(7*]B3=GF4NS15LD/4U?R]U]^CM7)
MC1"+]Y]S"2B%!M`3W\D?].=I>E.=-7_/Q!\\G6NXD&G^7_`.$CCY-SBK4S"F
MOO_U/_[]W_Z23HZF@\8O&(`^F62%;.3T31)1\.&KG/[Z[O(<@?8_W?_]=OX.
M;$'X`H!TTNZ=M3N7XTYWT.KWAZ/^:-0]:W>'YY-AJ]>=C,_?_76)2//D](VN
MIS^!A/H:@`S=2(Z[OLJS`R\(W___6JW>>&A^O--37@>>H^<@T"64>F1@>,PW
MDB4N78/8W.4=&;?OL<Z,G6.G7%.M("FN<:1MEAB&==3Q\YM-96L9E["?;(RL
MK$;96))[I]!PIK74TPT_YP?UT;'AI=UBHF"!`__(!HXH&MN6GF>>^?5=ZQU]
M5L`CD\]/)^T[UXEF\"?LZ1KC#L,3:C"[4/)]\L?F1CE1F/Z%62BX%/_7=^W!
M.RL$--`?TH=_CISLSW#M$+287]_U^C\51L@-O6ZT[,7V<]][]HO[\M[>+)0W
M^*H;W$29AK'<8D]KT"(--]"MR(JMM3JY%F?(QO*?3>NR_%>F+Q:RNL>6F>.M
M:[MR$5,;E2`H1D\4%$6XIRL?OGL8;(;?&J"T%S\LTD`M4'?P_YX%UK6<=SW@
M,)I#AE6![AL%0W\,*`;Z@ES4:>BAU6TUG@#0FN$>9BNA[_O]S'5`EI=K>#/"
M/1?A/F',_<OQC1E@>0RP^PKX^`A87Q-#U\98,]MC-"L=S7J,9HQFS,T8S0X"
MS;;F9L_2W:Z%_?V&LKU/C+?9MJ6<3FNEU)5=R"LM8OA@S?FE-@])'/#]:Y+]
MQN.J):#_LRQ0/8JEVYIHVT.&<+@ZT'1;P\J!LTN<*/T^O4SL>,."=>?"M!;8
M^`H<ZA%0'AX'ZX_+XV#/!1YS..9PK&.QCK4>-(,QJUC,@)@!,0-Z)09TU*^>
M`ZT24W7@JA:1'@Y:/*1+RK*+M041]LU>&Z58C8K>!17="6*,R7N1K:@'I7"_
M%:6_EJ"NR%Y\`)X[!M\>N;T>@V!ML.LU%3?6SUZ!KS'KVD]]K3*7UAH@,0-B
M!L2*53VYTQXJ5B7ZNEBO8K;&;(W96AW86ID>M&TA^"1/VOZAY'/<;#]3_N7:
MYQ].,7]*EG<A/_P+MO;]0JGY7Z7M":72VE%9KY!SJ>S0U0GUCZ>(7W;/.]W3
MT>EY:W+:[PW.)F>3SNG9Y>"\TVX/3GNGE:>(OV[/UB(0*R^A;"K!Z!;-5%4J
MZ8E$90ZNL==(F"Y*-U6!,\029_2G*5U';^:+1C9-&Z=P>4,PKH-UF+-BIDF-
M9JS28*F9"!]I\K:*OT_%PB44QBJ5T?T7#^LB^`XV^::&KE09X?XIU0V&[4F_
MVQZ?CUJ3B_YI?S+IG@TZ_?&HT[H<C3O=T6Y1MZK.(QM0-X4;E>VXC$/?53-@
MPU6C<''>:38OU<.CNAL.UI''_H.F=B0@JNG_F34%QV*\",@3C]JBR&@6.%FW
M0BJ>9OHEXEMR&GN6Y]["B1UE'4/+WREU:ZD`@$"ZY8\Z!7A4L%:J!7.<1/XF
MI:T.O!/+.B:W'9\J,+>D!S<\G^L`;H2[?G$+OG8VONR,3T]'$Y#&_=/SR?BL
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MX9RQ=2`96_U&>\A9HSO#CS<L19D',0_:$,K;&`^X.%"E.M,AJT;!'#U\68/=
MQ+^;W+\^1]/O/*+IOSA)ZE4);CSNE$5NAT)5]2.@V@GP-T(<[4:KUV+R8$/]
M6=CS)0RF4BF016"F3^6:F*82"*Q4P-:)\MJ=-NN!;(O61Y0=**6-F,[8WGIV
MA]5(AE)%260%:Y`K-5]*<V8<"@W5CUSV5R3M-VWTF39V:%JU#DKR/"VDKS0%
MIY+$_DWGMW_IU;O+^'_)S<<>E@(8-KJ='18YJ3U&LC%=3\V%N2=SS_IQSU%C
M-"HM")*YY[8J[',+IVR?YK(A.^;<58M`">\W.(6%TAF[@,58=B7`#E<PY&>=
M?1OX2E=HN<**!IA]<RH\X=OR:B8EYH-/`/\C\N!G15O44])LSLXO^]W6::M_
M.>Z=C=J3R67W]/RB<W[6;@]/+WO#`TJS^59(EM%I&J9Z">CGE";H8XJSOIY/
M>HZ),+S'YY,**?"]KD)`*GT^+R?M4C:?R]#&V,<@/45*2]2OS:3GP#I""S!`
M-J@0BDE+O-9G:RD\7%5N.D\AR'8YOV6+<SNP')G!*"<K7CU)IC<&Z#POJ6/T
MW!>'X^>^V7ONB_W#W>2>>-YKIY!SOL(CV3(6)\DPTNTX2<8J*S<F+R!KX[-X
M31/Z;+,VZ2:%>Z@L2DCIW4[.(L@IDP^K@N5*I8-SRVNX@[(OW5NR_UZ1K]82
M1J6Y>?8VR+_=Z'1'94'A4!PGK%<P?V#^8/A#OUN:/GXH_(%C`[:/2KL%-3X(
MGW;Q_];C0-N-;KLTH7SPD:!\2<P1U\^EM$&_O,O(0Z<SMK!7DHKD0K@/!KYI
MAT<5!+G?=-=NM`9;N]S>BEK)9B>31T(>PQY'9+/5]4STV=@QA$(P6#W<&I"=
M'B?DL1E6([%VJ'0V+*VTP\'3&9MARQ>=U]C:RK-HF=6)N/VFL':W,>2+/K:X
MV.+:0!^]1K_;9?I@D^MY^//_XH4G_7\9(<2JWQ,2@MHM-K+8R*J1)&-*8TIC
M,VMYD-^"P,$.;ZP[KNB.0Z[;RH85&U9,'&Q5E1P^.%\(-]1]G&<BO)%)FTNA
ME#N%`71U<;4VW[@2U?"1+*D#51V/1HW6L#S=\:5`S+!V7P/+C]G@JY&$?:-4
MK8$ZZK0[Y?D?G@O)-RW;=T^K.V-TWX((&Z,5PB%W+:;+*F^U=<V@5U:X&Z,2
M_3R/EEAZ"Y64ZD?`AR)LWQ9M=H:-5KNT6T:FS:JMZ=>@9%-7JO-0L:K=4_6C
MY4->MZI%K8%8&\`Q)KYE3'QQY9K=`/!5"]3D:QS6IDK-FW3]IN5K%N+^M6O7
MU,)KP2UM2["-&]T^M]5^`ZK+JZLKS(.8!VUH0U5B_?,ZX$3M;/L#UXJJZ;7S
M1J)1!HTN9\&P=YN#M3:1QW#$93D.S,'\2G>]>5?*<R]\7^$BJ?8=8[B'T6MS
MR6%C,"ZM.@OW,&(?!'>`8^[YAKAG>\#],W>NNF[7`2ZWKR?VUJJVG]FS`+'E
M9NC47K<U6RC3YFRFK=H"MDB]VJ(H=*]C_5@4/-1U;28B2X1IGS?I)+W6;/@9
MT5O@=RKIKH?7F3A1*&?25^ZMM+Q`82;%IDM.;M*VYMC+:]+67I37I*T]>&&7
MMF[K%;JT/?O-?>K2-GP+FWP3)[FK3>Y)2D'MS)]TN<-7:'U6FT9GWV:AE-9'
M^&&FK`L?XYD*#??*TL09X1CA:(Q/H'>5@&_,];CA8YEHR7U%&<UV@V:E7:`R
MFC&:,3=C--L/;L9A$ELZ@#_)R`KEK?3C>B8UU.9F9+^BC??P*J[3:`\&E<.N
M-OC$<0KUE+[,VIBUE9_I->A4WU.D-OC$K(U96TU0D5E;Y76\.^/JNT/7!I^8
MM3%KJPDJ,FNK//^HW2G-?5Y_?*I=UM(!>]W.`D4ACT_WO+V1W+^C8;NT2NVK
M.%%=NOZ>%&IFC>'-$%*GO-[=3$A,2&^7D-J-_K"T:JE,2DQ*;Y>4QIW2XT7>
M$"%Q;,.V]8GF`8#B7[HO#R:8`62$ZUO"_C-V0TI)BX1_XV*VE6X&4`6M'FB_
MCJ-.JWJ_[QND[CTBY/V5GX=*D\/J;YF9))DDF22?0)+CZBML,DTR33)-/D%U
MW4'=[3=(DWS+5QSDJU12A/:,ZN(Z\E9ZP0*+G;!':-6Y.BA-<WV#A%<_&MM?
MF;?GA-1IER;:F)"8D-XN(76[3$A,2$Q(+R:D`4LDONRK'J)7TO-@F0WK1OHR
M%%Z#K"[AS%W?51%6C;RMIKOW@?I(>HW!L+003/:2L.>2/9=E:*6-87FQ,TR5
M3)5,E65X+[N-_K"\)AQ,EDR63)8ED&6K,>Y7G\'W!LF2;_J6JF@%_HGI3>#?
M8*_V8"ZM(],7\RG,[JTXA=J<E,3.U3K(OOVF(PV;4:?=>0IP'@3(H:2<,Y$P
MD;"P86'#=,3"II[U36KDN]@9V_DP7P@WI(YO]DR$-]*:AL$<`"^4<J<P`.7J
M"67R\9[=JWE[W\<C-;0/U3<R:K2&[=)<(R\%(LO3.G*%_16T;Y2J*Y#0SX;D
MH8AVIE>F5Y;"+(69JIFJ60KOE8%=1*/601G2OV-[=+*=-S1(KP;UNH!Z3A!C
MQ9R7=)FJ3=';5RBBO"T\#ZN8\E&[W1@,RPO&V!:*3])I]@\MV8U?GE[#;)#9
M8/7YN8U!KR*+C[D@<T'F@LP%]X`+M@>-%BN#S`:9#>XSOC$;?&EJ?&/0+:VD
M/'/!YR<Q_!P)@-3:YW-_YW;CN;X\F4F"9+O3^NF7Y>W19]<'7A:]'PP`D-6Y
MFY_C6GUT*SM9^K>9M*:!!WP?TR;H#*Q%*!7,K"P%L*20()@DRZV`_9W80LTL
M-Y)S13G^MEBXD?`L2K=PW"B&$:Q0>B*2CA4%FQRDUI'K6]$LB&&1CCI^OP?P
MJN:H-V!MZX&=Y,8LB#I\9WF,_*1^$,Z%5^`[;7PF'5CC@"T]SSSSZ[O6._H,
MK,5./J^!X3=W#J?^2=Y97X.Y6%$@[EPGFKT?C'(L#=B5)Q9*OD_^6(%&MJK\
ME4/*YD9KKYRVN+2@Q?SZKC>&K3_*0HL2P+PZ>NZ+P_%SW^P]]\7^X6YR3]+@
M:J=<I\OMOO`&N0)8/JRZV,#59)B#Q*@$!I^.<247(-6N96AU6PVKTVJ7WB:%
MD8Z1[C&DV]HOPU'O3X]Z#Z8O#6TOG<[KWYJ66QU7WL6]S#C$VN,3QPO74T0S
M:V/6M@_1F+7'JIJ'8AZ4<G<N%Z&T79.YB#5'<VT'7Y/YU1):I;&QZ@!0M:[5
M+ZUOXJ&PE/IQC\-7C9@[U)([=,NKEGXHW('=3-N60(\"^_O)M5`2O9US+#[W
MZDI(+3*3]LO(JB=C&HZJ;_=\*!QKCYC3X2LZM<`VYD`O!TV_7WV)[4/A0.RD
M*0[R)0[M&2A&"B_@%B%&@47WY*V1?\;N4[MRLC'V-HRQHVYI.0K/"KZM)5IP
MED&-E9U:8@PS$BZ=R=Z=E^+0&4:]+X2K@X:$#7J+<NG2"52:_Q<O/.G_RZ(]
ME%;[@\VM-VQN'?5;I?5DY])C[!RJI;[$W.I0N%6WT>H/F%_5($TR^?LO/\?J
MY$:(Q?LK>R:=V).?I^>N6@1*>+\!<!?J@V][,4+K/)>B]SG-T/M`?92N(A%)
M=-"<"D_XMKR:21E-?&<"<,;'A(=O>X'"O+]O`+Y3+["___4__OW?_K(Z_\5\
MX07W4E[)\-;%L40H3_'"["QW7S;Q8`3ZZ_/TJ[2#&Q]`YWP!4`;PG(JR62Q<
M-7SX*J>_OKL\QXR-_^G^[[?S=Y;KP!?"CDXFDWZ[U[T8#8>35G\\.!M=GE^.
M)KUQOW76&U_V3]_]=0D#\J?Y2%;;.@1Z.#VQO^MT3A7/YR*$YY05P<]X+0DF
M`N9W@M:J-EQ86J9SED49FO@6+E\_Y5-4'>5VJ@0S:#`<()0S>,Z]E99']?%`
M4<;WHUDH)7G[?(".-8>USY0E85#'6B&#EU_#)@D5F8C;F,[SXLEH5YBTT;``
M_1?2QC[7WGTUR:V58L^S#,DMDUM7,FCV/)T52.K&]?4B11P%R1=:+-$W.N.U
MW0)`E)7PVAZ\-..U_=/S\C*?_5YGUQ/R!GF#==S@GEP(UL[B3)<[?(6LT=KD
MB'XC!>JCUILN2&\JI(V^I@G/"'>`"/<)]?27XQMSO8/(E=\^K^HU<;9^]1I*
MRT=C!#T0!"T]GH69).,@,TE&T$-"4"Z`4[9O]ZM44H3VC+S5CKR57O#J,;?U
MS^+?KWOA/:P-,2JO^&[MD8GSG>HII)FO,5\K&V[C#O,UYFO,UYBO'19?Z_19
M86/&QHR-&=N!,;9>M_KB&K7!IMIEDQVPX^TWZ<M0>+HNH3-W?5=%&%U]^Y2*
MT^E>7MKPO>*0A*J)M$2SZA%`'0HYUH_R:J=.,'%IE\6XO&1#)BXF+B:NW"#M
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MVUIL:)YQ*=SP[\*+Y40I&:F)[_SNBFO7<R-7JH]28`<.Y[,/8\=A"$@/*W#5
M-]S;4QIFG%]>GIU?7K2ZO<%I_[1S=MHY/QV?G_5[W>YIZ[+?VVW#C,%BMPTS
ME+4(I8*I+=>?8GL!<EZ*ZR".K"`.+4&@IWP^+P.^-3?0MT1D3>&8K%L\)PM?
MM<+D/-`MZJI'FFI<ZRXKEL(V*ZJT/A(EPW"\A<S,+:<@YFK;U8%;-G#!_SHM
ME#?(+1M>HF2559>3/MUIYGP=>(YF@@ZH,/K^[GT,C#Q$%JZG.Y?*#MT%_O0$
MI;5FU5)K4Q#U*>VLV(Q_KAG/V+<>^_XG#D`KS4#Z)03[1F6?/_@Y<#_\UY:J
MZ\ZV-J%>;=9'$7Z7C_1L?HWE'?V.=7JM=FF-;9G*F<HWR1B8PIW"<P#$%*Z?
MP4H-:T<6GZ_AIUMRV-27M7SP%S$:[YJ$.TS"3,)5H]P??K`_E%&[91E*[3ZG
M*_,6QN$<B,>3=0JEW]G5C_95/^RX?"Z%[Q"<^\`::P.LPY4IC'&,<8QQC'&,
M<6\#XYZEYAVP-G<FU,R2?\;NK?!`(2\M<^<Y(*LE@$J+=*H.`%5G'W8:@W9I
M@9B'$F[$GAUF$,P@F$$P@V`&P0SB80AHY!AUVIW2L(.Y!',)YA+,)=X&E^#+
MJ2==3EDSZ3G6-`@M);Q7:<Q3*NSK4YB]/6R,6CMK?+`1B(="UNS^+L']S:2Z
M*VG*],KTRO3*],KTRO3ZYNF55>'7MW"+&#0Z*$M6=RDRV>E9-KKO8/HY8LM2
M:GHUF%A^A1.N9?RB`B?[4K*XWVKTVN.=`;$V",9W!?6]*V#6QJRM=N$.S-J8
MM3%K8]96"]96N1.*^1OS-^9OS-\.T&GW5ED;QZ9LB7RYVIZ</?WJ`J4^"%@[
MP#'&,<8QQNT%X&H#+,:XMX!QG#U='.0?(@R%'REK$432CUSA>?>6DE$$RC0:
M`JYOV4+-7M-+4$NX<;)#>]`8#$JS1`_%EF0W&3,(9A!5N>*92S"78"YQ4%R"
MU0AF$,P@F$&P&L$75Y7AT!E\!\O$'FJ+.+1G0DEK@6TCJ-&9ZTC=->8YWC=.
M+ED[R*#1'W5*<P._]=P2]I.7X"=G2GV=B#FF5Z97IE>F5Z97IM<W2*^L";^Z
MR5M$H$/,LE[?^'L_4ZUK">9:Q:W7TU'7Z38ZO>[.X'0H'(U=_<R#F`?MBW'$
MC(@9$3,B9D2[#6M@'L0\B'D0\Z#:>)X.F`7E/$P_1]2Z>MWSN;]S^_)<7Y[,
M)#&:=J?U4X6*[G-V^9R5YMXI\(X6H#T=H^L#6]2?\X/Z03@77H%XVOA,.C#!
MUK*EYYEG?GW7>D>?`7'LY/,:&'USYU)9G^2=]368BQ6.?.<ZT0S^A#T9G`5<
M],1"R??)'[\LXU^VJ+Q/,</AP5IW\A9N25K,K^]Z[9\>)8\B+9H7G_U>9]<3
M\@9Y@W7<X-,N#%Y-S=PL$4<ER`T<@S[=:>9\'7B.9H(.W@]0\-O[&!AYB"Q<
M3W<NE1VZB^?&Q3V:E?K(3=9NDE-S8+=!BLFP`L`;:-IR?BW#3.7OMAM6I]7N
ML6E4_E4T(U]AC/^)@T@Z&4B_8.BKRCY_\'/@?OBO+=7+G6UM8D?NK;0^BO"[
M?*3W\VLL[^AW>2L]JWW,5,Y47C&N7<$4[A2>`R"F</T<`?1K1Q:?K^&G6S*N
MZ\M:/OB+.%*6(>$.DS"3<-4H]X<?[`]EU&Y9AE*[6U,JYT\]J2DEU_Q[]>N=
M^N!>[0#'&,<8QQBW%X"K#;`8X]X"QG'-OZ5L>*%FEOPS=F^%!PKYPXH\%]TH
M`2)[%SK2'C=ZPV%98#B4T!#V[#"#8`;!#((9!#,(9A!<MHNY!',)YA+,):J.
M0R_]<NH02R`<2J/Y.E3PJ&$6SJ.8O7>\KUP3ZOD`/!2&R1<+5=W([)3/U:;E
MY($QP7UL=EH3#ED;E&3VR>R3U<2WI2:^1DF;6F`7,SMF=LSLF-DQLWL-3^(!
MQS]5W<;^+<;8\9T6XP_C#^,/XT]MX</X4[:.5",KD1O&L[EX<-9@O]$=E5=0
MO@Y8P3ZM&O)^YD',@W;JD:H#;C`G8D[$G&B?.!%K0\R#F`<Q#V)M:+\X$5^_
M+94?@.]@F1*&6<2A/1-*6@NL2`H+])7K2%V/^#F>S9>V('UQ9M&K$N>@,>A7
MU'+F[88]LCK`Y+6CV!0F,B8R)C(F,B8R)C)6%.M&7IR/_79;TM?"1\$!Z+M(
M.>PT6MW2>O)P[#F[X2MRPS.?8SY79SN+F1TS.V9VS.SJP.S*C9Q@-L=LCMD<
ML[G:L;D*W7IOD<WE''X_4[/ZM<^O^?LO/\?JY$:(Q?LK>R:=V).?IY?"#?^.
M?B[=2FOB.[DLY(_&/?;9_RKM.`P!VTZ%<M4WG/4;@.C4"^SO?_V/?_^WOZR.
M3!T>/P5^L*#`"?_F@V\'<WGQ8R%])8M#8(0%@ORKG/[Z[O*\TVKW_Z?[O]_.
MWUFN`U\(.SKI]":#T:@_&7;'9_U^IS6>G'6'9Z/V\'PXZ$QZPW=_73K"_'%\
M<^=269_DG?4UF(O-[#;W.C:</IGIMM3M3NNG2LC#(&BKU1L/S8_Y3M@T!\'1
MTL"SC@SX'FXEM^MM/!^M'UHIT:#K@WB,W@_ZP-TJ6[H&L6M`+`V(+5=9*I[/
M10A/.Y90UC3P0&8KZ\CUK6@6Q#"LHXX?SM7?[BS&)>QG_$0%X#E8DGNG(/-;
M<#SY\\+/^4']()P+KR#"VOA,.C`Q,LN6GF>>^?5=ZQU]!BYM)Y^?3MIWKA/-
MX$_8DY$<0'.>6"CY/OGCEV5FGRTJ?Y^2"8S!VANS+:YD:#&_ONOU?WI4%A4E
MHGFQ_=SWGOWBOKRW-POE#;[J!I]V6?IJ`0J;U<]2&].^+%9A6.]8A6I[^GZ;
MA5):'^&'F;(N?+PVOI*+2,ZO09/HMAIEF3OLFF"$HS$^@395`KXQ`RR/`7*3
M^,(8:+4SVRN?[3&:+:-9:7$PC&:,9LS-&,WV@YL]2W>KT:7G[C(Y9\*_H9)?
M61RO%4RM:$:YG!NR/)/`X/O7)/M:W%YQ1OK+0=-ME=<@I`XXP8$;]12L.Q>F
MM<#&UX[;6`7EX7&P_KBB%D=/`!YS..9PK&.QCK4AL&S,*A8S(&9`S(!>B0$=
M]:OG0*O$5!VXJD6DAX,6#^F2LI+$]6!ME&(U*GI9,?YU:5#ZVO;B`_`\K-:X
M9;J]'HWTKPMV<?6<^NIGE?`U9EW[J:]5YM):`R1F0,R`6+&J)W?:0\6J1%\7
MZU7,UIBM,5NK`ULKTX.V+02?Y$G;/Y1\CIOMY8GD3TGWWI`Q?C43H3P52CIG
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MCP(^^%'H^LJU:[>ROS_:E6-_E(VGF2Z`XW6*T]V90_-S'*D(X(K^+!%9?Q-^
M+,+[C!&U&U:9V=JE@G@/7?*C1G_<JAR8M?&K<]1]/76&W47=UP85]RLD?P]9
M6[?9J5Y,U`:=F+/5D[-M[WA]'4WD54GTU1#S39#MTPV.(JH=5D/(WT+A/^:O
MJU@IJ:F<;`Q&G;+`<BBTPWZ^\B3;BTGE5<FCW1R6UK:)J8.IX["HHVI,.A2*
MJ<SY>UA*6G))6)J:5JI554_][:C+=0DJ")AFI\>^.3WJ(Q5;S2%7*V)".Z1[
MDUHR\UI<C=13*^AR15KVDSX'<<Z$C\DI):K@57?JJ0W-';4;K5YY=XY;PHUU
M<O8[O3F_4Z?9*ZTQS*'(,::.W<.GEORT-+5X;R5QI[06](?"'#CZ^!G1QVG7
MQ8S9=%LE!R`_6J#G\#W8[7:C/1J]/D0/A=;9HU8C#:$6V,8>M3),CE%I@2"U
M0`IF0<R"F`7M$PL:["!7ZU`XT$N]^H=EU^B2:I;4\354DJHF]LWAF#&#QJ!3
M6B`UEYQFKR5[+=^6U[+;['(B!K,'9@_,'M;J%^W2?*2'PAU*K6K\W)+$CU8X
M_B+NY]*/)G<B=/+#874;FF.B5#S7WSVYVO%@>-D9MGKC[J0U[I^U)Y/3X=G9
MI-N=#,[.V]WS_FZK'0\6%5<[-K6+K5C!PK&8\:D'ENP)@#WPTHK')XO0Q=*Z
MUCQPI&<)WZ%'LTK)=Z9ZVXG0U=(LD9V`%066(R,9SF&G^CWAAM8MEB+""LK"
M\RPW4K`3/*#`O'2CTTN?7U,YV_"X!*"-GRA1MEO91J0H2)DW53*Y\\*2R;UG
M%]S=FY+)O-#]7"C76GYA"%[_%0H@UJ;<X;=9**7U$7Z8*>L")(&3N1NM;JO!
M!B`C7+E%LU%=>SF^,=<[B`KS955`JA9GR[QI81RL&P[6"<U*BY9G-*L;FC&K
MJQINC*!O`T&W9I(<3;^-O_:KJ[Y;4S0#73PXJ2(K?*S^/=?NWK[V$K&&4:?=
M>0IO>!E(#[R=YD^UQ,T#4Y^8J!^,,F^5%T/&U%Q#I&1J/JSDM6:_^J#L9Q$L
MTR33Y-NDR?H*T?VF2<ZIR`WR]\`3D>NYT?UKNK7J28`5F*9OD-S8%<_TI`<9
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M=R/`.5L/2R`]N4:86GF@KB#,BW'0RE&HE2\XIXO'Z9ISBS"X=175?0NF],WE
MY.K4FER=6=^"A6M;P_:HD8[46<,(*X!1`2X9"\YMAW#:6GT.EM@N=XD:E$<Y
M""!L`"JY"8\;UMW,M6=6*/^,W="4\YM+H>)0(AU2W;Y0VL&-[^)B$=9V;O&6
M_(%_8UV_D*KR444^@R4+3<N60&)6UEPX$@O[R?G""^ZE5`W+#_R3Y*/EP`+L
M*`CA>YP5R%'%7B3\"+YP?=N+D8%:Q9)_^"",CH7_5-,`=^WZ](K@"]P@%0JT
M'!$5Z@I*%;ES@1X3U[>$;0>A@WU8K3LWFJU!.8!F=L0`5LM5":3^!6,(7%PZ
M/<IZ&H,`K5R8&0[MUH7A%W!X@=-\D.^^.D]XOGNN'DN_!/3<C#E)Y4@\-$0[
MUY&A1A]$:W-0>+JPU!`>N[XO8"[@9Y3C4BD2J/6HN`&[#`DBQ1!^+;&S?JM_
MTF^MT+/^NDC2N4>L77"]"UAX=&^1N+6,`*<2GI\`2-9%`J7RN5LSMV^:+.4E
M^I3SAZS/&!F<`-(/X``CZQ;3X=WY7#HNT+UW;\4+>$ES!Q!V=)*ALYF8\7WD
M28:$K4E$7Z.O%0Y0"F"L4]>'8W:%!X,M@C#W.+`3%[`+P&2&T5B4UCB%#TJN
M1=<&X:GP[-@C=A4K''6[0JP-S:9.#(_/OUPLL9K#Z%1^#7\AE)X#D#0Q)55=
MD1ILH69%A,]Q0R<.DVG,[F$9POEGK(CLB!S@`>\>F+B+9)$N:"["[S+*UO4@
M_49!D3!Q%A5?_Q/D"OYFSX1_0P1(P\<10$!#7<R#&`[=[%O_LIYZ[URL/4OB
MJ`"R#*8:_6$XUZ/1EOA.B.-[@&QX[/(1QK]&:7ZZ9EO4C'$U@!_`R90FW$]!
M),]=97L!KOXI=8][O6'OHC?J]@87P_[DO#T:="[;%^>#LXOS[J0W:%6N#U<A
M+\S56*O5&P_-C[I4,1A[GF-TX1P0<]1A:8#N@3S<3U&^0?Y\">54ALC,Z%QV
M:)#,4##$T2P(B<O%"^0RY<_?;[1:+?Q?^4-G*JQ"QD*:QR*%)[&N1@4[^D\,
MB6RM=@@N<3\+D;!FD#@6[:Y!^IRK5(RJ5Y..<FFSFK_/Q"WP[1@-(T1QD+CZ
M,0FOT0?WUO7DC53&/E(1R%CB[WE3Y38@<9\,D=[#)E\`@P5-0I&H-%_!.J3V
M;BQ/XKG`6QQA?LHM!E`0-@>+OI99S73243>)\-,`[#$\Z//$XM**#U94SP$G
M(`NIJ-LBPJ/FA(^AX(:O<@`D#&)+9L?L[TQK9`?*^SK#'7._O()[L*ROWHA^
M>#3Z"6Q&JH*,%>ZL+W$(I@@8$Y.;4&H_&[D!?@?9$7@^V-#A=^M,+'"$AO7[
M[V?6206(^-FWTF6AKQ275N3V5.N/_&%`VL):),L6VR[[Z/<O9\<-?!'QCFPP
M[6]<EBGD`,&CPD>4!&D&_\++E;&5_^RW+'C#J\:!#19FQE!R>_TOM<1>\L:I
M#",!+WKN'`"8&;F@)3BN_I@Z'LI?<G=0`1A@H^C<`I4D@<,J"C61&E+L6/],
M@U#!11>T0,LY><*I0MXT^Q4BQC98@5U!*T#XSKHDI)?O*)4PJ3,HH6NC(Y8_
MYZ#;;G0Z%4A0:[T6D/`B5'CH!S<BYC>5,KD_N1.JZ"V$YQ3YDVS-#YO6!+^%
MT6//^)E<E:!T*I=7',G2O27^JQ_S9827$+:4#BVR`BSI-<?5H3\8*U/@!F"F
M.+%-MA%!4ZF4V06P_Q"V!A8%_FR<;JII??`MO$$G\T<?1\&D22"4\@[T%,9A
M\1AC=-]O9#$Y%^74#>'P_HQ%&-%JJ!LO'+7,CF0G1]&KD!--PV"^`D801TK^
M&2-R)R"BW0F`.2!Q-1OM-(<[X;C+^-``]$I,=4-V.<I.K-G5#==*WSP\57D2
M61^US_^#X8K6E<#KC%195A4@X8D%ZO!'<6]U>J0)=PDESM8IPMLL\&CR[>.Q
MUHX__OYW;4/C_V#$)FG&R.P^BA_NW/HM#$#))6T9IYS<X`#'3>L2"31RYW1G
M3O_F.%1>IX*IB#?-A9&Y-+A6HF<P^(U6M_7`C0<)(A'A^EF,2?)0.Q5$$,`8
MA%>--MY=#3MZ.>4;\-R$@5(9KR:^1]<R<&;XC(9'PU@:":<C+;PBQMZIV/0H
M[EB[.0%)Z,KM5K@>M?8SRG;:RY&NJUST[%G:ATA7B\:+:/`A"//O-*WS)XG,
M2G3:;K6@+(CY%=0I?\YVI3)_,^D7.<6WCX0TH-/?X7_\@':\_L5,J4(4R[,H
M:CY&)J#"*_'E9E"$(8A2*^\@%_*QD]3#+_>>[\5B2;R-)`8I!Z8-'=,?>,IW
MH1M%T@>#_1J>L3X;+;T"1#72&*<WGJE^@5OA735=/VCT2Q:VT`M+S8=JU-5>
MH]L?-<;#U4X5+]]X[.,EC$"1BV$;,O.)F)U5P47;S7X5WA_T#.!^R/.\)(6K
MV4AW5"'S).WL78XF$OQ_!\K:!<;ZT&8I?DSI$"X@?^,;6;E70!XGTM@D..74
M)"U_Z:UUY;%+T:_$^NT1`F/(C`QM5TF#RA4I4\W6:DOV<I"7]J;5IS7'G@0!
M$1M"S^R)\+Q`VX\F_&QJ%*:42<E0%<Y:9%X-T#DKT*L;@WZW,>I50=X;?&6`
MV#_#MM/0K/QVJW+FMQNCSJ`Q[G1WMLWFJH!JK!YU0@!D5+GA!BS)0V@MV!!+
M;L"VO,&`Y6K4SM<!X`08@V>U6R4"\"!HB(+I,[ZP`U]COTJ[0[-0;5<O[R5:
MSUSS83044IN($O/*XXB`3V4!LV3'5.&C;34KU#E6_>4I=>`'QU4VAJTF]X1+
MKO1E)SKF8Y#I7PP-8@_G8%#ETJ\VT[B),TYN?TS,.>8;`,<C)J#2G*<CBEH.
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M)Z/8G%P,,!7'TR6HLA)6*H)O=8(#7:CK#+^F]9FRM@`J/MY8.IHE`&2DI^0=
MQ1&;DDL^<`R5A9[CX>)S&#.';)?@OFZZ8EZ<`PP:BU!0E0[\`JOVA;K&EJXX
M1?=V`88?%K[)I3?IDWUR\:5-W*S`\_Y0\O/TPE035%LPNHM6N]._/&V=GI\/
M^NWQY6G_M-4==\XNAN/SWN7%^*#KBOYA<LPR@`&R?`GE0I@:?%@++\6)JQ0G
M*J"!Y5(7B^(J-#D\BJSK"OSA9TRQP.IOH0MO+#">_D;Z,J2,9O@=J=U)".4/
MWXVHGA$!!*M-SF'9ML@*=<)1BQN=A`_T-!??LP*6.OY#9(5R-<,2TRFEFE.M
M0:Q%A[QKK@-(,)93*1DEM6;$M>NYD6N&<E(AK\,8:"-4V7/#.U'&0Y*2:NL`
ME:0;K5M.B!1J<IG2")9<JL!R.;VF-;&C6"OWL4?)2[&'2\<PF)1#`*A-%@<P
MJ`Q@!UL/8Y6%%9D3\2W8U/?WTR"(D#W_#A^L'_15&.!B9U&T>/_SSW=W=\T?
MUZ'7#,*;GSNM5O=G_/EG?/"=>3ZZ7\#S`!!*V'A'8_^\,CA\_9>?<23W/?X7
M/O[_`5!+`P04````"`".AFE'K_*T#1\<``!?&0$`%0`<`&=A;&4M,C`Q-3`Y
M,S!?8V%L+GAM;%54"0`#G!5!5IP5059U>`L``00E#@``!#D!``#D7>MOVSBV
M_WZ!^S_D=C]SPC>IP?0NTK2=+=!I@[:SL[A?!#X386PK*\EMLW_]'OJ1IHUC
MR[(D)WL'&-2Q>0[/B^3O')'4+W_].IV<?`Y5792SY\_(3_C929BYTA>SR^?/
M?O^(SCZ>OWGS[*__^]__]<O_(/2/%Q_>GKPLW7P:9LW)>15,$_S)EZ*Y.OG#
MA_K/DUB5TY,_RNK/XK-!:$5ULOPT*69_6E.'DZ]U\7/MKL+4O"V=:18]7S7-
M]<^GIU^^?/GIJZTF/Y75Y2G%F)W>4CW8(OV%ULU0^@H1BACYZ6OMGYV`?K.Z
M!?]5RY^_IB^^:_^%+5J3+,M.%[_>-JV+30V!+3G]QV]O/RY41,6L;LS,A6=@
M@Y.37ZIR$CZ$>)+^_?W#F^\87)I)F!E;E-=7IIJ:GUPY/4WM3L^<J^;!O_IZ
M'69UJ,]F_GUS%:KS>56!(]X60#,IFB+4(%J2\.>K*L3GSQ(_,`@1.&,XF>,O
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M_G59?03:<U-5-Y"SG$W+^4*T90M8\?8'E@-V.;Y=P$/E+'GKK&FJPLZ;M`9\
M*N'[::A<82;KA:)GXW3M=W0+]:OWL;5Y5S:[L4$77J-K\K&XG!41EDI8!9:M
M9I?OREF:0&&(G9OKHC&31:X$>'Q>]3VZ#^U^='NU@X6=F/6HRZIT!"9\!5(T
M-W=RJ)VBMZ#M3]+7IJC^;B;S\%LP-?AWL>+M$G$KT<"RG2_<>@D?+^:5NS)U
MN*@*%]+27?B5HU?M_5GSJFZ*:5K.;WF]GWT(;EY5P&.1)+;+E8\@RL!VA*[+
MF8/E>R'F^_@V?`X3=F])[V28/7D/K&F[&:,%:7]RO@WPTT55NA!2!3IEK].B
M67299MUU7+EOR*KEK'\PXZ/HV&HU[\JO1XU@<$.:<'99A7;SY(,$`\IT0$&P
M"Z\>-2EGEY]"-7T9;+-3T@UMAY&D[;A[F*0_N=Z%)B6?%Z'Z"+^$73(]T'PP
M>=*`+&>+C_6KKVXR][#65>5TU:Q=#!["<S#-VJT@6XGZDVWQL.3-#/X.JT<H
MK:;/'61#RK>P1,N!U(YZ<&F[RCF`A'<RM/-YW4"'U6K!@]FZJ580ZQPP9M%\
M*.H_6QKZ0+;'TZ]5M!_$]'BZ[=N^7:R.*T6/UDLU<<B,4F%VFL98J_QY.]70
MTAT`OSHS'%RGR23M7TDU\4T_MYUP>N`]N*9U/9]>+VI%K\OJ_>+3KQ6,@_H-
M_!+\08[<B_?0FBZ^70IQYIKB<]'<'*+<3G9#Z]-R)FQ!V[.D>SU7'.,IX/T^
M#IVS]F4VI"ZKA"%]?U8!PSI4GT,J][Z>I_)U&FKI2757[3JQ'U+?/>)^"UV/
M$LYM'?XY!YSPZG.;$LE#[?N3Z`]3+6;979+\V*Y_"<ZOS.PRU&]FWRK`<?7;
MNC;:<A+NSK%_K>YW#0O:;;'[]SI5MR?&_?G100"&>KE(I$(Y_/!;Z<-D/Y5[
M[JY_>Z3ML'X^^2;??NOKGFSZE[_=C+*Y=?_2W$;ZQ-0U)"7!GZUFL):P<V]&
M&W5P9N+FD\5:]A8:K9HF20?:V+R4(GQMPLP'/[X<&XUR*\Y"&!`'L/MWYE^)
ML-AY'DUM%_O$YS6Z-.;Z%-S"3\.DJ=??)$=QA,EJ#_M?5E_G*R'O2+.2;RW-
MQ-@P>?X,>L]WTN3$:\89I2C3W"$6`D6&&XRH=QFV&"LEV?=J+C*2LEH;?8.>
M]\,L?9.GAQ"5<4W"!:9R5Q?F)@V/#6)O:YX[A@-EG"/X7R$GK$92,X&8-"$R
MS20589?$=P+EK'(G905+__-GY-G)EU!<7C6+CTL.T/.]^/G^Z,"JQ2GD+TLX
MAXHF3-?TZ2C$(+XH!S$54._OV"6Z^ZV`J:XI9P%ZGVX.QRVM<Z9I)!PDI$IQ
M%(7WR%.A5[(:(T/LZ%;Z5-W:FZ4Z>759P?HM3,OZS,%24"\2EX2I9@&REX1'
MR^KFX;EG?R:YDUC%$#&27&%$2.#(,)XA"A[!A@1-,.T6`^RIQL#0!NP4&A=@
MC+0'!Z#"\E33155>5F:Z(QAVD.721JMBAE%F"$4^\Q#B-F.KP/:42-UQ"N!/
MU?W]FVR[P_N!**\`'98W`7#M)*4=>T&5G;2YEYD3S@D4'00Y(P:6-FH)RB@/
MEDEFE;#=PD0\P3`9TFYCQ,K*&A#7,=3UHC3V.NR!:1\@S*EVDDJG4(8I0X'A
MB&C@&N'(O2=$^(QT7$OD$XZ2WHTV8HA\*&_,9*]\YT>*7+/,2@.`25LCD`XV
M0S(C!.$00B:DE=+I;D&AGGY0]&"M,:+AS:P)%2#B59*S.Q@V$^36*D6CI("@
MC4366(4"=01I'AGA/K-$QVZQH)]P+/1FK$[`<J73+:Y=[QS>,N1;T>4P=ZG7
M+U^]9.>"L3.IN<;T]2LA7YTK)K(7+[LY.GN"CA["7G=\_<OI#T6XD2MSFRJN
MO=<)]SGD/G+GK1\PCBS7YO/E@PGQ\,'Q4;K<7A\>LN=1XG_?@]IC5<87!YBV
MP<)%@]P*H@R/!'&1*61QQA&56",E3)02,ZH#V;4@#*E!"WQ[MUTN5>19T,!0
M1(^XQ1:9(`P*64:8S90+IF.J,U)%O(-;?H2P!QID#.!Z>VJPODJ/UCZGT95.
MQJZ/$"^>VVYQ>BOZ/(/_)(X:284!KJF0(:U]A*3?PAI.E"#V"01#)T^6X]AK
MC%CY`!"\*AQ,JX=&S9Z<<I%Y:[$+D.\1A;A6R>(<H\",T!R`OV'R43^'Z2U^
MAK?<&)$$(.S:%&ODO`;.;1>:%M0Y)"#*"Q@WSF8>16\@-Q09_"FCU9D5`2OS
MJ)_:]!8QPUAKE!+;0L;W\6517Y>UF?Q:E?/K-[-TI`CB>^-Y\;8HI0O37'$>
M.8`!L(U@R))HP15<([">X1FE0DC^J!\%]193HQIQI&KNXJJ4#\$%F$HA77D7
MFE8EW0?)<N\8)H8:I+1EB$;ED**6(@DCS1$=,T;5HWXDU%^X]&NF<0JZJRH4
M2+JUC/NM66XP-H(&C+2'7$$1(9'"*D/42:J=(5+*CL7;D9[N].;P`\TR#@0I
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MAV3F\#H`.>?N"0"I[LX[U!ICX*=?R])_*2:3+5AIW23WA&K-&85UG\#"0+0&
M%"DMHA8@(&-@#]&Q&#/2#I?#<=$!MAC#FR\#Y/%%L[IN[UTY<SMSWX=(<L]T
M8,%@6#Y4`-#/(O+$$42P95C9:&/7,LE(>U@.]W:/MAG#^W>V*L"2\?")Y@U1
ML(LT-R&+D,DKI!4GR$?K$>4D(,(E#DXZI>7._=.#:]U.P9Q(%S!G,&RMID@(
M)Y#7F43"6<-=VIYH_6-^C-6OL\H^#35RF.\N[6W:V<25"IAZ9*77B/DH45!$
M(,TDC\&[('W'-'!T]^_GH8<]W=TT8U9U6^_*W$R06Z^L9-$@G!D8#`1C1&0,
M2!B'J:)8"]YQA^[HCN_DL`?*N0=;:<1]VH_H9.HQ*WS]1T)OANIVRO/^U0(7
M90,"%&8RN?D8FF824HR^65R/_5#VN1^7W!@5G2,.6>(89&4N@T`W?'V^B0?L
MW&,N!_84!..8;A1@<.<JT!;(X'[K'$M,O(0\@0BFD&/.(F=,A%F0<&)<1BWK
M"`W&*2?V/"_T8Z*1,6'/&PT.Y)QSP;C,+%A)T`Q1JS,$R2-%)!A"??#"JHZ@
M8YP*9M\A-;HYQZF[Q`#R^4_FZ[)6<$?-=Z%I68AIR2,GRGO&`9Q9;P'O4YZA
M2.`3UIPI&6-D77'L'?2"GD`&,Z3)NMUKT.*]!"#8^[@*YXNRNGNJ8],U)1W8
MY9$$'#)*D(M.(2.4`7.J]=T<,$8"V;D)_9$@FT[Q,;+QQL8VK::3S02YSJQF
MH!2*T3H4'=>(*.Q1U)8*3R0+XE%O?NNM^-&7><9P_EZEW`WU0"J#D`X"F7)C
M4=`R0QJR>X1A^G+.PA==*UZCI[O]%SQ[L==(NZV7R]U"XEU[\S>TSL%(RL/_
M2&0R(.Y41!Q2>&2LC9HP[(GHN)5QG`+8H:ZZOZ6Z!Q.-<KSGV^6G.T_R_-`T
MC]'C+`.<K(31B"O"D`T6(TK@'\N$A'3N,0_^GIW>@WU&J7?>GK6],(5/99?%
M^^#N2+^M\+F3.&=."(TQV,P$C10!J!.()T@$KD7F!*:\8U2,`Q%[CHI!+-8I
MA8"<IG!%<^;<?#I?7+?S<I[>4W9GKYZ9?&S,Y8.7&[;GD&LA&=-8(:*C0HJ&
M@((EZRN>,J^CP8\9#?84!<.;;8PIXU.U>'_:3:MEXG[C7)%,<1P$`E4T(%X%
M<Z`F$1G'$WXBF+C#]]H-65;H>4[HQ41CH8,'WL>V`R@\0)4;96U&A$=!<@'=
M`AY2E@8D*5.,<,$C%X]Y=1@T8>C7<,/?;W+0>^/'N=]AT!>XCZS"P^]@'^FJ
MBLTGBB]"592`;%R:U<++L/QWV_RP!YN<2ZLS82G2,0J4!::0YXXA8960/'/6
MV9U;0X>Q1CJB!BI<5.7G`FS_XN;W.EU.]+J80?RGEZLO+W??/E>V9Y)+KZQB
M5B+LK4*4`4!@2D$J250T.CH=NAX7'"?''L[MY8@V'>GH67HC:IW>BKA^_0B,
M_589VD[:W/K@F-(8:1T9<I)QP!NPL#C+I+5&,NL?]5T;0[GW_D&UW@TY=O#<
M>853_>IKJ%Q1!]\R>#;2YC3S2@K/4&9!9YD9C*($%)SV;BD'/UGUJ`N^1PB>
MO@S9*>D'?>_*LN[_NT#^\2TY/Z;]^_!(]XD`%LTH$DH0E#$FD79.K0^C!"WT
MH][[-'"`C&'0HRU153I4]C[N?)"TFQC6_TB5(3(]*2.0!1L8*.D<!`\LBX8[
MZD+'*N(X]:-C+E*'6G*,^/D0KI<OAH"D9M.;OS?>";69)!=":"$"Y,(J.A28
MYH@[')%CV#,>/%>A8TUAI/+22,'2HP''")$'K)*NCJB;`_.K#4SR:#%A7D2D
M`G:(&(Z1,)PB3JW7CAGB1<>]+>-`FV/G5_W8]'%%UK(&-X?O;O<+]A-MFQCG
MD2M/LDPBJY2'!1X&-]6.(^$I%MK&S-*.$]E1,[.#`Z-S_/5DY3%B\L<1^F;V
M_4U^6Z)N%VENC>?&99!A&"F0!""),KT\>B$8L31*UA&3DZ,ND(-X_-Y-1;T;
M=Q1\OEKI/Y6+%S!587WM<JA_K<IZVR2VBS17C#CJLXBT"0YA1M-=+AX,P`/E
MSE.)Q>%GG/Y#PVD`XQXEG!Z\QFF?P'J02<X4T<2D[?]"4N0"P-)(`?5JGN%@
MJ&,!=]Q,RO[_A5B?9A[EJ7,[PVT\S;'UN?0A?'.A>1`T"X@XY].N#(6P-08,
M!N,U.&>Q[0C.CEKY[!N<C6WD(^8+*[D/RT0W,,FMM,+1-.;3*VL,E1S!$B`1
M(9GW1E`E'W<-]=B9:#\V/=94MT'Z7J:ZUGQSQRV6AEI$B4PG%+A"0:6[5Z4Q
M6712"_:HKS,8*BQ:3'5#&GFD-+2<AK>`1%-)>;/HB[--G\S7[2EI:S8Y(T)I
MKPC2F39(4JD0B\PC&0(7REO'NEZ+.U)Z.F(@W,].A[3S*!$WO39%M=QPE:K2
M;XO/P2\/77XJ7X3E25[0)VX+M[8\<EA0,@%+#C+$.(#3@"T49/#IPKP@%?>$
MA8XWS8U7Y#U2J`UHX^,4V);"_RU,_.MR\<QLKQK;/>H<&VE)%!QIE5&DC$C7
M]SD'F1MG!F=<1?ZXD]:CSF,#F/=QY0;]/$MHR3AG`&6$RWR"U1QE&<M@GE<1
MD4@8L]1(AP\_RO_T,=SH5AX?Q&T2_/9*C-79]+-F>0EPNHGG4YF.+0,1^`M$
MNUR_7+4UW.NKPUQ0(;S*,+@S984"*Q0SF&`83"["&DE5U\,"CRT/.3RXM@+#
M(WIDG$M2KJO@BH5>\'D2%OK,_-DTJ?8O\\!-&/N0YTI&28B-2#J3UAQ07WKE
M$,-4>ZYU=,S^9\RGO<?B0/8=Y7Z$*U.%%V9Q(F.:WH^U*Y8V$Z1KS0RV3B`M
M'2Q,S&C$I)(HO<4/H+'&6'5,<8^Z*W*,Z.G-HMWNW;DRLTN`HW>NL=NP23-M
MO4OV`.5GP27Y_BB:J[^;JBCGJY-#MYNY'MQF.T!7N3=!"1<4XE1`%@:("&'_
M[=T;W'+5\5$M/^ISM"$#[Q$YH[^0_?'&HN\N*]HK(K=RRAEV'/-HD*/8HZ`S
MA1RVMSHJ!W/\4]R+>9R`Z]O6QZFSK%XPN;Y3;>.+)O<JO;1AF&/E%</!(,L`
MH&9".B333ED7A57,_;N](]MQVP9^T:"D2/$`^I*FVR)`DBV2]EG@F1CQVJV/
M;??O.[1EK[WK4Y8H]7A*%B;%X7`XG'N84K9A!0+QKZ7$["COR?"W7Y_Z.K/?
M_MS*ZFA5610@RP*EU8+HE)YA0)`@>.0%,;ZACIJG=<F@J.QVY/9&4"_*7%]+
M4R^F5Z6SVLB@P/M"0"&=!,TH2VU!E"0L&-_43Y&G1\K0R.IV_/943F$O^Q\5
MH%GXBF-&CRO;SCZ$F:H`X-$^6Y=.&["?QU71!(?BB@)N\8$0`7&MF/4H!EON
M"N^CX&=C6OZWEO[+K:5-Z>6_;/S<LM2++N6!T57JINRT$@G+*+MYCQ*;DP6H
M)*_Y6(K&W4OS$,X0CGO:!9JS6#A3'\A/X3%,EN%T9^,7(RNB!)-*6!`V:M!"
M1/!66L248"(J1I@>=#V2F\_HI:'R9OSD*>DU7U67JC6XTW6\]H=6,=4F2#VZ
M*4KA8(,TX%.APN"$"L02H^.P$S_:/O(6,)3KS.]C39IG#GP[KK*&N1!(!&(E
MRLF"</#(^%!B%EZG@&S*!ETGYK;#.7#2MZ`F3T[]NOEVZNK[7%JRWOZ)8S\Y
MKY*>6D=*#XP%O!H$=7!>,@96$D2!D=R[05=\:94,VD95EA<^K.2:G\,$F=\X
M^5W]PVB2VCXC^A[#>?JX[`-5J6A)"Q-!FB"`6J:@#+&$2%.Y?$6=:RI&9LI:
M:)-0.L-9#HK9=<S?1Q2(S>3+"$7ELZ;ZTQ,K1ZT4K$S==2(#XQ@N'D@`)2AW
MB@BGAUT4N%4*:1U7693-9.U_(475V#BM/)R>6&F-RCZ5&EP9"T"IF4"A4>N2
MQ!51154(VS#C*<\C,T05M&V,-W)&)Y3<3VI_^=U?;N7E/.9O/CBX,DP41N/6
M"\M+($YH**G1M9O3,%+$AG59,J6'M'D2TP[0E<=GLB;I*UC&L2F5H87C#AFN
M*4EJ%"E**`GN-4IN;4I;YDV#J?(PBP[HH0.<97M.D/=-#R+CW'-R=&)52"MY
M+`-81P4H3RP47EE`]%DI32QM''0/B@XII'7,_9^5.$PNTY4[Y1^99'AG9I,4
M@_=+F&WB24?N!*4<'%_%*`DS@H+QT8%VP@(EU$.I"6IQ1,="G?6P]>7#Q)VL
M-I$L%Z/Q,GF6T\9N<E,>^6;%&27.6-1E7>0@942QU7D41H(6O/1*2W9[0F^'
M5Z>%T[_:(]D>+H?&D&^EO$9?KU0(NE!6`&>*`:?<`.'X4!KMC/"(.]ZT@E`>
M]MTU#>;":O=A,X=W\BI_]"WJ24\I\NAA%6)V']<C<(<[<4$_AH49C8_%U;35
MYN-2B*</OT\GJVXP>\:"%(B>*D:;\:9XV*#`'A0P'Z>+,!!0/H^^3$9QY%!9
MWXKV*(AOB^6L^L*MY'`_6BQG`R/&7Q/M=0[+U"V30R796!&DQ=.[29S.'O:2
M%#I:>AMW_V'5FVL=<M?'FI=TEZ['^S>+N_EB])#B!)_S!B:?0FHZC-](++RF
MHEXB!>L,F`UDB=+&TP3X*<G[V)R*D<*(H!4X*5#KI2*"HA+_#,&7Q&O)SZ>6
M7&BUW$G"V*3Z_(*,!`_&C,=/G\-B,0[I/KR;'"G-VN`K*:,M.D>3=<8Q(-9I
MH,+P37MP'HB[O4IKEQ)+.R<WS8G!/-$7FPN]=X??CLU\CN]!*J+2Y*+<\MF*
M:50DN)1`#>*'%R;@V81D'5#!441B>3X:MU?IN%5:ZPFE65RYJW?\.LHZ.J=2
MMDQE^0QX(3Q0;VTJMV'`E0JOG57N@IRJCB[9P9*#5]ZH2[]144M%8+;$8Q82
M%"F1Y3CE@43\QQEMB6^8G9&'5;=TP@?JX76%OWQW94?FW9:Y:G)_+OQ.I823
MQ#(.DED.QD8"1)``3(L@(O?(-P9M9^Z&EKK&8?=FB8/"/8KFTXD;C4=UV,?[
M%$3&7AD@^M`[LBAX[P/^5#<M2M:M$QUO:^TWCQ)\!5PY+`KO4>%+Z;5?9B&+
M(OIJO>>N]3L:>!;:/-0,*L-2><CL8U@D^^O&IIMWM;I^1?KO_.ZO%(V$S!39
M>3TLR^F^`"D+SUEYO/=]Z!FN\.M55YO-0V='%N]ZV1T+Y]OE?(&KSVKVB>QE
M,:O?O+<SY+&+3Z/YMSS(N!:J'-1Q+4S7CL]SW*D4SM'B6%D7[>^].@+/>"6D
MI_3M0S]G(OS#H,U1LE]WHT71>MV7]N>=:D8]8FVG4VY='^"I1VCRW:&OTS$J
M;//]OJG9%NSY[NS!LE-CZ\TLI&R;65+YIK.?ELDEMFEQVJ-/8P?"VF6WEJB.
MPGK2A'OEMRI34LN8C!"#,A"$E&",*B$6W#EJ'8NQ+P-<,I)NS?3WLT_)\'"_
M7,P79I)4JE-H.#.U"H0[&;@$$J@$JZ0#*VP`:QR5W`C%2<-PSER9B)V>\TLS
M7/OH[*_4YINTB2\KI?2'I^<A=8^K-W^:F:];J^_L\./RP8;9J8RVMM>J+-.%
M$T8`D<GX5!(\-2(]A"@*HQ0QA1YV\]BL)#H$_#=*9ZG7/XJ5W_`%FJ4]F<DH
MI)R?Y*M\#*GSVC$O\0V?K((2VK,4RQ^9AH(K#5HRLLGU$$:)AE27*^4R!]7U
M@.9FA3NOQ<9]O'OX?3Q]"F$U:1LO<H+:VERC<LY(Y;E.#4\I>$H#T(!H6N/%
M&BE=0_++E<^9C?QZQGOW[H[7LGP>_6EIY^&/94K"?\Q@*-]$H61:9ET4=KY7
M%;;^;>,SRJ,A;P`Z$)#S;KZ-0?MMGH+.QL9]^^R0%,)\S713_!K^\&'JPS@K
MM`A%\,OQ,[!9K0H;*++<@\UB6\IY%;-R@<WI^^_23Q;9#/[Q-U!+`P04````
M"`".AFE'ZX2%7--4``#3W`,`%0`<`&=A;&4M,C`Q-3`Y,S!?9&5F+GAM;%54
M"0`#G!5!5IP5059U>`L``00E#@``!#D!``#D75]SVSB2?[^J^PZ^[+/'``$0
MP-3DM@`0V'55)G'%F<W6O;!H";9YD4@/23GV?/H#:$FV$_VA*))2<D^6):#9
M_>M&HP$TFK_]_6$Z.;FW19GFV=LW\!?PYL1FHWR<9C=OW_QQ>2HNU?GYF[__
M]W_^QV__=7KZ;_GQW4F4CV93FU4GJK!)9<<G7]/J]N3SV)9?3JZ+?'KR.2^^
MI/?)Z>F\U\G3ITF:?;E*2GOR4*:_EJ-;.TW>Y:.DJI]\6U5WOYZ=??WZ]9>'
MJV+R2U[<G`4`H+-EK[4M_'^GBV:G_JM3&)PB^,M#.7YSXN3+R@;TYRU_];^.
MJV6'EXW)V=./RZ:^[RO27U'=%G+.S^I?ETW+=%5#1Q2>_?OW=Y<U&J=I5E9)
M-K)O'%PG)[\5^<1^M-<G_N\?'\]?$;A))C9+KM+\[C8IILDOHWQZYMN=B=&H
MF-FQ?KBS66E+D8T_5+>V4+.B<#I[E[H^D[1*;>E8\QS^>EO8Z[=O/#V''22`
M(^"1^]O.A*K'._OV39E.[R8.S;,A9(ALE:23[D3YAMX!)/J47$TZU,UK<MW)
M(V=EFMG2/UDF95I^N+XH;.F>70_G;>PWZST4MV(\3OW?9'*>7>>NH__GR1+V
M$Z0!X:%DO,@GZ:C!H-^-2O?<JWQZE6;UPQKSNJI/OYPU=#L-NO;+9S-GLKUG
M=URJ/!M[ES5V'TIG36,?0,ADXF>]RUMKJZW<-J<P)-<7B7>\M[9*1\E6K]&2
M7,_R7+HQ;GU<]^'ZLLI'7V[SR=C%A?K/65H][MZC%0@]\3`4<LY=JJ2\-9/\
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M;U;[U>LTK>I'>J^[L*O1<V35T.OO3?@@,C::S=O2ZU`B-[C=,D'<%+:9GUS;
MH4>>]M@0;$.K0TGR[.:3+::1O:JV<KJB;3^<-!UWZ[MTQ]=[6_G%YX4M+MTO
M=AM/:YKWQH\?D'E6?RSUPV@R&[NYKLBG\V;-;'`?FKU)UFP&V=BI.][JPY+S
MS/UOYT<HC=SGEFY]\E<CT7`@->O=.[=M^>R!PQ<K-#4K*_?`8C[A.6]=%?,0
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M`%_/?UOLC39TPNTI=B_5]X]V$]IRL_N/TN]N3Y+1E\N1,T!;/DT2?J/<_?![
M/K:3W43N^''=X^'38<>SR3-_N\VO.Y+IGO]F'F5UZ^ZY65KZ)"E+MRBQ8S'W
M8`W#SIT)K90A*48+,>8?7TJRS+-.L^ILG$[/YFW.DLDW^EZ3R;U(SO8)X*1F
M^T7/+AERGWT62YZ=CNUU,IM4+=E;2Z<G9O-IDF;[\_J*3*>LUI1/IW9Z98NV
M?*ZBT263MXY6,9I=V=,E)"U9W4!I)</.2-*L#@O?N3;SEIZGGJX%/#%A'RJ;
MC>UX<#96>I2#<;/*17?-S"Y)\<,^N_%Z9,E6S91C:Y*/MLPM_IOX>:*^G$VG
M2?'H/CQOH#DM^;0Y%WPL\L^=C/:\LM.E1B;)E9V\?>,>%^]',-8H`B`,%1;<
M$&00T)&(M-)0,X@8UJ\%KC=>\F*AAOXDK@VP*VEK8C$D&I`(,15@A()(*H+I
M7%(0&<VW2?IL<J(8G>2%6QB]?0,7O>8.<Z?YW5\>&U:)^<`H.J'=%_5,\.MH
MDI=V_/9-Y5S0\Y=Y5KE1I"?UZ;&;!.R-_[#!P%[B>YV45S7(L_+T)DGNW,P#
M\9F=5.7B&V^*^!3`^?6XO\V_CC_Z19!X2%>-J._:Q%3K2.,HX!AH'D!).2<+
M?'4@Y4"FLV$*W=.4=M1MW@U0M74,H>C?7\5'ZU3]U"KVDFM-C&%$$!D&@8'1
M4@:F<;PR?.U-Z6O#YF>5[Z&'59K<"X<?4Z?#Z_+5LN+0JAQ>A;\[.*>SZ58E
MOFH7"\D-Q%(*C4)`#0T%,@LY.#!J*#6N6G6MT>&N&LB[DW\0/28/S?3XLET<
MZ8!I9]>2AI0@&C"JES9M$&6M]!@<M1[WD'\(/5X4N8LMJL>+2?*41O[G++WS
MD9A\_.28V!(I->@=PTAR!F1DE-$"!B%0+JB8RPQ<H#&0SH\UANH>PH.:C><Y
M>C7'[6(VS[WC(`@A%A('2BO`H`H$T0N9(=?D>*.Q3C7:U%KV1N[_A]4<7;QW
M[,:RBY&LV0):/M;,BJR^&.9X,>E#?45L;0#1M&LL*:6:.R^K(A8HQ1B-Z/,>
M"(^.*S;L5"=YKU"U4O;[F7]2?GV15*D_HX_2Y";S^S^?T^I6%C8I*^6S'HI%
M`Y%ELV0R>135/].;6Y\BF%]':>D:VJ<;3];7"5IC'_T\+494"PG"2`"DI`ZT
M(D;.<0H%'V[5N-FD#K%W>!2`#VN8G=M>;"1'@4.8*"7='[>PD(M5`#5!V&Z2
MZGP5]$.9UXZ8#A'L^&S5KYY9DQ=1/KNJKF>3.6#^TJ--[]<<=>Q&("9,(6TD
MQ%JZN8(KJ.$B.J"!6[.VLB;T@UM3KQBV\C^+C8#$3<BIF_]MD>9C7_SAZ0*P
M8]0[R,GCN]1-Y&-_-^P\*ZMB]G2YKEQ>LB]O_4Q_[P\XJ[7'@KT\+`88!1IS
MYL*(2%$40([A`B6OGE:6AG]P2SL:O(?P:>>93[S,B\?WMMK@N5XVBP,<2BH5
M`DPC%6H98J:6GEF3=O$Y^<&MI@.D!M6WKW1ZGM4WJLM-&X*K.\0DPCI`QBUJ
M$)-.0HSXTI(Q$.TBGO!GLX%],!O4&HQ31NE@^D>>CQM9PZL.,8^H9$@H`S&.
M!!/P1:P62@):60/]V:QA'\P.NIGW1VE=E/4NO=X4W#;H'0,I0P"I")VX1A@=
MJN>HS$7Y[;(OV$]B)]T#.(31^$)*95UPR4?@E[:X3T=VDPM9W2%F%`@FD41:
MDQ!(@IR$"\E$`$0KT^`_B6ET@MD@2^1I7E3I7_-+PN=9E60WJ5N//=7>VK0T
MWM@QYD"$*H@,99@!Q4/`"%U**EB["0:"G\0\.@7OA9G\=O8Z.7>`A-W5=9K[
M2AI>7W]YB"=N3A3O=Z`NM3!RLTRYD&MM:G*3;C%BQ.`0<P$9-A!1132+(H$-
ME4*I8.MN0D\3U'(XKF"^E(\O_EN7JMR65!P:P`0FAD$)B$9"8RKFB&`M0+M,
MB8X2E;M5Z;<35K]('6TR\@IIMR3<K.D1*QD1@'D$`Q5IPQB"""\`P9*B@4RG
M49)-_UK/^P!MB(!H%:?^8V&WIT=L[1M3@`7F7!I_2H)1Q+6)%O)"$YGC3:G9
M6X,-+*(+K'Y^&SFZ!)KC,XT.#HO^9W;G(L._-B?'O&H40Q5('O(@I*'DDC!*
M!%EP18-C2Y'N$.6\(T@&V?Y8O"B@OED^?Y/#EBE_;9]8!HAC1A"`%".#G50^
M*;F6CP10#I5-?9R3?E>P#6$6+UG<ZL._;QP[[V98&!D6(05"1`%7:"$1,QP=
M[\3>@9;RGN#Y&11_=+/U4>C[`'I^+@6U]<;,=VUC2A4"*C(:T4#2B$CBY\*G
M9;6@O)V?[VUJWT<AW^IV3RB&#,=?;-7YDO8W6?J7'9^/G:FGUVFRW%Z=1SGC
MUZ_$J>O]V?$\#V1S@L\P#XXY#2(4!2#D(`2<@8`#ND`::=QR#WW`>'+_;:FC
M0OA`2\NGLD?G664+6U9/U2<_%'7M.B=X75S+29C>9'[S>Y=UYPZ$8Z24)@(8
M:4(&=!AA`1=K.4%"UB[%L;=K@[W:XB`('LAOOGH9RJ<BR<IK6[@!]6(TG6=U
MSG@36VM'.#:!<J.2A9B%5!BIC.2+]88(<,M-^,[3:8?V>_TA>&2V5M=%@MV8
MUQ.M6$A$PY`"@ZC&.C2:AW`9L\``MK*HSM-FC\6B6H%V9$;4D?TX%`A2G`50
M*!D`JC4,0;3$&\IVI8LZSYT]%M/9%:]66[,M@\)D55#X,;VY79_$W_V38A4Q
M)'EHG%AN3!&%#)=S?*0A8;O)K?,\W%[LZ3@@'<)1^831K^GS(?X*)[1H$DN*
M(T8HQ8AS&$KDS'VQGI:L;<I!YZFXO3J8EE@,H<D7]8M?&^0&U:[M$P>*($XC
MI!"F`?='(GIQ'"(!A^U6])VGT_:JZZ[`&2KK;=N;ZKO..]OUG?/#/W_#"^,'
M8:;7%[</E,VWY&@YH)H</SZ//DXT5%&(0C?62&B,)!"[&5`K)+@,Y-9)HV>I
MMN;EO6H8BU`ZC\$(H)$D4:B8F\BU@1H1*!#20QV<;\RZVT<)Z\Y%VTA_M)ET
M2ZF6K]Y8O&J]X>'ZJGYQ*%P$`(1B)@J)6UL(:C@)!0/:+3,P:G?AM>^LNI;Z
M76<F'0`S1*CT#9M;#U-7MH^C`$,>88%%I)G05.E(&*QH%`5!('`4"P6HPA09
M2`/BUH4,TQ!2Y`:<#(0P!TB/:GS"OI\B\P/`]^/8C<2$$H:06P!*HK&2(6.2
MN4!2:JX-'2ISN\4Y_`!6L1LX/\!Q/(91"%&$)02$.IP"J(-`!I@%C$K8[C2J
MMY/1/76R_41^)S0&N56VK.)_D:3C\TPE=VF53+9J>F._6-,P``%7`>>8^$(A
M;J$H%5&2&I]D>&1GD-UJO4MDAK"`C_ZJ5&;'.BDR__KW[26C5W:(F8NC`R!0
MI#@E1``)I!$8AI(1'88\:*7SWLX"N]5Y)Y`,H>Q/OBS4K'ALYLY7M(Y=&!**
MB$".,"!8,2$(,2$UC$@`=-1N8ZRW`[INU;P_'L-4GAAY/FUDG_Z>9]]OI7S,
M)Q.3%U^38M/VZ(Z48LJD"`D`1AA(.">,"*,<J$AJ(B4XLNJ2'>X3]`O4(,GV
MMTEARP^SJJR2;.Q\V*9]@&_;Q@I"A!0+C1>+JTA`HAAWCB^2@0JCH5[]T5#Q
MO6GKVVV!/7$:YI+%MY([=":S<7V)OJ@U4E5%>C6K_`[)I_Q]GOEM*P>W8^5F
MD4^U<=.HBP?$"`7*!4F1@:$F+EYR4VN(_+I+<BC=VOFX(LK!+.P0X`YFEO/7
M=\\*+TY=)6X^HGS6RS:3V]@YQHA%!C-?,YB3@%,I0_<7Z!"82*F6";N]!:N#
MFE.7P!W05)Y.+MM9RG/?F"LL,=-1A`0E!C`)(=-NJ2Z%-!K@=M<)>@MW#VPH
MK7$[N$M1>7;O$*J+O#Q]KGR5ETM?=?G5"S!W=3=;"<=*<ZX#@64$#%&""TX0
MP9!(-\QH(-I59^HM;>TH7%'7H![:3?5@?<WHQD2&`@,601I1(ID2WKD#3#%0
M..*XW7EN;SENQ^#>NL;TX*Y/3^\F^:.U=:.+63&Z=<CZ0GFM?=YZBK%D,%#<
M8!491JC3@IL0*.!<."T)%+;;(>@MA>XHG%UG:![:RZT5I*5W6TLOAAB&2A@4
M`JV<UW>`8"P"'5"*22AUNQ/&WI+WCL&K=87E,$=6_SLKJ[H:^*=\S6G+I^1!
M7U_;464<W/4XDDF=:C;U+_5^]>[LE8=;G3PA#@4+G./7*O1OI6&2UU4YD(+,
M8,FB=IL6G1?>'-H.#X/NP>?9^L</=W5ZJGZPQ2@M-^8F[TXL-HJ8(`1N%C`.
M$2I<#.R+ERH``HPCT/+EW9V7\CP2Q]<=DH>>63LRK?6T8ABXX<4C1`@0A$O.
M3("X5"H*22!,V#*-X\??X>\9R"$,Z[VM'%SYU+[+-[ZMX%6[&)$`<L9@)$-,
MH&;.%1OL:T81%4G8<FJ#/_R&_#X@]7U/8G/"?>F6LTEY:R;YU\.4S=TWT5YR
MS)`)##0!=:LBQ2/((ZW\BXI(&)&MY7V.*]&>(21Q2`R`_JQ0NZ@;+:3!,FQ9
MKJS_1/O&2MB<:+^;]$>;:-]=R=K0EV$,$2*^+)`FD%(3+@'1@[VW<Y_D^L8Z
M;5B0=C=(#E01IL-BHP(:2$,%L8(FQ`"X.258#"V!.#C>NG5[:W#GJJ/ML/KY
M;61XVVA9D/9PIK&+2:RI>B"NRJK8D$/]?:.8B3#R%W1#Q-UZ$V@&.5YPA4(V
MV*NXNRI(VQCEO"-(6BFJ1>5@KC&A5-+`R:&,P08@N.`*4-(NTVW(ZEI=*&H?
M2`;*@)TOP?SVH5ON5&DV<ZOS#W?S.BAEQTEN_3PP#A3U^YLXU`$U!BD6:#<$
M-(T`0YK)([L\T^%RX"CP'&CSQ:^Z+XK\/G5+;/GXAUN]G&=S.;,;,:K2^Z="
M*K5S'&VRPMV)Q4K)R'"`0DA4%#!H=,@6"E(!;??R]M[<68<6UCM6@Y^$^=H\
MV2B=V%=[4)_R[NRKC\?%`''-"`AX%,%`0XED0!>H:@X'NPW:S`+[-)M-QV2'
M07L(&X[L76%':>W5W>>)K569C5^^>&V#33;I'D,.>>""&Q`"8#@25`(YEUH(
MK(\LNCZLXO/>\1WL.LLN1_YKSI@I1U0P;#B+N`8@0F`Y>`70+2.PWN;'H[*<
M3A!MM:Q3MTEV8\^S%P6L7ES%_IP41>(0>CJV._<%$C,[\KQ]3JO;?R5%FL_F
M)T(FS1('87:SMNQ@#X^*%0!"(PR,@4A)0B4&8H&0H:K=7F]O=Q..PN:.1!?=
M66O]%E.'Z2(5ZU45SYV,<2.EF$#GJ"G'(`!"JI#\'WO7UMPVKJ3_$NZ71USG
MI&K.))7D[#ZB-#:=Z*PB^4AR=KR_?D')I.6,+9$0"<*R'V;*E1)`X.L/0#>Z
MT:TL:=1G!2TJ[#5OX5P;$NII'@JW.#V$874P"KIW$J#%$A"DE.36L#KJ@;>+
M"6N5EMMYM,,THZH_&H;3L.C3NKJ=S:]MM<\T[/ZJ3_\J*HV[IT$GZU6G=1BP
M!5&E($P*9JB5DF'4W!<KQ%1AA5_&$/E)5HV`XS0,>ZCTO?DTNS\15G&R;5!"
M0VZ`\%1SX*!BRC4WX(I9D18TF3&0*0-OSH-L,HJL[Y[47.C+DE^:!Z*IC5LZ
M%L(;IS1"E+@63XO2[DHSOAG.0Y3S4"OKSOTYQ\,@]^_/=1P,1`A:A[PT#@*'
MF>+-JM*2Z[1TB:/Q*Z-ZE!77_/Y).]]<[<==73\..T[ZX\W7V5^=O8['NPD^
M+F6CM.648<Z$(<0VYH>F$*8=<Z-9>GF5[[%0S,*E'U&E6^]39O^^6G[[??ZS
MNMZK<E]7NHKSN:TC(C_>'"-2USZ"0%Y)QQ%AGD<;%@A.?3-_9DYGL\[[6#TG
MBT:"<"+E:3?P?U2+:[]:?YGUU;!_;1V0$`YRKAAS5E(.,=&FF3-2+"TWX&C/
MS">U_,\%+P=A.J+S_%YZA$IG]1L80)Y"32EA!!`+B!"-X:JY`VG72Z.]+<](
MLIRPEJ7`#Z*L!Z>UM`![)!RB4D(HH&L/?<W2#+_1GI,7J9CWQ'!"%GU8_JPV
M0X5>'>DL$*,)U%XQK9G'!%I-&J>Y=L:EW5>.9NZ-'WHU'%;3Z$R?X^C7\ZOM
MOGQQ+X7I:=,`B/;(QG6A!,3*8`M4:V0X:@N[R1Y3G">UI;.0R\&33[/[)M/!
M/O"Z"<FN-K^MCS^X/=4T$`$P=P)X+"V%AD"D6DM"NL2,V[G]:6/P9&#D)N%)
MQ"D>H]O[.@G+]J$8^NW^U6)WQKS825PI1%JNG640:<.E9Q`T"!","PLRF9([
M0V%8EDXSS-5VQXZ#5;)6**G3$$NFG+6HW9=M-"=>Q>7C&&S+BNM45P//S&:0
MJX'._091!QDJH04F&$4=`;JH#33[/6`G<P,4<6TY!O]RPEK6!CC(9A>(,\`)
M+D2]`(4"P&'RN`!%836BB]S8>F(X(8O:N-`AK@:.=!:T`@I+6IO1A`(-.&6M
M8D$E*<Q7-_[5P'!895'EUZNKJKK>N1/K:..Z'N^34.1C&ORIML$S#`1ED@-L
M7)R?0K2]2(.697OB?]:.,XA`?U7<!X8N-U7Z)G$[V38`J^)BTU`R2B'SPFC1
M7.MJY7E:1=;<]P-C4V4(Z)+B_N-\#\?1?/O91PLO1?SWZ2,809AP1!J,G9#>
M"N?:2P\4Q_8J3/XAZ3`VA),=-CN_\<>;IU73NYXV3QH';["@UBANN1,*.J`]
M?IBQ40:F/9W,;;EG.V[.P2X'6SY7MP_76_LHE:_5^H>M_CRFOK[4I*YD*37`
MTD`G`438*MJDZ#$V?OY5V-1C,&,@Q,HR=`8Q<`($TGLDF%'($JX18[YY:V6$
ME&F>K=SF\AB<&0W#7'=^:KGSP-4[W\\Z`>EVLT^%^ZO+[L057]=N`A6&*88(
M0U1:BBCSLD5!8I%F!HVV^PQH(H^(TG1<49']Z_5])/KN,65ODOS2/DBEHJE7
MVW06X5VY9=18>H9;G&;YC+;/C,Z.\^#)DJ_A[O9VGYUUMFC2$']8WJS6/W97
MS1VNV3KV$"RE@E(KF."&8107!&V5,AV!*"N8:\@4NZ,`E-W&><CE];FZJNH0
MZZ[6S2_-`N-Q*L)'_`1V4E`M8).TKE;/$DLEC$:#H65WS)@Y#ZH\P5?[(=8E
M0XX&6CW^+#CFH78`.Q`Q\O535BU:M4DDAMN-E^EL9(&?`4TN+:&><IW'+_[Y
MZ#5:7C^C$M?>R<5J<[>N.IP3YW8="((<4^B\=$`(1#&SNH5<)U8$':VHS\"Z
M14;DDBY5#_)Q'$_X<G"[5R<2B5*X5ANSVFR/7)L-_(4`C.`$`^JL4#@:B,)@
MT]X'F,17,:.=0?G$ORH![B3ZQ2\O9IO-_&9^M=NGVT$W+Z+O_W6[6C9WS"]1
MK%\O`5JE/3(<JZC->PT(HK:9EW.)-15'.]FFH=&HD!Y09:+"+:L?M^OJ>YUS
M_>>3,CZ_%'!I!GGF>)Z/!OK;P[7&YE0_=LDC/M[L?Q$%?9`?P%;;V7PQ3<69
M_<O?%D@]6]27^%^^5U4=Y_E8F>Z1A!M]OW_).5O\ME[=W3ZF(7X>D]\[E++)
M.(H`I7>:2DA(?2])I7,\&O[.$`64POSD5O%:Y7"J^$ZF$01O(#4&1#6=0",]
M)YR1!_PEXR17(M*C57V*Y..S;_9+D]>LU#I$OB9-M7N2'@V_V?);7;%ZOQOK
M^W_._KU:F_IT/%&;J$<O`0$EE:&4.D<8DG526-$`IX%)RV4R<KVBXDBURH5_
M#I/^R.@?Q_['[,?I,C@]>PK:>0:)E1YSJ@@36&K<8.&]E^463AI%XMU9-2":
M;YMA^9EUHNS2:R36`.;Y0X&AS_-OW[=U3I].%9I^^74@`AF!(,,`"TN1M1;0
M9IR8P#3?XFBW-J-)X9G"3><AE231ATI$^R]WJN-T^-,@B0364D>H5Z8>$O:N
MY394:?KX:%<G661Y/DR9GM^/K*N=4(;S#"`8P9P"D$.@A71:*`U:$6J:6!>N
M/T$O2H\N4G0Y%DVO.712E!)[#)0;(XGSVE$///%4*-/8_48(4JY*7AIY?BW7
MDE4@[Z0]Q*@X+?^-<G4`M;)V)M:NH-FBR1SR97]5=US%/-$L..)YU,@$UB@J
MP-&B,LXV(]<6I14/'<UT&%T^J]&@R[XQ'4>GR9_^QVI;[?Q?J]ERLX^OJC69
M:#%UW:[._4X@WG+C,0#(<T4\P]*T.')`"HLY>`V^B"GE4QC/:V?^,O+E'@[#
MY\?^`G>$:>X$@D8CXZ03LL7%8U58KJL+XVVR'`KCYT/]D\Z5:,[M.@#OB-!*
M0*85,=1@S7B#EI");K`Q2T9<$FN'$$EQ!.Z?%&Z([@/!%"DAC():40D$=*S5
MZ12W:6_'1WL&?'%$'D8LA9'YUSOLH72&I[T&*ZT`U$!+I.:2<FJM:C%BIK"7
M@A=&W3.E41AC?UNMKO]WOE@,I-ZVW06/HC;E"0.8$QYM9D)$XV-5CKFT[76T
M]XH7QM%4,63Q<V6M[N*9B4`3"*S7R@N"*`&M\1FUI"0:CE9!X370<"SL<W!O
M/\R/-SV6TA$6)O06)#;08PJHCK!@#X"@+>H8LC3S:;2WNJ^!C^-+H;`CNWNE
MT/1.@S=*.L*Y\%19;8R6AK0VI=5I+W!&>Q+X&GB:31CET;5[U=*S^@T8$&.P
M8E0BYP#&4JKF)D]#9A/?(H!WUN812`[B'HRNUY%A[M;KXY=29_8<7)U43<2%
MK1S4%'`@1&-&:D%LHB?U3?NQ\HID[#>3+\0K_.V-XNK'[6JYSY&S7<__O-O6
M9\C7U=_=T>\/%7.2V$OO-<-`>5!7%_=8Z;TE7@>N`G-R?;]6.93R4%'1J$1)
MB`EBF!"AA1?Z`?^XNE6N6*=B'BIVYN-$#Q7[R:O8AXIO):R;(QYM$P04)UQ+
M1)'0JJ&3TBC7\BHRK+LSE:<)Z^XGNK<5(<L!A$A#BIG`UD!-+'8--HAJ\.;#
MNCN39Z!0V32!O)/V$*.W&M9=&E?+#>LV0EI"XM"CF2NE,AIPUBJ'6J05'B\N
MK+NS?/J$=?>#KK#+VL_5SVIY-%MQ_\Z",0PR3A$`Q-8Q/0`KTB"BN2[L>?%K
ML,%&%T)AM*R3WFT^WM1A#9LOJ\6Q#*EG]!JP-LY[Z;`E'E"'.6>@P<C0Q)#`
MBXC(SD#4,Z51&&-M=;NNXB&Q(T.4QH_5>CO_OU,1!<-\(!!MD6`4:`2Q-!0K
MB7&#'(S_]G9CM#/P>#C!)"F$O8Z&316_\7VVO+;QE%BL7HJ['J;C8'C4AA@2
M7'$3]?`X8=W./LJBL,)+)=-R$H$4ML/^5BWC7XN=+'Y$7M3Y6K;SGY7[Z[;.
M+#I0/.OQCP2LK$!0*$NY`E1(Z@ZT*D#2PKDN(A([PTX[K'`*H_?#'\MO>Z$=
MIL`]C]+/=!R,9(P)BJ)HO,"`1XQ:I`1A:9?W%Q&LG8'&YPOD\L*VM:Z3WU`N
M$'7(4NLD:2(^@'")&NQ%A&TGNVU'PCY?:JQZ8=357%ZXUJOBQ+[._CKI">W6
M34"2UF\JM=.24HV5DFT*$,!$8AZUBPC4/B]P8!3X"PF]>@^HRLE#RJ1EF@HN
M'$(>4D>-MHY`$IF"/>.G5NAKE4,I`56$0@]%[3DA<2>`7HFH<#_@3XW(E2*V
MF("JSGR<**"JG[S>`ZJF#JABRA-#M%+,48&0D]`UXH).YDIK5&1`56<J3Q10
MU4MT;RLV)9JS!/JZ0JNW`EB#.6I%QRFQ[P%57<DS4)!*FD#>27N(T9L-J"J,
MJ^4&5$''B/'15L;QV#*.8`AI'#DBP%G)W(4$5'663Y^`JG[0)0G]4_Q^79CV
M6[6Z,?5*67^*<]N]H;JYJ:ZVU?6?]Q^6L^OJ/W=Q12WN340AXKFHKO6ZFOW/
M]GO$Z=OWIN5\J;]>?7J)*6-\*T`&@0!44R(0J"O=JFB,.`PQP!%\E79?>A$A
M5GVMLE)D-+;SW^S^Y5MU4"]R?RVW*UZYK<M3?EM7U4`1`3V^%A2MDRQ#1A'3
M@$LJ";81)P:X84;[M.CEBXC"2N)R$5*:@,U/UG"$<7[]<D:7,3\7``66`*X0
M449)S23`("+%"3(@*E!ISM6+B,::@,]#B2D?H3]7V_C_^$^^>C9UQD`]!T29
M4EX;#Y66P$.,+(_S5UY!#..)]7:CL_+1]!R)3,3(%Q?4/@EX]5RL=JY/!\`T
M4\8I;0&6RD(L4;VFM2/4<,'5VPW/FHC30XNL$,?O+OO]"V[?O!7*O\R_+7<E
MX9?;-J[HCRB.V>9[Y)"9W<ZWL\4N0.YZI]"])P')NNP`D(!A@*0%T#!'%:9-
M[(0`YK0N^%KE4(K/&@I")><2"^F]XPH+W;S$%UZAM'2@K]AGW9F/$_FL^\GK
MW6<]M<\::J6Q%3":418S;HQIGFP);:5YRS[KSE2>R&?=2W1OR_VGL:846L@8
M-DR!.-SV):*PG+)WGW57\@SD!TP3R#MI#S%ZLS[KPKA:KL^:4@VP\U(!BXF6
M,EKELAVY=(45UAM=/GU\UOV@N[SW.Y!R6E>Q%(@(H"%&1N!6V1$R[>+M(OS1
MR1;72-AG.10/GL3'OQ?53K#=LR)T:!X$=0!**[6+_R$KO&&->BVQ5F_8:YS*
MN!%@ST$VM=@)M[K^\GVVKO0L+HHZ)7)40G8C/OT\O%L'@0J*%=`UH'&^3@-"
M?3-S*A++SEZ$6S>5<*,`GX-RSX_W",6>;Q`011PP)^LH-RBY`T"Y=F;>I9V:
M%^&"3:74($#GH-"GV7T-8CS+U=5_[N;K*J4N9O=.@K><B*B94B2LLM)S+&R#
M`&/J#2>N2*7::.!/0K\>E2Q/M@W62D4TX40RS:5'$DG>S-=!DG8M?!'I)08C
MVYF8%^)'W]V4C^U(7UW=U=C5*S*.:'O_87FSBK\X/++'^;*/!MQ_S19WU3^K
M64V;G00G^.1C;,:GNSHIU"9N5?.KZDD\QL/OK]76;;;S'[56UO;UL8[6N%NO
M8Q_Q:)T_A!!,$D'0CFE/I2C3@YHOS1P.QAM_\,=JN7XR_"XQ`H-^)P!(+604
M`FKC<F3"H&@^.>0D4U)`<-)6+1?+4W[^P;X1B-(<(`.91=QJ"Q#0Y@%#H:)!
M6H(G?R+6K,K`O%AO?`N(OC_8%OVZ^L]=M;RZ/^%*[]`Z4*VP-IHBY4V$BE$B
M6Z"\=HF%Z,;U@T]`DY>(.ABR.53GYX[8=LPGO7L=6@<&5:VU:8QMG+3$A$=H
M'^:,A);ENI\'E>A+;!D<N;?!FN+\OZ63I0R2;-H-^$7G;I_F@1$;]VN));!2
M0HF,H[B9-2<P&TVZV>:#RK$#1\Z$*RM)]'W[YS_FT8R+IMW][W6VW^X*S9$.
M`I>00>2]Q@PA*(GAR+>GNN!IH;/]'6RO5Z<9#MS)]IZ_3R'IJ'JQGZ"-DM1!
M6I=%0]@#X4FS=J7BA+P*56<007?9G`:&\>W2JF1=J'PV3<BB#\O;N^UF!PCL
MK@_]O55`6$'FD16<:LL94\8W^[M$2.=Z&'*&&C2`_%YBR=EX3<4)E,2)AU:!
M<XN5@%Q*1FO`M**\F2,1)DTU'BVD:#I.I.$U%2=P$B<>6@6GL#0B6A2[K5<0
MP'$[1RE(6HC&:%$_TW$B#:\L\6$[4Z`=\Z,75_U9%Y"X.A9@<;)M/)$C<DB`
M>"H[3C3B`C0GLK0$I\55C'^.3.J@&!K5'"QJ'U1OOM=Q'3]K!^RS<SC"ILY]
M!"@=4DYHCIRVA`IL'U>1Z9#J.B^K!I3G*@]B^?:=@V"'-HJ['VMZ]1.HE!(Q
M+Z!C#"""@:OSZ`MK.''6P[0HU=%TF/&8,R9JDYY:*:=58-@QS'R<#2$*X[A$
M8+M36\H**Q`X-BO.1R@'`PY.YC3EI5L'06$HI(.&6.N=H$X>G.(RJG%E[1AE
M:#"C0)OT%/`Q2.OFOV?K]2P>CY]6NP0\L\7B_DNUW2ZJ^D+[PRXES#-L2>@E
M0$H1<%@Z+:1&#EF.:&OX15.B+/5D:&&M<@&71:]M8P.?A`.:Q6RSF=_,ZR=G
MM>:UO>^IZI[1;2"84HX9L`I@3[5A3,%6$A*GW=Z.MB.-1*\)D,S!MQ0RO3P_
MS1DDEDDAL4$,(NFY;.?G:6%OLD9FRE`PC1T;_I+??;6\BNCL2R3>["^5#A`K
M(>CXN*JQTRW^M5S]N:G6/_>;_NW=]NG$?N\3>SS@YP)V'FM`=31Q-'4"*N*I
MHHQ!9:/28T]&*!:/;.=(Y($^%9342BBD*>&:"F)57%#6$\T0\,[Q7-D2N@4D
M3T*EEZZ-IY'`:PA/'C6@AQE-.(Z*I[>,:BD4%AY:3+PFT08J,UG7=)Q)B^OI
MA_'E!F`@%#4-C0'`DC%'N'4*6(*Y$AP1BE10!G`3H?(PFD#1HA4DZB@<:Z0U
M4LIG\YL,'O#3F0%GA6@,C._E$I%(HSF()Q:0D!J&!=#>0P)L#1W5V>KP#!T)
ME(=F_=![G1Y^B+'1P`BKH*.00FT(@A(2R(%47!>6]6HD^?7P\/?#*RLGSE<2
MS&QQ]?_D75EO&SNR_D?W<BLNCRPN@P#)<9!D,+CWI:%C=Q+-D=6!EISXWP\I
M6TZ\2"VUNJE6!DB0Q623_*I(5A5K6<_N,Y0WLUEL%G]/%J^EM"\V=@54JL@!
M@*6=;H/5S!F#3"M%D1%7*K;L6/[\S32.7HCSWVK01;210!2:*`J$&6M("%II
MER21D`Z.WY:%3^6:/FW!QQ&ATV.4^SI)LWLS_^55Y)#<`[M>I3I^KHH.P5J2
M#@L7@6NFF3`,'40/S!';C=V&?]$<#;L5!/\LMN8264?>UNE'[Q?-=5WGO##+
MG$!TNMH,GQV:MDA>/UJVSUJ8XVVS7#Z9TR%VZMV=*JDU92"L8E$":*^!2V5!
M.W0N28^MIJ9"JVRS&;_>H>(V>&HAR=(,0'EFB$+@PA@EB+`=?:QZMOSV09SG
M3@]]H#%:*^QC_J?[&S2GCVOFF^VZW_BZMU_%E>!>1L8%`9#@+5$N)*T]J>TN
M.QN-T>9Z*IV?I^3K$:!R+]2/TVRU1[W:OLJ%BA$E8T'[I!@'KHR,@2;=A<K@
MG+]``VA/A'SUU7I@^"Z';X!JI`D\R-$T3A"K<^`5SSLO>A**N58=;*\LR17'
M@5-&V[Z];>8?5\WU7ZU&R!=M*Q#.:BG1V"A`QR29Q\`MHQ8!!'9TRQU,+SZ1
M)B]TV=/0*.*$_9C[\?UD>I-]^#;E]%HIO;=?E=0NH4V2OY0S(#U![;SD4@!*
MS[CK]@X[F'K:+]7[1*:3B>*I</.D//!&9=L4K4Q3VV63.+1_Y:2/`;S1@"9;
M771D"2?M**'<."P6@GZ@:UI_ZL*0,)78]"]2K6XK?M3+?RS2LO;L^[:NE55>
M&J=%^F7`ZF"<IP&UM9PQ0GRW:-+A/%O[UR%[1J@$/VRNJ#?+Y;J^\>MLB4O,
M/&WN<]8OKU9?]]X$[9TK2YA-IZE->X`"=3%Q/?-"08Q>.QF[Q5\,Y\/:/T_T
MCE$WV_6L6>:QLT4SFSH?I9.=UNE='2J4ABEF&8E.@"46.;6.<8*.<\)U-XH.
MEM:_[Z._+US.N+?O[=W=MO;/OI6R'&U26[E.ZPTH+`O.<JZ8,5:XB)WX8+"<
M^^5V=F>(AGXM.,)H7Z`"^-NT@>;+VGY9U"52A[\8[J>L_DO&]$YN^+MD\8<1
M,[2SM,.:^R>DGS/8]PIQY!<J2VTZ:6P,*BC(09[2JQ@I@B">F79'L+[6M.O-
MX8C>%15$);E(HV8,5/`Z':':*Z]I4"2P4BXAKSY`#$:79FB<1OLT$3.QZDWP
M^O.R#WCW;O+O9K'Q`&CS$C_\*Q55GIJ$&$DG/_@`&!.27B`3@1'GNMU<`SU;
M#,(0SQV)!L.NB'_<[MG_G/M!M6F/_%)EF2!4.5`Q.!$4&H88@V`8C7'$F@M\
M!1F$%0YGMQ(P_]X\22EZA]Y(KW/V*X)&,.F%,)0;3\IE_CO<(WR$''<<B"48
MRD^7J\7TS_7&^6GZY6N:>)N9?E>7*C@(+*:M(;*6H\!X5$2')*E$$M-"QV6[
M'8QV+PMB]P%7"6;XD'W76N2AQS95/ANI)Y9Q-(!<6\EX=!B\`&ITQY3H`V6Z
M+B'M=$6F&&5;=_8OK2J9+0LLTH!"&LLUB3SFRQ%`ZW3YT0N403H0Z#42#P/0
M.+E`2\TU&@**>O"28V1>*>9E+L_NV?CBP/JE\7'++T'"=PG.V_5M*Q&?M*O2
MC&W(CT/@+5BM-7++5=",.QJE&UG:YDX4:/I;?Q$Z3GX<1L=?VU5,<8\BRDAD
M$E*%M`"6&$O3RC1SSH_K(;07.IZP_L/IN*RO_^=+\_U_;^KI/0G37YY3+OU7
MM;%TWY?#W"$FO=*J(@0HD51'%$ERY-3F<J-$&.LP)CA*I1$\NZ!T.C;]4_1^
M*CNUY>=-*B:X<5X09F2ZWH5)ITBV&1!!+>3".1<D%IU$CJ8,/N<GN+;@":=>
MH`?`=&=PPF)`);ASW*HST'.'!#0(.8];?2</@G<^G3/U8IGCL.;7]<*E`Z9>
M[+P86_M4B)X!L21H&M,EH1`D"<'F!]AT6G$]#F&G.]3-,$"4D'JV;DL;+Z;E
M/<;[S0T[>E1"D%RUVQ$N$#R/J+1-R-'(C&+"=_,3/-Y9Y.QW:K\XG8L'[IW:
MVHW6K7VKN`E_$.G$\T8KIH-5\N'^D1X5OZ#[N3?2'L`J@X+X&W`5"QQ\!)!2
M@`L.K;"6!^^L##2J8I'X!YM!SL`S1T'425*X6M0_FOV"P2]-*@`G0[;19Z-<
MEGK0>A>=4I+KF-AW''+```@WO0#2B41V/E]/9N_2=%?U/$LDL=[IM?-:V\I$
MQHVQ7A$NP3'(BY12*F!.:.5'8JDJXJW3`SZ=:!C7J_6B?C>=U<M5,Z\??,]W
M4?'UUI4T)D243E(7@6F!5E%`B4S9D!;?S=>J=TM5$3KV@M"90SC^J%=7GS=E
M9>Y_LB^WTS&?J;P![_*)9C"`M,Y8%HEW+@;'!>^XWWMWXQ^:3PI`U^DH>.52
MRE/(]6'P;CN1>RUVU_EPQ"<J]!)U4);'D&ZYI/A$4$1+D4U'&-A((@"*'!K#
MP=:)$<)R-;V=K.J;_ZLGBZO/[R>Y6$/X\6VZ/Q512[<JBI@4"@O&"P.::JV,
MANS7[B+1HW'U+T+P?J&Z](@_GRV6#'@2>"E$2Y(BJJA')H%;G62@3HPA+XTQ
M!H*KG*/B[#7OJNWI1?<PR"'=JQB]#R8B@-_(PNFPTT2:0(.FV5C6B4G4I3+)
M`)!U4Q_:Y[$C(=].%:/S%ZO@T5"?5IU#L-!*XZ66UG-/)!)!NMD`]*6Q2%D4
M"W/-P^%X'R/7/PL]^7QEC2!&$F\B23*W"\9SI2-7`KQ/*^KFXFK^R_CI%$B[
M!2FG>>0:0>O)[.K/V?3+_2RV!<>VMVO&+VE9N>KESLBYX[^4[F8@Q!*-D2'P
M(`W146IM@A9!&-&Q?@2Y2)X9'+[^V&,[@4^IZ_)K,]MYM!S6NR)(A0S$6!$"
M6*HT\2H)\=9'8K);8C<VN$S+YB"0#1[EW,R_?*H7M[[^<_5TY-Y#BG\9Z9SI
M3?/X;^;+U6*=B?Y(\SUB^XX>530@LJW:IJT,TE!-34P,0H-/Q[YL+\Q=8GUM
M64U?:5T%EM5P+[P0.7VOLJAM(!`DIB&)+17QLC>EZ<DT>1[/<C(.HXT8SAMO
M];#Q/J6IMOBFO-:\LJ@T1T^TI$DA!["29^'9HV?><E?JJ?BHU*4GD?1%NMN3
M02EAGW@^S58G@=<[5,I[3X(DJ"Q-R].11K&I**2B1!O$!?J;G$;!%G88!K9+
MXAC&)"A.J'><`!JNN73"2.&]E5H4RT)QN"])"7XX#I2.%H;%<O5I,9E??]T=
M`[6C986.1.6\%,XI($@07?3H\DR-=G$D/J5]@=ST"<;X`E>55T!#X"(2#41J
M([/#&R5*&B-H+)5)]&Q7=%<DQAFBF-:K<XX[C,[E\BQ4"/9PE2A#I;[`&[@#
M@?8$,?8,T#BY@$J'TBC*!"IPTIIH'"4A0:1]L'0\81K#T/BXY8\WP)&G2]OG
M'*8B2J#28`1T+F<]9)8%Z!;@6"10]6`*[`UP/&[])>CX].)QD\7B;CK_8F^;
M]:L^@8=TJR)W7D30P-*:!#%:"462&.EX.JL<(^.B\K`&E).@Z20(/Q,EDISX
M)@<-U<O5U7RVTX]K?Z\*B4O3LYGM#4"@Z`R/Q#H`8YU1I9*!%"9I_\B4W]+;
MR7Z8K.I-58J;GVG'#][@^SY2<1:35B@<9<P"XP&I2VA28Z50071,BS=8JN9A
MMWN/0)5GE<S;AUO(4^,*'(N">P20!$C4Z$#IZ)W-R1?\V'(Z#VPJ/QZ0'L[W
M[#4:)[G6X>IN3S#&WDZ5"(1$0ZWVX-.L`5&3Z*)4B@MDKIMT/5A*Y@%/]].`
MZ8N<T_GC8_D1]/RE5\4(1H_2BB1D`-/!`,M%3FU4TKH@NA&T=__*4@3MCDPW
M?X.<6:[Y_*\D^4WF"==-5K@=9^O^#A4*`A*B<A0Y4$U01*H-9\)'%TCL)DGW
M[@(Y"!W[`J7$-;J9Z]5VKE?W<_UCG=&Z^OPQUZK=U*]UD]FLOL&[AW;+AX;[
MK)HG?KDR&23EI*3.@D)MM1$"!1KK)6CL]ES9NX/D4!=T6?3.QFGA1Y(QIP]U
MAQ]_^+B,?8[8G;Y726DE!1ZSK`,$`S)TFDKFF>+9M-6)JWIWDRS*53UCUM_%
M8[_7BZ1\O)LL_JI7F]G]<UG?Q&;Q9,9'74V'?;)*%VH.1M9!.0?&,:.2-,64
M4,8DB5AT])[IW3.RW.TU"&Y#^\7]4:]R#92DQFY*#PWK&O=LL(<R.9N21^''
M]6R=AHKWWJ.Y6:>J&SW50)ROIC?3V7HU_5[_O$A^G6.N#;A>;5P?KSZ'R6*>
M2Z=L%_;V`&>[OH:H9+1)S`6?KBT)/J"14>BH(HG,",U;@R2&0?#C]=?Z9CU+
M9^6)"VUS[.MWH,JAXTD,D)$!!0=@HPB"1:.8Y0YM-Y-'SSZ!Y5GG>8FC<V(^
M6O_#$['`N]<_T.(8,>"HE1,T78N2F40*8![2GXYIU!B-8!I&6<C]7+SYO.;K
M:,A20F]Y?;('5;)HZUHI914:Y$9)(K4T0:I[!PBM'6KF+M!#9!3,<1###D>'
M2V=+GE0&KG4Z%O)KCS)IF<8J3HBB1@I3S*?P8)>5BV2ZXU`NP5,/.E^K9\R3
M=I76%(W/1FF2;9N@?4(&)?4Q[9BHBZ6@.TQ7[H\L37^@E"!NN/TV:^[J>E/#
M\^I;QKN5T#O[5,SE#/6&,9:0(B+G=A%I=0I"]%'[D631&ISH?0%TOAOCX$.R
MU;&JE^]7$%#JJ`GUZ7"5VE@ME7,*&?%<"#JRW(AG5U?/`7IAN]U&61FX5NZF
M>/&;>?IW'7Y\RR'&!>H!OQQTL]3]@;7#CCWPJ!^G7^;3S]/K=$^Z]7*5!E\\
M%&+.CD:+!R9UB_IFNOHP7?YUSACC)Y/*DSG$\KF[4T61*AF14F\#B33I#L)[
M;T64F"X(;%7E"JVRS2;Y>H>*:F`B*J^9,*`H-33]XWYU::GMU9A+V!;[(,[S
M![4^T!BMU>_%ZO#N@.#C/;VJP+BQ0245.VG-28MB`<(69^=%*1/T45:W4VG<
MQC*=X2GR:O]B\8<$F.[IE20=`983Z1F8X#%R+G"[QL"UKYZ9F,9CVNJ%<JT'
MR*E(_9Y<,3J3T]B8H3P3O%\T-^OKU8M)MUH5]G>LE*(QL'2F`O<87(2DG6Q7
M2D6Q9\H#-<!>:/8\JV:?`)WE/,`[K.?77V\GB[^.EQ:>=*V,1(5.:B:9X2KA
MALIM5^L==C-&#QP3/;S(<`I&Y^&([82/OR:>=<VU%K5C+G"6ZTT0'85^Y'_&
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M%<OS,.+5O"6;W8N&5;K+5+`*<\YUYRPZ2_CC>L$7<W<\[(KN`>6F1SA.(M:G
MOUOJ5[YH6/$D<9`8T%!$([43'LAV=B:&;GY?@\E3`Q&K*QRG$2NU.G!O_=*T
M\HPR-$($%%Y)9=/LX-$L#6$D%>V&)EAG0$XB66S6+97C7[:LTNQH,()R2ZA3
MC'KGY79^2@K>B6"#Y2@9B&"=\3B-7M/O!^ZPGRTKI5U@&"QP'YTVBCG.MO/C
MQ'3S71LL&<E0].J*1R=ZW8?$-Y]SO&6]F%Y/9@^/)SL+I>SN426&8C;-&%R@
M3AH%!LW#?+D!5\Q<V-%"T-V=I5]@3B*D;Y;3^9>/JT4]_[+ZVDK%9\TKH8(T
M-"<K5,QP#8+'K56$QT"[J?SEC#P]D?`T5,YB]?^9;&QOTH<]W:J@:1*/B>*!
M2.Y1:"NVMG$NJ1V9?%/"&ZT[.B?MX4_-MS3RYV9QF[CP_<8']'JZNW152[?*
M!I0D:*:4,6@Y@*=;-8BC[EBG:C`Q:*@]W0\Z0_MN'^OA6\#-^M@I'=N^B.-T
MCB_!R3)7KKO-[MI/RE*6'-/>W&P^.9F]F6=FW/SG&=-9W`?PO9AECL7ZLG&7
MQ;N?31Y2J=F_)XN;MP>X<Y_^\<J[I*)D`5IK`X89PQ%0.V=YDJB2.-QV>`V$
MVF,D>>L2E[O6>'CVBA/'J(@4E"8]@MIHD^SBC7,"")/&>8U"E(H)VNM<7I)5
M=J:L*`OT:/W6/TU7&8TW\YOI]^G->C)K>3I\M7W%.08.D:O``!PJU!2LE49$
M1GBTHZR7=096:/K'LH0"\F*>_YJNOGZH9QN8EE^GWSXU8;Z:KNY:GZ"._%(E
M(P%B(UIG$IPR.&/"?;(!CXPBN<"D#R<2O8V%R@+Z>W.?`QV(\HH0H"")P.A-
MTD:D(E%Y7BZ^]N!GT?/RUG%P==*:/_W=_']2\/+OC]DMZ\U&SYA^K]_/)KM#
M]`_M6OD0F4?ON.`6%./6,*J"H,)X:4@864F+P>C3#`I;B3/CN%)B(NT.D((X
M;R,8%Y!I881!:F2NCU8J0<.%22]=\2M&_Z-*3S%+&7>:L*!!*:8\,-Q>C#["
M)98`[4"@/<6I>@9HG%Q@O,K60$T<H^"-,B97+?<`^0DG=`R@*5.`K`\:'[?\
M(FZM_V'ORIK<MI'P/]K"U3@><:92Y:Q=MI-]9"DSM*VR(GE%C;/97[\-22./
MQSHHB*2HR5:Y/#,2`0)?-X`^T-T(9ZL"9$^?J[@*!'B^AVTM&"&L5I1X&E3D
MWH$:F7.RB`+/[ZY>,/]AKB>7%)*S6D,BA*$,X4!8<-S29*E2-$AE"LT*O7DH
M.Z'C!?,?)-"DU'2W2?C4_+3.E_[S_$V]G"[N_U7GA-GU_39E]OK+,%G5:3)=
M_C:9/1PUF0X[DBI:'JG0GN7"%"`0?1N8(5Q2&5'*'5GJMFN:6$=-F,$6R>_/
M$=@D.+</JT^+Y?2_]?VO<V2!)\G0LD+5?)<C?KVAO'Y8-:L)ZGCSCUN`GD'R
MMLX<@5_[17:YW:U0$\P55-BIQ7/]$5:0=-(.O`E<``_$6"9T3($F%P5*D./:
MX*^]J&Z.8-=;;#\2Y?<#V\UO=9,G/K_/N;WN\-?WB_S1%K6L(;<$Y]A=G/$,
MLG+*)"TT:FN.H'!!K9`AZP@B!$5I88WEWF[^C&[)W0#-BBRKL5E-_YBL!SS'
M]^;=)"V6'^KIZF%9YSJ7^-?3`SI/YS&CY\';2A=U6@60+FKA@](6"'.664I8
MB$9P85)A5%)O=YFNP*F#8SP89[VKY]/%\I?)?++!KDL&>]YWI87+%9II=(&"
M%2S?#6.$H-)L$_.I+-BYMZOHM\1G%T(]2-3\;$W0^GX_KMN$GT>.]G8=5(!*
M"DDNL,@\.$<MF*!)4)PG(%:52;J]U>J\XK';"YYE&]=CPNIZ^15%Y_WC^76^
MK.\6'^=Y/3S]W"^:PW$5E_=<&822*L*U,02BD-88:84P/FHC/"^+=^JM9NC5
M-JVA@;X2HSV3)#>FD]<?WFY:/+W_VCTKGGYWA2M2$A$=[O,)$I,6_PZ$`^4V
M,B7*,A;V5I_T=IFU<U*,VJ2\*_'ZS`K2A]'XT+NJI!T1+B9.@P$NB?741ZMR
M^D*!YU&9JZFW(JG75J>O"/VH67FOZ?NGY:+IY<;]X;=5Q'E*\;@SEAD`ZXV6
MD6H4U)UR5`E;YN7HK9KK+?)S9^B/FJ.?K=JOD^DLF[Q025Q/?(`]^ODKJ\A%
MS@KCM/(<'%'&4<(2;B#$Y7I#A<ER_^_"ZXT$HV;P]7_9H)M##-=K^*0#H*/7
M5":%9***ECD.@3G-I=-446^%T;$TQN?%NLVN`WN1)E@\WOB?+]--N.5FM(?4
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M/AGK>JII%1ACCG&(3`7MF!?$"9PM;A,@".5BO*F?.Z?G<W[I![J7SC"CBXT:
M/9]<C3_R!</I_&%]_[?>*)G-Z7(AI]I65BKJI`5J<<Z"&!(%9"#SYFRU&5N(
M1&?DV\\7G0$U(&.$:7.W&79]?SYK'&M=*2*<Q,,[)J%M3%%:I?.<G0W<A3!4
M;;*1,$>'4`W!'IOJU[L-U4UFDWF6YNIZ9>?WW_*<Y6FAF/ZPK!OW%_[Q9=%,
M9C\M%P]?&NQB]I!##O9/_82T/,P`*B+`)Z6HX!$L'@G:)QER7E_%/)&D+`'$
M8)D`QB!LCY)00RR1L^:0\TF?E,@*>ZPD=3FWOO.*$$%1P[>X:6RQ49;9\4KV
M8V.>Q34)\G^F?8K1Z+2+ORFO=N%E6B=-OYM.9NZAF<[KYE$;.U%$X'BSBFEM
M/1BPPH*/EC/)R6;DT<7@1E:SL'?Z+'J#[@H"YZNMR'*>E/BT524EIU%2!AZ8
MI\FP!/11H'%,#97Q_.6(=A>@>T4..GF`'6U7:1:M988'XHV53`D:[.,\@Y/F
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M3?/ZPWJ@KUK<I-S[?!6$P+-"N.!0%I5>:6>3TU'9)$E2_*18W?=]R`W'_;4>
M_!EU7IZWJIB1UB@JB382G!`Z2J-$LM2YQ"F4E>[J^&[BA10Z7(SE0C1ZOB?8
MU'?_^+CXBMOZ=,,A^,MSQL"/JE<UKM:XSKE^P%*UYZF*!%""2P<Q*3#<.>6-
M"0$T45Y'4A8=/USQE'+2+;K"I+U(UY:2\7A%B>>/5"#!!YY0;2$465Y)%UV*
M@@M4E9GV^H;2AU]$CL4P^%R?X#(&9',+S#$"*'FZJ!-).4&;2%&&\1A[>B'G
M>;,O\A+A\7*WF,W?3):?_>3+=#69O7KECWN(CC2IHDI11TN]C!)E>FI`"T,3
M#E^`T&HDI3W*@5[T@D,1Y7YY]9M?_`-?.9G?K_-9KWU<)ZEWHEE%M0Q"4C`F
M,>!XGMAD4>2@)NBDM1JJ2L<@%.P6BT%L98\6H*<B8ML0B.=M*C!""LHE1^T>
MG&4:?W#K)7)JHD:5[:[#562Y6"3J&J$A..#I$$]Z4GY\N%)<1LU2#%X*ER_(
M"N8?1014)_@-B5`=DN]YV>K><;L%5L&5XYD0)"2"RRGBCFJ9!,(3&,UU8<;.
M04(1^F2$\U`9A,[?XIE/.DE^>+9">30R;I7A.D*,WI`0)0^<>O"B12#LL,;M
M2PCR0VWZRZ`8@K3_FN38^,-7MO8^5PFPV@C4]SB)X%'S4\0%S[PUP>/'(Y'A
M>B#I)3`,0<XWV%>]7&XC^<_(J'>\846!Q<BL#M&AAA&H1?T?`=0Z\F0)#+93
MGT_PR\V;G4(S/!.@^OAZN3ZX[M>%5M[4R_4<6C/#H0XJHT+BP$VN1(DJ*-$6
M5P$E4CE"#2^\BC?(+M`U4W0$T<!G^1G;PY%6E9;$0TS,*\E`6>%03E5!*2.I
M#-*6I<[L+8%0MVS0'2X#T[Y@5VC1NA(J&NGS1B@$X*2UU%ISF50D1H`N<W[U
MEBVH-U[H")]A#HO%75W?-PG1R7<-<O0#CGVROJW\G?M[[T%QJG$5;:0A0I*4
M97&)&Z<B:&E5]-2+5)9`JK>J#%T?$AW#4V3'??.PO/LT:6K[<5FOE==<C.:0
M]7;OPY4SVN&1I<`E!Q3/,Y1L#$F!29<K1Y59W7NK>M`-$3N#8QBS+<YU>U7H
M8;E+=K@YDQXG\?J#;9IZ;SF#HGXJ(%J$G$R1V`#6.RV-TD(E3C0D'D=6O*#C
M2P\](C4(Q^2!KO/5'6.'W4.H,?L<PT:CQ1FX1*S41!&CF8\4]ZZR?;RWW/\=
MT[H4AJLO_7_6?ZZ_*E[SNPXJ02&Z0%AD+H$@.<D*2ZCT,DZ"$JY,V^LM0_Z`
MB[T4HJ+#W*Y^F2P_UZM'<2(+$\WN=&IP7'?X<_%AG8C\4?XX=-@7=58Q(,YS
M`518@B*KTEI$J[3EVEH22P,T>\LMWZ$T,`1>?7#%MAIU%SRQKZL*-S[">4S>
M\91]XR;EH`_KA$]>)55XY7'DYL&!T"KBATW^]L4V?SORY:\([R&*[WVX"A`)
MM41X0SEJJD9K*@QS#@CR<])E51O[2T[>(4V[P&-`[^O6)?%Z^387#?JN2O#N
MRV;[;7,LMWU1?Y5B1B@\YHQ/#**B1LF<<BW$H,&D6.C-OQ7SWP"078V5=D4@
MZCN4>7+.+#^9S>I[]]?S*9W+5.U[KJ2QR5!OJ1`)C/%.,8M+D.18'M"N\+[?
MK5@4!P6OZ*0Y*AF_SO7+9K/%:I.#;34]7+_NW'XJY25H2:33#A>1,38&HICR
M"*KCM-#Y1$=N6!P"JC(;XQY+YV)MZ5QL+9W_K%?KLO9_9I[=)DAY0&;-5O-I
MDV_?-)/Y_>L/'^H\I<?(T(-FRI[>5W%';5!),"X)@.&:Q'R]#[5[PJ3E9<XL
M>A.FSG%`.DC\Y7?A=D_\-G99YQ#WY==U4>3TD&LB/V(Q6-3C=X,;).+QX?>F
M_O=#CN3_FK66?M_V>$H-\Q;_*5?^:'Z>I\ETN?;%[<[35U-L.#L5SWH%P>M5
M^QC+`PTK2."I("F%!"`)0^62RJ"\98PJQ4[&H@TXVU.QEH<;55[P&!B)D"TK
MTB7G-+7,14$]!RN'2C;7)M3R8D*U$0U+4.DYY+)C9CD1B7"P#1Y"#*PU*/0$
M#QRU+2D3EQR2]#G3[U`9%LZ*1.B"QFW8I@"@JRFE;:^9[VM562U#C,X3JYC'
MMS)!4Q!<6>6U`!IO,#2A`X*V89%^`+Q-+B(V:ID\"$HM1*^,Y3GLCJL4>31R
ML/OLK:,6AN61\^`IBTS$5I_>_[EX_VGQD%6.-/VPJNOYH\QW(CZQ3>/*6!&C
M8DZ9P(%[YZ*V2A"6JYUJ#85Z8,]JX&7T6/0,4IE]J?ZR6K_LR6#>?YHNGXSF
M.+E;=U"EI`Q3+II<G8\[H:DD$J<GM"9`1-D=][X='MV1O"^@BL@>ZKL?QO)G
M/?M:MZ)YN]89)A,L=8DRFO/E.A.\M(GQ@',QM$Q]Z-MST1W!>T&IS'W]93F=
M/1D&ZAI?6R[O%DTKJ9/7S,DH!0<PWNJ0>#*$2P4QTK*K2WV[$+JC<_<0=7)H
MGT'D%DVK%%'L)!J%T&`R/MI*[VPRW.LHG2J3ROIV!_1W8%\.42=$?E](X>?M
M*D5\<-$+A$2!""*[LA)'C5?BYX&7N7OZ-LOW1]X+\2FB[<Z"NMCYM-<I"O<&
M#IUH40630R%PB/F^.W"I!?>$&**=<,31D66\[-B(URTX1<1<SVCWYL5F1KLA
MO5W,9FFQS(6Q#]&V=0<5I9[BKJ.)3`8L51HU2T^<I]YXE"G*CM]AY>H+2=T7
M5I<MXV]74QX](=/##M?CK2HEJ-8V1.4Y'BT2#--&:N(BU8+%X3(Y'*=Q7\38
MNZR[`*IL::]=7L<\7D?HW*IQ):BT`24'!MX`ZGW..J4$8];C/YW*A*W.E_00
MY.X#K[Y=X(]\N8=5?VYBLYK^D0,7?VVF\X]N-KG[_.[N$S9K-K=)\JTV_.*7
MQ7T]>X&.TTQI9[77(GK4@YC%DU<&QZD.V@CS0ARGE(HHDM5:&`DD2$V]8ZCL
M<8:_:CU4+8-+'*>M"=7><7H>*G\3QRD1G"<"3AGM4',TCG''%?<T\6#=8(;P
MKARGK6G<VG%Z'D"WZ?)RAB@/-##*/5?"N^C\VN^7"]E%JUZ4X[0U0<]PBG4,
MX&UR400E8X3`2-"@#.I.$:?-;2!!!$'&DVOW.CQR'CQC=9PZJ@Q':5<D?#NR
ML'6$)I$D:LQ>1S-4^OL.#'6MZ7&^X_0\D,;N.#61<]S<1+YG#@%7!>#>%D)P
M3HD@TSBSP75'\KZ`&K'C-*2@<0HT*@HI>CS$1'*0'85.T\(DW%=QG!81O!>4
MQN@XI5X%2H#[B&>=#]I*F3.<YN3RR<5".E_%<5I$Y^XA&J/CE%(B($#.9).`
M.X=Z41+6"R)I"(*6E2VYBN.TDP/[<HC&Y3@-)MH8A224::!:.2,,YSI(;R0U
MI\LNC<=QV@EY+\2GB+;;%[Y;+:>?#Z;<.?!DI7EBDH2@%%@05CC-HXQ!4Z<U
M#404T>]:CM)SC7;=@-*1FVP7+_2D6%\.<KM;U??'4JJ=WU,5F`R<2DDT"R!#
MU(P1XK-I($H2Y2U<1;R0Z+V#=LE*_N8YV3.6WQ:SR6H]T!.KO&4OE1':Q,2%
M",E`HMHYJ7$#1$G#)&>_I=08L;3=S0[0#V"=,\+;:?,Y+>OZY_FJ7M;-ZNUD
M=6K#;]U/);R6BG@B8K#@C'$A$N=T2LCJBH\TP>I@S-`!9$,Y7[^5F=E^TJJZ
MZFTZ59-D.J"P9K+A(RH4H*GE6>*R-C)U^KK`;3A5`Q5!L4@`\A5:&0U/E''/
M`*@@'@KSH@WJ5&U-J/9.U?-0^9LX524>21:W/>8B`R>\%3YP[XC(L5A^L!"R
MKIRJK6G<VJEZ'D"WZ0[SU$3C#4*6@DZXZH(PD40%Q">JA'A13M76!#W#8=8Q
M@+?)1=;EF&]I700)Q!(C`^1L8J!D2%P/=I&Z`Z=J'SQR'CQC=:HF;R13AA(O
M"3B:-)[*'H*4*@1FQU+UM%-ZG.]4/0^DL3M5-0/<N$`XXQ0`RU$C-'H>5`"J
MA=%%)+^*4[6(Y'T!-5ZG*@LY2Q:WE!(.0H!33$G#F?*,",3N!LP\EQ"\%Y3&
MZ%3U7*`XHACUP0)+Q"ANA8T2*#5@8MF!?16G:A&=NX=HC$Y5QFQ2)-)DO0`B
MM/8Q,L=\$HPXD&6W9J_B5.WDP+X<HG$Y52E#E9<2HU'9`$ZC%909'A$DERB*
M'K?C5.V$O!?B4Q;EM)@WJ(OB.]L)VH>>KU!`I(:&`%)'W&R$=08"@"!<^1AL
M67ABWT5LNJ-E1[@,H3R_S:%6)VQNNV<J`Y)!RBE'K<Y!M,8;QL']K[QKVVT;
MAJ&?-(D2=0'V0MW>AGV"T2'ID(=M1;L.V]^/2EL@Q9K&5F0[P9Z*%I9KG2-1
M),5+`8^*C&B[*9FN0*_M8VL%9#%"3[8>/GBJ)L\+"R%'H7TQ!:0,]LGEDX2!
M&*[09]9`T%L4SP/09:X"E*G&W:'9-\[.QLL<3`EL%^A0C%\J?6V\SZLOQ].F
MOP2%GQC.;X_?3I+XZKD!O(`L8^&3)J`5-<TV\HHD,F"S*1>6*M#$P(]^\U^$
MQZ=^-:=Y/'QNL,638X'",T>,HI`SFF5+UD6!UO+"HI6Z\'C&_-NTW;>RV#\_
M_GQ@Q6VS^_ZUM6#'VZ\8C"I\BK"R'C6ARIJ@PH&U@>$^W^FR=F;G2^V9T5KM
MFNG@ZZ?>-1T,'9*SK&X**T,"!(@.<G+@-1K"K!MMWP5+?9Q+XIC+IW:\^DF'
M$[69WALSQ)R5TLDK31ZU%MX7UD]`A!AUIM-5$-:N[]&)X]Y`]2,W_[[;W4\D
M]WG,(`OPR:2$L*R&RJR#ID14N].3<D:T"??N%PTKDML&5#NY__8(VW_!384X
MO1,\.FKP4*LYUWR5Y%-!Z=`Y"PY,R0IUDHVQY-U=T0O2W1FQI0)&E^@$\_*_
M7G[N\=K=[K8;>NY'\Q2=>NPSKC,\-05TZ'U6TB=T);L<@3(;!8[WOK(G`^RO
M(SP5/62V2=B^<0JA6/+6@V(!5V0BM9A.?TYXZFBBQH>G3D/E/PE/53Y9"3E+
M[0EER`0R61ME\<H2EJ7ZZO1RG8_F>'RSE$D`76=@H2ODDM116DP@R=0J!4^]
M/O:%W\L5NMH[$#HA]+`S@->YBFP0M0:Q]0$$PP`D`:QSY"2@4VFQR,4>S5)F
M6"/3X#DK5>W99'W=W?J8:?'NH"&D&$MD31A93W:*G!5)*5O0@K"BL=;Z6N[!
MJ4I%=WQ6V]B+]PHG8ANZ[B#O/`J!+F(,6?$?:Y)FN)"RL6LHHYVA:Q(4+XLX
MW?QYH-I&^.MV<_OC_M6G'9,78\8.22*HC(FHEL41.6C'^\0Y$Z*M?6$OP_$T
MI]B8`:8EI,>XO.LC><[37S)XGVJ%1%0@>:63)JG01JHZ4K%>M,F)M9*<6^7$
M;'BMO6*.U,H8.W2@S,A%*#4(C6$$GXR+(F<O,ZE(%^+07'%U-*"TUIH862MA
MZBN&6"0DSQ.U)J*#[%CQ"E"+![%D]8TA"<L&Z,ZS1CJ@M;;\2+M?N\WV^^:,
M\^;P%8/0-K&-+GF?6+2Y..-+%"YD[>NU0MMILVP`\+SRY`RTFA31XYUQ[K;W
M>Q/KF!IZ>N1@HBZH6&<FK3"Q*<\*-`6M-*B(I;$^K;L2MN<!Z?T;L(\?ZJ-?
M;AZV_,M?4$L#!!0````(`(Z&:4=N@XC::=8```))"@`5`!P`9V%L92TR,#$U
M,#DS,%]L86(N>&UL550)``.<%4%6G!5!5G5X"P`!!"4.```$.0$``-1=:V_<
M.);]OL#^!VT&V-D%XI@4W[W3,^"S$<#="9+N[0$:"T.NDIU"RB6O5.XD_WY)
MU<-EQU46]:C2?IGV.#)Y[B'OT>6]%/FW?WR]G2=_YF4U*Q8_OH)OP*LD7TR*
MZ6QQ\^.KWSZ>R8_Z[=M7__C[O_[+W_[M[.R?ZL-%8HK)_6V^6":ZS+-E/DV^
MS):?DM^G>?4YN2Z+V^3WHOP\^S,[.UO_5;+Z:3Y;?/XA_,]55N7)UVKV0S7Y
ME-]F%\4D6];=?UHN[WXX/__RY<N;KU?E_$U1WIRG`*#S[5_M?2+\O[/-8V?A
M5V<P/4/PS==J^BKQ1BZJNN\&G6P>__K=\U]0_3040IS7_[I]M)H]]Z!O%I[_
M\^>+C[6=9[-%M<P6D_R59R-)5GR4Q3S_D%\GX;^_?7B[%YXX#T^<+_*;0/G[
MO)P5TX_+K%Q>9%?YW..H6_M4YM?/-S$ORT<M!(I$H`C20-%?7FAX^>TN__%5
M-;N]FWM^SKL8T`+Q\GNT@\&K:?BE#<I#O#YML&_`OWH/SON%_'V3?8->33:[
MF`XQAY\VVS?X?C$/.SF*93;O>7)\U^1^T//PV(7_:?UD:/Z`#->]K\5UI^7\
MZS)?3//I2CP?M9W,IC^^\C]=WE=G-UEV=_E[5I;98EG)Q?3#[.;3LOJE6.9F
M5DWF175?YO*J6I;99'DI&.%8*$D%<@0+K20T!B,F.5:,8'A9-W^9+\Y^^[A!
M4_^J77<&2R!$JAV#D%"02D:)XE8ZYZ2@%+R*(>A[[LN\*N[+R>K]Y7&&-_@*
M^M\W")-L,4U6&),`,GE`F?RQP?D_?SM_L/0QV\7DN0E4P[O.JJL:XYH5CQ7B
M\WR^K#:_.0N_.0-P_5;^2R1]3P>@F`PV`"L^YR$N*<K-9'XTY60Y28IRFI<^
M9MK\559.7ABY]1/GD\)'`7?+LT>#&$*G@<TJAIVW*]J\D<]2]IV7OKL+4=];
M[]1?@Z"\K:I[_\JQ_WL_6WXS>34I9_4#OWK/5YZ6SY?&`*B98I!`*Y&`2@&^
M<5=-%;M<;E]9+_IL=.><"H*9TCA%E%B#N&&.:J!5"KE@"L4X[W+/J[6!!^_W
MS2-QW$P23TIOG#:NH"9KK,FR2%9H_UHE*[RODQW$R1\!<U*#/K90QI)Z0#$'
M&Y^12.=P]A5'FNB18AIDNU@L9XO[?/KN+B_K%750=O\/=T65S7\JB_N[ZB'T
MT9@JS0G1V$JE,!*(&9NJ\'N'N6OHYWUW.YR;[R)-'J#6$=$&;+)">[I0*)+.
M`PX^U,",Q+\',Z\XSOR.].Z00)K>S_-WUX_[?;N8S.]#KNYYG/Z?B]O\X]*O
MV$+"3F7SD'[Z^"G/E]X$.9W.PF/9_"'FJQZ$*C4:(\`=ITQ)9!D1T'E3C(:`
M&$9L3+0U1OP#!VP;DY/B^JF^O$ZV=B=[9*E^Q-N>;(U_G:S-3VK[:]UZ8&!G
M(1<;(HYQ;!J^?<8(?;@WV.EFE`]ZLRO?\>E"WQ.,](&7ZYCGW4A>T*.FJ/C_
M(R.1@8*ZKV:+O*IT<7LU6ZRCE4UPPE,I0.K\ZB/EC#KN0Q5AC,2.:2RI$`U5
MMU,?P\GC!E:RB^MTH?PAE@Y(2R_DCD0#^K&E&&#V=?>J!Z=^\&EA`)$&*&DX
MLEQ@HY'=]@Y4&A,Q]]3EP$'NLSX7&7_V16YK\1J:U^XR]JA,<[H@K!EW<>+6
MA?SQREPGJUX6O.ZD-<\KYE?+9TI"6$(OM40`A(E@%H1Z4%TF8";4AQJG#Y]O
M7:G4"`*9D0X09JV$CA.*N+``<&@'7&,%0*,HBC[/S*&$7S<J1^)+7:UXFK[K
M@Y26OO+@FDHXEBK'%"-`*B)2+O7&630E477+O7T`JC!$0#NN"56,"XTDH3Q5
M2,.4DX$#@8MB<7/F_^XV"0`C(X#6O+41F6$HZZ@RIWNG[R&GL=#$TSE*I6EA
MQD&I:4M+8ZU951BWBN8DI(:D4#/GO+))HRU;E>VE@!32AJ[RI%5AB(2(6B.Y
M(408!0GDQCK*C4FY'=!#5D!.]_I]3,0!;VC)V$B<H"WZHI=I$UL$6WI_^E3,
MI]L"^^/]2@\^1XW3BCKJ8V`&G47,>]W&&U#J3%3IJG&OCG/@WU0$`HH)U<P'
M&1X`5IX$@P6G0Q><=H#^=;UU);84U!_##0LX)R$WLNSR#*_?;YX\86FD*8>'
M"AJ]C\-(!&X`PYX6#P:BKK$LOL^^A>)<V)0@)Y/R/IL_Y$-I"BVP*>'.64@H
M):E&*S?E`!BH&KKIP2XD9DXJ:"0$),6.2RB<"FE8[9RT`V[<VZ!:%2[7N$X7
M,AP@Z8#G]4'M2'RM%U.*_F=>I#_Y?HK[Q;):=UUWFT\O9MG5;#Y;SFHL[Y:?
M\G+G5P_NKN_+,E\L'[S>8J52*)ATF@(K&&(:;%Q0*!45B_0,#:8$:(X,15Z"
M7-C03:6P0'+A%]U6ZX$#EC7\Q'Z]RQ?5VH]K^,D::K)C1V0H<^Q1;":D(Q[`
M..W=&)*L+7F=;$9S!_GKG1'=^?5.W/1Z.](G#*#Z'90#6G^BT1_)Z^%4UA>C
M<,$6J>2W"_^BJ[^TKG=?72+-#+':8$>I2*6V-EU]FL$<M0SKV#3RT_9]<TSX
M%@W&BDC)I.+2`F*I\HX#Y.#KUYWM;8_3R<D#TLU6M`,:T1^?S=/+0U(9N5KM
MB<7!DLU/J'HAT=R6V)%H7B<3GDDP=Z.CL?J$B1/F3>CR5_^G\NNLNN26IA(`
M;`EP2#*D%(4;=X&.106RSW8@%>-(&<"I%U5$B*1("6B,,JF1WEF/6L)ZG01<
M?C7ID<6*33OZFJG-X,S%R4TKT@;1EN>(.2`NG7@<B;ITLZ'H<6)UU!=3W&:S
MQ24SQ@!+@6)^1<\I=]#AC8LH:7$7A5EWD::4,`2@T0@0)1!'5&-!L3&2<IP>
MMTR^<9<5MJXJTY3$=CHS`']]*,V+U!U%:U8H(M0FDLV1ZDVL%2\H3BM27M2<
MF\S'26Y65LM?RVSAH^.?\]NKO+Q$/F2R+A4I102F3B-F]<9/4DL;A3/[VE8:
M.*8-Q5HS`A102CNC=#!&<.WXP"I3(TK6D)(_5J":RDMKO@[KRC&HBA.4T[`T
M71^>5N_C/"E;CY`,QMH3_0V&!54E0"!0:^H>4Y\1TZZDG%A%.\,O^ID;D;':
M!S_ZJV`0.C^;,574``I9Z@@T<C.W_:)&Q81G#ZTRPPBT%F$'.`&4"^K"T@@P
M*@2&;N@B1`VDW3(O@IEF,=<PI,2I8C,^!HFJMN8?"*3B*1I)[-0">-%U=K3Q
M]+68$$LY5](HIW4JI(`8I^L9S02D/-K7U^U"JA45#*;A@#5-I7!"0V`]:&["
M-NSC>'N[!5<4/Q$>/P`UK7S^-&NI'0I>\OM(HL;D^;'0G_/]5N8W]OZ?LZ^S
MV_O;=2?,"40<<<KY:!9Q+*S=SF_%#8WQ_\<M(Q_Z&=\@P?[="*E0CBBMB00R
ME:DE9F`%6(.)C?=;LM1,!88C*$X'FG,SB!(\HN&`%K2C:R1JT!)\T<>,Z52#
MOI@M\K?+_+:Z!(8"X+5'``[]FD,A;+:S'B`=E:;=UX?SQJ1$20F`)%1`#H7#
MP$!KC'"4#ET+>E(O3?X(R)(:6K?*<P2+S;3C&`3&J4@[[HY0;]Z2T[CF'$_G
M2%2FLQD':\]M:6FI/#HKRV^SQ8V\#1MW+@$D%`%D)<=((JR5VV[;8%JJJ-#D
M8$<.A;TAA)/4BR@&@C/,0$J01C[ZUVG4<<VM:D79XG62U5@Z:4XL?VV$9T#J
MNI6)?BJ+ZL#>T2/(SF-J&FM/2T9'*4!M;3FH0IT(:E8V>K+EQL^JMPL_M_)J
M^6XQ_W9I`&<6,>R<TX!92I"BVR2`98V2)$WZ44!["V18Z0E"+%1:(`>D)D1(
M+5C4F4HMA"C@2:Z+,IFM026%1Y7<9=_JO60Q%9.NA#:H,1V1RTYQT>LD8`NG
M\JU)#?".R65$)>J(G+:K2G7CMEF-ZC`)^^I5/5$WAMI57Z84_<^L3O'EIL</
MV7)UFE^X0682YN!-?BD0AD@:"5),M9'6X?6'']Z-&+"N?;1YL-OP#:U?#FJ8
MII*DR"JH?4`-A:2861^S#2SY6\?9B'R2+9/EISRYGH4S\B?%_5VQ2$H/NE-D
MVHWY-G'JT4CO^&[8#D``^GIU9NLT><!ZTHCV$(F-X]M>1F*4T6X_EAV,?7LD
MK^TG*5ZJ+XVA$"KG.TP-80`*:+8Q!H\\\/"9YHE.'49&$4(!`8XK31AW1DMF
M>6KXT>+>NW*VF,SNLGG]/=OLJ39V^Q2E$8]MI*YW"GL(=T_[O8D'T%B>HM@;
MI0S%67#X8Y-X,MHLL'56?7+9)'QT]\WE^27#5IIPCI&`"D"&9$K<QBTL$HTR
M?0VZP18`)V`XK,9XPXA2'#CM*&,(JU0/O2<AP$FNUWB2ZSQ/[AJ\YGOG,GII
M/22-':6FIG2#+?'@CLACZV7UD'SVM*J.X+7-FOH)`\V6U&UI&]^*NK4E^Q?4
MW<AIK>&S139_OXJ.+H5_3:2$*DYQV"7)G+5HXS`NI;*+B._VDP+EC*(26X))
MRJT@*2`.2\>HU!8?1\4#H$U<V)^,1]'93L>'8K(7(:]97:,[)I7=I'PH2GO5
M\F;4MA;S'0XBU+P-<R.5\U:FO*#G[>EI)NAZGE55<;V^<;0HZ[MAZR6`I%HH
M!($!B!"K?#=PFY)S#C37\OU=*`P()8YIJ!"!?O&+'>0"I=@X;8$;NNB^1I0L
M#RY6>^6L@6`?AZXXK:XQA5,F-I05Y>IFZ9=6^KV2%R'1QR&QG3JW)K.9,N\U
M?9\H=^=J#'K<@Q5%KQ,H,N-:=_ANT^&[58>_W(<]G^^N/^:3^[(^G4AG\WD^
M5=\V5T2O'ZPN%:,""F,T5T#X.0&DV`8X&CL0DY[MBD4$;IBF%&I)F.*2"XP5
M5D(:2K@:>D/G"FGPL.I3%FZTR_[,9L',),R9Y$N[V[4''Z!F>=\QC4UO+Y&'
M$7NP(%F9D%Q]V_Q!M?V+8V_RZDCZ@43TL89S)%GKHYE;G,9K^A!]^S4O)[,J
M?U_.)OGV'[=8X"5/*9-6:Z<QQA0COPC8"904N_PS+Z^*3F+_(@9*)84$N5`F
M($!9E2K-(4U-RE#X/#%&1G;A-E:3#<)0L)ODR7_<5].0A%E)_G_VH>W=QZ&#
MHA]U`'K3\>V@U+!WGAF9=+_$;JQ@]S9:8Y;I_HQL(LX]4]HA&R*]/F4W^<]9
M^3E?UG!^J_*I*\I'$"\YX"!%`AK(4JBU%>$VRK4:8`H:;1[K#()*G5)CN65:
M$Z'3<%T;2!EF0CBC\=#'>IK[U76YP?.S%>+DMH:\ENE[#[K>9K$.PI/\D8QW
M3B3T-59M\S0G&*;>Q'N-/5F!7TMX@)]X_$^D?30#U34G=((!ZSUKU,_`=<@N
M-2,Q*O_4\[B,-D/5MYTOYK`&(;;Y3699N9@M;JKW>?DQ!.K;^QTT8!!HXU=8
MJ9`(N)2FZUC:6"I$T^S(WO:EC]*EI8R%.]<U!L(1AZF#D"C.J)##*>X&4MC0
MF]2@3GC3V1YZ#L2[G1D=24C;W8ZG]Z#U0TQKU]FYGXM*#!&Q7#B@`.'6&KCQ
M':@LC$G][N_%*0JD041R@`F$1GD#*;:.6$0%`%$>U":IZ]]L%T6UXT:1:_P.
M_+73GF&HZRX^I[M\8R]#$?H3S^I(!:B%(2\H4%MJFA\:-JL^ARLS?O,&E\ML
MMJBOT-CH'N/:Q^0$6<N!,*E%X9BL<"DY]=T#8YL>D]6ID^%<J<95?Q3P"-GI
M7N8'B3K@4?T0/!*OZLF8IT=P]4A1\V)`L'BQ7&50`H)G[^($V%`C=#@+#'#"
M.!7;OOUB+>HKG%XZ'/BU_W%VLYA=SR9AQ:OOJV5QZU]DP0D?@0_K8EWFT]DR
M"7;$9O][(;YALO_8G$>FAQZQ&O"-Y.+3)KP=RMKW2?M(I*]?FY[FY/LGK/G=
MS^MKC=Y=U_>MJF]U(F-]"8XSC@*F-%/*2L(=HM19C'#*K)#-=B4VZ2<5WB8&
M*>""$H4QMU0P["14RB%(ACZI>/=FIQI<V`:Q2@&VNQ.K$Z?-I.U8=,8I6A<F
MA[G">3]-!P2L#W)'HEN]F/+T8N;>Z'E1I:;Y[/(BO\GFUD>%RV_U(<U&&`H!
M=UK)5&$+K1!LXT$(TT:UO^?:!88PC*@BUC$BD%),"V$,X8!I;L'0YZ?6<)(5
MGKACTUN1=%AFAN8G3E:BJ#F@(U4^>7-3_'GNK5M)B/_AJ7(\8_DS2M&%GQ,K
M0R?H1??I$>'YJ];7M]<02K1!CEH`H&.(46759D:G7#<Z$^R[1JDU7K`D254*
MB$FYLMP!IX$"V%D?;0WL\YLI'7=L>CPU+SO[8*Q$IE";$M*#E^^:O,?%6[$R
M`O]NA[OH.!UB-O]<S!:38KYXGY6?=78W6V;SBPN].8>=I5P2C02'1DD_G1$&
MF^E,H&Y^@=2A3L)7B=Q*J*FEA'`H",<".F\A)IBSP<\@74%+`K9D#>YUXN&U
MNB^I$YN'Q>&H1$:&!>/A,&)GS+&X;+?SI0NGS3:U'+!_WZ:5/B@;PZ:47NPH
M>IY+,:K]\\5_Z^*-[R-;3.N3\G\JB_N[ASXQD"*%5#FL!=+8_P3UQD]PVNQR
MFT8=04X-II`(X5*"_/I2.JF,@L)PQSD;^K91#R_Y]^SV[K\2C[+VCI`EKX$F
M-=+6*M29X09J?DQRXQ1]Q+Q&*/PQ^6VG\GWQW$SQ7^!CG^KW1>,8E+\W6XH!
MYEELQ2`<BUB?F;#ZE*!.`M8I`"<LTT!S`KDQ&-O4LFW2*85,1-4+]O9"!*88
M(HJ8DT3)E/O_(*FI?[DY./RAW=N]P:L$=ZL+#CM0V+`\<!3V(LN=<<0-4P_8
MQ\NA:D!G+L=2"^ANR--*0$_4Q'[#6?>SN98=4<M39XVF6%$&%4ZW;VZG.&KQ
M+?YN\UXV=8HQ,`Y0HJSUAJ24`.2(X(B[H<^+?NHT[2Y8;$-;,Z$9F+%N"G.:
M>Q>_I^307HGV_(U$5;I8\/RWB>W)B-C^=7M;+.J.UL&207[:2T6XI*E"P#!$
MTHT_`"BC]G4_TSKA-D62"<0ML58+8"Q%!D%--+8"#:TB-:"-6[2[H/'_V+NZ
M)K=QY?I76)54[LOL+8`DOK)/^.+&%5_/9.U-59('E3SBV*J2Q8FH\:[WUP>D
M1([F0QP`!"AN51[N7I=GS#XX``\;C>Z&!V66$A*5+4<%<2,J4O;5,SX&4ZU\
MN9N+>O@/X$42U3@JK+7C6.+5&0$9R3(DF9`<%DUS>-B'AM-4(1?=>/KD'#6-
M+ZBD&=!(ZI02()1,)6=*FK^.'>/JFPGLJ^3>_,[795TFMX?WHQXC)([\V8E(
M/.K<!*0K&+V0=CRA84`W_.B:B69X@J]"K)@1^Y7W_>6.U+C8),>2BBS'"A1"
M$-6M>:F%DV:\;J$)'2B1"R601%@2*KAQZC7A!08%R::.D;SWON35DT#WS4L<
M[L;M7ZQHB[Z'>6]QN^LX)F>B*R,',;"9\:7$6F=NS-R7NUVY:LVU!6HU?]A_
MK7;K/\O5`M$<X[2Y5J(]SH`IROOWA12Y4R'+&Z8@2K5..55:`&,%<@"@V<%1
MJK."`Q0[7M*C._@H5WU7PAZAHP"-9=9.B28DU4V2'OG\>.#S@"WA%GQ&4:9A
MI@8D*A#%,]&J4*.IHJS#4>IUL]Q=[PYW;_WG<O-0=A6W"R.3,*-9EDF.6,XY
M12H[OFN%`FR$BITUR8Q?D:&,$0":'`I`N?$.(<!$`,@RXE0!&T+-[I>[Y'N#
M<&0/OE",^ZC;)&2/5#F#L>GY<[P=L(5ITPMA`L4[QYZU\HVF?Y8*.'Y4@TH8
MB#2?^/0+$1:```@EPQG%.D6:%RCO7LI<(ZO+NVSL4`PDTD4J"4X1X;F0@!!%
M",,0*\QCM[>3)Z&F\6[<*$*=X]A1N?2/:%_>>QO@R"[*[<WL3%0KR%#.1[Y'
MTN.C3V>E41&SIX5Y@5$*<T5RBF'_6@G&M:=.G;67$\VP;!S3/$=FK!132C-<
M$`U8CFCL*N*G>A7*40M"M+-^3<+Q&!V;DW]FP9N=MHUF?7X:-WY(Y[4N$%T.
MN]3JMBQ7=6$&_*ZN'Y:&#`-@V11"Z_]]6.]_+(#@*>+(2"T"18%SLR76_9L(
M.')K%F]A4',-E48%AFES@I$Q032BF!,MH<P+Z/(^>G6&[S`>;OOH4+;OYO+0
M!^"`U'E_.IYKV[WII"2[[DO'LAMI1_H69X.[T6"$ST3O0H[HQ2XT,%EV=3XW
MQ_-^_F57EOT]U;AI/4.R#!3FOZ1H6CWTT:#4>!_6U3VO/UXP*LRVF2!1"`3-
MGKK@@(%"I=@X,6D>NR*S`Y7TJ)RO6_.D;5BH)F+,49@N1I9#'4Y\TORJ;YS)
MLRNS>76XKPAQ`&[F4%(S<@15L(7B7#YC?-=&R\N5>MBMMU^,W[JN5H>=>X?D
M^H[7=;FO%QG0P@@\(JC(<LU1"EC7VJ%@3#FEI;I91H#F2A5,`ZX0EX)B1FA.
MB@Q0@T7'3ED]I$`<T"8'N,D!;Q?%,KO`[D4RCM`!M7,=3M"YL/,X+S<-;AH?
M>@8B%?0XD#G@E<:9E)DXJ)$&]Z(8*!Z%]NK:6#O<JH!$:OP'R5+C'E/($<D?
MP_KF/TZ%02>/S0L)<B2AY@:X*`#'%!#`:"HU-"ZXTV[01Q?;ON(N]\+X4&.I
M9'%8<90I&T+B:$\__"%A<>=H+JKA@?RY)/@./HPW]:'\O?U1O1`PS<R:Y[I`
M*:2:J^8^HRY8E`=THQY-YA!IH4"J4U&@'!2<&P!*B[2IE,E%[-21QV#1W9.L
M_>XH-:2GY,!S`!<I#L7A?2.#\_`;L_*)>O9\G2%W^N>B9X%'Y>+^^))F%Z[C
M^\,-4]T[W\0'ZWXSVUQ9T;27KNY^V55UW844%XIJ5BB%S7:&\:+`$O`^@)[G
M16X=SO,SGR(@9)8CF'.`J"24FCT5H3RCG)N-5NSR)K[OKG#KE;+%_1B4:;8W
M!^B-AK;@DPZ]2Z`KTNQ81`TO/S%NJOJ7GQ.'X.3EY\8O>!EKCNQBG%ZLG8N!
MQIV".<1((X^PFFP]!_P:MIV2'KX]Q5%D!:)(4"%RJG/(4Y#WH3VDF%7G(F_C
M9OL#LDP74A@4*J6LP!P++G)92%*0V(E+5F_T$7@\R?6;EO$?P>@S$N$3.-/)
M"/?UBSXI$;]]KI,3Y,/W&F&>G[U1W/\%/GKCQN?PR0M`I-T'[\-#4\)>W1TC
M[>7NM^UZO\AX2@F3'#*6<@D8R[.T#\5DVJI::N#Q"C4]7D`N&<P0(HQ2F+-4
M"`3,-[V@L:\J.X!J:Z4/*>U-]F<#S$4%/8FS^.C$Y\SMLW))NAP^"_%I\Q-^
M#_KL9/W5`9\3[G'LS$&:1XZ@"K94_-IX'%N&7!\N=W]RAWO_P_KXTQHN")0$
M82/SBC>]RU(H&>\=)I):750T$D'*<B+2@LDB19I`1C!CF"FM*&*%+B*+=-_/
MHNN*4^V2%MI5TD$_'-R=_$[=_]+487,OB@>BZ'&G;"9!]<B#?+VG1E1*[7RN
MP6C_]?=RM]QLJGWSI;F^;[][$F4I9Y`5!3=?`<V1Z._]*Y105E6;?I:)Q(AB
M@,W.S0R?,:X5("F1A)OO,XQ>PVYS5/8$=G+`[>*9A)\-"Q_OHA,1_KAR?G/@
MX#A>="[\?,KP<V+G<KI2=<X;C4;Y'!S5>(.KIEBU3K4>KY285&V)274L,?E0
M[G_;&K9_WZWW!F1S.7'U8+ZP32W>NJX-L'JY75W?W97-&/0?]^6V+NN%DAQ0
M``\WW.8Y2C$YNK\44`RMW-^X"#,!N6JZ-&48(,0R"G1S4ZG4$*289[$['/35
M7<5P=5>32K)/3@>8]".\2D[&V-[BT8TRZ8;I5)1QL<5@\<']2ZP#MP_S_R^!
MDR7@4MKS5U@*GM5!EUX2EM5&D6;@G+MQ\1F?@UMR>1*J.;V$OA<77=\5ZZU!
MNUYN;JIZW;R>_'.]WRUO]PN!(>48P0)*+/(\SS(LE$XUPZK(-`.N%_",L15S
M0WB$U^A)#S#I$";_TV&\V`4]`[P-9JX&I'TF(;:P8SIW@T\XPJS?QT,E4&]%
MXXPBP8Q?`*F`(%>4L,X*)LPI1]_QT;$S;#Y^U)\^.F;<N[)CITL1B7%,=&F!
M7$YHGA(Q("F>C,U$/'S15T&6C9<@R(?=S@A2;ZRY(,)\_+,FS@$$%87,8&>,
M8.;4+=_/0NQCL@.<9-F"^U<OG7`FS44N8O+EHQIF>W.D[,+R\8R8-U7$E\A9
MB8GW(%[5E'&4V)_@+^NO?+MJ_J_9FGPWFQ2S#^%[N=SM?IB]1]M!;"$)HX!H
MP(FA!^<H15QUQ@%QN\PGC,78TF/0M?&!V^8/Y2-.US:%8>BU$Z7IF743J9[4
M]@\G$*^2Y3[I4!ZZ%DZ=XV!#W5!.0U#J9R)K@0?U/&<A`F76LO=K:61U?;LO
M5W8P.,*4-"T36<$D3I74HM_I%1H)%P$,;3NR%#[";<7040"#$VTGA9?DV$T4
M3^@=T,>C-S"Q*CJR.*"/L>9C)DH9;7C5-,O:=3]Z>PA7_UK>EL;TYTWYH=P?
ME^B"9S27FBG`\J()BG&4Y@>;&I"<$Z=MZ1A#L8-71VS)K@=WE6Q+V\SQ,%Q:
M[E:GHM%QT]HQ^.L)@P;9I>1NB*:A+6P(=F<B9&'&\GQ#&XX@:XEZM_W>E-7N
MFJ.V10&:DW7$,HZH@ID&!42=#8"@54<'KP='EJ`.R]JY;8T;/78J$XT9-U7I
M8;1:,K&$G'(P(!E>5,U$(ORP5P'6BOOM:??+]>IX>FZ<I>O]UW+W)+JV8#@7
MFA:80"FA2,V>4H!>?5+@=&=0"'O1,^M:B$EYS"AH=QM5`S.Y?1)L=[\V;3S5
M=BHS-<MNXM,1?(1W2#%J^7T6H9_^KK2W6!N0JY"<ST3%@@[IY15I@>ER/"F\
MOE/K^KZJEYM?=M7#_;OM[>9AU>49;??K[4.YNKXO=VT"7H<(<`$ER;B2DDA1
M0)Y*@XB`C`G$"P#<CQ.CP)CTS#'Y6FY6R5VU2\P@_+9W$2?$Y:CRXG/AIJ,=
MV*1%>Y7T>)-3P$F/^.K"^NI/\IMGHU%G;B9J/,5(7SUEG8!<ORR/!34F8`95
M5A`LBYS`5)'N`P$U,G)<[9<;C^R.-Y_LI+`]".M7^U/S3\:YFXY,>:1T!"5I
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MQU8]#E'PBI"'HVT.U8=A!E*%7E%.;7O:%HW;E=GW[G?KSP_-`JL/?8(66&"$
MFZ[\@#+&-$"RJW+2`)/,*J%CM)'8R1QMFO4FV;5H7-S*\?19B/54S+EI];''
MJY&2)[C>[%(6F#^7=C@3\>C9^<:33\O^-N?'?DZA0]`U!X$.,HXJ\#H*),__
M_7"_*;=_+I!H:L^0,G9X3KB22M'.+`7,OJM,`%N1Q?H(XRC6@73&FL=Q<AV#
MPI"J?94<$4Y-:Q@5CT%O##&WH'FTJA\M>(B[*XLSUWCGX5A*O1]-=HK_"W^O
M<P`/$K?(97/DA*!B*98R$SQ__*8PXG##O-MC(^MX`^8G@\9#R!WIL=#L>,RX
MR?-TI#@H;CQR_,35FB0[$7TRO'-ZZ<?!'*31$WDU>@$XGG7]4E6KW]>;S8(6
ME*5(%X52&=!<2_H8H8;"K=K.^J&QQ>Z(P_&TRIX3NY.I*'0X*MR;3$0Y:^K,
M#IPK.9,SDS,D=]S5R%7A^&:K\K[IG50?CLP_F%$=3\T)YXAE64I`FN,40Y;F
MO9(H!)WRK[V-1'[S.UPGR=9>62_^)-I)PR3\N4E%3UV7%/.(:F+U.$?.@)J,
MYG,FZC)^'%7@A>:56+=@2!.)-:*L(-+X?TRRM`_,%8JZ9]2]^<A)4NE&I-"]
MS8F==$2@PTTH^!L<1,R5>S-)SIJ6F;SOKJA?38MS'+3UN_Q^O?R\WJSWZS8H
MTS:*_UIM#"/UH;-JWR\)X9QCI@'0@"@`=4$`[.QGA5T\/+C1R)[&^W=<O'O_
M[M,[_3'A'U3R\=.U_/=_NWZO]*\?_Y;H__CMW:?_<M2)<'S;*<E%J';3FA.(
M?0;=_L?E6J[94C8@5,%9GXF4A1]7%7FY^LOA\X9Q%"!&-#5VF,@R!!A1O44&
M=.8I@*YF(DM>5Z^U>43HVBAR#(?.HA:3/F\9FT'?R/,4V<F6+Z_S$RKOD9R7
MIG'D.+<%NEG^:)I\]!T^`)>Y1+K("ZY4)JG@O34"H5=#($<3L;/'ND8V]P=8
MGBV`7'FSW)O%I\QQK]:Q=41TZ78_3XD9VLZ-8W(F4C-V%&>:^XPBQ45B=@_E
MZJ6V+9"BLBFJ5P06>:H*#'@?.])8:D>5\;027V@:8$/].TX<(7<9\N766HDF
MH-59C%I&7_.&IM>CU^D9EJ21E,Y'E<8.Y*4P!:'&+E^G6*YW;<_%QXMV;ZJ]
ML;9>;C8_/I;[_:9L]/'=MFG9N(!:"I1FB'"<J8SE%&'<G[.EG%LG]`2V&UF_
M&K3)]P9N<[_.[]W-UO>/B).ZAYRLMRX=9Z-,P["P77H&W*2N);]%FER?7"M^
M`C9Y1)N\V[9M:"])OD."T@4GP2^#R>M-&%VFY4;3N4RH2&3/(54JUM"J^&O5
M-7)8;;]\*G??5/FY[\7)-$0"P1R"E!10IJ(0_9F-R+3335,^SY\H5GA?[=K+
MW,R+MS$H?S*/^I:L#$[7P*$/A981P\CL.88*>Y8:/(_1PG\L]P^[-[8:<:*%
M+^D9"A..(',F[O&H(3P/#(ZFP^=XPJO3$L*"*MJ$*V$A")`IS0NE"31_4D!S
ML/A>[CY7'J<84="XO("GP,<<=CSM4.=_\A%G>IR/1RX^+V["Z-ZF;@9QAI%T
MVYW'1)W(N8CR5,,]?[(S`<TCSJ(72FDA:<I3(4$A@$JU[IJ[0R13Y))RY_'X
M2=+OQ@=>?8CS/7@.RMGX`^>+GS([G2Y;DS<_@7(>P9NGR8YD.-0*W)7&P.K3
M\H]#*N&)Z0_E_B1=6*E<2DHDSI&FBACCJ#MC@JS08K$MORSWY<I.7\+9M7J%
MV.$5.H5H[W8<H2;[Y1^][OQP+B<(QK.=&$U,L&?!P9%9`_*QZ*"YDN:"E0>6
MM`U(67CJ9Z)P$0;VHE@A#G5VQTJR=>*^F,??F!7[=5F7-[OU;6G^NEZOCFZ=
M07%]=Q3EFT-H:X&EU(SD4BA.,T2Y@J0[XH(JQ]3Z?"D6@,BAOE$*&9=YBR.E
M.9#NIIN/B),.<M)B3IZ`;J2T.7SJ`AE'X+.8%X?3ICG,C]^QT\D\W7?S=-_.
MT^TI^+8!6A,?[S8WQY#YZ`,H3^;.G43%GH@Y'$E%'V,UX<H><4AU6B?($&6:
M<4QS)'@A"\1Y9ZV@R"FCU--$Y._7^R?G4N=>QQ'G52YLNA]912)RW*F5_J,+
MSL[J_,K*@1])[DR\];&C&#C(\B;%)[RY4(4B"F2"I*K(S$,AAEVS?Y@6O/",
M:[[YW$D"FD$"F6]3Y!S!#,J.=^CR<A%+NU"E-4MST00?Z.>#DX[#MW[[9?7M
MVWK?.-Q-H5_O)MTV)G.$<<YIF@*!(04<&AYZDXI+%W=DC)W8Z3./T-J\\]M3
M<(Y*,8I..^68BDG7C?)3$J4=B5&T98"A`:T)P>M,M"?(4*KPR\Y1FP;*CI6&
M6$`D44&P$!0PFG?)@Q!0:95G'L!,9&4Z1?:WI&RQN58!CR'13I`FXL]-CYY2
M=VQEP/>'5J=M[O&^2FZ6ERT.]NII$(#NF<A4B)%4P=>B^VW<AY!\:[K-?UX`
MC"33"`D,L.!Y5G#:FQ)0.-7L^3P_LBSUD)*ZP725_#/X.P``)O?+8^[_SPFZ
M,G_3_"^IOYJWS#@%#_NOU6[]9[GZ.=E6W=^NZ[I))&O+_1[V]=[\P7Q6W&_I
M=I\".VV+S;Z;J#T2__%`?`OH*GG7LCC]U=O/J1E0K3%$SD2N1@WAY57:(^EP
MVN%5VQ,[.,4$L4QG)(,`I=IX;GT<B6N:NV[KG!X^P5ZNV@[H4DH&E.DJ@3B]
M0N97\AR_(E%FSWW%S#\^^>F):B7+??+1K*/RV^=REV3@*FG.B8S)@[FS)LUO
MPAQ?93E\S63*KG("3W_ZS*0J;X\686LQ]]BRNJT/^WUJM*7AOCDUJV(&HOF<
ME#?VHU[\S40N_?&_LO,<081]#X;5:MV</BTW-\OUJJE2NU_OEYL3\PL!B&(8
M82VY($A1176?"@,@44[-&,:;BRRFCPB-@JY7/[75FBU(UPX,`9BU$YV)2763
MH1,^&W1-]>L1WU5R*E%3]V=XD[,!E0I(^$QT*^2(GK=N"$V67;*=*N_6M^L]
MO[U]^/:P:=)RU<.N*:9XO'QQN?FX7WXI%SR5`D,@"T@RA8C(>-]!"VK.<[O4
MX]!6K5[),8G')R"3U0&W2^Y62(*'=>XBS/IF'#<@DU-J#S"3)SB3%NBEV'9(
MCKL0ZW[Y<!W[R].%?6!__[4\O2+7S$#=@!Z=`F?/S[FLMP@,SR'1+<:PJK@+
MT]%S_K0KE_7#[L>)CYY"E%(,(99$(29HGLN^B$9F0+G5L'@8B/[->-]</+T_
M`NLW]OODMJKW5PD^Q!F.?^_H+_OP:><?QR+2ZQ/1@7FR,9_8^7U)R("S.X*]
MF3BW8T90!5M*H\^!%S*5K!"9(AEG"#$EFW:,W8ES1I5+HIK'XR?)5ZM/</W+
M/]$4DI^/9\"CCX#?YL_WZ#<H==&.?"]^SNMTOFO-Z4Q$9LP(WCS/=20CV`4<
M"\X5XR0762:P$"F!LK\-%:(<^-;\^QF;1(!.V[$T9Q'UDQ?,2XK&LVPG3),2
M["93KU^S,;.[-0;T*1BU,U&K<.-QO$/#D2AK)>O[\#7-4C:5\=$,@"X+1@JH
M$"4Y9IAC*)ON6$#E&>&4I`@6MNGK@S:4HBG&C#"`-<(%8Q04'&4P%TA2H2*6
MN9^T`CT!=KD$KR&:!EZQ(.S.Y/4*,Y8JPO+S?:U.WNM_M%N@<G6]_;5LRG36
MVR]B6:_KW[;5Y[K<?3^TN[Q_V)L?&[K,OVK#>)_^C[UK6V[CUK*_TH\S54H5
M[MUXQ#7'53K'J=BG\I`'%BVU+%8HMH:DG&B^?H`FFZ1LBP*Z@68[9QYB,[**
M>^T%8.V-VX;_^4SALH06RU)Q)(#`A):P&XJ:Q+T?D1R<X%)4`DE*2DDKHH73
M)6V)9`A88TJ4>>OQ.)!?E!8K.I^*9E4<O"I:MZZ*4\>*UK/BI6O%[ZUS9U1@
M(BT?*<)3;/2^PCUN>^=5_43M$A(IQNX"4XLNH_O_6D2Z3$/$1S'Y?/CXCT6]
M=E]P_WSM=PS$7XO-C`(+.7>1%$I_TQT#A&FG4`:RJ#."@2:9DJ3$%9=6,RIY
M)7!EG65B)8&,\MRWP$X5Z(#.98X.6N]X,9#CR"@P'KW]M3V<V;S*?):K$+U-
M0_;45#215Z]I8TK2XA5O+\?M%;9O<>CF8;Y8S1#""DGL2.2,&5)J(P[S8T)1
MU,6R.,N$*UD"8S'@D"J&*R"MA01HCX7*W$7D3T?I*=ZKXF12?3)\=ZA[2V.:
MQHA4R-';H??J10S1>94RA+,0P4S*_=1T,ZUSK\EG!@KC5;1-6#>M:N-_MA</
M9BZ),5P!KI@B%<-488ZZ8>J@L%Z:^1T[$&,E@:JT@(9""J4B"'+H)LR`BU+F
M7I/X=KJY*?ZK!5C@_RY^WX'L+8A]>(V4O\R4]L\*=\#<S']'9@"7>37O6Z)"
M%&X`O5/3LR&NO*9>@^FYQ$KM]6)5O]O6#YL9L0:J$DLL2TV=OD)N=#<8K2#@
M0JNU1X#8:;X$5%;02&HJ*(BE@C(&A79)E([;,I[.BJUWL&@]O."R;40W&'WI
M-D\/F,;R;5#C3WT-]]!`XZSCQO>'J46?BW"0;SVW;X-<(MZI^?+&GR%W'W]M
MEDO;K/^<KV]G58F1)4#PRI96N)DX,GRO>IB[N<6%@M\K:"EDI<644J09%494
M2'$N45664"*@?LQ(>%6<>%O\[OTM]@Y?,##V[2^C1\D1NLH40F:_7C+U"/K]
MQALGG`[L.'^_V#J4D'R!-DE31=15Z4J*OZ@BKI;SS69QMZAOQ?Z<WW<.*\V(
M9`)7PDH`)*M`B6`E.X&T5I6SQWJ]:&X_;.?K;5A8'01'2F$!M<0A@10@+C@P
MIBHK)80U;CH>(X-?(P]61%E_7JQ6.[5S_W!3G^IB=%&3G(T3%KTFTR)Q@>GD
M*867;UP<@1?SS?[8\HO=H2/\T:NJ]&?Z3!09I0$G$B#&\?6;RBZC$1SX+-&]
M&PDNM)P\91[R<L2,(L$HDQ1;0"IC44EYMRKD`@\/?+%M$`2K)!4"N)FELA17
MJ$*$(ZFHU10I(,($8\A]V!UP7]3$WS"O-]O%0WOM_,X+1%M]R[_TX/_M)NRQ
MEJC7<W(UW'FIOWR+]9/X75.]6YVJMW^^*.RUHTDT3,RS1A-HH)[/&KT84R]'
M4N`H&OZT43_VOA-71VF,*51\R.YC,V+O'G-:I)`H73@'`F.&2@4PAX=U(T@@
MW$^+S"JP;L0@,(X)6^J*,L`9Q<HE&)(H0;66U'%'HEXU>XD[>/R;797'J/G0
M?TR&'=H^?X<,.]C7E!EV','A"N&-O[_[;;Y>SU?;]^M?%Y_OM[M#[X1:HQBM
M;*64T(11-P,WP)04*%MRAJ-*T[YN1D.B2V0`I3Z78(9C"_U10THA`8KFWB!H
MD?D0OL?F^E[1HNMY/VD(H8%+&>-P&9G%]J<QCT:^2M(Y!1S.[%3T+8$G7ZM7
M*G*&:5-[.AT!`BO&+#84*DMH!:DXC"111M7T?]T*DY()51$D#:)>;8G2_HP4
M$;Q4BN'+*5.?BS`#V!R@2\F)3"9+E[CR\BI%L:(41>N4-2G.D1!)ZD'-,$7:
MG_56D!NNN%-`JRMKA-*$=Z,(EB2NDO\9.T(2J#`3TE"700B7#FK*.>.T9-KB
M*O>CL6=&5+];*(,X':!,&>A,IDV7N69RAJ98?8HD=\H*%>M*B$;UHB=LU^2?
M_O[)QS^;C_?-TV:^NK6+NVU=K_;V-_O#WD93X"^G5%(#"23VMQL.(9_:*D2L
M(LQ9Q1DJ.02*`2JAK01FBFK&2JW]*E-FS6I!M@^`=&-M$WM%)"6W`=L8X],:
MIUT[1AW`HD-8["%.@N&(_8CQF>ZW^Y"&\;!=AB!.7MM32$OH%'80$GO49.M]
M,7'B\#C2B?6/]XOUB?F]=6VMX=(`3BRG@"J,(>U&&Y,FJ#12I,D*T1);2B27
M):4("%-!H[`N-845X5&K_7V>^CP\'.7&!C[D9WT$+2'-`6'C,@S'A8XCN2_$
MK(,Y%;8C0LAE6.\71M*Q'Q9*@KEY+9RD)W<*(26#5TW6'AGWQ,W--\;_K)=?
MZI>F"170,L*LA,C]J1F0ARS.UQ4.CBN!]I`6NK180`@P)83*$I6,8U0J!(B;
M@F4.*H>G`=T@0<.RY%0$!T24"W`;%TX.M+[4LQ;CH%B2BN2H5VU&)[OOBS9)
M2`]]RR:$E=?B1V).IQ`\4KO4Y.N",6%#/*X7RQ.[9EE_^3I<E0A(9;6J@,4$
M<R(LU=UH,YRCX)@18DQA`IU?""HM*+*`EU@081B%D%-N<J^TMQ!]M(##HD42
M7@-"Q=B4QL6)'9LO]&H'<%"02,)M1(08F^-^X2$%UV&Q(8"/UP)#2BJG$!62
M^M-DZG-#=C*^9]<*3!$JC<;&(F&4&V&V&UN"`]5['^-[QA`2M@0&6J$(!:2J
ME#%((F6)&^&4L;%V,0;&@R2\]MC#R$WIX!V,!/$@";<#=B]R<YQL[R)3/`C@
M(W3?8@B54X@'2?TYMV<QG*A^\>#CUT8EK4K`%`6BM-I-OHUDAT3+\C*H7&R8
M)8@T)!#PRGTYQ=`(`A''1D@C+930CA4)0-I($,]HCS"0E<S!,>!CX@`03^D`
M]<]*;3+ICZ.XG^Y_S42HZ/=F<(J*W]^9<W(_D*+`N]_-:O.TW#HC7VV%ETQS
MK2$UHC("E64%$>N&C^94!FO\JQ8T8Y!#K2FKC)O*$"$YU902@$MEM,A=^ON(
M:YBV]V<P0--'(2].RR_/6\PEZ#'XZWG+N1>/@;>77W'[-74>3-,45'FX$TW*
MGA-YXOV?B]7BX>FA,T($`8*X[HZM*G55<:QV8T`#E^@''1O]_C<C#I"!;B0Q
M)FD)%%=0N;XC!',S969S/SBS!].W<'@D2^<5-C]!D5ER,#=93J6_H.$[2C&,
MKHF</.\)ODG18U+<@;D^E%6%3#!K"1-6`.P&0@4A[SI_5<*HZJ1OF+(,5=H(
MQ4O%J"FEY%!@!B`2PJ#27O!^WG7O.ME#V0V3EA&)C<SB!G(ZWKV8ZX!"THEH
MGHA&I?(FY(),7Y("9Y?>9-.9;'8FWS]M-RZO\C4^7E3/A99K80UE@OBW/S3D
MLAMQO&01$\X(HPQ;4"(W?U9$4&R(0-(RE\]9;BI)H;F4LET5)X#[U3U.WP`A
M\]4+<9](_"9)>\QT]T+T]YP!IVV&P*EQ.$6OSI8SL#R)"70.OYK,W3-%4GT"
M86:4I@0+0BVF2DC&(<#=<(0:XAXUBM\RJ:M240I**#6B"*D*&5TA3IPB4$/B
M-@]ZUR$^K$$U)T/OJCB6)_ZT*\>5(LV.XGM`HIV+Y!S19@JI]@F<V&2[#]53
M3K=[^1.2</<G:D#*_;/_7-_.N,"0&*E,!3$TP`+>%:#10"(5?L/PK!5E#,9$
M<S=OYI00P+GE%/O#F8H8P77FI'H/8W"^%DQ:W[PX!U^I5@%&)W%HEIN#S,1I
M[=ND#DAA]]\=E;/&<C;9)#7:D3>STG[4#)!H\]?C8NT-0EP)25RBBR&J$+:5
M]/F0YLC'"!->,.2L%6@1L1@#4#+@DFDBB=!"2`5*@2L&+KCNL4<X6'B"^>RK
MWCFH3)98CL[B4/G.P6;R58DW61V@W_OOCM+O6-(FJ]_1CKRIW_VH2;>,P%B)
MA`L1BKNDOH3*365ME^\@8'5T3>^W#&)48LTPE1Q22BCEB@.HL+!N<E&JDL<O
M(D37[7YE"6%?SOO-]8,?;IX;2OF/,L\-]B=VGAM'5$02=3"ZV5O=M..^%7P]
MW]8SJ(T&+FH1:S7DI733[</B>H5->.F#,'.86L:H=?FBMA16M*I*%RV9-9@2
M#9G,G%8=T40'_N%,AN91HY+8)Z%Z?W<\D/=^'_LWQ1%DX5%>@.#8%&M4HH?D
M6@,)CTBZWJ+D;/:5C,_)I&'I//HF'TM,5G!B)FYNFJ?V]8=?FN7B9E%OQ*?-
M=CV_V<Z`F[*32A$J,7+#S'!G61MEH"DM1RCT@<,!%O(IUQ%4T:$J?N]PC7V,
MYW6&SF1;"6B=2)Z5PI,F>9^+*EEX<U_?/BWK]W<?GAX>YNMG]V'Q>;6X6]RX
M$?TMF-WC!+ZN&]6X4HA@A\4%,%+ND%1`VXA<*X_YS+E7!]I'LSWL]N,1>/'=
M01KU]DG.U@G(WR[?,'&J^,.W24QMQ(NW3<\ZB9G:*+!J8A_67LL2\S;!%++&
MS!XVH_7GR*SREW7S6*^WS[\LO>W5K7\][-'W=?G\T7U3^Q(&U))70&JKK!$0
M,:"<R9UI"!R,F//X*>QECG<=Q*NB!5FTM28ZF%>%A]GO^9PD7(>E\F/3'!>]
M4C"<);\/H.U,HI^2](ED_$E=:O+UT52JYPWO7]9`B$$B)$'**%!!A00UG6G(
M#4VB>A'VIJ!Z_9[G2<+V0-W+1'0&W;O,PST!Q/51OAZT3UWY^K@4JGR]Z0I;
M_3C8L4_KU6+[M*Z%?R_B+_^INP0NR[(TW"652E=(J:HJ=9=G0ESQH,N7R8SE
MWE7J(+8CL<6YN7>9=[^R#TG8#5BK&)O8.(T[<GJ`5XCVI9D=P,M1&['D,#;%
M_188$E`=MI800,=K*P<IF9S".D%2?YI,72[GBOCUX5JMP1H`QA01W%)L,3!:
M'-&0H!=T,T.8Z,KX=?3=_MQ-E6&)/$\KC;-,/KT&RKA>GJ>AQETS#VJP/`OG
MUV>J.(S4'E,(C"-X.601O2^I84'T7T\^/C=WO[C>[OK\1B_FGU?-IK[];;&]
ME^MZOMDJ?T1TW?V"6*V>YLOEL]C^8_'Y_M?%YH_F3B\V[A?K7^N;I_6Z=K\]
MPZ41$C`M`%;2(*.HE7NH3'`3]![T)?%E#K\[K_R!]@YV<7"L\)X5.]>*G6_'
MW^J\*\2V\/X5WD'_/7L7BZ./,?)_J5X0$+Q_@`X0%]G_O^UW;1^1%_P`?:!?
MTG#9OA"65>0A_[64X\)-/85\Y-(4--,9>:-D,C,K.48N?Z)*2?>7ED;2/9K2
M(A:T7Y89PM3SD5$"SML-E3.?2-I&(Z<,$VF>,4)^TF:Z4%2_6,A.'I6#6^.'
M#KSA7B:)K9&DAM_36"Z;/[U%VZQU\_1I>_>TW*]';%SPKA=?VO-\M%+86.E+
MAU30%]8UL#O94B)I@E;/$YO,'!X/*(N[9EW<[G$6\SW0R$,EJ6@..U=R`8;C
M@MM+<CN(W6+IICB"'/O*3!!S9\Z6)*9^(L=+4GOU];6:'*2%OK'U5UM!?+Y]
M6B^VS[^T-^X_-O[5@84CU2'S<YKE\_7B?YX6M[K^M'VWVFS7;8:P$1LUW]R+
MU:W_RV^)?G%?Z7X^`P0C0W@ERU*K$B/(">R0^O7<B(>Y+@$OL[3N(/^T;#$7
MMPYTL3BB+A[VSA:W\^=0G;UD6P9,0*;?C''ZO?>GZ!PJ=AX5'YNB\ZEP3A4[
MKXJ=6X7WJSAQK!";POO4'@-I/YQX]P,T?-3#95/O`'U?.[M@1PA]*2T#]:]-
MFB[;SE.84%V8@68R@RYR(O9N]:7V59.>?VO6?[Q;_;)N;NK-9D8U,0C[UXUP
M):7R[ZD?K!$@HL[U]S21.1OH4"WJS57QIT/VTV+UT^,.6^0LJR^'8;.J$>B+
MB\('0%>%A^22J&(/ZJKX>=V<HR_+Y.G[!)V9+`UD="*3HZ%>-$F[65_9L0M_
MG+R^_;EI;C<SKDM98:$L)$2+2L"3U28F*>@E.W$FQI2=NSVRXK.'UE=U(BF,
M5)U\[/56G0Y2T6*ZL.B\X"=$=/H1.C71Z>G%:Z(SA)3A%QK_O:GOGI;7B[MZ
M!J1D`):".:M66,/4<;%'R2KH&:*4]C++D=EL%P_SK1M+3RVF8KGX4L<J41)>
MPV1I;$KC-.J-JXL[C(4'.96+BT?:SDA72M(GHF-)70J]N-B;KF"%^^`FBQN]
MV.S6L#_4ZR\+E\7-JA*(2F*)C:$,2(J=U<Z:0$#$B%I/$YEUS''^\/B\+1[G
MS\7M'MQ5X9KAQM_\:NZ*SSY'*#8>?*2Z]>4T3-!&H#-.PUI`Q0'15=%A&EFR
MOD_,&94:R.1$A&FH%TW2[A6[J__0K+>+_VW7<M_?O5MM7<=:?%K68K.IMRZM
M`X(II&U9D0HHSD!%RX-5447-[@::RKV+?X+.J\^-BP?SQ:J8W[A8L';9UN(`
MN)BWB&,W]@<R';BA/Q[)D1OY7_%[A%:(-^C,LW]_EJAS^_9I&)Z(>*7RYNM]
M^I0DA>=2^\M3F_=WRKN_VJ[W"/Q18_GL_[3S&T?XQ_JOK70\_#$SE='&4D(@
M)!@0AH`B6@MB_:R54QR5:&6PGUGV#I#]F'P!VO_``[XJ/CWO+A#LH.\+^17>
MA:+U(;9N3I9F"LS=+MQ"D8E=WL;)DP3&,WPN0\S87A-1X*PN?IU;9J<S8COA
MIGFH/VSGV[JMC;9[:^3#?5W[";BXO5UX8/.ESX27S<97BY#/[G\>&S<C_'G=
M/#UNW%<LG_QS%6VV[*_%/M6W[]T,LO6IJR]9$<K+DN.*6VO\&S)2:F,4X;:R
M`D6=1YT*YNP;'M[-XN#G5;'WM&A=;=?(CLX6)]YZ->K\+78.7Q4'EXM3GXNC
MTY'E>Z?6&L';,].`FW._9VK])M,^TB@->79C:EI=:2*1='*T?+-U-C%\4XO8
M;6G4$DHAL:Y@*9#&K%1*@0Z]U%Q-*V`'0<X<KU\J9_&O^4//0LX3H6LR`35Y
MX\;%TS[M^H-&O#<J4$^LJ?]CXET<*Z.'NQZ-%ASMHH#XH;FO;RNQI!1JR!A6
M3``WH-@!CBYIT(6>W!A&C4<AF?S57MSZU>'.UE1A<6@*K30DL"1MH"SQIR?#
M9P)*[C:;2(3([F8S[E"(>FZV>7BHUS>+^5(^;1:K>K/Y4'_V@6A?=)92";"Q
M7`"-B>1<&<$/-KE!X0_-#C2468V/\(H.7[$'V*MF]6!>SZOJZ)3&2>?DV(QY
M8W9$5GN^+CN(W<!G9<^S\)V@D92\*=R\2^9+DZ%W36Y5ZOI08A4`#A@&B&L`
M%3-48%IU+@`E@NJ63A'WWVX_Z3JZSO44FV4RZV!Y>M+4-Y>".M$/NMYV?::X
M]Y3[U43F59.D9O3EM[[-%Q[;'Q[GB[5'__[NNEE]OEY\J6]W1P@_-K+>@76(
M[F:0EA0(J2M$*B`A1JK"ARVOBHO9EWK]J0F.S<GLQNCA*<1P63Q`]4?"=@>3
MB_MZ>=O6R_*7)V(#8#K.`\/71<B.##XO6/8H?VIA[H\N%]NF^%07'53W.V,'
MC%`.S\E]\G:8BEBG=^QKJ<U$7?AF1?VXKMW4R\NR^[RL_0>O\B?'L&<5-0!R
MS:5Q_R%=6<6Z8P$<2Q%UER.)P=S;$"<8V_1P?GH%H?[KL5YM8M4Q#=&!^PIC
M<QRYB7`"[ZHX`-PEXB<0Q]XK"&#MW,9`2M(G(H!I??IZR3\]85$E:6_\5?@/
M]_-U+>=.8U7SX,=U:];LAOB,5A0+('U>ZFP:"0BUG75:D:"5_L0F,TO?`66Q
M\3"+3QYG<7,"M*?^I6(\3`$O0':<!AYY;A'^M./Y%&-AWN(Y6W7:MYD[HX.)
MJ9^($OX?>U?;W+:1I/\*/F:KG+MY?_DXKRG7Y6*7X]NMVWQ@T2(LLR(3/I+*
MQOOK=P`2%$6)%`;``*#V*HFCT`[1_73/T]V#GIZ^M7IF.FWOH#4__?;L0V>(
M(@Z8D]@X`B5W`"AW>)IW<9,$VCTB,=O]4JQ^O"EG06ZVQ<WO/SXEN]CS:2V!
M;$9J`V`81V+GJ&OH@V//XG*!HCH".1%*ZJK%Z0FO/D!I/IYI_KT:@?FQ4+MC
M\F<'J<R\Y400+2D25EGI.1:VEH`QY6>K_+:DSH\1PYKZ>WJCU25WJ^N)H(U7
MVOOP^9=@F^H\Y[>]L%7!E->2QLYQZM$`S>AK:-#;377:"UENS.W%S$XF/;UY
M/.IIZ.E.C5&\0(`)3#$14DRAV>G(IU3@M2?/)V,2K)6*:,*)9)I+CR22O'ZP
M@\3TP9G1#QV&*JO9WM_FR]U[C&H(RV99GWS_^_VWNWSUSVR]O/T2/8>E!]A;
M,F4:J'LCR+$GLKR(5PP5ML9ZJ@S87J&7B*\C5,VZ<=_OYKK-;_/B\\F]59\_
MYS>!)#Y]?[N:+T(B%!CC[KLI5MN`UUV^*.^Z^GW[95W<WWZI_\_E2G^\>3^#
M#`(!J*9$(""L,XI)ZS#$`$,"5*/9+>-)E[@J?M"I&F>UNTSN6WV9W'RO5]D<
MLSS2++LYJ)9].M+MX0N6J^R'4K^_9#^$'_?S^OX2T_,ZCB]<)NWK<(-(DG_D
M`4^N$SSR@&.EL@>MLF.U'K[@X`'3-WI$=_3DC=^NI7I$)VC6CYT"]W--W*/:
M>`J=W^,"4$QEN<5D+H]:XBYWQ)GJD]N@Q,_+^:?EW7+[W0?\;3F@>[O<WJ]S
M=;O.JW:\F0K+0%/(*&(:<$DEP:&HQ`QPPXSVC;HQQI0O<?;RZ_U->9E%]CG/
MLYN#V(&8%O=Y6;1LORS7BY"-A((])@J-9<P&R<<5V#&R0>11S_7++==OL@>]
MLH-B6:E9=J1:=M#M&@P?D8!<@0.T2T%&=(1F*4@:Y,\E(2/;>0IIR-@0%--9
M=L.E(H\RKOW-=CM:`A18`KA"1!DE-9,`@R`K)\@`SIJ=:QM5P.&2D3?9?)/-
MZVV/>G/E6-AL7=U#G"_>O)2X9#^TV3T9S0F2YS##V'^,).9-=E*&'VMW%<8?
M+(\9Q@G&3&1:.L,0J<Q9\-/D,MUM??W)3`\8])?-]&60A.G,AWP;?@T?^3S?
MS!!E2GEM/%1:`@\QLCR(I;R"&`J4>!<E3I;$2<I!F#)-V3S)/9)'F4C#I,HF
MTMEDP,3AP9:E%E,S7>I<()T)1PC[34V9,+P_PK/72-[.4E<;M%NJVSD^=X%Y
MJ%!\-G7XL"^'9X!IIHQ3V@(LE858HC*%T(Y0PP5O=!!A,L*.&\RS'^:;1GL0
MZ7<6^G:"0?*"8>T_6N)PL=+,:EVOSD4&S3^&=971$Y2N+C-4&O.B6=+E.?UY
MQ.M(A'K$H]],J6]#->[L_ZDH%O]8WMVIU>*TN?9AVI+ZM-FNYS?;F;`4`VL0
MY(H":X&SW%N"N1+"<DZ;CHN(>RC!"",ML4#04NNH,@136+ZR\N68QH2W!-5R
M5N=OGO2<'PUNRWZKI1UZ_EH4E!>ZTM.89"(=ZHF4*X;PZN@9H^>>_'!-GM#6
M<NJXYAJ%I6PULJI>Q=XI&#<;].7G2>MY>5TJ\]Y1B9QD'&*.J$8$H"!+X@+E
MY^5->9;]H0<C]AA.+Y@V8\:AX8SCP\L4.-Y%G@U0NT!]?6(^$<+K5:4GPQK[
MABOFHI/]H\I+01_.C'_([\JS>Z;8;#?5J?)J0D!]>NA`N9I(JJW'$`E+A$<<
M4E>M4:ZAL;;I[8@=I5#.,(M#C0$(I,(:@;%QQE$8\BG!K$A:KM>+M2J7CD:_
M[&7/*N'?/!H1<SA_-UJ.TPWP"RM_($M.A!2&TO;I11O#@=QQ`HU:K\."V0VA
M_?[P1_9"J7_,UZ&2*__@YMW]=A-XL*SS/A1W=[Y8E[\Y8PQ@'V0D`A`.&'>,
MFYIB&&51-P(F$E$[Z0EEV#KKRZ8_R10SAE+M*0$`)6]0.S=]ZDBQ\HC/,Q24
M5=J]R?;ZA1\>-,Q^*W7,]DI&7_,^DC<T"SA7X`AQ@6AL'QAP*%!7*UV(7B.[
MQ42BVM@H-!IJ-+!1QHB"O]Q75Z<`*H0,81J4#5@(4JP=/.38#O/9MWR]+!:_
M;N?K[>!A<"\C=\I;;26#`4*FD2*6\\#4P'G!D:4QQ'>J3F,._%ALYW?93J(R
M':]T"'Q6'/&9SF^7JU7UTVXD_GAAK:EY!X]H"6PZB6#V9N\;UQO%=O(/$\`B
MO>#UQ:Y8`-*%K5:F&"QB_13^X';S=O6^XNV?UL5F4XY\9A1B)[6CUG!/,"4U
MJ6%+4=R-'"DDM%Q(IW4I$PS"*J&`!]Q`*31C/"Y5;W5WQZ_EN-*LV$F8A;I\
M^4=U/.!<%*N4:-RO,:IQAXE8J:TZ7LS::98M5]E.M_*3H-V5Q:UG[),P<G7Q
MAE<2NSI!T'/TZFZ.YO&K)-*WF\U]OK#WZQ`N=\_<\6;UFWN9W)_E#95!WAD1
MDA*"O.-((.(@H)S6#$8-MBU&*[:00@8<,+<8AU\I@4HY#A"WG@-.(00#C:6-
MC4,'^6,C40(S-0PT(YEF]#A2ZW,42H:.(='07PH1Z>PXE0B04,-3@D\-YF#U
MAR_6G_-J_L(AWLQHB"Q$,B!9D-(1H)$X;*H`8V1-\,/4'\])B)46BA%F'<#4
M>*R%8Q8+@J32&L!F?<./R3\M[U?#MLH)7`-7(*W,.TP%DLRNHT>.(\W&BQW]
M6R=A_='%%Z82?<:$H.?ZH[LY1GSCXZUR@'F.B8#0.R\00S6]P5`K[=_XN-5`
M\>NIA`8!J7FHW;"$%&JG0V&G"-5<6:P\BIIL^EB97M_VN/U+GY=>]4R2O\;=
M]V]JX5?"71T`2+[O'V>*P7AK7QC,/]WE>T$=$-#A()UU3$M)0H+J:]ZRRMHA
M6[6>2J<#Z<OPC\9,4"^%#.(&0!7T!"%`4Q_J/<=7^8.@`V?6+0PX3%Z=UG:C
M[\>4>EWIN^@GEDD8D]I[P2N)21T`Z#DF=37%&+GTW_+R?J!\H?[(U_/;O-[&
M>K]>WN1E']CG?1\8X8H8%.B-,T")Q]CPPQ$&AX0<J;^XJ?C224<4@<P$^(4$
MH3P(=0YWW`O#/4I]UW"R5IU:_VP/P&$S.ZL@F$QS<F]N-GB;UQ@>-I$^L!>=
M:ZQS.<.;=YBBLF]?>R41/B5"Z<K2-,:<6HX0&-M#I`TP!&&`#?2:J,,N'//C
M]EU?E%R7>YS4`JY"<F:45@81Z(+,P`MI=-3-@JV[L<^]7WJ!>]\<M6A_&KM%
MNYM_3"JB]^H4UQ'&7V?L'C]@-W:E?Z\HW1R6<4)SI-GZB\>;J%[!BRHPIID1
M7%"/H-1"*H3K*HH3@T6OQ7J/<GM`G%`*8`(Q%0Y)1@'F&I2=_,J#J(%+;:KT
MMK$X4=/YD![14Q2>J#/T'XDW[;O4KRP>]V?2+C%Y!,>ZEK@\!C2QL7DT\PT7
MGP]MQ(VTH)ARY[2E4D.-K+18@)J00YHQ;(B.$QU;#)64VE!!J<%*4F9EJ/)4
MB"I.@N1[Z6VC=.N6_(EYQD"A>CRG&#%:/W,6X-4%["C#IHS9:3SLM83M1.CT
M';E3&G&XX/U,(^SE>@H8:SR00E"NO+;$H;JUGGM`T:#A.U9X28FT7FMAE:?$
M0@6)]")HX[0PS*9N\6H=P).=K1C<.P8*X6,ZQHA!_-EC&:\NC$<:-V4@3^5G
MKR64)\.G[V">UI"3>W=-"<"`(0:M#WD)<"H0=,W3UDLUX@F2RUD4)=!Y3*`!
M(8OB4*%RSH@%""OMG-<#G"MI7X7O#IN\^-+Z_U\^#N(BUT*Q0\,RTLO'.+.-
M<8CEHOC<,4<#C6H'$",J:*#K410\:-+OKF9/,AN,*`#&&.99J$J==AP(S0E%
MU`/!H\:B#UD-3>)$3#=O&/R<S&".,)'3,U=6\O1CR&$.V_3B2J\D^O8.2[J#
M.3V:;8QRYNUJNUZN-LN;O\[O[O,9*F==`BZ9UT)QI+#E=7-E^484C-I\>R*K
M8)10RZ"S`E,'B0*&*D"4$I1ZPJ/NJ.Z]W5;=WJZK\3#90>JL$GM2C;:QUA^\
MM3:AR2?23'OB'E<60<^::IB*M:5[O)(HV0,0Z:K23J9I=G]Z5VE/AV6&_[*!
ML0_4?:*"14Q0&2*W<DHZ;)F4^+"Y9WVC$ZMCR(VI8I99(I3B%!,AM:4:$RJA
M9A:#J,V]'NO1"Q$RKOUUDKYP.5)>NQNTB)V9OAP[]3YV[O_<H]A9A\ZZ]_5M
M_0YN]T%6JGW>GZ[9C2)N7;]B=VIW`?MDW:K9=>S#VNN9?&S*7C.%2]JG"DTQ
M_44_SMN$AW?,U="G$]FA8LQA(80"./Q-N8"RYEKE`!_A5<)E@8U3U'-=SA_;
M]>Y*%_X!`IGPGY",=7CI0MZ6K"%Z$/L/^O)@.-./_N;@<=/4=>]W-+%>^M<%
M_3C/*]D%Z1>3-"\*^C38,'LC[L]ORW6^J,4^W2B66F"%J77:&J.I5)@<ZA9&
MA]L*N2RF98QS`PS3UE+`K*2`8.V,H()!!>'T(FAL1_(4;#W`5L=P9AYK9V.O
MX5$-.N(N1D>'&'#38CC'&'N/HH.##+,?<=$4J;8?^K'_:]AMZ`F)/C<7^C3.
M!'HCC'."*&LE\<`HA+1BA^9N#(4>L;G[1%)&.(>40QE$I`13&:K>\O8%J7QY
M$4.+SHC>VKDO[1Z\DD;N";P(;^H`KZ0$[`&(P5Z$QYEF,-K[:[XIF]A6BT#:
M^4UYI6%1?G34Z'9N3UA!@0&#FE'G:-!.(F,.^VK`NR'W53MHX4-"RXDG,B1&
M#FLA`&;.06^TXA2RZ96*X[5K)_258?9@I^$FXVW,[O3/`C]E-0+9MJ@^/NGW
M[O[V<QKAN;7%$X;O]%[X2L+[`$#U'/Z',FVSO6"[W[JH_UW*M=J&^/)V];E8
M?]WIMI^\/H.*&RV18E!R0XCF1.PN01,J4#373;;[HA[HB=((!)4]5!1+)!T6
MV(`2!V*43=C36XN7'7Y0)2-6DF9'HC::2Y\:]HA-M='@;[=']M0,\_9F:+;7
M%8/0N:VK)"A/82<JC6)%:@=MR(B+?#G;/>Q#?KLLG[':_C+_FL_"EPG'B',\
M.`L!/JQ%7J]`8IQO4L><_7*$A,46&:<-ID03136&5@+-N362I>[EV"^F!Z&R
M4JJ&9-8>L<NA8A"PXB)"+$X7<MU-?O,?M\4?_QFTW*6YX8?3[/8<`L]03F>P
M1F:6[O(7/7E-!$]\7,_+'9Q?OW_]5-S-*"F_F(/@](`1@I1RMG9WSIAJ2A"/
MOY40*$*PM\8A0+'GVDK*)5=E\J<83?V.>B],MI,F@A$BL7F9"M+!$L<!31'I
M8>T_4OG,HF\'RP16>TO!BZX>$9T'F)"!K,NFG$7^YW_EWV=66^J=!LA#$!(,
MY,-C:E^&VL&X1.#TV[6%ABE*J05!=..$DIY9HR1'5""?>E;>/L+MI<HJL;(@
M5W0N$(U:TV0@)6"MLH$(K'K+!TY`N)@0M`5L`AS148$G*4$W*!IQAKE?K\-3
M_')S,[_[WWR^=JM%V3(_<XR&OX@1Q@*-?"CB+:@7@)&NT7N0BP\`J&2^0'U6
M88HU%!I0:[B`@10I<5&7O[=@CKU<V4ZPK)2L?&5;G9*)8(_V^+U,((-`%\<A
M[5#K@4?.87&&2CI#-P$VZ:Y#T:,O1><A?GF7KTUXQ&VQ_CY#Y9`CR"G!F@O!
MA`%'&;7V)"X+>?S=`$)-*5$6<$`%+H>"E?<#:HT)`<!$[?FUST$JF;):J.@$
M)!*NINE'.J1:)1]-0>HM\WBD_\6\HQU2$^")3N(_R3FZP-"('>I=TH_A?YE1
MRC4+7RI#P<T,<99S^O">P)BFM/#X2ZU%5#G(+0_?CZFDY88)IQPJ+I"2B?G@
ML.]?"A/!`W'`O$P`R3!I^5KJ,AP]K/ACA<\L]5:83&"-MY.[Z.@,+5;U^[J_
MLDHN(%>A4$%(<B.<M)03Y6LOEDXV.J1Z_MLQY](3"*T(]0^B4(>,!4L&>7B<
M(C+U))"#8^\;V%M4#RU1:[[VTP'6D@0:8]4C'SP"X05B:`?8A!BBI0+/4$47
M**(XXZ$H\>&3S<P1;KU!4E"OE<-(8D1J_W<0V5C6./U^BHV#&AO/"*7>4RT9
M<\1KJA%SS/"A>..XB*XD:\$<T=@UYXZ4L+5DCPC$>N2/$R!>8)"VL$V(0UJK
M\`R+=(.C!8_L:&OW,(T!`J&4]EAJJ`20PM6;<`(SU+@)XOP3/+%((RRT#=6Z
MYU00SC3DFCCE)"*I&ZU/5\8^O'9CDR@$8_DD%7C=&*49;KUSRA$8C5BE#7B3
MXY562IQEEO:0-.(6%9ZTJ)YV-[^=0<\$94J&)5%V_5OL!:Q7`]*F\2[FXV]%
M&#E"G9;<.8HXE<XAIKP2$@5.E*GW*P["9*4T$:P1B<W+3)$.ECAV:(I(#WSP
M2.4S'-`.E@FL^Y:"%UT](KYGHOCZM5A5IY:J1OCC`V\SCR%02#OA.;96&\J%
M/3@VE8TN[6C\*`5QJ*JL\XH:;%39A8@H@3X\$X/4=VW4'0*5B%DEXYO="9S-
M\93G^.:*3O`V?=4Q&+*MWGRT![6_+HP+`%UNR>@#V0GP49_:/&W6Z`^DAC.1
M;K[DB_N[_-WGO\W+HSQ;M3]G^;$\D;/[)?]SJX/VO\\P(,@P;YWS3`:RA(CN
M5QGWF)%&F4O\4XF5.&@N":>$`L.%%A`J!0-K&V,43<QGM:Q9\3G;2YO5XD8-
MH.D5Z<M\-B[(<=1VP/?=4WRS2LKLM]V_2FFS2MRH,T?]`A\SR&<L`[2<R_.B
M(3J/TXD`Y)E8D@[4*1PQ2J-8D=H?.P6;\GSG[F339G/_=7=.]$0."K#G5BC(
M0OD=DG8@+*P7)&"6M8\Y#1ZNI-!*(:)QV=`DO$*82,S+O@5%K2.)0X^?+]>[
MH^5'P6>3+3>9VVR77^?E&?7_V92-^?IN?O/[CT'%\*3-_E![=?U8^9O_72SR
MIL<8TMFI3<0:V$3=`]=!X.Q(XD,4ZRE^]6&-+F%L8*OT%\VZ6Z=EG'L9L<;A
MKD?P)QGU^M3O8O#K'<AF,=!\*><E;-ZN2G*ON/T@T<_+^:?EW2$>'\2P2&,E
M-(.@/-YC%2>0UHO9R&8-,&V?C4.L-YQ*X0F@H>HL`8&885QNH2F8NOC:2UP.
MRWXV&&8'N6,8-84-&H2WD>&/BVXU\F\?(?_N&>0[AK<4QHB(;B,;I5UP2V2<
M9M$M'K%SP2TA]E.(;2G5*X9QX<B)>W:Y^59LYG<_K8O[;V]7-W?WY<9E^#3`
MM5VN[O/%NV_YNO+U#_D?^:J<(&H89)P&<(E55`:,%;'.&2*]UUPWJN\2/CYQ
M?/LEWV;KG2B1`^M20'TYADT$Y<@>C;VP625M>=7&7M[L6.#L(/&;[,-+YD@R
MS"T>U&=(=0`+361\6DH-B\'</1V[FF*SW;S[_%-1+#:_%G>+&=;&>5_>IT<\
MH`YSSD`MDJ$6SU;5Y+7%QR1L&RU.(T*0.T)X(GGS-"J(5183R1DXWAR]4W$:
M$PS$R97PI:4J\;-2_NGR\RG2_1!U:_M='V.W5[4]=7>$-P6'V_S;.K]9[O:H
M5@OUM5AOE__<E;1$6R08!1I!+`W%2F)<2P?#9VGIO(MDPS#[L4@E;]SDZ^U\
MN<KF-_]W7UT9L@PE]^I?U%UKC]LXEOTK^K;=0&:A!R61^XVDR$&`3*K0G=X!
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M&0P#B+,XQ7X,4<S.-@U]P.TNZ<:BFR8Z_YIOQ']\_.`]-G`_U#*QO$!L;R$W
MVH/&%W.3>&VB"-[:TJSE+JSQ6G/<7=6]XP<S*SM3SO[Q5G?&+!^^PC-+OHWX
MTGZ0S?56Y;?\4UE5"XJ2)(%QR,4O&/DIDQ5$6U00)$H7=B:"8ON@O=S^K>Q@
M>46-R_LI;[SWL[V8,<@KQN.$;8?8C@U'_-['UG/2A!ZWS1T0WB#<3!`8X\D?
M3_A'63M<[,>3K"SP'[\]+XN=7*+</7PJMX^?1$Q9X_I$XDM)\@:T@/:P((2G
M((U3&,8LS.*,(<!J`-CW(1MTY&-N\&FF_R>\GEC@[1YS3SY=WFJSK*KBH5BU
MAP%5>Z3C/>6;M?=0[CSA]JEGC\K<]NB">?\X(@$6#"MM/]JZ+_91.K@P_TV9
MJ3[G`MV7Y5^+$,608$@807%,(HR1'W48$HACG7F:T8$MS\HDRN8=7I]'_O((
M5'-B9I9TM6G8;'SK3;HN)DX-YV_/MJH/GLQ*+1\\`?A\<G8O#[7DW:G]?E=\
M/>SKQ/)]Z8FIM?P:@6G3S-#$@Y!7ZCNVAO16PPU]DFO#FZZHKA7;KH77'H$Z
MJ^8W1KTO-\7JY90#3Q*>()(B'K,TI6D:Q9QG+!.S/!]DU$>:BV,#(UI6VQOO
MN_[BUP2YRFO<B7G57LJ^+:$-1._W]L\AUV^,+5K?9[!_;6K0`XXHH6&C7J\T
MC5.FK'V_5?G=0U<>H%I`#(@?L(1@Q(.(^RSB.&.4DR`,,0V5&C0._&K+:B;0
MU"G!1T#RDNC]+G]>[HYI?[S8+K>K8KGQ?MV+_R*7`[IRI\NGFJY9I%)/P`20
M"Q(=4JY+CGHD:B"9CFC14/2ED2=*4UVH$#+Q7*SK-^Q:T3(?PC0("!`RAJ-8
M+*7%@KH=DT.U;M%&!K*L//>[0HC*\Z;1GPNDFN(RCDXUJ9F,23WAN8#ED.KT
MT=6C0498=D21S-A26G@,-=5*O*CEKJGM_$M^N4N,U_\Z5'LY(<CR:K4KZOH?
MBPB%&4I(P!A@OFRLFP7\J)I)X.LHF/'!+:O:-4C=B9)YLM7T;5:>]33O&I]#
MLJ?+8H\46G.((_)HS[YRHB=;=]*WK)[P=BW_8'\<BN_+C5Q'76LX\'GH@Q"F
M$:5Q(&\Z0-@.'D&6:6VGF1G1LF!*='6V6OWA#*?N)-`,O8JSP<F9U9P6WB+5
M(:U4XK!OKFC4!XZHHF&CKF>/%B@;J7^_Y-5^5ZSV^;H/W"*%"44IHS$@+),=
M>;&\_M5@PBPV((N&@%B?7G8HZU?;B$::<L$8Z9R!?6.*>N63'U-WU1R@+<>&
M_>JT2INV54F\K1"LK.EGI=*.AP0?MP)1?<NM&YS%U$\8C"*:@BQ*`@[P,:"$
M+-$Z/3$SHF65OBRR>3H^.0.JJ=R&B%:3Z.DYUM-B!7H=TELE-GN$U:PW'%%0
MPT:5-A]@[>U2F7BW?[G?R-X`V[44X_KVY/4\F_HDC1FF+,IB,>,F*&1^.S[D
MG"OUUC4^J&5E/.*J9TG\L-L6U5.Q?=3?)C5%LNKVZ`S\ZJEB!U%(GP19$WR$
MZ9`>JE+9NS=JV!N.J*)YNU[MA5HA3ED;O^R6ZUR,>[=_RG=XM2H/]11VE8OI
MZM=-W@HS)"2&*$`1\#,*D(\I/0HSA;[6?3LS(UI6Q0Z7=P*FJ8>&B%43P^DY
MU5/"&E^M?S5"[PUZ'=)#)39[Q-"L-QQ10L-&E38?8.TK+=^%X):[EVO-C?P0
MX@@F<8"Y^"W6Y6=K=(BT]C@'#V)9Z3I<1:Y_*64H;6JB-@EC>CIVA.206MVB
MJ4>@1C/KB":-M^/5)0\CQ"@KCRS+^F>QD>47/AX+=S:W^:X1I,P/PS0A$0D1
MS`+&0YE5U,S_`%/K%V=A6,OJU"&MYPXGK!X>4MO4)-MJ$C83T7JBUL^Q0TJG
MSF:/]EEPB2-J:,.RTOKSK*F8;2L",34L'[?%FSF70<H#&A"0I)A#)F#X7;(0
MC!'1NG,\?C3KI\\U0.\,H:8H&B!430NGY5)/`M^@T2'=>Y>Y'KDSQ[HC*F?0
MH-+6`ZJI:>10%=N\JFCY[6NQ/;]5MV"`)R&@D`,Q2.1'&2#=KA\*641TQ&S$
M,-9WV_XX%%5->=7.0O[VJ5CE6]D#6%//QI"I)F03\:BG8!TH[QR5.Q)VF[,>
M[3)`M".B9<*2TOA3J-7>M;[X^RA6Q_+"2[%N;_\V(U[K9$`REM2IBBPE`&&?
MP>[:"TH@"=4;NYH<U7;:]!&K=P%6JV>H49;[Y6Q>@O74[1:W@P3.-NTZ35KG
MHG]@>];WW&"R&ZL&-6_$$'OTNE"NW(YAI>TG4R?@W"_W,C,(;]?-)_S\O&DO
M"=4]K=Y&D@"*XRPD'"0@PA1`"+M]6H1"K'15V^+PED-0"[J>0C>?O3/<3;<Y
M'5VTY`.%N#0__7H!JF,>]S!O*%A9<HI&U)K?.</"E\KK,6JM=".4#>+K5DRS
M2[X+P<VRA>5D3[+F-M"O3\M=3I95OA9K.EF_NZW96]^+E1ON*X&P^)[+5+%N
MJ<<1CQ/,,8QB/XVICY*LRXA`042T]H=LC&\YX-60__958O;.06ON&5EA7FTS
M:6[2]<+<+;YE)?.F1G&]>==BKM->'=J$&L!US^Z43<\YLFUEU<1RNA=!^XRQ
M:;6$+UHMM1TQVJ%]Q`"*(4@Q$T.!B/@DZ(9F-&)ZIXSCQ[-^SOAV^[*NA8UN
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MNX<AI(0CY,,HH)BF(87\>%B64E\K/]78H-8U[0RG)YMH:`N9*79556T&8G4E
M[IS3!J-3NJ;&8*_(&7:",XIGVJY7\F>%./TB1/_(E]5AEY_NLU\#@#SP(059
M@'B4!G&*HM-1"@:AUL5R<Z-:5L.S:CEG4(?6'QK/L9HDSD.OGB:^S:Q#JJA,
M8H\LFG>$([IHP;!;98@,4Z>LC&RYV\KB.O?YKC[P>+6LQ@0%(4ABRGR:H"0Z
M%8Q'898%.GHX=BS+*MC!\Y[SG5<#U%3`T5RJZ=Z4-.JIW9'!^XY!AY3N'=IZ
M],T4X8ZHFC%S2CO/I::"?<[_;.MSB,'O=^56?%SE9U7<KG$P%`0AXUQ>EN)1
M``A!LA=B@$!$:4JU),WXX+8U[N$A7]4]1V4M$YEO=D3O7<+7U#[S7E`3PUD=
MH*>.`NIMNAT22EU*>Y33FG<<D5)[]I43/>:Z*8&KIWQ]V,@.:-^>-^5+GO^:
M[[X7J_SM;!F\J5TD\V8>VFNL_\[73:>-.I_Q["HKQ3R#!$>13&-$D/(@S4"4
M8IC&69QJ+;SMH81)$$18;M!R&L,4$1B&(``AP9#'+(DLRW=GF!3P%G6^]G[=
M"VAO),%U*1NZR8?S^5A-\W\,]^H%AW//=E9YK5G>[2S'DVUM3&^M\QKSNA3R
M+W4+\1D3'6UYK"\=<O:GQ)$@Y0`1UZF5\R,:&O9.".^7+S+^XC^7NW6MP$UJ
M:"6W<QK8577XUOQ=_?Z=E4Y-`@)"F&049A!1`&GHMSJ(24RUNM\9AL93P%`:
M)@F(XI@2C..89"R-0))&+(&VLYW.@'D/Y:[+XO[[;BGOR7P4_YJO!X>S:7RG
M&\.<<]OPP'4>IUICO-J:#\T<I76G6.P<3?+./>Y0G#+A%:7@-*G[G8M(TUI_
M,PS-X(11L><\.IZCQ*M]\;W8OUPA`V',@@"B,,(\3$@6H0BWFD5``K42U0S`
M@2SE49C$"6<D3I``D'`*`&0PC%-,K2^BSJ3(ZR`:""JFG3(\D,SH#S/!XW*1
M<Q4[.BO<#!=ZW&N&"$N.=3@LV+)8(118)7N`_./5:B>FOY^*Y==B4^R+_#H`
M`9\%A`(_27R))<%!$#>*$E!..!TF\^\."SG&"$=^C&,:<\J(F!NC#(+$QR1)
M?=O]8B[VQ!JLQTM@9Q7^Z6&WD_/1,SL&:_YX3^AJ^Z1.&*[A'?]G.%U2Z?=8
M5%)C8ZYP3G7-679370V3IZRBM08TB8>RITTK#_AKM=\M5WNQJ*>A/"\A<A2,
M08B2L'U?,\B!:E>\=T;)(()!Q%'*2!KC$$#.$?&A"`XB:E!DL5Q9(X'MY:BZ
MZU,GD+]WZ*9^*_NYZGD3#9'LR-MGRIK2RI,X>*Y2C_^YW,I>4DMY9ME@:8%<
MO_,!C0#'$<0$"&018BGLWCZ0$:VN)@,AH)@&&#,:1P#&A$8P@XS3&*4Q10'D
M=,(YS,6[^E,+]^?!<Q6SGM"=M\SFA.%SF(;_<\ROG.'2G$:'8:7YC167.:*V
MMJV\.>^Q2*KZA;#-LJKN'OZYW,G3E+O=+\7CT_[NL*_V8D8@("U0D*4)0R$-
MPX2!.(9!>SR?,@JB4"LQ[MW!",DB+@P-$`(QHQ%*`\RS*$6<A&%D_:"I!59Y
MY0G3U!>2WJ&HYVTUQJXC[Z4Y>ZXO'IDE:F3I-"Q1/-9I6^3E[3.'=H_I#.+G
MP[>O^6X195GL4Q3S&/L`A!0SW^]>SI1G;/$]WWTMQY56&X./8\YB%/M<_(K%
M+!)'`049)IF?)C#VM7J@G9NBN:U?MD>)\[W6QJGMB]JSN=$1X9B1`*5R8=.Y
M0JV(<3N8+.:S^YZO>;GCA_UAE\O,BJ5@_+>M<)@T8+DM\NJBQMF")Y!"`D,N
MKQX%8E;"..D4*..14L.WT2"8>.N2.)!-3^0A:PQ]F@24I%'``\:9[?SY%KJW
M:['722H/-7JO:.%[!XG?$S,^KS'BY;\J3XR:7A4BU*FQ:]5O_8LZIURFN>W5
M>JN#[0G<7@/<ZY![-73OB-U5)VF40W;%6<.*(IM\Q?Y[;*7D$52^$;8G\XX+
M59,GL;.<^+'7ZU#S[5M[<DR7S\5^N:DG`+<!GJ7#RA^Z%R_(DY@MU``!8"2.
M@A!'8E6"0YA"E'7Z$""NM#8WCPIF,>9(*!>D09QF`",Q6X$T`3!(,`UM5W%I
MD*LJQ2FMOEXI=(9HR_RT?E4(SLZZ5"]:-V:TWFD-\5H7]T;PNX<?U+=:C7D<
M]?'0QCU3^UJUR8\YFF]-`&9QI0LS@GD,+^=^B_3KMNEA7'`49`@E+,V"A"&"
MT]1/.IV)8Q0M]J7X%L5]>^W1`Y@D4"Q=`BYL)GX*0P#"2"Q?Q%PJI8'>T>D1
MJ+*2?)$_TCL%T*_L9II_M5/3>:D?'JL_W!3PA]<"/GW1-SU.^PY=K/G'D<U4
MBP:^K@=GE4KU<QHQ;ZEW9^\>Z+)ZXIORSU.6#`@9CU.:`0#3"&68)K1M6PI`
MS(!R%N>8,2SF/'2PZHJ^`IA7(YLO(ZR/I[XS$!/T.O(&FK'E^F3"'$'Z[U6=
MVK"`441`$G,_X`2+&(F!&*L=A20$:F5XZ7VU[2V(XUO4Y`2I=LX;2I2FY)CG
M:*C(O$N/74VI1U=1$3W&7-,-3?2WE&(("<K:T#4*QZL_#D55U,>D?Q75(A'?
MFB91%'.812P.TI0GQ^$8RG1$8N@8EM6B@^6=X1(!5R#3U8W!)*H)R!3\Z2G)
M(.JL:,H-;GK$92R;CJC,:#-*LP^9`=V1'W=YGI7?EL5V@0,>I`D-``UX`GR?
M)*"M4`AB'"&MNASC1YM!BSYX'4;O]P:E"5W2)'FX0MGC=[Q6:5$[F6Y=,*:I
M8,/8=EC+!AJDH&ICJ%([;&X6=)M_Y'7J&,1)AG``DPCAF/D,!@AT(T0)5&KI
M,>!K+2M6"\;[O8&CU:1<DQ^%4U=[U.B)S82L:)Q7VF-GV(&C.DMJ!X47]MTZ
MZ1M&@@M'=0.1EZ.?`!W-^[_#\R;?_KL=`3$0IRE)0R&BE'/`_2CH1O#36*GS
M^("OM:QY+9A!;[<F/PJ:9X\:/<V;D!4-S;/'SC#-4V=)3?,N[+NE><-(<$'S
M!B(O1S\!0_?6/XEYYD?QL5H0!&#$0Q[P,`TIHB@+NIVZ.,GB:-#^NOK73[?'
M+C%Y-:C!&^T:K&ENMMLA;/"&NQ)7=G?=CXRH[+SKT^?(6G*,!;=VX(>2H=E4
M6W8^Y,(@6LK*\H=B^WC7W%`NMS)#>G.0]Y'NRUV]BMWO=\77P[Z^K%Q^%MR(
M'Q(\;>KKS.*]SJO](J0ID->%$Q:FG$<4ADS,\UB:^3!BD##]EMR30[2L9I_S
MO;<1-GGR0?)61ZN\\FC6H#[?T[M231Y_`"_J26Q7#4*:]'/CQ9-5WLFL#][1
M,*^US#LWS=N7WJ5Q7F?=+`W*3;NH1_-G?B8<B1MSL_!F:_69G:+1]FDOLUGN
M=^7W8IVOR<MO5;[^N+WK"FRT51J+\RI?E&0<^5$2Q#0+8<!9`KM(2D.]%B,6
MAK<<=^H4KX<ZQ:O6K%-YF^41Z_]H=WTR[P2UJ#(S_WH10X;\FOX.KO?UQ?M)
M(O:*[<_>$;1W0CU?&IX^LSU";]%-CHBX30M?-8&R3*:R^.+UOP[5OFX_]:64
M+3FVJV*3"WRG&/*EU,7J1XC!V`]1E@4A"TA$PK3#RE"@5:5\%H"VC[^.-LF9
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M(&\>@8>CC:,K^EC@_=91^)PN=N%`?5;[2T?>M=&SC[KELW@1N]H#XF\J,45J
MMF07<2![C"'@ASXF-(EQ!KK301QDH6]D<C$.PMQSAPZ]_'B"/3J6C/3+T-G!
M!+XP'/R/_!\KM5"7'#$V9D_G$-,A^>B8Y\XQ%V^(G5#;2Y=6)#5#O+.!TI!Y
M[\9!DS3J9)_L<C%8EC=_GJWTVX(0QV5^D$7(!R'&*,UH@@BEZ3'01@1K5:4W
M.*SMT[K:5=75%FY5Y?NFJ=GFU$%)=SO7)/?**2!ST*Z=UE&#\W[J8/XLV3]M
MI'95;F;;156GL3_UPK0O'-GQM&'9ZQ0).^2-$,[[7?Z\+-99_I#O=GG7ZPEO
MUW7/$5Q+QB+*?)@AD""8T%@6JXK"[OH%#A,,-98)EI%,LUIHH7KY>:/(LN[\
MTXCL:$TUXY:A^CJ=*TQJ;>>5%NY9]T[\CE,FTEL56K6TUZB?G-5ALU:^J\D6
M2!VASWBU*@_;?76_?*FKJF!(@I3ZD,<D]5F`$\RZV[\XR:!6M[OQH]G.66CA
M>,\-GM&RJLWF4`6U2:01L3Q2>_\>M1.)XQ5C6CHXE&UG)6^P0>^JVSBJQ@G9
M5>_>!2!Q%G`60<@IPR0,8\".D]PLU,JH-3*@?3FK^UN_,6U<M?W%-X/[BYMA
M?(3>V23;E.1=MQ=W0?6N>-,5OJ&TNZQ]@VU2D;]QA%FX8?#678D%#<(PR%C(
M$66!SZ($IYTN$Y02KE.5VS(4+=74+]']^3HI]?6EMXO\5&N7$(;Y24U1'7*1
MGM8.N)SPX>T+;\Y>5'B+<2.7%D:YTA']GLK:P9<9#)`\\%9T5E2M5.7KT]@"
M^=W#E^5?"XXC0C')TCB)T@12\!_NKJZY;1S+_A7^`&<+)#X(/.*SQU7I2:J3
MJ:Z:/*@4BXZUJXA>24[:^^L7($5*5LLR00(4,P\]G>EV&^>>2QP`%_?B(M7<
MC0F<IJQ?4#7<^..$4E_6,R^.('>J:!ZAH/4RC9>W:^&],9%I'\>VBR6E00D<
M<I"M(H#_*%:NS\`G=S&>4:K3/.>$:,5PGD(D9#-TQDD6Y'K$?]@Q,Z<Z734G
M\Y/Z=>_I'L]%O0^^<=P2]-Q;.\-A?'=?;MYMYU,(]YWRYG?N[<WZ=/0SG$EO
MGWH'TM6]^U2W/=EY*9\1D!GL6F@B@@!2`%':7*J(7(/4JQ-55"1C'WG/">60
M0V]D/W43T^FXR$]FO8^[QQ9<[\`[B.X+ZCR.&R>BVR,9>]KP:D2*(P0X9UH(
MI@`T&=499BQ-::K;O;D@*$XP\\UAQU;Q4:.5;Y,>.C(9E._H4<C)AAN#A!8[
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M/.9(]U%NTU+5@;C^\?.C=H_E??(;?Z_?(9`FF^6W!^\RG>&L=U.Z<9CNI70-
M-'=[MP>7'-#=)!6^D87N+;HN"%TPIB<B=.'L*2-]DD.%SNXD[8%]]_S1?I8[
MOEZXEU4>W8]8J45,Y4(KDF9"YLR0M.E%+A"$RF__%G#@^#NY%Y+7/L=@]:YH
M0%97\?=/F_5R^W#Y+:QQINBK;/I,UN$NF>JT#6#96Q,X%'D1HE]G4_849^[M
M8:Q%"AGA6JFLW4DIBE2`.X104*Z8$'TN0A8M0-;/3Z&#9=%=%#UP-NF$Z(Z,
M!PFH#7+E1+1\+&M[!]H"D#PH'^@,I%<NKBD@5'$J*$0PLP?I5-LC<[.G!,2K
M+UU<))'O02[G`P70_,A^ZI\/=!T7!<L'.J_VT\T'ZDRW9SY0>#=.1.U',K9#
M/E`LBB/L[V=(2Z!I3JE;;2@'0$-T6&UH'F<O_^:P8^_;1]VLOTUZZ(UY4+ZC
M;\(GN]L.LK/N[(N)Z&H,RWKOF#W)&ZJ8[3/19R['!0<<,NQZMR(,!,@Q:6,S
MF"&OYW\B##]R/E#[L'OX?*!!3ABDI&/Q'U116]!3S@>ZP*R_R(9PT[3%-HB%
MW40W')G=;Y8VY5U1+*K24O=VOQW_Y</^,T,@H)BP'$"I[4`\PVT6:*H(\-':
MX:.-$&)XW(/<)UON89XVX/"]-!_.<\=;\U$I]KPV?\'L[1&SQ]UMQKZ4>XNP
M2W=QP<B>B`8&-.CTYBTP5;T4KAKHPV,5`-!_%9N[I=7=&5"<*"Q21C!.B:%2
MT*:_I^`F)WT5KM]HHRM<L8?FYF'=6ZA\[%.`'H!H?XF+S_$0B:N[=>WA)2V^
M*RK<6;XZ*MPPKB>H<`,-NJ!P(:CJUN[(SN?C@9O!SC9GFDF*"-6(20@U9491
MK=OTI`RP3E=)X4>-K'@?7U6[/ET0P_)]6?"N2[7_R;AEV@%MY>[5[H77H]VC
M7='5Z._7J.CR\GZV@^#@%D4^%)U9:N+1/(6V1'$,*V-_H2'""-4;*Q_NZZY_
M,R,AQ4KR7.6:\E0#8>!^9,EEB@?'$?R&&W71>3'O7F_8J3]]_#B%T^\+)GV/
MO_W<,,'=X5"+NAR`AY#5>7+^43SNTUX_W+\OU]\^%YOOJOBZF^F<,`$@DZEF
M(,V@XI@TXRG[O?0HC^D]5H_T\%XM:Y;KN^7CJD@:F(F=?"L+])V=Y-^3A87J
M>>SMSVZWTVY<1GOM]0Z0W*;B?<N>NLA>%/UZC9T+JC68T(EHU7`[RL!?6K2+
MWUD*F#$9)9)G"N4B(\3D#0+*&`V0*M-GV+%291Z/;AO/W?9&N^Q]F_C0E[Q!
M.8]^N3O9&]T@-[F=?3$118QA6>^;6T_RO)+)^;JJJW;;QA]V`^D:V12;9;DX
M+<2>82H))QDB&68*9Y@8UF)@D`+?MR2##3R"<B[;YP@6Q\\15(+JZ@"K/Q0'
M2WHDBX?S0S<9O9H+_(14-A17?SA">I/46),S3T5<(>^[*Y5OI'D']\A$Y#2.
M;6>2N",1.%!2N57ZS>;9BGK5YGO&.(>`NIMHE4&0,9EES?VTS!4DL\<*]*?=
M?+,;HJB^X_K,XU.(_E/Z5#63^2[9/13)U^+;<KVNNM'<)_4PDYC1)VQZ3^6^
MWICT'.YM5*?).XRRP+,6TBSG/(42PA0B;2BDJAD\TX3O9ZU>=WP1(<RH_G.V
M`1AFQA:NY=Y_]#SMZH%?:IYV-JK7//6CK/,\_?3T^+@JJJO,E4-@5N7/V_5]
MN?E>76VV&:X*8XJQHH3FDL#,+NVXC7X+JQD^%T2AQHQ\2W0,LZIF797;ITU]
M5=LD^=LS2XO;-ZL_&/7=CB?78-WO9/*"\$HA'<;D".3UTO4[LG=!&4/S/Q%M
M#&Y6&?>S'7)WOK8J4FQW?Q1WQ?)'L9B1W/YB:B23%&I&L:!IVHR9:N95Z31H
MH,A*6,W%S1Y,LGC:N).$.U?46Y1M]:;3<@]Z2.Z]-\'=I&\T;OWT[B3C?@\L
M:9!=,]G@A*2N:09]N9V(EH6QY5)JP3""/!X2KL?Y.%\N9IJ85&@`-;`2:1#/
MB*!MJ)OZO<_N]8O'4*7J2;FPBN1'7C<%BL:;G^*T&N-PC/[6[X&""WK2BZF)
MZ$<_['][K[<W`5[1&;>1^J>UR_[Q4$^^7IRY+%/MV>?P`'J6YA"GVC`-*,TP
M)$JTNRV!O#0E.ICKG1/7Y?I==58\>D;#/7(9H"8\O@N[WWI-QGL];L(<]IMD
MC_[HU0WGI[,5XP<3KG<:'4KZ&P&\4?PY$<T>S]XS8;\1B>Y6L&3FRTT5;_QP
MWV2EWU89T;=KV>9#_[G</1REK]O-K//2@F]EN=VU^;)`TAQ!@+6B'*9(4`F;
M]IU22=(I8C@VIL@KA;,D^>%,.2YPNI!S_B(U?;.W*9EO[;^PF[C]X\F[9Y]:
MG3$]?'D%F;)S_1:2RJ^5%:Z<JK$CJ0VQ:TIR,"5QMKRLN&K,2?@V<0:YWZ$G
M[5>/"JV)^K=?_5:X^3L_F<&#R[S"\7QF;W`M3TZA1.P:9I?7G4`^&P8[U&J^
MW2[OEW?57&I1OE_.ORY7=MA_/9;KINQMEBHN3"9SR%4&C0`HP^TMIM9$>12U
MQ!B^DX0,KG,Y!7TD)LEJC]N=-)XL]+9"U&<M".V4#NOX-1S1LSSFA/S#BIVT
M6!,'MJV1OB;U'DOM%5W0;SGM,@^>7\Z"P>ND'TFOK861J)[">A?+M#+^E^H9
M!+6G[.6N>._N86[MI[O^MORZ*OAV6^RVXOGW^7^7&^E0\K^6VUD&..,28ZPU
M(ADS#'*JM):(`R:`-#[QSI#CQCZP5E#?55B3`]BD1NLJ<"J\204X^>(@7PB%
MQ?="MY#EM1S@>:@,RGV4,*0'D1<BCC'<,9'@8A33ROA?<S@E/0#XY_Q[H<KO
M\^5Z)K0A*5+,P!QS1"AD`C8PC#%>>3.AQ[ZJHMZ\F-,.=?*EQAU05ONY9+"T
M1O=&2'GMY8BQ-?8<H_UT=I!OIJ^UP\SKKK<!:.P6=:GO@%9_5!UB_UGL?B^^
M?RTV,T0S2;.40`"IPIE2"N!F*(C23F]E#OG]D;5SCRJI8=TDKH[T2PVMJSP.
M8J]#&&0$XOQD[MJ<><0O1N"N7YRB'X?=XA'GC7XM[C"0HBG$%X::4(;[8GP4
M]]]/CZMB_7_U4/MQ&&)`*:P1-ERZ7PR-;G?3*>_T:%KO7QY9:_>0]M]\+\GH
M15D'C8W-EI_`7HLH#V&-35@_5?4FKIN@GC'V-34=PLL4I'00_C+0!^(9*E#+
M[6.YG:]^VY1/C[?KN]738KG^=K8+'+^[*Y_65MC+7;'EZ\7[<K[>UIGS<[OE
MMGH_0T;ETD``,I-S9`AD4NU!\AP@KZK$<9'%WBKO$>ZK=APJSP#"R([J%EZ8
MKH_\%HW&CJ0RY"9I37FE[^9-TICC4E6M055Z:F52<K"IVIF.')X(ZI$+P8OK
M>'XBH8TK&5].8?+%6U]<QNW:^O4YG>4:$9%K>VB0(I.::<I:,`;R6.N(!X+(
MZT6#Q/^YPDB$!U\/(G$=6_=;V-/5]0.S8?2[AZ=^/9WN8V1_/>Y-:0S=_;@I
M7-6F718^[!Z*31TZGP&C$16<ID1P)+&$@N0-+LK\,BRB@XFLQGM0B?[KL5AO
M8TIR3U\$5^?X;H@MU(W/W,:\LF%_DSA=W3[+>1@)'^;.7T_-!]K;7]A#$!U'
MXTO[Q]WS1SNK=A:=RT!_=#'"&8(XXY1*G@J.&:"I)K+!QG/5J<O5J(`B:WT+
MI*X,?MJLE]L':X4]Z:\OG>:OZ*$(ZC^&<^*O`+45]D_.CLJ?K2537@9>(3_4
M4C#4M[_B<C#8YB%+0AC"XX1<7B;,S!13%&"9*L1$SG".E>(M)"*]^E?'Q!%Y
M$:AO7F)&7GQYCQ!_B4AY_"C,27[@=.7\E.=0,9F>WOOUQ+N_J4/B,X/HC2'5
MOY7EXN=RM4IG)I,B,X@`F*,<&(00;9+&N28ZUHZ].X#(XMP`B2?/'EP'U^4X
M-,<6Y+=]<FT=;GD-(\#^;OKUE+>'C?TEMR^AG;6V5O(/]QZ89@S*U$`,L$B!
M@@8`BIND&PY3XA4$CS%^[*R5NK3MH5@MJ@<<+>JB3Q@D"O7=E/?:K$?/0[G&
M]K<'J1=4-Z:+)B*Z44TLQ_OBXR<7?IP_NXR4F9&<:93GU&"NA)2"2=2&S)50
MD3,)N\(8*VWPL<83/V>P,__1$@1C4#]6-F#R\2T_77L;?,)RV`P_7]=-1)W'
ML'1X[EX_<B-I]<;^__>'IY%F$"`I(2>895H#"!GC31:+2(GJ5'HS#I+XBNT0
M)<4^5:2Z=2JK_(.[I\VF>/FD5%0]]_91#$F/Z9X15+WRY?LN#IN`L)]P'4S;
M^_KPEY3WWL8.4OAA%'<6^:,AO`X(LI:NF>:YRJE=;[A.!08YH+0)@PN*E/"1
M^=A8(@O]9]=G^9RFOPR7C"P8`TF](!ECN6LBHC&:N>5U9H5O6\*[AV+QM"H^
MW',[\F*Y>MHM?Q2?"OO]5UCU7PY<L7!-=63Y_?%IMW](3L\WKL^MZU'\Z6&^
M*3Y7>U@!59HC3#F1*!4$*P2X0C!WV1"YU3NO[H5AH4DA(66(F`RG6&+,#=+(
MM2_+.)2"QWZ/J+'&O;UX;$]R,"AI+*K[5!W9Y/ZCQBK7/#RI[$J^5);YOE@T
MMLN[[3XG[&V_[>A5'!VG%6-0EUQ8@J[D^XFL2->R_K3_XS6=T/VR;Q@V\7S^
M%U2/]DDI&9((<2HR1C%1B-%&R8C0?I>",7&BE`-`,F;)Q)G"]N\RHX(*PU!&
ML8X="7E%U'J]2GI5?W:\:?Q%7.FW3/7U8IQ[QW@47[J?G(!C)[(&38**T_O.
M*6`*L3H=O5&8YSP73$"6$T`H89KD62-)@F9R^!)S-!@4G$/7L"K-.,YR)C+!
M>`X!R%-&K!9>9YVX&?3<ZG"&AXA^)'*#*'=G7D=4\$[/I0:C>M):VL>>3H+8
MFZC.JJ:_/Z[*YZ*H6MY\>'1RNW^[BE)C3_Y,$@`P`(QIP=L=%L.Y5]CX]5$R
MF4&9LBS+K&D`$2$I(JG*L3;*T.@W?S66;;(KDT?[(P_S;?&RWY3G4W0!:.VF
M8>,PZB=>#:9]2[8:E?^;=&%$ZU6"+JC5<%(G(E,!#"E#?V_C!@/>+]?%[:[X
MOIT!HCA"#$B@!,2"24CR9L*EB'IU60X&BABN&<;*:CC!2@M&#*(F-\!D#%&(
MKG3,]XY=.HN2RJ21@P,>_ATE$A#'M6&._7&\.L5@0>N%>)$!?T=/9$T8W^ZP
M9_Z^Q(^UXO#O+N-O9H"`B"&8"0P8`KD12K=79CGR2JH+@PAK0:BA(%49Q80R
M3DDN92XRH"!":>RUIH*R=5+S8F/M^KVZRX2Z-=WNH6C;TR4_'Y9W#\G/8N/^
MV;%TN9^Z>RE?%3TN=:^1L4<K8ULWY+CK45?OC[(817#\55:BFZ2VY-=:A&K,
M\58@3^_^9RP_OD:'77MZ4>[3^6N^OEO.5[?K[6Y3O0*_=?E"JW+[M"D^%W_M
MA&7R?V:9AH2;E%"448USJ"&7M;A@@C5//3M^=1H3$Y3F#*.<`HTS2CAR3<Y,
M3E*0NM+ZR(O'45/XWXNY@U8A]>_C%8;@;NI]#6[]]+E%F!Q!3`X8DR\.95+!
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MK.L3\8.?DK]P`3]V@?F["Y(*=D?Y'LTK'CW0KN^=?EW2Y''@T4V4S?%$N:^]
MM-RC_Z^AS=-ZL71F81R!\BDT8(ML83G:]^M;G?7T=5O\[Y/]F+7K*[&M^W#>
M[69`</M;42Y0QC-DF*D*;UP4`C$M1.>BF]=^O\BYP(A*J%*!,27"_EZ%,XFQ
MH09RKQI,/[4\0$IJ3,F7!M7H]2^OL'.IDF4HH1/9>`ZWX[2Z)`PQO6?.T52%
MDH.,(05X*G(&!)*JF3HH2[57B>*KHQ"`*-((<99Q;&WDTHY#@%%V]XOM-CCV
MA=KI+/*M$>Q/7S_EB</<8.FYWBGZ58(\U,>?U(G*3P]#WM"?OM3T**RNJQ'F
MVV+A[H^*];9^&V*SL=]>?54AG@\_\W'^[/X9_SG?+.I*.H/S'(H<$9DRN[4@
MB'!6SSA%!&.H7TWU4%2`H#05FJ?<GA<05$Q*A$%&F%14(!0]8^"HRK:"^>ZK
MPYD<&Y,<6Y-\?7[Q@WN+DLJDP974T7W<454GZ5Y/%1[9LY%+IP<ZXI+:C^[L
MJ:P.XQO^:JWTN-1W7GT^+W<.W>UZL?RQ7#S-5U75&\P50%+8[1L`6II,4;C/
M/%*"4<I\5I)71H!"0VQ@KC.,I<@%33'GA"&3`6AX'GE5J$`YX3C`ZE>6W)._
M;BH=GSH_Q>W#6A35/$O,!04<1N1$U&R@$67(;VNHRORYW#W\4:SJ:Z&'Y>/G
M4J]WR]WSOCZ-&(`!-X)+9A6.:,E8.W^R5'@U(?(=6V*J0:YR`'"*[9Y?&,6X
M!B0')E<P>H;KN3GVTR).CB&[$K,:=-_RV.`>Z:EH(SK#3^MZTSV.X%WFS4<*
M`WE@JB(9RKRWY#,HC=VNN3__+/]=;*J_/A4_BO6M96CMDE)=H[E]01W$A`DA
MI"(FSPW@%`/3S%L$8*=7U#L/IK3=Z@@E(8(<YQGD+$MSC5+$%&%`Q^[99O_C
M/&EQ53T??4MNP_':X7YZ;$H]-WL_R\1!J_^G`C@9<CVNF<<FN=^E<A"RN]TH
M=R#DM?OCD%Q.X;8XJ#UEI(_.-YS\5ISAM3##^[8DSM`49@H*H33@J4QIUL88
MI9V4W"N./!R.DD0I`^RYF3+,,L:@P()*R6'&M04:.X#<(;3X1F3Q?>_"YC&\
MV3%B/"U'>H:*1_)AG!#Q8.8OQ8;'<^M$3@AC6GP:#1Z;[/BKQO[-F]_L#^ZV
MM^N/Q699+OXL7/?D8L%_%)OYMZ+ZEVJ^*UP!5E5_-1,:H12*C"*10H.IL6M?
M(THT-U[O:(R-77.H4T1E9O>B&"/&<ZXR!B!)B;8K=^S0=0,PF=<(#Z7.CYOE
M77&3?'.0B\58*TVL+R#RLC0!YX^\AMWL'U':WB2UU<ERG=1VWR3M5[4WO?Z1
MQ!F?'.HF?Y65KY]S_Y^[:VMN&T?6?X5ONU/EK<+]\HCKJ53-C%/9S)Z'>5`I
M-CW1EB/F2/+LY/SZ`Y"B)-]D@@0I^E2F)K[%Z/X:^+H!=#?&<),C3[/W[E/'
MAB>7`Y[$C&G>^LM3-9K>&.IA][7:K/ZWO/UM':Q^TF(K[CVW;N\L/D9?\2FJ
M??VPV^Z6ZUBUL]?RB5Z?RGB"&;YMJG6=BOFPO/]<;KZAP.%(>`<(U=A0`A31
M[K"UP([S9"\^`YUB-JG0U$B+"<462(6(<-Y"'SP6$*,WTVKDVQ8W1\&*\'N^
M]7'G,X#SS2F2X.9GH$[.V9''_5\5^YXX1QB*AXC#X\:)-11710M&4:-1U'"$
MN.`(R#%&>!81'%`I3F`I/I^=F^.%!9>?#&^%"Y>7L/-TG5,8\9Y@>RF\>$_R
MYP@[GD=/7UZ)GOY5;J/TZUOWU_?R)GSXN8I?VJL>L]PZ:@@7EB*J*#2Q12AB
MUE*K=>M6*$(9(H^+J*6Y](((98`&U`.H"+-0,DNLY1#"I'?G^P<?Q9]!_,CS
MV>*.><Z1(:''NY\>ESM\:`"IG\5M(8D)-O'+AP`EPO+^0I!+3(KD*&36,W?6
M@<B\D>L4B\Q;A83<)Q<\U+=E+>$Z#!3C*E]M[LI5K+W^%`]AJLWIH4V4OVT[
MOET8X+D4U!/&.918R^@=VEVIQYVN'S*(82G33A!CN5`4(*V0@@!9)PDFTJ.Q
M6WX<A`]<W$H?FQCLQ2\V\?`W-C6H]@\;[&\6(EN7K1(IN3\C&ZU#RM5\[)7F
M?X^F.@I>'"4O/M7G],%4[1L4>^F+SU7A9FBJA`2N^9BL7VI7EE4VN(_((!1?
MRP>;QC1SR!2;2--J\GD_ML_]9[E>59M?ENME$W7$IM;::HJ]<0Y;IY$A;2&!
M00YU[[*511I!M!2<0*<MI(H@*0-2`"C!E4?&C_V$_!!NV-:Z%-\.RHQ-[^FF
M',DACVK%Z?QRHT;QRXP-.+*;'M60TWOK9ROR(E[[*:@YG7=O@[U7']Y?X:&N
M?"#4'3UZ^Q!7N?ES=5.^G![QVWI3WE1_K*/8IU\WU7:W72!A)+:((<D$Q=)H
MXDC+(2SL`+K[\^&R2&$,Y``+*0%UL36&9/$Y)^.$)&;T/LFGPM5/BQQ.26^"
M>$GL/H%=NCCG>9DDT34?'A!LI-^_1Z6?GV$_LMNC[]0ZS,UP*4YY7@;LZ9+'
M-V1';SP8S5=]\71VFH4GGE#=ZC++85HO_.0HODE/O+[[U/R+FB=B<R@+E#%2
M8&@I<LJ(EE84YYVZ&4XG+06*`1*?L^6>>L14^-P"3"%6#G$R=LW7OF7Y^H^B
M_"O*7FZ+_SQ-N_]>BSVM<\AAYTG\_L0FOE!D\/R"NE&TN+XK3E1]?W-DTA!C
MXKERX2!D\)R9*E9YVRSC13,9I\3_CW@G)R!Y(Z+LIAJ_9O'7AUB`OV_)=Y*8
MN;`"6T7#_LMRZ*$,_,A-RXM0(31)5>*KTGFA`='.!\J6%+/`W]`XQ3$FF@A@
MV11U\,^?7GWT^L$J[7V0"UHR(?=OMD:</(6OT>K0;_6TYN"]5`:^9I@Q:O\&
M3X(Y9<-=!H!<]7N93'&A>OK_VE3;[8)H`P3S3$JJ'0:><`8.2358I+U',()\
M0!L((8_5!I)2%387S$%!D-1<0T[4-/YI^_#EW^7-+M['52=E38]\UI.[N_?"
M7:]C/UGE<IJEWSM_Y8!@U`KD/N:8/+[^<[FZC_G"OMK4TB^H\888+*@SG",1
MR!:VQP_649GT]/1H0CI,?'Q61G"#J09<:@B0#YX":$DTD].PV;*5Z_1QL9JV
MDA]JN9@UIPVU1S7D#"+N1Q.BUO"]N*\W##5!!-Y[;KQW1Y8-AY'B\8&&&=^E
MU?_[5U,6V;A>N*"",B!<<+&`:X09HAJVQ*<]\9.XL9<$D]YZZ;A32&-JD1:8
M:0$Y-(I(X49_<6<OS?Z"K#XQZAQPS\!J([NKL0TVN8MJ^B.V1O_XQJWHO%S2
M"\88PPT-L?E[=SV#=,_E;H8;H%LF1V\!W5_?5\TCZ8UX"^PQLU1:QR"UP0T*
MS(\T9;N]@)%9)`F%5-YBPKR@0%H%B+!`4:81\1R-G5W99M"74:X0_H8I6MS&
M;.S@7_XX'P=?U%`=\BWF::,>GN2E^_!33Z)_/+HW?]QB]ZC,FU[DH@9-2(Z8
MIV'[94!,:N!N20[9X'TMDV%Z^\TA7>$"6E<7730I+M[<5]L81<0^3==WYO@(
M_()09C$(#(&LYE;$)V+;?C/AZZ)[4X$S0V!&"<(``<>I\TQ)[XGTFG+/@U)C
M/Q:]%ZQI-!S][NYK67/!<OWC;]M'=RPIW#T`T@[.=1HTTYQE"V33A>_ZKFC$
M:EKV301=@AN;!L)^;NG9G#R=A8,+\%[5_#6/,1RJ.7B`#%I46>=/XCG?=2"F
MS8=UF`JE6M_6G[DFD=NNMC=!FH=->7S8FP"%O3!$>VBHDY82M7]NB%MD0:<W
MLOJ-C.,IE&,D1):0<@0DY(8I`P3"E!@Q>II[%*]HI"W^OI?SI\33N<Q8=SM^
MNQS,:43_".'8\:SYPE[6XBAL\7L4MZCEG?J!D20PSYR/C6.4F1R`C:1<-<6\
M3HEO#\W+J[O_7F[JF^9]3?*"8F"@(-P)Q[PUF#G?)%5R(Y7DW4M]SXQA9?C]
M(6C'FCM*,1,$&P`D$)IHH.'8CVL<GSJ(H40K7-NU(24R&X)CAZAV(@C3V&X>
MZ"4$MA.AV"^R[8MFM\CV==5?"VTS@#6'V#:'&E7>.91V_K#<;@]#59M/L?SB
M(,.GZO[>5YMX&K*@!B%`E41(4HLHUV&MM`L%"(L3SB.Z#@FA@4!0`9B75$$N
M*`$FIJ<9:2""XY]/!$%/%DN8244M[-7)&S;%[U'B8B]RTMNE&;'O='!Q"=A3
M#S+>#>))YQV70+[O^4=."W0]%>F(S^NG)+D!GH-G&4&K:M19V6M?<'UP<S^O
MEE]6]ZO=*O8;A!)3*T#,!=7(QK-'V"X_X9%9--E`_]PM-[N4'<++HW$"A5#6
M<8,E)8Q*)"030-=ISRZM3]A3P3JOO';!W>\%^W%5Z/*/U;KN3_YE>9]0")<%
MX91=P_BP]MXY7)_$NB?"38EDGQW$^(@.V$7\V>XB_O-DSJYBCOFVO<K93]IB
M^[4L=W5RQ>`#]//XO+G5&(;J')Q"+E5>W'+D@*?CMN-KO'W]L'X^].G(1`MA
ME=.><!];2WC#W6%O'IQ2]RU'M^$@4U9YB:B1%!&AE>:<(*1,^$_XL3.2&B'C
M*YIW+RVR),K*A&^7;<7DT"9N*1I4/ZR+%YU"7Y^0">"47<3D0/?<0>0`O./&
MH0LDKVX:LN(Y!]^06:-JM,F7<:,08B]D=-B:Q%,P*H&&F!^"+R+E?J/@UK?#
MMPDD['VD4UQKX2BW80S.F-20("+#NDYJ_O]8K"&;!-=4)+^Y0[A@@-45N#DL
MHERJ)`18:?!TKTZZ^5K>/MR'00_CJ^VVW&U5F'7'X7\IE_$:\/9Z_:F\>=AL
MPF32R^UJ^SE64!TO!Y'C"%@8?)E2##!#"=GO<E3X`)BD\J2LDEG)&$%041O^
M!+<J-3(>>N*XM(8:,W;85JUC'4#,2_T8?N3K\O`<:OC.=G5;-CF$5T6K3K'<
M%<>^X*?7,NOBH&A1:YI:V32MQ;OE5LS7V&F!9*M'#,F/1KLJ&F7J;(P3=8[6
M?F[5XO=:J>)R*1I9;7(FA>,RMI])BL>%E']:Y'1!$W1V50?1.DCTV[KZ$GN$
M1<$^K+\_[&)ON/5-^%<USQYE#6[4:*(E(U0K;JT3$K7\A2%.RL,;14!K<"#6
M(*`&C(;060,;_A(2>P4X5V!DQ_58K$AK/Y=_!N/@'GOBRQJRFR.:O0W[GG%?
M=74\5\6I7D6M6/%D&ES<-XUAIC,NZJ*S8B:>ZK(85#-:I@//L(][@78K4.\$
M'FT$%AAQ3##CB`OH"$>".1#^$`8<=R'*7JS+/^+6X'/_P^U.<D#*"0<$:PHX
M)<@H0KTPD!GB&`"TVW&&;*CKF<B#3[WC!=+-<6OUO=U:-849A_./$8X0NX"7
M<*B8U19S."$97<<W#AY'`+3;@O]EM;TI[\/L+:N'[4EJ]3ZE>L&I1HARYYT*
M,;$*,4OX9+^P,0+=*_;>&HA@09DD%E'O*9)46,09(-09'7C.C-U,[)%X1567
M(*SV51]E6M5''EP[7%--"6E:'/<8S4<5'GOA)L4RX49J2DS[W45UF:F#<Q+>
M@.$U5Y$+O3FXA&RZ5"-,KS[%?K]6ZZI]M.7QJ)@;PT48VE(#$`[[4(KW"RAL
M2SU/KNY[?2AMF98&,:,XH)083>.U5BQ7L%Q1,W;CK>LAQ)X+S6Y;^PF!3"/W
M!L-3R1+J(\>KSGL5JC,;Y4P8SV3+FTN;EPKN<H'4_:8ON,6ZE<7U75T'_;6Z
M#_!MW?\\A!V2^K+=;98WNP76VDH%.444(^>4M1!Z8KBU"&H)WBHB2!O,6JV<
MYMPR;ZG03D'C$(S%5AH(@9/NRA/O:5KYZC:G)Q+^K6AD+'YOI9S\VJ4+=.>N
M4[)"/Y.5F%FII]<?(T"6OBZ;X6)KDVH=/MVJOU;;1?C5')&P#KFAVDCLO!+[
M]8BP0FD-^,^.Q!3U\8$NX2VCBF+%O:1,">"PD02/_=3+?MD=A0HK,(C5M7(G
M$YJ)[#8ZD&FLEH[AN`SV$CQ=F&L0K'-CK&'*O,94&2#JS%!/QK+5M^5JO;"(
M0&F)(LHZH1PWSJIV+2%%DFY.7QXA'CM0@3'S5%,7`B$FA`X+6&HGG>=CU^4_
M74W%[XU<J934$[YN5#0^<L,HJ`-HHW#0B[B<X9YA.,Z$<P8J4>6<6HD<HVYO
MZX?[EO<?EZO;#VNS_+[:+>]_*6//]@6QU@AJG,/`&6LM`Y;O%PM6$+$4KCD_
MDN,,`12V7U(2"HG3F'!MJ-'<:\FD&YESCL(54;I_K-;%7K[B]T;"5/89"&PW
M%IH.TS0V&@3G*+QT%JDS_)0'X9GP5"9EJC$F82)O?2IW@17+6[?<Q!K<[7XT
M11C#RC&,`C^RX-*59NVZ`@AV:EOTQA`":8Z`PM9(3JD"&FBO"&1:4,>83#H\
MZ<-4-S</WQ[NZ_1D6]ZM;E:[OA35%\-NW#0!?&FDU`I4M!)=BHM>1N8,"0V$
M<B;L,U2+*NO\2N2;SYLZR^E'?4ZU'PIPSC`GW'N#G.'&6]UN)7#82G1**3C[
M^P5ARE(H,0&QQYM2E'K&O:`:`&?'3D%M16K.:?N23"_@NC',V)BET4LR7*-P
MRPN8G"&6(0C.A%4&J5#EFU")?/)A?1,'*VW9_/UA_?P$_+3-"Y<<.@>QXI!+
M)9!G`K1+1@J>Q#7)8PNM&`7`*P^IE%10Y4W8=V+MJ-9@[,ZUK;C%WUN!?XH9
MB2_?'O7I/C6:3;K1V"7-D49Q8UAB%!9,A/0,0XYEG)FPYVCJ5=/,\3YO`FZO
MCV]%+Q0$).QNJ`GD#C2F2A/9KF$!@.K>R^KU,0R$&!O!?-1)&JL@-4*&$-5J
M9)B=IH/5LW955\6VEK3/`WUI$':\W!L5M\0TA5J6J^)$FDL\<W>*QKG[N][(
MS82%!BCPTJMQ`Z!(R!YX2E^!XNX?XI`?JTW]B,UNMUE]>=C5-9K5KP&):KT+
MJ-S7B4<A#BJWNP4/4C'),*$0A."!$@</:T<AUH=^\@B&,3)&<^LA<]0$R)!F
M.%YR:@DU-TEGQ_DX*SDI81HC=<U>F)UE$EGQA3COJC@H4>RU*$[5*'95\5B1
MHM5D\NR('/"?3:.8U+YSX>Z)M7Z6F'$!T-.\Q(?M]J&\M0^;PX.D>R\5TU$7
M&$I$C#)88@L`HYYHTI(+E8XO_BPW7ZKNJ69O#DBPL)X(XPR0%$FN-0M_`\>`
MM\:0I!.R4]FZ[R*#>'7KR2</./4-2#-@G$#@TX';@YR+1KJB$6__\N)5<0AG
MHXR7H-VSH+U%J7D0GQ-=9M+H)2K,"=90FFM*0NN!H?':<4YA&,98S&.#DG8%
M6F-]6CKM6Z-)$Q:X<-9BQ:D'0D,H'-=0*^T=(&+L`\M7""X/L:6@.HC71@(T
M'ZWM^VO,B-6.D*636@^XY\UI?13J1FF]H<H3N)EJ'0*?;8@MZWKW\/%N%8++
M?\;N%TW30,`MT/'I3:L,(9(IALU^81+I65(:RD!1C)/2(46T#3M7HZ22%%,"
MJ0Y^@".E+L2%Q</W\&'Y5[FY66T?=5(>(PS,8+$,(>*TQLH?/A[EC_8ZT:`X
MJC`/'NZ(=]_(,Y\AY\W@V;5-B5AS@YPEFGU;*`=BA9J"$D#J'7)<\O92F$"?
M]L#L,$FH9HH$0H/<<JJ%43'T!X038(B59/S6JR=LWY)[L6H89K6._8/6Y4U]
M8/B?U>YK\4LPT-<B=G!X["BJN[MR<_8"YA)6'!Y93VO`[%'W^W$&W=#N&;#G
ML^*\74%N91,"_=P0Y]D$N&_?[ZL?95G_T*'755A%VX4$@!`N->&&A0^\=/&E
M\X8\")8H6_1_1@8M(#+Q,,!Z0;FC<4?$@92*`J`P&SUGZ[6P_P7B+_=:['_B
MV$PN_,8Q-@-#+)=A%S"1T?*'_ZW@^P378S_U*/L\J/XMA/L&_!EL-F]ZSZ=F
M2HB?#=8LL?VKTBS"KH)ZP)$1DB$#'62^;<X2_(Q2N6+ZUR6`!#*C/&8@-B&%
M`0="%'*(<T*9=F.79.>B\XPQ_`!K#8_=IS%4]IC]'(//@\#/H]LS1A]NK7F3
M=RXE$V+R7)`FU*G_^V&[BQTXMI^K5RI./R__<G=W@8M\0*[V,#I(=1LKZ<OU
MMNF9*7R0SWG.B`=&<&$H;J_,B%9*IU6TYY&)*8'";L49AA1U0DMOK578P""L
M%G;LVO?:AO_X$L6*Y'Z0J[BK-L7M:A.$KS;-&RHMMZ?&XY-9KQNUS]%P:61_
MHD',L'M2;U\<Z^VOVI:&09]"E^OR;K4K(K,T8?W>[*=:35Z8G\469US#U-:>
MB;.87.UG;0$N`7N>PYWZF]??X_A;M[^CO%TPCATC$C`</)GF@GBN]^RCPB:%
M9CO7>7EX;ZA'#(2-D`]`<"6EHPQH`P`BQ(*Q&XN_QA>%BD?[?S1=';_\>,0K
M'Y<_ZB^K6-1S5>Q5"H'H7JEM9*I&\WG$GV?P[WMV,,R8,R&3,35,.3'(`6:6
MPX*7!:$T,`3V3'FC@.(*>-8FFBI(65+_Z?31(0KD*"VF%"@J=7S?'DMMC&44
M*<\FB2//;T";']D+?F"!,VM_*KL,/Q(8WR39CP.2K3'Y24`F(LY@H'GS<`X%
M$W;_.:#LS,*_EKMF"_-SM=TN$)(.::^`UF$E*V8-$X<8S("DS+K'OQE3!*40
MT&I&*'0B1)V><*HH-5;#T7?A09CB/LB1R(6)Z'3CN?&`2>.PB$G;D3^*\M.S
MTK*/(2A83UU)]@B>,VS4#\:9,$U/X:L<,VEP5;_`AFF@"8P/)'.EE(:T70>8
M<]CUX?G71^"(68BYQTX+&G:$$D/+O<,*$Q#VJ4GG_#V?FW_\MOS;-^4SK%/O
MBN),UL0`!=ZL4T^#8NHZ=6H]Q<&YTYA48PE"0KF#8[%6)"^H/&))Y8Q%'(9@
MX__8.]O>MI$DCW\5OMP%O`#[F7WO^O$N@#/)98([X.:%H,BTPQM'S$JR=[R?
M_IJ4*,D9269WLREF<<!@)M8XJJI_D[^N:K*K(8'*"@T4D10V+9HTX5XMWP>Y
M"_]_3W/4.$WE/A\YZC1[FOU$[TV4YKW>:KNN*Y9W^_,>%U6YUM5ZX7+8IU6Y
M/[RC24:1,!)J2*FF#$!BV^.A"S<].Y#TS$C]C'*$$<#*8JL8X806E#$$M0(%
MT@P7"1O''/G9/C![Y6EV</5ZQ]QX*7F!#&E&9"(`2!1</<9%G>)V/IS5K!@P
MB!&94X80X[80#';WL\T-\JF_/4T[D!@KN`0":&(0+&PAL41.`5QP@%#B`OVV
M?&@>KZ[J15DV*&XW1%VXVST+^:''84"NIAF"5&!MO,U:=R>)UC['WB<:E9\)
MK@'1A=`U5$0/O#I-7&[6/BK]5*U__]SD;#-0$(@MTP7$G#``.'`_:($ME0!)
M"?PP&F0B,2Y?>94U;KE;LW',MRMKJ()]`9A</%_0^>N6B&:GE+E(K2@I)T.G
MN"C^1*$!1`FGC7SY[+ZA/:3,0.0J0E90+H2%A82&F)U)J#3F4<CQL#,^=QK7
MPDXUC-(S$$")I(RF4"\5QR'102(?'`4(.U4FA83R%IB"Y8G(A=S?WQUOUC00
M%BBG&A)NM+0(8=F9-*CPVC8?8^=:=`H[XC!*T=`$*8V8`_'I.J<>7A#)*V'R
MEW:JA`H)Y<W4*52>WH3ZN*KOGA:;/UG>G07"&+`&NH2-("V-LH28O56`A5<*
M%6DJ,:=VWF6GJI&P<X!BI>U'JQ%5]0-6E*!)F'59J@O8&DCCB9!KJ&CJ)!=B
M?/TGR^7BZ[?YZO<VL^-4,JEH`2GDB#E42J8ZNUI)KV.$HHV-GVOM_1NL'/24
M-[@F3*=L=.+57]2QJL-78OF5B&$Z3X1EP\7S=K$8(U0$SSJKNSP0,E0HJ`R"
ME&*2%Q87>XY"1+P.J(XV=E6>#51`>@L<2K2$V@Y)M(G4DS_(Y<6T0*4GR[30
M>-YD6I10_=_(G#^6ZT_E<[E\*O^]KN_6OY2;75:H`%0%Q90(#AEFFD.-.XN6
M(K\-IN%F$G.L]2S;N7:3=971;;4L0XO+&$W[`6PD.?W0]8.2K5\W6;-KXDHU
MY7F5+KUC&B_M1%@U1"0_O@LZE#C].ZTL%O73<N.,+LKJN7E:N;,'J,TQ+4B!
M.0)"8]6<)K&S5T#LUSHEU$AB-G5^90?'0ID4KF,_(HTBH1^/PM1+TU;DC#H7
M.!0MZ$0H%!_'CYT\AA&F-X'>S_^W7JFG]:;^YN[@MKY4$A!I<@"T,R"EM4CL
MGTA:3KS>EPKX^L34:3W*]BZ%+4Z%J-:/-(D%\RS7=GY<9['ISU)<`$J$;A-!
M24P$]6`7D>^&\?FW\L/]*WN[B@X11JQ1A@ID>,%SF_,]KW)7U'EM'@^VDA@F
MC6--G\[74`E=((H0LQ]<QM$QE#'76?XYJ\D%V,3K.!'F#!#(CYO0!Y+F30(]
MN&)MUIGXL.S2)`0I,X+)7'.KE)!*Y&C/.=+O\+O`KTZ])-W=*,*W2@J5ZC)4
M1E`ID"0?_!>W0B6ZJQ=/S;:';?N\*TKURI%4DOT`X":L!JLDYRAOH7HZT!,D
MC53DROB,];X>Y+((`>7G?]2=E>;8#FN:,Y<EIX7"FN2=%6Y-K_9I@5\]%BAE
M%`4\I/(`91J5`D'IG!E+H@!0II$J$I3])/,#Y3[0MT#IK\B40!G@_2E0AHK@
M"4HW<AV0-6S:K6%L)-:,,N%LD/TK^L08?U1Z?/E8L%1Q)/"1RP>7B90*!6;C
MSGA"A4`SD6"QV.PIG"<X#\&^B<X`728%SQ#_3^(S6`@_@%IW372/+J`$AF.`
M1`X4@T`K33LSC.)>?2Q"OWLL?.HH*OB(Y4'/1#H%PK/Q9C25`M"92*U(<O94
MS0^<AU#?XF:`*%/"9HC[IZ@9+(,G-*OGCLVL4`9*(PC25A6<085@9P;EO%?S
MW=#O'@N:)@X''F+Y0#.-3J'0=-Z,IE((--.H%0O-?JIY0G,?ZIO0]!=E4M`,
M</\D-$-E"-^S<%LMRW>;\MMZ!B1@U$H`M#"Y!4A"K#N+))>]'@0-8"8U2D]L
M<6R<RUKOHG<H>,AYF;`C*^D)VU`1Q]F/L)?HPA/I`72=R"/I(2)Y:_=!J#C]
MDKE?GAKDU?=-4[1R52WFC[O7[ITYK:!P("3*`$4Y:XYNV)E#G*A>6ZAB;:1^
M):;UK'DIYN!;M^^@;Y_&:!E[I'LC*>A'HDF(YY$%CB1B6#88*&:_I/!\Y.>2
MPP&TFD*2.$08];"74`B<=;VNE@^_;E;E\F'S=3W#S%`.D!ME!CDJ"$:VVX"&
MK`&]7GJ.,C`:EK>.97O/0K#BK9X'D%,*%TKCJV@6P.&4VL5"N+^&?@3^(>:W
M\!LJT938&QS#*?#&"1)>JG\L5\T'\X<2S$P!D-8Y0R:G2$M<"-RU-$`4B%Y/
MV`<Q-'JY?I,=W(NMUKT4#:S74XD96['WTW&<@OU((Y^2/43:J1;M0;&\5;:'
M"^27&WZNOSM3]_7J6W,*S-?YZMN\Z60^$T;2W!20,<ZE0(1HT+V8B62!E7>.
M&&IHM%S1.9@=/,P.+H8D0,&R>B2/8R@:FD1.0\R`K'(,46.SRP!Q_=+,,R*\
ME6[&:C>EM#,ZEE/IYS`"]0/\KXNOY=W38_GAWLQ7R^TYN^WI@)_K9OFA7K8_
M[$X#:YO''\ZL0`7-F5(0:4`),S!W_VP/@2D*:&#_Y_$Q3FA5.#D4SY5&Q#K+
MN;$`F@(#:[`AJ2>&K7_9]D#%S/S1')16WF7-Y=)V0KGM?Z9N^O'H,6M,92C\
M9I3.Z^S#?;;SNT'?=E@<"+/C8=HYGWW>-HCH=6#/R`/E,2--9<#"9JOD`]=O
M1HL0\=QL-\:X3&$F'"7.>N0+/N0$:#E?EW?.@^_E<MW>!&*U<I=ZV=P4\N7P
M*Q_G+\U'XA_SU9V=5ZOV2'NQ7C]]VYYHWY1U=E66W4&:G^:;<H8QXLY7R2'-
ME5`&2("WQ$`*4^75^CN]MYI85NB\V:='",@15[FB"N12H;S@)O7+=.WK"O?-
MV_75SJO,5<R^:TD3&-1^"U(_UWAZ3NR-XW_[TGB>'4>7'867?7G)CG]O%V+6
MQGB3-5%F;9C949PWVY=:FE"S+M;LT\6K)-T!YBD'[\)RVW0NG(FLV4U(D%,'
MMD_#LRM.C>:/[^5B4][]5_WHON:QVKRTKAN#K<VA008A;``$%MH]1Y'TZ@PX
MAK_20"N+PH&_R`G,16$-(DYV@['4A*9^'>G@S35GQ-"QO,*<.,(P3F96[&+-
M#L'^]-/BZ?$;:V*,O'K^%:?&6$E23HZ##)??]/CE;=>_^+C^N5Q]`S,BH:9(
M*HFL!8605@G1D50IO[,)$KII#$&%I1`S#0@"H)"YL%I+!8EB2J?N!K[GW6/U
M7*ZSO[R4\]7ZKR$3XY5&T6,^G/X`3F\:;&*\QMR79*S>FO*N>X%,:::[LA*G
M)K@I#,YURSY=/5=WY?*NG9`+P`3.M9%4:.&<IJ90'1AS1+Q.;$WO+<F!!#EC
M2")-.*:"*<`+K@I,";<R];FO>YS=[9S*7JKR\6X*]9_?H%ZQ^DLVGM.;]+I0
M_V4JO^.Q&[ON"[INIC073D.0,6J^B*'J/S/N'U_*IW6U+-=KL?C[4[6N6D_D
MR]%/[</+&;5Y(3"Q!9`Y,4@8W'8EPI9);$3>JRME,N.)YZW]ZP'U?=9YG!V[
M?-.@[NB#[+?6;^\#G`8?E)X3U37'(_`5F^&&(LW\X2GII>D@U>A,A>[)XOL1
MUFF%[,W>$]9O]_O>44$LII@+4&`+$%/$%#N;0BGHM5X692@Q4T_=O#$=,N)$
M[<?)T?3T8V*$E$G8=TFF"YP;1-V),&V86.H$EU\@JUQZ^Z5:;C?\E(OZ85G]
ML[Q[Y[+4375?-;!T>6RYV;JV*N_$\N[6?=P\N*C*=9OCNA1YOO[J_H=QO_(\
M?W1_=3WC#&JD84YY3G->Y)#GK/,:&9R'T.Y*KJ9^P]MYE,U=,;QH_E`>'`OD
MY+4&U(^T/\%8!K+Z*+*;[!!;=AQ<MHTNZ\)KQ_\HP&P7X4VVOSI,GPLC*?73
M#%F/>>/*U\K$9IYKJW%F[KJV6]&9>F-U\]*]L_;.>53>?5@U_VV\[Y9TJH=E
M>3=#2ADB<BLM+7)#-18`=UX16GAMGD_LRCC[D]:;>O%[?&(_Z!@$I_[7DC^^
M.+C)MKX?7CG>>N_HE'7^WQR6YML0KE]#>.CM5V6D&,B)S0:IHWV[4DDG<DPM
MH^KENG)CT/[P>35?KN_+E9MWCB:==\O%4_/1S$+EYIB"XH(R8:6RDG>K00)B
MOQ7PQ*XDI[F;KI</S;.\Q;'7\:7(H.,17&I<:RB&*"5>^9X=.7_SJG+H_+]^
MD>`AME\1D&(4)X;UU-&^G<2G$SD%UC]LOI8K,!,2,4I9;A$SV%!K.`6=(P)`
MKW/4A[>>&M[.DVJ3?2N_U>OLWF5\Y1_?JU6SXWGQ=;Y<-@(OGQW:ZY7OQHP$
M`S$XPA.,06)JMQY/%]-;08<AL^?@_'PP]@TPG+]!4J9`KO.!(,4+"(22,&?&
M`)KK_9,)(+TVC0]J.#%H/]>;^>-8"7(/F0=GZ;`*)\7H=/DY$#K[C\7/1TV/
MV,*!Z2M@O[Y6@<O>\U/+WI^JAZ^;]4SI`DE.K;OT'-")0I;+G9O2$MK_>.@K
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MI'/\&TPN?[*=,JSK;_-J.:-`8&ZY1,V!ZY"[%-WQ=6<:%GZ/0X>P-UI6>Y.=
MN2.WC@9S+D9K3\Z-)'-HXAFN<%KJG9>M#_4&$'UJU!LBI'/4&TRN*.JM]^GE
M^[(Y3FA&L7;I)$<\UYP##I4AJ+/-,(C&GK?!ZW#O53WXV];5(<CGKW<X^I)*
M/0C[/%4>C7X_*N>)OV#A)\R_\)AZ`#!2,'\"OEM^?]JL;\OG\A'L3$(D`+50
M%XQ(S2@5RG:I)H=0>FT"C+&3F'?_^50W/=L^KJI%N<ZJ9286F^JYS-[/5[\W
MSQS^TCJ;@;]&4R]$8T_8)98WG'%;QVZRG9A79]N?A>J#M`AYIT:RF%#.`2Q:
MGBANP9U)QC02!6"<4])DB5(0UIG$A=]93S%V$G/KU^IA6=U7B[FKF-J7IK,/
M7];EZKE]#V7K;L<N."B[>NL<SJX4$@_%+C@E=L$@=OG*.V%V>8?2@UUA\HSZ
M-/IVWSXI!Z0Y!1/D1+L2F1;*0;5SL@!YV-LTHW@V8AV[>WWDQ[?QNI"R>GGI
M86<;5TR+MY%'?+Q'UVD&.YS4XXWS9)]O[X<D\3-N_Z&?VBPR;O`)GG6'#D'O
MF6KKV]Y57:T7CW7CF?BRWJSFB\V,<8@L+'(`K6%80E;DMC.L,;(^LT^\M<0S
MRM;!?_.$_P`B]@/ZN/KY07KKVZO6^0?_LM\Z#\<&[IN278#H<')/!(P#!E2G
MNC(]`;9KN-;\YZCIV@E'9H`;*$PA&3128U(@C?:YOK+]-J<-;S4QT%1<1\X!
MU>U'N.L(ZT>Z?4/+]@]';IZ!W\C$ZRWA!?(-/PP3(6""P.K45W!02O<?Y>.=
MK5>_.O.W]?+AMGHN[TXY03CGD-H"&$ISB%%N<J1-H17#1EL`_=.[H2R/DNIE
M7YVW;:N9M?,W*.\;3&F?'/`:(H?D@UGCZ-^<OG]K]+W)&F>SUMMIP-)+S3=3
MQ:%'92+03!3<R10RC83Q]?",(D,1M>[K,18(.62#?0&N"46S3=-3);(.?M.*
M%Q3W#O6^:;=]8;9[&8<J@M]6+K+X'52T`8O>J52Z(15N;TTGA:BH0/I6M)[2
M]$;/T>K@I3I:(%!P`Q36VIJ"&'ZT$,@I\WKV/9#)Q)G:D9>^*W-#:=J/4%>0
MTP]71PY.;J&NGW@76#:P^A,!V]!1U4DO69_^4T=[Q/][WIQ*N5E_K#=-?XOY
MX^/+K^5F\U@V;[J\6S:U]`P0`G.#N)$%E]!`S2#9/ZH7$,V>R]67NE=WJ8$M
M^]ROQT[VOFT[)[/O!R^S]=[-YHW&YN2=V%8S?K*<N!-3BCN%%C&I0JO37YN^
MJ^K[+NJO>M*I1U<:5/=5>2?6VZ;YI_(CC`AAB.9:Y,@2J2@58`\+CK#70GM*
M1U*OO1]:T7]WO_)UOBZS[\T[R'T;;Z99'HY0]-**\1@#-9$Y>9Q8?UQ7'D_@
MWI@X;U`R"K"FO.!(00H@MXSO#5H"?59+PJV,LEKR>$BA/*N3"/GZ%23C*.=7
M@VQ]FL:220CHXC6=",4&"*0>^G+SJ1]NW4RZ7)?-L[;ZT7U:;X$H'E;E=H/5
MME&(906PG!2Y`!*+W!4K'%F#<PP$H=+VVN/D8P_@G"D-"EE`2)C112Y5H9DN
M@&&Y@:F[=>R\S$3S?/K8S^S@J&=KID'5O@RN:PGMNXPR;8T]&KI>0>NP)JW#
M:-ZO$.XGRKD">&!)IU#X#AU2G>X*],Q@W1RU655?GMHVJVVWU-W.D)Q+BMWW
MNIM+4*P%9R)W-QF4!H,<0Z\F3V>-&$4,M!(*S`0I&.%:LKPP0"";6YS\G/MC
MOW;MBD-WD87KV"^3'45"OUD@3+TD>>PY=2ZDL=&"3B2+C8^C'OA*\\EAWVO'
M/7?CNCI^[L)=J;(YA')_ZQ2``@D$0"R7EB**^&Z>IS+'O9[TO6U%2@U)+G+C
MD@HB,9.$YL:X"'7A>(N*Q`QZG^FL\R[;NI=M_?-%T0""]DA.1]/2#T:3DM$C
M_QQ-SK"L,TK6?LGF)07.I9B#J#:%Q'*80.JA+R@?A']8E7_4N^\7!FI%@-!6
M&40E0!;EW9W!`%2]B7W\I80HZA(FJMV_"'?WEQ1:6<48185E*O53C-:5((AX
M*=,#O:E$\2/M2'IX,#25+F'([*M//SH>Q78.AB'A3X%]07[7D>,^Z`+K[7YW
MJE#6`$4H+02FKE0W@-'N<G;7.1IND?7(ILN\<RFL88:1YE4\JIFU0!*<:\AE
MZK-J^RU(W7IW%!A<^B%67-.HGF+5=0*"#[G\FD;XE$NPO09@H'78VPN=$%+I
M.X6I(T587FNRH;+UFWC$<ODT?WP_KUSJOFRR>%N6,TXQYMI2R3%Q=YG-\QQT
MMYW-=?_G>*>_W4+$N=`L1Y0H2*1PD5#*"%2X8#IUA\*M3]FW@U/9?=EW.UJ$
M9CWFAN1R^<T".Z6._,GL&$IY0#VY8F'X]E6N'Z-/!7N.QE'"3(&[<0'40UTC
M7F]9/VV>5N7[ZK%<;^IE^7'^TEPY,VV!P4(+8C6"N"#8$+-/8E@A>M/TS/=3
MSHV55%&@+($%EH(!(JF$3!AG(/F9)9T_V?>M0^T6WX_M*YC(!Q:A\O4`ZPC*
M^:%UZU!VT&[GTAAZ>>!U!-W"`.NO7\_W\D\&?`ZRD?),`;.Q(=3#72V>KQ/L
MOG[]N=X=>-B=YEJN?RDW'^[;YA#=48@.\I@(5T82R(BT'`NINYN",K]7#+P,
M:TYT4\#BYO!%*A07T.4XRM6U"F&4/-EMVZ9\GU?;O@OMB:GKJJTCFV-`_X^Z
MJ^MM(\>R?Z5>%M@%T@M^?SSRLQ$@,PG2C5GLSH.A6&5':%GEE>1L>W[]DE4J
MV4ELF:QB2=7S$*3'2>ZYA\5S+\E+WO;*T3JO3_HT])_6\(LSGR?N/<QJW_0]
M5JLGI.^J@#72WX[-A7JPYC!YHK)AD@&92;7#-+XU9_BB<W+6WIYZDH9H,SX-
MH1][RVZS7^T?KPAB2CF)I7,8"<JH(L?=..QXTO.$V4:U95HXKK!WE#)MA*<<
M"$948$`[-/6%Z,]UW"B([YG&:W_=$S9#I;,\X0FI[Z6XSI/,'F7U#&8GD!%H
MI1^/0EEU6"]&>4;V?"GJAZ74!8<@+=?.H.>U!'P*AN>0E4_B5S/QIYD3=MQN
MO[I;[.OE?]>+[<>;3XMX[=;]>;_J=K^O!%7.(8:M40!B&L*</I[9@S`WDT/-
M6X8\\<QJ1:4ED@HH!)=AUGN'C0?">#UQ>#G"JQX#OAA9UMUYP#)D[?LVB:R/
M8',T;S3!":'EG-SFA9,G6B.TZN--U8&KW&7(S`@:YR1U6*`816Y::'B#A-?"
M02GNYA`"BOG23/!QE=NJ^77;['97&%@)E-".(6"D-IZ(_DB(.P5%H>V9SICU
MFDA$,:864J^`MI)#JQ&C6`GIIWX,\ZW=@1;D?+8#6CC#M@#RZ)[_LC_3G_2E
M_A"BTAODA.7KOE['QQW?!ZG?W*Z^K/L^"8=$#UXIZ;RA6G&.)1*0.`9U>W7(
M&F>!S9J`20:]M]9)KRFU[?E;R"0%8-)!)V"\9#;Q).PP_M*"K)Y0]BU/WMZ5
MFY#JM+W0L[.<><`UEN!I6L(DD'9"ZXIR/A.]*^O3CWU9RA.6>!3_MN%7'GFY
MTD("%Y(0A8TDV$O#O>OFIT/"&9A^7#\<@[-:0AN(09X%J6#2,L&4Q1;$6S]@
MZGL(B9/W7?7LV263]L[2>8<JI31@'J,TB;K.?X!R:A'F,5`#ZQ6F&[#$PH;!
M[+U:_##]>,QA'7X.-YOS?N;G":2']<ZG>KMJEE>:4TV,\XP!)L+LAP3)3@D\
M!58E+3"*`E*2`,F`E1XXRHR3%G/A,2?4VC!WIGX/8K0@O.M+GJK.H?,H>N:@
M3AI_IQO/,P?CO\10GB523S>D%PK;Z4,[=1C_CMKR,7W8R/VU`_Q`G\M$^S&$
MIX7^:#B^2/ZP6'_\LE[==F;[!Y+[[<S(YM_K?6PBL[LRT&)E-;0<(Z4$A0BH
MN(]O&1:,VO12]P&VHU`!!83V2%/LF`3",R&D$\012<S4E99/B*LGR&'^]Z"K
MX\9_A-T6`;;`<]1^BB%)B-$7'HV\</R7'8B,"'OA`1D63"<8F+2@F<_6:_%Q
M0M[G$`JG=*\YS^<[.L#U%G\/G]3N:[->7C%$)*5$0>),K.NP$K7/ZB$6S%.6
M_C98HCV@(6$.2$6<HPIR`2P7@BOK@?1&3WYEX)5I>IR.U1'J:,4<0/;0<#4M
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MK6W-\UM]&W^B_ESMKB3#'"F!H%=*`Q`,$FV=E$P2X95/NC-8VN;$T>F(KGJ"
M5_TS(LL.*J5(3@P3%^`W3_@'43N-7J=Q=4J!"[,]%TTM[=:/*CD);>FZUYEX
MP;AMXDWA*XL0T@A3A[@5&AD"-`EV%0"4`)C7D7&TL8LH78<M6^M&$YLH<N?D
MM(2ZO4GG-/KV!DVGA*T4PW-1M&+^_"AE98G*U;#N8/DA&#X@:#9]_XWX,+9F
MBD(5C!,@@2,TBF=,&)60>3L0HZV=8<.[0U8]01O:G*<`MUDZ=B9:\_>WAS`Z
MI9*]3M3;4E:`Y'EI60F'7A:S8E3EJEGL@-G9KI<_F>:`:!;6P,X3H9QW3'$1
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M/_Q5;9:V_E:OF_MHV_T9IWK=]P7U7CN%$"`*0>8`4TP?3W5UVOMX)>U-K((]
MQ&JQ65;/0`Y=T1:A.$W&SLUNGIB]2NP!X*66M@FLG5"VDIS/1-^*NM1,]XEF
M;]ZMPT]O?ZTW82F]#@#4\FZUB6W!@]!^JP\8^O4U,H8H[`GQVE(`&4+F*+C0
MT[QBDJ*6IU[^=F#?50>X[73]'O#PS;VB(Y"ZS7<I\O/D,87W'NSE=@$SN#RY
M'SC%F,Q$/B=R[J<]PNDH3);4,L6#'XY=!S$BW'"O`-!*:V&1H+*'R9U,ZC=[
M*6Q_L<7YD):J%QOV-*6?\XAGQH)7QK92VVWX<]U>P)?'[[Z!_O$']7^+;?M*
MQ+._%AT;UL*U3-PH/#(G(LNEOH&9Q)Z+N=_,8RKF7,G]KT6<3/O=K_'7>OGW
MAQ@IFYL6Z^XJ/DX-,9!<`B(\A$189PGF*IBS6B25)268T;&GCH%,4\:HP$IP
M8#'FGG($..!31Y4>7'5`]Z[J\,7`T2',N10ZDM'3*G]F,O,$>U8\9MRI/1^?
MPZ[2CN$U[0;M209>"#0%:9O#?=E"GC3%OZD<)>]-V,7C3GT+ZZ';>GG3;-V?
M]?9ZM:L_;4,(NN*(`L*I!#1V`"":``;[:6.$3"J63[=F(4784:N48)0"IXD(
M?@O!M`D8\-1564^S)**L>IAM9\8>:-4BS=&E,CPGR/S9*<Y3^SFSFR'^9V=Y
M8`^8GM'["*A:[:INP1/6-?NO=;7HD%?7ZV87JX"[/]6$_S?\./SAN\7FL=IO
M%\OXPV4<KX?[V`\C_MWE8M^6^<3?WT:Y^L^QX22%T]>B2M'QF$-P*>M0,]6G
MF]OD8K':_F.Q?HAOYSW<W;=%>7&[[3H$NW\TZ_!QKU?[Q\_AT[J"F'C&/0C3
M50IOG`?(]K.5()!U02O#K)36:*<I1A!0H8B"F'*C@L_`AZQQZD5%1%JU4*MG
M6-]5/=KJ"6X5\>9VOBC(?]K&TH6HSPM*Y5B?IAU&,H<G=G<F&(B9;-Q,X=F/
M#3*F(J^(<OY>;^^N"-+"*@9=6-92SKAPE/?S-4[=4GK9&E-.8&"0=U9!RC"*
M3Y@;X)R$3F&CIF['^.9\C2`+2F,:P>,%L3BWA67P-*UGU[X(9Z#B93']%]"Y
M/'\RU&T`4:,T[?-J]X??UO7[3="%>K?O<I%8NRR1X#HLW"3"0@#13STE9%*O
MGVRCQD-D9?"/,T,%<@(!KE'(B6-B+.&E-"YBK2+8JD=;*A$<1OUPU9N<]3+J
METWXV73P)0(S]7#4&,Q8%\?YE:"/!8@KDOO9U;?5LMXL6_M4*\2Y)%Z:,&L]
M\E:S?K)BX$;KY(M&`>$6<@I#:."4.R^8]`8([8AT1*&+KYA[L*77RWG,CT\.
M)R.]<)*8R/?9L\7G_`W,&@<-P8Q5<IQ?&5GD".(2^U_UQIN;'\[0[NMM>WQV
MI0F%C""BD6>.0TAH[)_=35'&,JH2$FPQ0SS%0FM%,+5$*@*%T@03A`T-&G$^
M36QNJI\/@@/.[@@XJX51`8H3SJ_.S.Y@\9L7L3EMG\Y+\,".3N.)3NS4]"8;
MKQTY%>1Q#@=.)=UIIOG<!E2H_;;?KOXXG&EY[1610GMCF`-&N+"0;2>10-(@
MCG++TI[_VP)[Q("UG%-%B2):8,><%5`+`>WDG8`[*-WY[8!JJ2R6$C1\8H+R
M-/L`ICIPE%U;,(2C_#*RJ;@:53N6R%E6M=@S1]\H$1M"R1R4=`S\%XK!AM.0
MF3I_[`7ZPVKQI3W0>G4_V'O+B=/8"Z.%IR;(=?_]AZ1^0"J=;MLB9C%D#`AD
M*;-.H#!`!G)$'0..3;TM>USFAK][5_W[8[W8[OYC4+97D.Z<M/HR3`].LS\>
ML[_J"/CYQL.@,[_)!F)(&GZ9`2F8EH\;F,PT/9FM-]/V\KS/(?A,Z=Z+:?U4
M-.9=1$DKT+BR)N1L&(19:SGU"#'&43^!!:?I/>(R[4HBI/.8$.LE]3`L=9@0
ME"O&I-<*HHF#UK/RI7\;<IFB%+OI2X=+$#MH6;&K7MX0?ZEV[)+4#[C8<H$A
M&'G3I<10Y%U]2>/HC85.::;G$(>F<NVEVS*3T#<^_KQX1&RAHQ@+&H^%8UM4
MRK`_3%2GN:)%(M"+EHD1C`,#B+.*:BFU=4"'+-:'(,RQF/I,(F+ZY2:646SC
MS8%B<6@8RR,CT>0$EXU%XVJ&)AJ"0A%I\J&8)B:-K2H:$)<2RX6F97SNL6F<
M<ZG1J0"%>;VS^[?#/BT>VW9S#`G.(2?6`*"]<X0)XET\<I'$.IM^%O*:`2,1
M1=(KA(6D$&B)K73,(`ZQLY+1B:.-"7]L=;U85_MM[%A_'9]$&-*C.9NWA,!R
M#LKRXD>/J#J^,WC`=!;*!O2QGI*Z<8VK,RC,:U/]@\NO"?=8AN:@SZ-]>*GS
M]#A"$M5V6R]7^[_5=\U.7?_OPVJWBM^0^;K8;.KU^\VW\%4UVT?SL-V&WUUY
MK9TWQH8)(0VU6`*E#A.#6HM4N@9GF94<0N.=P0"%[`Q#J:F$!F((D<'(3_U&
M;`>VNHMHVUO?]9_WJVV\8/P_#_?K>O.OZKH#7JUZY%DJ5'8(4N3\8NQGBGQ'
M?`NT>H:T.D"MCEC?50>T%R0^)RA<;``&AHJ2`Y$81'(H>C6T3,+S+`+.-)XU
MDW^D`]^<_%ROPX)CV9_8K.I=;]A@AJ5#'&')M-*(*</Z>0DAR.HH^+8UY0T-
M_[36X1?*N9$6B1"%,13:`*NFOCKPW3M_\<G8;8>T^E)OZIM5\HJA(+VGX\UE
MF,T+,SVV7WHRGZ'+U[.R;RB^RM<+DE>>ZYE<!"CHT"LO%Y:B*EG7U/7U]J%>
M?MHV-_5N%V;S8NWK)ZL0A-P"6\J=]E(YQ5U<B':S+DS&K+:";YA2P(?_*<[#
M$I=B30336",4YKOWC$Z^R?X<5G53)S^=5XK(-/DZ(X=YVG4`5GU'8X1V*>$Z
MS=0)U2I$\4PDJY0WS23?8<X.P:>0;(1_6P5SN_TB.!^,WVX7=[U-1RW5P'$F
MD(*$2.0#BL,,$UHGM4Y(,@1#(D(QBN]@&BIY2#.Q$5I`+$A8?DU>1GF`5RV.
M^*K[#N#ND(E]"2$D:\MV-+4):_USLIHG73VA3]"J`[9!J_G19&:LW\])ZK`5
M^RARTU;H;Y#PVIJ\%'=S6(47\Z69X.,:EI%^;AX7Z^<),!8AS>7*$B>DHHH@
MB$0_;Y##6:_:O6:#$:BH]9@[#&CT`F*F+)-`8T\8G+H)SA'/L-PSG[*LI'-2
MMH9EFT=(%\XR?Z3F[?1R,)GSRBN'N_%R0CF2EK1,\F#KN'7X*7QE7Q>[)Z/<
M,&^Q%R#>KE>>*>IL2&29Y\J$V)U^2>=-2T()0;1`Q$--I0]^2>L\]E@"J#"?
M^O+C$5AUWR/+277&$YF0.)Z5PV$R]$3C$=R@U'$\GQFYXUEY'98\CN,W+7M\
MBX;7TL=B],TA?RSG3#/%%Y9U)_-A_["M_[9:U[M]LZD/_8FNG%-:4B>X""F0
M="%^\./Q08@OXNI;O?W2I-V\?-F"@DY0J;@AA,1WGF/]&6<66N$H<3+K=/0Y
MF.39TA<!W/7(JOL.VNAN%2][_-K,&,G/'.;#6!>:<I]+=E/YKBSR4*MS/#V#
MSF#%<7SWA#H6]Z%I__D#@$Q>-_D737!KC`FI&18*42>Y"AD:0X@!A9`#5$V>
MRAQJ@>NN!V%VP_=AO*6MH,Y`65[F<F3K@.A2ZZ>7B3FQ?!K)Y$Q63V.]^*F)
M>P%2<C=H7CBCU!1H'Z0,6:TL!S;,$M?/%AXFTM6^V2_665LT+U4"<(*$4``K
M1ZB57F-NG,`$<\NY(B!+:(Z`LI/2NN^*&S?=F_W7>EM==PBK]1/HR^Q'9!W3
MCV=Z)K.J@",O[TJ,IB:]6_CUUWKYL*Z?MR9\OPP&5S>K>JEVNWK?%4%MPW]M
MG@-KKTC4R]^C`/Q>_[G7@9D_KIQ6*(0O0D+ZJP0(V440!*N(Y]IB"//ZB9\9
MV\0)0^].?(ZA7YETS_54IMGL5N%C;5>KN=W&SSV":1G(G`<O+W5Y/F[/N@P_
M.5-UWE2].ZU`/W.H.GA4_;/UJ8I.5:U79V]L7G903FC\I89_)I'A8N[_V#[]
MHL.0'(4^-+M=O/RQVMS6F^M@_??NW@?S@%MG%#&,:PTU@LP[*.)SM-[AK#[I
MKY@(X=1"%=-(1"FW2`*N*292<@+(]*]]1%35=[`.(I';JWPH@VEB?@;R\C1Y
M"&^3*.K+S)P0QI%4SD3?QGK1%/V^QJK-AV,#;NLEI`YH*CB@7D%)*3C,%^:<
M&J<X3V:8$!!1HCCRC%)A!<6,*RJ,-@:'7RZ@.A%<U:(;+3T9=`Z4GVF8'"]!
M222>1X>.%.5H43ZO<]6C`9Z\I4E#R4D[1OK>W..G.GQUF_WBMFYN/M2W7;7K
MI\5J>>7CU6QJJ<"`6&\1`5Z'.:6,15@2D+2SGF?1L'CF:Z6@6E)/A/#($"`,
M!!!+HZ>N&7@"%E=@ZPBMK9>OFB_KU6U[;V7?Q*.GG)/O<G0G5!1<A.E1:O;X
MKOJ>]A9G6U]?1:27H3JCV.`BE`\K.BA&?=K9:BHSKYVV%F=V#N>OY9UJIOP8
M<S=Y]V'M_CXLZ.NE?8CW]P."5;-L7_3??8PG"5=.$HV=MU!+"1R7"(7@=LC4
M"!1)C\QDF%,`*2BT"JY""HT/SB%+./7>BK!FE5.?W09P;6EXF%[7S=U=LZEV
M$73[R,%/Y0SONM.6<^_5O<GBJ>VW<D,PDPROI$<_;I*5)BMY8GX*WTN]W=;+
M%D)GL`-RI4&8_`A(!B"CSMFPC#+=FVS`X1`;<R;D"3,(\N`0P,Q!0H&CRA()
MC?#$P/"[R>M!C\BZ^?>NVK7@JE6++G,A.H;-M(7HF8C,2]V>./RMX[##5;U_
M@\-)5.MUADZH50%:9Z)2)3QIBG]S!53IX\,^WLE9!G6\X@)KHSA5&%."F:$:
M'I[6!QYSD_084JHM2)T6`,%@`\2,2(>T1(1O3S%K(33V0OK4/$$L(%)9Y`Y7
MJJEX+2-7'U,H/9MF/4.3*5Q#6)ZQ>@UR)T'"AM.4K&.FS>Q_EDTJ`C?(""*4
M%=@IB37OIQC"`N3HUVLV%'+!*2,T-2KV29-20_O_U5U-<Z.X%OTK+-ZBNRH]
M)3XDT.R$)-[F5:>KIZMF,0L7L4E"E0,I8_>;F5\_$E_&3DPD0,!LNM*.@^X]
MDH[N/4A7080=)#5P%ACF+=I):L8%58-!5..I.?#3XZ<:N@MRNELFF+H!3@\A
MC85S)40TVHU\VE$VEGBZ9.?XV/5<5Z`"7>H19!/?;B8.P`2K'0Q1:BKD)`BH
MCWP@+VND-K$Y#CV"(^*%%$/S)T3>I:'AL=,X7`<2DBE`IV"EY6*F/IAT^&D(
MNFLEJ4&^?,14PP%2IJL?AR0N3H>_.JUND$@_&".!9P/LHS#`5![K;V:37HST
MWO.A3%A=-[0#AT("04`9LF%@!V[`',Q,YW6-29?4I$E'@W!38R'3D.F13XO6
M!?W,S#CO0-)#-&,`7`F_C'(AGVX\:;()2XOM/A>-)?>/W:J==:5!*LO[EQ:$
M<9'LZM.)Q7F+*1+9G\\Q@`"&!"'B@OIZ+)^$.&!(AWG&VN(YV&&4$2A,@M"/
M!,O:@'$.(XQ\%QH_,5"^DRIML[KF:_*4\1Y1X[0U=88>_YTMER\,+TK1UL9;
MI?4U,WYY*'NL\<#Z8[D-_R,Q[R'8N7IS)60\F[OY,I-&D^3O#T]QEOY=FB(/
M+^7[=%?^AV2[;V(F-9M@[A^C-(NS;1KO?Q.?)*5U9Y_$MW]+G[+T,=W&V9%L
MM_FIW"7Q33ROW`;<^N%&PER/LP@Q%V.7$XYJN8F$'N)*=[$M9CR-`NIX@CQ=
MYD%JAR&BCA-`[C+$>.29/F00GHHT2XKJX*@8)VE1'D'K>*JYH*RO]]56H']U
MQ^LM65U7[ZP+9\MAT'57CH;68>OLL=59]^3?=)RVSEY;C=M+KG-S]VS/PKC:
M0;:2E72]^.3_$K;0KM"RS5^2UC3R4)27+&V\R/<"S_$P!L#&D-)(A/6<1J&-
MF!<ZJF']T,>;X[[*HC.167\T1LU-2S>PZ6&/L6BN9)*/=N--P9$I8-&<,G+;
M;B1<J[;NGL2<O7^MS^@7XAO[TZZ<QH>2$X['0_IP.I;'9?.O`B5YEUF^%XT\
M-=52-C!"86!C1D``?.)AXMJ\M99+456]7,E")FJ%JOJU3NJI^TGZ]=F2X\HZ
MNV:=?;NS6N^LVCVKZY\\$7+I87MWZR(4,'4_?<@@BPV,51'0<BB\RU\+=XKZ
M>8%XGQ3?DY])=DJ^)H)E.<,NH!X0[!I0.P*N@YMF`@9"K<,!FL\VG!L+$ZQ#
M98UNW15=D-3"*9/XZ(51M1%WEC!C[K,/ER#TL-U0N%9"4X/-OS[",`H&==FO
MHJOLB=>UR-I`#%#(D$-<%(2,X(`QZ(&F02Y^IZ7/#6[%^*ZZXEBI:$TMME]U
ME;/A`"I*7+-@IZE%-399C5'+960W\>E3=$9CNA*VF<"1:XUD(F@TMM851UG,
MJ&2Z#4?<"7P&'!3Y/@H]3I#=TAPD6JRC]^09F$;*LG5H8GU*_FS2G?A%!HA_
MM\KM-CD<XS2SXJ;Z6)H=Q:-2F07%98&GS]K;[+0P5B,F<_#JD5&#[/>/@CY#
MV^8Z*/3NDQN"UDIH9J#Q;W;"#8=`F4Z^US?-DVS'1$O[_%7*2S69;3`@'HTB
MU[$)LT-&@1?Y+8<YQ-:AEW$M&::;QK@RMMF=S=,DCI%HJA')?$#JIDL=##N6
M-4'/S$S3"U,/\TP#[TJ8:")G<A,C4%>324KIY[]))B*NO6B:[%[2+)71UC']
MF32MNRZ-B.?X;H0`BD(:0DQ:18AX7$NJF:9)P]Q5FU=.N_C"0%U!9R*$%76>
M^<'5X[/:P#NK"_"ED0M1FQIT?:+1M-BOA.RF]NI:8C(!FE;>5XA&FSQS0REU
M(@81M056@<<Y9T';#L1(YUV:]L,-OP7[(?_$REO9I%&;!N1Q>IBIIW+&X-+/
MYBI%CG^(D;&$KHO%!SG=(-A6PB_#[7\GLQL!A+Y:?7[[MI&W'T>1SZE-/,(9
MP92CIBD:1$R'-H8\WS!SG*76O;!FJ#BM@Y>F+&T(JJ&"],5^@Z6DZ#,F*B+T
M``170B"C7+@E/`^&0YE&ON99?ME:35SG74ANZ'`8XA![H4=02.V@?=L&L:OU
M?GQ\:X;SK;(@FI76$Z<.33[KO@B;`%0UYID73ST>ZMK64E%MWN?EWI%]"%D/
M34T']TI(:T*'<E,C4[?.]'WV>WPXQ%*SVCZ+`9EL(&0A8RQTW-".PM##(HEK
M6@(D@ILL*2LM_]"H+:W?BM),P]5,>V.0>LY0&B,8S'J,TX/U,]Z?RG-]_Z^L
M+:S7_"AO2(GW^[^L(CD>]TFYI5#\P38NGG5+'P\`NY_93`,\O'YTGEFU159C
MT@QH:5:%-HO:B!+0`KUZ"(J$OS+MERF*/;]Q^!WZG@"=M91Q'N'!=<WFL6!H
M7Z)[L0S(?5RA[0(48)<A1#A"P`'4J]OCT+&URC(/;L1P0-E>#7L=4]Y96=_.
MPXF15`LG9P%1CWI;_*XCR"5V;M["IR=D'`WI2B+%\7[<N&5W)##J>IG,[.[?
M#4EEJ]2G#F"V'<*`N:Z#L(\;E8X3#VDI[B.;FD5_S_+LRSD]FX*<Q@*LJ+7-
MAZVF[%8J!V_%MR7YJA^L/CUN&I17PEU3>7.MTDT)TL#3>_(D;G7>)MF=C]N(
MYN\??\1_;@BU?6K;$#O0D:5G,;.;$X3<$2&=7CG&29O6F8F#RC.6:4=YR&[7
ML;1Y\5@>LTO;8W;_">Z`;UOIRZO(FLN-32(F/HA$NGS`=A\717G&N2HQ4%C/
MR7Y7WJ=1B'"Z_.$H)FY522"3]Z2]B`:?"RO)=K(6M!BDR<N#X`<7W%DRD5GT
MG%Y_S_4&,P8&P$I(PHQOO2?E)@507?%/CIW7"@CPP.4>P`ZWHRB((`J;G>R<
M103KQ#UZ3S8<YLBS;_VO"<W(RUT,^J3D05BM9*X,-/Y:(AX!@?)HY_%!\/%3
M\2TY-)6DTJW<VYCN3\=DUZK1%(4NENI'``$$#B$A@DWS$:%:ARVF:M.P--',
M$$M03WM1E+17]W779!BKI0!+P*N7"S06RKONJJIY=V5IJFVU?;JR<[E78(H`
M]K#7U%VP$EZ;W*W<[,B=O/"',.S*IM+.#?-#`#G&(/2`PZ!(91!OR5ED-V/R
MB"GM,)Y4G&?QKI[%69=%BVJN;\]5/<[IAO4IS:Q=OM_'A\Z7=8^O&>Q#58UX
M#9VG*R*K%EZ1A/V6J4O[5U=:Y0;.ROF;B;Y;"9'/X*AV#91IH#6B$]TR#4`W
M<GQ'9)L!`\P)B=,><^;"9*VM7W/88SA@5B/_&VJ3"?HWU*M#%H+E.W3TDM!U
MH;,HU"M!\9H7\MS"XZWOE0*__+WP=[T+R:!^FD@2'#L*5KFX&'9YA(`X#=SC
ME)9-P-P(4>B)E<PAC-'0`6TJXP?0T]$7A[5@6&>L)OG;A6`:OA\(Z@@A95(\
M)Y)-UJ"/Z*HARCBNA-5&.J&B=&A"HLP\OR?IT[/43T1*'S\E7T_R5=O]8]EP
MYX:I*S+<T``RBER,G""@!`40NVW@32B(=*);0R88#F@;J[_$E=D7*O#%77:_
M6@_7P:\FDYGJ)#6J6T'_Z'%A8[!56VQ5)LOX\NV5PN^HRS-3YC!\>SC5<(>M
MA'1->YG/.@O>T'9W$/Y/_"0^;#X2_\B+A,0G_P!02P,$%`````@`CH9I1RVS
MT#HE?```?/L%`!4`'`!G86QE+3(P,34P.3,P7W!R92YX;6Q55`D``YP505:<
M%4%6=7@+``$$)0X```0Y`0``Y%WK<]LXDO]^5?<_^+*?/<&+)#"U<UMX[KK*
MB5UQYF;KOK!H";9YD4@/23GQ_/4'4`\KL2U1%$G9SM;46I'0C>[&#XT&&H^_
M_^/;=')T9XLRS;/?WL%?P+LCFXWR<9I=__;N]XMC?B%/3M[]X[__\S_^_E_'
MQ_\6GTZ/5#Z:36U6'<G")I4='WU-JYNC/\:V_')T5>33HS_RXDMZEQP?+ZB.
MYI\F:?;E,BGMT;<R_;4<W=AI<IJ/DJJN^::J;G]]__[KUZ^_?+LL)K_DQ?5[
M!`!^OZ)ZMH3_U_&RV+'_ZABB8PQ_^5:.WQTY_;*R`?]%R5^_^2^^*_\5UZ4A
M8^Q]_>NJ:)D^5="QA>___>'THE;Q.,W**LE&]IVSP='1WXM\8C_9JR/_]_=/
M)]\QN$XF-DLNT_SV)BFFR2^C?/K>EWO/1Z-B9L?ZVZW-2EOR;'Q6W=A"SHK"
M-<1IZF@F:97:THGF)?SUIK!7O[WS_)Q!8``8!MX<?]N9475_:W][5Z;3VXDS
MT?LA=%"V2M))=ZK\P.\`&GU.+B<=MLWW[+K31\S*-+.EKUDD95J>79T7MG1U
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MU:+-2[@1;_?`LL<JA[>+:Z$\\ZW%JZI(+V>5'P,^Y^[[J2U&:3)9#A0=&Z=M
MO8-;J%N]#ZW-Q[S:'ANTX36X)A?I=99>N:'2C0+S4MGUQSSS#M1U,9G<IE4R
MJ>=*+AZ?%5WW[GVK']Q>S<+"5LPZU&6Q=.1,J)T4U?W:'&JKZ`UHNY/4)&GQ
M/\ED9C_8I'3M6X]XVT3<2-2S;+)NUFOW\7Q6C&Z2TIX7Z<CZH3L=+QIZ47[,
M*UU6Z=0/YRM>9]DG.YH5A>-13Q*;S94/($K/=G15Y]G(#=^UF&=7I_;.3O"C
M(;V587;DW;.FS3Q&`]+NY#RU[J?S(A]9ZU>@_>QUFE9UE=[K+G$U>HBL&GK]
MO1D?1,=&HWE;?AUJY#JWFR;PZ\(V\Y//$O0HTQX+@FUX=:A)GEU_ML54V<MJ
MJZ1/E.U'DJ;][GF2[N3Z:"L_^3RWQ87[Q6Z3Z9GBO<GC.V2>U1]+_6TTF8W=
M6%?DTT6Q9AC<AV=OFC4;0382=2=;G2PYR=R_[2*%TLA];B'K4[[:$@T[4C/J
MWJ5M*V</$J[-T.2LK%R%Q6+`<]ZZ*A8AEG0Q9EI]2LLO#0V])]O#Z=<([7LQ
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M[5SNBRHI.K;U<XP[E/VS"QILMU(_9MFEO'F53#J6]Q'+;N1M`8;JL8@-6OYV
M;2/TJ2NU*.MY]G0R8RZ&_5;9;&S'\T,A3A`WVW]*VUK3JZ2\K-6=E<?727+K
M3`7)>SNIRN4WWK638P`7IU[^MO@Z/D_NZW'(B54+FDQ*?EE613):I8<FWD:_
MO7/UQPVHXI"3R'`!%8<@0,10#ID1G`$DC>$:?Z]FO8:1%TMS]Z:G$[/>A+>0
M?-$H:]9?MLMZKCTM1Y/<I[07C?79-8IP\GW98)IN*XHA"H"D6(68JL!0S4W(
MF0:<,F$B+>4V:Z[#EQ>CH[QP,YG?WL%W1^Z7*^MJFWON#>>?:A17C_Q.4HP>
M=8+O"1<EWM_6VYJ/1S?I9+RD]L?`>L!4_H(:PZF_\B+O?W0C0SN7)T.U5^MC
M#%5:\,@X+/"`&220)!$,M0R88HA$N_J8Q\&O_R;V6R-\?7ZUPK7FS4*D)X3>
M5#R6#`6(&8XP90$$@F'%="A1!+%6+`Q^CC[<N,WRSDVZUA-W:/PZ2_/!3O.2
MC]QTIZP7Y_RZ068G)YE?<\F+^T5/>Q82NS")602A-%IB@&@@,&0B8%!"#"&2
M&!G=$BCH9P!*CX;>#)]N?*1V06=^;UT0/*EGK`^>^WF$-::-N9$!)D@(]W]!
M%$FF$'4=!D,J)%!\:TSV#+#PVP967_8=`D^+P."\R*]L6=99!6.;@&DS8<R!
M<?_C442,#K`@-!18((0P,R8,:-MXE/P<2.K4N*U&M7-G>;]%WM4^OW3`R7)=
M)-,MX]@6LAB&F`48,4"HLT'DO"J65%"(*5&(AZ(E+(*W#8L>3#N@;_F4WR>3
M9B/4,Q1Q2"`/E,&1QB#PZD`<<A4R(+`A(30M81.^;=AT:]56;F11]2JP6A[C
MV("%1G0QY9020=T<'[J8S#BAF=(&&\P`Y#@B+1$1O6U$]&';5KB8)_,_I$ZO
M*L^LTW&Z`0U/EXXYU#1@/)*$D(!A*@0U4:B@HCH@FK6=!M%=,7!GB\O\M:&@
M$YL.,8J<9*Z/.2$7%M@^B#Q-$$=*2LG]FAQ'@681=UXN1"@$'"$-`MX2+>QM
M>XQ.C3I@T+'3Q/A9FEA&!%'*`>::!(H9@2.I*28X4E'$"6B[)`=V1LVC_-AK
M0$U7AGU12^1/;<AXM2ODV$T3N)0*Z!`%2(:"4@F4XH('.@IQ>)@LW,/6G,<(
MJLW?),/6G$E,#>>,NRB8!S(P4HM02:8H<7Y,A!%0/\?*>V,LY`,9>HANO\ME
M<P/U\D4V,LVNES>J->CDSQ/%E`&B9*@UA:%KX8A+;'0@5200-08<J(^?%==)
MEOY5F_GA6B#?@;+Q>A.<79DT2S)_T\O#C4$/R5=7>NTTS6,K-/$40XL22T,E
M(H'@6)%`0B%"B1`--%:AFVD1]';\31>PS%]5:QW>:34^(/!*_1F0;G9*I6L1
MC)1QLU*FC-)20QT9AE!76?V'8>UB-ITFQ;W[L!$PFW+^K9C%,'"3*(4]_+#3
M5<B`1'--*5!&LT/XB=LBS8NTNJ_SQ8,[C<9MGP]L_"'FMI_\603^+2TW])M5
MF3C26FFB$"-`,P1%Q%BPD!]J)-KF6EXJ>(9HZ;P;6P^&E0]V>FF+;6B9EXJ]
MYEH'QE`7G8L0(0/52@>JVRZIOU2\[-&(3\&@E1&'`,*'-$NGL^E6*'Q7+N:"
M&4B$X!J'(#)1R+%9ZL&`.<A^TJ'`L&M3YMT9<A!`)-^:`6*]7*PTHMIU$!&%
M48`C1".]ZAP&1_00>\Y>"R#V,.00@#@O\EM;5/?GDV1^*>*?L_36SY;$_6<G
MQ):`HP%U#)5@%`AEI-$<HA!(-[`N=`;!]GVXKPP\!PA%NF^%@R+/RZSR:9)F
M;9#W0!TC%$+"!4%22T"A1#S02YTATP?94SV`V^H4#DVAUMKLK;80K*HULR*K
M;\YULICT6WV'[K.#6U/26$11I)GK=5)1)"6ED5IV1(@I.TA*X)#`:=.X>:\V
M;X6:7;WR:9K9D\I.GQH!]V,8:ZP`"$-).#,!-AAHQ1^T)6VWK^RUV?IM#(J#
M-DPK&'Z<><#G5XM-G:5*D^LL+^WXC[2Z$85-RDKZ/9[%L@#/LEDRF=SSZE_I
M]8V_$RR_4FGI"MKY%<?6/PSV#$;[J2W&D>8"A(H#+(5&6@9&+.SDS[L=9,'@
M!6"V!9#RE]98PX*Z<]S&1C",G(4#*87[X^9M8CG)B@QJ?93N!9V0>E70W+$]
M!MDG-IGD7[VP)B]4/KNLKF:3Y3%@UVUL>O=,.F<W!G%`)=9&0**%"Y68A!HN
MH^P("7V04?Y5([%7^[?R>\OUG<3%LBYVFE\8XE^HF;]2X`3UCGER?YJZ&'CL
M+[`^R<JJF,UO`"]7+X&4-SY(OO-)W^K9>+.7RF)`,-*$41>!*QEA!!F!2ROY
MYFF)TKV.:[VT6'1/Y_D2&FZ8_=J+<P4?[>9=V@_%8D1"$0F)`=58AEJ$A,K5
M\*"#MI/M%W0L[$!.<@\K#XH5_]#S25:_/5%N6FQ^FB`.%-$(&\*%/[$@,<%L
MU0L(X&W#O1=T/NS0^-G'WH,BR:196CHS_3//QXV0]!U!S%0D*.;20$(4IQRN
M!:JA"-IN^']!Y\H.C:1]['W0G,3OI74AYFEZM6E6T(`Z!D*$`$8\=.H:;G0H
M'T)2-SUJNS%GYW-K;S/8ZJ\EAD"??S.OWJ1:SV,N;'&7CNPF/_8T04PCP*G`
M`FL=A$`$V&FXU(PC\`9.NQT(5IW8>Y`%CFE>5(MMTF=7)ZXML^O47VY6/]&X
M:6%C(V',``\E4B:BA`+)0D"#:*4IIP,>B7MKT.K4\(??AKXTS)O8<Z["$'$>
MA1009H!"C(<^YVD$1`A0M74_7#]:/OT(:RW\?9.#+XWH8Q&:D(G(@5E'D8PB
M'!BCM+,(]0<XP$%VH?>3_>X"`'G_)AYB^'!1TMG5\M;W3</%]P5CRHD`4(?"
M.3^(#=#8\*6=N$1M`X^7NM6K1^3L9=@A(/+=X:OF3F<36:P`I1&$@CCT<QRX
MN:!&2RT-U6UO^GFIFR)ZA$^'9AYFVNV,/%\4_V1'BR<$1HOS;/\W*^MW:)4M
M1T5ZNWXR]\DY^&ZL8LR08J&`6A,-(D*5@F;5M4+8-J1]J=F/'D'7L^D'\6I/
M)EIV<&]-Z&,"#`($T0A+&4`FW821+O3&5*NV,=5>&8_7";D^['TXG'VRSASI
MJ++C37KM#+]F;..(AI)%6@9$:(6$!ASCI96X#MJB<J\\REM"92_-,`18U]Z$
M6AVJ7TM/;T5E(_I8!Q*$FF(L(Z)P"`WAJTZ*=-AV[K!7\N5UPJ\/>Q\T^=)\
M_&W*(I9`1('F4F,5N,%!,*3!0GMJW/3[C:5A>HWZ>C'Y$(#[7"1CN[SKZ_'V
ML:V.K1%]3(4(*(,,$Z`D88!+N>IHTEG[]6=C>D17'R8>=$M"<]_U'$GL'R#@
MF(8!Y,;]YZ*`M8B`LM9+L"\HZ=(C@CHRZQ"@\;LBOJ:3B</[CPF@YC!JSB2.
M-$`HJN^/9U1!;9!?$YI[9*)5VXV?\*6?<^L!9;U9?9#K0JSK(C-_8"2_SM+=
M%G2WTL8*1@9**$@8<4.UTQXL5WEHP$3K4[@OZ#Q&C\#JVKY#X&F9&I;Y]-)-
M0-:27AN`]#Q1K(D)$9'4$*<4!E@1L8P<71")6U]F]!,F!CJS<JO#$K).AEX[
MU9<[W]<2%-M]SLX\8BB4#NM%/QT)PCC0=)GJ8"$5K>]:_(E6]_LV>BL@G2?5
M_(C9>/Z)W]Y.%JD&F9?+,;<AHEHQBT,B>:"0,"0DF$M"*5V&CXPAWC99"7^B
M5?S!K#_(YLT;9SZ1E';L?*N_1GR^E>MV<3GI239RRJ5WUJ^3;!\-6W"+#3-!
MR`VG.`!1(`$+U7(6S"!N?^??3[B"W[_YAXGKYP]B.HF5"R,G>;TNM[CD?BL$
M&U#'@&G"`DHBKIV.!`L@X%)G+7';`Z[P)URU[][<PZQSC?*I_9Q\VV6=ZVF2
M6&`2`>+FPEQR"AG&C"PGQDP&J/6(^A,NRG=DXX$VDGEG.@\H_046\U=:_:?-
M^\B>HXH#9Z.`<:&!)@H`)ETPNA9_MKUP#NZUXOXZ<=2=F8>!TM0UT(USF&YH
MGG>!IA.!75G$B$IA&`,40\EEA-R\>37)B21H?<G(7HORKQ5DO=A\T*T1'VSB
MWQ5XR'LVAUQC'C$U$%!)%&0&1S"(&'Z8]'""VF82T4^X7M^7T8<`G4Z*S-FB
M/+=%/4]I#K4ME+'@@D%$PD!J($,6XH>=P0PI!=L"["?<P-^MJ8>`U4?[=<T.
M19ZYCR.[MF6H.<YV916[Z0Q$VAB?NS#87YG-7"?3D!$L921;`^\%W934(]9Z
M-O>0IPG7\Q+?2S'0V<&G!&EP>G`364P19P`9XA\WBD)#22B84IR82!(>;M_`
M,9BF#P\D->GES1C$3(&`*R"XHEA31I3$>J4]:)^#>7E=NQL0;,_8[6_E0W7I
M^4-4;Z=GHU`$&$(C`AH!R!1F1LZM+HBS^]:(O*=4Q.KT^NJ0]NC/65K6VP=*
M<;_VK^?>K6K+*@X-H)P$AD(!`NU?>(WXTB*:@]:++Z^LMS<&QK//:?9B[R%W
M?ZR)NN45B6<H8BE4X$(A!9%4VE`W[<=DJ1L1$7X[6.JOV9\93?8S]:%@Y#\6
M=OOC$%MIXPBX3LB8\(].2H(5TT8M]85&M<XUO#QH[=WB#1"TCVU;[?_XW]FM
MBSK^VOS2PW>%8BB18"%#8>0"+^^6`QXLI8K081ZU&J[%6[90WI$Y!]F`L7SG
M5?JCQV=7%Y6+B[>,/,_2Q`)A1FB``8P(]E$[\0\^U?H%"(J#/'GURL>>KHP]
M2"II3<2MP\WCPK'SIX:&RE"%)0AQ!)C$2XVH86\I=-F_57_,!^UKSH%RC=,\
MJV7<^IC>H[)Q%$D,I#(:1TA$*A"!]\"U/IQ'K*UW>8'PV*<Q'^<)]S+C@:+6
MTPVO"#4ABS$-_#9'QB%U/0A',M!TJ:64J.TQG1>X-G[(:5!;>Q_H0,7B0,A?
M=GPR]GL1K])D=>)H$>V->38^=5^G$Z>@+=UOL^GJ\H'-KPT,4W',(J2P0B!D
M(`2,`L1`M+0TUJ3U=9(O#]G=`&[[TO#A6N=`WM4+7-V?9*X);5F=.&7L^*SP
M?[WB=8K__]F[MN7&;6S[2[A?'G'-N"HG[4KWG%2=%Y0BT6Z=LB67)&>Z\_4#
M2*+:;EL2!9(@K9D\3%P3`B+67@3V#7O'%<[O%]7LLOWW@HD#-L91!;SV3`#'
M+%&PMJ4592(W#7:$QD*O/"Z"_D#[]:M[,U]6D\5Z+]<?7^+-8MNPJPE/\R8.
M'IGX10M&1+HKJ(W7LCXN%2+9SOD1:A*E]MO^T!\93[<%&&`WU-S-%93&G#$.
M/.:...:=9/"@O4.4F_31ZF[>=;(Q"_"1$;`C[D44*#92(*B,1H`[!QFP![RA
M'J3ZWG72[E*LLT(!F4KPY#TE^/?Y_=?CW=>Z_Z5@K,!:,H]2<5]/#?92[_'1
MGK+<`WE$O8MZX>(XQ%&R),R)S:]^)&A.K*"<$RPE9!K'3Z7VAFF1GWHQHO9%
MO6YLF3@6O6;PZ>XUF9M<*_AY3$"&8LDM-IAP)%/XSM6A.PUD=L7C5M?L/A!/
MN@)VJ!R\K>?T>E+P%&!6<P4@DTHC`C71->C6H/--V_I.P7M[)E6S!OZXK92:
M9.%V_$O!16-4<4R(4UH)`*TPM95J4T;;]?EDV]'J:`+?$.(HL:=$;7^6[J3/
M?C09J&9Z\I#:,7_^6KWH+U5T;SG$H5]4O;U=[M-?SN\Q388'S:!0C$(/#=.$
M$(R9M@Y%.]IZ[.1`>\V>5`U:'+UZ,#@6CT`M*8JKTA!$I8?+>C6,RUS_R]AO
M$W8KZ9_;>+6!N(0JN7M!DSR2BTUCSOST?`"88Z@-1MQPH(7V!L-Z79S)[)I^
M(Z=.KG3?)4D[3(ODN+Q;IUYMS&2U^CY?W&^UX%-Y+TW&!\.E`-P!Q:-$&*&(
MQ@-NOV[`[75S*9L$C5H.M(.Z4(FBDTT1FI/MPIE""@URRI607AJ&K''ZL,-[
M1W.K98W^JG.GM.L7]"+GX9N:XK]5FST\IX[%$\."PH(8)RV0Q"?E05%$=JM,
M;8[4%859NV53AZ"6J7VUKRP>W_($55X^%CQ@S!,JL:+"0NR`A[1>!:`PMX3'
M"&.>W5*C!8@EJ'"[JIXF\]F^6MNA7\%+"$XPI,'H(!G13D2U$AH#-8KG=:K.
MNZ<_`KE)H*.O-MHIB[H'NIS)]NG.SM=/R_7DX9?5\OGI9C%]>)[%@_7='K,-
M#K#L20-0&AJ.E4VU(K2'"IF($`=8:JH\R(T?C#!HV?'Q5@KRXGZ$IOZ#(.(J
M8$0+1Z",)QPBR^N/"[KSSOK.0I3+S>3AH^YB;2`M<Q@>Z0AU6D\Z-2P0J+Q1
MT725Q`J!,*)`'HY\I'*3=CZ&M=;:X=0AM%DY.C>+^`;3:KVNB]R^J'![+-OF
MU)@``>7(.6.QX-IX`Z4]O+-Q,-=G-/J&$.WHT#6N65SX'/\G57N/Y]UF-?_S
M>1MV.YUX=6)(8)I1AK2G0$@I':"F=M0[P#C.M;5'W^"A`R9T!VO71-A?-<_@
MPWYDH#HA$JU"R52Z$V9L*L:^>W\!9&X4>X1)GCTS(0_0+$+\HGYU!,#5R;W@
MU4.!F*084V@E8L9@K<@/FDK.<L^!T9HB[<3<!KNQ)3L*+R2BSGMK,7#*&?%#
M:X$ZVWT_^L8#W2B$F3"6((&MGE(P?KU;Z6_+W>V9DS;FL2&!*T4EC@860(1%
MC"0B!XI;"G.=9J-O*-`-23J"M9PWXJP;(DCJN&&."NFYB8>/-!(=U!IO<^LN
M7-X98`C_0T=Y"Q>"6$+\+[/H%K-MA8BORX<HFO7N'FF#/)>F4P3*4KG.:!H[
MP"V`SG,`Z]5CGZU9CMT3T6O65$_@%Z9>\Z2JXX."`%1RMRT:J3&.&C*WAQ5*
MX`8I'%2`7MTSX#C%VD%>,BGA=O(]1<&;IR.\'A`44(:8J-X1KZ*"9X16AY5Q
M"`<IQEJ63-FR/I*:T`K@0M19/;^Z?]Z(/>^/"=0*DP*BED-/4-0.@#IH>HZ9
M00I;?%@"=8)QEF?EQ96E/R:KU63;&"`UVXR'^,/WS]5F\U`E6M\L4O[6,=?+
M9;,$Z(RF"%.N&+;;2G",'4Q+I-25^N@[Y$[_J!?1D):+^R_5ZM%6?S9(K'OG
MZ2`=I)I"`@%*K<Z1]OI@<&CLKJA01`\;3WM`"ZO1'2>ZM)PY*IQ:6)'0AUYS
M8)`@WCH.XU\6.)6;LG!Q).&O:O7G\@/2KRC\PUA\%UEZP5JGC4`*:0.\!A8Y
M5R>R0FI0N9A%61]4O]S*`[>,/WLGDR^3;SO_V8NW_JW:-'1P-YPCKI\8([AA
M)-UFYW'MM(822N_ZO]4@=^1:5/?I6N@5.1#ZDD&60F^V^^5]_+7;Y]7TZV1=
MW:[FT^I5(9[X4I_N]M_%[7*5_J]CFGWF=($9XR0G1MO4]5PH"WEMND!+6*X[
M_0.I^-URK:`P2FO^C?:Y]P<$+JF03BHF"-7*&T^5JE?F!1TDQ^>#,:M3A`MK
M6<W4JV"]C5!@S9'U.+XU9+!.A(7(JW(I/X/I5;U[SB_$N,@=Y>7CXWRS[769
MKA_6>^?T-&].C`J$LHB40`BD<!90,`KEL$:K<AO%M,HIN@8>=8=Y"5YE!9%/
MH&8=9#J:(-1SIK4`4I#:+Y?Z2^=Z0\>>K]0[JSJ#O-`UP9VHMF]][D;[.T\'
MP*B1CE+-`-.*8*_$84T:ZMR`S-@C>EU(^>U=P);HECK>]CU/SE;;^.G1P!#C
M5&*7KAD!BES<8`]*G7(B]Z[QV(-W/7"E);1%XKZSV3879_)P.YG/4C#H:1[U
MT!=O?BH`?'9PT'%;EHPR9Y3FU`HKW,&I`:(2>*6F?@]DZASL+`^2K>[FT_E&
M3:?/C\\/R5=GGU?)&?_C-M#DX?-F<O_>EG/A#$$A$_4Z8#SDV%*NL3HX>*%3
MY]LDMS;@A_)*=DB??C$OL45]6563]?/J>Z/3[.W#`4&*!(.0&6ZIU((0<_#M
M&PQRMZ#F!OX5L*@S>(>QP2ZRO8)!1GJ-+<=*4BJM25E:M56)12YAQAYIZX$N
MK<$=0Q9XB^SOH)25BA.-L8[`(0[-X?H;I`3D!FTOOTERO<[%+H!_0;,!Z]_>
M;K']6FWFT\G#ZQ>\HF*XR&*AJ)<@&C_44Y%NC!L/I/>>L`:9ZB5<+%$2GU;;
MU<RVA]QMM?H<Q=G<ZW)L@D`X4-P`J3SPU'BOJ$O_*.FHM](,TKIP+-=`&C/C
MI$NF(^C+^_6V;[E6SYNO41I_GVS2<'I@0`YZK)T4`*3^ZEP@FTY9C"T@!)GK
M]>`4(UE+R(<BUZXAXH7$V@V*>CZ'%`(<#U!"@:/*$@F-\,3`^!?/)=7X/3F%
M294%]U"$^O2\66\FBY2.>2&K7HP,D+IH5$1#4D-`/1&:(R_B6RAF+8R:VQ")
M&M=(K7S,"\<L,O2O!J.#5HPI@%(%:TRC-:N5HT0@'`T#(W!V&;FQ%\/LE6?=
MXUZ8:Q>H72=&!:-AB@+RN&$3:C55DB@'N<'(.N!%;J6YL:=_E.)62[P'X=19
M;>O(B*"0HRD?75.C:#SMI=30"B\1DY2"['(38T_Z*,NE+*P'X5$S)>O4L*"=
M$L)PQ@'!U!JHH).:*.D5T4;2W/R/B_V0KV\C71VG\B$O'DC;O7#32-KNZ4"3
M*8*QA@*9:.4"82R#5$"!A472YBKJE]?!N:*-J3W.@WFO7^#RU@5_^8BA7=Z9
MN9L-Q@=KH\ZK.;?,6RKBU@"-B[87!D8#(3`Z]^'TO/9M\\`FB]P^&!33!C%!
M`8^*EV5&`.B<APY3J#!VN:G.(^SUV+%TWX1'6\!:)I*^?\'ZDWY\6BZVF=C?
MYJ?.CI/C`HO;I`7*"&]9W-VPXEY2ID3<\HPD.+>\WICI<Z&`C_&D`SA+T.:G
MU[3+Q\G\O4N$)Y\/FE!.!<;,4TT=,9H)H05'4COI/!^D"E'/-&DGWV7WJ!:V
M=_ZG>ORS6C4S<G;/!DY@U(VP)<F/R2-."#J$-"("10T,#I+9W@]+6LKSN.V2
MA>2`R<EG67)R7'"<(8"D05(2"HG3F$15G1K-O99,#E*<ZB,PIDM42[#G]VH3
MEUO-W&2UB`;Y^BQMWA\0!-(<`86MD9Q2!330T8:'3`OJ&)-G=?>/TY:O6[YT
M`F=QO\A9EKSS=`"",&4IE)@`2HQ0BE+/N!=4`^!L;F!IA#?-NZ5(>RR+6D&_
M1CK?Q#\;F3Z'AU/A8V@LPTP90YGWJ8269-X9K*2.7\/U'#A=VSNY&)9@Q<UB
MFMA;V6KW[YO%6P_![\N'![]<_6NR.A4&NG"FP(56C`+@E8=42BJH\B9^:E@[
MJG7VA881JKQMB/"F$VB?(!?9ABX(!KT-1Q@(,3:"^;0L::R"U`@9CV&KD6$V
MM\+3Q:1YJE;S9?(#KS:]4J<W>?^\5[5$>I@+,8<B>OLJ0&JS:^"3MNTORU3A
M9;G81+3CJ]S?+.*'7JTO*V"0\P,!8V2BP6`]9(Y&VR&JB@PGWX>64/-R98.O
MCJ-#B*<8L7>!_-V%QMN=Y';?9&K2>XZT)P<'@H7U1!AG@*1(<JU9_#=P#'AK
M#,G5ZR\V_4H4\2Q*QBYA'Y!HNP++>3S[,39(0S01SEJL./5`:`B%XQIJI;T#
M)#??9X3FX\`DR\9\\,W,+!=Q$UA'`7^ZV_V]F<>]^G,UC8^>J7;6;N)@G)0.
M*:)MNC>CI)(44P*ICI\HSR_(/L*>B*/8`KL6R-#;8P_,;39OZCVI"!`6<LNI
M%D:E0P403H`A5I)!*K)=)7%[D<?@6ZY[?'I8?J^J76Y[75/U8;+(WFN/SQBT
M@.EB/#$VU<V,4H@'$0=2JB@EA5FN3Z=5RN]5<K5C20R]NQY=2.:N>G2^``ED
M1GG,@#/QM(F`$**00YP3RK3+]6*W:HIYE0SM5`YEPO3__[S>5>C\LCP2)?XR
M^>;N[JKIQD>XM]^@GFQS0Q^?JL5Z<J3*>,>_$)@2*!XXSC"DJ!-:>FNMP@8*
M3[2PN0ZF5OG+'YO#PTAF<-U@^Q\_/6T;GKMOU6HZ7Y^\Z7/Y9,$;ZA$#\?1)
ME0JXBCH_94`;`!`A%N1>*(/@/Y>LO4MA:&V@(UH>GRM`%#]-:3&E0%&II?`(
M2VV,910IS[+3[488?!R#&M"%$$J0\K=J$^%:/E:_+M>GS*-7SP5,$91"0*L9
MH=")>`1XDLIG4&,US#Z.X0@S(TJ1J0W`XP]B<\0LQ-QCIP4%#$L,+?<.*TQ`
MU!NR4\(O#LCL(H1N,;L*TK0%^K\Q[!]!4JF<L8C#N"LCBHQ7%AJJ&4I););*
M[,LM%P=SKHRB0TAG^(N5ZT]WJ3VK?UC^:_WZW<I?CSR\R&6W(M\,"P0Y3[FQ
MA`B.I56&&6"=\1H2DK)'SWTBX[H,*3#6A%$/8$KX<5*1N*;]:C33N<';$2K$
MW0CU]!W(R]`L<?#HY_5\4:W7:AJWG?V=[].W'X^,""PN@3.,J1<6.PHYCYM.
MO38GKS%O\T*A+OL`<BB2I#]7577V]N/9L4%!#SDSD!CH&0$@:O-HOUZJL!RD
M:&@_Q&DM\08,:H/M:2X=Z9FPVR./7UM[^U`0BEFIH(B:MZ(..`$EJ=\*,Y%;
M-_J#2#Q30LN.X,P2\O\]/T4-[^_30G[U4)".4,XU1W$=QGOB0;2R]F\%..V_
MZ>Y'%W(;.#_"Q2$MB<`>>>@11T8::6%];M)HKIPME?UQ"-*1PM`:PT(7A_;^
MN10/VS4T?(Y&ZJ&'_;ICST8_/QB0X2E@1YA#W'ML!$H]TQVW0&`GANDIUS,[
M,VCU]AK2\+(H%!%(1N+M:OG7?%;-]/=_KJO9S6*_SL6]FF[F?^T:.)QW)UP^
M63!&6R\!9I`:BP3TCHE:0`9EEZO^,#70VU.U=]"+YZ;\7L5O9SI_J%Y%2;XL
MNR-J'S\7`)9.4)`*OT'DH,8:\1I5)^$@A7`*4+E/_IW*8AE&;"4^!EM%@4_G
M6R+$OQ^J+2,6,_68CIJ_SV5A-1D>H(02104>,`"\Q(IKH/>K5HJX02S7`F0=
MED'+W@55+#9\25K@D5PR+C%7@G@I;&HM93$X[`(*N&S%=.Q'_Z@HV(EHLAPQ
MYNMD<5_=+/QDOMK=][I[4>OJC\EJ-8D([?)M;A91`U]4T_1N?\PW7_]W$L7T
MO`\P[DN]+N[?L]K[^JE@`%`.$^`]Q$93K@E0-4*>9_?":)[A\+I;Y9?_0`Z/
M1+;=L3\9F?<1TSJ//(6:(WBK8_MKYDR!PGB"<$D``DH;MNU94Z\/6M1_&:3_
M<K>,Z(:IKW/`:9]7WL`>:SY)@!9+0)!2DEO#4CHE/WR<6"MXI5I#02NK-V$,
M0\?;5?4TF<_L7KCN6U)SJJAF;R^8J_6ZVISR]^=-&+`%47<B3`IFJ)62852'
MLA1BJO]TDT'WV#XH=):E/<AE&,:JZ73YO$B-9K^?R7$Z.S8HH2$W0'BJ.7!0
M,>7J@)UB-KO?T=BWRT$(V`[[P;BVBJKQBT;-E]+MI^&!:&KC68.%\,8IC1`E
M[H"G1=?:@'(HQK6#?UPAIO?B;)V$F]Z;.!B(4.IB[J5Q$#C,%*\_3RVY]L6(
M^J+I^X=7'HO*I'P:@)VOI[OWKF8_7CLN^M/=E\FWQL']T],$'[<!H[3EE&'.
MA"'$UE:>IA#F'MI=&.@?GJ`]"J(('1^CCKO:97?_NES<_SK_JYKM=-LO2UW%
M]3PM(W:?[DYQL>D<02"OI..(,,\-HT!PZNOU,Y-=$OGBFE(E"NN5Y&!/`AA(
MA=R^^#^JAYE?KCY/+C58?AX=D!`.<JX8<U92#C'1IEXS4BRWD'_S>E#7O?MU
MC'\)SC5$Y_W-_`0;6\T;&$">0DTI8000"X@0M2M!<P=R/9&7UX*Z)OVQI$C&
M9?QT8N@$I[6T`'LD'*)20BB@.V@LFN5:WY>7?WI!RNMRC_<FC`'I>+/XJUIW
ME>YY8K)`C"90>\6T9AX3:#6ILUFT,R[7+3YVYU#_Z9[=@3Z,$OE[?/O5?!KU
MK;2ZBS3(UT,#(-HC&S\P)2!6!EN@#C:;H]E=V7,C+T,<S)V0X:SFV`KW$BR[
MG7RO*Y[M;C'5]YNJ]2^KTP5PS@T-1`#,G0`>2TO_S=Z5-3=N).E_M%OW\5BG
MP[$S[H[NWMB8?4'0$J3F#D5J*,IK[:_?!"E`AWFA`!1!2@]VR#10J,K\JBKO
MQ(YA8AK%3(?D;F/'^U5&HJ0,`;6>B7\2J`&=0"!8/56U(%=F?ET%&=U7C[0!
MW<Y!8+,Q[:4-7F!BG=11X#J-WS)*<X>?G5S0RP+#OM@Q+D&O'Z?+D0,7WNA*
MRN;!8JJ%"=Z3YI;PH*P-;MH^M=(\!%*S\N14!I\MJ^G%X'/TN(6JHJ"-LHHR
M2D#:P0'DFOK:02(USW>$'18R8C<G2\9U\/9RR!8L.!245*K:O,H@%"A[V;PJ
MU473OGO"*`P^ISU=6S+CA'!LHMW[,/CL&:RP!AFJ>6738!Q9)+EH)".NV?"N
M[$LU^/1']"SZT7)Q59;7:Y][E8P!4W^;J;%/+3KT;A$%18H++1%U`=9G"&_L
MK-B+"RJ\-"08WJL_/9,]-\S:%MD^^&Z!O(&-:K$6G&,1E;.J]AA8$V5JS="Q
MQ]*>"'-]\"`I-PO6^WH>];>W)I;MRLIJ,T;A%!,J,.TH#4I'KT)HS%D$YG:A
M3I$,N!J:%R>[.M>1&E]N-JF+;>_.-R\7T5'%O3/2RZ`,#LA&^KQB9QQ.K00P
MPJZ6I[X\N]`]!]*^E??/)L]-6-J/<GGGR]_W:02[7BF"%-HBJAT.&F%"O>%U
M)4CG$4Z-0SC>5C(2_\@0X.J)Z.-2/WM1.PN,=(Q$"6>(9](2(6*=A^N4UJG.
MWS.UA@P!OL&8D<NN;.9K?W5U"O]157M?/6P:N;QW<!\P(Q\[3,&5$T80)@C7
MGA,NHFZHH*E*54[;6XWS0K)'"\B`Y#X=Z`QLH^7R"7;,.O6_-=K>O5]H8T`;
MK]1N3R@BVA%2*^-.>IJJG+8^^3;]+(#[R]4%@:T;M2\'9501:0RFH!YARD)4
M5/EZW22(U";CK6.>WW=-N42,M:-UELI?C_?WLS4-)K.ZM<2O\YO%\F[#T",:
MCAPW0N$Y5YQ[)91T@A(XPWFC'%G8;-G"F,_6;3`,I;,;/)XKYWXKK\HJ2>I8
M4\>[UPHA82DJ`OT4#5IQJW!==+Q2EI*[=(X=3WV#8)^9HQO-\X0=;Z98M;W=
M&V+\\E@11,0V(!H0T"A614*L:I08E1RQ/G:C_]#(Z4#C7-)4M>2JCC?\^>+K
MGU]OT72KX)39XN%Q61YQ!78=NF`$2\IQB#H@I0BGPMN&Y):E(K)3=^SSNALS
MLR#)"_6J*-S^*H:OO!A5-3M@YK5Y<(N'U1[W0,]?*)!3DE'$@U>&8F:5HZXQ
M/+KDE-T1.N#S06<Q!E8E01>^/)L\/$QOIE=KCC:3KNO4//WG_6)>^^%VP;/=
M*`7VQD;B)#6@D4>+&.&-MA2"2`TL[B,A(\/A>!I8#LJB5]`[85?/Q1U\Y"<\
M`R+MZZ;96;M[;FJ6-/,ZKJ#FMC<*%B53C#"M$<*:.Q?K^CK",TL.6@F'7-_Y
MM]KA$017$$$,4D@:IN&`#0UU0[*IO_TU.'AR0V=\Y>FWTXXA64QH<!0]?"O_
M*.>/5<WA?::RMT\6+'BX91U#0%+E<$2TSM(07GET06WH^@97-TKF0$53/."Y
M:.DQP=@[WP$1CWM!#!7*KE-[/&>H7E^`_W>A\61]PZ8O`F>Q5ZQ%_&>,[S,^
MO'ZN""(0)3TB(DHI+`M&X&8C<'-!G8Y[X.5[&T('2N8)YGHHX3N5G\G#)&>+
M=:;J\_+W1G3M>:_0R#`7(R78>&R]0ZP.Z0!JD=-47S\7Q/1)V2RB2KD6IGXI
MYT")6=67Z/IN.I]65`!%LCP,I>,&*"AUT3`B:11(1.LLUZ8YGPU+[0/4Z;HZ
M%TP-0N(<X'K=X^K+#0CLD_GM%$3Y@_7X][]8J(B-<41*C[VGP@NJ:+U2R9/-
M0".,9NX?3+V2-I?4\U`58GBFP`'!Y_6CA7..1,^%PT![Q4((7C5;@NO4>*E.
M87GG`I2.Q,RJ4;U8%H[1I5Z>+C2))D89'#;,!*"/"Z)>DU,Q]23I%$I\+@#I
M3L\LP>F+^>+M1.N>(4>D0A]ZMV#4DL"MMII99H1U6#56!JYIJKUF[)G/?6OA
M?1,ZR:-5`?C+_-FY$?Z\6C?NVN6XVOIPP;FWWGM+J,716J9!(JMGB4P<ON%J
M]H28_ABWZ)FZ.6.-WBQ]O\5WURN%Q54#3DV]$"8(@0ARSV4E1.`$#U]L+E^*
M7N^@Z9FX6627JE_53DKL$V/VOE@0$I'D/G(#2B!7TDA4FQ@")2;5/35VN_!P
MF.J5WMF0]67K;/<?3?M?+)QT!'F,+5>>4B*TU+7\'PP3J<K4&*NZ#0NFODB<
MYX;+WQG'."P=QEP33B)35GM<2Y&!P$6?2VO/T9!D6!][KX3.E$I\E"[_YKE"
MH*!H8$B3@&-4D0M;:[#!1Y,:^#_VA.#>M;`.1,T!CC!9SJO>W5_+9=W2?GI5
M.5JFLT?0=HY0Z(\<H7#"4EWI&HHCCH@Q5O!Z[=$D-WYOW_7CO-7Z8<B=_]K;
M%JH$:WJWG/42.\6C[1BS\-(B'H#ZEB$"\H74(C1;$02%7"[\'!=B[YAI'836
M#Q?&)IQUQ6O2Z`7BM$K;`&E">>2)-:2Q+0>@Y07%L^7%;0YNG.Q*;WN!%Z`L
M1>$X@UU(C/?.$M305"I^DGY(9WQ#MZ1G#IS\5SF]_5EM([B")K?E;X]WOX,>
M?;.>\Y?'U<-J,J_"AM^A?@^0T@8L7%7-2U`MB%+."`6Z?G,'&(=25=-.:7GG
M@;0L!,^13K+]Z/U+A\6ZS(.Y6[>+_W*S>0*6]JJ1MR]7D^GL-/DF.]91D;[J
M3#J9_;)</-X?$Z3<<J3">5`G8]024XFB%W`-1A^"8P9I10_7[\J2?V,GLZJ>
MW_>?9;E:AUQ=3ZME368O>54/]NGM"IOTA>T4^5&E,1P4N`:?01$=AGV+@`$,
M.PW[60I6TU](-KR7,MLA-A@RMPIG8^-<CHLY3N?35;GN;?P^ELP^_7WR/XNE
MJ[('S9_3?>:\%J,4!!EM'.<\!":(CIH:5=/`(I=Z!8\0O:-#U2(7UTZ,W)>Y
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M*NU,9G6_Y._E;47#_8+%@=>*P**$NU112T#L`1G<!5_/W'J2ZJ<;(?0&Y^UB
M,+)?AN#QM[JRWTFECV86!=8Q6*XQ8U5S!*Y#D+7P9PR5)RFD<:ZG[MA%D%2N
M9Y=#]J_#7%VMG4J_+5;EVJ.TF,P?-B5Y*P;LC_+N]3L%BUZZ2!$B41H6!=6N
M.<$D8A=4%'*4Z-PGN&3F[<CV2%4=<0Y8>\+][(67\0H9F+`R*(*=)2[HH'1#
METC-!65J71CFDWDX,FQ_79;WD^DUL&"=3W*PG$;7H0L4`U/6*"RL88X[:H6L
MJ:5TLL_M0\I(61'?!SM'!_XJ-VOU]!4X4_&D*GF\+K+4UP;8,7S!*">FBD+"
MUG"-%`ZBT0"-]*E1V".L.G-QFZ`?EHYL([2HI]1AU,)KKQ!WV#-MI>:2>V\:
M&@F7K[7=)^RS<G)D:/]EL;C^W^ELUI,XWPQ71`(28&0"4<DDBHPQ5<<=F"!"
MZK'>/GGP$]]Y6)C%C'H'8M>RHO*F>^_:J;W9AC\6MMRL$M9RL\\(>NP8110.
M",TP\M&:J!A95W!Z5M1!LAL\73%WV9ES0/)0[,M2N'$]S2\W+7;C'B`GC%9H
MZG"D''$+9*$1(<4;JE,L4C7.3KT!/RZ6A^?@R*2-VCKZ=?)T(&@_?=`B.J,#
MDU)%;KQUSFK'&C7<VU3/T_B3B4:)\6R,'!_4E_#?K[*2>D/[NW$+BIASU`BN
M20B(4JU-;71=%\Y)=1:A3\0/C_ANS,P!^E>S:W55N<?E<K_]L./(13#22P6'
M@@G8<B214K7F;17SR>$UGV[2).#G9>>8DE(7=_>+>;GN0_ZZL])?XY0^9F:J
M4%;(B(4%4=42:]=M;RO&`M`HXP?WZ;G&9(TE,]5P$*0TIHP(RIBR*BI;TQ];
M<T$1L(,A\T29J>TX=QF1C.-(H9!$@M)!D)%,VJJ2G[+FF?+16')!>V9T6#Y-
M"D4[AG^L%`J),"86<RH4]0Y;YFFH:4.XS=><\P(V0SNP]91"T8Z!8TJA<$I[
MQF#JH`&`+NPLDJ*>>;0JM6O:"*$W.&_;I%"T(_ME"!Y_&UD*101:6T&1B<@(
M$R(U5C4\0.Z"JOQ]BB"I7!^9U?MP%]7V@Q7."2PD!UPQ7\63(6I831$K[065
M;!@ESM+-VVD,'!FDUPW;OMQ483$/WQ<OW.N&[?>C%M2Z$*,.U+.(>*!2"E33
MR/'D,-CC#_M+#C;)@/6.#!T9Z'T)J`'I<(TFX,:K[I;]X'_/!PIF/5&"(TLP
MU8Y3HRFM*8?AM\'3(CZW0J>MT!]ODQ315A?4IJWTY$U;Z5VJ:N>!"R=!DQ*D
M:F?D0/^'!=MF]<"+5$_]\;D.G\A^IP?GYNG(SOGT!N7]?:2@QBN"E?%<&L25
MYN&5>(C8\(V)/G=%MXCQ7OD[LAWRKJO8@09*W08NG!9"*$Z`-5%1)(%&#:44
M$ZE.IP^>-)%A"W1GYN6E3UA;U2CA4A$>B.<^:%:'$2$5DL7XS_2)+I@>BGWY
M/`!YFR82S:N4;ANLYMQ28W13ZPP)E5PF](,G3"2C=SC6C2B<\&,&">(`YPTF
MPCJ/!!)8<`+L(E9;%IF+[C-(<%C?&.,X8E6YD!GL2AR-`KD],,Q@UW"G+JA\
M^F#(/%&08#O.78:O?B1!@L(``I@U1@2N"`D:AYKR..C/,FW#8?E$08*M&/ZQ
M@@1!R64X(J)=]`IY1R5I6"<Y2\V[_)";H1W8>@H2;,?`,04)XB#@(@8U@L+1
MX0*C&(/"R@A#P6L1/H,$C^=MFR#!=F2_#,%C;$&"7&@O+%=2!4(BYH$[6S.6
M1B$_@P0O1P1)Y7K24?T5=GX%C-MR<>.JE2R_PBS628XW-^75JKS^_>G7^>2Z
M_-<CK'CVY&"^P,U9>6V7Y>2?JY^PHMN?]9O3N?UQ]777^3[$MPHL,%*(6\Y4
MU9DY.`-$"Q131(%.)EM[]TO8&0G(6XR+OT.'DKCU+[>PICH-^FECH_RC?%A-
M5T!S<[LLRY[B2UI\K3"\:LM162V$15)SS:@'.@DDG7`VIB;O?,@;HN,^&`6'
M3[`3WNQ_(./T>G=YJR$_5R"./$/2$&:<T59H1!%02C+B$*A;J0[V#UYQ^01[
MH2\6Y]L,W\H5_!M^BN766D`]C5P0+HR)UD5LK$814^(EK-]$@RF&FW+P&,-/
MB)^,FR="\\[-N&E\46[+F<CUZ0()*XP+QGI$M?&8:E*=!S8P[J229O#HPL_]
M,%YVC\CKO^X8\\%\_J@JF8V\Q58H03UR%#$?2!!"!X7EB7S^K;;$RV;Z`>RR
M,*-_]N5;V3)TP7AT1'KLHU3,6458($`Q@[6BB-,+,FH,AJ4NWI+N+!G1B?-]
M>CN?WDRO)O-5$[_Z&QR]DX>?0&8WN9^N)K-U$/?U6N'\H-7+D"7>!M"IN9<`
M+BHXC\_!:HH3=#`PYEP]'6,)3,**<2VEIDK'&*2ARM9)^RH:DEJ&_1*.O&.1
M>:+`I':<NPS_X$@"D[`UEGJX]PSQ5$CG7)U\K*S7!P6K\]DSH\/RB0*36C'\
M8P4F66HYQQX+09TP"*;;9.(K+_EG_9#!P-938%([!HXI,(ESBVB(VB!/F=7:
M!:.;F>MP00&B@_.V36!2.[)?AN`QML`DA#02%!'M$78B<$-YG>.CD$MVM7U(
MM_/819!4KE]>TBOFDB-CO2),(8LI<8HV/%(ZU=O0^L#_HUS^OCA[W"?@*CG?
MM1WGLDC0K^KHP-^S<@V*XZLQ'?%ZH7A`6'MM`_Q#O(I.U&>*IM9\!@=E1>L`
M+,L!5#-;`Z.\_OX36&$GL*&JEACE_&$]X\/%9(X;H."*4X-L15!8;["(-?8N
MS15+E:8_>/1.*E@'85H.N&Z?[QYX;G^A()Q()(*N4A^PE@$A$YJ5Q9!ZUW_P
M2)M4./;"I!SP^SIYJH@(\H>Y^M?C=%GN;*2^!Y+'#U)$+YD"+9@3Y8W745+E
M:PH(83[+:YT"K8/Q[R0(?M\3O0UP_]I/W6O#+)-,"RMU))IH6:\W8);JNSB^
M"-8G7H_`:T>VC2@,8FU<^6A!#=HQ89WBW+%@K&544[FN:0&_1Z8.7@H#2697
M/\OKQUGYKGW@(7@G;*!C@K5.,)N">,<H4E$):0T-DFL,TC+\BA'WDG_@8(>C
M$?M>+AP]%[.<A8NKQVH=E60!:UT]_3J_6<`3KS6?(X^^76'DSU_8]Z4]!UGK
M,8K(C"5(LABQX12NFT`5=2A2[IDS_J#I:M\1]E!>_=OMXH]_ORZGF],+_GA_
M:,%/Q69VW\K;=='3^:IR;&U9W*Y'"P(R'?4$U&)'.=R>AEN*O4962N^T.,EV
MOU].%TN8ZMJ*U^_>'Y#)BUXI?;P4?2Q2?BPGU6'S_>GN]\5L!T3>/%,PAA5(
M_MX%@CB-TGK-I9:&!VJ-X*E%+3J99L\>&UU(W#\H-FMSL-#E9/8KG+I__D?Y
MM/?\>/=L83V(\89S[A',V@5E=!3>&2T)5R2FVJ`ZF43/'B1]D+I_L#RWR8X@
M<$QF_R@GRP"R$H@G._"RZ_$"D0KM`'</RA^U6%D02IQ4&#8"9R$UA:"3V?+L
M(=,3M8<Z8N)T5BX=S.=VL=Q_P+QYLD`86\X9+%HBKB@V!%L9I+64,81<JGNP
M4_+<V6.E.Z'[ATF]V!\P_@Y\O'ZDX-X3;@*6H,YP2;GFE1`EN<1&*F)2JX5V
MJE1_]L#H0.'A$/&U!+)>[[]KMCY;4"EU9!A[!3<DX=C"B4>UP"!A.<-T:O_*
MXPO`7S)&NI!Z.+"\W'\1?MGF!]CS=,&I"]A2%P7C/$9NM1"!1<LM$4&XU%IF
MG8JM7PQ@NA%[:,ALX'P\:%X]#U3Y?_:NK+F-'$G_HUU<B>,1B6/6$;YBNF<G
M]@E!RV6;.S3+2U(]K7^_`"71DBQ>8!T4U=%N6=%=0`&97^4!Y.$9,JZS@:X@
M*M!"2:0*1;#!,%$;WV_^@DT'Y.X>.#8OZ_-Z:;/)URU@>?1,8IP%`0&-"@&8
M`A,"DS9:;5C&NJDN;4Y>-4).H7%O1RGM]^_M_+=5>_6O=3S(\L/U:KF:S,N9
MS^YSE1T#4^26\JQ.?8@6''>61&89"!J5]ISH6OS\=4S;*>&'N$>)D^GBOR>S
MZ^9=,RF7/NM+\5'NCC<K>7`#=<!%\:YAR2O#:#0\J'+$Q8+&P+SV%(SQS,'>
M$MX][70ZG\Q+LL^;>5[G&HQ'EMTX<(8$4F23&832)`LQ+:T@!DE4DA(*CEY0
M"?-N8-`.0>;1/NN?-8@^7I>^G\OFXV)ZU3RJ.W3W_&>["LO5]'L)&-K,]:%4
M);I>+/(<.%E.[\IG7(RP<!@4XUQ*,,Y$+@&C+@57C+39^]1[[Z=ZWNEMG$_6
M6O<U`Z?-\IY;#SB3'WC?SA>/&+6O\D5G[TA9;2K"')6>*8^>,(+NGH;6^%&:
M[O1H6'2+JZ?29R2N#!%QN=D;WCR04''1_-]U,[^ZV5-TXH#1"=!R=`C,KJL9
M21!FL^>(H;;1W8M!XG"@V0;;SI@S*""?6_/>2@X'C$Z2VA(ZBIS[O&G#A<JD
MO=LSTWCQHK$+.&R#6F=D'PMJR\T'N;4^PS'#DQ0^?[^&&^*-H8:Y`/Q^UTK0
MBP=;%X`X`&PGTGU@3;OY];^FV=K/'L#-V^:/9G:XLMTQ05*&2LIB1"X9HT8X
MQ>)&76A5&_EWKM%=9ZEON^//:'+PURU4*=^M\R1TUD"@^0]:QB/14=Q__L8J
M45O&X\5(QHY0<HAP[(@'@V+QS?S']6JY)@@]7!7_.BHQ;JF,S&L%Z)64UL7[
MS]DPAI<6"=TS$+;![63"CP4N5@6NNU%)*<^MILH8"85@:$'=[U%H5VO>O1AE
M.SBXZ@@_%KAX%;CN1J5@N7$Z6\5K9:`%47RS1Z/%I85@CP^N.L(/"JX3K-NW
M!]1QZ_0]B5#P5$+)3<N>GM0N2_U[.FI*:H-\7PR`QW=%1F#C('6!UMMZYK#_
M@*NGO6.S[9T%"=,DV]]!"61*DWO;VWC!:^M:O!B+<5C0/"W^TS%[AH#CIK'!
M\ENIKO%'N0Q^=@\[8'GP'(F:P&S0J%A`+T!S_U,[N?K&O.<.SPZ!T0Y#^N$D
MX8.B$YM:A,?![ZAY$AACF(R:!BD)$YP$PGW0WBD1?*2U]=+.L+A??ZCKD^*C
MZN`:W9LD#Y++F'<CA.4\?UYTHRX\R-K<P>--Q78UF5V"4.N*U$-`Z8&=46?3
M'39!LIQJ$Z@3WL>@(9@'-HG)SMZEG]:,:MCUPJ/=Z-Q24.1G'-V7?TX6I9##
M\F.[[@4XF<UN?FM6JUE3W*\WZXY5S\"N8I9$`1@)W`34!EE@7C'8'%A9-EA_
MM<?UFP=`7]=\;X?BP2">PR82]%'PIYM-ELOIEVFI*%U,TM7-D<[$"=,FP4M:
MJ"3>$AX!G926;CAA^"CU]5\N3D=@R1#`K4'E]OVADE1X:;3ACDG*3%1FL[\(
MP]5?'M;ZZQER7=%[M#CY;)&T\ZM,H?6\'[[<'M(_H-J%!;Y[KYF41ADB`\AH
M3+;U+7`J$)Q&OS>OO>>=[K8:UV;B/^;MIV6S^.-6Z?ZX7CUFX<'Q[QV]*EF#
M5EN&(!2"%MYFD/LH4#(20U`7U":I&V!MNT<8AQ^7%)8G'0K%L]T9O00TVG(=
MJ><BHJ`E(>$"D3@X:.H"\H[CS.4&Y`GC4)$0.3$4G.2:8(Q4$)\A8`!KRP*>
M,T([`L9),7C'D?UE1K)0SAT2I[VE`2A0=()10P55Q%B%EZB&N^7]$<$KQ]%Z
M4#R=KA".BF'I\'6)9R8A`=0T(`1-K8A@04IJO6/H:[/8SO#&Z_S4]WA\?&%?
MAYO,KJYGZU__WLYFL5W\>[+X/,RG\OR[$U"I(@<`EG6H#58S9PPRK11%1MPH
MV9]G_]U4P+6_;Z<3QK[6LW1$&PE$H8FB0)BQAH2@E7;6QI!5\E#P_[$NL_7;
M:K)8C7#O.#X(NSR,/XZG53>4[MLDK^[-_,']UB$U0[9=559.EZ)#L)9DV>,B
M<,TT$X:A@^B!.6)KT7NXT?.X8=)K1NZ`?'RMLCJ3(RJO01(C@;O\7:-P%KQ'
MR`04M<78CKZ$^G%?@/4UXWT$CHYVS35BG[`^;K&<(1YIY-:Y`"5NT3+G/2L_
MH\73VN=TT0'LV'"HG_D8Q_7VZN`]R1LI!:,9L_D?8VG^9%RD401EO`-WB;<&
M)T%J:XNNX9GQPLX.#JIVV,/KDG?<2H)&(I%92U@D/O^E#8^6*'5)C>)[@?@9
M\&0(Q?DVNP"SCXOVJFE*`==EJ>XZ7:W59TG=N+<2KC9!(?=_C:)6=ZWNF+CF
MH^9)0)RP6@3.)0=#B"6\I,5R)C..?!BI]>;;=KE\M/)]02#/#TC<!I]E+\'(
M`)1GAB@$+HQ1@@A;G7-RAJJP)ZX_C<?N@LQ#*+E-J\Q;0[\T86_G:^+L#LS8
M.2YQ);B7D7%!`"3X+-A<T`8Q>E=R(RX'3J<R^JE-U2%9AXM4W2QS;]#$L\]G
M_U4CS;N!4FG""6)UJ6[""P6C)]6]S<X0+AWQ]]E8U-.H.LS!U*9J_-Z(AU^>
M32"<U5*BL5&`CL'F?[G-+D-IP87566QGB)(3^?G+*<]IE!PDWW'3F?GC9/JY
M9)3\F*XFL[THV3DN*46%-L(JY0Q(3U`[+[D4@%E]\VH'_PR]GVX1TR55!TEQ
M?*J$#XEDV3XH2:TI@[Q#%B6`]AJX5!:T0^=X_G$YN.G8?.F,IE47>X_??O.Q
M65P5+GQMVB]K#S<VS;(`>MM-WJ'CDY,^!O!&`YIR5ZDCRU^7=I10;AR.4EUQ
M('Q4,+3MG\1#")F/DYO;"X767F5INVCP>IF)L5PVR[\M\K9VB)I]0Y-57AJG
M1?YCP.I@G*<!M;6<9:;YVF)D+T'@U`.J)^H.XW5G8^S-<GG=?/;7Y03QME/;
M72NEU;>=-L_^P<D29K/NM_G[H4!=S%\,\T)!C%X[&6MS\4^J#?9B\-0Y?>NB
M5&;MLKR[!!R42(2-#;\U#F7;@(32,,4L(]$)L,0BI]8Q3M!Q3KBN1<-)K<//
M'@V=TG1$F7(;RE(G4GZ.3<IRM#*[B=J5?H'"LN`LYXH98X6+M5V!3VHI?O88
MZHN\9W8G]+Y=C11A,<Y5D.&"T\P5$9V"[`)KJ11GWE'-O1)ZI$SB@_9PR$7T
M<1-E7<A#M`:II1X"9SIJ%,@S.80VE%_0L5Q/*'GFN*XW\@\B.;*RG"\;^W71
MC-AH\V]M^_G?T]DLT_!-WLW\Z_33["X^Y2C1<-0\27#&&1JN6>:&#V"=X$")
M08B8&;7WXJL?6FQ?^"'RX(#1R?BH:-!*QNRUFU+K0M&LO0"9(`S]*"TX!PCM
M[`D<;=\,&$4,_#Q5?M"+>,0B(^-(""!$*5>2G3/?A4'4``Z\$,Y9$8YOUKOM
M+/2.^D6#S/*BV]O0WI_<V!8H<L3H1`51SF='6#,&*GB=W1_ME=<T*!+8I78?
M[(GA;=\,&"1H<CJ?KIIUI=6GM,&;=Y/_;1?KZ/)]93\.GR51Y:G)FR?9.RM2
M%6,FBA=9\`5&G*OU3,_(_NP%$;\V@>Z)XB.C[N?:WT^^-_NK>APW4Z(4O4-O
MI->E4P9!(YC,'W<VO8TGXS1`ZD?J]8*0PU'8`?6'0&)6`*O%]-/U.D5G^O5;
M7OB^&(9M0U)P$%A$9D4Y9,I.I$=%=*"61Q+S1E\%MD[C>]L+J8<`TM]+-N(>
M-;EY)F6A+Z@GEG$T@%Q;R7AT&+P`:G1U)]0SND`<0@G6TG,P/.R5)0^>2EIJ
MKM$04,7=E!PC\THQ+[4WP;,+*CE5P;?G.%]%MR%X_RZ+Q^_7W_=R_]%S*:_8
MAG+I#=Z"U5HCMUP%S;BC4;H+,DVJN-=V1[M!,##Y\S`,/'PN,<4]BBACJ4V)
M0EH`2XRE>6>:.5=[+G=&>J%3#)Q`N\,QL&RN_N-K^\=_?FZFM^S/OSSE>OY/
M:7T#%^:KZ>IFBQWPS%.)$*!$4AU19-.(TVS1"$.$L0YC)L=PO3Z&.9/ITRPX
MG;S=@^)V*5O=V*>/)&W!$TZS[^4!,$LP3E@,J`1WCEMU:>W63F)9VPD-JZ)]
MWOD,WDRB4N)A?M4L7-YCL]@J[/>.28B>`;$D:!JS\%((DH1@2]!"_@1X;;V-
M<^9['<_:?B@ZA$EP'^>X#GM<KN]6]CB,6T8D(4C>D7"$"P3/(RIM,^5H9$8Q
MX6L#FD^*$'NA2J-;4H\%H]M`VOW'I7O'IL@"!Q\!I!3@@D,KK.7!.RL#C>I2
M&RJ>S/X#X'0*H:NTU(=%\V>[6RD]>"0!.!G*P5S^`47CHO4N.J4DUS$[ZJ^(
M]96L:CNA;%TRS3[Q^'9'CM61,R1++2=H8U!!0>F<)[V*D2((XIFIKHY^4G3I
M"]4__9*^"DIV/K^>S-YEY*^:>3&L8K,U\N"Y9Y.)C!MCO2)<@F-0OA<II0+F
MA%;^`DZR>N-:VRUMJ_@?KU?7B^;==-8L5^V\N<O7V8:`YY].TI@043I)702F
M!5I%`24R94/>_`74"!\$`YU0=^1TN_?-ZL.7=5_IV_^SJPCW,=,D;\"[HI0-
M!I#6&<LB\<[%X+C@U7+F99^=U0-N`!Y4R:-G#+2RA-(M&F_N%W)[FK!-2!TQ
M14(O40=E>0S9XLO:.X(B6@J;MX>!74#ZU2"2JS^25X$H+%?3[Z5P\O\TD\6'
M+Q\GI3-J^//'='>UZ#W#4A11>K1@O#"@J=;*:"B)02X2/5*>U0L603W0_*7G
MFOMR#LZ`9P^40K0$O5'4(Y/`K<[68"7"Y.L11SV1>KA`R=ES@5;W(I3N`-<A
MPU.,W@<3$<"O/8HL<361)M"@:7%9*P&F7A_`>B!WG0.W?QU;2HEO=?*J9TS!
MHZ$^[[HDX:*5QDLMK>>>2"2"U)XJZM<#KV$Y,##B[H3R;89U]_![-'VR1A`C
MB3>19&?%!>.YTI$K`=[G'=5&Z)J_L#@`.^K*<N1UE+2>Z\GLPZ?9].OM*MIB
M44Y+N;1;BZ#0+[NVOTT>M![XI5['T3-E>P)*"5J-D2'P(`W146IM@A9!&%%=
ML)Z\,KSU3OKNH'6_@-_ST.6W=K95I!TV.A&D0@9BK`@!+%6:>)4='NLC,250
MMA9"K^TLO1=R#Y*6V\Z__MXLOOOFT^KQVP=*NRTO/BJ_]OD!"9%Y`U3YTC!,
MA6!IS%X[SY\D(9J.E6K_>+&'I-=O&9$P6U."<N*B=B!1:>.X!:D9<D>9OJ#F
MCJ<R^&F23R<$'?I;'+.C0E>?)+&N2,T0!/<0(:*SSI;0>6LP2[N])]W][>[-
M/"_QN@C^?0T2GGDZ!5:.!+WP0I1>;\JBMH%`D)A?2>P%)>*=RMAG/L73B#G$
MH5CY#%=WG^'O^:U[@BB?>SS9+$\X>J(E9<`!K.3%2?;HF;?<C1+FUA]$JGGZ
M2[W@DTDY!D#VAD4^/R`Q)D%Q0KWC!$HA&"Z=,%)X;Z46X]3+Z`<DIS%V#TJJ
MJ%EY#+58KGY?3.97W[;G7FYY,J$C43DOA7,*"!)$%SVZLE*CLQ%RN=P^ED%M
MEX0\O^1LY15D>Y6+2#00J8V,B)(2)8T1-%Y0.?DN=4,M_<XS&9M*A](HR@0J
M<-*::!PE(:]>^^+97(XPJ.#;CF3LX^AVOHFX/&L67^J/BUB:_F6S&="Y4CF8
M679`V:\7QO]CN;<S$?<XV@U2Y>61G'N[(Q)^SX@4\ZY*T*TEQ((T5%,3!?$T
M>&^BE+5^PQE6:N]2-W1#S>&1XB:+Q<UT_M5^;Z^?C8`^9%B*W'D100/+Z!?$
M:"44R1:UXYERCM4V=3U#67(RGW?BYB2R5OD33[Z!;#*_*1FFS7+U83[;&FRZ
M>U1"XO+R;!&N!DIW2F=X)-8!&.N,NH#:/UW#H7NJ#B]*[A?[]\FJ67<5_/RS
MF<[!@F77)(FSF!USX2AC%A@/2%VF)C56"A5$=6'%LU=-78N9#HD\/,S*=W'X
M:7E^.(%C47"/`)(`B1H=*!V]LZ5\CK^D;B/]PJ:"F!WHI!)2'R>E:_GJ9D>:
MWLY!201"HJ%6>_!YU8"H272Q%,`7R%RMLWN&S4)ZU$BG$;4K*$SGFX"8([#P
M8%1B!*-'66H="V`Z&&`$HK!12>N"J`7#&<6;#P6&>JK6Q2.5HIOMEW]F*WDR
MSSQ9%\S<H@]V#T@H"$B(RE'D0#5!$:DVG`D?72"QUF,YHY#P7C#0%4&',!O6
M:_UPO]8/MVM]?UT.<#Y\^:VYNEY,5]-FZ2:S6?,9;^Z>6]X]N.OHY,29DRE$
M4DY*ZBPHU%8;(5"@L5Z"QMHCEC,*&._+(!F6\J.A-/R9[?'ILKEK\_9T&[L2
M8JKF2U):28''8ML!P8`,G::2>:9X.2"O1.318>-_-(M/[25@LF.*=Z<N;29Q
M=O/>31;_:E;KU?UCV7R.[>+1BH]2J(=-F;(94.K#Z*"<`^.84=E^9$HH8[+_
M(*ICELXH5GPXG=L+S8>(,'S?K$H_PX_-8MV^=)3HPC!9S$L'P?M%'!!?N&U(
MLBXZ&[+/XR@I'>U-S$:OC)0":B7-WD;)P^SPD+#?K6-2_'_VKJRWC1Q;_R5N
MA\LCUR!`>M)(TCW`O!!JN^+HCJ(RM+@[]]</J<V*;;FD4FU2_)`$CHM5Y#G?
M64B>Q7"D'04M$0.,G4FKY<P'\)2K!.4^CO<[*)MU/L_+=BC<@YQN.LVN.@[[
M?VXFRR2E89V.DA_KL6E6D\(,UBA./$E.H@1#G:(2!X,EX08C7EVJN)T5?K[Y
M5MPN)\F-T-/%^'8\62[&#\6CM[O/C\2G^^6:[1^_/L-;1:1QLQ^*UEB:_&L>
M"&"P`#HPSTA0@FAJC:Y[[CK`6\'S`?6T/V^?G.ABVW/FLLR/EU]0$0'7XE>C
M93BY=9RH1%4@#M*_ED@C35",2+B"DG!]@[,<*C/[$YBC.HA5#8TT[4BHE(G^
M^<I/J+0755I0A`16G*DKB@L>!&:.PG%M]G0!QLU>M#+B\*?GHI38*)>O!U`^
M*0;I$F4,QRY8)H*\HHR4YEA:-D?0+H#AO]]/RA]%\7F1=C4?[S.G*D%R<$PD
M-G>W48201"G$<MDTEE8GP`<7I+N""INM`Z8IXEZ`3_CAB*#7ICX1>=!>`;C$
M!0[.)R\_,!E$0($H)FG=FC\#A.9U>'MU.7<!N*\,W6WD_1&\X3)(A%UR9KA4
M6G)AK3`$.<H8OM;:^=WCKEG@U^)>#P>,*^W03[&!)D\0/5<AEQ]#1@JP4AK&
MF>?.&9EO74QE9MV15WN/2GDSDQT9R[V3VESP)4G+BK2OW0"<^\KHK!1*686L
MHQ"DE,@'3+QD.'CFH789J('KAO-14/;"@"[$^^/B6S%[/TT_%_Z?^USYZ%_E
MHB<!WYN+GMYNIC,_0LQ?'QBE0$Y*03#S&#P*)O?B\E0I185PJK))2!>K7?VT
MF?EI98!.>D^D6"#A<RJUP2`(4EA8KBV2A`*S\HK2"9L"1=D=N?L1^)6.ZK.*
M4%MR'VA2[#9QF!`#/"1WREN/E"0.@Z:N*2-OO^7$U??3,!K/_AQ-ELDR/!:=
M_'TYN_DVVL1Y'%7AMN;K8L(7$XA1`T@`(U:S9&$LYC:9-(2@;O7DXR5;K0$V
M+>YRJLJ7O@7\:.Z7G1._5IC8;TF]%)/):%J4R_ES*3X$IXIAD=&TT5#,$0@!
MB`+IB."(@<\G`-I>41)@&WAIEKI=G&*L)OFO<EK>K[`[O:M"T7$#5YTSE"7<
M:H$@V38#0@N++)9.:*C=LV^`27\-XZ@5^O;H25R7#^&DDI@&);P1H`F3(2B#
MI-"6`[>JTJJV'6KT.FHJCQ3.>V%48+'6W@)E$O*)L9,^6%!I-ZVPK%V@Z/)V
M$T?#Y&``48MT[T(9?![?3<=?QS>CZ<(NYXLT\]E\54-YFA.69YM33YL8.EY\
M&L__V^=^(W\_3^Z/W*I[D;L:CH]2%:^.B\@$39Q2/FT@K><\@<`YIUG@!K/@
M>PI*_(D!>0%5P84O#XA8`F%!.$F8`H&QPNF'S>JHJ=UH=8"2WA"7GV:?-$'6
M3A*=GD[4_#BBM.DKHZ(G5&DO)%=:!R(-\>`W:R36L2N*+SV7R568J4W47H!S
M5,'35T9%'ECRF!%/NR?EG0F4,K-=HZ?7=%;9"*<K-4Y=RG:!GM]GY>WR9O%L
MTI5A2:\/C$+@X-/&6P!UQML`X'<KQ>R:@ML;X??31G5-$K<GZV6*Z<VW[Z/9
M?T\W83\-C8H;82R7A)-D_!/=C+#;U3IKZH;?#O"DK'T[=@YE^\'1=L*G6[0G
M0R,15%IB/26<,T`R,+F3&D+ABIH"-,?X2D2=1>,N$+7J[_.I>"BFR^)=6=[F
M#M:5QNWPH&@QL9(S#EKE8`6GB&/;%09.KZ@D?'/,?GKXTA1U.XD^O+G)$6)I
MOC?%^"'KXTKT'!H2,0^(<0F2*8JU8Y8E'V"SNJ3<ZQ;HNP1+UA1V&J)M%\CY
M;?1_Y>SQ4.YU+^CYP]$:#,8CC%U:B#$A4+W;@`0%=8]^!GBST[#?<S8MNT!'
M3E[X^/6GJ5:Z.`?'1)KV`L%;SS7U2BH4D-JA'R6)NAZK=`YSRW;(6:_ZS.:+
M'Z<5C4J>/1B3SA1>"Y/[IEJKC=6([M8+[HI:$S3`H;)!4I[%Z"]_E\<Q>O=@
MI,DJHN"-PL8H+BUS@+:S4\'7S0@<H+_0$J/KDO(\1J>GCI3IO4>C(Y@8Q9@W
MS`DN=)H=[,X;H;H]YN68^[:879N89[$[E,O9<=Q^?#*FV6&O&*8:82L(=M;Q
M[?P$9Y67EI=3<[DE9M>FY7F\'C\<*=F/3T8AK2?&:Z`N6*D$L91LYT>1JANA
M-<#BRFWQNBXM>SFQ_'!$GNWA01$;+'@PR9G5'H6TSR%L>]%-`)FZSMT`-4/;
MI]UU:5I+0ZR+K)9?<RI2,1O?C":;.YR78%`Q(B851G3".5B/+5<"E%&;^5(%
M]II/JFLPK6R#J&>!P)7S\?3N\R)1X&[QK1(!3QZ/3'BN<&ZB)8BB$A@-V[,Q
M&CRN>_`S0+>_+?:?1]%>S,9CBY%7RQ>_,BQZB=/F%0GJ$:?.,*G9]E:'<JRO
M:`?1(&Y:H.Q9NN-+>9^^_+6<?<\IKJMHSYMQ4:E##@R+VAN.O"1"*&4T!7!X
M>\!!C61U(X4OP9UH2)<T0]DAQ@+WEW'<3B1PVAP(QH%Z+Y%RQ%/&MIL#(9"K
MU'\=:?K3THR/&1XY8FG/JVSNV(DDY*"UW<J3IKFBX_^&$%"E_,\G\A`%_M3G
M>\PK:D=#**F3$:<Y?\,EMT\S$;;'@N!(J#Q0;S>K:+Y*>MUGQ3IV)_\=TO3+
MV2DI12>\+?DWWOD`C&',*&*<(+L-NTAN"M0]CKPX_7$T/@ZD$[5'\T[422Z"
M9T;SXC:73"JF\Y_RY3L5_T?]FRGZ.)E/Q20GN=MROIBOZKW\E:>[Z;%UC'XX
M[\71&*)0\OJ`:P=2^]S138'PU`DK)*D\R^V96F9_4<<HDS/?'!E)-M(Z#8((
M`!&,53C980]!<4&AEZOJ#BH?=86RI_TH.^56?RI)WR8')?T[FKR?YHW9ZC][
M[+$P5&V%O7%<Y8(8`8'CU%!@4GB'/#/<LYX*,#WFWCYB\2?NYAJ^=\5J*>;'
M,[SJOT>SV^-;-9SYC8AX,M#&:ZR#!D:S_\\`$:ZLDX:Q:ZWKV!7R#N9E=\NW
M+HY\OXP7>6'OI[?CA_'M<C2I"`E]\?E(J?%)%5/A"8`UPD@,6G/%`D$TZ%ZJ
MA'>`QQZ`43;/CEY@]N_QXMM*;!.9YM_&]U]*GW8]BQ^5X:8GOBE:D!X))Q`"
M#!PQ$YS2'G&!@G#T:DO@G@F,*I@U2O1:5Q-?_B[_4\Q6?S[GK(WWJQWN^*'X
M?3(Z7+_^V*$Q[8*),\Y21K/G2;4B6"0;P50R(<C7;:YY<;!IBM%EJ_3O0H5]
MRJJ\PCKNGHDLB1EPAM+&)8"RWA#)%%,&*^XXL[VT0?@E+&)=%G0&H<I,K;VG
MHG(B'[Y)9`D&IX12+.U\'4".$O&UTXR'KH9J,/$E&-0B8B=96./I^/OR>R44
M?GHN4N$0T)QRJ#4HQK04&%GLA*>Y`EPO$5A=@>%45C[-OCJ#D-VDY?US'"#V
MGXM:2@@(D60/#3`-AFH<-!8".RY4[6W7T(U,(X`X@Y"=9(A7F<]#UO/#$9&^
MY[\\.LN=RP'34BI01"EJP$AK-27:4U*W',]985V_A'_3.>\&C?9U=ZSYN]Q@
M;?Y^^GN1('#[[R)W6R]N-_W65[]THT6QJ^/<AFC4FTGTFGK,I"6&Y4JN2==H
M1Q2B''.?-CI7>W+6(8J;$J!..-R9M/WUE`+K/N%ZN?B6F/__Q>T?TX2DO19T
M>7,^]_\4LYOQINKYR@Y_7"[FB]'T=CR]VQ#H"4D^%?FD(/TZUT[/Y_#+T>1+
M,?M.JJ2P_QE&"#)(`U8YRH`ZI'(U5Q\<#L8S)'OI&/<+2.?%<;X_J7W.E+\.
MZ*T_BWE>^+I>\4UNRE#F_]I0+?LD1Q+GM52`X4PR&J&"9%);9%!R[K%FW.53
M`^:<P!C7C?(8O(<Z--F]`.;7NH#P\\7X^V@UX6GZ;E9+H9Q]+<:+Y2RIG^0"
ME+-]ER$O9]O9]6#FQ%DOC0ZX\9)9)Z1.>PFCB<:(.*\892K4+KAR5E[%=4*^
M<V9U!M'/Q30Q[+?1=+2F79-(??KN*)E14K`<F(%!,Y*35A(`M!0Z$!OJUAX[
M*PO]#;!-\JR3:GB3%3**VY?I6MW-YK@71$@;.12,(YY8,`9K4$XB)R@-@+2H
MNQO@;V@]Y%&TPIAZJG3;D[V8/:3MQ<OS^6,Z*V[*NVD6K/W_7P6F'52D9[\Y
MJD1*+!"52B'PC&NEN&9,62\5L[1NIH1X`^;+:K1KCO6$V"?>]OK`Z^/73^L1
M^VD8S6.Z^MLQB39'S)MD>0($PG7ZV2$*F&I/!*M[!2'?4-\2ZAOGZ:"O)M:I
MVIN+HKVSJS8N'PY]*P9I$#,^4.P44(ZTQ=9KD4O^LV0AZX8,J#<9:?QZH2$>
M#EHF7KQ">3<KYZW<5A_^6D3&8IP,L-)$`6BK)/=8ILV,$08+INM>NZ$WP>CF
MWJT.&P<M&D_$_V$TGN03S[0C7RV\`ZOQ])/14Y;+%ALI+`6#A#(8D9`T$3**
M&5Z[7<[;Y73KUN-,7@Y:4E9_Y8N!7/IFI0PJ;Z0:^DQ4P07EA=?$4'#$2,J-
MQ`);S93T]?/N!E@%[1*%X'R6U=IIUYZO_^=^O*[)L)[MH>UT8Q^("DNE@Z.,
M!YE6X31BTB$-W.3REJ1V38VW6]&7-\U]<:Y>0>')JD+A*GYBE6#[O9RN@BP.
MX?+@@,@H!T9HCJ@5X`/7*@2F@@$11.X'5Q=G;U>1+^.L*4[T6#YA=]3_XJ_[
M;!$]W$H*0FCAM/20;!R63A#O//&*(V^4KTP.:KN2PE$GAAN^CU=UB79GAVNE
MMR+`\545&OQ>!(FH3'ZRY1A"+N(N.=G25DG;2UQN.RJK*Q`>+*K0']LZV>8D
M#*PT_\?[(AOTZ9V^68P?QKG$U^?B;F4`7D\J/?(-47$JB)8$!ZT-0KGJH'%>
M*:Z8##I<40>>GK'S%,FM\*<3;*YG]\*\*\LP5`V-CA!B"`5/A).&6(8,2ZO5
M"`%#F/92=Z$E-#;-_Z?X:I;4'0(KAV6.I\M5^'6QWLW,J]N<5HV-F@MLN`:L
MTYH94L@SR(3,0JJENB+;W!SK7\948T3N$%397UE/N[@]'5:OC8X",<.3`?"!
M2>V#YUK(O&:C'37.75%3[[:!U2"9NX#6^VG:G18[16Y&D]$T>Q-%L=#3V\?*
M?H^^\MS\2#_<E_/1Y-VL7-[/TRLFRYQI\O+2*WR\;B80$0,;A,",>M#)%$D;
MN,N]CP2QB*.Z56V&"/!!N8B#9&\7@G72&G*GKDK'L^8;(\<F=UHT5B#$L%=4
M)U6SH8W0I/:-__"@/S2P/:\'VP$#ZQV`KQHTW8Q'$[.<CZ?%?.N_5[37>WU8
M)%)J"PHTTV"]IH13M)ZY-]Z9NK6@!@B]UGE;MD;V'MR,#QN3<YIOL#\J<DZQ
MYYB`!6)Q4"0`WIV^$7%%W94&;=#/X$F/N*NTM:^.BY)XK8FB#EFE.1$,.[U=
MISLC/&AXV&N$V\<AJ!9M.ZE=EYB5OO,MN1"N>"@FY7V>]B8#I[JF7?7HB$(P
M7A."F":8>\0U-SM9-+5[35\.GD[E_=.2=XW3N)M3G4EZY]V[8IK\@LG*0?T^
MGH[GJV8E#\5F^L><[YSPGDBL99H&QH)Q@#`GQ.YHC$/M%A`#W`BW@[4VJ=T%
MZIKQ(3X<46NMX2]%2IBP(FB$C#9&.B)!;6DIDN=<$[D#[)TX+(^O7SY>4QHU
MPTQ@`$D$X,`EQUC0G39`[(JN;WK#3+TTZM,8TV.HV'R^_+Y."MD5+-ADAZ3?
M%+=O37>>1>DP:73@CCKL`"S7"4)>>6ZM]5A1VE>H6-UHR5UUO3THK-K9S8KB
M_30)=C%?Y'H6;>0%'/OMZ""('*)KK`;`B"J+++<8&4N15/Y:.T]TA=2FD@9:
MXN>@4VA>6O.VZ-:?9>[V,$D@Z5*"7OYZ-)X$(V4P2B(@2,O@*23Z>\;25H+7
MS5\>>@'&:Y"A1C@ZZ,**KZVZM4*)E1^-W@.5@2=?T6&@&*?=C@[.&4O`"NOJ
M7C<-/<6G3YD9`B,OUN"XW&HH.>=]F)O];T=`V&`D!#74@6)<"XN55%8R#BJ8
MN@5EAIZS=$W&Y@Q^]K>?W2MDO(G#^_&VA7V&,^UM0IFB.4(`I+.24NNM!^P<
MDKPZ.'-@&G%3U6*O1/6G<C()Y2S_L@TU^.H'DUNF`@-.G7<!<)(/KI,(`Y@`
M#*'J'N*7<RC7%0P;+G_2"-\&[2,\7^BZJ$4WPK#^5A0^N5C&*8X3%;DAFCDA
M$`W(!RE(;>?Y9#FX7YW_?EZ,9HL+R%YN"*/MB4PM[EZ"M/1?2LL)J;PQC`J-
MP7,M-0IHY6D9SD5MRW'R$<U#,?NKO(A<_V%*R_F\[2:=-OG*FVN>Y6Q7YV5=
M]FC/D=YU`WG5ESKY95$E2E#A*$U_`\-:>X&(<$$@`1BC]KM*J#7:I\7=:'U0
M\"M#OFW^78(%>*S@OA/>%BW`"U^+N:R8YHP[CRC80(WTR47.9?BT,0C73:TX
M_MSD9YGX=<6A=]Y>@KSTN[^P!"DCD@FE"@,VN42&T0R,T([J4+L`U\D=+];[
M"S^];76O?64"<BX[+T$\]KHMM2X>S[X535(R*OTQE$L(*GF?2";*:AP8(0CJ
MFI(KO^_MZTSJ7/Y=@CSLR?R3^O4_]QM,ZNEKEX>W1TXF*J\\TPQSF_@@%4H;
MMV33A1=!6E&_)]@`,\0N5(A:Y^D525G_HA5-]H7!(:&3AK/::$L8]I@'%*2R
MQKX=$/>$]7[$\D0\#$(6#W:F/Z;#=6/RV-PL8D#,2ZT199B"]$1Q0%2D[6G:
M%.B`ZF8.#MUKO"9I[`T-%R&1VP7V+I0G32121[%6ROR/O2MM;N-&VO]H7UP-
M-#[B?,M5=I)RDMV/4UJ)MEFAR2Q).=E_OPWJL&R3XA"<&<[(3N6R-,`,GGZ`
M;@!]!$"`()T%':W)]#,GDF47L3U_S,O)$&(24W//H>FE)N>)G])84#;F$DCF
M,JC('5<V8V8V>:2]4/_G]C^F9]_3LU]*C&*"OIB=I03:.&2R6@*CQ=%P)[A,
M-C)!5$EIN&+87U\-_)B2XV?#%&;BD]/B"\W$EE_0!"F`L1""SIHLE>238>B-
M`@&9H:G-`SMVQ3C1`]1^I#J%&?5D+7FUW*[GR\W\>A<9,8PV^_*=#6I0$#5/
M$24DKARC_393SI&MGY6I32Y;J;\&/AF=Z-SI2II5Z3:[]EBD/T4"V[U_O]YY
M`AV=$Q?X"M+K3D<=%3IG0"JT/H*7"BSWQ`!6:^7I'[KEZ?P8OV2GH%^^.=SY
M;;6]6@RF:MJ\O@G)03:^>.!$L)Y[F^@?AB+0'[FJ/?LW/^93C[9:ER*]B.K9
ME6><W3R,8AA-\^Q+FZBU,24EB8\1F(X6F)(^!034W/':DHOX8R)TKEBZ%.04
M],BX]BE:&</!<.L=V;@22J7-XMYL72Z>SK7[%#N!<[:):HVN9#F%N5+*5\]N
MW/+F,1?(JOSHR2%'^_W-Q;^I<5E"-"HK2RHX28_(I$Z)Y^#)2.:U^9LX^Z&5
M^IAH0PGZ<KDV=DE@?Y01?DJVQ%R$A-P'-)``K?">TS*:I1="\Z,AC3VMHUUG
M_R4I^\7^8N:]O[,IR51E"5*).0`:ZU$(Q97P#C,D71OV\_+2:[0F8]_EA"M%
M-XB)\3C6_8OYT\C7LCK?C?ASLJ3=&GC:?.CB14TV*EDCM"9##4@O.``?DY%*
M&YDT7B3I_OAM@?-GQ`6$=ZEI<""MUN8AK]99U#^M\P:3R5)HT#EYT%:CT3DH
MA0D%&!=JU_RQ>S^.B.Z]"FPP&_;#:D&"WZ3_W-(G7\1RO7MU"TOTRP<;&\%Q
MV@9$AQ'`1L^!T_8\:XQ18#J:3*G'%")?@/K3:CO[3-M6RT/;/II,.R$###C3
M"G0P7L08I/*$2%06JW?`(U\%:IFP+\-'#SA?9O)^KKWY:OEN10^7/UPPU6/M
MO-;<)4NK963*@T#F@E:*11NR1`['_?I[MP=V6___AL75YLZ,::?HOV[5"*N=
M-5PSM!I\T03:&I4=]SY+#H/%^@U0J:12P(>5\)E@MC<@-[/K?[Q???J_F]G\
MCBOT/U]3A'[4O)[13$W+;1GG_H*;>YYJ6`2CI/:0L@$KO3?!VAB!%IN`B=7F
M!!XA!3J1W:HK)+N7_]VG'*QY^?4C#2DK&K4#X04#4E(^868Y,,]43CJ^@/*6
M9TEIU0EL59?WI(VO5XOE+U?K/\+5G_/MU>+UZ_!\B>9GFC1D]2=,C@>=-`!R
M"Z@LS_3Y"A16^RV.3-!U0EKU@F&5U-^\_F=8_8->>;6\>7/U]_SCKLCT4<D?
M:=9PU%%I#M9F`9+6-)>=)_O41B23TM0F?!U1)<ANI-\MCL.DBKRO>;E39/=J
M[4BM[8-MFI)`7M$61IKLP#N!]!])=A&Q/'-K:M7!B'C2AR'0-:Y#\.;I)QXM
MD?WMPPW!$40QES,CC!)-+B=*"'H&BQ*KX[A&I$\ZE.JJ8S@'(<CJX\?[`\6C
M98F_>;:))2>!=,9*3)!2L"PF70*C`P157\!UA/0X1YA?\^),&(>@Q;^NBI_%
M]B@EOGBN4>#0*@PH68*0!!E+/@81G(V!?OP"[(\>Z'`.A$.KD-<MBD3O?;Z)
M2J7H%5E1$,J19BFTXS$9ES7+1M::'"-,W=:'R=$%ID-PY9<'6>R^='=YM7&W
MVP^K=7%)>(8TSS=L.(B4A,.8/-N%\C/&:;(A)ID=@XN8(0-</)PI]E6/&`_/
M)MJK_[S>66DW.S>]7V;KW1A:L^I0!XTU,4N0UC!6]OL,'2V]G.F29\E*\U)3
M;O7)KHZP'M@"/F'!>J95@YH%2%D$H\MEN_*!&1.-L9KKJ%WM->G8G26ZY5-W
M``],HHIUJD7K1IED=2A+LU)`@T:-B%)GDYA5@+7W=V//X]`;J3H">A@]N+J>
MS6XVF=`I%4*NEM<S^O:KG8?H%YXT>W7@L<9-<HG'!%ES4;8?TGJ3`+4S*?"@
M<FVTW<G)#KZL>C0%/G4.;M5MPB^WZ^L/5YN9>[^>[8ZP2LG=0W<(>Q]NO$5/
M*MB`SQXXZ6<R^2S+46AOG5"U]T9G1?*/F0"=03G,Y<$SI84>!O'S.[?9S+;/
M7RB<T$\##%6,V>Z<(%WP2%M=5"9+AI!EJCT;/"N8?<R4&@+EP8(&6V6_NDME
MI')@BO8`R=$(?&9.(S/,H@B)TYIYD5CO2?"D%L*++SD_S?[:_:IZK7GLH%$<
MDH],)+&KEY.=\R+'Y(5DT2A?NW4_.?YY<N3I`]XJX\5MWURM_YAM'\RG8CQM
M'C7JAK[KFOZ[>K<KXOA@;QTR;JHZ:P0P'Z2"DAB*#'R#J)(SZ&3)O)U\=9W<
MLP)[Q\RBP;#N@U$[AX_;CUWP:5]7#2VX3,J4@Y>Y>*38K)WVSJN0@\FFVM%V
MY)>B_;*I`Z2KN'17"FKU[M[ZFJU_7\[W.9<??KB)D!AW3`7+)8"QB%R50"!@
M-!<RUB:.YR._%3V3#UU@.>#MZ/TE[L_KMR5IYQ>Y.A]_N;G_[88_8_=4]=<8
M894AU6Q#%I`,MT9;JVU,$<'F5!N-RD=XO=KQ@>``<%^,AG=SB+":79.-MYW/
M-N%JL9C=^/]^/:13"=F^YT9;ERT/CBN5P=K@C7`T?4N)X@SHJSV2SSJXGBPU
M>P.^+O/<<[N(GTO>XL5BM2T*_"Y8]9#B/+6?Q@0-J)GVZ&D"6NM29$:80*!Z
MR:MO;/G)1]93(=40,->=7>\Y05_M3M!7]R?H/\VVOR])/'\5OB_?EWC)U2T1
MO=SES#>;$@-]M;SY^1U)C7Y=DOTL-WN/%GI]7R,]=]%D):1F`%8B2\6O)R3.
MA':R.C;VA1^ACT,<EPFA?7(;Z=:SM]3_^M/L)J_6^;94.7G`8X)!M2KRF)+)
M#"T2&T@4VBAC(=CD>#I>J'5`(^E)/KY3K:`G31OO(VU"`^?6*DA!6L-=CM+8
M[(60U?E@QNZA5BOW-K9./;Q3R(WX3?WU8[<EG=9ZSRXGL+1GIK]``ZV(/*CH
M/.EWC:2BAW)Y^_+*?SJ$O;1$JFRM^W<?5#0[/5O&<[6<EZS6Y?QV_FGVR^+J
MH.5^1I=-HB_4P'G@OF1A`F1!<]JF2)YYRJGVXF_L;G)G,G!@V*N(]L2PN8^N
MO=MC'/S>)YGN=KY9][?<SS&ORW<T&($VRQ@0`P<3E;,T#S%HA5R[(&IO@,;N
M7-<%%2\HAX$=.]L-KYV;9[N^2B"R1O3(,PW>,X-"T8XF94^3UP1>>Y=T^C%'
MJ6PP&5X.A?=E=HT7S/I;NQUT01GM404`!VBUU8J%''QB(8`XGI?@=+7SW'[Z
M:-[$^LX:XD^F(:$$H0&`V^!D,*4HFQ9!U%_V34N1M);W`472&^"#S-C;?V]F
M_[FE/M*G<G5]D9GZ]4>TF+.'FC3>.`\*@XS%8L0B6!M!D'`S9NF.!M\-,\)6
MF0X/M6DT4ZB2(H-#.*`!N^!5T"Q'R0"$J]V+C'W>GB_SK_?%'2$\Q$1]N#&[
MR`1]>+E;WMS=UWV9"[+%?&W90T-6-+-6A&PX!\V$,QH\)I=S=E8?+Q'3S_CO
M=K"O".F_2V6&W:W4@X439YOK]7SW0)M9?6I7I#,L*.-#N1R`%"5&DW5@P0N.
MUOB+9*T88+)W3IC5H'(8<DD('\HYWN;5,E_-U[OPL,?#Z==S:KC8#6ERUS*!
M8\Z"5F*I):CHK)110I1<8U"27RB'\=[#_V.I3@\W:F@H*0J6H+B8:I\][>><
M\$GQ4,I:NA<ZO6MEW>8JI@;8B[D]'4F+=K!-([T`YZP))@:09=NB<T&O+$J@
MF'FAQ.E"XFU(5('QQ3C4-E?:OE8-<PG+KE1Q[B`%8YTLR2.ER4DF>YD".9?B
MT6E";T.C*I"KKC'>4*L/O_VU^NW#ZK8XF>3YN^ULMGPP$H[DZFS3N+%.I62$
M-Y869QF\3^B,8G>'CP@7R:@_(#M.E>6J9X#KO"!G?VYW+WOR,;]]F*^??,WS
M5&G=09.SL<+X9&WV('VY%F&:AJ<0&3!5FP=IO*$$W=&E+Y"K*!-GU]]\RU^S
MQ:=9*[ZT:UU@LM%QG[G@$)+S-@;MLI"1QF)YK1T\]OOUSIG3"]QUD6T$W^+)
M9Z3%[%/+-:9%TT9C#BB\3KNZ6#:X4JDH6R:U@92JJVZ/_1:\<\)TCW4GYLL)
M;&G1M,E)F9)E@*=H"S[H=/`N6QDP:6]JK=RS7/"GR);NL>Z$+;]54N7K=HUA
M(?H4%$%B0$55XE"RI$VDII]'61NK<99?_$O@R9E`7VQK_;I]#MD##1LHKL"*
MY1PSE!-JKP+7T00G!#=&U!:RF4C"QMX/:FJ!KEIW'D_85X^!EO]?_KTW^^*1
M%DVT)7L;L;XDV0*I4<G`F&7HE6>>7^0$;T`N5`ANU0>P=4ZC942/;U[=C>CQ
MD]ZN%HN\6A<7ZH,>.VT[:(KS*VE39#I;<-P@*!:8#SS80-9[K:$[E6WTF33I
M"^?SEH_/<=H/-W3SPU&`S[=JC.*(+B83))E;&JQ`JY'YQ%&)-%S5BS_OXC.W
M5^MM_UJF+]GN76&ZP+UNE=G=[#YWL?L,;5HU;A37+I)Q+B!8$`J]\\8H(5R@
MOS'7;HS&:IT,P9L^@!_/<J,(!IN<(:,M@8G&&:.U]5P)90V9=4,=U-TM-VEY
M\S)(TRGJ0WJ?[/GP5YNTV<X_EFS%OV_FR_=^<77]QZ_7'ZC9YL[OIB0KH5^\
M6=W,%A=T31G.KRUQK75FD$A>8)QSV4A'[*#9+[CU1VW]:3BS<*Z2R@Y160TL
M:N3!"R:U%/2_B-69+D:J3'HC07LOE],0GYZ7"U-2$F+>6/3`D_5">FEDX%E&
MYR]SY7S9PY/6$F_MY7(:QM/T<B&EJ5."*%A$,);VCLD%)EUD4455'4(^21Z=
M)O03O%Q.`WFL7BZ>+"U)MKG*]';-C?.,9Y5USC%@LB^H]GPGLCS=R^4T@,?N
MY6*3E`&X*NFG(-*,@D`(Q>B]45'GEU=&L#NZ]`7RB+U<8HY(0^#)<,@IH$"5
M/11G#(^\NN+YE+U<JIC3"]QC]'+AP43.0(9$RCI$=%J7VKZ&%LKL4S5AINSE
M4D68[K$>HY<+YTQ!A%+*)8/TGG8(6;F@F.8Q*EY[U3QE+Y=.[)CSL1Z7ETNT
MR:6D-.,"@:/Q5EDI,>I@-;?5]6VG[.72"4_.!'K*7B[E9-L[#*A2`!N$DX'I
MZ"7'B#3H[]#+I=.#FEJ@J]:=^U?_NEW/_SA8'.G`DPW*$L@7HS'@0#GE42:=
M(G*/R"-3W]-)2X745EVBV]&MX6,4L=ML;C_>97,KN6NOM[.;YZKWG=Y3$X4N
M49^:H8B@8T)!L@C<"$B:)7V1F)&)LJ=W],]96SY?&^[YEG^N%B3`Q?Y2H16]
M-%:A35DJ%;.%S-%[C:3ER<"WV3L^V)WU"V!5K\AWSJBW\\T?>3V;O5H2]+/-
M]NW5]I@N:]U/HP)JPP)3*3KPUOJ8F/>8,\T9(U]ZD>/!6-4!]D/Z0_QZ_6%V
M<[OXO.JZZ^W\TV53<`SHYP`TNY404AH&I$EH_T/_(FW"LA<0C\Z):?@Y1*ZB
M$8D!E'`HG:S,7,@@`+AB`:IK\(U\YG=.@O9^#J<A/CT_!TV*T=&:*7P2X%5P
M*D09/%,E$4'XOK(PG"CQUGX.IV$\33\'YTL0C78^@0;FF-412K4O,#IFB=]5
M5IC3A'Z"G\-I((_5SR$'JX6QG`7-P/.,3NH`46L3HW#55TL3\W-H+<O3_1Q.
M`WCL?@XHP,@,REMO`$2)"N4IR&@B<%06OP\_ARJZ]`7R>/T<1"SUK*3CG$E0
M"KP11ELI3!!,$7;?TX'+.<SI!>XQ^CD$J3A]M."!]O,B,VND4RZ5TA\6;*JU
M6R9YEG(.8;K'>HQ^#D*X;%CBV04%3"&&E(07(2O!/.A:K_`I^SET8L><C_6X
M_!RXH%TD9Q83:5/)DU-<6)D())\Y663?H9]#)SPY$^BZ6-C5<G.[V-([VVV"
M#CW?D`'.+8\1-"9:_I3S%B*`8M*$%*NSYYOOC10=`3S$.<O;$I![Y&SN\9G&
M@A:02R56AR5]A`U62/!96)!.L]I[G:GL=,X[?JN%<3`:'%PU]CS5`(_%*Q2T
MY`%"TI8GK[,G6UOYK.U%`AK[H4*%W/9)O@JW(63_9KZ<?[S]>%3Z7SS7",M$
MXB'3DN;!L!+`'4@K.:>%23J_H%B@*NFMNL-N$`Y<_=V.`T^?:TRV#FGUHY$#
M!)8=:B5HGZ2R%$KQ%Y3&MA,.G('=E/U?LQ88DPNVA"@EX[WE3A:_7^>2,-5Y
M5"9YXM7#!5XMT'5;C7VI/IX40:Y-[[6_BT;+S`@HGX-R()-RHLPPB-FF76SN
MRU$R78GV:(*O3I"^V'+TY.M/79">EJ&/:&B:,<-]%"!$0)$B"JM`.TBJ^O1C
MJHG!SN5$FV6J'O[N%JHC"2F?:].$E*14T4KE+"C%K,UD]0OF0U#)72:*8V+\
MZ!KD[HB1_OYSOCZ1&/=M&IX%V6R2,4,;0YZ45RXZYP,S3J)FM3KJ+//FQ1"C
M#N2IJR<IS/_*NYK=MF$8_$B31-$B@5VHO^,N>P"C6](AEW5(L&)[^TEIN^XO
MC:TD=IV=@@218),418G\^$'L`,LNCVAK6WE6.H#DXC!=<*T@Q-$IOU?12&[J
MS6F<\-M]T'-3N,>'V.V-?:^T^$(Q_J#!?25EJK#;R#&C)B1RADR74R61T\UH
MH=>:!YS019U9]%,6X,](.3]=G;WC%"O-`A$G!-=YG2-!R+;3D(NZCUG^T/JR
M0V"&!V+S0=ST8^;H:U@$HMFZXI54<.1):Q%M.@DAR/]>63]8[7?3**"M:/'/
MYZF(GP>-/:-^&FWK^%2],'D18SUXA9&R&+`,#DHD+EBD.\<9Y^I,[.QZ:`M!
M!C`C#S.T\3/U4)9+<,B4K4+!4-]60U>.?IB\'.<O7NB-\$7M[.)JF#)0>?K<
M!UR;V\UZ)3\)R"M4\-IC&&,-)Q4CF*[VZ&)2@53MG=T!!YN/WD].>.0]`2N(
M;!*7LWR7"=!D)^RX>+H,64>!:[K=/[O>A\,#QPEY>?!`X.BT24E;%M0^B='1
MN:!SV3`%\RPL\9,G%`<K>3B_]RBQ+A,1Z+RJI&J.O2EAEC$EE#>.2$@;)(C7
M#O,:I^<1(,!Q<EUR:4/T2,B<0'-$RHE2,)*P`X*B)-?:/>45)86F=CZMLCVI
M/\IC^NG=UUJ9<W?[OD2EATE@7AS4^QA"#KJK]?_%V(6<B@`NHS/*J68VU:7X
ME`;U_:O9R3ED.YM?2=_6VX^;W4-;LK]OB_58=W-LOE[$>EM].!.C4D@!@T]0
M?JQ=A?PL1%6+L+DIQ=[DH)X60+SYOI/[]?;FTWIU>[?][=$.^:DA8_NHT4#"
M*%*;0:OD+94U1M3Y>C$`K=#E5Y2\OJ2[NH"(I_!:PQJ4'6@(-GZ2GCF6A>$1
MC"ZK1*QH0!>DO+S*CE6K?SH)P;H(([NXK.>VM@,M,H<.[245R063*W:JB-%P
M["BHE%@G@2"S9+FOQK(:)#R7/0UL9CAVBCYD;2*7%W5=0#*)2J#I3>V%73PZ
M-P,<3D+)+MZ^SB#IN?U6W-QO5NO/JQ/VR%^GZ)5U43O498TY="E3QSDH\LER
M+4UIW2%/`MXNWL[.(.FFH/TP_?J7]79_E#T4LA\?V7?!9H1ROA`+&"U+.6R(
MMV`-!,S-%%QT]99R&0$?2XJ^?5/__.%FMRY??@!02P,$%`````@`CH9I1\S\
MW`"%%0``1N4``!$`'`!G86QE+3(P,34P.3,P+GAS9%54"0`#G!5!5IP5059U
M>`L``00E#@``!#D!``#M/6MSVSB2WZ_J_@/.7W:F:A1;MI/=I,:S)<OR1G6R
MY;.4R>Y^V:))2$*%`C0`:%O[ZP\-OD7P*2EF5JK*@R+1C6YTH]%H-(!?__JZ
M=-$SYH(P>G72?7=V@C"UF4/H_.KDRZ33F_2'PY.__O;?__7K_W0Z?[]^'*$;
M9GM+3"7J<VQ)[*`7(A?HJX/%-S3C;(F^,OZ-/%N=3@"%_*=7X7P2]@(O+61)
MR<F3)_$MX\L;/+,\5UZ=>/0/SW+)C&!'4>%BJ"15(/%96GR.Y;VUQ&)EV?CJ
M9"'EZM/IZ<O+R[NYY6)J/1&V6EA\:;VSV?+T_*S[_NSCA6)/,4S%)RA3&\@E
M]%L*Z/6)N^\8GZN29Q>G\/G)$C@L3AFEWM(,X$A^*M<K?*H*=50IS(D=P94#
MI0&@@",CF"15[T_]C\FBI(`'0H6TJ!WQ\)KA^>5"E^Y^_/CQ5'^-B@K'5%"A
M[9[^_6XTT:(_49J`D-8%LEPQ+A'-R'!FB2<-ZHG.W+)6((?+SEFW<]$]0;X&
MC9AM2:VR29Z-@*?8E2)\TXE1O5,TG*#3FO1PYF*Q(X(TKJTI`H78%44:5R.*
MBC0IAYXL"/SJA'`=>-7IGF])1MPIZY$1PNV$C(^G%K=!W$IRMNS@UY5K44LR
MOKY5OZN1YG*>PC*(D0"-'X'&[H=M:-2H*9Z#4:].4Q)JMX34:)@08GL"S(:Y
M"AU)R'L?<)?D-"-E"SK,PTC%7A0"0,WO:]8IL/UNSIY/;>91R==@HBZJV#83
M7/BC$R-I2HW'N7*-UI5-K1$P^M7(RJ;P.IC4IB6$@8?M*<"O]J(V"1&0?MJ>
M"$*?L9"UE20!%CQOKR+4(K8>BKMU*(FA_,=.C*`A'8+8M:D(8>!A!Q3(%:]/
M0@BDGXJ(L"AE4F/2[\*WJQ6A,Q:\4B]A#/\4#N2/>(:TO_HI&$6+O=K3%6<K
MS"51SE7"L=<(%AS/KDY@QM`)IPC_LBWWG?*#PR*9"M(NAAZO%(CMN9J-44QD
MB`'L]]6)4.WMXI#Y[\Z5@V=UN5(@A)(V,^5:3W694B#8;2L_*X[K\J-`A)I=
M-],]P#!5)1!1$[Z>;7,/.\H;Q51@T:/.6"XP[^MA3HZ(FE*[!%@Y00#WY7%8
M.NW6%%;'&U$7TA=KX&_GW;,/W;,SU$$W1-@N$Q['ZD>`'(78D44=I/&CH`*4
MJ.'7TTVTFS5Z`CMC^IM^WFS:`#HH4@2Y80^J`Z:[G!DN>!O*;B<BO<'2(N[>
M)!NB+Q3PY=F'R[/S[02,?@JJ^ODHZAQ93*TG=W]].,!>*.B+LP\79]UM!>W7
M='!ROO8$H5B`"*XM0<1X]I#@J:982Y"5V..NP1Z'&+7T-$[$9BB)]2BP9&OT
M'$=79;E#Y?`JX<`/WX;M5)9%]918Y:[!*I>+&?T45XD2=?X<FNACSTT)Z(&Y
MQ*[O7%5$6BABY7Z>9^UQ%1&'^`]6EGVV?")4T]-4<BD4)1;WO,CB)A$=Y4$;
M^K1%F$H,Y7F1H4SB.UPOU=2ZC1S2`D0EON>YP??,D=*!NIA]1AUPP1WU()2%
M=V!!Z-IR82UOLL!8UA56!81%0E-&3_T!PS=1S:J3"=1S?WQ_,[B?#&[@:3(>
M#6]Z4_7CNC?JW?<':/)Y,)A.CJ+;;.D'"Z92"RR)HGGG<DQC+Q/J>]T3:PM5
M^1W):H[]$\00M>)X-I',_K9@KH.Y&/SA$;FN#[$+S=@U227J=%'91DRFZK^[
MP?T4C6_5CW'_?S^/1S>#Q\F?T.#_O@RG_V@,>%3%I!35;*1OB<6MRUYV,F28
M$9>HQ65]M9B`>/N]R6=T.QI_/0XBF;9G2\7E0I4ASWC$Q.Z%FZF@1,CG384\
MOGMX''Q6Y8:_#]!H/#DX88,?S*@DU%,85IC[OF]/"#6:?\:N<\OX1,FQ;W&^
M)G3>6T(6AA*17Z)'G:U7$?9!0?%,K?OA\NQB<PZ0)`/%=/R"_'H0D()FC",@
M!O0KH`<%!$%T)"@*$9/1\+@H45FY5'=G%+I^+T@GAHG7E*GW2\QM8KGA!&V_
M&E:;C'(UN]Q:S2*B4)(J)!F*Z8HGL$=5*Y;Q7A6HNEIDXD3UU.(HY6)!W#-9
M.Z)4"W5QG+9KRE2H*6%=SU&^9B%,R)R2F9K\JYFB7XK.[QF%.8'R!_K6BDC+
MU0O)#I&J^?<[;C2FIMQ.O-]V^$C0AB+BD**N8RORM*<2$(B2%!XM3(G,&P6M
MZ^$NCF-W33D4-6W,@<:WPVUOJG,.5&/)=6)YNJY$BU`5"?`LBFE'F_`2C]`M
M?7S)I?-#D].M1?COENOA.VR!@NO@0$T!F7&4++.^-PS?@`AI3"B)ZB@3U0A]
M;7/FZO'!X_;"$OB!$QM#=(<X@1$*RCL].1"2+"'B$^$:TT<,NRD4#IUHT"C_
MY7M25K(0_-[@X.?H#_HI)A&%-")-)$I1^4L(YB!+HHC2)%Y&442MG[%QN,DV
M1FU0K<.H35RBZ1O/1O@9NQ>9\-$N%*]J5>6:E`E4Y6I2NDZ(1^E:T44R<?*H
M$BDY-?+CBC"59!^\-WAMN0(]4/]LA%7+/W!F8PRG%T".QY)(W28PGPKMI1W'
M>YM-[YK74])K_W*9%;*N#"5J^P4EZO,G8LD:45#7X<[$:HBG2;RG-OH2I_$O
M!J>QMM`/-.PS4NX.%;@WY[B1EY^%+PG079J$Y2-!,9:#%\/NLM-KH2Z)BUV:
MS&M&>,<$](QX&9U/,9S"\R3KBB\)6F((_VSJ6PJ^(Q4"!!@.N>$;NBH&#"5.
MR)]-O20EAL-U+>ZQA*R2!\PGJJ%Q36%L0I>,-1>&_J!0(,"!%!*DL1RX",`M
M8E0_BL&K[7H.=FXY6P;%&HTYC:HH&7LN#*&=K#`AJ@.5^;\$"JOS3U4+RQ_N
M2+0AF4:3<#..DD63"\/TVR2^`YUYZ^VV0ZK:&`?;<)O,K/*PE-A)T^8F?_^O
MCPO]%&#[^5"G2=F&U7K:S*4H059B!TU[G7*$I=$>KJ^1T\X[$E>IQ3-M=\KK
M50=J]1(Y$GU/2-4H/`@!J3FEY$$$O\^QFDX^$O&M67]K6DM)1S2M-263/J*Z
MPFA37!NL$/CU(:CP<+MH7=$T&12;U5$R9)H6JIL*_S"'U+IBJ5N^D:W_3D25
MC!RFI:J&RM54)P]U0(*];]>6@`TR2QB<FZ0FY2`IL2BF,UTT)J11H22NHU@`
M]>YBY/7QE_@&7</^@SQA'L/E%<7MNG#T)>Q7,WUNZ!MN4U6Y$F0=Q'PE".OT
MRW2>,F5^/F`_T2PF(;SE"I[$+>-C_?0WKH8Z,51?L+-+6U"MJG*-R"05%6A$
M7*=.'?9K17ZUR*_W:"32<M)O_8;JV9(\$[G>H1;D8R\7?&9#0;[@_2^!N,.*
MCI).RZ*9?U^$JL0K[YJ\\EP9'K(#O<UY%C5/GSCOGGW,<YP#+']"/IZC*';L
M,%?&7;)>_C'/3]H0X-%1+A=QL-0*[WL</RH&^3.&[4VW'FPO`Z<!S@S:D=#K
MU5:N!F;G**,&X1*O-KZP:AC6K-TDOVX45G[4CEA>S<=,$YKB\1*.53>/EQEY
M'NI8Z3T)_(>GF!@\-TB]S("7!)A,V6$Q#N0C.309?+6XGD[5;/L(K*3-SPQM
M'L(>:E/W%Q:=8S&D\5ZO6?`MW"W3;,[6H(*2:=N9(8P7UJ*&(;\>1&AJ+]@L
M+!)M_CG@N5O86EE1B*&(]M)]$;#-S[7L;Q-;C0Y8^'-?V(RG/MPQ![M;:<2N
M:B]7EXP'$ZN+44>4]HC$GD)-"M*T=`)BPCA`0`[2]!P5"J["=#PWENA6X9ZJ
M6,L5(#.3B14@1)XT$<?H3M@^C7S3#>"2",Z9P2.-Q7.@7FC8`-'HZ5I"Z!N"
M>X&[WVQEI3K>\DZ5B9W&4HN>8OS($L'4XC!63'X]W;RY+7B3ON%-W^\67`F-
MK"<AN67+JQ/)/7RB-0%$^:^>_N#>X>43YB?ZCKJKD\V7Q'6ALX3`0LTB))&>
MORC"O-75B;XC^1.1>'F"_)NP_)N</SEL:1$Z5!^`@Q/D%UQA3I@SU04=CP>K
M[J?UZ7XD\X44]U@:&<A^?3M.8LK]ZW>&%"9@C*_#LPA$</E.Q$-YN2;<^&^6
MC*J.PM>;[#SY9TQ?G=@Z.\3$I7_9L"QA4C694B#58%*9"X7Q%N.(,?.WUC&3
MKWLK3MSI"YLNF"<LZ@Q<K&046*8-1:Q4M`U:*>\L_@W+,(P&YQ:)>(_?G?5*
MEMY242-$L,M61#PV`MVCN!W\9);V3IKB`7-(I&*S)HV1"]Q(!93\5S["(@6H
MU&&CZVUL-9(*/2[!L6IPCM7U6K]4?<@_*2EDM1[(6\B[%N>)&RG@?(\Y)?]6
MUM=19967`:0'Q^`&C%FIXW#UVCUV_`%GLX%VBKFU[>B'1U)1F,1Z03P/%WI0
MZROSA6V@^BN1B]\M59D7^(FW!$8%V,0?-N1^4+_)@%/-!!D9WCQ@*75J46%3
ME4'^Z"V1/6JJ5G,8P=L[/AEXV@AWZMO-<AO`6+CM[!:'=_5<?HI?Y;6K#$*:
M]YJ06_AB,D2SO3NF9[=Q]'+,??L_>%T1'_S&DI%#7;5P<QG#O0$[8HJ%=#*?
MS-ZSZG-S['M-NB=^$7I->?`*1VX'O3/%:F,46S1`P.">&D&+"CN%7,9EFK,A
M]"[IW<_&C01'O>Z1N:Z2QHO%BSG,`=B"70DG].U)9CHOLT1F<9D?1&9C3X*K
M!T<H595:+DA+Y0:G>Q0R%!1HA[%@L$*D[5?*YXT9R"^PQ912;\YO.J?,U[C,
M]0X3/`>0=,RDO%@+XB454Z%R').&P"WQ36+J@Q/-_<,W<OD8SP;+E<O6&&N@
MR.U6_J&A17:!<Y_6MJ'J4^&Y`!=Z:9LZG_N]%<H>3IE2LR1]*?':_]>@X[5@
MVJ+:Y7/#>RR5I?5C\`^,IV:;C<%;%_Q.-0FH-/1$2S'U8*V!TB3+YL_M9\FS
MW/&32^:A7'2L=KI0_1]2%C<Y+"W]@S'\P"1$("U7B4S'IF?^$4V:KT+FRR!;
MW!`:7)E6EHI:+RQ*L1NMM&TLQ-4%:AW[^:-2L$/\ECSCC?'(]*6%R\`1G<SC
M.1PDO[28@S'-$4'R0XOI!TN8PT'Z4YMY>&$Y'"0^M,`?@S,EAZK#<WV)B;Z@
MU;)U.#.QS%Y6Z*U7'`WT$1J-*05<I$NUBPV('0RIQ,HKD&/JKLUL&$J]8;0A
MMUO<8%LK?2)_8?J"W6=L3'6H7+H5'6A&;")[MNTM(7L+.S<>A)QNX!H'MH+"
M:@8JK7FB-]6`:)T'$#-.Q(H)R]5D#"D<E@E,F*[+BB<ST6()'.)YHSP"S0V/
MSYB.&FE?V/]3&S1(!U%:PV;&]<O]H7]SN]F$LT>L9QZ,JB%,;-5&FYC^PS0L
MQ5ZN&CPJDZTZG+.[EJQ2U0^D>6%40XUE"4/?H+ER$;5NW3W?&PCNS"NZB:\7
M`$<M5`_F[5>,HJ`RYL_$QCH(G3D_X@OE41I7\GV?B3CY:R>86J<=.VRHKQ@6
MV[`3K-X_:!+&LR!#+CD(?J>ZVNB"0]J:-A6W'J>^6T2=6_*J[XY-^]_5BK;`
M^8ZVO_F)X""P6\9G6-/\J#Y$)RZ)8/U\RD(5B+O7EDCV.`CMKQ4FF!+&[RRJ
M=#@Y$.T(5WO:Y!]JL!S/'BSP+.(TI@R[N<6:=^4YX-R>DX*,L\0Q7W`@M`W2
M2*0D-()L0ZZ"<=.M*2,WL=8+!I@[L$4,S/1X%AXAE-<46V!L[U!J8-.0R%E:
MJKTS&`/IT1*2NYY@*5T,I`_U_H$"AHNA?H`&B%*-Q$;V6&&)%J=GY].]BJ[\
M*>,P4?*M4I9B?F!/)G9AICI4TU@Z)YGM&3F)#1&?VV!HL0HW9BL(U?L^]_:M
MM(FNC5[[+>%"3I5VVXN-)3'CEQ;XY'YRU1UQL9!*DS8687*_ME=?_]8;#2[/
MNCRU(6OS96OW4@VIWAHH1!@W,D2?2LJTC;?<SA)>6`G'Z`/-S-?7>,_DB%!M
MV",QUH)XLYA2<X:GR02KRJ6K,>K(3XLU3-B\)]U$WXME:C-7V6X>IG>.1OVT
M92PNT@(3"3>7Q7<(I]96].W#.OQMD6B(JU'^K2/B0.HXW)4^>+7UOJDD'Z:/
MK9M0Y6K?W8WJ/9@+V)^L\/,^AK7WM/J5E&EATLK=Z/<^>Z<ZB44=O<=>$Y+I
M5^7%VL@;C&?53EBH5O0'X/&6S"2.*!?%7.85_@'XG%84I*%<"T:!X#2+.TMY
MQ/X*.R!@X12EY[J?E7?IKD=$S6*<=-J/Z`D(5<!0KOZ#R-0SG*84^Z?[0MZ&
M\.`=$396=%"LQ)N]8R]J@M)B+8Z&W,/V4_](#TAF";>?&D\K"!FN"=.Z43=F
MWH->RF;^]BUB6Z[BR_'L!*M%)9HS!N<(S7%AT+Z2%Q22=V.M1;!0Z,QR]B%7
M+-N&CA>1JG<*3B3'="X7&:%D/[='(@^*33!E-\2:4R:P`T'_:XXM(7UO+2S@
MKW_%:9?;(-@K^_5$5YO\GH2!`JYV4X)5^F@)_(AMO4,AJ\,[Q]ZBEO-W$:J!
M]`LE<I/QS8]OM6LP0_64K115D"$#>WOU08MV8BFHO%@+)!"L-^=NX/P"TRU(
MU+`H@3,Z8")+GE.;0K=#T;H]H&..7S?V%Z1?M<"]]=?2X4Y+_ZFW6KEJH(X2
M:0JW?#8%;L?>S\#*]80@(%Q;#>)LSJWEQFZP\F+M#8JGLC/3IGTVT_D$3^LA
MM1S\AZ<$Z*[U[C_FNMB!X>";7"CRYXL0DM#KJ?T0M<M^<+]Y3DK2.0\-#^.P
MU9$%R07*@]>6Z$7-V<+\3P].P%5N+E%JHDR8FLZ.52M`<#68R$3&?(_X6SQ3
M"O='1V'L9`I,WL<V>-/*T0D.'O8-6S9+Y\N*T7`>$')4&ZK%HO-/M*2.TD/)
MR9/GC]&I=;;B(FU;F:K"V3^]E8OIORLP&)=L+Y_1J?<#BU/P'8/T"0@UZ:`#
M_`BN[3&?8+(=BC<=\'/]LYBGB;=<JN97#_%UVCU;6UU@%1P8Y7!FUB6W0="^
M9<JZW*16+9L"MV`1T]``&Y=#^/I<TB\JP;3#\\T0#7E:_BISG'%:D=]*H"WM
M_W@E,SM8%X0G%EK2L[<Z`"V8VYGW3?2`3C\%_'H=%PER?'IPEEN<6IU.XMHE
MPC;X=HWY&4=)V9"X-@RX&E(P1(+8.NUQZT:K6$E[%PBVY3RX?SM@7/^"@TU[
M<S5-F,,!I7MI[]JUME@`L)84W%^N-Z_[//EAT#&L8K@NDP#C\QXU87VX]AUW
MJ6ST/S'7?R>0(9`*%Z;M>K6B+;#HP2`S41KX+;T^9?SRYMG5F?O9##M:?F=P
MFXZ;V`92&^JMTZF*"(95DUN.<7C\QV/B'.<&<&UA-4CE3Z^L;/*55ZAUD?I@
M#I^V"ILO6YAJ$Y#H!R*,U&]\^HX\^'=4"35?6%KJY_\#4$L!`AX#%`````@`
MCH9I1S_E*ZNB0@$`M'82`!$`&````````0```*2!`````&=A;&4M,C`Q-3`Y
M,S`N>&UL550%``.<%4%6=7@+``$$)0X```0Y`0``4$L!`AX#%`````@`CH9I
M1Z_RM`T?'```7QD!`!4`&````````0```*2![4(!`&=A;&4M,C`Q-3`Y,S!?
M8V%L+GAM;%54!0`#G!5!5G5X"P`!!"4.```$.0$``%!+`0(>`Q0````(`(Z&
M:4?KA(5<TU0``-/<`P`5`!@```````$```"D@5M?`0!G86QE+3(P,34P.3,P
M7V1E9BYX;6Q55`4``YP5059U>`L``00E#@``!#D!``!02P$"'@,4````"`".
MAFE';H.(VFG6```"20H`%0`8```````!````I(%]M`$`9V%L92TR,#$U,#DS
M,%]L86(N>&UL550%``.<%4%6=7@+``$$)0X```0Y`0``4$L!`AX#%`````@`
MCH9I1RVST#HE?```?/L%`!4`&````````0```*2!-8L"`&=A;&4M,C`Q-3`Y
M,S!?<')E+GAM;%54!0`#G!5!5G5X"P`!!"4.```$.0$``%!+`0(>`Q0````(
M`(Z&:4?,_-P`A14``$;E```1`!@```````$```"D@:D'`P!G86QE+3(P,34P
M.3,P+GAS9%54!0`#G!5!5G5X"P`!!"4.```$.0$``%!+!08`````!@`&`!H"
(``!Y'0,`````
`
end

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.0.814</span><table class="report" border="0" cellspacing="2" id="idm139922623732560">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock Based Compensation (Assumptions for Option Grants Issued) (Detail)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2015</div></th>
<th class="th"><div>Sep. 30, 2014</div></th>
<th class="th"><div>Sep. 30, 2015</div></th>
<th class="th"><div>Sep. 30, 2014</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Disclosure of Compensation Related Costs, Share-based Payments [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk free interest rate</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">2.02%<span></span>
</td>
<td class="nump">1.50%<span></span>
</td>
<td class="nump">2.02%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Volatility</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">79.10%<span></span>
</td>
<td class="nump">74.20%<span></span>
</td>
<td class="nump">79.47%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected lives (years)</a></td>
<td class="text">0 days<span></span>
</td>
<td class="text">6 years 1 month 13 days<span></span>
</td>
<td class="text">6 years 1 month 2 days<span></span>
</td>
<td class="text">6 years 1 month 24 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Expected dividend yield</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 718<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 2<br><br><br><br> -Subparagraph (f)(2)(iii)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 718<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 2<br><br><br><br> -Subparagraph (f)(2)(ii)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 718<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 2<br><br><br><br> -Subparagraph (f)(2)(iv)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expected term of share-based compensation awards, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 718<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SAB TOPIC 14.D.2)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=27013229&amp;loc=d3e301413-122809<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 718<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 2<br><br><br><br> -Subparagraph (f)(2)(i)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Staff Accounting Bulletin (SAB)<br><br><br><br> -Number Topic 14<br><br><br><br> -Section D<br><br><br><br> -Subsection 2<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.0.814</span><table class="report" border="0" cellspacing="2" id="idm139922623621040">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Business and Basis of Presentation (Additional Information) (Detail)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2014</div></th>
<th class="th"><div>Sep. 30, 2015</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_ScheduleOfSummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Schedule Of Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_MaximumMaturityPeriodToConsiderAllHighlyLiquidDebtInstrumentsAsCashAndCashEquivalents', window );">Highly-liquid debt instruments maturity days</a></td>
<td class="text">90 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RangeAxis=us-gaap_MinimumMember', window );">Minimum [Member] | Equipment and Furnishings [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_ScheduleOfSummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Schedule Of Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated useful lives</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RangeAxis=us-gaap_MaximumMember', window );">Maximum [Member] | Equipment and Furnishings [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_ScheduleOfSummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Schedule Of Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated useful lives</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gale_MaximumMaturityPeriodToConsiderAllHighlyLiquidDebtInstrumentsAsCashAndCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Maximum Maturity Period To Consider All Highly Liquid Debt Instruments As Cash And Cash Equivalents</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gale_MaximumMaturityPeriodToConsiderAllHighlyLiquidDebtInstrumentsAsCashAndCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gale_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gale_ScheduleOfSummaryOfSignificantAccountingPoliciesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Schedule Of Summary Of Significant Accounting Policies [Line Items]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gale_ScheduleOfSummaryOfSignificantAccountingPoliciesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gale_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RangeAxis=us-gaap_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RangeAxis=us-gaap_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=gale_EquipmentFurnitureAndFixturesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=gale_EquipmentFurnitureAndFixturesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RangeAxis=us-gaap_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RangeAxis=us-gaap_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.0.814</span><table class="report" border="0" cellspacing="2" id="idm139922644436320">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Discontinued Operations, Assets Held for Sale (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2015</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract', window );"><strong>Discontinued Operations and Disposal Groups [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock', window );">Schedule of Disposal Groups, Including Discontinued Operations, Income Statement, Balance Sheet and Additional Disclosures</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-indent:66px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">The following table presents a reconciliation of the carrying amounts of assets and liabilities of the commercial operations to assets held for sale, net in the balance sheets (in thousands):</font></div><div style="line-height:120%;text-align:center;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:682px;border-collapse:collapse;text-align:left;"><tr><td colspan="8" rowspan="1"></td></tr><tr><td width="490px" rowspan="1" colspan="1"></td><td width="8px" rowspan="1" colspan="1"></td><td width="79px" rowspan="1" colspan="1"></td><td width="4px" rowspan="1" colspan="1"></td><td width="5px" rowspan="1" colspan="1"></td><td width="8px" rowspan="1" colspan="1"></td><td width="79px" rowspan="1" colspan="1"></td><td width="4px" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">September 30, 2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">December 31, 2014</font></div></td></tr><tr><td colspan="8" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Carrying amounts of assets included as part of discontinued operations:</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Accounts receivable</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">1,238</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">1,535</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Inventories</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">1,318</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">655</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Prepaid expenses and other current assets</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">1,064</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">1,747</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Equipment and furnishings, net</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">241</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">270</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Abstral rights, net</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">13,738</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">14,533</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Zuplenz rights</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">8,101</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">8,101</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Goodwill</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">172</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">172</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Impairment charge from classification as assets held for sale</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(8,071</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Total current assets held for sale</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">17,801</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">27,013</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td colspan="8" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Carrying amounts of liabilities included as part of discontinued operations:</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Accounts payable</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">1,359</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">385</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Accrued expenses and other current liabilities</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">6,338</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">6,784</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Total current liabilities held for sale</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">7,697</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">7,169</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div><div style="line-height:120%;text-align:center;text-indent:66px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:66px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">The following table represents the components attributable to the commercial operations that are presented in the consolidated statement of comprehensive loss as discontinued operations (in thousands):</font></div><div style="line-height:120%;text-align:center;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:681px;border-collapse:collapse;text-align:left;"><tr><td colspan="16" rowspan="1"></td></tr><tr><td width="300px" rowspan="1" colspan="1"></td><td width="8px" rowspan="1" colspan="1"></td><td width="78px" rowspan="1" colspan="1"></td><td width="4px" rowspan="1" colspan="1"></td><td width="5px" rowspan="1" colspan="1"></td><td width="8px" rowspan="1" colspan="1"></td><td width="77px" rowspan="1" colspan="1"></td><td width="4px" rowspan="1" colspan="1"></td><td width="5px" rowspan="1" colspan="1"></td><td width="8px" rowspan="1" colspan="1"></td><td width="78px" rowspan="1" colspan="1"></td><td width="4px" rowspan="1" colspan="1"></td><td width="5px" rowspan="1" colspan="1"></td><td width="8px" rowspan="1" colspan="1"></td><td width="78px" rowspan="1" colspan="1"></td><td width="4px" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Three Months Ended September 30,</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Nine Months Ended September 30,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">2014</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">2014</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Net revenue</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">2,166</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">1,620</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">8,298</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">6,124</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Cost of revenue</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(712</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(247</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(1,573</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(925</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Amortization of certain acquired intangible assets</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(208</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(70</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(795</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(259</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Research and development</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(160</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(219</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(339</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(619</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Selling, general, and administrative</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(4,672</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(3,725</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(13,577</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(10,954</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Non-operating income (expense)</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(17</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(17</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Impairment charge from classification as assets held for sale</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(8,071</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(8,071</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Loss from discontinued operations</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(11,674</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(2,641</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(16,074</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(6,633</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td></tr></table></div></div><div style="line-height:120%;text-align:left;text-indent:66px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:66px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">The following table presents significant operating non-cash items and capital expenditures related to discontinued operations (in thousands):</font></div><div style="line-height:120%;text-indent:66px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:682px;border-collapse:collapse;text-align:left;"><tr><td colspan="8" rowspan="1"></td></tr><tr><td width="490px" rowspan="1" colspan="1"></td><td width="8px" rowspan="1" colspan="1"></td><td width="79px" rowspan="1" colspan="1"></td><td width="4px" rowspan="1" colspan="1"></td><td width="5px" rowspan="1" colspan="1"></td><td width="8px" rowspan="1" colspan="1"></td><td width="79px" rowspan="1" colspan="1"></td><td width="4px" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">September 30, 2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">September 30, 2014</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Impairment of assets held for sale</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">8,071</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Depreciation and amortization</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">858</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">319</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Stock-based compensation</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">788</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">557</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Purchases of property and equipment</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(34</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Cash paid for acquisition of Zuplenz rights</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(500</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(3,056</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of disposal groups, which may include the gain (loss) recognized in the income statement and the income statement caption that includes that gain (loss), amounts of revenues and pretax profit or loss reported in discontinued operations, the classification and carrying value of the assets and liabilities comprising the disposal group, and the segment in which the disposal group was reported. Also may include the amount of adjustments to amounts previously reported in discontinued operations such as resolution of contingencies arising from the disposal transaction or the operations of the component prior to disposal.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 205<br><br><br><br> -SubTopic 20<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 5<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6360339&amp;loc=d3e1510-107760<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 205<br><br><br><br> -SubTopic 20<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 3<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6892542&amp;loc=d3e957-107759<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 360<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 5<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=8077374&amp;loc=d3e2443-110228<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 205<br><br><br><br> -SubTopic 20<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 3<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6360339&amp;loc=d3e1474-107760<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 205<br><br><br><br> -SubTopic 20<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6360339&amp;loc=d3e1361-107760<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.0.814</span><table class="report" border="0" cellspacing="2" id="idm139922625864768">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock Based Compensation (Additional Information) (Detail)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th">
<div>Sep. 30, 2015 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted average exercise price, granted | $ / shares</a></td>
<td class="nump">$ 1.14<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2', window );">Averages contractual term</a></td>
<td class="text">10 years<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_EstimatedAnnualizedForfeitureRateForOptionsGrantedToEmployees', window );">Estimated annualized forfeiture rate for options granted to employees</a></td>
<td class="nump">15.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_EstimatedAnnualizedForfeitureRateForOptionsGrantedToSeniorManagement', window );">Estimated annualized forfeiture rate for options granted to senior management</a></td>
<td class="nump">8.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_EmployeeServiceShareBasedCompensationUnrecognizedCompensationCosts', window );">Unrecognized compensation cost | $</a></td>
<td class="nump">$ 4,815<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_EmployeeServiceShareBasedCompensationUnrecognizedCompensationCostsWeightedAveragePeriodOfRecognition', window );">Operating expenses weighted average period</a></td>
<td class="text">2 years 4 months 2 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Shares subject to outstanding common stock options granted</a></td>
<td class="nump">3,682,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RangeAxis=us-gaap_MinimumMember', window );">Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1', window );">Average vesting term</a></td>
<td class="text">4 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RangeAxis=us-gaap_MaximumMember', window );">Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1', window );">Average vesting term</a></td>
<td class="text">6 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TitleOfIndividualAxis=gale_TwoZeroZeroSevenIncentivePlanMember', window );">2007 Incentive Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Shares of common stock reserved for issuance</a></td>
<td class="nump">26,500,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Shares subject to outstanding common stock options granted</a></td>
<td class="nump">11,188,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Shares available for future grants</a></td>
<td class="nump">10,251,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting periods of options granted</a></td>
<td class="text">4 years<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationPeriod', window );">Options expire from date of grant</a></td>
<td class="text">10 years<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_ClosingPriceOfCommonStock', window );">Closing price of the Company's common stock | $ / shares</a></td>
<td class="nump">$ 1.58<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gale_ClosingPriceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Closing price of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gale_ClosingPriceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gale_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gale_EmployeeServiceShareBasedCompensationUnrecognizedCompensationCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Employee Service Share Based Compensation Unrecognized Compensation Costs</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gale_EmployeeServiceShareBasedCompensationUnrecognizedCompensationCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gale_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gale_EmployeeServiceShareBasedCompensationUnrecognizedCompensationCostsWeightedAveragePeriodOfRecognition">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Employee Service Share Based Compensation Unrecognized Compensation Costs Weighted Average Period Of Recognition</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gale_EmployeeServiceShareBasedCompensationUnrecognizedCompensationCostsWeightedAveragePeriodOfRecognition</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gale_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gale_EstimatedAnnualizedForfeitureRateForOptionsGrantedToEmployees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Estimated annualized forfeiture rate for options granted to employees.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gale_EstimatedAnnualizedForfeitureRateForOptionsGrantedToEmployees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gale_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gale_EstimatedAnnualizedForfeitureRateForOptionsGrantedToSeniorManagement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Estimated annualized forfeiture rate for options granted to senior management.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gale_EstimatedAnnualizedForfeitureRateForOptionsGrantedToSeniorManagement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gale_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gale_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share Based Compensation Arrangement By Share Based Payment Award Expiration Period</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gale_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gale_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period which an employee's right to exercise an award is no longer contingent on satisfaction of either a service condition, market condition or a performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 718<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 2<br><br><br><br> -Subparagraph (a)(1)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of shares (or other type of equity) originally approved (usually by shareholders and board of directors), net of any subsequent amendments and adjustments, for awards under the equity-based compensation plan. As stock or unit options and equity instruments other than options are awarded to participants, the shares or units remain authorized and become reserved for issuance under outstanding awards (not necessarily vested).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 718<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 2<br><br><br><br> -Subparagraph (a)(3)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 718<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 2<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 718<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 2<br><br><br><br> -Subparagraph (d)(1)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for fully vested and expected to vest options that are exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 718<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 2<br><br><br><br> -Subparagraph (e)(2)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term of outstanding stock options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 718<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 2<br><br><br><br> -Subparagraph (e)(1)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RangeAxis=us-gaap_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RangeAxis=us-gaap_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RangeAxis=us-gaap_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RangeAxis=us-gaap_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TitleOfIndividualAxis=gale_TwoZeroZeroSevenIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TitleOfIndividualAxis=gale_TwoZeroZeroSevenIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.0.814</span><table class="report" border="0" cellspacing="2" id="idm139922623403264">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Business Combinations (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Sep. 30, 2015</div></th>
<th class="th"><div>Dec. 31, 2014</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="nump">$ 5,898<span></span>
</td>
<td class="nump">$ 5,897<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 350<br><br><br><br> -SubTopic 20<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=35741047&amp;loc=d3e13816-109267<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 350<br><br><br><br> -SubTopic 20<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6388280&amp;loc=d3e13770-109266<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.0.814</span><table class="report" border="0" cellspacing="2" id="idm139922622902944">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair Value Measurements (Contingent Purchase Price Consideration, Measured at Estimated Fair Value on Recurring Basis) (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Sep. 30, 2015</div></th>
<th class="th"><div>Dec. 31, 2014</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_FairValueOfWarrantsPotentiallySettleableInCash', window );">Warrants potentially settleable in cash</a></td>
<td class="nump">$ 16,661<span></span>
</td>
<td class="nump">$ 5,383<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Unobservable Inputs (Level 3) [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContingentConsiderationClassifiedAsEquityFairValueDisclosure', window );">Contingent purchase price consideration</a></td>
<td class="nump">6,582<span></span>
</td>
<td class="nump">6,651<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents</a></td>
<td class="nump">32,618<span></span>
</td>
<td class="nump">19,477<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsHeldForSaleLongLivedFairValueDisclosure', window );">Assets held for sale</a></td>
<td class="nump">17,801<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets</a></td>
<td class="nump">50,419<span></span>
</td>
<td class="nump">19,477<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_FairValueOfWarrantsPotentiallySettleableInCash', window );">Warrants potentially settleable in cash</a></td>
<td class="nump">16,661<span></span>
</td>
<td class="nump">5,383<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContingentConsiderationClassifiedAsEquityFairValueDisclosure', window );">Contingent purchase price consideration</a></td>
<td class="nump">6,582<span></span>
</td>
<td class="nump">6,651<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityFairValueDisclosure', window );">Total liabilities</a></td>
<td class="nump">23,243<span></span>
</td>
<td class="nump">12,034<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring [Member] | Quoted Prices in Active Markets (Level 1) [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents</a></td>
<td class="nump">32,618<span></span>
</td>
<td class="nump">19,477<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsHeldForSaleLongLivedFairValueDisclosure', window );">Assets held for sale</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets</a></td>
<td class="nump">32,618<span></span>
</td>
<td class="nump">19,477<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_FairValueOfWarrantsPotentiallySettleableInCash', window );">Warrants potentially settleable in cash</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContingentConsiderationClassifiedAsEquityFairValueDisclosure', window );">Contingent purchase price consideration</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityFairValueDisclosure', window );">Total liabilities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring [Member] | Significant Other Observable Inputs (Level 2) [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsHeldForSaleLongLivedFairValueDisclosure', window );">Assets held for sale</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_FairValueOfWarrantsPotentiallySettleableInCash', window );">Warrants potentially settleable in cash</a></td>
<td class="nump">16,661<span></span>
</td>
<td class="nump">5,383<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContingentConsiderationClassifiedAsEquityFairValueDisclosure', window );">Contingent purchase price consideration</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityFairValueDisclosure', window );">Total liabilities</a></td>
<td class="nump">16,661<span></span>
</td>
<td class="nump">5,383<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring [Member] | Unobservable Inputs (Level 3) [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsHeldForSaleLongLivedFairValueDisclosure', window );">Assets held for sale</a></td>
<td class="nump">17,801<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets</a></td>
<td class="nump">17,801<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_FairValueOfWarrantsPotentiallySettleableInCash', window );">Warrants potentially settleable in cash</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContingentConsiderationClassifiedAsEquityFairValueDisclosure', window );">Contingent purchase price consideration</a></td>
<td class="nump">6,582<span></span>
</td>
<td class="nump">6,651<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityFairValueDisclosure', window );">Total liabilities</a></td>
<td class="nump">$ 6,582<span></span>
</td>
<td class="nump">$ 6,651<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gale_FairValueOfWarrantsPotentiallySettleableInCash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of warrants potentially settleable in cash.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gale_FairValueOfWarrantsPotentiallySettleableInCash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gale_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 820<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 2<br><br><br><br> -Subparagraph (a)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=36462937&amp;loc=d3e19207-110258<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsFairValueDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsFairValueDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsHeldForSaleLongLivedFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of assets classified as held for sale.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 820<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (a)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=36462937&amp;loc=d3e19190-110258<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsHeldForSaleLongLivedFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Glossary Cash<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6506951<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Glossary Cash Equivalents<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6507016<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContingentConsiderationClassifiedAsEquityFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of contingent consideration in a business combination that is classified in shareholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 820<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 2<br><br><br><br> -Subparagraph (a)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=36462937&amp;loc=d3e19207-110258<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContingentConsiderationClassifiedAsEquityFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of the entity's equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 820<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 2<br><br><br><br> -Subparagraph (a)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=36462937&amp;loc=d3e19207-110258<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesFairValueDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesFairValueDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.0.814</span><table class="report" border="0" cellspacing="2" id="idm139922623371552">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2015</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentsDisclosureTextBlock', window );">Fair Value Measurements</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#00497f;font-weight:bold;">Fair Value Measurements</font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:12px;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">The company follows ASC&#160;820, &#8220;Fair Value Measurements and Disclosures,&#8221; (&#8220;ASC 820&#8221;) for the company&#8217;s financial assets and liabilities that are re-measured and reported at fair value at each reporting period, and are re-measured and reported at fair value at least annually using a fair value hierarchy that is broken down into three levels. Level inputs are defined as follows:</font></div><div style="line-height:120%;padding-bottom:12px;padding-left:108px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Level&#160;1&#160;&#8212; quoted prices in active markets for identical assets or liabilities.</font></div><div style="line-height:120%;padding-bottom:12px;padding-left:108px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Level&#160;2&#160;&#8212; other significant observable inputs for the assets or liabilities through corroboration with market data at the measurement date.</font></div><div style="line-height:120%;padding-left:108px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Level&#160;3&#160;&#8212; significant unobservable inputs that reflect management&#8217;s best estimate of what market participants would use to price the assets or liabilities at the measurement date.</font></div><div style="line-height:120%;text-indent:106px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:66px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">The company categorized its cash equivalents as Level&#160;1. The valuations for Level&#160;1 were determined based on a &#8220;market approach&#8221; using quoted prices in active markets for identical assets. Valuation of these assets does not require a significant degree of judgment. The company categorized its warrants potentially settleable in cash as Level&#160;2 inputs. The warrants are measured at market value on a recurring basis and are being marked to market each quarter-end until they are completely settled. The warrants are valued using an appropriate pricing model, using assumptions consistent with our application of ASC&#160;718. The contingent purchase price consideration is categorized as Level 3 inputs and is measured at its estimated fair value on a recurring basis and is adjusted at each quarter-end until it is completely settled. The contingent purchase price consideration is valued based on the expected timing of milestones, the expected probability of success for each milestone and discount rates based on a corporate debt interest rate index publicly issued.</font></div><div style="line-height:120%;text-indent:66px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:66px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">As discussed in Note 12, the Company met the relevant criteria for reporting the commercial operations as held for sale as of September 30, 2015, and as a result, assessed the commercial asset group for impairment pursuant to ASC Topic 360, </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;">Property, Plant, and Equipment.</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> The net carrying value of the commercial asset group was compared to its fair value as of September 30, 2105. The Company determined that the fair value using a risk adjusted net present value of deal consideration received from bids from potential acquirers, which the Company concluded was a Level 3 input. The Company determined that the carrying value exceeded its fair value and as a result recorded an $8.1 million impairment charge on assets classified as held for sale in the quarterly period ended September 30, 2015.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:66px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">The following tables present information about our assets and liabilities measured at fair value on a recurring basis in the condensed consolidated balance sheets (in thousands):</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">&#160;</font><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16" rowspan="1"></td></tr><tr><td width="41%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="12%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="12%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="12%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="12%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;font-weight:bold;text-decoration:underline;">Description</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">September&#160;30, 2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Quoted&#160;Prices&#160;In&#160;&#160;&#160;&#160;</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Active Markets</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">(Level 1)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Significant&#160;Other</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Observable&#160;</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Inputs (Level 2)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Unobservable&#160;</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Inputs</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">(Level 3)</font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Assets:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Cash equivalents</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">32,618</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">32,618</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Assets held for sale</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">17,801</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">17,801</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:middle;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Total assets measured and recorded at fair value</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">50,419</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">32,618</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">17,801</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Liabilities:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Warrants potentially settleable in cash</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">16,661</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">16,661</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Contingent purchase price consideration</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">6,582</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">6,582</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:middle;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Total liabilities measured and recorded at fair value</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">23,243</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">16,661</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">6,582</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16" rowspan="1"></td></tr><tr><td width="41%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="12%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="12%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="12%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="12%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;font-weight:bold;text-decoration:underline;">Description</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">December&#160;31, 2014</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Quoted&#160;Prices&#160;In&#160;&#160;&#160;&#160;</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Active Markets</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">(Level 1)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Significant&#160;Other</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Observable&#160;</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Inputs (Level 2)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Unobservable&#160;</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Inputs</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">(Level 3)</font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Assets:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Cash equivalents</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">19,477</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">19,477</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Total assets measured and recorded at fair value</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">19,477</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">19,477</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Liabilities:</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Warrants potentially settleable in cash</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">5,383</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">5,383</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Contingent purchase price consideration</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">6,651</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">6,651</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Total liabilities measured and recorded at fair value</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">12,034</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">5,383</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">6,651</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">The company did not transfer any financial instruments into or out of Level 3 classification during the three and nine months ended </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">September&#160;30, 2015</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> or 2014. A reconciliation of the beginning and ending Level 3 liabilities for the nine months ended </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">September&#160;30, 2015</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> is as follows (in thousands):</font></div><div style="line-height:120%;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">&#160;</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="4" rowspan="1"></td></tr><tr><td width="86%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="12%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Fair Value</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Measurements</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Using&#160;Significant</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Unobservable</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Inputs</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">(Level 3)</font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Balance, January&#160;1, 2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">6,651</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Change in the estimated fair value of the contingent purchase price consideration</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(69</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Balance at September&#160;30, 2015</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">6,582</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">The fair value of the contingent purchase price consideration is measured at the end of each reporting period using Level 3 inputs in a probability-weighted, discounted cash-outflow model. The significant unobservable assumptions include the probability of achieving each milestone, the date we expect to reach the milestone, and a determination of present value factors used to discount future expected cash outflows.</font></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for financial instruments. This disclosure includes, but is not limited to, fair value measurements of short and long term marketable securities, international currencies forward contracts, and auction rate securities. Financial instruments may include hedging and non-hedging currency exchange instruments, derivatives, securitizations and securities available for sale at fair value. Also included are investment results, realized and unrealized gains and losses as well as impairments and risk management disclosures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.0.814</span><table class="report" border="0" cellspacing="2" id="idm139922622794240">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements (Reconciliation of Level 3 Liabilities) (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2015</div></th>
<th class="th"><div>Sep. 30, 2014</div></th>
<th class="th"><div>Sep. 30, 2015</div></th>
<th class="th"><div>Sep. 30, 2014</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward', window );"><strong>Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_ChangeInFairValueOfContingentPurchasePriceConsideration', window );">Change in the estimated fair value of the contingent purchase price consideration</a></td>
<td class="nump">$ 307<span></span>
</td>
<td class="nump">$ 597<span></span>
</td>
<td class="nump">$ 69<span></span>
</td>
<td class="num">$ (59)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Unobservable Inputs (Level 3) [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward', window );"><strong>Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContingentConsiderationClassifiedAsEquityFairValueDisclosure', window );">Beginning Balance Liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,651<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_ChangeInFairValueOfContingentPurchasePriceConsideration', window );">Change in the estimated fair value of the contingent purchase price consideration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">69<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContingentConsiderationClassifiedAsEquityFairValueDisclosure', window );">Ending Balance Liabilities</a></td>
<td class="nump">$ 6,582<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,582<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gale_ChangeInFairValueOfContingentPurchasePriceConsideration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Change in the fair value of contingent purchase price consideration.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gale_ChangeInFairValueOfContingentPurchasePriceConsideration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gale_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContingentConsiderationClassifiedAsEquityFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of contingent consideration in a business combination that is classified in shareholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 820<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 2<br><br><br><br> -Subparagraph (a)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=36462937&amp;loc=d3e19207-110258<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContingentConsiderationClassifiedAsEquityFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.0.814</span><table class="report" border="0" cellspacing="2" id="idm139922647127536">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Warrants (Changes in Fair Value of Warrant Liability) (Detail)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th">
<div>Sep. 30, 2015 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_FairValueofWarrantsGranted', window );">Fair Value of Warrants Granted</a></td>
<td class="nump">$ 10,296<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_ClassofWarrantorRightFairValueRollForward', window );"><strong>Class of Warrant or Right, Fair Value [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_FairValueOfWarrantsLiabilities', window );">Warrant liability, Beginning balance</a></td>
<td class="nump">5,383<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_ChangeInFairValueOfWarrantLiabilities', window );">Change in fair value of warrants</a></td>
<td class="nump">982<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_FairValueOfWarrantsLiabilities', window );">Warrant liability, Ending balance</a></td>
<td class="nump">16,661<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=gale_MarchTwoThousandFifteenWarrantsMember', window );">March 2015 Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_FairValueofWarrantsGranted', window );">Fair Value of Warrants Granted</a></td>
<td class="nump">10,296<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_ClassofWarrantorRightFairValueRollForward', window );"><strong>Class of Warrant or Right, Fair Value [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_FairValueOfWarrantsLiabilities', window );">Warrant liability, Beginning balance</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_ChangeInFairValueOfWarrantLiabilities', window );">Change in fair value of warrants</a></td>
<td class="nump">1,313<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_FairValueOfWarrantsLiabilities', window );">Warrant liability, Ending balance</a></td>
<td class="nump">11,609<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=gale_SeptemberTwoThousandThirteenWarrantMember', window );">September 2013 Warrant [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_FairValueofWarrantsGranted', window );">Fair Value of Warrants Granted</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_ClassofWarrantorRightFairValueRollForward', window );"><strong>Class of Warrant or Right, Fair Value [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_FairValueOfWarrantsLiabilities', window );">Warrant liability, Beginning balance</a></td>
<td class="nump">2,560<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_ChangeInFairValueOfWarrantLiabilities', window );">Change in fair value of warrants</a></td>
<td class="num">(157)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_FairValueOfWarrantsLiabilities', window );">Warrant liability, Ending balance</a></td>
<td class="nump">2,403<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=gale_DecemberTwoThousandTwelveWarrantMember', window );">December 2012 Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_ClassofWarrantorRightFairValueRollForward', window );"><strong>Class of Warrant or Right, Fair Value [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_FairValueOfWarrantsLiabilities', window );">Warrant liability, Beginning balance</a></td>
<td class="nump">2,027<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_ChangeInFairValueOfWarrantLiabilities', window );">Change in fair value of warrants</a></td>
<td class="num">(162)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_FairValueOfWarrantsLiabilities', window );">Warrant liability, Ending balance</a></td>
<td class="nump">1,865<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=gale_AprilTwoThousandElevenWarrantMember', window );">April 2011 Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_ClassofWarrantorRightFairValueRollForward', window );"><strong>Class of Warrant or Right, Fair Value [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_FairValueOfWarrantsLiabilities', window );">Warrant liability, Beginning balance</a></td>
<td class="nump">625<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_ChangeInFairValueOfWarrantLiabilities', window );">Change in fair value of warrants</a></td>
<td class="num">(10)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_FairValueOfWarrantsLiabilities', window );">Warrant liability, Ending balance</a></td>
<td class="nump">615<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=gale_MarchTwoThousandElevenWarrantMember', window );">March 2011 Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_ClassofWarrantorRightFairValueRollForward', window );"><strong>Class of Warrant or Right, Fair Value [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_FairValueOfWarrantsLiabilities', window );">Warrant liability, Beginning balance</a></td>
<td class="nump">163<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_ChangeInFairValueOfWarrantLiabilities', window );">Change in fair value of warrants</a></td>
<td class="nump">2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_FairValueOfWarrantsLiabilities', window );">Warrant liability, Ending balance</a></td>
<td class="nump">165<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=gale_MarchTwoThousandTenWarrantMember', window );">March 2010 Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_ClassofWarrantorRightFairValueRollForward', window );"><strong>Class of Warrant or Right, Fair Value [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_FairValueOfWarrantsLiabilities', window );">Warrant liability, Beginning balance</a></td>
<td class="nump">8<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_ChangeInFairValueOfWarrantLiabilities', window );">Change in fair value of warrants</a></td>
<td class="num">(4)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_FairValueOfWarrantsLiabilities', window );">Warrant liability, Ending balance</a></td>
<td class="nump">$ 4<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gale_ChangeInFairValueOfWarrantLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Change In Fair Value Of Warrant Liabilities</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gale_ChangeInFairValueOfWarrantLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gale_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gale_ClassofWarrantorRightFairValueRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Class of Warrant or Right, Fair Value [Roll Forward]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gale_ClassofWarrantorRightFairValueRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gale_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gale_FairValueOfWarrantsLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of warrant liabilities as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gale_FairValueOfWarrantsLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gale_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gale_FairValueofWarrantsGranted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair Value of Warrants Granted</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gale_FairValueofWarrantsGranted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gale_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=gale_MarchTwoThousandFifteenWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=gale_MarchTwoThousandFifteenWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=gale_SeptemberTwoThousandThirteenWarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=gale_SeptemberTwoThousandThirteenWarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=gale_DecemberTwoThousandTwelveWarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=gale_DecemberTwoThousandTwelveWarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=gale_AprilTwoThousandElevenWarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=gale_AprilTwoThousandElevenWarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=gale_MarchTwoThousandElevenWarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=gale_MarchTwoThousandElevenWarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=gale_MarchTwoThousandTenWarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=gale_MarchTwoThousandTenWarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.0.814</span><table class="report" border="0" cellspacing="2" id="idm139922623164608">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Sep. 30, 2015</div></th>
<th class="th"><div>Dec. 31, 2014</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 34,812<span></span>
</td>
<td class="nump">$ 23,650<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue', window );">Restricted cash</a></td>
<td class="nump">401<span></span>
</td>
<td class="nump">200<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">1,174<span></span>
</td>
<td class="nump">1,237<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent', window );">Current assets held for sale, net</a></td>
<td class="nump">17,801<span></span>
</td>
<td class="nump">27,013<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">54,188<span></span>
</td>
<td class="nump">52,100<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Equipment and furnishings, net</a></td>
<td class="nump">288<span></span>
</td>
<td class="nump">285<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_InProcessResearchDevelopment', window );">In-process research and development</a></td>
<td class="nump">12,864<span></span>
</td>
<td class="nump">12,864<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_GALE401rights', window );">GALE-401 rights</a></td>
<td class="nump">9,255<span></span>
</td>
<td class="nump">9,255<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="nump">5,898<span></span>
</td>
<td class="nump">5,897<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepositsAssetsNoncurrent', window );">Deposits and other assets</a></td>
<td class="nump">176<span></span>
</td>
<td class="nump">87<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">82,669<span></span>
</td>
<td class="nump">80,488<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">1,238<span></span>
</td>
<td class="nump">1,886<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued expenses and other current liabilities</a></td>
<td class="nump">7,329<span></span>
</td>
<td class="nump">8,885<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_FairValueOfWarrantsPotentiallySettleableInCash', window );">Fair value of warrants potentially settleable in cash</a></td>
<td class="nump">16,661<span></span>
</td>
<td class="nump">5,383<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtCurrent', window );">Current portion of long-term debt</a></td>
<td class="nump">4,166<span></span>
</td>
<td class="nump">3,910<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent', window );">Current liabilities held for sale</a></td>
<td class="nump">7,697<span></span>
</td>
<td class="nump">7,169<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">37,091<span></span>
</td>
<td class="nump">27,233<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsLiabilitiesNetNoncurrent', window );">Deferred tax liability</a></td>
<td class="nump">5,053<span></span>
</td>
<td class="nump">5,053<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_ContingentPurchasePriceConsiderationNetOfCurrentPortion', window );">Deferred tax liability</a></td>
<td class="nump">6,582<span></span>
</td>
<td class="nump">6,651<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Long-term debt, net of current portion</a></td>
<td class="nump">1,526<span></span>
</td>
<td class="nump">4,492<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">$ 50,252<span></span>
</td>
<td class="nump">$ 43,429<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and contingencies</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders' equity:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock, $0.0001 par value; 275,000,000 shares authorized, 162,575,446 shares issued and 161,900,446 shares outstanding at September 30, 2015; 200,000,000 shares authorized, 130,146,341 shares issued and 129,471,341 shares outstanding at December 31, 2014</a></td>
<td class="nump">$ 15<span></span>
</td>
<td class="nump">$ 12<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapitalCommonStock', window );">Additional paid-in capital</a></td>
<td class="nump">295,956<span></span>
</td>
<td class="nump">256,377<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_DeficitAccumulatedDuringDevelopmentalStage', window );">Accumulated deficit</a></td>
<td class="nump">259,705<span></span>
</td>
<td class="nump">215,481<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockValue', window );">Less treasury shares at cost, 675,000 shares</a></td>
<td class="num">(3,849)<span></span>
</td>
<td class="num">(3,849)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholders&#8217; equity</a></td>
<td class="nump">32,417<span></span>
</td>
<td class="nump">37,059<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and stockholders' equity</a></td>
<td class="nump">$ 82,669<span></span>
</td>
<td class="nump">$ 80,488<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gale_ContingentPurchasePriceConsiderationNetOfCurrentPortion">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contingent purchase price consideration, net of current portion.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gale_ContingentPurchasePriceConsiderationNetOfCurrentPortion</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gale_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gale_DeficitAccumulatedDuringDevelopmentalStage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Deficit accumulated during the developmental stage.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gale_DeficitAccumulatedDuringDevelopmentalStage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gale_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gale_FairValueOfWarrantsPotentiallySettleableInCash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of warrants potentially settleable in cash.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gale_FairValueOfWarrantsPotentiallySettleableInCash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gale_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gale_GALE401rights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>GALE-401 rights</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gale_GALE401rights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gale_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gale_InProcessResearchDevelopment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>In-process research and development.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gale_InProcessResearchDevelopment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gale_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.19(a))<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 19<br><br><br><br> -Subparagraph a<br><br><br><br> -Article 5<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.20)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 20<br><br><br><br> -Article 5<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapitalCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.30(a)(1))<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 31<br><br><br><br> -Article 5<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapitalCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.18)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 03<br><br><br><br> -Paragraph 12<br><br><br><br> -Article 7<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 18<br><br><br><br> -Article 5<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.9)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 3<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6801-107765<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6676-107765<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 9<br><br><br><br> -Article 5<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount classified as assets attributable to disposal group held for sale or disposed of, expected to be disposed of within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 205<br><br><br><br> -SubTopic 20<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 10<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6892542&amp;loc=d3e1107-107759<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Glossary Cash<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6506951<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (a)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6676-107765<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 230<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 4<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3044-108585<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Glossary Cash Equivalents<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6507016<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.1)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 1<br><br><br><br> -Article 5<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 944<br><br><br><br> -SubTopic 210<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.7-03.(a),19)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 450<br><br><br><br> -SubTopic 20<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=25496072&amp;loc=d3e14326-108349<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 942<br><br><br><br> -SubTopic 210<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.9-03.17)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.25)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 03<br><br><br><br> -Paragraph 19<br><br><br><br> -Article 7<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 25<br><br><br><br> -Article 5<br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 03<br><br><br><br> -Paragraph 17<br><br><br><br> -Article 9<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.29)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 30<br><br><br><br> -Article 5<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsLiabilitiesNetNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards, net of deferred tax liability attributable to taxable temporary differences expected to be realized or consumed after one year (or the normal operating cycle, if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 740<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 2<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32537-109319<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 740<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 4<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=37586315&amp;loc=d3e31917-109318<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 740<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 6<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=37586315&amp;loc=d3e31931-109318<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsLiabilitiesNetNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepositsAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value of amounts transferred to third parties for security purposes that are expected to be returned or applied towards payment after one year or beyond the operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.17)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 17<br><br><br><br> -Article 5<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepositsAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 350<br><br><br><br> -SubTopic 20<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=35741047&amp;loc=d3e13816-109267<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 350<br><br><br><br> -SubTopic 20<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6388280&amp;loc=d3e13770-109266<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.19-26)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.32)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 03<br><br><br><br> -Paragraph 25<br><br><br><br> -Article 7<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 32<br><br><br><br> -Article 5<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.21)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 21<br><br><br><br> -Article 5<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount classified as liabilities attributable to disposal group held for sale or disposed of, expected to be disposed of within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 205<br><br><br><br> -SubTopic 20<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 10<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6892542&amp;loc=d3e1107-107759<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 205<br><br><br><br> -SubTopic 20<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (a)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6360339&amp;loc=d3e1361-107760<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt, after unamortized discount or premium, scheduled to be repaid within one year or the normal operating cycle, if longer. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.19,20)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 20<br><br><br><br> -Article 5<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 19<br><br><br><br> -Article 5<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount of long-term debt, net of unamortized discount or premium, excluding amounts to be repaid within one year or the normal operating cycle, if longer (current maturities). Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.22)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 22<br><br><br><br> -Article 5<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6676-107765<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 8<br><br><br><br> -Article 5<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.13)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 360<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 13<br><br><br><br> -Subparagraph a<br><br><br><br> -Article 5<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 03<br><br><br><br> -Paragraph 8<br><br><br><br> -Article 7<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The carrying amounts of cash and cash equivalent items which are restricted as to withdrawal or usage. Restrictions may include legally restricted deposits held as compensating balances against short-term borrowing arrangements, contracts entered into with others, or entity statements of intention with regard to particular deposits; however, time deposits and short-term certificates of deposit are not generally included in legally restricted deposits. Excludes compensating balance arrangements that are not agreements which legally restrict the use of cash amounts shown on the balance sheet. For a classified balance sheet represents the current portion only (the noncurrent portion has a separate concept); there is a separate and distinct element for unclassified presentations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.1)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 1<br><br><br><br> -Article 5<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 310<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 2<br><br><br><br> -Subparagraph (SAB TOPIC 4.E)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=27010918&amp;loc=d3e74512-122707<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.29-31)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 29, 30, 31<br><br><br><br> -Article 5<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Staff Accounting Bulletin (SAB)<br><br><br><br> -Number Topic 4<br><br><br><br> -Section E<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount allocated to treasury stock. Treasury stock is common and preferred shares of an entity that were issued, repurchased by the entity, and are held in its treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 505<br><br><br><br> -SubTopic 30<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 4<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6405834&amp;loc=d3e23315-112656<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.0.814</span><table class="report" border="0" cellspacing="2" id="idm139922623741616">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock Based Compensation (Stock Option Activity) (Detail)<br> $ / shares in Units, shares in Thousands, $ in Thousands</strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th">
<div>Sep. 30, 2015 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Total Number of Shares, outstanding Beginning Balance</a></td>
<td class="nump">8,590<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Stock options activity, Total Number of Shares, Granted</a></td>
<td class="nump">3,682<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Stock options activity, Total Number of Shares, Exercised</a></td>
<td class="num">(39)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Stock options activity, Total Number of Shares, Cancelled</a></td>
<td class="num">(1,045)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Total Number of Shares, outstanding Ending Balance</a></td>
<td class="nump">11,188<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Total Number of Shares, exercisable</a></td>
<td class="nump">6,622<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Stock options activity, Weighted Average Exercise Price, Beginning balance | $ / shares</a></td>
<td class="nump">$ 3.25<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Stock options activity, Weighted Average Exercise Price, Granted | $ / shares</a></td>
<td class="nump">1.73<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Stock options activity, Weighted Average Exercise Price, Exercised | $ / shares</a></td>
<td class="nump">0.79<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice', window );">Stock options activity, Weighted Average Exercise Price, Cancelled | $ / shares</a></td>
<td class="nump">2.44<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Stock options activity, Weighted Average Exercise Price, Ending balance | $ / shares</a></td>
<td class="nump">2.83<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Stock options activity, Weighted Average Exercise Price, exercisable | $ / shares</a></td>
<td class="nump">$ 3.32<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Stock options activity, Aggregate Intrinsic Value, Beginning balance | $</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateAggregateIntrinsicValue', window );">Stock options activity, Aggregate Intrinsic Value, Granted | $</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue', window );">Stock options activity, Aggregate Intrinsic Value, Exercised | $</a></td>
<td class="nump">$ 37<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpiredInPeriodIntrinsicValue', window );">Stock options activity, Aggregate Intrinsic Value, Cancelled | $</a></td>
<td class="nump">21<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Stock options activity, Aggregate Intrinsic Value, Ending balance | $</a></td>
<td class="nump">690<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue', window );">Stock options activity, Aggregate Intrinsic Value, exercisable | $</a></td>
<td class="nump">$ 618<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gale_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpiredInPeriodIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share Based Compensation Arrangement By Share Based Payment Award Options Expired In Period Intrinsic Value</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gale_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpiredInPeriodIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gale_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gale_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateAggregateIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Grant Date Aggregate Intrinsic Value</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gale_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateAggregateIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gale_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 718<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 2<br><br><br><br> -Subparagraph (c)(1)(iii)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 718<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 2<br><br><br><br> -Subparagraph (c)(1)(iii)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 718<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 2<br><br><br><br> -Subparagraph (d)(2)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 718<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 2<br><br><br><br> -Subparagraph (c)(1)(iv)(3)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 718<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 2<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 718<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 2<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 718<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 2<br><br><br><br> -Subparagraph (c)(1)(i)-(ii)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 718<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 2<br><br><br><br> -Subparagraph (c)(1)(i)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of fully vested and expected to vest options that are exercisable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 718<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 2<br><br><br><br> -Subparagraph (e)(2)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 505<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 2<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 505<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.3-04)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 718<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 2<br><br><br><br> -Subparagraph (c)(1)(iv)(2)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.28,29)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 29, 30<br><br><br><br> -Article 5<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 04<br><br><br><br> -Article 3<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.0.814</span><table class="report" border="0" cellspacing="2" id="idm139922623278672">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2015</div></th>
<th class="th"><div>Sep. 30, 2014</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest', window );">Net loss from continuing operations</a></td>
<td class="num">$ (28,150)<span></span>
</td>
<td class="num">$ (22,017)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustment to reconcile net loss to net cash used in operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation and amortization expense</a></td>
<td class="nump">304<span></span>
</td>
<td class="nump">340<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Non-cash stock-based compensation</a></td>
<td class="nump">1,334<span></span>
</td>
<td class="nump">3,878<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_ChangeInFairValueOfCommonStockWarrantsIssuedInConnectionWithVariousEquityFinancings', window );">Change in fair value of common stock warrants</a></td>
<td class="nump">982<span></span>
</td>
<td class="num">(13,174)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_ChangeInFairValueOfContingentPurchaseConsideration', window );">Change in fair value of contingent consideration</a></td>
<td class="num">(69)<span></span>
</td>
<td class="nump">59<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Prepaid expenses and other assets</a></td>
<td class="num">(26)<span></span>
</td>
<td class="num">(348)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayable', window );">Accounts payable</a></td>
<td class="num">(648)<span></span>
</td>
<td class="nump">54<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccruedLiabilities', window );">Accrued expenses and other current liabilities</a></td>
<td class="num">(1,556)<span></span>
</td>
<td class="nump">2,465<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations', window );">Net cash used in continuing operating activities</a></td>
<td class="num">(27,829)<span></span>
</td>
<td class="num">(28,743)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax', window );">Net loss from discontinued operations</a></td>
<td class="nump">16,074<span></span>
</td>
<td class="nump">6,633<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf', window );">Impairment of assets held for sale</a></td>
<td class="nump">8,071<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAssetsHeldForSale', window );">Changes in operating assets and liabilities attributable to discontinued operations</a></td>
<td class="nump">2,956<span></span>
</td>
<td class="nump">3,241<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations', window );">Net cash used in discontinued operating activities</a></td>
<td class="num">(5,047)<span></span>
</td>
<td class="num">(3,392)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="num">(32,876)<span></span>
</td>
<td class="num">(32,135)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Cash flows from investing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInRestrictedCash', window );">Change in restricted cash</a></td>
<td class="num">(201)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireBusinessesGross', window );">Cash paid for acquisition of GALE-401 rights</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(2,315)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Cash paid for purchase of equipment and furnishings</a></td>
<td class="num">(81)<span></span>
</td>
<td class="num">(48)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations', window );">Net cash used in continuing investing activities</a></td>
<td class="num">(282)<span></span>
</td>
<td class="num">(2,363)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations', window );">Net cash used in discontinued investing activities</a></td>
<td class="num">(534)<span></span>
</td>
<td class="num">(3,056)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash used in investing activities</a></td>
<td class="num">(816)<span></span>
</td>
<td class="num">(5,419)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash flows from financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Net proceeds from issuance of common stock</a></td>
<td class="nump">47,416<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromStockOptionsExercised', window );">Net proceeds from exercise of stock options</a></td>
<td class="nump">31<span></span>
</td>
<td class="nump">4,342<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_NetProceedsFromExerciseOfCommonStockWarrants', window );">Proceeds from exercise of warrants</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">10,717<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOrSaleOfEquity', window );">Proceeds from common stock issued in connection with ESPP</a></td>
<td class="nump">309<span></span>
</td>
<td class="nump">263<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfLongTermDebt', window );">Principle payments on long-term debt</a></td>
<td class="num">(2,902)<span></span>
</td>
<td class="num">(908)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by financing activities</a></td>
<td class="nump">44,854<span></span>
</td>
<td class="nump">14,414<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease', window );">Net increase (decrease) in cash and cash equivalents</a></td>
<td class="nump">11,162<span></span>
</td>
<td class="num">(23,140)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents at the beginning of period</a></td>
<td class="nump">23,650<span></span>
</td>
<td class="nump">47,787<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents at end of period</a></td>
<td class="nump">34,812<span></span>
</td>
<td class="nump">24,647<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowInformationAbstract', window );"><strong>Supplemental disclosure of cash flow information:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromInterestReceived', window );">Cash received during the periods for interest</a></td>
<td class="nump">12<span></span>
</td>
<td class="nump">13<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestPaid', window );">Cash paid during the periods for interest</a></td>
<td class="nump">437<span></span>
</td>
<td class="nump">632<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract', window );"><strong>Supplemental disclosure of non-cash investing and financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_FairValueOfWarrantsIssuedInConnectionWithCommonStockRecordedAsCostOfEquity', window );">Fair value of warrants issued in connection with common stock recorded as cost of equity</a></td>
<td class="nump">$ 10,296<span></span>
</td>
<td class="nump">27,026<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_ReclassificationOfWarrantLiabilityUponExercise', window );">Reclassification of warrant liabilities upon exercise</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (27,020)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gale_ChangeInFairValueOfCommonStockWarrantsIssuedInConnectionWithVariousEquityFinancings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Change in fair value of common stock warrants issued in connection with various equity financings.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gale_ChangeInFairValueOfCommonStockWarrantsIssuedInConnectionWithVariousEquityFinancings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gale_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gale_ChangeInFairValueOfContingentPurchaseConsideration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Change in fair value of contingent purchase consideration.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gale_ChangeInFairValueOfContingentPurchaseConsideration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gale_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gale_FairValueOfWarrantsIssuedInConnectionWithCommonStockRecordedAsCostOfEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of warrants issued in connection with common stock recorded as a cost of equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gale_FairValueOfWarrantsIssuedInConnectionWithCommonStockRecordedAsCostOfEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gale_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gale_NetProceedsFromExerciseOfCommonStockWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Net proceeds from exercise of common stock warrants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gale_NetProceedsFromExerciseOfCommonStockWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gale_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gale_ReclassificationOfWarrantLiabilityUponExercise">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Reclassification of warrant liability upon exercise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gale_ReclassificationOfWarrantLiabilityUponExercise</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gale_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Glossary Cash<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6506951<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (a)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6676-107765<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 230<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 4<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3044-108585<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Glossary Cash Equivalents<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6507016<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.1)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 1<br><br><br><br> -Article 5<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash and cash equivalents. Cash and cash equivalents are the amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Includes effect from exchange rate changes.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 230<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 24<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3521-108585<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 830<br><br><br><br> -SubTopic 230<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6450594&amp;loc=d3e33268-110906<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) of investing activities of discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 230<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 24<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3521-108585<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) of operating activities of discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 230<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 24<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3521-108585<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationDepletionAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 230<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 28<br><br><br><br> -Subparagraph (b)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3602-108585<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationDepletionAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of write-downs for impairments recognized during the period for long-lived assets held for abandonment, exchange or sale.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 360<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 15<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=8077374&amp;loc=d3e2611-110228<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 230<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 28<br><br><br><br> -Subparagraph (b)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3602-108585<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This element represents the income or loss from continuing operations attributable to the economic entity which may also be defined as revenue less expenses and taxes from ongoing operations before extraordinary items, and noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 810<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 19<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=7656940&amp;loc=SL4569616-111683<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from a disposal group, net of income tax before extraordinary items allocable to noncontrolling interests. Includes, net of tax, income (loss) from operations during the phase-out period, gain (loss) on disposal, provision (or any reversals of earlier provisions) for loss on disposal, and adjustments of a prior period gain (loss) on disposal.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 944<br><br><br><br> -SubTopic 225<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.7-04.12)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 225<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 2<br><br><br><br> -Subparagraph (SX 210.5-03.14)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 205<br><br><br><br> -SubTopic 20<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (c)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6360339&amp;loc=d3e1361-107760<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 205<br><br><br><br> -SubTopic 20<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 3<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6892542&amp;loc=d3e957-107759<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 04<br><br><br><br> -Paragraph 13<br><br><br><br> -Article 7<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 03<br><br><br><br> -Paragraph 15<br><br><br><br> -Article 5<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 230<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 28<br><br><br><br> -Subparagraph (a)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3602-108585<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 230<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 28<br><br><br><br> -Subparagraph (a)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3602-108585<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAssetsHeldForSale">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the period in book value of long-lived assets that the reporting entity plans to sell within one year (or one business cycle).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 230<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 28<br><br><br><br> -Subparagraph (a)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3602-108585<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAssetsHeldForSale</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the value of prepaid expenses and other assets not separately disclosed in the statement of cash flows, for example, deferred expenses, intangible assets, or income taxes.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 230<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 28<br><br><br><br> -Subparagraph (a)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3602-108585<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInRestrictedCash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net cash inflow or outflow for the increase (decrease) associated with funds that are not available for withdrawal or use (such as funds held in escrow) and are associated with underlying transactions that are classified as investing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 230<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 12<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3179-108585<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 230<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 13<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3213-108585<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Glossary Investing Activities<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6516133<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInRestrictedCash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of cash paid for interest during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 230<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 2<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367179&amp;loc=d3e4297-108586<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 230<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 25<br><br><br><br> -Subparagraph (e)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3536-108585<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 230<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 24<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3521-108585<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 230<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 26<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3574-108585<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 230<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 24<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3521-108585<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 230<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 26<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3574-108585<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) of investing activities, excluding discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 230<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 26<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3574-108585<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 230<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 24<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3521-108585<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 230<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 24<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3521-108585<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 230<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 28<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3602-108585<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 230<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 25<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3536-108585<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, excluding discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 230<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 24<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3521-108585<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 230<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 28<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3602-108585<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 230<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 25<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3536-108585<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireBusinessesGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of business during the period. The cash portion only of the acquisition price.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Glossary Investing Activities<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6516133<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 230<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 13<br><br><br><br> -Subparagraph (b)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3213-108585<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireBusinessesGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Glossary Investing Activities<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6516133<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 230<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 13<br><br><br><br> -Subparagraph (c)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3213-108585<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromInterestReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Interest received on loans and other debt instruments during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 230<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 25<br><br><br><br> -Subparagraph (b)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3536-108585<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromInterestReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Glossary Financing Activities<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6513228<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 230<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 14<br><br><br><br> -Subparagraph (a)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3255-108585<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOrSaleOfEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the issuance of common stock, preferred stock, treasury stock, stock options, and other types of equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Glossary Financing Activities<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6513228<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 230<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 14<br><br><br><br> -Subparagraph (a)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3255-108585<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOrSaleOfEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from holders exercising their stock options. This item inherently excludes any excess tax benefit, which the entity may have realized and reported separately.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 718<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 2<br><br><br><br> -Subparagraph (j)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 230<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 14<br><br><br><br> -Subparagraph (a)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3255-108585<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Glossary Financing Activities<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6513228<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfLongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for debt initially having maturity due after one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 230<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 15<br><br><br><br> -Subparagraph (b)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3291-108585<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Glossary Financing Activities<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6513228<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfLongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of noncash, equity-based employee remuneration. This may include the value of stock or unit options, amortization of restricted stock or units, and adjustment for officers' compensation. As noncash, this element is an add back when calculating net cash generated by operating activities using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 230<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 28<br><br><br><br> -Subparagraph (a)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3602-108585<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalCashFlowInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.0.814</span><table class="report" border="0" cellspacing="2" id="idm139922623137216">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Legal Proceedings, Commitments and Contingencies Details (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2015</div></th>
<th class="th"><div>Sep. 30, 2014</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireBusinessesGross', window );">Payments to Acquire Businesses, Gross</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 2,315<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueOther', window );">Issuance of common stock</a></td>
<td class="nump">$ 47,416<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesOther', window );">Issuance of common stock for milestone payment, other</a></td>
<td class="nump">32,158,685<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueOther', window );">Issuance of common stock</a></td>
<td class="nump">$ 3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AdditionalPaidInCapitalMember', window );">Additional Paid-in Capital [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueOther', window );">Issuance of common stock</a></td>
<td class="nump">$ 47,413<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingenciesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingenciesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireBusinessesGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of business during the period. The cash portion only of the acquisition price.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Glossary Investing Activities<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6516133<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 230<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 13<br><br><br><br> -Subparagraph (b)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3213-108585<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireBusinessesGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of stock issued during the period that is attributable to transactions involving issuance of stock not separately disclosed.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of shares of stock issued during the period that is attributable to transactions involving issuance of stock not separately disclosed.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AdditionalPaidInCapitalMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AdditionalPaidInCapitalMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.0.814</span><table class="report" border="0" cellspacing="2" id="idm139922633299312">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accrued Expenses and Other Current Liabilities (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2015</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock', window );">Schedule of Accrued Expenses and Other Current Liabilities</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-indent:66px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Accrued expenses and other current liabilities consist of the following (in thousands):</font></div><div style="line-height:120%;text-indent:66px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8" rowspan="1"></td></tr><tr><td width="71%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="12%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="12%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">September&#160;30, 2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">December&#160;31, 2014</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Clinical trial costs</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">5,179</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">6,967</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Compensation and related benefits</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">992</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">1,040</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Professional fees</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">1,121</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">821</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Interest expense</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">37</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">57</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Accrued expenses and other current liabilities</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">7,329</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">8,885</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of accrued liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.0.814</span><table class="report" border="0" cellspacing="2" id="idm139922622319728">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity (Additional Information) (Detail) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Apr. 10, 2015</div></th>
<th class="th"><div>Mar. 18, 2015</div></th>
<th class="th"><div>Nov. 18, 2014</div></th>
<th class="th"><div>Apr. 10, 2015</div></th>
<th class="th"><div>Sep. 30, 2015</div></th>
<th class="th"><div>Sep. 30, 2015</div></th>
<th class="th"><div>Sep. 30, 2014</div></th>
<th class="th"><div>Dec. 31, 2014</div></th>
<th class="th"><div>May. 08, 2013</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,000,000<span></span>
</td>
<td class="nump">5,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value (usd per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,653,846<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">275,000,000<span></span>
</td>
<td class="nump">275,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">200,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (usd per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOrSaleOfEquity', window );">Proceeds from Issuance or Sale of Equity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 38,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 309,000<span></span>
</td>
<td class="nump">$ 263,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_PurchaseAgreementTerm', window );">Purchase Agreement Term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">36 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Share Price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.56<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">24,358,974<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_NumberofSharesPerUnit', window );">Number of Shares Per Unit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Class of Warrant or Right, Exercise Price of Warrants or Rights</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.08<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.47<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Number of shares availabe from warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,826,923<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_StockIssuedDuringPeriodSharesOverallotmentOption', window );">Stock Issued During Period, Shares, Overallotment Option</a></td>
<td class="nump">3,653,846<span></span>
</td>
<td class="nump">1,826,923<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_ProceedsFromIssuanceorSaleofEquityNetUnderwritingDiscountsCommissionsandOfferingExpenses', window );">Proceeds From Issuance or Sale of Equity, Net Underwriting Discounts, Commissions and Offering Expenses</a></td>
<td class="nump">$ 5,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 40,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=gale_LincolnParkCapitalLLCMember', window );">Lincoln Park Capital, LLC [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOrSaleOfEquity', window );">Proceeds from Issuance or Sale of Equity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets', window );">Stock Issued During Period, Shares, Purchase of Assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Share Price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=gale_LincolnParkCapitalLLCMember', window );">Lincoln Park Capital, LLC [Member] | Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOrSaleOfEquity', window );">Proceeds from Issuance or Sale of Equity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 50,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">631,221<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=gale_MLVCo.LLCandMaximGroupLLCMember', window );">MLV &amp; Co. LLC and Maxim Group LLC [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOrSaleOfEquity', window );">Proceeds from Issuance or Sale of Equity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_AtMarketIssuanceSalesAgreementsPercentofGrossProceeds', window );">At Market Issuance Sales Agreements, Percent of Gross Proceeds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_AtMarketIssuanceSalesAgreementsMaximumGrossProceeds', window );">At Market Issuance Sales Agreements, Maximum Gross Proceeds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gale_AtMarketIssuanceSalesAgreementsMaximumGrossProceeds">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>At Market Issuance Sales Agreements, Maximum Gross Proceeds</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gale_AtMarketIssuanceSalesAgreementsMaximumGrossProceeds</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gale_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gale_AtMarketIssuanceSalesAgreementsPercentofGrossProceeds">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>At Market Issuance Sales Agreements, Percent of Gross Proceeds</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gale_AtMarketIssuanceSalesAgreementsPercentofGrossProceeds</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gale_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gale_NumberofSharesPerUnit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of Shares Per Unit</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gale_NumberofSharesPerUnit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gale_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gale_ProceedsFromIssuanceorSaleofEquityNetUnderwritingDiscountsCommissionsandOfferingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Proceeds From Issuance or Sale of Equity, Net Underwriting Discounts, Commissions and Offering Expenses</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gale_ProceedsFromIssuanceorSaleofEquityNetUnderwritingDiscountsCommissionsandOfferingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gale_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gale_PurchaseAgreementTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Purchase Agreement Term</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gale_PurchaseAgreementTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gale_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gale_StockIssuedDuringPeriodSharesOverallotmentOption">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Stock Issued During Period, Shares, Overallotment Option</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gale_StockIssuedDuringPeriodSharesOverallotmentOption</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gale_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 235<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.4-08.(i)(4))<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 235<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.4-08.(i)(2))<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 08<br><br><br><br> -Paragraph i<br><br><br><br> -Subparagraph 2<br><br><br><br> -Article 4<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.29)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 30<br><br><br><br> -Article 5<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.29)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 30<br><br><br><br> -Article 5<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.28)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 29<br><br><br><br> -Article 5<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.28)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 29<br><br><br><br> -Article 5<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOrSaleOfEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the issuance of common stock, preferred stock, treasury stock, stock options, and other types of equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Glossary Financing Activities<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6513228<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 230<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 14<br><br><br><br> -Subparagraph (a)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3255-108585<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOrSaleOfEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Price of a single share of a number of saleable stocks of a company.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 505<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 2<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 505<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.3-04)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 04<br><br><br><br> -Article 3<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 29, 30<br><br><br><br> -Article 5<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of stock issued during the period as part of a transaction to acquire assets that do not qualify as a business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=gale_LincolnParkCapitalLLCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=gale_LincolnParkCapitalLLCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=gale_MLVCo.LLCandMaximGroupLLCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=gale_MLVCo.LLCandMaximGroupLLCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.0.814</span><table class="report" border="0" cellspacing="2" id="idm139922644940176">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Warrants (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2015</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsNoteDisclosureAbstract', window );"><strong>Warrants and Rights Note Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_ScheduleOfWarrantActivityTableTableTextBlock', window );">Schedule of Warrant Activity</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">The following is a summary of warrant activity for the nine months ended </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">September&#160;30, 2015</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> (in thousands):</font></div><div style="line-height:120%;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">&#160;</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="24" rowspan="1"></td></tr><tr><td width="21%" rowspan="1" colspan="1"></td><td width="8%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="8%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="8%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="8%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="8%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="8%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="8%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="8%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">March 2015 Warrants</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">September</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">2013</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Warrants</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">December</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">2012</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Warrants</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">April&#160;2011</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Warrants</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">March</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">2011</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Warrants</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">March</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">2010</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Warrants</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Consultant</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">and Oxford Warrants</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Total</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Outstanding, January 1, 2015</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">3,973</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">3,031</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">615</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">176</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">25</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">720</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">8,540</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Issued</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">14,006</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">14,006</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Expired</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">(238</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">(238</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Outstanding, September&#160;30, 2015</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">14,006</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">3,973</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">3,031</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">615</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">176</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">25</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">482</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">22,308</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Expiration</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">March 2020</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">September 2018</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">December 2017</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:3px double #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">April 2017</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">March 2016</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">March 2016</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Varies 2014-2020</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_ScheduleOfWarrantValuationAssumptionsTableTextBlock', window );">Fair Value of Warrants is Estimated Using Black-Scholes Option Pricing Model</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-indent:66px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">The fair value of the warrants is estimated using an appropriate pricing model with the following inputs:</font></div><div style="line-height:120%;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">&#160;</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="24" rowspan="1"></td></tr><tr><td width="23%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="10%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="10%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="10%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="10%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="10%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="10%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="23" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">As of September&#160;30, 2015</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">March 2015 Warrants</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">September</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">2013</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Warrants</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">December</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">2012</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Warrants</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">April&#160;2011</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Warrants</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">March</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">2011</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Warrants</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">March</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">2010</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Warrants</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">Strike price</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">2.08</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">2.50</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">1.83</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">0.65</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">0.65</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">2.02</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">Expected term (years)</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">4.47</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">2.97</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">2.23</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">1.56</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">0.43</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">0.49</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">Volatility %</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">74.99</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">76.85</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">75.45</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">69.48</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">72.42</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">68.33</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">%</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">Risk-free rate %</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">1.25</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">0.91</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">0.70</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">0.50</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">0.06</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">0.08</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">%</font></div></td></tr></table></div></div><div style="line-height:120%;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">&#160;</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="20" rowspan="1"></td></tr><tr><td width="36%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="10%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="10%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="10%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="10%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="10%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="19" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">As of December&#160;31, 2014</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">September</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">2013</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Warrants</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">December</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">2012</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Warrants</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">April&#160;2011</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Warrants</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">March</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">2011</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Warrants</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">March</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">2010</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Warrants</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">Strike price</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">2.50</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">1.90</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">0.65</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">0.65</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">2.15</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">Expected term (years)</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">3.72</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">2.98</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">2.31</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">1.18</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">1.24</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">Volatility %</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">75.60</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">76.85</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">78.24</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">77.38</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">77.12</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">%</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">Risk-free rate %</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">1.30</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">1.09</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">0.80</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">0.32</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">0.35</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">%</font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_ChangesInFairValueOfWarrantLiabilityTableTextBlock', window );">Changes in Fair Value of Warrant Liability</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">The changes in fair value of the warrant liability for the nine months ended </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">September&#160;30, 2015</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> were as follows (in thousands):</font></div><div style="line-height:120%;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">&#160;</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="28" rowspan="1"></td></tr><tr><td width="24%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="8%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="8%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="8%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="8%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="8%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="8%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="8%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">March 2015 Warrants</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">September</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">2013</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Warrants</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">December</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">2012</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Warrants</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">April&#160;2011</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Warrants</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">March</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">2011</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Warrants</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">March</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">2010</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Warrants</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Total</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">Warrant liability, January&#160;1, 2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">2,560</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">2,027</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">625</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">163</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">8</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">5,383</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">Fair value of warrants issued</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">10,296</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">10,296</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">Change in fair value of warrants</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">1,313</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">(157</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">(162</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">(10</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">2</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">(4</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">982</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">Warrant liability, September&#160;30, 2015</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">11,609</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">2,403</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">1,865</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">615</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">165</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">4</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">16,661</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gale_ChangesInFairValueOfWarrantLiabilityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Changes In Fair Value Of Warrant Liability Table [Text Block]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gale_ChangesInFairValueOfWarrantLiabilityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gale_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gale_ScheduleOfWarrantActivityTableTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Schedule Of Warrant Activity Table</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gale_ScheduleOfWarrantActivityTableTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gale_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gale_ScheduleOfWarrantValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Schedule Of Warrant Valuation Assumptions Table [Text Block]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gale_ScheduleOfWarrantValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gale_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsNoteDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsNoteDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/**
 * Rivet Software Inc.
 *
 * @copyright Copyright (c) 2006-2011 Rivet Software, Inc. All rights reserved.
 * Version 2.4.0.3
 *
 */

var Show = {};
Show.LastAR = null,

Show.hideAR = function(){
	Show.LastAR.style.display = 'none';
};

Show.showAR = function ( link, id, win ){
	if( Show.LastAR ){
		Show.hideAR();
	}

	var ref = link;
	do {
		ref = ref.nextSibling;
	} while (ref && ref.nodeName != 'TABLE');

	if (!ref || ref.nodeName != 'TABLE') {
		var tmp = win ?
			win.document.getElementById(id) :
			document.getElementById(id);

		if( tmp ){
			ref = tmp.cloneNode(true);
			ref.id = '';
			link.parentNode.appendChild(ref);
		}
	}

	if( ref ){
		ref.style.display = 'block';
		Show.LastAR = ref;
	}
};

Show.toggleNext = function( link ){
	var ref = link;

	do{
		ref = ref.nextSibling;
	}while( ref.nodeName != 'DIV' );

	if( ref.style &&
		ref.style.display &&
		ref.style.display == 'none' ){
		ref.style.display = 'block';

		if( link.textContent ){
			link.textContent = link.textContent.replace( '+', '-' );
		}else{
			link.innerText = link.innerText.replace( '+', '-' );
		}
	}else{
		ref.style.display = 'none';

		if( link.textContent ){
			link.textContent = link.textContent.replace( '-', '+' );
		}else{
			link.innerText = link.innerText.replace( '-', '+' );
		}
	}
};
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.0.814</span><table class="report" border="0" cellspacing="2" id="idm139922644429328">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Business and Basis of Presentation<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2015</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock', window );">Business and Basis of Presentation</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#00497f;font-weight:bold;"> Business and Basis of Presentation</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#006ebf;font-weight:bold;">Overview</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-weight:bold;">&#160;</font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;text-indent:66px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Galena Biopharma, Inc. (&#8220;we,&#8221; &#8220;us,&#8221; &#8220;our,&#8221; &#8220;Galena&#8221; or the &#8220;company&#8221;) is a biopharmaceutical company committed to the development and commercialization of targeted oncology therapeutics that address major unmet medical needs. Galena&#8217;s development portfolio is focused primarily on addressing the rapidly growing patient populations of cancer survivors by harnessing the power of the immune system to prevent cancer recurrence. The Company&#8217;s pipeline consists of multiple mid- to late-stage clinical assets, including novel cancer immunotherapy programs led by NeuVax&#8482; (nelipepimut-S),GALE-301 and GALE-302.&#160;NeuVax is currently in a pivotal, Phase 3 clinical trial with several concurrent Phase 2 trials ongoing both as a single agent and in combination with other therapies. GALE-301 is in a Phase 2a clinical trial in ovarian and endometrial cancers in addition to GALE-302 in combination with GALE-301 in ovarian and breast cancers.&#160;</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#006ebf;font-weight:bold;text-decoration:underline;">Novel Cancer Immunotherapies</font></div><div style="line-height:120%;text-align:left;text-indent:66px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;text-indent:66px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Our targeted cancer immunotherapy approach is currently based upon two key areas: preventing secondary recurrence of cancer, which is becoming increasingly important as the number of cancer survivors continues to grow; and, transitioning earlier in the breast cancer treatment spectrum via primary prevention. Once a patient&#8217;s tumor becomes metastatic, the outcome is most often fatal, making the prevention of recurrence a potentially critical component of overall patient care. Our programs primarily target patients in the adjuvant (after-surgery) setting who have relatively healthy immune systems, but may still have minimal residual disease.  Minimal residual disease, or single cancer cells (occult cancer cells) or micrometastasis, are undetectable by current radiographic scanning technologies, but we know can result in disease recurrence.</font></div><div style="line-height:120%;text-align:left;text-indent:66px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Our therapies utilize an immunodominant peptide combined with the immune adjuvant, recombinant human granulocyte macrophage-colony stimulating factor (rhGM-CSF), and work by harnessing the patient&#8217;s own immune system to seek out and attack any residual cancer cells. Using peptide immunogens has many potential clinical advantages, including a favorable safety profile, since these drugs may lack the toxicities typical of most cancer therapies. They also have the potential to evoke long-lasting protection through activation of the immune system and a convenient, intradermal mode of delivery. We are currently engaged in multiple clinical trials with NeuVax&#8482; (nelipepimut-S), GALE-301, and GALE-302, targeting the prevention of recurrence in breast, gastric, ovarian and endometrial cancers.</font></div><div style="line-height:120%;text-align:left;text-indent:66px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;padding-left:32px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#006ebf;font-style:italic;font-weight:bold;">NeuVax&#8482; (nelipepimut-S)</font></div><div style="line-height:120%;text-align:left;padding-left:32px;text-indent:66px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;text-indent:66px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">NeuVax&#8482; (nelipepimut-S), our lead product candidate, is a cancer immunotherapy targeting human epidermal growth factor receptor (HER2) expressing cancers. NeuVax is the immunodominant nonapeptide derived from the extracellular domain of the HER2 protein, a well-established and validated target for therapeutic intervention in breast and gastric carcinomas. The NeuVax vaccine is combined with GM-CSF for injection under the skin, or intradermal administration. Data has shown that an increased presence of circulating tumor cells (CTCs) may predict Disease Free Survival (DFS) and Overall Survival (OS)-suggesting a dormancy of isolated micrometastases, which, over time, may lead to recurrence. After binding to specific HLA molecules on antigen presenting cells, the nelipepimut-S sequence stimulates specific cytotoxic T lymphocyte (CTLs). These activated CTLs recognize, neutralize and destroy, through cell lysis, HER2 expressing cancer cells, including occult cancer cells and micrometastatic foci. The nelipepimut immune response can also generate CTLs to other immunogenic peptides through inter- and intra-antigenic epitope spreading.</font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;text-indent:66px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">We have multiple trials currently ongoing for NeuVax. For our pivotal, Phase 3 PRESENT (</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-weight:bold;">P</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">revention of </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-weight:bold;">R</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">ecurrence in </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-weight:bold;">E</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">arly-</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-weight:bold;">S</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">tage, Node- Positive Breast Cancer with Low to Intermediate HER2 </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-weight:bold;">E</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">xpression with </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-weight:bold;">NeuVax T</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">reatment) trial, NeuVax is targeting the </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">30,000</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">-</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">40,000</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> of the </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">230,000</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> female breast cancer patients annually diagnosed in the U.S. who are at a higher risk of their breast cancer recurring, which we refer to as &#8220;disease recurrence,&#8221; after achieving &#8220;no evidence of disease&#8221; (NED) status, (or becoming a &#8220;survivor&#8221;) with standard-of-care therapy (surgery, chemotherapy, radiation). These high-risk patients have a particular molecular signature and disease status: HER2 IHC 1+/2+ (oncoprotein associated with aggressive tumor growth), node positive (disease present in the axillary lymph nodes prior to surgery), and HLA A2/A3 (human leukocyte antigen from A2/A3 patients who have the same loci of genes which represents approximately </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">65%</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> of the population). Up to </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">25%</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> of resectable, node-positive breast cancer patients, having no radiographic evidence of disease following surgery and adjuvant chemo/radiation therapy, are expected to relapse within three years following diagnosis. The prognosis upon recurrence is very poor. These cancer patients presumably still had isolated, undetected tumor CTCs that led to a recurrence of cancer in the breast (local recurrence) or in another location (metastatic disease).  In addition to our Phase 3 trial, we currently have two additional Phase 2 breast cancer trials ongoing with NeuVax in combination with trastuzumab (Herceptin</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">&#174;</sup></font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">; Genentech/Roche) targeting the prevention of recurrence in expanded indications.  </font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;text-indent:66px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">We also recently announced our intent to initiate a Phase 2 trial with NeuVax as a single agent in patients with ductal carcinoma in situ (DCIS) in collaboration with the National Cancer Institute (NCI), potentially transitioning NeuVax earlier in the treatment cycle towards primary prevention.  The trial will have an immunological endpoint evaluating NeuVax peptide-specific cytotoxic T lymphocyte (CTL; CD8+ T cell) response in vaccinated patients. DCIS, is defined by the NCI as a noninvasive condition in which abnormal cells are found in the lining of a breast duct, and is the most common type of breast cancer.  The abnormal cells have not spread outside the duct to other tissues in the breast.  In some cases, DCIS may become invasive cancer and spread to other tissues, and at this time, there is no way to know which lesions could become invasive.  Current treatment options for DCIS include breast-conserving surgery and radiation therapy with or without tamoxifen, breast-conserving surgery without radiation therapy, or total mastectomy with or without tamoxifen.  According to the American Cancer Society, in 2014 there were an estimated </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">51,933</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> diagnoses of DCIS.</font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;text-indent:66px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">We currently have a number of ongoing or planned clinical trials designed to expand the clinical and geographical footprint of NeuVax:</font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:108px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:84px;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Phase 3 Ongoing: Our Phase 3 PRESENT (</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-weight:bold;">P</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">revention of </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-weight:bold;">R</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">ecurrence in </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-weight:bold;">E</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">arly- </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-weight:bold;">S</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">tage, Node-Positive Breast Cancer with Low to Intermediate HER2 </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-weight:bold;">E</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">xpression with </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-weight:bold;">NeuVax</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-weight:bold;">T</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">reatment) study targeted enrollment of </font><font style="font-family:Helvetica;font-size:10pt;">700</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> HER2 1+/2+ patients under a Special Protocol Assessment (SPA) granted by the U.S. Food and Drug Administration (FDA). The multinational, multicenter, randomized, double-blinded PRESENT trial is ongoing in North America, Western and Eastern Europe, and Israel. The trial is fully enrolled with </font><font style="font-family:Helvetica;font-size:10pt;">758</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> patients. </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:108px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:84px;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Phase 2b Ongoing: A randomized, multicenter, investigator-sponsored, </font><font style="font-family:Helvetica;font-size:10pt;">300</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> patient Phase 2b clinical trial is enrolling HER2 1+/2+ node-positive and high-risk node-negative breast cancer patients who are HLA A2+, A3+, A24+ or A26+ to study NeuVax in combination with trastuzumab in the adjuvant setting.  This trial is co-funded by Genentech/Roche (providing both trastuzumab and monetary support) and Galena (providing NeuVax and monetary support).</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:108px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:84px;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Phase 2 Ongoing: An investigator-sponsored trial is ongoing to study NeuVax in combination with trastuzumab. The study will enroll </font><font style="font-family:Helvetica;font-size:10pt;">100</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> node positive and negative HER2 IHC 3+ patients or HER2 gene-amplified breast cancer patients who are HLA A2+ or HLA A3+ and are determined to be at high-risk for recurrence. Partial funding for this trial comes from the Department of Defense (DoD) through the Congressionally Directed Medical Research Program via legislation known as the Defense Appropriations Act. The grant was awarded under a Breast Cancer Research Program with the Breakthrough Award given to the lead investigator for the trial.</font></div></td></tr></table><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:108px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br clear="none"/></font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:108px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:84px;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Phase 2 Planned: A clinical trial, entitled, VADIS: Phase 2 trial of the Nelipepimut-S Peptide </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-weight:bold;">VA</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">ccine in Women with </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-weight:bold;">D</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">C</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-weight:bold;">IS </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">of the Breast is planned to initiate by the end of 2015/early 2016. The Phase 2 trial will be a single-blind, double arm, randomized, controlled trial in pre- or post-menopausal patients with DCIS and are HLA-A2 positive.  VADIS will be co-funded and run in collaboration with the National Cancer Institute (NCI).</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:108px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:90px;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Phase 2 Planned: A Phase 2 clinical trial in patients with gastric cancer is expected to initiate in 2016.  The trial will be run in India by our partner, Dr. Reddy&#8217;s Laboratories, Ltd., as part of our NeuVax commercialization agreement in that region with Dr. Reddy&#8217;s. </font></div></td></tr></table><div style="line-height:120%;text-align:left;padding-left:32px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#006ebf;font-style:italic;font-weight:bold;">GALE-301 and GALE-302</font></div><div style="line-height:120%;text-align:left;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:66px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Our second immunotherapy franchise targets folate binding protein (FBP) receptor-alpha, a well-validated therapeutic target, which&#160;is highly over-expressed (20-80 fold) in ovarian, endometrial and breast cancers. Both GALE-301 (E39) and GALE-302 (E39&#8217;) are immunogenic peptides that can stimulate CTLs to recognize and destroy FBP-expressing cancer cells. GALE-301 consists of the FBP peptide E39 combined with GM-CSF, and is currently in a Phase 2a clinical trial for the prevention of recurrence in patients with ovarian and endometrial cancers. GALE-302 is an attenuated version of the E39 peptide and is currently in a Phase 1b randomized, single-center trial investigating a novel vaccination series using GALE-301 and GALE-302 to evaluate the immune response and monitor long-term immunity.  Current treatments after surgery for these diseases are principally with platinum based chemotherapeutic agents and patients suffer a high recurrence rate; and, most patients relapse with an extremely poor prognosis. Although not powered for efficacy, promising preliminary results from the Phase 2a clinical trial of GALE-301 were presented in September 2015 at the European Cancer Congress and demonstrated statistically significant data with the estimate for disease free survival at two years at 85.7% (1000 mcg dose group) vs. 33.6% for the control group (p &lt; .02), and that GALE-301 was well-tolerated with primarily Grade 1 and 2 toxicities and elicited a strong&#160;</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;">in vivo&#160;</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">immune response. </font></div><div style="line-height:120%;text-align:left;text-indent:66px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:66px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">According to the NCI Surveillance, Epidemiology, and End Results (SEER) Program, new cases of ovarian cancer occur at an annual rate of </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">12.1</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> per </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">100,000</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> women in the U.S., with an estimated </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">21,290</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> cases for 2015. Although ovarian cancer represents about </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">1.3%</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> of all cancers, it represents about </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">2.4%</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> of all cancer deaths, or an estimated </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">14,180</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> deaths in 2015. &#160;Approximately </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">1.3%</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> of women will be diagnosed with ovarian cancer at some point during their lifetime (2010 - 2012 data). &#160;The prevalence of ovarian cancer in the U.S. is about </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">192,000</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> women, and the five-year survivorship for women with ovarian cancer is </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">45.6%</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">.&#160;Due to the lack of specific symptoms, the majority of ovarian cancer patients are diagnosed at later stages of the disease, with an estimated </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">75%</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> of women presenting with advanced-stage (III or IV) disease. These patients have their tumors routinely surgically debulked to minimal residual disease, and then are treated with platinum- and/or taxane-based chemotherapy. While many patients respond to this treatment regimen and become clinically free-of-disease, the majority of these patients will relapse.  Depending upon their level of residual disease, the risk for recurrence after completion of primary therapy ranges from </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">60%</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> to </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">85%</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">.  Unfortunately for these women, once the disease recurs, treatment options are limited and the disease remains incurable.</font></div><div style="line-height:120%;text-align:left;text-indent:66px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:66px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">According to the NCI SEER Program, new cases of endometrial cancer occur at an annual rate of </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">25.1</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> per </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">100,000</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> women in the U.S., with an estimated </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">54,870</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> cases for 2015. Although endometrial cancer represents about </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">3.3%</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> of all cancers, it represents about </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">1.7%</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> of all cancer deaths, or an estimated </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">10,170</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> deaths in 2015. &#160;Approximately </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">2.8%</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> of women will be diagnosed with endometrial cancer at some point during their lifetime (2010 - 2012 data). &#160;The prevalence of endometrial cancer in the U.S. is about </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">620,000</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> women, and the five-year survivorship for women with endometrial cancer is </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">81.7%</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">.&#160;</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#006ebf;font-weight:bold;text-decoration:underline;">Hematology</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;padding-left:32px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#006ebf;font-style:italic;font-weight:bold;">GALE-401 (anagrelide controlled release (CR))</font></div><div style="line-height:120%;text-align:left;padding-left:32px;text-indent:66px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:66px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">In January 2014, we announced the acquisition of the worldwide rights to anagrelide controlled release (CR), which we renamed GALE-401, through our acquisition of Mills Pharmaceuticals, LLC. GALE-401 contains the active ingredient anagrelide, an FDA-approved product, for the treatment of patients with myeloproliferative neoplasms (MPNs) to lower abnormally elevated platelet levels. The currently available immediate release (IR) version of anagrelide causes adverse events that are believed to be dose and plasma concentration dependent. Therefore, reducing the maximum concentration (Cmax) is hypothesized to reduce the side effects, but preserve efficacy.</font></div><div style="line-height:120%;text-align:left;text-indent:66px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:66px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Multiple Phase 1 studies in </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">98</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> healthy subjects have shown GALE-401 reduces the Cmax of anagrelide following oral administration, appears to be well-tolerated at the doses administered, and to be capable of reducing platelet levels. The Phase 1 program provided the desired PK/PD (pharmacokinetic/pharmacodynamic) profile to enable the initiation of the ongoing Phase 2 proof-of-concept trial. The Phase 2, open label, single arm, proof-of-concept trial enrolled </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">18</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> patients in the United States for the treatment of thrombocytosis, or elevated platelet counts in patients with MPNs. Phase 2 top-line safety and efficacy data was presented in June 2015 at the European Hematology Association 20</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">th</sup></font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> Congress, and we expect to present a more mature data set at the 57th American Society of Hematology Annual Meeting in December 2015. Based on a regulatory meeting with the FDA, Galena believes a 505(b)(2) regulatory filing is an acceptable pathway for development and potential approval of GALE-401.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#006ebf;font-weight:bold;text-decoration:underline;">Strategic Review of Commercial Operations</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">During the quarter ended September 30, 2015, we completed a strategic review of the company&#8217;s commercial business including the ongoing sale, distribution and marketing of our two commercial products, Abstral</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">&#174;</sup></font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> (fentanyl) Sublingual Tablets and Zuplenz</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">&#174;</sup></font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> (ondansetron) Oral Soluble Film (our &#8220;commercial business&#8221; asset group). As a result of the review, we made a determination to sell or otherwise dispose of our commercial business.  </font></div><div style="line-height:120%;text-align:left;text-indent:66px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#006ebf;font-weight:bold;">Basis of Presentation and Significant Accounting Policies</font></div><div style="line-height:120%;text-indent:32px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:66px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">The accompanying consolidated financial statements included herein have been prepared by Galena pursuant to the rules and regulations of the Securities and Exchange Commission (SEC). Unless the context otherwise indicates, references in these notes to the &#8220;company,&#8221; &#8220;we,&#8221; &#8220;us&#8221; or &#8220;our&#8221; refer to Galena, our wholly owned subsidiary, Apthera, Inc., or &#8220;Apthera,&#8221; and our wholly owned subsidiary, Mills Pharmaceuticals, LLC or "Mills."</font></div><div style="line-height:120%;text-indent:66px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;">Discontinued Operations - </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">As described in Note 12, we met the relevant criteria for reporting our commercial business as held for sale and in discontinued operations in the accompanying unaudited interim financial statements as of the three and nine month periods ended September&#160;30, 2015 and 2014, pursuant to FASB Topic 205-20, Presentation of Financial Statements - Discontinued Operations, and FASB Topic 360, Property, Plant, and Equipment.</font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;">Uses of Estimates in Preparation of Financial Statements</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> &#8212; The preparation of these consolidated financial statements in accordance with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the reporting period. Actual results could differ materially from those estimates.</font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;">Principles of Consolidation</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> &#8212;&#160;The consolidated financial statements include the accounts of Galena and its wholly owned subsidiaries. All material intercompany accounts have been eliminated in consolidation.</font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;">Reclassifications</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> &#8212; Certain prior year amounts have been reclassified to conform to current year presentation. These reclassifications had no effect on net loss per share.</font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;">Cash and Cash Equivalents</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> &#8212; The company considers all highly liquid debt instruments with an original maturity of </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">90</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> days&#160;or less to be cash equivalents. Cash equivalents consist primarily of amounts invested in money market accounts and demand deposits.</font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;">Restricted Cash</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> &#8212; Restricted cash consists of certificates of deposit on hand with the company&#8217;s financial institutions as collateral for its corporate credit cards.</font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;">Fair Value of Financial Instruments</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> &#8212; The carrying amounts reported in the balance sheet for cash equivalents, accounts receivable, accounts payable, and capital leases approximate their fair values due to their short-term nature and market rates of interest.</font></div><div style="line-height:120%;text-indent:66px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:66px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;">Equipment and Furnishings</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> &#8212; Equipment and furnishings are stated at cost and depreciated using the straight-line method based on the estimated useful lives (generally </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">three</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> to </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">five</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> years) of the related assets.</font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:8px;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;">Goodwill and Intangible Assets</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> &#8212; Goodwill and indefinite-lived intangible assets are not amortized but are tested annually for impairment at the reporting unit level, or more frequently if events and circumstances indicate impairment may have occurred. Factors the company considers important that could trigger an interim review for impairment include, but are not limited to, the following:</font></div><div style="line-height:120%;padding-left:67px;padding-bottom:8px;text-align:left;"><font style="padding-bottom:8px;text-align:left;font-family:Helvetica,sans-serif;font-size:10pt;padding-right:28px;">&#8226;</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Significant changes in the manner of its use of acquired assets or the strategy for its overall business;</font></div><div style="line-height:120%;padding-left:67px;padding-bottom:8px;text-align:left;"><font style="padding-bottom:8px;text-align:left;font-family:Helvetica,sans-serif;font-size:10pt;padding-right:28px;">&#8226;</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Significant negative industry or economic trends;</font></div><div style="line-height:120%;padding-left:67px;padding-bottom:8px;text-align:left;"><font style="padding-bottom:8px;text-align:left;font-family:Helvetica,sans-serif;font-size:10pt;padding-right:28px;">&#8226;</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Significant decline in stock price for a sustained period; and</font></div><div style="line-height:120%;padding-left:67px;text-align:left;"><font style="text-align:left;font-family:Helvetica,sans-serif;font-size:10pt;padding-right:28px;">&#8226;</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Significant decline in market capitalization relative to net book value.</font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Goodwill and other intangible assets with indefinite lives are evaluated for impairment first by a qualitative assessment to determine the likelihood of impairment. If it is determined that impairment is more likely than not, the company will then proceed to the two step impairment test. The first step is to compare the fair value of the reporting unit to the carrying amount of the reporting unit. If the carrying amount exceeds the fair value, a second step must be followed to calculate impairment. Otherwise, if the fair value of the reporting unit exceeds the carrying amount, the goodwill is not considered to be impaired as of the measurement date. In its review of the carrying value of the goodwill for its single reporting unit and its indefinite-lived intangible assets, the company determines fair values of its goodwill using the market approach, and its indefinite-lived intangible assets using the income approach.</font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:66px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Intangible assets not considered indefinite-lived are reviewed for impairment when facts or circumstances suggest that the carrying value of these assets may not be recoverable. The company&#8217;s policy is to identify and record impairment losses, if necessary, on intangible assets when events and circumstances indicate that the assets might be impaired and the undiscounted cash flows estimated to be generated by those assets are less than the carrying amounts.</font></div><div style="line-height:120%;text-indent:66px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:66px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">The company performed its review for impairment using the qualitative assessment for both goodwill and indefinite-lived intangible assets, as well as assets not considered to be indefinite-lived, and has determined that there has been no impairment to these assets as of </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">September&#160;30, 2015</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">.</font></div><div style="line-height:120%;text-indent:66px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:66px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;">Assets Held for Sale </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">- The company generally considers assets to be held for sale when (i) when the transaction has been approved by the board of directors or management vested with authority to approve the transaction, (ii) the assets are available for immediate sale in their present condition, (iii) the company has initiated an active program to locate a buyer and other actions required to complete the plan to sell the assets, (iv) consummation of the transaction is probable, (v) the assets are being actively marketing for sale at a price that is reasonable in relation to the current fair value, and (vi) the transaction is expected to qualify for recognition as a completed sale, within one year. Following the classification of property and equipment for sale, the company discontinues depreciating the asset and writes down the asset to the lower of the carrying value or fair market value, if needed. As described in Note 12, actions taken by the company's management vested with the board of directors' authority caused the company to meet the relevant criteria for reporting the commercial operations as held for sale.</font></div><div style="line-height:120%;text-indent:32px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:66px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;">Acquisitions and In-Licensing &#8212;</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> For all in-licensed products and technologies, we perform an analysis to determine whether we hold a variable interest or a controlling financial interest in a variable interest entity. On the basis of our interpretations and conclusions, we determine whether the acquisition falls under the purview of variable interest entity accounting and if so, consider the necessity to consolidate the acquisition. As of </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">September&#160;30, 2015</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">, we determined there were no variable interest entities required to be consolidated.</font></div><div style="line-height:120%;text-indent:32px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:66px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">We also perform an analysis to determine if the assets and liabilities acquired in an acquisition qualify as a "business." The excess of the purchase price over the fair value of the net assets acquired can only be recognized as goodwill in a business combination. The Company completes its valuation analysis no later than twelve months from the date of the acquisition.</font></div><div style="line-height:120%;text-indent:32px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;">Contingent Purchase Price Consideration</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> &#8212; Contingent consideration in business combinations is recorded at the estimated fair value as of the acquisition date. The fair value of the contingent consideration is re-measured at each reporting period with any adjustments in fair value included in our consolidated statement of comprehensive loss.</font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;">Patents and Patent Application Costs</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> &#8212; Although the company believes that its patents and underlying technology have continuing value, the amount of future benefits to be derived from the patents is uncertain. Patent costs are, therefore, expensed as incurred.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;">Share-based Compensation</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> &#8212; The company follows the provisions of the FASB ASC Topic 718, &#8220;</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;">Compensation&#160;&#8212; Stock Compensation&#8221;</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> (&#8220;ASC 718&#8221;), which requires the measurement and recognition of compensation expense for all stock-based payment awards made to employees, non-employee directors, and consultants, including stock options and warrants. Stock compensation expense based on the grant date fair value estimated in accordance with the provisions of ASC&#160;718 is recognized as an expense over the requisite service period.</font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">For stock options and warrants granted as consideration for services rendered by non-employees, the company recognizes compensation expense in accordance with the requirements of FASB ASC Topic 505-50 (&#8220;ASC 505-50&#8221;), &#8220; </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;">Equity Based Payments to Non- Employees</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">.&#8221; Non-employee option and warrant grants that do not vest immediately upon grant are recorded as an expense over the vesting period. At the end of each financial reporting period prior to vesting, the value of these options and warrants, as calculated using the Black-Scholes option-pricing model, is re-measured using the fair value of the company&#8217;s common stock and the non-cash compensation recognized during the period is adjusted accordingly. Since the fair market value of options and warrants granted to non-employees is subject to change in the future, the amount of the future compensation expense will include fair value re-measurements until the stock options are fully vested.</font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;">Research and Development Expenses</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> &#8212; Research and development costs are expensed as incurred. Included in research and development costs are wages, benefits and other operating costs, facilities, supplies, external services and overhead related to our research and development departments, and clinical trial expenses.</font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Clinical trial expenses include direct costs associated with contract research organizations (CROs), as well as patient-related costs at sites at which our trials are being conducted.</font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Direct costs associated with our CROs are generally payable on a time and materials basis, or when certain enrollment and monitoring milestones are achieved. Expense related to a milestone is recognized in the period in which the milestone is achieved or in which we determine that it is more likely than not that it will be achieved.</font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">The invoicing from clinical trial sites can lag several months. We accrue these site costs based on our estimate of upfront set-up costs upon the screening of the first patient at each site, and the patient related costs based on our knowledge of patient enrollment status at each site.</font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;">Income Taxes</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> &#8212; The company recognizes liabilities or assets for the deferred tax consequences of temporary differences between the tax basis of assets or liabilities and their reported amounts in the financial statements in accordance with FASB ASC&#160;740-10, &#8220;</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;">Accounting for Income Taxes&#8221; (&#8220;ASC 740-10&#8221;).</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> These temporary differences will result in taxable or deductible amounts in future years when the reported amounts of the assets or liabilities are recovered or settled. </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;">ASC 740-10</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> requires that a valuation allowance be established when management determines that it is more likely than not that all or a portion of a deferred asset will not be realized. The company evaluates the realizability of its net deferred income tax assets and valuation allowances as necessary, at least on an annual basis. During this evaluation, the company reviews its forecasts of income in conjunction with other positive and negative evidence surrounding the realizability of its deferred income tax assets to determine if a valuation allowance is required. Adjustments to the valuation allowance will increase or decrease the company&#8217;s income tax provision or benefit. The recognition and measurement of benefits related to the company&#8217;s tax positions requires significant judgment, as uncertainties often exist with respect to new laws, new interpretations of existing laws, and rulings by taxing authorities. Differences between actual results and the company&#8217;s assumptions or changes in the company&#8217;s assumptions in future periods are recorded in the period they become known.</font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:66px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">There was no income tax expense or benefit for the three and nine months periods ended </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">September&#160;30, 2015</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> and 2014. We continue to maintain a full valuation allowance against our net deferred tax assets.</font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;">Concentrations of Credit Risk</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> &#8212; Financial instruments that potentially subject the company to significant concentrations of credit risk consist principally of cash and cash equivalents. The company maintains cash balances in several accounts with two banks, which at times are in excess of federally insured limits. As of </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">September&#160;30, 2015</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">, the company&#8217;s cash equivalents were invested in money market mutual funds. The company&#8217;s investment policy does not allow investment in any debt securities rated less than &#8220;investment grade&#8221; by national ratings services. The company has not experienced any losses on its deposits of cash and cash equivalents. The company maintains significant cash and cash equivalents at two financial institutions that are in excess of federally insured limits.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;">Comprehensive Loss</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> &#8212; Comprehensive loss consists of our net loss, with no other comprehensive income items for the periods presented.</font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;text-decoration:underline;">Effect of Recent Accounting Pronouncements</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> </font></div><div style="line-height:120%;text-align:left;text-indent:65px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">In April 2014, the FASB issued ASU 2014-08, Reporting Discontinued Operations and Disclosures of Disposals of Components of an Entity, or ASU 2014-08. Under ASU 2014-08, only disposals representing a strategic shift in operations that have a major effect on the company&#8217;s operations and financial results should be presented as discontinued operations. Additionally, ASU 2014-08 requires expanded disclosures about discontinued operations that will provide financial statement users with more information about the assets, liabilities, income, and expenses of discontinued operations. The amendments in ASU 2014-08 are effective for fiscal years, and interim periods within those years, beginning after December 15, 2014. The company adopted this guidance in the first quarter of 2015 and has applied it in the accompanying interim financial statements for presentation and disclosure of the commercial business as discontinued operations (see Note 12). </font></div><div style="line-height:120%;text-align:left;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">In May 2014, the FASB issued ASU No.&#160;2014-09,&#160;Revenue from Contracts with Customers: Topic 606,&#160;or ASU 2014-09. ASU 2014-09 establishes the principles for recognizing revenue and develops a common revenue standard for U.S. GAAP. The standard outlines a single comprehensive model for entities to use in accounting for revenue arising from contracts with customers and supersedes most current revenue recognition guidance, including industry-specific guidance. In applying the new revenue recognition model to contracts with customers, an entity: (1) identifies the contract(s) with a customer; (2) identifies the performance obligations in the contract(s); (3) determines the transaction price; (4) allocates the transaction price to the performance obligations in the contract(s); and (5) recognizes revenue when (or as) the entity satisfies a performance obligation.&#160;The accounting standards update applies to all contracts with customers except those that are within the scope of other topics in the FASB Accounting Standards Codification.&#160;The accounting standards update also requires significantly expanded quantitative and qualitative disclosures regarding the nature, amount, timing and uncertainty of revenue and cash flows arising from contracts with customers.&#160;This guidance is effective for fiscal years and interim periods within those years beginning after December 15, 2016, which is effective for the company for the year ending December 31, 2017. The FASB delayed in the effective date of the accounting standards update to fiscal years and interim periods within those years beginning on or after December 15, 2017, which is pending approval.&#160;The company is currently evaluating the impact that the implementation of ASU 2014-09 will have on the company&#8217;s financial statements. </font></div><div style="line-height:120%;text-align:left;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">In August 2014, the FASB issued ASU No. 2014-15,&#160;Disclosure of Uncertainties about an Entity&#8217;s Ability to Continue as a Going Concern, or ASU 2014-15. ASU 2014-15 will explicitly require management to assess an entity&#8217;s ability to continue as a going concern, and to provide related footnote disclosure in certain circumstances. The new standard will be effective for all entities in the first annual period ending after December 15, 2016. Earlier adoption is permitted. The company is not early adopting ASU 2014-15. The company is currently evaluating the impact that the implementation of ASU 2014-15 will have on the company&#8217;s financial statements, and the actual impact will be dependent upon the company&#8217;s liquidity and the nature or significance of future events or conditions that exist upon adopting the updated standard.</font></div><div style="line-height:120%;text-align:left;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">In January 2015, the FASB issued ASU No. 2015-01, Simplifying Income Statement Presentation by Eliminating the Concept of Extraordinary Items, or ASU 2015-01.&#160;ASU 2015-01 eliminates from GAAP the concept of extraordinary items. ASU 2015-01 is effective for fiscal years and interim periods beginning after December 15, 2015. Early adoption is permitted. The company does not expect that the adoption of ASU 2015-01 will have a material impact on its consolidated financial statements.</font></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the organization, consolidation and basis of presentation of financial statements disclosure, and significant accounting policies of the reporting entity. May be provided in more than one note to the financial statements, as long as users are provided with an understanding of (1) the significant judgments and assumptions made by an enterprise in determining whether it must consolidate a VIE and/or disclose information about its involvement with a VIE, (2) the nature of restrictions on a consolidated VIE's assets reported by an enterprise in its statement of financial position, including the carrying amounts of such assets, (3) the nature of, and changes in, the risks associated with an enterprise's involvement with the VIE, and (4) how an enterprise's involvement with the VIE affects the enterprise's financial position, financial performance, and cash flows.  Describes procedure if disclosures are provided in more than one note to the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 275<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 2<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6927468&amp;loc=d3e6003-108592<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.0.814</span><table class="report" border="0" cellspacing="2" id="idm139922623744016">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) - $ / shares<br></strong></div></th>
<th class="th"><div>Sep. 30, 2015</div></th>
<th class="th"><div>Dec. 31, 2014</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>Statement of Financial Position [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value (usd per share)</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized</a></td>
<td class="nump">5,000,000<span></span>
</td>
<td class="nump">5,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (usd per share)</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized</a></td>
<td class="nump">275,000,000<span></span>
</td>
<td class="nump">200,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued</a></td>
<td class="nump">161,900,446<span></span>
</td>
<td class="nump">110,100,701<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding</a></td>
<td class="nump">162,575,446<span></span>
</td>
<td class="nump">109,425,701<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockShares', window );">Treasury stock, shares</a></td>
<td class="nump">675,000<span></span>
</td>
<td class="nump">675,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.29)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 30<br><br><br><br> -Article 5<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.29)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 30<br><br><br><br> -Article 5<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.29)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 30<br><br><br><br> -Article 5<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 505<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 2<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.29)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 505<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.3-04)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 30<br><br><br><br> -Article 5<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 04<br><br><br><br> -Article 3<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.28)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 29<br><br><br><br> -Article 5<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.28)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 29<br><br><br><br> -Article 5<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of common and preferred shares that were previously issued and that were repurchased by the issuing entity and held in treasury on the financial statement date. This stock has no voting rights and receives no dividends.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.28,29)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 29, 30<br><br><br><br> -Article 5<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.0.814</span><table class="report" border="0" cellspacing="2" id="idm139922644385168">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>License Agreements<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2015</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsDisclosureTextBlock', window );">License Agreements</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#00497f;font-weight:bold;">License Agreements</font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">As part of its business, the company enters into licensing agreements with third parties that often require milestone and royalty payments based on the progress of the licensed assets through development and commercial stages. Milestone payments may be required, for example, upon approval of the product for marketing by a regulatory agency, and the company may be required to make royalty payments based upon a percentage of net sales of the product. The expenditures required under these arrangements in any period may be material and are likely to fluctuate from period to period.</font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">These arrangements sometimes permit the company to unilaterally terminate development of the product and thereby avoid future contingent payments; however, the company is unlikely to cease development if the compound successfully achieves clinical testing objectives.</font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">In conjunction with the acquisition of NeuVax</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">TM</sup></font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">, the company acquired rights and assumed obligations under a license agreement among Apthera and The University of Texas M. D. Anderson Cancer Center (&#8220;MDACC&#8221;) and The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc. (&#8220;HJF&#8221;) which grants exclusive worldwide rights to a U.S. patent covering the nelipepimut-S peptide and several U.S. and foreign patents and patent applications covering methods of using the peptide as a vaccine. Under the terms of this license, we are required to pay an annual maintenance fee of </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$200,000</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">, a milestone payment of </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$200,000</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> upon commencing the Phase 3 PRESENT trial of NeuVax and other clinical milestone payments, as well as royalty payments based on sales of NeuVax or other therapeutic products developed from the licensed technologies. </font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Effective April 30, 2009, we entered into a license agreement with Kwangdong Pharmaceutical Co, Ltd (Kwangdong).  Under the agreement, we granted Kwangdong exclusive rights to seek marketing approval in The Republic of Korea (South Korea) for our NeuVax product candidate for the treatment of breast cancer following its approval by the FDA or the European Medicines Agency, and to market, sell and distribute NeuVax in South Korea assuming such approval is obtained. </font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Effective December&#160;3, 2012, we entered into a license and supply agreement with ABIC Marketing Limited, a subsidiary of Teva Pharmaceuticals (&#8220;ABIC&#8221;), under which we granted ABIC exclusive rights to seek marketing approval in Israel for our NeuVax product candidate for intradermal injection for the treatment of breast cancer following its approval by the FDA or the European Medicines Agency, and to market, sell and distribute NeuVax in Israel assuming such approval is obtained. ABIC&#8217;s rights also include a right of first refusal in Israel for all future indications for which NeuVax may be approved. Under the license and supply agreement, ABIC will assume responsibility for regulatory registration of NeuVax in Israel, provide financial support for local development, and commercialize the product in the region in exchange for making royalty payments to us based on future sales of NeuVax. ABIC also agrees in the license and supply agreement to purchase from us all supplies of NeuVax at a price determined according to a specified formula.</font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Effective January 14, 2014, we entered into a strategic development and commercialization partnership with Dr. Reddy&#8217;s Laboratories Ltd. (&#8220;Dr. Reddy&#8217;s&#8221;), under which we licensed commercial rights in India to Dr. Reddy&#8217;s for NeuVax in breast and gastric cancers. Under the agreement, Dr. Reddy&#8217;s will lead the Phase 2 development of NeuVax in India in gastric cancer, significantly expanding the potential patient population addressable with NeuVax.</font></div><div style="line-height:120%;text-align:left;text-indent:66px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">On January 12, 2014, we acquired worldwide rights to anagrelide controlled release (CR) formulation, which we renamed GALE-401, through our acquisition of Mills Pharmaceuticals, LLC ("Mills") and Mills became a wholly owned subsidiary. GALE-401 contains the active ingredient anagrelide, an FDA-approved product that has been in use since the late 1990s for the treatment of essential thrombocythemia (ET). Mills holds an exclusive license to develop and commercialize anagrelide CR formulation, pursuant to a license agreement with BioVascular, Inc. Under the terms of the license agreement, Mills has agreed to pay BioVascular, Inc. a mid-to-low single digit royalty on net revenue from the sale of licensed products as well as future cash milestone payments based on the achievement of specified regulatory milestones. Mills is also responsible for patent prosecution and maintenance.</font></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all or part of the information related to intangible assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 350<br><br><br><br> -SubTopic 30<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=26713463&amp;loc=d3e16265-109275<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 350<br><br><br><br> -SubTopic 30<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 2<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=26713463&amp;loc=d3e16323-109275<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 350<br><br><br><br> -SubTopic 30<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 3<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=26713463&amp;loc=d3e16373-109275<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.0.814</span><table class="report" border="0" cellspacing="2" id="idm139922625742432">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Document and Entity Information - shares<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2015</div></th>
<th class="th"><div>Oct. 31, 2015</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_DocumentDocumentAndEntityInformationAbstract', window );"><strong>Document Document And Entity Information [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">Galena Biopharma, Inc.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">GALE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001390478<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-Q<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Sep. 30,  2015<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2015<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">Q2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">161,906,753<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>If the value is true, then the document is an amendment to previously-filed/accepted document.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal period of the document report. For a first quarter 2006 quarterly report, which may also provide financial information from prior periods, the first fiscal quarter should be given as the fiscal period focus. Values: FY, Q1, Q2, Q3, Q4, H1, H2, M9, T1, T2, T3, M8, CY.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in CCYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word "Other".</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation 12B<br><br><br><br> -Number 240<br><br><br><br> -Section 12b<br><br><br><br> -Subsection 1<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: (1) Large Accelerated Filer, (2) Accelerated Filer, (3) Non-accelerated Filer, (4) Smaller Reporting Company (Non-accelerated) or (5) Smaller Reporting Accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation 12B<br><br><br><br> -Number 240<br><br><br><br> -Section 12b<br><br><br><br> -Subsection 1<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gale_DocumentDocumentAndEntityInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Document Document and Entity Information [Abstract]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gale_DocumentDocumentAndEntityInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gale_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.0.814</span><table class="report" border="0" cellspacing="2" id="idm139922644491424">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Discontinued Operations, Assets Held for Sale (Notes)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2015</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract', window );"><strong>Discontinued Operations and Disposal Groups [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock', window );">Discontinued Operations,Assets Held for Sale</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#00497f;font-weight:bold;">Discontinued Operations, Assets Held for Sale</font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:66px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">As part of the company's strategic objective to focus its resources on its development pipeline, our management and board of directors have decided and committed to pursue a plan to sell or otherwise divest the company&#8217;s commercial business.  A brief summary of each product in our commercial business is provided below.</font></div><div style="line-height:120%;text-align:left;text-indent:66px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:66px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Abstral</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">&#174;</sup></font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> (fentanyl) Sublingual Tablets, is a treatment option for inadequately controlled breakthrough cancer pain (BTcP), which is estimated to affect more than </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">50%</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> of all cancer patients. Abstral is approved by the FDA, and is a sublingual (under the tongue) tablet for the management of breakthrough pain in patients with cancer, </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">18</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> years of age and older, who are already receiving, and who are tolerant to, opioid therapy for their persistent baseline cancer pain. The Abstral formulation delivers the analgesic power and increased bioavailability of micronized fentanyl in a sublingual tablet that is designed to dissolve under the tongue in seconds and provide relief of breakthrough pain within minutes. Abstral is a transmucosal immediate release fentanyl (TIRF) product with product class oversight by the TIRF Risk Evaluation and Mitigation Strategy (REMS) access program. </font></div><div style="line-height:120%;text-align:left;text-indent:66px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:66px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Zuplenz</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">&#174;</sup></font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> (ondansetron) Oral Soluble Film, is approved by the FDA in adult patients for the prevention of highly and moderately emetogenic chemotherapy-induced nausea and vomiting (CINV), radiotherapy-induced nausea and vomiting (RINV), and post-operative nausea and vomiting (PONV). Zuplenz is also approved in pediatric patients treated with moderately emetogenic CINV. Nausea and vomiting are two of the most common side-effects experienced by post-surgery patients and patients receiving chemotherapy or radiation. Zuplenz utilizes MonoSol&#8217;s proprietary PharmFilm</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">&#174; </sup></font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">technology, an oral soluble film that dissolves on the tongue in less than 30 seconds, therefore eliminating the burden of swallowing pills during periods of emesis. The active pharmaceutical ingredient in Zuplenz, ondansetron, belongs to a class of medications called serotonin 5-HT3 receptor antagonists and works by blocking the action of serotonin, a natural substance that may cause nausea and vomiting. </font></div><div style="line-height:120%;text-align:left;text-indent:66px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:66px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">The company met the relevant criteria for reporting the commercial business as held for sale and in discontinued operations in the accompanying unaudited interim financial statements as of and for the three and nine month periods ended September 30, 2015, and 2014, pursuant to FASB Topic 205-20,&#160;Presentation of Financial Statements--Discontinued Operations, and FASB Topic 360,&#160;Property, Plant, and Equipment. The company has assessed the commercial business net asset group for impairment pursuant to FASB Topic 360, as discussed in Note 2, determining that the carrying value exceed the fair value of the assets, therefore has recorded a $8.1 million impairment charge as of September 30, 2015. </font></div><div style="line-height:120%;text-align:left;text-indent:66px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:66px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">The company entered into an agreement with a third party firm to assist the company with the divestiture of its commercial operations including identifying potential acquirers. Pursuant to the terms of the agreement, in the event the company successfully completes a divestiture through the sale of its commercial operations to a third-party, the company is obligated to pay a success fee to the third party firm in an amount up to </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$900,000</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> of cash consideration received, 5% of realized future revenue and payment streams, as well as reimbursement for reasonable out-of-pocket expenses. </font></div><div style="line-height:120%;text-align:left;text-indent:66px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:66px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">The company has also entered into compensatory arrangements related to the divestiture of our commercial business with certain members of commercial management.  Under the terms of these arrangements, if the company meets certain sales and margin numbers in the fourth quarter of 2015 and successfully completes a divestiture through sale of its commercial operations to a third-party, the company may pay a retention fee to the three employees in a combined total amount equal to the lesser of </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$400,000</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> or </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">3%</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> of cash consideration received as upfront payment in the transaction, with payment to each employee portion conditioned on his or her continued employment through the closing date of such a divestiture of one or both products and satisfaction of other terms. These employees may also receive severance payments equal to one month&#8217;s salary for between four and seven months in event the divestiture does not result in continued employment with the acquirer</font><font style="font-family:inherit;font-size:10pt;">.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:66px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">The following table presents a reconciliation of the carrying amounts of assets and liabilities of the commercial operations to assets held for sale, net in the balance sheets (in thousands):</font></div><div style="line-height:120%;text-align:center;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:682px;border-collapse:collapse;text-align:left;"><tr><td colspan="8" rowspan="1"></td></tr><tr><td width="490px" rowspan="1" colspan="1"></td><td width="8px" rowspan="1" colspan="1"></td><td width="79px" rowspan="1" colspan="1"></td><td width="4px" rowspan="1" colspan="1"></td><td width="5px" rowspan="1" colspan="1"></td><td width="8px" rowspan="1" colspan="1"></td><td width="79px" rowspan="1" colspan="1"></td><td width="4px" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">September 30, 2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">December 31, 2014</font></div></td></tr><tr><td colspan="8" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Carrying amounts of assets included as part of discontinued operations:</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Accounts receivable</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">1,238</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">1,535</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Inventories</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">1,318</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">655</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Prepaid expenses and other current assets</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">1,064</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">1,747</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Equipment and furnishings, net</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">241</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">270</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Abstral rights, net</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">13,738</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">14,533</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Zuplenz rights</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">8,101</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">8,101</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Goodwill</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">172</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">172</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Impairment charge from classification as assets held for sale</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(8,071</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Total current assets held for sale</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">17,801</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">27,013</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td colspan="8" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Carrying amounts of liabilities included as part of discontinued operations:</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Accounts payable</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">1,359</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">385</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Accrued expenses and other current liabilities</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">6,338</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">6,784</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Total current liabilities held for sale</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">7,697</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">7,169</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div><div style="line-height:120%;text-align:center;text-indent:66px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:66px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">The following table represents the components attributable to the commercial operations that are presented in the consolidated statement of comprehensive loss as discontinued operations (in thousands):</font></div><div style="line-height:120%;text-align:center;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:681px;border-collapse:collapse;text-align:left;"><tr><td colspan="16" rowspan="1"></td></tr><tr><td width="300px" rowspan="1" colspan="1"></td><td width="8px" rowspan="1" colspan="1"></td><td width="78px" rowspan="1" colspan="1"></td><td width="4px" rowspan="1" colspan="1"></td><td width="5px" rowspan="1" colspan="1"></td><td width="8px" rowspan="1" colspan="1"></td><td width="77px" rowspan="1" colspan="1"></td><td width="4px" rowspan="1" colspan="1"></td><td width="5px" rowspan="1" colspan="1"></td><td width="8px" rowspan="1" colspan="1"></td><td width="78px" rowspan="1" colspan="1"></td><td width="4px" rowspan="1" colspan="1"></td><td width="5px" rowspan="1" colspan="1"></td><td width="8px" rowspan="1" colspan="1"></td><td width="78px" rowspan="1" colspan="1"></td><td width="4px" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Three Months Ended September 30,</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Nine Months Ended September 30,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">2014</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">2014</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Net revenue</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">2,166</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">1,620</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">8,298</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">6,124</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Cost of revenue</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(712</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(247</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(1,573</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(925</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Amortization of certain acquired intangible assets</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(208</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(70</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(795</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(259</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Research and development</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(160</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(219</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(339</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(619</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Selling, general, and administrative</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(4,672</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(3,725</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(13,577</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(10,954</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Non-operating income (expense)</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(17</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(17</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Impairment charge from classification as assets held for sale</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(8,071</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(8,071</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Loss from discontinued operations</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(11,674</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(2,641</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(16,074</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(6,633</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td></tr></table></div></div><div style="line-height:120%;text-align:left;text-indent:66px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:66px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">The following table presents significant operating non-cash items and capital expenditures related to discontinued operations (in thousands):</font></div><div style="line-height:120%;text-indent:66px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:682px;border-collapse:collapse;text-align:left;"><tr><td colspan="8" rowspan="1"></td></tr><tr><td width="490px" rowspan="1" colspan="1"></td><td width="8px" rowspan="1" colspan="1"></td><td width="79px" rowspan="1" colspan="1"></td><td width="4px" rowspan="1" colspan="1"></td><td width="5px" rowspan="1" colspan="1"></td><td width="8px" rowspan="1" colspan="1"></td><td width="79px" rowspan="1" colspan="1"></td><td width="4px" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">September 30, 2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">September 30, 2014</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Impairment of assets held for sale</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">8,071</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Depreciation and amortization</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">858</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">319</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Stock-based compensation</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">788</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">557</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Purchases of property and equipment</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(34</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Cash paid for acquisition of Zuplenz rights</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(500</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(3,056</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the facts and circumstances leading to the completed or expected disposal, manner and timing of disposal, the gain (loss) recognized in the income statement and the income statement caption that includes that gain (loss), amounts of revenues and pretax profit or loss reported in discontinued operations, the segment in which the disposal group was reported, and the classification (whether sold or classified as held for sale) and carrying value of the assets and liabilities comprising the disposal group. Includes all disposal groups, including those classified as components of the entity (discontinued operations).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 205<br><br><br><br> -SubTopic 20<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 2<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6360339&amp;loc=d3e1436-107760<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 205<br><br><br><br> -SubTopic 20<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6360339&amp;loc=d3e1361-107760<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 205<br><br><br><br> -SubTopic 20<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 3<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6360339&amp;loc=d3e1474-107760<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 205<br><br><br><br> -SubTopic 20<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 5<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6360339&amp;loc=d3e1510-107760<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 205<br><br><br><br> -SubTopic 20<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 3<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6892542&amp;loc=d3e957-107759<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 205<br><br><br><br> -SubTopic 20<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 5<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6892542&amp;loc=d3e1020-107759<br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 205<br><br><br><br> -SubTopic 20<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 4<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6892542&amp;loc=d3e1012-107759<br><br><br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 360<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 5<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=8077374&amp;loc=d3e2443-110228<br><br><br><br>Reference 9: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 360<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 3<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6391110&amp;loc=d3e2941-110230<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.0.814</span><table class="report" border="0" cellspacing="2" id="idm139922623046128">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2015</div></th>
<th class="th"><div>Sep. 30, 2014</div></th>
<th class="th"><div>Sep. 30, 2015</div></th>
<th class="th"><div>Sep. 30, 2014</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementAbstract', window );"><strong>Income Statement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest', window );">Income (Loss) from Continuing Operations, Including Portion Attributable to Noncontrolling Interest</a></td>
<td class="num">$ (6,352)<span></span>
</td>
<td class="num">$ (3,532)<span></span>
</td>
<td class="num">$ (28,150)<span></span>
</td>
<td class="num">$ (22,017)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Costs and expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">5,740<span></span>
</td>
<td class="nump">7,025<span></span>
</td>
<td class="nump">18,762<span></span>
</td>
<td class="nump">21,463<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SellingGeneralAndAdministrativeExpense', window );">General and administrative</a></td>
<td class="nump">2,895<span></span>
</td>
<td class="nump">3,542<span></span>
</td>
<td class="nump">7,869<span></span>
</td>
<td class="nump">12,744<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostsAndExpenses', window );">Total operating expenses</a></td>
<td class="nump">8,635<span></span>
</td>
<td class="nump">10,567<span></span>
</td>
<td class="nump">26,631<span></span>
</td>
<td class="nump">34,207<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Operating loss</a></td>
<td class="num">(8,635)<span></span>
</td>
<td class="num">(10,567)<span></span>
</td>
<td class="num">(26,631)<span></span>
</td>
<td class="num">(34,207)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpenseAbstract', window );"><strong>Other income (expense):</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_LossOnWarrantExchange', window );">Change in fair value of warrants potentially settleable in cash</a></td>
<td class="nump">2,134<span></span>
</td>
<td class="nump">6,735<span></span>
</td>
<td class="num">(981)<span></span>
</td>
<td class="nump">13,174<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestIncomeExpenseNet', window );">Interest income (expense), net</a></td>
<td class="num">(158)<span></span>
</td>
<td class="num">(297)<span></span>
</td>
<td class="num">(607)<span></span>
</td>
<td class="num">(925)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Other income (expense)</a></td>
<td class="nump">307<span></span>
</td>
<td class="nump">597<span></span>
</td>
<td class="nump">69<span></span>
</td>
<td class="num">(59)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherOperatingIncomeExpenseNet', window );">Total non-operating income (expense), net</a></td>
<td class="nump">2,283<span></span>
</td>
<td class="nump">7,035<span></span>
</td>
<td class="num">(1,519)<span></span>
</td>
<td class="nump">12,190<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax', window );">Loss from discontinued operations, including $8,071 impairment charge from classification as held for sale for three and nine months ended September 30, 2015</a></td>
<td class="num">(11,674)<span></span>
</td>
<td class="num">(2,641)<span></span>
</td>
<td class="num">(16,074)<span></span>
</td>
<td class="num">(6,633)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (18,026)<span></span>
</td>
<td class="num">$ (6,173)<span></span>
</td>
<td class="num">$ (44,224)<span></span>
</td>
<td class="num">$ (28,650)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAndDilutedAbstract', window );"><strong>Net loss per common share:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsPerBasicAndDilutedShare', window );">Basic and diluted net loss per share, continuing operations (in dollars per share)</a></td>
<td class="num">$ (0.04)<span></span>
</td>
<td class="num">$ (0.03)<span></span>
</td>
<td class="num">$ (0.18)<span></span>
</td>
<td class="num">$ (0.19)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicAndDilutedShare', window );">Basic and diluted net loss per share, discontinued operations (in dollars per share)</a></td>
<td class="num">(0.07)<span></span>
</td>
<td class="num">(0.02)<span></span>
</td>
<td class="num">(0.11)<span></span>
</td>
<td class="num">(0.06)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Basic net loss per share (in dollars per share)</a></td>
<td class="num">$ (110.00)<span></span>
</td>
<td class="num">$ (0.05)<span></span>
</td>
<td class="num">$ (0.29)<span></span>
</td>
<td class="num">$ (0.25)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted', window );">Weighted-average common shares outstanding: basic and diluted</a></td>
<td class="nump">161,857,522<span></span>
</td>
<td class="nump">119,038,656<span></span>
</td>
<td class="nump">153,000,857<span></span>
</td>
<td class="nump">117,767,791<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gale_LossOnWarrantExchange">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Loss on warrant exchange.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gale_LossOnWarrantExchange</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gale_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostsAndExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total costs of sales and operating expenses for the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 225<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 2<br><br><br><br> -Subparagraph (SX 210.5-03)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostsAndExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 260<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 225<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 2<br><br><br><br> -Subparagraph (SX 210.5-03.21)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 260<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 55<br><br><br><br> -Paragraph 52<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=32703322&amp;loc=d3e4984-109258<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 260<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 2<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=7655603&amp;loc=d3e1252-109256<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 944<br><br><br><br> -SubTopic 225<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.7-04.19)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 942<br><br><br><br> -SubTopic 225<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.9-04.23)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6879574&amp;loc=d3e536633-122882<br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 04<br><br><br><br> -Paragraph 18<br><br><br><br> -Article 7<br><br><br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 03<br><br><br><br> -Paragraph 20<br><br><br><br> -Article 5<br><br><br><br>Reference 9: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 04<br><br><br><br> -Paragraph 21<br><br><br><br> -Article 9<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAndDilutedAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicAndDilutedAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This element represents the income or loss from continuing operations attributable to the economic entity which may also be defined as revenue less expenses and taxes from ongoing operations before extraordinary items, and noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 810<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 19<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=7656940&amp;loc=SL4569616-111683<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsPerBasicAndDilutedShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) from continuing operations per each basic and diluted share of common stock or unit when the per share amount is the same for both basic and diluted shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsPerBasicAndDilutedShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from a disposal group, net of income tax before extraordinary items allocable to noncontrolling interests. Includes, net of tax, income (loss) from operations during the phase-out period, gain (loss) on disposal, provision (or any reversals of earlier provisions) for loss on disposal, and adjustments of a prior period gain (loss) on disposal.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 944<br><br><br><br> -SubTopic 225<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.7-04.12)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 225<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 2<br><br><br><br> -Subparagraph (SX 210.5-03.14)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 205<br><br><br><br> -SubTopic 20<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (c)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6360339&amp;loc=d3e1361-107760<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 205<br><br><br><br> -SubTopic 20<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 3<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6892542&amp;loc=d3e957-107759<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 04<br><br><br><br> -Paragraph 13<br><br><br><br> -Article 7<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 03<br><br><br><br> -Paragraph 15<br><br><br><br> -Article 5<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicAndDilutedShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per basic and diluted share amount, after tax, of income (loss) from the day-to-day business activities of the discontinued operation and gain (loss) from the disposal of the discontinued operation, when the per share amount is the same.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicAndDilutedShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestIncomeExpenseNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net amount of operating interest income (expense).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 942<br><br><br><br> -SubTopic 225<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.9-04.10)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6879574&amp;loc=d3e536633-122882<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 04<br><br><br><br> -Paragraph 10<br><br><br><br> -Article 9<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestIncomeExpenseNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Glossary Net Income<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6518256<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 230<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 28<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3602-108585<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 944<br><br><br><br> -SubTopic 225<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.7-04.19)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 260<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 225<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 2<br><br><br><br> -Subparagraph (SX 210.5-03.18)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 944<br><br><br><br> -SubTopic 225<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.7-04.22)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Glossary Other Comprehensive Income<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6519514<br><br><br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 03<br><br><br><br> -Paragraph 19<br><br><br><br> -Article 5<br><br><br><br>Reference 9: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 04<br><br><br><br> -Paragraph 20<br><br><br><br> -Article 9<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net amount of other income and expense amounts, the components of which are not separately disclosed on the income statement, resulting from ancillary business-related activities (that is, excluding major activities considered part of the normal operations of the business) also known as other nonoperating income (expense) recognized for the period. Such amounts may include: (a) dividends, (b) interest on securities, (c) net gains or losses on securities, (d) unusual costs, (e) gains or losses on foreign exchange transactions, and (f) miscellaneous other income and expense items.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 225<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 2<br><br><br><br> -Subparagraph (SX 210.5-03.9)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 03<br><br><br><br> -Paragraph 9<br><br><br><br> -Article 5<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherOperatingIncomeExpenseNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net amount of other operating income and expenses, the components of which are not separately disclosed on the income statement, from items that are associated with the entity's normal revenue producing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherOperatingIncomeExpenseNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 730<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 985<br><br><br><br> -SubTopic 20<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SellingGeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 225<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 2<br><br><br><br> -Subparagraph (SX 210.5-03.4)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 330<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 30<br><br><br><br> -Paragraph 8<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=34747878&amp;loc=d3e3636-108311<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 03<br><br><br><br> -Paragraph 4<br><br><br><br> -Article 5<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SellingGeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.0.814</span><table class="report" border="0" cellspacing="2" id="idm139922846163024">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2015</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">Stockholders' Equity</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#00497f;font-weight:bold;">Stockholders&#8217; Equity</font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;">Preferred Stock</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> &#8212; The company has authorized up to </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">5,000,000</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#160;shares of preferred stock, </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$0.0001</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#160;par value per share, for issuance. The preferred stock will have such rights, preferences, privileges and restrictions, including voting rights, dividend rights, conversion rights, redemption privileges and liquidation preferences, as shall be determined by the company&#8217;s Board of Directors upon its issuance. To date, the company has not issued any preferred shares.</font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;">Common Stock</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> &#8212; The company has authorized up to </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">275,000,000</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#160;shares of common stock, </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$0.0001</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#160;par value per share, for issuance.</font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;">November 2014 Purchase Agreement with Lincoln Park Capital, LLC - </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">On November 18, 2014, the company entered into a purchase agreement with Lincoln Park Capital, LLC (LPC), pursuant to which the company has the right to sell to LPC up to </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$50 million</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> in shares of the company's common stock, subject to certain limitations and conditions over the </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">36</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> month term of the purchase agreement. Pursuant to the purchase agreement, LPC initially purchased </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">2.5 million</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> shares of the company's common stock at </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$2.00</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> per share and the company issued </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">631,221</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> shares of common stock to LPC as a commitment fee, which was recorded as a cost of capital. As a result of this initial issuance, the company received initial net proceeds of </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$4.9 million</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">, after deducting commissions and other offering expenses. In addition to LPC&#8217;s initial purchase of our common stock under the purchase agreement, during the first quarter of 2015, we received net proceeds of </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$4.4 million</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> from LPC&#8217;s subsequent purchases of a total of </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">2.7 million</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> shares of our common stock, excluding the commitment fee shares. </font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;">At Market Issuance Sales Agreements </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">- On May 24, 2013 the Company entered into At Market Issuance Sales Agreements (ATM) with MLV &amp; Co. LLC and Maxim Group LLC (the Agents). From time to time during the term of the ATM, we may issue and sell through the Agents, shares of our common stock, and the Agents collect a fee equal to </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">3%</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> of the gross proceeds from the sale of shares, up to a total limit of </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$20 million</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> in gross proceeds. The ATM is available to the company until it is terminated by the Agents or the company. During the first quarter of 2015, we received </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$2.3 million</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> in net proceeds from the sale of </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">1.4 million</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> shares of our common stock through the ATM. There were no sales of our common stock under the ATM during the three months ended September 30, 2015 or during the three and nine months ended September 30, 2014.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;">March 2015 Underwritten Public Offering</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> - On March 18, 2015 the company closed an underwritten public offering of </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">24,358,974</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> units at a price to the public of </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$1.56</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> per unit for gross proceeds of </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$38 million</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> (the "March 2015 Offering"). Each unit consists of one share of common stock, and a warrant to purchase </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">0.50</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> of a share of common stock at an exercise price of </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$2.08</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> per share. The March 2015 Offering included an over-allotment option for the underwriters to purchase an additional </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">3,653,846</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> shares of common stock and/or warrants to purchase up to </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">1,826,923</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> shares of common stock. On March 18, 2015, the underwriters exercised their over-allotment option to purchase warrants to purchase an aggregate of </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">1,826,923</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> shares of common stock. On April 10, 2015, the underwriters exercised their over-allotment option to purchase </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">3,653,846</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> shares of common stock for additional net proceeds of </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$5.4 million</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">. The total net proceeds of the March 2015 Offering, including the exercise of the over-allotment option to purchase the warrants, were </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$40.8 million</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">, after deducting underwriting discounts and commissions and offering expenses payable by the company. </font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:66px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Shares of common stock for future issuance are reserved for as follows (in thousands):</font></div><div style="line-height:120%;text-indent:66px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="3" rowspan="1"></td></tr><tr><td width="84%" rowspan="1" colspan="1"></td><td width="15%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">As of September&#160;30, 2015</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Warrants outstanding</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">22,308</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Stock options outstanding</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">11,188</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Options reserved for future issuance under the Company&#8217;s 2007 Incentive Plan</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">10,251</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Shares reserved for future issuance under the Employee Stock Purchase Plan</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">528</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Total reserved for future issuance</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">44,275</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 235<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.4-08.(d),(e))<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 505<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 4<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21484-112644<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 310<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 2<br><br><br><br> -Subparagraph (SAB TOPIC 4.E)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=27010918&amp;loc=d3e74512-122707<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 505<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 5<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21488-112644<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.29-31)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 505<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 4<br><br><br><br> -Subparagraph (SAB TOPIC 4.C)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187143-122770<br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 505<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 6<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21506-112644<br><br><br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 505<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.3-04)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br><br><br>Reference 9: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 505<br><br><br><br> -SubTopic 30<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 2<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6405834&amp;loc=d3e23285-112656<br><br><br><br>Reference 10: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 505<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 3<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21475-112644<br><br><br><br>Reference 11: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Glossary Preferred Stock<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6521494<br><br><br><br>Reference 12: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 505<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 2<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br><br><br>Reference 13: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 505<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 11<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21564-112644<br><br><br><br>Reference 14: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 08<br><br><br><br> -Paragraph d<br><br><br><br> -Article 4<br><br><br><br>Reference 15: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 29, 30, 31<br><br><br><br> -Article 5<br><br><br><br>Reference 16: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Staff Accounting Bulletin (SAB)<br><br><br><br> -Number Topic 4<br><br><br><br> -Section E<br><br><br><br>Reference 17: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 08<br><br><br><br> -Article 4<br><br><br><br>Reference 18: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Staff Accounting Bulletin (SAB)<br><br><br><br> -Number Topic 4<br><br><br><br> -Section C<br><br><br><br>Reference 19: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 04<br><br><br><br> -Article 3<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.0.814</span><table class="report" border="0" cellspacing="2" id="idm139922644462816">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Legal Proceedings, Commitments and Contingencies (Notes)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2015</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">Legal Proceedings, Commitments and Contingencies</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:12px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#00497f;font-weight:bold;">Legal Proceedings, Commitments and Contingencies</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;">Legal Proceedings</font></div><div style="line-height:120%;text-align:left;text-indent:65px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;">In re Galena Biopharma, Inc. Securities Litigation and In Re Galena Biopharma, Inc. Derivative Litigation</font></div><div style="line-height:120%;text-align:left;padding-left:48px;text-indent:65px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">On August 4, 2015, plaintiffs in the voluntarily dismissed Delaware derivative action have filed a motion seeking to file under seal a derivative complaint in the District Court.  That motion was granted and on August 31, 2015, that action was consolidated with </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;">In Re Galena Biopharma, Inc. Derivative Litigation</font><font style="font-family:inherit;font-size:10pt;">.</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">On or about September 15, 2015, a federal securities lawsuit was filed in the U.S. District Court for the District of Oregon entitled, </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;">Riley v. Galena Biopharma, Inc., et al</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">.  The time to answer or otherwise plead has been extended by agreement of the parties.</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">We intend to vigorously defend against and seek resolution to the foregoing claims.  As of September 30, 2015, we have not recorded any</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-weight:bold;"> </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">liabilities with respect to the claims in our consolidated financial statements.  We believe that claims are covered under our liability insurance, and we have notified our insurance carriers of the claims.  The insurers have responded by requesting additional information and by reserving their rights under the policies, including the rights to deny coverage under various policy exclusions.  Subject to their reservation of rights, we are being reimbursed by our insurance carriers for significant portion of all legal fees relating to our defense of the claims. We have entered into certain undertaking agreements with our directors related to the litigation by which we have agreed to advance reasonable legal fees and costs for the litigation under certain conditions.</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;">SEC Investigation</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">We are aware that the Securities and Exchange Commission (SEC) is investigating certain matters relating to the use of certain outside investor-relations professionals by us and other public companies.  We have been in contact with the SEC staff through our counsel and are cooperating with the investigation.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;">ANDA Litigation</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> On October 23, 2015, Orexo AB (&#8220;Orexo&#8221;) and Galena Biopharma, Inc. (the &#8220;Company&#8221;) entered into a settlement and license agreement with Actavis Laboratories FL, Inc. (&#8220;Actavis&#8221;) to resolve pending patent litigation brought by the Orexo against Actavis involving Abstral&#174; (fentanyl) sublingual tablets.  The pending patent litigation was filed by Orexo in the U.S. District Court for the District of New Jersey in response to Actavis&#8217; submission of an Abbreviated New Drug Application (&#8220;ANDA&#8221;) to the U.S. Food and Drug Administration (&#8220;FDA&#8221;), seeking marketing approval for a generic version of Abstral.  As a result of the settlement and license agreement, Actavis will be permitted to enter the market with a generic or authorized generic version of Abstral in the United States June 2018 or earlier under certain circumstances. The Court has entered an order dismissing with prejudice the litigation against Actavis.  Details of the settlement are confidential, and the parties have submited the agreement to the Federal Trade Commission and the Department of Justice, as required by federal law. The expiration date for the latest expiring Abstral patent listed in the FDA&#8217;s Orange Book is September 2019.</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;">Commitments</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">The company acquires assets still in development and enters into research and development arrangements with third parties that often require milestone and royalty payments based on the progress of the asset through development stages. Milestone payments may be required, for example, upon approval of the product for marketing by a regulatory agency. In certain agreements, the company is required to make royalty payments based upon a percentage of the sales.</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">These arrangements may be material individually, and in the unlikely event that milestones for multiple products covered by these arrangements were reached in the same period, the aggregate charge to expense could be material to the results of operations. In addition, these arrangements often give the company the discretion to unilaterally terminate development of the product, which the company might do for clinical, business or other reasons, which would allow the company to avoid making the contingent payments.</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">The company applies the disclosure provisions FASB ASC Topic 460 (&#8220;ASC 460&#8221;), &#8220; </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;">Guarantor&#8217;s Accounting and Disclosure Requirements for Guarantees, Including Indirect Guarantees of Indebtedness of Others</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> &#8221;, to its agreements that contain guarantee or indemnification clauses. The company provides (i)&#160;indemnifications of varying scope and size to certain investors and other parties for certain losses suffered or incurred by the indemnified party in connection with various types of third-party claims and (ii)&#160;indemnifications of varying scope and size to officers and directors against third party claims arising from the services they provide to us. These indemnifications give rise only to the disclosure provisions of ASC&#160;460. To date, the company has not incurred costs as a result of these obligations and does not expect to incur material costs in the future. Accordingly, the company has not accrued any liabilities in its financial statements related to these indemnifications.</font></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 825<br><br><br><br> -SubTopic 20<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6449706&amp;loc=d3e16207-108621<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 460<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 8<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6398077&amp;loc=d3e12565-110249<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 450<br><br><br><br> -SubTopic 20<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 4<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=25496072&amp;loc=d3e14435-108349<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.25)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 440<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 2<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6394976&amp;loc=d3e25287-109308<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.0.814</span><table class="report" border="0" cellspacing="2" id="idm139922853459200">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2015</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_CommonStockAreReservedForFutureIssuanceTableTextBlock', window );">Common Stock are Reserved for Future Issuance</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;">March 2015 Underwritten Public Offering</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> - On March 18, 2015 the company closed an underwritten public offering of </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">24,358,974</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> units at a price to the public of </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$1.56</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> per unit for gross proceeds of </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$38 million</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> (the "March 2015 Offering"). Each unit consists of one share of common stock, and a warrant to purchase </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">0.50</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> of a share of common stock at an exercise price of </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$2.08</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> per share. The March 2015 Offering included an over-allotment option for the underwriters to purchase an additional </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">3,653,846</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> shares of common stock and/or warrants to purchase up to </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">1,826,923</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> shares of common stock. On March 18, 2015, the underwriters exercised their over-allotment option to purchase warrants to purchase an aggregate of </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">1,826,923</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> shares of common stock. On April 10, 2015, the underwriters exercised their over-allotment option to purchase </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">3,653,846</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> shares of common stock for additional net proceeds of </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$5.4 million</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">. The total net proceeds of the March 2015 Offering, including the exercise of the over-allotment option to purchase the warrants, were </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$40.8 million</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">, after deducting underwriting discounts and commissions and offering expenses payable by the company. </font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:66px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Shares of common stock for future issuance are reserved for as follows (in thousands):</font></div><div style="line-height:120%;text-indent:66px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="3" rowspan="1"></td></tr><tr><td width="84%" rowspan="1" colspan="1"></td><td width="15%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">As of September&#160;30, 2015</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Warrants outstanding</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">22,308</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Stock options outstanding</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">11,188</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Options reserved for future issuance under the Company&#8217;s 2007 Incentive Plan</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">10,251</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Shares reserved for future issuance under the Employee Stock Purchase Plan</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">528</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Total reserved for future issuance</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">44,275</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gale_CommonStockAreReservedForFutureIssuanceTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Common stock are reserved for future issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gale_CommonStockAreReservedForFutureIssuanceTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gale_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.0.814</span><table class="report" border="0" cellspacing="2" id="idm139922625141600">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Subsequent Events<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2015</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventsAbstract', window );"><strong>Subsequent Events [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventsTextBlock', window );">Subsequent Events</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#00497f;font-weight:bold;">Subsequent Events</font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">The company evaluated all events or transactions that occurred after </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">September&#160;30, 2015</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> up through the date these financial statements were issued. Other than as disclosed elsewhere in the notes to the condensed consolidated financial statements, the company did not have any material recognizable or unrecognizable subsequent events.</font></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.0.814</span><table class="report" border="0" cellspacing="2" id="idm139922636038976">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Other Income (Expense) (Notes)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2015</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherIncomeAndExpensesAbstract', window );"><strong>Other Income and Expenses [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherIncomeAndOtherExpenseDisclosureTextBlock', window );">Other Income (Expense)</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#00497f;font-weight:bold;">Other Income (Expense)</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Other income (expense) is summarized as follows (in thousands):</font></div><div style="line-height:120%;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">&#160;</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16" rowspan="1"></td></tr><tr><td width="45%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="11%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="11%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="11%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="11%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Three Months Ended September 30,</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Nine Months Ended September 30,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">2014</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">2014</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Change in fair value of the contingent purchase price liability</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">307</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">597</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">69</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(59</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Total other income (expense)</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">307</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">597</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">69</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(59</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherIncomeAndExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherIncomeAndExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherIncomeAndOtherExpenseDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for other income or other expense items (both operating and nonoperating). Sources of nonoperating income or nonoperating expense that may be disclosed, include amounts earned from dividends, interest on securities, profits (losses) on securities, net and miscellaneous other income or income deductions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 225<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 2<br><br><br><br> -Subparagraph (SX 210.5-03.3,6,7,9)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 03<br><br><br><br> -Paragraph 3, 6, 7, 9<br><br><br><br> -Article 5<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherIncomeAndOtherExpenseDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.0.814</span><table class="report" border="0" cellspacing="2" id="idm139922644447168">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Warrants<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2015</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsNoteDisclosureAbstract', window );"><strong>Warrants and Rights Note Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OptionIndexedToIssuersEquityDescriptionTextBlock', window );">Warrants</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#00497f;font-weight:bold;">Warrants</font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">The following is a summary of warrant activity for the nine months ended </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">September&#160;30, 2015</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> (in thousands):</font></div><div style="line-height:120%;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">&#160;</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="24" rowspan="1"></td></tr><tr><td width="21%" rowspan="1" colspan="1"></td><td width="8%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="8%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="8%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="8%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="8%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="8%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="8%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="8%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">March 2015 Warrants</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">September</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">2013</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Warrants</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">December</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">2012</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Warrants</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">April&#160;2011</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Warrants</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">March</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">2011</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Warrants</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">March</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">2010</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Warrants</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Consultant</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">and Oxford Warrants</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Total</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Outstanding, January 1, 2015</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">3,973</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">3,031</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">615</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">176</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">25</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">720</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">8,540</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Issued</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">14,006</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">14,006</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Expired</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">(238</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">(238</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Outstanding, September&#160;30, 2015</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">14,006</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">3,973</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">3,031</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">615</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">176</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">25</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">482</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">22,308</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Expiration</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">March 2020</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">September 2018</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">December 2017</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:3px double #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">April 2017</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">March 2016</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">March 2016</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Varies 2014-2020</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:66px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:66px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Warrants consist of warrants potentially settleable in cash, which are liability-classified warrants, and equity-classified warrants.</font></div><div style="line-height:120%;text-indent:32px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:66px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;">Warrants classified as liabilities</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:66px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Liability-classified warrants consist of warrants to purchase common stock issued in connection with equity financings in March 2015, September 2013, December 2012,&#160;April 2011,&#160;March 2011,&#160;and March 2010. These warrants are potentially settleable in cash and were determined not to be indexed to our common stock.</font></div><div style="line-height:120%;text-indent:32px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:66px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">The estimated fair value of outstanding warrants accounted for as liabilities is determined at each balance sheet date. Any decrease or increase in the estimated fair value of the warrant liability since the most recent balance sheet date is recorded in the condensed consolidated statement of comprehensive loss as other income (expense). The fair value of the warrants is estimated using an appropriate pricing model with the following inputs:</font></div><div style="line-height:120%;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">&#160;</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="24" rowspan="1"></td></tr><tr><td width="23%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="10%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="10%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="10%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="10%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="10%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="10%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="23" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">As of September&#160;30, 2015</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">March 2015 Warrants</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">September</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">2013</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Warrants</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">December</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">2012</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Warrants</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">April&#160;2011</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Warrants</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">March</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">2011</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Warrants</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">March</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">2010</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Warrants</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">Strike price</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">2.08</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">2.50</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">1.83</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">0.65</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">0.65</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">2.02</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">Expected term (years)</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">4.47</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">2.97</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">2.23</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">1.56</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">0.43</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">0.49</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">Volatility %</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">74.99</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">76.85</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">75.45</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">69.48</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">72.42</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">68.33</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">%</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">Risk-free rate %</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">1.25</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">0.91</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">0.70</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">0.50</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">0.06</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">0.08</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">%</font></div></td></tr></table></div></div><div style="line-height:120%;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">&#160;</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="20" rowspan="1"></td></tr><tr><td width="36%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="10%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="10%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="10%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="10%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="10%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="19" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">As of December&#160;31, 2014</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">September</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">2013</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Warrants</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">December</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">2012</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Warrants</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">April&#160;2011</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Warrants</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">March</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">2011</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Warrants</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">March</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">2010</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Warrants</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">Strike price</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">2.50</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">1.90</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">0.65</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">0.65</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">2.15</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">Expected term (years)</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">3.72</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">2.98</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">2.31</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">1.18</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">1.24</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">Volatility %</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">75.60</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">76.85</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">78.24</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">77.38</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">77.12</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">%</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">Risk-free rate %</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">1.30</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">1.09</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">0.80</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">0.32</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">0.35</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">%</font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">The expected volatility assumptions are based on the company's implied volatility in combination with the implied volatilities of similar publicly traded entities. The expected life assumption is based on the remaining contractual terms of the warrants. The risk-free rate is based on the zero coupon rates in effect at the time of valuation. The dividend yield used in the pricing model is zero, because the company has no present intention to pay cash dividends.</font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">The changes in fair value of the warrant liability for the nine months ended </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">September&#160;30, 2015</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> were as follows (in thousands):</font></div><div style="line-height:120%;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">&#160;</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="28" rowspan="1"></td></tr><tr><td width="24%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="8%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="8%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="8%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="8%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="8%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="8%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="8%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">March 2015 Warrants</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">September</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">2013</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Warrants</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">December</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">2012</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Warrants</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">April&#160;2011</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Warrants</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">March</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">2011</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Warrants</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">March</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">2010</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Warrants</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Total</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">Warrant liability, January&#160;1, 2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">2,560</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">2,027</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">625</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">163</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">8</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">5,383</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">Fair value of warrants issued</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">10,296</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">10,296</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">Change in fair value of warrants</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">1,313</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">(157</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">(162</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">(10</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">2</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">(4</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">982</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">Warrant liability, September&#160;30, 2015</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">11,609</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">2,403</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">1,865</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">615</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">165</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">4</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">16,661</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;">Warrants classified as equity</font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Equity-classified warrants consist of warrants issued in connection with consulting services provided to us. Additionally, on May 8, 2013 as a part of our Loan financing, we granted Oxford Financial LLC warrants to purchase up to </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">182,186</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> shares of common stock at an exercise price of </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$2.47</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">, which equaled to the </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">20</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">-day average market price of our common stock prior to the date of the grant. The warrants were valued using an appropriate pricing model as described in Note 9, below. The fair value assumptions for the grant included a volatility of </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">75.34%</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">, expected term of </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">seven</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> years, risk-free rate of </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">1.20%</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">, and a dividend rate of </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">0.00%</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">. The fair value of the warrants granted was </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$1.93</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> per share. These warrants are recorded in equity at fair value upon issuance, and not as liabilities, and are not subject to adjustment to fair value in subsequent reporting periods.</font></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OptionIndexedToIssuersEquityDescriptionTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for freestanding option contracts issued by an entity that are indexed to, and potentially settled in, an entity's own stock. Includes disclosure on the strike price and the number of shares to which the contract is indexed, the settlement date or dates of the contract, and the issuer's accounting for the contract. If the terms of the contract provide settlement alternatives, those settlement alternatives are disclosed, including who controls the settlement alternatives, and the maximum number of shares that could be required to be issued, to net share settle the contract, if applicable. If a contract does not have a fixed or determinable maximum number of shares that could be required to be issued, the fact that a potentially infinite number of shares that may be required to be issued to settle the contract is disclosed. Disclosure also includes the contract's current fair value for each settlement alternative and how changes in the price of the issuer's equity instruments affect those settlement amounts.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 815<br><br><br><br> -SubTopic 40<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 3<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6445032&amp;loc=d3e90193-114008<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Glossary Freestanding Contract<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6513800<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 480<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 55<br><br><br><br> -Paragraph 63<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6924035&amp;loc=d3e23176-110880<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 815<br><br><br><br> -SubTopic 40<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 5<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6445032&amp;loc=d3e90205-114008<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 815<br><br><br><br> -SubTopic 40<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 4<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6445032&amp;loc=d3e90198-114008<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OptionIndexedToIssuersEquityDescriptionTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsNoteDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsNoteDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.0.814</span><table class="report" border="0" cellspacing="2" id="idm139922644479552">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock Based Compensation<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2015</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Disclosure of Compensation Related Costs, Share-based Payments [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">Stock Based Compensation</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#00497f;font-weight:bold;">Stock-Based Compensation</font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;">Options to Purchase Shares of Common Stock</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> &#8212; The company follows the provisions ASC&#160;718, which requires the measurement and recognition of compensation expense for all share-based payment awards made to employees, non-employee directors, including employee stock options. Stock compensation expense based on the grant date fair value estimated in accordance with the provisions of ASC&#160;718 is recognized as an expense over the requisite service period.</font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">For stock options and warrants granted in consideration for services rendered by non-employees, the company recognizes compensation expense in accordance with the requirements of ASC Topic 505-50. Non-employee option and warrant grants that do not vest immediately upon grant are recorded as an expense over the vesting period. At the end of each financial reporting period prior to vesting, the value of these options and warrants, as calculated using the Black-Scholes option-pricing model, is re-measured using the fair value of the company&#8217;s common stock and the non-cash compensation recognized during the period is adjusted accordingly. Since the fair market value of options and warrants granted to non-employees is subject to change in the future, the amount of the future compensation expense will include fair value re-measurements until the stock options and warrants are fully vested.</font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">The following table summarizes the components of stock-based compensation expense in the condensed consolidated statements of comprehensive loss for the three and nine months ended </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">September&#160;30, 2015</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> and 2014, respectively (in thousands):</font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16" rowspan="1"></td></tr><tr><td width="41%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="12%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="12%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="12%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="12%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Three Months Ended September 30,</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Nine Months Ended September 30,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">2014</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">2014</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Research and development</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">83</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">92</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">253</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">438</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">General and administrative</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">492</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">990</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">1,081</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">3,440</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Total stock-based compensation from continuing operations</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">575</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">1,082</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">1,334</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">3,878</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Stock based compensation from discontinued operations</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">275</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">217</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">788</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">557</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:66px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">The company uses the Black-Scholes option-pricing model and the following weighted-average assumptions to determine the fair value of all its stock options granted:</font></div><div style="line-height:120%;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">&#160;</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12" rowspan="1"></td></tr><tr><td width="41%" rowspan="1" colspan="1"></td><td width="13%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="13%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="13%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="13%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Three Months Ended September 30,</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Nine Months Ended September 30,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">2014</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">2014</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Risk free interest rate</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">2.02</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">1.50</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">2.02</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">%</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Volatility</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">79.10</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">74.20</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">79.47</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">%</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Expected lives (years)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">0.00</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">6.12</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">6.09</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">6.15</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Expected dividend yield</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">%</font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">The weighted-average fair value of options granted during the nine months ended </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">September&#160;30, 2015</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> was </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$1.14</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> per share. There were no stock options granted during the three months ended </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">September&#160;30, 2015</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">.</font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">The company&#8217;s expected common stock price volatility assumption is based upon the company's own implied volatility in combination with the implied volatility of a basket of comparable companies. The expected life assumptions for employee grants were based upon the simplified method provided for under ASC&#160;718-10, which averages the contractual term of the company&#8217;s options of </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">ten years</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> with the average vesting term of </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">four years</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> for an average of </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">six years</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">. The expected life assumptions for non-employees were based upon the contractual term of the option. The dividend yield assumption is zero, because the company has never paid cash dividends and presently has no intention to do so. The risk-free interest rate used for each grant was also based upon prevailing short-term interest rates. The company has estimated an annualized forfeiture rate of </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">15%</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> for options granted to its employees, </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">8%</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> for options granted to senior management and zero for non-employee directors. The company will record additional expense if the actual forfeitures are lower than estimated and will record a recovery of prior expense if the actual forfeiture rates are higher than estimated.</font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">As of </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">September&#160;30, 2015</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">, there was </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$4,815,000</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> of unrecognized compensation cost related to outstanding options that is expected to be recognized as a component of the company&#8217;s operating expenses over a weighted-average period of </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">2.34</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> years.</font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">As of </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">September&#160;30, 2015</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">, an aggregate of </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">26,500,000</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> shares of common stock were reserved for issuance under the company&#8217;s 2007 Incentive Plan, including </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">11,188,000</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> shares subject to outstanding common stock options granted under the plan and </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">10,251,000</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> shares available for future grants. The administrator of the plan determines the times when an option may become exercisable. Vesting periods of options granted to date have not exceeded </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">four years</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">. The options will expire, unless previously exercised, no later than </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">ten years</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> from the grant date. </font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">The following table summarizes option activity of the company:</font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="11" rowspan="1"></td></tr><tr><td width="56%" rowspan="1" colspan="1"></td><td width="13%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="12%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="12%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Total</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Number of</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Shares </font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">(In Thousands)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Weighted</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Average</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Exercise</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Price</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Aggregate</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Intrinsic</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Value</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">(In Thousands)</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Outstanding at January&#160;1, 2015</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">8,590</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">3.25</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Granted</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">3,682</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">1.73</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Exercised</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(39</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">0.79</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">37</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Cancelled</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(1,045</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">2.44</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">21</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Outstanding at September&#160;30, 2015</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">11,188</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">2.83</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">690</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Options exercisable at September&#160;30, 2015</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">6,622</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">3.32</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">618</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">The aggregate intrinsic values of outstanding and exercisable options at </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">September&#160;30, 2015</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> were calculated based on the closing price of the company&#8217;s common stock as reported on The NASDAQ Capital Market on </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">September&#160;30, 2015</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> of </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$1.58</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> per share. The aggregate intrinsic value equals the positive difference between the closing fair market value of the company&#8217;s common stock and the exercise price of the underlying options.</font></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for compensation-related costs for equity-based compensation, which may include disclosure of policies, compensation plan details, allocation of equity compensation, incentive distributions, equity-based arrangements to obtain goods and services, deferred compensation arrangements, employee stock ownership plan details and employee stock purchase plan details.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 718<br><br><br><br> -SubTopic 40<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6418621&amp;loc=d3e17540-113929<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 505<br><br><br><br> -SubTopic 50<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6406099&amp;loc=d3e25284-112666<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 718<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 2<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 718<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5047-113901<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 718<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 4<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5444-113901<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Staff Accounting Bulletin (SAB)<br><br><br><br> -Number Topic 14<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.0.814</span><table class="report" border="0" cellspacing="2" id="idm139922644411712">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss Per Share<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2015</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareTextBlock', window );">Net Loss Per Share</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#00497f;font-weight:bold;">Net Loss Per Share</font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">The company accounts for and discloses net loss per common share in accordance with FASB ASC Topic 260 &#8220;</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;">Earnings per Share.&#8221;</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> Basic net loss per common share is computed by dividing net loss attributable to common stockholders by the weighted-average number of common shares outstanding. Diluted net loss per common share is computed by dividing net loss attributable to common stockholders by the weighted-average number of common shares that would have been outstanding during the period assuming the issuance of common shares for all potential dilutive common shares outstanding. Potential common shares consist of shares issuable upon the exercise of stock options and warrants. </font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">The following table sets forth the potentially dilutive common shares excluded from the calculation of net loss per common share because their inclusion would be anti-dilutive (in thousands):</font></div><div style="line-height:120%;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">&#160;</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="6" rowspan="1"></td></tr><tr><td width="67%" rowspan="1" colspan="1"></td><td width="15%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="15%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">&#160;Three and Nine Months Ended September 30,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">2014</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Warrants to purchase common stock</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">22,308</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">8,540</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Options to purchase common stock</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">11,188</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">8,994</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Total</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">33,496</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">17,534</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for earnings per share.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 260<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 3<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=7655603&amp;loc=d3e1278-109256<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 260<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (a)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 260<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 2<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=7655603&amp;loc=d3e1252-109256<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 260<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 55<br><br><br><br> -Paragraph 52<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=32703322&amp;loc=d3e4984-109258<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 225<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 2<br><br><br><br> -Subparagraph (SX 210.5-03.21)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.0.814</span><table class="report" border="0" cellspacing="2" id="idm139922622821520">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Long-term Debt (Details) - USD ($)<br> $ / shares in Units, $ in Millions</strong></div></th>
<th class="th"><div>May. 08, 2013</div></th>
<th class="th"><div>Mar. 18, 2015</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_DebtInstrumentTermInterestOnly', window );">Term for interest only payments</a></td>
<td class="text">12 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest payments at the fixed coupon rate</a></td>
<td class="nump">8.45%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentTerm', window );">Term for principal and interest payments</a></td>
<td class="text">30 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_DebtInstrumentCashFacilityFee', window );">Cash facility fee percentage</a></td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_DebtInstrumentCashFinalPayment', window );">Cash final payment percentage</a></td>
<td class="nump">5.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_ClassofWarrantorRightTerm', window );">Warrant term</a></td>
<td class="text">7 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Number of shares availabe from warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,826,923<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price (usd per share)</a></td>
<td class="nump">$ 2.47<span></span>
</td>
<td class="nump">$ 2.08<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_ClassofWarrantorRightAverageMarketPriceUsedForExercisePrice', window );">Duration of average market price used for warrant exercise price</a></td>
<td class="text">20 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RangeAxis=us-gaap_MaximumMember', window );">Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Number of shares availabe from warrants</a></td>
<td class="nump">182,186<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=gale_FirstTrancheMember', window );">First Tranche [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Loan, amount</a></td>
<td class="nump">$ 10<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gale_ClassofWarrantorRightAverageMarketPriceUsedForExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Class of Warrant or Right, Average Market Price Used For Exercise Price</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gale_ClassofWarrantorRightAverageMarketPriceUsedForExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gale_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gale_ClassofWarrantorRightTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Class of Warrant or Right, Term</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gale_ClassofWarrantorRightTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gale_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gale_DebtInstrumentCashFacilityFee">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Cash Facility Fee</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gale_DebtInstrumentCashFacilityFee</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gale_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gale_DebtInstrumentCashFinalPayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Cash Final Payment</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gale_DebtInstrumentCashFinalPayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gale_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gale_DebtInstrumentTermInterestOnly">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Term, Interest Only</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gale_DebtInstrumentTermInterestOnly</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gale_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 235<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.4-08.(i)(4))<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 235<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.4-08.(i)(2))<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 08<br><br><br><br> -Paragraph i<br><br><br><br> -Subparagraph 2<br><br><br><br> -Article 4<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentCarryingAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt before deduction of unamortized discount or premium. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt, with initial maturities beyond one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.22)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 22<br><br><br><br> -Article 5<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 20<br><br><br><br> -Article 5<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 03<br><br><br><br> -Paragraph 16<br><br><br><br> -Article 9<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentCarryingAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.22(a)(1))<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 22<br><br><br><br> -Article 5<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period of time between issuance and maturity of debt instrument, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RangeAxis=us-gaap_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RangeAxis=us-gaap_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=gale_FirstTrancheMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=gale_FirstTrancheMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.0.814</span><table class="report" border="0" cellspacing="2" id="idm139922645041376">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Discontinued Operations, Assets Held for Sale - Components Attributable to Commercial Business (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2015</div></th>
<th class="th"><div>Sep. 30, 2014</div></th>
<th class="th"><div>Sep. 30, 2015</div></th>
<th class="th"><div>Sep. 30, 2014</div></th>
<th class="th"><div>Dec. 31, 2014</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems', window );"><strong>Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf', window );">Impairment charge from classification as assets held for sale</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (8,071)<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax', window );">Loss from discontinued operations</a></td>
<td class="num">$ (11,674)<span></span>
</td>
<td class="num">$ (2,641)<span></span>
</td>
<td class="num">(16,074)<span></span>
</td>
<td class="num">(6,633)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=gale_CommercialBusinessSegmentMember', window );">Commercial Business Segment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems', window );"><strong>Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue', window );">Net revenue</a></td>
<td class="nump">2,166<span></span>
</td>
<td class="nump">1,620<span></span>
</td>
<td class="nump">8,298<span></span>
</td>
<td class="nump">6,124<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold', window );">Cost of revenue</a></td>
<td class="num">(712)<span></span>
</td>
<td class="num">(247)<span></span>
</td>
<td class="num">(1,573)<span></span>
</td>
<td class="num">(925)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationDepreciationAndAmortization', window );">Amortization of certain acquired intangible assets</a></td>
<td class="num">(208)<span></span>
</td>
<td class="num">(70)<span></span>
</td>
<td class="num">(795)<span></span>
</td>
<td class="num">(259)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_DisposalGroupIncludingDiscontinuedOperationResearchandDevelopment', window );">Research and development</a></td>
<td class="num">(160)<span></span>
</td>
<td class="num">(219)<span></span>
</td>
<td class="num">(339)<span></span>
</td>
<td class="num">(619)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense', window );">Selling, general, and administrative</a></td>
<td class="num">(4,672)<span></span>
</td>
<td class="num">(3,725)<span></span>
</td>
<td class="num">(13,577)<span></span>
</td>
<td class="num">(10,954)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss', window );">Non-operating income (expense)</a></td>
<td class="num">(17)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(17)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf', window );">Impairment charge from classification as assets held for sale</a></td>
<td class="num">(8,071)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(8,071)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax', window );">Loss from discontinued operations</a></td>
<td class="num">$ (11,674)<span></span>
</td>
<td class="num">$ (2,641)<span></span>
</td>
<td class="num">$ (16,074)<span></span>
</td>
<td class="num">$ (6,633)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gale_DisposalGroupIncludingDiscontinuedOperationResearchandDevelopment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disposal Group, Including Discontinued Operation, Research and Development</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gale_DisposalGroupIncludingDiscontinuedOperationResearchandDevelopment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gale_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of costs of goods sold attributable to the disposal group, including a component of the entity (discontinued operation), during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 205<br><br><br><br> -SubTopic 20<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (c)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6360339&amp;loc=d3e1361-107760<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationDepreciationAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of depreciation and amortization attributable to disposal group.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 205<br><br><br><br> -SubTopic 20<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (c)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6360339&amp;loc=d3e1361-107760<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupIncludingDiscontinuedOperationDepreciationAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of general and administrative expense attributable to disposal group.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 205<br><br><br><br> -SubTopic 20<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (c)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6360339&amp;loc=d3e1361-107760<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of operating income or loss attributable to the disposal group, including a component of the entity (discontinued operation), during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 205<br><br><br><br> -SubTopic 20<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (c)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6360339&amp;loc=d3e1361-107760<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of sales or other form of revenues attributable to the disposal group, including a component of the entity (discontinued operation), during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 205<br><br><br><br> -SubTopic 20<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (c)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6360339&amp;loc=d3e1361-107760<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of write-downs for impairments recognized during the period for long-lived assets held for abandonment, exchange or sale.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 360<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 15<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=8077374&amp;loc=d3e2611-110228<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 230<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 28<br><br><br><br> -Subparagraph (b)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3602-108585<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from a disposal group, net of income tax before extraordinary items allocable to noncontrolling interests. Includes, net of tax, income (loss) from operations during the phase-out period, gain (loss) on disposal, provision (or any reversals of earlier provisions) for loss on disposal, and adjustments of a prior period gain (loss) on disposal.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 944<br><br><br><br> -SubTopic 225<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.7-04.12)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 225<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 2<br><br><br><br> -Subparagraph (SX 210.5-03.14)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 205<br><br><br><br> -SubTopic 20<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (c)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6360339&amp;loc=d3e1361-107760<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 205<br><br><br><br> -SubTopic 20<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 3<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6892542&amp;loc=d3e957-107759<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 04<br><br><br><br> -Paragraph 13<br><br><br><br> -Article 7<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 03<br><br><br><br> -Paragraph 15<br><br><br><br> -Article 5<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=gale_CommercialBusinessSegmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=gale_CommercialBusinessSegmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.0.814</span><table class="report" border="0" cellspacing="2" id="idm139922644449904">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2015</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock', window );">Contingent Purchase Price Consideration, Measured at Estimated Fair Value on Recurring Basis</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-indent:66px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">The following tables present information about our assets and liabilities measured at fair value on a recurring basis in the condensed consolidated balance sheets (in thousands):</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">&#160;</font><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16" rowspan="1"></td></tr><tr><td width="41%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="12%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="12%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="12%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="12%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;font-weight:bold;text-decoration:underline;">Description</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">September&#160;30, 2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Quoted&#160;Prices&#160;In&#160;&#160;&#160;&#160;</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Active Markets</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">(Level 1)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Significant&#160;Other</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Observable&#160;</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Inputs (Level 2)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Unobservable&#160;</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Inputs</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">(Level 3)</font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Assets:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Cash equivalents</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">32,618</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">32,618</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Assets held for sale</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">17,801</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">17,801</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:middle;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Total assets measured and recorded at fair value</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">50,419</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">32,618</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">17,801</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Liabilities:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Warrants potentially settleable in cash</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">16,661</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">16,661</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Contingent purchase price consideration</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">6,582</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">6,582</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:middle;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Total liabilities measured and recorded at fair value</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">23,243</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">16,661</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">6,582</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16" rowspan="1"></td></tr><tr><td width="41%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="12%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="12%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="12%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="12%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;font-weight:bold;text-decoration:underline;">Description</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">December&#160;31, 2014</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Quoted&#160;Prices&#160;In&#160;&#160;&#160;&#160;</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Active Markets</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">(Level 1)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Significant&#160;Other</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Observable&#160;</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Inputs (Level 2)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Unobservable&#160;</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Inputs</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">(Level 3)</font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Assets:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Cash equivalents</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">19,477</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">19,477</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Total assets measured and recorded at fair value</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">19,477</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">19,477</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Liabilities:</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Warrants potentially settleable in cash</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">5,383</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">5,383</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Contingent purchase price consideration</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">6,651</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">6,651</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Total liabilities measured and recorded at fair value</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">12,034</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">5,383</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">6,651</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock', window );">Reconciliation of Level 3 Liabilities</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">A reconciliation of the beginning and ending Level 3 liabilities for the nine months ended </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">September&#160;30, 2015</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> is as follows (in thousands):</font></div><div style="line-height:120%;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">&#160;</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="4" rowspan="1"></td></tr><tr><td width="86%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="12%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Fair Value</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Measurements</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Using&#160;Significant</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Unobservable</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Inputs</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">(Level 3)</font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Balance, January&#160;1, 2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">6,651</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Change in the estimated fair value of the contingent purchase price consideration</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(69</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Balance at September&#160;30, 2015</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">6,582</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the fair value measurement of liabilities using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets), and gains or losses recognized in other comprehensive income (loss) and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs) by class of liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 820<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 3<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=36462937&amp;loc=d3e19279-110258<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 820<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 2<br><br><br><br> -Subparagraph (c)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=36462937&amp;loc=d3e19207-110258<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 820<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=36462937&amp;loc=d3e19190-110258<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.0.814</span><table class="report" border="0" cellspacing="2" id="idm139922623325168">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Other Income (Expense) (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2015</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherIncomeAndExpensesAbstract', window );"><strong>Other Income and Expenses [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock', window );">Schedule of Other Income (Expense)</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#00497f;font-weight:bold;">Other Income (Expense)</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Other income (expense) is summarized as follows (in thousands):</font></div><div style="line-height:120%;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">&#160;</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16" rowspan="1"></td></tr><tr><td width="45%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="11%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="11%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="11%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="11%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Three Months Ended September 30,</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Nine Months Ended September 30,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">2014</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">2014</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Change in fair value of the contingent purchase price liability</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">307</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">597</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">69</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(59</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Total other income (expense)</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">307</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">597</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">69</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(59</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherIncomeAndExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherIncomeAndExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of non-operating income or non-operating expense that may include amounts earned from dividends, interest on securities, gains (losses) on securities sold, equity earnings of unconsolidated affiliates, net gain (loss) on sales of business, interest expense and other miscellaneous income or expense items.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.0.814</span><table class="report" border="0" cellspacing="2" id="idm139922623529008">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Discontinued Operations, Assets Held for Sale (Details)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th">
<div>Sep. 30, 2015 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems', window );"><strong>Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_PercentageofCancerPatientsAffectedbyInadequatelyControlledBreakthroughCancerPainBTcP', window );">Percentage of cancer patients affected by inadequately controlled breakthrough cancer pain (BTcP) (in percent)</a></td>
<td class="nump">50.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=gale_CommercialBusinessSegmentMember', window );">Commercial Business Segment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems', window );"><strong>Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_DisposalGroupIncludingDiscontinuedOperationContingentLiabilityFromDivestitureAgreement', window );">Success fee contingently due to third party</a></td>
<td class="nump">$ 900,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_DisposalGroupIncludingDiscontinuedOperationContingentRetentionFees', window );">Retention fees contingently due</a></td>
<td class="nump">$ 400,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_DisposalGroupIncludingDiscontinuedOperationContingentRetentionFeesPercentageofConsiderationReceived', window );">Retention fees contingently due (as percentage of consideration received)</a></td>
<td class="nump">3.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gale_DisposalGroupIncludingDiscontinuedOperationContingentLiabilityFromDivestitureAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disposal Group, Including Discontinued Operation, Contingent Liability From Divestiture Agreement</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gale_DisposalGroupIncludingDiscontinuedOperationContingentLiabilityFromDivestitureAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gale_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gale_DisposalGroupIncludingDiscontinuedOperationContingentRetentionFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disposal Group, Including Discontinued Operation, Contingent Retention Fees</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gale_DisposalGroupIncludingDiscontinuedOperationContingentRetentionFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gale_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gale_DisposalGroupIncludingDiscontinuedOperationContingentRetentionFeesPercentageofConsiderationReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disposal Group, Including Discontinued Operation, Contingent Retention Fees, Percentage of Consideration Received</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gale_DisposalGroupIncludingDiscontinuedOperationContingentRetentionFeesPercentageofConsiderationReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gale_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gale_PercentageofCancerPatientsAffectedbyInadequatelyControlledBreakthroughCancerPainBTcP">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of Cancer Patients Affected by Inadequately Controlled Breakthrough Cancer Pain (BTcP)</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gale_PercentageofCancerPatientsAffectedbyInadequatelyControlledBreakthroughCancerPainBTcP</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gale_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=gale_CommercialBusinessSegmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=gale_CommercialBusinessSegmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.0.814</span><table class="report" border="0" cellspacing="2" id="idm139922623042704">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Warrants (Warrants Classified as Equity) (Details) - $ / shares<br></strong></div></th>
<th class="th"><div>May. 08, 2013</div></th>
<th class="th"><div>Mar. 18, 2015</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_WarrantsGrantedNumberofShares', window );">Warrants Granted, Number of Shares</a></td>
<td class="nump">182,186<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Class of Warrant or Right, Exercise Price of Warrants or Rights</a></td>
<td class="nump">$ 2.47<span></span>
</td>
<td class="nump">$ 2.08<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_NumberofDaysAveragedforExercisePrice', window );">Number of Days Averaged for Exercise Price</a></td>
<td class="text">20 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssumptionsExpectedVolatilityRate', window );">Fair Value Assumptions, Expected Volatility Rate</a></td>
<td class="nump">75.34%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssumptionsExpectedTerm', window );">Fair Value Assumptions, Expected Term</a></td>
<td class="text">7 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssumptionsRiskFreeInterestRate', window );">Fair Value Assumptions, Risk Free Interest Rate</a></td>
<td class="nump">1.20%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssumptionsExpectedDividendRate', window );">Fair Value Assumptions, Expected Dividend Rate</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_FairValueofWarrantsGrantedperShare', window );">Fair Value of Warrants Granted, per Share</a></td>
<td class="nump">$ 1.93<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gale_FairValueofWarrantsGrantedperShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair Value of Warrants Granted, per Share</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gale_FairValueofWarrantsGrantedperShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gale_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gale_NumberofDaysAveragedforExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Exercise price is based on the average closing price over this many trading days up to the date of the grant.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gale_NumberofDaysAveragedforExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gale_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gale_WarrantsGrantedNumberofShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Warrants Granted, Number of Shares</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gale_WarrantsGrantedNumberofShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gale_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 235<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.4-08.(i)(4))<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expected dividends to be paid to holders of the underlying shares or financial instruments (expressed as a percentage of the share or instrument's price).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 820<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 2<br><br><br><br> -Subparagraph (e)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=36462937&amp;loc=d3e19207-110258<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssumptionsExpectedTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period the instrument, asset or liability is expected to be outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 820<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 2<br><br><br><br> -Subparagraph (e)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=36462937&amp;loc=d3e19207-110258<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssumptionsExpectedTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssumptionsExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Measure of dispersion, in percentage terms (for instance, the standard deviation or variance), for a given stock price.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 820<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 2<br><br><br><br> -Subparagraph (e)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=36462937&amp;loc=d3e19207-110258<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssumptionsExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Risk-free interest rate assumption used in valuing an instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 820<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 2<br><br><br><br> -Subparagraph (e)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=36462937&amp;loc=d3e19207-110258<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.0.814</span><table class="report" border="0" cellspacing="2" id="idm139922623309792">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONDENSED CONSOLIDATED STATEMENT OF STOCKHOLDERS' EQUITY CONDENSED CONSOLIDATED STATEMENT OF STOCKHOLDERS' EQUITY - 9 months ended Sep. 30, 2015 - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Total</div></th>
<th class="th"><div>Common Stock [Member]</div></th>
<th class="th"><div>Additional Paid-in Capital [Member]</div></th>
<th class="th"><div>Accumulated Deficit [Member]</div></th>
<th class="th"><div>Treasury Stock [Member]</div></th>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Beginning balance, shares at Dec. 31, 2014</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">130,146,341<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Beginning balance at Dec. 31, 2014</a></td>
<td class="nump">$ 37,059<span></span>
</td>
<td class="nump">$ 12<span></span>
</td>
<td class="nump">$ 256,377<span></span>
</td>
<td class="num">$ (215,481)<span></span>
</td>
<td class="num">$ (3,849)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesOther', window );">Issuance of common stock, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">32,158,685<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueOther', window );">Issuance of common stock</a></td>
<td class="nump">47,416<span></span>
</td>
<td class="nump">$ 3<span></span>
</td>
<td class="nump">47,413<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities', window );">Issuance of common stock upon exercise of warrants, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities', window );">Common stock warrants issued in connection with March 2015 common stock offering</a></td>
<td class="num">(10,296)<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="num">(10,296)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans', window );">Issuance of common stock in connection with employee stock purchase plan, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">231,312<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan', window );">Issuance of common stock in connection with employee stock purchase plan</a></td>
<td class="nump">309<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">309<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalTaxEffectFromShareBasedCompensation', window );">Stock-based compensation for directors and employees</a></td>
<td class="nump">$ 2,122<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,122<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period</a></td>
<td class="nump">39,000<span></span>
</td>
<td class="nump">39,108<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Stock Issued During Period, Value, Stock Options Exercised</a></td>
<td class="nump">$ 31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(44,224)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(44,224)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending balance, shares at Sep. 30, 2015</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">162,575,446<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Ending balance at Sep. 30, 2015</a></td>
<td class="nump">$ 32,417<span></span>
</td>
<td class="nump">$ 15<span></span>
</td>
<td class="nump">$ 295,956<span></span>
</td>
<td class="num">$ (259,705)<span></span>
</td>
<td class="num">$ (3,849)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalTaxEffectFromShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in additional paid in capital (APIC) resulting from a tax benefit associated with share-based compensation plan other than an employee stock ownership plan (ESOP). Includes, but is not limited to, excess tax benefit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 718<br><br><br><br> -SubTopic 740<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 2<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6419406&amp;loc=d3e23524-113945<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 505<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.3-04)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 505<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 2<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalTaxEffectFromShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInStockholdersEquityRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Glossary Net Income<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6518256<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 230<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 28<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3602-108585<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 944<br><br><br><br> -SubTopic 225<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.7-04.19)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 260<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 225<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 2<br><br><br><br> -Subparagraph (SX 210.5-03.18)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 944<br><br><br><br> -SubTopic 225<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.7-04.22)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Glossary Other Comprehensive Income<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6519514<br><br><br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 03<br><br><br><br> -Paragraph 19<br><br><br><br> -Article 5<br><br><br><br>Reference 9: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 04<br><br><br><br> -Paragraph 20<br><br><br><br> -Article 9<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued which are neither cancelled nor held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of the conversion of convertible securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 505<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.3-04)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.29-30)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 505<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 2<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 505<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 3<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21475-112644<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 04<br><br><br><br> -Article 3<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 29, 30<br><br><br><br> -Article 5<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of an employee stock purchase plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 505<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 2<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 505<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.3-04)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 29, 30<br><br><br><br> -Article 5<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 04<br><br><br><br> -Article 3<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of stock issued during the period that is attributable to transactions involving issuance of stock not separately disclosed.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 505<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 2<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 505<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.3-04)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 718<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 2<br><br><br><br> -Subparagraph (c)(1)(iv)(2)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.28,29)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 29, 30<br><br><br><br> -Article 5<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 04<br><br><br><br> -Article 3<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The gross value of stock issued during the period upon the conversion of convertible securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.29-31)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 505<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 2<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 505<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.3-04)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 29, 30, 31<br><br><br><br> -Article 5<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 04<br><br><br><br> -Article 3<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate change in value for stock issued during the period as a result of employee stock purchase plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 505<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 2<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 505<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.3-04)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 04<br><br><br><br> -Article 3<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 29, 30, 31<br><br><br><br> -Article 5<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of shares of stock issued during the period that is attributable to transactions involving issuance of stock not separately disclosed.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued as a result of the exercise of stock options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 505<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 2<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.29-31)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 505<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.3-04)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 29, 30, 31<br><br><br><br> -Article 5<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 04<br><br><br><br> -Article 3<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 810<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 55<br><br><br><br> -Paragraph 4I<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=35736750&amp;loc=SL4590271-111686<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 810<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 16<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=7656940&amp;loc=SL4568740-111683<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 810<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 15<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=7656940&amp;loc=SL4568447-111683<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AdditionalPaidInCapitalMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AdditionalPaidInCapitalMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_RetainedEarningsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_RetainedEarningsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_TreasuryStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_TreasuryStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.0.814</span><table class="report" border="0" cellspacing="2" id="idm139922644428528">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Long-term Debt<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2015</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureTextBlock', window );">Long-term Debt</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#00497f;font-weight:bold;">Long-term Debt</font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:66px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">On May 8, 2013 we entered into a loan and security agreement with Oxford Finance LLC, as collateral agent, and related lenders under which we borrowed the first tranche of </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$10 million</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> (the "Loan"). The Loan payment terms include </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">12</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> months of interest-only payments at the fixed coupon rate of </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">8.45%</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">, followed by </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">30</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> months of amortization of principal and interest until maturity in November 2016. In connection with the Loan, we paid the lender a </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">1%</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> cash facility fee and a </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">5.5%</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> cash final payment and granted to the lenders </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">seven</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">-year warrants to purchase up to </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">182,186</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> shares of our common stock at an exercise price of </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$2.47</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">, which equaled a </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">20</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">-day average market price of our common stock prior to the date of the grant.</font></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 505<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 3<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21475-112644<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.19,20,22)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 19, 20, 22<br><br><br><br> -Article 5<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.0.814</span><table class="report" border="0" cellspacing="2" id="idm139922638284000">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss Per Share (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2015</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_ScheduleOfEarningPerShareToCommonShareholdersTableTextBlock', window );">Common Shares Excluded from Net Loss</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">The following table sets forth the potentially dilutive common shares excluded from the calculation of net loss per common share because their inclusion would be anti-dilutive (in thousands):</font></div><div style="line-height:120%;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">&#160;</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="6" rowspan="1"></td></tr><tr><td width="67%" rowspan="1" colspan="1"></td><td width="15%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="15%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">&#160;Three and Nine Months Ended September 30,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">2014</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Warrants to purchase common stock</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">22,308</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">8,540</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Options to purchase common stock</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">11,188</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">8,994</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Total</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">33,496</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">17,534</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gale_ScheduleOfEarningPerShareToCommonShareholdersTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Schedule Of Earning Per Share To Common Shareholders Table [Text Block]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gale_ScheduleOfEarningPerShareToCommonShareholdersTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gale_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XBRL>
<?xml version='1.0' encoding='UTF-8'?>
<FilingSummary>
  <Version>3.3.0.814</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>113</ContextCount>
  <ElementCount>253</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>33</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>4</UnitCount>
  <MyReports>
    <Report instance="gale-20150930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0001000 - Document - Document and Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.galenabiopharma.com/role/DocumentAndEntityInformation</Role>
      <ShortName>Document and Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="gale-20150930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>1001000 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.galenabiopharma.com/role/CondensedConsolidatedBalanceSheets</Role>
      <ShortName>CONDENSED CONSOLIDATED BALANCE SHEETS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="gale-20150930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>1001501 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.galenabiopharma.com/role/CondensedConsolidatedBalanceSheetsParenthetical</Role>
      <ShortName>CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="gale-20150930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>1002000 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.galenabiopharma.com/role/CondensedConsolidatedStatementsOfComprehensiveLoss</Role>
      <ShortName>CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="gale-20150930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>1003000 - Statement - CONDENSED CONSOLIDATED STATEMENT OF STOCKHOLDERS' EQUITY CONDENSED CONSOLIDATED STATEMENT OF STOCKHOLDERS' EQUITY</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.galenabiopharma.com/role/CondensedConsolidatedStatementOfStockholdersEquityCondensedConsolidatedStatementOfStockholdersEquity</Role>
      <ShortName>CONDENSED CONSOLIDATED STATEMENT OF STOCKHOLDERS' EQUITY CONDENSED CONSOLIDATED STATEMENT OF STOCKHOLDERS' EQUITY</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="gale-20150930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>1004000 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.galenabiopharma.com/role/CondensedConsolidatedStatementsOfCashFlows</Role>
      <ShortName>CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="gale-20150930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>2101100 - Disclosure - Business and Basis of Presentation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.galenabiopharma.com/role/BusinessAndBasisOfPresentation</Role>
      <ShortName>Business and Basis of Presentation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="gale-20150930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>2105100 - Disclosure - Fair Value Measurements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.galenabiopharma.com/role/FairValueMeasurements</Role>
      <ShortName>Fair Value Measurements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="gale-20150930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>2106100 - Disclosure - Accrued Expenses and Other Current Liabilities</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.galenabiopharma.com/role/AccruedExpensesAndOtherCurrentLiabilities</Role>
      <ShortName>Accrued Expenses and Other Current Liabilities</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="gale-20150930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>2107100 - Disclosure - Long-term Debt</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.galenabiopharma.com/role/LongTermDebt</Role>
      <ShortName>Long-term Debt</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="gale-20150930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>2108100 - Disclosure - Legal Proceedings, Commitments and Contingencies (Notes)</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://www.galenabiopharma.com/role/LegalProceedingsCommitmentsAndContingenciesNotes</Role>
      <ShortName>Legal Proceedings, Commitments and Contingencies (Notes)</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="gale-20150930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>2109100 - Disclosure - Stockholders' Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.galenabiopharma.com/role/StockholdersEquity</Role>
      <ShortName>Stockholders' Equity</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="gale-20150930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>2110100 - Disclosure - Warrants</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.galenabiopharma.com/role/Warrants</Role>
      <ShortName>Warrants</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="gale-20150930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>2111100 - Disclosure - Stock Based Compensation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.galenabiopharma.com/role/StockBasedCompensation</Role>
      <ShortName>Stock Based Compensation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="gale-20150930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>2112100 - Disclosure - Other Income (Expense) (Notes)</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://www.galenabiopharma.com/role/OtherIncomeExpenseNotes</Role>
      <ShortName>Other Income (Expense) (Notes)</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="gale-20150930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>2113100 - Disclosure - Net Loss Per Share</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.galenabiopharma.com/role/NetLossPerShare</Role>
      <ShortName>Net Loss Per Share</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="gale-20150930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>2114100 - Disclosure - License Agreements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.galenabiopharma.com/role/LicenseAgreements</Role>
      <ShortName>License Agreements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="gale-20150930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>2116100 - Disclosure - Discontinued Operations, Assets Held for Sale (Notes)</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://www.galenabiopharma.com/role/DiscontinuedOperationsAssetsHeldForSaleNotes</Role>
      <ShortName>Discontinued Operations, Assets Held for Sale (Notes)</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="gale-20150930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>2117100 - Disclosure - Subsequent Events</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.galenabiopharma.com/role/SubsequentEvents</Role>
      <ShortName>Subsequent Events</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="gale-20150930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>2201201 - Disclosure - Business and Basis of Presentation (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.galenabiopharma.com/role/BusinessAndBasisOfPresentationPolicies</Role>
      <ShortName>Business and Basis of Presentation (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="gale-20150930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>2305301 - Disclosure - Fair Value Measurements (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.galenabiopharma.com/role/FairValueMeasurementsTables</Role>
      <ShortName>Fair Value Measurements (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.galenabiopharma.com/role/FairValueMeasurements</ParentRole>
      <Position>21</Position>
    </Report>
    <Report instance="gale-20150930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>2306301 - Disclosure - Accrued Expenses and Other Current Liabilities (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.galenabiopharma.com/role/AccruedExpensesAndOtherCurrentLiabilitiesTables</Role>
      <ShortName>Accrued Expenses and Other Current Liabilities (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.galenabiopharma.com/role/AccruedExpensesAndOtherCurrentLiabilities</ParentRole>
      <Position>22</Position>
    </Report>
    <Report instance="gale-20150930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>2309301 - Disclosure - Stockholders' Equity (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.galenabiopharma.com/role/StockholdersEquityTables</Role>
      <ShortName>Stockholders' Equity (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.galenabiopharma.com/role/StockholdersEquity</ParentRole>
      <Position>23</Position>
    </Report>
    <Report instance="gale-20150930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>2310301 - Disclosure - Warrants (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.galenabiopharma.com/role/WarrantsTables</Role>
      <ShortName>Warrants (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.galenabiopharma.com/role/Warrants</ParentRole>
      <Position>24</Position>
    </Report>
    <Report instance="gale-20150930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>2311301 - Disclosure - Stock Based Compensation (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.galenabiopharma.com/role/StockBasedCompensationTables</Role>
      <ShortName>Stock Based Compensation (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.galenabiopharma.com/role/StockBasedCompensation</ParentRole>
      <Position>25</Position>
    </Report>
    <Report instance="gale-20150930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>2312301 - Disclosure - Other Income (Expense) (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.galenabiopharma.com/role/OtherIncomeExpenseTables</Role>
      <ShortName>Other Income (Expense) (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.galenabiopharma.com/role/OtherIncomeExpenseNotes</ParentRole>
      <Position>26</Position>
    </Report>
    <Report instance="gale-20150930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>2313301 - Disclosure - Net Loss Per Share (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.galenabiopharma.com/role/NetLossPerShareTables</Role>
      <ShortName>Net Loss Per Share (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.galenabiopharma.com/role/NetLossPerShare</ParentRole>
      <Position>27</Position>
    </Report>
    <Report instance="gale-20150930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>2316301 - Disclosure - Discontinued Operations, Assets Held for Sale (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.galenabiopharma.com/role/DiscontinuedOperationsAssetsHeldForSaleTables</Role>
      <ShortName>Discontinued Operations, Assets Held for Sale (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.galenabiopharma.com/role/DiscontinuedOperationsAssetsHeldForSaleNotes</ParentRole>
      <Position>28</Position>
    </Report>
    <Report instance="gale-20150930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>2401402 - Disclosure - Business and Basis of Presentation (Additional Information) (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.galenabiopharma.com/role/BusinessAndBasisOfPresentationAdditionalInformationDetail</Role>
      <ShortName>Business and Basis of Presentation (Additional Information) (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.galenabiopharma.com/role/BusinessAndBasisOfPresentationPolicies</ParentRole>
      <Position>29</Position>
    </Report>
    <Report instance="gale-20150930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>2402402 - Disclosure - Business Combinations (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.galenabiopharma.com/role/BusinessCombinationsDetails</Role>
      <ShortName>Business Combinations (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>30</Position>
    </Report>
    <Report instance="gale-20150930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>2405402 - Disclosure - Fair Value Measurements (Contingent Purchase Price Consideration, Measured at Estimated Fair Value on Recurring Basis) (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.galenabiopharma.com/role/FairValueMeasurementsContingentPurchasePriceConsiderationMeasuredAtEstimatedFairValueOnRecurringBasisDetail</Role>
      <ShortName>Fair Value Measurements (Contingent Purchase Price Consideration, Measured at Estimated Fair Value on Recurring Basis) (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.galenabiopharma.com/role/FairValueMeasurementsTables</ParentRole>
      <Position>31</Position>
    </Report>
    <Report instance="gale-20150930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>2405403 - Disclosure - Fair Value Measurements (Reconciliation of Level 3 Liabilities) (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.galenabiopharma.com/role/FairValueMeasurementsReconciliationOfLevel3LiabilitiesDetail</Role>
      <ShortName>Fair Value Measurements (Reconciliation of Level 3 Liabilities) (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.galenabiopharma.com/role/FairValueMeasurementsTables</ParentRole>
      <Position>32</Position>
    </Report>
    <Report instance="gale-20150930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>2406402 - Disclosure - Accrued Expenses and Other Current Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.galenabiopharma.com/role/AccruedExpensesAndOtherCurrentLiabilitiesDetails</Role>
      <ShortName>Accrued Expenses and Other Current Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.galenabiopharma.com/role/AccruedExpensesAndOtherCurrentLiabilitiesTables</ParentRole>
      <Position>33</Position>
    </Report>
    <Report instance="gale-20150930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>2407401 - Disclosure - Long-term Debt (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.galenabiopharma.com/role/LongTermDebtDetails</Role>
      <ShortName>Long-term Debt (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.galenabiopharma.com/role/LongTermDebt</ParentRole>
      <Position>34</Position>
    </Report>
    <Report instance="gale-20150930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>2408401 - Disclosure - Legal Proceedings, Commitments and Contingencies Details (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.galenabiopharma.com/role/LegalProceedingsCommitmentsAndContingenciesDetailsDetails</Role>
      <ShortName>Legal Proceedings, Commitments and Contingencies Details (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.galenabiopharma.com/role/LegalProceedingsCommitmentsAndContingenciesNotes</ParentRole>
      <Position>35</Position>
    </Report>
    <Report instance="gale-20150930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>2409402 - Disclosure - Stockholders' Equity (Additional Information) (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.galenabiopharma.com/role/StockholdersEquityAdditionalInformationDetail</Role>
      <ShortName>Stockholders' Equity (Additional Information) (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.galenabiopharma.com/role/StockholdersEquityTables</ParentRole>
      <Position>36</Position>
    </Report>
    <Report instance="gale-20150930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>2409403 - Disclosure - Stockholders' Equity (Common Stock are Reserved for Future Issuance) (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.galenabiopharma.com/role/StockholdersEquityCommonStockAreReservedForFutureIssuanceDetail</Role>
      <ShortName>Stockholders' Equity (Common Stock are Reserved for Future Issuance) (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.galenabiopharma.com/role/StockholdersEquityTables</ParentRole>
      <Position>37</Position>
    </Report>
    <Report instance="gale-20150930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>2410402 - Disclosure - Warrants (Schedule of Warrant Activity) (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.galenabiopharma.com/role/WarrantsScheduleOfWarrantActivityDetail</Role>
      <ShortName>Warrants (Schedule of Warrant Activity) (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.galenabiopharma.com/role/WarrantsTables</ParentRole>
      <Position>38</Position>
    </Report>
    <Report instance="gale-20150930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>2410403 - Disclosure - Warrants (Fair Value of Warrants is Estimated Using Black-Scholes Option Pricing Model) (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.galenabiopharma.com/role/WarrantsFairValueOfWarrantsIsEstimatedUsingBlackScholesOptionPricingModelDetail</Role>
      <ShortName>Warrants (Fair Value of Warrants is Estimated Using Black-Scholes Option Pricing Model) (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.galenabiopharma.com/role/WarrantsTables</ParentRole>
      <Position>39</Position>
    </Report>
    <Report instance="gale-20150930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>2410404 - Disclosure - Warrants (Changes in Fair Value of Warrant Liability) (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.galenabiopharma.com/role/WarrantsChangesInFairValueOfWarrantLiabilityDetail</Role>
      <ShortName>Warrants (Changes in Fair Value of Warrant Liability) (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.galenabiopharma.com/role/WarrantsTables</ParentRole>
      <Position>40</Position>
    </Report>
    <Report instance="gale-20150930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>2410405 - Disclosure - Warrants (Warrants Classified as Equity) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.galenabiopharma.com/role/WarrantsWarrantsClassifiedAsEquityDetails</Role>
      <ShortName>Warrants (Warrants Classified as Equity) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.galenabiopharma.com/role/WarrantsTables</ParentRole>
      <Position>41</Position>
    </Report>
    <Report instance="gale-20150930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>2411402 - Disclosure - Stock Based Compensation (Allocated Stock-based Compensation) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.galenabiopharma.com/role/StockBasedCompensationAllocatedStockBasedCompensationDetails</Role>
      <ShortName>Stock Based Compensation (Allocated Stock-based Compensation) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.galenabiopharma.com/role/StockBasedCompensationTables</ParentRole>
      <Position>42</Position>
    </Report>
    <Report instance="gale-20150930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>2411403 - Disclosure - Stock Based Compensation (Assumptions for Option Grants Issued) (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.galenabiopharma.com/role/StockBasedCompensationAssumptionsForOptionGrantsIssuedDetail</Role>
      <ShortName>Stock Based Compensation (Assumptions for Option Grants Issued) (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.galenabiopharma.com/role/StockBasedCompensationTables</ParentRole>
      <Position>43</Position>
    </Report>
    <Report instance="gale-20150930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>2411404 - Disclosure - Stock Based Compensation (Additional Information) (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.galenabiopharma.com/role/StockBasedCompensationAdditionalInformationDetail</Role>
      <ShortName>Stock Based Compensation (Additional Information) (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.galenabiopharma.com/role/StockBasedCompensationTables</ParentRole>
      <Position>44</Position>
    </Report>
    <Report instance="gale-20150930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>2411405 - Disclosure - Stock Based Compensation (Stock Option Activity) (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.galenabiopharma.com/role/StockBasedCompensationStockOptionActivityDetail</Role>
      <ShortName>Stock Based Compensation (Stock Option Activity) (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.galenabiopharma.com/role/StockBasedCompensationTables</ParentRole>
      <Position>45</Position>
    </Report>
    <Report instance="gale-20150930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>2412402 - Disclosure - Other Income (Expense) Table (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.galenabiopharma.com/role/OtherIncomeExpenseTableDetails</Role>
      <ShortName>Other Income (Expense) Table (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.galenabiopharma.com/role/OtherIncomeExpenseTables</ParentRole>
      <Position>46</Position>
    </Report>
    <Report instance="gale-20150930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>2413402 - Disclosure - Net Loss Per Share (Common Shares Excluded from Net Loss) (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.galenabiopharma.com/role/NetLossPerShareCommonSharesExcludedFromNetLossDetail</Role>
      <ShortName>Net Loss Per Share (Common Shares Excluded from Net Loss) (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.galenabiopharma.com/role/NetLossPerShareTables</ParentRole>
      <Position>47</Position>
    </Report>
    <Report instance="gale-20150930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>2414401 - Disclosure - License Agreements (Additional Information) (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.galenabiopharma.com/role/LicenseAgreementsAdditionalInformationDetail</Role>
      <ShortName>License Agreements (Additional Information) (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.galenabiopharma.com/role/LicenseAgreements</ParentRole>
      <Position>48</Position>
    </Report>
    <Report instance="gale-20150930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>2416402 - Disclosure - Discontinued Operations, Assets Held for Sale (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.galenabiopharma.com/role/DiscontinuedOperationsAssetsHeldForSaleDetails</Role>
      <ShortName>Discontinued Operations, Assets Held for Sale (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.galenabiopharma.com/role/DiscontinuedOperationsAssetsHeldForSaleTables</ParentRole>
      <Position>49</Position>
    </Report>
    <Report instance="gale-20150930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>2416403 - Disclosure - Discontinued Operations, Assets Held for Sale - Carrying Amounts of Assets and LIabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.galenabiopharma.com/role/DiscontinuedOperationsAssetsHeldForSaleCarryingAmountsOfAssetsAndLiabilitiesDetails</Role>
      <ShortName>Discontinued Operations, Assets Held for Sale - Carrying Amounts of Assets and LIabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>50</Position>
    </Report>
    <Report instance="gale-20150930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>2416404 - Disclosure - Discontinued Operations, Assets Held for Sale - Components Attributable to Commercial Business (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.galenabiopharma.com/role/DiscontinuedOperationsAssetsHeldForSaleComponentsAttributableToCommercialBusinessDetails</Role>
      <ShortName>Discontinued Operations, Assets Held for Sale - Components Attributable to Commercial Business (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>51</Position>
    </Report>
    <Report instance="gale-20150930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R52.htm</HtmlFileName>
      <LongName>2416405 - Disclosure - Discontinued Operations, Assets Held for Sale - Significant Operating Non-cash and Capital Expenditures (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.galenabiopharma.com/role/DiscontinuedOperationsAssetsHeldForSaleSignificantOperatingNonCashAndCapitalExpendituresDetails</Role>
      <ShortName>Discontinued Operations, Assets Held for Sale - Significant Operating Non-cash and Capital Expenditures (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>52</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <Logs>
    <Log type="Info">In ''CONDENSED CONSOLIDATED BALANCE SHEETS'', column(s) 3, 4 are contained in other reports, so were removed by flow through suppression.</Log>
    <Log type="Info">In ''CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical)'', column(s) 3 are contained in other reports, so were removed by flow through suppression.</Log>
    <Log type="Info">In ''CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS'', column(s) 1, 2, 3, 6 are contained in other reports, so were removed by flow through suppression.</Log>
  </Logs>
  <InputFiles>
    <File>gale-20150930.xml</File>
    <File>gale-20150930_cal.xml</File>
    <File>gale-20150930_def.xml</File>
    <File>gale-20150930_lab.xml</File>
    <File>gale-20150930_pre.xml</File>
    <File>gale-20150930.xsd</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies/>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>

</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.0.814</span><table class="report" border="0" cellspacing="2" id="idm139922636895088">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Warrants (Schedule of Warrant Activity) (Detail) - shares<br> shares in Thousands</strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2014</div></th>
<th class="th"><div>Sep. 30, 2015</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_ClassofWarrantorRightOutstandingRollForward', window );"><strong>Class of Warrant or Right, Outstanding [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrants outstanding , Beginning balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,540<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_ClassofWarrantorRightGranted', window );">Granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14,006<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_ClassofWarrantorRightExpired', window );">Class of Warrant or Right, Expired</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">238<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrants outstanding , Ending balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">22,308<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=gale_MarchTwoThousandFifteenWarrantsMember', window );">March 2015 Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_ClassofWarrantorRightOutstandingRollForward', window );"><strong>Class of Warrant or Right, Outstanding [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrants outstanding , Beginning balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_ClassofWarrantorRightGranted', window );">Granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14,006<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrants outstanding , Ending balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14,006<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_ClassOfWarrantsOrRightsExpirationDate', window );">Expiration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Mar. 18,  2020<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=gale_SeptemberTwoThousandThirteenWarrantMember', window );">September 2013 Warrant [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_ClassofWarrantorRightOutstandingRollForward', window );"><strong>Class of Warrant or Right, Outstanding [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrants outstanding , Beginning balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,973<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_ClassofWarrantorRightGranted', window );">Granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrants outstanding , Ending balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,973<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_ClassOfWarrantsOrRightsExpirationDate', window );">Expiration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Sep. 18,  2018<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=gale_DecemberTwoThousandTwelveWarrantMember', window );">December 2012 Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_ClassofWarrantorRightOutstandingRollForward', window );"><strong>Class of Warrant or Right, Outstanding [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrants outstanding , Beginning balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,031<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_ClassofWarrantorRightGranted', window );">Granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrants outstanding , Ending balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,031<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_ClassOfWarrantsOrRightsExpirationDate', window );">Expiration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Dec. 31,  2017<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=gale_AprilTwoThousandElevenWarrantMember', window );">April 2011 Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_ClassofWarrantorRightOutstandingRollForward', window );"><strong>Class of Warrant or Right, Outstanding [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrants outstanding , Beginning balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">615<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_ClassofWarrantorRightGranted', window );">Granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrants outstanding , Ending balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">615<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_ClassOfWarrantsOrRightsExpirationDate', window );">Expiration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Apr. 30,  2017<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=gale_MarchTwoThousandElevenWarrantMember', window );">March 2011 Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_ClassofWarrantorRightOutstandingRollForward', window );"><strong>Class of Warrant or Right, Outstanding [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrants outstanding , Beginning balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">176<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_ClassofWarrantorRightGranted', window );">Granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrants outstanding , Ending balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">176<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_ClassOfWarrantsOrRightsExpirationDate', window );">Expiration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Mar. 31,  2016<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=gale_MarchTwoThousandTenWarrantMember', window );">March 2010 Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_ClassofWarrantorRightOutstandingRollForward', window );"><strong>Class of Warrant or Right, Outstanding [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrants outstanding , Beginning balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_ClassofWarrantorRightGranted', window );">Granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrants outstanding , Ending balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_ClassOfWarrantsOrRightsExpirationDate', window );">Expiration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Mar. 31,  2016<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=gale_ConsultantWarrantsMember', window );">Consultant Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_ClassofWarrantorRightOutstandingRollForward', window );"><strong>Class of Warrant or Right, Outstanding [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrants outstanding , Beginning balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">720<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_ClassofWarrantorRightGranted', window );">Granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_ClassofWarrantorRightExpired', window );">Class of Warrant or Right, Expired</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">238<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrants outstanding , Ending balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">482<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=gale_ConsultantWarrantsMember', window );">Consultant Warrants [Member] | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_ClassofWarrantorRightOutstandingRollForward', window );"><strong>Class of Warrant or Right, Outstanding [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_ClassOfWarrantsOrRightsExpirationDate', window );">Expiration</a></td>
<td class="text">Dec. 31,  2014<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=gale_ConsultantWarrantsMember', window );">Consultant Warrants [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_ClassofWarrantorRightOutstandingRollForward', window );"><strong>Class of Warrant or Right, Outstanding [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_ClassOfWarrantsOrRightsExpirationDate', window );">Expiration</a></td>
<td class="text">Dec. 31,  2020<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gale_ClassOfWarrantsOrRightsExpirationDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Class Of Warrants Or Rights Expiration Date</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gale_ClassOfWarrantsOrRightsExpirationDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gale_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gale_ClassofWarrantorRightExpired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Class of Warrant or Right, Expired</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gale_ClassofWarrantorRightExpired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gale_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gale_ClassofWarrantorRightGranted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Class of Warrant or Right Granted</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gale_ClassofWarrantorRightGranted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gale_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gale_ClassofWarrantorRightOutstandingRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Class of Warrant or Right, Outstanding [Roll Forward]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gale_ClassofWarrantorRightOutstandingRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gale_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 235<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.4-08.(i))<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 08<br><br><br><br> -Paragraph i<br><br><br><br> -Article 4<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=gale_MarchTwoThousandFifteenWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=gale_MarchTwoThousandFifteenWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=gale_SeptemberTwoThousandThirteenWarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=gale_SeptemberTwoThousandThirteenWarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=gale_DecemberTwoThousandTwelveWarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=gale_DecemberTwoThousandTwelveWarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=gale_AprilTwoThousandElevenWarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=gale_AprilTwoThousandElevenWarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=gale_MarchTwoThousandElevenWarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=gale_MarchTwoThousandElevenWarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=gale_MarchTwoThousandTenWarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=gale_MarchTwoThousandTenWarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=gale_ConsultantWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=gale_ConsultantWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RangeAxis=us-gaap_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RangeAxis=us-gaap_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RangeAxis=us-gaap_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RangeAxis=us-gaap_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.0.814</span><table class="report" border="0" cellspacing="2" id="idm139922623788560">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Business and Basis of Presentation (Policies)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2015</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DiscontinuedOperationsPolicyTextBlock', window );">Discontinued Operations</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:left;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;">Discontinued Operations - </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">As described in Note 12, we met the relevant criteria for reporting our commercial business as held for sale and in discontinued operations in the accompanying unaudited interim financial statements as of the three and nine month periods ended September&#160;30, 2015 and 2014, pursuant to FASB Topic 205-20, Presentation of Financial Statements - Discontinued Operations, and FASB Topic 360, Property, Plant, and Equipment.</font></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Uses of Estimates in Preparation of Financial Statements</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;">Uses of Estimates in Preparation of Financial Statements</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> &#8212; The preparation of these consolidated financial statements in accordance with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the reporting period. Actual results could differ materially from those estimates.</font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br clear="none"/></font></div></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConsolidationPolicyTextBlock', window );">Principles of Consolidation</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;">Principles of Consolidation</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> &#8212;&#160;The consolidated financial statements include the accounts of Galena and its wholly owned subsidiaries. All material intercompany accounts have been eliminated in consolidation.</font></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PriorPeriodReclassificationAdjustmentDescription', window );">Reclassifications</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;">Reclassifications</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> &#8212; Certain prior year amounts have been reclassified to conform to current year presentation. These reclassifications had no effect on net loss per share.</font></div></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock', window );">Cash and Cash Equivalents</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;">Cash and Cash Equivalents</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> &#8212; The company considers all highly liquid debt instruments with an original maturity of </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">90</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> days&#160;or less to be cash equivalents. Cash equivalents consist primarily of amounts invested in money market accounts and demand deposits.</font></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy', window );">Restricted Cash</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;">Restricted Cash</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> &#8212; Restricted cash consists of certificates of deposit on hand with the company&#8217;s financial institutions as collateral for its corporate credit cards</font></div></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueOfFinancialInstrumentsPolicy', window );">Fair Value of Financial Instruments</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;">Fair Value of Financial Instruments</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> &#8212; The carrying amounts reported in the balance sheet for cash equivalents, accounts receivable, accounts payable, and capital leases approximate their fair values due to their short-term nature and market rates of interest.</font></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock', window );">Equipment and Furnishings</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-indent:66px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;">Equipment and Furnishings</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> &#8212; Equipment and furnishings are stated at cost and depreciated using the straight-line method based on the estimated useful lives (generally </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">three</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> to </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">five</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> years) of the related assets.</font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br clear="none"/></font></div></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock', window );">Goodwill and Intangible Assets</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:8px;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;">Goodwill and Intangible Assets</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> &#8212; Goodwill and indefinite-lived intangible assets are not amortized but are tested annually for impairment at the reporting unit level, or more frequently if events and circumstances indicate impairment may have occurred. Factors the company considers important that could trigger an interim review for impairment include, but are not limited to, the following:</font></div><div style="line-height:120%;padding-left:67px;padding-bottom:8px;text-align:left;"><font style="padding-bottom:8px;text-align:left;font-family:Helvetica,sans-serif;font-size:10pt;padding-right:28px;">&#8226;</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Significant changes in the manner of its use of acquired assets or the strategy for its overall business;</font></div><div style="line-height:120%;padding-left:67px;padding-bottom:8px;text-align:left;"><font style="padding-bottom:8px;text-align:left;font-family:Helvetica,sans-serif;font-size:10pt;padding-right:28px;">&#8226;</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Significant negative industry or economic trends;</font></div><div style="line-height:120%;padding-left:67px;padding-bottom:8px;text-align:left;"><font style="padding-bottom:8px;text-align:left;font-family:Helvetica,sans-serif;font-size:10pt;padding-right:28px;">&#8226;</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Significant decline in stock price for a sustained period; and</font></div><div style="line-height:120%;padding-left:67px;text-align:left;"><font style="text-align:left;font-family:Helvetica,sans-serif;font-size:10pt;padding-right:28px;">&#8226;</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Significant decline in market capitalization relative to net book value.</font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Goodwill and other intangible assets with indefinite lives are evaluated for impairment first by a qualitative assessment to determine the likelihood of impairment. If it is determined that impairment is more likely than not, the company will then proceed to the two step impairment test. The first step is to compare the fair value of the reporting unit to the carrying amount of the reporting unit. If the carrying amount exceeds the fair value, a second step must be followed to calculate impairment. Otherwise, if the fair value of the reporting unit exceeds the carrying amount, the goodwill is not considered to be impaired as of the measurement date. In its review of the carrying value of the goodwill for its single reporting unit and its indefinite-lived intangible assets, the company determines fair values of its goodwill using the market approach, and its indefinite-lived intangible assets using the income approach.</font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:66px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Intangible assets not considered indefinite-lived are reviewed for impairment when facts or circumstances suggest that the carrying value of these assets may not be recoverable. The company&#8217;s policy is to identify and record impairment losses, if necessary, on intangible assets when events and circumstances indicate that the assets might be impaired and the undiscounted cash flows estimated to be generated by those assets are less than the carrying amounts.</font></div><div style="line-height:120%;text-indent:66px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:66px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">The company performed its review for impairment using the qualitative assessment for both goodwill and indefinite-lived intangible assets, as well as assets not considered to be indefinite-lived, and has determined that there has been no impairment to these assets as of </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">September&#160;30, 2015</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">.</font></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationsPolicy', window );">Acquisitions and In-Licensing</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-indent:66px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">As of </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">September&#160;30, 2015</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">, we determined there were no variable interest entities required to be consolidated.</font></div><div style="line-height:120%;text-indent:32px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:66px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">We also perform an analysis to determine if the assets and liabilities acquired in an acquisition qualify as a "business." The excess of the purchase price over the fair value of the net assets acquired can only be recognized as goodwill in a business combination. The Company completes its valuation analysis no later than twelve months from the date of the acquisition.</font></div><div style="line-height:120%;text-indent:32px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br clear="none"/></font></div></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_ContingentConsiderationPolicyPolicyTextBlock', window );">Contingent Consideration</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;">Contingent Purchase Price Consideration</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> &#8212; Contingent consideration in business combinations is recorded at the estimated fair value as of the acquisition date. The fair value of the contingent consideration is re-measured at each reporting period with any adjustments in fair value included in our consolidated statement of comprehensive loss.</font></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_PatentsAndPatentApplicationCostsPolicyPolicyTextBlock', window );">Patents and Patent Application Costs</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;">Patents and Patent Application Costs</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> &#8212; Although the company believes that its patents and underlying technology have continuing value, the amount of future benefits to be derived from the patents is uncertain. Patent costs are, therefore, expensed as incurred.</font></div></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy', window );">Share-based Compensation</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;">Share-based Compensation</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> &#8212; The company follows the provisions of the FASB ASC Topic 718, &#8220;</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;">Compensation&#160;&#8212; Stock Compensation&#8221;</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> (&#8220;ASC 718&#8221;), which requires the measurement and recognition of compensation expense for all stock-based payment awards made to employees, non-employee directors, and consultants, including stock options and warrants. Stock compensation expense based on the grant date fair value estimated in accordance with the provisions of ASC&#160;718 is recognized as an expense over the requisite service period.</font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">For stock options and warrants granted as consideration for services rendered by non-employees, the company recognizes compensation expense in accordance with the requirements of FASB ASC Topic 505-50 (&#8220;ASC 505-50&#8221;), &#8220; </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;">Equity Based Payments to Non- Employees</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">.&#8221; Non-employee option and warrant grants that do not vest immediately upon grant are recorded as an expense over the vesting period. At the end of each financial reporting period prior to vesting, the value of these options and warrants, as calculated using the Black-Scholes option-pricing model, is re-measured using the fair value of the company&#8217;s common stock and the non-cash compensation recognized during the period is adjusted accordingly. Since the fair market value of options and warrants granted to non-employees is subject to change in the future, the amount of the future compensation expense will include fair value re-measurements until the stock options are fully vested.</font></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpensePolicy', window );">Research and Development Expenses</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;">Research and Development Expenses</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> &#8212; Research and development costs are expensed as incurred. Included in research and development costs are wages, benefits and other operating costs, facilities, supplies, external services and overhead related to our research and development departments, and clinical trial expenses.</font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Clinical trial expenses include direct costs associated with contract research organizations (CROs), as well as patient-related costs at sites at which our trials are being conducted.</font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Direct costs associated with our CROs are generally payable on a time and materials basis, or when certain enrollment and monitoring milestones are achieved. Expense related to a milestone is recognized in the period in which the milestone is achieved or in which we determine that it is more likely than not that it will be achieved.</font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">The invoicing from clinical trial sites can lag several months. We accrue these site costs based on our estimate of upfront set-up costs upon the screening of the first patient at each site, and the patient related costs based on our knowledge of patient enrollment status at each site.</font></div></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxPolicyTextBlock', window );">Income Taxes</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;">Income Taxes</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> &#8212; The company recognizes liabilities or assets for the deferred tax consequences of temporary differences between the tax basis of assets or liabilities and their reported amounts in the financial statements in accordance with FASB ASC&#160;740-10, &#8220;</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;">Accounting for Income Taxes&#8221; (&#8220;ASC 740-10&#8221;).</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> These temporary differences will result in taxable or deductible amounts in future years when the reported amounts of the assets or liabilities are recovered or settled. </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;">ASC 740-10</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> requires that a valuation allowance be established when management determines that it is more likely than not that all or a portion of a deferred asset will not be realized. The company evaluates the realizability of its net deferred income tax assets and valuation allowances as necessary, at least on an annual basis. During this evaluation, the company reviews its forecasts of income in conjunction with other positive and negative evidence surrounding the realizability of its deferred income tax assets to determine if a valuation allowance is required. Adjustments to the valuation allowance will increase or decrease the company&#8217;s income tax provision or benefit. The recognition and measurement of benefits related to the company&#8217;s tax positions requires significant judgment, as uncertainties often exist with respect to new laws, new interpretations of existing laws, and rulings by taxing authorities. Differences between actual results and the company&#8217;s assumptions or changes in the company&#8217;s assumptions in future periods are recorded in the period they become known.</font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:66px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">There was no income tax expense or benefit for the three and nine months periods ended </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">September&#160;30, 2015</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> and 2014. We continue to maintain a full valuation allowance against our net deferred tax assets.</font></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskCreditRisk', window );">Concentrations of Credit Risk</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;">Concentrations of Credit Risk</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> &#8212; Financial instruments that potentially subject the company to significant concentrations of credit risk consist principally of cash and cash equivalents. The company maintains cash balances in several accounts with two banks, which at times are in excess of federally insured limits. As of </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">September&#160;30, 2015</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">, the company&#8217;s cash equivalents were invested in money market mutual funds. The company&#8217;s investment policy does not allow investment in any debt securities rated less than &#8220;investment grade&#8221; by national ratings services. The company has not experienced any losses on its deposits of cash and cash equivalents. The company maintains significant cash and cash equivalents at two financial institutions that are in excess of federally insured limits.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br clear="none"/></font></div></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock', window );">Comprehensive Loss</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;">Comprehensive Loss</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> &#8212; Comprehensive loss consists of our net loss, with no other comprehensive income items for the periods presented.</font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br clear="none"/></font></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock', window );">Fair Value Measurement</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#00497f;font-weight:bold;">Fair Value Measurements</font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:12px;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">The company follows ASC&#160;820, &#8220;Fair Value Measurements and Disclosures,&#8221; (&#8220;ASC 820&#8221;) for the company&#8217;s financial assets and liabilities that are re-measured and reported at fair value at each reporting period, and are re-measured and reported at fair value at least annually using a fair value hierarchy that is broken down into three levels. Level inputs are defined as follows:</font></div><div style="line-height:120%;padding-bottom:12px;padding-left:108px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Level&#160;1&#160;&#8212; quoted prices in active markets for identical assets or liabilities.</font></div><div style="line-height:120%;padding-bottom:12px;padding-left:108px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Level&#160;2&#160;&#8212; other significant observable inputs for the assets or liabilities through corroboration with market data at the measurement date.</font></div><div style="line-height:120%;padding-left:108px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Level&#160;3&#160;&#8212; significant unobservable inputs that reflect management&#8217;s best estimate of what market participants would use to price the assets or liabilities at the measurement date.</font></div><div style="line-height:120%;text-indent:106px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:66px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">The company categorized its cash equivalents as Level&#160;1. The valuations for Level&#160;1 were determined based on a &#8220;market approach&#8221; using quoted prices in active markets for identical assets. Valuation of these assets does not require a significant degree of judgment. The company categorized its warrants potentially settleable in cash as Level&#160;2 inputs. The warrants are measured at market value on a recurring basis and are being marked to market each quarter-end until they are completely settled. The warrants are valued using an appropriate pricing model, using assumptions consistent with our application of ASC&#160;718. The contingent purchase price consideration is categorized as Level 3 inputs and is measured at its estimated fair value on a recurring basis and is adjusted at each quarter-end until it is completely settled. The contingent purchase price consideration is valued based on the expected timing of milestones, the expected probability of success for each milestone and discount rates based on a corporate debt interest rate index publicly issued.</font></div></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerSharePolicyTextBlock', window );">Earnings per Share</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#00497f;font-weight:bold;">Net Loss Per Share</font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">The company accounts for and discloses net loss per common share in accordance with FASB ASC Topic 260 &#8220;</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;">Earnings per Share.&#8221;</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> Basic net loss per common share is computed by dividing net loss attributable to common stockholders by the weighted-average number of common shares outstanding. Diluted net loss per common share is computed by dividing net loss attributable to common stockholders by the weighted-average number of common shares that would have been outstanding during the period assuming the issuance of common shares for all potential dilutive common shares outstanding. Potential common shares consist of shares issuable upon the exercise of stock options and warrants. </font></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Effect of Recent Accounting Pronouncements</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:left;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;text-decoration:underline;">Effect of Recent Accounting Pronouncements</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> </font></div><div style="line-height:120%;text-align:left;text-indent:65px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">In April 2014, the FASB issued ASU 2014-08, Reporting Discontinued Operations and Disclosures of Disposals of Components of an Entity, or ASU 2014-08. Under ASU 2014-08, only disposals representing a strategic shift in operations that have a major effect on the company&#8217;s operations and financial results should be presented as discontinued operations. Additionally, ASU 2014-08 requires expanded disclosures about discontinued operations that will provide financial statement users with more information about the assets, liabilities, income, and expenses of discontinued operations. The amendments in ASU 2014-08 are effective for fiscal years, and interim periods within those years, beginning after December 15, 2014. The company adopted this guidance in the first quarter of 2015 and has applied it in the accompanying interim financial statements for presentation and disclosure of the commercial business as discontinued operations (see Note 12). </font></div><div style="line-height:120%;text-align:left;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">In May 2014, the FASB issued ASU No.&#160;2014-09,&#160;Revenue from Contracts with Customers: Topic 606,&#160;or ASU 2014-09. ASU 2014-09 establishes the principles for recognizing revenue and develops a common revenue standard for U.S. GAAP. The standard outlines a single comprehensive model for entities to use in accounting for revenue arising from contracts with customers and supersedes most current revenue recognition guidance, including industry-specific guidance. In applying the new revenue recognition model to contracts with customers, an entity: (1) identifies the contract(s) with a customer; (2) identifies the performance obligations in the contract(s); (3) determines the transaction price; (4) allocates the transaction price to the performance obligations in the contract(s); and (5) recognizes revenue when (or as) the entity satisfies a performance obligation.&#160;The accounting standards update applies to all contracts with customers except those that are within the scope of other topics in the FASB Accounting Standards Codification.&#160;The accounting standards update also requires significantly expanded quantitative and qualitative disclosures regarding the nature, amount, timing and uncertainty of revenue and cash flows arising from contracts with customers.&#160;This guidance is effective for fiscal years and interim periods within those years beginning after December 15, 2016, which is effective for the company for the year ending December 31, 2017. The FASB delayed in the effective date of the accounting standards update to fiscal years and interim periods within those years beginning on or after December 15, 2017, which is pending approval.&#160;The company is currently evaluating the impact that the implementation of ASU 2014-09 will have on the company&#8217;s financial statements. </font></div><div style="line-height:120%;text-align:left;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">In August 2014, the FASB issued ASU No. 2014-15,&#160;Disclosure of Uncertainties about an Entity&#8217;s Ability to Continue as a Going Concern, or ASU 2014-15. ASU 2014-15 will explicitly require management to assess an entity&#8217;s ability to continue as a going concern, and to provide related footnote disclosure in certain circumstances. The new standard will be effective for all entities in the first annual period ending after December 15, 2016. Earlier adoption is permitted. The company is not early adopting ASU 2014-15. The company is currently evaluating the impact that the implementation of ASU 2014-15 will have on the company&#8217;s financial statements, and the actual impact will be dependent upon the company&#8217;s liquidity and the nature or significance of future events or conditions that exist upon adopting the updated standard.</font></div><div style="line-height:120%;text-align:left;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">In January 2015, the FASB issued ASU No. 2015-01, Simplifying Income Statement Presentation by Eliminating the Concept of Extraordinary Items, or ASU 2015-01.&#160;ASU 2015-01 eliminates from GAAP the concept of extraordinary items. ASU 2015-01 is effective for fiscal years and interim periods beginning after December 15, 2015. Early adoption is permitted. The company does not expect that the adoption of ASU 2015-01 will have a material impact on its consolidated financial statements.</font></div><div style="line-height:120%;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;"><br clear="none"/></font></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gale_ContingentConsiderationPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contingent Consideration Policy [Text Block]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gale_ContingentConsiderationPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gale_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gale_PatentsAndPatentApplicationCostsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Patents and Patent Application Costs [Policy Text Block]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gale_PatentsAndPatentApplicationCostsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gale_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for completed business combinations (purchase method, acquisition method or combination of entities under common control). This accounting policy may include a general discussion of the purchase method or acquisition method of accounting (including for example, the treatment accorded contingent consideration, the identification of assets and liabilities, the purchase price allocation process, how the fair values of acquired assets and liabilities are determined) and the entity's specific application thereof. An entity that acquires another entity in a leveraged buyout transaction generally discloses the accounting policy followed by the acquiring entity in determining the basis used to value its interest in the acquired entity, and the rationale for that accounting policy.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 235<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 3<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367646&amp;loc=d3e18780-107790<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 805<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 05<br><br><br><br> -Paragraph 4<br><br><br><br> -Subparagraph (a)-(d)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6909625&amp;loc=d3e227-128457<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 305<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 05<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6375392&amp;loc=d3e26790-107797<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 230<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367179&amp;loc=d3e4273-108586<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Glossary Cash<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6506951<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 235<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 3<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367646&amp;loc=d3e18780-107790<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Glossary Cash Equivalents<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6507016<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Financial Reporting Release (FRR)<br><br><br><br> -Number 203<br><br><br><br> -Paragraph 02-03<br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 1<br><br><br><br> -Article 5<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Entity's cash and cash equivalents accounting policy with respect to restricted balances.  Restrictions may include legally restricted deposits held as compensating balances against short-term borrowing arrangements, contracts entered into with others, or company statements of intention with regard to particular deposits; however, time deposits and short-term certificates of deposit are not generally included in legally restricted deposits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 235<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 3<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367646&amp;loc=d3e18780-107790<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 942<br><br><br><br> -SubTopic 210<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.9-03.1(a))<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 305<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 05<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6375392&amp;loc=d3e26790-107797<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 230<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367179&amp;loc=d3e4273-108586<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 03<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph a<br><br><br><br> -Article 9<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 1<br><br><br><br> -Article 5<br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Financial Reporting Release (FRR)<br><br><br><br> -Number 203<br><br><br><br> -Paragraph 02-03<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomePolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskCreditRisk">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for credit risk.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 825<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 55<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6875567&amp;loc=d3e14489-108613<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 942<br><br><br><br> -SubTopic 825<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 2<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6480020&amp;loc=d3e61082-112788<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 944<br><br><br><br> -SubTopic 825<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=28088331&amp;loc=SL29635902-196195<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 825<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 21<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=35750535&amp;loc=d3e13537-108611<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 825<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 20<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=35750535&amp;loc=d3e13531-108611<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 942<br><br><br><br> -SubTopic 825<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6480020&amp;loc=d3e61044-112788<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskCreditRisk</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConsolidationPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting.  The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 235<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 3<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367646&amp;loc=d3e18780-107790<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 810<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=18733093&amp;loc=d3e5614-111684<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 810<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 2<br><br><br><br> -Subparagraph (SX 210.3A-02)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=27015204&amp;loc=d3e355033-122828<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph k<br><br><br><br> -Article 1<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02, 03<br><br><br><br> -Article 3A<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConsolidationPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DiscontinuedOperationsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for any discontinued operations. The results of operations of a component of an entity that either has been disposed of or is classified as held for sale is reported in discontinued operations if both: (a) the operations and cash flows of the component have been (or will be) eliminated from the ongoing operations of the entity as a result of the disposal transaction and (b) the entity will not have any significant continuing involvement in the operations of the component after the disposal transaction. If the entity elects to allocate interest expense to a discontinued operation, it may disclose its accounting policy for this election and describe its method of allocation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 235<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 3<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367646&amp;loc=d3e18780-107790<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 205<br><br><br><br> -SubTopic 20<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6360339&amp;loc=d3e1361-107760<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 205<br><br><br><br> -SubTopic 20<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 3<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=26872618&amp;loc=d3e7436-122677<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 260<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DiscontinuedOperationsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerSharePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 260<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 260<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (c)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 260<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 2<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3630-109257<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 235<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 3<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367646&amp;loc=d3e18780-107790<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerSharePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueOfFinancialInstrumentsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for determining the fair value of financial instruments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 235<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 3<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367646&amp;loc=d3e18780-107790<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 825<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=35750535&amp;loc=d3e13279-108611<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 820<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 60<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=7493716&amp;loc=d3e21868-110260<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueOfFinancialInstrumentsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for goodwill and intangible assets. This accounting policy also may address how an entity assesses and measures impairment of goodwill and intangible assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 350<br><br><br><br> -SubTopic 30<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=26713463&amp;loc=d3e16265-109275<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 235<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 3<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367646&amp;loc=d3e18780-107790<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 350<br><br><br><br> -SubTopic 20<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=35741047&amp;loc=d3e13816-109267<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 235<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 3<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367646&amp;loc=d3e18780-107790<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 740<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 19<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32840-109319<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 740<br><br><br><br> -SubTopic 30<br><br><br><br> -Section 05<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6423966&amp;loc=d3e40913-109327<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 954<br><br><br><br> -SubTopic 740<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6491622&amp;loc=d3e9504-115650<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 740<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 17<br><br><br><br> -Subparagraph (b)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32809-109319<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 740<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 25<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=37586315&amp;loc=d3e32247-109318<br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 740<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 28<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=37586315&amp;loc=d3e32280-109318<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PriorPeriodReclassificationAdjustmentDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for reclassifications that affects the comparability of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 205<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6359566&amp;loc=d3e326-107755<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PriorPeriodReclassificationAdjustmentDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for long-lived, physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, basis of assets, depreciation and depletion methods used, including composite deprecation, estimated useful lives, capitalization policy, accounting treatment for costs incurred for repairs and maintenance, capitalized interest and the method it is calculated, disposals and impairments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 360<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 235<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 3<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367646&amp;loc=d3e18780-107790<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.13(a))<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 13<br><br><br><br> -Subparagraph a<br><br><br><br> -Article 5<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpensePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 730<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 235<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 3<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367646&amp;loc=d3e18780-107790<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Glossary Research and Development<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6523717<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpensePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for stock option and stock incentive plans. This disclosure may include (1) the types of stock option or incentive plans sponsored by the entity (2) the groups that participate in (or are covered by) each plan (3) significant plan provisions and (4) how stock compensation is measured, and the methodologies and significant assumptions used to determine that measurement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 718<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5047-113901<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 235<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 3<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367646&amp;loc=d3e18780-107790<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 718<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 2<br><br><br><br> -Subparagraph (b),(f)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 275<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 4<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6927468&amp;loc=d3e6061-108592<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 275<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 9<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6927468&amp;loc=d3e6143-108592<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 275<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 8<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6927468&amp;loc=d3e6132-108592<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>

</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
